<?xml version="1.0" encoding="UTF-8"?><extract createDate="2025-11-25"><manufacturerList><manufacturer id="686">New LU Code for Wyost (denosumab) effective August 2024</manufacturer><manufacturer id="AAP">A A Pharma Inc.</manufacturer><manufacturer id="ABB">Abbott Laboratories Limited</manufacturer><manufacturer id="ABD">Abbott Diabetes Care</manufacturer><manufacturer id="ABH">Manufacturer name not currently available</manufacturer><manufacturer id="ABI">Abiogen Pharma</manufacturer><manufacturer id="ABP">Manufacturer name not currently available</manufacturer><manufacturer id="ABT">Albert Pharma Inc - &quot; DO NOT USE &quot;</manufacturer><manufacturer id="ABV">AbbVie Corporation</manufacturer><manufacturer id="ACC">Accel Pharma Inc.</manufacturer><manufacturer id="ACH">Accord Healthcare Inc.</manufacturer><manufacturer id="ACO">Acon Laboratories Incorporated</manufacturer><manufacturer id="ACP">Accelera Pharma Canada, Inc.</manufacturer><manufacturer id="ACT">Actelion Pharmaceutiques Canada Inc.</manufacturer><manufacturer id="ACV">Actavis Pharma Company</manufacturer><manufacturer id="ADC">Ascensia Diabetes Care Canada Inc.</manufacturer><manufacturer id="ADI">Adria Laboratories of Canada Ltd.</manufacturer><manufacturer id="ADR">Manufacturer name not currently available</manufacturer><manufacturer id="ADV">Advanz Pharma Canada Inc.</manufacturer><manufacturer id="AEZ">AEterna Zentaris Inc.</manufacturer><manufacturer id="AGI">Agila Specialties Pvt. Ltd.</manufacturer><manufacturer id="AGN">Agnes Pharmaceutical Products Inc.</manufacturer><manufacturer id="AGO">Agouron Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="AGP">Actavis Group PTC ehf</manufacturer><manufacturer id="AHA">Manufacturer name not currently available</manufacturer><manufacturer id="AJC">Agila-Jamp Canada Inc.</manufacturer><manufacturer id="AKC">Akcea Therapeutics, Inc.</manufacturer><manufacturer id="AKN">Akorn Pharmaceuticals Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="AKO">Manufacturer name not currently available</manufacturer><manufacturer id="ALA">Altana Pharma Inc.</manufacturer><manufacturer id="ALB">Albert Pharma Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="ALC">Alcon Canada Inc.</manufacturer><manufacturer id="ALE">Alexion Pharmaceuticals Inc.</manufacturer><manufacturer id="ALG">Alexion Pharma GMBH</manufacturer><manufacturer id="ALH">Altius Healthcare Inc.</manufacturer><manufacturer id="ALK">ALK-Abello A/S</manufacturer><manufacturer id="ALL">Allergan Inc.</manufacturer><manufacturer id="ALM">Almirall Limited</manufacturer><manufacturer id="ALN">Alnylam Netherlands B.V.</manufacturer><manufacturer id="ALR">AllerPharma Inc.</manufacturer><manufacturer id="ALT">Altimed Pharmaceutical Company</manufacturer><manufacturer id="ALV">Alveda Pharmaceuticals Inc.</manufacturer><manufacturer id="ALZ">ALZA Canada</manufacturer><manufacturer id="AMA">Amada (Nutritional Products)</manufacturer><manufacturer id="AMB">Ambicare Pharmaceuticals Inc.</manufacturer><manufacturer id="AMC">Allmedicus Co., Ltd.</manufacturer><manufacturer id="AMD">Amdipharm Limited</manufacturer><manufacturer id="AMG">Amgen Canada Inc.</manufacturer><manufacturer id="AMP">Amphastar Pharmaceuticals Inc.</manufacturer><manufacturer id="AMT">Amicus Therapeutics UK Ltd., Buckinghamshire</manufacturer><manufacturer id="AMY">Amylyx Pharmaceuticals Inc.</manufacturer><manufacturer id="ANA">Analog Pharma Canada Inc.</manufacturer><manufacturer id="ANC">Manufacturer name not currently available</manufacturer><manufacturer id="ANG">Angita Pharma Inc.</manufacturer><manufacturer id="APC">Acerus Pharmaceuticals Corporation</manufacturer><manufacturer id="APO">ApoPharma Inc.</manufacturer><manufacturer id="APP">APP Pharmaceuticals LLC</manufacturer><manufacturer id="APU">Atnahs Pharma UK Limited</manufacturer><manufacturer id="APX">Apotex Inc.</manufacturer><manufacturer id="ARA">ARA Pharmaceuticals Inc.</manufacturer><manufacturer id="ARG">Argeny Canada Inc.</manufacturer><manufacturer id="ARZ">Aralez Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="ASC">Actavis Specialty Pharmaceuticals Co.</manufacturer><manufacturer id="ASE">Astellas Pharma Canada Inc.</manufacturer><manufacturer id="ASI">Aspen Pharmacare Canada Inc.</manufacturer><manufacturer id="ASN">Aspen Pharma Trading Limited</manufacturer><manufacturer id="ASP">Aspri Pharma Canada Inc.</manufacturer><manufacturer id="AST">Astra Pharma Inc.</manufacturer><manufacturer id="ASZ">Astra Zeneca - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="ATO">Aton Pharma Inc.</manufacturer><manufacturer id="AUR">Auro Pharma Inc.</manufacturer><manufacturer id="AUT">Auto Control Medical</manufacturer><manufacturer id="AVE">Aventis Pharma</manufacturer><manufacturer id="AVN">Aventis Pasteur Limited (S8)</manufacturer><manufacturer id="AVP">Avir Pharma Inc.</manufacturer><manufacturer id="AVR">Advanced Vision Research, Inc. (S8)</manufacturer><manufacturer id="AXC">Axcan Pharma Inc.</manufacturer><manufacturer id="AXX">Axxess  Pharma  Inc.</manufacturer><manufacturer id="AYE">Ayerst Laboratories, Division of Ayerst, McKenna &amp; Harrison</manufacturer><manufacturer id="AZC">AstraZeneca</manufacturer><manufacturer id="AZU">AstraZeneca USA</manufacturer><manufacturer id="BAC">Baxter Corporation - Clintec Nutrition Division (S8)</manufacturer><manufacturer id="BAH">Bayer Inc., Health Care Division</manufacturer><manufacturer id="BAK">Baker Cummins Inc</manufacturer><manufacturer id="BAL">Bayer Healthcare LLC Subsidiary of Bayer Corporation</manufacturer><manufacturer id="BAR">Barr Laboratories Inc.</manufacturer><manufacturer id="BAU">Bausch &amp; Lomb Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="BAX">Baxter Corporation</manufacturer><manufacturer id="BAY">Bayer Inc., Consumer Care Division</manufacturer><manufacturer id="BCA">Manufacturer name not currently available</manufacturer><manufacturer id="BCI">Baker Cummins Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="BCL">Biosimilar Collaborations Ireland Limited</manufacturer><manufacturer id="BCT">BioCryst Pharmaceutical Inc</manufacturer><manufacturer id="BDH">Manufacturer name not currently available</manufacturer><manufacturer id="BED">BD Consumer Healthcare</manufacturer><manufacturer id="BEE">Manufacturer name not currently available</manufacturer><manufacturer id="BEI">BeiGene Switzerland GmbH</manufacturer><manufacturer id="BER">Berlex Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="BEX">Berlex Canada Inc</manufacturer><manufacturer id="BFI">Axcan Pharma Inc.</manufacturer><manufacturer id="BGP">BGP Pharma ULC</manufacturer><manufacturer id="BHC">Bausch Health Canada Inc.</manufacturer><manufacturer id="BIC">Biocodex SA</manufacturer><manufacturer id="BIG">Biogen Idec Canada Inc.</manufacturer><manufacturer id="BII">Biomed 2002 Inc.</manufacturer><manufacturer id="BIM">BioMarin International Ltd.</manufacturer><manufacturer id="BIN">Bionime Corporation</manufacturer><manufacturer id="BIO">Biovail Pharmaceuticals Canada</manufacturer><manufacturer id="BIS">Biosyent Pharma Inc.</manufacturer><manufacturer id="BJH">Draxis Health Inc.</manufacturer><manufacturer id="BLI">Bausch &amp; Lomb Inc.</manufacturer><manufacturer id="BMN">Biomarin International Limited</manufacturer><manufacturer id="BMP">Biomed Pharma</manufacturer><manufacturer id="BMS">Bristol-Myers Squibb Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="BNQ">Bioniche Pharma (Canada) Ltd.  (S8)</manufacturer><manufacturer id="BNT">BioNTech Manufacturing GmbH</manufacturer><manufacturer id="BNY">Manufacturer name not currently available</manufacturer><manufacturer id="BOE">Boehringer-Ingelheim (Canada) Ltd./Ltee</manufacturer><manufacturer id="BOM">Boehringer - Mannheim Canada</manufacturer><manufacturer id="BOP">Boots Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="BQU">Bristol Myers Squibb Canada Inc</manufacturer><manufacturer id="BRA">B. Braun Medical Inc. (S8)</manufacturer><manufacturer id="BRD">Bard Pharmaceuticals (1990) Inc.</manufacturer><manufacturer id="BRI">Bristol-Myers Squibb Canada Inc. Nutritional Div. Ottawa</manufacturer><manufacturer id="BSH">Bausch &amp; Lomb Canada Inc</manufacturer><manufacturer id="BSS">Bauch &amp; Lomb Surgical Inc. (S8)</manufacturer><manufacturer id="BWE">Burroughs Wellcome Inc.</manufacturer><manufacturer id="BYK">Byk Canada Inc.</manufacturer><manufacturer id="CAM">Ajinomoto Cambrooke, Inc.</manufacturer><manufacturer id="CBF">C.B. Fleet Company Inc.</manufacturer><manufacturer id="CBS">Manufacturer name not currently available</manufacturer><manufacturer id="CBV">CIBA Vision</manufacturer><manufacturer id="CCI">Clement Clark International Ltd.</manufacturer><manufacturer id="CCP">CellChem Pharmaceuticals Inc.</manufacturer><manufacturer id="CDC">Church &amp; Dwight Canada Corp., Inc.</manufacturer><manufacturer id="CDI">Concordia Laboratories Inc.</manufacturer><manufacturer id="CDM">Canderm Pharmacal Ltd./Ltee - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="CDX">Canderm Pharmacal Ltd</manufacturer><manufacturer id="CEH">Celltrion Healthcare Co. Ltd.</manufacturer><manufacturer id="CEI">Celltrion Inc.</manufacturer><manufacturer id="CEL">Celgene Inc.</manufacturer><manufacturer id="CEN">Centocor Ortho Biotech Inc</manufacturer><manufacturer id="CEP">Cephalon Inc.</manufacturer><manufacturer id="CGP">Manufacturer name not currently available</manufacturer><manufacturer id="CGS">Ciba-Geigy Self Medication Products</manufacturer><manufacturer id="CHE">Cheplapharm Arzneimittel GmbH</manufacturer><manufacturer id="CHI">Chiesi Canada Corp.</manufacturer><manufacturer id="CHU">Church and Dwight Canada Corp.</manufacturer><manufacturer id="CIB">Ciba Pharmaceuticals, Division of Ciba-Geigy Canada Ltd.</manufacturer><manufacturer id="CIL">Chilcott Laboratories-Division of Warner-Lambert Canada Inc.</manufacturer><manufacturer id="CIP">Cipher Pharmaceuticals Inc.</manufacturer><manufacturer id="CLI">Clinigen Healthcare Ltd.</manufacturer><manufacturer id="CLK">Clark Laboratory - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="CLT">Clintec (Non-Formulary) - &quot; DO NOT USE&quot;</manufacturer><manufacturer id="CMA">Cosmair Canada Inc.</manufacturer><manufacturer id="CMH">Manufacturer name not currently available</manufacturer><manufacturer id="CMP">Can-Med Pharma Inc.</manufacturer><manufacturer id="CNG">Manufacturer name not currently available</manufacturer><manufacturer id="CNN">Connaught Novo Nordisk Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="COB">Cobalt Pharmaceuticals Company</manufacturer><manufacturer id="COL">Columbia Laboratories</manufacturer><manufacturer id="CON">Pasteur Merieux Connaught Canada</manufacturer><manufacturer id="COP">Covis Pharma GmbH</manufacturer><manufacturer id="COV">Covis Pharma B.V.</manufacturer><manufacturer id="CPL">Clay-Park Labs Inc.</manufacturer><manufacturer id="CRY">Crystaal Corp.</manufacturer><manufacturer id="CTS">Custom Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="CUB">Cubist Pharmaceuticals</manufacturer><manufacturer id="CUV">Chauvin Pharmaceuticals Limited (S8)</manufacturer><manufacturer id="CYC">Cycle Pharmaceuticals Ltd.</manufacturer><manufacturer id="CYI">Cytex Pharmaceutical Co.</manufacturer><manufacturer id="DBL">David Bull Laboratories - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="DBU">David Bull Laboratories (Canada) Inc.</manufacturer><manufacturer id="DCL">DC Labs</manufacturer><manufacturer id="DDC">Ddrops Company</manufacturer><manufacturer id="DEC">Deciphera Pharmaceuticals, LLC</manufacturer><manufacturer id="DER">Dermik Laboratories Canada Inc.</manufacturer><manufacturer id="DES">Desbergers Limited</manufacturer><manufacturer id="DEX">Dexcom Inc.</manufacturer><manufacturer id="DKT">Dioptic Laboratories, Division of Akorn Pharmaceuticals Cana</manufacturer><manufacturer id="DLU">L. P. Dey (S8)</manufacturer><manufacturer id="DME">Dupont Merck Pharma (Endo Canada Division) - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="DPC">Dominion Pharmacal</manufacturer><manufacturer id="DPL">DPT Laboratories - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="DPM">Dupont Merck Pharma - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="DPT">Dermtek Pharmaceuticals Ltd.</manufacturer><manufacturer id="DPY">Manufacturer Name currently not available</manufacturer><manufacturer id="DRR">Dr. Reddy&apos;s Laboratories Inc.</manufacturer><manufacturer id="DTC">Drug Trading Company Ltd. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="DUI">Duchesnay Inc.</manufacturer><manufacturer id="DUP">Du Pont Pharma</manufacturer><manufacturer id="EAT">Manufacturer name not currently available</manufacturer><manufacturer id="ECL">ECL Pharma Group Ltd.</manufacturer><manufacturer id="EDM">Endo Canada Division Du Pont Merck Pharma</manufacturer><manufacturer id="EDO">Endo</manufacturer><manufacturer id="EFM">Manufacturer name not currently available</manufacturer><manufacturer id="EHS">Entra Health Systems.</manufacturer><manufacturer id="EIS">Eisai Limited</manufacturer><manufacturer id="ELA">Elan Pharmaceuticals, Inc.</manufacturer><manufacturer id="ELD">Manufacturer name not currently available</manufacturer><manufacturer id="ELN">Elan Pharma International Ltd.</manufacturer><manufacturer id="ELV">Elvium Life Sciences</manufacturer><manufacturer id="EMS">EMD Serono Canada Inc.</manufacturer><manufacturer id="END">Endoceutics Inc.</manufacturer><manufacturer id="ENZ">Enzon Inc. (S8)</manufacturer><manufacturer id="EOL">Endo Operations Ltd.</manufacturer><manufacturer id="EPI">Endo Par Innovation Company, LLC</manufacturer><manufacturer id="ERF">Erfa Canada Inc.</manufacturer><manufacturer id="ETH">Ethypharm Inc.</manufacturer><manufacturer id="EUG">Euro Generics</manufacturer><manufacturer id="EUP">Eugia Pharma Inc.</manufacturer><manufacturer id="EUR">Euro-Pharm International Canada</manufacturer><manufacturer id="EVL">Endo Ventures Ltd.</manufacturer><manufacturer id="EVM">Evans Medical Ltd.</manufacturer><manufacturer id="FAB">Fabrigen Inc.</manufacturer><manufacturer id="FAM">Famy Care Ltd</manufacturer><manufacturer id="FAU">Faulding Canada Inc.</manufacturer><manufacturer id="FEI">Ferring Inc.</manufacturer><manufacturer id="FIC">Manufacturer name not currently available</manufacturer><manufacturer id="FIS">Fisons Corporation Limited</manufacturer><manufacturer id="FKC">Fresenius Kabi Canada Ltd.</manufacturer><manufacturer id="FLI">Boots Pharmaceuticals Ltd.</manufacturer><manufacturer id="FOM">Formative Pharma Inc.</manufacturer><manufacturer id="FOR">Forus Therapeutics Inc.</manufacturer><manufacturer id="FOU">Fournier Pharma Inc.</manufacturer><manufacturer id="FRS">Merck Frosst Canada &amp; Cie, Merck Frosst Canada &amp; Co.</manufacturer><manufacturer id="FUJ">Fujisawa Canada Inc.</manufacturer><manufacturer id="GAC">Galderma Canada Inc</manufacturer><manufacturer id="GAL">Galderma - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="GCC">Manufacturer name not currently available</manufacturer><manufacturer id="GCH">GlaxoSmithKline Consumer Healthcare Inc.</manufacturer><manufacturer id="GCU">GlaxoSmithKline Consumer Healthcare ULC</manufacturer><manufacturer id="GEB">Manufacturer name not currently available</manufacturer><manufacturer id="GED">GenDerm Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="GEI">Geigy Pharmaceuticals,Division of Ciba-Geigy Canada Ltd.</manufacturer><manufacturer id="GEM">Genmed, A Division of Pfizer Canada Inc.</manufacturer><manufacturer id="GEN">Genpharm Inc.</manufacturer><manufacturer id="GET">Genentech Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="GEZ">Genzyme - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="GIL">Gilead Sciences Canada, Inc.</manufacturer><manufacturer id="GLA">Glaxo Canada Inc.</manufacturer><manufacturer id="GLC">Glenwood Laboratories Canada Ltd. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="GLD">Glades, Division of Stiefel Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="GLE">Glenwood Laboratories Canada Ltd</manufacturer><manufacturer id="GLP">Glenmark Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="GLW">Glaxo Wellcome Inc.</manufacturer><manufacturer id="GMP">Generic Medical Partners Inc.</manufacturer><manufacturer id="GNT">Gentes and Bolduc Pharmaciens</manufacturer><manufacturer id="GPB">G Pohl Boskamp GMBH &amp; Co KG, hohenlockstedt</manufacturer><manufacturer id="GPE">Glenwood GmbH Pharmazeutische Erzeugnisse</manufacturer><manufacturer id="GPM">Manufacturer name not currently available</manufacturer><manufacturer id="GRA">Graceway Pharmaceuticals</manufacturer><manufacturer id="GRI">Grifols Therapeutics Inc.</manufacturer><manufacturer id="GSK">GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care</manufacturer><manufacturer id="GSS">GlaxoSmithKline Shire Biochem</manufacturer><manufacturer id="GWP">GW Pharma Limited</manufacturer><manufacturer id="GZM">Genzyme Canada Inc.</manufacturer><manufacturer id="HAL">Halewood Chemicals Limited</manufacturer><manufacturer id="HCI">Les Lab Charton, Division of Herdt &amp; Charton - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="HCM">Healthcomm International Inc. (S8)</manufacturer><manufacturer id="HEA">Healthpoint Canada</manufacturer><manufacturer id="HER">Manufacturer name not currently available</manufacturer><manufacturer id="HEY">HEYL Chemisch-pharmazeutische Fabrik GmbH &amp; Co. KG</manufacturer><manufacturer id="HIK">Hikma Canada Limited</manufacturer><manufacturer id="HIL">Hill Dermaceuticals Inc.</manufacturer><manufacturer id="HJS">H.J. Sutton Industries Ltd.</manufacturer><manufacturer id="HLL">Hollister Stier Laboratories LLC</manufacturer><manufacturer id="HLN">Haleon Canada ULC</manufacturer><manufacturer id="HLR">Hoffmann-La Roche Limited</manufacturer><manufacturer id="HLS">HLS Therapeutics Inc.</manufacturer><manufacturer id="HLZ">Manufacturer name not currently available</manufacturer><manufacturer id="HMR">Hoechst Marion Roussel Canada Inc.</manufacturer><manufacturer id="HOE">Hoechst Canada Inc.,Pharmaceutical Div.(Hoechst-Roussel Cana</manufacturer><manufacturer id="HOL">Manufacturer name not currently available</manufacturer><manufacturer id="HOM">Home Diagnostics Inc</manufacturer><manufacturer id="HOP">Hope Pharmaceuticals Ltd.</manufacturer><manufacturer id="HOR">Frank W. Horner Inc.</manufacturer><manufacturer id="HOS">Hospira Healthcare Corporation.</manufacturer><manufacturer id="HOZ">Horizon Therapeutics Ireland DC</manufacturer><manufacturer id="HPI">Horizon Pharma Ireland Ltd.</manufacturer><manufacturer id="HRA">HRA Pharma Rare Diseases</manufacturer><manufacturer id="HRU">Hoechst-Roussel Canada Inc.</manufacturer><manufacturer id="ICI">Manufacturer name not currently available</manufacturer><manufacturer id="ICN">ICN Canada Limited</manufacturer><manufacturer id="IDB">ID Biomedical Corporation of Quebec.</manufacturer><manufacturer id="IDL">Ideal Life Inc.</manufacturer><manufacturer id="IGN">Ignite Pharma Inc.</manufacturer><manufacturer id="IMM">Immunotech Research Ltd.</manufacturer><manufacturer id="IMU">Immunex Corporation</manufacturer><manufacturer id="INC">Incyte Corporation</manufacturer><manufacturer id="IND">Indivior UK Limited</manufacturer><manufacturer id="INF">Interfalk Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="INK">Manufacturer name not currently available</manufacturer><manufacturer id="INO">iNova Pharmaceuticals</manufacturer><manufacturer id="INP">Intercept Pharmaceuticals Inc.</manufacturer><manufacturer id="INR">Manufacturer name not currently available</manufacturer><manufacturer id="INS">InspiRx Inc.</manufacturer><manufacturer id="INT">InterMune Canada, Inc.</manufacturer><manufacturer id="IOB">Iolab Canada Inc.</manufacturer><manufacturer id="IOL">Manufacturer name not currently available</manufacturer><manufacturer id="IPB">Ipsen Biopharmaceuticals Canada Inc.</manufacturer><manufacturer id="IPC">Insight Pharmaceuticals Corporation</manufacturer><manufacturer id="IPL">Insight Pharmaceuticals, LLC</manufacturer><manufacturer id="IPS">Ipsen Limited</manufacturer><manufacturer id="ISE">I-Sens, Inc.</manufacturer><manufacturer id="IVA">Ivax Laboratories Incorporated</manufacturer><manufacturer id="JAC">Jacobus Pharmaceutical Company Inc.</manufacturer><manufacturer id="JAJ">Johnson &amp; Johnson Inc</manufacturer><manufacturer id="JAM">Jamieson Laboratories Ltd.</manufacturer><manufacturer id="JAN">Janssen Inc.</manufacturer><manufacturer id="JAS">Manufacturer name not currently available</manufacturer><manufacturer id="JAZ">Jazz Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="JFO">Chiron Canada ULC (S8)</manufacturer><manufacturer id="JHP">JHP Pharmaceuticals LLC</manufacturer><manufacturer id="JNO">Janssen-Ortho Inc.</manufacturer><manufacturer id="JOU">Jouveinal Inc.</manufacturer><manufacturer id="JPC">Jamp Pharma Corporation</manufacturer><manufacturer id="JUN">Juno Pharmaceuticals Corp.</manufacturer><manufacturer id="KAL">Kaleo Inc.</manufacturer><manufacturer id="KAP">Kabi Pharmacia</manufacturer><manufacturer id="KEY">Key Pharmaceuticals,Div.of Schering Canada Inc.</manufacturer><manufacturer id="KGW">Manufacturer name not currently available</manufacturer><manufacturer id="KNL">Knoll Pharma Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="KNO">Knoll Pharma Inc.</manufacturer><manufacturer id="KNR">Kenral Inc.,Division of The Upjohn Company of Canada</manufacturer><manufacturer id="KNT">Knight Therapeutics Inc.</manufacturer><manufacturer id="KUC">Kremers-Urban (Canada) - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="KUR">Manufacturer name not currently available</manufacturer><manufacturer id="KVR">KVR Pharmaceuticals</manufacturer><manufacturer id="KYE">KYE Pharmaceuticals Inc.</manufacturer><manufacturer id="KYK">Kyowa Kirin Limited</manufacturer><manufacturer id="KYO">Kyowa Kirin, Inc.</manufacturer><manufacturer id="LAA">Laboratoire Atlas Inc.</manufacturer><manufacturer id="LAB">Labopharm Inc.</manufacturer><manufacturer id="LAF">Laboratoires Fournier S.A.</manufacturer><manufacturer id="LAT">Laboratoires Trianon Inc.</manufacturer><manufacturer id="LBI">Leadiant Biosciences, Inc.</manufacturer><manufacturer id="LBT">Laboratoires Thea</manufacturer><manufacturer id="LDA">Leda Health Innovations Inc.</manufacturer><manufacturer id="LEA">Lee-Adams Lab.</manufacturer><manufacturer id="LED">Lederle Division-of Cyanamid Canada Inc.</manufacturer><manufacturer id="LEO">Leo Pharma Inc.</manufacturer><manufacturer id="LIF">Lifescan Canada Ltd.</manufacturer><manufacturer id="LIL">Eli Lilly Canada Inc.</manufacturer><manufacturer id="LIN">Linepharma International Limited</manufacturer><manufacturer id="LIO">LIOH Inc.</manufacturer><manufacturer id="LIP">The Liposome Company Inc. (S8)</manufacturer><manufacturer id="LON">Linson Pharma Inc.</manufacturer><manufacturer id="LOX">Loxo Oncology, Inc.</manufacturer><manufacturer id="LUI">Luitpold Pharmaceuticals Inc.</manufacturer><manufacturer id="LUN">Lundbeck Inc.</manufacturer><manufacturer id="LUP">Lupin Pharma Canada Limited</manufacturer><manufacturer id="LYP">Manufacturer name not currently available</manufacturer><manufacturer id="MAB">Meda AB</manufacturer><manufacturer id="MAL">Mallinckrodt Canada ULC</manufacturer><manufacturer id="MAN">Paul Maney Labs., Division of Canapharm Ind. Inc.</manufacturer><manufacturer id="MAR">Marcan Pharmaceuticals Inc.</manufacturer><manufacturer id="MAT">Mantra Pharma Inc.</manufacturer><manufacturer id="MAY">Mayne Pharma (Canada) Inc.</manufacturer><manufacturer id="MCG">Medicago Inc.</manufacturer><manufacturer id="MCL">McNeil Consumer Products Co.</manufacturer><manufacturer id="MCN">Manufacturer name not currently available</manufacturer><manufacturer id="MDA">Manufacturer name not currently available</manufacturer><manufacturer id="MDF">Medfhar Inc.</manufacturer><manufacturer id="MDI">MDA Inc.</manufacturer><manufacturer id="MDK">Medunik Canada</manufacturer><manufacturer id="MDO">Manufacturer name not currently available</manufacturer><manufacturer id="MDP">Manufacturer name not currently available</manufacturer><manufacturer id="MDX">Medexus Inc.</manufacturer><manufacturer id="MEA">Meta Pharmaceuticals Inc.</manufacturer><manufacturer id="MEC">Medicis Canada Ltd.</manufacturer><manufacturer id="MED">Medisense Canada Inc.</manufacturer><manufacturer id="MEF">Medical Futures Inc.</manufacturer><manufacturer id="MEH">MediHub International Inc., Ajax</manufacturer><manufacturer id="MEI">Medican Pharma</manufacturer><manufacturer id="MEK">Merck Canada Inc.</manufacturer><manufacturer id="MEL">MeliaPharm Inc.</manufacturer><manufacturer id="MEM">Medical Mart Supplies - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="MEN">Mendelikabs Inc.</manufacturer><manufacturer id="MEP">MedTech Products Inc.</manufacturer><manufacturer id="MER">Merrell Dow Pharmaceuticals (Canada) Inc.</manufacturer><manufacturer id="MET">Medican Technologies Inc.</manufacturer><manufacturer id="MEU">Merus Labs Inc.</manufacturer><manufacturer id="MEV">Meda Valeant Pharma Canada Inc.</manufacturer><manufacturer id="MEZ">Merz Pharmaceutical Gmbh</manufacturer><manufacturer id="MFC">Merck Frosst Canada Ltd.</manufacturer><manufacturer id="MFS">Merck Frosst/Schering Pharma GP</manufacturer><manufacturer id="MGI">MGI Pharma Inc.</manufacturer><manufacturer id="MIB">Mitsubishi Tanabe Pharma Corporation</manufacturer><manufacturer id="MIN">Mint Pharmaceuticals Inc.</manufacturer><manufacturer id="MIP">Miles Canada Inc Pharmaceutical Division - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="MIS">Miles Canada Inc.Diagnostic Division - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="MIT">Miles Canada Inc., Pharmaceuticals Division</manufacturer><manufacturer id="MJC">Mead Johnson &amp; Company LLC</manufacturer><manufacturer id="MJN">Mead Johnson Nutritionals</manufacturer><manufacturer id="MJO">Manufacturer name not currently available</manufacturer><manufacturer id="MJS">Mead Johnson Canada</manufacturer><manufacturer id="MMH">3M Pharmaceuticals, Division 3M Canada Inc.</manufacturer><manufacturer id="MMT">MM Therapeutics Inc.</manufacturer><manufacturer id="MMZ">Medical Mart Supplies Ltd</manufacturer><manufacturer id="MOB">Moderna Biopharma Canadian Corporation</manufacturer><manufacturer id="MOD">Moderna Therapeutics Inc.</manufacturer><manufacturer id="MOG">Med-O-Gen Medical Inc.</manufacturer><manufacturer id="MPC">Mission Pharmacal Company</manufacturer><manufacturer id="MPH">Mayne Pharma (Canada) Inc.  (S8)</manufacturer><manufacturer id="MPI">Medexus Pharmaceuticals Inc.</manufacturer><manufacturer id="MPU">Merit Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="MRR">Marion Merrell Dow Canada</manufacturer><manufacturer id="MSD">Merck Sharp &amp; Dohme Canada, Division of Merck Frosst Canada</manufacturer><manufacturer id="MYL">Mylan Pharmaceuticals ULC</manufacturer><manufacturer id="MYS">Mylan Specialty LP</manufacturer><manufacturer id="NAM">Manufacturer name not currently available</manufacturer><manufacturer id="NAT">Natco Pharma (Canada) Inc.</manufacturer><manufacturer id="NDA">Nadeau Laboratory Ltd.</manufacturer><manufacturer id="NEC">Nestle Canada Inc.</manufacturer><manufacturer id="NEO">Manufacturer name not currently available</manufacturer><manufacturer id="NEP">Nephro-Tech, Inc. (S8)</manufacturer><manufacturer id="NES">Nestle Health Science</manufacturer><manufacturer id="NEU">Neuraxpharm Arzneimittel GmbH</manufacturer><manufacturer id="NGP">Next Generation Pharma Inc.</manufacturer><manufacturer id="NOA">Novartis Vaccines And Diagnostics Inc.</manufacturer><manufacturer id="NOB">Nova Biomedical Corporation.</manufacturer><manufacturer id="NON">Novartis Nutrition Corporation</manufacturer><manufacturer id="NOO">Novo Nordisk Canada Inc</manufacturer><manufacturer id="NOP">Novopharm Ltd.</manufacturer><manufacturer id="NOV">Novartis Pharma Canada Inc.</manufacturer><manufacturer id="NOW">Manufacturer name not currently available</manufacturer><manufacturer id="NPI">Nutravite Pharmaceuticals Inc.</manufacturer><manufacturer id="NPS">NPS Pharma Holding Limited.</manufacturer><manufacturer id="NRA">Nora Pharma</manufacturer><manufacturer id="NRD">Nordic Laboratories Inc., Marion Merrell Dow (Canada) Inc.</manufacturer><manufacturer id="NSA">Nestle Enterprises S.A.</manufacturer><manufacturer id="NTP">NT Pharma Canada Ltd</manufacturer><manufacturer id="NUT">Nutricia North America</manufacturer><manufacturer id="NVV">Novavax Inc.</manufacturer><manufacturer id="NXP">Nu-Pharm Inc.</manufacturer><manufacturer id="NYC">Nycomed Canada Inc.</manufacturer><manufacturer id="OCI">Organon Canada Inc.</manufacturer><manufacturer id="OCU">Manufacturer name not currently available</manufacturer><manufacturer id="ODN">Odan Laboratories Ltd.</manufacturer><manufacturer id="OGN">Organon Teknika Canada Inc</manufacturer><manufacturer id="OGS">Organon Sanofi-Synthelabo Canada</manufacturer><manufacturer id="OMC">Ortho McNeil</manufacturer><manufacturer id="OMG">Omega Laboratories Ltd.</manufacturer><manufacturer id="OPI">OptimaPharma, a Division of Taro Pharmaceuticals Inc.</manufacturer><manufacturer id="OPS">OPI S.A.</manufacturer><manufacturer id="OPT">Optimer Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="ORC">Orchid Healthcare</manufacturer><manufacturer id="ORG">Organon Canada Ltd./Ltee</manufacturer><manufacturer id="ORI">Orimed Pharma</manufacturer><manufacturer id="ORP">Orphan Medical Inc.  (S8)</manufacturer><manufacturer id="ORT">Manufacturer name not currently available</manufacturer><manufacturer id="ORY">Oryx Pharmaceuticals Inc.</manufacturer><manufacturer id="OTK">Organon Teknika Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="OTS">Otsuka Pharmaceutical Co. Ltd.</manufacturer><manufacturer id="OVA">Ovation Pharmaceuticals Inc.</manufacturer><manufacturer id="PAL">Paladin Labs Inc.</manufacturer><manufacturer id="PAP">PAR Pharmaceutical</manufacturer><manufacturer id="PAR">Patriot, A Division of Janssen Inc.</manufacturer><manufacturer id="PAT">Pathogenesis Canada Ltd.</manufacturer><manufacturer id="PBN">Pharmalab (1982) Inc.  (S8)</manufacturer><manufacturer id="PCO">Manufacturer name not currently available</manufacturer><manufacturer id="PDA">Parke-Davis,Division Warner-Lambert Canada Inc.</manufacturer><manufacturer id="PDL">Pro Doc Laboratories - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="PED">Pediapharm Licensing Inc.</manufacturer><manufacturer id="PEN">Pendopharm, Division of Pharmascience Inc.</manufacturer><manufacturer id="PER">Perrigo International</manufacturer><manufacturer id="PFC">Pfizer Consumer Healthcare</manufacturer><manufacturer id="PFD">Pierre Fabre Dermo-Cosmetique Canada Inc.</manufacturer><manufacturer id="PFI">Pfizer Canada Inc.</manufacturer><manufacturer id="PFP">Purdue Pharma</manufacturer><manufacturer id="PFR">Purdue Frederick Inc.</manufacturer><manufacturer id="PGI">Proctor &amp; Gamble Inc.</manufacturer><manufacturer id="PGO">PanGeo Pharma (Canada) Inc.</manufacturer><manufacturer id="PGP">Proctor &amp; Gamble Pharmaceuticals Canada, Inc.</manufacturer><manufacturer id="PHA">Pharmacia Canada Inc.</manufacturer><manufacturer id="PHB">Phebra Canada</manufacturer><manufacturer id="PHC">Pharmacosmos A/S</manufacturer><manufacturer id="PHD">Manufacturer name not currently available</manufacturer><manufacturer id="PHE">Pharmel Inc.</manufacturer><manufacturer id="PHG">pharmaand GmbH</manufacturer><manufacturer id="PHI">Pharmetics (2011) Inc.</manufacturer><manufacturer id="PHO">Pharmaco Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="PHP">Pharmapar Inc.</manufacturer><manufacturer id="PHR">Pharmaco Canada Inc</manufacturer><manufacturer id="PHS">Pharma Stulln Inc.</manufacturer><manufacturer id="PMJ">Pharmacia &amp; Upjohn</manufacturer><manufacturer id="PMS">Pharmascience Inc.</manufacturer><manufacturer id="PMT">Pharmetics Inc.  (S8)</manufacturer><manufacturer id="PMV">Pharmavite Lab. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="POU">Manufacturer name not currently available</manufacturer><manufacturer id="PPC">Pharmaceutical Partners of Canada</manufacturer><manufacturer id="PPI">Paladin Pharma Inc.</manufacturer><manufacturer id="PRD">Pro Doc Limitee</manufacturer><manufacturer id="PRE">Prempharm Inc.</manufacturer><manufacturer id="PRO">Proval Pharma Inc.</manufacturer><manufacturer id="PRZ">Pharmaris Canada Inc.</manufacturer><manufacturer id="PVR">Pharmavite Corporation</manufacturer><manufacturer id="PWC">Manufacturer name not currently available</manufacturer><manufacturer id="QHP">Quality Home Products, a division of H.J. Sutton Ind. Ltd.</manufacturer><manufacturer id="QUO">Questcor Operations Ltd.</manufacturer><manufacturer id="QVS">Quest Vitamins, Division of Pangeo Health Brands Inc. (S8)</manufacturer><manufacturer id="RAI">Ratiopharm Inc.  (DO NOT USE)</manufacturer><manufacturer id="RAN">Ranbaxy Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="RBP">RB Pharmaceuticals Ltd.</manufacturer><manufacturer id="RBT">Roberts Pharmaceutical of Canada Inc.</manufacturer><manufacturer id="RCA">Reed &amp; Carnrick,Division of Block Drug Company (Canada) Ltd.</manufacturer><manufacturer id="RCH">Roche Diabetes Care GmbH</manufacturer><manufacturer id="RDC">Reddy-Cheminor Inc.</manufacturer><manufacturer id="REC">Recordati Rare Diseases Inc.</manufacturer><manufacturer id="REK">Rekah Pharmaceuticals Industry Ltd.</manufacturer><manufacturer id="RHO">Rhoxalpharma Inc.</manufacturer><manufacturer id="RHP">Rhodiapharm Inc.</manufacturer><manufacturer id="RHY">Rhythm Pharmaceuticals Inc.</manufacturer><manufacturer id="RIA">Laboratoire Riva Inc.</manufacturer><manufacturer id="RIC">Richmond Pharmaceuticals Inc.</manufacturer><manufacturer id="RIK">Manufacturer name not currently available</manufacturer><manufacturer id="RIP">Richmond Pharmaceuticals Inc.</manufacturer><manufacturer id="RIV">Rivex Pharma Inc.</manufacturer><manufacturer id="ROB">Manufacturer name not currently available</manufacturer><manufacturer id="ROC">Manufacturer Name currently not available</manufacturer><manufacturer id="ROD">Roche Diagnostics, a division of Hoffmann-La Roche Limited</manufacturer><manufacturer id="ROG">Rougier Pharma, Division of Ratiopharm Inc.</manufacturer><manufacturer id="ROM">Romark Laboratories</manufacturer><manufacturer id="ROP">Roberts Pharmaceutical - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="ROR">Rhone-Poulenc Rorer Consumer Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="ROS">Ross Laboratories-Abbott (Nutritional Products)</manufacturer><manufacturer id="ROU">Roussel Canada Inc.(Hoechst-Roussel Canada Inc.)</manufacturer><manufacturer id="ROY">C. A. Roy Limited - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="RPH">Ratiopharm Inc.</manufacturer><manufacturer id="RPP">Rhone-Poulenc Rorer-Ethical Division</manufacturer><manufacturer id="RPR">Rhone-Poulenc Rorer Consumer Inc.</manufacturer><manufacturer id="RRD">Respironics Respiratory Drug Delivery (UK) Ltd.</manufacturer><manufacturer id="SAB">Sabex Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="SAC">Sanofi-Aventis Canada Inc.</manufacturer><manufacturer id="SAE">Savient Pharmaceuticals Inc.</manufacturer><manufacturer id="SAF">Sanofi Pasteur Limited.</manufacturer><manufacturer id="SAG">Sanofi Genzyme, a Division of Sanofi-Aventis Canada Inc.</manufacturer><manufacturer id="SAI">Sanis Health Inc.</manufacturer><manufacturer id="SAL">Salix Pharmaceuticals Inc.</manufacturer><manufacturer id="SAM">Samsung Bioepis Co. Ltd</manufacturer><manufacturer id="SAN">Sandoz Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="SAO">Sanofi Canada Inc.</manufacturer><manufacturer id="SAS">Sanofi - Synthelabo Canada Inc.</manufacturer><manufacturer id="SAT">Santen Inc.</manufacturer><manufacturer id="SAV">Sanofi Aventis Pharma</manufacturer><manufacturer id="SAW">Sanofi Winthrop - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="SBI">Shire BioChem Inc.</manufacturer><manufacturer id="SBP">STIEFFEL BCD PHARMA</manufacturer><manufacturer id="SCC">Manufacturer name not currently available</manufacturer><manufacturer id="SCE">Schein Pharmaceutical</manufacturer><manufacturer id="SCH">Schering Canada Inc.</manufacturer><manufacturer id="SCJ">Manufacturer name not currently available</manufacturer><manufacturer id="SCK">Manufacturer name not currently available</manufacturer><manufacturer id="SCO">Sanofi Consumer Health Inc.</manufacturer><manufacturer id="SCP">Schering-Plough Canada Inc.</manufacturer><manufacturer id="SDM">Shoppers Drug Mart</manufacturer><manufacturer id="SDR">Stanley Pharmaceuticals Ltd.</manufacturer><manufacturer id="SDZ">Sandoz Canada Inc.</manufacturer><manufacturer id="SEA">Searle Canada Inc.</manufacturer><manufacturer id="SEF">Seaford Pharmaceuticals Inc</manufacturer><manufacturer id="SEG">Seattle Generics Inc.</manufacturer><manufacturer id="SEP">Sepracor Pharmaceuticals Inc.</manufacturer><manufacturer id="SEQ">Seqirus PTY LTD.</manufacturer><manufacturer id="SER">Manufacturer name not currently available</manufacturer><manufacturer id="SET">Septa Pharmaceuticals Inc.</manufacturer><manufacturer id="SEV">Servier Canada Inc.</manufacturer><manufacturer id="SGI">Seagen Inc.</manufacturer><manufacturer id="SHE">Shenzhen Techdow Pharmaceutical Co., Ltd.</manufacturer><manufacturer id="SHG">Shire Human Genetic Therapies Inc.</manufacturer><manufacturer id="SHI">Shire Pharma Canada ULC</manufacturer><manufacturer id="SHL">SHS International Ltd.</manufacturer><manufacturer id="SHM">Sherwood Inc.</manufacturer><manufacturer id="SHN">Shionogi Inc.</manufacturer><manufacturer id="SHS">SHS North America</manufacturer><manufacturer id="SIG">Sigma-Tau Pharmaceutical Inc.</manufacturer><manufacturer id="SIL">Sabex 2002 Inc</manufacturer><manufacturer id="SIV">Sivem Pharmaceuticals ULC</manufacturer><manufacturer id="SKB">SmithKline Beecham Consumer Healthcare.</manufacturer><manufacturer id="SKF">Seaford Pharmaceuticals Inc.  (S8)</manufacturer><manufacturer id="SKY">Skymed Corporation</manufacturer><manufacturer id="SLL">Manufacturer name not currently available</manufacturer><manufacturer id="SLO">Solvay Kingswood Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="SLP">Searchlight Pharma Inc.</manufacturer><manufacturer id="SMJ">Smith Kline Beecham Pharma Inc</manufacturer><manufacturer id="SMT">Sumitomo Pharma Canada INC.</manufacturer><manufacturer id="SNE">Smith &amp; Nephew Inc.</manufacturer><manufacturer id="SOL">Solvay Kingswood Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="SOR">Sorres Pharma Inc.</manufacturer><manufacturer id="SOT">Shire Orphan Therapies Inc.</manufacturer><manufacturer id="SPC">Sun Pharma</manufacturer><manufacturer id="SPG">Sun Pharma Global FZE</manufacturer><manufacturer id="SPH">Solvay Pharma Inc.</manufacturer><manufacturer id="SPI">Shire Pharmaceuticals Ireland Limited.</manufacturer><manufacturer id="SQI">Squire Pharmaceuticals Inc.</manufacturer><manufacturer id="SQU">Manufacturer name not currently available</manufacturer><manufacturer id="SRO">Serono Canada Inc.</manufacturer><manufacturer id="STA">Stason Pharmaceuticals Inc., Irvine</manufacturer><manufacturer id="STE">Sterimax Inc.</manufacturer><manufacturer id="STH">Sterling Health</manufacturer><manufacturer id="STI">Stiefel Canada Inc.</manufacturer><manufacturer id="STL">Stallergenes Canada Inc.</manufacturer><manufacturer id="STN">Sterinova Inc.</manufacturer><manufacturer id="STR">Strides Pharma Canada Inc.</manufacturer><manufacturer id="STW">Manufacturer name not currently available</manufacturer><manufacturer id="SUN">Sun Pharmaceutical Inc</manufacturer><manufacturer id="SUO">Sunovion Pharmaceuticals Canada Inc.</manufacturer><manufacturer id="SUP">Supplements Aromatik Inc.</manufacturer><manufacturer id="SWE">Swedish Orphan BioVitrum</manufacturer><manufacturer id="SWS">Swiss Herbal Remedies Ltd.</manufacturer><manufacturer id="SYN">Syntex Inc.</manufacturer><manufacturer id="SYP">SynCare Pharmaceutical Inc.</manufacturer><manufacturer id="TAH">Taiho Pharma Canada Inc.</manufacturer><manufacturer id="TAI">Taidoc Technology Corporation</manufacturer><manufacturer id="TAK">Takeda Canada Inc.</manufacturer><manufacturer id="TAN">Tanta Pharmaceutical Co.</manufacturer><manufacturer id="TAP">TAP Pharmaceuticals</manufacturer><manufacturer id="TAR">Taro Pharmaceuticals Inc.</manufacturer><manufacturer id="TAV">Tanvex BioPharma USA, Inc.</manufacturer><manufacturer id="TBP">Teva Branded Pharmaceutical Products R&amp;D Inc.</manufacturer><manufacturer id="TCD">Trans Canaderm Inc.</manufacturer><manufacturer id="TCH">Technilab Inc.</manufacturer><manufacturer id="TCI">Teligent Canada Inc.</manufacturer><manufacturer id="TEI">Teva Canada Innovation.</manufacturer><manufacturer id="TEL">Teligent OU</manufacturer><manufacturer id="TEP">Teligent Pharma Inc.</manufacturer><manufacturer id="TER">Therasense Canada Inc.</manufacturer><manufacturer id="TEV">Teva Canada Limited</manufacturer><manufacturer id="TEW">Teva Women&apos;s Health Inc.</manufacturer><manufacturer id="THE">Theramed Corporation</manufacturer><manufacturer id="THO">Thrombogenics NV</manufacturer><manufacturer id="THR">Thermor Ltd.</manufacturer><manufacturer id="TIC">Tican Pharmaceuticals Ltd.</manufacturer><manufacturer id="TIL">Tillomed Laboratories Ltd.</manufacturer><manufacturer id="TIP">Tillotts Pharma AG</manufacturer><manufacturer id="TKJ">TEVA Pharmaceutical Industries Ltd.</manufacturer><manufacturer id="TLI">Laboratory Trianon Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="TMI">Trudell Medical International</manufacturer><manufacturer id="TMP">3M Pharmaceuticals/3M Canada Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="TOL">Tolmar International Ltd.</manufacturer><manufacturer id="TPA">Takeda Pharmaceuticals America Inc.</manufacturer><manufacturer id="TPG">Tillotts Pharma GMBH:</manufacturer><manufacturer id="TPH">TaroPharma, a Division of Taro Pharmaceuticals Inc.</manufacturer><manufacturer id="TRA">Manufacturer name not currently available</manufacturer><manufacturer id="TRE">Tremblay Harrison Inc.</manufacturer><manufacturer id="TRI">Trillium Health Care Products Inc.</manufacturer><manufacturer id="TRO">Trophic Canada Ltd.</manufacturer><manufacturer id="TRS">TerSera Therapeutics LLC</manufacturer><manufacturer id="TRT">Triton Pharma Inc.</manufacturer><manufacturer id="UCB">UCB Canada Inc.</manufacturer><manufacturer id="UCY">Ucyclyd Pharma</manufacturer><manufacturer id="UJC">Upjohn Canada ULC</manufacturer><manufacturer id="ULT">Ultragenyx Pharmaceuticals Inc.</manufacturer><manufacturer id="UME">Unimed Canada Inc.</manufacturer><manufacturer id="UNV">Univar Ltd.</manufacturer><manufacturer id="UPJ">The Upjohn Company of Canada</manufacturer><manufacturer id="UPS">Manufacturer name not currently available</manufacturer><manufacturer id="USV">Manufacturer name not currently available</manufacturer><manufacturer id="UTC">United Therapeutics Corporation (S8)</manufacturer><manufacturer id="VAE">Valeo Pharma Inc.</manufacturer><manufacturer id="VAL">Valeant Canada Ltd.</manufacturer><manufacturer id="VAN">Vanc Pharmaceuticals Inc.</manufacturer><manufacturer id="VER">Vertex Pharmaceuticals (Canada) Inc.</manufacturer><manufacturer id="VET">Verity Pharmaceuticals Inc.</manufacturer><manufacturer id="VHL">Vita Health Products Inc. (S8)</manufacturer><manufacturer id="VIA">Viatris Canada</manufacturer><manufacturer id="VIF">Vifor Fresenius Medical Care Renal Pharma Ltd.</manufacturer><manufacturer id="VIH">ViiV Healthcare ULC</manufacturer><manufacturer id="VIP">Vita Health Products Inc.</manufacturer><manufacturer id="VIT">Vitaflo USA, LLC</manufacturer><manufacturer id="VIU">Vivus Inc.</manufacturer><manufacturer id="VIV">Viva Pharmaceuticals</manufacturer><manufacturer id="VLH">Lundbeck Canada Inc.</manufacturer><manufacturer id="VPI">VPI Pharmaceuticals Inc.</manufacturer><manufacturer id="VRO">Virco Pharmaceutical (Canada) Inc.</manufacturer><manufacturer id="WAB">Waymar Pharmaceuticals Inc.</manufacturer><manufacturer id="WAM">Manufacturer name not currently available</manufacturer><manufacturer id="WAP">Wampole</manufacturer><manufacturer id="WAR">Warner Chilcott Canada Co.</manufacturer><manufacturer id="WAT">Watson Laboratories Inc.</manufacturer><manufacturer id="WAY">Wyeth Pharmaceuticals</manufacturer><manufacturer id="WBP">Manufacturer name not currently available</manufacturer><manufacturer id="WCC">Women&apos;s Capital Corporation</manufacturer><manufacturer id="WEL">WellSpring Pharmaceutical Canada Corp.</manufacturer><manufacturer id="WHB">Whitehall-Robins Inc</manufacturer><manufacturer id="WHH">Manufacturer name not currently available</manufacturer><manufacturer id="WIN">Winthrop Laboratories</manufacturer><manufacturer id="WLA">Warner-Lambert - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="WLN">Manufacturer name not currently available</manufacturer><manufacturer id="WNP">WN Pharmaceuticals Ltd.</manufacturer><manufacturer id="WOC">Wockhardt UK Ltd.  (S8)</manufacturer><manufacturer id="WRI">Whitehall-Robins Inc. - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="WSD">Manufacturer name not currently available</manufacturer><manufacturer id="WSQ">Westwood Squibb Pharmaceuticals</manufacturer><manufacturer id="WTR">Westcan Pharmaceuticals - &quot;DO NOT USE&quot;</manufacturer><manufacturer id="WYA">Wyeth-Ayerst Canada Inc.</manufacturer><manufacturer id="WYE">Wyeth Ltd.</manufacturer><manufacturer id="WYM">Waymade PLC</manufacturer><manufacturer id="XED">Xediton Pharmaceuticals Inc.</manufacturer><manufacturer id="XEN">Xenex Laboratories Inc.</manufacturer><manufacturer id="XXX">Manufacturer cannot be identified</manufacturer><manufacturer id="YNO">Baxter AG (S8)</manufacturer><manufacturer id="YYY">Manufacturer for Gov&apos;t Pharmacy Items</manufacturer><manufacturer id="ZEN">Zeneca Pharma Inc.</manufacturer><manufacturer id="ZIL">Zila Pharmaceuticals Inc.</manufacturer><manufacturer id="ZOG">Zogenix, Inc.</manufacturer><manufacturer id="ZRP">ZR Pharma &amp; GMBH</manufacturer><manufacturer id="ZYN">Zymcan Pharmaceuticals Inc.</manufacturer></manufacturerList><formulary edition="4343" updateVer="L" formularyDate="2025-11-28" createDate="2025-11-25"><pcg2 id="040000000"><name>ANTIHISTAMINES</name><pcg6><genericName id="02412"><name>BILASTINE</name><pcgGroup><pcg9 id="040000089"><itemNumber>0001</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02454130" notABenefit="Y" sec3b="Y" sec3="Y"><name>Blexten</name><manufacturerId>ARZ</manufacturerId><listingDate>2024-12-30</listingDate></drug><drug id="02536269" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Bilastine</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1240</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02541556" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Bilastine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1229</individualPrice><listingDate>2025-01-31</listingDate></drug><drug id="02544369" notABenefit="Y" sec3b="Y" sec3="Y"><name>GLN-Bilastine</name><manufacturerId>GLP</manufacturerId><individualPrice>1.1243</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02546795" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Bilastine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1240</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02547279" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Bilastine</name><manufacturerId>MAR</manufacturerId><individualPrice>1.1240</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02548410" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Bilastine</name><manufacturerId>MAT</manufacturerId><individualPrice>1.1240</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02549883" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Bilastine Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>1.1240</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02551934" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Bilastine</name><manufacturerId>NRA</manufacturerId><individualPrice>1.1243</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00005"><name>CETIRIZINE HYDROCHLORIDE</name><pcgGroup><pcg9 id="040000086"><itemNumber>0002</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02223554" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reactine</name><manufacturerId>MCL</manufacturerId><listingDate>2007-12-19</listingDate></drug><drug id="02231603" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Cetirizine</name><manufacturerId>APX</manufacturerId><individualPrice>.4083</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02315955" notABenefit="Y" sec3b="Y" sec3="Y"><name>Extra Strength Allergy Relief</name><manufacturerId>PMS</manufacturerId><individualPrice>.3938</individualPrice><listingDate>2009-11-13</listingDate></drug><drug id="02427133" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Cetirizine</name><manufacturerId>MAR</manufacturerId><individualPrice>.4083</individualPrice><listingDate>2014-10-29</listingDate></drug><drug id="02451778" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Cetirizine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4083</individualPrice><listingDate>2016-08-30</listingDate></drug><drug id="02496461" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Cetirizine</name><manufacturerId>NAT</manufacturerId><individualPrice>.4083</individualPrice><listingDate>2020-05-29</listingDate></drug><drug id="02517566" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Cetirizine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4083</individualPrice><listingDate>2022-07-29</listingDate></drug></pcg9><pcg9 id="040000087"><itemNumber>0003</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="01900978" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reactine</name><manufacturerId>MCL</manufacturerId><listingDate>2008-12-23</listingDate></drug><drug id="02315963" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Cetirizine</name><manufacturerId>PMS</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2008-12-23</listingDate></drug><drug id="02427141" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Cetirizine</name><manufacturerId>MAR</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2014-10-29</listingDate></drug><drug id="02453363" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Cetirizine</name><manufacturerId>APX</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2016-06-29</listingDate></drug><drug id="02466171" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Cetirizine</name><manufacturerId>JPC</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2017-10-30</listingDate></drug><drug id="02491125" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Cetirizine</name><manufacturerId>MIN</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2020-02-28</listingDate></drug><drug id="02496488" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Cetirizine</name><manufacturerId>NAT</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2020-05-29</listingDate></drug><drug id="02512025" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Cetirizine</name><manufacturerId>MAT</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2021-11-30</listingDate></drug><drug id="02515695" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cetirizine</name><manufacturerId>SAI</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2021-07-30</listingDate></drug><drug id="02517353" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Cetirizine Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02521806" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Cetirizine</name><manufacturerId>NRA</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02528681" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Cetirizine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2022-11-30</listingDate></drug><drug id="02530236" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Cetirizine Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2023-05-31</listingDate></drug><drug id="02534126" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cetirizine</name><manufacturerId>SIV</manufacturerId><individualPrice>.7535</individualPrice><listingDate>2023-09-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00015"><name>LORATADINE</name><pcgGroup><pcg9 id="040000061"><itemNumber>0004</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00782696" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Claritin</name><manufacturerId>SCP</manufacturerId><listingDate>2007-12-19</listingDate></drug><drug id="02243880" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Loratadine</name><manufacturerId>APX</manufacturerId><individualPrice>.6267</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.6267</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02416"><name>RUPATADINE</name><pcgGroup><pcg9 id="040000090"><itemNumber>0005</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02456451" notABenefit="Y" sec3b="Y" sec3="Y"><name>Rupall</name><manufacturerId>MPI</manufacturerId><listingDate>2025-03-31</listingDate></drug><drug id="02552604" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Rupatadine</name><manufacturerId>PMS</manufacturerId><individualPrice>.9993</individualPrice><listingDate>2025-03-31</listingDate></drug><drug id="02553155" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Rupatadine</name><manufacturerId>APX</manufacturerId><individualPrice>.9993</individualPrice><listingDate>2025-03-31</listingDate></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="080000000"><name>ANTI-INFECTIVE AGENTS</name><pcg6 id="080800000"><name>ANTHELMINTICS</name><genericName id="00021"><name>MEBENDAZOLE</name><pcgGroup><pcg9 id="080800013"><itemNumber>0006</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00556734" sec3="Y"><name>Vermox</name><manufacturerId>JAN</manufacturerId><individualPrice>10.3400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>10.3400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081204000"><name>ANTIBIOTICS ANTIFUNGALS</name><genericName id="00023"><name>AMPHOTERICIN B</name><pcgGroup><pcg9 id="081204001"><itemNumber>0007</itemNumber><dosageForm>Inj Pd-50mg Pk</dosageForm><drug id="00029149" sec3="Y"><name>Fungizone</name><manufacturerId>CHE</manufacturerId><individualPrice>102.0109</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>102.0109</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01604"><name>CASPOFUNGIN ACETATE</name><pcgGroup><pcg9 id="081204027"><itemNumber>0008</itemNumber><strength>50mg/Vial</strength><dosageForm>Inj-Vial Pk</dosageForm><drug id="02244265" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cancidas</name><manufacturerId>FRS</manufacturerId><listingDate>2017-08-30</listingDate></drug><drug id="02460947" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Caspofungin for Injection</name><manufacturerId>JUN</manufacturerId><individualPrice>222.0000</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>222.0000</amountMOHLTCPays></drug><drug id="02486989" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Caspofungin for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>222.5000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>222.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00032"><name>FLUCONAZOLE</name><pcgGroup lccId="00001"><pcg9 id="081204025"><itemNumber>0009</itemNumber><strength>10mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02024152" sec3="Y" sec12="Y"><name>Diflucan P.O.S.</name><manufacturerId>PFI</manufacturerId><individualPrice>1.3654</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.3654</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="528">For patients who are unable to swallow or tolerate solid oral dosage forms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00002"><pcg9 id="081204023"><itemNumber>0010</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>2.5808</dailyCost><drug id="00891800" notABenefit="Y" sec3="Y"><name>Diflucan</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02236978" sec3="Y"><name>Teva-Fluconazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>2003-04-16</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug><drug id="02237370" sec3="Y"><name>Apo-Fluconazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>1999-09-15</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug><drug id="02245292" sec3="Y"><name>Mylan-Fluconazole</name><manufacturerId>MYL</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>2003-04-16</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug><drug id="02245643" sec3="Y"><name>PMS-Fluconazole</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>2003-01-30</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug><drug id="02281260" sec3="Y"><name>Act Fluconazole</name><manufacturerId>ACV</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug><drug id="02517396" sec3="Y"><name>Fluconazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug><drug id="02534886" sec3="Y"><name>Fluconazole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.2904</individualPrice><dailyCost>2.5808</dailyCost><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.2904</amountMOHLTCPays></drug></pcg9><pcg9 id="081204024"><itemNumber>0011</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>2.2891</dailyCost><drug id="00891819" notABenefit="Y" sec3="Y"><name>Diflucan</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02236979" sec3="Y"><name>Teva-Fluconazole</name><manufacturerId>TEV</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>2003-04-16</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug><drug id="02237371" sec3="Y"><name>Apo-Fluconazole</name><manufacturerId>APX</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>1999-09-15</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug><drug id="02245293" sec3="Y"><name>Mylan-Fluconazole</name><manufacturerId>MYL</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>2003-04-16</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug><drug id="02245644" sec3="Y"><name>PMS-Fluconazole</name><manufacturerId>PMS</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>2003-01-30</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug><drug id="02281279" sec3="Y"><name>Act Fluconazole</name><manufacturerId>ACV</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>2008-01-15</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug><drug id="02517418" sec3="Y"><name>Fluconazole</name><manufacturerId>SAI</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>2022-03-31</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug><drug id="02534894" sec3="Y"><name>Fluconazole</name><manufacturerId>SIV</manufacturerId><individualPrice>2.2891</individualPrice><dailyCost>2.2891</dailyCost><listingDate>2023-12-29</listingDate><amountMOHLTCPays>2.2891</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00031"><name>ITRACONAZOLE</name><pcgGroup><pcg9 id="081204040"><itemNumber>0012</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02047454" sec3="Y"><name>Sporanox</name><manufacturerId>JAN</manufacturerId><individualPrice>6.6750</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.9270</amountMOHLTCPays></drug><drug id="02462559" sec3="Y"><name>Mint-Itraconazole</name><manufacturerId>MIN</manufacturerId><individualPrice>3.9270</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>3.9270</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00327"><pcg9 id="081204043"><itemNumber>0013</itemNumber><strength>10mg/mL</strength><dosageForm>Oral Sol</dosageForm><drug id="02231347" notABenefit="Y" sec3="Y"><name>Sporanox</name><manufacturerId>JAN</manufacturerId><listingDate>1998-12-31</listingDate></drug><drug id="02484315" sec3="Y" sec12="Y"><name>Jamp Itraconazole Oral Solution</name><manufacturerId>JPC</manufacturerId><individualPrice>.4111</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.4111</amountMOHLTCPays></drug><drug id="02495988" sec3="Y" sec12="Y"><name>Odan-Itraconazole</name><manufacturerId>ODN</manufacturerId><individualPrice>.4111</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.4111</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="570">For patients who are unable to swallow or tolerate solid oral dosage forms.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00027"><name>KETOCONAZOLE</name><pcgGroup><pcg9 id="081204010"><itemNumber>0014</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><dailyCost>.9393</dailyCost><drug id="00633836" notABenefit="Y" sec3="Y"><name>Nizoral</name><manufacturerId>JAN</manufacturerId><note>A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.</note><listingDate>1996-10-01</listingDate></drug><drug id="02231061" sec3="Y"><name>Teva-Ketoconazole</name><manufacturerId>TEV</manufacturerId><individualPrice>.9393</individualPrice><dailyCost>.9393</dailyCost><note>A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.</note><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.9393</amountMOHLTCPays></drug><drug id="02237235" sec3="Y"><name>Apo-Ketoconazole</name><manufacturerId>APX</manufacturerId><individualPrice>.9393</individualPrice><dailyCost>.9393</dailyCost><note>A low pH is necessary for absorption. Antacids, anticholinergics/antispasmodics, H2-blockers, and omeprazole may decrease absorption. Ketoconazole is a potent inhibitor of hepatic oxidation of drugs and may cause significant elevation of blood levels of astemizole, cisapride, cyclosporine, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of ketoconazole and astemizole, cisapride or terfenadine. Insulin requirements may be reduced. Hepatotoxicity occurs in approximately 1 in 1500 patients treated with ketoconazole for onychomycosis; female gender, pre-existing disease, alcoholism and greater than 2 weeks of therapy are pre-disposing factors.</note><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.9393</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01938"><name>MICAFUNGIN SODIUM</name><pcgGroup><pcg9 id="081204035"><itemNumber>0015</itemNumber><strength>50mg/Vial</strength><dosageForm>Inj Pd-10mL Vial Pk</dosageForm><drug id="02294222" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mycamine</name><manufacturerId>SDZ</manufacturerId><listingDate>2023-09-28</listingDate></drug><drug id="02524953" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Micafungin Sodium for Injection</name><manufacturerId>JUN</manufacturerId><individualPrice>93.1000</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>93.1000</amountMOHLTCPays></drug></pcg9><pcg9 id="081204036"><itemNumber>0016</itemNumber><strength>100mg/Vial</strength><dosageForm>Inj Pd-10mL Vial Pk</dosageForm><drug id="02311054" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mycamine</name><manufacturerId>SDZ</manufacturerId><listingDate>2023-09-28</listingDate></drug><drug id="02524961" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Micafungin Sodium for Injection</name><manufacturerId>JUN</manufacturerId><individualPrice>186.2000</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>186.2000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00025"><name>NYSTATIN</name><pcgGroup><pcg9 id="081204006"><itemNumber>0017</itemNumber><strength>100000U/mL</strength><dosageForm>O/L</dosageForm><dailyCost>.2072</dailyCost><drug id="00248169" notABenefit="Y" sec3="Y"><name>Mycostatin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02194201" sec3="Y"><name>Ratio-Nystatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.0518</individualPrice><dailyCost>.2072</dailyCost><listingDate>1997-10-31</listingDate><amountMOHLTCPays>.0518</amountMOHLTCPays></drug><drug id="02433443" sec3="Y"><name>Jamp-Nystatin Oral Suspension USP</name><manufacturerId>JPC</manufacturerId><individualPrice>.0518</individualPrice><dailyCost>.2072</dailyCost><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.0518</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01704"><name>POSACONAZOLE</name><pcgGroup><pcg9 id="081204038"><itemNumber>0018</itemNumber><strength>100mg</strength><dosageForm>DR Tab</dosageForm><drug id="02424622" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Posanol</name><manufacturerId>MEK</manufacturerId><individualPrice>53.7642</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>42.6030</amountMOHLTCPays></drug><drug id="02496259" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Posaconazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>42.6030</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>42.6030</amountMOHLTCPays></drug><drug id="02542021" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>GLN-Posaconazole</name><manufacturerId>GLP</manufacturerId><individualPrice>42.6030</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>42.6030</amountMOHLTCPays></drug><drug id="02543311" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Posaconazole</name><manufacturerId>TAR</manufacturerId><individualPrice>42.6030</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>42.6030</amountMOHLTCPays></drug><drug id="02544644" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Posaconazole</name><manufacturerId>MIN</manufacturerId><individualPrice>42.6030</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>42.6030</amountMOHLTCPays></drug></pcg9><pcg9 id="081204037"><itemNumber>0019</itemNumber><strength>40mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02293404" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Posanol</name><manufacturerId>SCP</manufacturerId><individualPrice>10.1801</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>8.2765</amountMOHLTCPays></drug><drug id="02530333" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Posaconazole</name><manufacturerId>JPC</manufacturerId><individualPrice>8.2765</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>8.2765</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00030"><name>TERBINAFINE HCL</name><pcgGroup><pcg9 id="081204016"><itemNumber>0020</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02031116" notABenefit="Y" sec3="Y"><name>Lamisil</name><manufacturerId>NOV</manufacturerId><listingDate>2007-12-19</listingDate></drug><drug id="02239893" sec3="Y"><name>Apo-Terbinafine</name><manufacturerId>APX</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug><drug id="02240346" sec3="Y"><name>Teva-Terbinafine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug><drug id="02254727" sec3="Y"><name>Co Terbinafine</name><manufacturerId>COB</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug><drug id="02294273" sec3="Y"><name>PMS-Terbinafine</name><manufacturerId>PMS</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug><drug id="02320134" sec3="Y"><name>Auro-Terbinafine</name><manufacturerId>AUR</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug><drug id="02353121" sec3="Y"><name>Terbinafine</name><manufacturerId>SAI</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug><drug id="02385279" sec3="Y"><name>Terbinafine</name><manufacturerId>SIV</manufacturerId><individualPrice>.7714</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.7714</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01634"><name>VORICONAZOLE</name><pcgGroup lccId="00165"><pcg9 id="081204029"><itemNumber>0021</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02256460" sec3="Y" sec12="Y"><name>Vfend</name><manufacturerId>PFI</manufacturerId><individualPrice>13.5635</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>6.7818</amountMOHLTCPays></drug><drug id="02399245" sec3="Y" sec12="Y"><name>Sandoz Voriconazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.7818</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>6.7818</amountMOHLTCPays></drug><drug id="02525771" sec3="Y" sec12="Y"><name>Jamp Voriconazole</name><manufacturerId>JPC</manufacturerId><individualPrice>6.7818</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>6.7818</amountMOHLTCPays></drug></pcg9><pcg9 id="081204030"><itemNumber>0022</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02256479" sec3="Y" sec12="Y"><name>Vfend</name><manufacturerId>PFI</manufacturerId><individualPrice>54.2323</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>26.4807</amountMOHLTCPays></drug><drug id="02399253" sec3="Y" sec12="Y"><name>Sandoz Voriconazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>26.4807</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>26.4807</amountMOHLTCPays></drug><drug id="02525798" sec3="Y" sec12="Y"><name>Jamp Voriconazole</name><manufacturerId>JPC</manufacturerId><individualPrice>26.4807</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>26.4807</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="399">Outpatient continuation of treatment for documented invasive aspergillosis in patients who have demonstrated a clinical response to either oral or parenteral voriconazole.

* The first prescription must be written by a physician based at the hospital where the patient was hospitalized.

Note: Limited to 3 months of reimbursement.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="081207000"><name>ANTIBIOTICS CARBAPENEMS</name><genericName id="01375"><name>MEROPENEM</name><pcgGroup><pcg9 id="081207003"><itemNumber>0023</itemNumber><strength>1g/Vial</strength><dosageForm>Pd for Inj Sol</dosageForm><drug id="02218496" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Merrem</name><manufacturerId>PFI</manufacturerId><listingDate>2021-04-30</listingDate></drug><drug id="02378795" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>47.9900</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>47.9900</amountMOHLTCPays></drug><drug id="02415224" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection, USP</name><manufacturerId>FKC</manufacturerId><individualPrice>47.9900</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>47.9900</amountMOHLTCPays></drug><drug id="02421526" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Meropenem</name><manufacturerId>SPC</manufacturerId><individualPrice>47.9900</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>47.9900</amountMOHLTCPays></drug><drug id="02493349" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>47.9900</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>47.9900</amountMOHLTCPays></drug><drug id="02536374" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection</name><manufacturerId>JPC</manufacturerId><individualPrice>47.9900</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>47.9900</amountMOHLTCPays></drug></pcg9><pcg9 id="081207002"><itemNumber>0024</itemNumber><strength>500mg/Vial</strength><dosageForm>Pd for Inj Sol</dosageForm><drug id="02218488" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Merrem</name><manufacturerId>PFI</manufacturerId><listingDate>2021-04-30</listingDate></drug><drug id="02378787" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>23.9950</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>23.9950</amountMOHLTCPays></drug><drug id="02415216" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection, USP</name><manufacturerId>FKC</manufacturerId><individualPrice>23.9950</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>23.9950</amountMOHLTCPays></drug><drug id="02421518" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Meropenem</name><manufacturerId>SPC</manufacturerId><individualPrice>23.9950</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>23.9950</amountMOHLTCPays></drug><drug id="02493330" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Meropenem for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>23.9950</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>23.9950</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081212000"><name>ANTIBIOTICS ERYTHROMYCINS</name><note>Erythromycin alone is not adequate for the treatment of H. influenzae infections. It lacks consistently reliable activity against this organism. Erythromycin is a potent inhibitor of hepatic oxidation of some drugs and may cause significant elevation of blood levels of astemizole, carbamazepine, cyclosporine, digoxin, dihydropyridines, terfenadine, theophylline and warfarin. Potentially fatal arrhythmias (torsade de pointes) can occur with the combination of erythromycin and astemizole or terfenadine.</note><genericName id="00040"><name>AZITHROMYCIN</name><pcgGroup><pcg9 id="081212025"><itemNumber>0025</itemNumber><strength>100mg/5mL</strength><dosageForm>O/L-15mL Pk</dosageForm><drug id="02223716" dinStatus="E" sec3="Y"><name>Zithromax</name><manufacturerId>PFI</manufacturerId><individualPrice>17.6415</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>8.8208</amountMOHLTCPays></drug><drug id="02332388" sec3="Y"><name>Sandoz Azithromycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>8.8208</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>8.8208</amountMOHLTCPays></drug><drug id="02482363" sec3="Y"><name>Auro-Azithromycin</name><manufacturerId>AUR</manufacturerId><individualPrice>8.8208</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>8.8208</amountMOHLTCPays></drug></pcg9><pcg9 id="081212026"><itemNumber>0026</itemNumber><strength>200mg/5mL</strength><dosageForm>O/L-15mL Pk</dosageForm><drug id="02223724" dinStatus="E" sec3="Y"><name>Zithromax</name><manufacturerId>PFI</manufacturerId><individualPrice>24.9885</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>12.4943</amountMOHLTCPays></drug><drug id="02332396" sec3="Y"><name>Sandoz Azithromycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>12.4943</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>12.4943</amountMOHLTCPays></drug><drug id="02482371" sec3="Y"><name>Auro-Azithromycin</name><manufacturerId>AUR</manufacturerId><individualPrice>12.4943</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>12.4943</amountMOHLTCPays></drug></pcg9><pcg9 id="081212036"><itemNumber>0027</itemNumber><strength>200mg/5mL</strength><dosageForm>O/L-22.5mL Pk</dosageForm><drug id="09857315" dinStatus="E" sec3="Y"><name>Zithromax</name><manufacturerId>PFI</manufacturerId><individualPrice>37.4828</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>18.7425</amountMOHLTCPays></drug><drug id="09857351" sec3="Y"><name>Sandoz Azithromycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>18.7425</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>18.7425</amountMOHLTCPays></drug><drug id="09857636" sec3="Y"><name>Auro-Azithromycin</name><manufacturerId>AUR</manufacturerId><individualPrice>18.7425</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>18.7425</amountMOHLTCPays></drug></pcg9><pcg9 id="081212041"><itemNumber>0028</itemNumber><strength>200mg/5mL</strength><dosageForm>O/L-37.5mL Pk</dosageForm><note>Zithromax 200mg/5mL oral solution is not commercially available in the 37.5mL pack size and it is only shown in this interchangeable category to facilitate the interchangeability designation with Auro-Azithromycin 200mg/5mL - 37.5mL pack.</note><drug id="09857637" notABenefit="Y" sec3="Y"><name>Zithromax</name><manufacturerId>PFI</manufacturerId><listingDate>2020-05-29</listingDate></drug><drug id="09857638" sec3="Y"><name>Auro-Azithromycin</name><manufacturerId>AUR</manufacturerId><individualPrice>31.2375</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>31.2375</amountMOHLTCPays></drug></pcg9><pcg9 id="081212029"><itemNumber>0029</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02212021" dinStatus="E" sec3="Y"><name>Zithromax</name><manufacturerId>PFI</manufacturerId><individualPrice>5.4382</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02247423" sec3="Y"><name>Apo-Azithromycin</name><manufacturerId>APX</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02261634" sec3="Y"><name>PMS-Azithromycin</name><manufacturerId>PMS</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02265826" sec3="Y"><name>Sandoz Azithromycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02267845" sec3="Y"><name>Novo-Azithromycin</name><manufacturerId>NOP</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02275309" sec3="Y"><name>Riva-Azithromycin</name><manufacturerId>RIA</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02330881" sec3="Y"><name>Azithromycin</name><manufacturerId>SAI</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02415542" sec3="Y"><name>Apo-Azithromycin Z</name><manufacturerId>APX</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02442434" sec3="Y"><name>Azithromycin</name><manufacturerId>SIV</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02452308" sec3="Y"><name>Jamp-Azithromycin</name><manufacturerId>JPC</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02452324" sec3="Y"><name>Mar-Azithromycin</name><manufacturerId>MAR</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02479680" sec3="Y"><name>NRA-Azithromycin</name><manufacturerId>NRA</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02480700" sec3="Y"><name>AG-Azithromycin</name><manufacturerId>ANG</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug><drug id="02502038" sec3="Y"><name>M-Azithromycin</name><manufacturerId>MAT</manufacturerId><individualPrice>.9410</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.9410</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00313"><pcg9 id="081212028"><itemNumber>0030</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02231143" notABenefit="Y" sec3="Y"><name>Zithromax</name><manufacturerId>PFI</manufacturerId><listingDate>1998-12-31</listingDate></drug><drug id="02261642" sec3="Y" sec12="Y"><name>PMS-Azithromycin</name><manufacturerId>PMS</manufacturerId><individualPrice>10.6652</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>10.6652</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="549">For the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infections.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00039"><name>CLARITHROMYCIN</name><pcgGroup><pcg9 id="081212032"><itemNumber>0031</itemNumber><strength>500mg</strength><dosageForm>ER Tab</dosageForm><dailyCost>2.5144</dailyCost><drug id="02244756" sec3="Y"><name>Biaxin XL</name><manufacturerId>BGP</manufacturerId><individualPrice>2.5672</individualPrice><dailyCost>5.1344</dailyCost><listingDate>2003-01-30</listingDate><amountMOHLTCPays>1.2572</amountMOHLTCPays></drug><drug id="02403196" sec3="Y"><name>Act Clarithromycin XL</name><manufacturerId>ACV</manufacturerId><individualPrice>1.2572</individualPrice><dailyCost>2.5144</dailyCost><listingDate>2014-12-18</listingDate><amountMOHLTCPays>1.2572</amountMOHLTCPays></drug><drug id="02413345" sec3="Y"><name>Apo-Clarithromycin XL</name><manufacturerId>APX</manufacturerId><individualPrice>1.2572</individualPrice><dailyCost>2.5144</dailyCost><listingDate>2014-10-29</listingDate><amountMOHLTCPays>1.2572</amountMOHLTCPays></drug></pcg9><pcg9 id="081212030"><itemNumber>0032</itemNumber><strength>125mg/5mL</strength><dosageForm>Ped Gran</dosageForm><dailyCost>2.3880</dailyCost><drug id="02146908" sec3="Y"><name>Biaxin</name><manufacturerId>BGP</manufacturerId><individualPrice>.3425</individualPrice><dailyCost>3.4250</dailyCost><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.2388</amountMOHLTCPays></drug><drug id="02390442" sec3="Y"><name>Taro-Clarithromycin</name><manufacturerId>TAR</manufacturerId><individualPrice>.2388</individualPrice><dailyCost>2.3880</dailyCost><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.2388</amountMOHLTCPays></drug></pcg9><pcg9 id="081212031"><itemNumber>0033</itemNumber><strength>250mg/5mL</strength><dosageForm>Susp</dosageForm><dailyCost>4.6850</dailyCost><drug id="02244641" sec3="Y"><name>Biaxin</name><manufacturerId>BGP</manufacturerId><individualPrice>.6718</individualPrice><dailyCost>6.7180</dailyCost><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02390450" sec3="Y"><name>Taro-Clarithromycin</name><manufacturerId>TAR</manufacturerId><individualPrice>.4685</individualPrice><dailyCost>4.6850</dailyCost><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug></pcg9><pcg9 id="081212020"><itemNumber>0034</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.8244</dailyCost><drug id="01984853" sec3="Y"><name>Biaxin BID</name><manufacturerId>BGP</manufacturerId><individualPrice>1.9234</individualPrice><dailyCost>3.8468</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02247573" sec3="Y"><name>PMS-Clarithromycin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2007-10-03</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02248804" sec3="Y"><name>Teva-Clarithromycin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02266539" sec3="Y"><name>Sandoz Clarithromycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02274744" sec3="Y"><name>Apo-Clarithromycin</name><manufacturerId>APX</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02361426" sec3="Y"><name>Ran-Clarithromycin</name><manufacturerId>RAN</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02442469" sec3="Y"><name>Clarithromycin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02466120" sec3="Y"><name>Clarithromycin</name><manufacturerId>SAI</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug><drug id="02471388" sec3="Y"><name>M-Clarithromycin</name><manufacturerId>MAT</manufacturerId><individualPrice>.4122</individualPrice><dailyCost>.8244</dailyCost><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4122</amountMOHLTCPays></drug></pcg9><pcg9 id="081212024"><itemNumber>0035</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02126710" notABenefit="Y" sec3b="Y" sec3="Y"><name>Biaxin BID</name><manufacturerId>BGP</manufacturerId><listingDate>2007-10-03</listingDate></drug><drug id="02247574" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Clarithromycin</name><manufacturerId>PMS</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2007-10-03</listingDate></drug><drug id="02248805" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Clarithromycin</name><manufacturerId>TEV</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2013-01-29</listingDate></drug><drug id="02266547" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Clarithromycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2008-08-28</listingDate></drug><drug id="02274752" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Clarithromycin</name><manufacturerId>APX</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2007-10-03</listingDate></drug><drug id="02361434" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Clarithromycin</name><manufacturerId>RAN</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2011-08-04</listingDate></drug><drug id="02442485" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clarithromycin</name><manufacturerId>SIV</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02466139" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clarithromycin</name><manufacturerId>SAI</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2021-05-31</listingDate></drug><drug id="02471396" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Clarithromycin</name><manufacturerId>MAT</manufacturerId><individualPrice>2.2009</individualPrice><listingDate>2021-10-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00033"><name>ERYTHROMYCIN BASE</name><pcgGroup><pcg9 id="081212001"><itemNumber>0036</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.7460</dailyCost><drug id="00244635" notABenefit="Y" sec3="Y"><name>Erythromid</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00682020" sec3="Y"><name>Erythro-Base</name><manufacturerId>AAP</manufacturerId><individualPrice>.1865</individualPrice><dailyCost>.7460</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1865</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00036"><name>ERYTHROMYCIN ESTOLATE</name><pcgGroup><pcg9 id="081212007"><itemNumber>0037</itemNumber><strength>50mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.4260</dailyCost><drug id="00210641" notABenefit="Y" sec3="Y"><name>Ilosone</name><manufacturerId>LIL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00262595" sec3="Y"><name>Novo-Rythro Estolate</name><manufacturerId>NOP</manufacturerId><individualPrice>.0713</individualPrice><dailyCost>1.4260</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0713</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00034"><name>ERYTHROMYCIN ETHYLSUCCINATE</name><pcgGroup><pcg9 id="081212002"><itemNumber>0038</itemNumber><strength>40mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.0035</dailyCost><drug id="00000299" notABenefit="Y" sec3="Y"><name>EES-200</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00605859" sec3="Y"><name>Novo-Rythro Ethyl Succinate</name><manufacturerId>NOP</manufacturerId><individualPrice>.0669</individualPrice><dailyCost>1.0035</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug></pcg9><pcg9 id="081212009"><itemNumber>0039</itemNumber><strength>80mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.5195</dailyCost><drug id="00453617" notABenefit="Y" sec3="Y"><name>EES-400</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00652318" sec3="Y"><name>Novo-Rythro Ethyl Succinate</name><manufacturerId>NOP</manufacturerId><individualPrice>.1013</individualPrice><dailyCost>1.5195</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1013</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081216000"><name>ANTIBIOTICS PENICILLINS</name><genericName id="00050"><name>AMOXICILLIN</name><pcgGroup><pcg9 id="081216036"><itemNumber>0040</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><dailyCost>.2016</dailyCost><drug id="00406724" sec3="Y"><name>Novamoxin</name><manufacturerId>TEV</manufacturerId><individualPrice>.0672</individualPrice><dailyCost>.2016</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0672</amountMOHLTCPays></drug><drug id="00628115" sec3="Y"><name>Apo-Amoxi</name><manufacturerId>APX</manufacturerId><individualPrice>.0672</individualPrice><dailyCost>.2016</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0672</amountMOHLTCPays></drug><drug id="02041294" notABenefit="Y" sec3="Y"><name>Amoxil</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02388073" sec3="Y"><name>Auro-Amoxicillin</name><manufacturerId>AUR</manufacturerId><individualPrice>.0672</individualPrice><dailyCost>.2016</dailyCost><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.0672</amountMOHLTCPays></drug><drug id="02433060" sec3="Y"><name>Jamp-Amoxicillin</name><manufacturerId>JPC</manufacturerId><individualPrice>.0672</individualPrice><dailyCost>.2016</dailyCost><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.0672</amountMOHLTCPays></drug><drug id="02525348" sec3="Y"><name>Amoxicillin Capsules BP</name><manufacturerId>SAI</manufacturerId><individualPrice>.0672</individualPrice><dailyCost>.2016</dailyCost><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.0672</amountMOHLTCPays></drug><drug id="02532042" sec3="Y"><name>PRZ-Amoxicillin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.0672</individualPrice><dailyCost>.2016</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.0672</amountMOHLTCPays></drug></pcg9><pcg9 id="081216039"><itemNumber>0041</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><dailyCost>.3924</dailyCost><drug id="00406716" sec3="Y"><name>Novamoxin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="00628123" sec3="Y"><name>Apo-Amoxi</name><manufacturerId>APX</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="02041308" notABenefit="Y" sec3="Y"><name>Amoxil</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02388081" sec3="Y"><name>Auro-Amoxicillin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="02401509" sec3="Y"><name>Amoxicillin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="02433079" sec3="Y"><name>Jamp-Amoxicillin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="02477726" sec3="Y"><name>AG-Amoxicillin</name><manufacturerId>ANG</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="02525356" sec3="Y"><name>Amoxicillin Capsules BP</name><manufacturerId>SAI</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug><drug id="02532050" sec3="Y"><name>PRZ-Amoxicillin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1308</individualPrice><dailyCost>.3924</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.1308</amountMOHLTCPays></drug></pcg9><pcg9 id="081216090"><itemNumber>0042</itemNumber><strength>125mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02036347" notABenefit="Y" sec3b="Y" sec3="Y"><name>Novamoxin Chewable</name><manufacturerId>TEV</manufacturerId><individualPrice>.5099</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02041685" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amoxil Chewable</name><manufacturerId>AYE</manufacturerId><listingDate>2008-11-04</listingDate></drug></pcg9><pcg9 id="081216091"><itemNumber>0043</itemNumber><strength>250mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02036355" notABenefit="Y" sec3b="Y" sec3="Y"><name>Novamoxin Chewable</name><manufacturerId>TEV</manufacturerId><individualPrice>.8282</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02041286" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amoxil Chewable</name><manufacturerId>AYE</manufacturerId><listingDate>2008-11-04</listingDate></drug></pcg9><pcg9 id="081216038"><itemNumber>0044</itemNumber><strength>25mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>.3705</dailyCost><drug id="00628131" sec3="Y"><name>Apo-Amoxi</name><manufacturerId>APX</manufacturerId><individualPrice>.0247</individualPrice><dailyCost>.3705</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02041316" notABenefit="Y" sec3="Y"><name>Amoxil</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02535793" sec3="Y"><name>Jamp-Amoxicillin</name><manufacturerId>JPC</manufacturerId><individualPrice>.0247</individualPrice><dailyCost>.3705</dailyCost><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug></pcg9><pcg9 id="081216037"><itemNumber>0045</itemNumber><strength>50mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>.8100</dailyCost><drug id="00452130" sec3="Y"><name>Novamoxin</name><manufacturerId>TEV</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="00628158" sec3="Y"><name>Apo-Amoxi</name><manufacturerId>APX</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="01934163" sec3="Y"><name>Novamoxin (Sugar Reduced)</name><manufacturerId>TEV</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="02042592" notABenefit="Y" sec3="Y"><name>Amoxil</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02352753" sec3="Y"><name>Amoxicillin</name><manufacturerId>SAI</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="02352788" sec3="Y"><name>Amoxicillin (Sugar Reduced)</name><manufacturerId>SAI</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="02401541" sec3="Y"><name>Amoxicillin</name><manufacturerId>SIV</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="02458594" sec3="Y"><name>Auro-Amoxicillin</name><manufacturerId>AUR</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="02495864" sec3="Y"><name>Sandoz Amoxicillin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug><drug id="02535815" sec3="Y"><name>Jamp-Amoxicillin</name><manufacturerId>JPC</manufacturerId><individualPrice>.0540</individualPrice><dailyCost>.8100</dailyCost><listingDate>2023-08-31</listingDate><amountMOHLTCPays>.0540</amountMOHLTCPays></drug></pcg9><pcg9 id="081216130"><itemNumber>0046</itemNumber><strength>50mg/mL</strength><dosageForm>Pd for Oral Susp</dosageForm><drug id="09858237" sec3c="Y"><name>Moxilen Forte 250mg/5mL</name><manufacturerId>JUN</manufacturerId><individualPrice>.0810</individualPrice><listingDate>2023-01-20</listingDate><amountMOHLTCPays>.0810</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00054"><name>AMOXICILLIN &amp; CLAVULANIC ACID</name><note>Amoxicillin/clavulanic acid is not recommended as first line treatment for acute  otitis media and sinusitis. Antibiotic resistance (H. influenzae, M. catarrhalis) due to  B-lactamase production has caused only a minority of treatment failures with amoxicillin. Amoxicillin/clavulanic acid is first line treatment for infected bites of cat, dog or human.</note><pcgGroup><pcg9 id="081216054"><itemNumber>0047</itemNumber><strength>25mg &amp; 6.25mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.8615</dailyCost><drug id="01916882" sec3="Y"><name>Clavulin</name><manufacturerId>GSK</manufacturerId><individualPrice>.1241</individualPrice><dailyCost>1.8615</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1241</amountMOHLTCPays></drug></pcg9><pcg9 id="081216053"><itemNumber>0048</itemNumber><strength>50mg &amp; 12.5mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.8240</dailyCost><drug id="01916874" sec3="Y"><name>Clavulin</name><manufacturerId>GSK</manufacturerId><individualPrice>.2702</individualPrice><dailyCost>4.0530</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1216</amountMOHLTCPays></drug><drug id="02539438" sec3="Y"><name>Jamp Amoxi Clav Suspension</name><manufacturerId>JPC</manufacturerId><individualPrice>.1216</individualPrice><dailyCost>1.8240</dailyCost><listingDate>2024-09-27</listingDate><amountMOHLTCPays>.1216</amountMOHLTCPays></drug><drug id="02542226" sec3="Y"><name>M-Amoxi Clav</name><manufacturerId>MAT</manufacturerId><individualPrice>.1216</individualPrice><dailyCost>1.8240</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.1216</amountMOHLTCPays></drug></pcg9><pcg9 id="081216081"><itemNumber>0049</itemNumber><strength>200mg &amp; 28.5mg/5mL</strength><dosageForm>Susp</dosageForm><drug id="02238831" sec3="Y"><name>Clavulin (BID)</name><manufacturerId>GSK</manufacturerId><individualPrice>.1937</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1007</amountMOHLTCPays></drug><drug id="02539411" sec3="Y"><name>Jamp Amoxi Clav Suspension</name><manufacturerId>JPC</manufacturerId><individualPrice>.1007</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>.1007</amountMOHLTCPays></drug></pcg9><pcg9 id="081216082"><itemNumber>0050</itemNumber><strength>400mg &amp; 57mg/5mL</strength><dosageForm>Susp</dosageForm><drug id="02238830" sec3="Y"><name>Clavulin (BID)</name><manufacturerId>GSK</manufacturerId><individualPrice>.3779</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1591</amountMOHLTCPays></drug><drug id="02530694" sec3="Y"><name>M-Amoxi Clav</name><manufacturerId>MAT</manufacturerId><individualPrice>.1591</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.1591</amountMOHLTCPays></drug><drug id="02539446" sec3="Y"><name>Jamp Amoxi Clav Suspension</name><manufacturerId>JPC</manufacturerId><individualPrice>.1591</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>.1591</amountMOHLTCPays></drug></pcg9><pcg9 id="081216052"><itemNumber>0051</itemNumber><strength>250mg &amp; 125mg</strength><dosageForm>Tab</dosageForm><dailyCost>.7401</dailyCost><drug id="01916866" notABenefit="Y" sec3="Y"><name>Clavulin</name><manufacturerId>GSK</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02243350" sec3="Y"><name>Apo-Amoxi Clav</name><manufacturerId>APX</manufacturerId><individualPrice>.2467</individualPrice><dailyCost>.7401</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.2467</amountMOHLTCPays></drug><drug id="02471671" sec3="Y"><name>Auro-Amoxiclav</name><manufacturerId>AUR</manufacturerId><individualPrice>.2467</individualPrice><dailyCost>.7401</dailyCost><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.2467</amountMOHLTCPays></drug><drug id="02508249" sec3="Y"><name>Jamp Amoxi Clav</name><manufacturerId>JPC</manufacturerId><individualPrice>.2467</individualPrice><dailyCost>.7401</dailyCost><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2467</amountMOHLTCPays></drug></pcg9><pcg9 id="081216051"><itemNumber>0052</itemNumber><strength>500mg &amp; 125mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.1334</dailyCost><drug id="01916858" dinStatus="E" sec3="Y"><name>Clavulin</name><manufacturerId>GSK</manufacturerId><individualPrice>1.8875</individualPrice><dailyCost>5.6625</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3778</amountMOHLTCPays></drug><drug id="02243351" sec3="Y"><name>Apo-Amoxi Clav</name><manufacturerId>APX</manufacturerId><individualPrice>.3778</individualPrice><dailyCost>1.1334</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.3778</amountMOHLTCPays></drug><drug id="02471698" sec3="Y"><name>Auro-Amoxiclav</name><manufacturerId>AUR</manufacturerId><individualPrice>.3778</individualPrice><dailyCost>1.1334</dailyCost><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.3778</amountMOHLTCPays></drug><drug id="02482576" sec3="Y"><name>Sandoz Amoxi-Clav Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3778</individualPrice><dailyCost>1.1334</dailyCost><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.3778</amountMOHLTCPays></drug><drug id="02508257" sec3="Y"><name>Jamp Amoxi Clav</name><manufacturerId>JPC</manufacturerId><individualPrice>.3778</individualPrice><dailyCost>1.1334</dailyCost><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.3778</amountMOHLTCPays></drug><drug id="02536021" sec3="Y"><name>Amoxicillin/Clav</name><manufacturerId>SAI</manufacturerId><individualPrice>.3778</individualPrice><dailyCost>1.1334</dailyCost><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.3778</amountMOHLTCPays></drug></pcg9><pcg9 id="081216080"><itemNumber>0053</itemNumber><strength>875mg &amp; 125mg</strength><dosageForm>Tab</dosageForm><drug id="02238829" dinStatus="E" sec3="Y"><name>Clavulin (BID)</name><manufacturerId>GSK</manufacturerId><individualPrice>2.7515</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.5551</amountMOHLTCPays></drug><drug id="02245623" sec3="Y"><name>Apo-Amoxi Clav</name><manufacturerId>APX</manufacturerId><individualPrice>.5551</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.5551</amountMOHLTCPays></drug><drug id="02471701" sec3="Y"><name>Auro-Amoxiclav</name><manufacturerId>AUR</manufacturerId><individualPrice>.5551</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.5551</amountMOHLTCPays></drug><drug id="02482584" sec3="Y"><name>Sandoz Amoxi-Clav Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5551</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.5551</amountMOHLTCPays></drug><drug id="02508265" sec3="Y"><name>Jamp Amoxi Clav</name><manufacturerId>JPC</manufacturerId><individualPrice>.5551</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.5551</amountMOHLTCPays></drug><drug id="02536048" sec3="Y"><name>Amoxicillin/Clav</name><manufacturerId>SAI</manufacturerId><individualPrice>.5551</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.5551</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00042"><name>AMPICILLIN</name><note>Use with caution in urinary tract infections as even E. coli is resistant in approximately 20% of cases.</note><pcgGroup><pcg9 id="081216002"><itemNumber>0054</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><dailyCost>1.6892</dailyCost><drug id="00002003" notABenefit="Y" sec3="Y"><name>Penbritin</name><manufacturerId>AYE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00020877" sec3="Y"><name>Novo-Ampicillin</name><manufacturerId>NOP</manufacturerId><individualPrice>.4223</individualPrice><dailyCost>1.6892</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4223</amountMOHLTCPays></drug></pcg9><pcg9 id="081216001"><itemNumber>0055</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><dailyCost>3.2024</dailyCost><drug id="00002011" notABenefit="Y" sec3="Y"><name>Penbritin</name><manufacturerId>AYE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00020885" sec3="Y"><name>Novo-Ampicillin</name><manufacturerId>NOP</manufacturerId><individualPrice>.8006</individualPrice><dailyCost>3.2024</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.8006</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00043"><name>CLOXACILLIN</name><pcgGroup><pcg9 id="081216008"><itemNumber>0056</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><dailyCost>.8564</dailyCost><drug id="00002046" notABenefit="Y" sec3="Y"><name>Orbenin</name><manufacturerId>AYE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00337765" sec3="Y"><name>Teva-Cloxacillin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2141</individualPrice><dailyCost>.8564</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2141</amountMOHLTCPays></drug><drug id="02510731" sec3="Y"><name>Jamp Cloxacillin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2141</individualPrice><dailyCost>.8564</dailyCost><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.2141</amountMOHLTCPays></drug></pcg9><pcg9 id="081216007"><itemNumber>0057</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><dailyCost>1.6180</dailyCost><drug id="00002054" notABenefit="Y" sec3="Y"><name>Orbenin</name><manufacturerId>AYE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00337773" sec3="Y"><name>Teva-Cloxacillin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4045</individualPrice><dailyCost>1.6180</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4045</amountMOHLTCPays></drug><drug id="02510758" sec3="Y"><name>Jamp Cloxacillin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4045</individualPrice><dailyCost>1.6180</dailyCost><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.4045</amountMOHLTCPays></drug></pcg9><pcg9 id="081216009"><itemNumber>0058</itemNumber><strength>25mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>2.4240</dailyCost><drug id="00337757" sec3="Y"><name>Teva-Cloxacillin</name><manufacturerId>TEV</manufacturerId><individualPrice>.0606</individualPrice><dailyCost>2.4240</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02042975" notABenefit="Y" sec3="Y"><name>Orbenin</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00049"><name>PENICILLIN V (POTASSIUM)</name><pcgGroup><pcg9 id="081216035"><itemNumber>0059</itemNumber><strength>25mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.0700</dailyCost><drug id="00018635" notABenefit="Y" sec3="Y"><name>Nadopen-V</name><manufacturerId>NDA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00642223" sec3="Y"><name>Apo-Pen V-K</name><manufacturerId>APX</manufacturerId><individualPrice>.0535</individualPrice><dailyCost>1.0700</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0535</amountMOHLTCPays></drug></pcg9><pcg9 id="081216034"><itemNumber>0060</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><dailyCost>.7492</dailyCost><drug id="00248843" notABenefit="Y" sec3="Y"><name>PVF-K 500</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00642215" sec3="Y"><name>PEN V-K</name><manufacturerId>AAP</manufacturerId><individualPrice>.1873</individualPrice><dailyCost>.7492</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1873</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01429"><name>PIPERACILLIN SODIUM &amp; TAZOBACTAM SODIUM</name><pcgGroup><pcg9 id="081216101"><itemNumber>0061</itemNumber><strength>2g &amp; 250mg</strength><dosageForm>Inj Pd-2.25g Vial Pk</dosageForm><drug id="02170817" sec3b="Y" sec3="Y"><name>Tazocin</name><manufacturerId>PFI</manufacturerId><listingDate>2008-12-03</listingDate></drug><drug id="02308444" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>APX</manufacturerId><individualPrice>10.1300</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>10.1300</amountMOHLTCPays></drug><drug id="02362619" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>10.1300</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>10.1300</amountMOHLTCPays></drug><drug id="02401312" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin and Tazobactam for Inj</name><manufacturerId>TEL</manufacturerId><individualPrice>10.1300</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>10.1300</amountMOHLTCPays></drug><drug id="02402068" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam For Injection</name><manufacturerId>AUR</manufacturerId><individualPrice>10.1300</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>10.1300</amountMOHLTCPays></drug></pcg9><pcg9 id="081216097"><itemNumber>0062</itemNumber><strength>3g &amp; 375mg</strength><dosageForm>Inj Pd-3.375g Vial Pk</dosageForm><drug id="02170795" sec3b="Y" sec3="Y"><name>Tazocin</name><manufacturerId>WYE</manufacturerId><listingDate>2008-12-03</listingDate></drug><drug id="02308452" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>APX</manufacturerId><individualPrice>15.2000</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>15.2000</amountMOHLTCPays></drug><drug id="02362627" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>15.2000</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>15.2000</amountMOHLTCPays></drug><drug id="02370166" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin/Tazobactam powder for Inj.</name><manufacturerId>TEV</manufacturerId><individualPrice>15.2000</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>15.2000</amountMOHLTCPays></drug><drug id="02391538" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>MYL</manufacturerId><individualPrice>15.2000</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>15.2000</amountMOHLTCPays></drug><drug id="02401320" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin and Tazobactam for Inj</name><manufacturerId>TEL</manufacturerId><individualPrice>15.2000</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>15.2000</amountMOHLTCPays></drug><drug id="02402076" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam For Injection</name><manufacturerId>AUR</manufacturerId><individualPrice>15.2000</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>15.2000</amountMOHLTCPays></drug></pcg9><pcg9 id="081216102"><itemNumber>0063</itemNumber><strength>4g &amp; 500mg</strength><dosageForm>Inj Pd-4.5g Vial Pk</dosageForm><drug id="02170809" sec3b="Y" sec3="Y"><name>Tazocin</name><manufacturerId>WYE</manufacturerId><listingDate>2008-12-03</listingDate></drug><drug id="02308460" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>APX</manufacturerId><individualPrice>20.2700</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>20.2700</amountMOHLTCPays></drug><drug id="02362635" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>20.2700</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>20.2700</amountMOHLTCPays></drug><drug id="02370174" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin/Tazobactam powder for Inj.</name><manufacturerId>TEV</manufacturerId><individualPrice>20.2700</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>20.2700</amountMOHLTCPays></drug><drug id="02401339" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin and Tazobactam for Inj</name><manufacturerId>TEL</manufacturerId><individualPrice>20.2700</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>20.2700</amountMOHLTCPays></drug><drug id="02402084" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Piperacillin &amp; Tazobactam For Injection</name><manufacturerId>AUR</manufacturerId><individualPrice>20.2700</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>20.2700</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081224000"><name>ANTIBIOTICS TETRACYCLINES</name><genericName id="01347"><name>DOXYCYCLINE</name><pcgGroup><pcg9 id="081224027"><itemNumber>0064</itemNumber><strength>40mg</strength><dosageForm>MR Cap</dosageForm><drug id="02375885" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apprilon</name><manufacturerId>GAC</manufacturerId><listingDate>2021-07-30</listingDate></drug><drug id="02512645" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Doxycycline MR</name><manufacturerId>APX</manufacturerId><individualPrice>3.0850</individualPrice><listingDate>2021-07-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00062"><name>DOXYCYCLINE HYCLATE</name><pcgGroup><pcg9 id="081224028"><itemNumber>0065</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><drug id="02247104" notABenefit="Y" sec3b="Y" sec3="Y"><name>Periostat</name><manufacturerId>PEN</manufacturerId><listingDate>2024-06-28</listingDate></drug><drug id="02528568" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Doxycycline</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3538</individualPrice><listingDate>2024-06-28</listingDate></drug></pcg9><pcg9 id="081224015"><itemNumber>0066</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00578452" notABenefit="Y" sec3="Y"><name>Vibra-Tabs</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00874256" sec3="Y"><name>Apo-Doxy-Tabs</name><manufacturerId>APX</manufacturerId><individualPrice>.4560</individualPrice><listingDate>2009-05-20</listingDate><amountMOHLTCPays>.4560</amountMOHLTCPays></drug><drug id="02158574" sec3="Y"><name>Teva-Doxycycline</name><manufacturerId>TEV</manufacturerId><individualPrice>.4560</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.4560</amountMOHLTCPays></drug><drug id="02351242" sec3="Y"><name>Doxycycline Tablets</name><manufacturerId>SAI</manufacturerId><individualPrice>.4560</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.4560</amountMOHLTCPays></drug><drug id="02536250" sec3="Y"><name>PRZ-Doxycycline</name><manufacturerId>PRZ</manufacturerId><individualPrice>.4560</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.4560</amountMOHLTCPays></drug><drug id="02543478" sec3="Y"><name>M-Doxycycline</name><manufacturerId>MAT</manufacturerId><individualPrice>.4560</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.4560</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00063"><name>MINOCYCLINE HCL</name><pcgGroup><pcg9 id="081224021"><itemNumber>0067</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="02084090" sec3="Y"><name>Minocycline</name><manufacturerId>AAP</manufacturerId><individualPrice>.5616</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.5616</amountMOHLTCPays></drug><drug id="02173514" notABenefit="Y" sec3="Y"><name>Minocin</name><manufacturerId>STI</manufacturerId><listingDate>2008-01-15</listingDate></drug></pcg9><pcg9 id="081224022"><itemNumber>0068</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02084104" sec3="Y"><name>Minocycline</name><manufacturerId>AAP</manufacturerId><individualPrice>1.0836</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.0836</amountMOHLTCPays></drug><drug id="02173506" notABenefit="Y" sec3="Y"><name>Minocin</name><manufacturerId>STI</manufacturerId><listingDate>2008-01-15</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00060"><name>TETRACYCLINE</name><note>Tetracycline use during tooth development (last half of pregnancy and up to age 8) may cause permanent tooth discoloration or enamel hypoplasia. These reactions are more common during long-term use. Tetracyclines should not be used in these groups unless other antibiotics are unlikely to be effective or are contraindicated.</note><pcgGroup><pcg9 id="081224002"><itemNumber>0069</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><dailyCost>.2680</dailyCost><drug id="00024422" notABenefit="Y" sec3="Y"><name>Tetracyn</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00580929" sec3="Y"><name>Tetracycline</name><manufacturerId>AAP</manufacturerId><individualPrice>.0670</individualPrice><dailyCost>.2680</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0670</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01697"><name>TIGECYCLINE</name><pcgGroup><pcg9 id="081224020"><itemNumber>0070</itemNumber><strength>50mg/Vial</strength><dosageForm>Pd for Inj-5mLVial Pk (Preservative-Free)</dosageForm><drug id="02285401" sec3="Y"><name>Tygacil</name><manufacturerId>PFI</manufacturerId><individualPrice>83.4740</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>83.4740</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081228000"><name>ANTIBIOTICS OTHER ANTIBIOTICS</name><genericName id="00076"><name>CEFADROXIL</name><pcgGroup><pcg9 id="081228036"><itemNumber>0071</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><dailyCost>1.1790</dailyCost><drug id="00507245" notABenefit="Y" sec3="Y"><name>Duricef</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02235134" sec3="Y"><name>Teva-Cefadroxil</name><manufacturerId>TEV</manufacturerId><individualPrice>.5895</individualPrice><dailyCost>1.1790</dailyCost><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.5895</amountMOHLTCPays></drug><drug id="02240774" sec3="Y"><name>Apo-Cefadroxil</name><manufacturerId>APX</manufacturerId><individualPrice>.5895</individualPrice><dailyCost>1.1790</dailyCost><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.5895</amountMOHLTCPays></drug><drug id="02544792" sec3="Y"><name>Jamp Cefadroxil</name><manufacturerId>JPC</manufacturerId><individualPrice>.5895</individualPrice><dailyCost>1.1790</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.5895</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00074"><name>CEFAZOLIN SODIUM</name><pcgGroup><pcg9 id="081228112"><itemNumber>0072</itemNumber><strength>500mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02108119" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>TEV</manufacturerId><listingDate>2022-01-31</listingDate></drug><drug id="02308932" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.0000</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>4.0000</amountMOHLTCPays></drug><drug id="02437104" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>4.0000</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>4.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="081228103"><itemNumber>0073</itemNumber><strength>1g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02108127" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>TEV</manufacturerId><listingDate>2010-06-14</listingDate></drug><drug id="02297205" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>ORC</manufacturerId><individualPrice>6.0000</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>6.0000</amountMOHLTCPays></drug><drug id="02308959" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.0000</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>6.0000</amountMOHLTCPays></drug><drug id="02437112" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>6.0000</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>6.0000</amountMOHLTCPays></drug><drug id="02465469" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>6.0000</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>6.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="081228122"><itemNumber>0074</itemNumber><strength>10g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02108135" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>TEV</manufacturerId><listingDate>2010-06-14</listingDate></drug><drug id="02297213" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>ORC</manufacturerId><individualPrice>56.0000</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>56.0000</amountMOHLTCPays></drug><drug id="02308967" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>56.0000</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>56.0000</amountMOHLTCPays></drug><drug id="02437120" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection</name><manufacturerId>STE</manufacturerId><individualPrice>56.0000</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>56.0000</amountMOHLTCPays></drug><drug id="02465477" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>56.0000</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>56.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="081228194"><itemNumber>0075</itemNumber><strength>10g/Vial</strength><dosageForm>Inj Pd-Vial Pk (Preservative-Free)</dosageForm><drug id="01919628" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ancef</name><manufacturerId>SMJ</manufacturerId><listingDate>2025-08-29</listingDate></drug><drug id="02237140" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefazolin for Injection, USP</name><manufacturerId>FKC</manufacturerId><individualPrice>56.0000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>56.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00084"><name>CEFIXIME</name><pcgGroup><pcg9 id="081228054"><itemNumber>0076</itemNumber><strength>20mg/mL</strength><dosageForm>Oral Susp</dosageForm><drug id="00868965" sec3="Y"><name>Suprax</name><manufacturerId>ODN</manufacturerId><individualPrice>.3899</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3899</amountMOHLTCPays></drug><drug id="02468689" sec3="Y"><name>Auro-Cefixime</name><manufacturerId>AUR</manufacturerId><individualPrice>.3899</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.3899</amountMOHLTCPays></drug></pcg9><pcg9 id="081228056"><itemNumber>0077</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><dailyCost>2.7172</dailyCost><drug id="00868981" sec3="Y"><name>Suprax</name><manufacturerId>ODN</manufacturerId><individualPrice>2.7172</individualPrice><dailyCost>2.7172</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.7172</amountMOHLTCPays></drug><drug id="02432773" sec3="Y"><name>Auro-Cefixime</name><manufacturerId>AUR</manufacturerId><individualPrice>2.7172</individualPrice><dailyCost>2.7172</dailyCost><listingDate>2014-12-18</listingDate><amountMOHLTCPays>2.7172</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00095"><name>CEFOXITIN SODIUM</name><pcgGroup><pcg9 id="081228119"><itemNumber>0078</itemNumber><strength>1g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="00663697" sec3b="Y" sec3="Y"><name>Mefoxin</name><manufacturerId>MSD</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02128187" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefoxitin for Injection USP</name><manufacturerId>TEV</manufacturerId><individualPrice>10.6000</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>10.6000</amountMOHLTCPays></drug><drug id="02291711" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefoxitin for Injection</name><manufacturerId>ORC</manufacturerId><individualPrice>10.6000</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>10.6000</amountMOHLTCPays></drug></pcg9><pcg9 id="081228120"><itemNumber>0079</itemNumber><strength>2g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="00663700" sec3b="Y" sec3="Y"><name>Mefoxin</name><manufacturerId>MSD</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02128195" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefoxitin for Injection USP</name><manufacturerId>TEV</manufacturerId><individualPrice>21.2500</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>21.2500</amountMOHLTCPays></drug><drug id="02291738" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cefoxitin for Injection</name><manufacturerId>ORC</manufacturerId><individualPrice>21.2500</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>21.2500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00099"><name>CEFPROZIL</name><pcgGroup><pcg9 id="081228123"><itemNumber>0080</itemNumber><strength>125mg/5mL</strength><dosageForm>Oral Susp-100mL Pk</dosageForm><drug id="09857356" sec3="Y"><name>Ran-Cefprozil</name><manufacturerId>RAN</manufacturerId><individualPrice>9.7000</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>9.7000</amountMOHLTCPays></drug><drug id="09857358" notABenefit="Y" sec3="Y"><name>Cefzil</name><manufacturerId>BQU</manufacturerId><listingDate>2010-06-14</listingDate></drug><drug id="09858332" sec3="Y"><name>Auro-Cefprozil</name><manufacturerId>AUR</manufacturerId><individualPrice>9.7000</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>9.7000</amountMOHLTCPays></drug></pcg9><pcg9 id="081228124"><itemNumber>0081</itemNumber><strength>250mg/5mL</strength><dosageForm>Oral Susp-100mL Pk</dosageForm><drug id="09857359" notABenefit="Y" sec3="Y"><name>Cefzil</name><manufacturerId>BQU</manufacturerId><listingDate>2010-06-14</listingDate></drug><drug id="09857365" sec3="Y"><name>Ran-Cefprozil</name><manufacturerId>RAN</manufacturerId><individualPrice>19.3800</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>19.3800</amountMOHLTCPays></drug><drug id="09858333" sec3="Y"><name>Auro-Cefprozil</name><manufacturerId>AUR</manufacturerId><individualPrice>19.3800</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>19.3800</amountMOHLTCPays></drug></pcg9><pcg9 id="081228083"><itemNumber>0082</itemNumber><strength>125mg/5mL</strength><dosageForm>Oral Susp-75mL Pk</dosageForm><drug id="02163675" notABenefit="Y" sec3="Y"><name>Cefzil</name><manufacturerId>BQU</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02329204" sec3="Y"><name>Ran-Cefprozil</name><manufacturerId>RAN</manufacturerId><individualPrice>7.2750</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>7.2750</amountMOHLTCPays></drug><drug id="02347261" sec3="Y"><name>Auro-Cefprozil</name><manufacturerId>AUR</manufacturerId><individualPrice>7.2750</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>7.2750</amountMOHLTCPays></drug></pcg9><pcg9 id="081228084"><itemNumber>0083</itemNumber><strength>250mg/5mL</strength><dosageForm>Oral Susp-75mL Pk</dosageForm><drug id="02163683" notABenefit="Y" sec3="Y"><name>Cefzil</name><manufacturerId>BQU</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02293579" sec3="Y"><name>Ran-Cefprozil</name><manufacturerId>RAN</manufacturerId><individualPrice>14.5350</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>14.5350</amountMOHLTCPays></drug><drug id="02347288" sec3="Y"><name>Auro-Cefprozil</name><manufacturerId>AUR</manufacturerId><individualPrice>14.5350</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>14.5350</amountMOHLTCPays></drug></pcg9><pcg9 id="081228085"><itemNumber>0084</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02163659" notABenefit="Y" sec3="Y"><name>Cefzil</name><manufacturerId>BQU</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02293528" sec3="Y"><name>Ran-Cefprozil</name><manufacturerId>RAN</manufacturerId><individualPrice>1.7374</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>1.7374</amountMOHLTCPays></drug></pcg9><pcg9 id="081228086"><itemNumber>0085</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02163667" notABenefit="Y" sec3="Y"><name>Cefzil</name><manufacturerId>BQU</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02293536" sec3="Y"><name>Ran-Cefprozil</name><manufacturerId>RAN</manufacturerId><individualPrice>2.0038</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>2.0038</amountMOHLTCPays></drug><drug id="02347253" sec3="Y"><name>Auro-Cefprozil</name><manufacturerId>AUR</manufacturerId><individualPrice>2.0038</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>2.0038</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00078"><name>CEFTRIAXONE DISODIUM</name><pcgGroup><pcg9 id="081228043"><itemNumber>0086</itemNumber><strength>0.25g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="00657387" notABenefit="Y" sec3="Y"><name>Rocephin</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02325594" sec3="Y"><name>Ceftriaxone Sodium For Injection BP</name><manufacturerId>STE</manufacturerId><individualPrice>5.6430</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>5.6430</amountMOHLTCPays></drug></pcg9><pcg9 id="081228045"><itemNumber>0087</itemNumber><strength>1g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="00657417" notABenefit="Y" sec3="Y"><name>Rocephin</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02287633" sec3="Y"><name>Ceftriaxone Sodium for Injection</name><manufacturerId>TEV</manufacturerId><individualPrice>12.4950</individualPrice><listingDate>2008-03-25</listingDate><amountMOHLTCPays>12.4950</amountMOHLTCPays></drug><drug id="02289695" sec3="Y"><name>Ceftriaxone for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>12.4950</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>12.4950</amountMOHLTCPays></drug><drug id="02292270" sec3="Y"><name>Ceftriaxone</name><manufacturerId>SDZ</manufacturerId><individualPrice>12.4950</individualPrice><listingDate>2007-05-04</listingDate><amountMOHLTCPays>12.4950</amountMOHLTCPays></drug><drug id="02292874" sec3="Y"><name>Ceftriaxone for Injection USP</name><manufacturerId>ORC</manufacturerId><individualPrice>12.4950</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>12.4950</amountMOHLTCPays></drug><drug id="02325616" sec3="Y"><name>Ceftriaxone Sodium For Injection BP</name><manufacturerId>STE</manufacturerId><individualPrice>12.4950</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>12.4950</amountMOHLTCPays></drug></pcg9><pcg9 id="081228046"><itemNumber>0088</itemNumber><strength>2g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="00657409" notABenefit="Y" sec3="Y"><name>Rocephin</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02289709" sec3="Y"><name>Ceftriaxone for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>24.1395</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>24.1395</amountMOHLTCPays></drug><drug id="02292289" sec3="Y"><name>Ceftriaxone</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.1395</individualPrice><listingDate>2007-05-04</listingDate><amountMOHLTCPays>24.1395</amountMOHLTCPays></drug><drug id="02325624" sec3="Y"><name>Ceftriaxone Sodium For Injection BP</name><manufacturerId>STE</manufacturerId><individualPrice>24.1395</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>24.1395</amountMOHLTCPays></drug></pcg9><pcg9 id="081228121"><itemNumber>0089</itemNumber><strength>10g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="00851957" sec3b="Y" sec3="Y"><name>Rocephin</name><manufacturerId>HLR</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02292297" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ceftriaxone Sodium For Injection BP</name><manufacturerId>SDZ</manufacturerId><individualPrice>214.2000</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>214.2000</amountMOHLTCPays></drug><drug id="02325632" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ceftriaxone Sodium For Injection BP</name><manufacturerId>STE</manufacturerId><individualPrice>214.2000</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>214.2000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00088"><name>CEFUROXIME AXETIL</name><pcgGroup><pcg9 id="081228079"><itemNumber>0090</itemNumber><strength>125mg/5mL</strength><dosageForm>Susp</dosageForm><drug id="02212307" sec3="Y"><name>Ceftin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1791</individualPrice><listingDate>1998-10-21</listingDate><amountMOHLTCPays>.1791</amountMOHLTCPays></drug></pcg9><pcg9 id="081228064"><itemNumber>0091</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.8388</dailyCost><drug id="02212277" notABenefit="Y" sec3="Y"><name>Ceftin</name><manufacturerId>GSK</manufacturerId><listingDate>1998-10-21</listingDate></drug><drug id="02244393" sec3="Y"><name>Apo-Cefuroxime</name><manufacturerId>APX</manufacturerId><individualPrice>.4194</individualPrice><dailyCost>.8388</dailyCost><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.4194</amountMOHLTCPays></drug><drug id="02344823" sec3="Y"><name>Auro-Cefuroxime</name><manufacturerId>AUR</manufacturerId><individualPrice>.4194</individualPrice><dailyCost>.8388</dailyCost><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.4194</amountMOHLTCPays></drug><drug id="02547198" sec3="Y"><name>Jamp Cefuroxime</name><manufacturerId>JPC</manufacturerId><individualPrice>.4194</individualPrice><dailyCost>.8388</dailyCost><listingDate>2024-11-29</listingDate><amountMOHLTCPays>.4194</amountMOHLTCPays></drug></pcg9><pcg9 id="081228065"><itemNumber>0092</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.6616</dailyCost><drug id="02212285" notABenefit="Y" sec3="Y"><name>Ceftin</name><manufacturerId>GSK</manufacturerId><listingDate>1998-10-21</listingDate></drug><drug id="02244394" sec3="Y"><name>Apo-Cefuroxime</name><manufacturerId>APX</manufacturerId><individualPrice>.8308</individualPrice><dailyCost>1.6616</dailyCost><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.8308</amountMOHLTCPays></drug><drug id="02344831" sec3="Y"><name>Auro-Cefuroxime</name><manufacturerId>AUR</manufacturerId><individualPrice>.8308</individualPrice><dailyCost>1.6616</dailyCost><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.8308</amountMOHLTCPays></drug><drug id="02547201" sec3="Y"><name>Jamp Cefuroxime</name><manufacturerId>JPC</manufacturerId><individualPrice>.8308</individualPrice><dailyCost>1.6616</dailyCost><listingDate>2024-11-29</listingDate><amountMOHLTCPays>.8308</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00065"><name>CEPHALEXIN MONOHYDRATE</name><pcgGroup><pcg9 id="081228001"><itemNumber>0093</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><dailyCost>1.4812</dailyCost><drug id="00253154" notABenefit="Y" sec3="Y"><name>Ceporex</name><manufacturerId>GLA</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00342084" sec3="Y"><name>Teva-Cephalexin</name><manufacturerId>TEV</manufacturerId><individualPrice>.3703</individualPrice><dailyCost>1.4812</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3703</amountMOHLTCPays></drug></pcg9><pcg9 id="081228029"><itemNumber>0094</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><dailyCost>2.9008</dailyCost><drug id="00253146" notABenefit="Y" sec3="Y"><name>Ceporex</name><manufacturerId>GLA</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00342114" sec3="Y"><name>Teva-Cephalexin</name><manufacturerId>TEV</manufacturerId><individualPrice>.7252</individualPrice><dailyCost>2.9008</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7252</amountMOHLTCPays></drug></pcg9><pcg9 id="081228003"><itemNumber>0095</itemNumber><strength>25mg/mL</strength><dosageForm>Pd for Oral Susp</dosageForm><dailyCost>3.0700</dailyCost><drug id="00015547" notABenefit="Y" sec3="Y"><name>Keflex</name><manufacturerId>PHE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00342106" sec3="Y"><name>Teva-Cephalexin 125</name><manufacturerId>TEV</manufacturerId><individualPrice>.1535</individualPrice><dailyCost>3.0700</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1535</amountMOHLTCPays></drug><drug id="02469170" sec3="Y"><name>Lupin-Cephalexin</name><manufacturerId>LUP</manufacturerId><individualPrice>.1535</individualPrice><dailyCost>3.0700</dailyCost><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.1535</amountMOHLTCPays></drug><drug id="02497743" sec3="Y"><name>Auro-Cephalexin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1535</individualPrice><dailyCost>3.0700</dailyCost><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.1535</amountMOHLTCPays></drug><drug id="02528436" sec3="Y"><name>Jamp Cephalexin Suspension</name><manufacturerId>JPC</manufacturerId><individualPrice>.1535</individualPrice><dailyCost>3.0700</dailyCost><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.1535</amountMOHLTCPays></drug></pcg9><pcg9 id="081228002"><itemNumber>0096</itemNumber><strength>50mg/mL</strength><dosageForm>Pd for Oral Susp</dosageForm><dailyCost>5.1460</dailyCost><drug id="00035645" notABenefit="Y" sec3="Y"><name>Keflex</name><manufacturerId>PHE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00342092" sec3="Y"><name>Teva-Cephalexin 250</name><manufacturerId>TEV</manufacturerId><individualPrice>.2573</individualPrice><dailyCost>5.1460</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2573</amountMOHLTCPays></drug><drug id="02469189" sec3="Y"><name>Lupin-Cephalexin</name><manufacturerId>LUP</manufacturerId><individualPrice>.2573</individualPrice><dailyCost>5.1460</dailyCost><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.2573</amountMOHLTCPays></drug><drug id="02497751" sec3="Y"><name>Auro-Cephalexin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2573</individualPrice><dailyCost>5.1460</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.2573</amountMOHLTCPays></drug><drug id="02528444" sec3="Y"><name>Jamp Cephalexin Suspension</name><manufacturerId>JPC</manufacturerId><individualPrice>.2573</individualPrice><dailyCost>5.1460</dailyCost><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.2573</amountMOHLTCPays></drug></pcg9><pcg9 id="081228034"><itemNumber>0097</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.3464</dailyCost><drug id="00403628" notABenefit="Y" sec3="Y"><name>Keflex</name><manufacturerId>PHE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00583413" sec3="Y"><name>Teva-Cephalexin</name><manufacturerId>TEV</manufacturerId><individualPrice>.0866</individualPrice><dailyCost>.3464</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0866</amountMOHLTCPays></drug><drug id="00768723" sec3="Y"><name>Apo-Cephalex</name><manufacturerId>APX</manufacturerId><individualPrice>.0866</individualPrice><dailyCost>.3464</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0866</amountMOHLTCPays></drug><drug id="02470578" sec3="Y"><name>Auro-Cephalexin</name><manufacturerId>AUR</manufacturerId><individualPrice>.0866</individualPrice><dailyCost>.3464</dailyCost><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.0866</amountMOHLTCPays></drug><drug id="02494698" sec3="Y"><name>Jamp Cephalexin</name><manufacturerId>JPC</manufacturerId><individualPrice>.0866</individualPrice><dailyCost>.3464</dailyCost><listingDate>2023-02-28</listingDate><amountMOHLTCPays>.0866</amountMOHLTCPays></drug><drug id="02521253" sec3="Y"><name>Cephalexin</name><manufacturerId>SAI</manufacturerId><individualPrice>.0866</individualPrice><dailyCost>.3464</dailyCost><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.0866</amountMOHLTCPays></drug></pcg9><pcg9 id="081228028"><itemNumber>0098</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6924</dailyCost><drug id="00244392" notABenefit="Y" sec3="Y"><name>Keflex</name><manufacturerId>PHE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00583421" sec3="Y"><name>Teva-Cephalexin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1731</individualPrice><dailyCost>.6924</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1731</amountMOHLTCPays></drug><drug id="00768715" sec3="Y"><name>Apo-Cephalex</name><manufacturerId>APX</manufacturerId><individualPrice>.1731</individualPrice><dailyCost>.6924</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1731</amountMOHLTCPays></drug><drug id="02470586" sec3="Y"><name>Auro-Cephalexin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1731</individualPrice><dailyCost>.6924</dailyCost><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.1731</amountMOHLTCPays></drug><drug id="02494701" sec3="Y"><name>Jamp Cephalexin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1731</individualPrice><dailyCost>.6924</dailyCost><listingDate>2023-02-28</listingDate><amountMOHLTCPays>.1731</amountMOHLTCPays></drug><drug id="02495651" sec3="Y"><name>Cephalexin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1731</individualPrice><dailyCost>.6924</dailyCost><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.1731</amountMOHLTCPays></drug><drug id="02521261" sec3="Y"><name>Cephalexin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1731</individualPrice><dailyCost>.6924</dailyCost><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.1731</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00067"><name>CLINDAMYCIN HCL</name><pcgGroup><pcg9 id="081228006"><itemNumber>0099</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><dailyCost>1.7736</dailyCost><drug id="00030570" notABenefit="Y" sec3="Y"><name>Dalacin C</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02241709" sec3="Y"><name>Teva-Clindamycin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2000-11-30</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02245232" sec3="Y"><name>Apo-Clindamycin</name><manufacturerId>APX</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02400529" sec3="Y"><name>Clindamycin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02436906" sec3="Y"><name>Auro-Clindamycin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02462656" sec3="Y"><name>Med-Clindamycin</name><manufacturerId>GMP</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02468476" sec3="Y"><name>Riva-Clindamycin</name><manufacturerId>RIA</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02479923" sec3="Y"><name>M-Clindamycin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02483734" sec3="Y"><name>Jamp-Clindamycin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2019-10-31</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02493748" sec3="Y"><name>NRA-Clindamycin</name><manufacturerId>NRA</manufacturerId><individualPrice>.2217</individualPrice><dailyCost>1.7736</dailyCost><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug></pcg9><pcg9 id="081228088"><itemNumber>0100</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="02182866" dinStatus="E" sec3="Y"><name>Dalacin C</name><manufacturerId>PFI</manufacturerId><individualPrice>2.9008</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02241710" sec3="Y"><name>Teva-Clindamycin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02245233" sec3="Y"><name>Apo-Clindamycin</name><manufacturerId>APX</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02400537" sec3="Y"><name>Clindamycin</name><manufacturerId>SAI</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02436914" sec3="Y"><name>Auro-Clindamycin</name><manufacturerId>AUR</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02462664" sec3="Y"><name>Med-Clindamycin</name><manufacturerId>GMP</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02468484" sec3="Y"><name>Riva-Clindamycin</name><manufacturerId>RIA</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02479931" sec3="Y"><name>M-Clindamycin</name><manufacturerId>MAT</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02483742" sec3="Y"><name>Jamp-Clindamycin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug><drug id="02493756" sec3="Y"><name>NRA-Clindamycin</name><manufacturerId>NRA</manufacturerId><individualPrice>.4434</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.4434</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00068"><name>CLINDAMYCIN PALMITATE</name><pcgGroup><pcg9 id="081228007"><itemNumber>0101</itemNumber><strength>15mg/mL</strength><dosageForm>Pd for Oral Susp</dosageForm><drug id="00225851" sec3="Y"><name>Dalacin C Flavoured Granules</name><manufacturerId>PFI</manufacturerId><individualPrice>.3152</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3152</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00069"><name>CLINDAMYCIN PHOSPHATE</name><pcgGroup><pcg9 id="081228008"><itemNumber>0102</itemNumber><strength>300mg/2mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="00260436" sec3="Y"><name>Dalacin C</name><manufacturerId>PFI</manufacturerId><individualPrice>8.8938</individualPrice><note>Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>8.8938</amountMOHLTCPays></drug><drug id="02230540" notABenefit="Y" sec3="Y"><name>Clindamycin Phosphate Injection USP</name><manufacturerId>SDZ</manufacturerId><note>Clindamycin is well absorbed by the oral route, therefore stepdown therapy from IV to oral is possible.
</note><listingDate>2001-03-07</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02396"><name>DALBAVANCIN HYDROCHLORIDE</name><pcgGroup lccId="00393"><pcg9 id="081228193"><itemNumber>0103</itemNumber><strength>500mg/Vial</strength><dosageForm>Pd for Sol (Preservative-Free)</dosageForm><drug id="02480522" sec3="Y" sec12="Y"><name>Xydalba</name><manufacturerId>EVL</manufacturerId><individualPrice>985.8900</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>985.8900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="677">For the treatment of adults with methicillin resistant Staphylococcus aureus (MRSA) infection meeting all the following criteria;

1. Patient is 18 years of age or older; AND

2. Diagnosed with an acute bacterial skin and skin structure infection (ABSSSI) (e.g. cellulitis/erysipelas, major cutaneous abscess, wound infection) that is known (i.e. confirmed by culture and sensitivity test) or suspected to be caused by MRSA; AND

3. Treatment with standard orally administered antibiotics is inappropriate or inadequate; AND

4. Patient is deemed to be at high risk of nonadherence to a standard antibiotic treatment for MRSA ABSSSI or treatment with dalbavancin rather than a standard antibiotic treatment for MRSA ABSSSI will avoid the need for hospitalization OR will limit the need for prolonged hospitalization; AND

5. Patient&apos;s ABSSSI is not caused by non-MRSA or methicillin-sensitive Staphylococcus aureus (MSSA); AND

6. Patient does not have ABSSSI associated with any of the following types of infections:

- Known or suspected osteomyelitis or septic arthritis

- Infections complicated by the presence of prosthetic materials that would not be removed such as permanent cardiac pacemaker battery packs, or those involving joint replacement prosthesis 

- Self-limited infections such as isolated folliculitis and isolated furuncles or other infections that have a high cure rate after surgical incision alone

- Patients who have had more than 2 surgical interventions or are expected to need more than 2 surgical interventions (defined as surgery that cannot be performed at the bedside) for the ABSSSI

- Skin and skin structure infection with arterial insufficiency, such as deep diabetic foot ulcers, decubitus ulcers, and ischemic ulcers

- Necrotizing fasciitis, gas gangrene

- Burns greater than 20% of total body surface

Approved dose: Up to 1500mg intravenously (IV), administered either as a single dose OR A two dose regimen of 1000mg IV followed one week later by 500mg IV.

Duration: One treatment course using a single dose or a two dose regimen.

Retreatment within 30 days from the initial dose may be considered on a case-by-case basis through the Exceptional Access Program (EAP). Please submit the culture and sensitivity report and other relevant clinical details regarding the patient&apos;s infection presentation including the dose, duration, and approximate date of treatment of all anti-infectives used to manage the infection.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 7 days</lccNote></pcgGroup></genericName><genericName id="01791"><name>DAPTOMYCIN</name><pcgGroup><pcg9 id="081228125"><itemNumber>0104</itemNumber><strength>500mg/Vial</strength><dosageForm>Pd for Inj Sol-Vial Pk</dosageForm><drug id="02299909" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cubicin</name><manufacturerId>SUO</manufacturerId><listingDate>2020-11-30</listingDate></drug><drug id="02490463" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Daptomycin for Injection</name><manufacturerId>DRR</manufacturerId><individualPrice>162.3500</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>162.3500</amountMOHLTCPays></drug><drug id="02490838" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Daptomycin for Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>162.3500</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>162.3500</amountMOHLTCPays></drug><drug id="02511738" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Daptomycin for Injection</name><manufacturerId>JUN</manufacturerId><individualPrice>162.3500</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>162.3500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02011"><name>RIFAXIMIN</name><pcgGroup lccId="00264"><pcg9 id="081228164"><itemNumber>0105</itemNumber><strength>550mg</strength><dosageForm>Tab</dosageForm><drug id="02410702" sec3="Y" sec12="Y"><name>Zaxine</name><manufacturerId>SAL</manufacturerId><individualPrice>8.3030</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>8.3030</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="475">For reducing the risk of overt hepatic encephalopathy (HE) recurrence (i.e., 2 or more episodes) in patients who are unable to achieve adequate control of HE recurrence with maximal tolerated dose of lactulose alone. Rifaximin should be used in combination with a maximal tolerated dose of lactulose. For patients not maintained on lactulose, the nature of the patient&apos;s intolerance to lactulose should be documented.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00668"><name>TOBRAMYCIN</name><pcgGroup lccId="00265"><pcg9 id="081228163"><itemNumber>0106</itemNumber><strength>28mg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02365154" sec3="Y" sec12="Y"><name>TOBI Podhaler</name><manufacturerId>BGP</manufacturerId><individualPrice>14.6911</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>14.6911</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="472">For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.

Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="081228094"><itemNumber>0107</itemNumber><strength>300mg/5mL</strength><dosageForm>Inh Sol-5mL Pk</dosageForm><note>For the management of cystic fibrosis patients with chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections.

Tobramycin is administered in alternating periods of 28 days. After 28 days of therapy, patients should stop therapy for the next 28 days, and then resume therapy for the next 28 day on / 28 day off cycle.</note><drug id="02239630" sec3="Y"><name>TOBI</name><manufacturerId>BGP</manufacturerId><individualPrice>63.1930</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>41.0985</amountMOHLTCPays></drug><drug id="02389622" sec3="Y"><name>Teva-Tobramycin</name><manufacturerId>TEV</manufacturerId><individualPrice>41.0985</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>41.0985</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00075"><name>TOBRAMYCIN SULFATE</name><note>The prescriber should be aware that tobramycin injection products may be preservative-free or preservative-containing. If applicable, the prescriber should choose the most appropriate formulation (preservative-free or preservative containing) for use in the specific clinical situation in which the product was prescribed.</note><pcgGroup><pcg9 id="081228035"><itemNumber>0108</itemNumber><strength>80mg/2mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="00325449" notABenefit="Y" sec3="Y"><name>Nebcin</name><manufacturerId>LIL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02241210" sec3="Y"><name>Tobramycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.1500</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>3.1500</amountMOHLTCPays></drug><drug id="02502372" sec3="Y"><name>Tobramycin Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>3.1500</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>3.1500</amountMOHLTCPays></drug><drug id="02533103" sec3="Y"><name>Tobramycin Injection USP</name><manufacturerId>JPC</manufacturerId><individualPrice>3.1500</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>3.1500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00094"><name>VANCOMYCIN HCL</name><pcgGroup lccId="00322"><pcg9 id="081228075"><itemNumber>0109</itemNumber><strength>125mg</strength><dosageForm>Cap</dosageForm><drug id="00800430" sec3="Y" sec12="Y"><name>Vancocin</name><manufacturerId>SLP</manufacturerId><individualPrice>5.1800</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>5.1800</amountMOHLTCPays></drug><drug id="02407744" sec3="Y" sec12="Y"><name>Jamp-Vancomycin</name><manufacturerId>JPC</manufacturerId><individualPrice>5.1800</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>5.1800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="557">For the treatment of initial episodes of Clostridium difficile infection; mild cases, if no response or intolerance to an adequate trial of oral metronidazole*:

*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.

Notes:
- Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea.
- Discontinue antibiotics for other indications if possible.
- Higher doses of vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.


Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days

Maximum funded quantity: 56 capsules</lccNote><lccNote seq="002" type="R">LU Authorization Period: 14 days</lccNote><lccNote seq="003" reasonForUseId="558">For the treatment of initial episodes of Clostridium difficile infection; moderate or severe, uncomplicated cases*:

*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.

Notes:
- Metronidazole 500mg orally three times daily for 10-14 days can be used in patients with mild diarrhea.
- For mild to moderate cases, treatment should only be continued beyond 7 days if diarrhea persists, up to a maximum of 14 days.
- Severe, uncomplicated cases should be treated for 10-14 days. There is no evidence to support treatment durations beyond 14 days.
- Higher doses of vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.


Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days

Maximum funded quantity: 56 capsules</lccNote><lccNote seq="004" type="R">LU Authorization Period: 14 days</lccNote><lccNote seq="005" reasonForUseId="559">For the treatment of recurrent Clostridium difficile infection (CDI), first recurrence, mild to moderate* or severe, uncomplicated* cases:

*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.

Notes:
- Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment.
- Treatment should only be continued for 14 days.
- Higher doses or longer treatment duration with vancomycin have not been shown to be beneficial.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.


Maximum funded dose: Vancomycin 125mg four times daily, up to 14 days

Maximum funded quantity: 56 capsules</lccNote><lccNote seq="006" type="R">LU Authorization Period: 14 days</lccNote><lccNote seq="007" reasonForUseId="560">For the treatment of recurrent Clostridium difficile infection (CDI), second or subsequent recurrences, mild to moderate* or severe, uncomplicated* cases:

*As defined by the Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for Clostridium difficile infection, 2018.

Notes:
- Recurrent CDI is defined as the reoccurrence of CDI within 8 weeks following the onset of a previous episode which resolved with treatment.
- There is no evidence to support combination therapy with metronidazole or fidaxomicin.


Funded dose: Vancomycin 125mg four times daily for 10-14 days, followed by vancomycin taper.

Maximum funded quantity: 114 capsules</lccNote><lccNote seq="008" type="R">LU Authorization Period: 13 Weeks</lccNote></pcgGroup><pcgGroup><pcg9 id="081228074"><itemNumber>0110</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="00788716" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Vancocin</name><manufacturerId>SLP</manufacturerId><individualPrice>10.3600</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>10.3600</amountMOHLTCPays></drug><drug id="02407752" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Vancomycin</name><manufacturerId>JPC</manufacturerId><individualPrice>10.3600</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>10.3600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081600000"><name>ANTITUBERCULAR AGENTS</name><genericName id="00100"><name>ETHAMBUTOL HCL</name><pcgGroup><pcg9 id="081600004"><itemNumber>0111</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00127957" notABenefit="Y" sec3="Y"><name>Myambutol</name><manufacturerId>LED</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00247960" sec3="Y"><name>Etibi</name><manufacturerId>VAL</manufacturerId><individualPrice>.2784</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2784</amountMOHLTCPays></drug></pcg9><pcg9 id="081600003"><itemNumber>0112</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="00247979" sec3="Y"><name>Etibi</name><manufacturerId>VAL</manufacturerId><individualPrice>.8355</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.8355</amountMOHLTCPays></drug><drug id="02170078" notABenefit="Y" sec3="Y"><name>Myambutol</name><manufacturerId>WAY</manufacturerId><listingDate>1997-02-04</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00107"><name>RIFABUTIN</name><pcgGroup lccId="00005"><pcg9 id="081600018"><itemNumber>0113</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02063786" sec3="Y" sec12="Y"><name>Mycobutin</name><manufacturerId>PFI</manufacturerId><individualPrice>6.2161</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.2161</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the prevention of Mycobacterium Avium Intracellular (MAI) in:</lccNote><lccNote seq="002" reasonForUseId="103">Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis;</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="004" reasonForUseId="104">Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00102"><name>RIFAMPIN</name><note>Except when used for prophylaxis in contacts of H. influenzae or N. meningitidis, rifampin should not be used as monotherapy, as bacterial resistance will develop quickly.</note><pcgGroup><pcg9 id="081600009"><itemNumber>0114</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="00393444" sec3="Y"><name>Rofact</name><manufacturerId>VAL</manufacturerId><individualPrice>.9001</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9001</amountMOHLTCPays></drug></pcg9><pcg9 id="081600008"><itemNumber>0115</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="00343617" sec3="Y"><name>Rofact</name><manufacturerId>VAL</manufacturerId><individualPrice>1.4169</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.4169</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="081800000"><name>ANTIVIRALS</name><genericName id="01567"><name>ABACAVIR &amp; LAMIVUDINE &amp; ZIDOVUDINE</name><pcgGroup><pcg9 id="081800065"><itemNumber>0116</itemNumber><strength>300mg &amp; 150mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02244757" sec3="Y"><name>Trizivir</name><manufacturerId>VIH</manufacturerId><individualPrice>19.0426</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>13.6425</amountMOHLTCPays></drug><drug id="02416255" sec3="Y"><name>Apo-Abacavir-Lamivudine-Zidovudine</name><manufacturerId>APX</manufacturerId><individualPrice>13.6425</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>13.6425</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01426"><name>ABACAVIR SULFATE</name><pcgGroup><pcg9 id="081800054"><itemNumber>0117</itemNumber><strength>20mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02240358" sec3="Y"><name>Ziagen</name><manufacturerId>VIH</manufacturerId><individualPrice>.6142</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.6142</amountMOHLTCPays></drug></pcg9><pcg9 id="081800053"><itemNumber>0118</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02240357" sec3="Y"><name>Ziagen</name><manufacturerId>VIH</manufacturerId><individualPrice>8.6725</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>3.4828</amountMOHLTCPays></drug><drug id="02396769" sec3="Y"><name>Apo-Abacavir</name><manufacturerId>APX</manufacturerId><individualPrice>3.4828</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>3.4828</amountMOHLTCPays></drug><drug id="02480956" sec3="Y"><name>Mint-Abacavir</name><manufacturerId>MIN</manufacturerId><individualPrice>3.4828</individualPrice><listingDate>2019-05-31</listingDate><amountMOHLTCPays>3.4828</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01678"><name>ABACAVIR SULFATE &amp; LAMIVUDINE</name><pcgGroup><pcg9 id="081800094"><itemNumber>0119</itemNumber><strength>600mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02269341" sec3="Y"><name>Kivexa</name><manufacturerId>VIH</manufacturerId><individualPrice>28.3100</individualPrice><listingDate>2006-06-15</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug><drug id="02399539" sec3="Y"><name>Apo-Abacavir-Lamivudine</name><manufacturerId>APX</manufacturerId><individualPrice>5.9875</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug><drug id="02416662" sec3="Y"><name>Teva-Abacavir-Lamivudine</name><manufacturerId>TEV</manufacturerId><individualPrice>5.9875</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug><drug id="02450682" sec3="Y"><name>Mylan-Abacavir-Lamivudine</name><manufacturerId>MYL</manufacturerId><individualPrice>5.9875</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug><drug id="02454513" sec3="Y"><name>Auro-Abacavir/Lamivudine</name><manufacturerId>AUR</manufacturerId><individualPrice>5.9875</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug><drug id="02458381" sec3="Y"><name>PMS-Abacavir-Lamivudine</name><manufacturerId>PMS</manufacturerId><individualPrice>5.9875</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug><drug id="02497654" sec3="Y"><name>Jamp Abacavir/Lamivudine</name><manufacturerId>JPC</manufacturerId><individualPrice>5.9875</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>5.9875</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00109"><name>ACYCLOVIR</name><pcgGroup><pcg9 id="081800019"><itemNumber>0120</itemNumber><strength>200mg/5mL</strength><dosageForm>Oral Susp</dosageForm><drug id="00886157" dinStatus="E" sec3="Y"><name>Zovirax</name><manufacturerId>GLW</manufacturerId><individualPrice>.3142</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3142</amountMOHLTCPays></drug></pcg9><pcg9 id="081800100"><itemNumber>0121</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="00634506" notABenefit="Y" sec3="Y"><name>Zovirax</name><manufacturerId>GSK</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02207621" sec3="Y"><name>Apo-Acyclovir</name><manufacturerId>APX</manufacturerId><individualPrice>.3511</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.3511</amountMOHLTCPays></drug><drug id="02242784" sec3="Y"><name>Mylan-Acyclovir</name><manufacturerId>MYL</manufacturerId><individualPrice>.3511</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.3511</amountMOHLTCPays></drug><drug id="02285959" sec3="Y"><name>Teva-Acyclovir</name><manufacturerId>TEV</manufacturerId><individualPrice>.3511</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.3511</amountMOHLTCPays></drug><drug id="02524708" sec3="Y"><name>Mint-Acyclovir</name><manufacturerId>MIN</manufacturerId><individualPrice>.3511</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.3511</amountMOHLTCPays></drug></pcg9><pcg9 id="081800101"><itemNumber>0122</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="01911627" notABenefit="Y" sec3="Y"><name>Zovirax</name><manufacturerId>GSK</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02207648" sec3="Y"><name>Apo-Acyclovir</name><manufacturerId>APX</manufacturerId><individualPrice>.8890</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.8890</amountMOHLTCPays></drug><drug id="02242463" sec3="Y"><name>Mylan-Acyclovir</name><manufacturerId>MYL</manufacturerId><individualPrice>.8890</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.8890</amountMOHLTCPays></drug><drug id="02285967" sec3="Y"><name>Teva-Acyclovir</name><manufacturerId>TEV</manufacturerId><individualPrice>.8890</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.8890</amountMOHLTCPays></drug><drug id="02524716" sec3="Y"><name>Mint-Acyclovir</name><manufacturerId>MIN</manufacturerId><individualPrice>.8890</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.8890</amountMOHLTCPays></drug></pcg9><pcg9 id="081800002"><itemNumber>0123</itemNumber><strength>800mg</strength><dosageForm>Tab</dosageForm><drug id="01911635" sec3="Y"><name>Zovirax</name><manufacturerId>GSK</manufacturerId><individualPrice>5.0692</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2673</amountMOHLTCPays></drug><drug id="02207656" sec3="Y"><name>Apo-Acyclovir</name><manufacturerId>APX</manufacturerId><individualPrice>1.2673</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.2673</amountMOHLTCPays></drug><drug id="02242464" sec3="Y"><name>Mylan-Acyclovir</name><manufacturerId>MYL</manufacturerId><individualPrice>1.2673</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>1.2673</amountMOHLTCPays></drug><drug id="02285975" sec3="Y"><name>Teva-Acyclovir</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2673</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>1.2673</amountMOHLTCPays></drug><drug id="02524724" sec3="Y"><name>Mint-Acyclovir</name><manufacturerId>MIN</manufacturerId><individualPrice>1.2673</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>1.2673</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01734"><name>ADEFOVIR DIPIVOXIL</name><pcgGroup><pcg9 id="081800105"><itemNumber>0124</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02247823" notABenefit="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Hepsera</name><manufacturerId>GIL</manufacturerId><listingDate>2014-04-30</listingDate></drug><drug id="02420333" notABenefit="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>AA-Adefovir</name><manufacturerId>AAP</manufacturerId><individualPrice>20.9130</individualPrice><listingDate>2014-04-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01614"><name>ATAZANAVIR SULFATE</name><pcgGroup><pcg9 id="081800080"><itemNumber>0125</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02248610" sec3="Y"><name>Reyataz</name><manufacturerId>BQU</manufacturerId><individualPrice>11.6950</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>2.8386</amountMOHLTCPays></drug><drug id="02443791" sec3="Y"><name>Teva-Atazanavir</name><manufacturerId>TEV</manufacturerId><individualPrice>2.8386</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>2.8386</amountMOHLTCPays></drug><drug id="02456877" sec3="Y"><name>Mylan-Atazanavir</name><manufacturerId>MYL</manufacturerId><individualPrice>2.8386</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>2.8386</amountMOHLTCPays></drug><drug id="02513102" sec3="Y"><name>Jamp Atazanavir</name><manufacturerId>JPC</manufacturerId><individualPrice>2.8386</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>2.8386</amountMOHLTCPays></drug></pcg9><pcg9 id="081800081"><itemNumber>0126</itemNumber><strength>200mg</strength><dosageForm>Cap</dosageForm><drug id="02248611" sec3="Y"><name>Reyataz</name><manufacturerId>BQU</manufacturerId><individualPrice>11.7633</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>2.8552</amountMOHLTCPays></drug><drug id="02443813" sec3="Y"><name>Teva-Atazanavir</name><manufacturerId>TEV</manufacturerId><individualPrice>2.8552</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>2.8552</amountMOHLTCPays></drug><drug id="02456885" sec3="Y"><name>Mylan-Atazanavir</name><manufacturerId>MYL</manufacturerId><individualPrice>2.8552</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>2.8552</amountMOHLTCPays></drug><drug id="02513110" sec3="Y"><name>Jamp Atazanavir</name><manufacturerId>JPC</manufacturerId><individualPrice>2.8552</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>2.8552</amountMOHLTCPays></drug></pcg9><pcg9 id="081800388"><itemNumber>0127</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="02294176" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reyataz</name><manufacturerId>BQU</manufacturerId><listingDate>2017-06-29</listingDate></drug><drug id="02443821" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Atazanavir</name><manufacturerId>TEV</manufacturerId><individualPrice>19.0681</individualPrice><listingDate>2017-06-29</listingDate></drug><drug id="02456893" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Atazanavir</name><manufacturerId>MYL</manufacturerId><individualPrice>19.0681</individualPrice><listingDate>2017-06-29</listingDate></drug><drug id="02513129" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Atazanavir</name><manufacturerId>JPC</manufacturerId><individualPrice>19.0681</individualPrice><listingDate>2023-04-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02095"><name>BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE</name><pcgGroup><pcg9 id="081800393"><itemNumber>0128</itemNumber><strength>50mg &amp; 200mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02478579" sec3="Y"><name>Biktarvy</name><manufacturerId>GIL</manufacturerId><individualPrice>39.2227</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>39.2227</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02172"><name>CABOTEGRAVIR</name><pcgGroup><pcg9 id="081800417"><itemNumber>0129</itemNumber><strength>200mg/mL</strength><dosageForm>Inj Sol-ER Susp 3mL Vial Kit Pk</dosageForm><drug id="02547473" sec3="Y"><name>Apretude</name><manufacturerId>VIH</manufacturerId><individualPrice>1710.0000</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>1710.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="081800407"><itemNumber>0130</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02497204" sec3="Y"><name>Vocabria</name><manufacturerId>VIH</manufacturerId><individualPrice>30.8270</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>30.8270</amountMOHLTCPays></drug></pcg9><pcg9 id="081800416"><itemNumber>0131</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02547465" sec3="Y"><name>Apretude</name><manufacturerId>VIH</manufacturerId><individualPrice>30.0750</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>30.0750</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02174"><name>CABOTEGRAVIR &amp; RILPIVIRINE</name><pcgGroup><pcg9 id="081800405"><itemNumber>0132</itemNumber><strength>200mg/mL &amp; 300mg/mL</strength><dosageForm>Inj Sol-2mL Kit</dosageForm><drug id="02497220" sec3="Y"><name>Cabenuva</name><manufacturerId>VIH</manufacturerId><individualPrice>1316.4700</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>1316.4700</amountMOHLTCPays></drug></pcg9><pcg9 id="081800406"><itemNumber>0133</itemNumber><strength>200mg/mL &amp; 300mg/mL</strength><dosageForm>Inj Sol-3mL Kit</dosageForm><drug id="02497247" sec3="Y"><name>Cabenuva</name><manufacturerId>VIH</manufacturerId><individualPrice>2568.7100</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>2568.7100</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01918"><name>COBICISTAT &amp; ELVITEGRAVIR &amp; EMTRICITABINE &amp; TENOFOVIR DISOPROXIL FUMARATE</name><pcgGroup><pcg9 id="081800361"><itemNumber>0134</itemNumber><strength>150mg &amp; 150mg &amp; 200mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02397137" sec3="Y"><name>Stribild</name><manufacturerId>GIL</manufacturerId><individualPrice>48.0177</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>48.0177</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01702"><name>DARUNAVIR</name><pcgGroup><pcg9 id="081800337"><itemNumber>0135</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02324024" notABenefit="Y" sec3="Y"><name>Prezista</name><manufacturerId>JAN</manufacturerId><listingDate>2010-03-02</listingDate></drug><drug id="02486121" sec3="Y"><name>Auro-Darunavir</name><manufacturerId>AUR</manufacturerId><individualPrice>4.2970</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>4.2970</amountMOHLTCPays></drug><drug id="02487241" sec3="Y"><name>Apo-Darunavir</name><manufacturerId>APX</manufacturerId><individualPrice>4.2970</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>4.2970</amountMOHLTCPays></drug><drug id="02521342" sec3="Y"><name>Darunavir</name><manufacturerId>JPC</manufacturerId><individualPrice>4.2970</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>4.2970</amountMOHLTCPays></drug></pcg9><pcg9 id="081800360"><itemNumber>0136</itemNumber><strength>800mg</strength><dosageForm>Tab</dosageForm><drug id="02393050" notABenefit="Y" sec3="Y"><name>Prezista</name><manufacturerId>JAN</manufacturerId><listingDate>2013-07-30</listingDate></drug><drug id="02486148" sec3="Y"><name>Auro-Darunavir</name><manufacturerId>AUR</manufacturerId><individualPrice>5.8295</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>5.8295</amountMOHLTCPays></drug><drug id="02487268" sec3="Y"><name>Apo-Darunavir</name><manufacturerId>APX</manufacturerId><individualPrice>5.8295</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>5.8295</amountMOHLTCPays></drug><drug id="02521350" sec3="Y"><name>Darunavir</name><manufacturerId>JPC</manufacturerId><individualPrice>5.8295</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>5.8295</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02010"><name>DARUNAVIR &amp; COBICISTAT</name><pcgGroup><pcg9 id="081800377"><itemNumber>0137</itemNumber><strength>800mg &amp; 150mg</strength><dosageForm>Tab</dosageForm><drug id="02426501" sec3="Y"><name>Prezcobix</name><manufacturerId>JAN</manufacturerId><individualPrice>25.1870</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>25.1870</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01391"><name>DELAVIRDINE MESYLATE</name><pcgGroup><pcg9 id="081800043"><itemNumber>0138</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02238348" sec3="Y"><name>Rescriptor</name><manufacturerId>PFI</manufacturerId><individualPrice>.7609</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.7609</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01973"><name>DOLUTEGRAVIR</name><pcgGroup><pcg9 id="081800373"><itemNumber>0139</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02414945" sec3="Y"><name>Tivicay</name><manufacturerId>VIH</manufacturerId><individualPrice>23.5367</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>23.5367</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01974"><name>DOLUTEGRAVIR &amp; ABACAVIR &amp; LAMIVUDINE</name><pcgGroup><pcg9 id="081800374"><itemNumber>0140</itemNumber><strength>50mg &amp; 600mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02430932" sec3="Y"><name>Triumeq</name><manufacturerId>VIH</manufacturerId><individualPrice>52.1447</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>52.1447</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02081"><name>DOLUTEGRAVIR &amp; RILPIVIRINE</name><pcgGroup><pcg9 id="081800392"><itemNumber>0141</itemNumber><strength>50mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02475774" sec3="Y"><name>Juluca</name><manufacturerId>VIH</manufacturerId><individualPrice>40.9343</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>40.9343</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02119"><name>DOLUTEGRAVIR SODIUM/LAMIVUDINE</name><pcgGroup><pcg9 id="081800397"><itemNumber>0142</itemNumber><strength>50mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02491753" sec3="Y"><name>Dovato</name><manufacturerId>VIH</manufacturerId><individualPrice>35.7367</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>35.7367</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02108"><name>DORAVIRINE</name><pcgGroup><pcg9 id="081800396"><itemNumber>0143</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02481545" sec3="Y"><name>Pifeltro</name><manufacturerId>MEK</manufacturerId><individualPrice>16.6500</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>16.6500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02109"><name>DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE</name><pcgGroup><pcg9 id="081800395"><itemNumber>0144</itemNumber><strength>100mg &amp; 300mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02482592" sec3="Y"><name>Delstrigo</name><manufacturerId>MEK</manufacturerId><individualPrice>28.7900</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>28.7900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01416"><name>EFAVIRENZ</name><pcgGroup><pcg9 id="081800076"><itemNumber>0145</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02246045" notABenefit="Y" sec3="Y"><name>Sustiva</name><manufacturerId>BQU</manufacturerId><listingDate>2003-09-04</listingDate></drug><drug id="02381524" sec3="Y"><name>Mylan-Efavirenz</name><manufacturerId>MYL</manufacturerId><individualPrice>3.8030</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>3.8030</amountMOHLTCPays></drug><drug id="02389762" sec3="Y"><name>Teva-Efavirenz</name><manufacturerId>TEV</manufacturerId><individualPrice>3.8030</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>3.8030</amountMOHLTCPays></drug><drug id="02418428" sec3="Y"><name>Auro-Efavirenz</name><manufacturerId>AUR</manufacturerId><individualPrice>3.8030</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>3.8030</amountMOHLTCPays></drug><drug id="02458233" sec3="Y"><name>Jamp-Efavirenz</name><manufacturerId>JPC</manufacturerId><individualPrice>3.8030</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>3.8030</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01732"><name>EFAVIRENZ/TENOFOVIR DISOPROXIL FUMARATE/EMTRICITABINE</name><pcgGroup><pcg9 id="081800103"><itemNumber>0146</itemNumber><strength>600mg/300mg/200mg</strength><dosageForm>Tab</dosageForm><drug id="02300699" sec3="Y"><name>Atripla</name><manufacturerId>BQU</manufacturerId><individualPrice>45.3200</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug><drug id="02393549" sec3="Y"><name>Teva-Efavirenz/Emtricitabine/Tenofovir</name><manufacturerId>TEV</manufacturerId><individualPrice>11.3300</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug><drug id="02461412" sec3="Y"><name>Mylan-Efavirenz/Emtricitabine/Tenofovir</name><manufacturerId>MYL</manufacturerId><individualPrice>11.3300</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug><drug id="02468247" sec3="Y"><name>Apo-Efavirenz-Emtricitabine-Tenofovir</name><manufacturerId>APX</manufacturerId><individualPrice>11.3300</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug><drug id="02478404" sec3="Y"><name>Auro-Efavirenz-Emtricitabine-Tenofovir</name><manufacturerId>AUR</manufacturerId><individualPrice>11.3300</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug><drug id="02487284" sec3="Y"><name>PMS-Efavirenz-Emtricitabine-Tenofovir</name><manufacturerId>PMS</manufacturerId><individualPrice>11.3300</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug><drug id="02519461" sec3="Y"><name>Jamp Efavirenz/Emtricitabine/Tenofovir</name><manufacturerId>JPC</manufacturerId><individualPrice>11.3300</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>11.3300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02035"><name>ELVITEGRAVIR &amp; COBICISTAT &amp; EMTRICITABINE &amp; TENOFOVIR ALAFENAMIDE</name><pcgGroup><pcg9 id="081800387"><itemNumber>0147</itemNumber><strength>150mg &amp; 150mg &amp; 200mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="02449498" sec3="Y"><name>Genvoya</name><manufacturerId>GIL</manufacturerId><individualPrice>45.1440</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>45.1440</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02056"><name>EMTRICITABINE &amp; RILPIVIRINE HCL &amp; TENOFOVIR ALAFENAMIDE HEMIFUMARATE</name><pcgGroup><pcg9 id="081800390"><itemNumber>0148</itemNumber><strength>200mg &amp; 25mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02461463" sec3="Y"><name>Odefsey</name><manufacturerId>GIL</manufacturerId><individualPrice>42.3670</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>42.3670</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01889"><name>EMTRICITABINE &amp; RILPIVIRINE HCL &amp; TENOFOVIR DISOPROXIL</name><pcgGroup><pcg9 id="081800357"><itemNumber>0149</itemNumber><strength>200mg &amp; 25mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02374129" sec3="Y"><name>Complera</name><manufacturerId>GIL</manufacturerId><individualPrice>44.8643</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>44.8643</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01710"><name>EMTRICITABINE &amp; TENOFOVIR DISOPROXIL FUMARATE</name><pcgGroup><pcg9 id="081800099"><itemNumber>0150</itemNumber><strength>200mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02274906" sec3="Y"><name>Truvada</name><manufacturerId>GIL</manufacturerId><individualPrice>29.2140</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02399059" sec3="Y"><name>Teva-Emtricitabine/Tenofovir</name><manufacturerId>TEV</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02443902" sec3="Y"><name>Mylan-Emtricitabine/Tenofovir Disoproxil</name><manufacturerId>MYL</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02452006" sec3="Y"><name>Apo-Emtricitabine-Tenofovir</name><manufacturerId>APX</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02461110" sec3="Y"><name>PMS-Emtricitabine/Tenofovir</name><manufacturerId>PMS</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02487012" sec3="Y"><name>Jamp-Emtricitabine/Tenofovir Disoproxil</name><manufacturerId>JPC</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02490684" sec3="Y"><name>Auro-Emtricitabine-Tenofovir</name><manufacturerId>AUR</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02496356" sec3="Y"><name>AG-Emtricitabine &amp; Tenofovir Disoproxil</name><manufacturerId>ANG</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug><drug id="02521547" sec3="Y"><name>Mint-Emtricitabine/Tenofovir</name><manufacturerId>MIN</manufacturerId><individualPrice>7.3035</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>7.3035</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01735"><name>ENTECAVIR</name><pcgGroup lccId="00295"><pcg9 id="081800106"><itemNumber>0151</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02282224" sec3="Y" sec12="Y"><name>Baraclude</name><manufacturerId>BQU</manufacturerId><individualPrice>22.6600</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02396955" sec3="Y" sec12="Y"><name>Apo-Entecavir</name><manufacturerId>APX</manufacturerId><individualPrice>5.5000</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02430576" sec3="Y" sec12="Y"><name>PMS-Entecavir</name><manufacturerId>PMS</manufacturerId><individualPrice>5.5000</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02448777" sec3="Y" sec12="Y"><name>Auro-Entecavir</name><manufacturerId>AUR</manufacturerId><individualPrice>5.5000</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02467232" sec3="Y" sec12="Y"><name>Jamp-Entecavir</name><manufacturerId>JPC</manufacturerId><individualPrice>5.5000</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02479907" sec3="Y" sec12="Y"><name>Accel-Entecavir</name><manufacturerId>ACC</manufacturerId><individualPrice>4.4000</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02485907" sec3="Y" sec12="Y"><name>Mint-Entecavir</name><manufacturerId>MIN</manufacturerId><individualPrice>5.5000</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug><drug id="02527154" sec3="Y" sec12="Y"><name>Entecavir</name><manufacturerId>SAI</manufacturerId><individualPrice>5.5000</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>4.4000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="505">Confirmed chronic Hepatitis B infection in persons with

- HBV DNA greater than or equal to 1000 IU/mL

AND

- ALT levels greater than ULN

OR

- Evidence of fibrosis

or

- Documented evidence of cirrhosis</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="506">For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, tenofovir, adefovir or telbivudine.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="507">Patients with chronic Hepatitis B infection currently receiving treatment with entecavir and requires treatment continuation.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="508">Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01747"><name>ETRAVIRINE</name><pcgGroup><pcg9 id="081800104"><itemNumber>0152</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02306778" sec3="Y"><name>Intelence</name><manufacturerId>JAN</manufacturerId><individualPrice>6.5710</individualPrice><listingDate>2009-01-30</listingDate><amountMOHLTCPays>6.5710</amountMOHLTCPays></drug></pcg9><pcg9 id="081800354"><itemNumber>0153</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02375931" sec3="Y"><name>Intelence</name><manufacturerId>JAN</manufacturerId><individualPrice>12.6195</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>12.6195</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00114"><name>FAMCICLOVIR</name><pcgGroup><pcg9 id="081800028"><itemNumber>0154</itemNumber><strength>125mg</strength><dosageForm>Tab</dosageForm><drug id="02229110" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Famvir</name><manufacturerId>APU</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02292025" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Famciclovir</name><manufacturerId>APX</manufacturerId><individualPrice>2.0240</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>2.0240</amountMOHLTCPays></drug></pcg9><pcg9 id="081800029"><itemNumber>0155</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02229129" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Famvir</name><manufacturerId>APU</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02292041" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Famciclovir</name><manufacturerId>APX</manufacturerId><individualPrice>2.7200</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>2.7200</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00008"><pcg9 id="081800011"><itemNumber>0156</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02177102" sec3="Y" sec12="Y"><name>Famvir</name><manufacturerId>APU</manufacturerId><individualPrice>7.7438</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>4.2591</amountMOHLTCPays></drug><drug id="02292068" sec3="Y" sec12="Y"><name>Apo-Famciclovir</name><manufacturerId>APX</manufacturerId><individualPrice>4.2591</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>4.2591</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="147">Herpes zoster in patients 50 years of age or older, up to 72 hours* after appearance of lesions. Dose: 500mg 3 times/day for 7 days.</lccNote><lccNote seq="002" type="R">*The patient must begin treatment within the time frame specified for the product to be reimbursed. There is no benefit from the therapy begun after this time frame.</lccNote><lccNote seq="003" type="W">Network will limit supply to 7 days and 21 tablets.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01636"><name>FOSAMPRENAVIR CALCIUM</name><pcgGroup><pcg9 id="081800107"><itemNumber>0157</itemNumber><strength>50mg/mL</strength><dosageForm>Oral Susp</dosageForm><drug id="02261553" sec3="Y"><name>Telzir</name><manufacturerId>VIH</manufacturerId><individualPrice>.6535</individualPrice><listingDate>2009-01-30</listingDate><amountMOHLTCPays>.6535</amountMOHLTCPays></drug></pcg9><pcg9 id="081800093"><itemNumber>0158</itemNumber><strength>700mg</strength><dosageForm>Tab</dosageForm><drug id="02261545" sec3="Y"><name>Telzir</name><manufacturerId>VIH</manufacturerId><individualPrice>9.4389</individualPrice><listingDate>2006-01-12</listingDate><amountMOHLTCPays>9.4389</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00108"><name>GANCICLOVIR SODIUM</name><pcgGroup><pcg9 id="081800001"><itemNumber>0159</itemNumber><strength>500mg/Vial</strength><dosageForm>Pd Inj-10mL Pk</dosageForm><drug id="02162695" sec3="Y"><name>Cytovene</name><manufacturerId>CHE</manufacturerId><individualPrice>51.2041</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>51.2041</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02074"><name>GLECAPREVIR &amp; PIBRENTASVIR</name><pcgGroup lccId="00314"><pcg9 id="081800391"><itemNumber>0160</itemNumber><strength>100mg &amp; 40mg</strength><dosageForm>Tab</dosageForm><drug id="02467550" sec3="Y" sec12="Y"><name>Maviret</name><manufacturerId>ABV</manufacturerId><individualPrice>238.0952</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>238.0952</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="550">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C. 

(ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, or 6;

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).

Exclusion criteria:

- Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor

- For use in combination with other hepatitis C antiviral agents

- Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C)

Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program.

Treatment regimens for Maviret:

I. Treatment-naive, non-cirrhotic genotype 1, 2, 3, 4, 5, or 6.
Approved duration: 8 weeks

II. Treatment-naive genotype 1, 2, 3, 4, 5, or 6 with compensated cirrhosis.
Approved duration: 8 weeks

III. Treatment-experienced, non-cirrhotic genotype 1, 2, 4, 5, or 6 who have failed peginterferon/ribavirin and/or sofosbuvir ONLY.
Approved duration: 8 weeks

Notes:

(1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.

(2) NS3/4A Pls include simeprevir, boceprevir, and telepravir.

(3) NS5A inhibitors include daclatasvir and ledipasvir.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 8 Weeks</lccNote><lccNote seq="003" reasonForUseId="551">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C;

(ii) Laboratory confirmed hepatitis C genotype 1, 2, 4, 5, or 6;

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).

Exclusion criteria:

- Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor

- For use in combination with other hepatitis C antiviral agents

- Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C)

Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program.

Treatment regimens for Maviret:

I. Treatment-experienced, genotype 1, 2, 4, 5, or 6 with compensated cirrhosis who have failed peginterferon/ribavirin and/or sofosbuvir ONLY.
Approved duration: 12 weeks

II. Treatment-experienced genotype 1 non-cirrhotic or compensated cirrhosis who have failed an NS3/4A protease inhibitor (2) but are NS5A inhibitor naive.
Approved duration: 12 weeks

Notes:

(1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.

(2) NS3/4A PIs include simeprevir, boceprevir, and telepravir.

(3) NS5A inhibitors include daclatasvir and ledipasvir.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 12 Weeks.</lccNote><lccNote seq="005" reasonForUseId="552">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; 

(ii) Laboratory confirmed hepatitis C genotype 1 or 3;

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).

Exclusion criteria:

- Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor

- For use in combination with other hepatitis C antiviral agents

- Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C)

Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program.

Treatment regimens for Maviret:

I. Treatment-experienced genotype 1 non-cirrhotic or compensated cirrhosis who have failed an NS5A inhibitor (3) but is NS3/4A protease inhibitor naive.
Approved duration: 16 weeks

II. Treatment-experienced genotype 3 non-cirrhotic or compensated cirrhosis who have failed peginterferon/ribavirin and/or sofosbuvir ONLY.
Approved duration: 16 weeks

Notes:

(1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.

(2) NS3/4A PIs include simeprevir, boceprevir, and telepravir.

(3) NS5A inhibitors include daclatasvir and ledipasvir.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 16 Weeks.</lccNote></pcgGroup></genericName><genericName id="00111"><name>LAMIVUDINE</name><pcgGroup><pcg9 id="081800005"><itemNumber>0161</itemNumber><strength>10mg/mL</strength><dosageForm>O/L</dosageForm><note>Reimbursement will not be provided for the treatment of hepatitis.</note><drug id="02192691" sec3="Y"><name>3TC</name><manufacturerId>VIH</manufacturerId><individualPrice>.4267</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4267</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00296"><pcg9 id="081800048"><itemNumber>0162</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02239193" notABenefit="Y" sec3="Y"><name>Heptovir</name><manufacturerId>GSK</manufacturerId><listingDate>2012-11-27</listingDate></drug><drug id="02393239" sec3="Y" sec12="Y"><name>Apo-Lamivudine HBV</name><manufacturerId>APX</manufacturerId><individualPrice>2.6154</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>2.6154</amountMOHLTCPays></drug><drug id="02512467" sec3="Y" sec12="Y"><name>Jamp Lamivudine HBV</name><manufacturerId>JPC</manufacturerId><individualPrice>2.6154</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>2.6154</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="502">Confirmed chronic Hepatitis B infection in persons with

- HBV DNA greater than or equal to 1000 IU/mL

AND

- ALT levels greater than ULN

OR

- Evidence of fibrosis

or

- Documented evidence of cirrhosis</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="503">Patients with chronic Hepatitis B infection currently receiving treatment with lamivudine and requires treatment continuation.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="504">Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="081800004"><itemNumber>0163</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><note>Reimbursement will not be provided for the treatment of hepatitis.</note><drug id="02192683" sec3="Y"><name>3TC</name><manufacturerId>VIH</manufacturerId><individualPrice>6.6082</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.7323</amountMOHLTCPays></drug><drug id="02369052" sec3="Y"><name>Apo-Lamivudine</name><manufacturerId>APX</manufacturerId><individualPrice>2.7323</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>2.7323</amountMOHLTCPays></drug><drug id="02507110" sec3="Y"><name>Jamp Lamivudine</name><manufacturerId>JPC</manufacturerId><individualPrice>2.7323</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>2.7323</amountMOHLTCPays></drug></pcg9><pcg9 id="081800078"><itemNumber>0164</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><note>Reimbursement will not be provided for the treatment of hepatitis.</note><drug id="02247825" sec3="Y"><name>3TC</name><manufacturerId>VIH</manufacturerId><individualPrice>13.2673</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>5.4857</amountMOHLTCPays></drug><drug id="02369060" sec3="Y"><name>Apo-Lamivudine</name><manufacturerId>APX</manufacturerId><individualPrice>5.4857</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>5.4857</amountMOHLTCPays></drug><drug id="02507129" sec3="Y"><name>Jamp Lamivudine</name><manufacturerId>JPC</manufacturerId><individualPrice>5.4857</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>5.4857</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01404"><name>LAMIVUDINE &amp; ZIDOVUDINE</name><pcgGroup><pcg9 id="081800049"><itemNumber>0165</itemNumber><strength>150mg &amp; 300mg</strength><dosageForm>Tab</dosageForm><drug id="02239213" sec3="Y"><name>Combivir</name><manufacturerId>VIH</manufacturerId><individualPrice>13.2262</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>2.6103</amountMOHLTCPays></drug><drug id="02375540" sec3="Y"><name>Apo-Lamivudine-Zidovudine</name><manufacturerId>APX</manufacturerId><individualPrice>2.6103</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>2.6103</amountMOHLTCPays></drug><drug id="02414414" sec3="Y"><name>Auro-Lamivudine/Zidovudine</name><manufacturerId>AUR</manufacturerId><individualPrice>2.6103</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>2.6103</amountMOHLTCPays></drug><drug id="02502801" sec3="Y"><name>Jamp Lamivudine / Zidovudine</name><manufacturerId>JPC</manufacturerId><individualPrice>2.6103</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>2.6103</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01968"><name>LEDIPASVIR &amp; SOFOSBUVIR</name><pcgGroup lccId="00276"><pcg9 id="081800370"><itemNumber>0166</itemNumber><strength>90mg &amp; 400mg</strength><dosageForm>Tab</dosageForm><drug id="02432226" sec3="Y" sec12="Y"><name>Harvoni</name><manufacturerId>GIL</manufacturerId><individualPrice>797.6190</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>797.6190</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="482">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 1; AND

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).


Treatment regimens:

- Treatment-naive, non-cirrhotic, recent quantitative hepatitis C viral load less than 6 M IU/mL

Approved duration: 8 weeks

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 8 Weeks</lccNote><lccNote seq="003" reasonForUseId="483">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 1; AND

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).

Treatment regimens:

I. Treatment-naive, without cirrhosis, viral load greater than or equal to 6 M IU/mL; or treatment-naive with cirrhosis; or treatment-experienced without cirrhosis

Approved duration: 12 weeks

II. Treatment-naive or treatment-experienced with decompensated cirrhosis (2)

Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)

III. Treatment-naive or treatment-experienced liver transplant recipients without cirrhosis or with compensated cirrhosis (2)

Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 12 Weeks.</lccNote><lccNote seq="005" reasonForUseId="484">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 1; AND

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).

Treatment regimen:

- Treatment-experienced, cirrhotic:

Approved duration: 24 weeks

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 24 Weeks.</lccNote><lccNote seq="007" type="N">1. Treatment-experienced are those who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor.

2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Scores 5 to 6]) and decompensated cirrhosis (Child-Turcotte-Pugh B or C [i.e. Score 7 or above]) may be considered.

3. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote></pcgGroup></genericName><genericName id="01511"><name>LOPINAVIR &amp; RITONAVIR</name><pcgGroup><pcg9 id="081800061"><itemNumber>0167</itemNumber><strength>80mg/mL &amp; 20mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02243644" sec3="Y"><name>Kaletra</name><manufacturerId>ABV</manufacturerId><individualPrice>2.3688</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>2.3688</amountMOHLTCPays></drug></pcg9><pcg9 id="081800110"><itemNumber>0168</itemNumber><strength>100mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02312301" sec3="Y"><name>Kaletra</name><manufacturerId>ABV</manufacturerId><individualPrice>2.9317</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>2.9317</amountMOHLTCPays></drug></pcg9><pcg9 id="081800098"><itemNumber>0169</itemNumber><strength>200mg &amp; 50mg</strength><dosageForm>Tab</dosageForm><drug id="02285533" sec3="Y"><name>Kaletra</name><manufacturerId>ABV</manufacturerId><individualPrice>5.8633</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>5.8633</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01751"><name>MARAVIROC</name><pcgGroup><pcg9 id="081800111"><itemNumber>0170</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02299844" sec3="Y"><name>Celsentri</name><manufacturerId>VIH</manufacturerId><individualPrice>21.6208</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>21.6208</amountMOHLTCPays></drug></pcg9><pcg9 id="081800112"><itemNumber>0171</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02299852" sec3="Y"><name>Celsentri</name><manufacturerId>VIH</manufacturerId><individualPrice>21.6208</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>21.6208</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01390"><name>NELFINAVIR MESYLATE</name><pcgGroup><pcg9 id="081800042"><itemNumber>0172</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02238617" sec3="Y"><name>Viracept</name><manufacturerId>PFI</manufacturerId><individualPrice>2.1814</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>2.1814</amountMOHLTCPays></drug></pcg9><pcg9 id="081800086"><itemNumber>0173</itemNumber><strength>625mg</strength><dosageForm>Tab</dosageForm><drug id="02248761" sec3="Y"><name>Viracept</name><manufacturerId>PFI</manufacturerId><individualPrice>5.4642</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>5.4642</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01393"><name>NEVIRAPINE</name><pcgGroup><pcg9 id="081800356"><itemNumber>0174</itemNumber><strength>400mg</strength><dosageForm>ER Tab</dosageForm><drug id="02367289" notABenefit="Y" sec3="Y"><name>Viramune XR</name><manufacturerId>BOE</manufacturerId><listingDate>2012-07-27</listingDate></drug><drug id="02427931" sec3="Y"><name>Apo-Nevirapine XR</name><manufacturerId>APX</manufacturerId><individualPrice>1.8519</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>1.8519</amountMOHLTCPays></drug></pcg9><pcg9 id="081800044"><itemNumber>0175</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02238748" notABenefit="Y" sec3="Y"><name>Viramune</name><manufacturerId>BOE</manufacturerId><listingDate>1999-04-15</listingDate></drug><drug id="02318601" sec3="Y"><name>Auro-Nevirapine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2346</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.2346</amountMOHLTCPays></drug><drug id="02352893" sec3="Y"><name>Teva-Nevirapine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2346</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.2346</amountMOHLTCPays></drug><drug id="02387727" sec3="Y"><name>Mylan-Nevirapine</name><manufacturerId>MYL</manufacturerId><individualPrice>1.2346</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>1.2346</amountMOHLTCPays></drug><drug id="02405776" sec3="Y"><name>Jamp Nevirapine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2346</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>1.2346</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02198"><name>NIRMATRELVIR &amp; RITONAVIR</name><pcgGroup lccId="00391"><pcg9 id="081800413"><itemNumber>0176</itemNumber><strength>150mg &amp; 100mg</strength><dosageForm>Tab-20 Pk</dosageForm><drug id="02527804" sec3="Y" sec12="Y"><name>Paxlovid</name><manufacturerId>PFI</manufacturerId><individualPrice>1288.8800</individualPrice><listingDate>2024-05-17</listingDate><amountMOHLTCPays>1288.8800</amountMOHLTCPays></drug></pcg9><pcg9 id="081800412"><itemNumber>0177</itemNumber><strength>150mg &amp; 100mg</strength><dosageForm>Tab-30 Pk</dosageForm><drug id="02524031" sec3="Y" sec12="Y"><name>Paxlovid</name><manufacturerId>PFI</manufacturerId><individualPrice>1288.8800</individualPrice><listingDate>2024-05-17</listingDate><amountMOHLTCPays>1288.8800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="673">For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in patients 65 years of age or older with:

- a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and

- symptoms present for 5 days or fewer.

Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment.

Treatment decisions should be individualized based on the prescriber&apos;s assessment of patient risk because not all medical or social vulnerabilities carry the same risk. Prescribers should consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024).

Pharmacists and prescribers should be informed of and stay current with a drug product&apos;s official indications in accordance with Health Canada&apos;s approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.

Note: The funded treatment is one dose pack* for a treatment duration of 5 days.

* Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each).

* Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 5 days to align with funded treatment duration.</lccNote><lccNote seq="003" reasonForUseId="674">For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in immunocompromised* patients 18 years of age or older regardless of vaccine status or prior COVID-19 infections with:

- a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and
- symptoms present for 5 days or fewer.
* Prescribers should consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024).

Examples of immunocompromised include:

- Advanced untreated human immunodeficiency virus (HIV) or treated HIV with a CD4 count equal or less than 200 per mm3 or CD4 fraction equal or less than 15%
- Bone marrow or stem cell transplant
- Solid organ transplant
- Have active hematological malignancy or recently received treatment for hematological malignancy
  - E.g., have received treatment with any anti-CD20 agents or B-cell depleting     agents in the last 2 years
- Chimeric antigen receptor (CAR) T-cell therapy in the last 6 months
- Treatment for cancer (including solid tumors), limited to: systemic therapy in the last 6 months (e.g., chemotherapy, molecular therapy, immunotherapy, targeted therapies, monoclonal antibodies, excluding those receiving adjunctive hormonal therapy only) or radiation therapy in the last 3 months
- Prednisone use equal to or greater than 20mg/day (or corticosteriod equivalent) for 14 days or more, or other moderately or severely immunosuppressive therapies (e.g., alkylating agents)
- Primary immunodeficiencies. For example:
  - Hypogammaglobulinemia
  - Combined immune deficiencies affecting T-cells - Immune dysregulation (e.g.,   familial hemophagocytic lymphohistiocytosis)
  - Type 1 interferon defects caused by a genetic primary immunodeficiency   disorder or secondary to anti-interferon autoantibodies
  - Diagnosed by an immunologist and requires ongoing immunoglobulin replacement   therapy (IVIg or SCIg)
  - Primary immunodeficiency with a confirmed genetic cause (e.g., DiGeorge   syndrome, Wiskott-Aldrich syndrome)

Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment.

Treatment decisions should be individualized based on the prescriber&apos;s assessment of patient risk because not all medical or social vulnerabilities carry the same risk.

Pharmacists and prescribers should be informed of and stay current with a drug product&apos;s official indications in accordance with Health Canada&apos;s approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.

Note: The funded treatment is one dose pack** for a treatment duration of 5 days. In exceptional circumstances, the funded treatment is two dose packs** for a treatment duration of 10 days based on prescriber clinical judgement in consultation with an infectious disease specialist. Pharmacy operators must obtain and retain appropriate documentation to support claims for such extended therapy. For guidance, prescribers may consult Ontario Health - Frequently Asked Questions on Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024).</lccNote><lccNote seq="004" type="N">** Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each).

** Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each).</lccNote><lccNote seq="005" type="R">LU Authorization Period: 5 days or 10 days to align with funded treatment duration.</lccNote><lccNote seq="006" reasonForUseId="675">For the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in patients 18 to 64 years of age with at least 1 risk factor* associated with more severe COVID-19 outcomes with:

- a positive result from direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing (either using rapid antigen test or PCR), and

- symptoms present for 5 days or fewer.

The risk of progression to severe COVID-19 depends on the quantity of underlying medical conditions and how controlled the medical conditions are.
* When assessing risk factors, prescribers may want to consult Ontario Health Recommendations for Antiviral Therapy for Adults with Mild to Moderate COVID-19 (April 2024). Examples of risk factors include:

Vaccination Status:

- Have never received a COVID-19 vaccine

Medical Conditions:

- Active tuberculosis (treated or untreated)

- Cerebrovascular disease

- Chronic kidney disease, especially CKD stage 4 or 5 and dialysis

- Chronic lung diseases, limited to: asthma, bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension

- Chronic liver diseases, limited to: cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis

- Cystic fibrosis

- Diabetes mellitus, type 1 or type 2

- Disabilities and developmental delay, including Down syndrome

- Heart conditions (e.g., heart failure, coronary artery disease, cardiomyopathies)

- Mental health conditions, limited to: mood disorders (including depression), schizophrenia spectrum disorders

- Neurologic conditions that cause an inability to control respiratory secretions or communicate disease progression (e.g., cognitive disorders such as Alzheimer-type dementia)

- Obesity (body mass index above 30kg per m2)

- Pregnancy or recent pregnancy (42 days post-partum/end of pregnancy)

Note for consideration: Certain medical or social vulnerabilities may confer an increased risk of disease progression because affected individuals may experience challenges in recognizing, communicating or acting on progressive COVID-19 symptoms. People who are at a high risk of poor outcomes from COVID-19 based on social determinants of health should be considered priority populations for access to antivirals. Individuals at high risk include Indigenous people, Black people, other members of racialized communities; people experiencing intellectual, developmental, or cognitive disabilities; people who use substances regularly (e.g., alcohol); people who live with mental health conditions; and people who are underhoused.

Paxlovid (DIN: 02527804) is intended for patients with renal impairment or on dialysis. If Paxlovid (DIN: 02524031) is being dispensed for such patients, it requires dose adjustment.

Treatment decisions should be individualized based on the prescriber&apos;s assessment of patient risk because not all medical or social vulnerabilities carry the same risk.

Pharmacists and prescribers should be informed of and stay current with a drug product&apos;s official indications in accordance with Health Canada&apos;s approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for Paxlovid. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.

Note: The funded treatment is one dose pack** for a treatment duration of 5 days.</lccNote><lccNote seq="007" type="N">** Dose pack for DIN: 02524031 is package of 30 tablets divided in 5 daily-dose blister cards containing 4 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each).

** Dose pack for DIN: 02527804 is a package of 20 tablets divided in 5 daily-dose blister cards containing 2 nirmatrelvir tablets (150mg each) and 2 ritonavir tablets (100mg each).</lccNote><lccNote seq="008" type="R">LU Authorization Period: 5 days to align with funded treatment duration.</lccNote></pcgGroup></genericName><genericName id="01554"><name>OSELTAMIVIR PHOSPHATE</name><pcgGroup lccId="00143"><pcg9 id="081800341"><itemNumber>0178</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><drug id="02304848" sec3="Y" sec12="Y"><name>Tamiflu</name><manufacturerId>HLR</manufacturerId><individualPrice>2.1150</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.5243</amountMOHLTCPays></drug><drug id="02472635" sec3="Y" sec12="Y"><name>Nat-Oseltamivir</name><manufacturerId>NAT</manufacturerId><individualPrice>.5243</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.5243</amountMOHLTCPays></drug><drug id="02497409" sec3="Y" sec12="Y"><name>Jamp Oseltamivir</name><manufacturerId>JPC</manufacturerId><individualPrice>.5243</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.5243</amountMOHLTCPays></drug><drug id="02497441" sec3="Y" sec12="Y"><name>Mint-Oseltamivir</name><manufacturerId>MIN</manufacturerId><individualPrice>.5243</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.5243</amountMOHLTCPays></drug><drug id="02504006" sec3="Y" sec12="Y"><name>Sandoz Oseltamivir</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5243</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.5243</amountMOHLTCPays></drug></pcg9><pcg9 id="081800342"><itemNumber>0179</itemNumber><strength>45mg</strength><dosageForm>Cap</dosageForm><drug id="02304856" sec3="Y" sec12="Y"><name>Tamiflu</name><manufacturerId>HLR</manufacturerId><individualPrice>3.2540</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>1.6135</amountMOHLTCPays></drug><drug id="02472643" sec3="Y" sec12="Y"><name>Nat-Oseltamivir</name><manufacturerId>NAT</manufacturerId><individualPrice>1.6135</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.6135</amountMOHLTCPays></drug><drug id="02504014" sec3="Y" sec12="Y"><name>Sandoz Oseltamivir</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6135</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>1.6135</amountMOHLTCPays></drug></pcg9><pcg9 id="081800064"><itemNumber>0180</itemNumber><strength>75mg</strength><dosageForm>Cap</dosageForm><drug id="02241472" sec3="Y" sec12="Y"><name>Tamiflu</name><manufacturerId>HLR</manufacturerId><individualPrice>4.1940</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>1.0393</amountMOHLTCPays></drug><drug id="02457989" sec3="Y" sec12="Y"><name>Nat-Oseltamivir</name><manufacturerId>NAT</manufacturerId><individualPrice>1.0393</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>1.0393</amountMOHLTCPays></drug><drug id="02497425" sec3="Y" sec12="Y"><name>Jamp Oseltamivir</name><manufacturerId>JPC</manufacturerId><individualPrice>1.0393</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>1.0393</amountMOHLTCPays></drug><drug id="02497476" sec3="Y" sec12="Y"><name>Mint-Oseltamivir</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0393</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>1.0393</amountMOHLTCPays></drug><drug id="02504022" sec3="Y" sec12="Y"><name>Sandoz Oseltamivir</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0393</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>1.0393</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="371">For the prophylaxis (max: 75mg daily) of institutionalized individuals during confirmed* outbreaks of Influenza A or Influenza B.</lccNote><lccNote seq="002" type="N">Network will limit supply to 6 weeks.</lccNote><lccNote seq="003" type="R">*The outbreak must be confirmed by Public Health.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="372">For the treatment (max: 75mg bid) of institutionalized individuals during confirmed* outbreaks due to: Influenza B or, Influenza A (as an alternative to amantadine) or, Influenza A where new cases have developed despite amantadine prophylaxis.</lccNote><lccNote seq="006" type="N">Network will limit supply to 5 days.</lccNote><lccNote seq="007" type="R">*The outbreak must be confirmed by Public Health.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="639">For treatment of individuals who are at high risk* of complications from influenza infection and have either:

1. Laboratory-confirmed influenza A or influenza B infection;
OR
2. Illness consistent with influenza A or influenza B infection

*High risk of complications from influenza infection is defined by the presence of one or more of the following medical conditions, age-related factors, or other characteristics:

- Asthma and other chronic pulmonary diseases, including bronchopulmonary dysplasia, cystic fibrosis, chronic bronchitis, and emphysema

- Cardiovascular disease (excluding isolated hypertension), including congenital and acquired heart disease, such as heart failure and symptomatic coronary artery disease

- Renal disease

- Chronic liver disease

- Diabetes mellitus and other metabolic diseases

- Anemia and hemoglobinopathies, such as sickle cell disease

- Cancer, immunosuppression, or immunodeficiency due to disease (e.g., HIV infection, especially if CD4 is less than 200 per microlitre) or management of underlying conditions (e.g., solid organ transplant or hematopoietic stem cell transplant recipients, those receiving immunosuppressive therapies for autoimmune conditions or other disorders)

- Neurological disease and neurodevelopmental disorders that compromise handling of respiratory secretions (cognitive dysfunction; spinal cord injury; neuromuscular, neurovascular, neurodegenerative, and seizure disorders; cerebral palsy; metabolic disorders)

- Children aged younger than 5 years

- Individuals aged 65 years or older

- Individuals of any age who are residents of nursing homes or other chronic care facilities

- Pregnancy and up to 4 weeks postpartum regardless of how the pregnancy ended

- Obesity with a body mass index (BMI) greater than or equal to 40 or a BMI greater than 3 z-scores above the mean for age and gender

- Children and adolescents aged younger than 18 years undergoing treatment for long periods with acetylsalicylic acid

- Indigenous peoples

Maximum dosage: 75mg twice daily for 5 days


Treatment should be initiated as soon as possible (ideally no more than 48 hours) after onset of symptoms to achieve optimal benefits.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 6 Months</lccNote><lccNote seq="012" type="N">Prescribers and dispensers should be informed of the drug product&apos;s official indications as set out in Health Canada&apos;s approved product monograph. Aspects of the above funding criteria may differ from the official indications in the product monograph. Where there is a difference between the product monograph and the above reimbursement criteria, the criteria govern for the purpose of the drug product&apos;s funding under the Ontario Drug Benefit Program. The reimbursement criteria are intended for information purposes only and do not provide any medical diagnosis, symptom assessment, health counselling, or medical opinion for Ontario Drug Benefit Program recipients. This information also does not constitute medical advice for prescribers or dispensers.</lccNote></pcgGroup><pcgGroup><pcg9 id="081800403"><itemNumber>0181</itemNumber><strength>6mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02381842" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tamiflu</name><manufacturerId>HLR</manufacturerId><listingDate>2020-08-28</listingDate></drug><drug id="02499894" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Oseltamivir</name><manufacturerId>NAT</manufacturerId><individualPrice>.2811</individualPrice><listingDate>2020-08-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01723"><name>RALTEGRAVIR POTASSIUM</name><pcgGroup><pcg9 id="081800102"><itemNumber>0182</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="02301881" sec3="Y"><name>Isentress</name><manufacturerId>MFC</manufacturerId><individualPrice>14.0301</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>14.0301</amountMOHLTCPays></drug></pcg9><pcg9 id="081800394"><itemNumber>0183</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02465337" sec3="Y"><name>Isentress HD</name><manufacturerId>MEK</manufacturerId><individualPrice>14.0301</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>14.0301</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02324"><name>REMDESIVIR</name><pcgGroup lccId="00407"><pcg9 id="081800419"><itemNumber>0184</itemNumber><strength>100mg/vial</strength><dosageForm>Pd for Sol-100mg Vial Pk</dosageForm><drug id="02502143" sec3="Y" sec12="Y"><name>Veklury</name><manufacturerId>GIL</manufacturerId><individualPrice>660.5300</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>660.5300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="722">For the treatment of coronavirus disease 2019 (COVID-19) in non-hospitalized individuals who:

- have a diagnosis of COVID-19 based on a positive Rapid Antigen Test or PCR test; AND

- are at high-risk for progression to severe COVID-19 due to:

- being moderately or severely immunocompromised (see below), or
- being 65 years of age or older, or
- having one or more risk factors (see below); AND

- will not be using remdesivir in combination with any other antiviral medication for COVID-19 (e.g. Paxlovid).

Remdesivir is an alternative option for patients who cannot receive nirmatrelvir-ritonavir (Paxlovid) due to contraindications, intolerance, potential drug-drug interactions, and/or greater than 5 days since symptom onset.

Remdesivir should be initiated as soon as possible after a diagnosis of COVID-19 based on a positive Rapid Antigen Test or PCR test, and within 7 days of symptom onset.

The funded treatment duration is up to 3 days, unless the prescriber has prescribed treatment for up to 5 days in consultation with an infectious disease specialist and this is documented by the pharmacy, in which case the funded treatment duration is up to 5 days.

Pharmacists and prescribers should be informed of and stay current with a drug product&apos;s official indications in accordance with Health Canada&apos;s approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for remdesivir. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.</lccNote><lccNote seq="002" type="R">Examples of moderately or severely immunocompromised individuals include those with:

- Advanced untreated human immunodeficiency virus (HIV) or treated HIV with a CD4 count equal or less than 200 per mm3 or CD4 fraction equal or less than 15%
- Bone marrow or stem cell transplant
- Solid organ transplant
- Active hematological malignancy or recently received treatment for hematological malignancy E.g., have received treatment with any anti-CD20 agents or B-cell depleting agents in the last 2 years
- Chimeric antigen receptor (CAR) T-cell therapy in the last 6 months
- Treatment for cancer (including solid tumors), limited to: systemic therapy in the last 6 months (e.g., chemotherapy, molecular therapy, immunotherapy, targeted  therapies, monoclonal antibodies, excluding those receiving adjunctive hormonal therapy only) or radiation therapy in the last 3 months
- Prednisone use equal to or greater than 20mg/day (or corticosteroid equivalent) for 14 days or more, or other moderately or severely immunosuppressive therapies (e.g., alkylating agents)
- Primary immunodeficiencies. For example:
- Hypogammaglobulinemia
- Combined immune deficiencies affecting T-cells
- Immune dysregulation (e.g., familial hemophagocytic lymphohistiocytosis)
- Type 1 interferon defects caused by a genetic primary immunodeficiency disorder or secondary to anti-interferon autoantibodies
- Diagnosed by an immunologist and requires ongoing immunoglobulin replacement therapy (IVIg or SCIg)
- Primary immunodeficiency with a confirmed genetic cause (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)</lccNote><lccNote seq="003" type="R">The risk of progression to severe COVID-19 depends on the quantity of underlying chronic comorbidities and how controlled the conditions are. When assessing risk factors, prescribers may want to consult the most recent Ontario Health COVID-19 clinical guidance.

Examples of risk factors include:
- Has never received a COVID-19 vaccine
- Active tuberculosis (treated or untreated)
- Cerebrovascular disease
- Chronic kidney disease (CKD), especially CKD stage 4 or 5 and dialysis
- Chronic lung diseases (asthma, bronchiectasis, chronic obstructive pulmonary disease, interstitial lung disease, pulmonary embolism, pulmonary hypertension)
- Chronic liver diseases (cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, autoimmune hepatitis)
- Cystic fibrosis
- Diabetes mellitus type 1 or type 2
- Disabilities and developmental delay, including Down syndrome
- Heart conditions, e.g., heart failure, coronary artery disease, cardiomyopathies
- Mental health conditions, e.g., mood disorders (including depression), schizophrenia spectrum disorders
- Neurologic conditions that cause an inability to control respiratory secretions or communicate disease progression (e.g., cognitive disorders such as Alzheimer-type dementia)
- Obesity (body mass index above 30kg per metre squared)
- Pregnancy or recent pregnancy (42 days post-partum/end of pregnancy)
</lccNote><lccNote seq="004" type="R">LU Authorization Period: Length of funded treatment duration (see above)</lccNote></pcgGroup></genericName><genericName id="01888"><name>RILPIVIRINE HYDROCHLORIDE</name><pcgGroup><pcg9 id="081800355"><itemNumber>0185</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02370603" sec3="Y"><name>Edurant</name><manufacturerId>JAN</manufacturerId><individualPrice>17.7500</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>17.7500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00113"><name>RITONAVIR</name><pcgGroup><pcg9 id="081800350"><itemNumber>0186</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02357593" sec3="Y"><name>Norvir</name><manufacturerId>ABB</manufacturerId><individualPrice>1.5660</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>1.1745</amountMOHLTCPays></drug><drug id="02523620" sec3="Y"><name>Auro-Ritonavir</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1745</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>1.1745</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01967"><name>SOFOSBUVIR</name><pcgGroup lccId="00277"><pcg9 id="081800369"><itemNumber>0187</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="02418355" sec3="Y" sec12="Y"><name>Sovaldi</name><manufacturerId>GIL</manufacturerId><individualPrice>654.7619</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>654.7619</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="485">In combination with ribavirin (Ibavyr) for treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 2; AND

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use). 

For patients who meet the eligibility criteria for sofosbuvir (Sovaldi), clinicians are encouraged to choose sofosbuvir/velpatasvir (Epclusa) as the preferred therapeutic option over sofosbuvir with ribavirin regimens for treatment of genotype 2 or 3 patients only. This recommendation is based on evidence that Epclusa offers advantages in some patient populations, including potentially higher SVR rates and a shorter course of therapy for genotype 3 infections.

Treatment regimens for sofosbuvir (Sovaldi) for genotype 2:

- Treatment-naive or treatment-experienced genotype 2

Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote><lccNote seq="005" reasonForUseId="487">In combination with ribavirin (Ibavyr) for treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 3; AND

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use). 

For patients who meet the eligibility criteria for sofosbuvir (Sovaldi), clinicians are encouraged to choose sofosbuvir/velpatasvir (Epclusa) as the preferred therapeutic option over sofosbuvir with ribavirin regimens for treatment of genotype 2 or 3 patients only. This recommendation is based on evidence that Epclusa offers advantages in some patient populations, including potentially higher SVR rates and a shorter course of therapy for genotype 3 infections.

Treatment regimens for sofosbuvir (Sovaldi) for genotype 3:

- Treatment-naive or treatment-experienced without cirrhosis, or with compensated cirrhosis (2), or with decompensated cirrhosis (2), or post-liver transplant

Approved regimen: 24 weeks in combination with ribavirin (Ibavyr).

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 24 Weeks.</lccNote><lccNote seq="007" type="N">1. Treatment-experienced are those who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor. 

2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Score 5 to 6]) and decompensated cirrhosis (Child-Turcotte-Pugh B or C [i.e. Score 7 or above]) may be considered.

3. Combination therapy with Zepatier (elbasvir/grazoprevir) will not be considered for funding.

4. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote></pcgGroup></genericName><genericName id="02028"><name>SOFOSBUVIR &amp; VELPATASVIR</name><pcgGroup lccId="00278"><pcg9 id="081800382"><itemNumber>0188</itemNumber><strength>400mg &amp; 100mg</strength><dosageForm>Tab</dosageForm><drug id="02456370" sec3="Y" sec12="Y"><name>Epclusa</name><manufacturerId>GIL</manufacturerId><individualPrice>714.2857</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>714.2857</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="488">For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, 6 or mixed genotypes; AND

(iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use). 

Treatment regimens for Epclusa (sofosbuvir-velpatasvir):

I. Treatment-naive or treatment-experienced (1) non-cirrhotic or compensated cirrhosis (2)

Approved duration: 12 weeks

II. Treatment-naive or treatment-experienced patients with decompensated cirrhosis (2)

Approved regimen: 12 weeks in combination with ribavirin (Ibavyr)

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of direct-acting antiviral will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote><lccNote seq="003" type="N">1. Treatment-experienced are those who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor.

2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Scores 5 to 6]) and decompensated cirrhosis (Child-Turcotte-Pugh B or C [i.e. Score 7 or above]) may be considered.

3. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote></pcgGroup></genericName><genericName id="02046"><name>SOFOSBUVIR &amp; VELPATASVIR &amp; VOXILAPREVIR</name><pcgGroup lccId="00298"><pcg9 id="081800389"><itemNumber>0189</itemNumber><strength>400mg &amp; 100mg &amp; 100mg</strength><dosageForm>Tab</dosageForm><drug id="02467542" sec3="Y" sec12="Y"><name>Vosevi</name><manufacturerId>GIL</manufacturerId><individualPrice>714.2857</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>714.2857</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="524">For treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria:

(i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; AND

(ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, 6 or mixed genotypes; AND

(iii)  Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart;

OR

One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use).

Treatment regimen for Vosevi (sofosbuvir-velpatasvir-voxilaprevir):

Treatment-experienced, non-cirrhotic or compensated cirrhosis (2)

Approved duration: 12 weeks

Retreatment is not funded. Retreatment for failure or re-infection in patients who have received an adequate prior course of Vosevi will be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote><lccNote seq="003" type="N">1. Treatment-experienced are those who failed prior therapy with a HCV regimen containing: 

i. NS5A inhibitor* for genotype 1, 2, 3, 4, 5, or 6; OR 

ii. Sofosbuvir (Sovaldi) without an NS5A inhibitor for genotype 1, 2, 3, or 4

*NS5A inhibitors include: daclatasvir (Daklinza), elbasvir (as part of Zepatier), ledipasvir (as part of Harvoni), ombitasvir (as part of Holkira Pak), velpatasvir (as part of Epclusa), pibrentasvir (as part of Maviret)

2. Compensated cirrhosis (Child-Turcotte-Pugh A [i.e. Scores 5 to 6]) may be considered.

3. Health care professionals are advised to refer to the product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations.</lccNote></pcgGroup></genericName><genericName id="01619"><name>TENOFOVIR DISOPROXIL</name><pcgGroup lccId="00297"><pcg9 id="081800083"><itemNumber>0190</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02247128" sec3="Y" sec12="Y"><name>Viread</name><manufacturerId>GIL</manufacturerId><individualPrice>19.5537</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02403889" sec3="Y" sec12="Y"><name>Teva-Tenofovir</name><manufacturerId>TEV</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02451980" sec3="Y" sec12="Y"><name>Apo-Tenofovir</name><manufacturerId>APX</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02452634" sec3="Y" sec12="Y"><name>Mylan-Tenofovir Disoproxil</name><manufacturerId>MYL</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02453940" sec3="Y" sec12="Y"><name>PMS-Tenofovir</name><manufacturerId>PMS</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02460173" sec3="Y" sec12="Y"><name>Auro-Tenofovir</name><manufacturerId>AUR</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02472511" sec3="Y" sec12="Y"><name>Nat-Tenofovir</name><manufacturerId>NAT</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02479087" sec3="Y" sec12="Y"><name>Jamp-Tenofovir</name><manufacturerId>JPC</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02512327" sec3="Y" sec12="Y"><name>Tenofovir</name><manufacturerId>SAI</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02512939" sec3="Y" sec12="Y"><name>Mint-Tenofovir</name><manufacturerId>MIN</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug><drug id="02523922" sec3="Y" sec12="Y"><name>Tenofovir</name><manufacturerId>SIV</manufacturerId><individualPrice>4.8884</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>4.8884</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="517">Confirmed chronic Hepatitis B infection in persons with

- HBV DNA greater than or equal to 1000 IU/mL

AND

- ALT levels greater than ULN

OR

- Evidence of fibrosis

OR

- Documented evidence of cirrhosis</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="518">For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="519">Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="520">Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="521">Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="522">For HIV/AIDS.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00115"><name>VALACYCLOVIR</name><pcgGroup><pcg9 id="081800012"><itemNumber>0191</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02219492" sec3="Y"><name>Valtrex</name><manufacturerId>GSK</manufacturerId><individualPrice>4.5647</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02295822" sec3="Y"><name>Apo-Valacyclovir</name><manufacturerId>APX</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02298457" sec3="Y"><name>PMS-Valacyclovir</name><manufacturerId>PMS</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02316447" sec3="Y"><name>Riva-Valacyclovir</name><manufacturerId>RIA</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02331748" sec3="Y"><name>Co Valacyclovir</name><manufacturerId>COB</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02347091" sec3="Y"><name>Sandoz Valacyclovir</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02351579" sec3="Y"><name>Mylan-Valacyclovir</name><manufacturerId>MYL</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02357534" sec3="Y"><name>Teva-Valacyclovir</name><manufacturerId>TEV</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02405040" sec3="Y"><name>Auro-Valacyclovir</name><manufacturerId>AUR</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02440598" sec3="Y"><name>Jamp Valacyclovir</name><manufacturerId>JPC</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02441454" sec3="Y"><name>Jamp-Valacyclovir</name><manufacturerId>JPC</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2015-12-22</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02442000" sec3="Y"><name>Valacyclovir</name><manufacturerId>SIV</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug><drug id="02454645" sec3="Y"><name>Valacyclovir</name><manufacturerId>SAI</manufacturerId><individualPrice>.6198</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>.6198</amountMOHLTCPays></drug></pcg9><pcg9 id="081800339"><itemNumber>0192</itemNumber><strength>1000mg</strength><dosageForm>Tab</dosageForm><drug id="02246559" notABenefit="Y" sec3b="Y" sec3="Y"><name>Valtrex</name><manufacturerId>GSK</manufacturerId><listingDate>2010-07-20</listingDate></drug><drug id="02351560" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Valacyclovir</name><manufacturerId>MYL</manufacturerId><individualPrice>5.8537</individualPrice><listingDate>2010-07-20</listingDate></drug><drug id="02354705" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Valacyclovir</name><manufacturerId>APX</manufacturerId><individualPrice>5.8537</individualPrice><listingDate>2010-10-28</listingDate></drug><drug id="02381230" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Valacyclovir</name><manufacturerId>PMS</manufacturerId><individualPrice>5.8537</individualPrice><listingDate>2012-05-29</listingDate></drug><drug id="02405059" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Valacyclovir</name><manufacturerId>AUR</manufacturerId><individualPrice>5.8537</individualPrice><listingDate>2020-12-18</listingDate></drug><drug id="02519585" notABenefit="Y" sec3b="Y" sec3="Y"><name>Valacyclovir</name><manufacturerId>SAI</manufacturerId><individualPrice>5.8537</individualPrice><listingDate>2021-12-17</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01581"><name>VALGANCICLOVIR</name><pcgGroup lccId="00328"><pcg9 id="081800108"><itemNumber>0193</itemNumber><strength>50mg/mL</strength><dosageForm>Pd for Oral Sol-100mL Pk</dosageForm><drug id="02306085" sec3="Y" sec12="Y"><name>Valcyte</name><manufacturerId>CHE</manufacturerId><individualPrice>315.5347</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>150.9900</amountMOHLTCPays></drug><drug id="02535483" sec3="Y" sec12="Y"><name>Auro-Valganciclovir</name><manufacturerId>AUR</manufacturerId><individualPrice>150.9900</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>150.9900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="571">For those unable to swallow or tolerate solid oral dosage form AND

For the treatment of Cytomegalovirus (CMV) retinitis in patients with HIV/AIDS.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="572">For those unable to swallow or tolerate solid oral dosage form AND

For the prevention of Cytomegalovirus (CMV) in solid organ transplant patients (not lung or heart-lung).</lccNote><lccNote seq="004" type="R">LU Authorization Period: Up to 6 months</lccNote><lccNote seq="005" reasonForUseId="573">For those unable to swallow or tolerate solid oral dosage form AND

For the prevention of Cytomegalovirus (CMV) in lung or heart-lung transplant patients.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Up to 12 months</lccNote></pcgGroup><pcgGroup lccId="00145"><pcg9 id="081800066"><itemNumber>0194</itemNumber><strength>450mg</strength><dosageForm>Tab</dosageForm><drug id="02245777" sec3="Y" sec12="Y"><name>Valcyte</name><manufacturerId>CHE</manufacturerId><individualPrice>28.4003</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>5.8553</amountMOHLTCPays></drug><drug id="02413825" sec3="Y" sec12="Y"><name>Teva-Valganciclovir</name><manufacturerId>TEV</manufacturerId><individualPrice>5.8553</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>5.8553</amountMOHLTCPays></drug><drug id="02435179" sec3="Y" sec12="Y"><name>Auro-Valganciclovir</name><manufacturerId>AUR</manufacturerId><individualPrice>5.8553</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>5.8553</amountMOHLTCPays></drug><drug id="02495457" sec3="Y" sec12="Y"><name>Mint-Valganciclovir</name><manufacturerId>MIN</manufacturerId><individualPrice>5.8553</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>5.8553</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="374">For the treatment of CMV retinitis in patients with HIV/AIDS.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="568">For the prevention of Cytomegalovirus (CMV) in solid organ transplant patients (not lung or heart-lung).</lccNote><lccNote seq="004" type="R">LU Authorization Period: Up to 6 months</lccNote><lccNote seq="005" reasonForUseId="569">For the prevention of Cytomegalovirus (CMV) in lung or heart-lung transplant patients.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Up to 12 months</lccNote></pcgGroup></genericName><genericName id="01749"><name>ZANAMIVIR</name><pcgGroup lccId="00203"><pcg9 id="081800109"><itemNumber>0195</itemNumber><strength>5mg</strength><dosageForm>Pd Inh-5 Rotadisks Pk</dosageForm><drug id="02240863" sec3="Y" sec12="Y"><name>Relenza</name><manufacturerId>GSK</manufacturerId><individualPrice>49.2300</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>49.2300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the treatment or prophylaxis of institutionalized individuals during confirmed outbreaks due to influenza A or Influenza B when the predominant circulating strain is resistant to oseltamivir or for the prophylaxis of influenza A, where new cases have developed despite amantadine prophylaxis.

The outbreak must be confirmed by Public Health.</lccNote><lccNote seq="002" reasonForUseId="414">For treatment: 2 inhalations of 5mg (10mg) bid for 5 days,</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="004" reasonForUseId="415">For prophylaxis: 2 inhalations of 5mg (10mg) once daily for 10 days.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00144"><name>ZIDOVUDINE</name><pcgGroup><pcg9 id="081800031"><itemNumber>0196</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="01902660" notABenefit="Y" sec3b="Y" sec3="Y"><name>Retrovir</name><manufacturerId>VIH</manufacturerId><listingDate>2009-06-23</listingDate></drug><drug id="01946323" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Zidovudine</name><manufacturerId>APX</manufacturerId><individualPrice>2.2366</individualPrice><listingDate>2009-06-23</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="082000000"><name>PLASMODICIDES (ANTIMALARIALS)</name><genericName id="01672"><name>ATOVAQUONE &amp; PROGUANIL HCL</name><pcgGroup><pcg9 id="082000010"><itemNumber>0197</itemNumber><strength>250mg &amp; 100mg</strength><dosageForm>Tab</dosageForm><drug id="02238151" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Malarone</name><manufacturerId>GSK</manufacturerId><individualPrice>6.3558</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>4.1308</amountMOHLTCPays></drug><drug id="02380927" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Atovaquone Proguanil</name><manufacturerId>TEV</manufacturerId><individualPrice>4.1308</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>4.1308</amountMOHLTCPays></drug><drug id="02402165" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Atovaquone/Proguanil</name><manufacturerId>MYL</manufacturerId><individualPrice>4.1308</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>4.1308</amountMOHLTCPays></drug><drug id="02421429" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Atovaquone Proguanil</name><manufacturerId>SAI</manufacturerId><individualPrice>4.1308</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>4.1308</amountMOHLTCPays></drug><drug id="02466783" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Atovaquone and Proguanil Hydrochloride</name><manufacturerId>GLP</manufacturerId><individualPrice>4.1308</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>4.1308</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00118"><name>HYDROXYCHLOROQUINE SULFATE</name><pcgGroup><pcg9 id="082000002"><itemNumber>0198</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02017709" sec3="Y"><name>Plaquenil</name><manufacturerId>SAV</manufacturerId><individualPrice>.6516</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1576</amountMOHLTCPays></drug><drug id="02246691" sec3="Y"><name>Apo-Hydroxyquine</name><manufacturerId>APX</manufacturerId><individualPrice>.1576</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.1576</amountMOHLTCPays></drug><drug id="02424991" sec3="Y"><name>Mint-Hydroxychloroquine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1576</individualPrice><listingDate>2016-04-29</listingDate><amountMOHLTCPays>.1576</amountMOHLTCPays></drug><drug id="02491427" sec3="Y"><name>Jamp-Hydroxychloroquine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1576</individualPrice><listingDate>2020-04-07</listingDate><amountMOHLTCPays>.1576</amountMOHLTCPays></drug><drug id="02511886" sec3="Y"><name>NRA-Hydroxychloroquine</name><manufacturerId>NRA</manufacturerId><individualPrice>.1576</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.1576</amountMOHLTCPays></drug><drug id="02519348" sec3="Y"><name>Hydroxychloroquine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1576</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.1576</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00147"><name>MEFLOQUINE HCL</name><pcgGroup><pcg9 id="082000011"><itemNumber>0199</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02018055" sec3b="Y" sec3="Y"><name>Lariam</name><manufacturerId>HLR</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02244366" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mefloquine</name><manufacturerId>AAP</manufacturerId><individualPrice>3.6950</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>3.6950</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="082400000"><name>SULFONAMIDES</name><genericName id="00126"><name>SULFASALAZINE</name><pcgGroup><pcg9 id="082400006"><itemNumber>0200</itemNumber><strength>500mg</strength><dosageForm>Ent Tab</dosageForm><drug id="00598488" sec3="Y"><name>PMS-Sulfasalazine-E.C.</name><manufacturerId>PMS</manufacturerId><individualPrice>.3863</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02064472" sec3="Y"><name>Salazopyrin EN-TABS 500 MG</name><manufacturerId>PFI</manufacturerId><individualPrice>.5512</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug></pcg9><pcg9 id="082400005"><itemNumber>0201</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="00598461" sec3="Y"><name>PMS-Sulfasalazine</name><manufacturerId>PMS</manufacturerId><individualPrice>.2533</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2533</amountMOHLTCPays></drug><drug id="02064480" sec3="Y"><name>Salazopyrin</name><manufacturerId>PFI</manufacturerId><individualPrice>.3614</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2533</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="082600000"><name>SULFONES</name><genericName id="00129"><name>DAPSONE</name><pcgGroup><pcg9 id="082600002"><itemNumber>0202</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.1952</dailyCost><drug id="02041510" sec3="Y"><name>Dapsone</name><manufacturerId>JAC</manufacturerId><individualPrice>1.4061</individualPrice><dailyCost>1.4061</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.1952</amountMOHLTCPays></drug><drug id="02481227" sec3="Y"><name>Mar-Dapsone</name><manufacturerId>MAR</manufacturerId><individualPrice>1.1952</individualPrice><dailyCost>1.1952</dailyCost><listingDate>2019-05-31</listingDate><amountMOHLTCPays>1.1952</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="083000000"><name>ANTIPROTOZOALS</name><genericName id="00146"><name>ATOVAQUONE</name><pcgGroup><pcg9 id="083000001"><itemNumber>0203</itemNumber><strength>750mg/5mL</strength><dosageForm>O/L</dosageForm><drug id="02217422" sec3="Y"><name>Mepron</name><manufacturerId>GSK</manufacturerId><individualPrice>3.7661</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>2.3785</amountMOHLTCPays></drug><drug id="02528495" sec3="Y"><name>GLN-Atovaquone</name><manufacturerId>GLP</manufacturerId><individualPrice>2.3785</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>2.3785</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="083200000"><name>TRICHOMONACIDES</name><genericName id="00029"><name>METRONIDAZOLE</name><pcgGroup><pcg9 id="083200002"><itemNumber>0204</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><dailyCost>.8217</dailyCost><drug id="00783137" sec3="Y"><name>PMS-Metronidazole</name><manufacturerId>PMS</manufacturerId><individualPrice>.2739</individualPrice><dailyCost>.8217</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2739</amountMOHLTCPays></drug><drug id="01926853" notABenefit="Y" sec3="Y"><name>Flagyl</name><manufacturerId>SAC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02248562" sec3="Y"><name>Apo-Metronidazole</name><manufacturerId>APX</manufacturerId><individualPrice>.2739</individualPrice><dailyCost>.8217</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2739</amountMOHLTCPays></drug><drug id="02470284" sec3="Y"><name>Auro-Metronidazole</name><manufacturerId>AUR</manufacturerId><individualPrice>.2739</individualPrice><dailyCost>.8217</dailyCost><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.2739</amountMOHLTCPays></drug><drug id="02518767" sec3="Y"><name>Metronidazole</name><manufacturerId>JPC</manufacturerId><individualPrice>.2739</individualPrice><dailyCost>.8217</dailyCost><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.2739</amountMOHLTCPays></drug><drug id="02519755" sec3="Y"><name>M-Metronidazole</name><manufacturerId>MAT</manufacturerId><individualPrice>.2739</individualPrice><dailyCost>.8217</dailyCost><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.2739</amountMOHLTCPays></drug><drug id="02534592" sec3="Y"><name>Metronidazole</name><manufacturerId>SAI</manufacturerId><individualPrice>.2739</individualPrice><dailyCost>.8217</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.2739</amountMOHLTCPays></drug></pcg9><pcg9 id="083200001"><itemNumber>0205</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1716</dailyCost><drug id="00545066" sec3="Y"><name>Apo-Metronidazole Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.0572</individualPrice><dailyCost>.1716</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0572</amountMOHLTCPays></drug><drug id="01926896" notABenefit="Y" sec3="Y"><name>Flagyl</name><manufacturerId>RPP</manufacturerId><listingDate>2001-02-28</listingDate></drug><drug id="02535807" sec3="Y"><name>Mint-Metronidazole</name><manufacturerId>MIN</manufacturerId><individualPrice>.0572</individualPrice><dailyCost>.1716</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.0572</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="083600000"><name>URINARY ANTI-INFECTIVES</name><genericName id="01472"><name>FOSFOMYCIN TROMETHAMINE</name><pcgGroup><pcg9 id="083600019"><itemNumber>0206</itemNumber><dosageForm>Sachet-3g Pk</dosageForm><note>The recommended dosage for women over 18 years with acute uncomplicated urinary tract infections (acute cystitis) is one sachet containing the equivalent of 3 grams of fosfomycin.

A single dose of fosfomycin should be used to treat an episode of acute cystitis.</note><drug id="02240335" sec3="Y"><name>Monurol</name><manufacturerId>PAL</manufacturerId><individualPrice>21.6700</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>14.0250</amountMOHLTCPays></drug><drug id="02473801" sec3="Y"><name>Jamp-Fosfomycin</name><manufacturerId>JPC</manufacturerId><individualPrice>14.0250</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>14.0250</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00133"><name>NITROFURANTOIN</name><note>Nitrofurantoin macrocrystals may be better tolerated. Avoid use of nitrofurantoin during the last 6 weeks of pregnancy. Use with caution in patients with renal impairment.</note><pcgGroup><pcg9 id="083600013"><itemNumber>0207</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><dailyCost>1.1708</dailyCost><drug id="01997637" notABenefit="Y" sec3="Y"><name>Macrodantin</name><manufacturerId>PGP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02231015" sec3="Y"><name>Teva-Nitrofurantoin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2927</individualPrice><dailyCost>1.1708</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2927</amountMOHLTCPays></drug><drug id="02495503" sec3="Y"><name>Jamp Nitrofurantoin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2927</individualPrice><dailyCost>1.1708</dailyCost><listingDate>2025-05-30</listingDate><amountMOHLTCPays>.2927</amountMOHLTCPays></drug></pcg9><pcg9 id="083600012"><itemNumber>0208</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><dailyCost>2.1996</dailyCost><drug id="01997645" notABenefit="Y" sec3="Y"><name>Macrodantin</name><manufacturerId>PGP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02231016" sec3="Y"><name>Teva-Nitrofurantoin</name><manufacturerId>TEV</manufacturerId><individualPrice>.5499</individualPrice><dailyCost>2.1996</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.5499</amountMOHLTCPays></drug><drug id="02495511" sec3="Y"><name>Jamp Nitrofurantoin</name><manufacturerId>JPC</manufacturerId><individualPrice>.5499</individualPrice><dailyCost>2.1996</dailyCost><listingDate>2025-05-30</listingDate><amountMOHLTCPays>.5499</amountMOHLTCPays></drug></pcg9><pcg9 id="083600015"><itemNumber>0209</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6812</dailyCost><drug id="00017086" notABenefit="Y" sec3="Y"><name>Nifuran</name><manufacturerId>MAN</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00319511" sec3="Y"><name>Nitrofurantoin</name><manufacturerId>AAP</manufacturerId><individualPrice>.1703</individualPrice><dailyCost>.6812</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1703</amountMOHLTCPays></drug></pcg9><pcg9 id="083600008"><itemNumber>0210</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>.9088</dailyCost><drug id="00017094" notABenefit="Y" sec3="Y"><name>Nifuran</name><manufacturerId>MAN</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00312738" sec3="Y"><name>Nitrofurantoin</name><manufacturerId>AAP</manufacturerId><individualPrice>.2272</individualPrice><dailyCost>.9088</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2272</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00135"><name>NITROFURANTOIN MONO/MICRO CRYSTALS</name><pcgGroup><pcg9 id="083600018"><itemNumber>0211</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02063662" notABenefit="Y" sec3="Y"><name>MacroBID</name><manufacturerId>WAR</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02455676" sec3="Y"><name>PMS-Nitrofurantoin BID</name><manufacturerId>PMS</manufacturerId><individualPrice>.3983</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.3983</amountMOHLTCPays></drug><drug id="02466392" sec3="Y"><name>Auro-Nitrofurantoin BID</name><manufacturerId>AUR</manufacturerId><individualPrice>.3983</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.3983</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="084000000"><name>MISCELLANEOUS ANTI-INFECTIVES</name><genericName id="01616"><name>CEFEPIME</name><pcgGroup><pcg9 id="084000065"><itemNumber>0212</itemNumber><strength>1g</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02163632" notABenefit="Y" sec3b="Y" sec3="Y"><name>Maxipime</name><manufacturerId>BQU</manufacturerId><listingDate>2009-05-20</listingDate></drug><drug id="02319020" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cefepime for Injection</name><manufacturerId>APX</manufacturerId><individualPrice>12.9360</individualPrice><listingDate>2009-05-20</listingDate></drug><drug id="02467496" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Cefepime</name><manufacturerId>APX</manufacturerId><individualPrice>30.2000</individualPrice><listingDate>2018-08-30</listingDate></drug></pcg9><pcg9 id="084000072"><itemNumber>0213</itemNumber><strength>2g</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02163640" notABenefit="Y" sec3b="Y" sec3="Y"><name>Maxipime</name><manufacturerId>BQU</manufacturerId><listingDate>2009-05-20</listingDate></drug><drug id="02319039" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cefepime for Injection</name><manufacturerId>APX</manufacturerId><individualPrice>30.1963</individualPrice><listingDate>2009-05-20</listingDate></drug><drug id="02467518" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Cefepime</name><manufacturerId>APX</manufacturerId><individualPrice>30.2000</individualPrice><listingDate>2018-08-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00141"><name>CIPROFLOXACIN</name><note>Ciprofloxacin is not intended for the treatment of asymptomatic bacteriuria in the absence of risk factors. Avoid use in pregnancy and children &lt; 18 years of age. Ciprofloxacin inhibits theophylline clearance and also affects phenytoin kinetics. Theophylline doses should be decreased and blood levels of phenytoin or theophylline monitored when either of these drugs is used concomitantly with ciprofloxacin.</note><pcgGroup lccId="00307"><pcg9 id="084000050"><itemNumber>0214</itemNumber><strength>10g/100mL</strength><dosageForm>Oral Susp</dosageForm><dailyCost>5.7560</dailyCost><drug id="02237514" sec3="Y" sec12="Y"><name>Cipro</name><manufacturerId>BAY</manufacturerId><individualPrice>.5756</individualPrice><dailyCost>5.7560</dailyCost><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.5756</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="533">For patients who are unable to swallow or tolerate solid oral dosage forms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="084000014"><itemNumber>0215</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.8908</dailyCost><drug id="02155958" notABenefit="Y" sec3="Y"><name>Cipro</name><manufacturerId>BAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02161737" sec3="Y"><name>Teva-Ciprofloxacin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02229521" sec3="Y"><name>Apo-Ciproflox</name><manufacturerId>APX</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02246825" sec3="Y"><name>Ratio-Ciprofloxacin</name><manufacturerId>RPH</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02247339" sec3="Y"><name>Co Ciprofloxacin</name><manufacturerId>COB</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02248437" sec3="Y"><name>PMS-Ciprofloxacin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02248756" sec3="Y"><name>Sandoz Ciprofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02303728" sec3="Y"><name>Ran-Ciproflox</name><manufacturerId>RAN</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2008-03-25</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02353318" sec3="Y"><name>Ciprofloxacin</name><manufacturerId>SAI</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02379627" sec3="Y"><name>Septa-Ciprofloxacin</name><manufacturerId>SET</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02379686" sec3="Y"><name>Mar-Ciprofloxacin</name><manufacturerId>MAR</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02380358" sec3="Y"><name>Jamp-Ciprofloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02381907" sec3="Y"><name>Auro-Ciprofloxacin</name><manufacturerId>AUR</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02386119" sec3="Y"><name>Ciprofloxacin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug><drug id="02423553" sec3="Y"><name>Mint-Ciproflox</name><manufacturerId>MIN</manufacturerId><individualPrice>.4454</individualPrice><dailyCost>.8908</dailyCost><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.4454</amountMOHLTCPays></drug></pcg9><pcg9 id="084000015"><itemNumber>0216</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.0050</dailyCost><drug id="02155966" notABenefit="Y" sec3="Y"><name>Cipro</name><manufacturerId>BAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229522" sec3="Y"><name>Apo-Ciproflox</name><manufacturerId>APX</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02246826" sec3="Y"><name>Ratio-Ciprofloxacin</name><manufacturerId>RPH</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02247340" sec3="Y"><name>Co Ciprofloxacin</name><manufacturerId>COB</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02248438" sec3="Y"><name>PMS-Ciprofloxacin</name><manufacturerId>PMS</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02248757" sec3="Y"><name>Sandoz Ciprofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02303736" sec3="Y"><name>Ran-Ciproflox</name><manufacturerId>RAN</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2008-03-25</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02353326" sec3="Y"><name>Ciprofloxacin</name><manufacturerId>SAI</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02379635" sec3="Y"><name>Septa-Ciprofloxacin</name><manufacturerId>SET</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02379694" sec3="Y"><name>Mar-Ciprofloxacin</name><manufacturerId>MAR</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02380366" sec3="Y"><name>Jamp-Ciprofloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02381923" sec3="Y"><name>Auro-Ciprofloxacin</name><manufacturerId>AUR</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02386127" sec3="Y"><name>Ciprofloxacin</name><manufacturerId>SIV</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02423561" sec3="Y"><name>Mint-Ciproflox</name><manufacturerId>MIN</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug><drug id="02492008" sec3="Y"><name>NRA-Ciprofloxacin</name><manufacturerId>NRA</manufacturerId><individualPrice>.5025</individualPrice><dailyCost>1.0050</dailyCost><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug></pcg9><pcg9 id="084000016"><itemNumber>0217</itemNumber><strength>750mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.8402</dailyCost><drug id="02155974" notABenefit="Y" sec3="Y"><name>Cipro</name><manufacturerId>BAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229523" sec3="Y"><name>Apo-Ciproflox</name><manufacturerId>APX</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02246827" sec3="Y"><name>Ratio-Ciprofloxacin</name><manufacturerId>RPH</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02247341" sec3="Y"><name>Co Ciprofloxacin</name><manufacturerId>COB</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02248439" sec3="Y"><name>PMS-Ciprofloxacin</name><manufacturerId>PMS</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02248758" sec3="Y"><name>Sandoz Ciprofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02303744" sec3="Y"><name>Ran-Ciproflox</name><manufacturerId>RAN</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2008-03-25</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02379643" sec3="Y"><name>Septa-Ciprofloxacin</name><manufacturerId>SET</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02379708" sec3="Y"><name>Mar-Ciprofloxacin</name><manufacturerId>MAR</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02380374" sec3="Y"><name>Jamp-Ciprofloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02381931" sec3="Y"><name>Auro-Ciprofloxacin</name><manufacturerId>AUR</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug><drug id="02423588" sec3="Y"><name>Mint-Ciproflox</name><manufacturerId>MIN</manufacturerId><individualPrice>.9201</individualPrice><dailyCost>1.8402</dailyCost><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.9201</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01629"><name>CIPROFLOXACIN HCL &amp; CIPROFLOXACIN BASE</name><pcgGroup lccId="00161"><pcg9 id="084000066"><itemNumber>0218</itemNumber><strength>500mg</strength><dosageForm>ER Tab</dosageForm><drug id="02247916" notABenefit="Y" sec3="Y"><name>Cipro XL</name><manufacturerId>BAY</manufacturerId><listingDate>2005-02-22</listingDate></drug><drug id="02416433" sec3="Y" sec12="Y"><name>PMS-Ciprofloxacin XL</name><manufacturerId>PMS</manufacturerId><individualPrice>2.3110</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>2.3110</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="394">For patients with uncomplicated urinary tract infections (acute cystitis) who have failure, intolerance or hypersensitivity to all formulary antibiotic alternatives that are listed as General Benefits.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01773"><name>ERTAPENEM</name><pcgGroup><pcg9 id="084000077"><itemNumber>0219</itemNumber><strength>1g/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02247437" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Invanz</name><manufacturerId>MFC</manufacturerId><listingDate>2021-03-29</listingDate></drug><drug id="02490773" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ertapenem for Injection</name><manufacturerId>JUN</manufacturerId><individualPrice>52.2650</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>52.2650</amountMOHLTCPays></drug><drug id="02492148" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ertapenem for Injection</name><manufacturerId>AUR</manufacturerId><individualPrice>52.2650</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>52.2650</amountMOHLTCPays></drug><drug id="02496127" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ertapenem for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>52.2650</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>52.2650</amountMOHLTCPays></drug><drug id="02511150" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ertapenem for Injection</name><manufacturerId>DRR</manufacturerId><individualPrice>52.2650</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>52.2650</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01381"><name>LEVOFLOXACIN</name><pcgGroup><pcg9 id="084000051"><itemNumber>0220</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02236841" notABenefit="Y" sec3="Y"><name>Levaquin</name><manufacturerId>JAN</manufacturerId><listingDate>1999-09-15</listingDate></drug><drug id="02248262" sec3="Y"><name>Novo-Levofloxacin</name><manufacturerId>NOP</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2005-01-25</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug><drug id="02284707" sec3="Y"><name>Apo-Levofloxacin</name><manufacturerId>APX</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug><drug id="02298635" sec3="Y"><name>Sandoz Levofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug><drug id="02315424" sec3="Y"><name>Act Levofloxacin</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug><drug id="02492725" sec3="Y"><name>Riva-Levofloxacin</name><manufacturerId>RIA</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug><drug id="02505797" sec3="Y"><name>Mint-Levofloxacin</name><manufacturerId>MIN</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug><drug id="02508443" sec3="Y"><name>Jamp Levofloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2038</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>1.2038</amountMOHLTCPays></drug></pcg9><pcg9 id="084000049"><itemNumber>0221</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02236842" notABenefit="Y" sec3="Y"><name>Levaquin</name><manufacturerId>JAN</manufacturerId><listingDate>1999-09-15</listingDate></drug><drug id="02248263" sec3="Y"><name>Novo-Levofloxacin</name><manufacturerId>NOP</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2005-01-25</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug><drug id="02284715" sec3="Y"><name>Apo-Levofloxacin</name><manufacturerId>APX</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug><drug id="02298643" sec3="Y"><name>Sandoz Levofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug><drug id="02315432" sec3="Y"><name>Act Levofloxacin</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug><drug id="02492733" sec3="Y"><name>Riva-Levofloxacin</name><manufacturerId>RIA</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug><drug id="02505819" sec3="Y"><name>Mint-Levofloxacin</name><manufacturerId>MIN</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug><drug id="02508451" sec3="Y"><name>Jamp Levofloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3718</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>1.3718</amountMOHLTCPays></drug></pcg9><pcg9 id="084000075"><itemNumber>0222</itemNumber><strength>750mg</strength><dosageForm>Tab</dosageForm><drug id="02246804" notABenefit="Y" sec3b="Y" sec3="Y"><name>Levaquin</name><manufacturerId>JAN</manufacturerId><listingDate>2009-09-30</listingDate></drug><drug id="02285649" notABenefit="Y" sec3b="Y" sec3="Y"><name>Novo-Levofloxacin</name><manufacturerId>NOP</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2009-09-30</listingDate></drug><drug id="02298651" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Levofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2009-11-13</listingDate></drug><drug id="02315440" notABenefit="Y" sec3b="Y" sec3="Y"><name>Act Levofloxacin</name><manufacturerId>TEV</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2009-09-30</listingDate></drug><drug id="02325942" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Levofloxacin</name><manufacturerId>APX</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2009-09-30</listingDate></drug><drug id="02492741" notABenefit="Y" sec3b="Y" sec3="Y"><name>Riva-Levofloxacin</name><manufacturerId>RIA</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2020-08-28</listingDate></drug><drug id="02505800" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Levofloxacin</name><manufacturerId>MIN</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2021-11-30</listingDate></drug><drug id="02508478" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Levofloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>6.5484</individualPrice><listingDate>2024-07-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01514"><name>LINEZOLID</name><pcgGroup><pcg9 id="084000068"><itemNumber>0223</itemNumber><strength>2mg/mL</strength><dosageForm>Inj-300mL Pk</dosageForm><drug id="02243685" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zyvoxam</name><manufacturerId>PFI</manufacturerId><listingDate>2014-10-29</listingDate></drug><drug id="02481278" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Linezolid Injection</name><manufacturerId>JPC</manufacturerId><individualPrice>88.7400</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>88.7400</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00014"><pcg9 id="084000054"><itemNumber>0224</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02243684" notABenefit="Y" sec3="Y"><name>Zyvoxam</name><manufacturerId>PFI</manufacturerId><listingDate>2003-01-30</listingDate></drug><drug id="02422689" sec3="Y" sec12="Y"><name>Sandoz Linezolid</name><manufacturerId>SDZ</manufacturerId><individualPrice>19.3041</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>19.3041</amountMOHLTCPays></drug><drug id="02426552" sec3="Y" sec12="Y"><name>Apo-Linezolid</name><manufacturerId>APX</manufacturerId><individualPrice>19.3041</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>19.3041</amountMOHLTCPays></drug><drug id="02520354" sec3="Y" sec12="Y"><name>Jamp Linezolid</name><manufacturerId>JPC</manufacturerId><individualPrice>19.3041</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>19.3041</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the treatment of patients with:</lccNote><lccNote seq="002" reasonForUseId="362">Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="004" reasonForUseId="363">Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" reasonForUseId="364">Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge.</lccNote><lccNote seq="007" type="R">* Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01516"><name>MOXIFLOXACIN HYDROCHLORIDE</name><pcgGroup><pcg9 id="084000053"><itemNumber>0225</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="02242965" notABenefit="Y" sec3="Y"><name>Avelox</name><manufacturerId>BAY</manufacturerId><listingDate>2001-06-07</listingDate></drug><drug id="02375702" sec3="Y"><name>Teva-Moxifloxacin</name><manufacturerId>TEV</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02383381" sec3="Y"><name>Sandoz Moxifloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02404923" sec3="Y"><name>Apo-Moxifloxacin</name><manufacturerId>APX</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02432242" sec3="Y"><name>Auro-Moxifloxacin</name><manufacturerId>AUR</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02443929" sec3="Y"><name>Jamp-Moxifloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2015-12-22</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02447053" sec3="Y"><name>Mar-Moxifloxacin</name><manufacturerId>MAR</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02447061" sec3="Y"><name>Jamp-Moxifloxacin Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02457814" sec3="Y"><name>Med-Moxifloxacin</name><manufacturerId>GMP</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02472791" sec3="Y"><name>M-Moxifloxacin</name><manufacturerId>MAT</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02478137" sec3="Y"><name>AG-Moxifloxacin</name><manufacturerId>ANG</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug><drug id="02520710" sec3="Y"><name>Moxifloxacin</name><manufacturerId>SAI</manufacturerId><individualPrice>1.5230</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.5230</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00138"><name>NORFLOXACIN</name><pcgGroup><pcg9 id="084000010"><itemNumber>0226</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><dailyCost>3.7172</dailyCost><drug id="00643025" notABenefit="Y" sec3="Y"><name>Noroxin</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229524" sec3="Y"><name>Norfloxacin</name><manufacturerId>AAP</manufacturerId><individualPrice>1.8586</individualPrice><dailyCost>3.7172</dailyCost><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.8586</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00136"><name>SULFAMETHOXAZOLE &amp; TRIMETHOPRIM</name><note>Avoid using sulfamethoxazole/trimethoprim during the last 6 weeks of pregnancy.</note><pcgGroup><pcg9 id="084000002"><itemNumber>0227</itemNumber><strength>40mg &amp; 8mg/mL</strength><dosageForm>O/L</dosageForm><dailyCost>1.0260</dailyCost><drug id="00270644" notABenefit="Y" sec3="Y"><name>Septra</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00272485" notABenefit="Y" sec3="Y"><name>Bactrim Sugar Free</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00726540" sec3="Y"><name>Teva-Trimel</name><manufacturerId>TEV</manufacturerId><individualPrice>.1026</individualPrice><dailyCost>1.0260</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1026</amountMOHLTCPays></drug></pcg9><pcg9 id="084000001"><itemNumber>0228</itemNumber><strength>400mg &amp; 80mg</strength><dosageForm>Tab</dosageForm><dailyCost>.8736</dailyCost><drug id="00270636" notABenefit="Y" sec3="Y"><name>Septra</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00272469" notABenefit="Y" sec3="Y"><name>Bactrim</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00445274" sec3="Y"><name>Sulfatrim</name><manufacturerId>AAP</manufacturerId><individualPrice>.2184</individualPrice><dailyCost>.8736</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug></pcg9><pcg9 id="084000003"><itemNumber>0229</itemNumber><strength>800mg &amp; 160mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4148</dailyCost><drug id="00368040" notABenefit="Y" sec3="Y"><name>Septra DS</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00371823" notABenefit="Y" sec3="Y"><name>Bactrim-DS</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00445282" sec3="Y"><name>Sulfatrim-DS</name><manufacturerId>AAP</manufacturerId><individualPrice>.2074</individualPrice><dailyCost>.4148</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2074</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00137"><name>TRIMETHOPRIM</name><pcgGroup><pcg9 id="084000007"><itemNumber>0230</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>.5234</dailyCost><drug id="00675229" notABenefit="Y" sec3="Y"><name>Proloprim</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02243116" sec3="Y"><name>Trimethoprim</name><manufacturerId>AAP</manufacturerId><individualPrice>.2617</individualPrice><dailyCost>.5234</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.2617</amountMOHLTCPays></drug></pcg9><pcg9 id="084000009"><itemNumber>0231</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><dailyCost>.5378</dailyCost><drug id="00677590" notABenefit="Y" sec3="Y"><name>Proloprim</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02243117" sec3="Y"><name>Trimethoprim</name><manufacturerId>AAP</manufacturerId><individualPrice>.5378</individualPrice><dailyCost>.5378</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.5378</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="100000000"><name>ANTINEOPLASTIC AGENTS</name><pcg6><genericName id="01891"><name>ABIRATERONE ACETATE</name><pcgGroup><pcg9 id="100000210"><itemNumber>0232</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02371065" sec3="Y"><name>Zytiga</name><manufacturerId>JAN</manufacturerId><individualPrice>35.5230</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02477114" sec3="Y"><name>Reddy-Abiraterone</name><manufacturerId>DRR</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02486393" sec3="Y"><name>Sandoz Abiraterone</name><manufacturerId>SDZ</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02491397" sec3="Y"><name>Apo-Abiraterone Film Coated Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02492601" sec3="Y"><name>PMS-Abiraterone</name><manufacturerId>PMS</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02494132" sec3="Y"><name>Nat-Abiraterone</name><manufacturerId>NAT</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02502305" sec3="Y"><name>Jamp Abiraterone</name><manufacturerId>JPC</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug><drug id="02503980" sec3="Y"><name>Mar-Abiraterone</name><manufacturerId>MAR</manufacturerId><individualPrice>7.6563</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.6563</amountMOHLTCPays></drug></pcg9><pcg9 id="100000258"><itemNumber>0233</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02457113" sec3="Y"><name>Zytiga</name><manufacturerId>JAN</manufacturerId><individualPrice>71.0460</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02491400" sec3="Y"><name>Apo-Abiraterone Film Coated Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02501503" sec3="Y"><name>PMS-Abiraterone</name><manufacturerId>PMS</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02503999" sec3="Y"><name>Mar-Abiraterone</name><manufacturerId>MAR</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02521644" sec3="Y"><name>Sandoz Abiraterone</name><manufacturerId>SDZ</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02525380" sec3="Y"><name>Abiraterone</name><manufacturerId>JPC</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02529629" sec3="Y"><name>Jamp Abiraterone</name><manufacturerId>JPC</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug><drug id="02533251" sec3="Y"><name>Reddy-Abiraterone</name><manufacturerId>DRR</manufacturerId><individualPrice>15.3125</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>15.3125</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01954"><name>AFATINIB</name><pcgGroup><pcg9 id="100000232"><itemNumber>0234</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02415666" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Giotrif</name><manufacturerId>BOE</manufacturerId><individualPrice>77.4784</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug><drug id="02512777" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz AFAtinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>38.7392</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug><drug id="02517019" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Afatinib</name><manufacturerId>MAR</manufacturerId><individualPrice>38.7392</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug></pcg9><pcg9 id="100000233"><itemNumber>0235</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02415674" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Giotrif</name><manufacturerId>BOE</manufacturerId><individualPrice>77.4784</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug><drug id="02512785" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz AFAtinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>38.7392</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug><drug id="02517027" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Afatinib</name><manufacturerId>MAR</manufacturerId><individualPrice>38.7392</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug></pcg9><pcg9 id="100000234"><itemNumber>0236</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02415682" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Giotrif</name><manufacturerId>BOE</manufacturerId><individualPrice>77.4784</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug><drug id="02512793" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz AFAtinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>38.7392</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug><drug id="02517035" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Afatinib</name><manufacturerId>MAR</manufacturerId><individualPrice>38.7392</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>38.7392</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00202"><name>ALTRETAMINE</name><pcgGroup><pcg9 id="100000095"><itemNumber>0237</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="02126230" sec3="Y"><name>Hexalen</name><manufacturerId>LIL</manufacturerId><individualPrice>3.3600</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.3600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00208"><name>ANASTROZOLE</name><pcgGroup><pcg9 id="100000109"><itemNumber>0238</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02224135" sec3="Y"><name>Arimidex</name><manufacturerId>AZC</manufacturerId><individualPrice>6.2371</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02320738" sec3="Y"><name>PMS-Anastrozole</name><manufacturerId>PMS</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02328690" sec3="Y"><name>Ran-Anastrozole</name><manufacturerId>RAN</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02338467" sec3="Y"><name>Sandoz Anastrozole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02339080" sec3="Y"><name>Jamp-Anastrozole</name><manufacturerId>JPC</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02351218" sec3="Y"><name>Anastrozole</name><manufacturerId>ACH</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02365650" sec3="Y"><name>Taro-Anastrozole</name><manufacturerId>TAR</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02374420" sec3="Y"><name>Apo-Anastrozole</name><manufacturerId>APX</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02379104" sec3="Y"><name>Med-Anastrozole</name><manufacturerId>GMP</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02379562" sec3="Y"><name>Mar-Anastrozole</name><manufacturerId>MAR</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02392259" sec3="Y"><name>Riva-Anastrozole</name><manufacturerId>RIA</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02393573" sec3="Y"><name>Mint-Anastrozole</name><manufacturerId>MIN</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02394898" sec3="Y"><name>Co Anastrozole</name><manufacturerId>COB</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02417855" sec3="Y"><name>Nat-Anastrozole</name><manufacturerId>NAT</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02442736" sec3="Y"><name>Anastrozole</name><manufacturerId>SAI</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02458799" sec3="Y"><name>CCP-Anastrozole</name><manufacturerId>CCP</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug><drug id="02529904" sec3="Y"><name>Anastrozole</name><manufacturerId>SIV</manufacturerId><individualPrice>.9522</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>.9522</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00207"><name>BICALUTAMIDE</name><pcgGroup><pcg9 id="100000108"><itemNumber>0239</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02184478" dinStatus="E" sec3="Y"><name>Casodex</name><manufacturerId>AZC</manufacturerId><individualPrice>7.1277</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02270226" sec3="Y"><name>Teva-Bicalutamide</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2006-04-04</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02274337" sec3="Y"><name>Co Bicalutamide</name><manufacturerId>COB</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2006-04-04</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02275589" sec3="Y"><name>PMS-Bicalutamide</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2006-04-04</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02296063" sec3="Y"><name>Apo-Bicalutamide</name><manufacturerId>APX</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02325985" sec3="Y"><name>Bicalutamide Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02357216" sec3="Y"><name>Jamp-Bicalutamide</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02371324" sec3="Y"><name>Ran-Bicalutamide</name><manufacturerId>RAN</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug><drug id="02519178" sec3="Y"><name>Bicalutamide</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2690</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2690</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01996"><name>BOSUTINIB</name><pcgGroup><pcg9 id="100000251"><itemNumber>0240</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02419149" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Bosulif</name><manufacturerId>PFI</manufacturerId><individualPrice>38.9787</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>29.2340</amountMOHLTCPays></drug><drug id="02560038" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Bosutinib</name><manufacturerId>DRR</manufacturerId><individualPrice>29.2340</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>29.2340</amountMOHLTCPays></drug></pcg9><pcg9 id="100000252"><itemNumber>0241</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02419157" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Bosulif</name><manufacturerId>PFI</manufacturerId><individualPrice>152.2403</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>114.1802</amountMOHLTCPays></drug><drug id="02560046" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Bosutinib</name><manufacturerId>DRR</manufacturerId><individualPrice>114.1802</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>114.1802</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00187"><name>BUSERELIN ACETATE</name><pcgGroup><pcg9 id="100000111"><itemNumber>0242</itemNumber><strength>6.3mg</strength><dosageForm>Implant Kit</dosageForm><drug id="02228955" sec3="Y"><name>Suprefact Depot 2 Months</name><manufacturerId>CHE</manufacturerId><individualPrice>929.2348</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>929.2348</amountMOHLTCPays></drug></pcg9><pcg9 id="100000151"><itemNumber>0243</itemNumber><strength>9.45mg</strength><dosageForm>Implant Kit</dosageForm><drug id="02240749" sec3="Y"><name>Suprefact Depot 3 Months</name><manufacturerId>CHE</manufacturerId><individualPrice>1376.9938</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>1376.9938</amountMOHLTCPays></drug></pcg9><pcg9 id="100000075"><itemNumber>0244</itemNumber><strength>1mg/mL</strength><dosageForm>Inj Sol-5.5mL Pk</dosageForm><drug id="02225166" sec3="Y"><name>Suprefact</name><manufacturerId>CHE</manufacturerId><individualPrice>77.0464</individualPrice><listingDate>1999-01-08</listingDate><amountMOHLTCPays>77.0464</amountMOHLTCPays></drug></pcg9><pcg9 id="100000076"><itemNumber>0245</itemNumber><strength>1mg/mL</strength><dosageForm>Nas Sp-10mL Pk</dosageForm><drug id="02225158" sec3="Y"><name>Suprefact</name><manufacturerId>CHE</manufacturerId><individualPrice>85.5300</individualPrice><listingDate>1999-01-08</listingDate><amountMOHLTCPays>85.5300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00157"><name>BUSULFAN</name><pcgGroup><pcg9 id="100000005"><itemNumber>0246</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00004618" sec3="Y"><name>Myleran</name><manufacturerId>ASN</manufacturerId><individualPrice>2.2656</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.2656</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01399"><name>CAPECITABINE</name><pcgGroup><pcg9 id="100000136"><itemNumber>0247</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02238453" sec3="Y"><name>Xeloda</name><manufacturerId>HLR</manufacturerId><individualPrice>1.9478</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug><drug id="02400022" sec3="Y"><name>Teva-Capecitabine</name><manufacturerId>TEV</manufacturerId><individualPrice>.4575</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug><drug id="02421917" sec3="Y"><name>Sandoz Capecitabine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4575</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug><drug id="02426757" sec3="Y"><name>Ach-Capecitabine</name><manufacturerId>ACH</manufacturerId><individualPrice>.4575</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug><drug id="02457490" sec3="Y"><name>Taro-Capecitabine</name><manufacturerId>TAR</manufacturerId><individualPrice>.4575</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug><drug id="02514982" sec3="Y"><name>Capecitabine</name><manufacturerId>SAI</manufacturerId><individualPrice>.4575</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug><drug id="02519879" sec3="Y"><name>Capecitabine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4575</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.4575</amountMOHLTCPays></drug></pcg9><pcg9 id="100000137"><itemNumber>0248</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02238454" sec3="Y"><name>Xeloda</name><manufacturerId>HLR</manufacturerId><individualPrice>6.4933</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02400030" sec3="Y"><name>Teva-Capecitabine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02421925" sec3="Y"><name>Sandoz Capecitabine</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02426765" sec3="Y"><name>Ach-Capecitabine</name><manufacturerId>ACH</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02457504" sec3="Y"><name>Taro-Capecitabine</name><manufacturerId>TAR</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02508028" sec3="Y"><name>Mint-Capecitabine</name><manufacturerId>MIN</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02514990" sec3="Y"><name>Capecitabine</name><manufacturerId>SAI</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug><drug id="02519887" sec3="Y"><name>Capecitabine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>1.5250</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00158"><name>CHLORAMBUCIL</name><pcgGroup><pcg9 id="100000006"><itemNumber>0249</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00004626" sec3="Y"><name>Leukeran</name><manufacturerId>ASN</manufacturerId><individualPrice>2.1300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.1300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00159"><name>CYCLOPHOSPHAMIDE</name><pcgGroup><pcg9 id="100000008"><itemNumber>0250</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02241795" sec3="Y"><name>Procytox</name><manufacturerId>BAX</manufacturerId><individualPrice>.3545</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>.3545</amountMOHLTCPays></drug></pcg9><pcg9 id="100000007"><itemNumber>0251</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00344885" notABenefit="Y" sec3="Y"><name>Cytoxan</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02241796" sec3="Y"><name>Procytox</name><manufacturerId>BAX</manufacturerId><individualPrice>.4773</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>.4773</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00180"><name>CYPROTERONE ACETATE</name><pcgGroup><pcg9 id="100000057"><itemNumber>0252</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00704431" sec3="Y"><name>Androcur</name><manufacturerId>AMD</manufacturerId><individualPrice>1.4085</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.4000</amountMOHLTCPays></drug><drug id="02245898" sec3="Y"><name>Cyproterone</name><manufacturerId>AAP</manufacturerId><individualPrice>1.4085</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>1.4000</amountMOHLTCPays></drug><drug id="02390760" sec3="Y"><name>Med-Cyproterone</name><manufacturerId>GMP</manufacturerId><individualPrice>1.4000</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>1.4000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01716"><name>DASATINIB</name><pcgGroup><pcg9 id="100000192"><itemNumber>0253</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02293129" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sprycel</name><manufacturerId>BQU</manufacturerId><individualPrice>38.6850</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>32.8823</amountMOHLTCPays></drug><drug id="02470705" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dasatinib</name><manufacturerId>APX</manufacturerId><individualPrice>32.8823</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>32.8823</amountMOHLTCPays></drug><drug id="02478307" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Dasatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>32.8823</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>32.8823</amountMOHLTCPays></drug><drug id="02499282" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Dasatinib</name><manufacturerId>TAR</manufacturerId><individualPrice>32.8823</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>32.8823</amountMOHLTCPays></drug><drug id="02514737" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Dasatinib</name><manufacturerId>DRR</manufacturerId><individualPrice>32.8823</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>32.8823</amountMOHLTCPays></drug></pcg9><pcg9 id="100000193"><itemNumber>0254</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02293137" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sprycel</name><manufacturerId>BQU</manufacturerId><individualPrice>77.8567</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>66.1783</amountMOHLTCPays></drug><drug id="02470713" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dasatinib</name><manufacturerId>APX</manufacturerId><individualPrice>66.1782</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>66.1782</amountMOHLTCPays></drug><drug id="02478315" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Dasatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>66.1782</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>66.1782</amountMOHLTCPays></drug><drug id="02499304" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Dasatinib</name><manufacturerId>TAR</manufacturerId><individualPrice>66.1783</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>66.1783</amountMOHLTCPays></drug><drug id="02514745" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Dasatinib</name><manufacturerId>DRR</manufacturerId><individualPrice>66.1782</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>66.1782</amountMOHLTCPays></drug></pcg9><pcg9 id="100000194"><itemNumber>0255</itemNumber><strength>70mg</strength><dosageForm>Tab</dosageForm><drug id="02293145" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sprycel</name><manufacturerId>BQU</manufacturerId><individualPrice>85.8042</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>72.9337</amountMOHLTCPays></drug><drug id="02478323" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Dasatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>72.9336</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>72.9336</amountMOHLTCPays></drug><drug id="02481499" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dasatinib</name><manufacturerId>APX</manufacturerId><individualPrice>72.9336</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>72.9336</amountMOHLTCPays></drug><drug id="02499312" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Dasatinib</name><manufacturerId>TAR</manufacturerId><individualPrice>72.9337</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>72.9337</amountMOHLTCPays></drug><drug id="02514753" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Dasatinib</name><manufacturerId>DRR</manufacturerId><individualPrice>72.9336</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>72.9336</amountMOHLTCPays></drug></pcg9><pcg9 id="100000301"><itemNumber>0256</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02360810" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sprycel</name><manufacturerId>BQU</manufacturerId><listingDate>2020-01-31</listingDate></drug><drug id="02478331" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Dasatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>117.3255</individualPrice><listingDate>2021-04-30</listingDate></drug><drug id="02481502" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Dasatinib</name><manufacturerId>APX</manufacturerId><individualPrice>117.3255</individualPrice><listingDate>2020-01-31</listingDate></drug><drug id="02499320" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Dasatinib</name><manufacturerId>TAR</manufacturerId><individualPrice>117.3257</individualPrice><listingDate>2021-03-29</listingDate></drug><drug id="02514761" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reddy-Dasatinib</name><manufacturerId>DRR</manufacturerId><individualPrice>117.3255</individualPrice><listingDate>2021-06-30</listingDate></drug></pcg9><pcg9 id="100000207"><itemNumber>0257</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02320193" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sprycel</name><manufacturerId>BQU</manufacturerId><individualPrice>155.6083</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>132.2671</amountMOHLTCPays></drug><drug id="02470721" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dasatinib</name><manufacturerId>APX</manufacturerId><individualPrice>132.2671</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>132.2671</amountMOHLTCPays></drug><drug id="02478358" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Dasatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>132.2671</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>132.2671</amountMOHLTCPays></drug><drug id="02499339" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Dasatinib</name><manufacturerId>TAR</manufacturerId><individualPrice>132.2670</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>132.2670</amountMOHLTCPays></drug><drug id="02514788" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Dasatinib</name><manufacturerId>DRR</manufacturerId><individualPrice>132.2670</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>132.2670</amountMOHLTCPays></drug></pcg9><pcg9 id="100000322"><itemNumber>0258</itemNumber><strength>140mg</strength><dosageForm>Tab</dosageForm><drug id="02360829" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sprycel</name><manufacturerId>BQU</manufacturerId><listingDate>2021-03-29</listingDate></drug><drug id="02499347" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Dasatinib</name><manufacturerId>TAR</manufacturerId><individualPrice>141.8806</individualPrice><listingDate>2021-03-29</listingDate></drug><drug id="02514796" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reddy-Dasatinib</name><manufacturerId>DRR</manufacturerId><individualPrice>141.8806</individualPrice><listingDate>2021-06-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00161"><name>DAUNORUBICIN</name><pcgGroup><pcg9 id="100000014"><itemNumber>0259</itemNumber><dosageForm>Inj Pd-20mg Pk</dosageForm><drug id="01926683" sec3="Y"><name>Cerubidine</name><manufacturerId>SLP</manufacturerId><individualPrice>91.0000</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>91.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01793"><name>DEGARELIX ACETATE</name><pcgGroup><pcg9 id="100000198"><itemNumber>0260</itemNumber><strength>80mg</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><drug id="02337029" sec3="Y"><name>Firmagon</name><manufacturerId>FEI</manufacturerId><individualPrice>274.1760</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>274.1760</amountMOHLTCPays></drug></pcg9><pcg9 id="100000199"><itemNumber>0261</itemNumber><strength>120mg</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><drug id="02337037" sec3="Y"><name>Firmagon</name><manufacturerId>FEI</manufacturerId><individualPrice>370.9440</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>370.9440</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01677"><name>ERLOTINIB</name><pcgGroup><pcg9 id="100000204"><itemNumber>0262</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02269007" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tarceva</name><manufacturerId>HLR</manufacturerId><listingDate>2015-02-26</listingDate></drug><drug id="02377691" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Erlotinib</name><manufacturerId>TEV</manufacturerId><individualPrice>11.8666</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>11.8666</amountMOHLTCPays></drug><drug id="02461862" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Erlotinib</name><manufacturerId>APX</manufacturerId><individualPrice>11.8667</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>11.8667</amountMOHLTCPays></drug><drug id="02483912" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Erlotinib</name><manufacturerId>NAT</manufacturerId><individualPrice>11.8667</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>11.8667</amountMOHLTCPays></drug></pcg9><pcg9 id="100000183"><itemNumber>0263</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02269015" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tarceva</name><manufacturerId>HLR</manufacturerId><listingDate>2015-02-26</listingDate></drug><drug id="02377705" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Erlotinib</name><manufacturerId>TEV</manufacturerId><individualPrice>47.4666</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>47.4666</amountMOHLTCPays></drug><drug id="02454386" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Erlotinib</name><manufacturerId>PMS</manufacturerId><individualPrice>47.4667</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>47.4667</amountMOHLTCPays></drug><drug id="02461870" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Erlotinib</name><manufacturerId>APX</manufacturerId><individualPrice>47.4667</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>47.4667</amountMOHLTCPays></drug><drug id="02483920" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Erlotinib</name><manufacturerId>NAT</manufacturerId><individualPrice>47.4667</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>47.4667</amountMOHLTCPays></drug></pcg9><pcg9 id="100000184"><itemNumber>0264</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02269023" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tarceva</name><manufacturerId>HLR</manufacturerId><listingDate>2015-02-26</listingDate></drug><drug id="02377713" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Erlotinib</name><manufacturerId>TEV</manufacturerId><individualPrice>71.2000</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>71.2000</amountMOHLTCPays></drug><drug id="02454394" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Erlotinib</name><manufacturerId>PMS</manufacturerId><individualPrice>71.2000</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>71.2000</amountMOHLTCPays></drug><drug id="02461889" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Erlotinib</name><manufacturerId>APX</manufacturerId><individualPrice>71.2000</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>71.2000</amountMOHLTCPays></drug><drug id="02483939" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Erlotinib</name><manufacturerId>NAT</manufacturerId><individualPrice>71.2000</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>71.2000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00185"><name>ETOPOSIDE</name><pcgGroup><pcg9 id="100000072"><itemNumber>0265</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="00616192" sec3="Y"><name>Vepesid</name><manufacturerId>CHE</manufacturerId><individualPrice>47.8010</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>47.8010</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01794"><name>EVEROLIMUS</name><pcgGroup><pcg9 id="100000225"><itemNumber>0266</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02369257" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Afinitor</name><manufacturerId>NOV</manufacturerId><individualPrice>202.6540</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02463229" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Everolimus</name><manufacturerId>TEV</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02492911" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Everolimus</name><manufacturerId>SDZ</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02504677" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Everolimus</name><manufacturerId>PMS</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02530090" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Everolimus</name><manufacturerId>NAT</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02532409" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Everolimus</name><manufacturerId>DRR</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug></pcg9><pcg9 id="100000208"><itemNumber>0267</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02339501" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Afinitor</name><manufacturerId>NOV</manufacturerId><individualPrice>202.6540</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02463237" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Everolimus</name><manufacturerId>TEV</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02492938" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Everolimus</name><manufacturerId>SDZ</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02504685" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Everolimus</name><manufacturerId>PMS</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02530104" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Everolimus</name><manufacturerId>NAT</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02532417" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Everolimus</name><manufacturerId>DRR</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug></pcg9><pcg9 id="100000200"><itemNumber>0268</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02339528" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Afinitor</name><manufacturerId>NOV</manufacturerId><individualPrice>202.6540</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02463253" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Everolimus</name><manufacturerId>TEV</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02492946" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Everolimus</name><manufacturerId>SDZ</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02504693" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Everolimus</name><manufacturerId>PMS</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02530120" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Everolimus</name><manufacturerId>NAT</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug><drug id="02532433" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Everolimus</name><manufacturerId>DRR</manufacturerId><individualPrice>172.2559</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>172.2559</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01507"><name>EXEMESTANE</name><pcgGroup><pcg9 id="100000162"><itemNumber>0269</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02242705" sec3="Y"><name>Aromasin</name><manufacturerId>PFI</manufacturerId><individualPrice>6.2463</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>1.3263</amountMOHLTCPays></drug><drug id="02390183" sec3="Y"><name>Co Exemestane</name><manufacturerId>COB</manufacturerId><individualPrice>1.3263</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>1.3263</amountMOHLTCPays></drug><drug id="02407841" sec3="Y"><name>Med-Exemestane</name><manufacturerId>GMP</manufacturerId><individualPrice>1.3263</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>1.3263</amountMOHLTCPays></drug><drug id="02408473" sec3="Y"><name>Teva-Exemestane</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3263</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.3263</amountMOHLTCPays></drug><drug id="02419726" sec3="Y"><name>Apo-Exemestane</name><manufacturerId>APX</manufacturerId><individualPrice>1.3263</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>1.3263</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01583"><name>FLUDARABINE PHOSPHATE</name><pcgGroup lccId="00151"><pcg9 id="100000171"><itemNumber>0270</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02246226" sec3="Y" sec12="Y"><name>Fludara</name><manufacturerId>GZM</manufacturerId><individualPrice>41.8940</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>41.8940</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="424">For the first-line treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab (with or without cyclophosphamide).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="379">For second line therapy of patients with chronic lymphocytic leukemia (CLL) who have failed or are intolerant to chlorambucil.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02064"><name>FLUOROURACIL &amp; SALICYLIC ACID</name><pcgGroup><pcg9 id="100000288"><itemNumber>0271</itemNumber><strength>0.5% w/w &amp; 10% w/w</strength><dosageForm>Top Sol</dosageForm><drug id="02428946" sec3="Y"><name>Actikerall</name><manufacturerId>CIP</manufacturerId><individualPrice>2.0878</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>2.0878</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00177"><name>FLUTAMIDE</name><pcgGroup><pcg9 id="100000050"><itemNumber>0272</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="00637726" notABenefit="Y" sec3="Y"><name>Euflex</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02238560" sec3="Y"><name>Flutamide</name><manufacturerId>AAP</manufacturerId><individualPrice>1.8255</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.8255</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02077"><name>FULVESTRANT</name><pcgGroup><pcg9 id="100000291"><itemNumber>0273</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol</dosageForm><drug id="02248624" sec3="Y"><name>Faslodex</name><manufacturerId>AZC</manufacturerId><individualPrice>132.8093</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>40.8027</amountMOHLTCPays></drug><drug id="02460130" sec3="Y"><name>Teva-Fulvestrant Injection</name><manufacturerId>TEV</manufacturerId><individualPrice>40.8027</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>40.8027</amountMOHLTCPays></drug><drug id="02483610" sec3="Y"><name>Fulvestrant Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>40.8027</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>40.8027</amountMOHLTCPays></drug><drug id="02530635" sec3="Y"><name>Fulvestrant Injectable</name><manufacturerId>JPC</manufacturerId><individualPrice>40.8027</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>40.8027</amountMOHLTCPays></drug><drug id="02536293" sec3="Y"><name>Fulvestrant Injection</name><manufacturerId>FOM</manufacturerId><individualPrice>40.8027</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>40.8027</amountMOHLTCPays></drug><drug id="02558971" sec3="Y"><name>Fulvestrant Injection</name><manufacturerId>STE</manufacturerId><individualPrice>40.8027</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>40.8027</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01631"><name>GEFITINIB</name><pcgGroup><pcg9 id="100000178"><itemNumber>0274</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02248676" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Iressa</name><manufacturerId>AZC</manufacturerId><individualPrice>74.1063</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>62.3050</amountMOHLTCPays></drug><drug id="02468050" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Gefitinib</name><manufacturerId>APX</manufacturerId><individualPrice>62.3050</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>62.3050</amountMOHLTCPays></drug><drug id="02487748" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Gefitinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>62.3050</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>62.3050</amountMOHLTCPays></drug><drug id="02491796" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Gefitinib</name><manufacturerId>NAT</manufacturerId><individualPrice>62.3050</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>62.3050</amountMOHLTCPays></drug><drug id="02500663" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Gefitinib</name><manufacturerId>JPC</manufacturerId><individualPrice>62.3050</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>62.3050</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00182"><name>GOSERELIN ACETATE</name><pcgGroup><pcg9 id="100000069"><itemNumber>0275</itemNumber><strength>3.6mg</strength><dosageForm>Depot Inj</dosageForm><drug id="02049325" sec3="Y"><name>Zoladex</name><manufacturerId>TRS</manufacturerId><individualPrice>422.6778</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>422.6778</amountMOHLTCPays></drug></pcg9><pcg9 id="100000110"><itemNumber>0276</itemNumber><strength>10.8mg</strength><dosageForm>Depot Inj</dosageForm><drug id="02225905" sec3="Y"><name>Zoladex LA</name><manufacturerId>TRS</manufacturerId><individualPrice>1204.7322</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1204.7322</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00184"><name>HYDROXYUREA</name><pcgGroup><pcg9 id="100000071"><itemNumber>0277</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><drug id="00465283" sec3="Y"><name>Hydrea</name><manufacturerId>BQU</manufacturerId><individualPrice>1.1727</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0203</amountMOHLTCPays></drug><drug id="02242920" sec3="Y"><name>Mylan-Hydroxyurea</name><manufacturerId>MYL</manufacturerId><individualPrice>1.0203</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>1.0203</amountMOHLTCPays></drug><drug id="02247937" sec3="Y"><name>Apo-Hydroxyurea</name><manufacturerId>APX</manufacturerId><individualPrice>1.0203</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>1.0203</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01534"><name>IMATINIB MESYLATE</name><pcgGroup><pcg9 id="100000180"><itemNumber>0278</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><note>Pharmacists and prescribers should be informed of a drug product&apos;s official indications as set out in Health Canada&apos;s approved product monograph.</note><drug id="02253275" sec3="Y"><name>Gleevec</name><manufacturerId>NOV</manufacturerId><individualPrice>29.7475</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02355337" sec3="Y"><name>Apo-Imatinib</name><manufacturerId>APX</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02397285" sec3="Y"><name>Nat-Imatinib</name><manufacturerId>NAT</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02399806" sec3="Y"><name>Teva-Imatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02431114" sec3="Y"><name>PMS-Imatinib</name><manufacturerId>PMS</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02490986" sec3="Y"><name>Ach-Imatinib</name><manufacturerId>ACH</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02492334" sec3="Y"><name>Mint-Imatinib</name><manufacturerId>MIN</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02495066" sec3="Y"><name>Jamp Imatinib</name><manufacturerId>JPC</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02504596" sec3="Y"><name>Imatinib</name><manufacturerId>SAI</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug><drug id="02521202" sec3="Y"><name>Imatinib</name><manufacturerId>SIV</manufacturerId><individualPrice>5.2079</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>5.2079</amountMOHLTCPays></drug></pcg9><pcg9 id="100000177"><itemNumber>0279</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><note>Pharmacists and prescribers should be informed of a drug product&apos;s official indications as set out in Health Canada&apos;s approved product monograph.</note><drug id="02253283" sec3="Y"><name>Gleevec</name><manufacturerId>NOV</manufacturerId><individualPrice>118.9900</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02355345" sec3="Y"><name>Apo-Imatinib</name><manufacturerId>APX</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02397293" sec3="Y"><name>Nat-Imatinib</name><manufacturerId>NAT</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02399814" sec3="Y"><name>Teva-Imatinib</name><manufacturerId>TEV</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02431122" sec3="Y"><name>PMS-Imatinib</name><manufacturerId>PMS</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02490994" sec3="Y"><name>Ach-Imatinib</name><manufacturerId>ACH</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02492342" sec3="Y"><name>Mint-Imatinib</name><manufacturerId>MIN</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02495074" sec3="Y"><name>Jamp Imatinib</name><manufacturerId>JPC</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02504618" sec3="Y"><name>Imatinib</name><manufacturerId>SAI</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug><drug id="02521210" sec3="Y"><name>Imatinib</name><manufacturerId>SIV</manufacturerId><individualPrice>20.8314</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>20.8314</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01334"><name>LETROZOLE</name><pcgGroup><pcg9 id="100000116"><itemNumber>0280</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02231384" sec3="Y"><name>Femara</name><manufacturerId>NOV</manufacturerId><individualPrice>8.7543</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02309114" sec3="Y"><name>PMS-Letrozole</name><manufacturerId>PMS</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02322315" sec3="Y"><name>Med-Letrozole</name><manufacturerId>GMP</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02338459" sec3="Y"><name>Letrozole Tablets USP</name><manufacturerId>ACH</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02343657" sec3="Y"><name>Teva-Letrozole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02344815" sec3="Y"><name>Sandoz Letrozole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02348969" sec3="Y"><name>Letrozole</name><manufacturerId>COB</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02358514" sec3="Y"><name>Apo-Letrozole</name><manufacturerId>APX</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02372282" sec3="Y"><name>Ran-Letrozole</name><manufacturerId>RAN</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02373009" sec3="Y"><name>Jamp-Letrozole</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02373424" sec3="Y"><name>Mar-Letrozole</name><manufacturerId>MAR</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02378213" sec3="Y"><name>Zinda-Letrozole</name><manufacturerId>STA</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02398656" sec3="Y"><name>Riva-Letrozole</name><manufacturerId>RIA</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02421585" sec3="Y"><name>Nat-Letrozole</name><manufacturerId>NAT</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02459884" sec3="Y"><name>CCP-Letrozole</name><manufacturerId>CCP</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02504472" sec3="Y"><name>Letrozole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02508109" sec3="Y"><name>Mint-Letrozole</name><manufacturerId>MIN</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02520486" sec3="Y"><name>NRA-Letrozole</name><manufacturerId>NRA</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02524244" sec3="Y"><name>Letrozole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug><drug id="02541912" sec3="Y"><name>Jamp Letrozole Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3780</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>1.3780</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00178"><name>LEUPROLIDE ACETATE</name><pcgGroup><pcg9 id="100000084"><itemNumber>0281</itemNumber><strength>3.75mg</strength><dosageForm>Inj-Kit</dosageForm><drug id="00884502" sec3="Y"><name>Lupron Depot PDS</name><manufacturerId>ABB</manufacturerId><individualPrice>389.1300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>389.1300</amountMOHLTCPays></drug></pcg9><pcg9 id="100000066"><itemNumber>0282</itemNumber><strength>7.5mg</strength><dosageForm>Inj-Kit</dosageForm><drug id="00836273" sec3="Y"><name>Lupron Depot PDS</name><manufacturerId>ABB</manufacturerId><individualPrice>387.9700</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>387.9700</amountMOHLTCPays></drug></pcg9><pcg9 id="100000148"><itemNumber>0283</itemNumber><strength>11.25mg</strength><dosageForm>Inj-Kit</dosageForm><drug id="02239834" sec3="Y"><name>Lupron Depot PDS</name><manufacturerId>ABB</manufacturerId><individualPrice>1159.5200</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>1159.5200</amountMOHLTCPays></drug></pcg9><pcg9 id="100000113"><itemNumber>0284</itemNumber><strength>22.5mg</strength><dosageForm>Inj-Kit</dosageForm><drug id="02230248" sec3="Y"><name>Lupron Depot PDS</name><manufacturerId>ABB</manufacturerId><individualPrice>1071.0000</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>1071.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000146"><itemNumber>0285</itemNumber><strength>30mg</strength><dosageForm>Inj-Kit</dosageForm><drug id="02239833" sec3="Y"><name>Lupron Depot PDS</name><manufacturerId>ABB</manufacturerId><individualPrice>1428.0000</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>1428.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000310"><itemNumber>0286</itemNumber><strength>3.75mg/Vial</strength><dosageForm>Pd for Inj - Vial Pk</dosageForm><drug id="02429977" sec3="Y"><name>Zeulide Depot</name><manufacturerId>VET</manufacturerId><individualPrice>304.0000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>304.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000311"><itemNumber>0287</itemNumber><strength>22.5mg/Vial</strength><dosageForm>Pd for Inj - Vial Pk</dosageForm><drug id="02462699" sec3="Y"><name>Zeulide Depot</name><manufacturerId>VET</manufacturerId><individualPrice>873.0000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>873.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000172"><itemNumber>0288</itemNumber><strength>7.5mg</strength><dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm><drug id="02248239" sec3="Y"><name>Eligard</name><manufacturerId>TOL</manufacturerId><individualPrice>310.7200</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>310.7200</amountMOHLTCPays></drug></pcg9><pcg9 id="100000173"><itemNumber>0289</itemNumber><strength>22.5mg</strength><dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm><drug id="02248240" sec3="Y"><name>Eligard</name><manufacturerId>TOL</manufacturerId><individualPrice>891.0000</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>891.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000176"><itemNumber>0290</itemNumber><strength>30mg</strength><dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm><drug id="02248999" sec3="Y"><name>Eligard</name><manufacturerId>TOL</manufacturerId><individualPrice>1285.2000</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>1285.2000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000181"><itemNumber>0291</itemNumber><strength>45mg</strength><dosageForm>Pd Susp Inj-Pref Syr Kit</dosageForm><drug id="02268892" sec3="Y"><name>Eligard</name><manufacturerId>TOL</manufacturerId><individualPrice>1659.9000</individualPrice><listingDate>2006-06-15</listingDate><amountMOHLTCPays>1659.9000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00172"><name>LOMUSTINE (CCNU)</name><pcgGroup><pcg9 id="100000396"><itemNumber>0292</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="09858359" sec3c="Y"><name>Gleostine</name><manufacturerId>SET</manufacturerId><individualPrice>211.2400</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>211.2400</amountMOHLTCPays></drug></pcg9><pcg9 id="100000397"><itemNumber>0293</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="09858382" sec3c="Y"><name>Lomustine</name><manufacturerId>SET</manufacturerId><individualPrice>336.9200</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>336.9200</amountMOHLTCPays></drug></pcg9><pcg9 id="100000044"><itemNumber>0294</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="00360430" sec3="Y"><name>CeeNU</name><manufacturerId>BQU</manufacturerId><individualPrice>7.8900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>7.8900</amountMOHLTCPays></drug></pcg9><pcg9 id="100000043"><itemNumber>0295</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="00360422" sec3="Y"><name>CeeNU</name><manufacturerId>BQU</manufacturerId><individualPrice>13.6025</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>13.6025</amountMOHLTCPays></drug></pcg9><pcg9 id="100000042"><itemNumber>0296</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="00360414" sec3="Y"><name>CeeNU</name><manufacturerId>BQU</manufacturerId><individualPrice>22.4550</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>22.4550</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00173"><name>MEGESTROL ACETATE</name><pcgGroup><pcg9 id="100000045"><itemNumber>0297</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="00386391" notABenefit="Y" sec3="Y"><name>Megace</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02195917" sec3="Y"><name>Megestrol</name><manufacturerId>AAP</manufacturerId><individualPrice>1.3340</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.3340</amountMOHLTCPays></drug></pcg9><pcg9 id="100000063"><itemNumber>0298</itemNumber><strength>160mg</strength><dosageForm>Tab</dosageForm><drug id="00731323" notABenefit="Y" sec3="Y"><name>Megace</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02195925" sec3="Y"><name>Megestrol</name><manufacturerId>AAP</manufacturerId><individualPrice>5.8151</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>5.8151</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00163"><name>MELPHALAN</name><pcgGroup><pcg9 id="100000017"><itemNumber>0299</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00004715" sec3="Y"><name>Alkeran</name><manufacturerId>ASN</manufacturerId><individualPrice>2.4112</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.4112</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00164"><name>MERCAPTOPURINE</name><pcgGroup><pcg9 id="100000018"><itemNumber>0300</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00004723" sec3="Y"><name>Purinethol</name><manufacturerId>NOP</manufacturerId><individualPrice>2.8610</individualPrice><note>Decrease dose of mercaptopurine to 25-33% of initial dose if allopurinol used concomitantly.
</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.8610</amountMOHLTCPays></drug><drug id="02415275" sec3="Y"><name>Mercaptopurine Tablets USP</name><manufacturerId>STE</manufacturerId><individualPrice>2.8610</individualPrice><note>Decrease dose of mercaptopurine to 25-33% of initial dose if allopurinol used concomitantly.</note><listingDate>2014-03-27</listingDate><amountMOHLTCPays>2.8610</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00179"><name>METHOTREXATE</name><pcgGroup><pcg9 id="100000054"><itemNumber>0301</itemNumber><strength>20mg/2mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="02182947" sec3="Y"><name>Methotrexate Sodium</name><manufacturerId>MAY</manufacturerId><individualPrice>12.5000</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>12.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000032"><itemNumber>0302</itemNumber><strength>50mg/2mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="02170671" notABenefit="Y" sec3="Y"><name>Methotrexate</name><manufacturerId>WAY</manufacturerId><listingDate>1998-03-17</listingDate></drug><drug id="02182777" sec3="Y"><name>Methotrexate</name><manufacturerId>MAY</manufacturerId><individualPrice>8.9200</individualPrice><listingDate>2005-10-06</listingDate><amountMOHLTCPays>8.9200</amountMOHLTCPays></drug><drug id="02464365" sec3="Y"><name>Methotrexate Injection BP</name><manufacturerId>ACH</manufacturerId><individualPrice>8.9200</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>8.9200</amountMOHLTCPays></drug></pcg9><pcg9 id="100000302"><itemNumber>0303</itemNumber><strength>10mg/0.2mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454831" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>16.3000</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>16.3000</amountMOHLTCPays></drug><drug id="02539608" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>16.3020</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>16.3000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000303"><itemNumber>0304</itemNumber><strength>12.5mg/0.25mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454750" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>17.1600</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>17.1600</amountMOHLTCPays></drug><drug id="02539616" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>17.1600</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>17.1600</amountMOHLTCPays></drug></pcg9><pcg9 id="100000292"><itemNumber>0305</itemNumber><strength>15mg/0.3mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454858" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>16.3800</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>16.3800</amountMOHLTCPays></drug><drug id="02491311" sec3="Y"><name>Methotrexate Subcutaneous</name><manufacturerId>ACH</manufacturerId><individualPrice>16.3800</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>16.3800</amountMOHLTCPays></drug><drug id="02539624" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>16.3800</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>16.3800</amountMOHLTCPays></drug></pcg9><pcg9 id="100000275"><itemNumber>0306</itemNumber><strength>17.5mg/0.35mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454769" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>16.0000</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>16.0000</amountMOHLTCPays></drug><drug id="02491338" sec3="Y"><name>Methotrexate Subcutaneous</name><manufacturerId>ACH</manufacturerId><individualPrice>16.0000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>16.0000</amountMOHLTCPays></drug><drug id="02539632" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>16.0000</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>16.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000276"><itemNumber>0307</itemNumber><strength>20mg/0.4mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454866" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>17.5000</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>17.5000</amountMOHLTCPays></drug><drug id="02491346" sec3="Y"><name>Methotrexate Subcutaneous</name><manufacturerId>ACH</manufacturerId><individualPrice>17.5000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>17.5000</amountMOHLTCPays></drug><drug id="02539640" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>17.5000</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>17.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000277"><itemNumber>0308</itemNumber><strength>22.5mg/0.45mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454777" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>17.5000</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>17.5000</amountMOHLTCPays></drug><drug id="02491354" sec3="Y"><name>Methotrexate Subcutaneous</name><manufacturerId>ACH</manufacturerId><individualPrice>17.5000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>17.5000</amountMOHLTCPays></drug><drug id="02539659" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>17.5000</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>17.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000278"><itemNumber>0309</itemNumber><strength>25mg/0.5mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02454874" sec3="Y"><name>Metoject Subcutaneous</name><manufacturerId>MDX</manufacturerId><individualPrice>19.5000</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>19.5000</amountMOHLTCPays></drug><drug id="02491362" sec3="Y"><name>Methotrexate Subcutaneous</name><manufacturerId>ACH</manufacturerId><individualPrice>19.5000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>19.5000</amountMOHLTCPays></drug><drug id="02539667" sec3="Y"><name>PMS-Methotrexate Injection</name><manufacturerId>PMS</manufacturerId><individualPrice>19.5000</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>19.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000001"><itemNumber>0310</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02170698" sec3="Y"><name>PMS-Methotrexate</name><manufacturerId>PMS</manufacturerId><individualPrice>.2513</individualPrice><listingDate>1997-02-04</listingDate><amountMOHLTCPays>.2513</amountMOHLTCPays></drug><drug id="02182963" sec3="Y"><name>Apo-Methotrexate</name><manufacturerId>APX</manufacturerId><individualPrice>.2513</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.2513</amountMOHLTCPays></drug><drug id="02509067" sec3="Y"><name>Ach-Methotrexate</name><manufacturerId>ACH</manufacturerId><individualPrice>.2513</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2513</amountMOHLTCPays></drug><drug id="02524023" sec3="Y"><name>Auro-Methotrexate</name><manufacturerId>AUR</manufacturerId><individualPrice>.2513</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.2513</amountMOHLTCPays></drug><drug id="02534916" sec3="Y"><name>M-Methotrexate</name><manufacturerId>MAT</manufacturerId><individualPrice>.2513</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.2513</amountMOHLTCPays></drug></pcg9><pcg9 id="100000205"><itemNumber>0311</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02182750" notABenefit="Y" sec3b="Y" sec3="Y"><name>Methotrexate Tablets, USP</name><manufacturerId>PFI</manufacturerId><listingDate>2025-08-29</listingDate></drug><drug id="02553740" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Methotrexate Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>2.6588</individualPrice><listingDate>2025-08-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00193"><name>MITOTANE</name><pcgGroup><pcg9 id="100000086"><itemNumber>0312</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="00463221" sec3="Y"><name>Lysodren</name><manufacturerId>HRA</manufacturerId><individualPrice>9.7900</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.7900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01795"><name>NILOTINIB</name><pcgGroup><pcg9 id="100000209"><itemNumber>0313</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02368250" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tasigna</name><manufacturerId>NOV</manufacturerId><individualPrice>33.7762</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>16.5570</amountMOHLTCPays></drug><drug id="02550881" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Nilotinib</name><manufacturerId>APX</manufacturerId><individualPrice>16.5570</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>16.5570</amountMOHLTCPays></drug><drug id="02556634" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Nilotinib</name><manufacturerId>DRR</manufacturerId><individualPrice>16.5570</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>16.5570</amountMOHLTCPays></drug></pcg9><pcg9 id="100000201"><itemNumber>0314</itemNumber><strength>200mg</strength><dosageForm>Cap</dosageForm><drug id="02315874" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tasigna</name><manufacturerId>NOV</manufacturerId><individualPrice>47.0164</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>23.0473</amountMOHLTCPays></drug><drug id="02550903" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Nilotinib</name><manufacturerId>APX</manufacturerId><individualPrice>23.0473</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>23.0473</amountMOHLTCPays></drug><drug id="02556642" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Nilotinib</name><manufacturerId>DRR</manufacturerId><individualPrice>23.0473</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>23.0473</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02047"><name>PALBOCICLIB</name><pcgGroup><pcg9 id="100000317"><itemNumber>0315</itemNumber><strength>75mg</strength><dosageForm>Tab</dosageForm><drug id="02493535" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ibrance</name><manufacturerId>PFI</manufacturerId><individualPrice>253.9123</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug><drug id="02547635" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Palbociclib</name><manufacturerId>TAR</manufacturerId><individualPrice>126.9562</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug><drug id="02552124" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Palbociclib</name><manufacturerId>PMS</manufacturerId><individualPrice>126.9562</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug></pcg9><pcg9 id="100000318"><itemNumber>0316</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02493543" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ibrance</name><manufacturerId>PFI</manufacturerId><individualPrice>253.9123</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug><drug id="02547643" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Palbociclib</name><manufacturerId>TAR</manufacturerId><individualPrice>126.9562</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug><drug id="02552132" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Palbociclib</name><manufacturerId>PMS</manufacturerId><individualPrice>126.9562</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug></pcg9><pcg9 id="100000319"><itemNumber>0317</itemNumber><strength>125mg</strength><dosageForm>Tab</dosageForm><drug id="02493551" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ibrance</name><manufacturerId>PFI</manufacturerId><individualPrice>253.9123</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug><drug id="02547651" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Palbociclib</name><manufacturerId>TAR</manufacturerId><individualPrice>126.9562</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug><drug id="02552140" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Palbociclib</name><manufacturerId>PMS</manufacturerId><individualPrice>126.9562</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>126.9562</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01903"><name>PAZOPANIB</name><pcgGroup><pcg9 id="100000212"><itemNumber>0318</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02352303" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Votrient</name><manufacturerId>GSK</manufacturerId><individualPrice>41.3147</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>30.9655</amountMOHLTCPays></drug><drug id="02525666" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Pazopanib</name><manufacturerId>PMS</manufacturerId><individualPrice>30.9655</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>30.9655</amountMOHLTCPays></drug><drug id="02552957" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Eugia-Pazopanib</name><manufacturerId>EUP</manufacturerId><individualPrice>30.9655</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>30.9655</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01965"><name>POMALIDOMIDE</name><pcgGroup><pcg9 id="100000242"><itemNumber>0319</itemNumber><strength>1mg</strength><dosageForm>Cap</dosageForm><drug id="02419580" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pomalyst</name><manufacturerId>BQU</manufacturerId><individualPrice>500.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02504073" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Pomalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02506394" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Pomalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02520427" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pomalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02523973" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pomalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02538059" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pomalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000243"><itemNumber>0320</itemNumber><strength>2mg</strength><dosageForm>Cap</dosageForm><drug id="02419599" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pomalyst</name><manufacturerId>BQU</manufacturerId><individualPrice>500.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02504081" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Pomalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02506408" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Pomalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02520435" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pomalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02523981" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pomalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02538075" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pomalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000244"><itemNumber>0321</itemNumber><strength>3mg</strength><dosageForm>Cap</dosageForm><drug id="02419602" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pomalyst</name><manufacturerId>BQU</manufacturerId><individualPrice>500.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02504103" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Pomalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02506416" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Pomalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02520443" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pomalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02524007" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pomalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02538083" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pomalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000245"><itemNumber>0322</itemNumber><strength>4mg</strength><dosageForm>Cap</dosageForm><drug id="02419610" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pomalyst</name><manufacturerId>BQU</manufacturerId><individualPrice>500.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02504111" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Pomalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02506424" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Pomalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02520451" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pomalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02524015" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pomalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug><drug id="02538091" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pomalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>425.0000</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>425.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00165"><name>PROCARBAZINE HCL</name><pcgGroup><pcg9 id="100000021"><itemNumber>0323</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="00012750" sec3="Y"><name>Matulane</name><manufacturerId>LBI</manufacturerId><individualPrice>83.2680</individualPrice><note>Procarbazine inhibits monoamine oxidase. Avoid alcohol and foods with high tyramine content (e.g. aged cheese, red wine, yogurt, etc.)</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>83.2680</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01618"><name>RITUXIMAB</name><pcgGroup lccId="00337"><pcg9 id="100000315"><itemNumber>0324</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol (Preservative-Free)</dosageForm><drug id="02495724" sec3="Y" sec12="Y"><name>Ruxience</name><manufacturerId>PFI</manufacturerId><individualPrice>29.7000</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>29.7000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="583">For the treatment of adults with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.

1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:

A)  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) Leflunomide (20mg/day) for at least 3 months, in addition to
   iii) An adequate trial of at least one combination of DMARDs for 3 months;
  
  OR

B)  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) Leflunomide in combination with methotrexate for at least 3 months; OR

C)  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months.
    (Hydroxychloroquine is based by weight up to 400mg per day.)

2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).

3. Patient is not using rituximab in a maintenance setting.

4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.

5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.

6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. 

One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote><lccNote seq="003" reasonForUseId="584">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:

1. Patient has met the initiation criteria for rituximab in accordance with RFU 583;

2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND

3. Patient is not using rituximab in a maintenance setting; AND

4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND

5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.

6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote><lccNote seq="005" reasonForUseId="585">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:

1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.

AND

2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.

AND

3. Cyclophosphamide cannot be used by the patient for one of the following reasons:

a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.

4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.

Exclusion criteria:

The patient should not have received a course of rituximab in the prior 6 months.

The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.

Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.  

</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote><lccNote seq="007" reasonForUseId="586">Rituximab (Ruxience) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:

1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.

2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.

3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.

4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.

Exclusion criteria:

The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.

The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.

Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00338"><pcg9 id="100000316"><itemNumber>0325</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol (Preservative-Free)</dosageForm><drug id="02498316" sec3="Y" sec12="Y"><name>Riximyo</name><manufacturerId>SDZ</manufacturerId><individualPrice>29.7000</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>29.7000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="581">For the treatment of adults with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP postive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.

1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:

A)  i) Methotrexate (20mg/week) for at least 3 months, AND
   ii) Leflunomide (20mg/day) for at least 3 months, in addition to
  iii) An adequate trial of at least one combination of DMARDs for 3 months;
  
  OR

B)  i) Methotrexate (20mg/week) for at least 3 months, AND
   ii) Leflunomide in combination with methotrexate for at least 3 months; OR

C)  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine 400mg/day) for at least 3 months.

    (Hydroxychloroquine is based by weight up to 400mg per day.)

2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).

3. Patient is not using rituximab in a maintenance setting.

4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.

5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.

6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. 

One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote><lccNote seq="003" reasonForUseId="582">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:

1. Patient has met the initiation criteria for rituximab in accordance with RFU 581;

2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND

3. Patient is not using rituximab in a maintenance setting; AND

4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND

5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.

6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote><lccNote seq="005" reasonForUseId="616">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:

1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.

AND

2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.

AND

3. Cyclophosphamide cannot be used by the patient for one of the following reasons:

a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.

4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.

Exclusion criteria:

The patient should not have received a course of rituximab in the prior 6 months.

The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.

Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote><lccNote seq="007" reasonForUseId="617">Rituximab (Riximyo) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:

1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.

2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.

3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.

4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.

Exclusion criteria:

The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.

The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.

Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00330"><pcg9 id="100000304"><itemNumber>0326</itemNumber><strength>100mg/10mL</strength><dosageForm>Inj Sol-10mL Vial Pk</dosageForm><drug id="02478382" sec3="Y" sec12="Y"><name>Truxima</name><manufacturerId>CEH</manufacturerId><individualPrice>297.0000</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>297.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000305"><itemNumber>0327</itemNumber><strength>500mg/50mL</strength><dosageForm>Inj Sol-50mL Vial Pk</dosageForm><drug id="02478390" sec3="Y" sec12="Y"><name>Truxima</name><manufacturerId>CEH</manufacturerId><individualPrice>1485.0000</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>1485.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="575">For the treatment of adults with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria.

1. Patient has experienced failure to respond, documented intolerance, or contraindication to optimal use of one of the following disease modifying, anti-rheumatic (DMARD) regimens:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
   ii) Leflunomide (20mg/day) for at least 3 months, in addition to 
   iii) An adequate trial of at least one combination of DMARDs for 3 months;
   OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
   ii) Leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months.
(Hydroxychloroquine is based by weight up to 400mg per day.)

2. Patient has experienced failure to respond, documented intolerance, or contraindication to an adequate trial of at least ONE anti-TNF agent (e.g., adalimumab, etanercept, infliximab, golimumab, certolizumab pegol).

3. Patient is not using rituximab in a maintenance setting.

4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab.

5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.

6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

One course of treatment is 1000mg followed two weeks later by the second 1000mg dose.

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 3 Months</lccNote><lccNote seq="003" reasonForUseId="576">For the re-treatment of patients with severe active rheumatoid arthritis (RA) (greater than or equal to 5 swollen joints, and rheumatoid factor positive and/or anti-CCP positive, and radiographic evidence of rheumatoid arthritis) who meet ALL the following criteria:

1. Patient has met the initiation criteria for rituximab in accordance with RFU 575;

2. Patient has experienced loss of effect after having responded to the prior treatment course of rituximab (Response is defined as a 20% reduction in the swollen joint count compared to the joint count prior to the first, pre-treatment course evaluated at 3 to 4 months following the administered course AND improvement in 2 swollen joints); AND

3. Patient is not using rituximab in a maintenance setting; AND

4. Patient is not using a treatment course of rituximab earlier than 6 months after the completion of a prior course of rituximab; AND

5. Rituximab is not used in combination with another biologic to treat the patient&apos;s RA.

6. Treatment must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

One course of re-treatment is 1000mg followed two weeks later by the second 1000mg dose.
</lccNote><lccNote seq="004" type="R">LU Authorization Period: 3 Months</lccNote><lccNote seq="005" reasonForUseId="587">Rituximab is used in combination with glucocorticoids for the induction of remission in patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA), for patients who meet all of the following criteria:

1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.

AND

2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA.

AND

3. Cyclophosphamide cannot be used by the Patient for ONE of the following reasons:

a. The patient has failed a minimum of six IV pulses of cyclophosphamide; OR
b. The patient has failed three months of oral cyclophosphamide therapy; OR
c. The patient has a severe intolerance or an allergy to cyclophosphamide; OR
d. Cyclophosphamide is contraindicated; OR
e. The patient has received a cumulative lifetime dose of at least 25g of cyclophosphamide; OR
f. The patient wishes to preserve ovarian/testicular function for fertility.

4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.

Exclusion criteria:

The patient should not have received a course of rituximab in the prior 6 months.

The recommended dosing regimen for the initial treatment would be a once weekly infusion dosed at 375 milligrams per square metre x 4 weeks.

Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 month (1 treatment course)</lccNote><lccNote seq="007" reasonForUseId="588">Rituximab (Truxima) treatment will be used for patients with severely active Granulomatosis with Polyangiitis [(GPA), also known as Wegener&apos;s Granulomatosis (WG)] OR microscopic polyangiitis (MPA) who have achieved disease remission. Patient must meet all of the following criteria:

1. The patient must have severe active disease that is life- or organ-threatening as supported by laboratory and/or imaging reports.

2. There is a positive serum assay for either proteinase 3-ANCA (anti-neutrophil cytoplasmic autoantibodies) or myeloperoxidase-ANCA. A copy of the laboratory report must be provided.

3. Stabilization of the condition with induction doses of cyclophosphamide (injectable or oral doses are acceptable) and a glucocorticoid as combination over 4 to 6 months until disease remission prior to initiation of rituximab.

4. The request is from a prescriber experienced in the diagnosis and management of GPA, MPA, and vasculitis.

Exclusion criteria:

The patient should not have received a dose of rituximab in the prior 6 months. Doses of rituximab administered at intervals more frequently than every 6 months are not funded.

The recommended dosing regimen: A fixed dose regimen of Rituximab of 500mg IV every 6 months.

Case-by-case considerations for patients not meeting the LU criteria may be considered through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00171"><name>TAMOXIFEN CITRATE</name><pcgGroup><pcg9 id="100000040"><itemNumber>0328</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00812404" sec3="Y"><name>Apo-Tamox</name><manufacturerId>APX</manufacturerId><individualPrice>.1750</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1750</amountMOHLTCPays></drug><drug id="00851965" sec3="Y"><name>Teva-Tamoxifen</name><manufacturerId>TEV</manufacturerId><individualPrice>.1750</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1750</amountMOHLTCPays></drug><drug id="01926624" notABenefit="Y" sec3="Y"><name>Tamofen</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02048477" notABenefit="Y" sec3="Y"><name>Nolvadex</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="100000056"><itemNumber>0329</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00812390" sec3="Y"><name>Apo-Tamox</name><manufacturerId>APX</manufacturerId><individualPrice>.3500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3500</amountMOHLTCPays></drug><drug id="00851973" sec3="Y"><name>Teva-Tamoxifen</name><manufacturerId>TEV</manufacturerId><individualPrice>.3500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3500</amountMOHLTCPays></drug><drug id="01926632" notABenefit="Y" sec3="Y"><name>Tamofen</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02048485" dinStatus="E" sec3="Y"><name>Nolvadex D</name><manufacturerId>AZC</manufacturerId><individualPrice>.3910</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01449"><name>TEMOZOLOMIDE</name><pcgGroup><pcg9 id="100000156"><itemNumber>0330</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="02241093" sec3="Y"><name>Temodal</name><manufacturerId>MEK</manufacturerId><individualPrice>8.0340</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>1.9500</amountMOHLTCPays></drug><drug id="02441160" sec3="Y"><name>Teva-Temozolomide</name><manufacturerId>TEV</manufacturerId><individualPrice>1.9500</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>1.9500</amountMOHLTCPays></drug><drug id="02443473" sec3="Y"><name>Taro-Temozolomide</name><manufacturerId>TAR</manufacturerId><individualPrice>1.9500</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>1.9500</amountMOHLTCPays></drug><drug id="02516799" sec3="Y"><name>Jamp Temozolomide</name><manufacturerId>JPC</manufacturerId><individualPrice>1.9500</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>1.9500</amountMOHLTCPays></drug></pcg9><pcg9 id="100000157"><itemNumber>0331</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><drug id="02241094" sec3="Y"><name>Temodal</name><manufacturerId>MEK</manufacturerId><individualPrice>32.1360</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>7.8000</amountMOHLTCPays></drug><drug id="02395274" sec3="Y"><name>Teva-Temozolomide</name><manufacturerId>TEV</manufacturerId><individualPrice>7.8000</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>7.8000</amountMOHLTCPays></drug><drug id="02443481" sec3="Y"><name>Taro-Temozolomide</name><manufacturerId>TAR</manufacturerId><individualPrice>7.8000</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>7.8000</amountMOHLTCPays></drug><drug id="02516802" sec3="Y"><name>Jamp Temozolomide</name><manufacturerId>JPC</manufacturerId><individualPrice>7.8000</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>7.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="100000158"><itemNumber>0332</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02241095" sec3="Y"><name>Temodal</name><manufacturerId>MEK</manufacturerId><individualPrice>160.6862</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>39.0015</amountMOHLTCPays></drug><drug id="02395282" sec3="Y"><name>Teva-Temozolomide</name><manufacturerId>TEV</manufacturerId><individualPrice>39.0015</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>39.0015</amountMOHLTCPays></drug><drug id="02443511" sec3="Y"><name>Taro-Temozolomide</name><manufacturerId>TAR</manufacturerId><individualPrice>39.0015</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>39.0015</amountMOHLTCPays></drug><drug id="02516810" sec3="Y"><name>Jamp Temozolomide</name><manufacturerId>JPC</manufacturerId><individualPrice>39.0015</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>39.0015</amountMOHLTCPays></drug></pcg9><pcg9 id="100000196"><itemNumber>0333</itemNumber><strength>140mg</strength><dosageForm>Cap</dosageForm><drug id="02312794" sec3="Y"><name>Temodal</name><manufacturerId>MEK</manufacturerId><individualPrice>224.9623</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>54.6025</amountMOHLTCPays></drug><drug id="02395290" sec3="Y"><name>Teva-Temozolomide</name><manufacturerId>TEV</manufacturerId><individualPrice>54.6025</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>54.6025</amountMOHLTCPays></drug><drug id="02443538" sec3="Y"><name>Taro-Temozolomide</name><manufacturerId>TAR</manufacturerId><individualPrice>54.6025</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>54.6025</amountMOHLTCPays></drug><drug id="02516829" sec3="Y"><name>Jamp Temozolomide</name><manufacturerId>JPC</manufacturerId><individualPrice>54.6025</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>54.6025</amountMOHLTCPays></drug></pcg9><pcg9 id="100000159"><itemNumber>0334</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="02241096" sec3="Y"><name>Temodal</name><manufacturerId>MEK</manufacturerId><individualPrice>401.7041</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>97.5010</amountMOHLTCPays></drug><drug id="02395312" sec3="Y"><name>Teva-Temozolomide</name><manufacturerId>TEV</manufacturerId><individualPrice>97.5010</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>97.5010</amountMOHLTCPays></drug><drug id="02443554" sec3="Y"><name>Taro-Temozolomide</name><manufacturerId>TAR</manufacturerId><individualPrice>97.5010</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>97.5010</amountMOHLTCPays></drug><drug id="02516845" sec3="Y"><name>Jamp Temozolomide</name><manufacturerId>JPC</manufacturerId><individualPrice>97.5010</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>97.5010</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00166"><name>THIOGUANINE</name><pcgGroup><pcg9 id="100000023"><itemNumber>0335</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="00282081" sec3="Y"><name>Lanvis</name><manufacturerId>ASN</manufacturerId><individualPrice>6.4201</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.4201</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01690"><name>TRIPTORELIN PAMOATE</name><pcgGroup><pcg9 id="100000188"><itemNumber>0336</itemNumber><strength>3.75mg/Vial</strength><dosageForm>Inj Pd with Sterile Water-Vial Pk</dosageForm><drug id="09857199" sec3="Y"><name>Trelstar (1 Month)</name><manufacturerId>KNT</manufacturerId><individualPrice>346.3100</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>346.3100</amountMOHLTCPays></drug></pcg9><pcg9 id="100000189"><itemNumber>0337</itemNumber><strength>11.25mg/Vial</strength><dosageForm>Inj Pd with Sterile Water-Vial Pk</dosageForm><drug id="09857200" sec3="Y"><name>Trelstar LA (3 Month)</name><manufacturerId>KNT</manufacturerId><individualPrice>1038.9700</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>1038.9700</amountMOHLTCPays></drug></pcg9><pcg9 id="100000186"><itemNumber>0338</itemNumber><strength>3.75mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02240000" sec3="Y"><name>Trelstar (1 Month)</name><manufacturerId>KNT</manufacturerId><individualPrice>346.3100</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>346.3100</amountMOHLTCPays></drug></pcg9><pcg9 id="100000187"><itemNumber>0339</itemNumber><strength>11.25mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02243856" sec3="Y"><name>Trelstar LA (3 Month)</name><manufacturerId>KNT</manufacturerId><individualPrice>1038.9700</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>1038.9700</amountMOHLTCPays></drug></pcg9><pcg9 id="100000240"><itemNumber>0340</itemNumber><strength>22.5mg/Vial</strength><dosageForm>SR Inj Pd with Sterile Water-Vial Pk</dosageForm><drug id="02412322" sec3="Y"><name>Trelstar</name><manufacturerId>KNT</manufacturerId><individualPrice>1659.9000</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>1659.9000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00176"><name>VINCRISTINE SULFATE</name><pcgGroup><pcg9 id="100000049"><itemNumber>0341</itemNumber><strength>1mg/mL</strength><dosageForm>Inj Sol</dosageForm><drug id="00611182" notABenefit="Y" sec3="Y"><name>Oncovin</name><manufacturerId>LIL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02143305" sec3="Y"><name>Vincristine Sulfate</name><manufacturerId>NOP</manufacturerId><individualPrice>30.6000</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>30.6000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="120000000"><name>AUTONOMIC AGENTS</name><pcg6 id="120400000"><name>PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS</name><genericName id="00210"><name>BETHANECHOL CHLORIDE</name><pcgGroup><pcg9 id="120400002"><itemNumber>0342</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="01947958" sec3="Y"><name>Duvoid</name><manufacturerId>PPI</manufacturerId><individualPrice>.5025</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5025</amountMOHLTCPays></drug></pcg9><pcg9 id="120400001"><itemNumber>0343</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="01947931" sec3="Y"><name>Duvoid</name><manufacturerId>PPI</manufacturerId><individualPrice>.8137</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.8137</amountMOHLTCPays></drug></pcg9><pcg9 id="120400015"><itemNumber>0344</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="01947923" sec3="Y"><name>Duvoid</name><manufacturerId>PPI</manufacturerId><individualPrice>.9921</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9921</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00211"><name>CARBACHOL</name><pcgGroup><pcg9 id="120400005"><itemNumber>0345</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00885568" sec3="Y"><name>Carbachol</name><manufacturerId>GLA</manufacturerId><individualPrice>.3727</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3727</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01333"><name>DONEPEZIL HCL</name><pcgGroup><pcg9 id="120400033"><itemNumber>0346</itemNumber><strength>5mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02269457" notABenefit="Y" sec3b="Y" sec3="Y"><name>Aricept RDT</name><manufacturerId>PFI</manufacturerId><listingDate>2014-02-27</listingDate></drug><drug id="02367688" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Donepezil ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.6176</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02397617" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Donepezil ODT</name><manufacturerId>COB</manufacturerId><individualPrice>3.6176</individualPrice><listingDate>2014-02-27</listingDate></drug></pcg9><pcg9 id="120400034"><itemNumber>0347</itemNumber><strength>10mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02269465" notABenefit="Y" sec3b="Y" sec3="Y"><name>Aricept RDT</name><manufacturerId>PFI</manufacturerId><listingDate>2014-02-27</listingDate></drug><drug id="02367696" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Donepezil ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.6176</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02397625" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Donepezil ODT</name><manufacturerId>COB</manufacturerId><individualPrice>3.6176</individualPrice><listingDate>2014-02-27</listingDate></drug></pcg9></pcgGroup><pcgGroup lccId="00026"><pcg9 id="120400017"><itemNumber>0348</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02232043" sec3="Y" sec12="Y"><name>Aricept</name><manufacturerId>PFI</manufacturerId><individualPrice>5.1856</individualPrice><listingDate>1999-06-01</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02322331" sec3="Y" sec12="Y"><name>PMS-Donepezil</name><manufacturerId>PMS</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02328666" sec3="Y" sec12="Y"><name>Sandoz Donepezil</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02340607" sec3="Y" sec12="Y"><name>Teva-Donepezil</name><manufacturerId>TEV</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02362260" sec3="Y" sec12="Y"><name>Apo-Donepezil</name><manufacturerId>APX</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02381508" sec3="Y" sec12="Y"><name>Ran-Donepezil</name><manufacturerId>RAN</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02397595" sec3="Y" sec12="Y"><name>Co Donepezil</name><manufacturerId>COB</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02400561" sec3="Y" sec12="Y"><name>Auro-Donepezil</name><manufacturerId>AUR</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02402092" sec3="Y" sec12="Y"><name>Mar-Donepezil</name><manufacturerId>MAR</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02402645" sec3="Y" sec12="Y"><name>Ach-Donepezil</name><manufacturerId>ACH</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02404419" sec3="Y" sec12="Y"><name>Jamp-Donepezil</name><manufacturerId>JPC</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02408600" sec3="Y" sec12="Y"><name>Mint-Donepezil</name><manufacturerId>MIN</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2019-09-30</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02412853" sec3="Y" sec12="Y"><name>Bio-Donepezil</name><manufacturerId>BMP</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2016-04-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02416948" sec3="Y" sec12="Y"><name>Jamp-Donepezil Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02420597" sec3="Y" sec12="Y"><name>Donepezil</name><manufacturerId>SIV</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02426846" sec3="Y" sec12="Y"><name>Donepezil</name><manufacturerId>SAI</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02428482" sec3="Y" sec12="Y"><name>Septa-Donepezil</name><manufacturerId>SET</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02432684" sec3="Y" sec12="Y"><name>AG-Donepezil</name><manufacturerId>ANG</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02439557" sec3="Y" sec12="Y"><name>Nat-Donepezil</name><manufacturerId>NAT</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02467453" sec3="Y" sec12="Y"><name>M-Donepezil</name><manufacturerId>MAT</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02475278" sec3="Y" sec12="Y"><name>Donepezil</name><manufacturerId>RIA</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02535386" sec3="Y" sec12="Y"><name>NRA-Donepezil</name><manufacturerId>NRA</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug></pcg9><pcg9 id="120400018"><itemNumber>0349</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02232044" sec3="Y" sec12="Y"><name>Aricept</name><manufacturerId>PFI</manufacturerId><individualPrice>5.1856</individualPrice><listingDate>1999-06-01</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02322358" sec3="Y" sec12="Y"><name>PMS-Donepezil</name><manufacturerId>PMS</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02328682" sec3="Y" sec12="Y"><name>Sandoz Donepezil</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02340615" sec3="Y" sec12="Y"><name>Teva-Donepezil</name><manufacturerId>TEV</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02362279" sec3="Y" sec12="Y"><name>Apo-Donepezil</name><manufacturerId>APX</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02381516" sec3="Y" sec12="Y"><name>Ran-Donepezil</name><manufacturerId>RAN</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02397609" sec3="Y" sec12="Y"><name>Co Donepezil</name><manufacturerId>COB</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02400588" sec3="Y" sec12="Y"><name>Auro-Donepezil</name><manufacturerId>AUR</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02402106" sec3="Y" sec12="Y"><name>Mar-Donepezil</name><manufacturerId>MAR</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02402653" sec3="Y" sec12="Y"><name>Ach-Donepezil</name><manufacturerId>ACH</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02404427" sec3="Y" sec12="Y"><name>Jamp-Donepezil</name><manufacturerId>JPC</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02408619" sec3="Y" sec12="Y"><name>Mint-Donepezil</name><manufacturerId>MIN</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2019-09-30</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02412861" sec3="Y" sec12="Y"><name>Bio-Donepezil</name><manufacturerId>BMP</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2016-04-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02416956" sec3="Y" sec12="Y"><name>Jamp-Donepezil Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02420600" sec3="Y" sec12="Y"><name>Donepezil</name><manufacturerId>SIV</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02426854" sec3="Y" sec12="Y"><name>Donepezil</name><manufacturerId>SAI</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02428490" sec3="Y" sec12="Y"><name>Septa-Donepezil</name><manufacturerId>SET</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02432692" sec3="Y" sec12="Y"><name>AG-Donepezil</name><manufacturerId>ANG</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02439565" sec3="Y" sec12="Y"><name>Nat-Donepezil</name><manufacturerId>NAT</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02467461" sec3="Y" sec12="Y"><name>M-Donepezil</name><manufacturerId>MAT</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02475286" sec3="Y" sec12="Y"><name>Donepezil</name><manufacturerId>RIA</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug><drug id="02535394" sec3="Y" sec12="Y"><name>NRA-Donepezil</name><manufacturerId>NRA</manufacturerId><individualPrice>.4586</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4586</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="347">Initial Trial: For patients with mild to moderate Alzheimer&apos;s Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.

Network note: Maximum duration 3 months.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="348">Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01540"><name>GALANTAMINE HYDROBROMIDE</name><pcgGroup lccId="00027"><pcg9 id="120400031"><itemNumber>0350</itemNumber><strength>8mg</strength><dosageForm>ER Cap</dosageForm><drug id="02266717" notABenefit="Y" sec3="Y"><name>Reminyl ER</name><manufacturerId>JAN</manufacturerId><listingDate>2006-01-12</listingDate></drug><drug id="02316943" sec3="Y" sec12="Y"><name>Pat-Galantamine ER</name><manufacturerId>PAR</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02339439" sec3="Y" sec12="Y"><name>Mylan-Galantamine ER</name><manufacturerId>MYL</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02425157" sec3="Y" sec12="Y"><name>Auro-Galantamine ER</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02443015" sec3="Y" sec12="Y"><name>Galantamine ER</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug></pcg9><pcg9 id="120400029"><itemNumber>0351</itemNumber><strength>16mg</strength><dosageForm>ER Cap</dosageForm><drug id="02266725" notABenefit="Y" sec3="Y"><name>Reminyl ER</name><manufacturerId>JAN</manufacturerId><listingDate>2006-01-12</listingDate></drug><drug id="02316951" sec3="Y" sec12="Y"><name>Pat-Galantamine ER</name><manufacturerId>PAR</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02339447" sec3="Y" sec12="Y"><name>Mylan-Galantamine ER</name><manufacturerId>MYL</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02425165" sec3="Y" sec12="Y"><name>Auro-Galantamine ER</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02443023" sec3="Y" sec12="Y"><name>Galantamine ER</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug></pcg9><pcg9 id="120400030"><itemNumber>0352</itemNumber><strength>24mg</strength><dosageForm>ER Cap</dosageForm><drug id="02266733" notABenefit="Y" sec3="Y"><name>Reminyl ER</name><manufacturerId>JAN</manufacturerId><listingDate>2006-01-12</listingDate></drug><drug id="02316978" sec3="Y" sec12="Y"><name>Pat-Galantamine ER</name><manufacturerId>PAR</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02339455" sec3="Y" sec12="Y"><name>Mylan-Galantamine ER</name><manufacturerId>MYL</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02425173" sec3="Y" sec12="Y"><name>Auro-Galantamine ER</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug><drug id="02443031" sec3="Y" sec12="Y"><name>Galantamine ER</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2465</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2465</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="347">Initial Trial: For patients with mild to moderate Alzheimer&apos;s Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.

Network note: Maximum duration 3 months.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="348">Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00702"><name>PILOCARPINE HCL</name><pcgGroup><pcg9 id="120400032"><itemNumber>0353</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02216345" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Salagen</name><manufacturerId>AMD</manufacturerId><listingDate>2013-05-31</listingDate></drug><drug id="02496119" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Pilocarpine</name><manufacturerId>MAT</manufacturerId><individualPrice>1.1708</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>1.1708</amountMOHLTCPays></drug><drug id="02509571" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pilocarpine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1708</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1.1708</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00214"><name>PYRIDOSTIGMINE BROMIDE</name><pcgGroup><pcg9 id="120400011"><itemNumber>0354</itemNumber><strength>180mg</strength><dosageForm>LA Tab</dosageForm><drug id="00869953" sec3="Y"><name>Mestinon</name><manufacturerId>VAL</manufacturerId><individualPrice>1.4239</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.4239</amountMOHLTCPays></drug></pcg9><pcg9 id="120400010"><itemNumber>0355</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="00869961" sec3="Y"><name>Mestinon</name><manufacturerId>VAL</manufacturerId><individualPrice>.6384</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2673</amountMOHLTCPays></drug><drug id="02495643" sec3="Y"><name>Riva-Pyridostigmine</name><manufacturerId>RIA</manufacturerId><individualPrice>.2673</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2673</amountMOHLTCPays></drug><drug id="02508362" sec3="Y"><name>Jamp Pyridostigmine Bromide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2673</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.2673</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01491"><name>RIVASTIGMINE</name><pcgGroup lccId="00028"><pcg9 id="120400019"><itemNumber>0356</itemNumber><strength>1.5mg</strength><dosageForm>Cap</dosageForm><drug id="02242115" sec3="Y" sec12="Y"><name>Exelon</name><manufacturerId>KNT</manufacturerId><individualPrice>3.3050</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02324563" sec3="Y" sec12="Y"><name>Sandoz Rivastigmine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02336715" sec3="Y" sec12="Y"><name>Apo-Rivastigmine</name><manufacturerId>APX</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02401614" sec3="Y" sec12="Y"><name>Med-Rivastigmine</name><manufacturerId>GMP</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02406985" sec3="Y" sec12="Y"><name>Mint-Rivastigmine</name><manufacturerId>MIN</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02485362" sec3="Y" sec12="Y"><name>Jamp Rivastigmine</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02552256" sec3="Y" sec12="Y"><name>Jamp Rivastigmine Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug></pcg9><pcg9 id="120400020"><itemNumber>0357</itemNumber><strength>3mg</strength><dosageForm>Cap</dosageForm><drug id="02242116" sec3="Y" sec12="Y"><name>Exelon</name><manufacturerId>KNT</manufacturerId><individualPrice>3.3050</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02324571" sec3="Y" sec12="Y"><name>Sandoz Rivastigmine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02336723" sec3="Y" sec12="Y"><name>Apo-Rivastigmine</name><manufacturerId>APX</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02401622" sec3="Y" sec12="Y"><name>Med-Rivastigmine</name><manufacturerId>GMP</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02406993" sec3="Y" sec12="Y"><name>Mint-Rivastigmine</name><manufacturerId>MIN</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02485370" sec3="Y" sec12="Y"><name>Jamp Rivastigmine</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02552264" sec3="Y" sec12="Y"><name>Jamp Rivastigmine Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug></pcg9><pcg9 id="120400021"><itemNumber>0358</itemNumber><strength>4.5mg</strength><dosageForm>Cap</dosageForm><drug id="02242117" sec3="Y" sec12="Y"><name>Exelon</name><manufacturerId>KNT</manufacturerId><individualPrice>3.3050</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02324598" sec3="Y" sec12="Y"><name>Sandoz Rivastigmine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02336731" sec3="Y" sec12="Y"><name>Apo-Rivastigmine</name><manufacturerId>APX</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02401630" sec3="Y" sec12="Y"><name>Med-Rivastigmine</name><manufacturerId>GMP</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02407000" sec3="Y" sec12="Y"><name>Mint-Rivastigmine</name><manufacturerId>MIN</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02485389" sec3="Y" sec12="Y"><name>Jamp Rivastigmine</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02552272" sec3="Y" sec12="Y"><name>Jamp Rivastigmine Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug></pcg9><pcg9 id="120400022"><itemNumber>0359</itemNumber><strength>6mg</strength><dosageForm>Cap</dosageForm><drug id="02242118" sec3="Y" sec12="Y"><name>Exelon</name><manufacturerId>KNT</manufacturerId><individualPrice>3.3050</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02324601" sec3="Y" sec12="Y"><name>Sandoz Rivastigmine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02336758" sec3="Y" sec12="Y"><name>Apo-Rivastigmine</name><manufacturerId>APX</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02401649" sec3="Y" sec12="Y"><name>Med-Rivastigmine</name><manufacturerId>GMP</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02407019" sec3="Y" sec12="Y"><name>Mint-Rivastigmine</name><manufacturerId>MIN</manufacturerId><individualPrice>.6515</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02485397" sec3="Y" sec12="Y"><name>Jamp Rivastigmine</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug><drug id="02552280" sec3="Y" sec12="Y"><name>Jamp Rivastigmine Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.6514</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.6514</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="347">Initial Trial: For patients with mild to moderate Alzheimer&apos;s Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.

Network note: Maximum duration 3 months.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="348">Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="120400035"><itemNumber>0360</itemNumber><strength>9mg/5 Sq Cm</strength><dosageForm>Trans Patch</dosageForm><drug id="02302845" notABenefit="Y" sec3b="Y" sec3="Y"><name>Exelon Patch 5</name><manufacturerId>KNT</manufacturerId><listingDate>2017-01-31</listingDate></drug><drug id="02423413" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Rivastigmine Patch 5</name><manufacturerId>MYL</manufacturerId><individualPrice>3.9773</individualPrice><listingDate>2017-01-31</listingDate></drug><drug id="02426293" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Rivastigmine Patch 5</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.9773</individualPrice><listingDate>2017-01-31</listingDate></drug></pcg9><pcg9 id="120400036"><itemNumber>0361</itemNumber><strength>18mg/10 Sq Cm</strength><dosageForm>Trans Patch</dosageForm><drug id="02302853" notABenefit="Y" sec3b="Y" sec3="Y"><name>Exelon Patch 10</name><manufacturerId>KNT</manufacturerId><listingDate>2017-01-31</listingDate></drug><drug id="02423421" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Rivastigmine Patch 10</name><manufacturerId>MYL</manufacturerId><individualPrice>3.9773</individualPrice><listingDate>2017-01-31</listingDate></drug><drug id="02426307" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Rivastigmine Patch 10</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.9773</individualPrice><listingDate>2017-01-31</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="120800000"><name>PARASYMPATHOLYTIC (CHOLINERGIC BLOCKING) AGENTS</name><genericName id="01952"><name>ACLIDINIUM BROMIDE</name><pcgGroup><pcg9 id="120800071"><itemNumber>0362</itemNumber><strength>400mcg/actuation</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02409720" sec3="Y"><name>Tudorza Genuair</name><manufacturerId>COP</manufacturerId><individualPrice>57.0467</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>57.0467</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00215"><name>BENZTROPINE MESYLATE</name><pcgGroup><pcg9 id="120800072"><itemNumber>0363</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00706531" sec3="Y"><name>PDP-Benztropine</name><manufacturerId>PEN</manufacturerId><individualPrice>.0563</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.0563</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00223"><name>ETHOPROPAZINE HCL</name><pcgGroup><pcg9 id="120800021"><itemNumber>0364</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="01927744" sec3="Y"><name>Parsitan</name><manufacturerId>SLP</manufacturerId><individualPrice>.3153</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3153</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00226"><name>FLAVOXATE HCL</name><pcgGroup><pcg9 id="120800038"><itemNumber>0365</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="00728179" notABenefit="Y" sec3="Y"><name>Urispas</name><manufacturerId>PAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02244842" notABenefit="Y" sec3="Y"><name>Apo-Flavoxate</name><manufacturerId>APX</manufacturerId><listingDate>2002-07-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01921"><name>GLYCOPYRRONIUM BROMIDE</name><pcgGroup><pcg9 id="120800070"><itemNumber>0366</itemNumber><strength>50mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02394936" sec3="Y"><name>Seebri Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>1.8302</individualPrice><note>The dose of Seebri Breezhaler should not exceed 50mcg per day.</note><listingDate>2013-08-29</listingDate><amountMOHLTCPays>1.8302</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00218"><name>HYOSCINE BUTYLBROMIDE</name><pcgGroup lccId="00336"><pcg9 id="120800009"><itemNumber>0367</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00363812" sec3="Y" sec12="Y"><name>Buscopan</name><manufacturerId>SCO</manufacturerId><individualPrice>.3655</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2711</amountMOHLTCPays></drug><drug id="02512335" sec3="Y" sec12="Y"><name>Accel-Hyoscine</name><manufacturerId>ACC</manufacturerId><individualPrice>.2711</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.2711</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="00227"><name>IPRATROPIUM BROMIDE</name><pcgGroup lccId="00030"><pcg9 id="120800039"><itemNumber>0368</itemNumber><strength>250mcg/mL</strength><dosageForm>Inh Sol-20mL Pk</dosageForm><drug id="00731439" notABenefit="Y" sec3="Y"><name>Atrovent</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02126222" sec3="Y" sec12="Y"><name>AA-Ipravent</name><manufacturerId>AAP</manufacturerId><individualPrice>6.3140</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>6.3140</amountMOHLTCPays></drug><drug id="02210479" sec3="Y" sec12="Y"><name>Novo-Ipramide</name><manufacturerId>NOP</manufacturerId><individualPrice>6.3140</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>6.3140</amountMOHLTCPays></drug><drug id="02231136" sec3="Y" sec12="Y"><name>PMS-Ipratropium</name><manufacturerId>PMS</manufacturerId><individualPrice>6.3140</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>6.3140</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="256">Patients who have a tracheostomy;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="257">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="258">Patients with severe mental or physical disabilities;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="259">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00031"><pcg9 id="120800047"><itemNumber>0369</itemNumber><strength>125mcg/mL</strength><dosageForm>Inh Sol-2mL UDV Pk</dosageForm><drug id="02026759" notABenefit="Y" sec3="Y"><name>Atrovent UDV</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02231135" sec3="Y" sec12="Y"><name>PMS-Ipratropium</name><manufacturerId>PMS</manufacturerId><individualPrice>1.1505</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.1505</amountMOHLTCPays></drug></pcg9><pcg9 id="120800046"><itemNumber>0370</itemNumber><strength>250mcg/mL</strength><dosageForm>Inh Sol-2mL UDV Pk</dosageForm><drug id="01950681" notABenefit="Y" sec3="Y"><name>Atrovent UDV</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02097168" sec3="Y" sec12="Y"><name>Ratio-Ipratropium UDV</name><manufacturerId>RPH</manufacturerId><individualPrice>1.3180</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.3180</amountMOHLTCPays></drug><drug id="02216221" sec3="Y" sec12="Y"><name>Teva-Ipratropium Sterinebs</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3180</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>1.3180</amountMOHLTCPays></drug><drug id="02231245" sec3="Y" sec12="Y"><name>PMS-Ipratropium</name><manufacturerId>PMS</manufacturerId><individualPrice>1.3180</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.3180</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="265">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="266">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="267">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="268">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="120800056"><itemNumber>0371</itemNumber><strength>20mcg/Metered Dose</strength><dosageForm>Inh-200 Dose Pk</dosageForm><drug id="02247686" sec3="Y"><name>Atrovent HFA</name><manufacturerId>BOE</manufacturerId><individualPrice>20.4600</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>11.2530</amountMOHLTCPays></drug><drug id="02542587" sec3="Y"><name>Jamp Ipratropium HFA</name><manufacturerId>JPC</manufacturerId><individualPrice>11.2530</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>11.2530</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01365"><name>IPRATROPIUM BROMIDE/SALBUTAMOL</name><pcgGroup lccId="00029"><pcg9 id="120800050"><itemNumber>0372</itemNumber><strength>500mcg/2.5mg/2.5mL</strength><dosageForm>Inh Sol-2.5mL Amp Pk</dosageForm><drug id="02231675" notABenefit="Y" sec3="Y"><name>Combivent UDV</name><manufacturerId>BOE</manufacturerId><listingDate>1998-12-31</listingDate></drug><drug id="02272695" sec3="Y" sec12="Y"><name>Teva-Combo Sterinebs</name><manufacturerId>TEV</manufacturerId><individualPrice>.8066</individualPrice><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.8066</amountMOHLTCPays></drug><drug id="02483394" sec3="Y" sec12="Y"><name>Ipratropium Bromide and Salbutamol Sulph</name><manufacturerId>MDI</manufacturerId><individualPrice>.8066</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.8066</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="256">Patients who have a tracheostomy;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="257">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="258">Patients with severe mental or physical disabilities;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="259">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00225"><name>OXYBUTYNIN CHLORIDE</name><pcgGroup><pcg9 id="120800034"><itemNumber>0373</itemNumber><strength>1mg/mL</strength><dosageForm>O/L</dosageForm><drug id="01924753" notABenefit="Y" sec3="Y"><name>Ditropan</name><manufacturerId>JNO</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02223376" sec3="Y"><name>PMS-Oxybutynin</name><manufacturerId>PMS</manufacturerId><individualPrice>.0970</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0970</amountMOHLTCPays></drug></pcg9><pcg9 id="120800033"><itemNumber>0374</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="01924761" notABenefit="Y" sec3="Y"><name>Ditropan</name><manufacturerId>PGP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02163543" sec3="Y"><name>Apo-Oxybutynin</name><manufacturerId>APX</manufacturerId><individualPrice>.0986</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0986</amountMOHLTCPays></drug><drug id="02230394" sec3="Y"><name>Novo-Oxybutynin</name><manufacturerId>NOP</manufacturerId><individualPrice>.0986</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0986</amountMOHLTCPays></drug><drug id="02240550" sec3="Y"><name>PMS-Oxybutynin</name><manufacturerId>PMS</manufacturerId><individualPrice>.0986</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>.0986</amountMOHLTCPays></drug><drug id="02350238" dinStatus="E" sec3="Y"><name>Oxybutynin</name><manufacturerId>SAI</manufacturerId><individualPrice>.0986</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.0986</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00220"><name>PROCYCLIDINE HCL</name><pcgGroup><pcg9 id="120800037"><itemNumber>0375</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="00649392" sec3="Y"><name>Pdp-Procyclidine</name><manufacturerId>PEN</manufacturerId><individualPrice>.0577</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0577</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00230"><name>SCOPOLAMINE HYDROBROMIDE</name><pcgGroup lccId="00287"><pcg9 id="120800043"><itemNumber>0376</itemNumber><strength>0.4mg/mL</strength><dosageForm>Inj Sol  (Preservative Free)</dosageForm><drug id="00541869" notABenefit="Y" sec3="Y"><name>Scopolamine Hydrobromide Injection</name><manufacturerId>HOS</manufacturerId><listingDate>2011-05-19</listingDate></drug><drug id="02242810" sec3="Y" sec12="Y"><name>Scopolamine Hydrobromide Injection</name><manufacturerId>OMG</manufacturerId><individualPrice>6.5100</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>6.5100</amountMOHLTCPays></drug></pcg9><pcg9 id="120800065"><itemNumber>0377</itemNumber><strength>0.6mg/mL</strength><dosageForm>Inj Sol  (Preservative Free)</dosageForm><drug id="00541877" notABenefit="Y" sec3="Y"><name>Scopolamine Hydrobromide Injection</name><manufacturerId>HOS</manufacturerId><listingDate>2011-05-19</listingDate></drug><drug id="02242811" sec3="Y" sec12="Y"><name>Scopolamine Hydrobromide Injection</name><manufacturerId>OMG</manufacturerId><individualPrice>7.0400</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>7.0400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="00222"><name>TRIHEXYPHENIDYL HCL</name><pcgGroup><pcg9 id="120800018"><itemNumber>0378</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00015040" notABenefit="Y" sec3="Y"><name>Artane</name><manufacturerId>LED</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00545058" sec3="Y"><name>Trihexyphenidyl</name><manufacturerId>AAP</manufacturerId><individualPrice>.0376</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0376</amountMOHLTCPays></drug></pcg9><pcg9 id="120800017"><itemNumber>0379</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00015059" notABenefit="Y" sec3="Y"><name>Artane</name><manufacturerId>LED</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00545074" sec3="Y"><name>Trihexyphenidyl</name><manufacturerId>AAP</manufacturerId><individualPrice>.0681</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0681</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00818"><name>TRIMEBUTINE MALEATE</name><pcgGroup><pcg9 id="120800062"><itemNumber>0380</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00587869" sec3b="Y" sec3="Y"><name>Modulon</name><manufacturerId>BFI</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02245663" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Trimebutine</name><manufacturerId>APX</manufacturerId><individualPrice>.3265</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.3265</amountMOHLTCPays></drug><drug id="02538202" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Trimebutine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3265</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.3265</amountMOHLTCPays></drug></pcg9><pcg9 id="120800061"><itemNumber>0381</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="00803499" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Modulon</name><manufacturerId>BFI</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02245664" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Trimebutine</name><manufacturerId>APX</manufacturerId><individualPrice>.7677</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.7677</amountMOHLTCPays></drug><drug id="02538210" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Trimebutine</name><manufacturerId>MIN</manufacturerId><individualPrice>.7677</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.7677</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="120808000"><name>PARASYMPATHOLYTIC (CHOLINERGIC BLOCKING) AGENTS ANTIMUSCARINICS/ANTISPASMODICS</name><genericName id="00217"><name>GLYCOPYRROLATE</name><pcgGroup lccId="00288"><pcg9 id="120808010"><itemNumber>0382</itemNumber><strength>0.2mg/mL</strength><dosageForm>Inj Sol</dosageForm><drug id="02039508" sec3="Y" sec12="Y"><name>Sandoz Glycopyrrolate</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug><drug id="02043610" notABenefit="Y" sec3="Y"><name>Robinul</name><manufacturerId>WYA</manufacturerId><listingDate>2015-03-31</listingDate></drug><drug id="02382857" sec3="Y" sec12="Y"><name>Glycopyrrolate Injection</name><manufacturerId>OMG</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug><drug id="02473879" sec3="Y" sec12="Y"><name>Glycopyrrolate Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug></pcg9><pcg9 id="120808014"><itemNumber>0383</itemNumber><strength>0.4mg/2mL</strength><dosageForm>Inj Sol (Preservative Free)</dosageForm><drug id="02473895" sec3="Y" sec12="Y"><name>Glycopyrrolate Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug><drug id="02513749" sec3="Y" sec12="Y"><name>Glycopyrrolate Injection USP</name><manufacturerId>JPC</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug><drug id="09858163" notABenefit="Y" sec3="Y"><name>Robinul</name><manufacturerId>WYA</manufacturerId><listingDate>2022-08-31</listingDate></drug></pcg9><pcg9 id="120808015"><itemNumber>0384</itemNumber><strength>4mg/20mL</strength><dosageForm>Inj Sol (With Preservative)</dosageForm><drug id="02473887" sec3="Y" sec12="Y"><name>Glycopyrrolate Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug><drug id="02532379" sec3="Y" sec12="Y"><name>Glycopyrrolate Injection USP</name><manufacturerId>JPC</manufacturerId><individualPrice>2.7825</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>2.7825</amountMOHLTCPays></drug><drug id="09858164" notABenefit="Y" sec3="Y"><name>Robinul</name><manufacturerId>WYA</manufacturerId><listingDate>2022-08-31</listingDate></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="00218"><name>HYOSCINE BUTYLBROMIDE</name><pcgGroup lccId="00286"><pcg9 id="120808006"><itemNumber>0385</itemNumber><strength>20mg/mL</strength><dosageForm>Inj Sol</dosageForm><drug id="00363839" sec3="Y" sec12="Y"><name>Buscopan</name><manufacturerId>SCO</manufacturerId><individualPrice>4.8880</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>4.8880</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="01592"><name>TIOTROPIUM BROMIDE MONOHYDRATE</name><pcgGroup><pcg9 id="120808009"><itemNumber>0386</itemNumber><strength>18mcg</strength><dosageForm>Inh Cap</dosageForm><drug id="02246793" sec3="Y"><name>Spiriva</name><manufacturerId>BOE</manufacturerId><individualPrice>.9143</individualPrice><note>Each tiotropium 18mcg capsule contains 18mcg of tiotropium, equivalent to 22.5mcg of tiotropium bromide monohydrate.</note><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.9143</amountMOHLTCPays></drug><drug id="02537850" sec3="Y"><name>Lupin-Tiotropium</name><manufacturerId>LUP</manufacturerId><individualPrice>.9143</individualPrice><note>Each tiotropium 18mcg capsule contains 18mcg of tiotropium, equivalent to 22.5mcg of tiotropium bromide monohydrate.</note><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.9143</amountMOHLTCPays></drug><drug id="02550865" sec3="Y"><name>Apo-Tiotropium</name><manufacturerId>APX</manufacturerId><individualPrice>.9143</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.9143</amountMOHLTCPays></drug></pcg9><pcg9 id="120808013"><itemNumber>0387</itemNumber><strength>2.5mcg/Actuation</strength><dosageForm>Inh Sol-60 Actuation Pk</dosageForm><drug id="02435381" sec3="Y"><name>Spiriva Respimat</name><manufacturerId>BOE</manufacturerId><individualPrice>54.8580</individualPrice><note>Each actuation of Spiriva Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate.</note><listingDate>2016-03-30</listingDate><amountMOHLTCPays>54.8580</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01997"><name>TIOTROPIUM BROMIDE MONOHYDRATE &amp; OLODATEROL HYDROCHLORIDE</name><pcgGroup lccId="00263"><pcg9 id="120808012"><itemNumber>0388</itemNumber><strength>2.5mcg &amp; 2.5mcg/Actuation</strength><dosageForm>Inh Sol-60 Actuation Pk</dosageForm><drug id="02441888" sec3="Y" sec12="Y"><name>Inspiolto Respimat</name><manufacturerId>BOE</manufacturerId><individualPrice>64.3740</individualPrice><note>Each actuation of Inspiotto Respimat contains 2.5mcg of tiotropium, supplied as tiotropium bromide monohydrate, and 2.5mcg of olodaterol, supplied as olodaterol hydrochloride.</note><listingDate>2016-03-30</listingDate><amountMOHLTCPays>64.3740</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).

Classification

COPD Stages - Symptoms and disability:

Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.

Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level

Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure

Classification by impairment of lung function:

COPD stage and spirometry (post bronchodilator) FEV1 predicted:

Mild: Greater than or equal to 80 percent

Moderate: 50 to 79 percent

Severe: 30 to 49 percent

Very severe: Less than 30 percent
</lccNote></pcgGroup></genericName><genericName id="01993"><name>UMECLIDINIUM</name><pcgGroup><pcg9 id="120808011"><itemNumber>0389</itemNumber><strength>62.5mcg</strength><dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm><drug id="02423596" sec3="Y"><name>Incruse Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>50.0000</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>50.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="121200000"><name>SYMPATHOMIMETIC (ADRENERGIC) AGENTS</name><genericName id="01994"><name>ACLIDINIUM BROMIDE &amp; FORMOTEROL FUMARATE DIHYDRATE</name><pcgGroup lccId="00261"><pcg9 id="121200110"><itemNumber>0390</itemNumber><strength>400mcg &amp; 12mcg</strength><dosageForm>Metered Dose Pd Inh-60 Dose Pk</dosageForm><drug id="02439530" sec3="Y" sec12="Y"><name>Duaklir Genuair</name><manufacturerId>COP</manufacturerId><individualPrice>65.1686</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>65.1686</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).

Classification

COPD Stages - Symptoms and disability:

Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.

Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level

Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure

Classification by impairment of lung function:

COPD stage and spirometry (post bronchodilator) FEV1 predicted:

Mild: Greater than or equal to 80 percent

Moderate: 50 to 79 percent

Severe: 30 to 49 percent

Very severe: Less than 30 percent
</lccNote></pcgGroup></genericName><genericName id="01568"><name>BUDESONIDE &amp; FORMOTEROL FUMARATE DIHYDRATE</name><pcgGroup lccId="00032"><pcg9 id="121200087"><itemNumber>0391</itemNumber><strength>100mcg/6mcg</strength><dosageForm>Pd Inh-120 Dose Pk</dosageForm><drug id="02245385" sec3="Y" sec12="Y"><name>Symbicort 100 Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>78.3613</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>78.3613</amountMOHLTCPays></drug></pcg9><pcg9 id="121200088"><itemNumber>0392</itemNumber><strength>200mcg/6mcg</strength><dosageForm>Pd Inh-120 Dose Pk</dosageForm><drug id="02245386" sec3="Y" sec12="Y"><name>Symbicort 200 Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>101.8235</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>101.8235</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02390"><name>BUDESONIDE&amp;GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&amp;FORMOTEROL FUMARATE DIHYDRATE</name><pcgGroup lccId="00385"><pcg9 id="121200121"><itemNumber>0393</itemNumber><strength>160mcg &amp; 7.2mcg &amp; 5mcg/Act</strength><dosageForm>Metered Dose Inh-120 Dose Pk</dosageForm><drug id="02518058" sec3="Y" sec12="Y"><name>Breztri Aerosphere</name><manufacturerId>AZC</manufacturerId><individualPrice>127.0000</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>127.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="638">For the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00236"><name>EPINEPHRINE HCL</name><pcgGroup><pcg9 id="121200005"><itemNumber>0394</itemNumber><strength>30mg/30mL</strength><dosageForm>Inj Sol-30mL Pk</dosageForm><drug id="00155357" sec3="Y"><name>Adrenalin</name><manufacturerId>SLP</manufacturerId><individualPrice>22.2300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>22.2300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02104"><name>FLUTICASONE FUROATE &amp; UMECLIDINIUM BROMIDE &amp; VILANTEROL TRIFENATATE</name><pcgGroup lccId="00321"><pcg9 id="121200114"><itemNumber>0395</itemNumber><strength>100mcg &amp; 62.5mcg &amp; 25mcg</strength><dosageForm>Pd Inh-30 Dose Pk</dosageForm><drug id="02474522" sec3="Y" sec12="Y"><name>Trelegy Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>137.6700</individualPrice><note>Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><listingDate>2019-09-30</listingDate><amountMOHLTCPays>137.6700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="567">For the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema and to reduce exacerbations of COPD in patients with a history of exacerbations in patients who require a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta2-adrenergic agonist (LABA).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01969"><name>FLUTICASONE FUROATE &amp; VILANTEROL</name><pcgGroup lccId="00249"><pcg9 id="121200107"><itemNumber>0396</itemNumber><strength>100mcg &amp; 25mcg</strength><dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm><drug id="02408872" sec3="Y" sec12="Y"><name>Breo Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>110.5000</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>110.5000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="456">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).


</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification below).

Classification

COPD Stages - Symptoms and disability:

Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill

Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level

Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure

Classification by impairment of lung function:

COPD stage and spirometry (post bronchodilator) FEV1 predicted:

Mild: Greater than or equal to 80 percent

Moderate: 50 to 79 percent

Severe: 30 to 49 percent

Very severe: Less than 30 percent</lccNote></pcgGroup><pcgGroup lccId="00268"><pcg9 id="121200111"><itemNumber>0397</itemNumber><strength>200mcg &amp; 25mcg</strength><dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm><drug id="02444186" sec3="Y" sec12="Y"><name>Breo Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>171.8900</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>171.8900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01345"><name>FORMOTEROL FUMARATE</name><pcgGroup lccId="00036"><pcg9 id="121200075"><itemNumber>0398</itemNumber><strength>12mcg/Cap</strength><dosageForm>Inh Pd-Device Pk</dosageForm><drug id="02230898" sec3="Y" sec12="Y"><name>Foradil</name><manufacturerId>NOV</manufacturerId><individualPrice>55.7700</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>55.7700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="132">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="N">This drug is not for relief of acute symptoms.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01396"><name>FORMOTEROL FUMARATE DIHYDRATE</name><pcgGroup lccId="00037"><pcg9 id="121200082"><itemNumber>0399</itemNumber><strength>6mcg/Metered Dose</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02237225" sec3="Y" sec12="Y"><name>Oxeze Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>38.3350</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>38.3350</amountMOHLTCPays></drug></pcg9><pcg9 id="121200078"><itemNumber>0400</itemNumber><strength>12mcg/Metered Dose</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02237224" sec3="Y" sec12="Y"><name>Oxeze Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>51.0245</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>51.0245</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="132">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="N">This drug is not for relief of acute symptoms.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01914"><name>INDACATEROL</name><pcgGroup lccId="00231"><pcg9 id="121200104"><itemNumber>0401</itemNumber><strength>75mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02376938" sec3="Y" sec12="Y"><name>Onbrez Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5500</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.5500</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="443">For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.

Note: The dose of Onbrez Breezhaler should not exceed 75mcg per day.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01975"><name>INDACATEROL &amp; GLYCOPYRRONIUM</name><pcgGroup lccId="00252"><pcg9 id="121200108"><itemNumber>0402</itemNumber><strength>110mcg &amp; 50mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02418282" sec3="Y" sec12="Y"><name>Ultibro Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>2.5830</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>2.5830</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).

Classification

COPD Stages - Symptoms and disability:

Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.

Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level

Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure

Classification by impairment of lung function:

COPD stage and spirometry (post bronchodilator) FEV1 predicted:

Mild: Greater than or equal to 80 percent

Moderate: 50 to 79 percent

Severe: 30 to 49 percent

Very severe: Less than 30 percent
</lccNote></pcgGroup></genericName><genericName id="01876"><name>MOMETASONE FUROATE &amp; FORMOTEROL FUMARATE DIHYDRATE</name><pcgGroup lccId="00220"><pcg9 id="121200095"><itemNumber>0403</itemNumber><strength>100mcg &amp; 5mcg</strength><dosageForm>Metered Dose Inh-120 Dose Pk</dosageForm><drug id="02361752" sec3="Y" sec12="Y"><name>Zenhale</name><manufacturerId>OCI</manufacturerId><individualPrice>123.2300</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>123.2300</amountMOHLTCPays></drug></pcg9><pcg9 id="121200096"><itemNumber>0404</itemNumber><strength>200mcg &amp; 5mcg</strength><dosageForm>Metered Dose Inh-120 Dose Pk</dosageForm><drug id="02361760" sec3="Y" sec12="Y"><name>Zenhale</name><manufacturerId>OCI</manufacturerId><individualPrice>149.3300</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>149.3300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00241"><name>ORCIPRENALINE SULFATE</name><pcgGroup><pcg9 id="121200016"><itemNumber>0405</itemNumber><strength>2mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00249920" notABenefit="Y" sec3="Y"><name>Alupent</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02236783" sec3="Y"><name>Orciprenaline</name><manufacturerId>AAP</manufacturerId><individualPrice>.0574</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.0574</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00239"><name>SALBUTAMOL</name><pcgGroup lccId="00040"><pcg9 id="121200048"><itemNumber>0406</itemNumber><strength>1mg/mL</strength><dosageForm>Inh Sol- 2.5mL Pk</dosageForm><drug id="01926934" sec3="Y" sec12="Y"><name>Teva-Salbutamol Sterinebs P.F.</name><manufacturerId>TEV</manufacturerId><individualPrice>.3617</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3617</amountMOHLTCPays></drug><drug id="02208229" sec3="Y" sec12="Y"><name>PMS-Salbutamol</name><manufacturerId>PMS</manufacturerId><individualPrice>.3617</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.3617</amountMOHLTCPays></drug><drug id="02213419" notABenefit="Y" sec3="Y"><name>Ventolin Nebules P.F.</name><manufacturerId>GSK</manufacturerId><listingDate>1998-10-21</listingDate></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="265">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="266">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="267">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="268">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00041"><pcg9 id="121200070"><itemNumber>0407</itemNumber><strength>2mg/mL</strength><dosageForm>Inh Sol- 2.5mL Pk</dosageForm><drug id="02173360" sec3="Y" sec12="Y"><name>Teva-Salbutamol Sterinebs P.F.</name><manufacturerId>TEV</manufacturerId><individualPrice>.6871</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.6750</amountMOHLTCPays></drug><drug id="02208237" sec3="Y" sec12="Y"><name>PMS-Salbutamol</name><manufacturerId>PMS</manufacturerId><individualPrice>.6750</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.6750</amountMOHLTCPays></drug><drug id="02213427" notABenefit="Y" sec3="Y"><name>Ventolin Nebules P.F.</name><manufacturerId>GSK</manufacturerId><listingDate>2006-06-15</listingDate></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="265">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="266">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="267">Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="268">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00042"><pcg9 id="121200025"><itemNumber>0408</itemNumber><strength>5mg/mL</strength><dosageForm>Inh Sol-10mL Pk</dosageForm><drug id="02213486" sec3="Y" sec12="Y"><name>Ventolin</name><manufacturerId>GSK</manufacturerId><individualPrice>3.1110</individualPrice><listingDate>1998-04-03</listingDate><amountMOHLTCPays>3.1110</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="256">Patients who have a tracheostomy;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="257">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="258">Patients with severe mental or physical disabilities;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="259">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="121200012"><itemNumber>0409</itemNumber><strength>100mcg/Metered Dose</strength><dosageForm>Inh-200 dose Pk</dosageForm><drug id="00790419" notABenefit="Y" sec3="Y"><name>Apo-Salvent</name><manufacturerId>APX</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00851841" notABenefit="Y" sec3="Y"><name>Ratio-Salbutamol Inhaler</name><manufacturerId>RPH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00874086" notABenefit="Y" sec3="Y"><name>Novo-Salmol</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02213478" notABenefit="Y" sec3="Y"><name>Ventolin</name><manufacturerId>GLW</manufacturerId><listingDate>1997-07-12</listingDate></drug><drug id="02232570" sec3="Y"><name>Airomir HFA</name><manufacturerId>GRA</manufacturerId><individualPrice>6.2593</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug><drug id="02241497" sec3="Y"><name>Ventolin HFA</name><manufacturerId>GSK</manufacturerId><individualPrice>6.0000</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug><drug id="02245669" sec3="Y"><name>Apo-Salbutamol HFA</name><manufacturerId>APX</manufacturerId><individualPrice>5.0000</individualPrice><listingDate>2003-01-01</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug><drug id="02326450" sec3="Y"><name>Novo-Salbutamol HFA</name><manufacturerId>NOP</manufacturerId><individualPrice>5.0000</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug><drug id="02419858" sec3="Y"><name>Salbutamol HFA</name><manufacturerId>SAI</manufacturerId><individualPrice>5.0000</individualPrice><listingDate>2020-04-07</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="121200013"><itemNumber>0410</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="01961039" notABenefit="Y" sec3="Y"><name>Ventolin</name><manufacturerId>GLA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02146843" sec3="Y"><name>Apo-Salvent</name><manufacturerId>APX</manufacturerId><individualPrice>.1274</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1274</amountMOHLTCPays></drug></pcg9><pcg9 id="121200021"><itemNumber>0411</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="01932691" notABenefit="Y" sec3="Y"><name>Ventolin</name><manufacturerId>GLA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02146851" sec3="Y"><name>Apo-Salvent</name><manufacturerId>APX</manufacturerId><individualPrice>.2134</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2134</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00254"><name>SALMETEROL XINAFOATE</name><pcgGroup lccId="00043"><pcg9 id="121200077"><itemNumber>0412</itemNumber><strength>50mcg</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02231129" sec3="Y" sec12="Y"><name>SereVent Diskus</name><manufacturerId>GSK</manufacturerId><individualPrice>79.5600</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>79.5600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="132">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="N">This drug is not for relief of acute symptoms.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="391">For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01460"><name>SALMETEROL XINAFOATE &amp; FLUTICASONE PROPIONATE</name><pcgGroup lccId="00044"><pcg9 id="121200085"><itemNumber>0413</itemNumber><strength>25/125mcg/Metered Dose</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02245126" sec3="Y" sec12="Y"><name>Advair 125</name><manufacturerId>GSK</manufacturerId><individualPrice>135.8700</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>135.8700</amountMOHLTCPays></drug></pcg9><pcg9 id="121200086"><itemNumber>0414</itemNumber><strength>25/250mcg/Metered Dose</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02245127" sec3="Y" sec12="Y"><name>Advair 250</name><manufacturerId>GSK</manufacturerId><individualPrice>192.8800</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>192.8800</amountMOHLTCPays></drug></pcg9><pcg9 id="121200083"><itemNumber>0415</itemNumber><strength>50/100mcg</strength><dosageForm>Inh-60 Dose Pk</dosageForm><drug id="02240835" sec3="Y" sec12="Y"><name>Advair Diskus</name><manufacturerId>GSK</manufacturerId><individualPrice>113.4900</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>42.4050</amountMOHLTCPays></drug><drug id="02494507" sec3="Y" sec12="Y"><name>PMS-FluticasonePropionateSalmeterol DPI</name><manufacturerId>PMS</manufacturerId><individualPrice>42.4050</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>42.4050</amountMOHLTCPays></drug><drug id="02495597" sec3="Y" sec12="Y"><name>Wixela Inhub</name><manufacturerId>MYL</manufacturerId><individualPrice>42.4050</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>42.4050</amountMOHLTCPays></drug></pcg9><pcg9 id="121200080"><itemNumber>0416</itemNumber><strength>50/250mcg</strength><dosageForm>Inh-60 Dose Pk</dosageForm><drug id="02240836" sec3="Y" sec12="Y"><name>Advair Diskus</name><manufacturerId>GSK</manufacturerId><individualPrice>135.8700</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>50.7600</amountMOHLTCPays></drug><drug id="02494515" sec3="Y" sec12="Y"><name>PMS-FluticasonePropionateSalmeterol DPI</name><manufacturerId>PMS</manufacturerId><individualPrice>50.7600</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>50.7600</amountMOHLTCPays></drug><drug id="02495600" sec3="Y" sec12="Y"><name>Wixela Inhub</name><manufacturerId>MYL</manufacturerId><individualPrice>50.7600</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>50.7600</amountMOHLTCPays></drug></pcg9><pcg9 id="121200081"><itemNumber>0417</itemNumber><strength>50/500mcg</strength><dosageForm>Inh-60 Dose Pk</dosageForm><drug id="02240837" sec3="Y" sec12="Y"><name>Advair Diskus</name><manufacturerId>GSK</manufacturerId><individualPrice>192.8800</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>72.0600</amountMOHLTCPays></drug><drug id="02494523" sec3="Y" sec12="Y"><name>PMS-FluticasonePropionateSalmeterol DPI</name><manufacturerId>PMS</manufacturerId><individualPrice>72.0600</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>72.0600</amountMOHLTCPays></drug><drug id="02495619" sec3="Y" sec12="Y"><name>Wixela Inhub</name><manufacturerId>MYL</manufacturerId><individualPrice>72.0600</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>72.0600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="330">For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00245"><name>TERBUTALINE SULFATE</name><pcgGroup><pcg9 id="121200047"><itemNumber>0418</itemNumber><strength>0.5mg/Dose</strength><dosageForm>Inh-100 Dose Pk</dosageForm><drug id="00786616" sec3="Y"><name>Bricanyl Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>8.4900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>8.4900</amountMOHLTCPays></drug></pcg9><pcg9 id="121200120"><itemNumber>0419</itemNumber><strength>0.5mg/Dose</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="09858138" sec3="Y"><name>Bricanyl Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>11.3160</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>11.3160</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01978"><name>UMECLIDINIUM &amp; VILANTEROL</name><pcgGroup lccId="00255"><pcg9 id="121200109"><itemNumber>0420</itemNumber><strength>62.5mcg &amp; 25mcg</strength><dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm><drug id="02418401" sec3="Y" sec12="Y"><name>Anoro Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>88.5100</individualPrice><listingDate>2015-06-29</listingDate><amountMOHLTCPays>88.5100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="459">For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" type="N">COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).

Classification

COPD Stages - Symptoms and disability:

Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.

Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level

Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure

Classification by impairment of lung function:

COPD stage and spirometry (post bronchodilator) FEV1 predicted:

Mild: Greater than or equal to 80 percent

Moderate: 50 to 79 percent

Severe: 30 to 49 percent

Very severe: Less than 30 percent
</lccNote></pcgGroup></genericName></pcg6><pcg6 id="122000000"><name>SKELETAL MUSCLE RELAXANTS</name><note>Muscle relaxants, other than baclofen and dantrolene sodium, are not indicated for spasticity due to cerebral palsy, multiple sclerosis, spinal cord injury, etc.</note><genericName id="00271"><name>BACLOFEN</name><pcgGroup><pcg9 id="122000023"><itemNumber>0421</itemNumber><strength>2mg/mL</strength><dosageForm>Inj Sol (Preservative-Free)</dosageForm><drug id="02131064" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Lioresal Intrathecal</name><manufacturerId>NOV</manufacturerId><listingDate>2015-08-26</listingDate></drug><drug id="02413647" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Intrathecal</name><manufacturerId>STE</manufacturerId><individualPrice>35.4500</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>35.4500</amountMOHLTCPays></drug><drug id="02457075" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Injection</name><manufacturerId>TEL</manufacturerId><individualPrice>35.4500</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>35.4500</amountMOHLTCPays></drug><drug id="02485516" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Intrathecal</name><manufacturerId>AVP</manufacturerId><individualPrice>35.4500</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>35.4500</amountMOHLTCPays></drug><drug id="02553341" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Injection USP</name><manufacturerId>JPC</manufacturerId><individualPrice>35.4500</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>35.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="122000024"><itemNumber>0422</itemNumber><strength>0.05mg/mL</strength><dosageForm>Inj Sol-1mL Pk (Preservative-Free)</dosageForm><drug id="02131048" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Lioresal Intrathecal</name><manufacturerId>NOV</manufacturerId><listingDate>2015-08-26</listingDate></drug><drug id="02413620" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Injection</name><manufacturerId>STE</manufacturerId><individualPrice>11.2500</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>11.2500</amountMOHLTCPays></drug><drug id="02457059" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Injection</name><manufacturerId>TEL</manufacturerId><individualPrice>11.2500</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>11.2500</amountMOHLTCPays></drug></pcg9><pcg9 id="122000022"><itemNumber>0423</itemNumber><strength>0.5mg/mL</strength><dosageForm>Inj Sol-20mL Pk (Preservative-Free)</dosageForm><drug id="02131056" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Lioresal Intrathecal</name><manufacturerId>NOV</manufacturerId><listingDate>2015-08-26</listingDate></drug><drug id="02413639" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Intrathecal</name><manufacturerId>STE</manufacturerId><individualPrice>177.2500</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>177.2500</amountMOHLTCPays></drug><drug id="02457067" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Injection</name><manufacturerId>TEL</manufacturerId><individualPrice>177.2500</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>177.2500</amountMOHLTCPays></drug><drug id="02485508" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Baclofen Intrathecal</name><manufacturerId>AVP</manufacturerId><individualPrice>177.2500</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>177.2500</amountMOHLTCPays></drug></pcg9><pcg9 id="122000003"><itemNumber>0424</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00455881" sec3="Y"><name>Lioresal</name><manufacturerId>NOV</manufacturerId><individualPrice>.8795</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug><drug id="02063735" sec3="Y"><name>PMS-Baclofen</name><manufacturerId>PMS</manufacturerId><individualPrice>.1595</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug><drug id="02088398" sec3="Y"><name>Mylan-Baclofen</name><manufacturerId>MYL</manufacturerId><individualPrice>.1595</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug><drug id="02139332" sec3="Y"><name>Apo-Baclofen</name><manufacturerId>APX</manufacturerId><individualPrice>.1595</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug><drug id="02236507" sec3="Y"><name>Ratio-Baclofen</name><manufacturerId>RPH</manufacturerId><individualPrice>.1595</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug><drug id="02287021" sec3="Y"><name>Baclofen</name><manufacturerId>SAI</manufacturerId><individualPrice>.1595</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug><drug id="02544660" sec3="Y"><name>Baclofen</name><manufacturerId>SIV</manufacturerId><individualPrice>.1595</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.1595</amountMOHLTCPays></drug></pcg9><pcg9 id="122000006"><itemNumber>0425</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00636576" sec3="Y"><name>Lioresal DS</name><manufacturerId>NOV</manufacturerId><individualPrice>1.7122</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug><drug id="02063743" sec3="Y"><name>PMS-Baclofen</name><manufacturerId>PMS</manufacturerId><individualPrice>.3104</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug><drug id="02088401" sec3="Y"><name>Mylan-Baclofen</name><manufacturerId>MYL</manufacturerId><individualPrice>.3104</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug><drug id="02139391" sec3="Y"><name>Apo-Baclofen</name><manufacturerId>APX</manufacturerId><individualPrice>.3104</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug><drug id="02236508" sec3="Y"><name>Ratio-Baclofen</name><manufacturerId>RPH</manufacturerId><individualPrice>.3104</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug><drug id="02287048" sec3="Y"><name>Baclofen</name><manufacturerId>SAI</manufacturerId><individualPrice>.3104</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug><drug id="02544679" sec3="Y"><name>Baclofen</name><manufacturerId>SIV</manufacturerId><individualPrice>.3104</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.3104</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00272"><name>CYCLOBENZAPRINE HCL</name><pcgGroup><pcg9 id="122000005"><itemNumber>0426</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00782742" notABenefit="Y" sec3="Y"><name>Flexeril</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02080052" notABenefit="Y" sec3="Y"><name>Teva-Cyclobenzaprine HCL</name><manufacturerId>TEV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02177145" notABenefit="Y" sec3="Y"><name>Apo-Cyclobenzaprine</name><manufacturerId>APX</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02212048" notABenefit="Y" sec3="Y"><name>PMS-Cyclobenzaprine</name><manufacturerId>PMS</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02236506" notABenefit="Y" sec3="Y"><name>Ratio-Cyclobenzaprine</name><manufacturerId>RPH</manufacturerId><listingDate>1999-09-15</listingDate></drug><drug id="02242079" notABenefit="Y" sec3="Y"><name>Riva-Cyclobenzaprine</name><manufacturerId>RIA</manufacturerId><listingDate>2025-04-30</listingDate></drug><drug id="02287064" notABenefit="Y" sec3="Y"><name>Cyclobenzaprine</name><manufacturerId>SAI</manufacturerId><listingDate>2011-08-04</listingDate></drug><drug id="02348853" notABenefit="Y" sec3="Y"><name>Auro-Cyclobenzaprine</name><manufacturerId>AUR</manufacturerId><listingDate>2011-12-15</listingDate></drug><drug id="02357127" notABenefit="Y" sec3="Y"><name>Jamp-Cyclobenzaprine</name><manufacturerId>JPC</manufacturerId><listingDate>2012-11-27</listingDate></drug><drug id="02424584" notABenefit="Y" sec3="Y"><name>Cyclobenzaprine</name><manufacturerId>SIV</manufacturerId><listingDate>2020-08-28</listingDate></drug><drug id="02485419" notABenefit="Y" sec3="Y"><name>AG-Cyclobenzaprine</name><manufacturerId>ANG</manufacturerId><listingDate>2020-12-18</listingDate></drug><drug id="02495422" notABenefit="Y" sec3="Y"><name>Flexeril</name><manufacturerId>ORI</manufacturerId><listingDate>2020-06-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00270"><name>DANTROLENE SODIUM</name><pcgGroup><pcg9 id="122000002"><itemNumber>0427</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="01997602" sec3="Y"><name>Dantrium Capsules</name><manufacturerId>EDO</manufacturerId><individualPrice>.7198</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7198</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00273"><name>ORPHENADRINE CITRATE</name><pcgGroup><pcg9 id="122000007"><itemNumber>0428</itemNumber><strength>60mg/2mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="01966162" notABenefit="Y" sec3="Y"><name>Norflex</name><manufacturerId>MMH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229731" notABenefit="Y" sec3="Y"><name>Orphenadrine</name><manufacturerId>CYI</manufacturerId><listingDate>1998-12-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01453"><name>TIZANIDINE HCL</name><pcgGroup><pcg9 id="122000025"><itemNumber>0429</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02239170" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zanaflex</name><manufacturerId>ELA</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02259893" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tizanidine</name><manufacturerId>APX</manufacturerId><individualPrice>.8758</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.8758</amountMOHLTCPays></drug><drug id="02536765" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Tizanidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.8758</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.8758</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="200000000"><name>BLOOD FORMATION AND COAGULATION</name><pcg6 id="200400000"><name>ANTIANEMIA DRUGS</name><genericName id="02193"><name>FERRIC DERISOMALTOSE</name><pcgGroup lccId="00357"><pcg9 id="200400027"><itemNumber>0430</itemNumber><strength>100mg elemental iron/mL</strength><dosageForm>Inj Sol (Preservative-Free)</dosageForm><drug id="02477777" sec3="Y" sec12="Y"><name>Monoferric</name><manufacturerId>PHC</manufacturerId><individualPrice>45.0000</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>45.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="610">For the treatment of patients with Iron Deficiency Anemia (IDA) who meet ALL the following criteria:

- Patient has documented diagnosis of IDA confirmed by laboratory testing results (e.g. hemoglobin, ferritin); AND

- Patient&apos;s IDA has experienced a failure to respond, documented intolerance, or contraindication to an adequate trial (i.e. at least 4 weeks) of at least one oral iron therapy; AND

- Patient does not have hemochromatosis or other iron storage disorders; AND

- Monoferric is administered in a setting where appropriate monitoring and management of hypersensitivity reactions can be provided to the Patient.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00282"><name>FERROUS FUMARATE</name><pcgGroup><pcg9 id="200400013"><itemNumber>0431</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="01923420" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Palafer</name><manufacturerId>GSK</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02237556" chronicUseMed="Y" sec3="Y"><name>Euro-Fer</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1057</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.1057</amountMOHLTCPays></drug><drug id="80024232" chronicUseMed="Y" sec3="Y"><name>Jamp-Fer</name><manufacturerId>JPC</manufacturerId><individualPrice>.1057</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.1057</amountMOHLTCPays></drug></pcg9><pcg9 id="200400003"><itemNumber>0432</itemNumber><strength>60mg/mL</strength><dosageForm>O/L</dosageForm><drug id="01923439" sec3="Y"><name>Palafer</name><manufacturerId>GSK</manufacturerId><individualPrice>.0981</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0981</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00283"><name>FERROUS GLUCONATE</name><pcgGroup><pcg9 id="200400004" suppliedBy="L"><itemNumber>0433</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="00031097" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Ferrous Gluconate</name><manufacturerId>JPC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00545031" selfMed="Y" chronicUseMed="Y" sec3="Y"><name>Ferrous Gluconate 300mg</name><manufacturerId>AAP</manufacturerId><individualPrice>.0424</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0424</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00284"><name>FERROUS SULFATE</name><pcgGroup><pcg9 id="200400007"><itemNumber>0434</itemNumber><strength>75mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00762954" sec3="Y"><name>Fer-In-Sol</name><manufacturerId>MJS</manufacturerId><individualPrice>.2436</individualPrice><listingDate>1997-01-03</listingDate><amountMOHLTCPays>.2436</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01544"><name>IRON SUCROSE</name><pcgGroup><pcg9 id="200400023"><itemNumber>0435</itemNumber><strength>20mg/mL</strength><dosageForm>Inj Sol-5mL Pk (Preservative-Free)</dosageForm><drug id="02243716" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Venofer</name><manufacturerId>LUI</manufacturerId><listingDate>2021-03-29</listingDate></drug><drug id="02502917" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Iron Sucrose</name><manufacturerId>PMS</manufacturerId><individualPrice>27.5000</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>27.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="201200000"><name>COAGULANTS AND ANTI-COAGULANTS</name><genericName id="01922"><name>APIXABAN</name><pcgGroup><pcg9 id="201200089"><itemNumber>0436</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02377233" sec3="Y"><name>Eliquis</name><manufacturerId>BQU</manufacturerId><individualPrice>1.6336</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02484994" sec3="Y"><name>Teva-Apixaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02486806" sec3="Y"><name>Auro-Apixaban</name><manufacturerId>AUR</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02487381" sec3="Y"><name>Apo-Apixaban</name><manufacturerId>APX</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02487713" sec3="Y"><name>Ach-Apixaban</name><manufacturerId>ACH</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02489228" sec3="Y"><name>Sandoz Apixaban SDZ</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02492369" sec3="Y"><name>Mar-Apixaban</name><manufacturerId>MAR</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02492814" sec3="Y"><name>Nat-Apixaban</name><manufacturerId>NAT</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02495430" sec3="Y"><name>Mint-Apixaban</name><manufacturerId>MIN</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02510464" sec3="Y"><name>Taro-Apixaban</name><manufacturerId>TAR</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02525518" sec3="Y"><name>Riva-Apixaban</name><manufacturerId>RIA</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02526050" sec3="Y"><name>NRA-Apixaban</name><manufacturerId>NRA</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02528924" sec3="Y"><name>Jamp Apixaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02529009" sec3="Y"><name>M-Apixaban</name><manufacturerId>MAT</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02530708" sec3="Y"><name>Apixaban</name><manufacturerId>SIV</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02546884" sec3="Y"><name>NRA-Apixaban Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02548879" sec3="Y"><name>Apixaban</name><manufacturerId>SAI</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug></pcg9><pcg9 id="201200090"><itemNumber>0437</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02397714" sec3="Y"><name>Eliquis</name><manufacturerId>BQU</manufacturerId><individualPrice>1.6336</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02485001" sec3="Y"><name>Teva-Apixaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02486814" sec3="Y"><name>Auro-Apixaban</name><manufacturerId>AUR</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02487403" sec3="Y"><name>Apo-Apixaban</name><manufacturerId>APX</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02487721" sec3="Y"><name>Ach-Apixaban</name><manufacturerId>ACH</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02489236" sec3="Y"><name>Sandoz Apixaban SDZ</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02492377" sec3="Y"><name>Mar-Apixaban</name><manufacturerId>MAR</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02492822" sec3="Y"><name>Nat-Apixaban</name><manufacturerId>NAT</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02495449" sec3="Y"><name>Mint-Apixaban</name><manufacturerId>MIN</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02510472" sec3="Y"><name>Taro-Apixaban</name><manufacturerId>TAR</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02525526" sec3="Y"><name>Riva-Apixaban</name><manufacturerId>RIA</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02526069" sec3="Y"><name>NRA-Apixaban</name><manufacturerId>NRA</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02528932" sec3="Y"><name>Jamp Apixaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02529017" sec3="Y"><name>M-Apixaban</name><manufacturerId>MAT</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02530716" sec3="Y"><name>Apixaban</name><manufacturerId>SIV</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02546892" sec3="Y"><name>NRA-Apixaban Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug><drug id="02548887" sec3="Y"><name>Apixaban</name><manufacturerId>SAI</manufacturerId><individualPrice>.4084</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.4084</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01882"><name>DABIGATRAN ETEXILATE</name><pcgGroup><pcg9 id="201200098"><itemNumber>0438</itemNumber><strength>75mg</strength><dosageForm>Cap</dosageForm><drug id="02312433" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pradaxa</name><manufacturerId>BOE</manufacturerId><listingDate>2019-10-31</listingDate></drug><drug id="02468891" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Dabigatran</name><manufacturerId>APX</manufacturerId><individualPrice>1.6443</individualPrice><listingDate>2019-10-31</listingDate></drug></pcg9><pcg9 id="201200084"><itemNumber>0439</itemNumber><strength>110mg</strength><dosageForm>Cap</dosageForm><drug id="02312441" sec3="Y"><name>Pradaxa</name><manufacturerId>BOE</manufacturerId><individualPrice>1.7310</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>1.2540</amountMOHLTCPays></drug><drug id="02468905" sec3="Y"><name>Apo-Dabigatran</name><manufacturerId>APX</manufacturerId><individualPrice>1.2540</individualPrice><listingDate>2019-05-31</listingDate><amountMOHLTCPays>1.2540</amountMOHLTCPays></drug></pcg9><pcg9 id="201200085"><itemNumber>0440</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02358808" sec3="Y"><name>Pradaxa</name><manufacturerId>BOE</manufacturerId><individualPrice>1.7310</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>1.2540</amountMOHLTCPays></drug><drug id="02468913" sec3="Y"><name>Apo-Dabigatran</name><manufacturerId>APX</manufacturerId><individualPrice>1.2540</individualPrice><listingDate>2019-05-31</listingDate><amountMOHLTCPays>1.2540</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00298"><name>DALTEPARIN SODIUM</name><pcgGroup lccId="00045"><pcg9 id="201200099"><itemNumber>0441</itemNumber><strength>3500IU/0.28mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02430789" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>8.3110</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>8.3110</amountMOHLTCPays></drug></pcg9><pcg9 id="201200083"><itemNumber>0442</itemNumber><strength>7500IU/0.3mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02352648" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>17.8120</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>17.8120</amountMOHLTCPays></drug></pcg9><pcg9 id="201200038"><itemNumber>0443</itemNumber><strength>2500IU/0.2mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02132621" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>5.9370</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>5.9370</amountMOHLTCPays></drug></pcg9><pcg9 id="201200040"><itemNumber>0444</itemNumber><strength>5000IU/0.2mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02132648" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>11.8740</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>11.8740</amountMOHLTCPays></drug></pcg9><pcg9 id="201200064"><itemNumber>0445</itemNumber><strength>10000IU/0.4mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02352656" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>23.7500</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>23.7500</amountMOHLTCPays></drug></pcg9><pcg9 id="201200065"><itemNumber>0446</itemNumber><strength>12500IU/0.5mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02352664" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>29.6880</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>29.6880</amountMOHLTCPays></drug></pcg9><pcg9 id="201200066"><itemNumber>0447</itemNumber><strength>15000IU/0.6mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02352672" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>35.6160</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>35.6160</amountMOHLTCPays></drug></pcg9><pcg9 id="201200067"><itemNumber>0448</itemNumber><strength>18000IU/0.72mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02352680" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>42.7400</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>42.7400</amountMOHLTCPays></drug></pcg9><pcg9 id="201200105"><itemNumber>0449</itemNumber><strength>16500IU/0.66mL</strength><dosageForm>Inj Pref Syr-0.66mL Pk</dosageForm><drug id="02494582" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>39.1780</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>39.1780</amountMOHLTCPays></drug></pcg9><pcg9 id="201200043"><itemNumber>0450</itemNumber><strength>25000IU/mL</strength><dosageForm>Multidose 3.8mL Pk</dosageForm><drug id="02231171" sec3="Y" sec12="Y"><name>Fragmin</name><manufacturerId>PFI</manufacturerId><individualPrice>178.1000</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>178.1000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01229"><name>ENOXAPARIN</name><pcgGroup><pcg9 id="201200121"><itemNumber>0451</itemNumber><strength>20mg/0.2mL</strength><dosageForm>Inj Sol-0.2mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506440" sec3="Y"><name>Noromby</name><manufacturerId>JUN</manufacturerId><individualPrice>3.5280</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>3.5280</amountMOHLTCPays></drug></pcg9><pcg9 id="201200106"><itemNumber>0452</itemNumber><strength>30mg/0.3mL</strength><dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509075" sec3="Y"><name>Redesca</name><manufacturerId>SHE</manufacturerId><individualPrice>4.9620</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>4.9620</amountMOHLTCPays></drug></pcg9><pcg9 id="201200114"><itemNumber>0453</itemNumber><strength>30mg/0.3mL</strength><dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507501" sec3="Y"><name>Inclunox</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.9620</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>4.9620</amountMOHLTCPays></drug></pcg9><pcg9 id="201200122"><itemNumber>0454</itemNumber><strength>30mg/0.3mL</strength><dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506459" sec3="Y"><name>Noromby</name><manufacturerId>JUN</manufacturerId><individualPrice>4.9124</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>4.9124</amountMOHLTCPays></drug></pcg9><pcg9 id="201200130"><itemNumber>0455</itemNumber><strength>30mg/0.3mL</strength><dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532247" sec3="Y"><name>Elonox</name><manufacturerId>FKC</manufacturerId><individualPrice>4.9124</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>4.9124</amountMOHLTCPays></drug></pcg9><pcg9 id="201200137"><itemNumber>0456</itemNumber><strength>30mg/0.3mL</strength><dosageForm>Inj Sol-0.3mL Pref Syr (Preservative-Free)</dosageForm><drug id="02539977" sec3="Y"><name>Axberi</name><manufacturerId>BAX</manufacturerId><individualPrice>4.9124</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>4.9124</amountMOHLTCPays></drug></pcg9><pcg9 id="201200107"><itemNumber>0457</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509083" sec3="Y"><name>Redesca</name><manufacturerId>SHE</manufacturerId><individualPrice>6.6160</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>6.6160</amountMOHLTCPays></drug></pcg9><pcg9 id="201200115"><itemNumber>0458</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507528" sec3="Y"><name>Inclunox</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.6160</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>6.6160</amountMOHLTCPays></drug></pcg9><pcg9 id="201200123"><itemNumber>0459</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506467" sec3="Y"><name>Noromby</name><manufacturerId>JUN</manufacturerId><individualPrice>6.5498</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>6.5498</amountMOHLTCPays></drug></pcg9><pcg9 id="201200131"><itemNumber>0460</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532255" sec3="Y"><name>Elonox</name><manufacturerId>FKC</manufacturerId><individualPrice>6.5498</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>6.5498</amountMOHLTCPays></drug></pcg9><pcg9 id="201200138"><itemNumber>0461</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02539985" sec3="Y"><name>Axberi</name><manufacturerId>BAX</manufacturerId><individualPrice>6.5498</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>6.5498</amountMOHLTCPays></drug></pcg9><pcg9 id="201200108"><itemNumber>0462</itemNumber><strength>60mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509091" sec3="Y"><name>Redesca</name><manufacturerId>SHE</manufacturerId><individualPrice>9.9240</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>9.9240</amountMOHLTCPays></drug></pcg9><pcg9 id="201200116"><itemNumber>0463</itemNumber><strength>60mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507536" sec3="Y"><name>Inclunox</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.9240</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>9.9240</amountMOHLTCPays></drug></pcg9><pcg9 id="201200124"><itemNumber>0464</itemNumber><strength>60mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506475" sec3="Y"><name>Noromby</name><manufacturerId>JUN</manufacturerId><individualPrice>9.8248</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>9.8248</amountMOHLTCPays></drug></pcg9><pcg9 id="201200132"><itemNumber>0465</itemNumber><strength>60mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532263" sec3="Y"><name>Elonox</name><manufacturerId>FKC</manufacturerId><individualPrice>9.8248</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>9.8248</amountMOHLTCPays></drug></pcg9><pcg9 id="201200139"><itemNumber>0466</itemNumber><strength>60mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02540002" sec3="Y"><name>Axberi</name><manufacturerId>BAX</manufacturerId><individualPrice>9.8248</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>9.8248</amountMOHLTCPays></drug></pcg9><pcg9 id="201200109"><itemNumber>0467</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509105" sec3="Y"><name>Redesca</name><manufacturerId>SHE</manufacturerId><individualPrice>13.2320</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>13.2320</amountMOHLTCPays></drug></pcg9><pcg9 id="201200117"><itemNumber>0468</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507544" sec3="Y"><name>Inclunox</name><manufacturerId>SDZ</manufacturerId><individualPrice>13.2320</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>13.2320</amountMOHLTCPays></drug></pcg9><pcg9 id="201200125"><itemNumber>0469</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506483" sec3="Y"><name>Noromby</name><manufacturerId>JUN</manufacturerId><individualPrice>13.0997</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>13.0997</amountMOHLTCPays></drug></pcg9><pcg9 id="201200133"><itemNumber>0470</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532271" sec3="Y"><name>Elonox</name><manufacturerId>FKC</manufacturerId><individualPrice>13.0997</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>13.0997</amountMOHLTCPays></drug></pcg9><pcg9 id="201200140"><itemNumber>0471</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02540010" sec3="Y"><name>Axberi</name><manufacturerId>BAX</manufacturerId><individualPrice>13.0997</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>13.0997</amountMOHLTCPays></drug></pcg9><pcg9 id="201200111"><itemNumber>0472</itemNumber><strength>120mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509148" sec3="Y"><name>Redesca HP</name><manufacturerId>SHE</manufacturerId><individualPrice>19.8480</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>19.8480</amountMOHLTCPays></drug></pcg9><pcg9 id="201200119"><itemNumber>0473</itemNumber><strength>120mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507560" sec3="Y"><name>Inclunox HP</name><manufacturerId>SDZ</manufacturerId><individualPrice>19.8480</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>19.8480</amountMOHLTCPays></drug></pcg9><pcg9 id="201200127"><itemNumber>0474</itemNumber><strength>120mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506505" sec3="Y"><name>Noromby HP</name><manufacturerId>JUN</manufacturerId><individualPrice>19.6495</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>19.6495</amountMOHLTCPays></drug></pcg9><pcg9 id="201200135"><itemNumber>0475</itemNumber><strength>120mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532301" sec3="Y"><name>Elonox HP</name><manufacturerId>FKC</manufacturerId><individualPrice>19.6495</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>19.6495</amountMOHLTCPays></drug></pcg9><pcg9 id="201200142"><itemNumber>0476</itemNumber><strength>120mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02540029" sec3="Y"><name>Axberi HP</name><manufacturerId>BAX</manufacturerId><individualPrice>19.6495</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>19.6495</amountMOHLTCPays></drug></pcg9><pcg9 id="201200110"><itemNumber>0477</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509113" sec3="Y"><name>Redesca</name><manufacturerId>SHE</manufacturerId><individualPrice>16.5400</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>16.5400</amountMOHLTCPays></drug></pcg9><pcg9 id="201200118"><itemNumber>0478</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507552" sec3="Y"><name>Inclunox</name><manufacturerId>SDZ</manufacturerId><individualPrice>16.5400</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>16.5400</amountMOHLTCPays></drug></pcg9><pcg9 id="201200126"><itemNumber>0479</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506491" sec3="Y"><name>Noromby</name><manufacturerId>JUN</manufacturerId><individualPrice>16.3746</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>16.3746</amountMOHLTCPays></drug></pcg9><pcg9 id="201200134"><itemNumber>0480</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532298" sec3="Y"><name>Elonox</name><manufacturerId>FKC</manufacturerId><individualPrice>16.3746</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>16.3746</amountMOHLTCPays></drug></pcg9><pcg9 id="201200141"><itemNumber>0481</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02540045" sec3="Y"><name>Axberi</name><manufacturerId>BAX</manufacturerId><individualPrice>16.3746</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>16.3746</amountMOHLTCPays></drug></pcg9><pcg9 id="201200112"><itemNumber>0482</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02509156" sec3="Y"><name>Redesca HP</name><manufacturerId>SHE</manufacturerId><individualPrice>24.8100</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>24.8100</amountMOHLTCPays></drug></pcg9><pcg9 id="201200120"><itemNumber>0483</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02507579" sec3="Y"><name>Inclunox HP</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.8100</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>24.8100</amountMOHLTCPays></drug></pcg9><pcg9 id="201200128"><itemNumber>0484</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02506513" sec3="Y"><name>Noromby HP</name><manufacturerId>JUN</manufacturerId><individualPrice>24.5619</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>24.5619</amountMOHLTCPays></drug></pcg9><pcg9 id="201200136"><itemNumber>0485</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02532328" sec3="Y"><name>Elonox HP</name><manufacturerId>FKC</manufacturerId><individualPrice>24.5619</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>24.5619</amountMOHLTCPays></drug></pcg9><pcg9 id="201200143"><itemNumber>0486</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02540037" sec3="Y"><name>Axberi HP</name><manufacturerId>BAX</manufacturerId><individualPrice>24.5619</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>24.5619</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00046"><pcg9 id="201200070"><itemNumber>0487</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-3mL Vial Pk</dosageForm><drug id="02236564" sec3="Y" sec12="Y"><name>Lovenox</name><manufacturerId>SAV</manufacturerId><individualPrice>68.7500</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>68.7500</amountMOHLTCPays></drug></pcg9><lccNote seq="011" reasonForUseId="678">For the treatment of pulmonary embolism, deep vein thrombosis who meet the following criteria:

- Patients who become pregnant during the transition period of July 31, 2024, to January 31, 2025.</lccNote><lccNote seq="012" type="R">LU Authorization Period: Up to 12 months</lccNote><lccNote seq="013" reasonForUseId="679">For the treatment of pulmonary embolism, deep vein thrombosis who meet the following criteria:

- Patients who require palliative care during the transition period of July 31, 2024, to January 31, 2025.</lccNote><lccNote seq="014" type="R">LU Authorization Period: Up to 12 months</lccNote></pcgGroup><pcgGroup><pcg9 id="201200113"><itemNumber>0488</itemNumber><strength>300mg/3mL</strength><dosageForm>Inj Sol-3mL Vial Pk (With Preservative)</dosageForm><drug id="02509121" sec3="Y"><name>Redesca</name><manufacturerId>SHE</manufacturerId><individualPrice>49.6200</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>49.6200</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00046"><pcg9 id="201200071"><itemNumber>0489</itemNumber><strength>30mg/0.3mL</strength><dosageForm>Pref Syr-0.3mL Pk</dosageForm><drug id="02012472" sec3="Y" sec12="Y"><name>Lovenox</name><manufacturerId>SAV</manufacturerId><individualPrice>6.8750</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>6.8750</amountMOHLTCPays></drug></pcg9><pcg9 id="201200055"><itemNumber>0490</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Pref Syr-0.4mL Pk</dosageForm><drug id="02236883" sec3="Y" sec12="Y"><name>Lovenox</name><manufacturerId>SAV</manufacturerId><individualPrice>9.1660</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>9.1660</amountMOHLTCPays></drug></pcg9><pcg9 id="201200056"><itemNumber>0491</itemNumber><strength>60mg/0.6mL</strength><dosageForm>Pref Syr-0.6mL Pk</dosageForm><drug id="02378426" sec3="Y" sec12="Y"><name>Lovenox</name><manufacturerId>SAV</manufacturerId><individualPrice>13.7490</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>13.7490</amountMOHLTCPays></drug></pcg9><pcg9 id="201200057"><itemNumber>0492</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Pref Syr-0.8mL Pk</dosageForm><drug id="02378434" sec3="Y" sec12="Y"><name>Lovenox</name><manufacturerId>SAV</manufacturerId><individualPrice>18.3330</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>18.3330</amountMOHLTCPays></drug></pcg9><pcg9 id="201200073"><itemNumber>0493</itemNumber><strength>120mg/0.8mL</strength><dosageForm>Pref Syr-0.8mL Pk</dosageForm><drug id="02242692" sec3="Y" sec12="Y"><name>Lovenox HP</name><manufacturerId>SAV</manufacturerId><individualPrice>27.4990</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>27.4990</amountMOHLTCPays></drug></pcg9><pcg9 id="201200058"><itemNumber>0494</itemNumber><strength>100mg/mL</strength><dosageForm>Pref Syr-1mL Pk</dosageForm><drug id="02378442" sec3="Y" sec12="Y"><name>Lovenox</name><manufacturerId>SAV</manufacturerId><individualPrice>22.9160</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>22.9160</amountMOHLTCPays></drug></pcg9><pcg9 id="201200074"><itemNumber>0495</itemNumber><strength>150mg/mL</strength><dosageForm>Pref Syr-1mL Pk</dosageForm><drug id="02378469" sec3="Y" sec12="Y"><name>Lovenox HP</name><manufacturerId>SAV</manufacturerId><individualPrice>34.3750</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>34.3750</amountMOHLTCPays></drug></pcg9><lccNote seq="011" reasonForUseId="678">For the treatment of pulmonary embolism, deep vein thrombosis who meet the following criteria:

- Patients who become pregnant during the transition period of July 31, 2024, to January 31, 2025.</lccNote><lccNote seq="012" type="R">LU Authorization Period: Up to 12 months</lccNote><lccNote seq="013" reasonForUseId="679">For the treatment of pulmonary embolism, deep vein thrombosis who meet the following criteria:

- Patients who require palliative care during the transition period of July 31, 2024, to January 31, 2025.</lccNote><lccNote seq="014" type="R">LU Authorization Period: Up to 12 months</lccNote></pcgGroup></genericName><genericName id="01927"><name>EPTIFIBATIDE</name><pcgGroup><pcg9 id="201200091"><itemNumber>0496</itemNumber><strength>0.75mg/mL</strength><dosageForm>100mL Vial Pk</dosageForm><drug id="02240351" notABenefit="Y" sec3b="Y" sec3="Y"><name>Integrilin</name><manufacturerId>MEK</manufacturerId><listingDate>2013-09-27</listingDate></drug><drug id="02405083" notABenefit="Y" sec3b="Y" sec3="Y"><name>Eptifibatide Injection</name><manufacturerId>TEV</manufacturerId><individualPrice>94.5600</individualPrice><listingDate>2013-09-27</listingDate></drug></pcg9><pcg9 id="201200092"><itemNumber>0497</itemNumber><strength>2mg/mL</strength><dosageForm>10mL Vial Pk</dosageForm><drug id="02240352" notABenefit="Y" sec3b="Y" sec3="Y"><name>Integrilin</name><manufacturerId>MEK</manufacturerId><listingDate>2013-09-27</listingDate></drug><drug id="02367858" notABenefit="Y" sec3b="Y" sec3="Y"><name>Eptifibatide Injection</name><manufacturerId>TEV</manufacturerId><individualPrice>32.3000</individualPrice><listingDate>2013-09-27</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01576"><name>FONDAPARINUX SODIUM</name><pcgGroup lccId="00148"><pcg9 id="201200072"><itemNumber>0498</itemNumber><strength>2.5mg/0.5mL</strength><dosageForm>Inj Sol-Pref Syr 0.5mL Pk (Preservative Free)</dosageForm><drug id="02245531" sec3="Y" sec12="Y"><name>Arixtra</name><manufacturerId>ASN</manufacturerId><individualPrice>12.8230</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>11.1944</amountMOHLTCPays></drug><drug id="02406853" sec3="Y" sec12="Y"><name>Fondaparinux Sodium Injection</name><manufacturerId>DRR</manufacturerId><individualPrice>11.1944</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>11.1944</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="378">For the post-operative prophylaxis of venous thromboembolic events in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement or knee surgery.</lccNote><lccNote seq="002" type="N">Limited to 9 days of reimbursement.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="201200080"><itemNumber>0499</itemNumber><strength>7.5mg/0.6mL</strength><dosageForm>Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)</dosageForm><drug id="02258056" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Arixtra</name><manufacturerId>ASN</manufacturerId><listingDate>2014-07-30</listingDate></drug><drug id="02406896" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Fondaparinux Sodium Injection</name><manufacturerId>DRR</manufacturerId><individualPrice>18.1356</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>18.1356</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01409"><name>NADROPARIN CALCIUM</name><pcgGroup lccId="00047"><pcg9 id="201200050"><itemNumber>0500</itemNumber><strength>9500IU/mL</strength><dosageForm>Pref Syr-0.3mL Pk</dosageForm><drug id="09853936" sec3="Y" sec12="Y"><name>Fraxiparine</name><manufacturerId>ASN</manufacturerId><individualPrice>5.4150</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>5.4150</amountMOHLTCPays></drug></pcg9><pcg9 id="201200051"><itemNumber>0501</itemNumber><strength>9500IU/mL</strength><dosageForm>Pref Syr-0.4mL Pk</dosageForm><drug id="09853944" sec3="Y" sec12="Y"><name>Fraxiparine</name><manufacturerId>ASN</manufacturerId><individualPrice>6.8400</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>6.8400</amountMOHLTCPays></drug></pcg9><pcg9 id="201200052"><itemNumber>0502</itemNumber><strength>9500IU/mL</strength><dosageForm>Pref Syr-0.6mL Pk</dosageForm><drug id="09853952" sec3="Y" sec12="Y"><name>Fraxiparine</name><manufacturerId>ASN</manufacturerId><individualPrice>9.0580</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>9.0580</amountMOHLTCPays></drug></pcg9><pcg9 id="201200059"><itemNumber>0503</itemNumber><strength>19000IU/mL</strength><dosageForm>Pref Syr-0.6mL Pk</dosageForm><drug id="02240114" sec3="Y" sec12="Y"><name>Fraxiparine Forte</name><manufacturerId>ASN</manufacturerId><individualPrice>18.1170</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>18.1170</amountMOHLTCPays></drug></pcg9><pcg9 id="201200060"><itemNumber>0504</itemNumber><strength>19000IU/mL</strength><dosageForm>Pref Syr-0.8mL Pk</dosageForm><drug id="09854100" sec3="Y" sec12="Y"><name>Fraxiparine Forte</name><manufacturerId>ASN</manufacturerId><individualPrice>18.1170</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>18.1170</amountMOHLTCPays></drug></pcg9><pcg9 id="201200054"><itemNumber>0505</itemNumber><strength>9500IU/mL</strength><dosageForm>Pref Syr-1.0mL Pk</dosageForm><drug id="09853987" sec3="Y" sec12="Y"><name>Fraxiparine</name><manufacturerId>ASN</manufacturerId><individualPrice>9.0580</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>9.0580</amountMOHLTCPays></drug></pcg9><pcg9 id="201200061"><itemNumber>0506</itemNumber><strength>19000IU/mL</strength><dosageForm>Pref Syr-1.0mL Pk</dosageForm><drug id="09854118" sec3="Y" sec12="Y"><name>Fraxiparine Forte</name><manufacturerId>ASN</manufacturerId><individualPrice>18.1170</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>18.1170</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01756"><name>RIVAROXABAN</name><pcgGroup><pcg9 id="201200104"><itemNumber>0507</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02480808" sec3="Y"><name>Xarelto</name><manufacturerId>BAH</manufacturerId><individualPrice>1.4200</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02524503" sec3="Y"><name>Reddy-Rivaroxaban</name><manufacturerId>DRR</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02526786" sec3="Y"><name>Taro-Rivaroxaban</name><manufacturerId>TAR</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02527537" sec3="Y"><name>PMS-Rivaroxaban</name><manufacturerId>PMS</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02537877" sec3="Y"><name>Sandoz Rivaroxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02541467" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SIV</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02541734" sec3="Y"><name>Apo-Rivaroxaban</name><manufacturerId>APX</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02547295" sec3="Y"><name>Teva-Rivaroxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02547899" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SAI</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02551608" sec3="Y"><name>M-Rivaroxaban</name><manufacturerId>MAT</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug><drug id="02553368" sec3="Y"><name>Jamp Rivaroxaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.3550</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.3550</amountMOHLTCPays></drug></pcg9><pcg9 id="201200079"><itemNumber>0508</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02316986" sec3="Y"><name>Xarelto</name><manufacturerId>BAH</manufacturerId><individualPrice>2.8700</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02470497" sec3="Y"><name>Apo-Rivaroxaban</name><manufacturerId>APX</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02472414" sec3="Y"><name>Reddy-Rivaroxaban</name><manufacturerId>DRR</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02482223" sec3="Y"><name>Sandoz Rivaroxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02483807" sec3="Y"><name>Taro-Rivaroxaban</name><manufacturerId>TAR</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02507196" sec3="Y"><name>Teva-Rivaroxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02512041" sec3="Y"><name>PMS-Rivaroxaban</name><manufacturerId>PMS</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02516292" sec3="Y"><name>Jamp Rivaroxaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02541475" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SIV</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02547902" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SAI</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02551616" sec3="Y"><name>M-Rivaroxaban</name><manufacturerId>MAT</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug></pcg9><pcg9 id="201200086"><itemNumber>0509</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="02378604" sec3="Y"><name>Xarelto</name><manufacturerId>BAH</manufacturerId><individualPrice>2.8700</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02470500" sec3="Y"><name>Apo-Rivaroxaban</name><manufacturerId>APX</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02472430" sec3="Y"><name>Reddy-Rivaroxaban</name><manufacturerId>DRR</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02482231" sec3="Y"><name>Sandoz Rivaroxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02483815" sec3="Y"><name>Taro-Rivaroxaban</name><manufacturerId>TAR</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02507218" sec3="Y"><name>Teva-Rivaroxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02512068" sec3="Y"><name>PMS-Rivaroxaban</name><manufacturerId>PMS</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02516306" sec3="Y"><name>Jamp Rivaroxaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02541483" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SIV</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02547910" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SAI</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02551624" sec3="Y"><name>M-Rivaroxaban</name><manufacturerId>MAT</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug></pcg9><pcg9 id="201200087"><itemNumber>0510</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02378612" sec3="Y"><name>Xarelto</name><manufacturerId>BAH</manufacturerId><individualPrice>2.8700</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02470519" sec3="Y"><name>Apo-Rivaroxaban</name><manufacturerId>APX</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02472422" sec3="Y"><name>Reddy-Rivaroxaban</name><manufacturerId>DRR</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02482258" sec3="Y"><name>Sandoz Rivaroxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02483823" sec3="Y"><name>Taro-Rivaroxaban</name><manufacturerId>TAR</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02507226" sec3="Y"><name>Teva-Rivaroxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02512076" sec3="Y"><name>PMS-Rivaroxaban</name><manufacturerId>PMS</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02516314" sec3="Y"><name>Jamp Rivaroxaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02541491" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SIV</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02547929" sec3="Y"><name>Rivaroxaban</name><manufacturerId>SAI</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug><drug id="02551632" sec3="Y"><name>M-Rivaroxaban</name><manufacturerId>MAT</manufacturerId><individualPrice>.7175</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.7175</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01913"><name>TICAGRELOR</name><pcgGroup><pcg9 id="201200129"><itemNumber>0511</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="02455005" notABenefit="Y" sec3b="Y" sec3="Y"><name>Brilinta</name><manufacturerId>AZC</manufacturerId><listingDate>2022-05-31</listingDate></drug><drug id="02482622" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Ticagrelor</name><manufacturerId>APX</manufacturerId><individualPrice>1.2844</individualPrice><listingDate>2022-12-21</listingDate></drug><drug id="02492571" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Ticagrelor</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2844</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02529750" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Ticagrelor</name><manufacturerId>MAT</manufacturerId><individualPrice>1.2844</individualPrice><listingDate>2022-12-21</listingDate></drug><drug id="02531798" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Ticagrelor</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2844</individualPrice><listingDate>2024-02-29</listingDate></drug></pcg9></pcgGroup><pcgGroup lccId="00230"><pcg9 id="201200088"><itemNumber>0512</itemNumber><strength>90mg</strength><dosageForm>Tab</dosageForm><drug id="02368544" sec3="Y" sec12="Y"><name>Brilinta</name><manufacturerId>AZC</manufacturerId><individualPrice>1.7849</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3960</amountMOHLTCPays></drug><drug id="02482630" sec3="Y" sec12="Y"><name>Apo-Ticagrelor</name><manufacturerId>APX</manufacturerId><individualPrice>.3960</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.3960</amountMOHLTCPays></drug><drug id="02492598" sec3="Y" sec12="Y"><name>Taro-Ticagrelor</name><manufacturerId>TAR</manufacturerId><individualPrice>.3960</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.3960</amountMOHLTCPays></drug><drug id="02529769" sec3="Y" sec12="Y"><name>M-Ticagrelor</name><manufacturerId>MAT</manufacturerId><individualPrice>.3960</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.3960</amountMOHLTCPays></drug><drug id="02531801" sec3="Y" sec12="Y"><name>Jamp Ticagrelor</name><manufacturerId>JPC</manufacturerId><individualPrice>.3960</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>.3960</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="441">In combination with low-dose ASA for patients with:

- Non-ST elevation acute coronary syndrome (ACS)* (unstable angina or myocardial infarction [MI]); OR

- ST-segment elevation myocardial infarction (STEMI); OR

- Stent thrombosis while taking clopidogrel plus low-dose ASA.

Treatment must be initiated in hospital.

Notes:

A) *ACS without ST elevation is defined as 2 of 3 of the following criteria:

1. ST-segment changes on electrocardiogram (ECG) indicating ischemia

2. Positive biomarker indicating myocardial necrosis


3. One of the following:

- Greater than or equal to 60 years of age

- Previous MI or coronary artery bypass graft (CABG)

- Coronary artery disease (CAD) with greater than or equal to 50% stenosis in greater than or equal to 2 vessels

- Previous ischemic stroke, transient ischemic attack (TIA; hospital-based diagnosis), carotid stenosis (greater than or equal to 50%), or cerebral revascularization

- Diabetes mellitus

- Peripheral artery disease

- Chronic renal dysfunction


B) Co-administration of ticagrelor with high maintenance dose ASA (greater than 150mg daily) is not recommended.

C) Definite stent thrombosis, according to the Academic Research Consortium, is a total occlusion originating in or within 5 mm of the stent, or is a visible thrombus within the stent, or is within 5 mm of the stent in the presence of an acute ischemic clinical syndrome within 48 hours. Definite stent thrombosis must be confirmed by angiography or by pathologic confirmation of acute thrombosis.

D) Ticagrelor is contraindicated in patients with active pathological bleeding, in those with a history of intracranial hemorrhage and moderate to severe hepatic impairment.

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00299"><name>TINZAPARIN SODIUM</name><pcgGroup lccId="00048"><pcg9 id="201200081"><itemNumber>0513</itemNumber><strength>2500IU/0.25mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="09857367" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>7.1400</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>7.1400</amountMOHLTCPays></drug></pcg9><pcg9 id="201200095"><itemNumber>0514</itemNumber><strength>8000IU/0.4mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02429462" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>22.2100</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>22.2100</amountMOHLTCPays></drug></pcg9><pcg9 id="201200096"><itemNumber>0515</itemNumber><strength>12000IU/0.6mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02429470" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>34.9820</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>34.9820</amountMOHLTCPays></drug></pcg9><pcg9 id="201200097"><itemNumber>0516</itemNumber><strength>16000IU/0.8mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02429489" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>46.6430</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>46.6430</amountMOHLTCPays></drug></pcg9><pcg9 id="201200044"><itemNumber>0517</itemNumber><strength>3500IU/0.35mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02358158" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>9.9860</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>9.9860</amountMOHLTCPays></drug></pcg9><pcg9 id="201200045"><itemNumber>0518</itemNumber><strength>4500IU/0.45mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02358166" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>12.8420</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>12.8420</amountMOHLTCPays></drug></pcg9><pcg9 id="201200046"><itemNumber>0519</itemNumber><strength>10000IU/0.5mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02231478" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>29.1240</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>29.1240</amountMOHLTCPays></drug></pcg9><pcg9 id="201200047"><itemNumber>0520</itemNumber><strength>14000IU/0.7mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02358174" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>40.8110</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>40.8110</amountMOHLTCPays></drug></pcg9><pcg9 id="201200048"><itemNumber>0521</itemNumber><strength>18000IU/0.9mL</strength><dosageForm>Inj Pref Syr</dosageForm><drug id="02358182" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>52.4660</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>52.4660</amountMOHLTCPays></drug></pcg9><pcg9 id="201200039"><itemNumber>0522</itemNumber><strength>10000IU/mL</strength><dosageForm>Inj-2mL Pk</dosageForm><drug id="02167840" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>53.9070</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>53.9070</amountMOHLTCPays></drug></pcg9><pcg9 id="201200042"><itemNumber>0523</itemNumber><strength>20000IU/mL</strength><dosageForm>Inj-2mL Pk</dosageForm><drug id="02229515" sec3="Y" sec12="Y"><name>Innohep</name><manufacturerId>LEO</manufacturerId><individualPrice>114.9800</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>114.9800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="186">For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks;</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="187">For DVT in pregnant or lactating females;</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="188">For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated;</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="189">For DVT in patients who have failed treatment with warfarin.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="323">For the acute treatment of pulmonary embolism, maximum of three weeks.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00292"><name>WARFARIN</name><note>The use of International Normalized Ratio (INR) instead of Prothrombin Time results to control warfarin dosing is strongly recommended. Prothrombin Time results can vary three-fold depending on the reagent used; INR corrects for this and substantially improves safety and efficacy of warfarin therapy.</note><pcgGroup><pcg9 id="201200026"><itemNumber>0524</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="01918311" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242680" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.0796</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0796</amountMOHLTCPays></drug><drug id="02242924" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.0796</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0796</amountMOHLTCPays></drug></pcg9><pcg9 id="201200027"><itemNumber>0525</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="01918338" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242681" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.0841</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0841</amountMOHLTCPays></drug><drug id="02242925" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.0841</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0841</amountMOHLTCPays></drug></pcg9><pcg9 id="201200010"><itemNumber>0526</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="01918346" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242682" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.0674</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0674</amountMOHLTCPays></drug><drug id="02242926" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.0674</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0674</amountMOHLTCPays></drug></pcg9><pcg9 id="201200062"><itemNumber>0527</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="02240205" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>2001-06-07</listingDate></drug><drug id="02242683" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.1043</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.1043</amountMOHLTCPays></drug><drug id="02245618" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.1043</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.1043</amountMOHLTCPays></drug></pcg9><pcg9 id="201200028"><itemNumber>0528</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02007959" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242684" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.1043</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1043</amountMOHLTCPays></drug><drug id="02242927" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.1043</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1043</amountMOHLTCPays></drug></pcg9><pcg9 id="201200035"><itemNumber>0529</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="01918354" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242685" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.0675</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0675</amountMOHLTCPays></drug><drug id="02242928" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.0675</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0675</amountMOHLTCPays></drug></pcg9><pcg9 id="201200077"><itemNumber>0530</itemNumber><strength>6mg</strength><dosageForm>Tab</dosageForm><drug id="02240206" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02242686" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.5160</individualPrice><listingDate>2008-12-03</listingDate></drug></pcg9><pcg9 id="201200008"><itemNumber>0531</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="01918362" notABenefit="Y" sec3="Y"><name>Coumadin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242687" sec3="Y"><name>Taro-Warfarin</name><manufacturerId>TAR</manufacturerId><individualPrice>.1211</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1211</amountMOHLTCPays></drug><drug id="02242929" sec3="Y"><name>Apo-Warfarin</name><manufacturerId>APX</manufacturerId><individualPrice>.1211</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1211</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="201204000"><name>COAGULANTS AND ANTI-COAGULANTS DIRECT FACTOR XA INHIBITORS</name><genericName id="02082"><name>EDOXABAN</name><pcgGroup><pcg9 id="201204001"><itemNumber>0532</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="02458640" sec3="Y"><name>Lixiana</name><manufacturerId>SEV</manufacturerId><individualPrice>2.9393</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>1.4697</amountMOHLTCPays></drug><drug id="02553414" sec3="Y"><name>Sandoz Edoxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.4697</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>1.4697</amountMOHLTCPays></drug><drug id="02554208" sec3="Y"><name>Teva-Edoxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>1.4697</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>1.4697</amountMOHLTCPays></drug></pcg9><pcg9 id="201204002"><itemNumber>0533</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02458659" sec3="Y"><name>Lixiana</name><manufacturerId>SEV</manufacturerId><individualPrice>2.9393</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug><drug id="02553422" sec3="Y"><name>Sandoz Edoxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7348</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug><drug id="02554216" sec3="Y"><name>Teva-Edoxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.7348</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug><drug id="02557282" sec3="Y"><name>Jamp Edoxaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.7348</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug></pcg9><pcg9 id="201204003"><itemNumber>0534</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="02458667" sec3="Y"><name>Lixiana</name><manufacturerId>SEV</manufacturerId><individualPrice>2.9393</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug><drug id="02553430" sec3="Y"><name>Sandoz Edoxaban</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7348</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug><drug id="02554224" sec3="Y"><name>Teva-Edoxaban</name><manufacturerId>TEV</manufacturerId><individualPrice>.7348</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug><drug id="02557290" sec3="Y"><name>Jamp Edoxaban</name><manufacturerId>JPC</manufacturerId><individualPrice>.7348</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.7348</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="201216000"><name>COAGULANTS AND ANTI-COAGULANTS HEMOSTATICS</name><genericName id="00302"><name>FILGRASTIM</name><pcgGroup lccId="00235"><pcg9 id="201216005"><itemNumber>0535</itemNumber><strength>480mcg/1.6mL</strength><dosageForm>1.6mL Vial</dosageForm><drug id="09853464" sec3="Y" sec12="Y"><name>Neupogen</name><manufacturerId>AMG</manufacturerId><individualPrice>281.8120</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>281.8120</amountMOHLTCPays></drug></pcg9><pcg9 id="201216002"><itemNumber>0536</itemNumber><strength>300mcg/mL</strength><dosageForm>1mL Vial</dosageForm><drug id="01968017" sec3="Y" sec12="Y"><name>Neupogen</name><manufacturerId>AMG</manufacturerId><individualPrice>176.1330</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>176.1330</amountMOHLTCPays></drug></pcg9><lccNote seq="008" reasonForUseId="682">For the treatment of low white blood cell count in patients who meet the following criteria:

- Patients who become pregnant during the transition period of July 31, 2024, to January 31, 2025.</lccNote><lccNote seq="009" type="R">LU Authorization Period: 12 months from date of authorization.</lccNote><lccNote seq="010" reasonForUseId="683">For the treatment of low white blood cell count in patients who meet the following criteria:

- Patients who require palliative care during the transition period of July 31, 2024, to January 31, 2025.

</lccNote><lccNote seq="011" type="R">LU Authorization Period: 12 months from date of authorization.</lccNote></pcgGroup></genericName><genericName id="00296"><name>TRANEXAMIC ACID</name><pcgGroup><pcg9 id="201216003"><itemNumber>0537</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02064405" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cyklokapron</name><manufacturerId>PFI</manufacturerId><listingDate>2013-04-30</listingDate></drug><drug id="02401231" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tranexamic Acid Tablets</name><manufacturerId>STE</manufacturerId><individualPrice>.8071</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.8071</amountMOHLTCPays></drug><drug id="02409097" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Gd-Tranexamic Acid</name><manufacturerId>GEM</manufacturerId><individualPrice>.8071</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>.8071</amountMOHLTCPays></drug><drug id="02496232" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Tranexamic Acid</name><manufacturerId>MAR</manufacturerId><individualPrice>.8071</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.8071</amountMOHLTCPays></drug><drug id="02519194" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tranexamic Acid</name><manufacturerId>JPC</manufacturerId><individualPrice>.8071</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.8071</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="201600000"><name>HEMATOPOIETIC AGENTS</name><genericName id="01573"><name>DARBEPOETIN ALFA</name><pcgGroup lccId="00213"><pcg9 id="201600013"><itemNumber>0538</itemNumber><strength>150mcg/0.3mL</strength><dosageForm>Pref Syr-0.3mL Pk</dosageForm><drug id="02391791" sec3="Y" sec12="Y"><name>Aranesp</name><manufacturerId>AMG</manufacturerId><individualPrice>402.0000</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>402.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600037"><itemNumber>0539</itemNumber><strength>200mcg/0.4mL</strength><dosageForm>Pref Syr-0.4mL Pk</dosageForm><drug id="02391805" sec3="Y" sec12="Y"><name>Aranesp</name><manufacturerId>AMG</manufacturerId><individualPrice>701.0200</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>701.0200</amountMOHLTCPays></drug></pcg9><pcg9 id="201600038"><itemNumber>0540</itemNumber><strength>300mcg/0.6mL</strength><dosageForm>Pref Syr-0.6mL Pk</dosageForm><drug id="02391821" sec3="Y" sec12="Y"><name>Aranesp</name><manufacturerId>AMG</manufacturerId><individualPrice>1082.9500</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>1082.9500</amountMOHLTCPays></drug></pcg9><pcg9 id="201600039"><itemNumber>0541</itemNumber><strength>500mcg/1.0mL</strength><dosageForm>Pref Syr-1.0mL Pk</dosageForm><drug id="02392364" sec3="Y" sec12="Y"><name>Aranesp</name><manufacturerId>AMG</manufacturerId><individualPrice>1804.9400</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>1804.9400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="420">ESAs (Eprex or Aranesp) for patients with:

-Cancer diagnosis and receiving chemotherapy; AND
-Presence of anemia caused by chemotherapy with a hemoglobin count less than 100g/L; AND
-Patient has been informed of the risks and benefits of ESA therapy 

AND

Anemia cannot be managed by use of blood transfusions due to at least one of the following:

-Religious beliefs do not allow the patient to receive transfusions.
-Previous severe (potentially life-threatening) reaction to a transfusion or difficulty cross-matching.
-Myeloid cancers that cannot be managed with blood transfusions
-Patient lives far away from treatment centre and/or transfusions cannot be coordinated with chemotherapy
-Patients receiving neoadjuvant chemotherapy with anemia and at risk of high blood losses due to surgery

Please refer to the product monograph for starting dose, dose adjustment and discontinuation recommendations.

NOTE: Health Canada has issued the following statements regarding ESA therapy for the treatment of anemia due to chemotherapy in patients with non-myeloid malignancies:

In patients with a long life expectancy, the decision to administer ESAs should be based on a benefit-risk assessment with the participation of the individual patient. This should take into account the specific clinical context such as (but not limited to) the type of tumor and its stage, the degree of anemia, life expectancy, the environment in which the patient is being treated and known risks of transfusions and ESAs.

If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.

ESAs are not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.

Health Canada has also issued the following Serious Warnings and Precautions for cancer patients regarding ESAs:

ESAs increased the risks for death and serious cardiovascular and thromboembolic events in some controlled clinical trials.

ESAs shortened overall survival and/or increased the risk of tumour progression or recurrence in some clinical studies in patients with breast, head and neck, lymphoid, cervical and non-small cell lung cancers when dosed to target a hemoglobin of greater than or equal to 120g/L.
   
To minimize the above risks, use the lowest dose needed to avoid red blood cell (RBC) transfusions.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.

Discontinue ESAs following completion of a chemotherapy course.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01883"><name>ELTROMBOPAG OLAMINE</name><pcgGroup><pcg9 id="201600049"><itemNumber>0542</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02361825" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Revolade</name><manufacturerId>GSK</manufacturerId><individualPrice>65.0000</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>55.2500</amountMOHLTCPays></drug><drug id="02506742" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Eltrombopag</name><manufacturerId>APX</manufacturerId><individualPrice>55.2500</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>55.2500</amountMOHLTCPays></drug></pcg9><pcg9 id="201600050"><itemNumber>0543</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02361833" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Revolade</name><manufacturerId>GSK</manufacturerId><individualPrice>130.0000</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>110.5000</amountMOHLTCPays></drug><drug id="02506769" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Eltrombopag</name><manufacturerId>APX</manufacturerId><individualPrice>110.5000</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>110.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00304"><name>EPOETIN ALFA</name><pcgGroup lccId="00214"><pcg9 id="201600002"><itemNumber>0544</itemNumber><strength>10,000IU/mL</strength><dosageForm>Pref Syr - 1mL Pk</dosageForm><drug id="02231587" sec3="Y" sec12="Y"><name>Eprex</name><manufacturerId>JAN</manufacturerId><individualPrice>142.5000</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>142.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600006"><itemNumber>0545</itemNumber><strength>40,000IU/mL</strength><dosageForm>Pref Syr - 1mL Pk</dosageForm><drug id="02240722" sec3="Y" sec12="Y"><name>Eprex</name><manufacturerId>JAN</manufacturerId><individualPrice>486.7900</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>486.7900</amountMOHLTCPays></drug></pcg9><pcg9 id="201600046"><itemNumber>0546</itemNumber><strength>20,000IU/0.5mL</strength><dosageForm>Pref Syr-0.5mL Pk</dosageForm><drug id="02243239" sec3="Y" sec12="Y"><name>Eprex</name><manufacturerId>JAN</manufacturerId><individualPrice>325.0900</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>325.0900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="420">ESAs (Eprex or Aranesp) for patients with:

-Cancer diagnosis and receiving chemotherapy; AND
-Presence of anemia caused by chemotherapy with a hemoglobin count less than 100g/L; AND
-Patient has been informed of the risks and benefits of ESA therapy 

AND

Anemia cannot be managed by use of blood transfusions due to at least one of the following:

-Religious beliefs do not allow the patient to receive transfusions.
-Previous severe (potentially life-threatening) reaction to a transfusion or difficulty cross-matching.
-Myeloid cancers that cannot be managed with blood transfusions
-Patient lives far away from treatment centre and/or transfusions cannot be coordinated with chemotherapy
-Patients receiving neoadjuvant chemotherapy with anemia and at risk of high blood losses due to surgery

Please refer to the product monograph for starting dose, dose adjustment and discontinuation recommendations.

NOTE: Health Canada has issued the following statements regarding ESA therapy for the treatment of anemia due to chemotherapy in patients with non-myeloid malignancies:

In patients with a long life expectancy, the decision to administer ESAs should be based on a benefit-risk assessment with the participation of the individual patient. This should take into account the specific clinical context such as (but not limited to) the type of tumor and its stage, the degree of anemia, life expectancy, the environment in which the patient is being treated and known risks of transfusions and ESAs.

If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.

ESAs are not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.

Health Canada has also issued the following Serious Warnings and Precautions for cancer patients regarding ESAs:

ESAs increased the risks for death and serious cardiovascular and thromboembolic events in some controlled clinical trials.

ESAs shortened overall survival and/or increased the risk of tumour progression or recurrence in some clinical studies in patients with breast, head and neck, lymphoid, cervical and non-small cell lung cancers when dosed to target a hemoglobin of greater than or equal to 120g/L.
   
To minimize the above risks, use the lowest dose needed to avoid red blood cell (RBC) transfusions.

Use ESAs only for treatment of anemia due to concomitant myelosuppressive chemotherapy.
If appropriate, red blood cell transfusion should be the preferred treatment for the management of anemia in patients with a long life expectancy and who are receiving myelosuppressive chemotherapy.

Discontinue ESAs following completion of a chemotherapy course.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00302"><name>FILGRASTIM</name><pcgGroup><pcg9 id="201600056"><itemNumber>0547</itemNumber><strength>300mcg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr</dosageForm><drug id="02485575" sec3="Y"><name>Nivestym</name><manufacturerId>PFI</manufacturerId><individualPrice>138.5376</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>138.5376</amountMOHLTCPays></drug></pcg9><pcg9 id="201600065"><itemNumber>0548</itemNumber><strength>300mcg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr (Preservative-Free)</dosageForm><drug id="02520990" sec3="Y"><name>Nypozi</name><manufacturerId>TAV</manufacturerId><individualPrice>138.5376</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>138.5376</amountMOHLTCPays></drug></pcg9><pcg9 id="201600067"><itemNumber>0549</itemNumber><strength>300mcg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr (Preservative-Free)</dosageForm><drug id="02556537" sec3="Y"><name>Filra</name><manufacturerId>JPC</manufacturerId><individualPrice>105.6798</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>105.6798</amountMOHLTCPays></drug></pcg9><pcg9 id="201600058"><itemNumber>0550</itemNumber><strength>480mcg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr</dosageForm><drug id="02485583" sec3="Y"><name>Nivestym</name><manufacturerId>PFI</manufacturerId><individualPrice>221.6640</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>221.6640</amountMOHLTCPays></drug></pcg9><pcg9 id="201600066"><itemNumber>0551</itemNumber><strength>480mcg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02521008" sec3="Y"><name>Nypozi</name><manufacturerId>TAV</manufacturerId><individualPrice>221.6640</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>221.6640</amountMOHLTCPays></drug></pcg9><pcg9 id="201600068"><itemNumber>0552</itemNumber><strength>480mcg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02556545" sec3="Y"><name>Filra</name><manufacturerId>JPC</manufacturerId><individualPrice>169.0872</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>169.0872</amountMOHLTCPays></drug></pcg9><pcg9 id="201600059"><itemNumber>0553</itemNumber><strength>480mcg/1.6mL</strength><dosageForm>Inj Sol-1.6mL Vial Pk</dosageForm><drug id="02485656" sec3="Y"><name>Nivestym</name><manufacturerId>PFI</manufacturerId><individualPrice>221.6640</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>221.6640</amountMOHLTCPays></drug></pcg9><pcg9 id="201600057"><itemNumber>0554</itemNumber><strength>300mcg/mL</strength><dosageForm>Inj Sol-1mL Vial Pk</dosageForm><drug id="02485591" sec3="Y"><name>Nivestym</name><manufacturerId>PFI</manufacturerId><individualPrice>138.5376</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>138.5376</amountMOHLTCPays></drug></pcg9><pcg9 id="201600051"><itemNumber>0555</itemNumber><strength>300mcg/0.5mL</strength><dosageForm>Pref Syr-0.5mL Pk</dosageForm><drug id="02441489" sec3="Y"><name>Grastofil</name><manufacturerId>APX</manufacturerId><individualPrice>138.5380</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>138.5380</amountMOHLTCPays></drug></pcg9><pcg9 id="201600052"><itemNumber>0556</itemNumber><strength>480mcg/0.8mL</strength><dosageForm>Pref Syr-0.8mL Pk</dosageForm><drug id="02454548" sec3="Y"><name>Grastofil</name><manufacturerId>APX</manufacturerId><individualPrice>221.6600</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>221.6600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02097"><name>PEGFILGRASTIM</name><pcgGroup><pcg9 id="201600064"><itemNumber>0557</itemNumber><strength>6mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02529343" sec3="Y"><name>Lapelga</name><manufacturerId>APX</manufacturerId><individualPrice>1375.0000</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>1375.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600060"><itemNumber>0558</itemNumber><strength>6mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02497395" sec3="Y"><name>Ziextenzo</name><manufacturerId>SDZ</manufacturerId><individualPrice>492.0000</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>492.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600069"><itemNumber>0559</itemNumber><strength>6mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02546973" sec3="Y"><name>Niopeg</name><manufacturerId>NRA</manufacturerId><individualPrice>492.0000</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>492.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600070"><itemNumber>0560</itemNumber><strength>6mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr (Preservative-Free)</dosageForm><drug id="02553945" sec3="Y"><name>Pexegra</name><manufacturerId>JPC</manufacturerId><individualPrice>492.0000</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>492.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600061"><itemNumber>0561</itemNumber><strength>6mg/0.6mL</strength><dosageForm>Inj Sol-0.6mL Pref Syr Pk  (Preservative-Free)</dosageForm><drug id="02506238" sec3="Y"><name>Nyvepria</name><manufacturerId>PFI</manufacturerId><individualPrice>1375.0000</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>1375.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600055"><itemNumber>0562</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02484153" sec3="Y"><name>Fulphila</name><manufacturerId>BCL</manufacturerId><individualPrice>492.0000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>492.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="201600054"><itemNumber>0563</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol-Pref Syr - 0.6mL Pk (Preservative Free)</dosageForm><drug id="02474565" sec3="Y"><name>Lapelga</name><manufacturerId>APX</manufacturerId><individualPrice>492.0000</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>492.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="202400000"><name>HEMORRHEOLOGIC AGENTS</name><genericName id="00306"><name>PENTOXIFYLLINE</name><pcgGroup lccId="00049"><pcg9 id="202400001"><itemNumber>0564</itemNumber><strength>400mg</strength><dosageForm>SR Tab</dosageForm><drug id="02221977" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Trental</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="02230090" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Pentoxifylline SR</name><manufacturerId>AAP</manufacturerId><individualPrice>.7238</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.7238</amountMOHLTCPays></drug><drug id="02543087" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Pentoxifylline SR</name><manufacturerId>JPC</manufacturerId><individualPrice>.7238</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>.7238</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="76">For the treatment of patients with critical limb ischemia (with arterial ulcers, gangrene and/or rest pain) and documented arterial vascular disease.</lccNote><lccNote seq="002" type="N">Limited Use form must specify if arterial ulcers, gangrene and/or rest pain are present.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="529">For the treatment of patients with venous ulcers lasting, or expected to last, more than 8 weeks. 

Treatment should be discontinued after 3 months if there is no indication of objective benefit. 

The duration of therapy with pentoxifylline should not exceed 12 months.</lccNote><lccNote seq="005" type="N">Pentoxifylline should be used in combination with compression therapy.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6></pcg2><pcg2 id="240000000"><name>CARDIOVASCULAR DRUGS</name><pcg6 id="240400000"><name>CARDIAC DRUGS</name><genericName id="00325"><name>ACEBUTOLOL HCL</name><pcgGroup><pcg9 id="240400084"><itemNumber>0565</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>.3742</dailyCost><drug id="01926543" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Sectral</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02147602" chronicUseMed="Y" sec3="Y"><name>Apo-Acebutolol</name><manufacturerId>APX</manufacturerId><individualPrice>.1871</individualPrice><dailyCost>.3742</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1871</amountMOHLTCPays></drug><drug id="02204517" chronicUseMed="Y" sec3="Y"><name>Teva-Acebutolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1871</individualPrice><dailyCost>.3742</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1871</amountMOHLTCPays></drug></pcg9><pcg9 id="240400085"><itemNumber>0566</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><dailyCost>.5616</dailyCost><drug id="01926551" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Sectral</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02147610" chronicUseMed="Y" sec3="Y"><name>Apo-Acebutolol</name><manufacturerId>APX</manufacturerId><individualPrice>.2808</individualPrice><dailyCost>.5616</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2808</amountMOHLTCPays></drug><drug id="02204525" chronicUseMed="Y" sec3="Y"><name>Teva-Acebutolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.2808</individualPrice><dailyCost>.5616</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2808</amountMOHLTCPays></drug></pcg9><pcg9 id="240400116"><itemNumber>0567</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.0696</dailyCost><drug id="01926578" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Sectral</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02147629" chronicUseMed="Y" sec3="Y"><name>Apo-Acebutolol</name><manufacturerId>APX</manufacturerId><individualPrice>.5348</individualPrice><dailyCost>1.0696</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5348</amountMOHLTCPays></drug><drug id="02204533" chronicUseMed="Y" sec3="Y"><name>Teva-Acebutolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.5348</individualPrice><dailyCost>1.0696</dailyCost><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.5348</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00323"><name>AMIODARONE HCL</name><pcgGroup><pcg9 id="240400072"><itemNumber>0568</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02036282" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cordarone</name><manufacturerId>PFI</manufacturerId><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.
</note><listingDate>1996-10-01</listingDate></drug><drug id="02239835" chronicUseMed="Y" sec3="Y"><name>Teva-Amiodarone</name><manufacturerId>TEV</manufacturerId><individualPrice>.3706</individualPrice><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02242472" chronicUseMed="Y" sec3="Y"><name>PMS-Amiodarone</name><manufacturerId>PMS</manufacturerId><individualPrice>.3706</individualPrice><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02243836" chronicUseMed="Y" sec3="Y"><name>Sandoz Amiodarone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3706</individualPrice><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02246194" chronicUseMed="Y" sec3="Y"><name>Apo-Amiodarone</name><manufacturerId>APX</manufacturerId><individualPrice>.3706</individualPrice><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02247217" chronicUseMed="Y" sec3="Y"><name>Riva-Amiodarone</name><manufacturerId>RIA</manufacturerId><individualPrice>.3706</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02364336" chronicUseMed="Y" sec3="Y"><name>Amiodarone</name><manufacturerId>SAI</manufacturerId><individualPrice>.3706</individualPrice><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02385465" chronicUseMed="Y" sec3="Y"><name>Amiodarone</name><manufacturerId>SIV</manufacturerId><individualPrice>.3706</individualPrice><note>The manufacturer recommends that treatment with amiodarone be initiated in hospital and continued in a monitored environment under the care of a cardiologist, or internist with equivalent experience in such care.</note><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug><drug id="02531844" chronicUseMed="Y" sec3="Y"><name>Jamp Amiodarone</name><manufacturerId>JPC</manufacturerId><individualPrice>.3706</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.3706</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00328"><name>AMLODIPINE</name><pcgGroup lccId="00369"><pcg9 id="240400176"><itemNumber>0569</itemNumber><strength>1mg/mL</strength><dosageForm>Oral Sol</dosageForm><drug id="02484706" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PDP-Amlodipine</name><manufacturerId>PEN</manufacturerId><individualPrice>1.1667</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>1.1667</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="645">For patients unable to swallow or tolerate oral solid dosage forms of amlodipine.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="706">For pediatric patients (less than 18 years of age) where the appropriate dose cannot be achieved using a listed solid oral dosage form of amlodipine.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="240400179"><itemNumber>0570</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="00878901" notABenefit="Y" sec3b="Y" sec3="Y"><name>Norvasc</name><manufacturerId>UJC</manufacturerId><listingDate>2024-12-30</listingDate></drug><drug id="02295148" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Amlodipine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-02-28</listingDate></drug><drug id="02330474" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Amlodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02357186" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Amlodipine</name><manufacturerId>JPC</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-06-30</listingDate></drug><drug id="02371707" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Amlodipine</name><manufacturerId>MAR</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-03-31</listingDate></drug><drug id="02385783" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-02-28</listingDate></drug><drug id="02419556" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ach-Amlodipine</name><manufacturerId>ACH</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-09-29</listingDate></drug><drug id="02468018" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Amlodipine</name><manufacturerId>MAT</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-04-30</listingDate></drug><drug id="02478587" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3328</individualPrice><listingDate>2025-03-31</listingDate></drug></pcg9><pcg9 id="240400120"><itemNumber>0571</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1343</dailyCost><drug id="00878928" chronicUseMed="Y" sec3="Y"><name>Norvasc</name><manufacturerId>UJC</manufacturerId><individualPrice>1.7387</individualPrice><dailyCost>1.7387</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02250497" chronicUseMed="Y" sec3="Y"><name>Teva-Amlodipine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02259605" chronicUseMed="Y" sec3="Y"><name>Ratio-Amlodipine</name><manufacturerId>RPH</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02272113" chronicUseMed="Y" sec3="Y"><name>Mylan-Amlodipine</name><manufacturerId>MYL</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02273373" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02280132" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine</name><manufacturerId>GEM</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02284065" chronicUseMed="Y" sec3="Y"><name>PMS-Amlodipine</name><manufacturerId>PMS</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02284383" chronicUseMed="Y" sec3="Y"><name>Sandoz Amlodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02297485" chronicUseMed="Y" sec3="Y"><name>Act Amlodipine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02321858" chronicUseMed="Y" sec3="Y"><name>Ran-Amlodipine</name><manufacturerId>RAN</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02331284" chronicUseMed="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02357194" chronicUseMed="Y" sec3="Y"><name>Jamp-Amlodipine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02357712" chronicUseMed="Y" sec3="Y"><name>Septa-Amlodipine</name><manufacturerId>SET</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02362651" chronicUseMed="Y" sec3="Y"><name>Mint-Amlodipine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02371715" chronicUseMed="Y" sec3="Y"><name>Mar-Amlodipine Tablets</name><manufacturerId>MAR</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02385791" chronicUseMed="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>SIV</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02397072" chronicUseMed="Y" sec3="Y"><name>Auro-Amlodipine</name><manufacturerId>AUR</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02419564" chronicUseMed="Y" sec3="Y"><name>Ach-Amlodipine</name><manufacturerId>ACH</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02429217" chronicUseMed="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02468026" chronicUseMed="Y" sec3="Y"><name>M-Amlodipine</name><manufacturerId>MAT</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02476460" chronicUseMed="Y" sec3="Y"><name>NRA-Amlodipine</name><manufacturerId>NRA</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug><drug id="02522519" chronicUseMed="Y" sec3="Y"><name>PRZ-Amlodipine</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1343</individualPrice><dailyCost>.1343</dailyCost><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.1343</amountMOHLTCPays></drug></pcg9><pcg9 id="240400121"><itemNumber>0572</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1993</dailyCost><drug id="00878936" chronicUseMed="Y" sec3="Y"><name>Norvasc</name><manufacturerId>UJC</manufacturerId><individualPrice>2.5378</individualPrice><dailyCost>2.5378</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02250500" chronicUseMed="Y" sec3="Y"><name>Teva-Amlodipine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02259613" chronicUseMed="Y" sec3="Y"><name>Ratio-Amlodipine</name><manufacturerId>RPH</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02272121" chronicUseMed="Y" sec3="Y"><name>Mylan-Amlodipine</name><manufacturerId>MYL</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02273381" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02280140" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine</name><manufacturerId>GEM</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02284073" chronicUseMed="Y" sec3="Y"><name>PMS-Amlodipine</name><manufacturerId>PMS</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02284391" chronicUseMed="Y" sec3="Y"><name>Sandoz Amlodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02297493" chronicUseMed="Y" sec3="Y"><name>Act Amlodipine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02321866" chronicUseMed="Y" sec3="Y"><name>Ran-Amlodipine</name><manufacturerId>RAN</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02331292" chronicUseMed="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02357208" chronicUseMed="Y" sec3="Y"><name>Jamp-Amlodipine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02357720" chronicUseMed="Y" sec3="Y"><name>Septa-Amlodipine</name><manufacturerId>SET</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02362678" chronicUseMed="Y" sec3="Y"><name>Mint-Amlodipine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02371723" chronicUseMed="Y" sec3="Y"><name>Mar-Amlodipine Tablets</name><manufacturerId>MAR</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02385805" chronicUseMed="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>SIV</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02397080" chronicUseMed="Y" sec3="Y"><name>Auro-Amlodipine</name><manufacturerId>AUR</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02419572" chronicUseMed="Y" sec3="Y"><name>Ach-Amlodipine</name><manufacturerId>ACH</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02429225" chronicUseMed="Y" sec3="Y"><name>Amlodipine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02468034" chronicUseMed="Y" sec3="Y"><name>M-Amlodipine</name><manufacturerId>MAT</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02476479" chronicUseMed="Y" sec3="Y"><name>NRA-Amlodipine</name><manufacturerId>NRA</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug><drug id="02522527" chronicUseMed="Y" sec3="Y"><name>PRZ-Amlodipine</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1993</individualPrice><dailyCost>.1993</dailyCost><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.1993</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00324"><name>ATENOLOL</name><pcgGroup><pcg9 id="240400079"><itemNumber>0573</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.0938</dailyCost><drug id="00773689" chronicUseMed="Y" sec3="Y"><name>Apo-Atenol</name><manufacturerId>APX</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="01912062" chronicUseMed="Y" sec3="Y"><name>Teva-Atenolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02039532" chronicUseMed="Y" sec3="Y"><name>Tenormin</name><manufacturerId>AZC</manufacturerId><individualPrice>.6150</individualPrice><dailyCost>.6150</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02171791" chronicUseMed="Y" sec3="Y"><name>Ratio-Atenolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02237600" chronicUseMed="Y" sec3="Y"><name>PMS-Atenolol</name><manufacturerId>PMS</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02238316" chronicUseMed="Y" sec3="Y"><name>Atenolol</name><manufacturerId>SIV</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02267985" chronicUseMed="Y" sec3="Y"><name>Ran-Atenolol</name><manufacturerId>RAN</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02367564" chronicUseMed="Y" sec3="Y"><name>Jamp-Atenolol</name><manufacturerId>JPC</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02368021" chronicUseMed="Y" sec3="Y"><name>Mint-Atenol</name><manufacturerId>MIN</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02368641" chronicUseMed="Y" sec3="Y"><name>Septa-Atenolol</name><manufacturerId>SET</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02369184" chronicUseMed="Y" sec3="Y"><name>AG-Atenolol</name><manufacturerId>ANG</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02371987" chronicUseMed="Y" sec3="Y"><name>Mar-Atenolol</name><manufacturerId>MAR</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug><drug id="02466465" chronicUseMed="Y" sec3="Y"><name>Atenolol</name><manufacturerId>SAI</manufacturerId><individualPrice>.0938</individualPrice><dailyCost>.0938</dailyCost><listingDate>2018-04-01</listingDate><amountMOHLTCPays>.0938</amountMOHLTCPays></drug></pcg9><pcg9 id="240400078"><itemNumber>0574</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1543</dailyCost><drug id="00773697" chronicUseMed="Y" sec3="Y"><name>Apo-Atenol</name><manufacturerId>APX</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="01912054" chronicUseMed="Y" sec3="Y"><name>Teva-Atenolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02039540" chronicUseMed="Y" sec3="Y"><name>Tenormin</name><manufacturerId>AZC</manufacturerId><individualPrice>1.0117</individualPrice><dailyCost>1.0117</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02171805" chronicUseMed="Y" sec3="Y"><name>Ratio-Atenolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02237601" chronicUseMed="Y" sec3="Y"><name>PMS-Atenolol</name><manufacturerId>PMS</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02238318" chronicUseMed="Y" sec3="Y"><name>Atenolol</name><manufacturerId>SIV</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02267993" chronicUseMed="Y" sec3="Y"><name>Ran-Atenolol</name><manufacturerId>RAN</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02367572" chronicUseMed="Y" sec3="Y"><name>Jamp-Atenolol</name><manufacturerId>JPC</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02368048" chronicUseMed="Y" sec3="Y"><name>Mint-Atenol</name><manufacturerId>MIN</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02368668" chronicUseMed="Y" sec3="Y"><name>Septa-Atenolol</name><manufacturerId>SET</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02369192" chronicUseMed="Y" sec3="Y"><name>AG-Atenolol</name><manufacturerId>ANG</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02371995" chronicUseMed="Y" sec3="Y"><name>Mar-Atenolol</name><manufacturerId>MAR</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug><drug id="02466473" chronicUseMed="Y" sec3="Y"><name>Atenolol</name><manufacturerId>SAI</manufacturerId><individualPrice>.1543</individualPrice><dailyCost>.1543</dailyCost><listingDate>2018-04-01</listingDate><amountMOHLTCPays>.1543</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01508"><name>BISOPROLOL FUMARATE</name><pcgGroup><pcg9 id="240400177"><itemNumber>0575</itemNumber><strength>1.25mg</strength><dosageForm>Tab</dosageForm><drug id="02544245" chronicUseMed="Y" sec3="Y"><name>Sandoz Bisoprolol Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0152</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.0152</amountMOHLTCPays></drug></pcg9><pcg9 id="240400178"><itemNumber>0576</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02544253" chronicUseMed="Y" sec3="Y"><name>Sandoz Bisoprolol Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0303</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.0303</amountMOHLTCPays></drug></pcg9><pcg9 id="240400157"><itemNumber>0577</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02241148" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Monocor</name><manufacturerId>BIO</manufacturerId><listingDate>2001-06-07</listingDate></drug><drug id="02256134" chronicUseMed="Y" sec3="Y"><name>Apo-Bisoprolol</name><manufacturerId>APX</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2004-11-16</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02267470" chronicUseMed="Y" sec3="Y"><name>Teva-Bisoprolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2005-08-19</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02391589" chronicUseMed="Y" sec3="Y"><name>Bisoprolol</name><manufacturerId>SAI</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02465612" chronicUseMed="Y" sec3="Y"><name>Mint-Bisoprolol</name><manufacturerId>MIN</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02494035" chronicUseMed="Y" sec3="Y"><name>Sandoz Bisoprolol Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02495562" chronicUseMed="Y" sec3="Y"><name>Bisoprolol Tablets</name><manufacturerId>SIV</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug><drug id="02518805" chronicUseMed="Y" sec3="Y"><name>Jamp Bisoprolol</name><manufacturerId>JPC</manufacturerId><individualPrice>.0606</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.0606</amountMOHLTCPays></drug></pcg9><pcg9 id="240400158"><itemNumber>0578</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02241149" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Monocor</name><manufacturerId>CRY</manufacturerId><listingDate>2001-06-07</listingDate></drug><drug id="02256177" chronicUseMed="Y" sec3="Y"><name>Apo-Bisoprolol</name><manufacturerId>APX</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2004-11-16</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug><drug id="02267489" chronicUseMed="Y" sec3="Y"><name>Teva-Bisoprolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2005-08-19</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug><drug id="02391597" chronicUseMed="Y" sec3="Y"><name>Bisoprolol</name><manufacturerId>SAI</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug><drug id="02465620" chronicUseMed="Y" sec3="Y"><name>Mint-Bisoprolol</name><manufacturerId>MIN</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug><drug id="02494043" chronicUseMed="Y" sec3="Y"><name>Sandoz Bisoprolol Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug><drug id="02495570" chronicUseMed="Y" sec3="Y"><name>Bisoprolol Tablets</name><manufacturerId>SIV</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug><drug id="02518791" chronicUseMed="Y" sec3="Y"><name>Jamp Bisoprolol</name><manufacturerId>JPC</manufacturerId><individualPrice>.0885</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.0885</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00334"><name>CARVEDILOL</name><pcgGroup lccId="00050"><pcg9 id="240400140"><itemNumber>0579</itemNumber><strength>3.125mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4120</dailyCost><drug id="02229650" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Coreg</name><manufacturerId>GSK</manufacturerId><listingDate>1997-04-10</listingDate></drug><drug id="02245914" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Carvedilol</name><manufacturerId>PMS</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02247933" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Carvedilol</name><manufacturerId>APX</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02248752" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SIV</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02252309" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Carvedilol</name><manufacturerId>RPH</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02268027" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Carvedilol</name><manufacturerId>RAN</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2005-12-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02364913" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SAI</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02368897" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Carvedilol</name><manufacturerId>JPC</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02418495" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Carvedilol</name><manufacturerId>AUR</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug></pcg9><pcg9 id="240400141"><itemNumber>0580</itemNumber><strength>6.25mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4120</dailyCost><drug id="02229651" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Coreg</name><manufacturerId>GSK</manufacturerId><listingDate>1997-04-10</listingDate></drug><drug id="02245915" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Carvedilol</name><manufacturerId>PMS</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02247934" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Carvedilol</name><manufacturerId>APX</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02248753" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SIV</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02252317" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Carvedilol</name><manufacturerId>RPH</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02268035" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Carvedilol</name><manufacturerId>RAN</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2005-12-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02364921" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SAI</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02368900" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Carvedilol</name><manufacturerId>JPC</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02418509" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Carvedilol</name><manufacturerId>AUR</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug></pcg9><pcg9 id="240400142"><itemNumber>0581</itemNumber><strength>12.5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4120</dailyCost><drug id="02229652" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Coreg</name><manufacturerId>GSK</manufacturerId><listingDate>1997-04-10</listingDate></drug><drug id="02245916" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Carvedilol</name><manufacturerId>PMS</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02247935" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Carvedilol</name><manufacturerId>APX</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02248754" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SIV</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02252325" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Carvedilol</name><manufacturerId>RPH</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02268043" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Carvedilol</name><manufacturerId>RAN</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2005-12-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02364948" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SAI</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02368919" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Carvedilol</name><manufacturerId>JPC</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02418517" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Carvedilol</name><manufacturerId>AUR</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug></pcg9><pcg9 id="240400143"><itemNumber>0582</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4120</dailyCost><drug id="02229653" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Coreg</name><manufacturerId>GSK</manufacturerId><listingDate>1997-04-10</listingDate></drug><drug id="02245917" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Carvedilol</name><manufacturerId>PMS</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02247936" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Carvedilol</name><manufacturerId>APX</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02248755" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SIV</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02252333" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Carvedilol</name><manufacturerId>RPH</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02268051" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Carvedilol</name><manufacturerId>RAN</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2005-12-06</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02364956" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Carvedilol</name><manufacturerId>SAI</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02368927" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Carvedilol</name><manufacturerId>JPC</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug><drug id="02418525" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Carvedilol</name><manufacturerId>AUR</manufacturerId><individualPrice>.2060</individualPrice><dailyCost>.4120</dailyCost><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2060</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For patients with:</lccNote><lccNote seq="002" reasonForUseId="183">a) NYHA Class II or III Congestive Heart Failure (CHF); and
b) Currently being treated with an angiotensin converting enzyme (ACE) inhibitor, diuretics with or without digoxin, or previously treated, and failed these agents; and
c) An ejection fraction less than or equal to 35%; and 
d) At least one episode of symptomatic CHF within a 12 month period while receiving optimal management.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00307"><name>DIGOXIN</name><note>Digoxin toxicity is common and serious: digoxin levels should be monitored in the elderly, after adding drugs that affect urea clearance including diuretics, particularly spironolactone; verapamil and quinidine also interact significantly with digoxin. Dose should be reduced in renal impairment and in elderly patients. Chronic therapy should be re-evaluated.</note><pcgGroup><pcg9 id="240400004"><itemNumber>0583</itemNumber><strength>0.05mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02242320" sec3="Y"><name>PMS-Digoxin</name><manufacturerId>PMS</manufacturerId><individualPrice>.3692</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.3692</amountMOHLTCPays></drug></pcg9><pcg9 id="240400090"><itemNumber>0584</itemNumber><strength>0.0625mg</strength><dosageForm>Tab</dosageForm><drug id="02335700" chronicUseMed="Y" sec3="Y"><name>PMS-Digoxin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1850</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1089</amountMOHLTCPays></drug><drug id="02498502" chronicUseMed="Y" sec3="Y"><name>Jamp Digoxin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1089</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>.1089</amountMOHLTCPays></drug><drug id="02554399" chronicUseMed="Y" sec3="Y"><name>Auro-Digoxin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1089</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>.1089</amountMOHLTCPays></drug></pcg9><pcg9 id="240400003"><itemNumber>0585</itemNumber><strength>0.125mg</strength><dosageForm>Tab</dosageForm><drug id="02335719" chronicUseMed="Y" sec3="Y"><name>PMS-Digoxin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1751</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1030</amountMOHLTCPays></drug><drug id="02498510" chronicUseMed="Y" sec3="Y"><name>Jamp Digoxin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1030</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>.1030</amountMOHLTCPays></drug><drug id="02554402" chronicUseMed="Y" sec3="Y"><name>Auro-Digoxin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1030</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>.1030</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00320"><name>DILTIAZEM HCL</name><pcgGroup><pcg9 id="240400161"><itemNumber>0586</itemNumber><strength>120mg</strength><dosageForm>ER Tab</dosageForm><drug id="02256738" chronicUseMed="Y" sec3="Y"><name>Tiazac XC</name><manufacturerId>BIO</manufacturerId><individualPrice>1.0697</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>1.0697</amountMOHLTCPays></drug></pcg9><pcg9 id="240400162"><itemNumber>0587</itemNumber><strength>180mg</strength><dosageForm>ER Tab</dosageForm><drug id="02256746" chronicUseMed="Y" sec3="Y"><name>Tiazac XC</name><manufacturerId>BIO</manufacturerId><individualPrice>1.4218</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>.9195</amountMOHLTCPays></drug><drug id="02429322" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem XC</name><manufacturerId>TEV</manufacturerId><individualPrice>.9195</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.9195</amountMOHLTCPays></drug></pcg9><pcg9 id="240400163"><itemNumber>0588</itemNumber><strength>240mg</strength><dosageForm>ER Tab</dosageForm><drug id="02256754" chronicUseMed="Y" sec3="Y"><name>Tiazac XC</name><manufacturerId>BIO</manufacturerId><individualPrice>1.8882</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>1.2212</amountMOHLTCPays></drug><drug id="02429330" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem XC</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2212</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>1.2212</amountMOHLTCPays></drug></pcg9><pcg9 id="240400164"><itemNumber>0589</itemNumber><strength>300mg</strength><dosageForm>ER Tab</dosageForm><drug id="02256762" chronicUseMed="Y" sec3="Y"><name>Tiazac XC</name><manufacturerId>BIO</manufacturerId><individualPrice>1.8825</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>1.2175</amountMOHLTCPays></drug><drug id="02429349" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem XC</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2175</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>1.2175</amountMOHLTCPays></drug></pcg9><pcg9 id="240400165"><itemNumber>0590</itemNumber><strength>360mg</strength><dosageForm>ER Tab</dosageForm><drug id="02256770" chronicUseMed="Y" sec3="Y"><name>Tiazac XC</name><manufacturerId>BIO</manufacturerId><individualPrice>1.8880</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>1.2211</amountMOHLTCPays></drug><drug id="02429357" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem XC</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2211</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>1.2211</amountMOHLTCPays></drug></pcg9><pcg9 id="240400133"><itemNumber>0591</itemNumber><strength>120mg</strength><dosageForm>LA Cap</dosageForm><dailyCost>.3634</dailyCost><drug id="02097249" chronicUseMed="Y" sec3="Y"><name>Cardizem CD</name><manufacturerId>VAL</manufacturerId><individualPrice>1.6244</individualPrice><dailyCost>1.6244</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02230997" chronicUseMed="Y" sec3="Y"><name>Apo-Diltiaz CD</name><manufacturerId>APX</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02242538" chronicUseMed="Y" sec3="Y"><name>Teva-Diltazem CD</name><manufacturerId>TEV</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02243338" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem CD</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02370611" chronicUseMed="Y" sec3="Y"><name>Co Diltiazem CD</name><manufacturerId>COB</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02400421" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SAI</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02445999" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SIV</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02484064" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem CD</name><manufacturerId>MAR</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02528037" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem CD</name><manufacturerId>JPC</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug><drug id="02546086" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem CD</name><manufacturerId>MAT</manufacturerId><individualPrice>.3634</individualPrice><dailyCost>.3634</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.3634</amountMOHLTCPays></drug></pcg9><pcg9 id="240400123"><itemNumber>0592</itemNumber><strength>180mg</strength><dosageForm>LA Cap</dosageForm><dailyCost>.4824</dailyCost><drug id="02097257" chronicUseMed="Y" sec3="Y"><name>Cardizem CD</name><manufacturerId>VAL</manufacturerId><individualPrice>2.1565</individualPrice><dailyCost>2.1565</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02230998" chronicUseMed="Y" sec3="Y"><name>Apo-Diltiaz CD</name><manufacturerId>APX</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02242539" chronicUseMed="Y" sec3="Y"><name>Teva-Diltazem CD</name><manufacturerId>TEV</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02243339" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem CD</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02370638" chronicUseMed="Y" sec3="Y"><name>Co Diltiazem CD</name><manufacturerId>COB</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02400448" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SAI</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02446006" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SIV</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02484072" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem CD</name><manufacturerId>MAR</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02528045" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem CD</name><manufacturerId>JPC</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug><drug id="02546094" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem CD</name><manufacturerId>MAT</manufacturerId><individualPrice>.4824</individualPrice><dailyCost>.4824</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.4824</amountMOHLTCPays></drug></pcg9><pcg9 id="240400122"><itemNumber>0593</itemNumber><strength>240mg</strength><dosageForm>LA Cap</dosageForm><dailyCost>.6399</dailyCost><drug id="02097265" chronicUseMed="Y" sec3="Y"><name>Cardizem CD</name><manufacturerId>VAL</manufacturerId><individualPrice>2.8604</individualPrice><dailyCost>2.8604</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02230999" chronicUseMed="Y" sec3="Y"><name>Apo-Diltiaz CD</name><manufacturerId>APX</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02242540" chronicUseMed="Y" sec3="Y"><name>Teva-Diltazem CD</name><manufacturerId>TEV</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02243340" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem CD</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02370646" chronicUseMed="Y" sec3="Y"><name>Co Diltiazem CD</name><manufacturerId>COB</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02400456" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SAI</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02446014" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SIV</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02484080" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem CD</name><manufacturerId>MAR</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02528053" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem CD</name><manufacturerId>JPC</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug><drug id="02546108" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem CD</name><manufacturerId>MAT</manufacturerId><individualPrice>.6399</individualPrice><dailyCost>.6399</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.6399</amountMOHLTCPays></drug></pcg9><pcg9 id="240400134"><itemNumber>0594</itemNumber><strength>300mg</strength><dosageForm>LA Cap</dosageForm><dailyCost>.7999</dailyCost><drug id="02097273" chronicUseMed="Y" sec3="Y"><name>Cardizem CD</name><manufacturerId>VAL</manufacturerId><individualPrice>3.5755</individualPrice><dailyCost>3.5755</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02229526" chronicUseMed="Y" sec3="Y"><name>Apo-Diltiaz CD</name><manufacturerId>APX</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02242541" chronicUseMed="Y" sec3="Y"><name>Teva-Diltazem CD</name><manufacturerId>TEV</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02243341" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem CD</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02370654" chronicUseMed="Y" sec3="Y"><name>Co Diltiazem CD</name><manufacturerId>COB</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02400464" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SAI</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02446022" chronicUseMed="Y" sec3="Y"><name>Diltiazem CD</name><manufacturerId>SIV</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02484099" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem CD</name><manufacturerId>MAR</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02528061" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem CD</name><manufacturerId>JPC</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug><drug id="02546116" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem CD</name><manufacturerId>MAT</manufacturerId><individualPrice>.7999</individualPrice><dailyCost>.7999</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.7999</amountMOHLTCPays></drug></pcg9><pcg9 id="240400145"><itemNumber>0595</itemNumber><strength>120mg</strength><dosageForm>SR Cap</dosageForm><dailyCost>.2133</dailyCost><drug id="02231150" chronicUseMed="Y" sec3="Y"><name>Tiazac</name><manufacturerId>VAL</manufacturerId><individualPrice>1.2023</individualPrice><dailyCost>1.2023</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02245918" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem T</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02271605" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem HCL ER</name><manufacturerId>TEV</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02370441" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem T</name><manufacturerId>TEV</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02465353" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem T</name><manufacturerId>MAR</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02495376" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem T</name><manufacturerId>JPC</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02516101" chronicUseMed="Y" sec3="Y"><name>Diltiazem T</name><manufacturerId>SAI</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug><drug id="02546434" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem T</name><manufacturerId>MAT</manufacturerId><individualPrice>.2133</individualPrice><dailyCost>.2133</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.2133</amountMOHLTCPays></drug></pcg9><pcg9 id="240400146"><itemNumber>0596</itemNumber><strength>180mg</strength><dosageForm>SR Cap</dosageForm><dailyCost>.2889</dailyCost><drug id="02231151" chronicUseMed="Y" sec3="Y"><name>Tiazac</name><manufacturerId>VAL</manufacturerId><individualPrice>1.6062</individualPrice><dailyCost>1.6062</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02245919" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem T</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02271613" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem HCL ER</name><manufacturerId>TEV</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02370492" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem T</name><manufacturerId>TEV</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02465361" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem T</name><manufacturerId>MAR</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02495384" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem T</name><manufacturerId>JPC</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02516128" chronicUseMed="Y" sec3="Y"><name>Diltiazem T</name><manufacturerId>SAI</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug><drug id="02546442" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem T</name><manufacturerId>MAT</manufacturerId><individualPrice>.2889</individualPrice><dailyCost>.2889</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.2889</amountMOHLTCPays></drug></pcg9><pcg9 id="240400147"><itemNumber>0597</itemNumber><strength>240mg</strength><dosageForm>SR Cap</dosageForm><dailyCost>.3832</dailyCost><drug id="02231152" chronicUseMed="Y" sec3="Y"><name>Tiazac</name><manufacturerId>VAL</manufacturerId><individualPrice>2.1304</individualPrice><dailyCost>2.1304</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02245920" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem T</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02271621" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem HCL ER</name><manufacturerId>TEV</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02370506" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem T</name><manufacturerId>TEV</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02465388" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem T</name><manufacturerId>MAR</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02495392" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem T</name><manufacturerId>JPC</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02516136" chronicUseMed="Y" sec3="Y"><name>Diltiazem T</name><manufacturerId>SAI</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug><drug id="02546450" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem T</name><manufacturerId>MAT</manufacturerId><individualPrice>.3832</individualPrice><dailyCost>.3832</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.3832</amountMOHLTCPays></drug></pcg9><pcg9 id="240400148"><itemNumber>0598</itemNumber><strength>300mg</strength><dosageForm>SR Cap</dosageForm><dailyCost>.4720</dailyCost><drug id="02231154" chronicUseMed="Y" sec3="Y"><name>Tiazac</name><manufacturerId>VAL</manufacturerId><individualPrice>2.6682</individualPrice><dailyCost>2.6682</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02245921" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem T</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02271648" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem HCL ER</name><manufacturerId>TEV</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02370514" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem T</name><manufacturerId>TEV</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02465396" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem T</name><manufacturerId>MAR</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02495406" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem T</name><manufacturerId>JPC</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02516144" chronicUseMed="Y" sec3="Y"><name>Diltiazem T</name><manufacturerId>SAI</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug><drug id="02546469" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem T</name><manufacturerId>MAT</manufacturerId><individualPrice>.4720</individualPrice><dailyCost>.4720</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.4720</amountMOHLTCPays></drug></pcg9><pcg9 id="240400149"><itemNumber>0599</itemNumber><strength>360mg</strength><dosageForm>SR Cap</dosageForm><dailyCost>.5778</dailyCost><drug id="02231155" chronicUseMed="Y" sec3="Y"><name>Tiazac</name><manufacturerId>VAL</manufacturerId><individualPrice>3.2124</individualPrice><dailyCost>3.2124</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02245922" chronicUseMed="Y" sec3="Y"><name>Sandoz Diltiazem T</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02271656" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem HCL ER</name><manufacturerId>TEV</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02370522" chronicUseMed="Y" sec3="Y"><name>Teva-Diltiazem T</name><manufacturerId>TEV</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02465418" chronicUseMed="Y" sec3="Y"><name>Mar-Diltiazem T</name><manufacturerId>MAR</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02495414" chronicUseMed="Y" sec3="Y"><name>Jamp Diltiazem T</name><manufacturerId>JPC</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02516152" chronicUseMed="Y" sec3="Y"><name>Diltiazem T</name><manufacturerId>SAI</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug><drug id="02546477" chronicUseMed="Y" sec3="Y"><name>M-Diltiazem T</name><manufacturerId>MAT</manufacturerId><individualPrice>.5778</individualPrice><dailyCost>.5778</dailyCost><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.5778</amountMOHLTCPays></drug></pcg9><pcg9 id="240400054"><itemNumber>0600</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="00771376" chronicUseMed="Y" sec3="Y"><name>AA-Diltiaz</name><manufacturerId>AAP</manufacturerId><individualPrice>.2168</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2168</amountMOHLTCPays></drug><drug id="02097370" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cardizem</name><manufacturerId>BIO</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="240400053"><itemNumber>0601</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="00771384" chronicUseMed="Y" sec3="Y"><name>AA-Diltiaz</name><manufacturerId>AAP</manufacturerId><individualPrice>.3802</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3802</amountMOHLTCPays></drug><drug id="02097389" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cardizem</name><manufacturerId>BIO</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00313"><name>DISOPYRAMIDE</name><pcgGroup><pcg9 id="240400019"><itemNumber>0602</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02030799" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Norpace</name><manufacturerId>RBT</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02224801" chronicUseMed="Y" sec3="Y"><name>Rythmodan</name><manufacturerId>CHE</manufacturerId><individualPrice>.3390</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.3390</amountMOHLTCPays></drug></pcg9><pcg9 id="240400180"><itemNumber>0603</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="09858365" chronicUseMed="Y" sec3c="Y"><name>Disopyramide Phosphate USP</name><manufacturerId>DRR</manufacturerId><individualPrice>1.4000</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>1.4000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00327"><name>FLECAINIDE ACETATE</name><pcgGroup><pcg9 id="240400119"><itemNumber>0604</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="01966197" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tambocor</name><manufacturerId>GRA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02275538" chronicUseMed="Y" sec3="Y"><name>Apo-Flecainide</name><manufacturerId>APX</manufacturerId><individualPrice>.1389</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.1389</amountMOHLTCPays></drug><drug id="02459957" chronicUseMed="Y" sec3="Y"><name>Auro-Flecainide</name><manufacturerId>AUR</manufacturerId><individualPrice>.1389</individualPrice><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.1389</amountMOHLTCPays></drug><drug id="02476177" chronicUseMed="Y" sec3="Y"><name>Mar-Flecainide</name><manufacturerId>MAR</manufacturerId><individualPrice>.1389</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.1389</amountMOHLTCPays></drug><drug id="02493705" chronicUseMed="Y" sec3="Y"><name>Jamp Flecainide</name><manufacturerId>JPC</manufacturerId><individualPrice>.1389</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.1389</amountMOHLTCPays></drug><drug id="02530066" chronicUseMed="Y" sec3="Y"><name>NRA-Flecainide</name><manufacturerId>NRA</manufacturerId><individualPrice>.1389</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.1389</amountMOHLTCPays></drug><drug id="02534800" chronicUseMed="Y" sec3="Y"><name>Flecainide</name><manufacturerId>SAI</manufacturerId><individualPrice>.1389</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.1389</amountMOHLTCPays></drug></pcg9><pcg9 id="240400095"><itemNumber>0605</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="01966200" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tambocor</name><manufacturerId>GRA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02275546" chronicUseMed="Y" sec3="Y"><name>Apo-Flecainide</name><manufacturerId>APX</manufacturerId><individualPrice>.2779</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.2779</amountMOHLTCPays></drug><drug id="02459965" chronicUseMed="Y" sec3="Y"><name>Auro-Flecainide</name><manufacturerId>AUR</manufacturerId><individualPrice>.2779</individualPrice><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.2779</amountMOHLTCPays></drug><drug id="02476185" chronicUseMed="Y" sec3="Y"><name>Mar-Flecainide</name><manufacturerId>MAR</manufacturerId><individualPrice>.2779</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2779</amountMOHLTCPays></drug><drug id="02493713" chronicUseMed="Y" sec3="Y"><name>Jamp Flecainide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2779</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.2779</amountMOHLTCPays></drug><drug id="02530074" chronicUseMed="Y" sec3="Y"><name>NRA-Flecainide</name><manufacturerId>NRA</manufacturerId><individualPrice>.2779</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.2779</amountMOHLTCPays></drug><drug id="02534819" chronicUseMed="Y" sec3="Y"><name>Flecainide</name><manufacturerId>SAI</manufacturerId><individualPrice>.2779</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.2779</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02068"><name>IVABRADINE HCL</name><pcgGroup lccId="00311"><pcg9 id="240400174"><itemNumber>0606</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02459973" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lancora</name><manufacturerId>SEV</manufacturerId><individualPrice>.9136</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.9136</amountMOHLTCPays></drug></pcg9><pcg9 id="240400175"><itemNumber>0607</itemNumber><strength>7.5mg</strength><dosageForm>Tab</dosageForm><drug id="02459981" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lancora</name><manufacturerId>SEV</manufacturerId><individualPrice>1.6707</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.6707</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="538">For the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (LVEF) (less than or equal to 35%) in adult patients with New York Heart Association (NYHA) classes II or III who are in sinus rhythm with a resting heart rate greater than or equal to 77 beats per minute (bpm), to reduce the incidence of cardiovascular mortality and hospitalizations for worsening heart failure, administered in combination with standard chronic heart failure therapies if the following are met:

- Patients with NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) in combination with a beta blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA); AND

- Patients with at least one hospitalization due to heart failure in the last year; AND

- Resting heart rate must be documented as greater than or equal to 77 bpm on average using either an ECG on at least three separate visits or by continuous monitoring.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00315"><name>METOPROLOL TARTRATE</name><pcgGroup><pcg9 id="240400069"><itemNumber>0608</itemNumber><strength>100mg</strength><dosageForm>LA Tab</dosageForm><drug id="00658855" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lopresor SR</name><manufacturerId>NOV</manufacturerId><listingDate>2001-10-11</listingDate></drug><drug id="02285169" chronicUseMed="Y" sec3="Y"><name>AA-Metoprolol SR</name><manufacturerId>AAP</manufacturerId><individualPrice>.1415</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.1415</amountMOHLTCPays></drug></pcg9><pcg9 id="240400044"><itemNumber>0609</itemNumber><strength>200mg</strength><dosageForm>LA Tab</dosageForm><drug id="00534560" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lopresor SR</name><manufacturerId>NOV</manufacturerId><listingDate>2001-10-11</listingDate></drug><drug id="02285177" chronicUseMed="Y" sec3="Y"><name>AA-Metoprolol SR</name><manufacturerId>AAP</manufacturerId><individualPrice>.2568</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.2568</amountMOHLTCPays></drug></pcg9><pcg9 id="240400037"><itemNumber>0610</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1248</dailyCost><drug id="00397423" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lopresor</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00402605" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Betaloc</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00618632" chronicUseMed="Y" sec3="Y"><name>Apo-Metoprolol</name><manufacturerId>APX</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="00648035" chronicUseMed="Y" sec3="Y"><name>Teva-Metoprolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="00749354" chronicUseMed="Y" sec3="Y"><name>Apo-Metoprolol (Type L)</name><manufacturerId>APX</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="00842648" chronicUseMed="Y" sec3="Y"><name>Teva-Metoprolol (Uncoated)</name><manufacturerId>TEV</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="02230803" chronicUseMed="Y" sec3="Y"><name>PMS-Metoprolol-L</name><manufacturerId>PMS</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="02350394" chronicUseMed="Y" sec3="Y"><name>Metoprolol</name><manufacturerId>SAI</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>2016-09-29</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="02354187" chronicUseMed="Y" sec3="Y"><name>Sandoz Metoprolol (Type L)</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="02356821" chronicUseMed="Y" sec3="Y"><name>Jamp-Metoprolol-L</name><manufacturerId>JPC</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="02442124" chronicUseMed="Y" sec3="Y"><name>Metoprolol-L</name><manufacturerId>SIV</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug><drug id="02481316" chronicUseMed="Y" sec3="Y"><name>AG-Metoprolol-L</name><manufacturerId>ANG</manufacturerId><individualPrice>.0624</individualPrice><dailyCost>.1248</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.0624</amountMOHLTCPays></drug></pcg9><pcg9 id="240400036"><itemNumber>0611</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2722</dailyCost><drug id="00397431" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lopresor</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00402540" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Betaloc</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00618640" chronicUseMed="Y" sec3="Y"><name>Apo-Metoprolol</name><manufacturerId>APX</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="00648043" chronicUseMed="Y" sec3="Y"><name>Teva-Metoprolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="00751170" chronicUseMed="Y" sec3="Y"><name>Apo-Metoprolol (Type L)</name><manufacturerId>APX</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="00842656" chronicUseMed="Y" sec3="Y"><name>Teva-Metoprolol (Uncoated)</name><manufacturerId>TEV</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="02230804" chronicUseMed="Y" sec3="Y"><name>PMS-Metoprolol-L</name><manufacturerId>PMS</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="02350408" chronicUseMed="Y" sec3="Y"><name>Metoprolol</name><manufacturerId>SAI</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>2016-09-29</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="02354195" chronicUseMed="Y" sec3="Y"><name>Sandoz Metoprolol (Type L)</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="02356848" chronicUseMed="Y" sec3="Y"><name>Jamp-Metoprolol-L</name><manufacturerId>JPC</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="02442132" chronicUseMed="Y" sec3="Y"><name>Metoprolol-L</name><manufacturerId>SIV</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug><drug id="02481324" chronicUseMed="Y" sec3="Y"><name>AG-Metoprolol-L</name><manufacturerId>ANG</manufacturerId><individualPrice>.1361</individualPrice><dailyCost>.2722</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1361</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00321"><name>MEXILETINE HCL</name><pcgGroup><pcg9 id="240400064"><itemNumber>0612</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="00599956" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Mexitil</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230359" chronicUseMed="Y" sec3="Y"><name>Teva-Mexiletine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7346</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.7346</amountMOHLTCPays></drug><drug id="02536846" chronicUseMed="Y" sec3="Y"><name>Mint-Mexiletine</name><manufacturerId>MIN</manufacturerId><individualPrice>.7346</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>.7346</amountMOHLTCPays></drug></pcg9><pcg9 id="240400063"><itemNumber>0613</itemNumber><strength>200mg</strength><dosageForm>Cap</dosageForm><drug id="00599964" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Mexitil</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230360" chronicUseMed="Y" sec3="Y"><name>Teva-Mexiletine</name><manufacturerId>TEV</manufacturerId><individualPrice>.9837</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.9837</amountMOHLTCPays></drug><drug id="02536854" chronicUseMed="Y" sec3="Y"><name>Mint-Mexiletine</name><manufacturerId>MIN</manufacturerId><individualPrice>.9837</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.9837</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00308"><name>NADOLOL</name><pcgGroup><pcg9 id="240400058"><itemNumber>0614</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2375</dailyCost><drug id="00607126" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Corgard</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00782505" chronicUseMed="Y" sec3="Y"><name>Apo-Nadolol</name><manufacturerId>APX</manufacturerId><individualPrice>.2375</individualPrice><dailyCost>.2375</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2375</amountMOHLTCPays></drug><drug id="02496380" chronicUseMed="Y" sec3="Y"><name>Mint-Nadolol</name><manufacturerId>MIN</manufacturerId><individualPrice>.2375</individualPrice><dailyCost>.2375</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2375</amountMOHLTCPays></drug></pcg9><pcg9 id="240400042"><itemNumber>0615</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6820</dailyCost><drug id="00463256" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Corgard</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00782467" chronicUseMed="Y" sec3="Y"><name>Apo-Nadolol</name><manufacturerId>APX</manufacturerId><individualPrice>.3410</individualPrice><dailyCost>.6820</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3410</amountMOHLTCPays></drug><drug id="02496399" chronicUseMed="Y" sec3="Y"><name>Mint-Nadolol</name><manufacturerId>MIN</manufacturerId><individualPrice>.3410</individualPrice><dailyCost>.6820</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3410</amountMOHLTCPays></drug></pcg9><pcg9 id="240400008"><itemNumber>0616</itemNumber><strength>160mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.2046</dailyCost><drug id="00523372" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Corgard</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00782475" chronicUseMed="Y" sec3="Y"><name>Apo-Nadolol</name><manufacturerId>APX</manufacturerId><individualPrice>1.2046</individualPrice><dailyCost>1.2046</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2046</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00318"><name>NIFEDIPINE</name><pcgGroup><pcg9 id="240400081"><itemNumber>0617</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="00725110" chronicUseMed="Y" sec3="Y"><name>Nifedipine</name><manufacturerId>AAP</manufacturerId><individualPrice>.3679</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3679</amountMOHLTCPays></drug><drug id="02155869" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Adalat</name><manufacturerId>BAH</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="240400049"><itemNumber>0618</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="00755907" chronicUseMed="Y" sec3="Y"><name>Nifedipine</name><manufacturerId>AAP</manufacturerId><individualPrice>.4877</individualPrice><note>Rapid absorption of liquid nifedipine from pulvules can cause severe hypotension and aggravation of myocardial or cerebral ischemia.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4877</amountMOHLTCPays></drug><drug id="02155877" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Adalat</name><manufacturerId>BAH</manufacturerId><note>Rapid absorption of liquid nifedipine from pulvules can cause severe hypotension and aggravation of myocardial or cerebral ischemia.</note><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00326"><name>PROPAFENONE HCL</name><pcgGroup><pcg9 id="240400091"><itemNumber>0619</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="00603708" chronicUseMed="Y" sec3="Y"><name>Rythmol</name><manufacturerId>ABB</manufacturerId><individualPrice>1.4940</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6306</amountMOHLTCPays></drug><drug id="02243324" chronicUseMed="Y" sec3="Y"><name>Apo-Propafenone</name><manufacturerId>APX</manufacturerId><individualPrice>.6306</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.6306</amountMOHLTCPays></drug><drug id="02457172" chronicUseMed="Y" sec3="Y"><name>Mylan-Propafenone</name><manufacturerId>MYL</manufacturerId><individualPrice>.6306</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>.6306</amountMOHLTCPays></drug></pcg9><pcg9 id="240400092"><itemNumber>0620</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="00603716" chronicUseMed="Y" sec3="Y"><name>Rythmol</name><manufacturerId>ABB</manufacturerId><individualPrice>2.6335</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.1116</amountMOHLTCPays></drug><drug id="02243325" chronicUseMed="Y" sec3="Y"><name>Apo-Propafenone</name><manufacturerId>APX</manufacturerId><individualPrice>1.1116</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>1.1116</amountMOHLTCPays></drug><drug id="02457164" chronicUseMed="Y" sec3="Y"><name>Mylan-Propafenone</name><manufacturerId>MYL</manufacturerId><individualPrice>1.1116</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>1.1116</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00310"><name>PROPRANOLOL</name><pcgGroup><pcg9 id="240400152"><itemNumber>0621</itemNumber><strength>60mg</strength><dosageForm>LA Cap</dosageForm><drug id="02042231" notABenefit="Y" sec3b="Y" sec3="Y"><name>Inderal-LA</name><manufacturerId>WAY</manufacturerId><listingDate>2023-04-28</listingDate></drug><drug id="02491893" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Propranolol LA</name><manufacturerId>LUP</manufacturerId><individualPrice>.8813</individualPrice><listingDate>2023-04-28</listingDate></drug></pcg9><pcg9 id="240400167"><itemNumber>0622</itemNumber><strength>80mg</strength><dosageForm>LA Cap</dosageForm><drug id="02042258" notABenefit="Y" sec3b="Y" sec3="Y"><name>Inderal-LA</name><manufacturerId>WAY</manufacturerId><listingDate>2023-04-28</listingDate></drug><drug id="02491907" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Propranolol LA</name><manufacturerId>LUP</manufacturerId><individualPrice>.9950</individualPrice><listingDate>2023-04-28</listingDate></drug></pcg9><pcg9 id="240400060"><itemNumber>0623</itemNumber><strength>120mg</strength><dosageForm>LA Cap</dosageForm><drug id="02042266" notABenefit="Y" sec3b="Y" sec3="Y"><name>Inderal-LA</name><manufacturerId>PFI</manufacturerId><listingDate>2023-04-28</listingDate></drug><drug id="02491915" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Propranolol LA</name><manufacturerId>LUP</manufacturerId><individualPrice>1.5313</individualPrice><listingDate>2023-04-28</listingDate></drug></pcg9><pcg9 id="240400048"><itemNumber>0624</itemNumber><strength>160mg</strength><dosageForm>LA Cap</dosageForm><drug id="02042274" notABenefit="Y" sec3b="Y" sec3="Y"><name>Inderal-LA</name><manufacturerId>WAY</manufacturerId><listingDate>2023-04-28</listingDate></drug><drug id="02491923" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Propranolol LA</name><manufacturerId>LUP</manufacturerId><individualPrice>1.8113</individualPrice><listingDate>2023-04-28</listingDate></drug></pcg9><pcg9 id="240400013"><itemNumber>0625</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00496480" chronicUseMed="Y" sec3="Y"><name>Teva-Propranolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.0774</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0774</amountMOHLTCPays></drug><drug id="02042177" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Inderal</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="240400059"><itemNumber>0626</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00740675" chronicUseMed="Y" sec3="Y"><name>Teva-Propranolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1119</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1119</amountMOHLTCPays></drug><drug id="02042193" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Inderal</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02550814" chronicUseMed="Y" sec3="Y"><name>PRZ-Propranolol</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1119</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.1119</amountMOHLTCPays></drug></pcg9><pcg9 id="240400012"><itemNumber>0627</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2478</dailyCost><drug id="00496499" chronicUseMed="Y" sec3="Y"><name>Teva-Propranolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1239</individualPrice><dailyCost>.2478</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1239</amountMOHLTCPays></drug><drug id="02042207" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Inderal-40</name><manufacturerId>AYE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02550822" chronicUseMed="Y" sec3="Y"><name>PRZ-Propranolol</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1239</individualPrice><dailyCost>.2478</dailyCost><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.1239</amountMOHLTCPays></drug></pcg9><pcg9 id="240400015"><itemNumber>0628</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4114</dailyCost><drug id="00496502" chronicUseMed="Y" sec3="Y"><name>Teva-Propranolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.2057</individualPrice><dailyCost>.4114</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2057</amountMOHLTCPays></drug><drug id="02042215" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Inderal</name><manufacturerId>WAY</manufacturerId><listingDate>1997-02-04</listingDate></drug><drug id="02550830" chronicUseMed="Y" sec3="Y"><name>PRZ-Propranolol</name><manufacturerId>PRZ</manufacturerId><individualPrice>.2057</individualPrice><dailyCost>.4114</dailyCost><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.2057</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00322"><name>SOTALOL HCL</name><pcgGroup><pcg9 id="240400131"><itemNumber>0629</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="00897272" notABenefit="Y" sec3="Y"><name>Sotacor</name><manufacturerId>BQU</manufacturerId><listingDate>2007-12-19</listingDate></drug><drug id="02210428" chronicUseMed="Y" sec3="Y"><name>Apo-Sotalol</name><manufacturerId>APX</manufacturerId><individualPrice>.2966</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2966</amountMOHLTCPays></drug><drug id="02238326" chronicUseMed="Y" sec3="Y"><name>PMS-Sotalol</name><manufacturerId>PMS</manufacturerId><individualPrice>.2966</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2966</amountMOHLTCPays></drug><drug id="02368617" chronicUseMed="Y" sec3="Y"><name>Jamp-Sotalol</name><manufacturerId>JPC</manufacturerId><individualPrice>.2966</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2966</amountMOHLTCPays></drug></pcg9><pcg9 id="240400068"><itemNumber>0630</itemNumber><strength>160mg</strength><dosageForm>Tab</dosageForm><drug id="00483923" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Sotacor</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02084236" chronicUseMed="Y" sec3="Y"><name>Ratio-Sotalol</name><manufacturerId>RPH</manufacturerId><individualPrice>.1623</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1623</amountMOHLTCPays></drug><drug id="02167794" chronicUseMed="Y" sec3="Y"><name>Apo-Sotalol</name><manufacturerId>APX</manufacturerId><individualPrice>.1623</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1623</amountMOHLTCPays></drug><drug id="02231182" chronicUseMed="Y" sec3="Y"><name>Novo-Sotalol</name><manufacturerId>NOP</manufacturerId><individualPrice>.1623</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1623</amountMOHLTCPays></drug><drug id="02238327" chronicUseMed="Y" sec3="Y"><name>PMS-Sotalol</name><manufacturerId>PMS</manufacturerId><individualPrice>.1623</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.1623</amountMOHLTCPays></drug><drug id="02270633" chronicUseMed="Y" sec3="Y"><name>Co Sotalol</name><manufacturerId>COB</manufacturerId><individualPrice>.1623</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.1623</amountMOHLTCPays></drug><drug id="02368625" chronicUseMed="Y" sec3="Y"><name>Jamp-Sotalol</name><manufacturerId>JPC</manufacturerId><individualPrice>.1623</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.1623</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00314"><name>TIMOLOL MALEATE</name><pcgGroup><pcg9 id="240400023"><itemNumber>0631</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4154</dailyCost><drug id="00353914" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Blocadren</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00755842" chronicUseMed="Y" sec3="Y"><name>Timolol</name><manufacturerId>AAP</manufacturerId><individualPrice>.2077</individualPrice><dailyCost>.4154</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2077</amountMOHLTCPays></drug></pcg9><pcg9 id="240400022"><itemNumber>0632</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6478</dailyCost><drug id="00353922" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Blocadren</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00755850" chronicUseMed="Y" sec3="Y"><name>Timolol</name><manufacturerId>AAP</manufacturerId><individualPrice>.3239</individualPrice><dailyCost>.6478</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3239</amountMOHLTCPays></drug></pcg9><pcg9 id="240400043"><itemNumber>0633</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.2608</dailyCost><drug id="00495611" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Blocadren</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00755869" chronicUseMed="Y" sec3="Y"><name>Timolol</name><manufacturerId>AAP</manufacturerId><individualPrice>.6304</individualPrice><dailyCost>1.2608</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6304</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00319"><name>VERAPAMIL HCL</name><pcgGroup><pcg9 id="240400051"><itemNumber>0634</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><dailyCost>.8205</dailyCost><drug id="00554316" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Isoptin</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00782483" chronicUseMed="Y" sec3="Y"><name>Apo-Verap</name><manufacturerId>APX</manufacturerId><individualPrice>.2735</individualPrice><dailyCost>.8205</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2735</amountMOHLTCPays></drug><drug id="02237921" chronicUseMed="Y" sec3="Y"><name>Mylan-Verapamil</name><manufacturerId>MYL</manufacturerId><individualPrice>.2735</individualPrice><dailyCost>.8205</dailyCost><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2735</amountMOHLTCPays></drug></pcg9><pcg9 id="240400050"><itemNumber>0635</itemNumber><strength>120mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.2750</dailyCost><drug id="00554324" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Isoptin</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00782491" chronicUseMed="Y" sec3="Y"><name>Apo-Verap</name><manufacturerId>APX</manufacturerId><individualPrice>.4250</individualPrice><dailyCost>1.2750</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4250</amountMOHLTCPays></drug><drug id="02237922" chronicUseMed="Y" sec3="Y"><name>Mylan-Verapamil</name><manufacturerId>MYL</manufacturerId><individualPrice>.4250</individualPrice><dailyCost>1.2750</dailyCost><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.4250</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="240600000"><name>ANTILIPEMIC DRUGS</name><genericName id="01685"><name>AMLODIPINE BESYLATE &amp; ATORVASTATIN CALCIUM</name><pcgGroup><pcg9 id="240600056"><itemNumber>0636</itemNumber><strength>5mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="02273233" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>2.7922</individualPrice><note>Note:  Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>1.1603</amountMOHLTCPays></drug><drug id="02362759" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>1.1603</individualPrice><note>Note:  Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.1603</amountMOHLTCPays></drug><drug id="02411253" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>1.1603</individualPrice><note>Note:  Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>1.1603</amountMOHLTCPays></drug></pcg9><pcg9 id="240600057"><itemNumber>0637</itemNumber><strength>5mg &amp; 20mg</strength><dosageForm>Tab</dosageForm><drug id="02273241" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>3.2927</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>1.3683</amountMOHLTCPays></drug><drug id="02362767" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>1.3683</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.3683</amountMOHLTCPays></drug><drug id="02411261" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>1.3683</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>1.3683</amountMOHLTCPays></drug></pcg9><pcg9 id="240600058"><itemNumber>0638</itemNumber><strength>5mg &amp; 40mg</strength><dosageForm>Tab</dosageForm><drug id="02273268" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>3.4805</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.7232</amountMOHLTCPays></drug><drug id="02362775" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>.7232</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.7232</amountMOHLTCPays></drug><drug id="02411288" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.7232</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.7232</amountMOHLTCPays></drug></pcg9><pcg9 id="240600059"><itemNumber>0639</itemNumber><strength>5mg &amp; 80mg</strength><dosageForm>Tab</dosageForm><drug id="02273276" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>3.4805</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.7232</amountMOHLTCPays></drug><drug id="02362783" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>.7232</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.7232</amountMOHLTCPays></drug><drug id="02411296" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.7232</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.7232</amountMOHLTCPays></drug></pcg9><pcg9 id="240600060"><itemNumber>0640</itemNumber><strength>10mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="02273284" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>2.9480</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02362791" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>1.2250</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02411318" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>1.2250</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug></pcg9><pcg9 id="240600061"><itemNumber>0641</itemNumber><strength>10mg &amp; 20mg</strength><dosageForm>Tab</dosageForm><drug id="02273292" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>3.6752</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>1.5272</amountMOHLTCPays></drug><drug id="02362805" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>1.5272</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.5272</amountMOHLTCPays></drug><drug id="02411326" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>1.5272</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>1.5272</amountMOHLTCPays></drug></pcg9><pcg9 id="240600062"><itemNumber>0642</itemNumber><strength>10mg &amp; 40mg</strength><dosageForm>Tab</dosageForm><drug id="02273306" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>3.8504</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.8000</amountMOHLTCPays></drug><drug id="02362813" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>.8000</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.8000</amountMOHLTCPays></drug><drug id="02411334" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.8000</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="240600063"><itemNumber>0643</itemNumber><strength>10mg &amp; 80mg</strength><dosageForm>Tab</dosageForm><drug id="02273314" chronicUseMed="Y" sec3="Y"><name>Caduet</name><manufacturerId>UJC</manufacturerId><individualPrice>3.8504</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.8000</amountMOHLTCPays></drug><drug id="02362821" chronicUseMed="Y" sec3="Y"><name>Gd-Amlodipine/Atorvastatin</name><manufacturerId>UJC</manufacturerId><individualPrice>.8000</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.8000</amountMOHLTCPays></drug><drug id="02411342" chronicUseMed="Y" sec3="Y"><name>Apo-Amlodipine-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.8000</individualPrice><note>Note:   Patients should be stabilized on a statin or a calcium channel blocker before being initiated on Amlodipine Besylate &amp; Atrovastatin Calcium.</note><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.8000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00347"><name>ATORVASTATIN CALCIUM</name><pcgGroup><pcg9 id="240600036"><itemNumber>0644</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02230711" chronicUseMed="Y" sec3="Y"><name>Lipitor</name><manufacturerId>UJC</manufacturerId><individualPrice>2.1393</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02295261" chronicUseMed="Y" sec3="Y"><name>Apo-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02310899" chronicUseMed="Y" sec3="Y"><name>Teva-Atorvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02313707" chronicUseMed="Y" sec3="Y"><name>Taro-Atorvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02324946" chronicUseMed="Y" sec3="Y"><name>Sandoz Atorvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02348705" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02350297" chronicUseMed="Y" sec3="Y"><name>Ratio-Atorvastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02391058" chronicUseMed="Y" sec3="Y"><name>Jamp-Atorvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02392933" chronicUseMed="Y" sec3="Y"><name>Mylan-Atorvastatin</name><manufacturerId>MYL</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02407256" chronicUseMed="Y" sec3="Y"><name>Auro-Atorvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02411350" chronicUseMed="Y" sec3="Y"><name>Atorvastatin-10</name><manufacturerId>SIV</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02417936" chronicUseMed="Y" sec3="Y"><name>Reddy-Atorvastatin</name><manufacturerId>DRR</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02454017" chronicUseMed="Y" sec3="Y"><name>Mar-Atorvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02457741" chronicUseMed="Y" sec3="Y"><name>Ach-Atorvastatin Calcium</name><manufacturerId>ACH</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02471167" chronicUseMed="Y" sec3="Y"><name>M-Atorvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02475022" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>RIA</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02476517" chronicUseMed="Y" sec3="Y"><name>NRA-Atorvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02477149" chronicUseMed="Y" sec3="Y"><name>PMS-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02478145" chronicUseMed="Y" sec3="Y"><name>AG-Atorvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02479508" chronicUseMed="Y" sec3="Y"><name>Mint-Atorvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02504197" chronicUseMed="Y" sec3="Y"><name>Jamp Atorvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02507234" chronicUseMed="Y" sec3="Y"><name>PMSC-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug><drug id="02521555" chronicUseMed="Y" sec3="Y"><name>PRZ-Atorvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1743</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.1743</amountMOHLTCPays></drug></pcg9><pcg9 id="240600034"><itemNumber>0645</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02230713" chronicUseMed="Y" sec3="Y"><name>Lipitor</name><manufacturerId>UJC</manufacturerId><individualPrice>2.6741</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02295288" chronicUseMed="Y" sec3="Y"><name>Apo-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02310902" chronicUseMed="Y" sec3="Y"><name>Teva-Atorvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02313715" chronicUseMed="Y" sec3="Y"><name>Taro-Atorvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02324954" chronicUseMed="Y" sec3="Y"><name>Sandoz Atorvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02348713" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02350319" chronicUseMed="Y" sec3="Y"><name>Ratio-Atorvastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02391066" chronicUseMed="Y" sec3="Y"><name>Jamp-Atorvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02392941" chronicUseMed="Y" sec3="Y"><name>Mylan-Atorvastatin</name><manufacturerId>MYL</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02407264" chronicUseMed="Y" sec3="Y"><name>Auro-Atorvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02411369" chronicUseMed="Y" sec3="Y"><name>Atorvastatin-20</name><manufacturerId>SIV</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02417944" chronicUseMed="Y" sec3="Y"><name>Reddy-Atorvastatin</name><manufacturerId>DRR</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02454025" chronicUseMed="Y" sec3="Y"><name>Mar-Atorvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02457768" chronicUseMed="Y" sec3="Y"><name>Ach-Atorvastatin Calcium</name><manufacturerId>ACH</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02471175" chronicUseMed="Y" sec3="Y"><name>M-Atorvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02475030" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>RIA</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02476525" chronicUseMed="Y" sec3="Y"><name>NRA-Atorvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02477157" chronicUseMed="Y" sec3="Y"><name>PMS-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02478153" chronicUseMed="Y" sec3="Y"><name>AG-Atorvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02479516" chronicUseMed="Y" sec3="Y"><name>Mint-Atorvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02504200" chronicUseMed="Y" sec3="Y"><name>Jamp Atorvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02507242" chronicUseMed="Y" sec3="Y"><name>PMSC-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug><drug id="02521563" chronicUseMed="Y" sec3="Y"><name>PRZ-Atorvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.2179</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.2179</amountMOHLTCPays></drug></pcg9><pcg9 id="240600037"><itemNumber>0646</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02230714" chronicUseMed="Y" sec3="Y"><name>Lipitor</name><manufacturerId>UJC</manufacturerId><individualPrice>2.8747</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02295296" chronicUseMed="Y" sec3="Y"><name>Apo-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02310910" chronicUseMed="Y" sec3="Y"><name>Teva-Atorvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02313723" chronicUseMed="Y" sec3="Y"><name>Taro-Atorvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02324962" chronicUseMed="Y" sec3="Y"><name>Sandoz Atorvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02348721" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02350327" chronicUseMed="Y" sec3="Y"><name>Ratio-Atorvastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02391074" chronicUseMed="Y" sec3="Y"><name>Jamp-Atorvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02392968" chronicUseMed="Y" sec3="Y"><name>Mylan-Atorvastatin</name><manufacturerId>MYL</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02407272" chronicUseMed="Y" sec3="Y"><name>Auro-Atorvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02411377" chronicUseMed="Y" sec3="Y"><name>Atorvastatin-40</name><manufacturerId>SIV</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02417952" chronicUseMed="Y" sec3="Y"><name>Reddy-Atorvastatin</name><manufacturerId>DRR</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02454033" chronicUseMed="Y" sec3="Y"><name>Mar-Atorvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02457776" chronicUseMed="Y" sec3="Y"><name>Ach-Atorvastatin Calcium</name><manufacturerId>ACH</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02471183" chronicUseMed="Y" sec3="Y"><name>M-Atorvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02475049" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>RIA</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02476533" chronicUseMed="Y" sec3="Y"><name>NRA-Atorvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02477165" chronicUseMed="Y" sec3="Y"><name>PMS-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02478161" chronicUseMed="Y" sec3="Y"><name>AG-Atorvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02479524" chronicUseMed="Y" sec3="Y"><name>Mint-Atorvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02504219" chronicUseMed="Y" sec3="Y"><name>Jamp Atorvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02507250" chronicUseMed="Y" sec3="Y"><name>PMSC-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02521571" chronicUseMed="Y" sec3="Y"><name>PRZ-Atorvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug></pcg9><pcg9 id="240600045"><itemNumber>0647</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02243097" chronicUseMed="Y" sec3="Y"><name>Lipitor</name><manufacturerId>UJC</manufacturerId><individualPrice>2.8747</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02295318" chronicUseMed="Y" sec3="Y"><name>Apo-Atorvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02310929" chronicUseMed="Y" sec3="Y"><name>Teva-Atorvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02313758" chronicUseMed="Y" sec3="Y"><name>Taro-Atorvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02324970" chronicUseMed="Y" sec3="Y"><name>Sandoz Atorvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02348748" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02350335" chronicUseMed="Y" sec3="Y"><name>Ratio-Atorvastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2010-06-18</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02391082" chronicUseMed="Y" sec3="Y"><name>Jamp-Atorvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02392976" chronicUseMed="Y" sec3="Y"><name>Mylan-Atorvastatin</name><manufacturerId>MYL</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02407280" chronicUseMed="Y" sec3="Y"><name>Auro-Atorvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02411385" chronicUseMed="Y" sec3="Y"><name>Atorvastatin-80</name><manufacturerId>SIV</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02417960" chronicUseMed="Y" sec3="Y"><name>Reddy-Atorvastatin</name><manufacturerId>DRR</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02454041" chronicUseMed="Y" sec3="Y"><name>Mar-Atorvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02457784" chronicUseMed="Y" sec3="Y"><name>Ach-Atorvastatin Calcium</name><manufacturerId>ACH</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02471191" chronicUseMed="Y" sec3="Y"><name>M-Atorvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02475057" chronicUseMed="Y" sec3="Y"><name>Atorvastatin</name><manufacturerId>RIA</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02476541" chronicUseMed="Y" sec3="Y"><name>NRA-Atorvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02478188" chronicUseMed="Y" sec3="Y"><name>AG-Atorvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02479532" chronicUseMed="Y" sec3="Y"><name>Mint-Atorvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02504235" chronicUseMed="Y" sec3="Y"><name>Jamp Atorvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02507269" chronicUseMed="Y" sec3="Y"><name>PMSC-Atorvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug><drug id="02521598" chronicUseMed="Y" sec3="Y"><name>PRZ-Atorvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.2342</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.2342</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00346"><name>BEZAFIBRATE</name><pcgGroup><pcg9 id="240600027"><itemNumber>0648</itemNumber><strength>400mg</strength><dosageForm>SR Tab</dosageForm><drug id="02083523" chronicUseMed="Y" sec3="Y"><name>Bezalip</name><manufacturerId>ALL</manufacturerId><individualPrice>2.9427</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.7460</amountMOHLTCPays></drug><drug id="02453312" chronicUseMed="Y" sec3="Y"><name>Jamp-Bezafibrate SR</name><manufacturerId>JPC</manufacturerId><individualPrice>1.7460</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>1.7460</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00336"><name>CHOLESTYRAMINE RESIN</name><pcgGroup><pcg9 id="240600003"><itemNumber>0649</itemNumber><dosageForm>Oral Pd-Pouch Pk</dosageForm><drug id="01918486" notABenefit="Y" sec3="Y"><name>Questran Light 4g Pk</name><manufacturerId>BQU</manufacturerId><listingDate>2004-07-20</listingDate></drug><drug id="02210320" chronicUseMed="Y" sec3="Y"><name>Olestyr 4g/9g Pk</name><manufacturerId>PMS</manufacturerId><individualPrice>.9217</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.9217</amountMOHLTCPays></drug><drug id="02455609" chronicUseMed="Y" sec3="Y"><name>Cholestyramine-Odan 4g/sachet</name><manufacturerId>ODN</manufacturerId><individualPrice>.9217</individualPrice><listingDate>2017-03-28</listingDate><amountMOHLTCPays>.9217</amountMOHLTCPays></drug><drug id="02478595" chronicUseMed="Y" sec3="Y"><name>Jamp-Cholestyramine 4g/Sachet</name><manufacturerId>JPC</manufacturerId><individualPrice>.9217</individualPrice><listingDate>2019-09-30</listingDate><amountMOHLTCPays>.9217</amountMOHLTCPays></drug></pcg9><pcg9 id="240600078"><itemNumber>0650</itemNumber><strength>4g</strength><dosageForm>Pd for Oral Susp</dosageForm><drug id="09858335" chronicUseMed="Y" sec3c="Y"><name>Cholestyramine for Oral Suspension USP</name><manufacturerId>JUN</manufacturerId><individualPrice>.9000</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>.9000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00335"><name>CLOFIBRATE</name><pcgGroup><pcg9 id="240600001"><itemNumber>0651</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><drug id="00002038" notABenefit="Y" sec3="Y"><name>Atromid-S</name><manufacturerId>AYE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00337382" notABenefit="Y" sec3="Y"><name>Novo-Fibrate</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01946"><name>COLESEVELAM HYDROCHLORIDE</name><pcgGroup><pcg9 id="240600072"><itemNumber>0652</itemNumber><strength>625mg</strength><dosageForm>Tab</dosageForm><note>Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:

. who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone,
 
or

. who are unable to tolerate a statin.</note><drug id="02373955" chronicUseMed="Y" sec3="Y"><name>Lodalis</name><manufacturerId>VAL</manufacturerId><individualPrice>1.3906</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.5931</amountMOHLTCPays></drug><drug id="02494051" chronicUseMed="Y" sec3="Y"><name>Apo-Colesevelam</name><manufacturerId>APX</manufacturerId><individualPrice>.5931</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.5931</amountMOHLTCPays></drug></pcg9><pcg9 id="240600077"><itemNumber>0653</itemNumber><strength>625mg</strength><dosageForm>Tab</dosageForm><note>Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:

. who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone,
 
or

. who are unable to tolerate a statin.</note><drug id="09858334" chronicUseMed="Y" sec3c="Y"><name>Colesevelam</name><manufacturerId>GLP</manufacturerId><individualPrice>.5931</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.5931</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00338"><name>COLESTIPOL HCL</name><note>Combining psyllium with Colestid therapy improves the efficacy, and decreases costs, of antilipemic treatment.</note><pcgGroup><pcg9 id="240600009"><itemNumber>0654</itemNumber><dosageForm>Gran-5g Pk</dosageForm><drug id="00642975" dinStatus="E" chronicUseMed="Y" sec3="Y"><name>Colestid Regular</name><manufacturerId>PFI</manufacturerId><individualPrice>1.4595</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.4595</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02052"><name>EVOLOCUMAB</name><pcgGroup lccId="00302"><pcg9 id="240600075"><itemNumber>0655</itemNumber><strength>140mg/mL</strength><dosageForm>Inj Sol-Pref Syr Autoinj</dosageForm><drug id="02446057" sec3="Y" sec12="Y"><name>Repatha</name><manufacturerId>AMG</manufacturerId><individualPrice>291.6650</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>291.6650</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="527">For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:

- Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;

AND

- Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline despite:

A. Confirmed adherence to high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg) in combination with ezetimibe for at least a total of 3 months;

OR

B. Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:

(i). Inability to tolerate at least 2 statins with at least one started at the lowest starting dose; AND

(ii). For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether; AND

(iii). For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; AND

(iv). One of the following:

I) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out; OR

II) Patient developed confirmed and documented rhabdomyolysis; OR

III) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal

Treatment with Repatha should be discontinued if the patient does not meet all of the following:

1. Patient is adherent to therapy.
2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of Repatha).
3. Patient continues to have a significant reduction in LDL-C (with continuation of Repatha) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).

Patients prescribed Repatha 140mg every two weeks are limited to 26 prefilled syringes (PFS) per year. Patients prescribed Repatha 420mg every month must use the automated mini doser (AMD) and are limited to 12 AMD per year.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01607"><name>EZETIMIBE</name><pcgGroup lccId="00150"><pcg9 id="240600049"><itemNumber>0656</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02247521" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ezetrol</name><manufacturerId>OCI</manufacturerId><individualPrice>2.1436</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02354101" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Teva-Ezetimibe</name><manufacturerId>TEV</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02414716" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Act Ezetimibe</name><manufacturerId>ACV</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02416409" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Ezetimibe</name><manufacturerId>PMS</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02416778" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Ezetimibe</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02419548" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Ezetimibe</name><manufacturerId>RAN</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02422662" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mar-Ezetimibe</name><manufacturerId>MAR</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02423235" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Ezetimibe</name><manufacturerId>JPC</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02423243" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mint-Ezetimibe</name><manufacturerId>MIN</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02425610" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ach-Ezetimibe</name><manufacturerId>ACH</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02427826" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Ezetimibe</name><manufacturerId>APX</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02429659" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ezetimibe</name><manufacturerId>SIV</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02431300" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ezetimibe</name><manufacturerId>SAI</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02460750" chronicUseMed="Y" sec3="Y" sec12="Y"><name>GLN-Ezetimibe</name><manufacturerId>GLP</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02467437" chronicUseMed="Y" sec3="Y" sec12="Y"><name>M-Ezetimibe</name><manufacturerId>MAT</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02469286" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Ezetimibe</name><manufacturerId>AUR</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02475898" chronicUseMed="Y" sec3="Y" sec12="Y"><name>AG-Ezetimibe</name><manufacturerId>ANG</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02481669" chronicUseMed="Y" sec3="Y" sec12="Y"><name>NRA-Ezetimibe</name><manufacturerId>NRA</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug><drug id="02536420" chronicUseMed="Y" sec3="Y" sec12="Y"><name>NRA-Ezetimibe Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.1811</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.1811</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="380">For use in combination with a HMG-CoA reductase inhibitor (&apos;statin&apos;) in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="381">For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00342"><name>FENOFIBRATE</name><pcgGroup><pcg9 id="240600018"><itemNumber>0657</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="00885827" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lipidil</name><manufacturerId>JOU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02225980" chronicUseMed="Y" sec3="Y"><name>Apo-Fenofibrate</name><manufacturerId>APX</manufacturerId><individualPrice>.6105</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.6105</amountMOHLTCPays></drug></pcg9><pcg9 id="240600067"><itemNumber>0658</itemNumber><strength>67mg</strength><dosageForm>Cap</dosageForm><drug id="02230283" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lipidil Micro</name><manufacturerId>FOU</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02243180" notABenefit="Y" sec3b="Y" sec3="Y"><name>AA-Feno-Micro</name><manufacturerId>AAP</manufacturerId><individualPrice>.6025</individualPrice><listingDate>2008-01-15</listingDate></drug></pcg9><pcg9 id="240600030"><itemNumber>0659</itemNumber><strength>200mg</strength><dosageForm>Cap</dosageForm><drug id="02146959" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lipidil Micro</name><manufacturerId>SPH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02239864" chronicUseMed="Y" sec3="Y"><name>AA-Feno-Micro</name><manufacturerId>AAP</manufacturerId><individualPrice>.9257</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.9257</amountMOHLTCPays></drug></pcg9><pcg9 id="240600046"><itemNumber>0660</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02241601" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lipidil Supra</name><manufacturerId>LAF</manufacturerId><listingDate>2008-11-04</listingDate></drug><drug id="02246859" notABenefit="Y" sec3b="Y" sec3="Y"><name>AA-Feno-Super</name><manufacturerId>AAP</manufacturerId><individualPrice>.9883</individualPrice><listingDate>2008-12-03</listingDate></drug><drug id="02288044" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Fenofibrate S</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7874</individualPrice><listingDate>2009-08-18</listingDate></drug></pcg9><pcg9 id="240600043"><itemNumber>0661</itemNumber><strength>160mg</strength><dosageForm>Tab</dosageForm><drug id="02241602" chronicUseMed="Y" sec3="Y"><name>Lipidil Supra</name><manufacturerId>BGP</manufacturerId><individualPrice>1.4513</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>1.0022</amountMOHLTCPays></drug><drug id="02246860" chronicUseMed="Y" sec3="Y"><name>AA-Feno-Super</name><manufacturerId>AAP</manufacturerId><individualPrice>1.0022</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>1.0022</amountMOHLTCPays></drug></pcg9><pcg9 id="240600054"><itemNumber>0662</itemNumber><strength>48mg</strength><dosageForm>Tab</dosageForm><drug id="02269074" chronicUseMed="Y" sec3="Y"><name>Lipidil EZ</name><manufacturerId>FOU</manufacturerId><individualPrice>.4986</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.3560</amountMOHLTCPays></drug><drug id="02390698" chronicUseMed="Y" sec3="Y"><name>Sandoz Fenofibrate E</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3560</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.3560</amountMOHLTCPays></drug></pcg9><pcg9 id="240600055"><itemNumber>0663</itemNumber><strength>145mg</strength><dosageForm>Tab</dosageForm><drug id="02269082" chronicUseMed="Y" sec3="Y"><name>Lipidil EZ</name><manufacturerId>FOU</manufacturerId><individualPrice>1.2768</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>.5489</amountMOHLTCPays></drug><drug id="02390701" chronicUseMed="Y" sec3="Y"><name>Sandoz Fenofibrate E</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5489</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.5489</amountMOHLTCPays></drug><drug id="02454696" chronicUseMed="Y" sec3="Y"><name>Taro-Fenofibrate E</name><manufacturerId>SPC</manufacturerId><individualPrice>.5489</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.5489</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00345"><name>FLUVASTATIN SODIUM</name><pcgGroup><pcg9 id="240600024"><itemNumber>0664</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><drug id="02061562" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lescol</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02299224" chronicUseMed="Y" sec3="Y"><name>Teva-Fluvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.6882</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.6882</amountMOHLTCPays></drug></pcg9><pcg9 id="240600025"><itemNumber>0665</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="02061570" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lescol</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02299232" chronicUseMed="Y" sec3="Y"><name>Teva-Fluvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.9671</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.9671</amountMOHLTCPays></drug></pcg9><pcg9 id="240600050"><itemNumber>0666</itemNumber><strength>80mg</strength><dosageForm>ER Tab</dosageForm><drug id="02250527" chronicUseMed="Y" sec3="Y"><name>Lescol XL</name><manufacturerId>NOV</manufacturerId><individualPrice>1.6225</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>1.6225</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00337"><name>GEMFIBROZIL</name><pcgGroup><pcg9 id="240600007"><itemNumber>0667</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="00599026" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lopid</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01979574" chronicUseMed="Y" sec3="Y"><name>Apo-Gemfibrozil</name><manufacturerId>APX</manufacturerId><individualPrice>.1340</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1340</amountMOHLTCPays></drug><drug id="02241704" chronicUseMed="Y" sec3="Y"><name>Teva-Gemfibrozil</name><manufacturerId>TEV</manufacturerId><individualPrice>.1340</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1340</amountMOHLTCPays></drug></pcg9><pcg9 id="240600068"><itemNumber>0668</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="00659606" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lopid</name><manufacturerId>PFI</manufacturerId><listingDate>2008-02-12</listingDate></drug><drug id="01979582" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Gemfibrozil</name><manufacturerId>APX</manufacturerId><individualPrice>.7520</individualPrice><listingDate>2008-02-12</listingDate></drug><drug id="02142074" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Gemfibrozil</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3982</individualPrice><listingDate>2008-02-12</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00339"><name>LOVASTATIN</name><pcgGroup><pcg9 id="240600011"><itemNumber>0669</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00795860" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Mevacor</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02220172" chronicUseMed="Y" sec3="Y"><name>Lovastatin</name><manufacturerId>AAP</manufacturerId><individualPrice>1.1931</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>1.1931</amountMOHLTCPays></drug></pcg9><pcg9 id="240600015"><itemNumber>0670</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="00795852" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Mevacor</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02220180" chronicUseMed="Y" sec3="Y"><name>Lovastatin</name><manufacturerId>AAP</manufacturerId><individualPrice>2.1793</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>2.1793</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00340"><name>PRAVASTATIN SODIUM</name><pcgGroup><pcg9 id="240600013"><itemNumber>0671</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00893749" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Pravachol</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02243506" chronicUseMed="Y" sec3="Y"><name>Apo-Pravastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02246930" chronicUseMed="Y" sec3="Y"><name>Ratio-Pravastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02247008" chronicUseMed="Y" sec3="Y"><name>Teva-Pravastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02247655" chronicUseMed="Y" sec3="Y"><name>PMS-Pravastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02248182" chronicUseMed="Y" sec3="Y"><name>Co Pravastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02284421" chronicUseMed="Y" sec3="Y"><name>Ran-Pravastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02317451" chronicUseMed="Y" sec3="Y"><name>Mint-Pravastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02330954" chronicUseMed="Y" sec3="Y"><name>Jamp-Pravastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02356546" chronicUseMed="Y" sec3="Y"><name>Pravastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02389703" chronicUseMed="Y" sec3="Y"><name>Pravastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02432048" chronicUseMed="Y" sec3="Y"><name>Mar-Pravastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02440644" chronicUseMed="Y" sec3="Y"><name>Ach-Pravastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02458977" chronicUseMed="Y" sec3="Y"><name>Auro-Pravastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02468700" chronicUseMed="Y" sec3="Y"><name>Sandoz Pravastatin Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02476142" chronicUseMed="Y" sec3="Y"><name>AG-Pravastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug><drug id="02476274" chronicUseMed="Y" sec3="Y"><name>M-Pravastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2916</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.2916</amountMOHLTCPays></drug></pcg9><pcg9 id="240600014"><itemNumber>0672</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00893757" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Pravachol</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02243507" chronicUseMed="Y" sec3="Y"><name>Apo-Pravastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02246931" chronicUseMed="Y" sec3="Y"><name>Ratio-Pravastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02247009" chronicUseMed="Y" sec3="Y"><name>Teva-Pravastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02247656" chronicUseMed="Y" sec3="Y"><name>PMS-Pravastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02248183" chronicUseMed="Y" sec3="Y"><name>Co Pravastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02284448" chronicUseMed="Y" sec3="Y"><name>Ran-Pravastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02317478" chronicUseMed="Y" sec3="Y"><name>Mint-Pravastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02330962" chronicUseMed="Y" sec3="Y"><name>Jamp-Pravastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02356554" chronicUseMed="Y" sec3="Y"><name>Pravastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02389738" chronicUseMed="Y" sec3="Y"><name>Pravastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02432056" chronicUseMed="Y" sec3="Y"><name>Mar-Pravastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02440652" chronicUseMed="Y" sec3="Y"><name>Ach-Pravastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02458985" chronicUseMed="Y" sec3="Y"><name>Auro-Pravastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02468719" chronicUseMed="Y" sec3="Y"><name>Sandoz Pravastatin Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02476150" chronicUseMed="Y" sec3="Y"><name>AG-Pravastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="02476282" chronicUseMed="Y" sec3="Y"><name>M-Pravastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.3440</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug></pcg9><pcg9 id="240600035"><itemNumber>0673</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02222051" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Pravachol</name><manufacturerId>BQU</manufacturerId><listingDate>1997-08-28</listingDate></drug><drug id="02243508" chronicUseMed="Y" sec3="Y"><name>Apo-Pravastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02246932" chronicUseMed="Y" sec3="Y"><name>Ratio-Pravastatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02247010" chronicUseMed="Y" sec3="Y"><name>Teva-Pravastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02247657" chronicUseMed="Y" sec3="Y"><name>PMS-Pravastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02248184" chronicUseMed="Y" sec3="Y"><name>Co Pravastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02284456" chronicUseMed="Y" sec3="Y"><name>Ran-Pravastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02317486" chronicUseMed="Y" sec3="Y"><name>Mint-Pravastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02330970" chronicUseMed="Y" sec3="Y"><name>Jamp-Pravastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02356562" chronicUseMed="Y" sec3="Y"><name>Pravastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02389746" chronicUseMed="Y" sec3="Y"><name>Pravastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02432064" chronicUseMed="Y" sec3="Y"><name>Mar-Pravastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02440660" chronicUseMed="Y" sec3="Y"><name>Ach-Pravastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02458993" chronicUseMed="Y" sec3="Y"><name>Auro-Pravastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02468727" chronicUseMed="Y" sec3="Y"><name>Sandoz Pravastatin Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02476169" chronicUseMed="Y" sec3="Y"><name>AG-Pravastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug><drug id="02476290" chronicUseMed="Y" sec3="Y"><name>M-Pravastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.4143</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4143</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01590"><name>ROSUVASTATIN CALCIUM</name><pcgGroup><pcg9 id="240600066"><itemNumber>0674</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02265540" chronicUseMed="Y" sec3="Y"><name>Crestor</name><manufacturerId>AZC</manufacturerId><individualPrice>1.4893</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02337975" chronicUseMed="Y" sec3="Y"><name>Apo-Rosuvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02338726" chronicUseMed="Y" sec3="Y"><name>Sandoz Rosuvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02339765" chronicUseMed="Y" sec3="Y"><name>Co Rosuvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02354608" chronicUseMed="Y" sec3="Y"><name>Teva-Rosuvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02378523" chronicUseMed="Y" sec3="Y"><name>PMS-Rosuvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02382644" chronicUseMed="Y" sec3="Y"><name>Taro-Rosuvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02391252" chronicUseMed="Y" sec3="Y"><name>Jamp-Rosuvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02397781" chronicUseMed="Y" sec3="Y"><name>Mint-Rosuvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02399164" chronicUseMed="Y" sec3="Y"><name>Med-Rosuvastatin</name><manufacturerId>GMP</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02405628" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02411628" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02413051" chronicUseMed="Y" sec3="Y"><name>Mar-Rosuvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2014-04-01</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02438917" chronicUseMed="Y" sec3="Y"><name>Ach-Rosuvastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02442574" chronicUseMed="Y" sec3="Y"><name>Auro-Rosuvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02477483" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02496534" chronicUseMed="Y" sec3="Y"><name>M-Rosuvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02498332" chronicUseMed="Y" sec3="Y"><name>Jamp Rosuvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02505576" chronicUseMed="Y" sec3="Y"><name>PRZ-Rosuvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug><drug id="02536595" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.1284</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.1284</amountMOHLTCPays></drug></pcg9><pcg9 id="240600044"><itemNumber>0675</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02247162" chronicUseMed="Y" sec3="Y"><name>Crestor</name><manufacturerId>AZC</manufacturerId><individualPrice>1.5816</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02337983" chronicUseMed="Y" sec3="Y"><name>Apo-Rosuvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02338734" chronicUseMed="Y" sec3="Y"><name>Sandoz Rosuvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02339773" chronicUseMed="Y" sec3="Y"><name>Co Rosuvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02354616" chronicUseMed="Y" sec3="Y"><name>Teva-Rosuvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02378531" chronicUseMed="Y" sec3="Y"><name>PMS-Rosuvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02382652" chronicUseMed="Y" sec3="Y"><name>Taro-Rosuvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02391260" chronicUseMed="Y" sec3="Y"><name>Jamp-Rosuvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02397803" chronicUseMed="Y" sec3="Y"><name>Mint-Rosuvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02399172" chronicUseMed="Y" sec3="Y"><name>Med-Rosuvastatin</name><manufacturerId>GMP</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02405636" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02411636" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02413078" chronicUseMed="Y" sec3="Y"><name>Mar-Rosuvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2014-04-01</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02438925" chronicUseMed="Y" sec3="Y"><name>Ach-Rosuvastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02442582" chronicUseMed="Y" sec3="Y"><name>Auro-Rosuvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02477491" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02496542" chronicUseMed="Y" sec3="Y"><name>M-Rosuvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02498340" chronicUseMed="Y" sec3="Y"><name>Jamp Rosuvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02505584" chronicUseMed="Y" sec3="Y"><name>PRZ-Rosuvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug><drug id="02536609" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.1354</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.1354</amountMOHLTCPays></drug></pcg9><pcg9 id="240600047"><itemNumber>0676</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02247163" chronicUseMed="Y" sec3="Y"><name>Crestor</name><manufacturerId>AZC</manufacturerId><individualPrice>1.9683</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02337991" chronicUseMed="Y" sec3="Y"><name>Apo-Rosuvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02338742" chronicUseMed="Y" sec3="Y"><name>Sandoz Rosuvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02339781" chronicUseMed="Y" sec3="Y"><name>Co Rosuvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02354624" chronicUseMed="Y" sec3="Y"><name>Teva-Rosuvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02378558" chronicUseMed="Y" sec3="Y"><name>PMS-Rosuvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02382660" chronicUseMed="Y" sec3="Y"><name>Taro-Rosuvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02391279" chronicUseMed="Y" sec3="Y"><name>Jamp-Rosuvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02397811" chronicUseMed="Y" sec3="Y"><name>Mint-Rosuvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02399180" chronicUseMed="Y" sec3="Y"><name>Med-Rosuvastatin</name><manufacturerId>GMP</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02405644" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02411644" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02413086" chronicUseMed="Y" sec3="Y"><name>Mar-Rosuvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2014-04-01</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02438933" chronicUseMed="Y" sec3="Y"><name>Ach-Rosuvastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02442590" chronicUseMed="Y" sec3="Y"><name>Auro-Rosuvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02477505" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02496550" chronicUseMed="Y" sec3="Y"><name>M-Rosuvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02498359" chronicUseMed="Y" sec3="Y"><name>Jamp Rosuvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02505592" chronicUseMed="Y" sec3="Y"><name>PRZ-Rosuvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug><drug id="02536625" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.1692</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.1692</amountMOHLTCPays></drug></pcg9><pcg9 id="240600048"><itemNumber>0677</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02247164" chronicUseMed="Y" sec3="Y"><name>Crestor</name><manufacturerId>AZC</manufacturerId><individualPrice>2.3104</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02338009" chronicUseMed="Y" sec3="Y"><name>Apo-Rosuvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02338750" chronicUseMed="Y" sec3="Y"><name>Sandoz Rosuvastatin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02339803" chronicUseMed="Y" sec3="Y"><name>Co Rosuvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02354632" chronicUseMed="Y" sec3="Y"><name>Teva-Rosuvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02378566" chronicUseMed="Y" sec3="Y"><name>PMS-Rosuvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02382679" chronicUseMed="Y" sec3="Y"><name>Taro-Rosuvastatin</name><manufacturerId>SPC</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02391287" chronicUseMed="Y" sec3="Y"><name>Jamp-Rosuvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02397838" chronicUseMed="Y" sec3="Y"><name>Mint-Rosuvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02399199" chronicUseMed="Y" sec3="Y"><name>Med-Rosuvastatin</name><manufacturerId>GMP</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02405652" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02411652" chronicUseMed="Y" sec3="Y"><name>Rosuvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02413108" chronicUseMed="Y" sec3="Y"><name>Mar-Rosuvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2014-04-01</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02438941" chronicUseMed="Y" sec3="Y"><name>Ach-Rosuvastatin</name><manufacturerId>ACH</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02442604" chronicUseMed="Y" sec3="Y"><name>Auro-Rosuvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02477513" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02496569" chronicUseMed="Y" sec3="Y"><name>M-Rosuvastatin</name><manufacturerId>MAT</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02498367" chronicUseMed="Y" sec3="Y"><name>Jamp Rosuvastatin Calcium</name><manufacturerId>JPC</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02505606" chronicUseMed="Y" sec3="Y"><name>PRZ-Rosuvastatin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug><drug id="02536633" chronicUseMed="Y" sec3="Y"><name>NRA-Rosuvastatin Tablets</name><manufacturerId>NRA</manufacturerId><individualPrice>.1990</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.1990</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00341"><name>SIMVASTATIN</name><pcgGroup><pcg9 id="240600017"><itemNumber>0678</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00884324" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Zocor</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02247011" chronicUseMed="Y" sec3="Y"><name>Apo-Simvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02248103" chronicUseMed="Y" sec3="Y"><name>Co Simvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02250144" chronicUseMed="Y" sec3="Y"><name>Teva-Simvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02284723" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02329131" chronicUseMed="Y" sec3="Y"><name>Ran-Simvastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02372932" chronicUseMed="Y" sec3="Y"><name>Mint-Simvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02375036" chronicUseMed="Y" sec3="Y"><name>Mar-Simvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02375591" chronicUseMed="Y" sec3="Y"><name>Jamp-Simvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02386291" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02405148" chronicUseMed="Y" sec3="Y"><name>Auro-Simvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02469979" chronicUseMed="Y" sec3="Y"><name>Pharma-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02480050" chronicUseMed="Y" sec3="Y"><name>AG-Simvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug><drug id="02549638" chronicUseMed="Y" sec3="Y"><name>PMSC-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1023</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.1023</amountMOHLTCPays></drug></pcg9><pcg9 id="240600016"><itemNumber>0679</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00884332" chronicUseMed="Y" sec3="Y"><name>Zocor</name><manufacturerId>OCI</manufacturerId><individualPrice>2.8190</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02247012" chronicUseMed="Y" sec3="Y"><name>Apo-Simvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02248104" chronicUseMed="Y" sec3="Y"><name>Co Simvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02250152" chronicUseMed="Y" sec3="Y"><name>Teva-Simvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02265885" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Simvastatin</name><manufacturerId>TAR</manufacturerId><listingDate>2005-10-06</listingDate></drug><drug id="02284731" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02329158" chronicUseMed="Y" sec3="Y"><name>Ran-Simvastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02372940" chronicUseMed="Y" sec3="Y"><name>Mint-Simvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02375044" chronicUseMed="Y" sec3="Y"><name>Mar-Simvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02375605" chronicUseMed="Y" sec3="Y"><name>Jamp-Simvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02386305" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02405156" chronicUseMed="Y" sec3="Y"><name>Auro-Simvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02469987" chronicUseMed="Y" sec3="Y"><name>Pharma-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02480069" chronicUseMed="Y" sec3="Y"><name>AG-Simvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug><drug id="02549646" chronicUseMed="Y" sec3="Y"><name>PMSC-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2023</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.2023</amountMOHLTCPays></drug></pcg9><pcg9 id="240600028"><itemNumber>0680</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00884340" chronicUseMed="Y" sec3="Y"><name>Zocor</name><manufacturerId>OCI</manufacturerId><individualPrice>3.4841</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02247013" chronicUseMed="Y" sec3="Y"><name>Apo-Simvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02248105" chronicUseMed="Y" sec3="Y"><name>Co Simvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02250160" chronicUseMed="Y" sec3="Y"><name>Teva-Simvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02265893" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Simvastatin</name><manufacturerId>TAR</manufacturerId><listingDate>2005-10-06</listingDate></drug><drug id="02284758" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02329166" chronicUseMed="Y" sec3="Y"><name>Ran-Simvastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02372959" chronicUseMed="Y" sec3="Y"><name>Mint-Simvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02375052" chronicUseMed="Y" sec3="Y"><name>Mar-Simvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02375613" chronicUseMed="Y" sec3="Y"><name>Jamp-Simvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02386313" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02405164" chronicUseMed="Y" sec3="Y"><name>Auro-Simvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02469995" chronicUseMed="Y" sec3="Y"><name>Pharma-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02480077" chronicUseMed="Y" sec3="Y"><name>AG-Simvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02549654" chronicUseMed="Y" sec3="Y"><name>PMSC-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug></pcg9><pcg9 id="240600032"><itemNumber>0681</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="00884359" chronicUseMed="Y" sec3="Y"><name>Zocor</name><manufacturerId>OCI</manufacturerId><individualPrice>3.4841</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02247014" chronicUseMed="Y" sec3="Y"><name>Apo-Simvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02248106" chronicUseMed="Y" sec3="Y"><name>Co Simvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02250179" chronicUseMed="Y" sec3="Y"><name>Teva-Simvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02265907" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Simvastatin</name><manufacturerId>TAR</manufacturerId><listingDate>2005-10-06</listingDate></drug><drug id="02284766" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02329174" chronicUseMed="Y" sec3="Y"><name>Ran-Simvastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02372967" chronicUseMed="Y" sec3="Y"><name>Mint-Simvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02375060" chronicUseMed="Y" sec3="Y"><name>Mar-Simvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02375621" chronicUseMed="Y" sec3="Y"><name>Jamp-Simvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02386321" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02405172" chronicUseMed="Y" sec3="Y"><name>Auro-Simvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02470004" chronicUseMed="Y" sec3="Y"><name>Pharma-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02480085" chronicUseMed="Y" sec3="Y"><name>AG-Simvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02549662" chronicUseMed="Y" sec3="Y"><name>PMSC-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug></pcg9><pcg9 id="240600040"><itemNumber>0682</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02240332" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Zocor</name><manufacturerId>MFC</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02247015" chronicUseMed="Y" sec3="Y"><name>Apo-Simvastatin</name><manufacturerId>APX</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02248107" chronicUseMed="Y" sec3="Y"><name>Co Simvastatin</name><manufacturerId>COB</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02250187" chronicUseMed="Y" sec3="Y"><name>Teva-Simvastatin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02284774" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02329182" chronicUseMed="Y" sec3="Y"><name>Ran-Simvastatin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02372975" chronicUseMed="Y" sec3="Y"><name>Mint-Simvastatin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02375079" chronicUseMed="Y" sec3="Y"><name>Mar-Simvastatin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02375648" chronicUseMed="Y" sec3="Y"><name>Jamp-Simvastatin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02386348" chronicUseMed="Y" sec3="Y"><name>Simvastatin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02405180" chronicUseMed="Y" sec3="Y"><name>Auro-Simvastatin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02470012" chronicUseMed="Y" sec3="Y"><name>Pharma-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02480093" chronicUseMed="Y" sec3="Y"><name>AG-Simvastatin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02549670" chronicUseMed="Y" sec3="Y"><name>PMSC-Simvastatin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="240624000"><name>ANTILIPEMIC DRUGS PCSK9 INHIBITORS</name><genericName id="02078"><name>ALIROCUMAB</name><pcgGroup lccId="00315"><pcg9 id="240624002"><itemNumber>0683</itemNumber><strength>75mg/mL</strength><dosageForm>Inj Sol-Pref Pen</dosageForm><drug id="02453819" sec3="Y" sec12="Y"><name>Praluent</name><manufacturerId>SAC</manufacturerId><individualPrice>267.8300</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>267.8300</amountMOHLTCPays></drug></pcg9><pcg9 id="240624004"><itemNumber>0684</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-Pref Pen</dosageForm><drug id="02453835" sec3="Y" sec12="Y"><name>Praluent</name><manufacturerId>SAC</manufacturerId><individualPrice>267.8300</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>267.8300</amountMOHLTCPays></drug></pcg9><pcg9 id="240624005"><itemNumber>0685</itemNumber><strength>300mg/2mL</strength><dosageForm>Inj Sol-Pref Pen 2mL Pk (Preservative-Free)</dosageForm><drug id="02547732" sec3="Y" sec12="Y"><name>Praluent</name><manufacturerId>SAC</manufacturerId><individualPrice>535.6600</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>535.6600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="555">For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:

1. Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;

AND

2. Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline for primary prevention despite:

A) Confirmed adherence to ezetimibe for at least a total of 3 months in combination with high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg);

OR

B) Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:

(i) Inability to tolerate at least 2 statins with at least one started at the lowest starting dose;

(ii) For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether;

(iii) For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; and

(iv) One of the following:

(I.) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out;

(II.) Patient developed confirmed and documented rhabdomyolysis;

(III.) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.

Treatment with alirocumab should be discontinued if the patient does not meet all of the following:

1. Patient is adherent to therapy.

2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of alirocumab).

3. Patient continues to have a significant reduction in LDL-C (with continuation of alirocumab) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).

Patients prescribed alirocumab 75mg every two weeks must use the 75mg/mL dosage strength and are limited to 26 pre-filled pens (PFP) per year.

Patients prescribed alirocumab 150mg every two weeks must use the 150mg/mL dosage strength and are limited to 26 PFP per year.

Patients prescribed alirocumab 300mg every four weeks may use either the 150mg/mL dosage strength (limited to 26 PFP per year) or the 300mg/2mL dosage strength (limited to 13 PFP per year).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="240692000"><name>ANTILIPEMIC DRUGS MISCELLANEOUS ANTILIPEMIC AGENTS</name><genericName id="02444"><name>INCLISIRAN</name><pcgGroup lccId="00418"><pcg9 id="240692003"><itemNumber>0686</itemNumber><strength>284mg/1.5mL</strength><dosageForm>Inj Sol-1.5mL Pref Syr</dosageForm><drug id="02518376" sec3="Y" sec12="Y"><name>Leqvio</name><manufacturerId>NOV</manufacturerId><individualPrice>2839.2800</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>2839.2800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="732">For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:

1. Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;

AND

2. Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline for primary prevention despite:

A) Confirmed adherence to ezetimibe for at least a total of 3 months in combination with high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg);

OR

B) Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:

(i) Inability to tolerate at least 2 statins with at least one started at the lowest starting dose; AND

(ii) For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether; AND

(iii) For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; AND

(iv) One of the following:

(I.) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out;

(II.) Patient developed confirmed and documented rhabdomyolysis;

(III.) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.

Inclisiran will not be funded when used in combination with proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies.

Treatment with inclisiran should be discontinued if the patient does not meet all of the following:

1. Patient is adherent to therapy.

2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of inclisiran).

3. Patient continues to have a significant reduction in LDL-C (with continuation of inclisiran) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).

Dosing: 284mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="240800000"><name>HYPOTENSIVE DRUGS (FOR DIURETICS SEE 40:28)</name><genericName id="00369"><name>ATENOLOL &amp; CHLORTHALIDONE</name><pcgGroup><pcg9 id="240800107"><itemNumber>0687</itemNumber><strength>50 &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02049961" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tenoretic 50/25</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02248763" chronicUseMed="Y" sec3="Y"><name>AA-Atenidone</name><manufacturerId>AAP</manufacturerId><individualPrice>.5342</individualPrice><listingDate>2004-09-14</listingDate><amountMOHLTCPays>.5342</amountMOHLTCPays></drug></pcg9><pcg9 id="240800108"><itemNumber>0688</itemNumber><strength>100 &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02049988" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tenoretic 100/25</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02248764" chronicUseMed="Y" sec3="Y"><name>AA-Atenidone</name><manufacturerId>AAP</manufacturerId><individualPrice>.8755</individualPrice><listingDate>2004-09-14</listingDate><amountMOHLTCPays>.8755</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00381"><name>BENAZEPRIL</name><pcgGroup><pcg9 id="240800186"><itemNumber>0689</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.9485</dailyCost><drug id="00885835" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lotensin</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02290332" chronicUseMed="Y" sec3="Y"><name>Benazepril</name><manufacturerId>AAP</manufacturerId><individualPrice>.9485</individualPrice><dailyCost>.9485</dailyCost><listingDate>2007-10-03</listingDate><amountMOHLTCPays>.9485</amountMOHLTCPays></drug></pcg9><pcg9 id="240800187"><itemNumber>0690</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.9938</dailyCost><drug id="00885843" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lotensin</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02290340" chronicUseMed="Y" sec3="Y"><name>Benazepril</name><manufacturerId>AAP</manufacturerId><individualPrice>.9938</individualPrice><dailyCost>.9938</dailyCost><listingDate>2007-10-03</listingDate><amountMOHLTCPays>.9938</amountMOHLTCPays></drug></pcg9><pcg9 id="240800188"><itemNumber>0691</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.2875</dailyCost><drug id="00885851" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lotensin</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02273918" chronicUseMed="Y" sec3="Y"><name>Benazepril</name><manufacturerId>AAP</manufacturerId><individualPrice>1.2875</individualPrice><dailyCost>1.2875</dailyCost><listingDate>2006-06-14</listingDate><amountMOHLTCPays>1.2875</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01422"><name>CANDESARTAN CILEXETIL</name><pcgGroup><pcg9 id="240800260"><itemNumber>0692</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02239090" chronicUseMed="Y" sec3="Y"><name>Atacand</name><manufacturerId>CHE</manufacturerId><individualPrice>.9527</individualPrice><listingDate>2006-04-19</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02326957" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02365340" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02376520" chronicUseMed="Y" sec3="Y"><name>Co Candesartan</name><manufacturerId>COB</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02379260" chronicUseMed="Y" sec3="Y"><name>Candesartan Cilexetil Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02380684" chronicUseMed="Y" sec3="Y"><name>Ran-Candesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02386496" chronicUseMed="Y" sec3="Y"><name>Jamp-Candesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02388901" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02391171" chronicUseMed="Y" sec3="Y"><name>PMS-Candesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02445786" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02476908" chronicUseMed="Y" sec3="Y"><name>Mint-Candesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02527006" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02528258" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug><drug id="02541289" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.1700</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.1700</amountMOHLTCPays></drug></pcg9><pcg9 id="240800235"><itemNumber>0693</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02239091" chronicUseMed="Y" sec3="Y"><name>Atacand</name><manufacturerId>CHE</manufacturerId><individualPrice>1.5845</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02326965" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02365359" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02366312" chronicUseMed="Y" sec3="Y"><name>Teva-Candesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02376539" chronicUseMed="Y" sec3="Y"><name>Co Candesartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02379279" chronicUseMed="Y" sec3="Y"><name>Candesartan Cilexetil Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02380692" chronicUseMed="Y" sec3="Y"><name>Ran-Candesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02386518" chronicUseMed="Y" sec3="Y"><name>Jamp-Candesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02388707" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02388928" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02391198" chronicUseMed="Y" sec3="Y"><name>PMS-Candesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02445794" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02476916" chronicUseMed="Y" sec3="Y"><name>Mint-Candesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02527014" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02541297" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9><pcg9 id="240800234"><itemNumber>0694</itemNumber><strength>16mg</strength><dosageForm>Tab</dosageForm><drug id="02239092" chronicUseMed="Y" sec3="Y"><name>Atacand</name><manufacturerId>CHE</manufacturerId><individualPrice>1.5845</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02326973" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02365367" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02366320" chronicUseMed="Y" sec3="Y"><name>Teva-Candesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02376547" chronicUseMed="Y" sec3="Y"><name>Co Candesartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02379287" chronicUseMed="Y" sec3="Y"><name>Candesartan Cilexetil Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02380706" chronicUseMed="Y" sec3="Y"><name>Ran-Candesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02386526" chronicUseMed="Y" sec3="Y"><name>Jamp-Candesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02388715" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02388936" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02391201" chronicUseMed="Y" sec3="Y"><name>PMS-Candesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02445808" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02476924" chronicUseMed="Y" sec3="Y"><name>Mint-Candesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02527022" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02541300" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9><pcg9 id="240800279"><itemNumber>0695</itemNumber><strength>32mg</strength><dosageForm>Tab</dosageForm><drug id="02311658" chronicUseMed="Y" sec3="Y"><name>Atacand</name><manufacturerId>CHE</manufacturerId><individualPrice>1.5845</individualPrice><listingDate>2009-05-20</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02366339" chronicUseMed="Y" sec3="Y"><name>Teva-Candesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02376555" chronicUseMed="Y" sec3="Y"><name>Co Candesartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02379295" chronicUseMed="Y" sec3="Y"><name>Candesartan Cilexetil Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02380714" chronicUseMed="Y" sec3="Y"><name>Ran-Candesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02386534" chronicUseMed="Y" sec3="Y"><name>Jamp-Candesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02391228" chronicUseMed="Y" sec3="Y"><name>PMS-Candesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02399105" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02417340" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02435845" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02445816" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02476932" chronicUseMed="Y" sec3="Y"><name>Mint-Candesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02527030" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02528266" chronicUseMed="Y" sec3="Y"><name>Candesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02541319" chronicUseMed="Y" sec3="Y"><name>Apo-Candesartan Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01558"><name>CANDESARTAN CILEXETIL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800248"><itemNumber>0696</itemNumber><strength>16mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02244021" chronicUseMed="Y" sec3="Y"><name>Atacand Plus</name><manufacturerId>CHE</manufacturerId><individualPrice>1.5845</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02327902" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan Plus</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02391295" chronicUseMed="Y" sec3="Y"><name>PMS-Candesartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02394804" chronicUseMed="Y" sec3="Y"><name>Candesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02394812" chronicUseMed="Y" sec3="Y"><name>Candesartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02395541" chronicUseMed="Y" sec3="Y"><name>Teva-Candesartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02421038" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02473240" chronicUseMed="Y" sec3="Y"><name>Jamp Candesartan-HCT</name><manufacturerId>JPC</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02531240" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug></pcg9><pcg9 id="240800291"><itemNumber>0697</itemNumber><strength>32mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02332922" chronicUseMed="Y" sec3="Y"><name>Atacand Plus</name><manufacturerId>CHE</manufacturerId><individualPrice>1.5845</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02395568" chronicUseMed="Y" sec3="Y"><name>Teva-Candesartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02420732" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan Plus</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02421046" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02473259" chronicUseMed="Y" sec3="Y"><name>Jamp Candesartan-HCT</name><manufacturerId>JPC</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02531259" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="02536064" chronicUseMed="Y" sec3="Y"><name>Candesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2156</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug></pcg9><pcg9 id="240800292"><itemNumber>0698</itemNumber><strength>32mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02332957" chronicUseMed="Y" sec3="Y"><name>Atacand Plus</name><manufacturerId>CHE</manufacturerId><individualPrice>1.5845</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.3008</amountMOHLTCPays></drug><drug id="02420740" chronicUseMed="Y" sec3="Y"><name>Sandoz Candesartan Plus</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3008</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.3008</amountMOHLTCPays></drug><drug id="02421054" chronicUseMed="Y" sec3="Y"><name>Auro-Candesartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.3008</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.3008</amountMOHLTCPays></drug><drug id="02473267" chronicUseMed="Y" sec3="Y"><name>Jamp Candesartan-HCT</name><manufacturerId>JPC</manufacturerId><individualPrice>.3008</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.3008</amountMOHLTCPays></drug><drug id="02531267" chronicUseMed="Y" sec3="Y"><name>NRA-Candesartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.3008</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.3008</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00363"><name>CAPTOPRIL</name><pcgGroup lccId="00419"><pcg9 id="240800312"><itemNumber>0699</itemNumber><strength>5mg/5mL</strength><dosageForm>Oral Sol</dosageForm><drug id="02543907" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Noyada</name><manufacturerId>ETH</manufacturerId><individualPrice>.6000</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>.6000</amountMOHLTCPays></drug></pcg9><pcg9 id="240800313"><itemNumber>0700</itemNumber><strength>25mg/5mL</strength><dosageForm>Oral Sol</dosageForm><drug id="02543915" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Noyada</name><manufacturerId>ETH</manufacturerId><individualPrice>.6500</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>.6500</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="707">For pediatric patients (less than 18 years of age) where the appropriate dose cannot be achieved using a listed solid oral dosage form of captopril.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">Pharmacists and prescribers should be informed of and stay current with a drug product&apos;s official indications in accordance with Health Canada&apos;s approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for this drug product. The Executive Officer&apos;s funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.</lccNote><lccNote seq="004" reasonForUseId="723">For patients unable to swallow or tolerate solid oral dosage forms of captopril.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="240800130"><itemNumber>0701</itemNumber><strength>12.5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6360</dailyCost><drug id="00695661" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Capoten</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00893595" chronicUseMed="Y" sec3="Y"><name>Apo-Capto</name><manufacturerId>APX</manufacturerId><individualPrice>.2120</individualPrice><dailyCost>.6360</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2120</amountMOHLTCPays></drug><drug id="01942964" chronicUseMed="Y" sec3="Y"><name>Teva-Captopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2120</individualPrice><dailyCost>.6360</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2120</amountMOHLTCPays></drug></pcg9><pcg9 id="240800078"><itemNumber>0702</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><dailyCost>.9000</dailyCost><drug id="00546283" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Capoten</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00893609" chronicUseMed="Y" sec3="Y"><name>Apo-Capto</name><manufacturerId>APX</manufacturerId><individualPrice>.3000</individualPrice><dailyCost>.9000</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3000</amountMOHLTCPays></drug><drug id="01942972" chronicUseMed="Y" sec3="Y"><name>Teva-Captopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.3000</individualPrice><dailyCost>.9000</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3000</amountMOHLTCPays></drug></pcg9><pcg9 id="240800077"><itemNumber>0703</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.6770</dailyCost><drug id="00546291" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Capoten</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00893617" chronicUseMed="Y" sec3="Y"><name>Apo-Capto</name><manufacturerId>APX</manufacturerId><individualPrice>.5590</individualPrice><dailyCost>1.6770</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5590</amountMOHLTCPays></drug><drug id="01942980" chronicUseMed="Y" sec3="Y"><name>Teva-Captopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.5590</individualPrice><dailyCost>1.6770</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5590</amountMOHLTCPays></drug></pcg9><pcg9 id="240800076"><itemNumber>0704</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00546305" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Capoten</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00893625" chronicUseMed="Y" sec3="Y"><name>Apo-Capto</name><manufacturerId>APX</manufacturerId><individualPrice>1.0395</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0395</amountMOHLTCPays></drug><drug id="01942999" chronicUseMed="Y" sec3="Y"><name>Teva-Captopril</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0395</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0395</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00382"><name>CILAZAPRIL</name><pcgGroup><pcg9 id="240800189"><itemNumber>0705</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="01911465" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Inhibace</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02283778" chronicUseMed="Y" sec3="Y"><name>Mylan-Cilazapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.3426</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.3426</amountMOHLTCPays></drug></pcg9><pcg9 id="240800190"><itemNumber>0706</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4295</dailyCost><drug id="01911473" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Inhibace</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02283786" chronicUseMed="Y" sec3="Y"><name>Mylan-Cilazapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.4295</individualPrice><dailyCost>.4295</dailyCost><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.4295</amountMOHLTCPays></drug><drug id="02291142" chronicUseMed="Y" sec3="Y"><name>Apo-Cilazapril</name><manufacturerId>APX</manufacturerId><individualPrice>.4295</individualPrice><dailyCost>.4295</dailyCost><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.4295</amountMOHLTCPays></drug></pcg9><pcg9 id="240800191"><itemNumber>0707</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4989</dailyCost><drug id="01911481" chronicUseMed="Y" sec3="Y"><name>Inhibace</name><manufacturerId>CHE</manufacturerId><individualPrice>1.1469</individualPrice><dailyCost>1.1469</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4989</amountMOHLTCPays></drug><drug id="02283794" chronicUseMed="Y" sec3="Y"><name>Mylan-Cilazapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.4989</individualPrice><dailyCost>.4989</dailyCost><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.4989</amountMOHLTCPays></drug><drug id="02291150" chronicUseMed="Y" sec3="Y"><name>Apo-Cilazapril</name><manufacturerId>APX</manufacturerId><individualPrice>.4989</individualPrice><dailyCost>.4989</dailyCost><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.4989</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01436"><name>CILAZAPRIL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800236"><itemNumber>0708</itemNumber><strength>5mg/12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02181479" chronicUseMed="Y" sec3="Y"><name>Inhibace Plus</name><manufacturerId>CHE</manufacturerId><individualPrice>1.1465</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.6306</amountMOHLTCPays></drug><drug id="02284987" chronicUseMed="Y" sec3="Y"><name>Apo-Cilazapril/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.6306</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.6306</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00355"><name>CLONIDINE HCL</name><note>Significant rebound hypertension can occur after missing even one or two doses; this drug should be avoided in patients with cardiovascular fragility or suspected problems with compliance.</note><pcgGroup><pcg9 id="240800171"><itemNumber>0709</itemNumber><strength>0.025mg</strength><dosageForm>Tab</dosageForm><drug id="00519251" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dixarit</name><manufacturerId>BOE</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02304163" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Clonidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2008-05-16</listingDate></drug><drug id="02516217" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Clonidine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2022-02-28</listingDate></drug><drug id="02524198" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Clonidine</name><manufacturerId>MAR</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02528207" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Clonidine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2023-01-31</listingDate></drug><drug id="02534738" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Clonidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2023-07-31</listingDate></drug><drug id="02540061" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clonidine</name><manufacturerId>SIV</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2024-03-28</listingDate></drug></pcg9><pcg9 id="240800022"><itemNumber>0710</itemNumber><strength>0.1mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2716</dailyCost><drug id="00259527" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Catapres</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02046121" chronicUseMed="Y" sec3="Y"><name>Teva-Clonidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.0679</individualPrice><dailyCost>.2716</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0679</amountMOHLTCPays></drug><drug id="02462192" chronicUseMed="Y" sec3="Y"><name>Mint-Clonidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.0679</individualPrice><dailyCost>.2716</dailyCost><listingDate>2017-10-30</listingDate><amountMOHLTCPays>.0679</amountMOHLTCPays></drug><drug id="02515784" chronicUseMed="Y" sec3="Y"><name>Sandoz Clonidine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0679</individualPrice><dailyCost>.2716</dailyCost><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.0679</amountMOHLTCPays></drug><drug id="02538490" chronicUseMed="Y" sec3="Y"><name>Clonidine</name><manufacturerId>SIV</manufacturerId><individualPrice>.0679</individualPrice><dailyCost>.2716</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.0679</amountMOHLTCPays></drug></pcg9><pcg9 id="240800021"><itemNumber>0711</itemNumber><strength>0.2mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4848</dailyCost><drug id="00291889" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Catapres</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02046148" chronicUseMed="Y" sec3="Y"><name>Teva-Clonidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1212</individualPrice><dailyCost>.4848</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1212</amountMOHLTCPays></drug><drug id="02462206" chronicUseMed="Y" sec3="Y"><name>Mint-Clonidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1212</individualPrice><dailyCost>.4848</dailyCost><listingDate>2017-10-30</listingDate><amountMOHLTCPays>.1212</amountMOHLTCPays></drug><drug id="02515792" chronicUseMed="Y" sec3="Y"><name>Sandoz Clonidine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1212</individualPrice><dailyCost>.4848</dailyCost><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.1212</amountMOHLTCPays></drug><drug id="02538504" chronicUseMed="Y" sec3="Y"><name>Clonidine</name><manufacturerId>SIV</manufacturerId><individualPrice>.1212</individualPrice><dailyCost>.4848</dailyCost><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.1212</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00375"><name>DOXAZOSIN MESYLATE</name><pcgGroup><pcg9 id="240800168"><itemNumber>0712</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1719</dailyCost><drug id="01958100" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cardura-1</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02240588" chronicUseMed="Y" sec3="Y"><name>Apo-Doxazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.1719</individualPrice><dailyCost>.1719</dailyCost><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1719</amountMOHLTCPays></drug><drug id="02242728" chronicUseMed="Y" sec3="Y"><name>Teva-Doxazosin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1719</individualPrice><dailyCost>.1719</dailyCost><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.1719</amountMOHLTCPays></drug><drug id="02489937" chronicUseMed="Y" sec3="Y"><name>Jamp-Doxazosin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1719</individualPrice><dailyCost>.1719</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1719</amountMOHLTCPays></drug></pcg9><pcg9 id="240800169"><itemNumber>0713</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2062</dailyCost><drug id="01958097" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cardura-2</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02240589" chronicUseMed="Y" sec3="Y"><name>Apo-Doxazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.2062</individualPrice><dailyCost>.2062</dailyCost><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.2062</amountMOHLTCPays></drug><drug id="02242729" chronicUseMed="Y" sec3="Y"><name>Teva-Doxazosin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2062</individualPrice><dailyCost>.2062</dailyCost><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2062</amountMOHLTCPays></drug><drug id="02489945" chronicUseMed="Y" sec3="Y"><name>Jamp-Doxazosin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2062</individualPrice><dailyCost>.2062</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2062</amountMOHLTCPays></drug></pcg9><pcg9 id="240800170"><itemNumber>0714</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2681</dailyCost><drug id="01958119" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cardura-4</name><manufacturerId>AZC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02240590" chronicUseMed="Y" sec3="Y"><name>Apo-Doxazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.2681</individualPrice><dailyCost>.2681</dailyCost><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.2681</amountMOHLTCPays></drug><drug id="02242730" chronicUseMed="Y" sec3="Y"><name>Teva-Doxazosin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2681</individualPrice><dailyCost>.2681</dailyCost><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2681</amountMOHLTCPays></drug><drug id="02489953" chronicUseMed="Y" sec3="Y"><name>Jamp-Doxazosin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2681</individualPrice><dailyCost>.2681</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2681</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00368"><name>ENALAPRIL MALEATE</name><pcgGroup><pcg9 id="240800149"><itemNumber>0715</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1863</dailyCost><drug id="00851795" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Vasotec</name><manufacturerId>MFC</manufacturerId><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.

Discontinuation Letter from MFR.</note><listingDate>1996-10-01</listingDate></drug><drug id="02020025" chronicUseMed="Y" sec3="Y"><name>Apo-Enalapril</name><manufacturerId>APX</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02291878" chronicUseMed="Y" sec3="Y"><name>Co Enalapril</name><manufacturerId>COB</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02299933" chronicUseMed="Y" sec3="Y"><name>Sandoz Enalapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02299984" chronicUseMed="Y" sec3="Y"><name>Ratio-Enalapril</name><manufacturerId>RPH</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02300036" chronicUseMed="Y" sec3="Y"><name>Mylan-Enalapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02300117" chronicUseMed="Y" sec3="Y"><name>Taro-Enalapril</name><manufacturerId>TAR</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02300680" chronicUseMed="Y" sec3="Y"><name>Novo-Enalapril</name><manufacturerId>NOP</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><note>** Each tablet is made with 2.5mg of enalapril maleate that is equivalent to 2mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-05-16</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02352230" chronicUseMed="Y" sec3="Y"><name>Ran-Enalapril</name><manufacturerId>RAN</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><listingDate>2011-01-07</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02400650" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02442957" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02459450" chronicUseMed="Y" sec3="Y"><name>Mar-Enalapril</name><manufacturerId>MAR</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug><drug id="02474786" chronicUseMed="Y" sec3="Y"><name>Jamp-Enalapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.1863</individualPrice><dailyCost>.1863</dailyCost><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.1863</amountMOHLTCPays></drug></pcg9><pcg9 id="240800105"><itemNumber>0716</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2203</dailyCost><drug id="00708879" chronicUseMed="Y" sec3="Y"><name>Vasotec</name><manufacturerId>OCI</manufacturerId><individualPrice>1.2182</individualPrice><dailyCost>1.2182</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02019884" chronicUseMed="Y" sec3="Y"><name>Apo-Enalapril</name><manufacturerId>APX</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02233005" chronicUseMed="Y" sec3="Y"><name>Teva-Enalapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-05-16</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02291886" chronicUseMed="Y" sec3="Y"><name>Co Enalapril</name><manufacturerId>COB</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02299941" chronicUseMed="Y" sec3="Y"><name>Sandoz Enalapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02299992" chronicUseMed="Y" sec3="Y"><name>Ratio-Enalapril</name><manufacturerId>RPH</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02300044" chronicUseMed="Y" sec3="Y"><name>Mylan-Enalapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02300125" chronicUseMed="Y" sec3="Y"><name>Taro-Enalapril</name><manufacturerId>TAR</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><note>** Each tablet is made with 5mg of enalapril maleate that is equivalent to 4mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02352249" chronicUseMed="Y" sec3="Y"><name>Ran-Enalapril</name><manufacturerId>RAN</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><listingDate>2011-01-07</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02400669" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02442965" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02459469" chronicUseMed="Y" sec3="Y"><name>Mar-Enalapril</name><manufacturerId>MAR</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug><drug id="02474794" chronicUseMed="Y" sec3="Y"><name>Jamp-Enalapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2203</individualPrice><dailyCost>.2203</dailyCost><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2203</amountMOHLTCPays></drug></pcg9><pcg9 id="240800104"><itemNumber>0717</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2647</dailyCost><drug id="00670901" chronicUseMed="Y" sec3="Y"><name>Vasotec</name><manufacturerId>OCI</manufacturerId><individualPrice>1.4638</individualPrice><dailyCost>1.4638</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02019892" chronicUseMed="Y" sec3="Y"><name>Apo-Enalapril</name><manufacturerId>APX</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02233006" chronicUseMed="Y" sec3="Y"><name>Teva-Enalapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-05-16</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02291894" chronicUseMed="Y" sec3="Y"><name>Co Enalapril</name><manufacturerId>COB</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02299968" chronicUseMed="Y" sec3="Y"><name>Sandoz Enalapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02300001" chronicUseMed="Y" sec3="Y"><name>Ratio-Enalapril</name><manufacturerId>RPH</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02300052" chronicUseMed="Y" sec3="Y"><name>Mylan-Enalapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02300133" chronicUseMed="Y" sec3="Y"><name>Taro-Enalapril</name><manufacturerId>TAR</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><note>** Each tablet is made with 10mg of enalapril maleate that is equivalent to 8mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02352257" chronicUseMed="Y" sec3="Y"><name>Ran-Enalapril</name><manufacturerId>RAN</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><listingDate>2011-01-07</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02400677" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02442973" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02444771" chronicUseMed="Y" sec3="Y"><name>Mar-Enalapril</name><manufacturerId>MAR</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02474808" chronicUseMed="Y" sec3="Y"><name>Jamp-Enalapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2647</individualPrice><dailyCost>.2647</dailyCost><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug></pcg9><pcg9 id="240800103"><itemNumber>0718</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>.3195</dailyCost><drug id="00670928" chronicUseMed="Y" sec3="Y"><name>Vasotec</name><manufacturerId>OCI</manufacturerId><individualPrice>1.7665</individualPrice><dailyCost>1.7665</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02019906" chronicUseMed="Y" sec3="Y"><name>Apo-Enalapril</name><manufacturerId>APX</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02233007" chronicUseMed="Y" sec3="Y"><name>Teva-Enalapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-05-16</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02291908" chronicUseMed="Y" sec3="Y"><name>Co Enalapril</name><manufacturerId>COB</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02299976" chronicUseMed="Y" sec3="Y"><name>Sandoz Enalapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02300028" chronicUseMed="Y" sec3="Y"><name>Ratio-Enalapril</name><manufacturerId>RPH</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02300060" chronicUseMed="Y" sec3="Y"><name>Mylan-Enalapril</name><manufacturerId>MYL</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02300141" chronicUseMed="Y" sec3="Y"><name>Taro-Enalapril</name><manufacturerId>TAR</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><note>** Each tablet is made with 20mg of enalapril maleate that is equivalent to 16mg of enalapril sodium, in the finished tablets.</note><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02352265" chronicUseMed="Y" sec3="Y"><name>Ran-Enalapril</name><manufacturerId>RAN</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><listingDate>2011-01-07</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02400685" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02442981" chronicUseMed="Y" sec3="Y"><name>Enalapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02444798" chronicUseMed="Y" sec3="Y"><name>Mar-Enalapril</name><manufacturerId>MAR</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug><drug id="02474816" chronicUseMed="Y" sec3="Y"><name>Jamp-Enalapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.3195</individualPrice><dailyCost>.3195</dailyCost><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.3195</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01838"><name>ENALAPRIL MALEATE &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800293"><itemNumber>0719</itemNumber><strength>5mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02242826" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vaseretic</name><manufacturerId>MFC</manufacturerId><listingDate>2011-05-19</listingDate></drug><drug id="02352923" notABenefit="Y" sec3b="Y" sec3="Y"><name>Enalapril Maleate/HCTZ</name><manufacturerId>AAP</manufacturerId><individualPrice>.8762</individualPrice><listingDate>2011-05-19</listingDate></drug></pcg9><pcg9 id="240800294"><itemNumber>0720</itemNumber><strength>10mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="00657298" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vaseretic</name><manufacturerId>OCI</manufacturerId><listingDate>2011-05-19</listingDate></drug><drug id="02352931" notABenefit="Y" sec3b="Y" sec3="Y"><name>Enalapril Maleate/HCTZ</name><manufacturerId>AAP</manufacturerId><individualPrice>1.2284</individualPrice><listingDate>2011-05-19</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01777"><name>EPLERENONE</name><pcgGroup lccId="00251"><pcg9 id="240800289"><itemNumber>0721</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02323052" sec3="Y" sec12="Y"><name>Inspra</name><manufacturerId>UJC</manufacturerId><individualPrice>3.2850</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>1.3730</amountMOHLTCPays></drug><drug id="02471442" sec3="Y" sec12="Y"><name>Mint-Eplerenone</name><manufacturerId>MIN</manufacturerId><individualPrice>1.3730</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>1.3730</amountMOHLTCPays></drug><drug id="02543389" sec3="Y" sec12="Y"><name>Jamp Eplerenone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3730</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>1.3730</amountMOHLTCPays></drug></pcg9><pcg9 id="240800290"><itemNumber>0722</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02323060" sec3="Y" sec12="Y"><name>Inspra</name><manufacturerId>UJC</manufacturerId><individualPrice>3.2850</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>1.3730</amountMOHLTCPays></drug><drug id="02471450" sec3="Y" sec12="Y"><name>Mint-Eplerenone</name><manufacturerId>MIN</manufacturerId><individualPrice>1.3730</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>1.3730</amountMOHLTCPays></drug><drug id="02543397" sec3="Y" sec12="Y"><name>Jamp Eplerenone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3730</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>1.3730</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="458">For persons suffering from New York Heart Association (NYHA) class II chronic heart failure with left ventricular systolic dysfunction (with ejection fraction less than or equal to 35 percent), as a complement to standard therapy.

Note: Patients must be on optimal therapy with an angiotensin-converting-enzyme (ACE) inhibitor, an angiotensin-receptor blocker (ARB), or both and a beta-blocker (unless contraindicated) at the recommended dose or maximal tolerated dose.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01561"><name>EPROSARTAN MESYLATE</name><pcgGroup><pcg9 id="240800247"><itemNumber>0723</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="02240432" chronicUseMed="Y" sec3="Y"><name>Teveten</name><manufacturerId>SPH</manufacturerId><individualPrice>.7790</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.7790</amountMOHLTCPays></drug></pcg9><pcg9 id="240800252"><itemNumber>0724</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02243942" chronicUseMed="Y" sec3="Y"><name>Teveten</name><manufacturerId>SPH</manufacturerId><individualPrice>1.1910</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>1.1910</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01632"><name>EPROSARTAN MESYLATE &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800259"><itemNumber>0725</itemNumber><strength>600mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02253631" chronicUseMed="Y" sec3="Y"><name>Teveten Plus</name><manufacturerId>SPH</manufacturerId><individualPrice>1.1910</individualPrice><listingDate>2005-05-25</listingDate><amountMOHLTCPays>1.1910</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00372"><name>FELODIPINE</name><note>Grapefruit juice or erythromycin triple the blood levels of felodipine and markedly increase both efficacy and adverse effects. Other dihydropyridines are affected to differing degrees by grapefruit juice.</note><pcgGroup><pcg9 id="240800202"><itemNumber>0726</itemNumber><strength>2.5mg</strength><dosageForm>ER Tab</dosageForm><drug id="02057778" chronicUseMed="Y" sec3="Y"><name>Plendil</name><manufacturerId>GPE</manufacturerId><individualPrice>.6063</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4050</amountMOHLTCPays></drug><drug id="02452367" chronicUseMed="Y" sec3="Y"><name>Apo-Felodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.4050</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.4050</amountMOHLTCPays></drug></pcg9><pcg9 id="240800164"><itemNumber>0727</itemNumber><strength>5mg</strength><dosageForm>ER Tab</dosageForm><dailyCost>.3565</dailyCost><drug id="00851779" chronicUseMed="Y" sec3="Y"><name>Plendil</name><manufacturerId>GPE</manufacturerId><individualPrice>.8020</individualPrice><dailyCost>.8020</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3565</amountMOHLTCPays></drug><drug id="02280264" chronicUseMed="Y" sec3="Y"><name>Sandoz Felodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3565</individualPrice><dailyCost>.3565</dailyCost><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.3565</amountMOHLTCPays></drug><drug id="02452375" chronicUseMed="Y" sec3="Y"><name>Apo-Felodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.3565</individualPrice><dailyCost>.3565</dailyCost><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.3565</amountMOHLTCPays></drug></pcg9><pcg9 id="240800165"><itemNumber>0728</itemNumber><strength>10mg</strength><dosageForm>ER Tab</dosageForm><dailyCost>.5350</dailyCost><drug id="00851787" chronicUseMed="Y" sec3="Y"><name>Plendil</name><manufacturerId>GPE</manufacturerId><individualPrice>1.2027</individualPrice><dailyCost>1.2027</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5350</amountMOHLTCPays></drug><drug id="02280272" chronicUseMed="Y" sec3="Y"><name>Sandoz Felodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5350</individualPrice><dailyCost>.5350</dailyCost><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.5350</amountMOHLTCPays></drug><drug id="02452383" chronicUseMed="Y" sec3="Y"><name>Apo-Felodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.5350</individualPrice><dailyCost>.5350</dailyCost><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.5350</amountMOHLTCPays></drug></pcg9><pcg9 id="240800154"><itemNumber>0729</itemNumber><strength>5mg</strength><dosageForm>SR Tab</dosageForm><dailyCost>.5592</dailyCost><drug id="02221993" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Renedil</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="09857203" chronicUseMed="Y" sec3="Y"><name>Sandoz Felodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5592</individualPrice><dailyCost>.5592</dailyCost><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.5592</amountMOHLTCPays></drug></pcg9><pcg9 id="240800155"><itemNumber>0730</itemNumber><strength>10mg</strength><dosageForm>SR Tab</dosageForm><dailyCost>.8390</dailyCost><drug id="02222000" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Renedil</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="09857204" chronicUseMed="Y" sec3="Y"><name>Sandoz Felodipine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8390</individualPrice><dailyCost>.8390</dailyCost><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.8390</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00373"><name>FOSINOPRIL SODIUM</name><pcgGroup><pcg9 id="240800156"><itemNumber>0731</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2178</dailyCost><drug id="01907107" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Monopril</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02247802" chronicUseMed="Y" sec3="Y"><name>Teva-Fosinopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2178</individualPrice><dailyCost>.2178</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2178</amountMOHLTCPays></drug><drug id="02266008" chronicUseMed="Y" sec3="Y"><name>Apo-Fosinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.2178</individualPrice><dailyCost>.2178</dailyCost><listingDate>2005-07-14</listingDate><amountMOHLTCPays>.2178</amountMOHLTCPays></drug><drug id="02294524" chronicUseMed="Y" sec3="Y"><name>Ran-Fosinopril</name><manufacturerId>RAN</manufacturerId><individualPrice>.2178</individualPrice><dailyCost>.2178</dailyCost><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.2178</amountMOHLTCPays></drug><drug id="02331004" chronicUseMed="Y" sec3="Y"><name>Jamp-Fosinopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2178</individualPrice><dailyCost>.2178</dailyCost><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2178</amountMOHLTCPays></drug><drug id="02459388" chronicUseMed="Y" sec3="Y"><name>Fosinopril</name><manufacturerId>SAI</manufacturerId><individualPrice>.2178</individualPrice><dailyCost>.2178</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2178</amountMOHLTCPays></drug></pcg9><pcg9 id="240800157"><itemNumber>0732</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2619</dailyCost><drug id="01907115" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Monopril</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02247803" chronicUseMed="Y" sec3="Y"><name>Teva-Fosinopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2619</individualPrice><dailyCost>.2619</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2619</amountMOHLTCPays></drug><drug id="02266016" chronicUseMed="Y" sec3="Y"><name>Apo-Fosinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.2619</individualPrice><dailyCost>.2619</dailyCost><listingDate>2005-07-14</listingDate><amountMOHLTCPays>.2619</amountMOHLTCPays></drug><drug id="02294532" chronicUseMed="Y" sec3="Y"><name>Ran-Fosinopril</name><manufacturerId>RAN</manufacturerId><individualPrice>.2619</individualPrice><dailyCost>.2619</dailyCost><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.2619</amountMOHLTCPays></drug><drug id="02331012" chronicUseMed="Y" sec3="Y"><name>Jamp-Fosinopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2619</individualPrice><dailyCost>.2619</dailyCost><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2619</amountMOHLTCPays></drug><drug id="02459396" chronicUseMed="Y" sec3="Y"><name>Fosinopril</name><manufacturerId>SAI</manufacturerId><individualPrice>.2619</individualPrice><dailyCost>.2619</dailyCost><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2619</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00350"><name>HYDRALAZINE HCL</name><pcgGroup><pcg9 id="240800044"><itemNumber>0733</itemNumber><strength>20mg/mL</strength><dosageForm>Inj Sol-1mL Vial Pk</dosageForm><drug id="00723754" sec3="Y"><name>Apresoline</name><manufacturerId>STE</manufacturerId><individualPrice>11.6500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>8.7375</amountMOHLTCPays></drug><drug id="02516160" sec3="Y"><name>Hydralazine Hydrochloride Injection, USP</name><manufacturerId>AUR</manufacturerId><individualPrice>8.7375</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>8.7375</amountMOHLTCPays></drug></pcg9><pcg9 id="240800010"><itemNumber>0734</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1420</dailyCost><drug id="00005525" notABenefit="Y" sec3="Y"><name>Apresoline</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00441619" sec3="Y"><name>Apo-Hydralazine</name><manufacturerId>APX</manufacturerId><individualPrice>.0355</individualPrice><dailyCost>.1420</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0355</amountMOHLTCPays></drug><drug id="02457865" sec3="Y"><name>Jamp-Hydralazine</name><manufacturerId>JPC</manufacturerId><individualPrice>.0355</individualPrice><dailyCost>.1420</dailyCost><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.0355</amountMOHLTCPays></drug><drug id="02468778" sec3="Y"><name>Mint-Hydralazine</name><manufacturerId>MIN</manufacturerId><individualPrice>.0355</individualPrice><dailyCost>.1420</dailyCost><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.0355</amountMOHLTCPays></drug><drug id="02539802" sec3="Y"><name>Hydralazine</name><manufacturerId>SAI</manufacturerId><individualPrice>.0355</individualPrice><dailyCost>.1420</dailyCost><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.0355</amountMOHLTCPays></drug></pcg9><pcg9 id="240800041"><itemNumber>0735</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2436</dailyCost><drug id="00005533" notABenefit="Y" sec3="Y"><name>Apresoline</name><manufacturerId>STE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00441627" sec3="Y"><name>Apo-Hydralazine</name><manufacturerId>APX</manufacturerId><individualPrice>.0609</individualPrice><dailyCost>.2436</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0609</amountMOHLTCPays></drug><drug id="02457873" sec3="Y"><name>Jamp-Hydralazine</name><manufacturerId>JPC</manufacturerId><individualPrice>.0609</individualPrice><dailyCost>.2436</dailyCost><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.0609</amountMOHLTCPays></drug><drug id="02468786" sec3="Y"><name>Mint-Hydralazine</name><manufacturerId>MIN</manufacturerId><individualPrice>.0609</individualPrice><dailyCost>.2436</dailyCost><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.0609</amountMOHLTCPays></drug><drug id="02539810" sec3="Y"><name>Hydralazine</name><manufacturerId>SAI</manufacturerId><individualPrice>.0609</individualPrice><dailyCost>.2436</dailyCost><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.0609</amountMOHLTCPays></drug></pcg9><pcg9 id="240800008"><itemNumber>0736</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.3824</dailyCost><drug id="00005541" notABenefit="Y" sec3="Y"><name>Apresoline</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00441635" sec3="Y"><name>Apo-Hydralazine</name><manufacturerId>APX</manufacturerId><individualPrice>.0956</individualPrice><dailyCost>.3824</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0956</amountMOHLTCPays></drug><drug id="02457881" sec3="Y"><name>Jamp-Hydralazine</name><manufacturerId>JPC</manufacturerId><individualPrice>.0956</individualPrice><dailyCost>.3824</dailyCost><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.0956</amountMOHLTCPays></drug><drug id="02468794" sec3="Y"><name>Mint-Hydralazine</name><manufacturerId>MIN</manufacturerId><individualPrice>.0956</individualPrice><dailyCost>.3824</dailyCost><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.0956</amountMOHLTCPays></drug><drug id="02539829" sec3="Y"><name>Hydralazine</name><manufacturerId>SAI</manufacturerId><individualPrice>.0956</individualPrice><dailyCost>.3824</dailyCost><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.0956</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01402"><name>IRBESARTAN</name><pcgGroup><pcg9 id="240800231"><itemNumber>0737</itemNumber><strength>75mg</strength><dosageForm>Tab</dosageForm><drug id="02237923" dinStatus="E" chronicUseMed="Y" sec3="Y"><name>Avapro</name><manufacturerId>SAV</manufacturerId><individualPrice>1.2671</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02316390" chronicUseMed="Y" sec3="Y"><name>Teva-Irbesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02317060" chronicUseMed="Y" sec3="Y"><name>PMS-Irbesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328461" chronicUseMed="Y" sec3="Y"><name>Sandoz Irbesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02372347" chronicUseMed="Y" sec3="Y"><name>Irbesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02385287" chronicUseMed="Y" sec3="Y"><name>Irbesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02386968" chronicUseMed="Y" sec3="Y"><name>Apo-Irbesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02406098" chronicUseMed="Y" sec3="Y"><name>Auro-Irbesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02406810" chronicUseMed="Y" sec3="Y"><name>Ran-Irbesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02418193" chronicUseMed="Y" sec3="Y"><name>Jamp-Irbesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02422980" chronicUseMed="Y" sec3="Y"><name>Mint-Irbesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02524813" chronicUseMed="Y" sec3="Y"><name>M-Irbesartan</name><manufacturerId>MAT</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02545225" chronicUseMed="Y" sec3="Y"><name>Jamp Irbesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9><pcg9 id="240800232"><itemNumber>0738</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02237924" chronicUseMed="Y" sec3="Y"><name>Avapro</name><manufacturerId>SAV</manufacturerId><individualPrice>1.2671</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02316404" chronicUseMed="Y" sec3="Y"><name>Teva-Irbesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02317079" chronicUseMed="Y" sec3="Y"><name>PMS-Irbesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328089" chronicUseMed="Y" sec3="Y"><name>Co Irbesartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328488" chronicUseMed="Y" sec3="Y"><name>Sandoz Irbesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02372371" chronicUseMed="Y" sec3="Y"><name>Irbesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02385295" chronicUseMed="Y" sec3="Y"><name>Irbesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02386976" chronicUseMed="Y" sec3="Y"><name>Apo-Irbesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02406101" chronicUseMed="Y" sec3="Y"><name>Auro-Irbesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02406829" chronicUseMed="Y" sec3="Y"><name>Ran-Irbesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02418207" chronicUseMed="Y" sec3="Y"><name>Jamp-Irbesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02422999" chronicUseMed="Y" sec3="Y"><name>Mint-Irbesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02524821" chronicUseMed="Y" sec3="Y"><name>M-Irbesartan</name><manufacturerId>MAT</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02545233" chronicUseMed="Y" sec3="Y"><name>Jamp Irbesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9><pcg9 id="240800233"><itemNumber>0739</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02237925" chronicUseMed="Y" sec3="Y"><name>Avapro</name><manufacturerId>SAV</manufacturerId><individualPrice>1.2671</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02316412" chronicUseMed="Y" sec3="Y"><name>Teva-Irbesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02317087" chronicUseMed="Y" sec3="Y"><name>PMS-Irbesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328100" chronicUseMed="Y" sec3="Y"><name>Co Irbesartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328496" chronicUseMed="Y" sec3="Y"><name>Sandoz Irbesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02372398" chronicUseMed="Y" sec3="Y"><name>Irbesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02385309" chronicUseMed="Y" sec3="Y"><name>Irbesartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02386984" chronicUseMed="Y" sec3="Y"><name>Apo-Irbesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02406128" chronicUseMed="Y" sec3="Y"><name>Auro-Irbesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02406837" chronicUseMed="Y" sec3="Y"><name>Ran-Irbesartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02418215" chronicUseMed="Y" sec3="Y"><name>Jamp-Irbesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02423006" chronicUseMed="Y" sec3="Y"><name>Mint-Irbesartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02524848" chronicUseMed="Y" sec3="Y"><name>M-Irbesartan</name><manufacturerId>MAT</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02545241" chronicUseMed="Y" sec3="Y"><name>Jamp Irbesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01500"><name>IRBESARTAN &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800242"><itemNumber>0740</itemNumber><strength>150mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02241818" chronicUseMed="Y" sec3="Y"><name>Avalide</name><manufacturerId>SAV</manufacturerId><individualPrice>1.3166</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328518" chronicUseMed="Y" sec3="Y"><name>PMS-Irbesartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02330512" chronicUseMed="Y" sec3="Y"><name>Teva-Irbesartan HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02337428" chronicUseMed="Y" sec3="Y"><name>Sandoz Irbesartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02357399" chronicUseMed="Y" sec3="Y"><name>Co Irbesartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02363208" chronicUseMed="Y" sec3="Y"><name>Ran-Irbesartan HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02372886" chronicUseMed="Y" sec3="Y"><name>Irbesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02385317" chronicUseMed="Y" sec3="Y"><name>Irbesartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02387646" chronicUseMed="Y" sec3="Y"><name>Apo-Irbesartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02392992" chronicUseMed="Y" sec3="Y"><name>Mint Irbesartan/HCTZ</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02418223" chronicUseMed="Y" sec3="Y"><name>Jamp-Irbesartan and Hydrochlorothiazide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02447878" chronicUseMed="Y" sec3="Y"><name>Auro-Irbesartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9><pcg9 id="240800243"><itemNumber>0741</itemNumber><strength>300mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02241819" chronicUseMed="Y" sec3="Y"><name>Avalide</name><manufacturerId>SAV</manufacturerId><individualPrice>1.3166</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02328526" chronicUseMed="Y" sec3="Y"><name>PMS-Irbesartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02330520" chronicUseMed="Y" sec3="Y"><name>Teva-Irbesartan HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02337436" chronicUseMed="Y" sec3="Y"><name>Sandoz Irbesartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02357402" chronicUseMed="Y" sec3="Y"><name>Co Irbesartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02363216" chronicUseMed="Y" sec3="Y"><name>Ran-Irbesartan HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02372894" chronicUseMed="Y" sec3="Y"><name>Irbesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02385325" chronicUseMed="Y" sec3="Y"><name>Irbesartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02387654" chronicUseMed="Y" sec3="Y"><name>Apo-Irbesartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02393018" chronicUseMed="Y" sec3="Y"><name>Mint Irbesartan/HCTZ</name><manufacturerId>MIN</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02418231" chronicUseMed="Y" sec3="Y"><name>Jamp-Irbesartan and Hydrochlorothiazide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug><drug id="02447886" chronicUseMed="Y" sec3="Y"><name>Auro-Irbesartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2281</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.2281</amountMOHLTCPays></drug></pcg9><pcg9 id="240800263"><itemNumber>0742</itemNumber><strength>300mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02280213" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Avalide</name><manufacturerId>SAV</manufacturerId><listingDate>2007-03-09</listingDate></drug><drug id="02328534" chronicUseMed="Y" sec3="Y"><name>PMS-Irbesartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02330539" chronicUseMed="Y" sec3="Y"><name>Teva-Irbesartan HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02337444" chronicUseMed="Y" sec3="Y"><name>Sandoz Irbesartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02357410" chronicUseMed="Y" sec3="Y"><name>Co Irbesartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02363224" chronicUseMed="Y" sec3="Y"><name>Ran-Irbesartan HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02372908" chronicUseMed="Y" sec3="Y"><name>Irbesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02385333" chronicUseMed="Y" sec3="Y"><name>Irbesartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02387662" chronicUseMed="Y" sec3="Y"><name>Apo-Irbesartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02393026" chronicUseMed="Y" sec3="Y"><name>Mint Irbesartan/HCTZ</name><manufacturerId>MIN</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02418258" chronicUseMed="Y" sec3="Y"><name>Jamp-Irbesartan and Hydrochlorothiazide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug><drug id="02447894" chronicUseMed="Y" sec3="Y"><name>Auro-Irbesartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2184</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.2184</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00367"><name>LABETALOL HCL</name><pcgGroup><pcg9 id="240800093"><itemNumber>0743</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02106272" chronicUseMed="Y" sec3="Y"><name>Trandate</name><manufacturerId>PPI</manufacturerId><individualPrice>.4044</individualPrice><listingDate>1998-03-17</listingDate><amountMOHLTCPays>.1983</amountMOHLTCPays></drug><drug id="02243538" chronicUseMed="Y" sec3="Y"><name>Apo-Labetalol</name><manufacturerId>APX</manufacturerId><individualPrice>.1983</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1983</amountMOHLTCPays></drug><drug id="02489406" chronicUseMed="Y" sec3="Y"><name>Riva-Labetalol</name><manufacturerId>RIA</manufacturerId><individualPrice>.1983</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>.1983</amountMOHLTCPays></drug></pcg9><pcg9 id="240800094"><itemNumber>0744</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02106280" chronicUseMed="Y" sec3="Y"><name>Trandate</name><manufacturerId>PPI</manufacturerId><individualPrice>.7148</individualPrice><listingDate>1998-03-17</listingDate><amountMOHLTCPays>.3504</amountMOHLTCPays></drug><drug id="02243539" chronicUseMed="Y" sec3="Y"><name>Apo-Labetalol</name><manufacturerId>APX</manufacturerId><individualPrice>.3504</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.3504</amountMOHLTCPays></drug><drug id="02489414" chronicUseMed="Y" sec3="Y"><name>Riva-Labetalol</name><manufacturerId>RIA</manufacturerId><individualPrice>.3504</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>.3504</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00371"><name>LISINOPRIL</name><pcgGroup><pcg9 id="240800146"><itemNumber>0745</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1428</dailyCost><drug id="00839388" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Prinivil</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02285061" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril (Type P)</name><manufacturerId>TEV</manufacturerId><individualPrice>.1428</individualPrice><dailyCost>.1428</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1428</amountMOHLTCPays></drug><drug id="09853685" chronicUseMed="Y" sec3="Y"><name>Apo-Lisinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.1428</individualPrice><dailyCost>.1428</dailyCost><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.1428</amountMOHLTCPays></drug><drug id="09857272" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1428</individualPrice><dailyCost>.1428</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1428</amountMOHLTCPays></drug></pcg9><pcg9 id="240800147"><itemNumber>0746</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1716</dailyCost><drug id="00839396" chronicUseMed="Y" sec3="Y"><name>Prinivil</name><manufacturerId>MFC</manufacturerId><individualPrice>.9489</individualPrice><dailyCost>.9489</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1716</amountMOHLTCPays></drug><drug id="02285088" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril (Type P)</name><manufacturerId>TEV</manufacturerId><individualPrice>.1716</individualPrice><dailyCost>.1716</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1716</amountMOHLTCPays></drug><drug id="09853960" chronicUseMed="Y" sec3="Y"><name>Apo-Lisinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.1716</individualPrice><dailyCost>.1716</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1716</amountMOHLTCPays></drug><drug id="09857286" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1716</individualPrice><dailyCost>.1716</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1716</amountMOHLTCPays></drug></pcg9><pcg9 id="240800148"><itemNumber>0747</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2063</dailyCost><drug id="00839418" chronicUseMed="Y" sec3="Y"><name>Prinivil</name><manufacturerId>MFC</manufacturerId><individualPrice>1.1408</individualPrice><dailyCost>1.1408</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2063</amountMOHLTCPays></drug><drug id="02285096" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril (Type P)</name><manufacturerId>TEV</manufacturerId><individualPrice>.2063</individualPrice><dailyCost>.2063</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2063</amountMOHLTCPays></drug><drug id="09854010" chronicUseMed="Y" sec3="Y"><name>Apo-Lisinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.2063</individualPrice><dailyCost>.2063</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.2063</amountMOHLTCPays></drug><drug id="09857287" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2063</individualPrice><dailyCost>.2063</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.2063</amountMOHLTCPays></drug></pcg9><pcg9 id="240800150"><itemNumber>0748</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1347</dailyCost><drug id="02049333" chronicUseMed="Y" sec3="Y"><name>Zestril</name><manufacturerId>AZC</manufacturerId><individualPrice>.5770</individualPrice><dailyCost>.5770</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02217481" chronicUseMed="Y" sec3="Y"><name>Apo-Lisinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02271443" chronicUseMed="Y" sec3="Y"><name>Co Lisinopril</name><manufacturerId>COB</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02285118" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril (Type Z)</name><manufacturerId>TEV</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02289199" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02294230" chronicUseMed="Y" sec3="Y"><name>Ran-Lisinopril</name><manufacturerId>RAN</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02361531" chronicUseMed="Y" sec3="Y"><name>Jamp-Lisinopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02386232" chronicUseMed="Y" sec3="Y"><name>Lisinopril</name><manufacturerId>SIV</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02394472" chronicUseMed="Y" sec3="Y"><name>Auro-Lisinopril</name><manufacturerId>AUR</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug><drug id="02525186" chronicUseMed="Y" sec3="Y"><name>Lisinopril</name><manufacturerId>SAI</manufacturerId><individualPrice>.1347</individualPrice><dailyCost>.1347</dailyCost><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.1347</amountMOHLTCPays></drug></pcg9><pcg9 id="240800151"><itemNumber>0749</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1619</dailyCost><drug id="02049376" chronicUseMed="Y" sec3="Y"><name>Zestril</name><manufacturerId>AZC</manufacturerId><individualPrice>.6935</individualPrice><dailyCost>.6935</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02217503" chronicUseMed="Y" sec3="Y"><name>Apo-Lisinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02271451" chronicUseMed="Y" sec3="Y"><name>Co Lisinopril</name><manufacturerId>COB</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02285126" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril (Type Z)</name><manufacturerId>TEV</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02289202" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02294249" chronicUseMed="Y" sec3="Y"><name>Ran-Lisinopril</name><manufacturerId>RAN</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02361558" chronicUseMed="Y" sec3="Y"><name>Jamp-Lisinopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02386240" chronicUseMed="Y" sec3="Y"><name>Lisinopril</name><manufacturerId>SIV</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02394480" chronicUseMed="Y" sec3="Y"><name>Auro-Lisinopril</name><manufacturerId>AUR</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug><drug id="02525194" chronicUseMed="Y" sec3="Y"><name>Lisinopril</name><manufacturerId>SAI</manufacturerId><individualPrice>.1619</individualPrice><dailyCost>.1619</dailyCost><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.1619</amountMOHLTCPays></drug></pcg9><pcg9 id="240800152"><itemNumber>0750</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1945</dailyCost><drug id="02049384" chronicUseMed="Y" sec3="Y"><name>Zestril</name><manufacturerId>AZC</manufacturerId><individualPrice>.8330</individualPrice><dailyCost>.8330</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02217511" chronicUseMed="Y" sec3="Y"><name>Apo-Lisinopril</name><manufacturerId>APX</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02271478" chronicUseMed="Y" sec3="Y"><name>Co Lisinopril</name><manufacturerId>COB</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02285134" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril (Type Z)</name><manufacturerId>TEV</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02289229" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02294257" chronicUseMed="Y" sec3="Y"><name>Ran-Lisinopril</name><manufacturerId>RAN</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02361566" chronicUseMed="Y" sec3="Y"><name>Jamp-Lisinopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02386259" chronicUseMed="Y" sec3="Y"><name>Lisinopril</name><manufacturerId>SIV</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02394499" chronicUseMed="Y" sec3="Y"><name>Auro-Lisinopril</name><manufacturerId>AUR</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug><drug id="02525208" chronicUseMed="Y" sec3="Y"><name>Lisinopril</name><manufacturerId>SAI</manufacturerId><individualPrice>.1945</individualPrice><dailyCost>.1945</dailyCost><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.1945</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00383"><name>LISINOPRIL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800207"><itemNumber>0751</itemNumber><strength>10mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02103729" chronicUseMed="Y" sec3="Y"><name>Zestoretic</name><manufacturerId>AZC</manufacturerId><individualPrice>.9286</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2084</amountMOHLTCPays></drug><drug id="02301768" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril/HCTZ (Type Z)</name><manufacturerId>TEV</manufacturerId><individualPrice>.2084</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.2084</amountMOHLTCPays></drug><drug id="02302365" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2084</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.2084</amountMOHLTCPays></drug><drug id="02362945" chronicUseMed="Y" sec3="Y"><name>Lisinopril/HCTZ (Type Z)</name><manufacturerId>SAI</manufacturerId><individualPrice>.2084</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.2084</amountMOHLTCPays></drug></pcg9><pcg9 id="240800214"><itemNumber>0752</itemNumber><strength>10mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02108194" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Prinzide</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02302136" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril/HCTZ (Type P)</name><manufacturerId>TEV</manufacturerId><individualPrice>.3334</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.3334</amountMOHLTCPays></drug></pcg9><pcg9 id="240800196"><itemNumber>0753</itemNumber><strength>20mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="00884413" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Prinzide</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02302144" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril/HCTZ (Type P)</name><manufacturerId>TEV</manufacturerId><individualPrice>.4006</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.4006</amountMOHLTCPays></drug></pcg9><pcg9 id="240800215"><itemNumber>0754</itemNumber><strength>20mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02045737" chronicUseMed="Y" sec3="Y"><name>Zestoretic</name><manufacturerId>AZC</manufacturerId><individualPrice>1.1159</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2504</amountMOHLTCPays></drug><drug id="02301776" chronicUseMed="Y" sec3="Y"><name>Teva-Lisinopril/HCTZ (Type Z)</name><manufacturerId>TEV</manufacturerId><individualPrice>.2504</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.2504</amountMOHLTCPays></drug><drug id="02302373" chronicUseMed="Y" sec3="Y"><name>Sandoz Lisinopril HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2504</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.2504</amountMOHLTCPays></drug><drug id="02362953" chronicUseMed="Y" sec3="Y"><name>Lisinopril/HCTZ (Type Z)</name><manufacturerId>SAI</manufacturerId><individualPrice>.2504</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.2504</amountMOHLTCPays></drug></pcg9><pcg9 id="240800274"><itemNumber>0755</itemNumber><strength>20mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02045729" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zestoretic</name><manufacturerId>AZC</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02301784" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Lisinopril/HCTZ (Type Z)</name><manufacturerId>TEV</manufacturerId><individualPrice>.7011</individualPrice><listingDate>2008-08-28</listingDate></drug><drug id="02302381" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Lisinopril HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7011</individualPrice><listingDate>2008-12-23</listingDate></drug><drug id="02362961" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lisinopril/HCTZ (Type Z)</name><manufacturerId>SAI</manufacturerId><individualPrice>.7011</individualPrice><listingDate>2011-12-15</listingDate></drug></pcg9><pcg9 id="240800273"><itemNumber>0756</itemNumber><strength>20mg/25mg</strength><dosageForm>Tab</dosageForm><drug id="00884421" notABenefit="Y" sec3b="Y" sec3="Y"><name>Prinzide</name><manufacturerId>MFC</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02302152" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Lisinopril/HCTZ (Type P)</name><manufacturerId>TEV</manufacturerId><individualPrice>.7011</individualPrice><listingDate>2008-08-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00387"><name>LOSARTAN POTASSIUM</name><pcgGroup><pcg9 id="240800212"><itemNumber>0757</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02182815" chronicUseMed="Y" sec3="Y"><name>Cozaar</name><manufacturerId>OCI</manufacturerId><individualPrice>1.9924</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02309750" chronicUseMed="Y" sec3="Y"><name>PMS-Losartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02313332" chronicUseMed="Y" sec3="Y"><name>Sandoz Losartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02354829" chronicUseMed="Y" sec3="Y"><name>Co Losartan</name><manufacturerId>COB</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02379058" chronicUseMed="Y" sec3="Y"><name>Apo-Losartan</name><manufacturerId>APX</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02380838" chronicUseMed="Y" sec3="Y"><name>Teva-Losartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388790" chronicUseMed="Y" sec3="Y"><name>Losartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388863" chronicUseMed="Y" sec3="Y"><name>Losartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02398834" chronicUseMed="Y" sec3="Y"><name>Jamp-Losartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02403323" chronicUseMed="Y" sec3="Y"><name>Auro-Losartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02404451" chronicUseMed="Y" sec3="Y"><name>Ran-Losartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02405733" chronicUseMed="Y" sec3="Y"><name>Mint-Losartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02424967" chronicUseMed="Y" sec3="Y"><name>Septa-Losartan</name><manufacturerId>SET</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02445964" chronicUseMed="Y" sec3="Y"><name>Bio-Losartan</name><manufacturerId>BMP</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug></pcg9><pcg9 id="240800216"><itemNumber>0758</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02182874" chronicUseMed="Y" sec3="Y"><name>Cozaar</name><manufacturerId>OCI</manufacturerId><individualPrice>1.9924</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02309769" chronicUseMed="Y" sec3="Y"><name>PMS-Losartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02313340" chronicUseMed="Y" sec3="Y"><name>Sandoz Losartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02353504" chronicUseMed="Y" sec3="Y"><name>Apo-Losartan</name><manufacturerId>APX</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02354837" chronicUseMed="Y" sec3="Y"><name>Co Losartan</name><manufacturerId>COB</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02357968" chronicUseMed="Y" sec3="Y"><name>Teva-Losartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388804" chronicUseMed="Y" sec3="Y"><name>Losartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388871" chronicUseMed="Y" sec3="Y"><name>Losartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02398842" chronicUseMed="Y" sec3="Y"><name>Jamp-Losartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02403331" chronicUseMed="Y" sec3="Y"><name>Auro-Losartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02404478" chronicUseMed="Y" sec3="Y"><name>Ran-Losartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02405741" chronicUseMed="Y" sec3="Y"><name>Mint-Losartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02424975" chronicUseMed="Y" sec3="Y"><name>Septa-Losartan</name><manufacturerId>SET</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02445972" chronicUseMed="Y" sec3="Y"><name>Bio-Losartan</name><manufacturerId>BMP</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug></pcg9><pcg9 id="240800230"><itemNumber>0759</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02182882" chronicUseMed="Y" sec3="Y"><name>Cozaar</name><manufacturerId>OCI</manufacturerId><individualPrice>1.9924</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02309777" chronicUseMed="Y" sec3="Y"><name>PMS-Losartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02313359" chronicUseMed="Y" sec3="Y"><name>Sandoz Losartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02353512" chronicUseMed="Y" sec3="Y"><name>Apo-Losartan</name><manufacturerId>APX</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02354845" chronicUseMed="Y" sec3="Y"><name>Co Losartan</name><manufacturerId>COB</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02357976" chronicUseMed="Y" sec3="Y"><name>Teva-Losartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388812" chronicUseMed="Y" sec3="Y"><name>Losartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388898" chronicUseMed="Y" sec3="Y"><name>Losartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02398850" chronicUseMed="Y" sec3="Y"><name>Jamp-Losartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02403358" chronicUseMed="Y" sec3="Y"><name>Auro-Losartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02404486" chronicUseMed="Y" sec3="Y"><name>Ran-Losartan</name><manufacturerId>RAN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02405768" chronicUseMed="Y" sec3="Y"><name>Mint-Losartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02424983" chronicUseMed="Y" sec3="Y"><name>Septa-Losartan</name><manufacturerId>SET</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02445980" chronicUseMed="Y" sec3="Y"><name>Bio-Losartan</name><manufacturerId>BMP</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01378"><name>LOSARTAN POTASSIUM &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800282"><itemNumber>0760</itemNumber><strength>100mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02297841" chronicUseMed="Y" sec3="Y"><name>Hyzaar</name><manufacturerId>OCI</manufacturerId><individualPrice>1.9508</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02362449" chronicUseMed="Y" sec3="Y"><name>Sandoz Losartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02371243" chronicUseMed="Y" sec3="Y"><name>Apo-Losartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02377144" chronicUseMed="Y" sec3="Y"><name>Teva-Losartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02388278" chronicUseMed="Y" sec3="Y"><name>Co Losartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02388979" chronicUseMed="Y" sec3="Y"><name>Losartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02389665" chronicUseMed="Y" sec3="Y"><name>Mint-Losartan/HCTZ</name><manufacturerId>MIN</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02392232" chronicUseMed="Y" sec3="Y"><name>PMS-Losartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02423650" chronicUseMed="Y" sec3="Y"><name>Auro-Losartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug><drug id="02427656" chronicUseMed="Y" sec3="Y"><name>Losartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.3082</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3082</amountMOHLTCPays></drug></pcg9><pcg9 id="240800226"><itemNumber>0761</itemNumber><strength>50mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02230047" chronicUseMed="Y" sec3="Y"><name>Hyzaar</name><manufacturerId>OCI</manufacturerId><individualPrice>1.9924</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02313375" chronicUseMed="Y" sec3="Y"><name>Sandoz Losartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02358263" chronicUseMed="Y" sec3="Y"><name>Teva-Losartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02371235" chronicUseMed="Y" sec3="Y"><name>Apo-Losartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388251" chronicUseMed="Y" sec3="Y"><name>Co Losartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388960" chronicUseMed="Y" sec3="Y"><name>Losartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02389657" chronicUseMed="Y" sec3="Y"><name>Mint-Losartan/HCTZ</name><manufacturerId>MIN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02392224" chronicUseMed="Y" sec3="Y"><name>PMS-Losartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02408244" chronicUseMed="Y" sec3="Y"><name>Jamp-Losartan HCTZ</name><manufacturerId>JPC</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02423642" chronicUseMed="Y" sec3="Y"><name>Auro-Losartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02427648" chronicUseMed="Y" sec3="Y"><name>Losartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02428539" chronicUseMed="Y" sec3="Y"><name>Septa-Losartan HCTZ</name><manufacturerId>SET</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug></pcg9><pcg9 id="240800241"><itemNumber>0762</itemNumber><strength>100mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02241007" chronicUseMed="Y" sec3="Y"><name>Hyzaar DS</name><manufacturerId>OCI</manufacturerId><individualPrice>1.9924</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02313383" chronicUseMed="Y" sec3="Y"><name>Sandoz Losartan HCT DS</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02371251" chronicUseMed="Y" sec3="Y"><name>Apo-Losartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02377152" chronicUseMed="Y" sec3="Y"><name>Teva-Losartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.3148</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388286" chronicUseMed="Y" sec3="Y"><name>Co Losartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02388987" chronicUseMed="Y" sec3="Y"><name>Losartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02389673" chronicUseMed="Y" sec3="Y"><name>Mint-Losartan/HCTZ DS</name><manufacturerId>MIN</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02392240" chronicUseMed="Y" sec3="Y"><name>PMS-Losartan-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02408252" chronicUseMed="Y" sec3="Y"><name>Jamp-Losartan HCTZ</name><manufacturerId>JPC</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02423669" chronicUseMed="Y" sec3="Y"><name>Auro-Losartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02427664" chronicUseMed="Y" sec3="Y"><name>Losartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug><drug id="02428547" chronicUseMed="Y" sec3="Y"><name>Septa-Losartan HCTZ</name><manufacturerId>SET</manufacturerId><individualPrice>.3147</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.3147</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00353"><name>METHYLDOPA</name><pcgGroup><pcg9 id="240800023"><itemNumber>0763</itemNumber><strength>125mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4036</dailyCost><drug id="00016551" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Aldomet</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00360252" chronicUseMed="Y" sec3="Y"><name>Methyldopa</name><manufacturerId>AAP</manufacturerId><individualPrice>.1009</individualPrice><dailyCost>.4036</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1009</amountMOHLTCPays></drug></pcg9><pcg9 id="240800013"><itemNumber>0764</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6316</dailyCost><drug id="00016578" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Aldomet</name><manufacturerId>MSD</manufacturerId><listingDate>2002-11-22</listingDate></drug><drug id="00360260" chronicUseMed="Y" sec3="Y"><name>Methyldopa</name><manufacturerId>AAP</manufacturerId><individualPrice>.1579</individualPrice><dailyCost>.6316</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1579</amountMOHLTCPays></drug></pcg9><pcg9 id="240800045"><itemNumber>0765</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><dailyCost>.5176</dailyCost><drug id="00016586" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Aldomet</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00426830" chronicUseMed="Y" sec3="Y"><name>Methyldopa</name><manufacturerId>AAP</manufacturerId><individualPrice>.2588</individualPrice><dailyCost>.5176</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2588</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00362"><name>MINOXIDIL</name><pcgGroup><pcg9 id="240800072"><itemNumber>0766</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="00514497" chronicUseMed="Y" sec3="Y"><name>Loniten</name><manufacturerId>PFI</manufacturerId><individualPrice>.5387</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5387</amountMOHLTCPays></drug></pcg9><pcg9 id="240800071"><itemNumber>0767</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00514500" chronicUseMed="Y" sec3="Y"><name>Loniten</name><manufacturerId>PFI</manufacturerId><individualPrice>1.1884</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.1884</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00318"><name>NIFEDIPINE</name><pcgGroup><pcg9 id="240800158"><itemNumber>0768</itemNumber><strength>30mg</strength><dosageForm>ER Tab</dosageForm><dailyCost>.6171</dailyCost><drug id="02155907" chronicUseMed="Y" sec3="Y"><name>Adalat XL</name><manufacturerId>BAY</manufacturerId><individualPrice>.6171</individualPrice><dailyCost>.6171</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6171</amountMOHLTCPays></drug><drug id="02349167" chronicUseMed="Y" sec3="Y"><name>Mylan-Nifedipine Extended Release</name><manufacturerId>MYL</manufacturerId><individualPrice>.6171</individualPrice><dailyCost>.6171</dailyCost><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.6171</amountMOHLTCPays></drug></pcg9><pcg9 id="240800159"><itemNumber>0769</itemNumber><strength>60mg</strength><dosageForm>ER Tab</dosageForm><dailyCost>.9374</dailyCost><drug id="02155990" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Adalat XL</name><manufacturerId>BAY</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02321149" chronicUseMed="Y" sec3="Y"><name>Mylan-Nifedipine Extended Release</name><manufacturerId>MYL</manufacturerId><individualPrice>.9374</individualPrice><dailyCost>.9374</dailyCost><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.9374</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01768"><name>OLMESARTAN MEDOXOMIL</name><pcgGroup><pcg9 id="240800284"><itemNumber>0770</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02318660" chronicUseMed="Y" sec3="Y"><name>Olmetec</name><manufacturerId>OCI</manufacturerId><individualPrice>1.3327</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02442191" chronicUseMed="Y" sec3="Y"><name>Teva-Olmesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443414" chronicUseMed="Y" sec3="Y"><name>Sandoz Olmesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443864" chronicUseMed="Y" sec3="Y"><name>Auro-Olmesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02453452" chronicUseMed="Y" sec3="Y"><name>Apo-Olmesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02456311" chronicUseMed="Y" sec3="Y"><name>Ach-Olmesartan</name><manufacturerId>ACH</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02461307" chronicUseMed="Y" sec3="Y"><name>PMS-Olmesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02461641" chronicUseMed="Y" sec3="Y"><name>Jamp-Olmesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02469812" chronicUseMed="Y" sec3="Y"><name>GLN-Olmesartan</name><manufacturerId>GLP</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02481057" chronicUseMed="Y" sec3="Y"><name>Olmesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02499258" chronicUseMed="Y" sec3="Y"><name>NRA-Olmesartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug></pcg9><pcg9 id="240800285"><itemNumber>0771</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02318679" chronicUseMed="Y" sec3="Y"><name>Olmetec</name><manufacturerId>OCI</manufacturerId><individualPrice>1.3327</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02442205" chronicUseMed="Y" sec3="Y"><name>Teva-Olmesartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443422" chronicUseMed="Y" sec3="Y"><name>Sandoz Olmesartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443872" chronicUseMed="Y" sec3="Y"><name>Auro-Olmesartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02453460" chronicUseMed="Y" sec3="Y"><name>Apo-Olmesartan</name><manufacturerId>APX</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02456338" chronicUseMed="Y" sec3="Y"><name>Ach-Olmesartan</name><manufacturerId>ACH</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02461315" chronicUseMed="Y" sec3="Y"><name>PMS-Olmesartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02461668" chronicUseMed="Y" sec3="Y"><name>Jamp-Olmesartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02469820" chronicUseMed="Y" sec3="Y"><name>GLN-Olmesartan</name><manufacturerId>GLP</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02481065" chronicUseMed="Y" sec3="Y"><name>Olmesartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02499266" chronicUseMed="Y" sec3="Y"><name>NRA-Olmesartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01769"><name>OLMESARTAN MEDOXOMIL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800286"><itemNumber>0772</itemNumber><strength>20mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02319616" chronicUseMed="Y" sec3="Y"><name>Olmetec Plus</name><manufacturerId>OCI</manufacturerId><individualPrice>1.3993</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443112" chronicUseMed="Y" sec3="Y"><name>Act Olmesartan HCT</name><manufacturerId>TEV</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02453606" chronicUseMed="Y" sec3="Y"><name>Apo-Olmesartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02468948" chronicUseMed="Y" sec3="Y"><name>Ach-Olmesartan HCTZ</name><manufacturerId>ACH</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02475707" chronicUseMed="Y" sec3="Y"><name>GLN-Olmesartan HCTZ</name><manufacturerId>GLP</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02476487" chronicUseMed="Y" sec3="Y"><name>Auro-Olmesartan HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02508273" chronicUseMed="Y" sec3="Y"><name>NRA-Olmesartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02509601" chronicUseMed="Y" sec3="Y"><name>Olmesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02526468" chronicUseMed="Y" sec3="Y"><name>PRZ-Olmesartan/HCTZ</name><manufacturerId>PRZ</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug></pcg9><pcg9 id="240800287"><itemNumber>0773</itemNumber><strength>40mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02319624" chronicUseMed="Y" sec3="Y"><name>Olmetec Plus</name><manufacturerId>OCI</manufacturerId><individualPrice>1.3993</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443120" chronicUseMed="Y" sec3="Y"><name>Act Olmesartan HCT</name><manufacturerId>TEV</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02453614" chronicUseMed="Y" sec3="Y"><name>Apo-Olmesartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02468956" chronicUseMed="Y" sec3="Y"><name>Ach-Olmesartan HCTZ</name><manufacturerId>ACH</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02475715" chronicUseMed="Y" sec3="Y"><name>GLN-Olmesartan HCTZ</name><manufacturerId>GLP</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02476495" chronicUseMed="Y" sec3="Y"><name>Auro-Olmesartan HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02508281" chronicUseMed="Y" sec3="Y"><name>NRA-Olmesartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02509636" chronicUseMed="Y" sec3="Y"><name>Olmesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02526476" chronicUseMed="Y" sec3="Y"><name>PRZ-Olmesartan/HCTZ</name><manufacturerId>PRZ</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug></pcg9><pcg9 id="240800288"><itemNumber>0774</itemNumber><strength>40mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02319632" chronicUseMed="Y" sec3="Y"><name>Olmetec Plus</name><manufacturerId>OCI</manufacturerId><individualPrice>1.3993</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02443139" chronicUseMed="Y" sec3="Y"><name>Act Olmesartan HCT</name><manufacturerId>TEV</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02453622" chronicUseMed="Y" sec3="Y"><name>Apo-Olmesartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02468964" chronicUseMed="Y" sec3="Y"><name>Ach-Olmesartan HCTZ</name><manufacturerId>ACH</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02475723" chronicUseMed="Y" sec3="Y"><name>GLN-Olmesartan HCTZ</name><manufacturerId>GLP</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02476509" chronicUseMed="Y" sec3="Y"><name>Auro-Olmesartan HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02508303" chronicUseMed="Y" sec3="Y"><name>NRA-Olmesartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02509628" chronicUseMed="Y" sec3="Y"><name>Olmesartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug><drug id="02526484" chronicUseMed="Y" sec3="Y"><name>PRZ-Olmesartan/HCTZ</name><manufacturerId>PRZ</manufacturerId><individualPrice>.3019</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.3019</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02096"><name>PERINDOPRIL ARGININE &amp; AMLODIPINE BESYLATE</name><pcgGroup><pcg9 id="240800304"><itemNumber>0775</itemNumber><strength>3.5mg &amp; 2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02451530" notABenefit="Y" sec3b="Y" sec3="Y"><name>Viacoram</name><manufacturerId>SEV</manufacturerId><listingDate>2019-07-31</listingDate></drug><drug id="02468565" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Perindopril/Amlodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.8075</individualPrice><listingDate>2019-07-31</listingDate></drug><drug id="02541696" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Perindopril-Amlodipine</name><manufacturerId>PMS</manufacturerId><individualPrice>.8075</individualPrice><listingDate>2024-04-30</listingDate></drug></pcg9><pcg9 id="240800305"><itemNumber>0776</itemNumber><strength>7mg &amp; 5mg</strength><dosageForm>Tab</dosageForm><drug id="02451549" notABenefit="Y" sec3b="Y" sec3="Y"><name>Viacoram</name><manufacturerId>SEV</manufacturerId><listingDate>2019-07-31</listingDate></drug><drug id="02468573" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Perindopril/Amlodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.8925</individualPrice><listingDate>2019-07-31</listingDate></drug><drug id="02541718" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Perindopril-Amlodipine</name><manufacturerId>PMS</manufacturerId><individualPrice>.8925</individualPrice><listingDate>2024-04-30</listingDate></drug></pcg9><pcg9 id="240800306"><itemNumber>0777</itemNumber><strength>14mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="02451557" notABenefit="Y" sec3b="Y" sec3="Y"><name>Viacoram</name><manufacturerId>SEV</manufacturerId><listingDate>2019-07-31</listingDate></drug><drug id="02468581" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Perindopril/Amlodipine</name><manufacturerId>APX</manufacturerId><individualPrice>.9775</individualPrice><listingDate>2019-07-31</listingDate></drug><drug id="02541726" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Perindopril-Amlodipine</name><manufacturerId>PMS</manufacturerId><individualPrice>.9775</individualPrice><listingDate>2024-04-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00386"><name>PERINDOPRIL ERBUMINE</name><pcgGroup><pcg9 id="240800208"><itemNumber>0778</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02123274" chronicUseMed="Y" sec3="Y"><name>Coversyl</name><manufacturerId>SEV</manufacturerId><individualPrice>.7790</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02289261" chronicUseMed="Y" sec3="Y"><name>Apo-Perindopril</name><manufacturerId>APX</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02459817" chronicUseMed="Y" sec3="Y"><name>Auro-Perindopril</name><manufacturerId>AUR</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02464985" chronicUseMed="Y" sec3="Y"><name>Teva-Perindopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02470225" chronicUseMed="Y" sec3="Y"><name>Sandoz Perindopril Erbumine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02470675" chronicUseMed="Y" sec3="Y"><name>PMS-Perindopril</name><manufacturerId>PMS</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02474824" chronicUseMed="Y" sec3="Y"><name>Mar-Perindopril</name><manufacturerId>MAR</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02476762" chronicUseMed="Y" sec3="Y"><name>Mint-Perindopril</name><manufacturerId>MIN</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02477009" chronicUseMed="Y" sec3="Y"><name>Jamp-Perindopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2019-09-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02479877" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine</name><manufacturerId>SIV</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02481634" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02481677" chronicUseMed="Y" sec3="Y"><name>AG-Perindopril</name><manufacturerId>ANG</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02482924" chronicUseMed="Y" sec3="Y"><name>M-Perindopril Erbumine</name><manufacturerId>MAT</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02489015" chronicUseMed="Y" sec3="Y"><name>NRA-Perindopril</name><manufacturerId>NRA</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug><drug id="02527200" chronicUseMed="Y" sec3="Y"><name>Jamp Perindopril Erbumine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1632</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1632</amountMOHLTCPays></drug></pcg9><pcg9 id="240800209"><itemNumber>0779</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02123282" chronicUseMed="Y" sec3="Y"><name>Coversyl</name><manufacturerId>SEV</manufacturerId><individualPrice>.9753</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02289288" chronicUseMed="Y" sec3="Y"><name>Apo-Perindopril</name><manufacturerId>APX</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02459825" chronicUseMed="Y" sec3="Y"><name>Auro-Perindopril</name><manufacturerId>AUR</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02464993" chronicUseMed="Y" sec3="Y"><name>Teva-Perindopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02470233" chronicUseMed="Y" sec3="Y"><name>Sandoz Perindopril Erbumine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02470683" chronicUseMed="Y" sec3="Y"><name>PMS-Perindopril</name><manufacturerId>PMS</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02474832" chronicUseMed="Y" sec3="Y"><name>Mar-Perindopril</name><manufacturerId>MAR</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02476770" chronicUseMed="Y" sec3="Y"><name>Mint-Perindopril</name><manufacturerId>MIN</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02477017" chronicUseMed="Y" sec3="Y"><name>Jamp-Perindopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02479885" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine</name><manufacturerId>SIV</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02481642" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine</name><manufacturerId>SAI</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02481685" chronicUseMed="Y" sec3="Y"><name>AG-Perindopril</name><manufacturerId>ANG</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02482932" chronicUseMed="Y" sec3="Y"><name>M-Perindopril Erbumine</name><manufacturerId>MAT</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02489023" chronicUseMed="Y" sec3="Y"><name>NRA-Perindopril</name><manufacturerId>NRA</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug><drug id="02527219" chronicUseMed="Y" sec3="Y"><name>Jamp Perindopril Erbumine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2042</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2042</amountMOHLTCPays></drug></pcg9><pcg9 id="240800257"><itemNumber>0780</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02246624" chronicUseMed="Y" sec3="Y"><name>Coversyl</name><manufacturerId>SEV</manufacturerId><individualPrice>1.3660</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02289296" chronicUseMed="Y" sec3="Y"><name>Apo-Perindopril</name><manufacturerId>APX</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2008-03-25</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02459833" chronicUseMed="Y" sec3="Y"><name>Auro-Perindopril</name><manufacturerId>AUR</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02465000" chronicUseMed="Y" sec3="Y"><name>Teva-Perindopril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02470241" chronicUseMed="Y" sec3="Y"><name>Sandoz Perindopril Erbumine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02470691" chronicUseMed="Y" sec3="Y"><name>PMS-Perindopril</name><manufacturerId>PMS</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02474840" chronicUseMed="Y" sec3="Y"><name>Mar-Perindopril</name><manufacturerId>MAR</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02476789" chronicUseMed="Y" sec3="Y"><name>Mint-Perindopril</name><manufacturerId>MIN</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02477025" chronicUseMed="Y" sec3="Y"><name>Jamp-Perindopril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02479893" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine</name><manufacturerId>SIV</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02481650" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine</name><manufacturerId>SAI</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02481693" chronicUseMed="Y" sec3="Y"><name>AG-Perindopril</name><manufacturerId>ANG</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02482940" chronicUseMed="Y" sec3="Y"><name>M-Perindopril Erbumine</name><manufacturerId>MAT</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02489031" chronicUseMed="Y" sec3="Y"><name>NRA-Perindopril</name><manufacturerId>NRA</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug><drug id="02527227" chronicUseMed="Y" sec3="Y"><name>Jamp Perindopril Erbumine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2831</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2831</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01699"><name>PERINDOPRIL ERBUMINE &amp; INDAPAMIDE</name><pcgGroup><pcg9 id="240800265"><itemNumber>0781</itemNumber><strength>2mg &amp; 0.625mg</strength><dosageForm>Tab</dosageForm><drug id="02246568" chronicUseMed="Y" sec3="Y"><name>Coversyl Plus LD</name><manufacturerId>SEV</manufacturerId><individualPrice>1.0160</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.4227</amountMOHLTCPays></drug><drug id="02470411" chronicUseMed="Y" sec3="Y"><name>Sandoz Perindopril Erbumine/IndapamideLD</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4227</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.4227</amountMOHLTCPays></drug><drug id="02537990" chronicUseMed="Y" sec3="Y"><name>PMS-Perindopril-Indapamide</name><manufacturerId>PMS</manufacturerId><individualPrice>.4227</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.4227</amountMOHLTCPays></drug></pcg9><pcg9 id="240800264"><itemNumber>0782</itemNumber><strength>4mg &amp; 1.25mg</strength><dosageForm>Tab</dosageForm><drug id="02246569" chronicUseMed="Y" sec3="Y"><name>Coversyl Plus</name><manufacturerId>SEV</manufacturerId><individualPrice>1.2080</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug><drug id="02297574" chronicUseMed="Y" sec3="Y"><name>Apo-Perindopril-Indapamide</name><manufacturerId>APX</manufacturerId><individualPrice>.2556</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug><drug id="02464020" chronicUseMed="Y" sec3="Y"><name>Teva-Perindopril/Indapamide</name><manufacturerId>TEV</manufacturerId><individualPrice>.2556</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug><drug id="02470438" chronicUseMed="Y" sec3="Y"><name>Sandoz Perindopril Erbumine/Indapamide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2556</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug><drug id="02479834" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine/Indapamide</name><manufacturerId>SIV</manufacturerId><individualPrice>.2556</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug><drug id="02519720" chronicUseMed="Y" sec3="Y"><name>Perindopril/Indapamide</name><manufacturerId>SAI</manufacturerId><individualPrice>.2556</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug><drug id="02538008" chronicUseMed="Y" sec3="Y"><name>PMS-Perindopril-Indapamide</name><manufacturerId>PMS</manufacturerId><individualPrice>.2556</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.2556</amountMOHLTCPays></drug></pcg9><pcg9 id="240800283"><itemNumber>0783</itemNumber><strength>8mg &amp; 2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02321653" chronicUseMed="Y" sec3="Y"><name>Coversyl Plus HD</name><manufacturerId>SEV</manufacturerId><individualPrice>1.3660</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug><drug id="02453061" chronicUseMed="Y" sec3="Y"><name>Apo-Perindopril-Indapamide</name><manufacturerId>APX</manufacturerId><individualPrice>.2859</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug><drug id="02464039" chronicUseMed="Y" sec3="Y"><name>Teva-Perindopril/Indapamide</name><manufacturerId>TEV</manufacturerId><individualPrice>.2859</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug><drug id="02470446" chronicUseMed="Y" sec3="Y"><name>Sandoz Perindopril Erbumine/IndapamideHD</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2859</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug><drug id="02479842" chronicUseMed="Y" sec3="Y"><name>Perindopril Erbumine/Indapamide HD</name><manufacturerId>SIV</manufacturerId><individualPrice>.2859</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug><drug id="02519739" chronicUseMed="Y" sec3="Y"><name>Perindopril/Indapamide</name><manufacturerId>SAI</manufacturerId><individualPrice>.2859</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug><drug id="02537982" chronicUseMed="Y" sec3="Y"><name>PMS-Perindopril-Indapamide</name><manufacturerId>PMS</manufacturerId><individualPrice>.2859</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.2859</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00359"><name>PINDOLOL</name><pcgGroup><pcg9 id="240800058"><itemNumber>0784</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.8136</dailyCost><drug id="00417270" chronicUseMed="Y" sec3="Y"><name>Visken</name><manufacturerId>ARZ</manufacturerId><individualPrice>.8502</individualPrice><dailyCost>1.7004</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4068</amountMOHLTCPays></drug><drug id="00869007" chronicUseMed="Y" sec3="Y"><name>Teva-Pindolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.4068</individualPrice><dailyCost>.8136</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4068</amountMOHLTCPays></drug></pcg9><pcg9 id="240800057"><itemNumber>0785</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.3894</dailyCost><drug id="00443174" chronicUseMed="Y" sec3="Y"><name>Visken</name><manufacturerId>ARZ</manufacturerId><individualPrice>1.4517</individualPrice><dailyCost>2.9034</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6947</amountMOHLTCPays></drug><drug id="00869015" chronicUseMed="Y" sec3="Y"><name>Teva-Pindolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.6947</individualPrice><dailyCost>1.3894</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6947</amountMOHLTCPays></drug></pcg9><pcg9 id="240800056"><itemNumber>0786</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.9566</dailyCost><drug id="00417289" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Visken</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00869023" chronicUseMed="Y" sec3="Y"><name>Teva-Pindolol</name><manufacturerId>TEV</manufacturerId><individualPrice>.9783</individualPrice><dailyCost>1.9566</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9783</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00365"><name>PINDOLOL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800086"><itemNumber>0787</itemNumber><strength>10mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="00568627" chronicUseMed="Y" sec3="Y"><name>Viskazide</name><manufacturerId>ARZ</manufacturerId><individualPrice>1.3398</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.3398</amountMOHLTCPays></drug></pcg9><pcg9 id="240800085"><itemNumber>0788</itemNumber><strength>10mg &amp; 50mg</strength><dosageForm>Tab</dosageForm><drug id="00568635" chronicUseMed="Y" sec3="Y"><name>Viskazide</name><manufacturerId>ARZ</manufacturerId><individualPrice>1.3398</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.3398</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00366"><name>PRAZOSIN HCL</name><pcgGroup><pcg9 id="240800309"><itemNumber>0789</itemNumber><strength>1mg</strength><dosageForm>Cap</dosageForm><drug id="09858281" chronicUseMed="Y" sec3c="Y"><name>Prazosin Hydrochloride Capsules, USP</name><manufacturerId>STE</manufacturerId><individualPrice>.2743</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>.2743</amountMOHLTCPays></drug></pcg9><pcg9 id="240800310"><itemNumber>0790</itemNumber><strength>2mg</strength><dosageForm>Cap</dosageForm><drug id="09858282" chronicUseMed="Y" sec3c="Y"><name>Prazosin Hydrochloride Capsules, USP</name><manufacturerId>STE</manufacturerId><individualPrice>.3725</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>.3725</amountMOHLTCPays></drug></pcg9><pcg9 id="240800311"><itemNumber>0791</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="09858283" chronicUseMed="Y" sec3c="Y"><name>Prazosin Hydrochloride Capsules, USP</name><manufacturerId>STE</manufacturerId><individualPrice>.5121</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>.5121</amountMOHLTCPays></drug></pcg9><pcg9 id="240800089"><itemNumber>0792</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><dailyCost>.5486</dailyCost><drug id="00560952" chronicUseMed="Y" sec3="Y"><name>Minipress</name><manufacturerId>PFI</manufacturerId><individualPrice>.2743</individualPrice><dailyCost>.5486</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2743</amountMOHLTCPays></drug><drug id="00882801" chronicUseMed="Y" sec3="Y"><name>Apo-Prazo</name><manufacturerId>APX</manufacturerId><individualPrice>.2743</individualPrice><dailyCost>.5486</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2743</amountMOHLTCPays></drug><drug id="01934198" chronicUseMed="Y" sec3="Y"><name>Teva-Prazosin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2743</individualPrice><dailyCost>.5486</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2743</amountMOHLTCPays></drug></pcg9><pcg9 id="240800088"><itemNumber>0793</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><dailyCost>.7450</dailyCost><drug id="00560960" chronicUseMed="Y" sec3="Y"><name>Minipress</name><manufacturerId>PFI</manufacturerId><individualPrice>.3725</individualPrice><dailyCost>.7450</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3725</amountMOHLTCPays></drug><drug id="00882828" chronicUseMed="Y" sec3="Y"><name>Apo-Prazo</name><manufacturerId>APX</manufacturerId><individualPrice>.3725</individualPrice><dailyCost>.7450</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3725</amountMOHLTCPays></drug><drug id="01934201" chronicUseMed="Y" sec3="Y"><name>Teva-Prazosin</name><manufacturerId>TEV</manufacturerId><individualPrice>.3725</individualPrice><dailyCost>.7450</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3725</amountMOHLTCPays></drug></pcg9><pcg9 id="240800087"><itemNumber>0794</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>1.0242</dailyCost><drug id="00560979" chronicUseMed="Y" sec3="Y"><name>Minipress</name><manufacturerId>PFI</manufacturerId><individualPrice>.5121</individualPrice><dailyCost>1.0242</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5121</amountMOHLTCPays></drug><drug id="00882836" chronicUseMed="Y" sec3="Y"><name>Apo-Prazo</name><manufacturerId>APX</manufacturerId><individualPrice>.5121</individualPrice><dailyCost>1.0242</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5121</amountMOHLTCPays></drug><drug id="01934228" chronicUseMed="Y" sec3="Y"><name>Teva-Prazosin</name><manufacturerId>TEV</manufacturerId><individualPrice>.5121</individualPrice><dailyCost>1.0242</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5121</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01930"><name>QUINAPRIL</name><pcgGroup><pcg9 id="240800160"><itemNumber>0795</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4642</dailyCost><drug id="01947664" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accupril</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02248499" chronicUseMed="Y" sec3="Y"><name>Apo-Quinapril</name><manufacturerId>APX</manufacturerId><individualPrice>.4642</individualPrice><dailyCost>.4642</dailyCost><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.4642</amountMOHLTCPays></drug><drug id="02340550" chronicUseMed="Y" sec3="Y"><name>PMS-Quinapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.4642</individualPrice><dailyCost>.4642</dailyCost><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.4642</amountMOHLTCPays></drug></pcg9><pcg9 id="240800161"><itemNumber>0796</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2321</dailyCost><drug id="01947672" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accupril</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02248500" chronicUseMed="Y" sec3="Y"><name>Apo-Quinapril</name><manufacturerId>APX</manufacturerId><individualPrice>.2321</individualPrice><dailyCost>.2321</dailyCost><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.2321</amountMOHLTCPays></drug><drug id="02340569" chronicUseMed="Y" sec3="Y"><name>PMS-Quinapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.2321</individualPrice><dailyCost>.2321</dailyCost><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.2321</amountMOHLTCPays></drug><drug id="02517450" chronicUseMed="Y" sec3="Y"><name>Jamp Quinapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.2321</individualPrice><dailyCost>.2321</dailyCost><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.2321</amountMOHLTCPays></drug></pcg9><pcg9 id="240800162"><itemNumber>0797</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4642</dailyCost><drug id="01947680" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accupril</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02340577" chronicUseMed="Y" sec3="Y"><name>PMS-Quinapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.4642</individualPrice><dailyCost>.4642</dailyCost><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.4642</amountMOHLTCPays></drug><drug id="02517469" chronicUseMed="Y" sec3="Y"><name>Jamp Quinapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.4642</individualPrice><dailyCost>.4642</dailyCost><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4642</amountMOHLTCPays></drug></pcg9><pcg9 id="240800163"><itemNumber>0798</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><dailyCost>.4642</dailyCost><drug id="01947699" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accupril</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02340585" chronicUseMed="Y" sec3="Y"><name>PMS-Quinapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.4642</individualPrice><dailyCost>.4642</dailyCost><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.4642</amountMOHLTCPays></drug><drug id="02517477" chronicUseMed="Y" sec3="Y"><name>Jamp Quinapril</name><manufacturerId>JPC</manufacturerId><individualPrice>.4642</individualPrice><dailyCost>.4642</dailyCost><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4642</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01931"><name>QUINAPRIL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800239"><itemNumber>0799</itemNumber><strength>10mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02237367" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accuretic</name><manufacturerId>PFI</manufacturerId><listingDate>2000-07-17</listingDate></drug><drug id="02408767" chronicUseMed="Y" sec3="Y"><name>Apo-Quinapril/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2393</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.2393</amountMOHLTCPays></drug><drug id="02473291" chronicUseMed="Y" sec3="Y"><name>Auro-Quinapril HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.2393</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.2393</amountMOHLTCPays></drug><drug id="02547430" chronicUseMed="Y" sec3="Y"><name>Jamp Quinapril / HCTZ</name><manufacturerId>JPC</manufacturerId><individualPrice>.2393</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.2393</amountMOHLTCPays></drug></pcg9><pcg9 id="240800240"><itemNumber>0800</itemNumber><strength>20mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02237368" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accuretic</name><manufacturerId>PFI</manufacturerId><listingDate>2000-07-17</listingDate></drug><drug id="02408775" chronicUseMed="Y" sec3="Y"><name>Apo-Quinapril/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.4786</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.4786</amountMOHLTCPays></drug><drug id="02473305" chronicUseMed="Y" sec3="Y"><name>Auro-Quinapril HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.4786</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.4786</amountMOHLTCPays></drug></pcg9><pcg9 id="240800256"><itemNumber>0801</itemNumber><strength>20mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02237369" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Accuretic</name><manufacturerId>PFI</manufacturerId><listingDate>2004-04-06</listingDate></drug><drug id="02408783" chronicUseMed="Y" sec3="Y"><name>Apo-Quinapril/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2301</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.2301</amountMOHLTCPays></drug><drug id="02473321" chronicUseMed="Y" sec3="Y"><name>Auro-Quinapril HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.2301</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.2301</amountMOHLTCPays></drug><drug id="02547449" chronicUseMed="Y" sec3="Y"><name>Jamp Quinapril / HCTZ</name><manufacturerId>JPC</manufacturerId><individualPrice>.2301</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.2301</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00385"><name>RAMIPRIL</name><pcgGroup><pcg9 id="240800203"><itemNumber>0802</itemNumber><strength>1.25mg</strength><drug id="02221829" chronicUseMed="Y" sec3="Y"><name>Altace Cap</name><manufacturerId>SAV</manufacturerId><individualPrice>.9829</individualPrice><listingDate>1999-01-06</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02251515" chronicUseMed="Y" sec3="Y"><name>Apo-Ramipril Cap</name><manufacturerId>APX</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02295369" chronicUseMed="Y" sec3="Y"><name>PMS-Ramipril Cap</name><manufacturerId>PMS</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02295482" chronicUseMed="Y" sec3="Y"><name>Co Ramipril Cap</name><manufacturerId>COB</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02299372" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>RIA</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02308363" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SIV</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02310503" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril Cap</name><manufacturerId>RAN</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02331101" chronicUseMed="Y" sec3="Y"><name>Jamp-Ramipril Cap</name><manufacturerId>JPC</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02387387" chronicUseMed="Y" sec3="Y"><name>Auro-Ramipril Cap</name><manufacturerId>AUR</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02420457" chronicUseMed="Y" sec3="Y"><name>Mar-Ramipril Cap</name><manufacturerId>MAR</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug><drug id="02469057" chronicUseMed="Y" sec3="Y"><name>Pharma-Ramipril</name><manufacturerId>PMS</manufacturerId><individualPrice>.0708</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.0708</amountMOHLTCPays></drug></pcg9><pcg9 id="240800204"><itemNumber>0803</itemNumber><strength>2.5mg</strength><drug id="02221837" chronicUseMed="Y" sec3="Y"><name>Altace Cap</name><manufacturerId>SAV</manufacturerId><individualPrice>1.1058</individualPrice><listingDate>1999-01-06</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02247945" chronicUseMed="Y" sec3="Y"><name>Teva-Ramipril Cap</name><manufacturerId>TEV</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02251531" chronicUseMed="Y" sec3="Y"><name>Apo-Ramipril Cap</name><manufacturerId>APX</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02255316" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>RIA</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02287706" chronicUseMed="Y" sec3="Y"><name>Ratio-Ramipril Cap</name><manufacturerId>RPH</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02287927" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SIV</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02295490" chronicUseMed="Y" sec3="Y"><name>Co Ramipril Cap</name><manufacturerId>COB</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02310511" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril Cap</name><manufacturerId>RAN</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02331128" chronicUseMed="Y" sec3="Y"><name>Jamp-Ramipril Cap</name><manufacturerId>JPC</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02374846" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SAI</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02387395" chronicUseMed="Y" sec3="Y"><name>Auro-Ramipril Cap</name><manufacturerId>AUR</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02420465" chronicUseMed="Y" sec3="Y"><name>Mar-Ramipril Cap</name><manufacturerId>MAR</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02421305" chronicUseMed="Y" sec3="Y"><name>Mint-Ramipril Cap</name><manufacturerId>MIN</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02469065" chronicUseMed="Y" sec3="Y"><name>Pharma-Ramipril</name><manufacturerId>PMS</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02477572" chronicUseMed="Y" sec3="Y"><name>AG-Ramipril Cap</name><manufacturerId>ANG</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02486172" chronicUseMed="Y" sec3="Y"><name>NRA-Ramipril Cap</name><manufacturerId>NRA</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug></pcg9><pcg9 id="240800205"><itemNumber>0804</itemNumber><strength>5mg</strength><drug id="02221845" chronicUseMed="Y" sec3="Y"><name>Altace Cap</name><manufacturerId>SAV</manufacturerId><individualPrice>1.1346</individualPrice><listingDate>1999-01-06</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02247946" chronicUseMed="Y" sec3="Y"><name>Teva-Ramipril Cap</name><manufacturerId>TEV</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02251574" chronicUseMed="Y" sec3="Y"><name>Apo-Ramipril Cap</name><manufacturerId>APX</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02255324" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>RIA</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02287935" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SIV</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02295504" chronicUseMed="Y" sec3="Y"><name>Co Ramipril Cap</name><manufacturerId>COB</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02310538" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril Cap</name><manufacturerId>RAN</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02331136" chronicUseMed="Y" sec3="Y"><name>Jamp-Ramipril Cap</name><manufacturerId>JPC</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02374854" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SAI</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02387409" chronicUseMed="Y" sec3="Y"><name>Auro-Ramipril Cap</name><manufacturerId>AUR</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02420473" chronicUseMed="Y" sec3="Y"><name>Mar-Ramipril Cap</name><manufacturerId>MAR</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02421313" chronicUseMed="Y" sec3="Y"><name>Mint-Ramipril Cap</name><manufacturerId>MIN</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02469073" chronicUseMed="Y" sec3="Y"><name>Pharma-Ramipril</name><manufacturerId>PMS</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02477580" chronicUseMed="Y" sec3="Y"><name>AG-Ramipril Cap</name><manufacturerId>ANG</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug><drug id="02486180" chronicUseMed="Y" sec3="Y"><name>NRA-Ramipril Cap</name><manufacturerId>NRA</manufacturerId><individualPrice>.0817</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.0817</amountMOHLTCPays></drug></pcg9><pcg9 id="240800206"><itemNumber>0805</itemNumber><strength>10mg</strength><drug id="02221853" chronicUseMed="Y" sec3="Y"><name>Altace Cap</name><manufacturerId>SAV</manufacturerId><individualPrice>1.4577</individualPrice><listingDate>1999-01-06</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02247947" chronicUseMed="Y" sec3="Y"><name>Teva-Ramipril Cap</name><manufacturerId>TEV</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02251582" chronicUseMed="Y" sec3="Y"><name>Apo-Ramipril Cap</name><manufacturerId>APX</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02255332" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>RIA</manufacturerId><listingDate>2008-08-28</listingDate></drug><drug id="02287943" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SIV</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02295512" chronicUseMed="Y" sec3="Y"><name>Co Ramipril Cap</name><manufacturerId>COB</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02310546" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril Cap</name><manufacturerId>RAN</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02331144" chronicUseMed="Y" sec3="Y"><name>Jamp-Ramipril Cap</name><manufacturerId>JPC</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02374862" chronicUseMed="Y" sec3="Y"><name>Ramipril Cap</name><manufacturerId>SAI</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02387417" chronicUseMed="Y" sec3="Y"><name>Auro-Ramipril Cap</name><manufacturerId>AUR</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02420481" chronicUseMed="Y" sec3="Y"><name>Mar-Ramipril Cap</name><manufacturerId>MAR</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02421321" chronicUseMed="Y" sec3="Y"><name>Mint-Ramipril Cap</name><manufacturerId>MIN</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02469081" chronicUseMed="Y" sec3="Y"><name>Pharma-Ramipril</name><manufacturerId>PMS</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02477599" chronicUseMed="Y" sec3="Y"><name>AG-Ramipril Cap</name><manufacturerId>ANG</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug><drug id="02486199" chronicUseMed="Y" sec3="Y"><name>NRA-Ramipril Cap</name><manufacturerId>NRA</manufacturerId><individualPrice>.1034</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.1034</amountMOHLTCPays></drug></pcg9><pcg9 id="240800280"><itemNumber>0806</itemNumber><strength>15mg</strength><dosageForm>Cap</dosageForm><drug id="02281112" notABenefit="Y" sec3b="Y" sec3="Y"><name>Altace</name><manufacturerId>SAV</manufacturerId><listingDate>2009-06-23</listingDate></drug><drug id="02325381" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Ramipril</name><manufacturerId>APX</manufacturerId><individualPrice>.8550</individualPrice><listingDate>2009-06-23</listingDate></drug><drug id="02420503" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Ramipril</name><manufacturerId>MAR</manufacturerId><individualPrice>.8550</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02421348" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Ramipril</name><manufacturerId>MIN</manufacturerId><individualPrice>.8132</individualPrice><listingDate>2014-06-26</listingDate></drug><drug id="02425548" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Ramipril</name><manufacturerId>RAN</manufacturerId><individualPrice>.8550</individualPrice><listingDate>2015-02-26</listingDate></drug><drug id="02440334" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Ramipril</name><manufacturerId>JPC</manufacturerId><individualPrice>.8550</individualPrice><listingDate>2016-09-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01705"><name>RAMIPRIL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800266"><itemNumber>0807</itemNumber><strength>2.5mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02283131" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Altace HCT</name><manufacturerId>SAV</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02449439" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2242</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.2242</amountMOHLTCPays></drug></pcg9><pcg9 id="240800267"><itemNumber>0808</itemNumber><strength>5mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02283158" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Altace HCT</name><manufacturerId>SAV</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02449447" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.3016</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.3016</amountMOHLTCPays></drug></pcg9><pcg9 id="240800269"><itemNumber>0809</itemNumber><strength>5mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02283174" chronicUseMed="Y" sec3="Y"><name>Altace HCT</name><manufacturerId>SAV</manufacturerId><individualPrice>.4981</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.2872</amountMOHLTCPays></drug><drug id="02449463" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2872</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.2872</amountMOHLTCPays></drug></pcg9><pcg9 id="240800268"><itemNumber>0810</itemNumber><strength>10mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02283166" chronicUseMed="Y" sec3="Y"><name>Altace HCT</name><manufacturerId>SAV</manufacturerId><individualPrice>.6675</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.2634</amountMOHLTCPays></drug><drug id="02342154" chronicUseMed="Y" sec3="Y"><name>PMS-Ramipril-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.2634</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2634</amountMOHLTCPays></drug><drug id="02449455" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2634</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.2634</amountMOHLTCPays></drug></pcg9><pcg9 id="240800270"><itemNumber>0811</itemNumber><strength>10mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02283182" chronicUseMed="Y" sec3="Y"><name>Altace HCT</name><manufacturerId>SAV</manufacturerId><individualPrice>.6525</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.2634</amountMOHLTCPays></drug><drug id="02342170" chronicUseMed="Y" sec3="Y"><name>PMS-Ramipril-HCTZ</name><manufacturerId>PMS</manufacturerId><individualPrice>.2634</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2634</amountMOHLTCPays></drug><drug id="02449471" chronicUseMed="Y" sec3="Y"><name>Ran-Ramipril HCTZ</name><manufacturerId>RAN</manufacturerId><individualPrice>.2634</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.2634</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01435"><name>TELMISARTAN</name><pcgGroup><pcg9 id="240800237"><itemNumber>0812</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02240769" chronicUseMed="Y" sec3="Y"><name>Micardis</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3897</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02320177" chronicUseMed="Y" sec3="Y"><name>Teva-Telmisartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02375958" chronicUseMed="Y" sec3="Y"><name>Sandoz Telmisartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02386755" chronicUseMed="Y" sec3="Y"><name>Jamp Telmisartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02388944" chronicUseMed="Y" sec3="Y"><name>Telmisartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02390345" chronicUseMed="Y" sec3="Y"><name>Telmisartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02407485" chronicUseMed="Y" sec3="Y"><name>Ach-Telmisartan</name><manufacturerId>ACH</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02420082" chronicUseMed="Y" sec3="Y"><name>Apo-Telmisartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02453568" chronicUseMed="Y" sec3="Y"><name>Auro-Telmisartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02486369" chronicUseMed="Y" sec3="Y"><name>Mint-Telmisartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02499622" chronicUseMed="Y" sec3="Y"><name>PMS-Telmisartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02503794" chronicUseMed="Y" sec3="Y"><name>NRA-Telmisartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug></pcg9><pcg9 id="240800238"><itemNumber>0813</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02240770" chronicUseMed="Y" sec3="Y"><name>Micardis</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3897</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02320185" chronicUseMed="Y" sec3="Y"><name>Teva-Telmisartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02375966" chronicUseMed="Y" sec3="Y"><name>Sandoz Telmisartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02386763" chronicUseMed="Y" sec3="Y"><name>Jamp Telmisartan</name><manufacturerId>JPC</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02388952" chronicUseMed="Y" sec3="Y"><name>Telmisartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02390353" chronicUseMed="Y" sec3="Y"><name>Telmisartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02393255" chronicUseMed="Y" sec3="Y"><name>Co Telmisartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02407493" chronicUseMed="Y" sec3="Y"><name>Ach-Telmisartan</name><manufacturerId>ACH</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02420090" chronicUseMed="Y" sec3="Y"><name>Apo-Telmisartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02453576" chronicUseMed="Y" sec3="Y"><name>Auro-Telmisartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02486377" chronicUseMed="Y" sec3="Y"><name>Mint-Telmisartan</name><manufacturerId>MIN</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02499630" chronicUseMed="Y" sec3="Y"><name>PMS-Telmisartan</name><manufacturerId>PMS</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug><drug id="02503808" chronicUseMed="Y" sec3="Y"><name>NRA-Telmisartan</name><manufacturerId>NRA</manufacturerId><individualPrice>.2161</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.2161</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01875"><name>TELMISARTAN &amp; AMLODIPINE BESYLATE</name><pcgGroup><pcg9 id="240800298"><itemNumber>0814</itemNumber><strength>40mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="02371030" chronicUseMed="Y" sec3="Y"><name>Twynsta</name><manufacturerId>BOE</manufacturerId><individualPrice>.8128</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.8128</amountMOHLTCPays></drug></pcg9><pcg9 id="240800296"><itemNumber>0815</itemNumber><strength>40mg &amp; 5mg</strength><dosageForm>Tab</dosageForm><drug id="02371022" chronicUseMed="Y" sec3="Y"><name>Twynsta</name><manufacturerId>BOE</manufacturerId><individualPrice>.8128</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.8128</amountMOHLTCPays></drug></pcg9><pcg9 id="240800299"><itemNumber>0816</itemNumber><strength>80mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="02371057" chronicUseMed="Y" sec3="Y"><name>Twynsta</name><manufacturerId>BOE</manufacturerId><individualPrice>.8128</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.8128</amountMOHLTCPays></drug></pcg9><pcg9 id="240800297"><itemNumber>0817</itemNumber><strength>80mg &amp; 5mg</strength><dosageForm>Tab</dosageForm><drug id="02371049" chronicUseMed="Y" sec3="Y"><name>Twynsta</name><manufacturerId>BOE</manufacturerId><individualPrice>.8128</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.8128</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01559"><name>TELMISARTAN &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800249"><itemNumber>0818</itemNumber><strength>80mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02244344" chronicUseMed="Y" sec3="Y"><name>Micardis Plus</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3897</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02330288" chronicUseMed="Y" sec3="Y"><name>Teva-Telmisartan HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02389940" chronicUseMed="Y" sec3="Y"><name>Jamp Telmisartan-HCT</name><manufacturerId>JPC</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02390302" chronicUseMed="Y" sec3="Y"><name>Telmisartan HCTZ</name><manufacturerId>SIV</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02393263" chronicUseMed="Y" sec3="Y"><name>Co Telmisartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02393557" chronicUseMed="Y" sec3="Y"><name>Sandoz Telmisartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02395355" chronicUseMed="Y" sec3="Y"><name>Telmisartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02419114" chronicUseMed="Y" sec3="Y"><name>Telmisartan and Hydrochlorothiazide Tab</name><manufacturerId>ACH</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02420023" chronicUseMed="Y" sec3="Y"><name>Apo-Telmisartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02456389" chronicUseMed="Y" sec3="Y"><name>Auro-Telmisartan HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02504146" chronicUseMed="Y" sec3="Y"><name>NRA-Telmisartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug></pcg9><pcg9 id="240800281"><itemNumber>0819</itemNumber><strength>80mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02318709" chronicUseMed="Y" sec3="Y"><name>Micardis Plus</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3897</individualPrice><listingDate>2009-11-13</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02379252" chronicUseMed="Y" sec3="Y"><name>Teva-Telmisartan HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02389959" chronicUseMed="Y" sec3="Y"><name>Jamp Telmisartan-HCT</name><manufacturerId>JPC</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02390310" chronicUseMed="Y" sec3="Y"><name>Telmisartan HCTZ</name><manufacturerId>SIV</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02393271" chronicUseMed="Y" sec3="Y"><name>Co Telmisartan/HCT</name><manufacturerId>COB</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02393565" chronicUseMed="Y" sec3="Y"><name>Sandoz Telmisartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02395363" chronicUseMed="Y" sec3="Y"><name>Telmisartan/HCTZ</name><manufacturerId>SAI</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02419122" chronicUseMed="Y" sec3="Y"><name>Telmisartan and Hydrochlorothiazide Tab</name><manufacturerId>ACH</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02420031" chronicUseMed="Y" sec3="Y"><name>Apo-Telmisartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02456397" chronicUseMed="Y" sec3="Y"><name>Auro-Telmisartan HCTZ</name><manufacturerId>AUR</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02504138" chronicUseMed="Y" sec3="Y"><name>NRA-Telmisartan HCTZ</name><manufacturerId>NRA</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00370"><name>TERAZOSIN HCL</name><pcgGroup><pcg9 id="240800131"><itemNumber>0820</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><dailyCost>.3938</dailyCost><drug id="00818658" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Hytrin</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02234502" chronicUseMed="Y" sec3="Y"><name>Apo-Terazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.3938</individualPrice><dailyCost>.3938</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.3938</amountMOHLTCPays></drug><drug id="02243518" chronicUseMed="Y" sec3="Y"><name>PMS-Terazosin</name><manufacturerId>PMS</manufacturerId><individualPrice>.3938</individualPrice><dailyCost>.3938</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.3938</amountMOHLTCPays></drug></pcg9><pcg9 id="240800132"><itemNumber>0821</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><dailyCost>.5005</dailyCost><drug id="00818682" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Hytrin</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02234503" chronicUseMed="Y" sec3="Y"><name>Apo-Terazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.5005</individualPrice><dailyCost>.5005</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.5005</amountMOHLTCPays></drug><drug id="02243519" chronicUseMed="Y" sec3="Y"><name>PMS-Terazosin</name><manufacturerId>PMS</manufacturerId><individualPrice>.5005</individualPrice><dailyCost>.5005</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.5005</amountMOHLTCPays></drug></pcg9><pcg9 id="240800133"><itemNumber>0822</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.6797</dailyCost><drug id="00818666" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Hytrin</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02234504" chronicUseMed="Y" sec3="Y"><name>Apo-Terazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.6797</individualPrice><dailyCost>.6797</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.6797</amountMOHLTCPays></drug><drug id="02243520" chronicUseMed="Y" sec3="Y"><name>PMS-Terazosin</name><manufacturerId>PMS</manufacturerId><individualPrice>.6797</individualPrice><dailyCost>.6797</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.6797</amountMOHLTCPays></drug></pcg9><pcg9 id="240800213"><itemNumber>0823</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><dailyCost>.9950</dailyCost><drug id="00818674" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Hytrin</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02234505" chronicUseMed="Y" sec3="Y"><name>Apo-Terazosin</name><manufacturerId>APX</manufacturerId><individualPrice>.9950</individualPrice><dailyCost>.9950</dailyCost><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.9950</amountMOHLTCPays></drug><drug id="02243521" chronicUseMed="Y" sec3="Y"><name>PMS-Terazosin</name><manufacturerId>PMS</manufacturerId><individualPrice>.9950</individualPrice><dailyCost>.9950</dailyCost><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.9950</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01398"><name>TRANDOLAPRIL</name><pcgGroup><pcg9 id="240800303"><itemNumber>0824</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02231457" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mavik</name><manufacturerId>BGP</manufacturerId><listingDate>2018-07-31</listingDate></drug><drug id="02325721" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Trandolapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2372</individualPrice><listingDate>2018-09-27</listingDate></drug><drug id="02357755" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Trandolapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.2372</individualPrice><listingDate>2018-07-31</listingDate></drug><drug id="02415429" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Trandolapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2372</individualPrice><listingDate>2018-11-29</listingDate></drug><drug id="02471868" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Trandolapril</name><manufacturerId>AUR</manufacturerId><individualPrice>.2372</individualPrice><listingDate>2018-11-29</listingDate></drug></pcg9><pcg9 id="240800228"><itemNumber>0825</itemNumber><strength>1mg</strength><dosageForm>Cap</dosageForm><drug id="02231459" chronicUseMed="Y" sec3="Y"><name>Mavik</name><manufacturerId>BGP</manufacturerId><individualPrice>.7471</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug><drug id="02325748" chronicUseMed="Y" sec3="Y"><name>Sandoz Trandolapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1762</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug><drug id="02357763" chronicUseMed="Y" sec3="Y"><name>PMS-Trandolapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.1762</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug><drug id="02415437" chronicUseMed="Y" sec3="Y"><name>Teva-Trandolapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.1762</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug><drug id="02471876" chronicUseMed="Y" sec3="Y"><name>Auro-Trandolapril</name><manufacturerId>AUR</manufacturerId><individualPrice>.1762</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug><drug id="02525046" chronicUseMed="Y" sec3="Y"><name>Trandolapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.1762</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug><drug id="02526565" chronicUseMed="Y" sec3="Y"><name>Trandolapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.1762</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1762</amountMOHLTCPays></drug></pcg9><pcg9 id="240800229"><itemNumber>0826</itemNumber><strength>2mg</strength><dosageForm>Cap</dosageForm><drug id="02231460" chronicUseMed="Y" sec3="Y"><name>Mavik</name><manufacturerId>BGP</manufacturerId><individualPrice>.8586</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="02325756" chronicUseMed="Y" sec3="Y"><name>Sandoz Trandolapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="02357771" chronicUseMed="Y" sec3="Y"><name>PMS-Trandolapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="02415445" chronicUseMed="Y" sec3="Y"><name>Teva-Trandolapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="02471884" chronicUseMed="Y" sec3="Y"><name>Auro-Trandolapril</name><manufacturerId>AUR</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="02525054" chronicUseMed="Y" sec3="Y"><name>Trandolapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="02526573" chronicUseMed="Y" sec3="Y"><name>Trandolapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug></pcg9><pcg9 id="240800258"><itemNumber>0827</itemNumber><strength>4mg</strength><dosageForm>Cap</dosageForm><drug id="02239267" chronicUseMed="Y" sec3="Y"><name>Mavik</name><manufacturerId>BGP</manufacturerId><individualPrice>1.0594</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug><drug id="02325764" chronicUseMed="Y" sec3="Y"><name>Sandoz Trandolapril</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2498</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug><drug id="02357798" chronicUseMed="Y" sec3="Y"><name>PMS-Trandolapril</name><manufacturerId>PMS</manufacturerId><individualPrice>.2498</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug><drug id="02415453" chronicUseMed="Y" sec3="Y"><name>Teva-Trandolapril</name><manufacturerId>TEV</manufacturerId><individualPrice>.2498</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug><drug id="02471892" chronicUseMed="Y" sec3="Y"><name>Auro-Trandolapril</name><manufacturerId>AUR</manufacturerId><individualPrice>.2498</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug><drug id="02525070" chronicUseMed="Y" sec3="Y"><name>Trandolapril</name><manufacturerId>SAI</manufacturerId><individualPrice>.2498</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug><drug id="02526581" chronicUseMed="Y" sec3="Y"><name>Trandolapril</name><manufacturerId>SIV</manufacturerId><individualPrice>.2498</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2498</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01362"><name>VALSARTAN</name><pcgGroup><pcg9 id="240800295"><itemNumber>0828</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02270528" notABenefit="Y" sec3b="Y" sec3="Y"><name>Diovan</name><manufacturerId>NOV</manufacturerId><listingDate>2011-06-08</listingDate></drug><drug id="02337487" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Valsartan</name><manufacturerId>COB</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2011-08-04</listingDate></drug><drug id="02356643" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Valsartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2011-06-08</listingDate></drug><drug id="02356740" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Valsartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2011-08-04</listingDate></drug><drug id="02363062" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Valsartan</name><manufacturerId>SPC</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2011-06-08</listingDate></drug><drug id="02366940" notABenefit="Y" sec3b="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2020-10-30</listingDate></drug><drug id="02371510" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Valsartan</name><manufacturerId>APX</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2011-12-15</listingDate></drug><drug id="02384523" notABenefit="Y" sec3b="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2021-09-30</listingDate></drug><drug id="02414201" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Valsartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2014-08-28</listingDate></drug><drug id="02524511" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Valsartan</name><manufacturerId>MAT</manufacturerId><individualPrice>.5823</individualPrice><listingDate>2023-01-31</listingDate></drug></pcg9><pcg9 id="240800254"><itemNumber>0829</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02244781" chronicUseMed="Y" sec3="Y"><name>Diovan</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5275</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02337495" chronicUseMed="Y" sec3="Y"><name>Co Valsartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02356651" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02356759" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02363100" chronicUseMed="Y" sec3="Y"><name>Taro-Valsartan</name><manufacturerId>SPC</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02366959" chronicUseMed="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02371529" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02384531" chronicUseMed="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02414228" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02524538" chronicUseMed="Y" sec3="Y"><name>M-Valsartan</name><manufacturerId>MAT</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug></pcg9><pcg9 id="240800255"><itemNumber>0830</itemNumber><strength>160mg</strength><dosageForm>Tab</dosageForm><drug id="02244782" chronicUseMed="Y" sec3="Y"><name>Diovan</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5225</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02337509" chronicUseMed="Y" sec3="Y"><name>Co Valsartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02356678" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02356767" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02363119" chronicUseMed="Y" sec3="Y"><name>Taro-Valsartan</name><manufacturerId>SPC</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02366967" chronicUseMed="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02371537" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02384558" chronicUseMed="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02414236" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug><drug id="02524546" chronicUseMed="Y" sec3="Y"><name>M-Valsartan</name><manufacturerId>MAT</manufacturerId><individualPrice>.2159</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.2159</amountMOHLTCPays></drug></pcg9><pcg9 id="240800272"><itemNumber>0831</itemNumber><strength>320mg</strength><dosageForm>Tab</dosageForm><drug id="02289504" chronicUseMed="Y" sec3="Y"><name>Diovan</name><manufacturerId>NOV</manufacturerId><individualPrice>1.4828</individualPrice><listingDate>2008-02-12</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02337517" chronicUseMed="Y" sec3="Y"><name>Co Valsartan</name><manufacturerId>COB</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02356686" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan</name><manufacturerId>TEV</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02356775" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02366975" chronicUseMed="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SAI</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02371545" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan</name><manufacturerId>APX</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02384566" chronicUseMed="Y" sec3="Y"><name>Valsartan</name><manufacturerId>SIV</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug><drug id="02414244" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan</name><manufacturerId>AUR</manufacturerId><individualPrice>.2098</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.2098</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01490"><name>VALSARTAN &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="240800244"><itemNumber>0832</itemNumber><strength>80mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02241900" chronicUseMed="Y" sec3="Y"><name>Diovan-HCT</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5139</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug><drug id="02356694" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2213</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug><drug id="02356996" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2213</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug><drug id="02367009" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SAI</manufacturerId><individualPrice>.2213</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug><drug id="02382547" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2213</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug><drug id="02384736" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2213</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug><drug id="02408112" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2213</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2213</amountMOHLTCPays></drug></pcg9><pcg9 id="240800245"><itemNumber>0833</itemNumber><strength>160mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02241901" chronicUseMed="Y" sec3="Y"><name>Diovan-HCT</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5310</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02356708" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02357003" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02367017" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SAI</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02382555" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02384744" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02408120" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug></pcg9><pcg9 id="240800253"><itemNumber>0834</itemNumber><strength>160mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02246955" chronicUseMed="Y" sec3="Y"><name>Diovan-HCT</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5310</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug><drug id="02356716" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2238</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug><drug id="02357011" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2238</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug><drug id="02367025" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SAI</manufacturerId><individualPrice>.2238</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug><drug id="02382563" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2238</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug><drug id="02384752" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2238</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug><drug id="02408139" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2238</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2238</amountMOHLTCPays></drug></pcg9><pcg9 id="240800277"><itemNumber>0835</itemNumber><strength>320mg &amp; 12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02308908" chronicUseMed="Y" sec3="Y"><name>Diovan-HCT</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5275</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug><drug id="02356724" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2235</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug><drug id="02357038" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2235</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug><drug id="02367033" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SAI</manufacturerId><individualPrice>.2235</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug><drug id="02382571" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2235</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug><drug id="02384760" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SIV</manufacturerId><individualPrice>.2235</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug><drug id="02408147" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2235</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2235</amountMOHLTCPays></drug></pcg9><pcg9 id="240800278"><itemNumber>0836</itemNumber><strength>320mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="02308916" chronicUseMed="Y" sec3="Y"><name>Diovan-HCT</name><manufacturerId>NOV</manufacturerId><individualPrice>1.5250</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02356732" chronicUseMed="Y" sec3="Y"><name>Sandoz Valsartan HCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02357046" chronicUseMed="Y" sec3="Y"><name>Teva-Valsartan/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02367041" chronicUseMed="Y" sec3="Y"><name>Valsartan HCT</name><manufacturerId>SAI</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02382598" chronicUseMed="Y" sec3="Y"><name>Apo-Valsartan/HCTZ</name><manufacturerId>APX</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02408155" chronicUseMed="Y" sec3="Y"><name>Auro-Valsartan HCT</name><manufacturerId>AUR</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00319"><name>VERAPAMIL HCL</name><pcgGroup><pcg9 id="240800271"><itemNumber>0837</itemNumber><strength>120mg</strength><dosageForm>LA Tab</dosageForm><drug id="01907123" notABenefit="Y" sec3b="Y" sec3="Y"><name>Isoptin SR</name><manufacturerId>BGP</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02210347" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Verapamil SR</name><manufacturerId>MYL</manufacturerId><individualPrice>.6900</individualPrice><listingDate>2007-10-03</listingDate></drug><drug id="02246893" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Verap SR</name><manufacturerId>APX</manufacturerId><individualPrice>.6900</individualPrice><listingDate>2007-09-04</listingDate></drug></pcg9><pcg9 id="240800197"><itemNumber>0838</itemNumber><strength>180mg</strength><dosageForm>LA Tab</dosageForm><dailyCost>.5204</dailyCost><drug id="01934317" chronicUseMed="Y" sec3="Y"><name>Isoptin SR</name><manufacturerId>BGP</manufacturerId><individualPrice>2.0488</individualPrice><dailyCost>2.0488</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5204</amountMOHLTCPays></drug><drug id="02246894" chronicUseMed="Y" sec3="Y"><name>Apo-Verap SR</name><manufacturerId>APX</manufacturerId><individualPrice>.5204</individualPrice><dailyCost>.5204</dailyCost><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.5204</amountMOHLTCPays></drug><drug id="02450488" chronicUseMed="Y" sec3="Y"><name>Mylan-Verapamil SR</name><manufacturerId>MYL</manufacturerId><individualPrice>.5204</individualPrice><dailyCost>.5204</dailyCost><listingDate>2016-11-30</listingDate><amountMOHLTCPays>.5204</amountMOHLTCPays></drug></pcg9><pcg9 id="240800128"><itemNumber>0839</itemNumber><strength>240mg</strength><dosageForm>LA Tab</dosageForm><dailyCost>1.7143</dailyCost><drug id="00742554" chronicUseMed="Y" sec3="Y"><name>Isoptin SR</name><manufacturerId>BGP</manufacturerId><individualPrice>2.7323</individualPrice><dailyCost>2.7323</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.7143</amountMOHLTCPays></drug><drug id="02450496" chronicUseMed="Y" sec3="Y"><name>Mylan-Verapamil SR</name><manufacturerId>MYL</manufacturerId><individualPrice>1.7143</individualPrice><dailyCost>1.7143</dailyCost><listingDate>2016-10-27</listingDate><amountMOHLTCPays>1.7143</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="240816000"><name>HYPOTENSIVE DRUGS (FOR DIURETICS SEE 40:28) CENTRAL ALPHA-AGONISTS</name><genericName id="02117"><name>GUANFACINE</name><pcgGroup lccId="00326"><pcg9 id="240816001"><itemNumber>0840</itemNumber><strength>1mg</strength><dosageForm>ER Tab</dosageForm><drug id="02409100" sec3="Y" sec12="Y"><name>Intuniv XR</name><manufacturerId>TAK</manufacturerId><individualPrice>3.0750</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>1.5375</amountMOHLTCPays></drug><drug id="02523558" sec3="Y" sec12="Y"><name>Jamp Guanfacine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>1.5375</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.5375</amountMOHLTCPays></drug><drug id="02523728" sec3="Y" sec12="Y"><name>Apo-Guanfacine XR</name><manufacturerId>APX</manufacturerId><individualPrice>1.5375</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.5375</amountMOHLTCPays></drug></pcg9><pcg9 id="240816002"><itemNumber>0841</itemNumber><strength>2mg</strength><dosageForm>ER Tab</dosageForm><drug id="02409119" sec3="Y" sec12="Y"><name>Intuniv XR</name><manufacturerId>TAK</manufacturerId><individualPrice>3.7413</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>1.8707</amountMOHLTCPays></drug><drug id="02523566" sec3="Y" sec12="Y"><name>Jamp Guanfacine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>1.8707</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.8707</amountMOHLTCPays></drug><drug id="02523736" sec3="Y" sec12="Y"><name>Apo-Guanfacine XR</name><manufacturerId>APX</manufacturerId><individualPrice>1.8707</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.8707</amountMOHLTCPays></drug></pcg9><pcg9 id="240816003"><itemNumber>0842</itemNumber><strength>3mg</strength><dosageForm>ER Tab</dosageForm><drug id="02409127" sec3="Y" sec12="Y"><name>Intuniv XR</name><manufacturerId>TAK</manufacturerId><individualPrice>4.4075</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>2.2038</amountMOHLTCPays></drug><drug id="02523574" sec3="Y" sec12="Y"><name>Jamp Guanfacine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>2.2038</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>2.2038</amountMOHLTCPays></drug><drug id="02523744" sec3="Y" sec12="Y"><name>Apo-Guanfacine XR</name><manufacturerId>APX</manufacturerId><individualPrice>2.2038</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>2.2038</amountMOHLTCPays></drug></pcg9><pcg9 id="240816004"><itemNumber>0843</itemNumber><strength>4mg</strength><dosageForm>ER Tab</dosageForm><drug id="02409135" sec3="Y" sec12="Y"><name>Intuniv XR</name><manufacturerId>TAK</manufacturerId><individualPrice>5.0738</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>2.5369</amountMOHLTCPays></drug><drug id="02523582" sec3="Y" sec12="Y"><name>Jamp Guanfacine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>2.5369</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>2.5369</amountMOHLTCPays></drug><drug id="02523752" sec3="Y" sec12="Y"><name>Apo-Guanfacine XR</name><manufacturerId>APX</manufacturerId><individualPrice>2.5369</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>2.5369</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="540">For the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 to 17 years who meet the following criteria:

(i) As adjunctive therapy to psychostimulants; OR

(ii) As monotherapy in patients who have significant intolerance to psychostimulants AND who have had an inadequate response to either atomoxetine or other non-stimulant alternative(s).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="241200000"><name>VASODILATING DRUGS</name><genericName id="01753"><name>AMBRISENTAN</name><pcgGroup><pcg9 id="241200092"><itemNumber>0844</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02307065" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Volibris</name><manufacturerId>GSK</manufacturerId><individualPrice>133.9247</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug><drug id="02475375" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Ambrisentan</name><manufacturerId>APX</manufacturerId><individualPrice>106.3288</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug><drug id="02521938" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Ambrisentan</name><manufacturerId>JPC</manufacturerId><individualPrice>106.3288</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug><drug id="02526875" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Ambrisentan Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>106.3288</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug></pcg9><pcg9 id="241200093"><itemNumber>0845</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02307073" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Volibris</name><manufacturerId>GSK</manufacturerId><individualPrice>133.9247</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug><drug id="02475383" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Ambrisentan</name><manufacturerId>APX</manufacturerId><individualPrice>106.3288</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug><drug id="02521946" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Ambrisentan</name><manufacturerId>JPC</manufacturerId><individualPrice>106.3288</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug><drug id="02526883" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Ambrisentan Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>106.3288</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>106.3288</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00393"><name>BETAHISTINE DIHYDROCHLORIDE</name><pcgGroup><pcg9 id="241200077"><itemNumber>0846</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02240601" sec3b="Y" sec3="Y"><name>Serc</name><manufacturerId>SPH</manufacturerId><listingDate>2011-05-19</listingDate></drug><drug id="02280183" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Betahistine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2259</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>.2259</amountMOHLTCPays></drug><drug id="02449145" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Betahistine</name><manufacturerId>AUR</manufacturerId><individualPrice>.2070</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.2070</amountMOHLTCPays></drug><drug id="02519682" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Betahistine</name><manufacturerId>MAT</manufacturerId><individualPrice>.2259</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.2259</amountMOHLTCPays></drug><drug id="02538121" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Betahistine</name><manufacturerId>MIN</manufacturerId><individualPrice>.2259</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.2259</amountMOHLTCPays></drug><drug id="02544911" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Betahistine</name><manufacturerId>NRA</manufacturerId><individualPrice>.2259</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.2259</amountMOHLTCPays></drug></pcg9><pcg9 id="241200080"><itemNumber>0847</itemNumber><strength>16mg</strength><dosageForm>Tab</dosageForm><drug id="02243878" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Serc</name><manufacturerId>BGP</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02280191" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Betahistine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02330210" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Betahistine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02374757" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Betahistine</name><manufacturerId>COB</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02449153" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Betahistine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02466449" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Betahistine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02519690" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Betahistine</name><manufacturerId>MAT</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02538148" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Betahistine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="02544938" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Betahistine</name><manufacturerId>NRA</manufacturerId><individualPrice>.3557</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug></pcg9><pcg9 id="241200087"><itemNumber>0848</itemNumber><strength>24mg</strength><dosageForm>Tab</dosageForm><drug id="02247998" notABenefit="Y" sec3b="Y" sec3="Y"><name>Serc</name><manufacturerId>BGP</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02280205" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Betahistine</name><manufacturerId>TEV</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2007-09-04</listingDate></drug><drug id="02330237" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Betahistine</name><manufacturerId>PMS</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2014-04-30</listingDate></drug><drug id="02374765" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Betahistine</name><manufacturerId>COB</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2012-01-19</listingDate></drug><drug id="02449161" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Betahistine</name><manufacturerId>AUR</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2016-02-25</listingDate></drug><drug id="02466457" notABenefit="Y" sec3b="Y" sec3="Y"><name>Betahistine</name><manufacturerId>SAI</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02519704" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Betahistine</name><manufacturerId>MAT</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02538156" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Betahistine</name><manufacturerId>MIN</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2024-01-31</listingDate></drug><drug id="02544946" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Betahistine</name><manufacturerId>NRA</manufacturerId><individualPrice>.4983</individualPrice><listingDate>2024-08-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01549"><name>BOSENTAN MONOHYDRATE</name><pcgGroup><pcg9 id="241200096"><itemNumber>0849</itemNumber><strength>62.5mg</strength><dosageForm>Tab</dosageForm><drug id="02244981" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tracleer</name><manufacturerId>JAN</manufacturerId><individualPrice>87.5600</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02383012" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Bosentan</name><manufacturerId>PMS</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02386194" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Bosentan</name><manufacturerId>COB</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02386275" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Bosentan</name><manufacturerId>SDZ</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02399202" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Bosentan</name><manufacturerId>APX</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02467984" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Bosentan</name><manufacturerId>NAT</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02483130" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Bosentan</name><manufacturerId>TAR</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug></pcg9><pcg9 id="241200097"><itemNumber>0850</itemNumber><strength>125mg</strength><dosageForm>Tab</dosageForm><drug id="02244982" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tracleer</name><manufacturerId>JAN</manufacturerId><individualPrice>87.5600</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02383020" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Bosentan</name><manufacturerId>PMS</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02386208" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Bosentan</name><manufacturerId>COB</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02386283" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Bosentan</name><manufacturerId>SDZ</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02399210" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Bosentan</name><manufacturerId>APX</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02467992" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Bosentan</name><manufacturerId>NAT</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug><drug id="02483149" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Bosentan</name><manufacturerId>TAR</manufacturerId><individualPrice>32.0893</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>32.0893</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00394"><name>DIPYRIDAMOLE</name><pcgGroup><pcg9 id="241200081"><itemNumber>0851</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00067385" notABenefit="Y" sec3b="Y" sec3="Y"><name>Persantine</name><manufacturerId>BOE</manufacturerId><listingDate>2009-03-02</listingDate></drug><drug id="00895644" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Dipyridamole</name><manufacturerId>APX</manufacturerId><individualPrice>.2633</individualPrice><listingDate>2009-03-02</listingDate></drug></pcg9><pcg9 id="241200090"><itemNumber>0852</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00067393" sec3b="Y" sec3="Y"><name>Persantine</name><manufacturerId>BOE</manufacturerId><listingDate>2009-03-02</listingDate></drug><drug id="00895652" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dipyridamole</name><manufacturerId>APX</manufacturerId><individualPrice>.3685</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.3685</amountMOHLTCPays></drug></pcg9><pcg9 id="241200091"><itemNumber>0853</itemNumber><strength>75mg</strength><dosageForm>Tab</dosageForm><drug id="00452092" notABenefit="Y" sec3b="Y" sec3="Y"><name>Persantine</name><manufacturerId>BOE</manufacturerId><listingDate>2009-03-02</listingDate></drug><drug id="00895660" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Dipyridamole</name><manufacturerId>APX</manufacturerId><individualPrice>.4963</individualPrice><listingDate>2009-03-02</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00400"><name>DIPYRIDAMOLE &amp; ACETYLSALICYLIC ACID</name><pcgGroup lccId="00062"><pcg9 id="241200078"><itemNumber>0854</itemNumber><strength>200mg/25mg</strength><dosageForm>Cap</dosageForm><drug id="02242119" notABenefit="Y" sec3="Y"><name>Aggrenox</name><manufacturerId>BOE</manufacturerId><listingDate>2001-10-11</listingDate></drug><drug id="02471051" sec3="Y" sec12="Y"><name>Taro-Dipyridamole/ASA</name><manufacturerId>TAR</manufacturerId><individualPrice>.6656</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.6656</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="349">For the secondary prevention of stroke.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00389"><name>ISOSORBIDE DINITRATE</name><pcgGroup><pcg9 id="241200002"><itemNumber>0855</itemNumber><strength>5mg</strength><dosageForm>SL Tab</dosageForm><drug id="00670944" sec3="Y"><name>ISDN</name><manufacturerId>AAP</manufacturerId><individualPrice>.0633</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0633</amountMOHLTCPays></drug><drug id="02042606" notABenefit="Y" sec3="Y"><name>Isordil</name><manufacturerId>WAY</manufacturerId><listingDate>1997-02-04</listingDate></drug></pcg9><pcg9 id="241200006"><itemNumber>0856</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00441686" chronicUseMed="Y" sec3="Y"><name>ISDN</name><manufacturerId>AAP</manufacturerId><individualPrice>.0485</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0485</amountMOHLTCPays></drug><drug id="02042622" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Isordil</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="241200005"><itemNumber>0857</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="00441694" chronicUseMed="Y" sec3="Y"><name>ISDN</name><manufacturerId>AAP</manufacturerId><individualPrice>.1135</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1135</amountMOHLTCPays></drug><drug id="02042614" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Isordil</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00401"><name>ISOSORBIDE-5-MONONITRATE</name><pcgGroup><pcg9 id="241200088"><itemNumber>0858</itemNumber><strength>60mg</strength><dosageForm>ER Tab</dosageForm><drug id="02126559" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Imdur</name><manufacturerId>AZC</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02272830" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-ISMN</name><manufacturerId>APX</manufacturerId><individualPrice>.4950</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.4950</amountMOHLTCPays></drug><drug id="02301288" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-ISMN</name><manufacturerId>PMS</manufacturerId><individualPrice>.4950</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.4950</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00402"><name>NIMODIPINE</name><pcgGroup lccId="00215"><pcg9 id="241200095"><itemNumber>0859</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02325926" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Nimotop</name><manufacturerId>BAH</manufacturerId><individualPrice>10.3006</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>10.3006</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="42">As adjunctive therapy to improve the neurologic outcome following subarachnoid haemorrhage during the acute management period (within 4 days of haemorrhage).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="43">As prophylaxis of ischemia if surgery is delayed.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00390"><name>NITROGLYCERIN</name><pcgGroup><pcg9 id="241200034"><itemNumber>0860</itemNumber><strength>0.4mg/Hr/20 Sq Cm</strength><dosageForm>Patch</dosageForm><drug id="00852384" sec3="Y"><name>Transderm-Nitro</name><manufacturerId>NOV</manufacturerId><individualPrice>1.0010</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.0010</amountMOHLTCPays></drug></pcg9><pcg9 id="241200059"><itemNumber>0861</itemNumber><strength>0.6mg/Hr/30 Sq Cm</strength><dosageForm>Patch</dosageForm><drug id="02046156" sec3="Y"><name>Transderm-Nitro</name><manufacturerId>NOV</manufacturerId><individualPrice>1.0290</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>1.0290</amountMOHLTCPays></drug></pcg9><pcg9 id="241200067"><itemNumber>0862</itemNumber><strength>0.4mg/Hr/14 Sq Cm</strength><dosageForm>Patch</dosageForm><drug id="02230733" sec3="Y"><name>Trinipatch</name><manufacturerId>PPI</manufacturerId><individualPrice>.8773</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.8773</amountMOHLTCPays></drug></pcg9><pcg9 id="241200068"><itemNumber>0863</itemNumber><strength>0.6mg/Hr/21 Sq Cm</strength><dosageForm>Patch</dosageForm><drug id="02230734" sec3="Y"><name>Trinipatch</name><manufacturerId>PPI</manufacturerId><individualPrice>.8773</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.8773</amountMOHLTCPays></drug></pcg9><pcg9 id="241200004"><itemNumber>0864</itemNumber><strength>0.3mg</strength><dosageForm>SL Tab</dosageForm><drug id="00037613" sec3="Y"><name>Nitrostat</name><manufacturerId>UJC</manufacturerId><individualPrice>.1847</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1847</amountMOHLTCPays></drug></pcg9><pcg9 id="241200003" suppliedBy="L"><itemNumber>0865</itemNumber><strength>0.6mg</strength><dosageForm>SL Tab</dosageForm><drug id="00037621" selfMed="Y" sec3="Y"><name>Nitrostat</name><manufacturerId>UJC</manufacturerId><individualPrice>.1847</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1847</amountMOHLTCPays></drug></pcg9><pcg9 id="241200111"><itemNumber>0866</itemNumber><strength>0.4mg/Metered Dose</strength><dosageForm>Sp-180 Dose Pk</dosageForm><drug id="09858317" sec3c="Y"><name>Nitrolingual Pumpspray</name><manufacturerId>JUN</manufacturerId><individualPrice>8.4200</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>8.4200</amountMOHLTCPays></drug></pcg9><pcg9 id="241200112"><itemNumber>0867</itemNumber><strength>0.4mg/Metered Dose</strength><dosageForm>Sp-75 Dose Pk</dosageForm><drug id="09858327" sec3c="Y"><name>Nitrolingual Pumpspray</name><manufacturerId>SAC</manufacturerId><individualPrice>9.4000</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>9.4000</amountMOHLTCPays></drug></pcg9><pcg9 id="241200017"><itemNumber>0868</itemNumber><strength>0.4mg/Metered Dose</strength><dosageForm>Spray-200 Dose Pk</dosageForm><drug id="01926721" notABenefit="Y" sec3="Y"><name>Nitrolingual</name><manufacturerId>AVE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02243588" sec3="Y"><name>Mylan-Nitro Sublingual Spray</name><manufacturerId>MYL</manufacturerId><individualPrice>8.4600</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>8.4600</amountMOHLTCPays></drug></pcg9><pcg9 id="241200069"><itemNumber>0869</itemNumber><strength>0.4mg/Metered Dose</strength><dosageForm>Spray-200 Dose Pk</dosageForm><drug id="02231441" sec3="Y"><name>Nitrolingual Pump Spray</name><manufacturerId>SAV</manufacturerId><individualPrice>16.0000</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>8.4200</amountMOHLTCPays></drug><drug id="02238998" sec3="Y"><name>Rho-Nitro Pumpspray</name><manufacturerId>SDZ</manufacturerId><individualPrice>8.4200</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>8.4200</amountMOHLTCPays></drug></pcg9><pcg9 id="241200033"><itemNumber>0870</itemNumber><strength>0.2mg/Hr</strength><dosageForm>Transdermal Patch</dosageForm><drug id="01911910" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nitro-Dur 0.2</name><manufacturerId>DRR</manufacturerId><listingDate>2013-11-28</listingDate></drug><drug id="02407442" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Nitro 0.2</name><manufacturerId>MYL</manufacturerId><individualPrice>.4463</individualPrice><listingDate>2013-11-28</listingDate></drug></pcg9><pcg9 id="241200071"><itemNumber>0871</itemNumber><strength>0.4mg/Hr</strength><dosageForm>Transdermal Patch</dosageForm><drug id="01911902" sec3="Y"><name>Nitro-Dur</name><manufacturerId>DRR</manufacturerId><individualPrice>.5040</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5040</amountMOHLTCPays></drug><drug id="02407450" sec3="Y"><name>Mylan-Nitro 0.4</name><manufacturerId>MYL</manufacturerId><individualPrice>.5040</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.5040</amountMOHLTCPays></drug></pcg9><pcg9 id="241200072"><itemNumber>0872</itemNumber><strength>0.6mg/Hr</strength><dosageForm>Transdermal Patch</dosageForm><drug id="01911929" sec3="Y"><name>Nitro-Dur</name><manufacturerId>DRR</manufacturerId><individualPrice>.5040</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5040</amountMOHLTCPays></drug><drug id="02407469" sec3="Y"><name>Mylan-Nitro 0.6</name><manufacturerId>MYL</manufacturerId><individualPrice>.5040</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>.5040</amountMOHLTCPays></drug></pcg9><pcg9 id="241200058"><itemNumber>0873</itemNumber><strength>0.8mg/Hr</strength><dosageForm>Transdermal Patch</dosageForm><drug id="02011271" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nitro-Dur 0.8</name><manufacturerId>DRR</manufacturerId><listingDate>2013-11-28</listingDate></drug><drug id="02407477" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Nitro 0.8</name><manufacturerId>MYL</manufacturerId><individualPrice>.8743</individualPrice><listingDate>2013-11-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01966"><name>RIOCIGUAT</name><pcgGroup><pcg9 id="241200098"><itemNumber>0874</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02412764" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Adempas</name><manufacturerId>BAH</manufacturerId><individualPrice>43.7200</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug><drug id="02533545" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Riociguat</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.0460</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug></pcg9><pcg9 id="241200100"><itemNumber>0875</itemNumber><strength>1.5mg</strength><dosageForm>Tab</dosageForm><drug id="02412799" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Adempas</name><manufacturerId>BAH</manufacturerId><individualPrice>43.7200</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug><drug id="02533588" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Riociguat</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.0460</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug></pcg9><pcg9 id="241200099"><itemNumber>0876</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02412772" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Adempas</name><manufacturerId>BAH</manufacturerId><individualPrice>43.7200</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug><drug id="02533561" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Riociguat</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.0460</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug></pcg9><pcg9 id="241200102"><itemNumber>0877</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02412810" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Adempas</name><manufacturerId>BAH</manufacturerId><individualPrice>43.7200</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug><drug id="02533618" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Riociguat</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.0460</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug></pcg9><pcg9 id="241200101"><itemNumber>0878</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02412802" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Adempas</name><manufacturerId>BAH</manufacturerId><individualPrice>43.7200</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug><drug id="02533596" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Riociguat</name><manufacturerId>SDZ</manufacturerId><individualPrice>24.0460</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>24.0460</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01792"><name>TADALAFIL</name><pcgGroup><pcg9 id="241200103"><itemNumber>0879</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02296888" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cialis</name><manufacturerId>LIL</manufacturerId><listingDate>2016-09-29</listingDate></drug><drug id="02409410" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Tadalafil</name><manufacturerId>PMS</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02410621" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Tadalafil</name><manufacturerId>MYL</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02422085" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tadalafil</name><manufacturerId>APX</manufacturerId><individualPrice>3.6470</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6470</amountMOHLTCPays></drug><drug id="02428628" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Tadalafil</name><manufacturerId>ACV</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02435896" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Tadalafil</name><manufacturerId>AUR</manufacturerId><individualPrice>3.6470</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6470</amountMOHLTCPays></drug><drug id="02440148" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Tadalafil</name><manufacturerId>TEV</manufacturerId><individualPrice>3.8616</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>3.8616</amountMOHLTCPays></drug><drug id="02451824" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Tadalafil</name><manufacturerId>JPC</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02452081" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Tadalafil</name><manufacturerId>RAN</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02452286" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Tadalafil</name><manufacturerId>MAR</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02512262" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Tadalafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>3.6470</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>3.6470</amountMOHLTCPays></drug><drug id="02536676" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SIV</manufacturerId><individualPrice>3.8616</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>3.8616</amountMOHLTCPays></drug></pcg9><pcg9 id="241200104"><itemNumber>0880</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02296896" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cialis</name><manufacturerId>LIL</manufacturerId><listingDate>2016-09-29</listingDate></drug><drug id="02409429" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Tadalafil</name><manufacturerId>PMS</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02410648" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Tadalafil</name><manufacturerId>MYL</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02422093" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tadalafil</name><manufacturerId>APX</manufacturerId><individualPrice>3.6470</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6470</amountMOHLTCPays></drug><drug id="02428636" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Tadalafil</name><manufacturerId>ACV</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02435926" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Tadalafil</name><manufacturerId>AUR</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02440156" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Tadalafil</name><manufacturerId>TEV</manufacturerId><individualPrice>3.8616</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>3.8616</amountMOHLTCPays></drug><drug id="02451670" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Tadalafil</name><manufacturerId>MIN</manufacturerId><individualPrice>3.6472</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6472</amountMOHLTCPays></drug><drug id="02451832" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Tadalafil</name><manufacturerId>JPC</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02452073" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Tadalafil</name><manufacturerId>RAN</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02452278" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Tadalafil</name><manufacturerId>MAR</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02452480" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Priva-Tadalafil</name><manufacturerId>NRA</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02454726" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Riva-Tadalafil</name><manufacturerId>RIA</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02457016" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SAI</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02512114" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Tadalafil</name><manufacturerId>MAT</manufacturerId><individualPrice>3.6470</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>3.6470</amountMOHLTCPays></drug><drug id="02512270" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Tadalafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02515989" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Tadalafil</name><manufacturerId>ACH</manufacturerId><individualPrice>3.6470</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>3.6470</amountMOHLTCPays></drug><drug id="02520931" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Tadalafil</name><manufacturerId>NRA</manufacturerId><individualPrice>3.6471</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>3.6471</amountMOHLTCPays></drug><drug id="02536684" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SIV</manufacturerId><individualPrice>3.8616</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>3.8616</amountMOHLTCPays></drug></pcg9><pcg9 id="241200105"><itemNumber>0881</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02248088" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cialis</name><manufacturerId>LIL</manufacturerId><listingDate>2016-09-29</listingDate></drug><drug id="02409437" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Tadalafil</name><manufacturerId>PMS</manufacturerId><individualPrice>11.9255</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9255</amountMOHLTCPays></drug><drug id="02410656" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Tadalafil</name><manufacturerId>MYL</manufacturerId><individualPrice>11.9255</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9255</amountMOHLTCPays></drug><drug id="02422107" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tadalafil</name><manufacturerId>APX</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02428644" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Tadalafil</name><manufacturerId>ACV</manufacturerId><individualPrice>11.9255</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9255</amountMOHLTCPays></drug><drug id="02435934" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Tadalafil</name><manufacturerId>AUR</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02440164" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Tadalafil</name><manufacturerId>TEV</manufacturerId><individualPrice>12.6270</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>12.6270</amountMOHLTCPays></drug><drug id="02451689" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Tadalafil</name><manufacturerId>MIN</manufacturerId><individualPrice>11.9255</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>11.9255</amountMOHLTCPays></drug><drug id="02451840" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Tadalafil</name><manufacturerId>JPC</manufacturerId><individualPrice>11.9255</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9255</amountMOHLTCPays></drug><drug id="02452103" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Tadalafil</name><manufacturerId>RAN</manufacturerId><individualPrice>11.9255</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9255</amountMOHLTCPays></drug><drug id="02452251" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Tadalafil</name><manufacturerId>MAR</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02452499" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Priva-Tadalafil</name><manufacturerId>NRA</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02457024" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SAI</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02512122" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Tadalafil</name><manufacturerId>MAT</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02512289" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Tadalafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02515997" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Tadalafil</name><manufacturerId>ACH</manufacturerId><individualPrice>11.9250</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>11.9250</amountMOHLTCPays></drug><drug id="02536692" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SIV</manufacturerId><individualPrice>12.6270</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>12.6270</amountMOHLTCPays></drug></pcg9><pcg9 id="241200094"><itemNumber>0882</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02338327" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Adcirca</name><manufacturerId>LIL</manufacturerId><individualPrice>15.0555</individualPrice><listingDate>2015-12-22</listingDate><amountMOHLTCPays>11.4725</amountMOHLTCPays></drug><drug id="02421933" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tadalafil PAH</name><manufacturerId>APX</manufacturerId><individualPrice>11.4725</individualPrice><listingDate>2015-12-22</listingDate><amountMOHLTCPays>11.4725</amountMOHLTCPays></drug></pcg9><pcg9 id="241200106"><itemNumber>0883</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02248089" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cialis</name><manufacturerId>LIL</manufacturerId><listingDate>2016-09-29</listingDate></drug><drug id="02409445" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Tadalafil</name><manufacturerId>PMS</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02410664" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Tadalafil</name><manufacturerId>MYL</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02422115" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tadalafil</name><manufacturerId>APX</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02428652" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Tadalafil</name><manufacturerId>ACV</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02435942" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Tadalafil</name><manufacturerId>AUR</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02440172" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Tadalafil</name><manufacturerId>TEV</manufacturerId><individualPrice>13.0838</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>13.0838</amountMOHLTCPays></drug><drug id="02451697" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Tadalafil</name><manufacturerId>MIN</manufacturerId><individualPrice>12.3576</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3576</amountMOHLTCPays></drug><drug id="02451859" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Tadalafil</name><manufacturerId>JPC</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02452111" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Tadalafil</name><manufacturerId>RAN</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02452243" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Tadalafil</name><manufacturerId>MAR</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02452502" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Priva-Tadalafil</name><manufacturerId>NRA</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02454742" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Riva-Tadalafil</name><manufacturerId>RIA</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02457032" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SAI</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02481421" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>AG-Tadalafil</name><manufacturerId>ANG</manufacturerId><individualPrice>12.3569</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>12.3569</amountMOHLTCPays></drug><drug id="02512130" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Tadalafil</name><manufacturerId>MAT</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02512297" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Tadalafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02516004" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Tadalafil</name><manufacturerId>ACH</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02520966" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Tadalafil</name><manufacturerId>NRA</manufacturerId><individualPrice>12.3575</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>12.3575</amountMOHLTCPays></drug><drug id="02536706" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tadalafil</name><manufacturerId>SIV</manufacturerId><individualPrice>13.0838</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>13.0838</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02071"><name>VARDENAFIL HCL</name><pcgGroup><pcg9 id="241200110"><itemNumber>0884</itemNumber><strength>10mg</strength><dosageForm>Orally Disintergrating Tab</dosageForm><drug id="02372436" notABenefit="Y" sec3b="Y" sec3="Y"><name>Staxyn</name><manufacturerId>BAH</manufacturerId><listingDate>2019-09-30</listingDate></drug><drug id="02476088" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Vardenafil ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>5.8778</individualPrice><listingDate>2019-09-30</listingDate></drug></pcg9><pcg9 id="241200107"><itemNumber>0885</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02250462" notABenefit="Y" sec3b="Y" sec3="Y"><name>Levitra</name><manufacturerId>BAY</manufacturerId><listingDate>2018-12-21</listingDate></drug><drug id="02464209" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Vardenafil</name><manufacturerId>MYL</manufacturerId><individualPrice>9.3203</individualPrice><listingDate>2018-12-21</listingDate></drug><drug id="02471647" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Vardenafil</name><manufacturerId>APX</manufacturerId><individualPrice>9.3203</individualPrice><listingDate>2019-01-31</listingDate></drug><drug id="02475677" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Vardenafil IR</name><manufacturerId>JPC</manufacturerId><individualPrice>9.3203</individualPrice><listingDate>2018-12-21</listingDate></drug></pcg9><pcg9 id="241200108"><itemNumber>0886</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02250470" notABenefit="Y" sec3b="Y" sec3="Y"><name>Levitra</name><manufacturerId>BAY</manufacturerId><listingDate>2018-12-21</listingDate></drug><drug id="02464225" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Vardenafil</name><manufacturerId>MYL</manufacturerId><individualPrice>10.3976</individualPrice><listingDate>2018-12-21</listingDate></drug><drug id="02471655" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Vardenafil</name><manufacturerId>APX</manufacturerId><individualPrice>10.3976</individualPrice><listingDate>2019-01-31</listingDate></drug><drug id="02475685" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Vardenafil IR</name><manufacturerId>JPC</manufacturerId><individualPrice>10.4019</individualPrice><listingDate>2018-12-21</listingDate></drug><drug id="02520397" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vardenafil</name><manufacturerId>SAI</manufacturerId><individualPrice>10.3976</individualPrice><listingDate>2021-12-17</listingDate></drug></pcg9><pcg9 id="241200109"><itemNumber>0887</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02250489" notABenefit="Y" sec3b="Y" sec3="Y"><name>Levitra</name><manufacturerId>BAY</manufacturerId><listingDate>2018-12-21</listingDate></drug><drug id="02464233" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Vardenafil</name><manufacturerId>MYL</manufacturerId><individualPrice>11.6811</individualPrice><listingDate>2018-12-21</listingDate></drug><drug id="02471663" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Vardenafil</name><manufacturerId>APX</manufacturerId><individualPrice>11.6811</individualPrice><listingDate>2019-01-31</listingDate></drug><drug id="02475693" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Vardenafil IR</name><manufacturerId>JPC</manufacturerId><individualPrice>11.6811</individualPrice><listingDate>2018-12-21</listingDate></drug><drug id="02520400" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vardenafil</name><manufacturerId>SAI</manufacturerId><individualPrice>11.6811</individualPrice><listingDate>2021-12-17</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02402"><name>VERICIGUAT</name><pcgGroup lccId="00400"><pcg9 id="241200113"><itemNumber>0888</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02537044" sec3="Y" sec12="Y"><name>Verquvo</name><manufacturerId>BAH</manufacturerId><individualPrice>4.8300</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>4.8300</amountMOHLTCPays></drug></pcg9><pcg9 id="241200114"><itemNumber>0889</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02537052" sec3="Y" sec12="Y"><name>Verquvo</name><manufacturerId>BAH</manufacturerId><individualPrice>4.8300</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>4.8300</amountMOHLTCPays></drug></pcg9><pcg9 id="241200115"><itemNumber>0890</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02537060" sec3="Y" sec12="Y"><name>Verquvo</name><manufacturerId>BAH</manufacturerId><individualPrice>4.8300</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>4.8300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="685">For the treatment of symptomatic chronic heart failure (HF) as an adjunct to standard-of-care therapy in adult patients with reduced ejection fraction who are stabilized after a recent HF decompensation event, if all the following conditions are met:

(a) Left ventricular ejection fraction (LVEF) less than 45%;

(b) New York Heart Association (NYHA) class II to IV symptoms;

(c) HF decompensation event requiring hospitalization within the previous 6 months and/or intravenous diuretic treatment for HF (without hospitalization) within the previous 3 months;

(d) Vericiquat is used in combination with standard-of-care* HF therapy; and

(e) Initiated under the supervision of a prescriber who is experienced in the management of HF.

* Standard-of-care HF therapy includes one medication from each of the following categories, unless there is a contraindication or intolerance:

(a) angiotensin receptor-neprilysin inhibitor (ARNI) or angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB);

(b) beta blocker;

(c) mineralocorticoid receptor antagonist (MRA); and

(d) sodium-glucose cotransporter-2 (SGLT2) inhibitor</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="243208000"><name>RENIN-ANGIOTENSIN ALDOSTERONE INHIBITORS ANGIOTENSIN II RECEPTOR ANTAGONISTS</name><genericName id="02418"><name>AZILSARTAN MEDOXOMIL</name><pcgGroup><pcg9 id="243208005"><itemNumber>0891</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02381389" notABenefit="Y" sec3b="Y" sec3="Y"><name>Edarbi</name><manufacturerId>BHC</manufacturerId><listingDate>2025-04-30</listingDate></drug><drug id="02547015" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Azilsartan Medoxomil</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1177</individualPrice><listingDate>2025-04-30</listingDate></drug></pcg9><pcg9 id="243208006"><itemNumber>0892</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02381397" notABenefit="Y" sec3b="Y" sec3="Y"><name>Edarbi</name><manufacturerId>BHC</manufacturerId><listingDate>2025-04-30</listingDate></drug><drug id="02547023" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Azilsartan Medoxomil</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1177</individualPrice><listingDate>2025-04-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02033"><name>SACUBITRIL &amp; VALSARTAN</name><pcgGroup lccId="00283"><pcg9 id="243208002"><itemNumber>0893</itemNumber><strength>24.3mg &amp; 25.7mg</strength><dosageForm>Tab</dosageForm><drug id="02446928" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Entresto</name><manufacturerId>NOV</manufacturerId><individualPrice>3.7060</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>3.7060</amountMOHLTCPays></drug></pcg9><pcg9 id="243208003"><itemNumber>0894</itemNumber><strength>48.6mg &amp; 51.4mg</strength><dosageForm>Tab</dosageForm><drug id="02446936" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Entresto</name><manufacturerId>NOV</manufacturerId><individualPrice>3.7060</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>3.7060</amountMOHLTCPays></drug></pcg9><pcg9 id="243208004"><itemNumber>0895</itemNumber><strength>97.2mg &amp; 102.8mg</strength><dosageForm>Tab</dosageForm><drug id="02446944" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Entresto</name><manufacturerId>NOV</manufacturerId><individualPrice>3.7060</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>3.7060</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="497">For the treatment of heart failure (HF) with reduced ejection fraction in patients with New York Heart Association (NYHA) class II or III HF to reduce the incidence of cardiovascular (CV) death and HF hospitalization, if all of the following clinical criteria are met:

- Reduced left ventricular ejection fraction (LVEF) (Less than 40%);

- Patient has NYHA class II to III symptoms despite at least four weeks of treatment with a stable dose of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB); and

- In combination with a beta blocker and other recommended therapies, including an aldosterone antagonist (if tolerable).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="243220000"><name>RENIN-ANGIOTENSIN ALDOSTERONE INHIBITORS ALDOSTERONE ANTAGONIS</name><genericName id="02392"><name>FINERENONE</name><pcgGroup lccId="00386"><pcg9 id="243220001"><itemNumber>0896</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02531917" sec3="Y" sec12="Y"><name>Kerendia</name><manufacturerId>BAH</manufacturerId><individualPrice>3.2565</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>3.2565</amountMOHLTCPays></drug></pcg9><pcg9 id="243220002"><itemNumber>0897</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02531925" sec3="Y" sec12="Y"><name>Kerendia</name><manufacturerId>BAH</manufacturerId><individualPrice>3.2565</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>3.2565</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="700">For use as an adjunct to standard-of-care (SOC) therapy in adult patients diagnosed with BOTH chronic kidney disease (CKD) and type 2 diabetes (T2D) to reduce the risk of end-stage kidney disease and a sustained decrease in estimated
glomerular filtration rate (eGFR), and cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in patients who meet the following criteria:

1. 18 years of age or older; AND

2. Diagnosed with CKD with an eGFR level greater than or equal to 25mL/min/1.73 square metres AND an albuminuria level greater than or equal to 30mg/g (or 3mg/mmol); AND

3. Patient is also diagnosed with T2D; AND

4. Finerenone is prescribed in addition to standard-of-care (SOC)* therapy for patients diagnosed with CKD with comorbid T2D; AND

* SOC therapy is defined as maximally tolerated doses of angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy in combination with a sodium-glucose cotransporter-2 (SGLT2) inhibitor unless SGLT2 inhibitors are contraindicated or not tolerated.

5. Patient does not have a diagnosis of chronic heart failure (CHF) with reduced ejection fraction and persistent symptoms meeting New York Heart Association Class II to IV; AND

6. Patient is not using finerenone in combination with another mineralocorticoid receptor antagonist (MRA); AND

7. Finerenone is prescribed in consultation with a nephrologist or other clinician with experience in the diagnosis and management of patients with CKD and T2D.

Discontinuation Criteria:

Patients meeting the initiation criteria and started on finerenone should be discontinued on treatment if the patient&apos;s eGFR is less than 15mL/min/1.73 square metres and/or if the urinary albumin-to-creatinine ratio (UACR) has increased from baseline level after starting treatment with finerenone.

Approved Dosage:

Up to 20mg once daily as per the product monograph</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6></pcg2><pcg2 id="280000000"><name>CENTRAL NERVOUS SYSTEM DRUGS</name><pcg6 id="280804000"><name>ANALGESICS NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</name><genericName id="01430"><name>CELECOXIB</name><pcgGroup lccId="00064"><pcg9 id="280804075"><itemNumber>0898</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02239941" sec3="Y" sec12="Y"><name>Celebrex</name><manufacturerId>UJC</manufacturerId><individualPrice>.8299</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02288915" sec3="Y" sec12="Y"><name>Teva-Celecoxib</name><manufacturerId>TEV</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02355442" sec3="Y" sec12="Y"><name>PMS-Celecoxib</name><manufacturerId>PMS</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02412373" sec3="Y" sec12="Y"><name>Ran-Celecoxib</name><manufacturerId>RAN</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02412497" sec3="Y" sec12="Y"><name>Mint-Celecoxib</name><manufacturerId>MIN</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02418932" sec3="Y" sec12="Y"><name>Apo-Celecoxib</name><manufacturerId>APX</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02420058" sec3="Y" sec12="Y"><name>Mar-Celecoxib</name><manufacturerId>MAR</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02420155" sec3="Y" sec12="Y"><name>Act Celecoxib</name><manufacturerId>ACV</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02424533" sec3="Y" sec12="Y"><name>Jamp-Celecoxib</name><manufacturerId>JPC</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02426382" sec3="Y" sec12="Y"><name>Bio-Celecoxib</name><manufacturerId>BMP</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02429675" sec3="Y" sec12="Y"><name>Celecoxib</name><manufacturerId>SIV</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02436299" sec3="Y" sec12="Y"><name>Celecoxib</name><manufacturerId>SAI</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02437570" sec3="Y" sec12="Y"><name>AG-Celecoxib</name><manufacturerId>ANG</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02442639" sec3="Y" sec12="Y"><name>Sdz Celecoxib</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02445670" sec3="Y" sec12="Y"><name>Auro-Celecoxib</name><manufacturerId>AUR</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02479737" sec3="Y" sec12="Y"><name>NRA-Celecoxib</name><manufacturerId>NRA</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02495465" sec3="Y" sec12="Y"><name>M-Celecoxib</name><manufacturerId>MAT</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug><drug id="02517116" sec3="Y" sec12="Y"><name>PMSC-Celecoxib</name><manufacturerId>PMS</manufacturerId><individualPrice>.1279</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.1279</amountMOHLTCPays></drug></pcg9><pcg9 id="280804076"><itemNumber>0899</itemNumber><strength>200mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02239942" sec3="Y" sec12="Y"><name>Celebrex</name><manufacturerId>UJC</manufacturerId><individualPrice>1.6601</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02288923" sec3="Y" sec12="Y"><name>Teva-Celecoxib</name><manufacturerId>TEV</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02355450" sec3="Y" sec12="Y"><name>PMS-Celecoxib</name><manufacturerId>PMS</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02412381" sec3="Y" sec12="Y"><name>Ran-Celecoxib</name><manufacturerId>RAN</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02412500" sec3="Y" sec12="Y"><name>Mint-Celecoxib</name><manufacturerId>MIN</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02418940" sec3="Y" sec12="Y"><name>Apo-Celecoxib</name><manufacturerId>APX</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02420066" sec3="Y" sec12="Y"><name>Mar-Celecoxib</name><manufacturerId>MAR</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02420163" sec3="Y" sec12="Y"><name>Act Celecoxib</name><manufacturerId>ACV</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02424541" sec3="Y" sec12="Y"><name>Jamp-Celecoxib</name><manufacturerId>JPC</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02426390" sec3="Y" sec12="Y"><name>Bio-Celecoxib</name><manufacturerId>BMP</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02429683" sec3="Y" sec12="Y"><name>Celecoxib</name><manufacturerId>SIV</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02436302" sec3="Y" sec12="Y"><name>Celecoxib</name><manufacturerId>SAI</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02437589" sec3="Y" sec12="Y"><name>AG-Celecoxib</name><manufacturerId>ANG</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02442647" sec3="Y" sec12="Y"><name>Sdz Celecoxib</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02445689" sec3="Y" sec12="Y"><name>Auro-Celecoxib</name><manufacturerId>AUR</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02479745" sec3="Y" sec12="Y"><name>NRA-Celecoxib</name><manufacturerId>NRA</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02495473" sec3="Y" sec12="Y"><name>M-Celecoxib</name><manufacturerId>MAT</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug><drug id="02517124" sec3="Y" sec12="Y"><name>PMSC-Celecoxib</name><manufacturerId>PMS</manufacturerId><individualPrice>.2558</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.2558</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="T">Osteoarthritis</lccNote><lccNote seq="002" reasonForUseId="316">For patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1g QID for several weeks) and have had:</lccNote><lccNote seq="003" type="R">History of a documented, clinically significant ulcer or GI bleed; or
Failure or intolerance to at least three listed NSAIDS.</lccNote><lccNote seq="004" type="N">The maximum daily dose of celecoxib which will be reimbursed for the treatment of osteoarthritis is 200mg.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" type="T">Rheumatoid arthritis</lccNote><lccNote seq="007" reasonForUseId="317">For patients who have had:</lccNote><lccNote seq="008" type="R">History of a documented, clinically significant ulcer or GI bleed; or
Failure or intolerance to at least three listed NSAIDS.</lccNote><lccNote seq="009" type="N">The maximum daily dose of celecoxib which will be reimbursed for the treatment of rheumatoid arthritis is 400mg.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01721"><name>DICLOFENAC POTASSIUM</name><pcgGroup><pcg9 id="280804099"><itemNumber>0900</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00881635" notABenefit="Y" sec3b="Y" sec3="Y"><name>Voltaren Rapide</name><manufacturerId>NOV</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02239355" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Diclofenac-K</name><manufacturerId>TEV</manufacturerId><individualPrice>.3937</individualPrice><listingDate>2008-01-15</listingDate></drug><drug id="02243433" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Diclo Rapide</name><manufacturerId>APX</manufacturerId><individualPrice>.3937</individualPrice><listingDate>2008-01-15</listingDate></drug><drug id="02261774" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Diclofenac Rapide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4165</individualPrice><listingDate>2008-01-15</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00425"><name>DICLOFENAC SODIUM</name><pcgGroup><pcg9 id="280804005"><itemNumber>0901</itemNumber><strength>25mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00514004" notABenefit="Y" sec3="Y"><name>Voltaren</name><manufacturerId>GEI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00808539" sec3="Y"><name>Teva-Diclofenac</name><manufacturerId>TEV</manufacturerId><individualPrice>.0781</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0781</amountMOHLTCPays></drug><drug id="00839175" sec3="Y"><name>Apo-Diclo</name><manufacturerId>APX</manufacturerId><individualPrice>.0781</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0781</amountMOHLTCPays></drug><drug id="02302616" sec3="Y"><name>PMS-Diclofenac</name><manufacturerId>PMS</manufacturerId><individualPrice>.0781</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>.0781</amountMOHLTCPays></drug></pcg9><pcg9 id="280804006"><itemNumber>0902</itemNumber><strength>50mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00514012" sec3="Y"><name>Voltaren</name><manufacturerId>NOV</manufacturerId><individualPrice>1.1384</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2064</amountMOHLTCPays></drug><drug id="00808547" sec3="Y"><name>Teva-Diclofenac</name><manufacturerId>TEV</manufacturerId><individualPrice>.2064</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2064</amountMOHLTCPays></drug><drug id="00839183" sec3="Y"><name>Apo-Diclo</name><manufacturerId>APX</manufacturerId><individualPrice>.2064</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2064</amountMOHLTCPays></drug><drug id="02261960" sec3="Y"><name>Sandoz Diclofenac</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2064</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2064</amountMOHLTCPays></drug><drug id="02302624" sec3="Y"><name>PMS-Diclofenac</name><manufacturerId>PMS</manufacturerId><individualPrice>.2064</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>.2064</amountMOHLTCPays></drug></pcg9><pcg9 id="280804058"><itemNumber>0903</itemNumber><strength>75mg</strength><dosageForm>LA Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00782459" notABenefit="Y" sec3="Y"><name>Voltaren SR</name><manufacturerId>NOV</manufacturerId><listingDate>1998-08-26</listingDate></drug><drug id="02162814" sec3="Y"><name>Apo-Diclo SR</name><manufacturerId>APX</manufacturerId><individualPrice>.7699</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.7699</amountMOHLTCPays></drug></pcg9><pcg9 id="280804059"><itemNumber>0904</itemNumber><strength>100mg</strength><dosageForm>LA Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00590827" notABenefit="Y" sec3="Y"><name>Voltaren SR</name><manufacturerId>NOV</manufacturerId><listingDate>1998-08-26</listingDate></drug><drug id="02091194" sec3="Y"><name>Apo-Diclo SR</name><manufacturerId>APX</manufacturerId><individualPrice>1.1053</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.1053</amountMOHLTCPays></drug></pcg9><pcg9 id="280804007"><itemNumber>0905</itemNumber><strength>50mg</strength><dosageForm>Sup</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00632724" sec3="Y"><name>Voltaren</name><manufacturerId>NOV</manufacturerId><individualPrice>2.0130</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2818</amountMOHLTCPays></drug><drug id="02261928" sec3="Y"><name>Sandoz Diclofenac</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2818</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>1.2818</amountMOHLTCPays></drug></pcg9><pcg9 id="280804008"><itemNumber>0906</itemNumber><strength>100mg</strength><dosageForm>Sup</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00632732" notABenefit="Y" sec3="Y"><name>Voltaren</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02261936" dinStatus="E" sec3="Y"><name>Sandoz Diclofenac</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5840</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.5840</amountMOHLTCPays></drug></pcg9><pcg9 id="280804098"><itemNumber>0907</itemNumber><strength>1.5% W/W</strength><dosageForm>Top Sol</dosageForm><drug id="02247265" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pennsaid</name><manufacturerId>PAL</manufacturerId><listingDate>2014-10-29</listingDate></drug><drug id="02356783" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Diclofenac</name><manufacturerId>PMS</manufacturerId><individualPrice>.6227</individualPrice><listingDate>2015-01-28</listingDate></drug><drug id="02420988" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Diclofenac</name><manufacturerId>TAR</manufacturerId><individualPrice>.6226</individualPrice><listingDate>2014-10-29</listingDate></drug><drug id="02434571" notABenefit="Y" sec3b="Y" sec3="Y"><name>Diclofenac Topical Solution</name><manufacturerId>STE</manufacturerId><individualPrice>.6226</individualPrice><listingDate>2018-06-29</listingDate></drug><drug id="02472309" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Diclofenac</name><manufacturerId>JPC</manufacturerId><individualPrice>.6226</individualPrice><listingDate>2018-06-29</listingDate></drug><drug id="02476134" dinStatus="E" notABenefit="Y" sec3b="Y" sec3="Y"><name>Diclofenac Sodium Solution</name><manufacturerId>TEL</manufacturerId><individualPrice>.6226</individualPrice><listingDate>2018-11-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00460"><name>DICLOFENAC SODIUM &amp; MISOPROSTOL</name><pcgGroup><pcg9 id="280804049"><itemNumber>0908</itemNumber><strength>50mg &amp; 200mcg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="01917056" sec3="Y"><name>Arthrotec 50</name><manufacturerId>PFI</manufacturerId><individualPrice>.7643</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3149</amountMOHLTCPays></drug><drug id="02341689" sec3="Y"><name>Gd-Diclofenac/Misoprostol 50</name><manufacturerId>GEM</manufacturerId><individualPrice>.3149</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>.3149</amountMOHLTCPays></drug><drug id="02413469" sec3="Y"><name>PMS-Diclofenac-Misoprostol</name><manufacturerId>PMS</manufacturerId><individualPrice>.3149</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3149</amountMOHLTCPays></drug></pcg9><pcg9 id="280804056"><itemNumber>0909</itemNumber><strength>75mg &amp; 200mcg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02229837" sec3="Y"><name>Arthrotec 75</name><manufacturerId>PFI</manufacturerId><individualPrice>1.0402</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.4286</amountMOHLTCPays></drug><drug id="02341697" sec3="Y"><name>Gd-Diclofenac/Misoprostol 75</name><manufacturerId>GEM</manufacturerId><individualPrice>.4286</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>.4286</amountMOHLTCPays></drug><drug id="02413477" sec3="Y"><name>PMS-Diclofenac-Misoprostol</name><manufacturerId>PMS</manufacturerId><individualPrice>.4286</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.4286</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00433"><name>FLURBIPROFEN</name><pcgGroup><pcg9 id="280804017"><itemNumber>0910</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00647942" notABenefit="Y" sec3="Y"><name>Ansaid</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01912046" sec3="Y"><name>Flurbiprofen</name><manufacturerId>AAP</manufacturerId><individualPrice>.4530</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4530</amountMOHLTCPays></drug></pcg9><pcg9 id="280804018"><itemNumber>0911</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00600792" notABenefit="Y" sec3="Y"><name>Ansaid</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01912038" sec3="Y"><name>Flurbiprofen</name><manufacturerId>AAP</manufacturerId><individualPrice>.5930</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5930</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00407"><name>IBUPROFEN</name><pcgGroup><pcg9 id="280804019"><itemNumber>0912</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00252409" notABenefit="Y" sec3="Y"><name>Motrin</name><manufacturerId>UPJ</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00441643" sec3="Y"><name>Apo-Ibuprofen</name><manufacturerId>APX</manufacturerId><individualPrice>.0309</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0309</amountMOHLTCPays></drug><drug id="02257912" sec3="Y"><name>Ibuprofen</name><manufacturerId>JPC</manufacturerId><individualPrice>.0309</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>.0309</amountMOHLTCPays></drug></pcg9><pcg9 id="280804020"><itemNumber>0913</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00327794" notABenefit="Y" sec3="Y"><name>Motrin</name><manufacturerId>UPJ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00441651" sec3="Y"><name>Apo-Ibuprofen</name><manufacturerId>APX</manufacturerId><individualPrice>.1377</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1377</amountMOHLTCPays></drug></pcg9><pcg9 id="280804021"><itemNumber>0914</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00364142" sec3="Y"><name>Motrin</name><manufacturerId>UPJ</manufacturerId><individualPrice>.1871</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0468</amountMOHLTCPays></drug><drug id="00506052" sec3="Y"><name>Apo-Ibuprofen</name><manufacturerId>APX</manufacturerId><individualPrice>.0468</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0468</amountMOHLTCPays></drug><drug id="02317338" sec3="Y"><name>Ibuprofen</name><manufacturerId>JPC</manufacturerId><individualPrice>.0468</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>.0468</amountMOHLTCPays></drug></pcg9><pcg9 id="280804022"><itemNumber>0915</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00484911" notABenefit="Y" sec3="Y"><name>Motrin</name><manufacturerId>UPJ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00585114" sec3="Y"><name>Apo-Ibuprofen</name><manufacturerId>APX</manufacturerId><individualPrice>.1313</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1313</amountMOHLTCPays></drug><drug id="00629359" sec3="Y"><name>Novo-Profen</name><manufacturerId>NOP</manufacturerId><individualPrice>.1313</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1313</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00408"><name>INDOMETHACIN</name><pcgGroup><pcg9 id="280804023"><itemNumber>0916</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00016039" notABenefit="Y" sec3="Y"><name>Indocid</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00337420" sec3="Y"><name>Teva-Indomethacin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1519</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1519</amountMOHLTCPays></drug><drug id="02461811" sec3="Y"><name>Mint-Indomethacin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1519</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.1519</amountMOHLTCPays></drug></pcg9><pcg9 id="280804024"><itemNumber>0917</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00016047" notABenefit="Y" sec3="Y"><name>Indocid</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00337439" sec3="Y"><name>Teva-Indomethacin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2469</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2469</amountMOHLTCPays></drug><drug id="02461536" sec3="Y"><name>Mint-Indomethacin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2469</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.2469</amountMOHLTCPays></drug></pcg9><pcg9 id="280804025"><itemNumber>0918</itemNumber><strength>50mg</strength><dosageForm>Sup</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00594466" notABenefit="Y" sec3="Y"><name>Indocid</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02231799" sec3="Y"><name>Odan-Indomethacin</name><manufacturerId>ODN</manufacturerId><individualPrice>1.2500</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.2500</amountMOHLTCPays></drug></pcg9><pcg9 id="280804026"><itemNumber>0919</itemNumber><strength>100mg</strength><dosageForm>Sup</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00016233" notABenefit="Y" sec3="Y"><name>Indocid</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02231800" sec3="Y"><name>Odan-Indomethacin</name><manufacturerId>ODN</manufacturerId><individualPrice>1.6500</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.6500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00420"><name>KETOPROFEN</name><pcgGroup><pcg9 id="280804027"><itemNumber>0920</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00790427" sec3="Y"><name>Ketoprofen</name><manufacturerId>AAP</manufacturerId><individualPrice>.3440</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3440</amountMOHLTCPays></drug><drug id="01926403" notABenefit="Y" sec3="Y"><name>Orudis</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280804028"><itemNumber>0921</itemNumber><strength>50mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00790435" sec3="Y"><name>Ketoprofen-E</name><manufacturerId>AAP</manufacturerId><individualPrice>.3379</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3379</amountMOHLTCPays></drug><drug id="01926381" notABenefit="Y" sec3="Y"><name>Orudis E-50</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280804029"><itemNumber>0922</itemNumber><strength>100mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00761680" notABenefit="Y" sec3="Y"><name>Rhodis-EC</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00842664" sec3="Y"><name>Ketoprofen-E</name><manufacturerId>AAP</manufacturerId><individualPrice>.6959</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6959</amountMOHLTCPays></drug><drug id="01926365" notABenefit="Y" sec3="Y"><name>Orudis E-100</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280804060"><itemNumber>0923</itemNumber><strength>200mg</strength><dosageForm>LA Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="01926373" notABenefit="Y" sec3="Y"><name>Orudis SR-200</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02172577" sec3="Y"><name>Ketoprofen SR</name><manufacturerId>AAP</manufacturerId><individualPrice>1.3925</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.3925</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00442"><name>KETOROLAC TROMETHAMINE</name><pcgGroup><pcg9 id="280804105"><itemNumber>0924</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02162660" notABenefit="Y" sec3b="Y" sec3="Y"><name>Toradol</name><manufacturerId>AAP</manufacturerId><listingDate>2008-10-01</listingDate></drug><drug id="02229080" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Ketorolac</name><manufacturerId>APX</manufacturerId><individualPrice>.6028</individualPrice><listingDate>2008-10-01</listingDate></drug><drug id="02461455" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Ketorolac</name><manufacturerId>MIN</manufacturerId><individualPrice>.6028</individualPrice><listingDate>2019-11-29</listingDate></drug><drug id="02465124" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Ketorolac</name><manufacturerId>MAR</manufacturerId><individualPrice>.6028</individualPrice><listingDate>2017-08-30</listingDate></drug><drug id="02510855" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Ketorolac</name><manufacturerId>JPC</manufacturerId><individualPrice>.6028</individualPrice><listingDate>2021-04-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00427"><name>MEFENAMIC ACID</name><pcgGroup><pcg9 id="280804031"><itemNumber>0925</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00155225" notABenefit="Y" sec3="Y"><name>Ponstan</name><manufacturerId>AAP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229452" sec3="Y"><name>Mefenamic</name><manufacturerId>AAP</manufacturerId><individualPrice>.4988</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.4988</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01501"><name>MELOXICAM</name><pcgGroup><pcg9 id="280804083"><itemNumber>0926</itemNumber><strength>7.5mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02242785" notABenefit="Y" sec3="Y"><name>Mobicox</name><manufacturerId>BOE</manufacturerId><listingDate>2001-03-07</listingDate></drug><drug id="02248267" sec3="Y"><name>PMS-Meloxicam</name><manufacturerId>PMS</manufacturerId><individualPrice>.2003</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2003</amountMOHLTCPays></drug><drug id="02248973" sec3="Y"><name>Apo-Meloxicam</name><manufacturerId>APX</manufacturerId><individualPrice>.2003</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2003</amountMOHLTCPays></drug><drug id="02250012" sec3="Y"><name>Co Meloxicam</name><manufacturerId>COB</manufacturerId><individualPrice>.2003</individualPrice><listingDate>2004-09-14</listingDate><amountMOHLTCPays>.2003</amountMOHLTCPays></drug><drug id="02258315" sec3="Y"><name>Teva-Meloxicam</name><manufacturerId>TEV</manufacturerId><individualPrice>.2003</individualPrice><listingDate>2004-11-16</listingDate><amountMOHLTCPays>.2003</amountMOHLTCPays></drug><drug id="02353148" sec3="Y"><name>Meloxicam</name><manufacturerId>SAI</manufacturerId><individualPrice>.2003</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2003</amountMOHLTCPays></drug><drug id="02390884" sec3="Y"><name>Auro-Meloxicam</name><manufacturerId>AUR</manufacturerId><individualPrice>.2003</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2003</amountMOHLTCPays></drug></pcg9><pcg9 id="280804084"><itemNumber>0927</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02242786" notABenefit="Y" sec3="Y"><name>Mobicox</name><manufacturerId>BOE</manufacturerId><listingDate>2024-08-30</listingDate></drug><drug id="02248268" sec3="Y"><name>PMS-Meloxicam</name><manufacturerId>PMS</manufacturerId><individualPrice>.2311</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2311</amountMOHLTCPays></drug><drug id="02248974" sec3="Y"><name>Apo-Meloxicam</name><manufacturerId>APX</manufacturerId><individualPrice>.2311</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2311</amountMOHLTCPays></drug><drug id="02250020" sec3="Y"><name>Co Meloxicam</name><manufacturerId>COB</manufacturerId><individualPrice>.2311</individualPrice><listingDate>2004-09-14</listingDate><amountMOHLTCPays>.2311</amountMOHLTCPays></drug><drug id="02258323" sec3="Y"><name>Teva-Meloxicam</name><manufacturerId>TEV</manufacturerId><individualPrice>.2311</individualPrice><listingDate>2004-11-16</listingDate><amountMOHLTCPays>.2311</amountMOHLTCPays></drug><drug id="02353156" sec3="Y"><name>Meloxicam</name><manufacturerId>SAI</manufacturerId><individualPrice>.2311</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2311</amountMOHLTCPays></drug><drug id="02390892" sec3="Y"><name>Auro-Meloxicam</name><manufacturerId>AUR</manufacturerId><individualPrice>.2311</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2311</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00456"><name>NABUMETONE</name><pcgGroup><pcg9 id="280804072"><itemNumber>0928</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02083531" notABenefit="Y" sec3b="Y" sec3="Y"><name>Relafen</name><manufacturerId>GSK</manufacturerId><listingDate>2007-07-12</listingDate></drug><drug id="02238639" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nabumetone</name><manufacturerId>AAP</manufacturerId><individualPrice>.7363</individualPrice><listingDate>2007-09-04</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00416"><name>NAPROXEN</name><pcgGroup><pcg9 id="280804100"><itemNumber>0929</itemNumber><strength>250mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02162792" notABenefit="Y" sec3b="Y" sec3="Y"><name>Naprosyn E</name><manufacturerId>HLR</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02243312" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Naproxen EC</name><manufacturerId>TEV</manufacturerId><individualPrice>.2835</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02246699" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Naproxen EC</name><manufacturerId>APX</manufacturerId><individualPrice>.2835</individualPrice><listingDate>2008-01-15</listingDate></drug></pcg9><pcg9 id="280804101"><itemNumber>0930</itemNumber><strength>375mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02162415" notABenefit="Y" sec3b="Y" sec3="Y"><name>Naprosyn E</name><manufacturerId>HLR</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02243313" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Naproxen EC</name><manufacturerId>TEV</manufacturerId><individualPrice>.3675</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02246700" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Naproxen EC</name><manufacturerId>APX</manufacturerId><individualPrice>.3675</individualPrice><listingDate>2008-01-15</listingDate></drug></pcg9><pcg9 id="280804102"><itemNumber>0931</itemNumber><strength>500mg</strength><dosageForm>Ent Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02162423" notABenefit="Y" sec3b="Y" sec3="Y"><name>Naprosyn E</name><manufacturerId>HLR</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="02243314" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Naproxen EC</name><manufacturerId>TEV</manufacturerId><individualPrice>.6894</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02246701" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Naproxen EC</name><manufacturerId>APX</manufacturerId><individualPrice>.6894</individualPrice><listingDate>2008-01-15</listingDate></drug></pcg9><pcg9 id="280804054"><itemNumber>0932</itemNumber><strength>25mg/mL</strength><dosageForm>O/L</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02162431" sec3="Y"><name>Pediapharm Naproxen Suspension</name><manufacturerId>MPI</manufacturerId><individualPrice>.0949</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0949</amountMOHLTCPays></drug></pcg9><pcg9 id="280804033"><itemNumber>0933</itemNumber><strength>125mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00299413" notABenefit="Y" sec3="Y"><name>Naprosyn</name><manufacturerId>SYN</manufacturerId><listingDate>2001-02-28</listingDate></drug><drug id="00522678" sec3="Y"><name>Apo-Naproxen</name><manufacturerId>APX</manufacturerId><individualPrice>.0781</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0781</amountMOHLTCPays></drug></pcg9><pcg9 id="280804034"><itemNumber>0934</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00522651" sec3="Y"><name>Apo-Naproxen</name><manufacturerId>APX</manufacturerId><individualPrice>.1068</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1068</amountMOHLTCPays></drug><drug id="00565350" sec3="Y"><name>Teva-Naproxen</name><manufacturerId>TEV</manufacturerId><individualPrice>.1068</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1068</amountMOHLTCPays></drug><drug id="02162474" notABenefit="Y" sec3="Y"><name>Naprosyn</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280804035"><itemNumber>0935</itemNumber><strength>375mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00600806" sec3="Y"><name>Apo-Naproxen</name><manufacturerId>APX</manufacturerId><individualPrice>.1458</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1458</amountMOHLTCPays></drug><drug id="00627097" sec3="Y"><name>Teva-Naproxen</name><manufacturerId>TEV</manufacturerId><individualPrice>.1458</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1458</amountMOHLTCPays></drug><drug id="02162482" notABenefit="Y" sec3="Y"><name>Naprosyn</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280804036"><itemNumber>0936</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00589861" sec3="Y"><name>Teva-Naproxen</name><manufacturerId>TEV</manufacturerId><individualPrice>.4522</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4522</amountMOHLTCPays></drug><drug id="00592277" sec3="Y"><name>Apo-Naproxen</name><manufacturerId>APX</manufacturerId><individualPrice>.4522</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4522</amountMOHLTCPays></drug><drug id="02162490" notABenefit="Y" sec3="Y"><name>Naprosyn</name><manufacturerId>HLR</manufacturerId><listingDate>2000-04-17</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02034"><name>NAPROXEN &amp; ESOMEPRAZOLE MAGNESIUM</name><pcgGroup><pcg9 id="280804106"><itemNumber>0937</itemNumber><strength>375mg &amp; 20mg</strength><dosageForm>MR Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02361701" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vimovo</name><manufacturerId>XED</manufacturerId><listingDate>2017-04-27</listingDate></drug><drug id="02458608" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Naproxen &amp; Esomeprazole MR</name><manufacturerId>MYL</manufacturerId><individualPrice>.9308</individualPrice><listingDate>2017-04-27</listingDate></drug></pcg9><pcg9 id="280804107"><itemNumber>0938</itemNumber><strength>500mg &amp; 20mg</strength><dosageForm>MR Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02361728" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vimovo</name><manufacturerId>XED</manufacturerId><listingDate>2017-04-27</listingDate></drug><drug id="02443449" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Naproxen &amp; Esomeprazole MR</name><manufacturerId>MYL</manufacturerId><individualPrice>.9274</individualPrice><listingDate>2017-04-27</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00446"><name>NAPROXEN SODIUM</name><pcgGroup><pcg9 id="280804103"><itemNumber>0939</itemNumber><strength>275mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00778389" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Naproxen Sodium</name><manufacturerId>TEV</manufacturerId><individualPrice>.3422</individualPrice><listingDate>2022-08-31</listingDate></drug><drug id="00784354" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Napro-Na</name><manufacturerId>APX</manufacturerId><individualPrice>.3422</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02162725" notABenefit="Y" sec3b="Y" sec3="Y"><name>Anaprox</name><manufacturerId>HLR</manufacturerId><listingDate>2007-12-19</listingDate></drug></pcg9><pcg9 id="280804104"><itemNumber>0940</itemNumber><strength>550mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="01940309" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Napro-Na DS</name><manufacturerId>APX</manufacturerId><individualPrice>.6667</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02026600" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Naproxen Sodium DS</name><manufacturerId>TEV</manufacturerId><individualPrice>.6667</individualPrice><listingDate>2022-08-31</listingDate></drug><drug id="02162717" notABenefit="Y" sec3b="Y" sec3="Y"><name>Anaprox DS</name><manufacturerId>HLR</manufacturerId><listingDate>2007-12-19</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01317"><name>OXAPROZIN.</name><pcgGroup><pcg9 id="280804055"><itemNumber>0941</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02027860" notABenefit="Y" sec3b="Y" sec3="Y"><name>Daypro</name><manufacturerId>HLR</manufacturerId><listingDate>2007-07-12</listingDate></drug><drug id="02243661" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Oxaprozin</name><manufacturerId>APX</manufacturerId><individualPrice>.6892</individualPrice><listingDate>2007-07-12</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00429"><name>PIROXICAM</name><pcgGroup><pcg9 id="280804038"><itemNumber>0942</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00525596" notABenefit="Y" sec3="Y"><name>Feldene</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00642886" sec3="Y"><name>Apo-Piroxicam</name><manufacturerId>APX</manufacturerId><individualPrice>.4426</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4426</amountMOHLTCPays></drug><drug id="00695718" sec3="Y"><name>Teva-Piroxicam</name><manufacturerId>TEV</manufacturerId><individualPrice>.4426</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4426</amountMOHLTCPays></drug></pcg9><pcg9 id="280804039"><itemNumber>0943</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00525618" notABenefit="Y" sec3="Y"><name>Feldene</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00642894" sec3="Y"><name>Apo-Piroxicam</name><manufacturerId>APX</manufacturerId><individualPrice>.7422</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7422</amountMOHLTCPays></drug><drug id="00695696" sec3="Y"><name>Teva-Piroxicam</name><manufacturerId>TEV</manufacturerId><individualPrice>.7422</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7422</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00422"><name>SULINDAC</name><pcgGroup><pcg9 id="280804042"><itemNumber>0944</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00456888" notABenefit="Y" sec3="Y"><name>Clinoril</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00745588" sec3="Y"><name>Teva-Sulindac</name><manufacturerId>TEV</manufacturerId><individualPrice>.4427</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4427</amountMOHLTCPays></drug></pcg9><pcg9 id="280804043"><itemNumber>0945</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="00432369" notABenefit="Y" sec3="Y"><name>Clinoril</name><manufacturerId>FRS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00745596" sec3="Y"><name>Teva-Sulindac</name><manufacturerId>TEV</manufacturerId><individualPrice>.5253</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5253</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00434"><name>TIAPROFENIC ACID</name><pcgGroup><pcg9 id="280804044"><itemNumber>0946</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="01989782" notABenefit="Y" sec3="Y"><name>Surgam</name><manufacturerId>HRU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02179679" sec3="Y"><name>Teva-Tiaprofenic</name><manufacturerId>TEV</manufacturerId><individualPrice>.5728</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5728</amountMOHLTCPays></drug></pcg9><pcg9 id="280804045"><itemNumber>0947</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><note>NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.</note><drug id="02179687" sec3="Y"><name>Teva-Tiaprofenic</name><manufacturerId>TEV</manufacturerId><individualPrice>.8070</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.8070</amountMOHLTCPays></drug><drug id="02221950" notABenefit="Y" sec3="Y"><name>Surgam</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="280808000"><name>ANALGESICS OPIATE AGONISTS</name><note>Narcotic analgesics can produce dependence and may be abused. Physical dependence, psychological dependence and tolerance may develop. Prescribers are cautioned about ordering these drugs for patients with a history of either emotional disturbances or drug abuse, including alcohol.</note><genericName id="01867"><name>ACETAMINOPHEN &amp; CAFFEINE &amp; CODEINE PHOSPHATE</name><pcgGroup><pcg9 id="280808004"><itemNumber>0948</itemNumber><strength>300mg &amp; 15mg &amp; 15mg</strength><dosageForm>Tab</dosageForm><drug id="00653241" sec3="Y"><name>Teva-Lenoltec No.2</name><manufacturerId>TEV</manufacturerId><individualPrice>.0889</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0889</amountMOHLTCPays></drug><drug id="02163934" notABenefit="Y" sec3="Y"><name>Tylenol with Codeine No. 2</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280808005"><itemNumber>0949</itemNumber><strength>300mg &amp; 15mg &amp; 30mg</strength><dosageForm>Tab</dosageForm><drug id="00653276" sec3="Y"><name>Teva-Lenoltec No.3</name><manufacturerId>TEV</manufacturerId><individualPrice>.0933</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0933</amountMOHLTCPays></drug><drug id="02163926" notABenefit="Y" sec3="Y"><name>Tylenol with Codeine No. 3</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00421"><name>ACETAMINOPHEN &amp; CODEINE PHOSPHATE</name><pcgGroup><pcg9 id="280808001"><itemNumber>0950</itemNumber><strength>160mg &amp; 8mg/5mL</strength><dosageForm>O/L</dosageForm><drug id="00816027" sec3="Y"><name>PMS-Acetaminophen With Codeine</name><manufacturerId>PMS</manufacturerId><individualPrice>.1074</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1074</amountMOHLTCPays></drug><drug id="02163942" notABenefit="Y" sec3="Y"><name>Tylenol With Codeine Elixir</name><manufacturerId>JAN</manufacturerId><listingDate>2007-01-02</listingDate></drug></pcg9><pcg9 id="280808002"><itemNumber>0951</itemNumber><strength>300mg &amp; 30mg</strength><dosageForm>Tab</dosageForm><drug id="00608882" sec3="Y"><name>Teva-Emtec-30</name><manufacturerId>TEV</manufacturerId><individualPrice>.1300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1300</amountMOHLTCPays></drug><drug id="00666130" notABenefit="Y" sec3="Y"><name>Empracet-30</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280808003"><itemNumber>0952</itemNumber><strength>300mg &amp; 60mg</strength><dosageForm>Tab</dosageForm><drug id="00621463" sec3="Y"><name>Teva-Lenoltec No.4</name><manufacturerId>TEV</manufacturerId><individualPrice>.1685</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1685</amountMOHLTCPays></drug><drug id="02163918" notABenefit="Y" sec3="Y"><name>Tylenol with Codeine No. 4</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01743"><name>ACETYLSALICYLIC ACID &amp; BUTALBITAL &amp; CAFFEINE</name><pcgGroup><pcg9 id="280808136"><itemNumber>0953</itemNumber><strength>330mg &amp; 50mg &amp; 40mg</strength><dosageForm>Cap</dosageForm><drug id="00226327" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fiorinal</name><manufacturerId>NOV</manufacturerId><listingDate>2008-12-23</listingDate></drug><drug id="00608238" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Tecnal</name><manufacturerId>RPH</manufacturerId><individualPrice>1.6192</individualPrice><listingDate>2008-12-23</listingDate></drug><drug id="02554690" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Butalbital-ASA-Caffeine</name><manufacturerId>APX</manufacturerId><individualPrice>1.7939</individualPrice><listingDate>2025-05-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01744"><name>ACETYLSALICYLIC ACID &amp; BUTALBITAL &amp; CAFFEINE &amp; CODEINE PHOSPHATE</name><pcgGroup><pcg9 id="280808168"><itemNumber>0954</itemNumber><strength>330mg &amp; 50mg &amp; 40mg &amp; 15mg</strength><dosageForm>Cap</dosageForm><drug id="00176192" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fiorinal C1/4</name><manufacturerId>NOV</manufacturerId><listingDate>2008-12-23</listingDate></drug><drug id="00608203" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Tecnal C1/4</name><manufacturerId>RPH</manufacturerId><individualPrice>1.7363</individualPrice><listingDate>2008-12-23</listingDate></drug><drug id="02554615" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Butalbital-ASA-Caffeine-Codeine-C1/4</name><manufacturerId>APX</manufacturerId><individualPrice>1.7363</individualPrice><listingDate>2025-03-31</listingDate></drug></pcg9><pcg9 id="280808138"><itemNumber>0955</itemNumber><strength>330mg &amp; 50mg &amp; 40mg &amp; 30mg</strength><dosageForm>Cap</dosageForm><drug id="00176206" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fiorinal C1/2</name><manufacturerId>NOV</manufacturerId><listingDate>2008-12-23</listingDate></drug><drug id="00608181" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Tecnal C1/2</name><manufacturerId>RPH</manufacturerId><individualPrice>2.1261</individualPrice><listingDate>2008-12-23</listingDate></drug><drug id="02554623" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Butalbital-ASA-Caffeine-Codeine-C1/2</name><manufacturerId>APX</manufacturerId><individualPrice>2.1261</individualPrice><listingDate>2025-03-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00406"><name>CODEINE PHOSPHATE</name><pcgGroup><pcg9 id="280808010"><itemNumber>0956</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="00593435" sec3="Y"><name>Teva-Codeine</name><manufacturerId>TEV</manufacturerId><individualPrice>.0596</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0596</amountMOHLTCPays></drug><drug id="00779458" notABenefit="Y" sec3="Y"><name>Codeine</name><manufacturerId>ROG</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280808011"><itemNumber>0957</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="00593451" sec3="Y"><name>Teva-Codeine</name><manufacturerId>TEV</manufacturerId><individualPrice>.0966</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0966</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00462"><name>CODEINE SULFATE TRIHYDRATE &amp; MONOHYDRATE</name><pcgGroup lccId="00066"><pcg9 id="280808101"><itemNumber>0958</itemNumber><strength>50mg</strength><dosageForm>CR Tab</dosageForm><drug id="02230302" sec3="Y" sec12="Y"><name>Codeine Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>.5032</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.5032</amountMOHLTCPays></drug></pcg9><pcg9 id="280808107"><itemNumber>0959</itemNumber><strength>100mg</strength><dosageForm>CR Tab</dosageForm><drug id="02163748" sec3="Y" sec12="Y"><name>Codeine Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>1.0074</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>1.0074</amountMOHLTCPays></drug></pcg9><pcg9 id="280808108"><itemNumber>0960</itemNumber><strength>150mg</strength><dosageForm>CR Tab</dosageForm><drug id="02163780" sec3="Y" sec12="Y"><name>Codeine Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>1.5116</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>1.5116</amountMOHLTCPays></drug></pcg9><pcg9 id="280808109"><itemNumber>0961</itemNumber><strength>200mg</strength><dosageForm>CR Tab</dosageForm><drug id="02163799" sec3="Y" sec12="Y"><name>Codeine Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>2.0148</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>2.0148</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="201">For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a listed long-acting opioid.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00466"><name>FENTANYL TRANSDERMAL SYSTEM</name><pcgGroup lccId="00402"><pcg9 id="280808169"><itemNumber>0962</itemNumber><strength>12mcg/hr</strength><dosageForm>Trans Patch</dosageForm><drug id="02280345" notABenefit="Y" sec3="Y"><name>Duragesic 12</name><manufacturerId>JNO</manufacturerId><listingDate>2008-12-23</listingDate></drug><drug id="02311925" sec3="Y" sec12="Y"><name>Teva-Fentanyl</name><manufacturerId>TEV</manufacturerId><individualPrice>3.3200</individualPrice><listingDate>2008-12-23</listingDate><amountMOHLTCPays>3.3200</amountMOHLTCPays></drug><drug id="02327112" sec3="Y" sec12="Y"><name>Sandoz Fentanyl Patch</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.3200</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>3.3200</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="511">For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00403"><pcg9 id="280808469"><itemNumber>0963</itemNumber><strength>12mcg/hr</strength><dosageForm>Trans Patch</dosageForm><drug id="09858348" sec3="Y" sec12="Y"><name>Sandoz Fentanyl Patch</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.3200</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>3.3200</amountMOHLTCPays></drug><drug id="09858349" sec3="Y" sec12="Y"><name>Teva-Fentanyl</name><manufacturerId>TEV</manufacturerId><individualPrice>3.3200</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>3.3200</amountMOHLTCPays></drug><drug id="09858350" notABenefit="Y" sec3="Y"><name>Duragesic 12</name><manufacturerId>JNO</manufacturerId><listingDate>2024-09-27</listingDate></drug></pcg9><lccNote seq="001" reasonForUseId="689">For the treatment of chronic pain in patients who have been stabilized on fentanyl and require the use of fentanyl 12mcg/hr patches for dose adjustment up or down to the lowest optimal opioid dose.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00067"><pcg9 id="280808079"><itemNumber>0964</itemNumber><strength>25mcg/hr</strength><dosageForm>Trans Patch</dosageForm><drug id="01937383" notABenefit="Y" sec3="Y"><name>Duragesic 25</name><manufacturerId>JNO</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02275813" notABenefit="Y" sec3="Y"><name>Duragesic</name><manufacturerId>JAN</manufacturerId><listingDate>2010-04-23</listingDate></drug><drug id="02282941" sec3="Y" sec12="Y"><name>Teva-Fentanyl</name><manufacturerId>TEV</manufacturerId><individualPrice>8.5600</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>8.5600</amountMOHLTCPays></drug><drug id="02327120" sec3="Y" sec12="Y"><name>Sandoz Fentanyl Patch</name><manufacturerId>SDZ</manufacturerId><individualPrice>8.5600</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>8.5600</amountMOHLTCPays></drug></pcg9><pcg9 id="280808080"><itemNumber>0965</itemNumber><strength>50mcg/hr</strength><dosageForm>Trans Patch</dosageForm><drug id="01937391" notABenefit="Y" sec3="Y"><name>Duragesic 50</name><manufacturerId>JNO</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02275821" notABenefit="Y" sec3="Y"><name>Duragesic</name><manufacturerId>JAN</manufacturerId><listingDate>2010-04-23</listingDate></drug><drug id="02282968" sec3="Y" sec12="Y"><name>Teva-Fentanyl</name><manufacturerId>TEV</manufacturerId><individualPrice>16.1100</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>16.1100</amountMOHLTCPays></drug><drug id="02327147" sec3="Y" sec12="Y"><name>Sandoz Fentanyl Patch</name><manufacturerId>SDZ</manufacturerId><individualPrice>16.1100</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>16.1100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="511">For the treatment of chronic pain in patients who cannot tolerate, or have failed treatment with a long-acting opioid. Intolerance or failed treatment with a long-acting opioid will be subject to verification at the time of dispensing.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="280808081"><itemNumber>0966</itemNumber><strength>75mcg/hr</strength><dosageForm>Trans Patch</dosageForm><drug id="01937405" notABenefit="Y" sec3b="Y" sec3="Y"><name>Duragesic 75</name><manufacturerId>JNO</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02275848" notABenefit="Y" sec3b="Y" sec3="Y"><name>Duragesic</name><manufacturerId>JAN</manufacturerId><listingDate>2010-04-23</listingDate></drug><drug id="02282976" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Fentanyl</name><manufacturerId>TEV</manufacturerId><individualPrice>22.6500</individualPrice><listingDate>2007-01-02</listingDate></drug><drug id="02327155" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Fentanyl Patch</name><manufacturerId>SDZ</manufacturerId><individualPrice>22.6500</individualPrice><listingDate>2010-03-02</listingDate></drug></pcg9><pcg9 id="280808082"><itemNumber>0967</itemNumber><strength>100mcg/hr</strength><dosageForm>Trans Patch</dosageForm><drug id="01937413" notABenefit="Y" sec3b="Y" sec3="Y"><name>Duragesic 100</name><manufacturerId>JNO</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02275856" notABenefit="Y" sec3b="Y" sec3="Y"><name>Duragesic</name><manufacturerId>JAN</manufacturerId><listingDate>2010-04-23</listingDate></drug><drug id="02282984" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Fentanyl</name><manufacturerId>TEV</manufacturerId><individualPrice>28.1950</individualPrice><listingDate>2007-01-02</listingDate></drug><drug id="02327163" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Fentanyl Patch</name><manufacturerId>SDZ</manufacturerId><individualPrice>28.1950</individualPrice><listingDate>2010-03-02</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00432"><name>HYDROMORPHONE HCL</name><pcgGroup><pcg9 id="280808306"><itemNumber>0968</itemNumber><strength>4.5mg</strength><dosageForm>CR Cap</dosageForm><drug id="02359502" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>.9549</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.9549</amountMOHLTCPays></drug></pcg9><pcg9 id="280808307"><itemNumber>0969</itemNumber><strength>9mg</strength><dosageForm>CR Cap</dosageForm><drug id="02359510" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>1.5600</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.5600</amountMOHLTCPays></drug></pcg9><pcg9 id="280808097"><itemNumber>0970</itemNumber><strength>3mg</strength><dosageForm>CR Cap</dosageForm><drug id="02125323" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>.7913</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.7913</amountMOHLTCPays></drug></pcg9><pcg9 id="280808098"><itemNumber>0971</itemNumber><strength>6mg</strength><dosageForm>CR Cap</dosageForm><drug id="02125331" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>1.1823</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.1823</amountMOHLTCPays></drug></pcg9><pcg9 id="280808099"><itemNumber>0972</itemNumber><strength>12mg</strength><dosageForm>CR Cap</dosageForm><drug id="02125366" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>2.0559</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>2.0559</amountMOHLTCPays></drug></pcg9><pcg9 id="280808123"><itemNumber>0973</itemNumber><strength>18mg</strength><dosageForm>CR Cap</dosageForm><drug id="02243562" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>2.9661</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>2.9661</amountMOHLTCPays></drug></pcg9><pcg9 id="280808100"><itemNumber>0974</itemNumber><strength>24mg</strength><dosageForm>CR Cap</dosageForm><drug id="02125382" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>4.3022</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>4.3022</amountMOHLTCPays></drug></pcg9><pcg9 id="280808102"><itemNumber>0975</itemNumber><strength>30mg</strength><dosageForm>CR Cap</dosageForm><drug id="02125390" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Hydromorph Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>5.1553</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>5.1553</amountMOHLTCPays></drug></pcg9><pcg9 id="280808014"><itemNumber>0976</itemNumber><strength>2mg/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="00627100" notABenefit="Y" sec3="Y"><name>Dilaudid</name><manufacturerId>PFP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02145901" sec3="Y"><name>Hydromorphone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7830</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.7830</amountMOHLTCPays></drug></pcg9><pcg9 id="280808015"><itemNumber>0977</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="00622133" notABenefit="Y" sec3="Y"><name>Dilaudid-HP</name><manufacturerId>PFP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02145928" sec3="Y"><name>Hydromorphone HP-10</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.3460</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>4.3460</amountMOHLTCPays></drug></pcg9><pcg9 id="280808013"><itemNumber>0978</itemNumber><strength>1mg/mL</strength><dosageForm>Oral Sol</dosageForm><drug id="00786535" notABenefit="Y" sec3="Y"><name>Dilaudid</name><manufacturerId>PFP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01916386" sec3="Y"><name>PMS-HYDROmorphone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0827</individualPrice><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.0827</amountMOHLTCPays></drug></pcg9><pcg9 id="280808017"><itemNumber>0979</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00705438" sec3="Y"><name>Dilaudid</name><manufacturerId>PFP</manufacturerId><individualPrice>.1039</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0959</amountMOHLTCPays></drug><drug id="00885444" sec3="Y"><name>PMS-HYDROmorphone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0959</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.0959</amountMOHLTCPays></drug><drug id="02319403" sec3="Y"><name>Teva-Hydromorphone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0959</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.0959</amountMOHLTCPays></drug><drug id="02364115" sec3="Y"><name>Apo-Hydromorphone</name><manufacturerId>APX</manufacturerId><individualPrice>.0959</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.0959</amountMOHLTCPays></drug></pcg9><pcg9 id="280808018"><itemNumber>0980</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00125083" sec3="Y"><name>Dilaudid</name><manufacturerId>PFP</manufacturerId><individualPrice>.1533</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1417</amountMOHLTCPays></drug><drug id="00885436" sec3="Y"><name>PMS-HYDROmorphone</name><manufacturerId>PMS</manufacturerId><individualPrice>.1417</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.1417</amountMOHLTCPays></drug><drug id="02319411" sec3="Y"><name>Teva-Hydromorphone</name><manufacturerId>TEV</manufacturerId><individualPrice>.1417</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.1417</amountMOHLTCPays></drug><drug id="02364123" sec3="Y"><name>Apo-Hydromorphone</name><manufacturerId>APX</manufacturerId><individualPrice>.1417</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.1417</amountMOHLTCPays></drug></pcg9><pcg9 id="280808019"><itemNumber>0981</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="00125121" sec3="Y"><name>Dilaudid</name><manufacturerId>PFP</manufacturerId><individualPrice>.2418</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="00885401" sec3="Y"><name>PMS-HYDROmorphone</name><manufacturerId>PMS</manufacturerId><individualPrice>.2240</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02319438" sec3="Y"><name>Teva-Hydromorphone</name><manufacturerId>TEV</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug><drug id="02364131" sec3="Y"><name>Apo-Hydromorphone</name><manufacturerId>APX</manufacturerId><individualPrice>.2240</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.2240</amountMOHLTCPays></drug></pcg9><pcg9 id="280808020"><itemNumber>0982</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="00786543" sec3="Y"><name>Dilaudid</name><manufacturerId>PFP</manufacturerId><individualPrice>.3812</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3528</amountMOHLTCPays></drug><drug id="00885428" sec3="Y"><name>PMS-HYDROmorphone</name><manufacturerId>PMS</manufacturerId><individualPrice>.3528</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.3528</amountMOHLTCPays></drug><drug id="02319446" sec3="Y"><name>Teva-Hydromorphone</name><manufacturerId>TEV</manufacturerId><individualPrice>.3528</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.3528</amountMOHLTCPays></drug><drug id="02364158" sec3="Y"><name>Apo-Hydromorphone</name><manufacturerId>APX</manufacturerId><individualPrice>.3528</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.3528</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01643"><name>METHADONE HCL</name><pcgGroup><pcg9 id="280808450"><itemNumber>0983</itemNumber><strength>10mg/mL</strength><dosageForm>Oral Concentrate</dosageForm><note>For methadone maintenance treatment for addiction.</note><drug id="02244290" sec3="Y"><name>Metadol-D</name><manufacturerId>PAL</manufacturerId><individualPrice>.1607</individualPrice><listingDate>2017-01-31</listingDate><amountMOHLTCPays>.1607</amountMOHLTCPays></drug></pcg9><pcg9 id="280808421"><itemNumber>0984</itemNumber><strength>10mg/mL</strength><dosageForm>Oral Concentrate (Cherry Flavour)</dosageForm><note>For methadone maintenance treatment for addiction.</note><drug id="02394596" sec3="Y"><name>Methadose</name><manufacturerId>MAL</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug><drug id="02495872" sec3="Y"><name>Odan-Methadone</name><manufacturerId>ODN</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug><drug id="02552736" sec3="Y"><name>PMS-Methadone HCl Oral Concentrate</name><manufacturerId>PMS</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug></pcg9><pcg9 id="280808422"><itemNumber>0985</itemNumber><strength>10mg/mL</strength><dosageForm>Oral Concentrate (Unflavoured)</dosageForm><note>For methadone maintenance treatment for addiction.</note><drug id="02394618" sec3="Y"><name>Methadose</name><manufacturerId>MAL</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug><drug id="02495783" sec3="Y"><name>Jamp Methadone Oral Concentrate</name><manufacturerId>JPC</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug><drug id="02495880" sec3="Y"><name>Odan-Methadone</name><manufacturerId>ODN</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug><drug id="02552728" sec3="Y"><name>PMS-Methadone HCl Oral Concentrate</name><manufacturerId>PMS</manufacturerId><individualPrice>.0525</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.0525</amountMOHLTCPays></drug></pcg9><pcg9 id="280808142"><itemNumber>0986</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02247698" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Metadol</name><manufacturerId>PMS</manufacturerId><individualPrice>.1399</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.1026</amountMOHLTCPays></drug><drug id="02533642" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Methadone</name><manufacturerId>APX</manufacturerId><individualPrice>.1026</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.1026</amountMOHLTCPays></drug></pcg9><pcg9 id="280808143"><itemNumber>0987</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02247699" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Metadol</name><manufacturerId>PMS</manufacturerId><individualPrice>.4659</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.3417</amountMOHLTCPays></drug><drug id="02533650" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Methadone</name><manufacturerId>APX</manufacturerId><individualPrice>.3417</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.3417</amountMOHLTCPays></drug></pcg9><pcg9 id="280808144"><itemNumber>0988</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02247700" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Metadol</name><manufacturerId>PMS</manufacturerId><individualPrice>.7454</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.5466</amountMOHLTCPays></drug><drug id="02533669" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Methadone</name><manufacturerId>APX</manufacturerId><individualPrice>.5466</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.5466</amountMOHLTCPays></drug></pcg9><pcg9 id="280808145"><itemNumber>0989</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02247701" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Metadol</name><manufacturerId>PMS</manufacturerId><individualPrice>1.3850</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>1.0157</amountMOHLTCPays></drug><drug id="02533677" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Methadone</name><manufacturerId>APX</manufacturerId><individualPrice>1.0157</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>1.0157</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00411"><name>MORPHINE SULFATE</name><pcgGroup><pcg9 id="280808068"><itemNumber>0990</itemNumber><strength>10mg</strength><dosageForm>ER Cap</dosageForm><drug id="02019930" sec3="Y"><name>M-Eslon</name><manufacturerId>ETH</manufacturerId><individualPrice>.3416</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3416</amountMOHLTCPays></drug></pcg9><pcg9 id="280808086"><itemNumber>0991</itemNumber><strength>15mg</strength><dosageForm>ER Cap</dosageForm><drug id="02177749" sec3="Y"><name>M-Eslon</name><manufacturerId>ETH</manufacturerId><individualPrice>.3941</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.3941</amountMOHLTCPays></drug></pcg9><pcg9 id="280808069"><itemNumber>0992</itemNumber><strength>30mg</strength><dosageForm>ER Cap</dosageForm><drug id="02019949" sec3="Y"><name>M-Eslon</name><manufacturerId>ETH</manufacturerId><individualPrice>.5875</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5875</amountMOHLTCPays></drug></pcg9><pcg9 id="280808070"><itemNumber>0993</itemNumber><strength>60mg</strength><dosageForm>ER Cap</dosageForm><drug id="02019957" sec3="Y"><name>M-Eslon</name><manufacturerId>ETH</manufacturerId><individualPrice>1.0457</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0457</amountMOHLTCPays></drug></pcg9><pcg9 id="280808071"><itemNumber>0994</itemNumber><strength>100mg</strength><dosageForm>ER Cap</dosageForm><drug id="02019965" sec3="Y"><name>M-Eslon</name><manufacturerId>ETH</manufacturerId><individualPrice>2.2554</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.2554</amountMOHLTCPays></drug></pcg9><pcg9 id="280808150"><itemNumber>0995</itemNumber><strength>2mg/mL</strength><dosageForm>Inj Sol Amp</dosageForm><drug id="02242484" sec3="Y"><name>Morphine Sulfate Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.2510</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>2.2510</amountMOHLTCPays></drug></pcg9><pcg9 id="280808151"><itemNumber>0996</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol Amp</dosageForm><drug id="00392588" sec3="Y"><name>Morphine Sulfate</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.3860</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>2.3860</amountMOHLTCPays></drug></pcg9><pcg9 id="280808040"><itemNumber>0997</itemNumber><strength>15mg/mL</strength><dosageForm>Inj Sol Amp</dosageForm><drug id="00392561" sec3="Y"><name>Morphine Sulfate</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.0940</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>2.0940</amountMOHLTCPays></drug><drug id="00850330" notABenefit="Y" sec3="Y"><name>Morphine Sulfate Injection USP</name><manufacturerId>HOS</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="280808041"><itemNumber>0998</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="00617288" sec3="Y"><name>Morphine HP-50</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.8195</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.8195</amountMOHLTCPays></drug></pcg9><pcg9 id="280808125"><itemNumber>0999</itemNumber><strength>10mg</strength><dosageForm>SR Cap</dosageForm><drug id="02242163" sec3="Y"><name>Kadian</name><manufacturerId>BGP</manufacturerId><individualPrice>.4648</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.4648</amountMOHLTCPays></drug></pcg9><pcg9 id="280808093"><itemNumber>1000</itemNumber><strength>20mg</strength><dosageForm>SR Cap</dosageForm><drug id="02184435" sec3="Y"><name>Kadian</name><manufacturerId>BGP</manufacturerId><individualPrice>.9029</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.9029</amountMOHLTCPays></drug></pcg9><pcg9 id="280808094"><itemNumber>1001</itemNumber><strength>50mg</strength><dosageForm>SR Cap</dosageForm><drug id="02184443" sec3="Y"><name>Kadian</name><manufacturerId>BGP</manufacturerId><individualPrice>1.7080</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>1.7080</amountMOHLTCPays></drug></pcg9><pcg9 id="280808095"><itemNumber>1002</itemNumber><strength>100mg</strength><dosageForm>SR Cap</dosageForm><drug id="02184451" sec3="Y"><name>Kadian</name><manufacturerId>BGP</manufacturerId><individualPrice>2.9793</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>2.9793</amountMOHLTCPays></drug></pcg9><pcg9 id="280808053"><itemNumber>1003</itemNumber><strength>15mg</strength><dosageForm>SR Tab</dosageForm><drug id="02015439" sec3="Y"><name>MS Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>.9878</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02244790" sec3="Y"><name>Sandoz Morphine SR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02302764" sec3="Y"><name>Teva-Morphine SR</name><manufacturerId>TEV</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug></pcg9><pcg9 id="280808054"><itemNumber>1004</itemNumber><strength>30mg</strength><dosageForm>SR Tab</dosageForm><drug id="02014297" sec3="Y"><name>MS Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>1.4931</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6580</amountMOHLTCPays></drug><drug id="02244791" sec3="Y"><name>Sandoz Morphine SR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6580</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.6580</amountMOHLTCPays></drug><drug id="02302772" sec3="Y"><name>Teva-Morphine SR</name><manufacturerId>TEV</manufacturerId><individualPrice>.6580</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>.6580</amountMOHLTCPays></drug></pcg9><pcg9 id="280808055"><itemNumber>1005</itemNumber><strength>60mg</strength><dosageForm>SR Tab</dosageForm><drug id="02014300" sec3="Y"><name>MS Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>2.6322</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2180</amountMOHLTCPays></drug><drug id="02244792" sec3="Y"><name>Sandoz Morphine SR</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2180</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>1.2180</amountMOHLTCPays></drug><drug id="02302780" sec3="Y"><name>Teva-Morphine SR</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2180</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>1.2180</amountMOHLTCPays></drug></pcg9><pcg9 id="280808056"><itemNumber>1006</itemNumber><strength>100mg</strength><dosageForm>SR Tab</dosageForm><drug id="02014319" sec3="Y"><name>MS Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>4.0069</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.5395</amountMOHLTCPays></drug><drug id="02302799" sec3="Y"><name>Teva-Morphine SR</name><manufacturerId>TEV</manufacturerId><individualPrice>1.5395</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>1.5395</amountMOHLTCPays></drug><drug id="02478889" sec3="Y"><name>Sandoz Morphine SR</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.5395</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>1.5395</amountMOHLTCPays></drug></pcg9><pcg9 id="280808057"><itemNumber>1007</itemNumber><strength>200mg</strength><dosageForm>SR Tab</dosageForm><drug id="02014327" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>MS Contin</name><manufacturerId>PFP</manufacturerId><individualPrice>7.4705</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>4.5738</amountMOHLTCPays></drug><drug id="02302802" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Morphine SR</name><manufacturerId>TEV</manufacturerId><individualPrice>4.5737</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>4.5737</amountMOHLTCPays></drug><drug id="02478897" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Morphine SR</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.5738</individualPrice><listingDate>2019-02-28</listingDate><amountMOHLTCPays>4.5738</amountMOHLTCPays></drug></pcg9><pcg9 id="280808051"><itemNumber>1008</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02014238" sec3="Y"><name>MS-IR</name><manufacturerId>PFP</manufacturerId><individualPrice>.4605</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4605</amountMOHLTCPays></drug></pcg9><pcg9 id="280808052"><itemNumber>1009</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02014254" sec3="Y"><name>MS-IR</name><manufacturerId>PFP</manufacturerId><individualPrice>.5912</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5912</amountMOHLTCPays></drug></pcg9><pcg9 id="280808047"><itemNumber>1010</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00594652" sec3="Y"><name>Statex</name><manufacturerId>PPI</manufacturerId><individualPrice>.0709</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0709</amountMOHLTCPays></drug><drug id="02549794" sec3="Y"><name>PMS-Morphine Sulfate</name><manufacturerId>PMS</manufacturerId><individualPrice>.0709</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.0709</amountMOHLTCPays></drug></pcg9><pcg9 id="280808048"><itemNumber>1011</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00594644" sec3="Y"><name>Statex</name><manufacturerId>PPI</manufacturerId><individualPrice>.1096</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1096</amountMOHLTCPays></drug><drug id="02549808" sec3="Y"><name>PMS-Morphine Sulfate</name><manufacturerId>PMS</manufacturerId><individualPrice>.1096</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.1096</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00448"><name>OXYCODONE HCL</name><pcgGroup><pcg9 id="280808119"><itemNumber>1012</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00789739" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Supeudol</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2333</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2333</amountMOHLTCPays></drug><drug id="02231934" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Oxy.IR</name><manufacturerId>PFP</manufacturerId><listingDate>2009-01-30</listingDate></drug><drug id="02319977" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Oxycodone</name><manufacturerId>PMS</manufacturerId><individualPrice>.2333</individualPrice><listingDate>2009-01-30</listingDate><amountMOHLTCPays>.2333</amountMOHLTCPays></drug></pcg9><pcg9 id="280808120"><itemNumber>1013</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00443948" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Supeudol</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3451</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3451</amountMOHLTCPays></drug><drug id="02240131" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Oxy.IR</name><manufacturerId>PFP</manufacturerId><listingDate>2009-01-30</listingDate></drug><drug id="02319985" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Oxycodone</name><manufacturerId>PMS</manufacturerId><individualPrice>.3451</individualPrice><listingDate>2009-01-30</listingDate><amountMOHLTCPays>.3451</amountMOHLTCPays></drug></pcg9><pcg9 id="280808121"><itemNumber>1014</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02240132" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Oxy.IR</name><manufacturerId>PFP</manufacturerId><listingDate>2008-10-01</listingDate></drug><drug id="02262983" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Supeudol</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6001</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>.6001</amountMOHLTCPays></drug><drug id="02319993" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Oxycodone</name><manufacturerId>PMS</manufacturerId><individualPrice>.6001</individualPrice><listingDate>2009-01-30</listingDate><amountMOHLTCPays>.6001</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00424"><name>OXYCODONE HCL &amp; ACETAMINOPHEN</name><pcgGroup><pcg9 id="280808064"><itemNumber>1015</itemNumber><strength>5mg &amp; 325mg</strength><dosageForm>Tab</dosageForm><drug id="00608165" sec3="Y"><name>Teva-Oxycocet</name><manufacturerId>TEV</manufacturerId><individualPrice>.1285</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1285</amountMOHLTCPays></drug><drug id="01916475" notABenefit="Y" sec3="Y"><name>Percocet</name><manufacturerId>BQU</manufacturerId><listingDate>2008-12-23</listingDate></drug><drug id="01916548" sec3="Y"><name>Endocet</name><manufacturerId>BQU</manufacturerId><individualPrice>.1285</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1285</amountMOHLTCPays></drug><drug id="02307898" sec3="Y"><name>Sandoz Oxycodone/Acetaminophen</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1285</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>.1285</amountMOHLTCPays></drug><drug id="02324628" sec3="Y"><name>Apo-Oxycodone/Acet</name><manufacturerId>APX</manufacturerId><individualPrice>.1285</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1285</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00418"><name>OXYCODONE HCL &amp; ACETYLSALICYLIC ACID</name><pcgGroup><pcg9 id="280808065"><itemNumber>1016</itemNumber><strength>5mg &amp; 325mg</strength><dosageForm>Tab</dosageForm><drug id="00608157" sec3="Y"><name>Ratio-Oxycodan</name><manufacturerId>RPH</manufacturerId><individualPrice>.4599</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4599</amountMOHLTCPays></drug><drug id="01916572" notABenefit="Y" sec3="Y"><name>Percodan</name><manufacturerId>BQU</manufacturerId><listingDate>2008-12-23</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01840"><name>TRAMADOL HCL</name><pcgGroup><pcg9 id="280808298"><itemNumber>1017</itemNumber><strength>100mg</strength><dosageForm>ER Tab</dosageForm><drug id="02296381" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tridural</name><manufacturerId>PAL</manufacturerId><listingDate>2016-04-29</listingDate></drug><drug id="02450429" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Tramadol ER</name><manufacturerId>TAR</manufacturerId><individualPrice>.7853</individualPrice><listingDate>2016-04-29</listingDate></drug></pcg9><pcg9 id="280808288"><itemNumber>1018</itemNumber><strength>200mg</strength><dosageForm>ER Tab</dosageForm><drug id="02296403" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tridural</name><manufacturerId>PAL</manufacturerId><listingDate>2016-06-29</listingDate></drug><drug id="02450437" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Tramadol ER</name><manufacturerId>TAR</manufacturerId><individualPrice>.9244</individualPrice><listingDate>2016-06-29</listingDate></drug></pcg9><pcg9 id="280808281"><itemNumber>1019</itemNumber><strength>300mg</strength><dosageForm>ER Tab</dosageForm><drug id="02296411" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tridural</name><manufacturerId>PAL</manufacturerId><listingDate>2016-06-29</listingDate></drug><drug id="02450445" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Tramadol ER</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2854</individualPrice><listingDate>2016-06-29</listingDate></drug></pcg9><pcg9 id="280808287"><itemNumber>1020</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02349469" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ultram</name><manufacturerId>JAN</manufacturerId><listingDate>2014-08-28</listingDate></drug><drug id="02426153" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Tramadol</name><manufacturerId>APX</manufacturerId><individualPrice>.6386</individualPrice><listingDate>2014-08-28</listingDate></drug><drug id="02479672" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Tramadol</name><manufacturerId>AUR</manufacturerId><individualPrice>.6386</individualPrice><listingDate>2019-06-28</listingDate></drug><drug id="02480859" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Tramadol</name><manufacturerId>MAR</manufacturerId><individualPrice>.6386</individualPrice><listingDate>2019-09-30</listingDate></drug><drug id="02493764" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Tramadol</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6386</individualPrice><listingDate>2021-02-26</listingDate></drug><drug id="02507005" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Tramadol</name><manufacturerId>JPC</manufacturerId><individualPrice>.6386</individualPrice><listingDate>2021-05-31</listingDate></drug><drug id="02518759" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Tramadol HCl</name><manufacturerId>JPC</manufacturerId><individualPrice>.6386</individualPrice><listingDate>2023-03-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01766"><name>TRAMADOL HCL &amp; ACETAMINOPHEN</name><pcgGroup><pcg9 id="280808299"><itemNumber>1021</itemNumber><strength>37.5mg &amp; 325mg</strength><dosageForm>Tab</dosageForm><drug id="02264846" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tramacet</name><manufacturerId>JAN</manufacturerId><listingDate>2010-03-02</listingDate></drug><drug id="02336790" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Tramadol/Acet</name><manufacturerId>APX</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2010-03-02</listingDate></drug><drug id="02347180" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Tramadol/Acetaminophen</name><manufacturerId>TEV</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2012-10-30</listingDate></drug><drug id="02383209" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Tramadol/Acet</name><manufacturerId>COB</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2012-06-26</listingDate></drug><drug id="02388197" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Tramadol/Acet</name><manufacturerId>SPC</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2012-11-27</listingDate></drug><drug id="02388308" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Acet-Tramadol</name><manufacturerId>JPC</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02388324" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Tramadol/Acet</name><manufacturerId>MAR</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2012-10-30</listingDate></drug><drug id="02389800" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Tramadol/Acet</name><manufacturerId>MIN</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02401657" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Tramadol-Acet</name><manufacturerId>PMS</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2013-06-27</listingDate></drug><drug id="02439050" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Tramadol/Acetaminophen</name><manufacturerId>AUR</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2016-02-25</listingDate></drug><drug id="02469650" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Tramadol/ACET</name><manufacturerId>NRA</manufacturerId><individualPrice>.6264</individualPrice><listingDate>2022-04-29</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="280812000"><name>ANALGESICS OPIATE PARTIAL AGONISTS</name><genericName id="01803"><name>BUPRENORPHINE</name><pcgGroup><pcg9 id="280812024"><itemNumber>1022</itemNumber><strength>100mg/0.5mL</strength><dosageForm>Inj Sol- 0.5mL Pref Syr</dosageForm><drug id="02483084" sec3="Y"><name>Sublocade</name><manufacturerId>IND</manufacturerId><individualPrice>550.0000</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>550.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="280812025"><itemNumber>1023</itemNumber><strength>300mg/1.5mL</strength><dosageForm>Inj Sol- 1.5mL Pref Syr</dosageForm><drug id="02483092" sec3="Y"><name>Sublocade</name><manufacturerId>IND</manufacturerId><individualPrice>550.0000</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>550.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01790"><name>BUPRENORPHINE &amp; NALOXONE</name><pcgGroup><pcg9 id="280812006"><itemNumber>1024</itemNumber><strength>2mg &amp; 0.5mg</strength><dosageForm>SL Tab</dosageForm><drug id="02295695" sec3="Y"><name>Suboxone</name><manufacturerId>IND</manufacturerId><individualPrice>2.7261</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>1.3350</amountMOHLTCPays></drug><drug id="02424851" sec3="Y"><name>PMS-Buprenorphine-Naloxone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.3350</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>1.3350</amountMOHLTCPays></drug><drug id="02453908" sec3="Y"><name>Act Buprenorphine/Naloxone</name><manufacturerId>ACV</manufacturerId><individualPrice>1.3350</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>1.3350</amountMOHLTCPays></drug></pcg9><pcg9 id="280812010"><itemNumber>1025</itemNumber><strength>8mg &amp; 2mg</strength><dosageForm>SL Tab</dosageForm><drug id="02295709" sec3="Y"><name>Suboxone</name><manufacturerId>IND</manufacturerId><individualPrice>4.8293</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>2.3650</amountMOHLTCPays></drug><drug id="02424878" sec3="Y"><name>PMS-Buprenorphine-Naloxone</name><manufacturerId>PMS</manufacturerId><individualPrice>2.3650</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>2.3650</amountMOHLTCPays></drug><drug id="02453916" sec3="Y"><name>Act Buprenorphine/Naloxone</name><manufacturerId>ACV</manufacturerId><individualPrice>2.3650</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>2.3650</amountMOHLTCPays></drug></pcg9><pcg9 id="280812032"><itemNumber>1026</itemNumber><strength>2mg &amp; 0.5mg</strength><dosageForm>Soluble Film</dosageForm><drug id="02502313" sec3="Y"><name>Suboxone</name><manufacturerId>IND</manufacturerId><individualPrice>2.6700</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>2.6700</amountMOHLTCPays></drug></pcg9><pcg9 id="280812034"><itemNumber>1027</itemNumber><strength>8mg &amp; 2mg</strength><dosageForm>Soluble Film</dosageForm><drug id="02502348" sec3="Y"><name>Suboxone</name><manufacturerId>IND</manufacturerId><individualPrice>4.7300</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>4.7300</amountMOHLTCPays></drug></pcg9><pcg9 id="280812031"><itemNumber>1028</itemNumber><strength>12mg &amp; 3mg</strength><dosageForm>Soluble Film</dosageForm><drug id="02502356" sec3="Y"><name>Suboxone</name><manufacturerId>IND</manufacturerId><individualPrice>7.0950</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>7.0950</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02085"><name>BUPRENORPHINE HYDROCHLORIDE</name><pcgGroup lccId="00333"><pcg9 id="280812023"><itemNumber>1029</itemNumber><strength>80mg</strength><dosageForm>Subdermal Implant-Kit Pk</dosageForm><drug id="02474921" sec3="Y" sec12="Y"><name>Probuphine</name><manufacturerId>KNT</manufacturerId><individualPrice>1495.0000</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>1495.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="578">For the management of opioid use disorder in combination with counseling and psychosocial support in adult patients who meet the following criteria:

- The patient is stabilized on a dose of no more than 8mg per day of sublingual buprenorphine for the preceding 90 days; AND
- The patient is under the care of a health care provider with experience in the diagnosis and management of opioid use disorder and has been trained to implant and remove the buprenorphine subdermal implant.

Recommended dose: Four 80mg implants inserted subdermally in the inner side of the upper arm for up to six months.

The maximum quantity that can be claimed per patient is four (4) implant cycles (i.e. two (2) years of therapy).

NOTE: The product monograph indicates that dosing beyond two (2) years cannot be recommended at this time. Probuphine subdermal implants are intended to be in place for six months of treatment. Probuphine implants are removed at the end of the six-month period. If continued treatment is desired, the implants should be replaced by new implants (implanted in the opposite arm) at the time of removal.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 2 years</lccNote></pcgGroup></genericName><genericName id="00461"><name>BUTORPHANOL TARTRATE</name><pcgGroup><pcg9 id="280812003"><itemNumber>1030</itemNumber><strength>10mg/mL</strength><dosageForm>Nas Sp-2.5mL Pk</dosageForm><drug id="02113031" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Stadol NS</name><manufacturerId>BQU</manufacturerId><listingDate>2020-11-30</listingDate></drug><drug id="02242504" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Butorphanol Nasal Spray</name><manufacturerId>AAP</manufacturerId><individualPrice>64.0200</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>64.0200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="280892000"><name>ANALGESICS MISCELLANEOUS ANALGESICS AND ANTIPYRETICS</name><genericName id="00403"><name>ACETAMINOPHEN</name><pcgGroup><pcg9 id="280892006" suppliedBy="L"><itemNumber>1031</itemNumber><strength>325mg</strength><drug id="00293482" notABenefit="Y" sec3="Y"><name>Atasol Tab</name><manufacturerId>HOR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00389218" selfMed="Y" sec3="Y"><name>Novo-Gesic Tab</name><manufacturerId>NOP</manufacturerId><individualPrice>.0114</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0114</amountMOHLTCPays></drug><drug id="00544981" selfMed="Y" sec3="Y"><name>Apo-Acetaminophen Tab</name><manufacturerId>APX</manufacturerId><individualPrice>.0114</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0114</amountMOHLTCPays></drug><drug id="01938088" selfMed="Y" sec3="Y"><name>Jamp Acetaminophen 325 Caplets</name><manufacturerId>JPC</manufacturerId><individualPrice>.0114</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.0114</amountMOHLTCPays></drug><drug id="02229873" selfMed="Y" sec3="Y"><name>Apo-Acetaminophen Caplets</name><manufacturerId>APX</manufacturerId><individualPrice>.0114</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.0114</amountMOHLTCPays></drug></pcg9><pcg9 id="280892007" suppliedBy="L"><itemNumber>1032</itemNumber><strength>500mg</strength><drug id="00013668" notABenefit="Y" sec3="Y"><name>Atasol Forte Tab</name><manufacturerId>HOR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00482323" selfMed="Y" sec3="Y"><name>Novo-Gesic Forte Tab</name><manufacturerId>NOP</manufacturerId><individualPrice>.0149</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0149</amountMOHLTCPays></drug><drug id="00545007" selfMed="Y" sec3="Y"><name>Apo-Acetaminophen Tab</name><manufacturerId>APX</manufacturerId><individualPrice>.0149</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0149</amountMOHLTCPays></drug><drug id="01939122" selfMed="Y" sec3="Y"><name>Jamp Acetaminophen 500 Caplets</name><manufacturerId>JPC</manufacturerId><individualPrice>.0149</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.0149</amountMOHLTCPays></drug><drug id="02229977" selfMed="Y" sec3="Y"><name>Apo-Acetaminophen Caplets</name><manufacturerId>APX</manufacturerId><individualPrice>.0149</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.0149</amountMOHLTCPays></drug></pcg9><pcg9 id="280892002"><itemNumber>1033</itemNumber><strength>80mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00631353" notABenefit="Y" sec3="Y"><name>Atasol</name><manufacturerId>HOR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00642401" notABenefit="Y" sec3="Y"><name>Tempra</name><manufacturerId>MJS</manufacturerId><listingDate>1999-01-01</listingDate></drug><drug id="02027801" sec3="Y"><name>Pediatrix</name><manufacturerId>RPH</manufacturerId><individualPrice>.1436</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1436</amountMOHLTCPays></drug></pcg9><pcg9 id="280892003"><itemNumber>1034</itemNumber><strength>120mg</strength><dosageForm>Sup</dosageForm><drug id="01919385" notABenefit="Y" sec3="Y"><name>Abenol</name><manufacturerId>PEN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230434" sec3="Y"><name>ACET 120</name><manufacturerId>PEN</manufacturerId><individualPrice>.5367</individualPrice><listingDate>1998-03-17</listingDate><amountMOHLTCPays>.5367</amountMOHLTCPays></drug></pcg9><pcg9 id="280892004"><itemNumber>1035</itemNumber><strength>325mg</strength><dosageForm>Sup</dosageForm><drug id="01919393" notABenefit="Y" sec3="Y"><name>Abenol</name><manufacturerId>PEN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230436" sec3="Y"><name>ACET 325</name><manufacturerId>PEN</manufacturerId><individualPrice>.6625</individualPrice><listingDate>1998-03-17</listingDate><amountMOHLTCPays>.6625</amountMOHLTCPays></drug></pcg9><pcg9 id="280892005"><itemNumber>1036</itemNumber><strength>650mg</strength><dosageForm>Sup</dosageForm><drug id="01919407" notABenefit="Y" sec3="Y"><name>Abenol</name><manufacturerId>PEN</manufacturerId><listingDate>2007-01-02</listingDate></drug><drug id="02230437" sec3="Y"><name>ACET 650</name><manufacturerId>PEN</manufacturerId><individualPrice>.7608</individualPrice><listingDate>1998-03-17</listingDate><amountMOHLTCPays>.7608</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="281000000"><name>OPIATE ANTAGONISTS</name><genericName id="00470"><name>NALTREXONE HCL</name><pcgGroup><pcg9 id="281000003"><itemNumber>1037</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02213826" sec3="Y"><name>Revia</name><manufacturerId>TEV</manufacturerId><individualPrice>2.8075</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>2.8075</amountMOHLTCPays></drug><drug id="02444275" sec3="Y"><name>Apo-Naltrexone</name><manufacturerId>APX</manufacturerId><individualPrice>2.8075</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>2.8075</amountMOHLTCPays></drug><drug id="02451883" sec3="Y"><name>Naltrexone Hydrochloride Tablets USP</name><manufacturerId>STN</manufacturerId><individualPrice>2.8075</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>2.8075</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="281200000"><name>ANTICONVULSANTS</name><genericName id="02070"><name>BRIVARACETAM</name><pcgGroup lccId="00312"><pcg9 id="281200177"><itemNumber>1038</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02452936" sec3="Y" sec12="Y"><name>Brivlera</name><manufacturerId>UCB</manufacturerId><individualPrice>4.3200</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>2.3760</amountMOHLTCPays></drug><drug id="02538679" sec3="Y" sec12="Y"><name>Apo-Brivaracetam</name><manufacturerId>APX</manufacturerId><individualPrice>2.3760</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.3760</amountMOHLTCPays></drug></pcg9><pcg9 id="281200178"><itemNumber>1039</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02452944" sec3="Y" sec12="Y"><name>Brivlera</name><manufacturerId>UCB</manufacturerId><individualPrice>4.3200</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>2.3760</amountMOHLTCPays></drug><drug id="02538687" sec3="Y" sec12="Y"><name>Apo-Brivaracetam</name><manufacturerId>APX</manufacturerId><individualPrice>2.3760</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.3760</amountMOHLTCPays></drug></pcg9><pcg9 id="281200179"><itemNumber>1040</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02452952" sec3="Y" sec12="Y"><name>Brivlera</name><manufacturerId>UCB</manufacturerId><individualPrice>4.3200</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>2.1600</amountMOHLTCPays></drug><drug id="02538695" sec3="Y" sec12="Y"><name>Apo-Brivaracetam</name><manufacturerId>APX</manufacturerId><individualPrice>2.1600</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.1600</amountMOHLTCPays></drug><drug id="02539292" sec3="Y" sec12="Y"><name>Auro-Brivaracetam</name><manufacturerId>AUR</manufacturerId><individualPrice>2.1600</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.1600</amountMOHLTCPays></drug></pcg9><pcg9 id="281200180"><itemNumber>1041</itemNumber><strength>75mg</strength><dosageForm>Tab</dosageForm><drug id="02452960" sec3="Y" sec12="Y"><name>Brivlera</name><manufacturerId>UCB</manufacturerId><individualPrice>4.3200</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>2.3760</amountMOHLTCPays></drug><drug id="02538709" sec3="Y" sec12="Y"><name>Apo-Brivaracetam</name><manufacturerId>APX</manufacturerId><individualPrice>2.3760</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.3760</amountMOHLTCPays></drug></pcg9><pcg9 id="281200181"><itemNumber>1042</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02452979" sec3="Y" sec12="Y"><name>Brivlera</name><manufacturerId>UCB</manufacturerId><individualPrice>4.3200</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>2.1600</amountMOHLTCPays></drug><drug id="02538717" sec3="Y" sec12="Y"><name>Apo-Brivaracetam</name><manufacturerId>APX</manufacturerId><individualPrice>2.1600</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.1600</amountMOHLTCPays></drug><drug id="02539306" sec3="Y" sec12="Y"><name>Auro-Brivaracetam</name><manufacturerId>AUR</manufacturerId><individualPrice>2.1600</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>2.1600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="548">-  As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND

-  Patients are not receiving concurrent therapy with levetiracetam; AND

-  Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following: 

Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00476"><name>CARBAMAZEPINE</name><pcgGroup><pcg9 id="281200049"><itemNumber>1043</itemNumber><strength>100mg</strength><dosageForm>Chew Tab</dosageForm><drug id="00369810" notABenefit="Y" sec3="Y"><name>Tegretol</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02244403" sec3="Y"><name>Taro-Carbamazepine</name><manufacturerId>TAR</manufacturerId><individualPrice>.1702</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.1702</amountMOHLTCPays></drug></pcg9><pcg9 id="281200050"><itemNumber>1044</itemNumber><strength>200mg</strength><dosageForm>Chew Tab</dosageForm><drug id="00665088" notABenefit="Y" sec3="Y"><name>Tegretol</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02244404" sec3="Y"><name>Taro-Carbamazepine</name><manufacturerId>TAR</manufacturerId><individualPrice>.3302</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.3302</amountMOHLTCPays></drug></pcg9><pcg9 id="281200186"><itemNumber>1045</itemNumber><strength>200mg</strength><dosageForm>ER Tab</dosageForm><drug id="09858341" sec3c="Y"><name>Carbamazepine ER Tablets, USP 200mg</name><manufacturerId>SET</manufacturerId><individualPrice>4.7080</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>4.7080</amountMOHLTCPays></drug></pcg9><pcg9 id="281200187"><itemNumber>1046</itemNumber><strength>400mg</strength><dosageForm>ER Tab</dosageForm><drug id="09858342" sec3c="Y"><name>Carbamazepine ER Tablets, USP 400mg</name><manufacturerId>SET</manufacturerId><individualPrice>5.2216</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>5.2216</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00070"><pcg9 id="281200065"><itemNumber>1047</itemNumber><strength>200mg</strength><dosageForm>LA Tab</dosageForm><drug id="00773611" sec3="Y" sec12="Y"><name>Tegretol CR</name><manufacturerId>NOV</manufacturerId><individualPrice>.6041</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3845</amountMOHLTCPays></drug><drug id="02261839" sec3="Y" sec12="Y"><name>Sandoz Carbamazepine CR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3845</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.3845</amountMOHLTCPays></drug></pcg9><pcg9 id="281200066"><itemNumber>1048</itemNumber><strength>400mg</strength><dosageForm>LA Tab</dosageForm><drug id="00755583" sec3="Y" sec12="Y"><name>Tegretol CR</name><manufacturerId>NOV</manufacturerId><individualPrice>1.2083</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7689</amountMOHLTCPays></drug><drug id="02261847" sec3="Y" sec12="Y"><name>Sandoz Carbamazepine CR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7689</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.7689</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="67">For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="281200067"><itemNumber>1049</itemNumber><strength>100mg/5mL</strength><dosageForm>Oral Susp</dosageForm><drug id="02194333" sec3="Y"><name>Tegretol</name><manufacturerId>NOV</manufacturerId><individualPrice>.1159</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.0578</amountMOHLTCPays></drug><drug id="02367394" sec3="Y"><name>Taro-Carbamazepine</name><manufacturerId>TAR</manufacturerId><individualPrice>.0578</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.0578</amountMOHLTCPays></drug></pcg9><pcg9 id="281200015"><itemNumber>1050</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="00010405" notABenefit="Y" sec3="Y"><name>Tegretol</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00782718" sec3="Y"><name>Teva-Carbamazepine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2217</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug><drug id="02541238" sec3="Y"><name>Mint-Carbamazepine</name><manufacturerId>MIN</manufacturerId><individualPrice>.2217</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.2217</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02420"><name>CENOBAMATE</name><pcgGroup lccId="00409"><pcg9 id="281200189"><itemNumber>1051</itemNumber><strength>12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02538652" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200190"><itemNumber>1052</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02538660" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200191"><itemNumber>1053</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02538725" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200192"><itemNumber>1054</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02538733" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200193"><itemNumber>1055</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02538741" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200194"><itemNumber>1056</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02538768" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200195"><itemNumber>1057</itemNumber><strength>12.5mg &amp; 25mg</strength><dosageForm>Tab - (Starter Kit)</dosageForm><drug id="02538776" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200196"><itemNumber>1058</itemNumber><strength>50mg &amp; 100mg</strength><dosageForm>Tab - (Starter Kit)</dosageForm><drug id="02538784" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="281200197"><itemNumber>1059</itemNumber><strength>150mg &amp; 200mg</strength><dosageForm>Tab - (Starter Kit)</dosageForm><drug id="02538792" sec3="Y" sec12="Y"><name>Xcopri</name><manufacturerId>EVL</manufacturerId><individualPrice>8.8000</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>8.8000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="719">As adjunctive therapy in the treatment of patients with partial onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND

Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following: Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00488"><name>CLOBAZAM</name><pcgGroup lccId="00071"><pcg9 id="281200061"><itemNumber>1060</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02221799" notABenefit="Y" sec3="Y"><name>Frisium</name><manufacturerId>OVA</manufacturerId><listingDate>1999-01-06</listingDate></drug><drug id="02238334" sec3="Y" sec12="Y"><name>Teva-Clobazam</name><manufacturerId>TEV</manufacturerId><individualPrice>.2197</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2197</amountMOHLTCPays></drug><drug id="02244638" sec3="Y" sec12="Y"><name>Apo-Clobazam</name><manufacturerId>APX</manufacturerId><individualPrice>.2197</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2197</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="23">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote><lccNote seq="002" type="N">Because a large number of patients will become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00479"><name>CLONAZEPAM</name><pcgGroup><pcg9 id="281200032"><itemNumber>1061</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="00382825" sec3="Y"><name>Rivotril</name><manufacturerId>HLR</manufacturerId><individualPrice>.2849</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0418</amountMOHLTCPays></drug><drug id="02048701" sec3="Y"><name>PMS-Clonazepam</name><manufacturerId>PMS</manufacturerId><individualPrice>.0418</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0418</amountMOHLTCPays></drug><drug id="02177889" sec3="Y"><name>Apo-Clonazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0418</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0418</amountMOHLTCPays></drug><drug id="02207818" sec3="Y"><name>PMS-Clonazepam-R</name><manufacturerId>PMS</manufacturerId><individualPrice>.0418</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0418</amountMOHLTCPays></drug><drug id="02239024" sec3="Y"><name>Teva-Clonazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0418</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.0418</amountMOHLTCPays></drug></pcg9><pcg9 id="281200031"><itemNumber>1062</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00382841" sec3="Y"><name>Rivotril</name><manufacturerId>HLR</manufacturerId><individualPrice>.4912</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0721</amountMOHLTCPays></drug><drug id="02048736" sec3="Y"><name>PMS-Clonazepam</name><manufacturerId>PMS</manufacturerId><individualPrice>.0721</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0721</amountMOHLTCPays></drug><drug id="02177897" sec3="Y"><name>Apo-Clonazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0721</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0721</amountMOHLTCPays></drug><drug id="02239025" sec3="Y"><name>Teva-Clonazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0721</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.0721</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00483"><name>DIVALPROEX SODIUM</name><pcgGroup><pcg9 id="281200047"><itemNumber>1063</itemNumber><strength>125mg</strength><dosageForm>Ent Tab</dosageForm><drug id="00596418" sec3="Y"><name>Epival</name><manufacturerId>BGP</manufacturerId><individualPrice>.3746</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1539</amountMOHLTCPays></drug><drug id="02239698" sec3="Y"><name>Apo-Divalproex</name><manufacturerId>APX</manufacturerId><individualPrice>.1539</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.1539</amountMOHLTCPays></drug><drug id="02458926" sec3="Y"><name>Mylan-Divalproex</name><manufacturerId>MYL</manufacturerId><individualPrice>.1539</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.1539</amountMOHLTCPays></drug></pcg9><pcg9 id="281200046"><itemNumber>1064</itemNumber><strength>250mg</strength><dosageForm>Ent Tab</dosageForm><drug id="00596426" sec3="Y"><name>Epival</name><manufacturerId>BGP</manufacturerId><individualPrice>.6735</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2767</amountMOHLTCPays></drug><drug id="02239699" sec3="Y"><name>Apo-Divalproex</name><manufacturerId>APX</manufacturerId><individualPrice>.2767</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.2767</amountMOHLTCPays></drug><drug id="02458934" sec3="Y"><name>Mylan-Divalproex</name><manufacturerId>MYL</manufacturerId><individualPrice>.2767</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.2767</amountMOHLTCPays></drug></pcg9><pcg9 id="281200045"><itemNumber>1065</itemNumber><strength>500mg</strength><dosageForm>Ent Tab</dosageForm><drug id="00596434" sec3="Y"><name>Epival</name><manufacturerId>BGP</manufacturerId><individualPrice>1.3476</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5537</amountMOHLTCPays></drug><drug id="02239700" sec3="Y"><name>Apo-Divalproex</name><manufacturerId>APX</manufacturerId><individualPrice>.5537</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.5537</amountMOHLTCPays></drug><drug id="02459019" sec3="Y"><name>Mylan-Divalproex</name><manufacturerId>MYL</manufacturerId><individualPrice>.5537</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>.5537</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01990"><name>ESLICARBAZEPINE ACETATE</name><pcgGroup lccId="00259"><pcg9 id="281200169"><itemNumber>1066</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02426862" sec3="Y" sec12="Y"><name>Aptiom</name><manufacturerId>SUO</manufacturerId><individualPrice>9.8700</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02527421" sec3="Y" sec12="Y"><name>Auro-Eslicarbazepine</name><manufacturerId>AUR</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02537931" sec3="Y" sec12="Y"><name>Apo-Eslicarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug></pcg9><pcg9 id="281200170"><itemNumber>1067</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="02426870" sec3="Y" sec12="Y"><name>Aptiom</name><manufacturerId>SUO</manufacturerId><individualPrice>9.8700</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02527448" sec3="Y" sec12="Y"><name>Auro-Eslicarbazepine</name><manufacturerId>AUR</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02537958" sec3="Y" sec12="Y"><name>Apo-Eslicarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug></pcg9><pcg9 id="281200171"><itemNumber>1068</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02426889" sec3="Y" sec12="Y"><name>Aptiom</name><manufacturerId>SUO</manufacturerId><individualPrice>9.8700</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02527456" sec3="Y" sec12="Y"><name>Auro-Eslicarbazepine</name><manufacturerId>AUR</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02537966" sec3="Y" sec12="Y"><name>Apo-Eslicarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug></pcg9><pcg9 id="281200172"><itemNumber>1069</itemNumber><strength>800mg</strength><dosageForm>Tab</dosageForm><drug id="02426897" sec3="Y" sec12="Y"><name>Aptiom</name><manufacturerId>SUO</manufacturerId><individualPrice>9.8700</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02527464" sec3="Y" sec12="Y"><name>Auro-Eslicarbazepine</name><manufacturerId>AUR</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug><drug id="02537974" sec3="Y" sec12="Y"><name>Apo-Eslicarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>4.9350</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>4.9350</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="430">As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND

Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following:
 
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00473"><name>ETHOSUXIMIDE</name><pcgGroup><pcg9 id="281200008"><itemNumber>1070</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="00022799" sec3="Y"><name>Zarontin</name><manufacturerId>SLP</manufacturerId><individualPrice>.5255</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2628</amountMOHLTCPays></drug><drug id="02545772" sec3="Y"><name>Mar-Ethosuximide</name><manufacturerId>MAR</manufacturerId><individualPrice>.2628</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.2628</amountMOHLTCPays></drug><drug id="02547171" sec3="Y"><name>Odan-Ethosuximide</name><manufacturerId>ODN</manufacturerId><individualPrice>.2628</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.2628</amountMOHLTCPays></drug></pcg9><pcg9 id="281200009"><itemNumber>1071</itemNumber><strength>50mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00023485" sec3="Y"><name>Zarontin</name><manufacturerId>SLP</manufacturerId><individualPrice>.0740</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0740</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00487"><name>GABAPENTIN</name><pcgGroup><pcg9 id="281200062"><itemNumber>1072</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02084260" sec3="Y"><name>Neurontin</name><manufacturerId>UJC</manufacturerId><individualPrice>.5494</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02243446" sec3="Y"><name>PMS-Gabapentin</name><manufacturerId>PMS</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02244304" sec3="Y"><name>Apo-Gabapentin</name><manufacturerId>APX</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02244513" sec3="Y"><name>Teva-Gabapentin</name><manufacturerId>TEV</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02246314" sec3="Y"><name>Gabapentin</name><manufacturerId>SIV</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02256142" sec3="Y"><name>Co Gabapentin</name><manufacturerId>COB</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2005-03-31</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02319055" sec3="Y"><name>Ran-Gabapentin</name><manufacturerId>RAN</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02321203" sec3="Y"><name>Auro-Gabapentin</name><manufacturerId>AUR</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02353245" sec3="Y"><name>Gabapentin</name><manufacturerId>SAI</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02361469" sec3="Y"><name>Jamp-Gabapentin</name><manufacturerId>JPC</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02391473" sec3="Y"><name>Mar-Gabapentin</name><manufacturerId>MAR</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02408880" sec3="Y"><name>Mint-Gabapentin</name><manufacturerId>MIN</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02416840" sec3="Y"><name>Gabapentin Capsules USP</name><manufacturerId>ACH</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02477912" sec3="Y"><name>AG-Gabapentin</name><manufacturerId>ANG</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02535246" sec3="Y"><name>Jamp Gabapentin Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug><drug id="02550016" sec3="Y"><name>NRA-Gabapentin</name><manufacturerId>NRA</manufacturerId><individualPrice>.0416</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.0416</amountMOHLTCPays></drug></pcg9><pcg9 id="281200063"><itemNumber>1073</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="02084279" sec3="Y"><name>Neurontin</name><manufacturerId>UJC</manufacturerId><individualPrice>1.3141</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02243447" sec3="Y"><name>PMS-Gabapentin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02244305" sec3="Y"><name>Apo-Gabapentin</name><manufacturerId>APX</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02244514" sec3="Y"><name>Teva-Gabapentin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02246315" sec3="Y"><name>Gabapentin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02256150" sec3="Y"><name>Co Gabapentin</name><manufacturerId>COB</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2005-03-31</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02319063" sec3="Y"><name>Ran-Gabapentin</name><manufacturerId>RAN</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02321211" sec3="Y"><name>Auro-Gabapentin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02353253" sec3="Y"><name>Gabapentin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02361485" sec3="Y"><name>Jamp-Gabapentin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02391481" sec3="Y"><name>Mar-Gabapentin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02408899" sec3="Y"><name>Mint-Gabapentin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02416859" sec3="Y"><name>Gabapentin Capsules USP</name><manufacturerId>ACH</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02477920" sec3="Y"><name>AG-Gabapentin</name><manufacturerId>ANG</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02535254" sec3="Y"><name>Jamp Gabapentin Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug><drug id="02550024" sec3="Y"><name>NRA-Gabapentin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1012</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.1012</amountMOHLTCPays></drug></pcg9><pcg9 id="281200064"><itemNumber>1074</itemNumber><strength>400mg</strength><dosageForm>Cap</dosageForm><drug id="02084287" sec3="Y"><name>Neurontin</name><manufacturerId>UJC</manufacturerId><individualPrice>1.5660</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02243448" sec3="Y"><name>PMS-Gabapentin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02244306" sec3="Y"><name>Apo-Gabapentin</name><manufacturerId>APX</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02244515" sec3="Y"><name>Teva-Gabapentin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02246316" sec3="Y"><name>Gabapentin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02256169" sec3="Y"><name>Co Gabapentin</name><manufacturerId>COB</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2005-03-31</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02260905" sec3="Y"><name>Ratio-Gabapentin</name><manufacturerId>RPH</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2005-07-14</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02319071" sec3="Y"><name>Ran-Gabapentin</name><manufacturerId>RAN</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02321238" sec3="Y"><name>Auro-Gabapentin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02353261" sec3="Y"><name>Gabapentin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02361493" sec3="Y"><name>Jamp-Gabapentin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02391503" sec3="Y"><name>Mar-Gabapentin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02408902" sec3="Y"><name>Mint-Gabapentin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02416867" sec3="Y"><name>Gabapentin Capsules USP</name><manufacturerId>ACH</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02477939" sec3="Y"><name>AG-Gabapentin</name><manufacturerId>ANG</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02535262" sec3="Y"><name>Jamp Gabapentin Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug><drug id="02550032" sec3="Y"><name>NRA-Gabapentin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1206</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.1206</amountMOHLTCPays></drug></pcg9><pcg9 id="281200122"><itemNumber>1075</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02239717" notABenefit="Y" sec3b="Y" sec3="Y"><name>Neurontin</name><manufacturerId>UJC</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02248457" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Gabapentin</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02293358" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Gabapentin</name><manufacturerId>APX</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2008-08-28</listingDate></drug><drug id="02388200" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin</name><manufacturerId>SIV</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2020-08-28</listingDate></drug><drug id="02392526" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin Tablets USP</name><manufacturerId>ACH</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02402289" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Gabapentin Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2013-06-27</listingDate></drug><drug id="02410990" notABenefit="Y" sec3b="Y" sec3="Y"><name>GLN-Gabapentin</name><manufacturerId>GLP</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2016-05-31</listingDate></drug><drug id="02428334" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Gabapentin Tablets</name><manufacturerId>AUR</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2019-04-30</listingDate></drug><drug id="02431289" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin</name><manufacturerId>SAI</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2020-07-31</listingDate></drug><drug id="02432072" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3045</individualPrice><listingDate>2023-06-30</listingDate></drug></pcg9><pcg9 id="281200123"><itemNumber>1076</itemNumber><strength>800mg</strength><dosageForm>Tab</dosageForm><drug id="02239718" notABenefit="Y" sec3b="Y" sec3="Y"><name>Neurontin</name><manufacturerId>UJC</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02247346" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Gabapentin</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02293366" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Gabapentin</name><manufacturerId>APX</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2008-08-28</listingDate></drug><drug id="02388219" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin</name><manufacturerId>SIV</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2020-08-28</listingDate></drug><drug id="02392534" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin Tablets USP</name><manufacturerId>ACH</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02402297" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Gabapentin Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2013-06-27</listingDate></drug><drug id="02411008" notABenefit="Y" sec3b="Y" sec3="Y"><name>GLN-Gabapentin</name><manufacturerId>GLP</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2016-05-31</listingDate></drug><drug id="02428342" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Gabapentin Tablets</name><manufacturerId>AUR</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2019-04-30</listingDate></drug><drug id="02431297" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin</name><manufacturerId>SAI</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2020-07-31</listingDate></drug><drug id="02432080" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gabapentin</name><manufacturerId>JPC</manufacturerId><individualPrice>1.7393</individualPrice><listingDate>2023-06-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01851"><name>LACOSAMIDE</name><pcgGroup lccId="00221"><pcg9 id="281200148"><itemNumber>1077</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02357615" sec3="Y" sec12="Y"><name>Vimpat</name><manufacturerId>UCB</manufacturerId><individualPrice>2.5250</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02472902" sec3="Y" sec12="Y"><name>Teva-Lacosamide</name><manufacturerId>TEV</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02474670" sec3="Y" sec12="Y"><name>Sandoz Lacosamide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02475332" sec3="Y" sec12="Y"><name>Auro-Lacosamide</name><manufacturerId>AUR</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02478196" sec3="Y" sec12="Y"><name>Pharma-Lacosamide</name><manufacturerId>PMS</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02487802" sec3="Y" sec12="Y"><name>Mar-Lacosamide</name><manufacturerId>MAR</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02488388" sec3="Y" sec12="Y"><name>Jamp-Lacosamide</name><manufacturerId>JPC</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02489287" sec3="Y" sec12="Y"><name>Ach-Lacosamide</name><manufacturerId>ACH</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02490544" sec3="Y" sec12="Y"><name>Mint-Lacosamide</name><manufacturerId>MIN</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02499568" sec3="Y" sec12="Y"><name>NRA-Lacosamide</name><manufacturerId>NRA</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug><drug id="02512874" sec3="Y" sec12="Y"><name>Lacosamide</name><manufacturerId>SAI</manufacturerId><individualPrice>.6313</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.6313</amountMOHLTCPays></drug></pcg9><pcg9 id="281200149"><itemNumber>1078</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02357623" sec3="Y" sec12="Y"><name>Vimpat</name><manufacturerId>UCB</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02472910" sec3="Y" sec12="Y"><name>Teva-Lacosamide</name><manufacturerId>TEV</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02474689" sec3="Y" sec12="Y"><name>Sandoz Lacosamide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02475340" sec3="Y" sec12="Y"><name>Auro-Lacosamide</name><manufacturerId>AUR</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02478218" sec3="Y" sec12="Y"><name>Pharma-Lacosamide</name><manufacturerId>PMS</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02487810" sec3="Y" sec12="Y"><name>Mar-Lacosamide</name><manufacturerId>MAR</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02488396" sec3="Y" sec12="Y"><name>Jamp-Lacosamide</name><manufacturerId>JPC</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02489295" sec3="Y" sec12="Y"><name>Ach-Lacosamide</name><manufacturerId>ACH</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02490552" sec3="Y" sec12="Y"><name>Mint-Lacosamide</name><manufacturerId>MIN</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02499576" sec3="Y" sec12="Y"><name>NRA-Lacosamide</name><manufacturerId>NRA</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug><drug id="02512882" sec3="Y" sec12="Y"><name>Lacosamide</name><manufacturerId>SAI</manufacturerId><individualPrice>.8750</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.8750</amountMOHLTCPays></drug></pcg9><pcg9 id="281200150"><itemNumber>1079</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02357631" sec3="Y" sec12="Y"><name>Vimpat</name><manufacturerId>UCB</manufacturerId><individualPrice>4.7050</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02472929" sec3="Y" sec12="Y"><name>Teva-Lacosamide</name><manufacturerId>TEV</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02474697" sec3="Y" sec12="Y"><name>Sandoz Lacosamide</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02475359" sec3="Y" sec12="Y"><name>Auro-Lacosamide</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02478226" sec3="Y" sec12="Y"><name>Pharma-Lacosamide</name><manufacturerId>PMS</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02487829" sec3="Y" sec12="Y"><name>Mar-Lacosamide</name><manufacturerId>MAR</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02488418" sec3="Y" sec12="Y"><name>Jamp-Lacosamide</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02489309" sec3="Y" sec12="Y"><name>Ach-Lacosamide</name><manufacturerId>ACH</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02490560" sec3="Y" sec12="Y"><name>Mint-Lacosamide</name><manufacturerId>MIN</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02499584" sec3="Y" sec12="Y"><name>NRA-Lacosamide</name><manufacturerId>NRA</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug><drug id="02512890" sec3="Y" sec12="Y"><name>Lacosamide</name><manufacturerId>SAI</manufacturerId><individualPrice>1.1763</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>1.1763</amountMOHLTCPays></drug></pcg9><pcg9 id="281200151"><itemNumber>1080</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02357658" sec3="Y" sec12="Y"><name>Vimpat</name><manufacturerId>UCB</manufacturerId><individualPrice>5.8000</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02472937" sec3="Y" sec12="Y"><name>Teva-Lacosamide</name><manufacturerId>TEV</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02474700" sec3="Y" sec12="Y"><name>Sandoz Lacosamide</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02475367" sec3="Y" sec12="Y"><name>Auro-Lacosamide</name><manufacturerId>AUR</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02478234" sec3="Y" sec12="Y"><name>Pharma-Lacosamide</name><manufacturerId>PMS</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02487837" sec3="Y" sec12="Y"><name>Mar-Lacosamide</name><manufacturerId>MAR</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02488426" sec3="Y" sec12="Y"><name>Jamp-Lacosamide</name><manufacturerId>JPC</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02489317" sec3="Y" sec12="Y"><name>Ach-Lacosamide</name><manufacturerId>ACH</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02490579" sec3="Y" sec12="Y"><name>Mint-Lacosamide</name><manufacturerId>MIN</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02499592" sec3="Y" sec12="Y"><name>NRA-Lacosamide</name><manufacturerId>NRA</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug><drug id="02512904" sec3="Y" sec12="Y"><name>Lacosamide</name><manufacturerId>SAI</manufacturerId><individualPrice>1.4500</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>1.4500</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="430">As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND

Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following:
 
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00486"><name>LAMOTRIGINE</name><pcgGroup><pcg9 id="281200055"><itemNumber>1081</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02142082" sec3="Y"><name>Lamictal</name><manufacturerId>GSK</manufacturerId><individualPrice>.5402</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02243352" sec3="Y"><name>Ratio-Lamotrigine</name><manufacturerId>RPH</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02245208" sec3="Y"><name>Apo-Lamotrigine</name><manufacturerId>APX</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02246897" sec3="Y"><name>PMS-Lamotrigine</name><manufacturerId>PMS</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02248232" sec3="Y"><name>Teva-Lamotrigine</name><manufacturerId>TEV</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02265494" sec3="Y"><name>Mylan-Lamotrigine</name><manufacturerId>MYL</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2005-07-14</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02343010" sec3="Y"><name>Lamotrigine</name><manufacturerId>SAI</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02381354" sec3="Y"><name>Auro-Lamotrigine</name><manufacturerId>AUR</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02428202" sec3="Y"><name>Lamotrigine</name><manufacturerId>SIV</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug><drug id="02542730" sec3="Y"><name>Jamp Lamotrigine</name><manufacturerId>JPC</manufacturerId><individualPrice>.0698</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.0698</amountMOHLTCPays></drug></pcg9><pcg9 id="281200059"><itemNumber>1082</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02142104" sec3="Y"><name>Lamictal</name><manufacturerId>GSK</manufacturerId><individualPrice>2.1580</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02245209" sec3="Y"><name>Apo-Lamotrigine</name><manufacturerId>APX</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02246898" sec3="Y"><name>PMS-Lamotrigine</name><manufacturerId>PMS</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02248233" sec3="Y"><name>Teva-Lamotrigine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02265508" sec3="Y"><name>Mylan-Lamotrigine</name><manufacturerId>MYL</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2005-07-14</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02343029" sec3="Y"><name>Lamotrigine</name><manufacturerId>SAI</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02381362" sec3="Y"><name>Auro-Lamotrigine</name><manufacturerId>AUR</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02428210" sec3="Y"><name>Lamotrigine</name><manufacturerId>SIV</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug><drug id="02542749" sec3="Y"><name>Jamp Lamotrigine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2787</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.2787</amountMOHLTCPays></drug></pcg9><pcg9 id="281200060"><itemNumber>1083</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02142112" sec3="Y"><name>Lamictal</name><manufacturerId>GSK</manufacturerId><individualPrice>3.1803</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02245210" sec3="Y"><name>Apo-Lamotrigine</name><manufacturerId>APX</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02246899" sec3="Y"><name>PMS-Lamotrigine</name><manufacturerId>PMS</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02248234" sec3="Y"><name>Teva-Lamotrigine</name><manufacturerId>TEV</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02265516" sec3="Y"><name>Mylan-Lamotrigine</name><manufacturerId>MYL</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2005-07-14</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02343037" sec3="Y"><name>Lamotrigine</name><manufacturerId>SAI</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02381370" sec3="Y"><name>Auro-Lamotrigine</name><manufacturerId>AUR</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02428229" sec3="Y"><name>Lamotrigine</name><manufacturerId>SIV</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug><drug id="02542757" sec3="Y"><name>Jamp Lamotrigine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4107</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.4107</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01603"><name>LEVETIRACETAM</name><pcgGroup lccId="00365"><pcg9 id="281200183"><itemNumber>1084</itemNumber><strength>100mg/mL</strength><dosageForm>Oral Sol</dosageForm><drug id="02490447" sec3="Y" sec12="Y"><name>PDP-Levetiracetam</name><manufacturerId>PEN</manufacturerId><individualPrice>.8142</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.6107</amountMOHLTCPays></drug><drug id="02558416" sec3="Y" sec12="Y"><name>Mint-Levetiracetam Solution</name><manufacturerId>MIN</manufacturerId><individualPrice>.6107</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>.6107</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="640">For patients unable to swallow or tolerate oral solid dosage forms and who are using this as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="705">As adjunctive therapy in the treatment of seizure disorders in pediatric patients (less than 18 years of age) where control by other listed anticonvulsants has been unsatisfactory and where the appropriate dose cannot be achieved using listed solid oral levetiracetam dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00266"><pcg9 id="281200091"><itemNumber>1085</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02247027" sec3="Y" sec12="Y"><name>Keppra</name><manufacturerId>UCB</manufacturerId><individualPrice>1.7836</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02274183" sec3="Y" sec12="Y"><name>Act Levetiracetam</name><manufacturerId>ACV</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02285924" sec3="Y" sec12="Y"><name>Apo-Levetiracetam</name><manufacturerId>APX</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02296101" sec3="Y" sec12="Y"><name>PMS-Levetiracetam</name><manufacturerId>PMS</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02353342" sec3="Y" sec12="Y"><name>Levetiracetam</name><manufacturerId>SAI</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02375249" sec3="Y" sec12="Y"><name>Auro-Levetiracetam</name><manufacturerId>AUR</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02399776" sec3="Y" sec12="Y"><name>Ach-Levetiracetam</name><manufacturerId>ACH</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02403005" sec3="Y" sec12="Y"><name>Jamp-Levetiracetam</name><manufacturerId>JPC</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02440202" sec3="Y" sec12="Y"><name>Nat-Levetiracetam</name><manufacturerId>NAT</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02442388" sec3="Y" sec12="Y"><name>Mint-Levetiracetam</name><manufacturerId>MIN</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02442531" sec3="Y" sec12="Y"><name>Levetiracetam</name><manufacturerId>SIV</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02461986" sec3="Y" sec12="Y"><name>Sandoz Levetiracetam</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02482274" sec3="Y" sec12="Y"><name>Riva-Levetiracetam</name><manufacturerId>RIA</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02499193" sec3="Y" sec12="Y"><name>NRA-Levetiracetam</name><manufacturerId>NRA</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02504553" sec3="Y" sec12="Y"><name>Jamp Levetiracetam Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug><drug id="02524562" sec3="Y" sec12="Y"><name>M-Levetiracetam</name><manufacturerId>MAT</manufacturerId><individualPrice>.3210</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.3210</amountMOHLTCPays></drug></pcg9><pcg9 id="281200092"><itemNumber>1086</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02247028" sec3="Y" sec12="Y"><name>Keppra</name><manufacturerId>UCB</manufacturerId><individualPrice>2.1725</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02274191" sec3="Y" sec12="Y"><name>Act Levetiracetam</name><manufacturerId>ACV</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02285932" sec3="Y" sec12="Y"><name>Apo-Levetiracetam</name><manufacturerId>APX</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02296128" sec3="Y" sec12="Y"><name>PMS-Levetiracetam</name><manufacturerId>PMS</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02353350" sec3="Y" sec12="Y"><name>Levetiracetam</name><manufacturerId>SAI</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02375257" sec3="Y" sec12="Y"><name>Auro-Levetiracetam</name><manufacturerId>AUR</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02399784" sec3="Y" sec12="Y"><name>Ach-Levetiracetam</name><manufacturerId>ACH</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02403021" sec3="Y" sec12="Y"><name>Jamp-Levetiracetam</name><manufacturerId>JPC</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02440210" sec3="Y" sec12="Y"><name>Nat-Levetiracetam</name><manufacturerId>NAT</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02442396" sec3="Y" sec12="Y"><name>Mint-Levetiracetam</name><manufacturerId>MIN</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02442558" sec3="Y" sec12="Y"><name>Levetiracetam</name><manufacturerId>SIV</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02461994" sec3="Y" sec12="Y"><name>Sandoz Levetiracetam</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02482282" sec3="Y" sec12="Y"><name>Riva-Levetiracetam</name><manufacturerId>RIA</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02499207" sec3="Y" sec12="Y"><name>NRA-Levetiracetam</name><manufacturerId>NRA</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02504561" sec3="Y" sec12="Y"><name>Jamp Levetiracetam Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug><drug id="02524570" sec3="Y" sec12="Y"><name>M-Levetiracetam</name><manufacturerId>MAT</manufacturerId><individualPrice>.3911</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.3911</amountMOHLTCPays></drug></pcg9><pcg9 id="281200093"><itemNumber>1087</itemNumber><strength>750mg</strength><dosageForm>Tab</dosageForm><drug id="02247029" sec3="Y" sec12="Y"><name>Keppra</name><manufacturerId>UCB</manufacturerId><individualPrice>3.0089</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02274205" sec3="Y" sec12="Y"><name>Act Levetiracetam</name><manufacturerId>ACV</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02285940" sec3="Y" sec12="Y"><name>Apo-Levetiracetam</name><manufacturerId>APX</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02296136" sec3="Y" sec12="Y"><name>PMS-Levetiracetam</name><manufacturerId>PMS</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02353369" sec3="Y" sec12="Y"><name>Levetiracetam</name><manufacturerId>SAI</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02375265" sec3="Y" sec12="Y"><name>Auro-Levetiracetam</name><manufacturerId>AUR</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02399792" sec3="Y" sec12="Y"><name>Ach-Levetiracetam</name><manufacturerId>ACH</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02403048" sec3="Y" sec12="Y"><name>Jamp-Levetiracetam</name><manufacturerId>JPC</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02440229" sec3="Y" sec12="Y"><name>Nat-Levetiracetam</name><manufacturerId>NAT</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02442418" sec3="Y" sec12="Y"><name>Mint-Levetiracetam</name><manufacturerId>MIN</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02442566" sec3="Y" sec12="Y"><name>Levetiracetam</name><manufacturerId>SIV</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02462001" sec3="Y" sec12="Y"><name>Sandoz Levetiracetam</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02482290" sec3="Y" sec12="Y"><name>Riva-Levetiracetam</name><manufacturerId>RIA</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02499215" sec3="Y" sec12="Y"><name>NRA-Levetiracetam</name><manufacturerId>NRA</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02504588" sec3="Y" sec12="Y"><name>Jamp Levetiracetam Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug><drug id="02524589" sec3="Y" sec12="Y"><name>M-Levetiracetam</name><manufacturerId>MAT</manufacturerId><individualPrice>.5416</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.5416</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="473">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00339"><pcg9 id="281200182"><itemNumber>1088</itemNumber><strength>1000mg</strength><dosageForm>Tab</dosageForm><drug id="02462028" sec3="Y" sec12="Y"><name>Sandoz Levetiracetam</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7221</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.7221</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="473">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01593"><name>OXCARBAZEPINE</name><pcgGroup><pcg9 id="281200087"><itemNumber>1089</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02242067" notABenefit="Y" sec3="Y"><name>Trileptal</name><manufacturerId>NOV</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02284294" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Oxcarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>.6209</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.6209</amountMOHLTCPays></drug><drug id="02440717" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Oxcarbazepine</name><manufacturerId>JPC</manufacturerId><individualPrice>.6210</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.6210</amountMOHLTCPays></drug></pcg9><pcg9 id="281200088"><itemNumber>1090</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02242068" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Trileptal</name><manufacturerId>NOV</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02284308" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Oxcarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>.9102</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.9102</amountMOHLTCPays></drug><drug id="02440725" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Oxcarbazepine</name><manufacturerId>JPC</manufacturerId><individualPrice>.9102</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.9102</amountMOHLTCPays></drug></pcg9><pcg9 id="281200089"><itemNumber>1091</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="02242069" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Trileptal</name><manufacturerId>NOV</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02284316" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Oxcarbazepine</name><manufacturerId>APX</manufacturerId><individualPrice>1.8204</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>1.8204</amountMOHLTCPays></drug><drug id="02440733" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Oxcarbazepine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.8204</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>1.8204</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01936"><name>PERAMPANEL</name><pcgGroup lccId="00240"><pcg9 id="281200161"><itemNumber>1092</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02404516" sec3="Y" sec12="Y"><name>Fycompa</name><manufacturerId>EIS</manufacturerId><individualPrice>10.3869</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug><drug id="02522632" sec3="Y" sec12="Y"><name>Taro-Perampanel</name><manufacturerId>TAR</manufacturerId><individualPrice>5.7128</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug></pcg9><pcg9 id="281200162"><itemNumber>1093</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02404524" sec3="Y" sec12="Y"><name>Fycompa</name><manufacturerId>EIS</manufacturerId><individualPrice>10.3869</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug><drug id="02522640" sec3="Y" sec12="Y"><name>Taro-Perampanel</name><manufacturerId>TAR</manufacturerId><individualPrice>5.7128</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug></pcg9><pcg9 id="281200163"><itemNumber>1094</itemNumber><strength>6mg</strength><dosageForm>Tab</dosageForm><drug id="02404532" sec3="Y" sec12="Y"><name>Fycompa</name><manufacturerId>EIS</manufacturerId><individualPrice>10.3869</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug><drug id="02522659" sec3="Y" sec12="Y"><name>Taro-Perampanel</name><manufacturerId>TAR</manufacturerId><individualPrice>5.7128</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug></pcg9><pcg9 id="281200164"><itemNumber>1095</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02404540" sec3="Y" sec12="Y"><name>Fycompa</name><manufacturerId>EIS</manufacturerId><individualPrice>10.3869</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug><drug id="02522667" sec3="Y" sec12="Y"><name>Taro-Perampanel</name><manufacturerId>TAR</manufacturerId><individualPrice>5.7128</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug></pcg9><pcg9 id="281200165"><itemNumber>1096</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02404559" sec3="Y" sec12="Y"><name>Fycompa</name><manufacturerId>EIS</manufacturerId><individualPrice>10.3869</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug><drug id="02522675" sec3="Y" sec12="Y"><name>Taro-Perampanel</name><manufacturerId>TAR</manufacturerId><individualPrice>5.7128</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug></pcg9><pcg9 id="281200166"><itemNumber>1097</itemNumber><strength>12mg</strength><dosageForm>Tab</dosageForm><drug id="02404567" sec3="Y" sec12="Y"><name>Fycompa</name><manufacturerId>EIS</manufacturerId><individualPrice>10.3869</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug><drug id="02522683" sec3="Y" sec12="Y"><name>Taro-Perampanel</name><manufacturerId>TAR</manufacturerId><individualPrice>5.7128</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>5.7128</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="430">As adjunctive therapy in the treatment of patients with partial onset seizures who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies; AND

Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following:
 
Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="564">For adjunctive therapy in the management of primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy who have had an inadequate response or have significant intolerance to at least 3 less costly anticonvulsant therapies;
AND

Patients are under the care of a physician experienced in the treatment of epilepsy.

Note: Less costly anticonvulsant therapies may include the following:

Phenytoin, Carbamazepine, Gabapentin, Lamotrigine, Vigabatrin, Topiramate, etc.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00480"><name>PHENOBARBITAL</name><pcgGroup lccId="00294"><pcg9 id="281200073"><itemNumber>1098</itemNumber><strength>120mg/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="02304090" sec3="Y" sec12="Y"><name>Phenobarbital Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>15.7000</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>15.7000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="00471"><name>PHENYTOIN (DIPHENYLHYDANTOIN)</name><pcgGroup><pcg9 id="281200003"><itemNumber>1099</itemNumber><strength>6mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00023442" sec3="Y"><name>Dilantin-30 Suspension</name><manufacturerId>UJC</manufacturerId><individualPrice>.0588</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0588</amountMOHLTCPays></drug></pcg9><pcg9 id="281200002"><itemNumber>1100</itemNumber><strength>25mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00023450" sec3="Y"><name>Dilantin-125 Suspension</name><manufacturerId>UJC</manufacturerId><individualPrice>.0697</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0444</amountMOHLTCPays></drug><drug id="02250896" sec3="Y"><name>Taro-Phenytoin</name><manufacturerId>TAR</manufacturerId><individualPrice>.0444</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.0444</amountMOHLTCPays></drug></pcg9><pcg9 id="281200001"><itemNumber>1101</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00023698" sec3="Y"><name>Dilantin Infatabs</name><manufacturerId>UJC</manufacturerId><individualPrice>.1069</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1069</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00472"><name>PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM</name><pcgGroup><pcg9 id="281200005"><itemNumber>1102</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><drug id="00022772" sec3="Y"><name>Dilantin</name><manufacturerId>UJC</manufacturerId><individualPrice>.1782</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1782</amountMOHLTCPays></drug></pcg9><pcg9 id="281200004"><itemNumber>1103</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="00022780" sec3="Y"><name>Dilantin</name><manufacturerId>UJC</manufacturerId><individualPrice>.1083</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0665</amountMOHLTCPays></drug><drug id="02460912" sec3="Y"><name>Phenytoin Sodium</name><manufacturerId>AAP</manufacturerId><individualPrice>.0665</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.0665</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00270"><pcg9 id="281200081"><itemNumber>1104</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol (Preservative Free)</dosageForm><drug id="00780626" sec3="Y" sec12="Y"><name>Phenytoin Sodium Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.0785</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>6.0785</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote><lccNote seq="004" reasonForUseId="657">For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" type="N">*e.g., home care recipients, long-term care home residents.</lccNote></pcgGroup></genericName><genericName id="01676"><name>PREGABALIN</name><pcgGroup><pcg9 id="281200094"><itemNumber>1105</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02268418" sec3="Y"><name>Lyrica</name><manufacturerId>UJC</manufacturerId><individualPrice>1.0002</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02359596" sec3="Y"><name>PMS-Pregabalin</name><manufacturerId>PMS</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02361159" sec3="Y"><name>Teva-Pregabalin</name><manufacturerId>TEV</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02390817" sec3="Y"><name>Sandoz Pregabalin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02392801" sec3="Y"><name>Ran-Pregabalin</name><manufacturerId>RAN</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02394235" sec3="Y"><name>Apo-Pregabalin</name><manufacturerId>APX</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02402912" sec3="Y"><name>Co Pregabalin</name><manufacturerId>COB</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02403692" sec3="Y"><name>Pregabalin</name><manufacturerId>SIV</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02405539" sec3="Y"><name>Pregabalin</name><manufacturerId>SAI</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02417529" sec3="Y"><name>Mar-Pregabalin</name><manufacturerId>MAR</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02423804" sec3="Y"><name>Mint-Pregabalin</name><manufacturerId>MIN</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02433869" sec3="Y"><name>Auro-Pregabalin</name><manufacturerId>AUR</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02435977" sec3="Y"><name>Jamp-Pregabalin</name><manufacturerId>JPC</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02449838" sec3="Y"><name>Ach-Pregabalin</name><manufacturerId>ACH</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02467291" sec3="Y"><name>M-Pregabalin</name><manufacturerId>MAT</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02479117" sec3="Y"><name>NRA-Pregabalin</name><manufacturerId>NRA</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02480727" sec3="Y"><name>AG-Pregabalin</name><manufacturerId>ANG</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug><drug id="02494841" sec3="Y"><name>Nat-Pregabalin</name><manufacturerId>NAT</manufacturerId><individualPrice>.1481</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>.1481</amountMOHLTCPays></drug></pcg9><pcg9 id="281200095"><itemNumber>1106</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="02268426" sec3="Y"><name>Lyrica</name><manufacturerId>UJC</manufacturerId><individualPrice>1.5689</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02359618" sec3="Y"><name>PMS-Pregabalin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02361175" sec3="Y"><name>Teva-Pregabalin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02390825" sec3="Y"><name>Sandoz Pregabalin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02392828" sec3="Y"><name>Ran-Pregabalin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02394243" sec3="Y"><name>Apo-Pregabalin</name><manufacturerId>APX</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02402920" sec3="Y"><name>Co Pregabalin</name><manufacturerId>COB</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02403706" sec3="Y"><name>Pregabalin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02405547" sec3="Y"><name>Pregabalin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02417537" sec3="Y"><name>Mar-Pregabalin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02423812" sec3="Y"><name>Mint-Pregabalin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02433877" sec3="Y"><name>Auro-Pregabalin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02435985" sec3="Y"><name>Jamp-Pregabalin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02449846" sec3="Y"><name>Ach-Pregabalin</name><manufacturerId>ACH</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02467305" sec3="Y"><name>M-Pregabalin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02479125" sec3="Y"><name>NRA-Pregabalin</name><manufacturerId>NRA</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02480735" sec3="Y"><name>AG-Pregabalin</name><manufacturerId>ANG</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug><drug id="02494868" sec3="Y"><name>Nat-Pregabalin</name><manufacturerId>NAT</manufacturerId><individualPrice>.2324</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>.2324</amountMOHLTCPays></drug></pcg9><pcg9 id="281200096"><itemNumber>1107</itemNumber><strength>75mg</strength><dosageForm>Cap</dosageForm><drug id="02268434" sec3="Y"><name>Lyrica</name><manufacturerId>UJC</manufacturerId><individualPrice>2.0300</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02359626" sec3="Y"><name>PMS-Pregabalin</name><manufacturerId>PMS</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02361183" sec3="Y"><name>Teva-Pregabalin</name><manufacturerId>TEV</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02390833" sec3="Y"><name>Sandoz Pregabalin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02392836" sec3="Y"><name>Ran-Pregabalin</name><manufacturerId>RAN</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02394251" sec3="Y"><name>Apo-Pregabalin</name><manufacturerId>APX</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02402939" sec3="Y"><name>Co Pregabalin</name><manufacturerId>COB</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02403714" sec3="Y"><name>Pregabalin</name><manufacturerId>SIV</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02405555" sec3="Y"><name>Pregabalin</name><manufacturerId>SAI</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02417545" sec3="Y"><name>Mar-Pregabalin</name><manufacturerId>MAR</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02424185" sec3="Y"><name>Mint-Pregabalin</name><manufacturerId>MIN</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02433885" sec3="Y"><name>Auro-Pregabalin</name><manufacturerId>AUR</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02435993" sec3="Y"><name>Jamp-Pregabalin</name><manufacturerId>JPC</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02449854" sec3="Y"><name>Ach-Pregabalin</name><manufacturerId>ACH</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02467313" sec3="Y"><name>M-Pregabalin</name><manufacturerId>MAT</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02479133" sec3="Y"><name>NRA-Pregabalin</name><manufacturerId>NRA</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02480743" sec3="Y"><name>AG-Pregabalin</name><manufacturerId>ANG</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug><drug id="02494876" sec3="Y"><name>Nat-Pregabalin</name><manufacturerId>NAT</manufacturerId><individualPrice>.3007</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>.3007</amountMOHLTCPays></drug></pcg9><pcg9 id="281200097"><itemNumber>1108</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02268450" sec3="Y"><name>Lyrica</name><manufacturerId>UJC</manufacturerId><individualPrice>2.7982</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02359634" sec3="Y"><name>PMS-Pregabalin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02361205" sec3="Y"><name>Teva-Pregabalin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02390841" sec3="Y"><name>Sandoz Pregabalin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02392844" sec3="Y"><name>Ran-Pregabalin</name><manufacturerId>RAN</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02394278" sec3="Y"><name>Apo-Pregabalin</name><manufacturerId>APX</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02402955" sec3="Y"><name>Co Pregabalin</name><manufacturerId>COB</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02403722" sec3="Y"><name>Pregabalin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02405563" sec3="Y"><name>Pregabalin</name><manufacturerId>SAI</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02417561" sec3="Y"><name>Mar-Pregabalin</name><manufacturerId>MAR</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02424207" sec3="Y"><name>Mint-Pregabalin</name><manufacturerId>MIN</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02433907" sec3="Y"><name>Auro-Pregabalin</name><manufacturerId>AUR</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02436000" sec3="Y"><name>Jamp-Pregabalin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02449870" sec3="Y"><name>Ach-Pregabalin</name><manufacturerId>ACH</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02467321" sec3="Y"><name>M-Pregabalin</name><manufacturerId>MAT</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02479168" sec3="Y"><name>NRA-Pregabalin</name><manufacturerId>NRA</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02480751" sec3="Y"><name>AG-Pregabalin</name><manufacturerId>ANG</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02494884" sec3="Y"><name>Nat-Pregabalin</name><manufacturerId>NAT</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug></pcg9><pcg9 id="281200158"><itemNumber>1109</itemNumber><strength>225mg</strength><dosageForm>Cap</dosageForm><drug id="02268477" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lyrica</name><manufacturerId>UJC</manufacturerId><listingDate>2013-04-30</listingDate></drug><drug id="02361221" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Pregabalin</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2013-04-30</listingDate></drug><drug id="02392852" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Pregabalin</name><manufacturerId>RAN</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2013-04-30</listingDate></drug><drug id="02394286" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Pregabalin</name><manufacturerId>APX</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2013-04-30</listingDate></drug><drug id="02398079" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Pregabalin</name><manufacturerId>PMS</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2013-04-30</listingDate></drug><drug id="02402971" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Pregabalin</name><manufacturerId>COB</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2013-04-30</listingDate></drug><drug id="02417596" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Pregabalin</name><manufacturerId>MAR</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02449897" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ach-Pregabalin</name><manufacturerId>ACH</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2021-08-31</listingDate></drug><drug id="02494892" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Pregabalin</name><manufacturerId>NAT</manufacturerId><individualPrice>1.7270</individualPrice><listingDate>2020-02-28</listingDate></drug></pcg9><pcg9 id="281200098"><itemNumber>1110</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="02268485" sec3="Y"><name>Lyrica</name><manufacturerId>UJC</manufacturerId><individualPrice>2.7982</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02359642" sec3="Y"><name>PMS-Pregabalin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02361248" sec3="Y"><name>Teva-Pregabalin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02390868" sec3="Y"><name>Sandoz Pregabalin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02392860" sec3="Y"><name>Ran-Pregabalin</name><manufacturerId>RAN</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02394294" sec3="Y"><name>Apo-Pregabalin</name><manufacturerId>APX</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02402998" sec3="Y"><name>Co Pregabalin</name><manufacturerId>COB</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02403730" sec3="Y"><name>Pregabalin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02405598" sec3="Y"><name>Pregabalin</name><manufacturerId>SAI</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02417618" sec3="Y"><name>Mar-Pregabalin</name><manufacturerId>MAR</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02436019" sec3="Y"><name>Jamp-Pregabalin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02449900" sec3="Y"><name>Ach-Pregabalin</name><manufacturerId>ACH</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02479192" sec3="Y"><name>NRA-Pregabalin</name><manufacturerId>NRA</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02480778" sec3="Y"><name>AG-Pregabalin</name><manufacturerId>ANG</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02494906" sec3="Y"><name>Nat-Pregabalin</name><manufacturerId>NAT</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug><drug id="02541963" sec3="Y"><name>M-Pregabalin</name><manufacturerId>MAT</manufacturerId><individualPrice>.4145</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>.4145</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00477"><name>PRIMIDONE</name><pcgGroup><pcg9 id="281200025"><itemNumber>1111</itemNumber><strength>125mg</strength><dosageForm>Tab</dosageForm><drug id="00399310" sec3="Y"><name>Primidone</name><manufacturerId>AAP</manufacturerId><individualPrice>.0564</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0564</amountMOHLTCPays></drug><drug id="02042363" notABenefit="Y" sec3="Y"><name>Mysoline</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281200024"><itemNumber>1112</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="00396761" sec3="Y"><name>Primidone</name><manufacturerId>AAP</manufacturerId><individualPrice>.0887</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0887</amountMOHLTCPays></drug><drug id="02042355" notABenefit="Y" sec3="Y"><name>Mysoline</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01885"><name>RUFINAMIDE</name><pcgGroup><pcg9 id="281200156"><itemNumber>1113</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02369621" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Banzel</name><manufacturerId>EIS</manufacturerId><individualPrice>1.9047</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>1.0083</amountMOHLTCPays></drug><drug id="02545985" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Rufinamide</name><manufacturerId>AUR</manufacturerId><individualPrice>1.0083</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>1.0083</amountMOHLTCPays></drug></pcg9><pcg9 id="281200157"><itemNumber>1114</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="02369648" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Banzel</name><manufacturerId>EIS</manufacturerId><individualPrice>4.1503</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>2.1970</amountMOHLTCPays></drug><drug id="02545993" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Rufinamide</name><manufacturerId>AUR</manufacturerId><individualPrice>2.1970</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>2.1970</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00490"><name>TOPIRAMATE</name><pcgGroup lccId="00074"><pcg9 id="281200079"><itemNumber>1115</itemNumber><strength>15mg</strength><dosageForm>Sprinkle Cap</dosageForm><drug id="02239907" sec3="Y" sec12="Y"><name>Topamax Sprinkle</name><manufacturerId>JNO</manufacturerId><individualPrice>2.2095</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>2.2095</amountMOHLTCPays></drug></pcg9><pcg9 id="281200080"><itemNumber>1116</itemNumber><strength>25mg</strength><dosageForm>Sprinkle Cap</dosageForm><drug id="02239908" sec3="Y" sec12="Y"><name>Topamax Sprinkle</name><manufacturerId>JNO</manufacturerId><individualPrice>2.3100</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>2.3100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="321">In children age 16 and under, as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="281200188"><itemNumber>1117</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02231385" notABenefit="Y" sec3b="Y" sec3="Y"><name>Topamax</name><manufacturerId>JNO</manufacturerId><listingDate>2024-11-29</listingDate></drug><drug id="02312085" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Topiramate</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2434</individualPrice><listingDate>2025-02-28</listingDate></drug><drug id="02544377" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Topiramate Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2434</individualPrice><listingDate>2024-11-29</listingDate></drug></pcg9><pcg9 id="281200069"><itemNumber>1118</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02230893" sec3="Y"><name>Topamax</name><manufacturerId>JNO</manufacturerId><individualPrice>2.3213</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02248860" sec3="Y"><name>Teva-Topiramate</name><manufacturerId>TEV</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02262991" sec3="Y"><name>PMS-Topiramate</name><manufacturerId>PMS</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02263351" sec3="Y"><name>Mylan-Topiramate</name><manufacturerId>MYL</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02279614" sec3="Y"><name>Apo-Topiramate</name><manufacturerId>APX</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02315645" sec3="Y"><name>Mint-Topiramate</name><manufacturerId>MIN</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02345250" sec3="Y"><name>Jamp Topiramate Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02345803" sec3="Y"><name>Auro-Topiramate</name><manufacturerId>AUR</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02356856" sec3="Y"><name>Topiramate</name><manufacturerId>SAI</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02389460" sec3="Y"><name>Topiramate</name><manufacturerId>SIV</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02395738" sec3="Y"><name>Ach-Topiramate</name><manufacturerId>ACH</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02431807" sec3="Y"><name>Sandoz Topiramate Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02432099" sec3="Y"><name>Mar-Topiramate</name><manufacturerId>MAR</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02435608" sec3="Y"><name>Jamp-Topiramate</name><manufacturerId>JPC</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02475936" sec3="Y"><name>AG-Topiramate</name><manufacturerId>ANG</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug><drug id="02538466" sec3="Y"><name>NRA-Topiramate</name><manufacturerId>NRA</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug></pcg9><pcg9 id="281200070"><itemNumber>1119</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02230894" sec3="Y"><name>Topamax</name><manufacturerId>JNO</manufacturerId><individualPrice>4.3530</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02248861" sec3="Y"><name>Teva-Topiramate</name><manufacturerId>TEV</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02263009" sec3="Y"><name>PMS-Topiramate</name><manufacturerId>PMS</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02263378" sec3="Y"><name>Mylan-Topiramate</name><manufacturerId>MYL</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02279630" sec3="Y"><name>Apo-Topiramate</name><manufacturerId>APX</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02315653" sec3="Y"><name>Mint-Topiramate</name><manufacturerId>MIN</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02345269" sec3="Y"><name>Jamp Topiramate Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02345838" sec3="Y"><name>Auro-Topiramate</name><manufacturerId>AUR</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02356864" sec3="Y"><name>Topiramate</name><manufacturerId>SAI</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02389487" sec3="Y"><name>Topiramate</name><manufacturerId>SIV</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02395746" sec3="Y"><name>Ach-Topiramate</name><manufacturerId>ACH</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02396084" sec3="Y"><name>Ran-Topiramate</name><manufacturerId>RAN</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02431815" sec3="Y"><name>Sandoz Topiramate Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02432102" sec3="Y"><name>Mar-Topiramate</name><manufacturerId>MAR</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02435616" sec3="Y"><name>Jamp-Topiramate</name><manufacturerId>JPC</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02475944" sec3="Y"><name>AG-Topiramate</name><manufacturerId>ANG</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug><drug id="02538458" sec3="Y"><name>NRA-Topiramate</name><manufacturerId>NRA</manufacturerId><individualPrice>.4583</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.4583</amountMOHLTCPays></drug></pcg9><pcg9 id="281200071"><itemNumber>1120</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02230896" sec3="Y"><name>Topamax</name><manufacturerId>JNO</manufacturerId><individualPrice>6.4275</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02248862" sec3="Y"><name>Teva-Topiramate</name><manufacturerId>TEV</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02263017" sec3="Y"><name>PMS-Topiramate</name><manufacturerId>PMS</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02263386" sec3="Y"><name>Mylan-Topiramate</name><manufacturerId>MYL</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2005-11-08</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02279649" sec3="Y"><name>Apo-Topiramate</name><manufacturerId>APX</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02315661" sec3="Y"><name>Mint-Topiramate</name><manufacturerId>MIN</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02345277" sec3="Y"><name>Jamp Topiramate Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02345846" sec3="Y"><name>Auro-Topiramate</name><manufacturerId>AUR</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02356872" sec3="Y"><name>Topiramate</name><manufacturerId>SAI</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02395754" sec3="Y"><name>Ach-Topiramate</name><manufacturerId>ACH</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02396092" sec3="Y"><name>Ran-Topiramate</name><manufacturerId>RAN</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02431823" sec3="Y"><name>Sandoz Topiramate Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02432110" sec3="Y"><name>Mar-Topiramate</name><manufacturerId>MAR</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2015-02-26</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02435624" sec3="Y"><name>Jamp-Topiramate</name><manufacturerId>JPC</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug><drug id="02538474" sec3="Y"><name>NRA-Topiramate</name><manufacturerId>NRA</manufacturerId><individualPrice>.6748</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>.6748</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00481"><name>VALPROATE SODIUM</name><pcgGroup><pcg9 id="281200040"><itemNumber>1121</itemNumber><strength>50mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00443832" sec3="Y"><name>Depakene</name><manufacturerId>BGP</manufacturerId><individualPrice>.1473</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0398</amountMOHLTCPays></drug><drug id="02236807" sec3="Y"><name>PMS-Valproic Acid</name><manufacturerId>PMS</manufacturerId><individualPrice>.0398</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.0398</amountMOHLTCPays></drug><drug id="02238370" sec3="Y"><name>Apo-Valproic</name><manufacturerId>APX</manufacturerId><individualPrice>.0605</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.0398</amountMOHLTCPays></drug><drug id="02532441" sec3="Y"><name>Jamp Valproic Acid Oral Solution</name><manufacturerId>JPC</manufacturerId><individualPrice>.0398</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.0398</amountMOHLTCPays></drug><drug id="02549190" sec3="Y"><name>Odan-Valproic Acid</name><manufacturerId>ODN</manufacturerId><individualPrice>.0398</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.0398</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00482"><name>VALPROIC ACID</name><pcgGroup><pcg9 id="281200041"><itemNumber>1122</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="00443840" notABenefit="Y" sec3="Y"><name>Depakene</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230768" sec3="Y"><name>PMS-Valproic Acid</name><manufacturerId>PMS</manufacturerId><individualPrice>.2905</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2905</amountMOHLTCPays></drug><drug id="02238048" sec3="Y"><name>Apo-Valproic</name><manufacturerId>APX</manufacturerId><individualPrice>.2905</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2905</amountMOHLTCPays></drug></pcg9><pcg9 id="281200042"><itemNumber>1123</itemNumber><strength>500mg</strength><dosageForm>Ent Cap</dosageForm><drug id="00507989" notABenefit="Y" sec3="Y"><name>Depakene</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229628" sec3="Y"><name>PMS-Valproic Acid</name><manufacturerId>PMS</manufacturerId><individualPrice>.8102</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.8102</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00485"><name>VIGABATRIN</name><pcgGroup><pcg9 id="281200184"><itemNumber>1124</itemNumber><strength>500mg/Sachet</strength><dosageForm>Pd for Oral Sol</dosageForm><drug id="09858315" sec3c="Y"><name>Vigabatrin for Oral Solution, USP 500mg</name><manufacturerId>DRR</manufacturerId><individualPrice>5.0000</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00076"><pcg9 id="281200054"><itemNumber>1125</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02065819" sec3="Y" sec12="Y"><name>Sabril</name><manufacturerId>OVA</manufacturerId><individualPrice>.9566</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9566</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="136">As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.</lccNote><lccNote seq="002" type="N">Because a large number of patients may become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months.</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="281200185"><itemNumber>1126</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="09858318" sec3c="Y"><name>Vigabatrin Tablets, USP</name><manufacturerId>DRR</manufacturerId><individualPrice>5.0000</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>5.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="281604000"><name>PSYCHOTHERAPEUTIC AGENTS ANTIDEPRESSANTS</name><genericName id="00491"><name>AMITRIPTYLINE</name><pcgGroup><pcg9 id="281604003"><itemNumber>1127</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00335053" sec3="Y"><name>Elavil</name><manufacturerId>AAP</manufacturerId><individualPrice>.0664</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0305</amountMOHLTCPays></drug><drug id="00654523" sec3="Y"><name>PMS-Amitriptyline</name><manufacturerId>PMS</manufacturerId><individualPrice>.0305</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.0305</amountMOHLTCPays></drug><drug id="02429861" sec3="Y"><name>Mar-Amitriptyline</name><manufacturerId>MAR</manufacturerId><individualPrice>.0305</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.0305</amountMOHLTCPays></drug></pcg9><pcg9 id="281604002"><itemNumber>1128</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00335061" sec3="Y"><name>Elavil</name><manufacturerId>AAP</manufacturerId><individualPrice>.1211</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0829</amountMOHLTCPays></drug><drug id="00654515" sec3="Y"><name>PMS-Amitriptyline</name><manufacturerId>PMS</manufacturerId><individualPrice>.0829</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.0829</amountMOHLTCPays></drug><drug id="02326051" sec3="Y"><name>Teva-Amitriptyline</name><manufacturerId>TEV</manufacturerId><individualPrice>.0829</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.0829</amountMOHLTCPays></drug><drug id="02429888" sec3="Y"><name>Mar-Amitriptyline</name><manufacturerId>MAR</manufacturerId><individualPrice>.0829</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.0829</amountMOHLTCPays></drug></pcg9><pcg9 id="281604001"><itemNumber>1129</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00335088" sec3="Y"><name>Elavil</name><manufacturerId>AAP</manufacturerId><individualPrice>.2347</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1540</amountMOHLTCPays></drug><drug id="00654507" sec3="Y"><name>PMS-Amitriptyline</name><manufacturerId>PMS</manufacturerId><individualPrice>.1540</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.1540</amountMOHLTCPays></drug><drug id="02326078" sec3="Y"><name>Teva-Amitriptyline</name><manufacturerId>TEV</manufacturerId><individualPrice>.1540</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.1540</amountMOHLTCPays></drug><drug id="02429896" sec3="Y"><name>Mar-Amitriptyline</name><manufacturerId>MAR</manufacturerId><individualPrice>.1540</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.1540</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01383"><name>BUPROPION HCL</name><pcgGroup lccId="00077"><pcg9 id="281604120"><itemNumber>1130</itemNumber><strength>150mg</strength><dosageForm>ER Tab</dosageForm><drug id="02275090" sec3="Y" sec12="Y"><name>Wellbutrin XL</name><manufacturerId>VAL</manufacturerId><individualPrice>.6211</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.2926</amountMOHLTCPays></drug><drug id="02439654" sec3="Y" sec12="Y"><name>Act Bupropion XL</name><manufacturerId>ACV</manufacturerId><individualPrice>.2926</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.2926</amountMOHLTCPays></drug><drug id="02475804" sec3="Y" sec12="Y"><name>Taro-Bupropion XL</name><manufacturerId>SPC</manufacturerId><individualPrice>.2926</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.2926</amountMOHLTCPays></drug></pcg9><pcg9 id="281604121"><itemNumber>1131</itemNumber><strength>300mg</strength><dosageForm>ER Tab</dosageForm><drug id="02275104" sec3="Y" sec12="Y"><name>Wellbutrin XL</name><manufacturerId>VAL</manufacturerId><individualPrice>1.2425</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.5853</amountMOHLTCPays></drug><drug id="02439662" sec3="Y" sec12="Y"><name>Act Bupropion XL</name><manufacturerId>ACV</manufacturerId><individualPrice>.5853</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.5853</amountMOHLTCPays></drug><drug id="02475812" sec3="Y" sec12="Y"><name>Taro-Bupropion XL</name><manufacturerId>SPC</manufacturerId><individualPrice>.5853</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.5853</amountMOHLTCPays></drug></pcg9><pcg9 id="281604102"><itemNumber>1132</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02237824" notABenefit="Y" sec3="Y"><name>Wellbutrin SR</name><manufacturerId>BIO</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02275074" sec3="Y" sec12="Y"><name>Odan Bupropion SR</name><manufacturerId>ODN</manufacturerId><individualPrice>.5260</individualPrice><listingDate>2006-08-24</listingDate><amountMOHLTCPays>.5260</amountMOHLTCPays></drug></pcg9><pcg9 id="281604103"><itemNumber>1133</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02237825" notABenefit="Y" sec3="Y"><name>Wellbutrin SR</name><manufacturerId>VAL</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02275082" sec3="Y" sec12="Y"><name>Odan Bupropion SR</name><manufacturerId>ODN</manufacturerId><individualPrice>.9169</individualPrice><listingDate>2006-08-24</listingDate><amountMOHLTCPays>.9169</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="315">For the treatment of depression.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01421"><name>CITALOPRAM HYDROBROMIDE</name><pcgGroup><pcg9 id="281604143"><itemNumber>1134</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02239606" notABenefit="Y" sec3b="Y" sec3="Y"><name>Celexa</name><manufacturerId>VLH</manufacturerId><listingDate>2024-12-30</listingDate></drug><drug id="02270609" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Citalopram</name><manufacturerId>PMS</manufacturerId><individualPrice>.4464</individualPrice><listingDate>2025-02-28</listingDate></drug><drug id="02371871" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Citalopram</name><manufacturerId>MAR</manufacturerId><individualPrice>.4464</individualPrice><listingDate>2025-03-31</listingDate></drug><drug id="02387948" notABenefit="Y" sec3b="Y" sec3="Y"><name>Citalopram</name><manufacturerId>SIV</manufacturerId><individualPrice>.4464</individualPrice><listingDate>2025-02-28</listingDate></drug><drug id="02409003" notABenefit="Y" sec3b="Y" sec3="Y"><name>Natco-Citalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.4464</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02430517" notABenefit="Y" sec3b="Y" sec3="Y"><name>Citalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.4464</individualPrice><listingDate>2024-12-30</listingDate></drug><drug id="02532123" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Citalopram</name><manufacturerId>MAT</manufacturerId><individualPrice>.4464</individualPrice><listingDate>2025-05-30</listingDate></drug></pcg9><pcg9 id="281604096"><itemNumber>1135</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02239607" sec3="Y"><name>Celexa</name><manufacturerId>VLH</manufacturerId><individualPrice>1.8408</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02246056" sec3="Y"><name>Apo-Citalopram</name><manufacturerId>APX</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02248010" sec3="Y"><name>PMS-Citalopram</name><manufacturerId>PMS</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02248050" sec3="Y"><name>Co Citalopram</name><manufacturerId>COB</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02248170" sec3="Y"><name>Sandoz Citalopram</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02275562" sec3="Y"><name>Auro-Citalopram</name><manufacturerId>AUR</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02285622" sec3="Y"><name>Ran-Citalo</name><manufacturerId>RAN</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2007-05-04</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02293218" sec3="Y"><name>Teva-Citalopram</name><manufacturerId>TEV</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02303264" sec3="Y"><name>Riva-Citalopram</name><manufacturerId>RIA</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02353660" sec3="Y"><name>Citalopram</name><manufacturerId>SAI</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02355256" sec3="Y"><name>Accel Citalopram Tablets</name><manufacturerId>ACC</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02355272" sec3="Y"><name>Septa-Citalopram</name><manufacturerId>SET</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02371898" sec3="Y"><name>Mar-Citalopram</name><manufacturerId>MAR</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02387956" sec3="Y"><name>Citalopram</name><manufacturerId>SIV</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02409011" dinStatus="E" sec3="Y"><name>Nat-Citalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02429705" sec3="Y"><name>Mint-Citalopram</name><manufacturerId>MIN</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2015-12-22</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02430541" sec3="Y"><name>Citalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02443880" sec3="Y"><name>Natco-Citalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02459914" sec3="Y"><name>CCP-Citalopram</name><manufacturerId>CCP</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02467836" sec3="Y"><name>M-Citalopram</name><manufacturerId>MAT</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02477645" sec3="Y"><name>NRA-Citalopram</name><manufacturerId>NRA</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug></pcg9><pcg9 id="281604097"><itemNumber>1136</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02239608" sec3="Y"><name>Celexa</name><manufacturerId>VLH</manufacturerId><individualPrice>1.8408</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02246057" sec3="Y"><name>Apo-Citalopram</name><manufacturerId>APX</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02248011" sec3="Y"><name>PMS-Citalopram</name><manufacturerId>PMS</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02248051" sec3="Y"><name>Co Citalopram</name><manufacturerId>COB</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02248171" sec3="Y"><name>Sandoz Citalopram</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02275570" sec3="Y"><name>Auro-Citalopram</name><manufacturerId>AUR</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02285630" sec3="Y"><name>Ran-Citalo</name><manufacturerId>RAN</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2007-05-04</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02293226" sec3="Y"><name>Teva-Citalopram</name><manufacturerId>TEV</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02303272" sec3="Y"><name>Riva-Citalopram</name><manufacturerId>RIA</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02353679" sec3="Y"><name>Citalopram</name><manufacturerId>SAI</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02355264" sec3="Y"><name>Accel Citalopram Tablets</name><manufacturerId>ACC</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02355280" sec3="Y"><name>Septa-Citalopram</name><manufacturerId>SET</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02371901" sec3="Y"><name>Mar-Citalopram</name><manufacturerId>MAR</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02387964" sec3="Y"><name>Citalopram</name><manufacturerId>SIV</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02409038" dinStatus="E" sec3="Y"><name>Nat-Citalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02429713" sec3="Y"><name>Mint-Citalopram</name><manufacturerId>MIN</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2015-12-22</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02430568" sec3="Y"><name>Citalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02443899" sec3="Y"><name>Natco-Citalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02459922" sec3="Y"><name>CCP-Citalopram</name><manufacturerId>CCP</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02467844" sec3="Y"><name>M-Citalopram</name><manufacturerId>MAT</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug><drug id="02477653" sec3="Y"><name>NRA-Citalopram</name><manufacturerId>NRA</manufacturerId><individualPrice>.1332</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1332</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00492"><name>CLOMIPRAMINE HCL</name><pcgGroup><pcg9 id="281604005"><itemNumber>1137</itemNumber><strength>25mg</strength><drug id="00324019" sec3="Y"><name>Anafranil Tab</name><manufacturerId>APX</manufacturerId><individualPrice>.4020</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3417</amountMOHLTCPays></drug><drug id="02497506" sec3="Y"><name>Taro-Clomipramine Cap</name><manufacturerId>TAR</manufacturerId><individualPrice>.3417</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3417</amountMOHLTCPays></drug></pcg9><pcg9 id="281604035"><itemNumber>1138</itemNumber><strength>50mg</strength><drug id="00402591" sec3="Y"><name>Anafranil Tab</name><manufacturerId>APX</manufacturerId><individualPrice>.7401</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6291</amountMOHLTCPays></drug><drug id="02497514" sec3="Y"><name>Taro-Clomipramine Cap</name><manufacturerId>TAR</manufacturerId><individualPrice>.6291</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.6291</amountMOHLTCPays></drug></pcg9><pcg9 id="281604026"><itemNumber>1139</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00330566" sec3="Y"><name>Anafranil</name><manufacturerId>APX</manufacturerId><individualPrice>.2949</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2949</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00493"><name>DESIPRAMINE</name><pcgGroup><pcg9 id="281604007"><itemNumber>1140</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00010448" notABenefit="Y" sec3="Y"><name>Pertofrane</name><manufacturerId>GEI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02099128" notABenefit="Y" sec3="Y"><name>Norpramin</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="02216256" sec3="Y"><name>Desipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.4345</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.4345</amountMOHLTCPays></drug></pcg9><pcg9 id="281604006"><itemNumber>1141</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02099136" notABenefit="Y" sec3="Y"><name>Norpramin</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="02216264" sec3="Y"><name>Desipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.7659</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.7659</amountMOHLTCPays></drug></pcg9><pcg9 id="281604034"><itemNumber>1142</itemNumber><strength>75mg</strength><dosageForm>Tab</dosageForm><drug id="02099144" notABenefit="Y" sec3="Y"><name>Norpramin</name><manufacturerId>HMR</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="02216272" sec3="Y"><name>Desipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>1.0184</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.0184</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02038"><name>DESVENLAFAXINE</name><pcgGroup><pcg9 id="281604130"><itemNumber>1143</itemNumber><strength>50mg</strength><dosageForm>ER Tab</dosageForm><drug id="02321092" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pristiq</name><manufacturerId>PFI</manufacturerId><listingDate>2017-12-21</listingDate></drug><drug id="02458217" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Desvenlafaxine</name><manufacturerId>TEV</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2022-04-29</listingDate></drug><drug id="02466988" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Desvenlafaxine</name><manufacturerId>APX</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2017-12-21</listingDate></drug><drug id="02467119" notABenefit="Y" sec3b="Y" sec3="Y"><name>Desvenlafaxine</name><manufacturerId>APX</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2022-04-29</listingDate></drug><drug id="02495139" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Desvenlafaxine</name><manufacturerId>JPC</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02532158" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Desvenlafaxine</name><manufacturerId>TAR</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2023-10-31</listingDate></drug><drug id="02535106" notABenefit="Y" sec3b="Y" sec3="Y"><name>Desvenlafaxine</name><manufacturerId>SAI</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2023-05-31</listingDate></drug><drug id="02538415" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Desvenlafaxine</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2024-02-29</listingDate></drug><drug id="02554968" notABenefit="Y" sec3b="Y" sec3="Y"><name>Desvenlafaxine</name><manufacturerId>SIV</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2025-05-30</listingDate></drug></pcg9><pcg9 id="281604131"><itemNumber>1144</itemNumber><strength>100mg</strength><dosageForm>ER Tab</dosageForm><drug id="02321106" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pristiq</name><manufacturerId>PFI</manufacturerId><listingDate>2017-12-21</listingDate></drug><drug id="02458225" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Desvenlafaxine</name><manufacturerId>TEV</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2022-04-29</listingDate></drug><drug id="02466996" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Desvenlafaxine</name><manufacturerId>APX</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2017-12-21</listingDate></drug><drug id="02467127" notABenefit="Y" sec3b="Y" sec3="Y"><name>Desvenlafaxine</name><manufacturerId>APX</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2022-04-29</listingDate></drug><drug id="02495147" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Desvenlafaxine</name><manufacturerId>JPC</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02532166" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Desvenlafaxine</name><manufacturerId>TAR</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2023-10-31</listingDate></drug><drug id="02535114" notABenefit="Y" sec3b="Y" sec3="Y"><name>Desvenlafaxine</name><manufacturerId>SAI</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2023-05-31</listingDate></drug><drug id="02538423" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Desvenlafaxine</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2024-02-29</listingDate></drug><drug id="02554976" notABenefit="Y" sec3b="Y" sec3="Y"><name>Desvenlafaxine</name><manufacturerId>SIV</manufacturerId><individualPrice>2.3409</individualPrice><listingDate>2025-05-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00494"><name>DOXEPIN HCL</name><pcgGroup><pcg9 id="281604010"><itemNumber>1145</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="00024325" sec3="Y"><name>Sinequan</name><manufacturerId>AAP</manufacturerId><individualPrice>.4075</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2241</amountMOHLTCPays></drug><drug id="02559080" sec3="Y"><name>Mar-Doxepin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2241</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.2241</amountMOHLTCPays></drug></pcg9><pcg9 id="281604009"><itemNumber>1146</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="00024333" sec3="Y"><name>Sinequan</name><manufacturerId>AAP</manufacturerId><individualPrice>.5000</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2750</amountMOHLTCPays></drug><drug id="02559099" sec3="Y"><name>Mar-Doxepin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2750</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.2750</amountMOHLTCPays></drug></pcg9><pcg9 id="281604008"><itemNumber>1147</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="00024341" sec3="Y"><name>Sinequan</name><manufacturerId>AAP</manufacturerId><individualPrice>.9274</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5101</amountMOHLTCPays></drug><drug id="02559102" sec3="Y"><name>Mar-Doxepin</name><manufacturerId>MAR</manufacturerId><individualPrice>.5101</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.5101</amountMOHLTCPays></drug></pcg9><pcg9 id="281604028"><itemNumber>1148</itemNumber><strength>75mg</strength><dosageForm>Cap</dosageForm><drug id="00400750" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sinequan</name><manufacturerId>AAP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02050021" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Doxepin</name><manufacturerId>APX</manufacturerId><individualPrice>1.1363</individualPrice><listingDate>1996-10-01</listingDate></drug><drug id="02559110" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Doxepin</name><manufacturerId>MAR</manufacturerId><individualPrice>1.1363</individualPrice><listingDate>2025-09-29</listingDate></drug></pcg9><pcg9 id="281604027"><itemNumber>1149</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="00326925" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sinequan</name><manufacturerId>AAP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02050048" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Doxepin</name><manufacturerId>APX</manufacturerId><individualPrice>1.4944</individualPrice><listingDate>1996-10-01</listingDate></drug><drug id="02559129" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Doxepin</name><manufacturerId>MAR</manufacturerId><individualPrice>1.4944</individualPrice><listingDate>2025-09-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01745"><name>DULOXETINE</name><pcgGroup><pcg9 id="281604123"><itemNumber>1150</itemNumber><strength>30mg</strength><dosageForm>DR Cap</dosageForm><drug id="02301482" dinStatus="E" sec3="Y"><name>Cymbalta</name><manufacturerId>LIL</manufacturerId><individualPrice>2.6004</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02429446" sec3="Y"><name>PMS-Duloxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02436647" sec3="Y"><name>Auro-Duloxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02437082" sec3="Y"><name>Duloxetine DR</name><manufacturerId>TEV</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02438259" sec3="Y"><name>Ran-Duloxetine</name><manufacturerId>RAN</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02438984" sec3="Y"><name>Mint-Duloxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02439948" sec3="Y"><name>Sandoz Duloxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02440423" sec3="Y"><name>Apo-Duloxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02446081" sec3="Y"><name>Mar-Duloxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02451913" sec3="Y"><name>Jamp-Duloxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02453630" sec3="Y"><name>Duloxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02456753" sec3="Y"><name>Teva-Duloxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02457199" sec3="Y"><name>Taro-Duloxetine</name><manufacturerId>TAR</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02473208" sec3="Y"><name>M-Duloxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02475308" sec3="Y"><name>AG-Duloxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02482126" sec3="Y"><name>NRA-Duloxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02490889" sec3="Y"><name>Duloxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02512505" sec3="Y"><name>Jamp Duloxetine Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.4814</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug><drug id="02522861" sec3="Y"><name>Accel-Duloxetine</name><manufacturerId>ACC</manufacturerId><individualPrice>.3611</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.3611</amountMOHLTCPays></drug></pcg9><pcg9 id="281604124"><itemNumber>1151</itemNumber><strength>60mg</strength><dosageForm>DR Cap</dosageForm><drug id="02301490" dinStatus="E" sec3="Y"><name>Cymbalta</name><manufacturerId>LIL</manufacturerId><individualPrice>5.2779</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02429454" sec3="Y"><name>PMS-Duloxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02436655" sec3="Y"><name>Auro-Duloxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02437090" sec3="Y"><name>Duloxetine DR</name><manufacturerId>TEV</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02438267" sec3="Y"><name>Ran-Duloxetine</name><manufacturerId>RAN</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02438992" sec3="Y"><name>Mint-Duloxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02439956" sec3="Y"><name>Sandoz Duloxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02440431" sec3="Y"><name>Apo-Duloxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02446103" sec3="Y"><name>Mar-Duloxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02451921" sec3="Y"><name>Jamp-Duloxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02453649" sec3="Y"><name>Duloxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02456761" sec3="Y"><name>Teva-Duloxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02457202" sec3="Y"><name>Taro-Duloxetine</name><manufacturerId>TAR</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02473216" sec3="Y"><name>M-Duloxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02475316" sec3="Y"><name>AG-Duloxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02482134" sec3="Y"><name>NRA-Duloxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02490897" sec3="Y"><name>Duloxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02512513" sec3="Y"><name>Jamp Duloxetine Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.9769</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug><drug id="02522888" sec3="Y"><name>Accel-Duloxetine</name><manufacturerId>ACC</manufacturerId><individualPrice>.7327</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.7327</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01714"><name>ESCITALOPRAM</name><pcgGroup><pcg9 id="281604127"><itemNumber>1152</itemNumber><strength>10mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02391449" notABenefit="Y" sec3="Y"><name>Cipralex MELTZ</name><manufacturerId>VLH</manufacturerId><listingDate>2014-01-03</listingDate></drug><drug id="02454297" sec3="Y"><name>Act Escitalopram ODT</name><manufacturerId>ACV</manufacturerId><individualPrice>1.3199</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>1.3199</amountMOHLTCPays></drug></pcg9><pcg9 id="281604128"><itemNumber>1153</itemNumber><strength>20mg</strength><dosageForm>Orally Disintegrating Tablet</dosageForm><drug id="02391457" notABenefit="Y" sec3="Y"><name>Cipralex MELTZ</name><manufacturerId>VLH</manufacturerId><listingDate>2014-01-03</listingDate></drug><drug id="02454300" sec3="Y"><name>Act Escitalopram ODT</name><manufacturerId>ACV</manufacturerId><individualPrice>1.4052</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>1.4052</amountMOHLTCPays></drug></pcg9><pcg9 id="281604118"><itemNumber>1154</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02263238" sec3="Y"><name>Cipralex</name><manufacturerId>VLH</manufacturerId><individualPrice>2.3358</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02295016" sec3="Y"><name>Apo-Escitalopram</name><manufacturerId>APX</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02309467" sec3="Y"><name>Mylan-Escitalopram</name><manufacturerId>MYL</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02318180" sec3="Y"><name>Teva-Escitalopram</name><manufacturerId>TEV</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02364077" sec3="Y"><name>Sandoz Escitalopram</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02385481" sec3="Y"><name>Ran-Escitalopram</name><manufacturerId>RAN</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02397358" sec3="Y"><name>Auro-Escitalopram</name><manufacturerId>AUR</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02407418" sec3="Y"><name>Mint-Escitalopram</name><manufacturerId>MIN</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02423480" sec3="Y"><name>Mar-Escitalopram</name><manufacturerId>MAR</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02429039" sec3="Y"><name>Escitalopram</name><manufacturerId>SIV</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02429780" sec3="Y"><name>Jamp-Escitalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02430118" sec3="Y"><name>Escitalopram</name><manufacturerId>SAI</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02434652" sec3="Y"><name>Ach-Escitalopram</name><manufacturerId>ACH</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02440296" sec3="Y"><name>Nat-Escitalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02469243" sec3="Y"><name>PMS-Escitalopram</name><manufacturerId>PMS</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02471418" sec3="Y"><name>M-Escitalopram</name><manufacturerId>MAT</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02476851" sec3="Y"><name>NRA-Escitalopram</name><manufacturerId>NRA</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02508893" sec3="Y"><name>Jamp Escitalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug><drug id="02554909" sec3="Y"><name>Natco-Escitalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.3109</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>.3109</amountMOHLTCPays></drug></pcg9><pcg9 id="281604119"><itemNumber>1155</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02263254" sec3="Y"><name>Cipralex</name><manufacturerId>VLH</manufacturerId><individualPrice>2.4939</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02295024" sec3="Y"><name>Apo-Escitalopram</name><manufacturerId>APX</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02309475" sec3="Y"><name>Mylan-Escitalopram</name><manufacturerId>MYL</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02318202" sec3="Y"><name>Teva-Escitalopram</name><manufacturerId>TEV</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02364085" sec3="Y"><name>Sandoz Escitalopram</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02385503" sec3="Y"><name>Ran-Escitalopram</name><manufacturerId>RAN</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02397374" sec3="Y"><name>Auro-Escitalopram</name><manufacturerId>AUR</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02407434" sec3="Y"><name>Mint-Escitalopram</name><manufacturerId>MIN</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02423502" sec3="Y"><name>Mar-Escitalopram</name><manufacturerId>MAR</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02429047" sec3="Y"><name>Escitalopram</name><manufacturerId>SIV</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02429799" sec3="Y"><name>Jamp-Escitalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02430126" sec3="Y"><name>Escitalopram</name><manufacturerId>SAI</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02434660" sec3="Y"><name>Ach-Escitalopram</name><manufacturerId>ACH</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02440318" sec3="Y"><name>Nat-Escitalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02469251" sec3="Y"><name>PMS-Escitalopram</name><manufacturerId>PMS</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02471426" sec3="Y"><name>M-Escitalopram</name><manufacturerId>MAT</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02476878" sec3="Y"><name>NRA-Escitalopram</name><manufacturerId>NRA</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02508907" sec3="Y"><name>Jamp Escitalopram</name><manufacturerId>JPC</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug><drug id="02554933" sec3="Y"><name>Natco-Escitalopram</name><manufacturerId>NAT</manufacturerId><individualPrice>.3310</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>.3310</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00505"><name>FLUOXETINE HCL</name><note>Because of the long half-life of the fluoxetine metabolite, steady-state concentrations occur only after 4-6 weeks. Use with caution in anorexic patients. Fluoxetine therapy should be discontinued for 5 weeks before starting irreversible monoamine oxidase inhibitors (MAOI). Similarly irreversible MAOI should be discontinued for 2 weeks before starting fluoxetine.</note><pcgGroup><pcg9 id="281604122"><itemNumber>1156</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02018985" notABenefit="Y" sec3b="Y" sec3="Y"><name>Prozac</name><manufacturerId>LIL</manufacturerId><listingDate>2008-02-12</listingDate></drug><drug id="02177579" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Fluoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2008-02-12</listingDate></drug><drug id="02216353" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Fluoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2008-02-12</listingDate></drug><drug id="02216582" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Fluoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2008-02-12</listingDate></drug><drug id="02242177" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Fluoxetine</name><manufacturerId>COB</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2013-06-27</listingDate></drug><drug id="02286068" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fluoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2017-06-29</listingDate></drug><drug id="02374447" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fluoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2021-02-26</listingDate></drug><drug id="02380560" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Fluoxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2012-05-29</listingDate></drug><drug id="02385627" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Fluoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02392909" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Fluoxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2012-11-27</listingDate></drug><drug id="02393441" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ach-Fluoxetine</name><manufacturerId>ACH</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02401894" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Fluoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2013-06-27</listingDate></drug><drug id="02448424" notABenefit="Y" sec3b="Y" sec3="Y"><name>Bio-Fluoxetine</name><manufacturerId>BMP</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2016-03-30</listingDate></drug><drug id="02479486" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Fluoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2019-06-28</listingDate></drug><drug id="02485052" notABenefit="Y" sec3b="Y" sec3="Y"><name>AG-Fluoxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2020-10-30</listingDate></drug><drug id="02503875" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Fluoxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2021-01-29</listingDate></drug><drug id="02529432" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Fluoxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>1.1773</individualPrice><listingDate>2023-03-31</listingDate></drug></pcg9><pcg9 id="281604051"><itemNumber>1157</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><drug id="00636622" dinStatus="E" sec3="Y"><name>Prozac</name><manufacturerId>LIL</manufacturerId><individualPrice>2.4865</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02177587" sec3="Y"><name>PMS-Fluoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3311</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02216361" sec3="Y"><name>Apo-Fluoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.3311</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02216590" sec3="Y"><name>Teva-Fluoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3311</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02242178" sec3="Y"><name>Co Fluoxetine</name><manufacturerId>COB</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02286076" sec3="Y"><name>Fluoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02374455" sec3="Y"><name>Fluoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02380579" sec3="Y"><name>Mint-Fluoxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02383241" sec3="Y"><name>Ach-Fluoxetine</name><manufacturerId>ACH</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02385635" sec3="Y"><name>Auro-Fluoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02386402" sec3="Y"><name>Jamp-Fluoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02392917" sec3="Y"><name>Mar-Fluoxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02405709" sec3="Y"><name>Ran-Fluoxetine</name><manufacturerId>RAN</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02448432" sec3="Y"><name>Bio-Fluoxetine</name><manufacturerId>BMP</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02479494" sec3="Y"><name>Sandoz Fluoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02485060" sec3="Y"><name>AG-Fluoxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02503883" sec3="Y"><name>NRA-Fluoxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug><drug id="02529440" sec3="Y"><name>M-Fluoxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>.3311</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.3311</amountMOHLTCPays></drug></pcg9><pcg9 id="281604136"><itemNumber>1158</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="02464640" sec3="Y"><name>PMS-Fluoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.6622</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.6622</amountMOHLTCPays></drug></pcg9><pcg9 id="281604137"><itemNumber>1159</itemNumber><strength>60mg</strength><dosageForm>Cap</dosageForm><drug id="02464659" sec3="Y"><name>PMS-Fluoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.9933</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.9933</amountMOHLTCPays></drug></pcg9><pcg9 id="281604064"><itemNumber>1160</itemNumber><strength>20mg/5mL</strength><dosageForm>Oral Sol</dosageForm><drug id="01917021" notABenefit="Y" sec3="Y"><name>Prozac</name><manufacturerId>LIL</manufacturerId><listingDate>2017-04-27</listingDate></drug><drug id="02231328" sec3="Y"><name>Apo-Fluoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.2158</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.2158</amountMOHLTCPays></drug><drug id="02459361" sec3="Y"><name>Odan-Fluoxetine</name><manufacturerId>ODN</manufacturerId><individualPrice>.2158</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>.2158</amountMOHLTCPays></drug><drug id="02546752" sec3="Y"><name>Jamp Fluoxetine Solution</name><manufacturerId>JPC</manufacturerId><individualPrice>.2158</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.2158</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00506"><name>FLUVOXAMINE MALEATE</name><note>Fluvoxamine therapy should be discontinued for 2 weeks before starting irreversible monoamine oxidase inhibitors (MAOI). Similarly irreversible MAOI should be discontinued for 2 weeks before starting fluvoxamine.</note><pcgGroup><pcg9 id="281604058"><itemNumber>1161</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="01919342" sec3="Y"><name>Luvox</name><manufacturerId>BGP</manufacturerId><individualPrice>1.1241</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5410</amountMOHLTCPays></drug><drug id="02231329" sec3="Y"><name>Apo-Fluvoxamine</name><manufacturerId>APX</manufacturerId><individualPrice>.5410</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.5410</amountMOHLTCPays></drug><drug id="02255529" sec3="Y"><name>Teva-Fluvoxamine</name><manufacturerId>TEV</manufacturerId><individualPrice>.5410</individualPrice><listingDate>2004-10-14</listingDate><amountMOHLTCPays>.5410</amountMOHLTCPays></drug></pcg9><pcg9 id="281604059"><itemNumber>1162</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="01919369" sec3="Y"><name>Luvox</name><manufacturerId>BGP</manufacturerId><individualPrice>2.0214</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9728</amountMOHLTCPays></drug><drug id="02231330" sec3="Y"><name>Apo-Fluvoxamine</name><manufacturerId>APX</manufacturerId><individualPrice>.9728</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.9728</amountMOHLTCPays></drug><drug id="02255537" sec3="Y"><name>Teva-Fluvoxamine</name><manufacturerId>TEV</manufacturerId><individualPrice>.9728</individualPrice><listingDate>2004-10-14</listingDate><amountMOHLTCPays>.9728</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00495"><name>IMIPRAMINE</name><pcgGroup><pcg9 id="281604013"><itemNumber>1163</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00010464" notABenefit="Y" sec3="Y"><name>Tofranil</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00360201" sec3="Y"><name>Apo-Imipramine Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.1257</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1257</amountMOHLTCPays></drug><drug id="02546337" sec3="Y"><name>Jamp Imipramine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1257</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.1257</amountMOHLTCPays></drug></pcg9><pcg9 id="281604012"><itemNumber>1164</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00010472" notABenefit="Y" sec3="Y"><name>Tofranil</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00312797" sec3="Y"><name>Apo-Imipramine Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.2316</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2316</amountMOHLTCPays></drug><drug id="02546345" sec3="Y"><name>Jamp Imipramine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2316</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.2316</amountMOHLTCPays></drug></pcg9><pcg9 id="281604011"><itemNumber>1165</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00010480" notABenefit="Y" sec3="Y"><name>Tofranil</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00326852" sec3="Y"><name>Apo-Imipramine Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.4519</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4519</amountMOHLTCPays></drug><drug id="02546353" sec3="Y"><name>Jamp Imipramine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4519</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.4519</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01529"><name>MIRTAZAPINE</name><pcgGroup><pcg9 id="281604112"><itemNumber>1166</itemNumber><strength>15mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02248542" sec3="Y"><name>Remeron RD</name><manufacturerId>OCI</manufacturerId><individualPrice>.5529</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>.4046</amountMOHLTCPays></drug><drug id="02299801" sec3="Y"><name>Auro-Mirtazapine OD</name><manufacturerId>AUR</manufacturerId><individualPrice>.4046</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.4046</amountMOHLTCPays></drug></pcg9><pcg9 id="281604113"><itemNumber>1167</itemNumber><strength>30mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02248543" sec3="Y"><name>Remeron RD</name><manufacturerId>OCI</manufacturerId><individualPrice>1.1052</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>.8087</amountMOHLTCPays></drug><drug id="02299828" sec3="Y"><name>Auro-Mirtazapine OD</name><manufacturerId>AUR</manufacturerId><individualPrice>.8087</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.8087</amountMOHLTCPays></drug></pcg9><pcg9 id="281604114"><itemNumber>1168</itemNumber><strength>45mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02248544" sec3="Y"><name>Remeron RD</name><manufacturerId>OCI</manufacturerId><individualPrice>1.6580</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>1.2132</amountMOHLTCPays></drug><drug id="02299836" sec3="Y"><name>Auro-Mirtazapine OD</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2132</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>1.2132</amountMOHLTCPays></drug></pcg9><pcg9 id="281604138"><itemNumber>1169</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="02243909" notABenefit="Y" sec3b="Y" sec3="Y"><name>Remeron</name><manufacturerId>ORG</manufacturerId><listingDate>2024-10-31</listingDate></drug><drug id="02411695" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Mirtazapine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3750</individualPrice><listingDate>2025-01-31</listingDate></drug><drug id="02496666" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mirtazapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3750</individualPrice><listingDate>2025-03-31</listingDate></drug><drug id="02532689" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mirtazapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3750</individualPrice><listingDate>2025-07-31</listingDate></drug><drug id="02541572" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Mirtazapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3750</individualPrice><listingDate>2024-10-31</listingDate></drug></pcg9><pcg9 id="281604107"><itemNumber>1170</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02243910" sec3="Y"><name>Remeron</name><manufacturerId>OCI</manufacturerId><individualPrice>1.8987</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02248762" sec3="Y"><name>PMS-Mirtazapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02250608" sec3="Y"><name>Sandoz Mirtazapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02256118" sec3="Y"><name>Mylan-Mirtazapine</name><manufacturerId>MYL</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2004-09-14</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02259354" sec3="Y"><name>Teva-Mirtazapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2004-12-21</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02286629" sec3="Y"><name>Apo-Mirtazapine</name><manufacturerId>APX</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02370689" sec3="Y"><name>Mirtazapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02411709" sec3="Y"><name>Auro-Mirtazapine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02496674" sec3="Y"><name>Mirtazapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug><drug id="02534932" sec3="Y"><name>NRA-Mirtazapine</name><manufacturerId>NRA</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug></pcg9><pcg9 id="281604139"><itemNumber>1171</itemNumber><strength>45mg</strength><dosageForm>Tab</dosageForm><drug id="02243911" notABenefit="Y" sec3b="Y" sec3="Y"><name>Remeron</name><manufacturerId>ORG</manufacturerId><listingDate>2024-10-31</listingDate></drug><drug id="02411717" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Mirtazapine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1250</individualPrice><listingDate>2025-01-31</listingDate></drug><drug id="02496682" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mirtazapine</name><manufacturerId>SIV</manufacturerId><individualPrice>1.1250</individualPrice><listingDate>2025-03-31</listingDate></drug><drug id="02541580" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Mirtazapine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.1250</individualPrice><listingDate>2024-10-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00509"><name>MOCLOBEMIDE</name><pcgGroup><pcg9 id="281604066"><itemNumber>1172</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00899348" notABenefit="Y" sec3="Y"><name>Manerix</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02232148" sec3="Y"><name>Moclobemide</name><manufacturerId>AAP</manufacturerId><individualPrice>.3400</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.3400</amountMOHLTCPays></drug></pcg9><pcg9 id="281604067"><itemNumber>1173</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="00899356" sec3="Y"><name>Manerix</name><manufacturerId>MAB</manufacturerId><individualPrice>.8946</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5295</amountMOHLTCPays></drug><drug id="02232150" sec3="Y"><name>Moclobemide</name><manufacturerId>AAP</manufacturerId><individualPrice>.5295</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.5295</amountMOHLTCPays></drug></pcg9><pcg9 id="281604084"><itemNumber>1174</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02166747" sec3="Y"><name>Manerix</name><manufacturerId>MAB</manufacturerId><individualPrice>1.7570</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>1.0399</amountMOHLTCPays></drug><drug id="02240456" sec3="Y"><name>Moclobemide</name><manufacturerId>AAP</manufacturerId><individualPrice>1.0399</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>1.0399</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00497"><name>NORTRIPTYLINE</name><pcgGroup><pcg9 id="281604016"><itemNumber>1175</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="00015229" sec3="Y"><name>Aventyl</name><manufacturerId>AAP</manufacturerId><individualPrice>.2995</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2995</amountMOHLTCPays></drug></pcg9><pcg9 id="281604015"><itemNumber>1176</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="00015237" sec3="Y"><name>Aventyl</name><manufacturerId>AAP</manufacturerId><individualPrice>.6054</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6054</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00511"><name>PAROXETINE HCL</name><pcgGroup><pcg9 id="281604094"><itemNumber>1177</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02027887" notABenefit="Y" sec3b="Y" sec3="Y"><name>Paxil</name><manufacturerId>SMJ</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02240907" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Paroxetine</name><manufacturerId>APX</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02247750" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Paroxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02248556" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Paroxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02262746" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Paroxetine</name><manufacturerId>COB</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02282844" notABenefit="Y" sec3b="Y" sec3="Y"><name>Paroxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2011-08-04</listingDate></drug><drug id="02368862" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Paroxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2012-08-27</listingDate></drug><drug id="02383276" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Paroxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2012-12-21</listingDate></drug><drug id="02388227" notABenefit="Y" sec3b="Y" sec3="Y"><name>Paroxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2020-12-18</listingDate></drug><drug id="02411946" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Paroxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2014-01-03</listingDate></drug><drug id="02421372" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Paroxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02431777" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Paroxetine Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2015-01-28</listingDate></drug><drug id="02467402" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Paroxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2021-11-30</listingDate></drug><drug id="02475537" notABenefit="Y" sec3b="Y" sec3="Y"><name>AG-Paroxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2020-11-30</listingDate></drug><drug id="02479753" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Paroxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2020-07-31</listingDate></drug><drug id="02507773" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Paroxetine Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.0430</individualPrice><listingDate>2021-07-30</listingDate></drug></pcg9><pcg9 id="281604078"><itemNumber>1178</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="01940481" sec3="Y"><name>Paxil</name><manufacturerId>GSK</manufacturerId><individualPrice>2.5021</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02240908" sec3="Y"><name>Apo-Paroxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02247751" sec3="Y"><name>PMS-Paroxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02248557" sec3="Y"><name>Teva-Paroxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02262754" sec3="Y"><name>Co Paroxetine</name><manufacturerId>COB</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2005-04-28</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02282852" sec3="Y"><name>Paroxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02368870" sec3="Y"><name>Jamp-Paroxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02383284" sec3="Y"><name>Auro-Paroxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02388235" sec3="Y"><name>Paroxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02411954" sec3="Y"><name>Mar-Paroxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02421380" sec3="Y"><name>Mint-Paroxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02431785" sec3="Y"><name>Sandoz Paroxetine Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02467410" sec3="Y"><name>M-Paroxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02475545" sec3="Y"><name>AG-Paroxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02479761" sec3="Y"><name>NRA-Paroxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug><drug id="02507781" sec3="Y"><name>Jamp Paroxetine Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.3250</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.3250</amountMOHLTCPays></drug></pcg9><pcg9 id="281604079"><itemNumber>1179</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="01940473" sec3="Y"><name>Paxil</name><manufacturerId>GSK</manufacturerId><individualPrice>2.6577</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02240909" sec3="Y"><name>Apo-Paroxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02247752" sec3="Y"><name>PMS-Paroxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02248558" sec3="Y"><name>Teva-Paroxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02282860" sec3="Y"><name>Paroxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02368889" sec3="Y"><name>Jamp-Paroxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02383292" sec3="Y"><name>Auro-Paroxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02388243" sec3="Y"><name>Paroxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02411962" sec3="Y"><name>Mar-Paroxetine</name><manufacturerId>MAR</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02421399" sec3="Y"><name>Mint-Paroxetine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02431793" sec3="Y"><name>Sandoz Paroxetine Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02467429" sec3="Y"><name>M-Paroxetine</name><manufacturerId>MAT</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02475553" sec3="Y"><name>AG-Paroxetine</name><manufacturerId>ANG</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02479788" sec3="Y"><name>NRA-Paroxetine</name><manufacturerId>NRA</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug><drug id="02507803" sec3="Y"><name>Jamp Paroxetine Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.3453</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.3453</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00498"><name>PHENELZINE SULFATE</name><pcgGroup><pcg9 id="281604017"><itemNumber>1180</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="00476552" maO="Y" sec3="Y"><name>Nardil</name><manufacturerId>SLP</manufacturerId><individualPrice>.4905</individualPrice><note>Consult the scientific literature regarding cautions and contraindications prior to prescribing and/or dispensing irreversible monoamine oxidase inhibitors.

</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4905</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01762"><name>RASAGILINE MESYLATE</name><pcgGroup><pcg9 id="281604125"><itemNumber>1181</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02284642" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Azilect</name><manufacturerId>TEI</manufacturerId><individualPrice>9.5147</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug><drug id="02404680" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Rasagiline</name><manufacturerId>APX</manufacturerId><individualPrice>6.1285</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug><drug id="02418436" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Rasagiline</name><manufacturerId>TEV</manufacturerId><individualPrice>6.1285</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug><drug id="02491974" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Rasagiline</name><manufacturerId>JPC</manufacturerId><individualPrice>6.1285</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug></pcg9><pcg9 id="281604126"><itemNumber>1182</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02284650" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Azilect</name><manufacturerId>TEI</manufacturerId><individualPrice>9.5147</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug><drug id="02404699" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Rasagiline</name><manufacturerId>APX</manufacturerId><individualPrice>6.1285</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug><drug id="02418444" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Rasagiline</name><manufacturerId>TEV</manufacturerId><individualPrice>6.1285</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug><drug id="02491982" maO="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Rasagiline</name><manufacturerId>JPC</manufacturerId><individualPrice>6.1285</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>6.1285</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00507"><name>SERTRALINE HCL</name><note>Sertraline therapy should be discontinued for 2 weeks before starting irreversible monoamine oxidase inhibitors (MAOI). Similarly irreversible MAOI should be discontinued for 2 weeks before starting sertraline.</note><pcgGroup><pcg9 id="281604093"><itemNumber>1183</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02132702" sec3="Y"><name>Zoloft</name><manufacturerId>UJC</manufacturerId><individualPrice>1.0235</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02238280" sec3="Y"><name>Apo-Sertraline</name><manufacturerId>APX</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02240485" sec3="Y"><name>Teva-Sertraline</name><manufacturerId>TEV</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02244838" sec3="Y"><name>PMS-Sertraline</name><manufacturerId>PMS</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02245159" sec3="Y"><name>Sandoz Sertraline</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02287390" sec3="Y"><name>Co Sertraline</name><manufacturerId>COB</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02353520" sec3="Y"><name>Sertraline</name><manufacturerId>SAI</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02357143" sec3="Y"><name>Jamp-Sertraline</name><manufacturerId>JPC</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02386070" sec3="Y"><name>Sertraline</name><manufacturerId>SIV</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02390906" sec3="Y"><name>Auro-Sertraline</name><manufacturerId>AUR</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02399415" sec3="Y"><name>Mar-Sertraline</name><manufacturerId>MAR</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02402378" sec3="Y"><name>Mint-Sertraline</name><manufacturerId>MIN</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02469626" sec3="Y"><name>Sertraline</name><manufacturerId>JPC</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02477882" sec3="Y"><name>AG-Sertraline</name><manufacturerId>ANG</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02488434" sec3="Y"><name>NRA-Sertraline</name><manufacturerId>NRA</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug><drug id="02530937" sec3="Y"><name>M-Sertraline</name><manufacturerId>MAT</manufacturerId><individualPrice>.1516</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.1516</amountMOHLTCPays></drug></pcg9><pcg9 id="281604060"><itemNumber>1184</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="01962817" sec3="Y"><name>Zoloft</name><manufacturerId>UJC</manufacturerId><individualPrice>2.0468</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02238281" sec3="Y"><name>Apo-Sertraline</name><manufacturerId>APX</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02240484" sec3="Y"><name>Teva-Sertraline</name><manufacturerId>TEV</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02244839" sec3="Y"><name>PMS-Sertraline</name><manufacturerId>PMS</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02245160" sec3="Y"><name>Sandoz Sertraline</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02287404" sec3="Y"><name>Co Sertraline</name><manufacturerId>COB</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02353539" sec3="Y"><name>Sertraline</name><manufacturerId>SAI</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02357151" sec3="Y"><name>Jamp-Sertraline</name><manufacturerId>JPC</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02386089" sec3="Y"><name>Sertraline</name><manufacturerId>SIV</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02390914" sec3="Y"><name>Auro-Sertraline</name><manufacturerId>AUR</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02399423" sec3="Y"><name>Mar-Sertraline</name><manufacturerId>MAR</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02402394" sec3="Y"><name>Mint-Sertraline</name><manufacturerId>MIN</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02469634" sec3="Y"><name>Sertraline</name><manufacturerId>JPC</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02477890" sec3="Y"><name>AG-Sertraline</name><manufacturerId>ANG</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02488442" sec3="Y"><name>NRA-Sertraline</name><manufacturerId>NRA</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug><drug id="02530945" sec3="Y"><name>M-Sertraline</name><manufacturerId>MAT</manufacturerId><individualPrice>.3032</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.3032</amountMOHLTCPays></drug></pcg9><pcg9 id="281604061"><itemNumber>1185</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="01962779" sec3="Y"><name>Zoloft</name><manufacturerId>UJC</manufacturerId><individualPrice>2.2301</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02238282" sec3="Y"><name>Apo-Sertraline</name><manufacturerId>APX</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02240481" sec3="Y"><name>Teva-Sertraline</name><manufacturerId>TEV</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02244840" sec3="Y"><name>PMS-Sertraline</name><manufacturerId>PMS</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02245161" sec3="Y"><name>Sandoz Sertraline</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02287412" sec3="Y"><name>Co Sertraline</name><manufacturerId>COB</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02353547" sec3="Y"><name>Sertraline</name><manufacturerId>SAI</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02357178" sec3="Y"><name>Jamp-Sertraline</name><manufacturerId>JPC</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02374579" sec3="Y"><name>Ran-Sertraline</name><manufacturerId>RAN</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02386097" sec3="Y"><name>Sertraline</name><manufacturerId>SIV</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02390922" sec3="Y"><name>Auro-Sertraline</name><manufacturerId>AUR</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02399431" sec3="Y"><name>Mar-Sertraline</name><manufacturerId>MAR</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02402408" sec3="Y"><name>Mint-Sertraline</name><manufacturerId>MIN</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02469642" sec3="Y"><name>Sertraline</name><manufacturerId>JPC</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2018-02-28</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02477904" sec3="Y"><name>AG-Sertraline</name><manufacturerId>ANG</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02488450" sec3="Y"><name>NRA-Sertraline</name><manufacturerId>NRA</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug><drug id="02530953" sec3="Y"><name>M-Sertraline</name><manufacturerId>MAT</manufacturerId><individualPrice>.3303</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.3303</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00500"><name>TRANYLCYPROMINE SULFATE</name><pcgGroup><pcg9 id="281604020"><itemNumber>1186</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="01919598" maO="Y" sec3="Y"><name>Parnate</name><manufacturerId>GSK</manufacturerId><individualPrice>.5374</individualPrice><note>Consult the scientific literature regarding cautions and contraindications prior to prescribing and/or dispensing irreversible monoamine oxidase inhibitors.

</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5374</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00504"><name>TRAZODONE HYDROCHLORIDE</name><pcgGroup><pcg9 id="281604040"><itemNumber>1187</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00579351" notABenefit="Y" sec3="Y"><name>Desyrel</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01937227" sec3="Y"><name>PMS-Trazodone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0554</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0554</amountMOHLTCPays></drug><drug id="02144263" sec3="Y"><name>Teva-Trazodone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0554</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0554</amountMOHLTCPays></drug><drug id="02147637" sec3="Y"><name>Apo-Trazodone</name><manufacturerId>APX</manufacturerId><individualPrice>.0554</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0554</amountMOHLTCPays></drug><drug id="02348772" sec3="Y"><name>Trazodone</name><manufacturerId>SAI</manufacturerId><individualPrice>.0554</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.0554</amountMOHLTCPays></drug><drug id="02442809" sec3="Y"><name>Jamp Trazodone</name><manufacturerId>JPC</manufacturerId><individualPrice>.0554</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.0554</amountMOHLTCPays></drug></pcg9><pcg9 id="281604041"><itemNumber>1188</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00579378" notABenefit="Y" sec3="Y"><name>Desyrel</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01937235" sec3="Y"><name>PMS-Trazodone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0989</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0989</amountMOHLTCPays></drug><drug id="02144271" sec3="Y"><name>Teva-Trazodone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0989</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0989</amountMOHLTCPays></drug><drug id="02147645" sec3="Y"><name>Apo-Trazodone</name><manufacturerId>APX</manufacturerId><individualPrice>.0989</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0989</amountMOHLTCPays></drug><drug id="02348780" sec3="Y"><name>Trazodone</name><manufacturerId>SAI</manufacturerId><individualPrice>.0989</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.0989</amountMOHLTCPays></drug><drug id="02442817" sec3="Y"><name>Jamp Trazodone</name><manufacturerId>JPC</manufacturerId><individualPrice>.0989</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.0989</amountMOHLTCPays></drug></pcg9><pcg9 id="281604050"><itemNumber>1189</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="00702277" notABenefit="Y" sec3="Y"><name>Desyrel Dividose</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02144298" sec3="Y"><name>Teva-Trazodone</name><manufacturerId>TEV</manufacturerId><individualPrice>.1453</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1453</amountMOHLTCPays></drug><drug id="02147653" sec3="Y"><name>Apo-Trazodone D</name><manufacturerId>APX</manufacturerId><individualPrice>.1453</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1453</amountMOHLTCPays></drug><drug id="02348799" sec3="Y"><name>Trazodone</name><manufacturerId>SAI</manufacturerId><individualPrice>.1453</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.1453</amountMOHLTCPays></drug><drug id="02442825" sec3="Y"><name>Jamp Trazodone</name><manufacturerId>JPC</manufacturerId><individualPrice>.1453</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>.1453</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00501"><name>TRIMIPRAMINE</name><pcgGroup><pcg9 id="281604033"><itemNumber>1190</itemNumber><strength>75mg</strength><dosageForm>Cap</dosageForm><drug id="01926349" notABenefit="Y" sec3="Y"><name>Surmontil</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02070987" sec3="Y"><name>Trimipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.7800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="281604024"><itemNumber>1191</itemNumber><strength>12.5mg</strength><dosageForm>Tab</dosageForm><drug id="00740799" sec3="Y"><name>Trimipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2156</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2156</amountMOHLTCPays></drug><drug id="01926357" notABenefit="Y" sec3="Y"><name>Surmontil</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281604023"><itemNumber>1192</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00740802" sec3="Y"><name>Trimipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2960</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2960</amountMOHLTCPays></drug><drug id="01926322" notABenefit="Y" sec3="Y"><name>Surmontil</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281604022"><itemNumber>1193</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00740810" sec3="Y"><name>Trimipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.5795</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5795</amountMOHLTCPays></drug><drug id="01926330" notABenefit="Y" sec3="Y"><name>Surmontil</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281604021"><itemNumber>1194</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00740829" sec3="Y"><name>Trimipramine</name><manufacturerId>AAP</manufacturerId><individualPrice>.9889</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9889</amountMOHLTCPays></drug><drug id="01926284" notABenefit="Y" sec3="Y"><name>Surmontil</name><manufacturerId>RPP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00513"><name>VENLAFAXINE  HCL</name><pcgGroup><pcg9 id="281604087"><itemNumber>1195</itemNumber><strength>37.5mg</strength><dosageForm>ER Cap</dosageForm><drug id="02237279" sec3="Y"><name>Effexor XR</name><manufacturerId>UJC</manufacturerId><individualPrice>1.1374</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02275023" sec3="Y"><name>Teva-Venlafaxine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02278545" sec3="Y"><name>PMS-Venlafaxine XR</name><manufacturerId>PMS</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02304317" sec3="Y"><name>ACT  Venlafaxine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02310317" sec3="Y"><name>Sandoz Venlafaxine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02331683" sec3="Y"><name>Apo-Venlafaxine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02354713" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02380072" sec3="Y"><name>Taro-Venlafaxine XR</name><manufacturerId>SPC</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02385929" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02452839" sec3="Y"><name>Auro-Venlafaxine XR</name><manufacturerId>AUR</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02471280" sec3="Y"><name>M-Venlafaxine XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02489678" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>RIA</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02516535" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02521466" sec3="Y"><name>PMSC-Venlafaxine XR</name><manufacturerId>PMS</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug><drug id="02522977" sec3="Y"><name>Mint-Venlafaxine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.0913</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0913</amountMOHLTCPays></drug></pcg9><pcg9 id="281604088"><itemNumber>1196</itemNumber><strength>75mg</strength><dosageForm>ER Cap</dosageForm><drug id="02237280" sec3="Y"><name>Effexor XR</name><manufacturerId>UJC</manufacturerId><individualPrice>2.2741</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02275031" sec3="Y"><name>Teva-Venlafaxine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02278553" sec3="Y"><name>PMS-Venlafaxine XR</name><manufacturerId>PMS</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02304325" sec3="Y"><name>ACT Venlafaxine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02310325" sec3="Y"><name>Sandoz Venlafaxine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02331691" sec3="Y"><name>Apo-Venlafaxine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02354721" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02380080" sec3="Y"><name>Taro-Venlafaxine XR</name><manufacturerId>SPC</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02385937" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02452847" sec3="Y"><name>Auro-Venlafaxine XR</name><manufacturerId>AUR</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02471299" sec3="Y"><name>M-Venlafaxine XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02489686" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>RIA</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02516543" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02521482" sec3="Y"><name>PMSC-Venlafaxine XR</name><manufacturerId>PMS</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug><drug id="02522985" sec3="Y"><name>Mint-Venlafaxine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.1825</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.1825</amountMOHLTCPays></drug></pcg9><pcg9 id="281604089"><itemNumber>1197</itemNumber><strength>150mg</strength><dosageForm>ER Cap</dosageForm><drug id="02237282" sec3="Y"><name>Effexor XR</name><manufacturerId>UJC</manufacturerId><individualPrice>2.4018</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02275058" sec3="Y"><name>Teva-Venlafaxine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02278561" sec3="Y"><name>PMS-Venlafaxine XR</name><manufacturerId>PMS</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02304333" sec3="Y"><name>ACT Venlafaxine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02310333" sec3="Y"><name>Sandoz Venlafaxine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02331705" sec3="Y"><name>Apo-Venlafaxine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02354748" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02380099" sec3="Y"><name>Taro-Venlafaxine XR</name><manufacturerId>SPC</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02385945" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02452855" sec3="Y"><name>Auro-Venlafaxine XR</name><manufacturerId>AUR</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02471302" sec3="Y"><name>M-Venlafaxine XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02489694" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>RIA</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02516551" sec3="Y"><name>Venlafaxine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02521474" sec3="Y"><name>PMSC-Venlafaxine XR</name><manufacturerId>PMS</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug><drug id="02522993" sec3="Y"><name>Mint-Venlafaxine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.1927</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.1927</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02413"><name>VILAZODONE HYDROCHLORIDE</name><pcgGroup><pcg9 id="281604140"><itemNumber>1198</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02443724" notABenefit="Y" sec3b="Y" sec3="Y"><name>Viibryd</name><manufacturerId>ABV</manufacturerId><listingDate>2024-12-30</listingDate></drug><drug id="02551810" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Vilazodone</name><manufacturerId>APX</manufacturerId><individualPrice>3.0482</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9><pcg9 id="281604141"><itemNumber>1199</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02443732" notABenefit="Y" sec3b="Y" sec3="Y"><name>Viibryd</name><manufacturerId>ABV</manufacturerId><listingDate>2024-12-30</listingDate></drug><drug id="02551829" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Vilazodone</name><manufacturerId>APX</manufacturerId><individualPrice>3.0482</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9><pcg9 id="281604142"><itemNumber>1200</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02443740" notABenefit="Y" sec3b="Y" sec3="Y"><name>Viibryd</name><manufacturerId>ABV</manufacturerId><listingDate>2024-12-30</listingDate></drug><drug id="02551837" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Vilazodone</name><manufacturerId>APX</manufacturerId><individualPrice>4.0577</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02142"><name>VORTIOXETINE HYDROBROMIDE</name><pcgGroup><pcg9 id="281604133"><itemNumber>1201</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02432919" sec3="Y"><name>Trintellix</name><manufacturerId>VLH</manufacturerId><individualPrice>2.8824</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>1.5853</amountMOHLTCPays></drug><drug id="02552744" sec3="Y"><name>Apo-Vortioxetine</name><manufacturerId>APX</manufacturerId><individualPrice>1.5853</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>1.5853</amountMOHLTCPays></drug></pcg9><pcg9 id="281604134"><itemNumber>1202</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02432927" sec3="Y"><name>Trintellix</name><manufacturerId>VLH</manufacturerId><individualPrice>3.0192</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>1.6606</amountMOHLTCPays></drug><drug id="02552752" sec3="Y"><name>Apo-Vortioxetine</name><manufacturerId>APX</manufacturerId><individualPrice>1.6606</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>1.6606</amountMOHLTCPays></drug></pcg9><pcg9 id="281604135"><itemNumber>1203</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02432943" sec3="Y"><name>Trintellix</name><manufacturerId>VLH</manufacturerId><individualPrice>3.2779</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>1.8028</amountMOHLTCPays></drug><drug id="02552779" sec3="Y"><name>Apo-Vortioxetine</name><manufacturerId>APX</manufacturerId><individualPrice>1.8028</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>1.8028</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="281608000"><name>PSYCHOTHERAPEUTIC AGENTS TRANQUILIZERS</name><genericName id="00540"><name>ALPRAZOLAM</name><pcgGroup><pcg9 id="281608119"><itemNumber>1204</itemNumber><strength>0.25mg</strength><dosageForm>Tab</dosageForm><drug id="00548359" sec3="Y"><name>Xanax</name><manufacturerId>UJC</manufacturerId><individualPrice>.3599</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0633</amountMOHLTCPays></drug><drug id="00865397" sec3="Y"><name>Apo-Alpraz</name><manufacturerId>APX</manufacturerId><individualPrice>.0633</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0633</amountMOHLTCPays></drug><drug id="01913484" sec3="Y"><name>Teva-Alprazolam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0633</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0633</amountMOHLTCPays></drug><drug id="02417634" dinStatus="E" sec3="Y"><name>Nat-Alprazolam</name><manufacturerId>NAT</manufacturerId><individualPrice>.0633</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.0633</amountMOHLTCPays></drug></pcg9><pcg9 id="281608118"><itemNumber>1205</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="00548367" sec3="Y"><name>Xanax</name><manufacturerId>UJC</manufacturerId><individualPrice>.4304</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0757</amountMOHLTCPays></drug><drug id="00865400" sec3="Y"><name>Apo-Alpraz</name><manufacturerId>APX</manufacturerId><individualPrice>.0757</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0757</amountMOHLTCPays></drug><drug id="01913492" sec3="Y"><name>Teva-Alprazolam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0757</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0757</amountMOHLTCPays></drug><drug id="02417642" dinStatus="E" sec3="Y"><name>Nat-Alprazolam</name><manufacturerId>NAT</manufacturerId><individualPrice>.0757</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.0757</amountMOHLTCPays></drug></pcg9><pcg9 id="281608233"><itemNumber>1206</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00723770" notABenefit="Y" sec3b="Y" sec3="Y"><name>Xanax</name><manufacturerId>UJC</manufacturerId><listingDate>2008-03-25</listingDate></drug><drug id="02243611" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Alpraz</name><manufacturerId>APX</manufacturerId><individualPrice>.6585</individualPrice><listingDate>2008-03-25</listingDate></drug><drug id="02397056" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Alprazolam</name><manufacturerId>JPC</manufacturerId><individualPrice>.4603</individualPrice><listingDate>2025-01-31</listingDate></drug><drug id="02417650" dinStatus="E" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Alprazolam</name><manufacturerId>NAT</manufacturerId><individualPrice>.3099</individualPrice><listingDate>2015-10-29</listingDate></drug></pcg9><pcg9 id="281608234"><itemNumber>1207</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00813958" notABenefit="Y" sec3b="Y" sec3="Y"><name>Xanax TS</name><manufacturerId>UJC</manufacturerId><listingDate>2008-03-25</listingDate></drug><drug id="02243612" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Alpraz TS</name><manufacturerId>APX</manufacturerId><individualPrice>1.1704</individualPrice><listingDate>2008-03-25</listingDate></drug><drug id="02397064" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Alprazolam</name><manufacturerId>JPC</manufacturerId><individualPrice>.9271</individualPrice><listingDate>2025-01-31</listingDate></drug><drug id="02417669" dinStatus="E" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Alprazolam</name><manufacturerId>NAT</manufacturerId><individualPrice>.5508</individualPrice><listingDate>2016-11-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01856"><name>ARIPIPRAZOLE</name><pcgGroup><pcg9 id="281608323"><itemNumber>1208</itemNumber><strength>300mg/Vial</strength><dosageForm>Prolong-Rel Inj Pd-Vial Pk</dosageForm><note>For the maintenance treatment of schizophrenia in patients who are stabilized on oral aripiprazole who have:

A history of non-adherence; AND one of the following:

a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02420864" sec3="Y"><name>Abilify Maintena</name><manufacturerId>OTS</manufacturerId><individualPrice>487.2002</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>487.2002</amountMOHLTCPays></drug></pcg9><pcg9 id="281608324"><itemNumber>1209</itemNumber><strength>400mg/Vial</strength><dosageForm>Prolong-Rel Inj Pd-Vial Pk</dosageForm><note>For the maintenance treatment of schizophrenia in patients who are stabilized on oral aripiprazole who have:

A history of non-adherence; AND one of the following:

a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02420872" sec3="Y"><name>Abilify Maintena</name><manufacturerId>OTS</manufacturerId><individualPrice>487.2002</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>487.2002</amountMOHLTCPays></drug></pcg9><pcg9 id="281608301"><itemNumber>1210</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.

Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><drug id="02322374" sec3="Y"><name>Abilify</name><manufacturerId>OTS</manufacturerId><individualPrice>3.3143</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02460025" sec3="Y"><name>Auro-Aripiprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02464144" sec3="Y"><name>Teva-Aripiprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02466635" sec3="Y"><name>PMS-Aripiprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02471086" sec3="Y"><name>Apo-Aripiprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02472201" sec3="Y"><name>NRA-Aripiprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02473658" sec3="Y"><name>Sandoz Aripiprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02483556" sec3="Y"><name>Mint-Aripiprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02506688" sec3="Y"><name>Aripiprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02534320" sec3="Y"><name>Aripiprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug></pcg9><pcg9 id="281608302"><itemNumber>1211</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.

Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><drug id="02322382" sec3="Y"><name>Abilify</name><manufacturerId>OTS</manufacturerId><individualPrice>3.7052</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02460033" sec3="Y"><name>Auro-Aripiprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02464152" sec3="Y"><name>Teva-Aripiprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02466643" sec3="Y"><name>PMS-Aripiprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02471094" sec3="Y"><name>Apo-Aripiprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02472228" sec3="Y"><name>NRA-Aripiprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02473666" sec3="Y"><name>Sandoz Aripiprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02483564" sec3="Y"><name>Mint-Aripiprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02506718" sec3="Y"><name>Aripiprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug><drug id="02534339" sec3="Y"><name>Aripiprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>.9046</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>.9046</amountMOHLTCPays></drug></pcg9><pcg9 id="281608303"><itemNumber>1212</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.

Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><drug id="02322390" sec3="Y"><name>Abilify</name><manufacturerId>OTS</manufacturerId><individualPrice>4.4049</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02460041" sec3="Y"><name>Auro-Aripiprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02464160" sec3="Y"><name>Teva-Aripiprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02466651" sec3="Y"><name>PMS-Aripiprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02471108" sec3="Y"><name>Apo-Aripiprazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02472244" sec3="Y"><name>NRA-Aripiprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02473674" sec3="Y"><name>Sandoz Aripiprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02483572" sec3="Y"><name>Mint-Aripiprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02506726" sec3="Y"><name>Aripiprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug><drug id="02534347" sec3="Y"><name>Aripiprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.0754</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>1.0754</amountMOHLTCPays></drug></pcg9><pcg9 id="281608304"><itemNumber>1213</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.

Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><drug id="02322404" sec3="Y"><name>Abilify</name><manufacturerId>OTS</manufacturerId><individualPrice>5.1985</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02460068" sec3="Y"><name>Auro-Aripiprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02464179" sec3="Y"><name>Teva-Aripiprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02466678" sec3="Y"><name>PMS-Aripiprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02471116" sec3="Y"><name>Apo-Aripiprazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02472252" sec3="Y"><name>NRA-Aripiprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02473682" sec3="Y"><name>Sandoz Aripiprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02483580" sec3="Y"><name>Mint-Aripiprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02506734" sec3="Y"><name>Aripiprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug><drug id="02534355" sec3="Y"><name>Aripiprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.2692</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>1.2692</amountMOHLTCPays></drug></pcg9><pcg9 id="281608305"><itemNumber>1214</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.

Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><drug id="02322412" sec3="Y"><name>Abilify</name><manufacturerId>OTS</manufacturerId><individualPrice>4.1028</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02460076" sec3="Y"><name>Auro-Aripiprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02464187" sec3="Y"><name>Teva-Aripiprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02466686" sec3="Y"><name>PMS-Aripiprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02471124" sec3="Y"><name>Apo-Aripiprazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02472260" sec3="Y"><name>NRA-Aripiprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02473690" sec3="Y"><name>Sandoz Aripiprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02483599" sec3="Y"><name>Mint-Aripiprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02506750" sec3="Y"><name>Aripiprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02534363" sec3="Y"><name>Aripiprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug></pcg9><pcg9 id="281608306"><itemNumber>1215</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><note>Notes: Subject to the specific drug&apos;s product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.

Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.

Prescribers should be informed and stay current with a drug&apos;s official indications in accordance with Health Canada&apos;s approved product monograph.</note><drug id="02322455" sec3="Y"><name>Abilify</name><manufacturerId>OTS</manufacturerId><individualPrice>4.1028</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02460084" sec3="Y"><name>Auro-Aripiprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02464195" sec3="Y"><name>Teva-Aripiprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02466694" sec3="Y"><name>PMS-Aripiprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02471132" sec3="Y"><name>Apo-Aripiprazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02472279" sec3="Y"><name>NRA-Aripiprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02473704" sec3="Y"><name>Sandoz Aripiprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02483602" sec3="Y"><name>Mint-Aripiprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02506785" sec3="Y"><name>Aripiprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug><drug id="02534371" sec3="Y"><name>Aripiprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.0017</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>1.0017</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01937"><name>ASENAPINE</name><pcgGroup><pcg9 id="281608317"><itemNumber>1216</itemNumber><strength>5mg</strength><dosageForm>SL Tab</dosageForm><note>For the acute treatment of manic or mixed episodes associated with bipolar I disorder as either:

Monotherapy, after a trial of lithium or divalproex sodium has failed, and trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response; 

OR

Co-therapy with lithium or divalproex sodium, after trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response.
</note><drug id="02374803" sec3="Y"><name>Saphris</name><manufacturerId>OCI</manufacturerId><individualPrice>1.5910</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>1.5910</amountMOHLTCPays></drug></pcg9><pcg9 id="281608318"><itemNumber>1217</itemNumber><strength>10mg</strength><dosageForm>SL Tab</dosageForm><note>For the acute treatment of manic or mixed episodes associated with bipolar I disorder as either:
Monotherapy, after a trial of lithium or divalproex sodium has failed, and trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response; 
OR
Co-therapy with lithium or divalproex sodium, after trials of less expensive atypical antipsychotic agents have failed due to intolerance or lack of response.</note><drug id="02374811" sec3="Y"><name>Saphris</name><manufacturerId>OCI</manufacturerId><individualPrice>1.5910</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>1.5910</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02079"><name>BREXPIPRAZOLE</name><pcgGroup><pcg9 id="281608344"><itemNumber>1218</itemNumber><strength>0.25mg</strength><dosageForm>Tab</dosageForm><drug id="02461749" sec3="Y"><name>Rexulti</name><manufacturerId>OTS</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608345"><itemNumber>1219</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02461757" sec3="Y"><name>Rexulti</name><manufacturerId>OTS</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608346"><itemNumber>1220</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02461765" sec3="Y"><name>Rexulti</name><manufacturerId>OTS</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608347"><itemNumber>1221</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02461773" sec3="Y"><name>Rexulti</name><manufacturerId>OTS</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608348"><itemNumber>1222</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="02461781" sec3="Y"><name>Rexulti</name><manufacturerId>OTS</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608349"><itemNumber>1223</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02461803" sec3="Y"><name>Rexulti</name><manufacturerId>OTS</manufacturerId><individualPrice>3.5000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00541"><name>BROMAZEPAM</name><pcgGroup><pcg9 id="281608146"><itemNumber>1224</itemNumber><strength>1.5mg</strength><dosageForm>Tab</dosageForm><drug id="00682314" notABenefit="Y" sec3="Y"><name>Lectopam</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02177153" sec3="Y"><name>Apo-Bromazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.1028</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1028</amountMOHLTCPays></drug></pcg9><pcg9 id="281608123"><itemNumber>1225</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="00518123" notABenefit="Y" sec3="Y"><name>Lectopam</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02177161" sec3="Y"><name>Apo-Bromazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0897</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0897</amountMOHLTCPays></drug><drug id="02230584" sec3="Y"><name>Teva-Bromazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0897</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0897</amountMOHLTCPays></drug></pcg9><pcg9 id="281608122"><itemNumber>1226</itemNumber><strength>6mg</strength><dosageForm>Tab</dosageForm><drug id="00518131" notABenefit="Y" sec3="Y"><name>Lectopam</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02177188" sec3="Y"><name>Apo-Bromazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.1310</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1310</amountMOHLTCPays></drug><drug id="02230585" sec3="Y"><name>Teva-Bromazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.1310</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1310</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02408"><name>CARIPRAZINE</name><pcgGroup><pcg9 id="281608356"><itemNumber>1227</itemNumber><strength>1.5mg</strength><dosageForm>Cap</dosageForm><drug id="02526794" sec3="Y"><name>Vraylar</name><manufacturerId>ABV</manufacturerId><individualPrice>4.9000</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>4.9000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608357"><itemNumber>1228</itemNumber><strength>3mg</strength><dosageForm>Cap</dosageForm><drug id="02526808" sec3="Y"><name>Vraylar</name><manufacturerId>ABV</manufacturerId><individualPrice>4.9000</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>4.9000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608358"><itemNumber>1229</itemNumber><strength>4.5mg</strength><dosageForm>Cap</dosageForm><drug id="02526816" sec3="Y"><name>Vraylar</name><manufacturerId>ABV</manufacturerId><individualPrice>4.9000</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>4.9000</amountMOHLTCPays></drug></pcg9><pcg9 id="281608359"><itemNumber>1230</itemNumber><strength>6mg</strength><dosageForm>Cap</dosageForm><drug id="02526824" sec3="Y"><name>Vraylar</name><manufacturerId>ABV</manufacturerId><individualPrice>4.9000</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>4.9000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00515"><name>CHLORDIAZEPOXIDE</name><pcgGroup><pcg9 id="281608003"><itemNumber>1231</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="00012629" notABenefit="Y" sec3="Y"><name>Librium</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00522724" sec3="Y"><name>Chlordiazepoxide</name><manufacturerId>AAP</manufacturerId><individualPrice>.0825</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0825</amountMOHLTCPays></drug></pcg9><pcg9 id="281608002"><itemNumber>1232</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="00012637" notABenefit="Y" sec3="Y"><name>Librium</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00522988" sec3="Y"><name>Chlordiazepoxide</name><manufacturerId>AAP</manufacturerId><individualPrice>.1115</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1115</amountMOHLTCPays></drug></pcg9><pcg9 id="281608001"><itemNumber>1233</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="00012645" notABenefit="Y" sec3="Y"><name>Librium</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00522996" sec3="Y"><name>Chlordiazepoxide</name><manufacturerId>AAP</manufacturerId><individualPrice>.2014</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2014</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00517"><name>CHLORPROMAZINE</name><pcgGroup><pcg9 id="281608009"><itemNumber>1234</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00232823" sec3="Y"><name>Teva-Chlorpromazine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2454</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2454</amountMOHLTCPays></drug><drug id="01929917" notABenefit="Y" sec3="Y"><name>Largactil</name><manufacturerId>RPP</manufacturerId><listingDate>1999-07-22</listingDate></drug></pcg9><pcg9 id="281608008"><itemNumber>1235</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00232807" sec3="Y"><name>Teva-Chlorpromazine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2808</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2808</amountMOHLTCPays></drug><drug id="01929925" notABenefit="Y" sec3="Y"><name>Largactil</name><manufacturerId>RPP</manufacturerId><listingDate>1999-07-22</listingDate></drug></pcg9><pcg9 id="281608007"><itemNumber>1236</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00232831" sec3="Y"><name>Teva-Chlorpromazine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7475</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7475</amountMOHLTCPays></drug><drug id="01929933" notABenefit="Y" sec3="Y"><name>Largactil</name><manufacturerId>RPP</manufacturerId><listingDate>1999-07-22</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00519"><name>CLORAZEPATE DIPOTASSIUM</name><pcgGroup><pcg9 id="281608022"><itemNumber>1237</itemNumber><strength>3.75mg</strength><dosageForm>Cap</dosageForm><drug id="00264938" notABenefit="Y" sec3="Y"><name>Tranxene</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00860689" sec3="Y"><name>Clorazepate</name><manufacturerId>AAP</manufacturerId><individualPrice>.1793</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1793</amountMOHLTCPays></drug></pcg9><pcg9 id="281608021"><itemNumber>1238</itemNumber><strength>7.5mg</strength><dosageForm>Cap</dosageForm><drug id="00264946" notABenefit="Y" sec3="Y"><name>Tranxene</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00860700" sec3="Y"><name>Clorazepate</name><manufacturerId>AAP</manufacturerId><individualPrice>.2337</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2337</amountMOHLTCPays></drug></pcg9><pcg9 id="281608020"><itemNumber>1239</itemNumber><strength>15mg</strength><dosageForm>Cap</dosageForm><drug id="00264911" notABenefit="Y" sec3="Y"><name>Tranxene</name><manufacturerId>ABB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00860697" sec3="Y"><name>Clorazepate</name><manufacturerId>AAP</manufacturerId><individualPrice>.4405</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4405</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00544"><name>CLOZAPINE</name><pcgGroup><pcg9 id="281608351"><itemNumber>1240</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02458748" notABenefit="Y" sec3b="Y" sec3="Y"><name>AA-Clozapine</name><manufacturerId>AAP</manufacturerId><individualPrice>1.3206</individualPrice><listingDate>2021-12-17</listingDate></drug><drug id="02490668" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clozaril</name><manufacturerId>HLS</manufacturerId><listingDate>2021-12-17</listingDate></drug></pcg9><pcg9 id="281608352"><itemNumber>1241</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02458756" notABenefit="Y" sec3b="Y" sec3="Y"><name>AA-Clozapine</name><manufacturerId>AAP</manufacturerId><individualPrice>5.2892</individualPrice><listingDate>2021-12-17</listingDate></drug><drug id="02490676" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clozaril</name><manufacturerId>HLS</manufacturerId><listingDate>2021-12-17</listingDate></drug></pcg9><pcg9 id="281608157"><itemNumber>1242</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00894737" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clozaril</name><manufacturerId>NOV</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02247243" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gen-Clozapine</name><manufacturerId>MYL</manufacturerId><individualPrice>.6594</individualPrice><listingDate>2007-09-04</listingDate></drug><drug id="02248034" notABenefit="Y" sec3b="Y" sec3="Y"><name>AA-Clozapine</name><manufacturerId>AAP</manufacturerId><individualPrice>.6594</individualPrice><listingDate>2007-09-04</listingDate></drug></pcg9><pcg9 id="281608158"><itemNumber>1243</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00894745" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clozaril</name><manufacturerId>NOV</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02247244" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gen-Clozapine</name><manufacturerId>MYL</manufacturerId><individualPrice>2.6446</individualPrice><listingDate>2007-09-04</listingDate></drug><drug id="02248035" notABenefit="Y" sec3b="Y" sec3="Y"><name>AA-Clozapine</name><manufacturerId>AAP</manufacturerId><individualPrice>2.6446</individualPrice><listingDate>2007-09-04</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00520"><name>DIAZEPAM</name><pcgGroup lccId="00274"><pcg9 id="281608205"><itemNumber>1244</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol (Preservative Free)</dosageForm><drug id="00399728" sec3="Y" sec12="Y"><name>Diazepam Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6415</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>1.6415</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup><pcgGroup><pcg9 id="281608201"><itemNumber>1245</itemNumber><strength>5mg/mL</strength><dosageForm>Rect Gel-2x 5mg Pk</dosageForm><drug id="02238162" sec3="Y"><name>Diastat</name><manufacturerId>VAL</manufacturerId><individualPrice>214.0310</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>214.0310</amountMOHLTCPays></drug></pcg9><pcg9 id="281608202"><itemNumber>1246</itemNumber><strength>5mg/mL</strength><dosageForm>Rect Gel-2x10mg Pk</dosageForm><drug id="09853340" sec3="Y"><name>Diastat</name><manufacturerId>VAL</manufacturerId><individualPrice>214.0310</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>214.0310</amountMOHLTCPays></drug></pcg9><pcg9 id="281608203"><itemNumber>1247</itemNumber><strength>5mg/mL</strength><dosageForm>Rect Gel-2x15mg Pk</dosageForm><drug id="09853430" sec3="Y"><name>Diastat</name><manufacturerId>VAL</manufacturerId><individualPrice>214.0310</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>214.0310</amountMOHLTCPays></drug></pcg9><pcg9 id="281608025"><itemNumber>1248</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00013277" notABenefit="Y" sec3="Y"><name>Valium</name><manufacturerId>HLR</manufacturerId><listingDate>2005-02-22</listingDate></drug><drug id="00405329" sec3="Y"><name>Diazepam</name><manufacturerId>AAP</manufacturerId><individualPrice>.0532</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0532</amountMOHLTCPays></drug></pcg9><pcg9 id="281608024"><itemNumber>1249</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00013285" notABenefit="Y" sec3="Y"><name>Valium</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00362158" sec3="Y"><name>Diazepam</name><manufacturerId>AAP</manufacturerId><individualPrice>.1662</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1662</amountMOHLTCPays></drug></pcg9><pcg9 id="281608023"><itemNumber>1250</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00013293" notABenefit="Y" sec3="Y"><name>Valium</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00405337" sec3="Y"><name>Diazepam</name><manufacturerId>AAP</manufacturerId><individualPrice>.1204</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1204</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00539"><name>FLUPENTIXOL DECANOATE</name><pcgGroup><pcg9 id="281608111"><itemNumber>1251</itemNumber><strength>20mg/mL</strength><dosageForm>Inj Sol-1mL Amp Pk</dosageForm><drug id="02156032" sec3="Y"><name>Fluanxol Depot</name><manufacturerId>VLH</manufacturerId><individualPrice>10.2708</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>10.2708</amountMOHLTCPays></drug></pcg9><pcg9 id="281608110"><itemNumber>1252</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Amp Pk</dosageForm><drug id="02156040" sec3="Y"><name>Fluanxol Depot</name><manufacturerId>VLH</manufacturerId><individualPrice>51.3536</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>51.3536</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00542"><name>FLUPENTIXOL DIHYDROCHLORIDE</name><pcgGroup><pcg9 id="281608134"><itemNumber>1253</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02156008" sec3="Y"><name>Fluanxol</name><manufacturerId>VLH</manufacturerId><individualPrice>.3548</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3548</amountMOHLTCPays></drug></pcg9><pcg9 id="281608130"><itemNumber>1254</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="02156016" sec3="Y"><name>Fluanxol</name><manufacturerId>VLH</manufacturerId><individualPrice>.7663</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7663</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00521"><name>FLUPHENAZINE HCL</name><pcgGroup><pcg9 id="281608030"><itemNumber>1255</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00029378" notABenefit="Y" sec3="Y"><name>Moditen HCL</name><manufacturerId>BQU</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00405345" sec3="Y"><name>Fluphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1739</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1739</amountMOHLTCPays></drug></pcg9><pcg9 id="281608029"><itemNumber>1256</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00029386" notABenefit="Y" sec3="Y"><name>Moditen HCL</name><manufacturerId>BQU</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="00410632" sec3="Y"><name>Fluphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2252</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2252</amountMOHLTCPays></drug></pcg9><pcg9 id="281608028"><itemNumber>1257</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00029408" notABenefit="Y" sec3="Y"><name>Moditen HCL</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00405361" sec3="Y"><name>Fluphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1720</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1720</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00523"><name>HALOPERIDOL</name><pcgGroup><pcg9 id="281608038"><itemNumber>1258</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="00017574" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00808652" sec3="Y"><name>Haloperidol</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.8300</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>4.8300</amountMOHLTCPays></drug></pcg9><pcg9 id="281608036"><itemNumber>1259</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="00017655" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00363685" sec3="Y"><name>Teva-Haloperidol</name><manufacturerId>TEV</manufacturerId><individualPrice>.1430</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1430</amountMOHLTCPays></drug></pcg9><pcg9 id="281608035"><itemNumber>1260</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00017663" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00363677" sec3="Y"><name>Teva-Haloperidol</name><manufacturerId>TEV</manufacturerId><individualPrice>.2148</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2148</amountMOHLTCPays></drug></pcg9><pcg9 id="281608034"><itemNumber>1261</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00017671" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00363669" sec3="Y"><name>Teva-Haloperidol</name><manufacturerId>TEV</manufacturerId><individualPrice>.3211</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3211</amountMOHLTCPays></drug></pcg9><pcg9 id="281608033"><itemNumber>1262</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00017698" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00363650" sec3="Y"><name>Teva-Haloperidol</name><manufacturerId>TEV</manufacturerId><individualPrice>.5121</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5121</amountMOHLTCPays></drug></pcg9><pcg9 id="281608101"><itemNumber>1263</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00381772" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00713449" sec3="Y"><name>Teva-Haloperidol</name><manufacturerId>TEV</manufacturerId><individualPrice>.7450</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7450</amountMOHLTCPays></drug></pcg9><pcg9 id="281608112"><itemNumber>1264</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00499579" notABenefit="Y" sec3="Y"><name>Haldol</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00768820" sec3="Y"><name>Teva-Haloperidol</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3047</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.3047</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00543"><name>HALOPERIDOL DECANOATE</name><pcgGroup><pcg9 id="281608140"><itemNumber>1265</itemNumber><strength>100mg/mL Oily</strength><dosageForm>Inj Sol-5mL Pk</dosageForm><drug id="00980803" notABenefit="Y" sec3="Y"><name>Haldol-LA</name><manufacturerId>OMC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="09853758" sec3="Y"><name>Haloperidol LA</name><manufacturerId>SDZ</manufacturerId><individualPrice>84.6150</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>84.6150</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00524"><name>HYDROXYZINE HCL</name><pcgGroup><pcg9 id="281608041"><itemNumber>1266</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="00024376" notABenefit="Y" sec3="Y"><name>Atarax</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00646059" notABenefit="Y" sec3="Y"><name>Hydroxyzine</name><manufacturerId>AAP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00738824" notABenefit="Y" sec3="Y"><name>Novo-Hydroxyzin</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608040"><itemNumber>1267</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="00024384" notABenefit="Y" sec3="Y"><name>Atarax</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00646024" notABenefit="Y" sec3="Y"><name>Hydroxyzine</name><manufacturerId>AAP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608039"><itemNumber>1268</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="00024392" notABenefit="Y" sec3="Y"><name>Atarax</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00646016" notABenefit="Y" sec3="Y"><name>Hydroxyzine</name><manufacturerId>AAP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00738840" notABenefit="Y" sec3="Y"><name>Novo-Hydroxyzin</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00536"><name>LORAZEPAM</name><pcgGroup><pcg9 id="281608136"><itemNumber>1269</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="00655740" sec3="Y"><name>Apo-Lorazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0359</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0359</amountMOHLTCPays></drug><drug id="00711101" sec3="Y"><name>Teva-Lorazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0359</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0359</amountMOHLTCPays></drug><drug id="00728187" sec3="Y"><name>PMS-Lorazepam</name><manufacturerId>PMS</manufacturerId><individualPrice>.0359</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.0359</amountMOHLTCPays></drug><drug id="02041413" sec3="Y"><name>Ativan</name><manufacturerId>PFI</manufacturerId><individualPrice>.0479</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0359</amountMOHLTCPays></drug></pcg9><pcg9 id="281608098"><itemNumber>1270</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00637742" sec3="Y"><name>Teva-Lorazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0447</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0447</amountMOHLTCPays></drug><drug id="00655759" sec3="Y"><name>Apo-Lorazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0447</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0447</amountMOHLTCPays></drug><drug id="00728195" sec3="Y"><name>PMS-Lorazepam</name><manufacturerId>PMS</manufacturerId><individualPrice>.0447</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.0447</amountMOHLTCPays></drug><drug id="02041421" sec3="Y"><name>Ativan</name><manufacturerId>PFI</manufacturerId><individualPrice>.0565</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0447</amountMOHLTCPays></drug></pcg9><pcg9 id="281608099"><itemNumber>1271</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00637750" sec3="Y"><name>Teva-Lorazepam</name><manufacturerId>TEV</manufacturerId><individualPrice>.0699</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0699</amountMOHLTCPays></drug><drug id="00655767" sec3="Y"><name>Apo-Lorazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0699</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0699</amountMOHLTCPays></drug><drug id="00728209" sec3="Y"><name>PMS-Lorazepam</name><manufacturerId>PMS</manufacturerId><individualPrice>.0699</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.0699</amountMOHLTCPays></drug><drug id="02041448" sec3="Y"><name>Ativan</name><manufacturerId>PFI</manufacturerId><individualPrice>.0885</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0699</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00555"><name>LOXAPINE SUCCINATE</name><pcgGroup><pcg9 id="281608241"><itemNumber>1272</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02170019" notABenefit="Y" sec3="Y"><name>Loxapac</name><manufacturerId>WAY</manufacturerId><listingDate>1998-03-17</listingDate></drug><drug id="02230837" sec3="Y"><name>Xylac</name><manufacturerId>PEN</manufacturerId><individualPrice>.1801</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.1801</amountMOHLTCPays></drug></pcg9><pcg9 id="281608242"><itemNumber>1273</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02170027" notABenefit="Y" sec3="Y"><name>Loxapac</name><manufacturerId>WAY</manufacturerId><listingDate>1998-11-19</listingDate></drug><drug id="02230838" sec3="Y"><name>Xylac</name><manufacturerId>PEN</manufacturerId><individualPrice>.3233</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.3233</amountMOHLTCPays></drug></pcg9><pcg9 id="281608243"><itemNumber>1274</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02170132" notABenefit="Y" sec3="Y"><name>Loxapac</name><manufacturerId>WAY</manufacturerId><listingDate>1998-11-19</listingDate></drug><drug id="02230839" sec3="Y"><name>Xylac</name><manufacturerId>PEN</manufacturerId><individualPrice>.5012</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.5012</amountMOHLTCPays></drug></pcg9><pcg9 id="281608244"><itemNumber>1275</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02170035" notABenefit="Y" sec3="Y"><name>Loxapac</name><manufacturerId>WAY</manufacturerId><listingDate>1998-03-17</listingDate></drug><drug id="02230840" sec3="Y"><name>Xylac</name><manufacturerId>PEN</manufacturerId><individualPrice>.6197</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.6197</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01945"><name>LURASIDONE HYDROCHLORIDE</name><pcgGroup><pcg9 id="281608332"><itemNumber>1276</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><note>For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.</note><drug id="02422050" sec3="Y"><name>Latuda</name><manufacturerId>SUO</manufacturerId><individualPrice>4.2500</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02504499" sec3="Y"><name>Taro-Lurasidone</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02505878" sec3="Y"><name>PMS-Lurasidone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02513986" sec3="Y"><name>Auro-Lurasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02516438" sec3="Y"><name>Jamp Lurasidone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02521075" sec3="Y"><name>Sandoz Lurasidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02522314" sec3="Y"><name>NRA-Lurasidone</name><manufacturerId>NRA</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02548585" sec3="Y"><name>Lurasidone</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug></pcg9><pcg9 id="281608319"><itemNumber>1277</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><note>For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.


Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.</note><drug id="02387751" sec3="Y"><name>Latuda</name><manufacturerId>SUO</manufacturerId><individualPrice>4.9000</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02504502" sec3="Y"><name>Taro-Lurasidone</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02505886" sec3="Y"><name>PMS-Lurasidone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02513994" sec3="Y"><name>Auro-Lurasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02516446" sec3="Y"><name>Jamp Lurasidone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02521091" sec3="Y"><name>Sandoz Lurasidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02522322" sec3="Y"><name>NRA-Lurasidone</name><manufacturerId>NRA</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02548593" sec3="Y"><name>Lurasidone</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug></pcg9><pcg9 id="281608333"><itemNumber>1278</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><note>For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.</note><drug id="02413361" sec3="Y"><name>Latuda</name><manufacturerId>SUO</manufacturerId><individualPrice>4.9000</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02504510" sec3="Y"><name>Taro-Lurasidone</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02505894" sec3="Y"><name>PMS-Lurasidone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02514001" sec3="Y"><name>Auro-Lurasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02516454" sec3="Y"><name>Jamp Lurasidone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02521105" sec3="Y"><name>Sandoz Lurasidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02522330" sec3="Y"><name>NRA-Lurasidone</name><manufacturerId>NRA</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02548607" sec3="Y"><name>Lurasidone</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug></pcg9><pcg9 id="281608320"><itemNumber>1279</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><note>For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.


Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.</note><drug id="02387778" sec3="Y"><name>Latuda</name><manufacturerId>SUO</manufacturerId><individualPrice>4.5000</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02504529" sec3="Y"><name>Taro-Lurasidone</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02505908" sec3="Y"><name>PMS-Lurasidone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02514028" sec3="Y"><name>Auro-Lurasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02516462" sec3="Y"><name>Jamp Lurasidone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02521113" sec3="Y"><name>Sandoz Lurasidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02522349" sec3="Y"><name>NRA-Lurasidone</name><manufacturerId>NRA</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02548615" sec3="Y"><name>Lurasidone</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug></pcg9><pcg9 id="281608321"><itemNumber>1280</itemNumber><strength>120mg</strength><dosageForm>Tab</dosageForm><note>For the management of the manifestations of schizophrenia after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.


Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.</note><drug id="02387786" notABenefit="Y" sec3="Y"><name>Latuda</name><manufacturerId>SUO</manufacturerId><listingDate>2014-05-29</listingDate></drug><drug id="02504537" sec3="Y"><name>Taro-Lurasidone</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02505916" sec3="Y"><name>PMS-Lurasidone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02514036" sec3="Y"><name>Auro-Lurasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02516470" sec3="Y"><name>Jamp Lurasidone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug><drug id="02521121" sec3="Y"><name>Sandoz Lurasidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2250</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>1.2250</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00553"><name>OLANZAPINE</name><pcgGroup><pcg9 id="281608206"><itemNumber>1281</itemNumber><strength>5mg</strength><dosageForm>Rapid Dissolve Tab</dosageForm><drug id="02243086" sec3="Y"><name>Zyprexa Zydis</name><manufacturerId>LIL</manufacturerId><individualPrice>4.4982</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02303191" sec3="Y"><name>PMS-Olanzapine ODT</name><manufacturerId>PMS</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02327562" sec3="Y"><name>Act Olanzapine ODT</name><manufacturerId>TEV</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02327775" sec3="Y"><name>Sandoz Olanzapine ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02343665" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SIV</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02352974" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SAI</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02360616" sec3="Y"><name>Apo-Olanzapine ODT</name><manufacturerId>APX</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02406624" sec3="Y"><name>Jamp-Olanzapine ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02414090" sec3="Y"><name>Ran-Olanzapine ODT</name><manufacturerId>RAN</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02436965" sec3="Y"><name>Mint-Olanzapine ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02448726" sec3="Y"><name>Auro-Olanzapine ODT</name><manufacturerId>AUR</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug><drug id="02536188" sec3="Y"><name>NRA-Olanzapine ODT</name><manufacturerId>NRA</manufacturerId><individualPrice>.3574</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.3574</amountMOHLTCPays></drug></pcg9><pcg9 id="281608207"><itemNumber>1282</itemNumber><strength>10mg</strength><dosageForm>Rapid Dissolve Tab</dosageForm><drug id="02243087" sec3="Y"><name>Zyprexa Zydis</name><manufacturerId>LIL</manufacturerId><individualPrice>8.9886</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02303205" sec3="Y"><name>PMS-Olanzapine ODT</name><manufacturerId>PMS</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02321351" sec3="Y"><name>Novo-Olanzapine OD</name><manufacturerId>NOP</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02327570" sec3="Y"><name>Act Olanzapine ODT</name><manufacturerId>TEV</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02327783" sec3="Y"><name>Sandoz Olanzapine ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02343673" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SIV</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02352982" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SAI</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02360624" sec3="Y"><name>Apo-Olanzapine ODT</name><manufacturerId>APX</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02406632" sec3="Y"><name>Jamp-Olanzapine ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02414104" sec3="Y"><name>Ran-Olanzapine ODT</name><manufacturerId>RAN</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02436973" sec3="Y"><name>Mint-Olanzapine ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02448734" sec3="Y"><name>Auro-Olanzapine ODT</name><manufacturerId>AUR</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug><drug id="02536196" sec3="Y"><name>NRA-Olanzapine ODT</name><manufacturerId>NRA</manufacturerId><individualPrice>.7143</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.7143</amountMOHLTCPays></drug></pcg9><pcg9 id="281608225"><itemNumber>1283</itemNumber><strength>15mg</strength><dosageForm>Rapid Dissolve Tab</dosageForm><drug id="02243088" sec3="Y"><name>Zyprexa Zydis</name><manufacturerId>LIL</manufacturerId><individualPrice>13.5861</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02303213" sec3="Y"><name>PMS-Olanzapine ODT</name><manufacturerId>PMS</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02321378" sec3="Y"><name>Novo-Olanzapine OD</name><manufacturerId>NOP</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02327589" sec3="Y"><name>Act Olanzapine ODT</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02327791" sec3="Y"><name>Sandoz Olanzapine ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02343681" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SIV</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02352990" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SAI</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02360632" sec3="Y"><name>Apo-Olanzapine ODT</name><manufacturerId>APX</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02406640" sec3="Y"><name>Jamp-Olanzapine ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02414112" sec3="Y"><name>Ran-Olanzapine ODT</name><manufacturerId>RAN</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02436981" sec3="Y"><name>Mint-Olanzapine ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02448742" sec3="Y"><name>Auro-Olanzapine ODT</name><manufacturerId>AUR</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug><drug id="02536218" sec3="Y"><name>NRA-Olanzapine ODT</name><manufacturerId>NRA</manufacturerId><individualPrice>1.0711</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>1.0711</amountMOHLTCPays></drug></pcg9><pcg9 id="281608249"><itemNumber>1284</itemNumber><strength>20mg</strength><dosageForm>Rapid Dissolve Tab</dosageForm><drug id="02243089" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zyprexa Zydis</name><manufacturerId>LIL</manufacturerId><listingDate>2010-01-05</listingDate></drug><drug id="02327597" notABenefit="Y" sec3b="Y" sec3="Y"><name>Act Olanzapine ODT</name><manufacturerId>TEV</manufacturerId><individualPrice>7.5978</individualPrice><listingDate>2010-01-05</listingDate></drug><drug id="02327805" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Olanzapine ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>7.5978</individualPrice><listingDate>2010-01-05</listingDate></drug><drug id="02343703" notABenefit="Y" sec3b="Y" sec3="Y"><name>Olanzapine ODT</name><manufacturerId>SIV</manufacturerId><individualPrice>7.5977</individualPrice><listingDate>2020-12-18</listingDate></drug><drug id="02360640" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Olanzapine ODT</name><manufacturerId>APX</manufacturerId><individualPrice>7.5977</individualPrice><listingDate>2011-06-08</listingDate></drug><drug id="02406659" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Olanzapine ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>7.5977</individualPrice><listingDate>2013-08-29</listingDate></drug><drug id="02414120" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Olanzapine ODT</name><manufacturerId>RAN</manufacturerId><individualPrice>7.5979</individualPrice><listingDate>2014-01-03</listingDate></drug><drug id="02437007" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Olanzapine ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>7.5977</individualPrice><listingDate>2015-07-29</listingDate></drug><drug id="02448750" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Olanzapine ODT</name><manufacturerId>AUR</manufacturerId><individualPrice>7.5977</individualPrice><listingDate>2017-05-31</listingDate></drug><drug id="02536226" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Olanzapine ODT</name><manufacturerId>NRA</manufacturerId><individualPrice>7.5977</individualPrice><listingDate>2024-08-30</listingDate></drug></pcg9><pcg9 id="281608195"><itemNumber>1285</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02229250" sec3="Y"><name>Zyprexa</name><manufacturerId>LIL</manufacturerId><individualPrice>2.2996</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02276712" sec3="Y"><name>Teva-Olanzapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2007-07-12</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02281791" sec3="Y"><name>Apo-Olanzapine</name><manufacturerId>APX</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02303116" sec3="Y"><name>PMS-Olanzapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02310341" sec3="Y"><name>Sandoz Olanzapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02325659" sec3="Y"><name>Co Olanzapine</name><manufacturerId>COB</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02372819" sec3="Y"><name>Olanzapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02385864" sec3="Y"><name>Olanzapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02410141" sec3="Y"><name>Mint-Olanzapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02417243" sec3="Y"><name>Jamp Olanzapine FC</name><manufacturerId>JPC</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02487608" sec3="Y"><name>AG-Olanzapine FC</name><manufacturerId>ANG</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug><drug id="02545586" sec3="Y"><name>NRA-Olanzapine</name><manufacturerId>NRA</manufacturerId><individualPrice>.1772</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.1772</amountMOHLTCPays></drug></pcg9><pcg9 id="281608187"><itemNumber>1286</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02229269" sec3="Y"><name>Zyprexa</name><manufacturerId>LIL</manufacturerId><individualPrice>4.5232</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02276720" sec3="Y"><name>Teva-Olanzapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2007-07-12</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02281805" sec3="Y"><name>Apo-Olanzapine</name><manufacturerId>APX</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02303159" sec3="Y"><name>PMS-Olanzapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02310368" sec3="Y"><name>Sandoz Olanzapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02325667" sec3="Y"><name>Co Olanzapine</name><manufacturerId>COB</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02372827" sec3="Y"><name>Olanzapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02385872" sec3="Y"><name>Olanzapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02403072" sec3="Y"><name>Ran-Olanzapine</name><manufacturerId>RAN</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02410168" sec3="Y"><name>Mint-Olanzapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02417251" sec3="Y"><name>Jamp Olanzapine FC</name><manufacturerId>JPC</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02487616" sec3="Y"><name>AG-Olanzapine FC</name><manufacturerId>ANG</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug><drug id="02545594" sec3="Y"><name>NRA-Olanzapine</name><manufacturerId>NRA</manufacturerId><individualPrice>.3544</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.3544</amountMOHLTCPays></drug></pcg9><pcg9 id="281608188"><itemNumber>1287</itemNumber><strength>7.5mg</strength><dosageForm>Tab</dosageForm><drug id="02229277" sec3="Y"><name>Zyprexa</name><manufacturerId>LIL</manufacturerId><individualPrice>6.7850</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02276739" sec3="Y"><name>Teva-Olanzapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2007-07-12</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02281813" sec3="Y"><name>Apo-Olanzapine</name><manufacturerId>APX</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02303167" sec3="Y"><name>PMS-Olanzapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02310376" sec3="Y"><name>Sandoz Olanzapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02325675" sec3="Y"><name>Co Olanzapine</name><manufacturerId>COB</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02372835" sec3="Y"><name>Olanzapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02385880" sec3="Y"><name>Olanzapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02410176" sec3="Y"><name>Mint-Olanzapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02417278" sec3="Y"><name>Jamp Olanzapine FC</name><manufacturerId>JPC</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug><drug id="02545608" sec3="Y"><name>NRA-Olanzapine</name><manufacturerId>NRA</manufacturerId><individualPrice>.5316</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.5316</amountMOHLTCPays></drug></pcg9><pcg9 id="281608248"><itemNumber>1288</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02238851" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zyprexa</name><manufacturerId>LIL</manufacturerId><listingDate>2010-01-05</listingDate></drug><drug id="02325713" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Olanzapine</name><manufacturerId>COB</manufacturerId><individualPrice>10.3093</individualPrice><listingDate>2010-01-05</listingDate></drug><drug id="02333015" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Olanzapine</name><manufacturerId>APX</manufacturerId><individualPrice>10.3093</individualPrice><listingDate>2010-01-05</listingDate></drug><drug id="02359707" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Olanzapine</name><manufacturerId>TEV</manufacturerId><individualPrice>10.3093</individualPrice><listingDate>2011-09-15</listingDate></drug><drug id="02385910" notABenefit="Y" sec3b="Y" sec3="Y"><name>Olanzapine</name><manufacturerId>SIV</manufacturerId><individualPrice>10.3093</individualPrice><listingDate>2023-08-31</listingDate></drug><drug id="02417308" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Olanzapine FC</name><manufacturerId>JPC</manufacturerId><individualPrice>10.3093</individualPrice><listingDate>2015-11-26</listingDate></drug><drug id="02545632" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Olanzapine</name><manufacturerId>NRA</manufacturerId><individualPrice>10.3093</individualPrice><listingDate>2025-01-31</listingDate></drug></pcg9><pcg9 id="281608189"><itemNumber>1289</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02229285" sec3="Y"><name>Zyprexa</name><manufacturerId>LIL</manufacturerId><individualPrice>9.0468</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02276747" sec3="Y"><name>Teva-Olanzapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2007-07-12</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02281821" sec3="Y"><name>Apo-Olanzapine</name><manufacturerId>APX</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02303175" sec3="Y"><name>PMS-Olanzapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02310384" sec3="Y"><name>Sandoz Olanzapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02325683" sec3="Y"><name>Co Olanzapine</name><manufacturerId>COB</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02372843" sec3="Y"><name>Olanzapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02385899" sec3="Y"><name>Olanzapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02403099" sec3="Y"><name>Ran-Olanzapine</name><manufacturerId>RAN</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02410184" sec3="Y"><name>Mint-Olanzapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02417286" sec3="Y"><name>Jamp Olanzapine FC</name><manufacturerId>JPC</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02487632" sec3="Y"><name>AG-Olanzapine FC</name><manufacturerId>ANG</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug><drug id="02545616" sec3="Y"><name>NRA-Olanzapine</name><manufacturerId>NRA</manufacturerId><individualPrice>.7088</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.7088</amountMOHLTCPays></drug></pcg9><pcg9 id="281608211"><itemNumber>1290</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="02238850" sec3="Y"><name>Zyprexa</name><manufacturerId>LIL</manufacturerId><individualPrice>13.8011</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02276755" sec3="Y"><name>Teva-Olanzapine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2007-07-12</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02281848" sec3="Y"><name>Apo-Olanzapine</name><manufacturerId>APX</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02303183" sec3="Y"><name>PMS-Olanzapine</name><manufacturerId>PMS</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02310392" sec3="Y"><name>Sandoz Olanzapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02325691" sec3="Y"><name>Co Olanzapine</name><manufacturerId>COB</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02372851" sec3="Y"><name>Olanzapine</name><manufacturerId>SAI</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02385902" sec3="Y"><name>Olanzapine</name><manufacturerId>SIV</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02403102" sec3="Y"><name>Ran-Olanzapine</name><manufacturerId>RAN</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02410192" sec3="Y"><name>Mint-Olanzapine</name><manufacturerId>MIN</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02417294" sec3="Y"><name>Jamp Olanzapine FC</name><manufacturerId>JPC</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug><drug id="02545624" sec3="Y"><name>NRA-Olanzapine</name><manufacturerId>NRA</manufacturerId><individualPrice>1.0631</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>1.0631</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00528"><name>OXAZEPAM</name><pcgGroup><pcg9 id="281608052"><itemNumber>1291</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00402680" sec3="Y"><name>Apo-Oxazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0350</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0350</amountMOHLTCPays></drug><drug id="02043653" notABenefit="Y" sec3="Y"><name>Serax</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608051"><itemNumber>1292</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="00402745" sec3="Y"><name>Apo-Oxazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0550</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0550</amountMOHLTCPays></drug><drug id="02043661" notABenefit="Y" sec3="Y"><name>Serax</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608050"><itemNumber>1293</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="00402737" sec3="Y"><name>Apo-Oxazepam</name><manufacturerId>APX</manufacturerId><individualPrice>.0750</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0750</amountMOHLTCPays></drug><drug id="02043688" notABenefit="Y" sec3="Y"><name>Serax</name><manufacturerId>WAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01759"><name>PALIPERIDONE</name><pcgGroup><pcg9 id="281608245"><itemNumber>1294</itemNumber><strength>3mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300273" sec3="Y"><name>Invega</name><manufacturerId>JAN</manufacturerId><individualPrice>4.5570</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>4.5570</amountMOHLTCPays></drug></pcg9><pcg9 id="281608246"><itemNumber>1295</itemNumber><strength>6mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300281" sec3="Y"><name>Invega</name><manufacturerId>JAN</manufacturerId><individualPrice>6.8160</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>6.8160</amountMOHLTCPays></drug></pcg9><pcg9 id="281608247"><itemNumber>1296</itemNumber><strength>9mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300303" sec3="Y"><name>Invega</name><manufacturerId>JAN</manufacturerId><individualPrice>9.0850</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>9.0850</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01871"><name>PALIPERIDONE PALMITATE</name><pcgGroup><pcg9 id="281608307"><itemNumber>1297</itemNumber><strength>50mg</strength><dosageForm>Inj Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02354217" sec3="Y"><name>Invega Sustenna</name><manufacturerId>JAN</manufacturerId><individualPrice>327.4500</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>327.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="281608308"><itemNumber>1298</itemNumber><strength>75mg</strength><dosageForm>Inj Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02354225" sec3="Y"><name>Invega Sustenna</name><manufacturerId>JAN</manufacturerId><individualPrice>491.1800</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>491.1800</amountMOHLTCPays></drug></pcg9><pcg9 id="281608309"><itemNumber>1299</itemNumber><strength>100mg</strength><dosageForm>Inj Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02354233" sec3="Y"><name>Invega Sustenna</name><manufacturerId>JAN</manufacturerId><individualPrice>544.4400</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>544.4400</amountMOHLTCPays></drug></pcg9><pcg9 id="281608310"><itemNumber>1300</itemNumber><strength>150mg</strength><dosageForm>Inj Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot 
antipsychotic agents.</note><drug id="02354241" sec3="Y"><name>Invega Sustenna</name><manufacturerId>JAN</manufacturerId><individualPrice>725.9100</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>725.9100</amountMOHLTCPays></drug></pcg9><pcg9 id="281608334"><itemNumber>1301</itemNumber><strength>175mg/0.875mL</strength><dosageForm>Inj Susp-Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:

A history of non-adherence

AND 

One of the following:

a)       Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

b)       Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. 

AND

Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.</note><drug id="02455943" sec3="Y"><name>Invega Trinza</name><manufacturerId>JAN</manufacturerId><individualPrice>953.7300</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>953.7300</amountMOHLTCPays></drug></pcg9><pcg9 id="281608335"><itemNumber>1302</itemNumber><strength>263mg/1.315mL</strength><dosageForm>Inj Susp-Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:

A history of non-adherence

AND 

One of the following:

a)       Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

b)       Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. 

AND

Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.</note><drug id="02455986" sec3="Y"><name>Invega Trinza</name><manufacturerId>JAN</manufacturerId><individualPrice>1430.6100</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1430.6100</amountMOHLTCPays></drug></pcg9><pcg9 id="281608336"><itemNumber>1303</itemNumber><strength>350mg/1.75mL</strength><dosageForm>Inj Susp-Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:

A history of non-adherence

AND 

One of the following:

a)       Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

b)       Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. 

AND

Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.</note><drug id="02455994" sec3="Y"><name>Invega Trinza</name><manufacturerId>JAN</manufacturerId><individualPrice>1430.6100</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1430.6100</amountMOHLTCPays></drug></pcg9><pcg9 id="281608337"><itemNumber>1304</itemNumber><strength>525mg/2.625mL</strength><dosageForm>Inj Susp-Pref Syr</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:

A history of non-adherence

AND 

One of the following:

a)       Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

b)       Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents. 

AND

Adequate treatment of using 1-month paliperidone palmitate prolonged-release injectable suspension has been established for at least four months.</note><drug id="02456001" sec3="Y"><name>Invega Trinza</name><manufacturerId>JAN</manufacturerId><individualPrice>1907.4900</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1907.4900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00527"><name>PERICYAZINE</name><pcgGroup><pcg9 id="281608054"><itemNumber>1305</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="01926780" sec3="Y"><name>Neuleptil</name><manufacturerId>SLP</manufacturerId><individualPrice>.2566</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2566</amountMOHLTCPays></drug></pcg9><pcg9 id="281608053"><itemNumber>1306</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="01926772" sec3="Y"><name>Neuleptil</name><manufacturerId>SLP</manufacturerId><individualPrice>.4428</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4428</amountMOHLTCPays></drug></pcg9><pcg9 id="281608049"><itemNumber>1307</itemNumber><strength>10mg/mL</strength><dosageForm>O/L</dosageForm><drug id="01926756" sec3="Y"><name>Neuleptil</name><manufacturerId>SLP</manufacturerId><individualPrice>.4450</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4450</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00529"><name>PERPHENAZINE</name><pcgGroup><pcg9 id="281608057"><itemNumber>1308</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00028290" notABenefit="Y" sec3="Y"><name>Trilafon</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00335134" sec3="Y"><name>Perphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.0668</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0668</amountMOHLTCPays></drug></pcg9><pcg9 id="281608056"><itemNumber>1309</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="00028304" notABenefit="Y" sec3="Y"><name>Trilafon</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00335126" sec3="Y"><name>Perphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.0808</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0808</amountMOHLTCPays></drug></pcg9><pcg9 id="281608055"><itemNumber>1310</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="00028312" notABenefit="Y" sec3="Y"><name>Trilafon</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00335118" sec3="Y"><name>Perphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.0888</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0888</amountMOHLTCPays></drug></pcg9><pcg9 id="281608097"><itemNumber>1311</itemNumber><strength>16mg</strength><dosageForm>Tab</dosageForm><drug id="00028320" notABenefit="Y" sec3="Y"><name>Trilafon</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00335096" sec3="Y"><name>Perphenazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1359</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1359</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00535"><name>PIMOZIDE</name><pcgGroup><pcg9 id="281608096"><itemNumber>1312</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00313815" sec3="Y"><name>Orap</name><manufacturerId>AAP</manufacturerId><individualPrice>.2279</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02245432" sec3="Y"><name>Pimozide</name><manufacturerId>AAP</manufacturerId><individualPrice>.3093</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug></pcg9><pcg9 id="281608095"><itemNumber>1313</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="00313823" sec3="Y"><name>Orap</name><manufacturerId>AAP</manufacturerId><individualPrice>.4136</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4136</amountMOHLTCPays></drug><drug id="02245433" sec3="Y"><name>Pimozide</name><manufacturerId>AAP</manufacturerId><individualPrice>.4136</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4136</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00530"><name>PROCHLORPERAZINE</name><pcgGroup><pcg9 id="281608063"><itemNumber>1314</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00886440" sec3="Y"><name>Prochlorazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1659</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.1659</amountMOHLTCPays></drug><drug id="01927752" notABenefit="Y" sec3="Y"><name>Stemetil</name><manufacturerId>AVE</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608062"><itemNumber>1315</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00886432" sec3="Y"><name>Prochlorazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2025</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.2025</amountMOHLTCPays></drug><drug id="01927760" notABenefit="Y" sec3="Y"><name>Stemetil</name><manufacturerId>AVE</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01361"><name>QUETIAPINE</name><pcgGroup><pcg9 id="281608235"><itemNumber>1316</itemNumber><strength>50mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300184" sec3="Y"><name>Seroquel XR</name><manufacturerId>AZC</manufacturerId><individualPrice>1.1297</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02395444" sec3="Y"><name>Teva-Quetiapine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02407671" sec3="Y"><name>Sandoz Quetiapine XRT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02417359" sec3="Y"><name>Quetiapine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02450860" sec3="Y"><name>Ach-Quetiapine Fumarate XR</name><manufacturerId>ACH</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02457229" sec3="Y"><name>Apo-Quetiapine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02510677" sec3="Y"><name>NRA-Quetiapine XR</name><manufacturerId>NRA</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02516616" sec3="Y"><name>Quetiapine Fumarate XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02519607" sec3="Y"><name>Quetiapine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02522187" sec3="Y"><name>Mint-Quetiapine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug><drug id="02527928" sec3="Y"><name>M-Quetiapine Fumarate XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.2501</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.2501</amountMOHLTCPays></drug></pcg9><pcg9 id="281608256"><itemNumber>1317</itemNumber><strength>150mg</strength><dosageForm>ER Tab</dosageForm><drug id="02321513" sec3="Y"><name>Seroquel XR</name><manufacturerId>AZC</manufacturerId><individualPrice>2.2253</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02395452" sec3="Y"><name>Teva-Quetiapine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02407698" sec3="Y"><name>Sandoz Quetiapine XRT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02417367" sec3="Y"><name>Quetiapine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02450879" sec3="Y"><name>Ach-Quetiapine Fumarate XR</name><manufacturerId>ACH</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02457237" sec3="Y"><name>Apo-Quetiapine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02510685" sec3="Y"><name>NRA-Quetiapine XR</name><manufacturerId>NRA</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02516624" sec3="Y"><name>Quetiapine Fumarate XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02519615" sec3="Y"><name>Quetiapine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02522195" sec3="Y"><name>Mint-Quetiapine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug><drug id="02527936" sec3="Y"><name>M-Quetiapine Fumarate XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.4926</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.4926</amountMOHLTCPays></drug></pcg9><pcg9 id="281608236"><itemNumber>1318</itemNumber><strength>200mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300192" sec3="Y"><name>Seroquel XR</name><manufacturerId>AZC</manufacturerId><individualPrice>3.0091</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02395460" sec3="Y"><name>Teva-Quetiapine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02407701" sec3="Y"><name>Sandoz Quetiapine XRT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02417375" sec3="Y"><name>Quetiapine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02450887" sec3="Y"><name>Ach-Quetiapine Fumarate XR</name><manufacturerId>ACH</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02457245" sec3="Y"><name>Apo-Quetiapine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02510693" sec3="Y"><name>NRA-Quetiapine XR</name><manufacturerId>NRA</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02516632" sec3="Y"><name>Quetiapine Fumarate XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02519623" sec3="Y"><name>Quetiapine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02522209" sec3="Y"><name>Mint-Quetiapine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug><drug id="02527944" sec3="Y"><name>M-Quetiapine Fumarate XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.6661</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.6661</amountMOHLTCPays></drug></pcg9><pcg9 id="281608237"><itemNumber>1319</itemNumber><strength>300mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300206" sec3="Y"><name>Seroquel XR</name><manufacturerId>AZC</manufacturerId><individualPrice>4.4162</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02395479" sec3="Y"><name>Teva-Quetiapine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02407728" sec3="Y"><name>Sandoz Quetiapine XRT</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02417383" sec3="Y"><name>Quetiapine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02450895" sec3="Y"><name>Ach-Quetiapine Fumarate XR</name><manufacturerId>ACH</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02457253" sec3="Y"><name>Apo-Quetiapine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02510707" sec3="Y"><name>NRA-Quetiapine XR</name><manufacturerId>NRA</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02516640" sec3="Y"><name>Quetiapine Fumarate XR</name><manufacturerId>SAI</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02519747" sec3="Y"><name>Quetiapine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02522217" sec3="Y"><name>Mint-Quetiapine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug><drug id="02527952" sec3="Y"><name>M-Quetiapine Fumarate XR</name><manufacturerId>MAT</manufacturerId><individualPrice>.9776</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.9776</amountMOHLTCPays></drug></pcg9><pcg9 id="281608238"><itemNumber>1320</itemNumber><strength>400mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300214" sec3="Y"><name>Seroquel XR</name><manufacturerId>AZC</manufacturerId><individualPrice>5.9951</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02395487" sec3="Y"><name>Teva-Quetiapine XR</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02407736" sec3="Y"><name>Sandoz Quetiapine XRT</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02417391" sec3="Y"><name>Quetiapine XR</name><manufacturerId>SIV</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02450909" sec3="Y"><name>Ach-Quetiapine Fumarate XR</name><manufacturerId>ACH</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02457261" sec3="Y"><name>Apo-Quetiapine XR</name><manufacturerId>APX</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02510715" sec3="Y"><name>NRA-Quetiapine XR</name><manufacturerId>NRA</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02516659" sec3="Y"><name>Quetiapine Fumarate XR</name><manufacturerId>SAI</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02519763" sec3="Y"><name>Quetiapine XR</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02522225" sec3="Y"><name>Mint-Quetiapine XR</name><manufacturerId>MIN</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug><drug id="02527960" sec3="Y"><name>M-Quetiapine Fumarate XR</name><manufacturerId>MAT</manufacturerId><individualPrice>1.3270</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>1.3270</amountMOHLTCPays></drug></pcg9><pcg9 id="281608191"><itemNumber>1321</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02236951" sec3="Y"><name>Seroquel</name><manufacturerId>AZC</manufacturerId><individualPrice>.5383</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02284235" sec3="Y"><name>Teva-Quetiapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02296551" sec3="Y"><name>PMS-Quetiapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02313901" sec3="Y"><name>Apo-Quetiapine</name><manufacturerId>APX</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02313995" sec3="Y"><name>Sandoz Quetiapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02316080" sec3="Y"><name>Co Quetiapine</name><manufacturerId>COB</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02317893" sec3="Y"><name>Quetiapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02330415" sec3="Y"><name>Jamp-Quetiapine</name><manufacturerId>JPC</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02353164" sec3="Y"><name>Quetiapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02387794" sec3="Y"><name>Quetiapine Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02390140" sec3="Y"><name>Jamp Quetiapine Fumarate</name><manufacturerId>JPC</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02390205" sec3="Y"><name>Auro-Quetiapine</name><manufacturerId>AUR</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02397099" sec3="Y"><name>Ran-Quetiapine</name><manufacturerId>RAN</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02399822" sec3="Y"><name>Mar-Quetiapine</name><manufacturerId>MAR</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02438003" sec3="Y"><name>Mint-Quetiapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02439158" sec3="Y"><name>Nat-Quetiapine</name><manufacturerId>NAT</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02447193" sec3="Y"><name>Bio-Quetiapine</name><manufacturerId>BMP</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02475979" sec3="Y"><name>AG-Quetiapine</name><manufacturerId>ANG</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02486237" sec3="Y"><name>NRA-Quetiapine</name><manufacturerId>NRA</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug><drug id="02501635" sec3="Y"><name>Apo-Quetiapine Fumarate</name><manufacturerId>APX</manufacturerId><individualPrice>.0494</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.0494</amountMOHLTCPays></drug></pcg9><pcg9 id="281608192"><itemNumber>1322</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02236952" sec3="Y"><name>Seroquel</name><manufacturerId>AZC</manufacturerId><individualPrice>1.4362</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02284243" sec3="Y"><name>Teva-Quetiapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02296578" sec3="Y"><name>PMS-Quetiapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02313928" sec3="Y"><name>Apo-Quetiapine</name><manufacturerId>APX</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02314002" sec3="Y"><name>Sandoz Quetiapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02316099" sec3="Y"><name>Co Quetiapine</name><manufacturerId>COB</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02317907" sec3="Y"><name>Quetiapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02330423" sec3="Y"><name>Jamp-Quetiapine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02353172" sec3="Y"><name>Quetiapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02387808" sec3="Y"><name>Quetiapine Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02390159" sec3="Y"><name>Jamp Quetiapine Fumarate</name><manufacturerId>JPC</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02390213" sec3="Y"><name>Auro-Quetiapine</name><manufacturerId>AUR</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02397102" sec3="Y"><name>Ran-Quetiapine</name><manufacturerId>RAN</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02399830" sec3="Y"><name>Mar-Quetiapine</name><manufacturerId>MAR</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02438011" sec3="Y"><name>Mint-Quetiapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02439166" sec3="Y"><name>Nat-Quetiapine</name><manufacturerId>NAT</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02447207" sec3="Y"><name>Bio-Quetiapine</name><manufacturerId>BMP</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug><drug id="02501643" sec3="Y"><name>Apo-Quetiapine Fumarate</name><manufacturerId>APX</manufacturerId><individualPrice>.1318</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.1318</amountMOHLTCPays></drug></pcg9><pcg9 id="281608209"><itemNumber>1323</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02240862" notABenefit="Y" sec3b="Y" sec3="Y"><name>Seroquel</name><manufacturerId>AZC</manufacturerId><listingDate>2002-04-04</listingDate></drug><drug id="02284251" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Quetiapine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7288</individualPrice><listingDate>2008-12-03</listingDate></drug><drug id="02387816" notABenefit="Y" sec3b="Y" sec3="Y"><name>Quetiapine Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>1.3518</individualPrice><listingDate>2012-08-27</listingDate></drug><drug id="02439174" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nat-Quetiapine</name><manufacturerId>NAT</manufacturerId><individualPrice>1.6222</individualPrice><listingDate>2015-10-29</listingDate></drug></pcg9><pcg9 id="281608193"><itemNumber>1324</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02236953" sec3="Y"><name>Seroquel</name><manufacturerId>AZC</manufacturerId><individualPrice>2.8839</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02284278" sec3="Y"><name>Teva-Quetiapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02296594" sec3="Y"><name>PMS-Quetiapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02313936" sec3="Y"><name>Apo-Quetiapine</name><manufacturerId>APX</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02314010" sec3="Y"><name>Sandoz Quetiapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02316110" sec3="Y"><name>Co Quetiapine</name><manufacturerId>COB</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02317923" sec3="Y"><name>Quetiapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02330458" sec3="Y"><name>Jamp-Quetiapine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02353199" sec3="Y"><name>Quetiapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02387824" sec3="Y"><name>Quetiapine Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02390167" sec3="Y"><name>Jamp Quetiapine Fumarate</name><manufacturerId>JPC</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02390248" sec3="Y"><name>Auro-Quetiapine</name><manufacturerId>AUR</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02397110" sec3="Y"><name>Ran-Quetiapine</name><manufacturerId>RAN</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02399849" sec3="Y"><name>Mar-Quetiapine</name><manufacturerId>MAR</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02438046" sec3="Y"><name>Mint-Quetiapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02439182" sec3="Y"><name>Nat-Quetiapine</name><manufacturerId>NAT</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02447223" sec3="Y"><name>Bio-Quetiapine</name><manufacturerId>BMP</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug><drug id="02501651" sec3="Y"><name>Apo-Quetiapine Fumarate</name><manufacturerId>APX</manufacturerId><individualPrice>.2647</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.2647</amountMOHLTCPays></drug></pcg9><pcg9 id="281608210"><itemNumber>1325</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02244107" sec3="Y"><name>Seroquel</name><manufacturerId>AZC</manufacturerId><individualPrice>4.2083</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02284286" sec3="Y"><name>Teva-Quetiapine</name><manufacturerId>TEV</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02296608" sec3="Y"><name>PMS-Quetiapine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02313944" sec3="Y"><name>Apo-Quetiapine</name><manufacturerId>APX</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02314029" sec3="Y"><name>Sandoz Quetiapine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02316129" sec3="Y"><name>Co Quetiapine</name><manufacturerId>COB</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02317931" sec3="Y"><name>Quetiapine</name><manufacturerId>SIV</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02330466" sec3="Y"><name>Jamp-Quetiapine</name><manufacturerId>JPC</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02353202" sec3="Y"><name>Quetiapine</name><manufacturerId>SAI</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02387832" sec3="Y"><name>Quetiapine Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02390175" sec3="Y"><name>Jamp Quetiapine Fumarate</name><manufacturerId>JPC</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02390256" sec3="Y"><name>Auro-Quetiapine</name><manufacturerId>AUR</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02397129" sec3="Y"><name>Ran-Quetiapine</name><manufacturerId>RAN</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02399857" sec3="Y"><name>Mar-Quetiapine</name><manufacturerId>MAR</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02438054" sec3="Y"><name>Mint-Quetiapine</name><manufacturerId>MIN</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2016-04-01</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02439190" sec3="Y"><name>Nat-Quetiapine</name><manufacturerId>NAT</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02447258" sec3="Y"><name>Bio-Quetiapine</name><manufacturerId>BMP</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug><drug id="02501678" sec3="Y"><name>Apo-Quetiapine Fumarate</name><manufacturerId>APX</manufacturerId><individualPrice>.3863</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3863</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00546"><name>RISPERIDONE</name><pcgGroup><pcg9 id="281608194"><itemNumber>1326</itemNumber><strength>1mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02236950" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>1999-04-15</listingDate></drug><drug id="02279266" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.7080</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.7080</amountMOHLTCPays></drug><drug id="02454319" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.7080</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.7080</amountMOHLTCPays></drug></pcg9><pcg9 id="281608217"><itemNumber>1327</itemNumber><strength>0.5mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02247704" notABenefit="Y" sec3="Y"><name>Risperdal M-Tab</name><manufacturerId>JAN</manufacturerId><listingDate>2004-07-20</listingDate></drug><drug id="02413485" sec3="Y"><name>Mylan-Risperidone ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>.5588</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.5588</amountMOHLTCPays></drug></pcg9><pcg9 id="281608216"><itemNumber>1328</itemNumber><strength>1mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02247705" notABenefit="Y" sec3="Y"><name>Risperdal M-Tab</name><manufacturerId>JAN</manufacturerId><listingDate>2004-07-20</listingDate></drug><drug id="02413493" sec3="Y"><name>Mylan-Risperidone ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>.5150</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.5150</amountMOHLTCPays></drug></pcg9><pcg9 id="281608218"><itemNumber>1329</itemNumber><strength>2mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02247706" notABenefit="Y" sec3="Y"><name>Risperdal M-Tab</name><manufacturerId>JAN</manufacturerId><listingDate>2004-07-20</listingDate></drug><drug id="02413507" sec3="Y"><name>Mylan-Risperidone ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>1.0188</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.0188</amountMOHLTCPays></drug></pcg9><pcg9 id="281608229"><itemNumber>1330</itemNumber><strength>3mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02268086" notABenefit="Y" sec3="Y"><name>Risperdal M-Tab</name><manufacturerId>JAN</manufacturerId><listingDate>2006-04-19</listingDate></drug><drug id="02413515" sec3="Y"><name>Mylan-Risperidone ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>1.5275</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.5275</amountMOHLTCPays></drug></pcg9><pcg9 id="281608230"><itemNumber>1331</itemNumber><strength>4mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02268094" notABenefit="Y" sec3="Y"><name>Risperdal M-Tab</name><manufacturerId>JAN</manufacturerId><listingDate>2006-04-19</listingDate></drug><drug id="02413523" sec3="Y"><name>Mylan-Risperidone ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>2.0425</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>2.0425</amountMOHLTCPays></drug></pcg9><pcg9 id="281608226"><itemNumber>1332</itemNumber><strength>25mg</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02255707" sec3="Y"><name>Risperdal Consta</name><manufacturerId>JAN</manufacturerId><individualPrice>208.3500</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>208.3500</amountMOHLTCPays></drug></pcg9><pcg9 id="281608227"><itemNumber>1333</itemNumber><strength>37.5mg</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02255723" sec3="Y"><name>Risperdal Consta</name><manufacturerId>JAN</manufacturerId><individualPrice>312.5100</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>312.5100</amountMOHLTCPays></drug></pcg9><pcg9 id="281608228"><itemNumber>1334</itemNumber><strength>50mg</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><note>For the treatment of schizophrenia or schizoaffective disorders in patients who have:
A history of non-adherence; AND one of the following:

(a) Inadequate control or significant side-effects from two or more formulary oral antipsychotic medications, including at least one atypical agent; OR

(b) Inadequate control or significant side-effects from one or more conventional depot antipsychotic agents.</note><drug id="02255758" sec3="Y"><name>Risperdal Consta</name><manufacturerId>JAN</manufacturerId><individualPrice>416.6800</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>416.6800</amountMOHLTCPays></drug></pcg9><pcg9 id="281608198"><itemNumber>1335</itemNumber><strength>0.25mg</strength><dosageForm>Tab</dosageForm><drug id="02240551" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>2000-07-17</listingDate></drug><drug id="02252007" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02282119" sec3="Y"><name>Apo-Risperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02282690" sec3="Y"><name>Teva-Risperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02303655" sec3="Y"><name>Sandoz Risperidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02328305" sec3="Y"><name>Ran-Risperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02356880" sec3="Y"><name>Risperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02359529" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02359790" sec3="Y"><name>Mint-Risperidon</name><manufacturerId>MIN</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02371766" sec3="Y"><name>Mar-Risperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug><drug id="02533804" sec3="Y"><name>Risperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.0878</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.0878</amountMOHLTCPays></drug></pcg9><pcg9 id="281608200"><itemNumber>1336</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02240552" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>2000-07-17</listingDate></drug><drug id="02252015" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02264188" sec3="Y"><name>Teva-Risperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02282127" sec3="Y"><name>Apo-Risperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02303663" sec3="Y"><name>Sandoz Risperidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02328313" sec3="Y"><name>Ran-Risperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02356899" sec3="Y"><name>Risperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02359537" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02359804" sec3="Y"><name>Mint-Risperidon</name><manufacturerId>MIN</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02371774" sec3="Y"><name>Mar-Risperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug><drug id="02533928" sec3="Y"><name>Risperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.1470</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.1470</amountMOHLTCPays></drug></pcg9><pcg9 id="281608174"><itemNumber>1337</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02025280" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02252023" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02264196" sec3="Y"><name>Teva-Risperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02279800" sec3="Y"><name>Sandoz Risperidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02282135" sec3="Y"><name>Apo-Risperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02328321" sec3="Y"><name>Ran-Risperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02356902" sec3="Y"><name>Risperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02359545" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02359812" sec3="Y"><name>Mint-Risperidon</name><manufacturerId>MIN</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02371782" sec3="Y"><name>Mar-Risperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug><drug id="02533936" sec3="Y"><name>Risperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.2031</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.2031</amountMOHLTCPays></drug></pcg9><pcg9 id="281608175"><itemNumber>1338</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02025299" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02252031" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02264218" sec3="Y"><name>Teva-Risperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02279819" sec3="Y"><name>Sandoz Risperidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02282143" sec3="Y"><name>Apo-Risperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02328348" sec3="Y"><name>Ran-Risperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02356910" sec3="Y"><name>Risperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02359553" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02359820" sec3="Y"><name>Mint-Risperidon</name><manufacturerId>MIN</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02371790" sec3="Y"><name>Mar-Risperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug><drug id="02533944" sec3="Y"><name>Risperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.4062</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.4062</amountMOHLTCPays></drug></pcg9><pcg9 id="281608176"><itemNumber>1339</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="02025302" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02252058" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02264226" sec3="Y"><name>Teva-Risperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02279827" sec3="Y"><name>Sandoz Risperidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02282151" sec3="Y"><name>Apo-Risperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02328364" sec3="Y"><name>Ran-Risperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02356929" sec3="Y"><name>Risperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02359561" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02359839" sec3="Y"><name>Mint-Risperidon</name><manufacturerId>MIN</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02371804" sec3="Y"><name>Mar-Risperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug><drug id="02533952" sec3="Y"><name>Risperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.6083</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.6083</amountMOHLTCPays></drug></pcg9><pcg9 id="281608177"><itemNumber>1340</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02025310" notABenefit="Y" sec3="Y"><name>Risperdal</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02252066" sec3="Y"><name>PMS-Risperidone</name><manufacturerId>PMS</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02264234" sec3="Y"><name>Teva-Risperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02279835" sec3="Y"><name>Sandoz Risperidone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02282178" sec3="Y"><name>Apo-Risperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2006-09-06</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02328372" sec3="Y"><name>Ran-Risperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02356937" sec3="Y"><name>Risperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02359588" sec3="Y"><name>Jamp-Risperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02359847" sec3="Y"><name>Mint-Risperidon</name><manufacturerId>MIN</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02371812" sec3="Y"><name>Mar-Risperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug><drug id="02533960" sec3="Y"><name>Risperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.8111</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.8111</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00532"><name>TRIFLUOPERAZINE</name><pcgGroup><pcg9 id="281608082"><itemNumber>1341</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00345539" sec3="Y"><name>Trifluoperazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1340</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1340</amountMOHLTCPays></drug><drug id="01918206" notABenefit="Y" sec3="Y"><name>Stelazine</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608081"><itemNumber>1342</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="00312754" sec3="Y"><name>Trifluoperazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1793</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1793</amountMOHLTCPays></drug><drug id="01918214" notABenefit="Y" sec3="Y"><name>Stelazine</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608080"><itemNumber>1343</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00312746" sec3="Y"><name>Trifluoperazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2375</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2375</amountMOHLTCPays></drug><drug id="01918222" notABenefit="Y" sec3="Y"><name>Stelazine</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="281608079"><itemNumber>1344</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00326836" sec3="Y"><name>Trifluoperazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2846</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2846</amountMOHLTCPays></drug><drug id="01918230" notABenefit="Y" sec3="Y"><name>Stelazine</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01779"><name>ZIPRASIDONE HCL MONOHYDRATE</name><pcgGroup><pcg9 id="281608252"><itemNumber>1345</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><drug id="02298597" sec3="Y"><name>Zeldox</name><manufacturerId>UJC</manufacturerId><individualPrice>2.1916</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.3784</amountMOHLTCPays></drug><drug id="02449544" sec3="Y"><name>Auro-Ziprasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.3784</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.3784</amountMOHLTCPays></drug></pcg9><pcg9 id="281608253"><itemNumber>1346</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="02298600" sec3="Y"><name>Zeldox</name><manufacturerId>UJC</manufacturerId><individualPrice>2.5105</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.5786</amountMOHLTCPays></drug><drug id="02449552" sec3="Y"><name>Auro-Ziprasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.5786</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.5786</amountMOHLTCPays></drug></pcg9><pcg9 id="281608254"><itemNumber>1347</itemNumber><strength>60mg</strength><dosageForm>Cap</dosageForm><drug id="02298619" sec3="Y"><name>Zeldox</name><manufacturerId>UJC</manufacturerId><individualPrice>2.5105</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.5786</amountMOHLTCPays></drug><drug id="02449560" sec3="Y"><name>Auro-Ziprasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.5786</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.5786</amountMOHLTCPays></drug></pcg9><pcg9 id="281608255"><itemNumber>1348</itemNumber><strength>80mg</strength><dosageForm>Cap</dosageForm><drug id="02298627" sec3="Y"><name>Zeldox</name><manufacturerId>UJC</manufacturerId><individualPrice>2.5105</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>1.5786</amountMOHLTCPays></drug><drug id="02449579" sec3="Y"><name>Auro-Ziprasidone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.5786</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.5786</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00552"><name>ZUCLOPENTHIXOL DECANOATE</name><pcgGroup><pcg9 id="281608186"><itemNumber>1349</itemNumber><strength>200mg/mL</strength><dosageForm>Inj-1mL Pk</dosageForm><drug id="02230406" sec3="Y"><name>Clopixol Depot</name><manufacturerId>VLH</manufacturerId><individualPrice>21.3154</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>21.3154</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00551"><name>ZUCLOPENTHIXOL DIHYDROCHLORIDE</name><pcgGroup><pcg9 id="281608184"><itemNumber>1350</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02230402" sec3="Y"><name>Clopixol</name><manufacturerId>VLH</manufacturerId><individualPrice>.5483</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>.5483</amountMOHLTCPays></drug></pcg9><pcg9 id="281608183"><itemNumber>1351</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02230403" sec3="Y"><name>Clopixol</name><manufacturerId>VLH</manufacturerId><individualPrice>1.3705</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>1.3705</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="281612000"><name>PSYCHOTHERAPEUTIC AGENTS OTHER PSYCHOTROPICS</name><genericName id="00554"><name>LITHIUM CARBONATE</name><pcgGroup><pcg9 id="281612008"><itemNumber>1352</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="00461733" sec3="Y"><name>Carbolith</name><manufacturerId>VAL</manufacturerId><individualPrice>.1560</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0667</amountMOHLTCPays></drug><drug id="02216132" sec3="Y"><name>PMS-Lithium Carbonate</name><manufacturerId>PMS</manufacturerId><individualPrice>.0667</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.0667</amountMOHLTCPays></drug><drug id="02242837" sec3="Y"><name>Apo-Lithium Carbonate</name><manufacturerId>APX</manufacturerId><individualPrice>.0667</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.0667</amountMOHLTCPays></drug></pcg9><pcg9 id="281612014"><itemNumber>1353</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02013231" sec3="Y"><name>Lithane</name><manufacturerId>SLP</manufacturerId><individualPrice>.1892</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0667</amountMOHLTCPays></drug><drug id="09857532" sec3="Y"><name>Apo-Lithium Carbonate</name><manufacturerId>APX</manufacturerId><individualPrice>.0667</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.0667</amountMOHLTCPays></drug></pcg9><pcg9 id="281612002"><itemNumber>1354</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="00236683" sec3="Y"><name>Carbolith</name><manufacturerId>VAL</manufacturerId><individualPrice>.1212</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0657</amountMOHLTCPays></drug><drug id="02216140" sec3="Y"><name>PMS-Lithium Carbonate</name><manufacturerId>PMS</manufacturerId><individualPrice>.0657</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.0657</amountMOHLTCPays></drug><drug id="02242838" sec3="Y"><name>Apo-Lithium Carbonate</name><manufacturerId>APX</manufacturerId><individualPrice>.0657</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.0657</amountMOHLTCPays></drug></pcg9><pcg9 id="281612016"><itemNumber>1355</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="00406775" sec3="Y"><name>Lithane</name><manufacturerId>SLP</manufacturerId><individualPrice>.1892</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0657</amountMOHLTCPays></drug><drug id="09857540" sec3="Y"><name>Apo-Lithium Carbonate</name><manufacturerId>APX</manufacturerId><individualPrice>.0657</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.0657</amountMOHLTCPays></drug></pcg9><pcg9 id="281612027"><itemNumber>1356</itemNumber><strength>300mg</strength><dosageForm>ER Tab</dosageForm><drug id="00590665" sec3b="Y" sec3="Y"><name>Duralith</name><manufacturerId>JNO</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02266695" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Lithmax</name><manufacturerId>AAP</manufacturerId><individualPrice>.2880</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.2880</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00558"><name>TRYPTOPHAN</name><pcgGroup><pcg9 id="281612028"><itemNumber>1357</itemNumber><strength>500mg</strength><dosageForm>Cap</dosageForm><drug id="00718149" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tryptan</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02240334" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Tryptophan</name><manufacturerId>RPH</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2008-12-03</listingDate></drug><drug id="02248540" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Tryptophan</name><manufacturerId>APX</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2008-06-27</listingDate></drug></pcg9><pcg9 id="281612029"><itemNumber>1358</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02029456" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tryptan</name><manufacturerId>VAL</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02240333" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Tryptophan</name><manufacturerId>RPH</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2008-12-03</listingDate></drug><drug id="02248538" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Tryptophan</name><manufacturerId>APX</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2008-06-27</listingDate></drug></pcg9><pcg9 id="281612019"><itemNumber>1359</itemNumber><strength>750mg</strength><dosageForm>Tab</dosageForm><drug id="02239327" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tryptan</name><manufacturerId>VAL</manufacturerId><listingDate>2017-05-31</listingDate></drug><drug id="02458721" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Tryptophan</name><manufacturerId>APX</manufacturerId><individualPrice>1.2444</individualPrice><listingDate>2017-05-31</listingDate></drug></pcg9><pcg9 id="281612030"><itemNumber>1360</itemNumber><strength>1g</strength><dosageForm>Tab</dosageForm><drug id="00654531" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tryptan</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02237250" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Tryptophan</name><manufacturerId>RPH</manufacturerId><individualPrice>.8978</individualPrice><listingDate>2000-04-17</listingDate></drug><drug id="02248539" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Tryptophan</name><manufacturerId>APX</manufacturerId><individualPrice>.8978</individualPrice><listingDate>2008-06-27</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="282000000"><name>C.N.S. STIMULANTS</name><note>Stimulant medication should only be used when diagnostic criteria for narcolepsy or attention deficit disorder have been met and when stimulant medication has been demonstrated to produce clinical benefits. The use of conventional-release medication should almost always precede the use of extended-release preparations.</note><genericName id="00562"><name>DEXTROAMPHETAMINE SULFATE</name><pcgGroup><pcg9 id="282000010"><itemNumber>1361</itemNumber><strength>10mg</strength><dosageForm>SR Cap</dosageForm><note>Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor     symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="01924559" sec3="Y"><name>Dexedrine Spansules</name><manufacturerId>PPI</manufacturerId><individualPrice>1.2207</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.8096</amountMOHLTCPays></drug><drug id="02448319" sec3="Y"><name>Act Dextroamphetamine SR</name><manufacturerId>ACV</manufacturerId><individualPrice>.8096</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.8096</amountMOHLTCPays></drug></pcg9><pcg9 id="282000009"><itemNumber>1362</itemNumber><strength>15mg</strength><dosageForm>SR Cap</dosageForm><note>Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="01924567" sec3="Y"><name>Dexedrine Spansules</name><manufacturerId>PPI</manufacturerId><individualPrice>1.4924</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.9898</amountMOHLTCPays></drug><drug id="02448327" sec3="Y"><name>Act Dextroamphetamine SR</name><manufacturerId>ACV</manufacturerId><individualPrice>.9898</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.9898</amountMOHLTCPays></drug></pcg9><pcg9 id="282000003"><itemNumber>1363</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="01924516" sec3="Y"><name>Dexedrine</name><manufacturerId>PPI</manufacturerId><individualPrice>.8267</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5081</amountMOHLTCPays></drug><drug id="02443236" sec3="Y"><name>Dextroamphetamine</name><manufacturerId>AAP</manufacturerId><individualPrice>.5081</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>.5081</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01833"><name>LISDEXAMFETAMINE DIMESYLATE</name><pcgGroup><pcg9 id="282000064"><itemNumber>1364</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><note>Notes:  Patients greater than or equal to 6 years of age diagnosed with ADHD according to
DSM-IV criteria and where symptoms are not due to other medical conditions which affect
concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.

</note><drug id="02439603" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>2.3656</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>.5692</amountMOHLTCPays></drug><drug id="02535122" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>.5692</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.5692</amountMOHLTCPays></drug><drug id="02545861" sec3="Y"><name>Teva-Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>.5692</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.5692</amountMOHLTCPays></drug><drug id="02546248" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5692</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.5692</amountMOHLTCPays></drug><drug id="02546647" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>.5692</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.5692</amountMOHLTCPays></drug></pcg9><pcg9 id="282000061"><itemNumber>1365</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced             unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02347156" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>2.9426</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.7081</amountMOHLTCPays></drug><drug id="02535130" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>.7081</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.7081</amountMOHLTCPays></drug><drug id="02545888" sec3="Y"><name>Teva-Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7081</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.7081</amountMOHLTCPays></drug><drug id="02546256" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7081</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.7081</amountMOHLTCPays></drug><drug id="02546655" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>.7081</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.7081</amountMOHLTCPays></drug></pcg9><pcg9 id="282000056"><itemNumber>1366</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><note>Notes:- Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND 
        
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 
        
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced
unsatisfactory results due to poor symptom control, side effects, administrative barriers,
or societal barriers.


Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;    
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02322951" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>3.5196</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.8469</amountMOHLTCPays></drug><drug id="02535149" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>.8469</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.8469</amountMOHLTCPays></drug><drug id="02545896" sec3="Y"><name>Teva-Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>.8469</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.8469</amountMOHLTCPays></drug><drug id="02546264" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8469</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.8469</amountMOHLTCPays></drug><drug id="02546663" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>.8469</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.8469</amountMOHLTCPays></drug></pcg9><pcg9 id="282000062"><itemNumber>1367</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric  psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02347164" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>4.0966</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>.9857</amountMOHLTCPays></drug><drug id="02535157" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>.9857</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.9857</amountMOHLTCPays></drug><drug id="02545918" sec3="Y"><name>Teva-Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>.9857</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.9857</amountMOHLTCPays></drug><drug id="02546272" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9857</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.9857</amountMOHLTCPays></drug><drug id="02546671" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>.9857</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.9857</amountMOHLTCPays></drug></pcg9><pcg9 id="282000057"><itemNumber>1368</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><note>Notes:  Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND  
        
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND 
        
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
     
Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;                 
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02322978" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>4.6736</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>1.1246</amountMOHLTCPays></drug><drug id="02535165" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1246</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>1.1246</amountMOHLTCPays></drug><drug id="02545926" sec3="Y"><name>Teva-Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.1246</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.1246</amountMOHLTCPays></drug><drug id="02546280" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1246</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.1246</amountMOHLTCPays></drug><drug id="02546698" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>1.1246</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>1.1246</amountMOHLTCPays></drug></pcg9><pcg9 id="282000063"><itemNumber>1369</itemNumber><strength>60mg</strength><dosageForm>Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02347172" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>5.2505</individualPrice><listingDate>2011-06-08</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug><drug id="02535173" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2634</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug><drug id="02545934" sec3="Y"><name>Teva-Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2634</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug><drug id="02546299" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2634</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug><drug id="02546701" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>1.2634</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug></pcg9><pcg9 id="282000066"><itemNumber>1370</itemNumber><strength>70mg</strength><dosageForm>Cap</dosageForm><drug id="02458071" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><listingDate>2024-07-31</listingDate></drug><drug id="02535181" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Lisdexamfetamine</name><manufacturerId>JPC</manufacturerId><individualPrice>4.6968</individualPrice><listingDate>2025-09-29</listingDate></drug><drug id="02545942" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva Lisdexamfetamine</name><manufacturerId>TEV</manufacturerId><individualPrice>4.6968</individualPrice><listingDate>2024-07-31</listingDate></drug><drug id="02546302" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Lisdexamfetamine Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.6968</individualPrice><listingDate>2024-07-31</listingDate></drug><drug id="02546728" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Lisdexamfetamine Capsules</name><manufacturerId>APX</manufacturerId><individualPrice>4.6968</individualPrice><listingDate>2024-08-30</listingDate></drug></pcg9><pcg9 id="282000074"><itemNumber>1371</itemNumber><strength>10mg</strength><dosageForm>Chew Tab</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02490226" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>2.3656</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>1.1385</amountMOHLTCPays></drug><drug id="02533340" sec3="Y"><name>Taro-Lisdexamfetamine Chewable Tablets</name><manufacturerId>TAR</manufacturerId><individualPrice>1.1385</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.1385</amountMOHLTCPays></drug><drug id="02534444" sec3="Y"><name>Apo-Lisdexamfetamine Chewable Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>1.1385</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>1.1385</amountMOHLTCPays></drug></pcg9><pcg9 id="282000075"><itemNumber>1372</itemNumber><strength>20mg</strength><dosageForm>Chew Tab</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02490234" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>2.9426</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>1.4161</amountMOHLTCPays></drug><drug id="02533359" sec3="Y"><name>Taro-Lisdexamfetamine Chewable Tablets</name><manufacturerId>TAR</manufacturerId><individualPrice>1.4161</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.4161</amountMOHLTCPays></drug><drug id="02534452" sec3="Y"><name>Apo-Lisdexamfetamine Chewable Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>1.4161</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>1.4161</amountMOHLTCPays></drug></pcg9><pcg9 id="282000076"><itemNumber>1373</itemNumber><strength>30mg</strength><dosageForm>Chew Tab</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02490242" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>3.5196</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>1.6938</amountMOHLTCPays></drug><drug id="02533367" sec3="Y"><name>Taro-Lisdexamfetamine Chewable Tablets</name><manufacturerId>TAR</manufacturerId><individualPrice>1.6938</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.6938</amountMOHLTCPays></drug><drug id="02534460" sec3="Y"><name>Apo-Lisdexamfetamine Chewable Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>1.6938</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>1.6938</amountMOHLTCPays></drug></pcg9><pcg9 id="282000077"><itemNumber>1374</itemNumber><strength>40mg</strength><dosageForm>Chew Tab</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02490250" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>4.0966</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>1.9715</amountMOHLTCPays></drug><drug id="02533375" sec3="Y"><name>Taro-Lisdexamfetamine Chewable Tablets</name><manufacturerId>TAR</manufacturerId><individualPrice>1.9715</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>1.9715</amountMOHLTCPays></drug><drug id="02534479" sec3="Y"><name>Apo-Lisdexamfetamine Chewable Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>1.9715</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>1.9715</amountMOHLTCPays></drug></pcg9><pcg9 id="282000078"><itemNumber>1375</itemNumber><strength>50mg</strength><dosageForm>Chew Tab</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02490269" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>4.6736</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>2.2491</amountMOHLTCPays></drug><drug id="02533383" sec3="Y"><name>Taro-Lisdexamfetamine Chewable Tablets</name><manufacturerId>TAR</manufacturerId><individualPrice>2.2491</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>2.2491</amountMOHLTCPays></drug><drug id="02534487" sec3="Y"><name>Apo-Lisdexamfetamine Chewable Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>2.2491</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>2.2491</amountMOHLTCPays></drug></pcg9><pcg9 id="282000079"><itemNumber>1376</itemNumber><strength>60mg</strength><dosageForm>Chew Tab</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02490277" sec3="Y"><name>Vyvanse</name><manufacturerId>TAK</manufacturerId><individualPrice>5.2505</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>2.5268</amountMOHLTCPays></drug><drug id="02533391" sec3="Y"><name>Taro-Lisdexamfetamine Chewable Tablets</name><manufacturerId>TAR</manufacturerId><individualPrice>2.5268</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>2.5268</amountMOHLTCPays></drug><drug id="02534495" sec3="Y"><name>Apo-Lisdexamfetamine Chewable Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>2.5268</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>2.5268</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00560"><name>METHYLPHENIDATE HCL</name><pcgGroup><pcg9 id="282000080"><itemNumber>1377</itemNumber><strength>25mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470292" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>2.9050</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>2.9050</amountMOHLTCPays></drug></pcg9><pcg9 id="282000081"><itemNumber>1378</itemNumber><strength>35mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470306" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>3.1950</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>3.1950</amountMOHLTCPays></drug></pcg9><pcg9 id="282000082"><itemNumber>1379</itemNumber><strength>45mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470314" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>3.4725</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>3.4725</amountMOHLTCPays></drug></pcg9><pcg9 id="282000083"><itemNumber>1380</itemNumber><strength>55mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470322" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>3.7580</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>3.7580</amountMOHLTCPays></drug></pcg9><pcg9 id="282000084"><itemNumber>1381</itemNumber><strength>70mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470330" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>4.1880</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>4.1880</amountMOHLTCPays></drug></pcg9><pcg9 id="282000085"><itemNumber>1382</itemNumber><strength>85mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470349" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>4.6080</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>4.6080</amountMOHLTCPays></drug></pcg9><pcg9 id="282000086"><itemNumber>1383</itemNumber><strength>100mg</strength><dosageForm>CR Cap</dosageForm><note>Notes: Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:

- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:

- the patient or patient&apos;s caregiver(s) has/have a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02470357" sec3="Y"><name>Foquest</name><manufacturerId>ELV</manufacturerId><individualPrice>5.0230</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>5.0230</amountMOHLTCPays></drug></pcg9><pcg9 id="282000032"><itemNumber>1384</itemNumber><strength>10mg</strength><dosageForm>ER Cap</dosageForm><note>Note:  Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277166" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>1.0074</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.5128</amountMOHLTCPays></drug><drug id="02536943" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>.5128</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.5128</amountMOHLTCPays></drug></pcg9><pcg9 id="282000033"><itemNumber>1385</itemNumber><strength>15mg</strength><dosageForm>ER Cap</dosageForm><note>Note: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277131" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>1.4447</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.7354</amountMOHLTCPays></drug><drug id="02536951" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>.7354</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.7354</amountMOHLTCPays></drug></pcg9><pcg9 id="282000034"><itemNumber>1386</itemNumber><strength>20mg</strength><dosageForm>ER Cap</dosageForm><note>Note: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects,administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277158" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>1.8615</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.9477</amountMOHLTCPays></drug><drug id="02536978" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>.9477</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.9477</amountMOHLTCPays></drug></pcg9><pcg9 id="282000035"><itemNumber>1387</itemNumber><strength>30mg</strength><dosageForm>ER Cap</dosageForm><note>Note: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277174" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>2.5581</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>1.3021</amountMOHLTCPays></drug><drug id="02536986" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>1.3021</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.3021</amountMOHLTCPays></drug></pcg9><pcg9 id="282000036"><itemNumber>1388</itemNumber><strength>40mg</strength><dosageForm>ER Cap</dosageForm><note>Note:  Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277182" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>3.2588</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>1.6588</amountMOHLTCPays></drug><drug id="02536994" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>1.6588</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>1.6588</amountMOHLTCPays></drug></pcg9><pcg9 id="282000037"><itemNumber>1389</itemNumber><strength>50mg</strength><dosageForm>ER Cap</dosageForm><note>Note:  Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277190" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>3.9544</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>2.0130</amountMOHLTCPays></drug><drug id="02537001" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>2.0130</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>2.0130</amountMOHLTCPays></drug></pcg9><pcg9 id="282000038"><itemNumber>1390</itemNumber><strength>60mg</strength><dosageForm>ER Cap</dosageForm><note>Note: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277204" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>4.6017</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>2.3425</amountMOHLTCPays></drug><drug id="02537028" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>2.3425</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>2.3425</amountMOHLTCPays></drug></pcg9><pcg9 id="282000041"><itemNumber>1391</itemNumber><strength>80mg</strength><dosageForm>ER Cap</dosageForm><note>Note:  Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning AND
 
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD AND
  
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
          
</note><drug id="02277212" sec3="Y"><name>Biphentin</name><manufacturerId>ELV</manufacturerId><individualPrice>6.0670</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>3.0883</amountMOHLTCPays></drug><drug id="02537036" sec3="Y"><name>PMS-Methylphenidate CR</name><manufacturerId>PMS</manufacturerId><individualPrice>3.0883</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>3.0883</amountMOHLTCPays></drug></pcg9><pcg9 id="282000006"><itemNumber>1392</itemNumber><strength>20mg</strength><dosageForm>ER Tab</dosageForm><drug id="00632775" notABenefit="Y" sec3="Y"><name>Ritalin SR</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02266687" sec3="Y"><name>Apo-Methylphenidate SR</name><manufacturerId>APX</manufacturerId><individualPrice>.6796</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.6796</amountMOHLTCPays></drug></pcg9><pcg9 id="282000028"><itemNumber>1393</itemNumber><strength>18mg</strength><dosageForm>SR Tab</dosageForm><note>Notes:  Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02247732" sec3="Y"><name>Concerta</name><manufacturerId>JAN</manufacturerId><individualPrice>3.2995</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>1.0493</amountMOHLTCPays></drug><drug id="02441934" sec3="Y"><name>Act Methylphenidate ER</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0493</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.0493</amountMOHLTCPays></drug><drug id="02452731" sec3="Y"><name>Apo-Methylphenidate ER</name><manufacturerId>APX</manufacturerId><individualPrice>1.0493</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>1.0493</amountMOHLTCPays></drug></pcg9><pcg9 id="282000031"><itemNumber>1394</itemNumber><strength>27mg</strength><dosageForm>SR Tab</dosageForm><note>Notes:  Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02250241" sec3="Y"><name>Concerta</name><manufacturerId>JAN</manufacturerId><individualPrice>3.8076</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>1.2109</amountMOHLTCPays></drug><drug id="02441942" sec3="Y"><name>Act Methylphenidate ER</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2109</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.2109</amountMOHLTCPays></drug><drug id="02452758" sec3="Y"><name>Apo-Methylphenidate ER</name><manufacturerId>APX</manufacturerId><individualPrice>1.2109</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>1.2109</amountMOHLTCPays></drug></pcg9><pcg9 id="282000029"><itemNumber>1395</itemNumber><strength>36mg</strength><dosageForm>SR Tab</dosageForm><note>Notes:  Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02247733" sec3="Y"><name>Concerta</name><manufacturerId>JAN</manufacturerId><individualPrice>4.3163</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>1.3726</amountMOHLTCPays></drug><drug id="02441950" sec3="Y"><name>Act Methylphenidate ER</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3726</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.3726</amountMOHLTCPays></drug><drug id="02452766" sec3="Y"><name>Apo-Methylphenidate ER</name><manufacturerId>APX</manufacturerId><individualPrice>1.3726</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>1.3726</amountMOHLTCPays></drug></pcg9><pcg9 id="282000030"><itemNumber>1396</itemNumber><strength>54mg</strength><dosageForm>SR Tab</dosageForm><note>Notes:  Patients greater than or equal to 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02247734" sec3="Y"><name>Concerta</name><manufacturerId>JAN</manufacturerId><individualPrice>5.3326</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>1.6958</amountMOHLTCPays></drug><drug id="02330377" sec3="Y"><name>Apo-Methylphenidate ER</name><manufacturerId>APX</manufacturerId><individualPrice>1.6958</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.6958</amountMOHLTCPays></drug><drug id="02441969" sec3="Y"><name>Act Methylphenidate ER</name><manufacturerId>TEV</manufacturerId><individualPrice>1.6958</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>1.6958</amountMOHLTCPays></drug></pcg9><pcg9 id="282000004"><itemNumber>1397</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00005606" sec3="Y"><name>Ritalin</name><manufacturerId>NOV</manufacturerId><individualPrice>.4556</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2216</amountMOHLTCPays></drug><drug id="00584991" sec3="Y"><name>PMS-Methylphenidate</name><manufacturerId>PMS</manufacturerId><individualPrice>.2216</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2216</amountMOHLTCPays></drug><drug id="02249324" sec3="Y"><name>Apo-Methylphenidate</name><manufacturerId>APX</manufacturerId><individualPrice>.2216</individualPrice><listingDate>2005-03-31</listingDate><amountMOHLTCPays>.2216</amountMOHLTCPays></drug></pcg9><pcg9 id="282000039"><itemNumber>1398</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00005614" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ritalin</name><manufacturerId>NOV</manufacturerId><listingDate>2008-01-15</listingDate></drug><drug id="00585009" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Methylphenidate</name><manufacturerId>PMS</manufacturerId><individualPrice>.3536</individualPrice><listingDate>2008-01-15</listingDate></drug><drug id="02249332" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Methylphenidate</name><manufacturerId>APX</manufacturerId><individualPrice>.3536</individualPrice><listingDate>2008-01-15</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01752"><name>MIXED SALT AMPHETAMINE</name><pcgGroup><pcg9 id="282000042"><itemNumber>1399</itemNumber><strength>5mg</strength><dosageForm>ER Cap</dosageForm><note>Notes:  Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include:
 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02248808" sec3="Y"><name>Adderall XR</name><manufacturerId>TAK</manufacturerId><individualPrice>2.4898</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.5372</amountMOHLTCPays></drug><drug id="02439239" sec3="Y"><name>Act Amphetamine XR</name><manufacturerId>ACV</manufacturerId><individualPrice>.5372</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.5372</amountMOHLTCPays></drug><drug id="02445492" sec3="Y"><name>Apo-Amphetamine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.5372</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.5372</amountMOHLTCPays></drug><drug id="02457288" sec3="Y"><name>Sandoz Amphetamine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5372</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.5372</amountMOHLTCPays></drug></pcg9><pcg9 id="282000043"><itemNumber>1400</itemNumber><strength>10mg</strength><dosageForm>ER Cap</dosageForm><note>Notes: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02248809" sec3="Y"><name>Adderall XR</name><manufacturerId>TAK</manufacturerId><individualPrice>2.8296</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.6105</amountMOHLTCPays></drug><drug id="02439247" sec3="Y"><name>Act Amphetamine XR</name><manufacturerId>ACV</manufacturerId><individualPrice>.6105</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.6105</amountMOHLTCPays></drug><drug id="02445506" sec3="Y"><name>Apo-Amphetamine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.6105</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.6105</amountMOHLTCPays></drug><drug id="02457296" sec3="Y"><name>Sandoz Amphetamine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6105</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.6105</amountMOHLTCPays></drug></pcg9><pcg9 id="282000044"><itemNumber>1401</itemNumber><strength>15mg</strength><dosageForm>ER Cap</dosageForm><note>Notes: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02248810" sec3="Y"><name>Adderall XR</name><manufacturerId>TAK</manufacturerId><individualPrice>3.1694</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.6838</amountMOHLTCPays></drug><drug id="02439255" sec3="Y"><name>Act Amphetamine XR</name><manufacturerId>ACV</manufacturerId><individualPrice>.6838</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.6838</amountMOHLTCPays></drug><drug id="02445514" sec3="Y"><name>Apo-Amphetamine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.6838</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.6838</amountMOHLTCPays></drug><drug id="02457318" sec3="Y"><name>Sandoz Amphetamine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6838</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.6838</amountMOHLTCPays></drug></pcg9><pcg9 id="282000045"><itemNumber>1402</itemNumber><strength>20mg</strength><dosageForm>ER Cap</dosageForm><note>Notes: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02248811" sec3="Y"><name>Adderall XR</name><manufacturerId>TAK</manufacturerId><individualPrice>3.5092</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.7572</amountMOHLTCPays></drug><drug id="02439263" sec3="Y"><name>Act Amphetamine XR</name><manufacturerId>ACV</manufacturerId><individualPrice>.7572</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.7572</amountMOHLTCPays></drug><drug id="02445522" sec3="Y"><name>Apo-Amphetamine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.7572</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.7572</amountMOHLTCPays></drug><drug id="02457326" sec3="Y"><name>Sandoz Amphetamine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7572</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.7572</amountMOHLTCPays></drug></pcg9><pcg9 id="282000046"><itemNumber>1403</itemNumber><strength>25mg</strength><dosageForm>ER Cap</dosageForm><note>Notes:  Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02248812" sec3="Y"><name>Adderall XR</name><manufacturerId>TAK</manufacturerId><individualPrice>3.8489</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.8305</amountMOHLTCPays></drug><drug id="02439271" sec3="Y"><name>Act Amphetamine XR</name><manufacturerId>ACV</manufacturerId><individualPrice>.8305</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.8305</amountMOHLTCPays></drug><drug id="02445530" sec3="Y"><name>Apo-Amphetamine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.8305</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.8305</amountMOHLTCPays></drug><drug id="02457334" sec3="Y"><name>Sandoz Amphetamine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8305</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.8305</amountMOHLTCPays></drug></pcg9><pcg9 id="282000047"><itemNumber>1404</itemNumber><strength>30mg</strength><dosageForm>ER Cap</dosageForm><note>Notes: Patients &gt; 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:

1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND

2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND

3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR or Dexedrine SR (Spansules), and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.

Administrative barriers include: 
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.

Societal barriers include:
- the patient or patient&apos;s caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient&apos;s caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.</note><drug id="02248813" sec3="Y"><name>Adderall XR</name><manufacturerId>TAK</manufacturerId><individualPrice>4.1888</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>.9038</amountMOHLTCPays></drug><drug id="02439298" sec3="Y"><name>Act Amphetamine XR</name><manufacturerId>ACV</manufacturerId><individualPrice>.9038</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.9038</amountMOHLTCPays></drug><drug id="02445549" sec3="Y"><name>Apo-Amphetamine XR</name><manufacturerId>APX</manufacturerId><individualPrice>.9038</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.9038</amountMOHLTCPays></drug><drug id="02457342" sec3="Y"><name>Sandoz Amphetamine XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9038</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.9038</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01448"><name>MODAFINIL</name><pcgGroup><pcg9 id="282000040"><itemNumber>1405</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02239665" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Alertec</name><manufacturerId>BJH</manufacturerId><individualPrice>1.8270</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug><drug id="02285398" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Modafinil</name><manufacturerId>APX</manufacturerId><individualPrice>.9293</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug><drug id="02420260" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Modafinil</name><manufacturerId>TEV</manufacturerId><individualPrice>.9293</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug><drug id="02430487" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Modafinil</name><manufacturerId>AUR</manufacturerId><individualPrice>.9293</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug><drug id="02432560" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Modafinil</name><manufacturerId>MAR</manufacturerId><individualPrice>.9293</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug><drug id="02503727" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Modafinil</name><manufacturerId>JPC</manufacturerId><individualPrice>.9293</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug><drug id="02530244" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Modafinil</name><manufacturerId>SAI</manufacturerId><individualPrice>.9293</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.9293</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="282400000"><name>SEDATIVES AND HYPNOTICS</name><genericName id="00581"><name>BUSPIRONE HYDROCHLORIDE</name><pcgGroup><pcg9 id="282400166"><itemNumber>1406</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00603821" notABenefit="Y" sec3="Y"><name>Buspar</name><manufacturerId>BQU</manufacturerId><listingDate>2007-11-10</listingDate></drug><drug id="02211076" sec3="Y"><name>Apo-Buspirone</name><manufacturerId>APX</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2007-11-16</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02230942" sec3="Y"><name>PMS-Buspirone</name><manufacturerId>PMS</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2007-11-16</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02231492" sec3="Y"><name>Teva-Buspirone</name><manufacturerId>TEV</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02447851" sec3="Y"><name>Buspirone</name><manufacturerId>SAI</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02500213" sec3="Y"><name>Auro-Buspirone</name><manufacturerId>AUR</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02509911" sec3="Y"><name>Jamp Buspirone</name><manufacturerId>JPC</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02519054" sec3="Y"><name>Mint-Buspirone</name><manufacturerId>MIN</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug><drug id="02550555" sec3="Y"><name>AMB-Buspirone</name><manufacturerId>AMB</manufacturerId><individualPrice>.2713</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.2713</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02405"><name>ESZOPICLONE</name><pcgGroup><pcg9 id="282400240"><itemNumber>1407</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02453207" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lunesta</name><manufacturerId>SMT</manufacturerId><listingDate>2024-10-31</listingDate></drug><drug id="02549433" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Eszopiclone</name><manufacturerId>MAR</manufacturerId><individualPrice>1.4365</individualPrice><listingDate>2024-10-31</listingDate></drug></pcg9><pcg9 id="282400241"><itemNumber>1408</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02453215" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lunesta</name><manufacturerId>SMT</manufacturerId><listingDate>2024-10-31</listingDate></drug><drug id="02549441" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Eszopiclone</name><manufacturerId>MAR</manufacturerId><individualPrice>1.4365</individualPrice><listingDate>2024-10-31</listingDate></drug></pcg9><pcg9 id="282400242"><itemNumber>1409</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="02453223" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lunesta</name><manufacturerId>SMT</manufacturerId><listingDate>2024-10-31</listingDate></drug><drug id="02549468" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Eszopiclone</name><manufacturerId>MAR</manufacturerId><individualPrice>1.4365</individualPrice><listingDate>2024-10-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00573"><name>FLURAZEPAM</name><pcgGroup><pcg9 id="282400016"><itemNumber>1410</itemNumber><strength>15mg</strength><dosageForm>Cap</dosageForm><drug id="00012696" notABenefit="Y" sec3="Y"><name>Dalmane</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00521698" sec3="Y"><name>Flurazepam</name><manufacturerId>AAP</manufacturerId><individualPrice>.1166</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1166</amountMOHLTCPays></drug></pcg9><pcg9 id="282400015"><itemNumber>1411</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><drug id="00012718" notABenefit="Y" sec3="Y"><name>Dalmane</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00521701" sec3="Y"><name>Flurazepam</name><manufacturerId>AAP</manufacturerId><individualPrice>.1364</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1364</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00536"><name>LORAZEPAM</name><pcgGroup lccId="00275"><pcg9 id="282400076"><itemNumber>1412</itemNumber><strength>4mg/mL</strength><dosageForm>Inj Sol (with preservative)</dosageForm><drug id="02041405" notABenefit="Y" sec3="Y"><name>Ativan</name><manufacturerId>WAY</manufacturerId><listingDate>2017-02-28</listingDate></drug><drug id="02243278" sec3="Y" sec12="Y"><name>Lorazepam Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>21.2000</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>21.2000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup><pcgGroup><pcg9 id="282400078"><itemNumber>1413</itemNumber><strength>0.5mg</strength><dosageForm>SL Tab</dosageForm><drug id="02041456" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ativan</name><manufacturerId>PFI</manufacturerId><listingDate>2013-10-31</listingDate></drug><drug id="02410745" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lorazepam Sublingual</name><manufacturerId>AAP</manufacturerId><individualPrice>.1099</individualPrice><listingDate>2013-10-31</listingDate></drug></pcg9><pcg9 id="282400169"><itemNumber>1414</itemNumber><strength>1mg</strength><dosageForm>SL Tab</dosageForm><drug id="02041464" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ativan</name><manufacturerId>PFI</manufacturerId><listingDate>2013-10-31</listingDate></drug><drug id="02410753" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lorazepam Sublingual</name><manufacturerId>AAP</manufacturerId><individualPrice>.1385</individualPrice><listingDate>2013-10-31</listingDate></drug></pcg9><pcg9 id="282400079"><itemNumber>1415</itemNumber><strength>2mg</strength><dosageForm>SL Tab</dosageForm><drug id="02041472" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ativan</name><manufacturerId>PFI</manufacturerId><listingDate>2013-10-31</listingDate></drug><drug id="02410761" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lorazepam Sublingual</name><manufacturerId>AAP</manufacturerId><individualPrice>.2152</individualPrice><listingDate>2013-10-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00574"><name>METHOTRIMEPRAZINE</name><pcgGroup><pcg9 id="282400022"><itemNumber>1416</itemNumber><strength>25mg/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="01927698" sec3="Y"><name>Nozinan</name><manufacturerId>NEU</manufacturerId><individualPrice>4.1626</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>4.1626</amountMOHLTCPays></drug></pcg9><pcg9 id="282400041"><itemNumber>1417</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="01927647" notABenefit="Y" sec3="Y"><name>Nozinan</name><manufacturerId>AVE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02238403" sec3="Y"><name>Methoprazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.0721</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.0721</amountMOHLTCPays></drug></pcg9><pcg9 id="282400019"><itemNumber>1418</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="01927655" notABenefit="Y" sec3="Y"><name>Nozinan</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02238404" sec3="Y"><name>Methoprazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.1043</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.1043</amountMOHLTCPays></drug></pcg9><pcg9 id="282400018"><itemNumber>1419</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="01927663" notABenefit="Y" sec3="Y"><name>Nozinan</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02238405" sec3="Y"><name>Methoprazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2681</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.2681</amountMOHLTCPays></drug></pcg9><pcg9 id="282400017"><itemNumber>1420</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="01927671" notABenefit="Y" sec3="Y"><name>Nozinan</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02238406" sec3="Y"><name>Methoprazine</name><manufacturerId>AAP</manufacturerId><individualPrice>.4060</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.4060</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01836"><name>MIDAZOLAM</name><pcgGroup lccId="00284"><pcg9 id="282400180"><itemNumber>1421</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol (with Preservative)</dosageForm><drug id="00766011" notABenefit="Y" sec3="Y"><name>Versed</name><manufacturerId>HLR</manufacturerId><listingDate>2017-05-31</listingDate></drug><drug id="02240286" sec3="Y" sec12="Y"><name>Midazolam Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.1000</individualPrice><listingDate>2017-05-31</listingDate><amountMOHLTCPays>4.1000</amountMOHLTCPays></drug><drug id="02242905" sec3="Y" sec12="Y"><name>Midazolam Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>4.1000</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>4.1000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="495">For intermittent injection used for symptomatic relief in patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote><lccNote seq="004" reasonForUseId="496">For continuous infusion in patients receiving palliative sedation*.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="00580"><name>NITRAZEPAM</name><pcgGroup><pcg9 id="282400165"><itemNumber>1422</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00511528" sec3="Y"><name>Mogadon</name><manufacturerId>AAP</manufacturerId><individualPrice>.1826</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1826</amountMOHLTCPays></drug></pcg9><pcg9 id="282400164"><itemNumber>1423</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00511536" sec3="Y"><name>Mogadon</name><manufacturerId>AAP</manufacturerId><individualPrice>.2732</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2732</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00480"><name>PHENOBARBITAL</name><pcgGroup><pcg9 id="282400235"><itemNumber>1424</itemNumber><strength>5mg/mL</strength><dosageForm>Oral Elixir</dosageForm><drug id="00645575" sec3="Y"><name>Phenobarb Elixir</name><manufacturerId>PEN</manufacturerId><individualPrice>.1535</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>.1535</amountMOHLTCPays></drug></pcg9><pcg9 id="282400236"><itemNumber>1425</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="00178799" sec3="Y"><name>Phenobarb</name><manufacturerId>PEN</manufacturerId><individualPrice>.1508</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>.1508</amountMOHLTCPays></drug></pcg9><pcg9 id="282400237"><itemNumber>1426</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="00178802" sec3="Y"><name>Phenobarb</name><manufacturerId>PEN</manufacturerId><individualPrice>.1795</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>.1795</amountMOHLTCPays></drug></pcg9><pcg9 id="282400238"><itemNumber>1427</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="00178810" sec3="Y"><name>Phenobarb</name><manufacturerId>PEN</manufacturerId><individualPrice>.2433</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>.2433</amountMOHLTCPays></drug></pcg9><pcg9 id="282400174"><itemNumber>1428</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00178829" sec3="Y"><name>Phenobarb</name><manufacturerId>PEN</manufacturerId><individualPrice>.3329</individualPrice><listingDate>2018-01-31</listingDate><amountMOHLTCPays>.3329</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00579"><name>TEMAZEPAM</name><pcgGroup><pcg9 id="282400063"><itemNumber>1429</itemNumber><strength>15mg</strength><dosageForm>Cap</dosageForm><drug id="00604453" sec3="Y"><name>Restoril</name><manufacturerId>AAP</manufacturerId><individualPrice>.2461</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2461</amountMOHLTCPays></drug></pcg9><pcg9 id="282400062"><itemNumber>1430</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><drug id="00604461" sec3="Y"><name>Restoril</name><manufacturerId>AAP</manufacturerId><individualPrice>.2980</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2980</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00578"><name>TRIAZOLAM</name><pcgGroup><pcg9 id="282400057"><itemNumber>1431</itemNumber><strength>0.125mg</strength><dosageForm>Tab</dosageForm><drug id="00512559" notABenefit="Y" sec3="Y"><name>Halcion</name><manufacturerId>UPJ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00808563" sec3="Y"><name>Triazolam</name><manufacturerId>AAP</manufacturerId><individualPrice>.1496</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1496</amountMOHLTCPays></drug></pcg9><pcg9 id="282400056"><itemNumber>1432</itemNumber><strength>0.25mg</strength><dosageForm>Tab</dosageForm><drug id="00443158" notABenefit="Y" sec3="Y"><name>Halcion</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00808571" sec3="Y"><name>Triazolam</name><manufacturerId>AAP</manufacturerId><individualPrice>.2551</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2551</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01878"><name>ZOLPIDEM TARTRATE</name><pcgGroup><pcg9 id="282400214"><itemNumber>1433</itemNumber><strength>5mg</strength><dosageForm>SL Tab</dosageForm><drug id="02391678" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sublinox</name><manufacturerId>VAL</manufacturerId><listingDate>2015-02-26</listingDate></drug><drug id="02436159" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Zolpidem ODT</name><manufacturerId>APX</manufacturerId><individualPrice>1.1825</individualPrice><listingDate>2015-02-26</listingDate></drug><drug id="02436175" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Zolpidem ODT</name><manufacturerId>PMS</manufacturerId><individualPrice>1.1827</individualPrice><listingDate>2017-02-28</listingDate></drug><drug id="02472821" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Zolpidem ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>1.1827</individualPrice><listingDate>2021-09-30</listingDate></drug><drug id="02540592" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Zolpidem ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1827</individualPrice><listingDate>2024-04-30</listingDate></drug></pcg9><pcg9 id="282400212"><itemNumber>1434</itemNumber><strength>10mg</strength><dosageForm>SL Tab</dosageForm><drug id="02370433" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sublinox</name><manufacturerId>VAL</manufacturerId><listingDate>2015-02-26</listingDate></drug><drug id="02434946" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Zolpidem ODT</name><manufacturerId>APX</manufacturerId><individualPrice>1.1884</individualPrice><listingDate>2015-02-26</listingDate></drug><drug id="02436183" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Zolpidem ODT</name><manufacturerId>PMS</manufacturerId><individualPrice>1.1883</individualPrice><listingDate>2017-02-28</listingDate></drug><drug id="02472848" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Zolpidem ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>1.1883</individualPrice><listingDate>2021-09-30</listingDate></drug><drug id="02540606" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Zolpidem ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1883</individualPrice><listingDate>2024-04-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00585"><name>ZOPICLONE</name><pcgGroup><pcg9 id="282400243"><itemNumber>1435</itemNumber><strength>3.75mg</strength><dosageForm>Tab</dosageForm><drug id="02125285" notABenefit="Y" sec3b="Y" sec3="Y"><name>Imovane</name><manufacturerId>SAV</manufacturerId><listingDate>2025-05-30</listingDate></drug><drug id="02458543" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Zopiclone</name><manufacturerId>PMS</manufacturerId><individualPrice>.2343</individualPrice><listingDate>2025-07-31</listingDate></drug><drug id="02549271" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Zopiclone</name><manufacturerId>JPC</manufacturerId><individualPrice>.2343</individualPrice><listingDate>2025-05-30</listingDate></drug></pcg9><pcg9 id="282400064"><itemNumber>1436</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02216167" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Imovane</name><manufacturerId>SAV</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02243426" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Zopiclone</name><manufacturerId>PMS</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02245077" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Zopiclone</name><manufacturerId>APX</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02246534" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ratio-Zopiclone</name><manufacturerId>RPH</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02257572" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Zopiclone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02267918" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Zopiclone</name><manufacturerId>RAN</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02271931" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Zopiclone</name><manufacturerId>COB</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02278030" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Riva-Zopiclone</name><manufacturerId>RIA</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02344122" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zopiclone</name><manufacturerId>SAI</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02385821" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zopiclone</name><manufacturerId>SIV</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02386771" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Zopiclone</name><manufacturerId>MAR</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02386909" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Septa-Zopiclone</name><manufacturerId>SET</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02391716" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Zopiclone</name><manufacturerId>MIN</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02406969" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Zopiclone Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02467941" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Zopiclone</name><manufacturerId>MAT</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02475839" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>AG-Zopiclone</name><manufacturerId>ANG</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02477378" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Zopiclone</name><manufacturerId>NRA</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug><drug id="02549298" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Zopiclone</name><manufacturerId>JPC</manufacturerId><individualPrice>.2231</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>.2231</amountMOHLTCPays></drug></pcg9><pcg9 id="282400179"><itemNumber>1437</itemNumber><strength>7.5mg</strength><dosageForm>Tab</dosageForm><drug id="01926799" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Imovane</name><manufacturerId>SAV</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02008203" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Zopiclone Tablet</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02218313" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Zopiclone</name><manufacturerId>APX</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02240606" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Zopiclone</name><manufacturerId>PMS</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02242481" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ratio-Zopiclone</name><manufacturerId>RPH</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02267926" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Zopiclone</name><manufacturerId>RAN</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02271958" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Zopiclone</name><manufacturerId>COB</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02278049" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Riva-Zopiclone</name><manufacturerId>RIA</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02282445" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zopiclone</name><manufacturerId>SAI</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02356805" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Zopiclone</name><manufacturerId>JPC</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02385848" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zopiclone</name><manufacturerId>SIV</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02386798" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Zopiclone</name><manufacturerId>MAR</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02386917" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Septa-Zopiclone</name><manufacturerId>SET</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02391724" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Zopiclone</name><manufacturerId>MIN</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02406977" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Zopiclone Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02467968" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Zopiclone</name><manufacturerId>MAT</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02475847" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>AG-Zopiclone</name><manufacturerId>ANG</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02477386" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Zopiclone</name><manufacturerId>NRA</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug><drug id="02549301" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Zopiclone</name><manufacturerId>JPC</manufacturerId><individualPrice>.4685</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.4685</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="283620000"><name>ANTIPARKINSONIAN AGENTS DOPAMINE RECEPTOR AGONISTS</name><genericName id="02042"><name>ROTIGOTINE</name><pcgGroup lccId="00290"><pcg9 id="283620001"><itemNumber>1438</itemNumber><strength>2mg/24hr</strength><dosageForm>Trans Patch</dosageForm><drug id="02403900" sec3="Y" sec12="Y"><name>Neupro</name><manufacturerId>UCB</manufacturerId><individualPrice>3.7170</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>3.7170</amountMOHLTCPays></drug></pcg9><pcg9 id="283620002"><itemNumber>1439</itemNumber><strength>4mg/24hr</strength><dosageForm>Trans Patch</dosageForm><drug id="02403927" sec3="Y" sec12="Y"><name>Neupro</name><manufacturerId>UCB</manufacturerId><individualPrice>6.8250</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>6.8250</amountMOHLTCPays></drug></pcg9><pcg9 id="283620003"><itemNumber>1440</itemNumber><strength>6mg/24hr</strength><dosageForm>Trans Patch</dosageForm><drug id="02403935" sec3="Y" sec12="Y"><name>Neupro</name><manufacturerId>UCB</manufacturerId><individualPrice>7.6333</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>7.6333</amountMOHLTCPays></drug></pcg9><pcg9 id="283620004"><itemNumber>1441</itemNumber><strength>8mg/24hr</strength><dosageForm>Trans Patch</dosageForm><drug id="02403943" sec3="Y" sec12="Y"><name>Neupro</name><manufacturerId>UCB</manufacturerId><individualPrice>7.6333</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>7.6333</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="510">For adjunctive therapy to levodopa for the treatment of patients with advanced stage Parkinson&apos;s disease (APD).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="289200000"><name>MISCELLANEOUS CENTRAL NERVOUS SYSTEM DRUGS</name><genericName id="01731"><name>ACAMPROSATE CALCIUM</name><pcgGroup lccId="00305"><pcg9 id="289200029"><itemNumber>1442</itemNumber><strength>333mg</strength><dosageForm>DR Tab</dosageForm><drug id="02293269" sec3="Y" sec12="Y"><name>Campral</name><manufacturerId>MYL</manufacturerId><individualPrice>.9976</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>.9976</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="531">For the treatment of alcohol use disorder in patients who:

- Meet clinical criteria for alcohol use disorder; and

- Express a commitment to abstain from alcohol; and

- Have been abstinent from alcohol for at least 3 days prior to starting acamprosate; and

- Have confirmed participation in counselling and treatment for alcohol use disorder*


* An individualized treatment plan will have one or more of the following components: Counselling and follow-up with the patient&apos;s family physician, addiction physician, or psychiatrist; self-help groups such as Alcoholics Anonymous; and outpatient, day, or inpatient psychosocial rehabilitation programs.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01615"><name>ALMOTRIPTAN</name><pcgGroup><pcg9 id="289200017"><itemNumber>1443</itemNumber><strength>6.25mg</strength><dosageForm>Tab</dosageForm><drug id="02248128" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Axert</name><manufacturerId>JNO</manufacturerId><listingDate>2013-09-27</listingDate></drug><drug id="02398435" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Almotriptan</name><manufacturerId>MYL</manufacturerId><individualPrice>9.7833</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>9.7833</amountMOHLTCPays></drug><drug id="02405792" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Almotriptan</name><manufacturerId>APX</manufacturerId><individualPrice>9.7833</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>9.7833</amountMOHLTCPays></drug></pcg9><pcg9 id="289200016"><itemNumber>1444</itemNumber><strength>12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02248129" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Axert</name><manufacturerId>JNO</manufacturerId><listingDate>2013-09-27</listingDate></drug><drug id="02398443" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Almotriptan</name><manufacturerId>MYL</manufacturerId><individualPrice>9.7833</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>9.7833</amountMOHLTCPays></drug><drug id="02405334" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Almotriptan</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.7825</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>9.7825</amountMOHLTCPays></drug><drug id="02405806" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Almotriptan</name><manufacturerId>APX</manufacturerId><individualPrice>9.7833</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>9.7833</amountMOHLTCPays></drug><drug id="02434849" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Almotriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>9.7833</individualPrice><listingDate>2015-06-29</listingDate><amountMOHLTCPays>9.7833</amountMOHLTCPays></drug><drug id="02466821" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Almotriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>9.7833</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>9.7833</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01666"><name>ATOMOXETINE HCL</name><pcgGroup><pcg9 id="289200018"><itemNumber>1445</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02262800" notABenefit="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02314541" sec3="Y"><name>Teva-Atomoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02318024" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02381028" sec3="Y"><name>PMS-Atomoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02386410" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02445883" sec3="Y"><name>Atomoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02467747" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02471485" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug><drug id="02506807" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.5106</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.5106</amountMOHLTCPays></drug></pcg9><pcg9 id="289200019"><itemNumber>1446</itemNumber><strength>18mg</strength><dosageForm>Cap</dosageForm><drug id="02262819" notABenefit="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02314568" sec3="Y"><name>Teva-Atomoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02318032" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02381036" sec3="Y"><name>PMS-Atomoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02386429" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02445905" sec3="Y"><name>Atomoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02467755" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02471493" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug><drug id="02506815" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.5748</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.5748</amountMOHLTCPays></drug></pcg9><pcg9 id="289200020"><itemNumber>1447</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02262827" notABenefit="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02314576" sec3="Y"><name>Teva-Atomoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02318040" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02381044" sec3="Y"><name>PMS-Atomoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02386437" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02445913" sec3="Y"><name>Atomoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02467763" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02471507" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug><drug id="02506823" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.6420</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.6420</amountMOHLTCPays></drug></pcg9><pcg9 id="289200021"><itemNumber>1448</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="02262835" notABenefit="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02314584" sec3="Y"><name>Teva-Atomoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02318059" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02381052" sec3="Y"><name>PMS-Atomoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02386445" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02445948" sec3="Y"><name>Atomoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02467771" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02471515" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug><drug id="02506831" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.7369</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.7369</amountMOHLTCPays></drug></pcg9><pcg9 id="289200022"><itemNumber>1449</itemNumber><strength>60mg</strength><dosageForm>Cap</dosageForm><drug id="02262843" notABenefit="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02314592" sec3="Y"><name>Teva-Atomoxetine</name><manufacturerId>TEV</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02318067" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02381060" sec3="Y"><name>PMS-Atomoxetine</name><manufacturerId>PMS</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02386453" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02445956" sec3="Y"><name>Atomoxetine</name><manufacturerId>SIV</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02467798" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02471523" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug><drug id="02506858" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>.8092</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.8092</amountMOHLTCPays></drug></pcg9><pcg9 id="289200038"><itemNumber>1450</itemNumber><strength>80mg</strength><dosageForm>Cap</dosageForm><drug id="02279347" notABenefit="Y" sec3b="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02318075" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>3.9961</individualPrice><listingDate>2010-12-14</listingDate></drug><drug id="02362511" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Atomoxetin</name><manufacturerId>TEV</manufacturerId><individualPrice>3.9960</individualPrice><listingDate>2013-09-27</listingDate></drug><drug id="02386461" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.9963</individualPrice><listingDate>2012-07-27</listingDate></drug><drug id="02467801" notABenefit="Y" sec3b="Y" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>3.9960</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02471531" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>3.9960</individualPrice><listingDate>2019-03-28</listingDate></drug><drug id="02506866" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>3.9960</individualPrice><listingDate>2022-09-29</listingDate></drug></pcg9><pcg9 id="289200039"><itemNumber>1451</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02279355" notABenefit="Y" sec3b="Y" sec3="Y"><name>Strattera</name><manufacturerId>LIL</manufacturerId><listingDate>2010-12-14</listingDate></drug><drug id="02318083" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Atomoxetine</name><manufacturerId>APX</manufacturerId><individualPrice>4.3521</individualPrice><listingDate>2010-12-14</listingDate></drug><drug id="02362538" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Atomoxetin</name><manufacturerId>TEV</manufacturerId><individualPrice>4.3520</individualPrice><listingDate>2013-09-27</listingDate></drug><drug id="02386488" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Atomoxetine</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.3524</individualPrice><listingDate>2012-07-27</listingDate></drug><drug id="02467828" notABenefit="Y" sec3b="Y" sec3="Y"><name>Atomoxetine</name><manufacturerId>SAI</manufacturerId><individualPrice>4.3520</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02471558" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Atomoxetine</name><manufacturerId>AUR</manufacturerId><individualPrice>4.3520</individualPrice><listingDate>2019-03-28</listingDate></drug><drug id="02506874" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Atomoxetine</name><manufacturerId>JPC</manufacturerId><individualPrice>4.3520</individualPrice><listingDate>2022-09-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01944"><name>DIMETHYL FUMARATE</name><pcgGroup><pcg9 id="289200051"><itemNumber>1452</itemNumber><strength>120mg</strength><dosageForm>DR Cap</dosageForm><drug id="02404508" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tecfidera</name><manufacturerId>BIG</manufacturerId><individualPrice>18.3866</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02494809" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>GLN-Dimethyl Fumarate</name><manufacturerId>GLP</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02495341" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Dimethyl Fumarate</name><manufacturerId>ACH</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02497026" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Dimethyl Fumarate</name><manufacturerId>PMS</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02502690" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Dimethyl Fumarate</name><manufacturerId>MAR</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02505762" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dimethyl Fumarate</name><manufacturerId>APX</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02513781" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Dimethyl Fumarate DR Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02516047" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Dimethyl Fumarate</name><manufacturerId>JPC</manufacturerId><individualPrice>9.1933</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>9.1933</amountMOHLTCPays></drug><drug id="02540746" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Dimethyl Fumarate</name><manufacturerId>AUR</manufacturerId><individualPrice>4.4266</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>4.4266</amountMOHLTCPays></drug></pcg9><pcg9 id="289200053"><itemNumber>1453</itemNumber><strength>240mg</strength><dosageForm>DR Cap</dosageForm><drug id="02420201" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tecfidera</name><manufacturerId>BIG</manufacturerId><individualPrice>36.7734</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02494817" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>GLN-Dimethyl Fumarate</name><manufacturerId>GLP</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02495368" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Dimethyl Fumarate</name><manufacturerId>ACH</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02497034" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Dimethyl Fumarate</name><manufacturerId>PMS</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02502704" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Dimethyl Fumarate</name><manufacturerId>MAR</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02505770" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Dimethyl Fumarate</name><manufacturerId>APX</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02513803" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Dimethyl Fumarate DR Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02516055" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Dimethyl Fumarate</name><manufacturerId>JPC</manufacturerId><individualPrice>18.3867</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>18.3867</amountMOHLTCPays></drug><drug id="02540754" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Dimethyl Fumarate</name><manufacturerId>AUR</manufacturerId><individualPrice>8.6888</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>8.6888</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01906"><name>ELETRIPTAN</name><pcgGroup><pcg9 id="289200049"><itemNumber>1454</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02256290" notABenefit="Y" sec3b="Y" sec3="Y"><name>Relpax</name><manufacturerId>UJC</manufacturerId><listingDate>2013-01-29</listingDate></drug><drug id="02342235" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gd-Eletriptan</name><manufacturerId>UJC</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2013-01-29</listingDate></drug><drug id="02382091" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Eletriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2013-11-28</listingDate></drug><drug id="02386054" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Eletriptan</name><manufacturerId>APX</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2013-05-31</listingDate></drug><drug id="02479451" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Eletriptan</name><manufacturerId>AUR</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2019-04-30</listingDate></drug><drug id="02493683" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Eletriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2021-07-30</listingDate></drug><drug id="02511266" notABenefit="Y" sec3b="Y" sec3="Y"><name>Eletriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2021-06-30</listingDate></drug><drug id="02518015" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Eletriptan Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2022-05-31</listingDate></drug></pcg9><pcg9 id="289200050"><itemNumber>1455</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="02256304" notABenefit="Y" sec3b="Y" sec3="Y"><name>Relpax</name><manufacturerId>UJC</manufacturerId><listingDate>2013-01-29</listingDate></drug><drug id="02342243" notABenefit="Y" sec3b="Y" sec3="Y"><name>Gd-Eletriptan</name><manufacturerId>UJC</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2013-01-29</listingDate></drug><drug id="02382105" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Eletriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2013-11-28</listingDate></drug><drug id="02386062" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Eletriptan</name><manufacturerId>APX</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2013-05-31</listingDate></drug><drug id="02479478" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Eletriptan</name><manufacturerId>AUR</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2019-04-30</listingDate></drug><drug id="02493691" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Eletriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2021-07-30</listingDate></drug><drug id="02511274" notABenefit="Y" sec3b="Y" sec3="Y"><name>Eletriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2021-06-30</listingDate></drug><drug id="02518023" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Eletriptan Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>10.0850</individualPrice><listingDate>2022-05-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01536"><name>ENTACAPONE</name><pcgGroup lccId="00142"><pcg9 id="289200014"><itemNumber>1456</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="02243763" sec3="Y" sec12="Y"><name>Comtan</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6837</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.4010</amountMOHLTCPays></drug><drug id="02375559" sec3="Y" sec12="Y"><name>Teva-Entacapone</name><manufacturerId>TEV</manufacturerId><individualPrice>.4010</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.4010</amountMOHLTCPays></drug><drug id="02380005" sec3="Y" sec12="Y"><name>Sandoz Entacapone</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4010</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>.4010</amountMOHLTCPays></drug><drug id="02535939" sec3="Y" sec12="Y"><name>Mint-Entacapone</name><manufacturerId>MIN</manufacturerId><individualPrice>.4010</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.4010</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="367">For the treatment of patients with Parkinson&apos;s disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01957"><name>FROVATRIPTAN SUCCINATE</name><pcgGroup><pcg9 id="289200052"><itemNumber>1457</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02257084" notABenefit="Y" sec3b="Y" sec3="Y"><name>Frova</name><manufacturerId>EDO</manufacturerId><listingDate>2014-08-28</listingDate></drug><drug id="02415844" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Frovatriptan</name><manufacturerId>EDO</manufacturerId><individualPrice>12.5033</individualPrice><listingDate>2016-03-30</listingDate></drug><drug id="02426471" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Frovatriptan</name><manufacturerId>APX</manufacturerId><individualPrice>12.5033</individualPrice><listingDate>2014-08-28</listingDate></drug><drug id="02497131" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Frovatriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>12.5033</individualPrice><listingDate>2021-02-26</listingDate></drug><drug id="02509687" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Frovatriptan</name><manufacturerId>MIN</manufacturerId><individualPrice>12.5033</individualPrice><listingDate>2022-08-31</listingDate></drug><drug id="02535475" notABenefit="Y" sec3b="Y" sec3="Y"><name>Frovatriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>12.5033</individualPrice><listingDate>2023-08-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01763"><name>MEMANTINE HCL</name><pcgGroup><pcg9 id="289200037"><itemNumber>1458</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02260638" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ebixa</name><manufacturerId>VLH</manufacturerId><listingDate>2010-01-05</listingDate></drug><drug id="02320908" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Memantine</name><manufacturerId>RPH</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2010-01-05</listingDate></drug><drug id="02321130" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Memantine</name><manufacturerId>PMS</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2010-01-05</listingDate></drug><drug id="02324067" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Memantine</name><manufacturerId>COB</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2010-06-14</listingDate></drug><drug id="02366487" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Memantine</name><manufacturerId>APX</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2011-12-15</listingDate></drug><drug id="02375532" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Memantine FCT</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2015-02-26</listingDate></drug><drug id="02409895" notABenefit="Y" sec3b="Y" sec3="Y"><name>Med-Memantine</name><manufacturerId>GMP</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2015-05-28</listingDate></drug><drug id="02421364" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Memantine</name><manufacturerId>RAN</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2014-09-25</listingDate></drug><drug id="02443082" notABenefit="Y" sec3b="Y" sec3="Y"><name>Memantine</name><manufacturerId>SAI</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02446049" notABenefit="Y" sec3b="Y" sec3="Y"><name>Memantine</name><manufacturerId>SIV</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02531887" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Memantine</name><manufacturerId>MIN</manufacturerId><individualPrice>1.6357</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01505"><name>NARATRIPTAN HYDROCHLORIDE</name><pcgGroup><pcg9 id="289200004"><itemNumber>1459</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02237820" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Amerge</name><manufacturerId>GSK</manufacturerId><listingDate>2010-03-02</listingDate></drug><drug id="02314290" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Naratriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>12.4990</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>12.4990</amountMOHLTCPays></drug></pcg9><pcg9 id="289200005"><itemNumber>1460</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02237821" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Amerge</name><manufacturerId>GSK</manufacturerId><listingDate>2010-03-02</listingDate></drug><drug id="02314304" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Naratriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>8.2125</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>8.2125</amountMOHLTCPays></drug><drug id="02322323" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Naratriptan</name><manufacturerId>SDZ</manufacturerId><individualPrice>8.2125</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>8.2125</amountMOHLTCPays></drug><drug id="02365502" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Naratriptan</name><manufacturerId>APX</manufacturerId><individualPrice>8.2125</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>8.2125</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00260"><name>PIZOTYLINE</name><pcgGroup><pcg9 id="289200031"><itemNumber>1461</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00511552" sec3="Y"><name>Sandomigran DS</name><manufacturerId>PPI</manufacturerId><individualPrice>1.1698</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.1698</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01364"><name>PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE</name><pcgGroup><pcg9 id="289200001"><itemNumber>1462</itemNumber><strength>0.25mg</strength><dosageForm>Tab</dosageForm><drug id="02237145" sec3="Y"><name>Mirapex</name><manufacturerId>BOE</manufacturerId><individualPrice>1.2915</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug><drug id="02292378" sec3="Y"><name>Apo-Pramipexole</name><manufacturerId>APX</manufacturerId><individualPrice>.1950</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug><drug id="02297302" sec3="Y"><name>Act Pramipexole</name><manufacturerId>TEV</manufacturerId><individualPrice>.1950</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug><drug id="02309122" sec3="Y"><name>Pramipexole</name><manufacturerId>SIV</manufacturerId><individualPrice>.1950</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug><drug id="02315262" sec3="Y"><name>Sandoz Pramipexole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1950</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug><drug id="02367602" sec3="Y"><name>Pramipexole</name><manufacturerId>SAI</manufacturerId><individualPrice>.1950</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug><drug id="02424061" sec3="Y"><name>Auro-Pramipexole</name><manufacturerId>AUR</manufacturerId><individualPrice>.1950</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.1950</amountMOHLTCPays></drug></pcg9><pcg9 id="289200011"><itemNumber>1463</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02241594" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mirapex</name><manufacturerId>BOE</manufacturerId><listingDate>2007-09-04</listingDate></drug><drug id="02292386" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Pramipexole</name><manufacturerId>APX</manufacturerId><individualPrice>1.3860</individualPrice><listingDate>2007-09-04</listingDate></drug><drug id="02297310" notABenefit="Y" sec3b="Y" sec3="Y"><name>Act Pramipexole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3860</individualPrice><listingDate>2009-06-23</listingDate></drug><drug id="02309130" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pramipexole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.3860</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02315270" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Pramipexole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3860</individualPrice><listingDate>2009-05-20</listingDate></drug><drug id="02367610" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pramipexole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.3860</individualPrice><listingDate>2022-06-30</listingDate></drug><drug id="02424088" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Pramipexole</name><manufacturerId>AUR</manufacturerId><individualPrice>1.3860</individualPrice><listingDate>2017-05-31</listingDate></drug></pcg9><pcg9 id="289200024"><itemNumber>1464</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02292394" sec3="Y"><name>Apo-Pramipexole</name><manufacturerId>APX</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02297329" sec3="Y"><name>Act Pramipexole</name><manufacturerId>TEV</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02309149" sec3="Y"><name>Pramipexole</name><manufacturerId>SIV</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02315289" sec3="Y"><name>Sandoz Pramipexole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02367629" sec3="Y"><name>Pramipexole</name><manufacturerId>SAI</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02424096" sec3="Y"><name>Auro-Pramipexole</name><manufacturerId>AUR</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="09857269" notABenefit="Y" sec3="Y"><name>Mirapex</name><manufacturerId>BOE</manufacturerId><listingDate>2007-03-09</listingDate></drug></pcg9><pcg9 id="289200025"><itemNumber>1465</itemNumber><strength>1.5mg</strength><dosageForm>Tab</dosageForm><drug id="02292408" sec3="Y"><name>Apo-Pramipexole</name><manufacturerId>APX</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02297337" sec3="Y"><name>Act Pramipexole</name><manufacturerId>TEV</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02309157" sec3="Y"><name>Pramipexole</name><manufacturerId>SIV</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02315297" sec3="Y"><name>Sandoz Pramipexole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02367645" sec3="Y"><name>Pramipexole</name><manufacturerId>SAI</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="02424118" sec3="Y"><name>Auro-Pramipexole</name><manufacturerId>AUR</manufacturerId><individualPrice>.3901</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.3901</amountMOHLTCPays></drug><drug id="09857270" notABenefit="Y" sec3="Y"><name>Mirapex</name><manufacturerId>BOE</manufacturerId><listingDate>2007-03-09</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01506"><name>RIZATRIPTAN</name><pcgGroup><pcg9 id="289200047"><itemNumber>1466</itemNumber><strength>5mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02240518" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Maxalt RPD</name><manufacturerId>OCI</manufacturerId><individualPrice>22.5608</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1650</amountMOHLTCPays></drug><drug id="02351870" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Rizatriptan ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02374730" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Rizatriptan ODT</name><manufacturerId>COB</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02379198" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Rizatriptan ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02393360" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Rizatriptan RDT</name><manufacturerId>PMS</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02393484" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Rizatriptan RPD</name><manufacturerId>APX</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02396661" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Rizatriptan ODT</name><manufacturerId>TEV</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02436604" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Rizatriptan  ODT</name><manufacturerId>NAT</manufacturerId><individualPrice>11.1650</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>11.1650</amountMOHLTCPays></drug><drug id="02439573" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Rizatriptan ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02442906" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rizatriptan ODT</name><manufacturerId>SAI</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02446111" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rizatriptan ODT</name><manufacturerId>SIV</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02458764" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>CCP-Rizatriptan</name><manufacturerId>CCP</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02462788" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Rizatriptan ODT</name><manufacturerId>MAR</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02465086" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Rizatriptan ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02483270" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel-Rizatriptan ODT</name><manufacturerId>ACC</manufacturerId><individualPrice>7.7800</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>7.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="289200048"><itemNumber>1467</itemNumber><strength>10mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02240519" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Maxalt RPD</name><manufacturerId>OCI</manufacturerId><individualPrice>22.5608</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1650</amountMOHLTCPays></drug><drug id="02351889" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Rizatriptan ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02374749" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Rizatriptan ODT</name><manufacturerId>COB</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02379201" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Rizatriptan ODT</name><manufacturerId>MYL</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02393379" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Rizatriptan RDT</name><manufacturerId>PMS</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02393492" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Rizatriptan RPD</name><manufacturerId>APX</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02396688" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Rizatriptan ODT</name><manufacturerId>TEV</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02436612" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Rizatriptan  ODT</name><manufacturerId>NAT</manufacturerId><individualPrice>11.1650</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>11.1650</amountMOHLTCPays></drug><drug id="02439581" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Rizatriptan ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02442914" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rizatriptan ODT</name><manufacturerId>SAI</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02446138" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rizatriptan ODT</name><manufacturerId>SIV</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02458772" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>CCP-Rizatriptan</name><manufacturerId>CCP</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02462796" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Rizatriptan ODT</name><manufacturerId>MAR</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02465094" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Rizatriptan ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02483289" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel-Rizatriptan ODT</name><manufacturerId>ACC</manufacturerId><individualPrice>7.7800</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>7.7800</amountMOHLTCPays></drug><drug id="02489384" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Rizatriptan ODT</name><manufacturerId>NRA</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02492490" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>AG-Rizatriptan ODT</name><manufacturerId>ANG</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug></pcg9><pcg9 id="289200045"><itemNumber>1468</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02240520" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Maxalt</name><manufacturerId>FRS</manufacturerId><listingDate>2012-05-29</listingDate></drug><drug id="02380455" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Rizatriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02393468" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Rizatriptan</name><manufacturerId>APX</manufacturerId><individualPrice>12.5970</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>12.5970</amountMOHLTCPays></drug><drug id="02429233" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Rizatriptan IR</name><manufacturerId>JPC</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug></pcg9><pcg9 id="289200046"><itemNumber>1469</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02240521" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Maxalt</name><manufacturerId>OCI</manufacturerId><individualPrice>22.5608</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02379678" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Rizatriptan</name><manufacturerId>MAR</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02380463" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Rizatriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02381702" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Rizatriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02393476" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Rizatriptan</name><manufacturerId>APX</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02429241" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Rizatriptan IR</name><manufacturerId>JPC</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02441144" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Rizatriptan</name><manufacturerId>AUR</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug><drug id="02516756" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rizatriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>11.1150</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>11.1150</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00265"><name>SUMATRIPTAN SUCCINATE</name><pcgGroup><pcg9 id="289200007"><itemNumber>1470</itemNumber><strength>6mg/0.5mL</strength><dosageForm>Inj Sol-Pref Syr 0.5mL Pk</dosageForm><drug id="02212188" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Imitrex</name><manufacturerId>GLW</manufacturerId><individualPrice>52.8600</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>42.4650</amountMOHLTCPays></drug><drug id="02361698" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Sumatriptan</name><manufacturerId>TAR</manufacturerId><individualPrice>42.4650</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>42.4650</amountMOHLTCPays></drug></pcg9><pcg9 id="289200012"><itemNumber>1471</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02256428" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Sumatriptan</name><manufacturerId>PMS</manufacturerId><individualPrice>8.9900</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>8.9900</amountMOHLTCPays></drug><drug id="02257882" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Sumatriptan</name><manufacturerId>COB</manufacturerId><individualPrice>8.9900</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>8.9900</amountMOHLTCPays></drug><drug id="02268906" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Sumatriptan</name><manufacturerId>MYL</manufacturerId><individualPrice>8.9900</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>8.9900</amountMOHLTCPays></drug><drug id="09857299" sec3b="Y" sec3="Y"><name>Imitrex</name><manufacturerId>GSK</manufacturerId><listingDate>2007-06-06</listingDate></drug></pcg9><pcg9 id="289200026"><itemNumber>1472</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02239738" notABenefit="Y" sec3b="Y" sec3="Y"><name>Imitrex DF</name><manufacturerId>GSK</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02286815" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Sumatriptan DF</name><manufacturerId>TEV</manufacturerId><individualPrice>8.9900</individualPrice><listingDate>2007-06-06</listingDate></drug><drug id="02545292" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Sumatriptan DF</name><manufacturerId>JPC</manufacturerId><individualPrice>8.9900</individualPrice><listingDate>2025-01-31</listingDate></drug></pcg9><pcg9 id="289200009"><itemNumber>1473</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02163764" sec3b="Y" sec3="Y"><name>Imitrex</name><manufacturerId>GSK</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02256436" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Sumatriptan</name><manufacturerId>PMS</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02257890" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Sumatriptan</name><manufacturerId>COB</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02263025" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Sumatriptan</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02268388" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Sumatriptan</name><manufacturerId>APX</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02268914" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Sumatriptan</name><manufacturerId>MYL</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02271583" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ratio-Sumatriptan</name><manufacturerId>RPH</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02286521" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sumatriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02545357" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Sumatriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02546035" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sumatriptan</name><manufacturerId>SIV</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug></pcg9><pcg9 id="289200027"><itemNumber>1474</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02212153" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Imitrex DF</name><manufacturerId>GSK</manufacturerId><individualPrice>19.7817</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02286823" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sumatriptan DF</name><manufacturerId>TEV</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02385570" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sumatriptan DF</name><manufacturerId>SIV</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug><drug id="02545306" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Sumatriptan DF</name><manufacturerId>JPC</manufacturerId><individualPrice>9.0650</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>9.0650</amountMOHLTCPays></drug></pcg9><pcg9 id="289200006"><itemNumber>1475</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="01950614" sec3b="Y" sec3="Y"><name>Imitrex</name><manufacturerId>GSK</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02256444" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Sumatriptan</name><manufacturerId>PMS</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02257904" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Sumatriptan</name><manufacturerId>COB</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02263033" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Sumatriptan</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02268396" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Sumatriptan</name><manufacturerId>APX</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02268922" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Sumatriptan</name><manufacturerId>MYL</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02271591" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ratio-Sumatriptan</name><manufacturerId>RPH</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02286548" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sumatriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug><drug id="02545365" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Sumatriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>9.9866</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>9.9866</amountMOHLTCPays></drug><drug id="02546043" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sumatriptan</name><manufacturerId>SIV</manufacturerId><individualPrice>9.9867</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>9.9867</amountMOHLTCPays></drug></pcg9><pcg9 id="289200028"><itemNumber>1476</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02212161" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Imitrex DF</name><manufacturerId>GSK</manufacturerId><individualPrice>21.7933</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9866</amountMOHLTCPays></drug><drug id="02286831" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sumatriptan DF</name><manufacturerId>TEV</manufacturerId><individualPrice>9.9866</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>9.9866</amountMOHLTCPays></drug><drug id="02385589" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sumatriptan DF</name><manufacturerId>SIV</manufacturerId><individualPrice>9.9866</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>9.9866</amountMOHLTCPays></drug><drug id="02545314" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Sumatriptan DF</name><manufacturerId>JPC</manufacturerId><individualPrice>9.9866</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>9.9866</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01532"><name>ZOLMITRIPTAN</name><pcgGroup><pcg9 id="289200015"><itemNumber>1477</itemNumber><strength>2.5mg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02243045" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zomig Rapimelt</name><manufacturerId>AZC</manufacturerId><individualPrice>17.3848</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02342545" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Zolmitriptan OD</name><manufacturerId>TEV</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02362996" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Zolmitriptan ODT</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.8625</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>6.8625</amountMOHLTCPays></drug><drug id="02381575" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Zolmitriptan Rapid</name><manufacturerId>APX</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02419513" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Zolmitriptan ODT</name><manufacturerId>MIN</manufacturerId><individualPrice>6.8625</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>6.8625</amountMOHLTCPays></drug><drug id="02428237" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Zolmitriptan ODT</name><manufacturerId>JPC</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02428474" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Septa-Zolmitriptan-ODT</name><manufacturerId>SET</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02442671" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zolmitriptan ODT</name><manufacturerId>SAI</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug></pcg9><pcg9 id="289200013"><itemNumber>1478</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="02238660" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zomig</name><manufacturerId>AZC</manufacturerId><individualPrice>17.3848</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02313960" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Zolmitriptan</name><manufacturerId>TEV</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02362988" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Zolmitriptan</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.8586</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>6.8586</amountMOHLTCPays></drug><drug id="02380951" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Zolmitriptan</name><manufacturerId>APX</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02399458" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Zolmitriptan</name><manufacturerId>MAR</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02419521" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Zolmitriptan</name><manufacturerId>MIN</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02421534" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Zolmitriptan</name><manufacturerId>NAT</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02421623" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Zolmitriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02442655" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zolmitriptan</name><manufacturerId>SAI</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02458780" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>CCP-Zolmitriptan</name><manufacturerId>CCP</manufacturerId><individualPrice>6.8586</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>6.8586</amountMOHLTCPays></drug><drug id="02477106" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Zolmitriptan</name><manufacturerId>JPC</manufacturerId><individualPrice>6.8583</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>6.8583</amountMOHLTCPays></drug><drug id="02481030" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Zolmitriptan</name><manufacturerId>AUR</manufacturerId><individualPrice>6.8633</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>6.8633</amountMOHLTCPays></drug><drug id="02489392" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Zolmitriptan</name><manufacturerId>NRA</manufacturerId><individualPrice>6.8600</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>6.8600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="360000000"><name>DIAGNOSTIC AGENTS</name><pcg6 id="360400000"><name>ADRENAL INSUFFICIENCY</name><genericName id="00587"><name>COSYNTROPIN ZINC HYDROXIDE</name><pcgGroup><pcg9 id="360400003"><itemNumber>1479</itemNumber><strength>1mg/mL</strength><dosageForm>Inj Susp-1mL Pk</dosageForm><drug id="00253952" sec3="Y"><name>Synacthen Depot</name><manufacturerId>QUO</manufacturerId><individualPrice>680.0000</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>680.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="400000000"><name>ELECTROLYTIC, CALORIC  AND WATER BALANCE</name><pcg6 id="401200000"><name>REPLACEMENT AGENTS</name><genericName id="00619"><name>ELECTROLYTE &amp; DEXTROSE</name><pcgGroup><pcg9 id="401200037"><itemNumber>1480</itemNumber><dosageForm>O/L</dosageForm><drug id="80072902" sec3="Y"><name>Pedialyte Regular</name><manufacturerId>ABB</manufacturerId><individualPrice>.0079</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.0079</amountMOHLTCPays></drug><drug id="80074173" sec3="Y"><name>Pedialyte Flavored</name><manufacturerId>ABB</manufacturerId><individualPrice>.0079</individualPrice><listingDate>2018-08-30</listingDate><amountMOHLTCPays>.0079</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00621"><name>PEG-ELECTROLYTES</name><pcgGroup><pcg9 id="401200040"><itemNumber>1481</itemNumber><dosageForm>Pd-4L Pk</dosageForm><drug id="00677442" notABenefit="Y" sec3="Y"><name>Colyte</name><manufacturerId>PEN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00777838" sec3="Y"><name>PegLyte Powder</name><manufacturerId>PEN</manufacturerId><individualPrice>17.7331</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>17.7331</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="401800000"><name>POTASSIUM-REMOVING RESINS</name><genericName id="01862"><name>LANTHANUM</name><pcgGroup><pcg9 id="401800005"><itemNumber>1482</itemNumber><strength>250mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02287145" notABenefit="Y" sec3="Y"><name>Fosrenol</name><manufacturerId>TAK</manufacturerId><listingDate>2020-08-28</listingDate></drug><drug id="02498731" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Lanthanum</name><manufacturerId>NAT</manufacturerId><individualPrice>1.2034</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>1.2034</amountMOHLTCPays></drug></pcg9><pcg9 id="401800006"><itemNumber>1483</itemNumber><strength>500mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02287153" notABenefit="Y" sec3="Y"><name>Fosrenol</name><manufacturerId>TAK</manufacturerId><listingDate>2020-07-31</listingDate></drug><drug id="02498758" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Lanthanum</name><manufacturerId>NAT</manufacturerId><individualPrice>2.4069</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>2.4069</amountMOHLTCPays></drug></pcg9><pcg9 id="401800007"><itemNumber>1484</itemNumber><strength>750mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02287161" notABenefit="Y" sec3="Y"><name>Fosrenol</name><manufacturerId>TAK</manufacturerId><listingDate>2020-07-31</listingDate></drug><drug id="02498766" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Lanthanum</name><manufacturerId>NAT</manufacturerId><individualPrice>3.6219</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>3.6219</amountMOHLTCPays></drug></pcg9><pcg9 id="401800008"><itemNumber>1485</itemNumber><strength>1000mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02287188" notABenefit="Y" sec3="Y"><name>Fosrenol</name><manufacturerId>TAK</manufacturerId><listingDate>2020-07-31</listingDate></drug><drug id="02498774" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Lanthanum</name><manufacturerId>NAT</manufacturerId><individualPrice>4.8018</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>4.8018</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00631"><name>POLYSTYRENE SODIUM SULFONATE</name><pcgGroup><pcg9 id="401800004"><itemNumber>1486</itemNumber><strength>250mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00769541" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Solystat</name><manufacturerId>PEN</manufacturerId><listingDate>2019-07-31</listingDate></drug><drug id="02473968" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Odan-Sodium Polystyrene Sulfonate</name><manufacturerId>ODN</manufacturerId><individualPrice>.1954</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.1954</amountMOHLTCPays></drug></pcg9><pcg9 id="401800001"><itemNumber>1487</itemNumber><strength>1mEq/g</strength><dosageForm>Oral Pd-454g Pk</dosageForm><drug id="00755338" sec3="Y"><name>Solystat</name><manufacturerId>PEN</manufacturerId><individualPrice>29.4175</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>29.4175</amountMOHLTCPays></drug><drug id="02026961" sec3="Y"><name>Kayexalate</name><manufacturerId>SAV</manufacturerId><individualPrice>43.6300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>29.4175</amountMOHLTCPays></drug><drug id="02473941" sec3="Y"><name>Odan-Sodium Polystyrene Sulfonate</name><manufacturerId>ODN</manufacturerId><individualPrice>29.4175</individualPrice><listingDate>2019-05-31</listingDate><amountMOHLTCPays>29.4175</amountMOHLTCPays></drug><drug id="02497557" sec3="Y"><name>Jamp Sodium Polystyrene Sulfonate</name><manufacturerId>JPC</manufacturerId><individualPrice>29.4175</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>29.4175</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02072"><name>SEVELAMER CARBONATE</name><pcgGroup><pcg9 id="401800009"><itemNumber>1488</itemNumber><strength>800mg</strength><dosageForm>Tab</dosageForm><drug id="02354586" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Renvela</name><manufacturerId>SAV</manufacturerId><individualPrice>1.3125</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug><drug id="02461501" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel-Sevelamer</name><manufacturerId>ACC</manufacturerId><individualPrice>1.2634</individualPrice><listingDate>2021-06-07</listingDate><amountMOHLTCPays>1.2634</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="402000000"><name>CALORIC AGENTS</name><genericName id="02128"><name>OLIVE OIL &amp; SOYBEAN OIL</name><pcgGroup lccId="00334"><pcg9 id="402000003"><itemNumber>1489</itemNumber><strength>16% &amp; 4% w/w</strength><dosageForm>Inj Emuls-250mL Pk</dosageForm><drug id="02344327" sec3="Y" sec12="Y"><name>Clinoleic 20%</name><manufacturerId>BAX</manufacturerId><individualPrice>25.0000</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>25.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="402000004"><itemNumber>1490</itemNumber><strength>16% &amp; 4% w/w</strength><dosageForm>Inj Emuls-500mL Pk</dosageForm><drug id="09858109" sec3="Y" sec12="Y"><name>Clinoleic 20%</name><manufacturerId>BAX</manufacturerId><individualPrice>30.0000</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>30.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="579">As part of a parenteral nutrition regimen for adult patients when oral or enteral nutrition is not possible, insufficient, or contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02048"><name>SOYBEAN OIL &amp; MEDIUM CHAIN TRIGLYCERIDES &amp; OLIVE OIL &amp; FISH OIL</name><pcgGroup lccId="00299"><pcg9 id="402000001"><itemNumber>1491</itemNumber><strength>6% &amp; 6% &amp; 5% &amp; 3% w/v</strength><dosageForm>Inj Emuls-250mL Pk</dosageForm><drug id="02396963" sec3="Y" sec12="Y"><name>SMOFLipid 20%</name><manufacturerId>FKC</manufacturerId><individualPrice>27.5000</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>27.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="402000002"><itemNumber>1492</itemNumber><strength>6% &amp; 6% &amp; 5% &amp; 3% w/v</strength><dosageForm>Inj Emuls-500mL Pk</dosageForm><drug id="09857595" sec3="Y" sec12="Y"><name>SMOFLipid 20%</name><manufacturerId>FKC</manufacturerId><individualPrice>33.3300</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>33.3300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="525">As part of a parenteral nutrition regimen for adult patients where oral or enteral nutrition is not possible, insufficient or contra-indicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="402800000"><name>DIURETICS</name><genericName id="00638"><name>AMILORIDE HCL</name><pcgGroup><pcg9 id="402800031"><itemNumber>1493</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02249510" chronicUseMed="Y" sec3="Y"><name>Midamor</name><manufacturerId>AAP</manufacturerId><individualPrice>.3297</individualPrice><listingDate>2004-08-11</listingDate><amountMOHLTCPays>.3297</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00639"><name>AMILORIDE HCL &amp; HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="402800032"><itemNumber>1494</itemNumber><strength>5mg &amp; 50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.0440</dailyCost><drug id="00487813" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Moduret</name><manufacturerId>PRE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00784400" chronicUseMed="Y" sec3="Y"><name>AA-Amilzide</name><manufacturerId>AAP</manufacturerId><individualPrice>.0881</individualPrice><dailyCost>.0440</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0881</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00632"><name>CHLORTHALIDONE</name><pcgGroup><pcg9 id="402800007"><itemNumber>1495</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.1277</dailyCost><drug id="00010413" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Hygroton</name><manufacturerId>GEI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00360279" chronicUseMed="Y" sec3="Y"><name>Apo-Chlorthalidone</name><manufacturerId>APX</manufacturerId><individualPrice>.1277</individualPrice><dailyCost>.1277</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1277</amountMOHLTCPays></drug><drug id="02523817" chronicUseMed="Y" sec3="Y"><name>Jamp Chlorthalidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.1277</individualPrice><dailyCost>.1277</dailyCost><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.1277</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00351"><name>FUROSEMIDE</name><pcgGroup lccId="00272"><pcg9 id="402800047"><itemNumber>1496</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol (Preservative Free)</dosageForm><drug id="00527033" sec3="Y" sec12="Y"><name>Furosemide Injection USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6055</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.6055</amountMOHLTCPays></drug><drug id="02527502" sec3="Y" sec12="Y"><name>Furosemide Injection USP</name><manufacturerId>JPC</manufacturerId><individualPrice>.6055</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.6055</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote><lccNote seq="004" reasonForUseId="657">For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" type="N">*e.g., home care recipients, long-term care home residents.</lccNote></pcgGroup><pcgGroup><pcg9 id="402800030"><itemNumber>1497</itemNumber><strength>10mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02224720" sec3="Y"><name>Lasix</name><manufacturerId>SAV</manufacturerId><individualPrice>.3465</individualPrice><listingDate>1999-01-07</listingDate><amountMOHLTCPays>.3465</amountMOHLTCPays></drug></pcg9><pcg9 id="402800019"><itemNumber>1498</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00337730" chronicUseMed="Y" sec3="Y"><name>Teva-Furosemide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0219</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0218</amountMOHLTCPays></drug><drug id="00396788" chronicUseMed="Y" sec3="Y"><name>Apo-Furosemide</name><manufacturerId>APX</manufacturerId><individualPrice>.0219</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0218</amountMOHLTCPays></drug><drug id="02224690" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lasix</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-06</listingDate></drug><drug id="02351420" chronicUseMed="Y" sec3="Y"><name>Furosemide</name><manufacturerId>SAI</manufacturerId><individualPrice>.0218</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.0218</amountMOHLTCPays></drug><drug id="02466759" chronicUseMed="Y" sec3="Y"><name>Mint-Furosemide</name><manufacturerId>MIN</manufacturerId><individualPrice>.0219</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.0218</amountMOHLTCPays></drug></pcg9><pcg9 id="402800009"><itemNumber>1499</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="00337749" chronicUseMed="Y" sec3="Y"><name>Teva-Furosemide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0327</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0327</amountMOHLTCPays></drug><drug id="00362166" chronicUseMed="Y" sec3="Y"><name>Apo-Furosemide</name><manufacturerId>APX</manufacturerId><individualPrice>.0327</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0327</amountMOHLTCPays></drug><drug id="02224704" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lasix</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-07</listingDate></drug><drug id="02351439" chronicUseMed="Y" sec3="Y"><name>Furosemide</name><manufacturerId>SAI</manufacturerId><individualPrice>.0327</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.0327</amountMOHLTCPays></drug><drug id="02466767" chronicUseMed="Y" sec3="Y"><name>Mint-Furosemide</name><manufacturerId>MIN</manufacturerId><individualPrice>.0327</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.0327</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00078"><pcg9 id="402800043"><itemNumber>1500</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02224755" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lasix Special</name><manufacturerId>SAV</manufacturerId><individualPrice>3.5700</individualPrice><listingDate>1999-01-07</listingDate><amountMOHLTCPays>3.5700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="33">For patients with severely impaired renal function refractory to conventional dosages of the drug.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00352"><name>HYDROCHLOROTHIAZIDE</name><pcgGroup><pcg9 id="402800050"><itemNumber>1501</itemNumber><strength>12.5mg</strength><dosageForm>Tab</dosageForm><drug id="02274086" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Hydrochlorothiazide</name><manufacturerId>PMS</manufacturerId><listingDate>2010-04-23</listingDate></drug><drug id="02327856" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Hydro</name><manufacturerId>APX</manufacturerId><individualPrice>.0322</individualPrice><listingDate>2010-04-23</listingDate></drug><drug id="02425947" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Hydrochlorothiazide</name><manufacturerId>MIN</manufacturerId><individualPrice>.0322</individualPrice><listingDate>2014-09-25</listingDate></drug></pcg9><pcg9 id="402800012"><itemNumber>1502</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><dailyCost>.0157</dailyCost><drug id="00016500" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>HydroDIURIL</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00021474" chronicUseMed="Y" sec3="Y"><name>Teva-Hydrochlorothiazide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0157</individualPrice><dailyCost>.0157</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0157</amountMOHLTCPays></drug><drug id="00326844" chronicUseMed="Y" sec3="Y"><name>Apo-Hydro 25</name><manufacturerId>APX</manufacturerId><individualPrice>.0157</individualPrice><dailyCost>.0157</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0157</amountMOHLTCPays></drug><drug id="02247386" chronicUseMed="Y" sec3="Y"><name>PMS-Hydrochlorothiazide</name><manufacturerId>PMS</manufacturerId><individualPrice>.0157</individualPrice><dailyCost>.0157</dailyCost><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.0157</amountMOHLTCPays></drug><drug id="02426196" chronicUseMed="Y" sec3="Y"><name>Mint-Hydrochlorothiazide</name><manufacturerId>MIN</manufacturerId><individualPrice>.0157</individualPrice><dailyCost>.0157</dailyCost><listingDate>2015-03-31</listingDate><amountMOHLTCPays>.0157</amountMOHLTCPays></drug></pcg9><pcg9 id="402800011"><itemNumber>1503</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00016519" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>HydroDIURIL</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00021482" chronicUseMed="Y" sec3="Y"><name>Teva-Hydrochlorothiazide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0217</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0217</amountMOHLTCPays></drug><drug id="00312800" chronicUseMed="Y" sec3="Y"><name>Apo-Hydro 50</name><manufacturerId>APX</manufacturerId><individualPrice>.0217</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0217</amountMOHLTCPays></drug><drug id="02247387" chronicUseMed="Y" sec3="Y"><name>PMS-Hydrochlorothiazide</name><manufacturerId>PMS</manufacturerId><individualPrice>.0217</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.0217</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00636"><name>HYDROCHLOROTHIAZIDE &amp; SPIRONOLACTONE</name><pcgGroup><pcg9 id="402800024"><itemNumber>1504</itemNumber><strength>25mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><dailyCost>.0686</dailyCost><drug id="00180408" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Aldactazide-25</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00613231" chronicUseMed="Y" sec3="Y"><name>Teva-Spironolactone/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.1372</individualPrice><dailyCost>.0686</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1372</amountMOHLTCPays></drug></pcg9><pcg9 id="402800037"><itemNumber>1505</itemNumber><strength>50mg &amp; 50mg</strength><dosageForm>Tab</dosageForm><drug id="00594377" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Aldactazide-50</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00657182" chronicUseMed="Y" sec3="Y"><name>Teva-Spironolactone/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.2903</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2903</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00637"><name>HYDROCHLOROTHIAZIDE &amp; TRIAMTERENE</name><pcgGroup><pcg9 id="402800025"><itemNumber>1506</itemNumber><strength>25mg &amp; 50mg</strength><dosageForm>Tab</dosageForm><dailyCost>.0608</dailyCost><drug id="00441775" chronicUseMed="Y" sec3="Y"><name>Apo-Triazide</name><manufacturerId>APX</manufacturerId><individualPrice>.0608</individualPrice><dailyCost>.0608</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0608</amountMOHLTCPays></drug><drug id="00532657" chronicUseMed="Y" sec3="Y"><name>Teva-Triamterene/HCTZ</name><manufacturerId>TEV</manufacturerId><individualPrice>.0608</individualPrice><dailyCost>.0608</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0608</amountMOHLTCPays></drug><drug id="01919547" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Dyazide</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00641"><name>INDAPAMIDE</name><pcgGroup><pcg9 id="402800040"><itemNumber>1507</itemNumber><strength>1.25mg</strength><dosageForm>Tab</dosageForm><drug id="02179709" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lozide</name><manufacturerId>SEV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02240067" chronicUseMed="Y" sec3="Y"><name>Mylan-Indapamide</name><manufacturerId>MYL</manufacturerId><individualPrice>.1490</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.1490</amountMOHLTCPays></drug><drug id="02245246" chronicUseMed="Y" sec3="Y"><name>Apo-Indapamide</name><manufacturerId>APX</manufacturerId><individualPrice>.1490</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.1490</amountMOHLTCPays></drug></pcg9><pcg9 id="402800036"><itemNumber>1508</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><dailyCost>.2364</dailyCost><drug id="00564966" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Lozide</name><manufacturerId>SEV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02153483" chronicUseMed="Y" sec3="Y"><name>Mylan-Indapamide</name><manufacturerId>MYL</manufacturerId><individualPrice>.2364</individualPrice><dailyCost>.2364</dailyCost><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2364</amountMOHLTCPays></drug><drug id="02223678" chronicUseMed="Y" sec3="Y"><name>Apo-Indapamide</name><manufacturerId>APX</manufacturerId><individualPrice>.2364</individualPrice><dailyCost>.2364</dailyCost><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.2364</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00640"><name>METOLAZONE</name><pcgGroup><pcg9 id="402800035"><itemNumber>1509</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="00888400" chronicUseMed="Y" sec3="Y"><name>Zaroxolyn</name><manufacturerId>SAV</manufacturerId><individualPrice>.2294</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2294</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00642"><name>MIDODRINE HCL</name><pcgGroup lccId="00079"><pcg9 id="402800041"><itemNumber>1510</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="01934392" notABenefit="Y" sec3="Y"><name>Amatine</name><manufacturerId>SHI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02278677" sec3="Y" sec12="Y"><name>Apo-Midodrine</name><manufacturerId>APX</manufacturerId><individualPrice>.1153</individualPrice><listingDate>2006-08-24</listingDate><amountMOHLTCPays>.1153</amountMOHLTCPays></drug><drug id="02473984" sec3="Y" sec12="Y"><name>Mar-Midodrine</name><manufacturerId>MAR</manufacturerId><individualPrice>.1153</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.1153</amountMOHLTCPays></drug><drug id="02517701" sec3="Y" sec12="Y"><name>Jamp Midodrine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1153</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.1153</amountMOHLTCPays></drug><drug id="02533200" sec3="Y" sec12="Y"><name>Midodrine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1153</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.1153</amountMOHLTCPays></drug></pcg9><pcg9 id="402800042"><itemNumber>1511</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="01934406" notABenefit="Y" sec3="Y"><name>Amatine</name><manufacturerId>SHI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02278685" sec3="Y" sec12="Y"><name>Apo-Midodrine</name><manufacturerId>APX</manufacturerId><individualPrice>.1921</individualPrice><listingDate>2006-08-24</listingDate><amountMOHLTCPays>.1921</amountMOHLTCPays></drug><drug id="02473992" sec3="Y" sec12="Y"><name>Mar-Midodrine</name><manufacturerId>MAR</manufacturerId><individualPrice>.1921</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.1921</amountMOHLTCPays></drug><drug id="02517728" sec3="Y" sec12="Y"><name>Jamp Midodrine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1921</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.1921</amountMOHLTCPays></drug><drug id="02533219" sec3="Y" sec12="Y"><name>Midodrine</name><manufacturerId>SAI</manufacturerId><individualPrice>.1921</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.1921</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="01">For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00634"><name>SPIRONOLACTONE</name><note>Spironolactone can double digoxin blood levels within two weeks, and commonly causes mastalgia and gynaecomastia in men.</note><pcgGroup><pcg9 id="402800014"><itemNumber>1512</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00028606" chronicUseMed="Y" sec3="Y"><name>Aldactone</name><manufacturerId>PFI</manufacturerId><individualPrice>.2746</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0405</amountMOHLTCPays></drug><drug id="00613215" chronicUseMed="Y" sec3="Y"><name>Teva-Spironolactone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0405</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0405</amountMOHLTCPays></drug><drug id="02488140" chronicUseMed="Y" sec3="Y"><name>Mint-Spironolactone</name><manufacturerId>MIN</manufacturerId><individualPrice>.0405</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.0405</amountMOHLTCPays></drug><drug id="02518821" chronicUseMed="Y" sec3="Y"><name>Jamp Spironolactone</name><manufacturerId>JPC</manufacturerId><individualPrice>.0405</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.0405</amountMOHLTCPays></drug></pcg9><pcg9 id="402800021"><itemNumber>1513</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00285455" chronicUseMed="Y" sec3="Y"><name>Aldactone</name><manufacturerId>PFI</manufacturerId><individualPrice>.6410</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0955</amountMOHLTCPays></drug><drug id="00613223" chronicUseMed="Y" sec3="Y"><name>Teva-Spironolactone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0955</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0955</amountMOHLTCPays></drug><drug id="02488159" chronicUseMed="Y" sec3="Y"><name>Mint-Spironolactone</name><manufacturerId>MIN</manufacturerId><individualPrice>.0955</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.0955</amountMOHLTCPays></drug><drug id="02518848" chronicUseMed="Y" sec3="Y"><name>Jamp Spironolactone</name><manufacturerId>JPC</manufacturerId><individualPrice>.0955</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>.0955</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02429"><name>TOLVAPTAN</name><pcgGroup><pcg9 id="402800057"><itemNumber>1514</itemNumber><strength>15mg &amp; 15mg</strength><dosageForm>14-Tabs Pk</dosageForm><drug id="02491575" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jinarc</name><manufacturerId>OTS</manufacturerId><listingDate>2025-07-31</listingDate></drug><drug id="02557177" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Tolvaptan</name><manufacturerId>LUP</manufacturerId><individualPrice>863.8125</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9><pcg9 id="402800058"><itemNumber>1515</itemNumber><strength>30mg &amp; 15mg</strength><dosageForm>14-Tabs Pk</dosageForm><drug id="02491583" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jinarc</name><manufacturerId>OTS</manufacturerId><listingDate>2025-07-31</listingDate></drug><drug id="02557185" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Tolvaptan</name><manufacturerId>LUP</manufacturerId><individualPrice>863.8125</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9><pcg9 id="402800059"><itemNumber>1516</itemNumber><strength>45mg &amp; 15mg</strength><dosageForm>14-Tabs Pk</dosageForm><drug id="02437503" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jinarc</name><manufacturerId>OTS</manufacturerId><listingDate>2025-07-31</listingDate></drug><drug id="02557193" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Tolvaptan</name><manufacturerId>LUP</manufacturerId><individualPrice>863.8125</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9><pcg9 id="402800060"><itemNumber>1517</itemNumber><strength>60mg &amp; 30mg</strength><dosageForm>14-Tabs Pk</dosageForm><drug id="02437511" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jinarc</name><manufacturerId>OTS</manufacturerId><listingDate>2025-07-31</listingDate></drug><drug id="02557207" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Tolvaptan</name><manufacturerId>LUP</manufacturerId><individualPrice>864.0000</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9><pcg9 id="402800061"><itemNumber>1518</itemNumber><strength>90mg &amp; 30mg</strength><dosageForm>14-Tabs Pk</dosageForm><drug id="02437538" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jinarc</name><manufacturerId>OTS</manufacturerId><listingDate>2025-07-31</listingDate></drug><drug id="02557215" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lupin-Tolvaptan</name><manufacturerId>LUP</manufacturerId><individualPrice>864.0000</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="480000000"><name>COUGH PREPARATIONS</name><pcg6 id="480200000"><name>ANTI FIBROTIC AGENTS</name><genericName id="01953"><name>PIRFENIDONE</name><pcgGroup><pcg9 id="480200003"><itemNumber>1519</itemNumber><strength>267mg</strength><dosageForm>Tab</dosageForm><drug id="02464489" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Esbriet</name><manufacturerId>HLR</manufacturerId><individualPrice>13.4240</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug><drug id="02488507" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pirfenidone Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.7120</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug><drug id="02514702" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pirfenidone</name><manufacturerId>JPC</manufacturerId><individualPrice>6.7120</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug><drug id="02531526" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Pirfenidone</name><manufacturerId>PMS</manufacturerId><individualPrice>6.7120</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug><drug id="02537753" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Pirfenidone</name><manufacturerId>AUR</manufacturerId><individualPrice>6.7119</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>6.7119</amountMOHLTCPays></drug><drug id="02550644" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Pirfenidone</name><manufacturerId>MAT</manufacturerId><individualPrice>6.7120</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug></pcg9><pcg9 id="480200004"><itemNumber>1520</itemNumber><strength>801mg</strength><dosageForm>Tab</dosageForm><drug id="02464500" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Esbriet</name><manufacturerId>HLR</manufacturerId><individualPrice>40.2720</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>20.1361</amountMOHLTCPays></drug><drug id="02488515" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pirfenidone Tablets</name><manufacturerId>SDZ</manufacturerId><individualPrice>20.1360</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>20.1360</amountMOHLTCPays></drug><drug id="02514710" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pirfenidone</name><manufacturerId>JPC</manufacturerId><individualPrice>20.1360</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>20.1360</amountMOHLTCPays></drug><drug id="02531534" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Pirfenidone</name><manufacturerId>PMS</manufacturerId><individualPrice>20.1360</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>20.1360</amountMOHLTCPays></drug><drug id="02537761" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Pirfenidone</name><manufacturerId>AUR</manufacturerId><individualPrice>20.1361</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>20.1361</amountMOHLTCPays></drug><drug id="02550652" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Pirfenidone</name><manufacturerId>MAT</manufacturerId><individualPrice>20.1360</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>20.1360</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="480400000"><name>ANTITUSSIVES</name><genericName id="00650"><name>DEXTROMETHORPHAN HBR</name><pcgGroup><pcg9 id="480400010" suppliedBy="L"><itemNumber>1521</itemNumber><strength>3mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00391069" notABenefit="Y" sec3="Y"><name>DM-Syrup</name><manufacturerId>PDA</manufacturerId><listingDate>2006-06-15</listingDate></drug><drug id="01928783" selfMed="Y" sec3="Y"><name>Koffex DM</name><manufacturerId>ROG</manufacturerId><individualPrice>.0190</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0190</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00441"><name>HYDROCODONE BITARTRATE</name><pcgGroup><pcg9 id="480400007"><itemNumber>1522</itemNumber><strength>1mg/mL</strength><dosageForm>O/L</dosageForm><drug id="01916580" notABenefit="Y" sec3="Y"><name>Hycodan</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02324253" sec3="Y"><name>PMS-Hydrocodone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0617</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.0617</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="480800000"><name>EXPECTORANTS</name><genericName id="00660"><name>GUAIFENESIN</name><pcgGroup><pcg9 id="480800003" suppliedBy="L"><itemNumber>1523</itemNumber><strength>20mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00026468" notABenefit="Y" sec3="Y"><name>Robitussin</name><manufacturerId>WHB</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00026794" notABenefit="Y" sec3="Y"><name>Guaifenesin</name><manufacturerId>ROG</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00990930" notABenefit="Y" sec3="Y"><name>Guaifenesin Sugar Free</name><manufacturerId>ROG</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="520000000"><name>EYE, EAR, NOSE AND THROAT PREPARATIONS</name><pcg6 id="520404000"><name>ANTI-INFECTIVES ANTIBIOTICS</name><genericName id="01728"><name>CIPROFLOXACIN AND DEXAMETHASONE</name><pcgGroup lccId="00306"><pcg9 id="520404046"><itemNumber>1524</itemNumber><strength>0.3% w/v &amp; 0.1% w/v</strength><dosageForm>Otic Susp-7.5mL Pk (With Preservative)</dosageForm><drug id="02252716" sec3="Y" sec12="Y"><name>Ciprodex</name><manufacturerId>NOV</manufacturerId><individualPrice>31.9700</individualPrice><listingDate>2018-06-29</listingDate><amountMOHLTCPays>14.4203</amountMOHLTCPays></drug><drug id="02481901" sec3="Y" sec12="Y"><name>Taro-Ciprofloxacin/Dexamethasone</name><manufacturerId>TAR</manufacturerId><individualPrice>14.4203</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>14.4203</amountMOHLTCPays></drug><drug id="02506882" sec3="Y" sec12="Y"><name>Sandoz Ciprofloxacin/Dexamethasone</name><manufacturerId>SDZ</manufacturerId><individualPrice>14.4203</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>14.4203</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="509">The treatment of otitis externa in patients:

-    With known perforated tympanic membrane or ventilation tubes;

OR

-    Requiring chronic therapy (i.e., more than 14 days);

OR

-    Who have been receiving more than 7 days of topical aminoglycoside therapy without improvement, where there is concern of a resistant pathogen;

OR

-    With documented pre-existing hearing impairment.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00090"><name>FRAMYCETIN SULFATE</name><pcgGroup><pcg9 id="520404011"><itemNumber>1525</itemNumber><strength>0.5%</strength><dosageForm>Oph Oint-5g Pk</dosageForm><drug id="02224895" sec3="Y"><name>Soframycin</name><manufacturerId>SLP</manufacturerId><individualPrice>19.6100</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>19.6100</amountMOHLTCPays></drug></pcg9><pcg9 id="520404010"><itemNumber>1526</itemNumber><strength>0.5%</strength><dosageForm>Oph Sol</dosageForm><drug id="02224887" sec3="Y"><name>Soframycin</name><manufacturerId>SLP</manufacturerId><individualPrice>1.3663</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>1.3663</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00667"><name>FRAMYCETIN SULFATE &amp; GRAMICIDIN &amp; DEXAMETHASONE</name><pcgGroup><pcg9 id="520404012"><itemNumber>1527</itemNumber><strength>5mg &amp; 50mcg &amp; 0.5mg/mL</strength><dosageForm>Oph/Ot Sol</dosageForm><drug id="02224623" sec3="Y"><name>Sofracort</name><manufacturerId>SAV</manufacturerId><individualPrice>2.1263</individualPrice><note>The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.</note><listingDate>2001-10-11</listingDate><amountMOHLTCPays>2.1263</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01528"><name>GATIFLOXACIN</name><pcgGroup><pcg9 id="520404049"><itemNumber>1528</itemNumber><strength>0.3% w/v</strength><dosageForm>Oph Sol</dosageForm><drug id="02257270" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zymar (with preservative)</name><manufacturerId>ALL</manufacturerId><listingDate>2019-12-20</listingDate></drug><drug id="02327260" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Gatifloxacin (with preservative)</name><manufacturerId>APX</manufacturerId><individualPrice>2.0320</individualPrice><listingDate>2019-12-20</listingDate></drug><drug id="02533235" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Gatifloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>2.0320</individualPrice><listingDate>2024-09-27</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00670"><name>GENTAMICIN &amp; BETAMETHASONE SODIUM PHOSPHATE</name><pcgGroup><pcg9 id="520404025"><itemNumber>1529</itemNumber><strength>3mg &amp; 1mg/mL</strength><dosageForm>Oph/Ot Drops</dosageForm><drug id="00682217" sec3="Y"><name>Garasone</name><manufacturerId>SCH</manufacturerId><individualPrice>1.2813</individualPrice><note>The risk of ototoxicity with topical aminoglycoside may increase with prolonged therapy. Topical use of antibiotics increases the likelihood of development of bacterial resistance, especially with prolonged use, sometimes rendering the systemic use of this antibiotic class useless in these patients.
</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2813</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00070"><name>GENTAMICIN SULFATE</name><pcgGroup><pcg9 id="520404014"><itemNumber>1530</itemNumber><strength>0.3%</strength><dosageForm>Oph Oint-3.5g Pk</dosageForm><drug id="00028339" sec3="Y"><name>Garamycin</name><manufacturerId>SCH</manufacturerId><individualPrice>4.0000</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>4.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01516"><name>MOXIFLOXACIN HYDROCHLORIDE</name><pcgGroup><pcg9 id="520404048"><itemNumber>1531</itemNumber><strength>0.5%</strength><dosageForm>Oph Sol-3mL Pk (Preservative-Free)</dosageForm><drug id="02252260" notABenefit="Y" sec3b="Y" sec3="Y"><name>Vigamox</name><manufacturerId>NOV</manufacturerId><listingDate>2015-12-22</listingDate></drug><drug id="02404656" notABenefit="Y" sec3b="Y" sec3="Y"><name>Act Moxifloxacin</name><manufacturerId>ACV</manufacturerId><individualPrice>11.2700</individualPrice><listingDate>2015-12-22</listingDate></drug><drug id="02406373" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Moxifloxacin</name><manufacturerId>APX</manufacturerId><individualPrice>11.2700</individualPrice><listingDate>2016-01-28</listingDate></drug><drug id="02411520" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Moxifloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>11.2700</individualPrice><listingDate>2015-12-22</listingDate></drug><drug id="02432218" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Moxifloxacin</name><manufacturerId>PMS</manufacturerId><individualPrice>11.2701</individualPrice><listingDate>2016-05-31</listingDate></drug><drug id="02472120" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Moxifloxacin</name><manufacturerId>JPC</manufacturerId><individualPrice>11.2700</individualPrice><listingDate>2019-04-30</listingDate></drug><drug id="02484757" notABenefit="Y" sec3b="Y" sec3="Y"><name>AG-Moxifloxacin</name><manufacturerId>ANG</manufacturerId><individualPrice>11.2700</individualPrice><listingDate>2020-11-30</listingDate></drug><drug id="02529076" notABenefit="Y" sec3b="Y" sec3="Y"><name>Moxifloxacin</name><manufacturerId>SAI</manufacturerId><individualPrice>11.2700</individualPrice><listingDate>2023-01-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00665"><name>POLYMYXIN B SULFATE &amp; BACITRACIN (ZINC)</name><pcgGroup><pcg9 id="520404006"><itemNumber>1532</itemNumber><strength>10000U &amp; 500U/g</strength><dosageForm>Oph Oint 3.5g Pk</dosageForm><drug id="02239157" sec3="Y"><name>Polysporin</name><manufacturerId>PFI</manufacturerId><individualPrice>5.5400</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>5.5400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00666"><name>POLYMYXIN B SULFATE &amp; GRAMICIDIN</name><pcgGroup><pcg9 id="520404007"><itemNumber>1533</itemNumber><strength>10000U &amp; 0.025mg/mL</strength><dosageForm>Oph/Ot Sol</dosageForm><drug id="02239156" sec3="Y"><name>Polysporin Eye and Ear Drops Sterile</name><manufacturerId>JAJ</manufacturerId><individualPrice>.9139</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.9139</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00668"><name>TOBRAMYCIN</name><pcgGroup><pcg9 id="520404024"><itemNumber>1534</itemNumber><strength>0.3%</strength><dosageForm>Oph Oint</dosageForm><drug id="00614254" sec3="Y"><name>Tobrex</name><manufacturerId>NOV</manufacturerId><individualPrice>2.7514</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.7514</amountMOHLTCPays></drug></pcg9><pcg9 id="520404020"><itemNumber>1535</itemNumber><strength>0.3%</strength><dosageForm>Oph Sol</dosageForm><drug id="00513962" sec3="Y"><name>Tobrex</name><manufacturerId>NOV</manufacturerId><individualPrice>1.9400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.3620</amountMOHLTCPays></drug><drug id="02241755" sec3="Y"><name>Sandoz Tobramycin</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3620</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>1.3620</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00674"><name>TOBRAMYCIN &amp; DEXAMETHASONE</name><pcgGroup><pcg9 id="520404032"><itemNumber>1536</itemNumber><strength>0.3% &amp; 0.1%</strength><dosageForm>Oph Oint</dosageForm><drug id="00778915" sec3="Y"><name>TobraDex</name><manufacturerId>NOV</manufacturerId><individualPrice>3.3171</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.3171</amountMOHLTCPays></drug></pcg9><pcg9 id="520404031"><itemNumber>1537</itemNumber><strength>0.3% &amp; 0.1%</strength><dosageForm>Oph Susp</dosageForm><drug id="00778907" sec3="Y"><name>TobraDex</name><manufacturerId>NOV</manufacturerId><individualPrice>2.2500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.2500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="520412000"><name>ANTI-INFECTIVES OTHER ANTI-INFECTIVES</name><genericName id="00141"><name>CIPROFLOXACIN</name><note>Ciprofloxacin is not intended for the treatment of asymptomatic bacteriuria in the absence of risk factors. Avoid use in pregnancy and children &lt; 18 years of age. Ciprofloxacin inhibits theophylline clearance and also affects phenytoin kinetics. Theophylline doses should be decreased and blood levels of phenytoin or theophylline monitored when either of these drugs is used concomitantly with ciprofloxacin.</note><pcgGroup><pcg9 id="520412012"><itemNumber>1538</itemNumber><strength>0.3%</strength><dosageForm>Oph Sol-5mL Pk</dosageForm><drug id="01945270" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ciloxan</name><manufacturerId>NOV</manufacturerId><listingDate>2009-01-30</listingDate></drug><drug id="02263130" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Ciproflox</name><manufacturerId>APX</manufacturerId><individualPrice>1.7600</individualPrice><listingDate>2010-06-14</listingDate></drug><drug id="02387131" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Ciprofloxacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.3000</individualPrice><listingDate>2012-09-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00145"><name>OFLOXACIN</name><pcgGroup lccId="00080"><pcg9 id="520412008"><itemNumber>1539</itemNumber><strength>0.3%</strength><dosageForm>Oph Sol</dosageForm><drug id="02143291" sec3="Y" sec12="Y"><name>Ocuflox</name><manufacturerId>ALL</manufacturerId><individualPrice>2.8720</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>2.8720</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="170">For the treatment of conjunctivitis caused by susceptible strain(s) of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Hemophilus influenzae which is/are resistant or unresponsive to listed alternative agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="520800000"><name>ANTI-INFLAMMATORY AGENTS</name><note>Topical corticosteroid can reactivate pre-existing viral keratitis. These agents should be used with caution in patients with a history of previous corneal ulceration. In some patients, prolonged use of these agents can result in significant problems such as increased intraocular pressure.</note><genericName id="02364"><name>AZELASTINE HCL &amp; FLUTICASONE PROPIONATE</name><pcgGroup><pcg9 id="520800048"><itemNumber>1540</itemNumber><strength>137mcg/Actuation&amp;50mcg/Actuation</strength><dosageForm>Nas-Sp-120 Dose Pk</dosageForm><drug id="02432889" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dymista</name><manufacturerId>BGP</manufacturerId><listingDate>2023-08-31</listingDate></drug><drug id="02530341" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mylan-Azelastine/Fluticasone</name><manufacturerId>MYL</manufacturerId><individualPrice>89.9215</individualPrice><listingDate>2023-08-31</listingDate></drug><drug id="02540886" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Azelastine/Fluticasone</name><manufacturerId>APX</manufacturerId><individualPrice>89.9215</individualPrice><listingDate>2023-10-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00687"><name>BECLOMETHASONE DIPROPIONATE</name><pcgGroup><pcg9 id="520800028"><itemNumber>1541</itemNumber><strength>50mcg</strength><dosageForm>Nas-Sp-200 Dose Pk</dosageForm><drug id="02172712" sec3="Y"><name>Mylan-Beclo AQ</name><manufacturerId>MYL</manufacturerId><individualPrice>12.2600</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>12.2600</amountMOHLTCPays></drug><drug id="02213702" notABenefit="Y" sec3="Y"><name>Beconase Aqueous</name><manufacturerId>GLW</manufacturerId><listingDate>1998-03-17</listingDate></drug><drug id="02238796" sec3="Y"><name>Apo-Beclomethasone Nasal Spray</name><manufacturerId>APX</manufacturerId><individualPrice>12.2600</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>12.2600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02333"><name>BROMFENAC</name><pcgGroup><pcg9 id="520800047"><itemNumber>1542</itemNumber><strength>0.07% w/v</strength><dosageForm>Oph Sol (With Preservative)</dosageForm><drug id="02439123" notABenefit="Y" sec3b="Y" sec3="Y"><name>Prolensa</name><manufacturerId>BSH</manufacturerId><listingDate>2023-07-31</listingDate></drug><drug id="02537788" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Bromfenac</name><manufacturerId>APX</manufacturerId><individualPrice>8.5000</individualPrice><listingDate>2023-07-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00696"><name>BUDESONIDE</name><pcgGroup><pcg9 id="520800039"><itemNumber>1543</itemNumber><strength>64mcg/Metered Dose</strength><dosageForm>Nas Sp-120 Dose Pk</dosageForm><drug id="02231923" sec3="Y"><name>Rhinocort Aqua</name><manufacturerId>MCL</manufacturerId><individualPrice>11.0400</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>11.0400</amountMOHLTCPays></drug></pcg9><pcg9 id="520800032"><itemNumber>1544</itemNumber><strength>100mcg/Metered Dose</strength><dosageForm>Nas Sp-165 Dose Pk</dosageForm><drug id="01974432" notABenefit="Y" sec3="Y"><name>Rhinocort Aqua</name><manufacturerId>AST</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230648" sec3="Y"><name>Mylan-Budesonide AQ</name><manufacturerId>MYL</manufacturerId><individualPrice>12.7400</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>12.7400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00685"><name>DEXAMETHASONE</name><pcgGroup><pcg9 id="520800015"><itemNumber>1545</itemNumber><strength>0.1%</strength><dosageForm>Oph Oint-3.5g Pk</dosageForm><drug id="00042579" sec3="Y"><name>Maxidex</name><manufacturerId>NOV</manufacturerId><individualPrice>9.7200</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>9.7200</amountMOHLTCPays></drug></pcg9><pcg9 id="520800014"><itemNumber>1546</itemNumber><strength>0.1%</strength><dosageForm>Oph Susp</dosageForm><drug id="00042560" sec3="Y"><name>Maxidex</name><manufacturerId>NOV</manufacturerId><individualPrice>1.7900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.7900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00686"><name>FLUMETHASONE PIVALATE &amp; IODOCHLORHYDROXYQUIN</name><pcgGroup><pcg9 id="520800012"><itemNumber>1547</itemNumber><strength>0.02% &amp; 1%</strength><dosageForm>Ot Sol</dosageForm><drug id="00074454" sec3="Y"><name>Locacorten Vioform Eardrops</name><manufacturerId>PPI</manufacturerId><individualPrice>2.5782</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.5782</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00690"><name>FLUOROMETHOLONE</name><pcgGroup><pcg9 id="520800021"><itemNumber>1548</itemNumber><strength>0.1%</strength><dosageForm>Oph Susp</dosageForm><drug id="00247855" sec3="Y"><name>FML</name><manufacturerId>ALL</manufacturerId><individualPrice>3.5440</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.5440</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00693"><name>FLUOROMETHOLONE ACETATE</name><pcgGroup><pcg9 id="520800026"><itemNumber>1549</itemNumber><strength>0.1%</strength><dosageForm>Oph Susp</dosageForm><drug id="00756784" sec3="Y"><name>Flarex</name><manufacturerId>NOV</manufacturerId><individualPrice>2.0240</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.0240</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00255"><name>FLUTICASONE PROPIONATE</name><pcgGroup><pcg9 id="520800035"><itemNumber>1550</itemNumber><strength>50mcg/Actuation</strength><dosageForm>Nas Sp-120 Dose Pk</dosageForm><drug id="02213672" notABenefit="Y" sec3b="Y" sec3="Y"><name>Flonase</name><manufacturerId>GSK</manufacturerId><listingDate>2007-11-10</listingDate></drug><drug id="02294745" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Fluticasone</name><manufacturerId>APX</manufacturerId><individualPrice>21.9700</individualPrice><listingDate>2007-11-10</listingDate></drug><drug id="02296071" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Fluticasone</name><manufacturerId>RPH</manufacturerId><individualPrice>21.9700</individualPrice><listingDate>2007-11-10</listingDate></drug><drug id="02453738" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Fluticasone</name><manufacturerId>TEV</manufacturerId><individualPrice>21.9700</individualPrice><listingDate>2017-12-21</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00442"><name>KETOROLAC TROMETHAMINE</name><pcgGroup><pcg9 id="520800030"><itemNumber>1551</itemNumber><strength>0.5%</strength><dosageForm>Oph Sol</dosageForm><drug id="01968300" sec3="Y"><name>Acular</name><manufacturerId>ALL</manufacturerId><individualPrice>3.6780</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.8997</amountMOHLTCPays></drug><drug id="02245821" sec3="Y"><name>Ketorolac</name><manufacturerId>AAP</manufacturerId><individualPrice>2.8997</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>2.8997</amountMOHLTCPays></drug></pcg9><pcg9 id="520800046"><itemNumber>1552</itemNumber><strength>0.45% w/v</strength><dosageForm>Oph Sol-0.4mL Vial Pk (Preservative-Free)</dosageForm><drug id="02369362" sec3="Y"><name>Acuvail</name><manufacturerId>ABV</manufacturerId><individualPrice>.2593</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2593</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00697"><name>LODOXAMIDE TROMETHAMINE</name><pcgGroup><pcg9 id="520800034"><itemNumber>1553</itemNumber><strength>0.1%</strength><dosageForm>Oph Sol</dosageForm><drug id="00893560" sec3="Y"><name>Alomide</name><manufacturerId>NOV</manufacturerId><individualPrice>1.4890</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.4890</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01029"><name>MOMETASONE FUROATE</name><pcgGroup><pcg9 id="520800041"><itemNumber>1554</itemNumber><strength>50mcg/Dose</strength><dosageForm>Nas Sp-140 Dose Pk</dosageForm><drug id="02238465" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nasonex</name><manufacturerId>OCI</manufacturerId><listingDate>2013-11-28</listingDate></drug><drug id="02403587" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Mometasone</name><manufacturerId>APX</manufacturerId><individualPrice>21.6900</individualPrice><listingDate>2013-11-28</listingDate></drug><drug id="02449811" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Mometasone</name><manufacturerId>SDZ</manufacturerId><individualPrice>21.6860</individualPrice><listingDate>2017-01-31</listingDate></drug><drug id="02475863" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Mometasone</name><manufacturerId>TEV</manufacturerId><individualPrice>21.6900</individualPrice><listingDate>2018-11-29</listingDate></drug><drug id="02519127" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mometasone</name><manufacturerId>SAI</manufacturerId><individualPrice>21.6900</individualPrice><listingDate>2022-04-29</listingDate></drug><drug id="02551756" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mometasone</name><manufacturerId>SIV</manufacturerId><individualPrice>21.6860</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00688"><name>PREDNISOLONE ACETATE</name><pcgGroup><pcg9 id="520800017"><itemNumber>1555</itemNumber><strength>1%</strength><dosageForm>Oph Susp</dosageForm><drug id="00301175" notABenefit="Y" sec3="Y"><name>Pred Forte</name><manufacturerId>ALL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00700401" sec3="Y"><name>Ratio-Prednisolone</name><manufacturerId>RPH</manufacturerId><individualPrice>1.9400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.9400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00695"><name>TRIAMCINOLONE ACETONIDE</name><pcgGroup><pcg9 id="520800036"><itemNumber>1556</itemNumber><strength>55mcg/Metered Dose</strength><dosageForm>Nas Sp-120 Dose Pk (with Preservative)</dosageForm><drug id="02213834" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nasacort  AQ</name><manufacturerId>SCO</manufacturerId><listingDate>2016-08-30</listingDate></drug><drug id="02437635" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Triamcinolone AQ</name><manufacturerId>APX</manufacturerId><individualPrice>18.0000</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>18.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="520892000"><name>ANTI-INFLAMMATORY AGENTS ANTI-INFLAMMATORY AGENTS, MISCELLANEOUS</name><genericName id="01189"><name>CYCLOSPORINE</name><pcgGroup><pcg9 id="520892001"><itemNumber>1557</itemNumber><strength>0.05% w/v</strength><dosageForm>Oph Emuls-0.4mL Pk</dosageForm><drug id="02355655" notABenefit="Y" sec3b="Y" sec3="Y"><name>Restasis</name><manufacturerId>ALL</manufacturerId><listingDate>2018-01-31</listingDate></drug><drug id="02462486" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Cyclosporine</name><manufacturerId>TEV</manufacturerId><individualPrice>4.1658</individualPrice><listingDate>2018-01-31</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="521600000"><name>LOCAL ANESTHETICS</name><genericName id="00699"><name>BENZYDAMINE HCL</name><pcgGroup lccId="00081"><pcg9 id="521600002"><itemNumber>1558</itemNumber><strength>0.15%</strength><dosageForm>Oral Rinse</dosageForm><drug id="01966065" notABenefit="Y" sec3="Y"><name>Tantum</name><manufacturerId>GRA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229777" notABenefit="Y" sec3="Y"><name>Pharixia</name><manufacturerId>PEN</manufacturerId><listingDate>1998-12-31</listingDate></drug><drug id="02239537" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Benzydamine</name><manufacturerId>PMS</manufacturerId><individualPrice>.0960</individualPrice><listingDate>2018-03-29</listingDate></drug><drug id="02463105" notABenefit="Y" sec3b="Y" sec3="Y"><name>Odan-Benzydamine</name><manufacturerId>ODN</manufacturerId><individualPrice>.0960</individualPrice><listingDate>2017-11-30</listingDate></drug></pcg9><lccNote seq="001" reasonForUseId="240">For the symptomatic relief of treatment induced mucositis in cancer patients.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="522000000"><name>MIOTICS</name><genericName id="00702"><name>PILOCARPINE HCL</name><pcgGroup><pcg9 id="522000011"><itemNumber>1559</itemNumber><strength>2%</strength><dosageForm>Oph Sol</dosageForm><drug id="00000868" sec3="Y"><name>Isopto Carpine</name><manufacturerId>NOV</manufacturerId><individualPrice>.3320</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3320</amountMOHLTCPays></drug><drug id="02023741" notABenefit="Y" sec3="Y"><name>Pilocarpine</name><manufacturerId>PHS</manufacturerId><listingDate>1999-04-15</listingDate></drug></pcg9><pcg9 id="522000009"><itemNumber>1560</itemNumber><strength>4%</strength><dosageForm>Oph Sol</dosageForm><drug id="00000884" sec3="Y"><name>Isopto Carpine</name><manufacturerId>NOV</manufacturerId><individualPrice>.3360</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3360</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="522400000"><name>MYDRIATICS</name><genericName id="00232"><name>ATROPINE SULFATE</name><pcgGroup><pcg9 id="522400002"><itemNumber>1561</itemNumber><strength>1%</strength><dosageForm>Oph Sol</dosageForm><drug id="00035017" sec3="Y"><name>Isopto Atropine</name><manufacturerId>ALC</manufacturerId><individualPrice>.8420</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5490</amountMOHLTCPays></drug><drug id="02023695" sec3="Y"><name>Atropine</name><manufacturerId>PHS</manufacturerId><individualPrice>.5490</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.5490</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00710"><name>CYCLOPENTOLATE HCL</name><pcgGroup><pcg9 id="522400030"><itemNumber>1562</itemNumber><strength>1%</strength><dosageForm>Oph Sol</dosageForm><drug id="00252506" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cyclogyl</name><manufacturerId>NOV</manufacturerId><listingDate>2022-10-31</listingDate></drug><drug id="00626627" notABenefit="Y" sec3b="Y" sec3="Y"><name>Odan-Cyclopentolate</name><manufacturerId>ODN</manufacturerId><individualPrice>.8925</individualPrice><listingDate>2022-10-31</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="523200000"><name>VASOCONSTRICTORS</name><genericName id="00712"><name>NAPHAZOLINE HCL</name><pcgGroup><pcg9 id="523200001"><itemNumber>1563</itemNumber><strength>0.1%</strength><dosageForm>Oph Sol</dosageForm><drug id="00001147" notABenefit="Y" sec3="Y"><name>Albalon</name><manufacturerId>ALL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00390283" notABenefit="Y" sec3="Y"><name>Naphcon Forte</name><manufacturerId>ALC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00759880" notABenefit="Y" sec3="Y"><name>Vasocon</name><manufacturerId>IOB</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="523600000"><name>OTHER EYE, EAR, NOSE AND THROAT AGENTS</name><genericName id="00717"><name>ACETAZOLAMIDE</name><pcgGroup><pcg9 id="523600001"><itemNumber>1564</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="00545015" sec3="Y"><name>Acetazolamide</name><manufacturerId>AAP</manufacturerId><individualPrice>.1414</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1414</amountMOHLTCPays></drug><drug id="02238072" notABenefit="Y" sec3="Y"><name>Diamox</name><manufacturerId>WAY</manufacturerId><listingDate>2000-11-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01982"><name>AFLIBERCEPT</name><pcgGroup lccId="00416"><pcg9 id="523600155"><itemNumber>1565</itemNumber><strength>2mg/0.05mL</strength><dosageForm>Inj Sol-0.05mL Pref Syr (Preservative-Free)</dosageForm><drug id="02554178" sec3="Y" sec12="Y"><name>Aflivu</name><manufacturerId>APX</manufacturerId><individualPrice>850.8000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>850.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="523600157"><itemNumber>1566</itemNumber><strength>2mg/0.05mL</strength><dosageForm>Inj Sol-0.05mL Pref Syr (Preservative-Free)</dosageForm><drug id="02558238" sec3="Y" sec12="Y"><name>Yesafili</name><manufacturerId>BCL</manufacturerId><individualPrice>850.8000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>850.8000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="729">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="730">For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment should be initiated with an intravitreal injection once every month. The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months based on visual and anatomic outcomes.

Prescribers are advised to periodically assess the need for continued therapy.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="731">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent.

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 5 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00256"><pcg9 id="523600147"><itemNumber>1567</itemNumber><strength>40mg/mL</strength><dosageForm>Inj Sol-0.05mL Pref Syr (Preservative-Free)</dosageForm><drug id="02505355" sec3="Y" sec12="Y"><name>Eylea</name><manufacturerId>BAH</manufacturerId><individualPrice>1418.0000</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1418.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="463">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye, but only for patients established on Eylea (aflibercept) therapy prior to August 29, 2025.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of verteporfin PDT (Visudyne) or ranibizumab (Lucentis) are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with Lucentis who switch to Eylea. Coverage will NOT be provided for patients who have failed to respond to Lucentis.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="464">For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), but only for patients established on Eylea (aflibercept) therapy prior to August 29, 2025.

Treatment should be initiated with an intravitreal injection once every month. The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months based on visual and anatomic outcomes.

Prescribers are advised to periodically assess the need for continued therapy.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with Lucentis who switch to Eylea. Coverage will NOT be provided for patients who have failed to respond to Lucentis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="465">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent, but only for patients established on Eylea (aflibercept) therapy prior to August 29, 2025.

Treatment should be initiated with a monthly intravitreal injection for the first 5 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with Lucentis who switch to Eylea. Coverage will NOT be provided for patients who have failed to respond to Lucentis.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00404"><pcg9 id="523600154"><itemNumber>1568</itemNumber><strength>8mg/0.07mL</strength><dosageForm>Inj Sol-0.07mL Pref Syr</dosageForm><drug id="02554798" sec3="Y" sec12="Y"><name>Eylea HD</name><manufacturerId>BAH</manufacturerId><individualPrice>1250.0000</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>1250.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="523600153"><itemNumber>1569</itemNumber><strength>8mg/0.07mL</strength><dosageForm>Inj Sol-0.07mL Vial Pk</dosageForm><drug id="02545004" sec3="Y" sec12="Y"><name>Eylea HD</name><manufacturerId>BAH</manufacturerId><individualPrice>1250.0000</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>1250.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="694">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Eylea HD. Coverage will not be provided for patients who have failed to respond to other anti-VEGF agents.

Recommended Dose: Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 8 to 16 weeks. 

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="695">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent.

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Eylea HD. Coverage will not be provided for patients who have failed to respond to other anti-VEGF agents.

Recommended Dose: Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 8 to 16 weeks.

</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00416"><pcg9 id="523600156"><itemNumber>1570</itemNumber><strength>2mg/0.05mL</strength><dosageForm>Sol for Intravitreal Inj-0.05mL Vial Pk</dosageForm><drug id="02554194" sec3="Y" sec12="Y"><name>Aflivu</name><manufacturerId>APX</manufacturerId><individualPrice>850.8000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>850.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="523600158"><itemNumber>1571</itemNumber><strength>2mg/0.05mL</strength><dosageForm>Sol for Intravitreal Inj-0.05mL Vial Pk</dosageForm><drug id="02535858" sec3="Y" sec12="Y"><name>Yesafili</name><manufacturerId>BCL</manufacturerId><individualPrice>850.8000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>850.8000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="729">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="730">For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment should be initiated with an intravitreal injection once every month. The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months based on visual and anatomic outcomes.

Prescribers are advised to periodically assess the need for continued therapy.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="731">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent.

Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 5 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00256"><pcg9 id="523600141"><itemNumber>1572</itemNumber><strength>40mg/mL</strength><dosageForm>Sol for Intravitreal Inj-0.05mL Vial Pk</dosageForm><drug id="02415992" sec3="Y" sec12="Y"><name>Eylea</name><manufacturerId>BAH</manufacturerId><individualPrice>1418.0000</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>1418.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="463">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye, but only for patients established on Eylea (aflibercept) therapy prior to August 29, 2025.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of verteporfin PDT (Visudyne) or ranibizumab (Lucentis) are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with Lucentis who switch to Eylea. Coverage will NOT be provided for patients who have failed to respond to Lucentis.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="464">For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), but only for patients established on Eylea (aflibercept) therapy prior to August 29, 2025.

Treatment should be initiated with an intravitreal injection once every month. The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months based on visual and anatomic outcomes.

Prescribers are advised to periodically assess the need for continued therapy.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with Lucentis who switch to Eylea. Coverage will NOT be provided for patients who have failed to respond to Lucentis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="465">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent, but only for patients established on Eylea (aflibercept) therapy prior to August 29, 2025.

Treatment should be initiated with a monthly intravitreal injection for the first 5 consecutive doses, followed by one injection every 2 months.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with Lucentis who switch to Eylea. Coverage will NOT be provided for patients who have failed to respond to Lucentis.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00720"><name>BETAXOLOL HCL</name><pcgGroup><pcg9 id="523600064"><itemNumber>1573</itemNumber><strength>0.25%</strength><dosageForm>Oph Susp</dosageForm><drug id="01908448" sec3="Y"><name>Betoptic S</name><manufacturerId>NOV</manufacturerId><individualPrice>2.5580</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.5580</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01579"><name>BIMATOPROST</name><pcgGroup lccId="00152"><pcg9 id="523600104"><itemNumber>1574</itemNumber><strength>0.03%</strength><dosageForm>Oph Sol</dosageForm><drug id="02245860" notABenefit="Y" sec3="Y"><name>Lumigan</name><manufacturerId>ALL</manufacturerId><listingDate>2004-04-06</listingDate></drug><drug id="02429063" sec3="Y" sec12="Y"><name>Vistitan</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.1936</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>9.1936</amountMOHLTCPays></drug></pcg9><pcg9 id="523600133"><itemNumber>1575</itemNumber><strength>0.01%</strength><dosageForm>Oph Sol-5mL Pk</dosageForm><drug id="09857368" sec3="Y" sec12="Y"><name>Lumigan RC</name><manufacturerId>ALL</manufacturerId><individualPrice>60.1892</individualPrice><listingDate>2010-09-09</listingDate><amountMOHLTCPays>60.1892</amountMOHLTCPays></drug></pcg9><pcg9 id="523600134"><itemNumber>1576</itemNumber><strength>0.01%</strength><dosageForm>Oph Sol-7.5mL Pk</dosageForm><drug id="09857398" sec3="Y" sec12="Y"><name>Lumigan RC</name><manufacturerId>ALL</manufacturerId><individualPrice>90.2838</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>90.2838</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01360"><name>BRIMONIDINE</name><pcgGroup lccId="00082"><pcg9 id="523600107"><itemNumber>1577</itemNumber><strength>0.15%</strength><dosageForm>Oph Sol</dosageForm><drug id="02248151" sec3="Y" sec12="Y"><name>Alphagan P</name><manufacturerId>ALL</manufacturerId><individualPrice>2.6017</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>2.0305</amountMOHLTCPays></drug><drug id="02301334" sec3="Y" sec12="Y"><name>Brimonidine P</name><manufacturerId>AAP</manufacturerId><individualPrice>2.0305</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>2.0305</amountMOHLTCPays></drug></pcg9><pcg9 id="523600090"><itemNumber>1578</itemNumber><strength>0.2%</strength><dosageForm>Oph Sol</dosageForm><drug id="02236876" sec3="Y" sec12="Y"><name>Alphagan</name><manufacturerId>ALL</manufacturerId><individualPrice>3.7970</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.1550</amountMOHLTCPays></drug><drug id="02305429" sec3="Y" sec12="Y"><name>Sandoz Brimonidine</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1550</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>1.1550</amountMOHLTCPays></drug><drug id="02449226" sec3="Y" sec12="Y"><name>Jamp-Brimonidine</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1550</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>1.1550</amountMOHLTCPays></drug><drug id="02507811" sec3="Y" sec12="Y"><name>Med-Brimonidine</name><manufacturerId>GMP</manufacturerId><individualPrice>1.1550</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.1550</amountMOHLTCPays></drug><drug id="02515377" sec3="Y" sec12="Y"><name>Brimonidine Tartrate Ophthalmic Solution</name><manufacturerId>TCI</manufacturerId><individualPrice>1.1550</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>1.1550</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01623"><name>BRIMONIDINE TARTRATE &amp; TIMOLOL MALEATE</name><pcgGroup lccId="00156"><pcg9 id="523600115"><itemNumber>1579</itemNumber><strength>0.2% &amp; 0.5%</strength><dosageForm>Oph Sol-10mL Pk</dosageForm><drug id="02375311" sec3="Y" sec12="Y"><name>Apo-Brimonidine-Timop</name><manufacturerId>APX</manufacturerId><individualPrice>23.2900</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>23.2900</amountMOHLTCPays></drug><drug id="02531704" sec3="Y" sec12="Y"><name>Jamp Brimonidine/Timolol</name><manufacturerId>JPC</manufacturerId><individualPrice>23.2900</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>23.2900</amountMOHLTCPays></drug><drug id="09857298" sec3="Y" sec12="Y"><name>Combigan</name><manufacturerId>ALL</manufacturerId><individualPrice>46.5800</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>23.2900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="310">As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="393">For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01423"><name>BRINZOLAMIDE</name><pcgGroup lccId="00083"><pcg9 id="523600096"><itemNumber>1580</itemNumber><strength>1%</strength><dosageForm>Oph Susp</dosageForm><drug id="02238873" sec3="Y" sec12="Y"><name>Azopt</name><manufacturerId>NOV</manufacturerId><individualPrice>3.5560</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>3.5560</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01988"><name>BRINZOLAMIDE &amp; BRIMONIDINE TARTRATE</name><pcgGroup lccId="00258"><pcg9 id="523600143"><itemNumber>1581</itemNumber><strength>1.0% &amp; 0.2%</strength><dosageForm>Oph Susp-10mL Pk</dosageForm><drug id="02435411" sec3="Y" sec12="Y"><name>Simbrinza</name><manufacturerId>NOV</manufacturerId><individualPrice>50.6900</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>50.6900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="466">As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with brinzolamide or brimonidine.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="393">For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01774"><name>BRINZOLAMIDE &amp; TIMOLOL MALEATE</name><pcgGroup lccId="00204"><pcg9 id="523600131"><itemNumber>1582</itemNumber><strength>1% &amp; 0.5%</strength><dosageForm>Oph Susp-5mL Pk</dosageForm><drug id="02331624" sec3="Y" sec12="Y"><name>Azarga</name><manufacturerId>NOV</manufacturerId><individualPrice>20.4000</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>20.4000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="310">As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="393">For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02177"><name>BROLUCIZUMAB</name><pcgGroup lccId="00349"><pcg9 id="523600148"><itemNumber>1583</itemNumber><strength>6mg/0.05mL</strength><dosageForm>Inj Sol-0.05mL Pref Syr (Preservative-Free)</dosageForm><drug id="02496976" sec3="Y" sec12="Y"><name>Beovu</name><manufacturerId>NOV</manufacturerId><individualPrice>1390.0000</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>1390.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="620">For the treatment of patients with mild-to-moderate neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified opthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis) or aflibercept (Eylea) are not eligible for reimbursement.

Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 3 months.

The interval between two doses should not be shorter than eight weeks.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy and should be discontinued if any of the following occurs:

i. reduction in best corrected visual acuity (BCVA) in the treated eye to less than 15 letters (absolute) on two consecutive visits attributed to AMD in the absence of other pathology

ii. reduction of BCVA of 30 letters or more compared to baseline and/or best recorded level since baseline as this may indicate either poor treatment effect or adverse event or both

iii. evidence of deterioration of the lesion morphology despite treatment over three consecutive visits.

For clarity, coverage will be provided for patients responding to therapy with Lucentis or Eylea who switch to Beovu. Coverage will NOT be provided for patients who have failed to respond to Lucentis or Eylea.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="648">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent.

Treatment should be initiated with an intravitreal injection every 6 weeks for the first 5 consecutive doses, followed by one injection every 8 to 12 weeks. An interval of 8 weeks may be considered for those with disease activity, whereas an interval of up to 12 weeks may be considered for those without disease activity.

After the first 5 initiation doses, the interval between two doses should not be shorter than 8 weeks.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Beovu. Coverage will NOT be provided for patients who have failed to respond to another anti-VEGF agent.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01003"><name>CHLORHEXIDINE GLUCONATE</name><pcgGroup><pcg9 id="523600086"><itemNumber>1584</itemNumber><strength>0.12%</strength><dosageForm>Oral Rinse</dosageForm><drug id="02237452" notABenefit="Y" sec3b="Y" sec3="Y"><name>Peridex</name><manufacturerId>ZIL</manufacturerId><listingDate>2024-02-29</listingDate></drug><drug id="02240433" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Chlorhexidine</name><manufacturerId>PMS</manufacturerId><individualPrice>.0253</individualPrice><listingDate>2024-02-29</listingDate></drug><drug id="02493160" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Chlorhexidine Without Alcohol</name><manufacturerId>PMS</manufacturerId><individualPrice>.0253</individualPrice><listingDate>2024-03-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00741"><name>DEXTRAN 70 &amp; HYDROXYPROPYL METHYLCELLULOSE &amp; POLYQUAD</name><pcgGroup lccId="00084"><pcg9 id="523600073"><itemNumber>1585</itemNumber><strength>0.1%/0.3%/0.001%</strength><dosageForm>Oph-Sol</dosageForm><drug id="00743445" sec3="Y" sec12="Y"><name>Tears Naturale II</name><manufacturerId>ALC</manufacturerId><individualPrice>.4387</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4387</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="49">For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00425"><name>DICLOFENAC SODIUM</name><pcgGroup><pcg9 id="523600065"><itemNumber>1586</itemNumber><strength>0.1%</strength><dosageForm>Oph Sol</dosageForm><note>The prescriber should be aware that diclofenac sodium 0.1% ophthalmic solution products may be preservative-free or preservative-containing. If applicable, the prescriber should choose the most appropriate formulation (preservative-free or preservative containing) for use in the specific clinical situation in which the product was prescribed.</note><drug id="01940414" sec3="Y"><name>Voltaren Ophtha</name><manufacturerId>NOV</manufacturerId><individualPrice>4.3500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2397</amountMOHLTCPays></drug><drug id="02441020" sec3="Y"><name>Apo-Diclofenac Ophthalmic</name><manufacturerId>APX</manufacturerId><individualPrice>1.2397</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>1.2397</amountMOHLTCPays></drug><drug id="02454807" sec3="Y"><name>Sandoz Diclofenac Ophtha</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2397</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>1.2397</amountMOHLTCPays></drug><drug id="02475065" sec3="Y"><name>Diclofenac</name><manufacturerId>PHS</manufacturerId><individualPrice>1.2397</individualPrice><note>Diclofenac sodium 0.1% ophthalmic solution (DIN 02475065) is in a unit dose container of 0.3mL and it is preservative-free. Its Drug Benefit Price is displayed on a per mL basis. Dispensers must ensure that the unit of reimbursement for this product is accurate in the submitted claims. (For example, when dispensing a package of 10 x 0.3mL containers, a unit of 3 must be selected in the Health Network System claim to reflect that 3mL is being dispensed.)</note><listingDate>2019-12-20</listingDate><amountMOHLTCPays>1.2397</amountMOHLTCPays></drug><drug id="02475197" sec3="Y"><name>Mint-Diclofenac</name><manufacturerId>MIN</manufacturerId><individualPrice>1.2397</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>1.2397</amountMOHLTCPays></drug><drug id="02534525" sec3="Y"><name>Jamp Diclofenac</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2397</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>1.2397</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00743"><name>DORZOLAMIDE HCL</name><pcgGroup lccId="00086"><pcg9 id="523600083"><itemNumber>1587</itemNumber><strength>2%</strength><dosageForm>Oph Sol</dosageForm><drug id="02216205" sec3="Y" sec12="Y"><name>Trusopt</name><manufacturerId>ELV</manufacturerId><individualPrice>6.1267</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.4757</amountMOHLTCPays></drug><drug id="02316307" sec3="Y" sec12="Y"><name>Sandoz Dorzolamide</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.4757</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>1.4757</amountMOHLTCPays></drug><drug id="02453347" sec3="Y" sec12="Y"><name>Jamp-Dorzolamide</name><manufacturerId>JPC</manufacturerId><individualPrice>1.4757</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>1.4757</amountMOHLTCPays></drug><drug id="02457210" sec3="Y" sec12="Y"><name>Med-Dorzolamide</name><manufacturerId>GMP</manufacturerId><individualPrice>1.4757</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>1.4757</amountMOHLTCPays></drug><drug id="02522373" sec3="Y" sec12="Y"><name>Dorzolamide</name><manufacturerId>JPC</manufacturerId><individualPrice>1.4757</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>1.4757</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01431"><name>DORZOLAMIDE HCL &amp; TIMOLOL MALEATE</name><pcgGroup lccId="00087"><pcg9 id="523600098"><itemNumber>1588</itemNumber><strength>2% &amp; 0.5%</strength><dosageForm>Oph Sol</dosageForm><drug id="02240113" sec3="Y" sec12="Y"><name>Cosopt</name><manufacturerId>ELV</manufacturerId><individualPrice>9.6613</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02299615" sec3="Y" sec12="Y"><name>Apo-Dorzo-Timop</name><manufacturerId>APX</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02344351" sec3="Y" sec12="Y"><name>Sandoz Dorzolamide/Timolol</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02404389" sec3="Y" sec12="Y"><name>Co Dorzotimolol</name><manufacturerId>COB</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02437686" sec3="Y" sec12="Y"><name>Med-Dorzolamide-Timolol</name><manufacturerId>GMP</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02441659" sec3="Y" sec12="Y"><name>Riva-Dorzolamide/Timolol</name><manufacturerId>RIA</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02443090" sec3="Y" sec12="Y"><name>Mint-Dorzolamide/Timolol</name><manufacturerId>MIN</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02457539" sec3="Y" sec12="Y"><name>Jamp Dorzolamide-Timolol</name><manufacturerId>JPC</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02489635" dinStatus="E" sec3="Y" sec12="Y"><name>Dorzolamide and Timolol Eye Drops BP</name><manufacturerId>TCI</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02522020" sec3="Y" sec12="Y"><name>Dorzolamide-Timolol</name><manufacturerId>JPC</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug><drug id="02537796" sec3="Y" sec12="Y"><name>M-Dorzolamide-Timolol</name><manufacturerId>MAT</manufacturerId><individualPrice>2.0951</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>2.0951</amountMOHLTCPays></drug></pcg9><pcg9 id="523600113"><itemNumber>1589</itemNumber><strength>2% &amp; 0.5%</strength><dosageForm>Oph Sol-0.2mL Pk</dosageForm><drug id="02258692" sec3="Y" sec12="Y"><name>Cosopt Preservative free</name><manufacturerId>ELV</manufacturerId><individualPrice>.8505</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.8505</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="310">As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="393">For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02328"><name>FARICIMAB</name><pcgGroup lccId="00371"><pcg9 id="523600159"><itemNumber>1590</itemNumber><strength>6mg/0.05mL</strength><dosageForm>Inj Sol-0.05mL Pref Syr (Preservative-Free)</dosageForm><drug id="02554003" sec3="Y" sec12="Y"><name>Vabysmo</name><manufacturerId>HLR</manufacturerId><individualPrice>1350.0000</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>1350.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="523600150"><itemNumber>1591</itemNumber><strength>6mg/0.05mL</strength><dosageForm>Inj Sol-0.24mL Vial Pk (Preservative-Free)</dosageForm><drug id="02527618" sec3="Y" sec12="Y"><name>Vabysmo</name><manufacturerId>HLR</manufacturerId><individualPrice>1350.0000</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>1350.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="649">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration of verteporfin PDT (Visudyne), ranibizumab (Lucentis), aflibercept (Eylea) or brolucizumab (Beovu) are not eligible for reimbursement.

Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses, followed by one injection every 8 to 16 weeks based upon disease activity.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="650">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 12 percent.

Vabysmo is to be administered using one of the following dosing regimens:

Treatment should be initiated with an intravitreal injection every 4 weeks for the first 6 doses, followed by an intravitreal injection at a dosing interval of every 8 weeks.

OR

Treatment should be initiated with an intravitreal injection every 4 weeks for the first 4 doses or until macular edema is resolved. Thereafter, the dosing interval may be extended up to every 16 weeks (4 months) in up to 4-week increments. If anatomic and/or visual outcomes deteriorate, then the treatment interval should be shortened accordingly.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to Vabysmo. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="725">For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Treatment should be initiated with an intravitreal injection every 4 weeks until stable visual acuity improvement and disease control are achieved.

The treatment interval may be extended up to 16 weeks (4 months) in up to 4-week increments at a time in patients without disease activity.

If anatomic and/or visual outcomes deteriorate, the treatment interval should be shortened accordingly. The interval between doses should not be shorter than one month.

Patients should be assessed regularly. Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00227"><name>IPRATROPIUM BROMIDE</name><pcgGroup lccId="00088"><pcg9 id="523600082"><itemNumber>1592</itemNumber><strength>0.03%</strength><dosageForm>Nasal Spray</dosageForm><drug id="02163705" notABenefit="Y" sec3="Y"><name>Atrovent</name><manufacturerId>BOE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02239627" sec3="Y" sec12="Y"><name>PMS-Ipratropium</name><manufacturerId>PMS</manufacturerId><individualPrice>.8693</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>.8693</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="03">For the treatment of non-allergic vasomotor rhinitis</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="523600117"><itemNumber>1593</itemNumber><strength>0.06%</strength><dosageForm>Nasal Spray</dosageForm><drug id="02163713" notABenefit="Y" sec3b="Y" sec3="Y"><name>Atrovent</name><manufacturerId>BOE</manufacturerId><listingDate>2009-06-23</listingDate></drug><drug id="02246084" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ipravent</name><manufacturerId>AAP</manufacturerId><individualPrice>2.9700</individualPrice><listingDate>2009-06-23</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01195"><name>KETOTIFEN</name><pcgGroup><pcg9 id="523600136"><itemNumber>1594</itemNumber><strength>0.25mg/mL</strength><dosageForm>Oph Sol-5mL Pk</dosageForm><drug id="02242324" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zaditor</name><manufacturerId>LBT</manufacturerId><listingDate>2013-07-30</listingDate></drug><drug id="02400871" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ketotifen Ophthalmic Solution</name><manufacturerId>STE</manufacturerId><individualPrice>21.1700</individualPrice><listingDate>2013-07-30</listingDate></drug><drug id="02542722" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Ketotifen Ophthalmic</name><manufacturerId>JPC</manufacturerId><individualPrice>25.7800</individualPrice><listingDate>2024-06-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01339"><name>LATANOPROST</name><pcgGroup lccId="00089"><pcg9 id="523600088"><itemNumber>1595</itemNumber><strength>0.005%</strength><dosageForm>Oph Sol-2.5mL Pk</dosageForm><drug id="02231493" sec3="Y" sec12="Y"><name>Xalatan</name><manufacturerId>UJC</manufacturerId><individualPrice>35.4927</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02254786" sec3="Y" sec12="Y"><name>Co Latanoprost</name><manufacturerId>COB</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02296527" sec3="Y" sec12="Y"><name>Apo-Latanoprost</name><manufacturerId>APX</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02341085" sec3="Y" sec12="Y"><name>Riva-Latanoprost</name><manufacturerId>RIA</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02367335" sec3="Y" sec12="Y"><name>Sandoz Latanoprost</name><manufacturerId>SDZ</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02373041" sec3="Y" sec12="Y"><name>Gd-Latanoprost</name><manufacturerId>UJC</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02426935" sec3="Y" sec12="Y"><name>Med-Latanoprost</name><manufacturerId>GMP</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02453355" sec3="Y" sec12="Y"><name>Jamp Latanoprost</name><manufacturerId>JPC</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02489570" dinStatus="E" sec3="Y" sec12="Y"><name>Latanoprost Ophthalmic Solution</name><manufacturerId>TCI</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug><drug id="02513285" sec3="Y" sec12="Y"><name>M-Latanoprost</name><manufacturerId>MAT</manufacturerId><individualPrice>9.5830</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>9.5830</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01624"><name>LATANOPROST &amp; TIMOLOL MALEATE</name><pcgGroup lccId="00157"><pcg9 id="523600108"><itemNumber>1596</itemNumber><strength>50mcg/mL &amp; 5mg/mL</strength><dosageForm>Oph Sol-2.5mL Pk</dosageForm><drug id="02246619" sec3="Y" sec12="Y"><name>Xalacom</name><manufacturerId>UJC</manufacturerId><individualPrice>40.1739</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02373068" sec3="Y" sec12="Y"><name>Gd-Latanoprost/Timolol</name><manufacturerId>UJC</manufacturerId><individualPrice>11.0700</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02394685" sec3="Y" sec12="Y"><name>Sandoz Latanoprost/Timolol</name><manufacturerId>SDZ</manufacturerId><individualPrice>11.0700</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02414155" sec3="Y" sec12="Y"><name>Apo-Latanoprost-Timop</name><manufacturerId>APX</manufacturerId><individualPrice>11.0700</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02436256" sec3="Y" sec12="Y"><name>Act Latanoprost/Timolol</name><manufacturerId>ACV</manufacturerId><individualPrice>11.0700</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02453770" sec3="Y" sec12="Y"><name>Jamp-Latanoprost/Timolol</name><manufacturerId>JPC</manufacturerId><individualPrice>11.0700</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02454505" sec3="Y" sec12="Y"><name>Med-Latanoprost-Timolol</name><manufacturerId>GMP</manufacturerId><individualPrice>11.0700</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug><drug id="02514516" sec3="Y" sec12="Y"><name>M-Latanoprost-Timolol</name><manufacturerId>MAT</manufacturerId><individualPrice>11.0670</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>11.0670</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="310">As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="393">For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02113"><name>LATANOPROSTENE BUNOD</name><pcgGroup lccId="00324"><pcg9 id="523600145"><itemNumber>1597</itemNumber><strength>0.024%w/v</strength><dosageForm>Oph Sol</dosageForm><drug id="02484218" sec3="Y" sec12="Y"><name>Vyzulta</name><manufacturerId>BSH</manufacturerId><individualPrice>5.2500</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>5.2500</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00719"><name>LEVOBUNOLOL HCL</name><pcgGroup><pcg9 id="523600035"><itemNumber>1598</itemNumber><strength>0.5%</strength><dosageForm>Oph Sol</dosageForm><drug id="00637661" sec3="Y"><name>Betagan</name><manufacturerId>ALL</manufacturerId><individualPrice>3.8153</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.8153</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00722"><name>METHAZOLAMIDE</name><pcgGroup><pcg9 id="523600043"><itemNumber>1599</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02238071" notABenefit="Y" sec3="Y"><name>Neptazane</name><manufacturerId>WAY</manufacturerId><listingDate>1999-12-16</listingDate></drug><drug id="02245882" sec3="Y"><name>Methazolamide</name><manufacturerId>AAP</manufacturerId><individualPrice>.4913</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.4913</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00738"><name>METHYLCELLULOSE</name><pcgGroup lccId="00090"><pcg9 id="523600067" suppliedBy="L"><itemNumber>1600</itemNumber><strength>0.5%</strength><dosageForm>Oph-Sol</dosageForm><drug id="00000809" sec3="Y" sec12="Y"><name>Isopto Tears</name><manufacturerId>ALC</manufacturerId><individualPrice>.5147</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5147</amountMOHLTCPays></drug></pcg9><pcg9 id="523600068" suppliedBy="L"><itemNumber>1601</itemNumber><strength>1%</strength><dosageForm>Oph-Sol</dosageForm><drug id="00000817" sec3="Y" sec12="Y"><name>Isopto Tears</name><manufacturerId>ALC</manufacturerId><individualPrice>.5147</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5147</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="49">For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01412"><name>OLOPATADINE HCL</name><pcgGroup><pcg9 id="523600137"><itemNumber>1602</itemNumber><strength>0.2%</strength><dosageForm>Oph Sol-2.5mL Pk</dosageForm><drug id="02362171" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pataday</name><manufacturerId>NOV</manufacturerId><listingDate>2014-05-29</listingDate></drug><drug id="02402823" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Olopatadine</name><manufacturerId>APX</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02404095" notABenefit="Y" sec3b="Y" sec3="Y"><name>Act Olopatadine 0.2%</name><manufacturerId>ACV</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2014-05-29</listingDate></drug><drug id="02420171" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Olopatadine 0.2%</name><manufacturerId>SDZ</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2014-06-26</listingDate></drug><drug id="02508605" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Olopatadine 0.2%</name><manufacturerId>MIN</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2022-03-31</listingDate></drug><drug id="02541653" notABenefit="Y" sec3b="Y" sec3="Y"><name>Olopatadine 0.2%</name><manufacturerId>SAI</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2024-05-31</listingDate></drug></pcg9><pcg9 id="523600094"><itemNumber>1603</itemNumber><strength>0.1%</strength><dosageForm>Oph Sol-5mL Pk</dosageForm><drug id="02233143" notABenefit="Y" sec3b="Y" sec3="Y"><name>Patanol</name><manufacturerId>NOV</manufacturerId><listingDate>2013-01-29</listingDate></drug><drug id="02305054" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Olopatadine</name><manufacturerId>APX</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2013-01-29</listingDate></drug><drug id="02358913" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Olopatadine</name><manufacturerId>SDZ</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2013-04-30</listingDate></drug><drug id="02403986" notABenefit="Y" sec3b="Y" sec3="Y"><name>Co Olopatadine 0.1%</name><manufacturerId>COB</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2014-02-27</listingDate></drug><drug id="02422727" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Olopatadine</name><manufacturerId>MIN</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2014-11-27</listingDate></drug><drug id="02458411" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Olopatadine</name><manufacturerId>JPC</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2017-03-28</listingDate></drug><drug id="02521172" notABenefit="Y" sec3b="Y" sec3="Y"><name>Olopatadine</name><manufacturerId>SAI</manufacturerId><individualPrice>26.1300</individualPrice><listingDate>2022-05-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00739"><name>PETROLATUM/MINERAL OIL</name><pcgGroup lccId="00091"><pcg9 id="523600070"><itemNumber>1604</itemNumber><strength>55% &amp; 42.5%</strength><dosageForm>Oph Oint-3.5g Pk</dosageForm><drug id="00210889" sec3="Y" sec12="Y"><name>Lacri-Lube</name><manufacturerId>ALL</manufacturerId><individualPrice>7.9000</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>7.9000</amountMOHLTCPays></drug></pcg9><pcg9 id="523600076"><itemNumber>1605</itemNumber><strength>80%/20%</strength><dosageForm>Oph Oint-3.5g Pk</dosageForm><drug id="02125706" sec3="Y" sec12="Y"><name>Soothe Night Time</name><manufacturerId>BLI</manufacturerId><individualPrice>5.4800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>5.4800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="49">For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00736"><name>POLYVINYL ALCOHOL</name><pcgGroup lccId="00093"><pcg9 id="523600069"><itemNumber>1606</itemNumber><strength>1.4%</strength><dosageForm>Oph-Sol</dosageForm><drug id="00045616" sec3="Y" sec12="Y"><name>Liquifilm Tears</name><manufacturerId>ALL</manufacturerId><individualPrice>.6373</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6373</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="49">For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00742"><name>POLYVINYL ALCOHOL &amp; POLYVINYLPYRROLIDONE</name><pcgGroup lccId="00092"><pcg9 id="523600075"><itemNumber>1607</itemNumber><dosageForm>Oph-Sol</dosageForm><drug id="00579408" sec3="Y" sec12="Y"><name>Tears Plus</name><manufacturerId>ALL</manufacturerId><individualPrice>.3840</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="49">For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01726"><name>RANIBIZUMAB</name><pcgGroup lccId="00372"><pcg9 id="523600151"><itemNumber>1608</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol-0.23mL Vial Pk (Preservative-Free)</dosageForm><drug id="02525852" sec3="Y" sec12="Y"><name>Byooviz</name><manufacturerId>SAM</manufacturerId><individualPrice>900.0000</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>900.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="523600152"><itemNumber>1609</itemNumber><strength>10mg/mL</strength><dosageForm>Inj Sol-0.23mL Vial Pk (Preservative-Free)</dosageForm><drug id="02542250" sec3="Y" sec12="Y"><name>Ranopto</name><manufacturerId>TEI</manufacturerId><individualPrice>900.0000</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>900.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="651">For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a verteporfin PDT (Visudyne)-naive eye.

Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.

Patients receiving concurrent administration with another anti-VEGF agent are not eligible for reimbursement.

Treatment should be initiated with a loading phase of one injection per month for three consecutive months, followed by a maintenance phase.

During the maintenance phase, patients should be monitored for best corrected visual acuity or continued disease activity. If there is clinical or diagnostic evidence of disease activity such as a loss of greater than 5 letters in visual acuity (Early Treatment Diabetic Retinopathy Score (ETDRS) chart or one Snellen line equivalent), ranibizumab may be administered.

The interval between two doses should not be shorter than one month.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="652">For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and who have a hemoglobin A1c of less than 11 percent.

Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity.

Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to DME and continued until stable visual acuity is reached again for three consecutive monthly assessments.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="653">For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

Treatment to be given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on ranibizumab treatment. Thereafter patients should be monitored monthly for visual acuity.

Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to macular edema secondary to retinal vein occlusion and continued until stable visual acuity is reached again for three consecutive monthly assessments.

Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.

For clarity, coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="654">For the treatment of patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia.

Treatment is initiated with a single intravitreal injection. Monitoring is recommended monthly for the first 2 months and at least every 3 months thereafter during the first year. If monitoring reveals signs of disease activity (e.g. reduced visual acuity and/or signs of lesion activity), further treatment is recommended at a frequency of 1 injection per month until no disease activity is seen.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00718"><name>SODIUM CROMOGLYCATE</name><pcgGroup><pcg9 id="523600019"><itemNumber>1610</itemNumber><strength>2%</strength><dosageForm>Oph Sol</dosageForm><drug id="02009277" sec3="Y"><name>Cromolyn Eye Drops</name><manufacturerId>PEN</manufacturerId><individualPrice>.9500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9500</amountMOHLTCPays></drug><drug id="02230621" notABenefit="Y" sec3="Y"><name>Opticrom</name><manufacturerId>ALL</manufacturerId><listingDate>1998-02-17</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00314"><name>TIMOLOL MALEATE</name><pcgGroup><pcg9 id="523600080"><itemNumber>1611</itemNumber><strength>0.25%</strength><dosageForm>Oph Gellan Sol</dosageForm><drug id="02171880" notABenefit="Y" sec3="Y"><name>Timoptic-XE</name><manufacturerId>PFP</manufacturerId><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>1996-10-01</listingDate></drug><drug id="02242275" sec3="Y"><name>Timolol Maleate-EX</name><manufacturerId>ALC</manufacturerId><individualPrice>2.9540</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>2006-08-24</listingDate><amountMOHLTCPays>2.9540</amountMOHLTCPays></drug></pcg9><pcg9 id="523600081"><itemNumber>1612</itemNumber><strength>0.5%</strength><dosageForm>Oph Gellan Sol</dosageForm><drug id="02171899" sec3="Y"><name>Timoptic-XE</name><manufacturerId>ELV</manufacturerId><individualPrice>9.1190</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.5320</amountMOHLTCPays></drug><drug id="02242276" sec3="Y"><name>Timolol Maleate-EX</name><manufacturerId>ALC</manufacturerId><individualPrice>3.5320</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>2006-08-24</listingDate><amountMOHLTCPays>3.5320</amountMOHLTCPays></drug></pcg9><pcg9 id="523600021"><itemNumber>1613</itemNumber><strength>0.25%</strength><dosageForm>Oph Sol</dosageForm><drug id="00451193" notABenefit="Y" sec3="Y"><name>Timoptic</name><manufacturerId>MFC</manufacturerId><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.

Highest historical DBP for this product is $2.7650.</note><listingDate>1996-10-01</listingDate></drug><drug id="02166712" sec3="Y"><name>Sandoz Timolol</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.3503</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>1999-04-15</listingDate><amountMOHLTCPays>2.3503</amountMOHLTCPays></drug></pcg9><pcg9 id="523600022"><itemNumber>1614</itemNumber><strength>0.5%</strength><dosageForm>Oph Sol</dosageForm><drug id="00451207" sec3="Y"><name>Timoptic</name><manufacturerId>ELV</manufacturerId><individualPrice>7.1408</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2145</amountMOHLTCPays></drug><drug id="00755834" sec3="Y"><name>Apo-Timop</name><manufacturerId>APX</manufacturerId><individualPrice>1.2145</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2145</amountMOHLTCPays></drug><drug id="02166720" sec3="Y"><name>Sandoz Timolol</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2145</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.2145</amountMOHLTCPays></drug><drug id="02447800" sec3="Y"><name>Jamp-Timolol</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2145</individualPrice><note>Timolol maleate can potentiate bronchospasm in asthmatic patients and should not be used in patients with a history of asthma.</note><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2145</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01746"><name>TIMOLOL MALEATE &amp; TRAVOPROST</name><pcgGroup lccId="00198"><pcg9 id="523600116"><itemNumber>1615</itemNumber><strength>0.5% &amp; 0.004%</strength><dosageForm>Oph Sol</dosageForm><drug id="02278251" notABenefit="Y" sec3="Y"><name>DuoTrav</name><manufacturerId>ALC</manufacturerId><listingDate>2009-01-30</listingDate></drug><drug id="02415305" dinStatus="E" sec3="Y" sec12="Y"><name>Apo-Travoprost-Timop</name><manufacturerId>APX</manufacturerId><individualPrice>8.8425</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>8.8425</amountMOHLTCPays></drug></pcg9><pcg9 id="523600139"><itemNumber>1616</itemNumber><strength>0.5% &amp; 0.004%</strength><dosageForm>Oph Sol-5mL Pk</dosageForm><drug id="09857513" sec3="Y" sec12="Y"><name>DuoTrav PQ</name><manufacturerId>NOV</manufacturerId><individualPrice>56.7000</individualPrice><note>This product is stable for 120 days after opening. Please refer to the product monograph for more information.</note><listingDate>2014-11-27</listingDate><amountMOHLTCPays>44.2125</amountMOHLTCPays></drug><drug id="09857644" sec3="Y" sec12="Y"><name>Apo-Travoprost-Timop PQ</name><manufacturerId>APX</manufacturerId><individualPrice>44.2125</individualPrice><note>This product is stable for 120 days after opening. Please refer to the product monograph for more information.</note><listingDate>2020-06-30</listingDate><amountMOHLTCPays>44.2125</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="310">As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="393">For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01557"><name>TRAVOPROST</name><pcgGroup lccId="00318"><pcg9 id="523600144"><itemNumber>1617</itemNumber><strength>0.003%</strength><dosageForm>Oph Sol (with Preservative)</dosageForm><drug id="02457997" sec3="Y" sec12="Y"><name>IZBA</name><manufacturerId>NOV</manufacturerId><individualPrice>3.9400</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>3.9400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00094"><pcg9 id="523600119"><itemNumber>1618</itemNumber><strength>0.004%</strength><dosageForm>Oph Sol-5mL Pk</dosageForm><drug id="02413167" sec3="Y" sec12="Y"><name>Sandoz Travoprost</name><manufacturerId>SDZ</manufacturerId><individualPrice>28.7600</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>28.7600</amountMOHLTCPays></drug><drug id="02548089" sec3="Y" sec12="Y"><name>Jamp Travoprost Z</name><manufacturerId>JPC</manufacturerId><individualPrice>28.7600</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>28.7600</amountMOHLTCPays></drug><drug id="09857332" sec3="Y" sec12="Y"><name>Travatan Z</name><manufacturerId>NOV</manufacturerId><individualPrice>58.9600</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>28.7600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="171">As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="172">As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="387">For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6></pcg2><pcg2 id="560000000"><name>GASTROINTESTINAL DRUGS</name><pcg6 id="560400000"><name>ANTACIDS AND ADSORBENTS</name><genericName id="00748"><name>ALUMINUM HYDROXIDE &amp; MAGNESIUM HYDROXIDE</name><pcgGroup><pcg9 id="560400007" suppliedBy="L" dpp="Y"><itemNumber>1619</itemNumber><strength>40mg &amp; 40mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00261173" notABenefit="Y" selfMed="Y" sec3="Y"><name>Neutralca-S</name><manufacturerId>DES</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02163136" notABenefit="Y" selfMed="Y" sec3="Y"><name>Maalox</name><manufacturerId>NOV</manufacturerId><listingDate>1998-03-17</listingDate></drug></pcg9><pcg9 id="560400016" dpp="Y"><itemNumber>1620</itemNumber><strength>120mg &amp; 60mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00491217" notABenefit="Y" sec3="Y"><name>Diovol EX</name><manufacturerId>HOR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02162369" notABenefit="Y" sec3="Y"><name>Maalox TC</name><manufacturerId>NOV</manufacturerId><listingDate>1998-03-17</listingDate></drug></pcg9><pcg9 id="560400005" dpp="Y"><itemNumber>1621</itemNumber><strength>400mg &amp; 400mg</strength><dosageForm>Tab</dosageForm><drug id="00483605" notABenefit="Y" sec3="Y"><name>Gelusil Extra Strength</name><manufacturerId>PDA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02208253" notABenefit="Y" sec3="Y"><name>Maalox</name><manufacturerId>NOV</manufacturerId><listingDate>1998-03-17</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="560800000"><name>ANTIDIARRHEA AGENTS</name><genericName id="00761"><name>DIPHENOXYLATE HYDROCHLORIDE &amp; ATROPINE SULFATE</name><pcgGroup lccId="00095"><pcg9 id="560800016"><itemNumber>1622</itemNumber><strength>2.5mg &amp; 0.025mg</strength><dosageForm>Tab</dosageForm><drug id="00036323" sec3="Y" sec12="Y"><name>Lomotil</name><manufacturerId>PFI</manufacturerId><individualPrice>.5729</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5729</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the treatment of diarrhea associated with:</lccNote><lccNote seq="002" reasonForUseId="110">An ileostomy or a colostomy;.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="004" reasonForUseId="111">Bowel resection, including short bowel syndrome;</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" reasonForUseId="112">Inflammatory Bowel Diseases, i.e. Crohn&apos;s Disease and Ulcerative Colitis;</lccNote><lccNote seq="007" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="008" reasonForUseId="113">Cancer, including chemotherapy or radiation therapy;</lccNote><lccNote seq="009" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="010" reasonForUseId="114">HIV/AIDS;</lccNote><lccNote seq="011" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="012" reasonForUseId="115">Acute diarrhea in patients in congregated housing, i.e. Long Term Care Facilities (LTCF), or for patients receiving Home Care;</lccNote><lccNote seq="013" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="014" reasonForUseId="224">Fecal incontinence.</lccNote><lccNote seq="015" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00760"><name>LOPERAMIDE HCL</name><pcgGroup lccId="00096"><pcg9 id="560800015"><itemNumber>1623</itemNumber><strength>2mg</strength><dosageForm>Caplet</dosageForm><drug id="00860743" notABenefit="Y" sec3="Y"><name>Imodium</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02132591" sec3="Y" sec12="Y"><name>Teva-Loperamide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0952</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.0952</amountMOHLTCPays></drug><drug id="02212005" sec3="Y" sec12="Y"><name>Apo-Loperamide</name><manufacturerId>APX</manufacturerId><individualPrice>.0952</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.0952</amountMOHLTCPays></drug><drug id="02228351" sec3="Y" sec12="Y"><name>PMS-Loperamide</name><manufacturerId>PMS</manufacturerId><individualPrice>.0952</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0952</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the treatment of diarrhea associated with:</lccNote><lccNote seq="002" reasonForUseId="110">An ileostomy or a colostomy;.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="004" reasonForUseId="111">Bowel resection, including short bowel syndrome;</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" reasonForUseId="112">Inflammatory Bowel Diseases, i.e. Crohn&apos;s Disease and Ulcerative Colitis;</lccNote><lccNote seq="007" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="008" reasonForUseId="113">Cancer, including chemotherapy or radiation therapy;</lccNote><lccNote seq="009" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="010" reasonForUseId="114">HIV/AIDS;</lccNote><lccNote seq="011" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="012" reasonForUseId="115">Acute diarrhea in patients in congregated housing, i.e. Long Term Care Facilities (LTCF), or for patients receiving Home Care;</lccNote><lccNote seq="013" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="014" reasonForUseId="224">Fecal incontinence.</lccNote><lccNote seq="015" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="561200000"><name>CATHARTICS</name><genericName id="00768"><name>BISACODYL</name><pcgGroup><pcg9 id="561200001" suppliedBy="L"><itemNumber>1624</itemNumber><strength>5mg</strength><dosageForm>Ent Tab</dosageForm><drug id="00254142" selfMed="Y" sec3="Y"><name>Dulcolax</name><manufacturerId>SCO</manufacturerId><individualPrice>.2009</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2009</amountMOHLTCPays></drug></pcg9><pcg9 id="561200002" suppliedBy="L"><itemNumber>1625</itemNumber><strength>10mg</strength><dosageForm>Sup</dosageForm><drug id="00003875" selfMed="Y" sec3="Y"><name>Dulcolax</name><manufacturerId>SCO</manufacturerId><individualPrice>1.2267</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4206</amountMOHLTCPays></drug><drug id="02361450" selfMed="Y" sec3="Y"><name>Bisacodyl Suppository</name><manufacturerId>JPC</manufacturerId><individualPrice>.4206</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.4206</amountMOHLTCPays></drug><drug id="02458853" selfMed="Y" sec3="Y"><name>Bisacodyl 10mg</name><manufacturerId>CCP</manufacturerId><individualPrice>.4206</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.4206</amountMOHLTCPays></drug><drug id="02520478" selfMed="Y" sec3="Y"><name>AMB-Bisacodyl</name><manufacturerId>AMB</manufacturerId><individualPrice>.4206</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>.4206</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00770"><name>DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE)</name><pcgGroup><pcg9 id="561200008" suppliedBy="L"><itemNumber>1626</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="00716731" selfMed="Y" sec3="Y"><name>Docusate Sodium</name><manufacturerId>TAR</manufacturerId><individualPrice>.0328</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0328</amountMOHLTCPays></drug><drug id="01994344" selfMed="Y" sec3="Y"><name>Soflax</name><manufacturerId>PMS</manufacturerId><individualPrice>.0328</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0328</amountMOHLTCPays></drug><drug id="02106256" selfMed="Y" sec3="Y"><name>Colace</name><manufacturerId>WEL</manufacturerId><individualPrice>.1310</individualPrice><listingDate>2006-04-19</listingDate><amountMOHLTCPays>.0328</amountMOHLTCPays></drug><drug id="02245946" selfMed="Y" sec3="Y"><name>Jamp-Docusate Sodium</name><manufacturerId>JPC</manufacturerId><individualPrice>.0328</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.0328</amountMOHLTCPays></drug></pcg9><pcg9 id="561200009"><itemNumber>1627</itemNumber><strength>4mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02086018" sec3="Y"><name>Colace</name><manufacturerId>WEL</manufacturerId><individualPrice>.0232</individualPrice><listingDate>1998-11-19</listingDate><amountMOHLTCPays>.0232</amountMOHLTCPays></drug></pcg9><pcg9 id="561200010"><itemNumber>1628</itemNumber><strength>10mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02090163" sec3="Y"><name>Colace</name><manufacturerId>WEL</manufacturerId><individualPrice>.1770</individualPrice><listingDate>1998-11-19</listingDate><amountMOHLTCPays>.1770</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00777"><name>GRAIN &amp; CITRUS FIBRE</name><pcgGroup><pcg9 id="561200037" suppliedBy="L"><itemNumber>1629</itemNumber><dosageForm>Tab</dosageForm><drug id="00595829" selfMed="Y" sec3="Y"><name>Novo-Fibre</name><manufacturerId>NOP</manufacturerId><individualPrice>.0706</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0706</amountMOHLTCPays></drug><drug id="00779768" notABenefit="Y" sec3="Y"><name>Fibyrax</name><manufacturerId>LED</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00779"><name>LACTULOSE</name><pcgGroup><pcg9 id="561200047"><itemNumber>1630</itemNumber><strength>667mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00703486" sec3="Y"><name>PMS-Lactulose</name><manufacturerId>PMS</manufacturerId><individualPrice>.0147</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0147</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01675"><name>MAGNESIUM OXIDE &amp; CITRIC ACID &amp; SODIUM PICOSULFATE</name><pcgGroup><pcg9 id="561200088"><itemNumber>1631</itemNumber><strength>3.5g &amp; 12g &amp; 10mg</strength><dosageForm>Pd for Sol-12g Sachet</dosageForm><drug id="02254794" sec3="Y"><name>Pico-Salax</name><manufacturerId>FEI</manufacturerId><individualPrice>14.5808</individualPrice><listingDate>2006-04-19</listingDate><amountMOHLTCPays>12.3500</amountMOHLTCPays></drug><drug id="02317966" sec3="Y"><name>Purg-Odan</name><manufacturerId>ODN</manufacturerId><individualPrice>12.3500</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>12.3500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00772"><name>MINERAL OIL</name><pcgGroup><pcg9 id="561200016"><itemNumber>1632</itemNumber><strength>100%</strength><dosageForm>Enema</dosageForm><drug id="00107875" sec3="Y"><name>Fleet Enema Mineral Oil</name><manufacturerId>CBF</manufacturerId><individualPrice>.0452</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0452</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00773"><name>PSYLLIUM MUCILLOID</name><pcgGroup><pcg9 id="561200017" suppliedBy="L"><itemNumber>1633</itemNumber><dosageForm>Oral Pd</dosageForm><drug id="02174812" selfMed="Y" sec3="Y"><name>Metamucil Fibre Therapy-Original Texture</name><manufacturerId>PGI</manufacturerId><individualPrice>.0246</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.0246</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00774"><name>SENNOSIDES A &amp; B</name><pcgGroup><pcg9 id="561200018" suppliedBy="L"><itemNumber>1634</itemNumber><strength>8.6mg</strength><dosageForm>Tab</dosageForm><drug id="00026158" selfMed="Y" sec3="Y"><name>Senokot</name><manufacturerId>INO</manufacturerId><individualPrice>.0464</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0464</amountMOHLTCPays></drug><drug id="80009595" selfMed="Y" sec3="Y"><name>Jamp-Senna</name><manufacturerId>JPC</manufacturerId><individualPrice>.0464</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.0464</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00775"><name>SODIUM BIPHOSPHATE &amp; SODIUM PHOSPHATE</name><pcgGroup><pcg9 id="561200024"><itemNumber>1635</itemNumber><strength>160mg &amp; 60mg/mL</strength><dosageForm>Ped Rect Sol</dosageForm><drug id="00108065" sec3="Y"><name>Fleet Enema Pediatric</name><manufacturerId>CBF</manufacturerId><individualPrice>.0630</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0630</amountMOHLTCPays></drug></pcg9><pcg9 id="561200023" suppliedBy="L"><itemNumber>1636</itemNumber><strength>160mg &amp; 60mg/mL</strength><dosageForm>Rect Sol (with Preservative)</dosageForm><drug id="00009911" sec3="Y"><name>Fleet Enema</name><manufacturerId>CBF</manufacturerId><individualPrice>.0313</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0313</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="561600000"><name>DIGESTANTS</name><genericName id="02166"><name>LIPASE &amp; AMYLASE &amp; PROTEASE</name><pcgGroup lccId="00348"><pcg9 id="561600057"><itemNumber>1637</itemNumber><strength>35000 &amp; 35700 &amp; 2240 Units</strength><drug id="02494639" sec3="Y" sec12="Y"><name>Creon Minimicrospheres 35</name><manufacturerId>BGP</manufacturerId><individualPrice>.9531</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.9531</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="124">Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="125">Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="126">Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="007" reasonForUseId="225">Replacement therapy for pancreatic insufficiency due to cystic fibrosis.</lccNote><lccNote seq="008" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00795"><name>PANCRELIPASE EQUIVALENT TO LIPASE &amp; AMYLASE &amp; PROTEASE</name><pcgGroup lccId="00097"><pcg9 id="561600022"><itemNumber>1638</itemNumber><strength>10000 &amp; 40000 &amp; 35000 USP Units</strength><dosageForm>Cap</dosageForm><drug id="00263818" sec3="Y" sec12="Y"><name>Cotazym</name><manufacturerId>ORG</manufacturerId><individualPrice>.2752</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2752</amountMOHLTCPays></drug></pcg9><pcg9 id="561600023"><itemNumber>1639</itemNumber><strength>8000 &amp; 30000 &amp; 30000 USP Units</strength><dosageForm>Ent Microsph Cap</dosageForm><drug id="00502790" sec3="Y" sec12="Y"><name>Cotazym ECS 8</name><manufacturerId>ORG</manufacturerId><individualPrice>.4968</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4968</amountMOHLTCPays></drug></pcg9><pcg9 id="561600014"><itemNumber>1640</itemNumber><strength>20000 &amp; 55000 &amp; 55000 USP Units</strength><dosageForm>Ent Microsph Cap</dosageForm><drug id="00821373" sec3="Y" sec12="Y"><name>Cotazym ECS 20</name><manufacturerId>ORG</manufacturerId><individualPrice>1.3025</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>1.3025</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="124">Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="125">Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="126">Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="007" reasonForUseId="225">Replacement therapy for pancreatic insufficiency due to cystic fibrosis.</lccNote><lccNote seq="008" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00098"><pcg9 id="561600026"><itemNumber>1641</itemNumber><strength>4000 &amp; 12000 &amp; 12000 USP Units</strength><dosageForm>Ent Microsph Cap</dosageForm><drug id="00789445" sec3="Y" sec12="Y"><name>Pancrease MT4</name><manufacturerId>VIU</manufacturerId><individualPrice>.7274</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7274</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="124">Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="125">Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="126">Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00097"><pcg9 id="561600030"><itemNumber>1642</itemNumber><strength>10000 &amp; 33200 &amp; 37500 USP Units</strength><dosageForm>Ent Minimicrosph Cap</dosageForm><drug id="02200104" sec3="Y" sec12="Y"><name>Creon 10</name><manufacturerId>SPH</manufacturerId><individualPrice>.2891</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.2891</amountMOHLTCPays></drug></pcg9><pcg9 id="561600025"><itemNumber>1643</itemNumber><strength>25000 &amp; 74000 &amp; 62500 USP Units</strength><dosageForm>Ent Minimicrosph Cap</dosageForm><drug id="01985205" sec3="Y" sec12="Y"><name>Creon 25</name><manufacturerId>SPH</manufacturerId><individualPrice>.9031</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9031</amountMOHLTCPays></drug></pcg9><pcg9 id="561600056"><itemNumber>1644</itemNumber><strength>5100 &amp; 500 &amp; 320 Units/100mg</strength><dosageForm>Gran - 100mg/Scoop</dosageForm><drug id="02445158" sec3="Y" sec12="Y"><name>Creon Minimicrospheres Micro</name><manufacturerId>BGP</manufacturerId><individualPrice>.1871</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>.1871</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="124">Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="125">Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="126">Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="007" reasonForUseId="225">Replacement therapy for pancreatic insufficiency due to cystic fibrosis.</lccNote><lccNote seq="008" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00098"><pcg9 id="561600029"><itemNumber>1645</itemNumber><strength>10440 &amp; 56400 &amp; 57100 USP Units</strength><dosageForm>Tab</dosageForm><drug id="02230019" sec3="Y" sec12="Y"><name>Viokace</name><manufacturerId>NSA</manufacturerId><individualPrice>.4054</individualPrice><listingDate>1997-03-14</listingDate><amountMOHLTCPays>.4054</amountMOHLTCPays></drug></pcg9><pcg9 id="561600034"><itemNumber>1646</itemNumber><strength>16mg</strength><dosageForm>Tab</dosageForm><drug id="02241933" sec3="Y" sec12="Y"><name>Viokace</name><manufacturerId>NSA</manufacturerId><individualPrice>.6222</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.6222</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="124">Replacement therapy for pancreatic insufficiency secondary to pancreatic surgery (resection).</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="125">Replacement therapy for pancreatic insufficiency due to chronic pancreatitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="126">Replacement therapy for pancreatic insufficiency due to carcinoma of the pancreas.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="562200000"><name>ANTIEMETICS AND ANTINAUSEANTS</name><genericName id="01754"><name>APREPITANT</name><pcgGroup lccId="00243"><pcg9 id="562200043"><itemNumber>1647</itemNumber><strength>125mg &amp; 80mg</strength><dosageForm>Cap</dosageForm><drug id="02298813" sec3="Y" sec12="Y"><name>Emend Tri-Pack</name><manufacturerId>MEK</manufacturerId><individualPrice>106.9839</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>106.9839</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="452">In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens:

-  Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared

-  Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared

-  Cisplatin (any dose) given for 3 to 5 consecutive days

-  Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide)

Dosage: Recommend aprepitant 125mg orally on Day 1 of HEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="453">For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle.

Dosage: Recommend aprepitant 125mg orally on Day 1 of MEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00803"><name>DIMENHYDRINATE</name><pcgGroup lccId="00273"><pcg9 id="562200036"><itemNumber>1648</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol (with Preservative)</dosageForm><drug id="00392537" sec3="Y" sec12="Y"><name>Dimenhydrinate Inj 50mg USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3800</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>1.3800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote></pcgGroup></genericName><genericName id="00811"><name>DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL</name><pcgGroup><pcg9 id="562200030"><itemNumber>1649</itemNumber><strength>10mg &amp; 10mg</strength><dosageForm>SR Tab</dosageForm><drug id="00609129" sec3="Y"><name>Diclectin</name><manufacturerId>DUI</manufacturerId><individualPrice>1.2803</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3201</amountMOHLTCPays></drug><drug id="02406187" sec3="Y"><name>PMS-Doxylamine-Pyridoxine</name><manufacturerId>PMS</manufacturerId><individualPrice>.3201</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.3201</amountMOHLTCPays></drug><drug id="02413248" sec3="Y"><name>Apo-Doxylamine/B6</name><manufacturerId>APX</manufacturerId><individualPrice>.3201</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>.3201</amountMOHLTCPays></drug><drug id="02552574" sec3="Y"><name>ALOG-Doxylamine/Pyridoxine</name><manufacturerId>ANA</manufacturerId><individualPrice>.3201</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.3201</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00810"><name>GRANISETRON HCL</name><pcgGroup lccId="00101"><pcg9 id="562200024"><itemNumber>1650</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02185881" notABenefit="Y" sec3="Y"><name>Kytril</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02308894" sec3="Y" sec12="Y"><name>Apo-Granisetron</name><manufacturerId>APX</manufacturerId><individualPrice>4.5000</individualPrice><listingDate>2009-05-20</listingDate><amountMOHLTCPays>4.5000</amountMOHLTCPays></drug><drug id="02452359" sec3="Y" sec12="Y"><name>Nat-Granisetron</name><manufacturerId>NAT</manufacturerId><individualPrice>4.5000</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>4.5000</amountMOHLTCPays></drug><drug id="02472686" sec3="Y" sec12="Y"><name>Jamp Granisetron</name><manufacturerId>JPC</manufacturerId><individualPrice>4.5000</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>4.5000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="91">For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="92">For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="93">For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti- emetics.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="326">For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.</lccNote><lccNote seq="008" type="N">The therapeutic value of GRANISETRON HCL more than 24 hours after the last dose of chemotherapy is unproven.</lccNote><lccNote seq="009" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="010" reasonForUseId="454">For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens.</lccNote><lccNote seq="011" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00804"><name>MECLIZINE HCL</name><pcgGroup><pcg9 id="562200008"><itemNumber>1651</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="00220442" sec3="Y"><name>Bonamine</name><manufacturerId>PFI</manufacturerId><individualPrice>.2919</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2919</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00805"><name>NABILONE</name><pcgGroup><pcg9 id="562200044"><itemNumber>1652</itemNumber><strength>0.25mg</strength><dosageForm>Cap</dosageForm><drug id="02312263" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cesamet</name><manufacturerId>VAL</manufacturerId><listingDate>2013-05-31</listingDate></drug><drug id="02358077" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Nabilone</name><manufacturerId>RAN</manufacturerId><individualPrice>1.3962</individualPrice><listingDate>2013-08-29</listingDate></drug><drug id="02380897" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Nabilone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.4660</individualPrice><listingDate>2021-03-29</listingDate></drug><drug id="02392925" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Nabilone</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3962</individualPrice><listingDate>2013-05-31</listingDate></drug></pcg9><pcg9 id="562200034"><itemNumber>1653</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02256193" sec3="Y"><name>Cesamet</name><manufacturerId>VAL</manufacturerId><individualPrice>4.1793</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>1.8886</amountMOHLTCPays></drug><drug id="02380900" sec3="Y"><name>PMS-Nabilone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.8886</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>1.8886</amountMOHLTCPays></drug><drug id="02384884" sec3="Y"><name>Teva-Nabilone</name><manufacturerId>TEV</manufacturerId><individualPrice>1.8886</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>1.8886</amountMOHLTCPays></drug></pcg9><pcg9 id="562200011"><itemNumber>1654</itemNumber><strength>1mg</strength><dosageForm>Cap</dosageForm><drug id="00548375" sec3="Y"><name>Cesamet</name><manufacturerId>VAL</manufacturerId><individualPrice>8.3582</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.6669</amountMOHLTCPays></drug><drug id="02380919" sec3="Y"><name>PMS-Nabilone</name><manufacturerId>PMS</manufacturerId><individualPrice>3.6669</individualPrice><listingDate>2012-05-29</listingDate><amountMOHLTCPays>3.6669</amountMOHLTCPays></drug><drug id="02384892" sec3="Y"><name>Teva-Nabilone</name><manufacturerId>TEV</manufacturerId><individualPrice>3.6669</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>3.6669</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02092"><name>NETUPITANT &amp; PALONOSETRON HYDROCHLORIDE</name><pcgGroup lccId="00319"><pcg9 id="562200052"><itemNumber>1655</itemNumber><strength>300mg &amp; 0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02468735" sec3="Y" sec12="Y"><name>Akynzeo</name><manufacturerId>KNT</manufacturerId><individualPrice>144.0075</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>144.0075</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="561">In combination with dexamethasone for once per-cycle treatment in adult patients for:

- Prevention of acute and delayed nausea and vomting associated with highly emetogenic cancer chemotherapy (HEC).

Highly emetogenic chemotherapy (HEC) regimens:

- Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70mg per meter squared

- Cisplatin and cyclophosphamide combinations where the single daily dose of cisplatin is greater than or equal to 50mg per meter squared

- Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide).

Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each HEC.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="562">In combination with dexamethasone for once per-cycle treatment in adult patients for:

- Prevention of acute nausea and vomiting associated with moderately emetogenic cancer therapy (MEC) that is uncontrolled by a 5-hydroxytryptamine-3 (5-HT3) receptor antagonist (RA) alone in a previous cycle.

Dosage: Recommend Netupitant/Palonosetron 300mg/0.5mg orally on Day 1 approximately 1 hour prior to the start of each MEC cycle.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00807"><name>ONDANSETRON HCL DIHYDRATE</name><pcgGroup><pcg9 id="562200014"><itemNumber>1656</itemNumber><strength>2mg/mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="02213745" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zofran</name><manufacturerId>NOV</manufacturerId><listingDate>2009-05-20</listingDate></drug><drug id="02464578" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ondansetron Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>13.2180</individualPrice><listingDate>2018-11-29</listingDate></drug><drug id="02491524" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Ondansetron Injection</name><manufacturerId>AUR</manufacturerId><individualPrice>13.2180</individualPrice><listingDate>2022-06-30</listingDate></drug></pcg9><pcg9 id="562200040"><itemNumber>1657</itemNumber><strength>2mg/mL</strength><dosageForm>Inj Sol-4mL Pk</dosageForm><drug id="02491532" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Ondansetron Injection</name><manufacturerId>AUR</manufacturerId><individualPrice>26.4360</individualPrice><listingDate>2022-06-30</listingDate></drug><drug id="09857324" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zofran</name><manufacturerId>NOV</manufacturerId><listingDate>2009-05-20</listingDate></drug><drug id="09857602" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ondansetron Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>26.4360</individualPrice><listingDate>2018-11-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00809"><name>ONDANSETRON HYDROCHLORIDE</name><pcgGroup lccId="00102"><pcg9 id="562200029"><itemNumber>1658</itemNumber><strength>4mg</strength><drug id="02239372" notABenefit="Y" sec3="Y"><name>Zofran ODT (Tablet)</name><manufacturerId>SDZ</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02389983" sec3="Y" sec12="Y"><name>Ondissolve ODF (Film)</name><manufacturerId>TAK</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02481723" sec3="Y" sec12="Y"><name>Ondansetron ODT (Tablet)</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02487330" sec3="Y" sec12="Y"><name>Mint-Ondansetron ODT (Tablet)</name><manufacturerId>MIN</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02511282" sec3="Y" sec12="Y"><name>Auro-Ondansetron ODT (Tablet)</name><manufacturerId>AUR</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02514966" sec3="Y" sec12="Y"><name>Mar-Ondansetron ODT Tablet</name><manufacturerId>MAR</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02519232" sec3="Y" sec12="Y"><name>Ondansetron ODT (Tablet)</name><manufacturerId>JPC</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02519445" sec3="Y" sec12="Y"><name>PMS-Ondansetron ODT Tablet</name><manufacturerId>PMS</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02524279" sec3="Y" sec12="Y"><name>Ondansetron ODT (Tablet)</name><manufacturerId>SAI</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02535319" sec3="Y" sec12="Y"><name>Accel-Ondansetron ODT (Tablet)</name><manufacturerId>ACC</manufacturerId><individualPrice>2.5450</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02541351" sec3="Y" sec12="Y"><name>Jamp Ondansetron ODF (Film)</name><manufacturerId>JPC</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug></pcg9><pcg9 id="562200031"><itemNumber>1659</itemNumber><strength>8mg</strength><drug id="02239373" notABenefit="Y" sec3="Y"><name>Zofran ODT (Tablet)</name><manufacturerId>SDZ</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02389991" sec3="Y" sec12="Y"><name>Ondissolve ODF (Film)</name><manufacturerId>TAK</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02481731" sec3="Y" sec12="Y"><name>Ondansetron ODT (Tablet)</name><manufacturerId>SDZ</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02487349" sec3="Y" sec12="Y"><name>Mint-Ondansetron ODT (Tablet)</name><manufacturerId>MIN</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02511290" sec3="Y" sec12="Y"><name>Auro-Ondansetron ODT (Tablet)</name><manufacturerId>AUR</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02514974" sec3="Y" sec12="Y"><name>Mar-Ondansetron ODT Tablet</name><manufacturerId>MAR</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02519240" sec3="Y" sec12="Y"><name>Ondansetron ODT (Tablet)</name><manufacturerId>JPC</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02519453" sec3="Y" sec12="Y"><name>PMS-Ondansetron ODT Tablet</name><manufacturerId>PMS</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02524287" sec3="Y" sec12="Y"><name>Ondansetron ODT (Tablet)</name><manufacturerId>SAI</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02535327" sec3="Y" sec12="Y"><name>Accel-Ondansetron ODT (Tablet)</name><manufacturerId>ACC</manufacturerId><individualPrice>3.8840</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02541378" sec3="Y" sec12="Y"><name>Jamp Ondansetron ODF (Film)</name><manufacturerId>JPC</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug></pcg9><pcg9 id="562200025"><itemNumber>1660</itemNumber><strength>4mg/5mL</strength><dosageForm>O/L</dosageForm><drug id="02229639" notABenefit="Y" sec3="Y"><name>Zofran</name><manufacturerId>NOV</manufacturerId><listingDate>1997-08-28</listingDate></drug><drug id="02291967" sec3="Y" sec12="Y"><name>Apo-Ondansetron</name><manufacturerId>APX</manufacturerId><individualPrice>.7952</individualPrice><listingDate>2009-05-20</listingDate><amountMOHLTCPays>.7952</amountMOHLTCPays></drug><drug id="02490617" sec3="Y" sec12="Y"><name>Jamp Ondansetron</name><manufacturerId>JPC</manufacturerId><individualPrice>.7952</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.7952</amountMOHLTCPays></drug><drug id="02524090" sec3="Y" sec12="Y"><name>Mint-Ondansetron Solution</name><manufacturerId>MIN</manufacturerId><individualPrice>.7952</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.7952</amountMOHLTCPays></drug></pcg9><pcg9 id="562200022"><itemNumber>1661</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02213567" notABenefit="Y" sec3="Y"><name>Zofran</name><manufacturerId>NOV</manufacturerId><listingDate>1997-01-20</listingDate></drug><drug id="02258188" sec3="Y" sec12="Y"><name>PMS-Ondansetron</name><manufacturerId>PMS</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02274310" sec3="Y" sec12="Y"><name>Sandoz Ondansetron</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02288184" sec3="Y" sec12="Y"><name>Apo-Ondansetron</name><manufacturerId>APX</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02296349" sec3="Y" sec12="Y"><name>Teva-Ondansetron</name><manufacturerId>TEV</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02297868" sec3="Y" sec12="Y"><name>Mylan-Ondansetron</name><manufacturerId>MYL</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02305259" sec3="Y" sec12="Y"><name>Mint-Ondansetron</name><manufacturerId>MIN</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2008-12-23</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02313685" sec3="Y" sec12="Y"><name>Jamp-Ondansetron</name><manufacturerId>JPC</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2009-01-30</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02371731" sec3="Y" sec12="Y"><name>Mar-Ondansetron</name><manufacturerId>MAR</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02376091" sec3="Y" sec12="Y"><name>Septa-Ondansetron</name><manufacturerId>SET</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02417839" sec3="Y" sec12="Y"><name>Nat-Ondansetron</name><manufacturerId>NAT</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2015-06-29</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02421402" sec3="Y" sec12="Y"><name>Ondansetron</name><manufacturerId>SAI</manufacturerId><individualPrice>3.2720</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02478927" sec3="Y" sec12="Y"><name>Accel-Ondansetron</name><manufacturerId>ACC</manufacturerId><individualPrice>2.5450</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug><drug id="02541424" sec3="Y" sec12="Y"><name>Ondansetron</name><manufacturerId>SIV</manufacturerId><individualPrice>3.3495</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>2.5450</amountMOHLTCPays></drug></pcg9><pcg9 id="562200023"><itemNumber>1662</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02213575" notABenefit="Y" sec3="Y"><name>Zofran</name><manufacturerId>NOV</manufacturerId><listingDate>1997-01-20</listingDate></drug><drug id="02258196" sec3="Y" sec12="Y"><name>PMS-Ondansetron</name><manufacturerId>PMS</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02274329" sec3="Y" sec12="Y"><name>Sandoz Ondansetron</name><manufacturerId>SDZ</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2006-06-14</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02288192" sec3="Y" sec12="Y"><name>Apo-Ondansetron</name><manufacturerId>APX</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02296357" sec3="Y" sec12="Y"><name>Teva-Ondansetron</name><manufacturerId>TEV</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02297876" sec3="Y" sec12="Y"><name>Mylan-Ondansetron</name><manufacturerId>MYL</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02305267" sec3="Y" sec12="Y"><name>Mint-Ondansetron</name><manufacturerId>MIN</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2008-12-23</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02313693" sec3="Y" sec12="Y"><name>Jamp-Ondansetron</name><manufacturerId>JPC</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02371758" sec3="Y" sec12="Y"><name>Mar-Ondansetron</name><manufacturerId>MAR</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02376105" sec3="Y" sec12="Y"><name>Septa-Ondansetron</name><manufacturerId>SET</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02417847" sec3="Y" sec12="Y"><name>Nat-Ondansetron</name><manufacturerId>NAT</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2015-06-29</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02421410" sec3="Y" sec12="Y"><name>Ondansetron</name><manufacturerId>SAI</manufacturerId><individualPrice>4.9930</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02478935" sec3="Y" sec12="Y"><name>Accel-Ondansetron</name><manufacturerId>ACC</manufacturerId><individualPrice>3.8840</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug><drug id="02541432" sec3="Y" sec12="Y"><name>Ondansetron</name><manufacturerId>SIV</manufacturerId><individualPrice>5.1110</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>3.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="215">For the treatment of emesis in cancer patients receiving highly emetogenic chemotherapy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="216">For patients receiving intravenous chemotherapy or radiation therapy who have not experienced adequate control with other available anti-emetics.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="217">For patients receiving intravenous chemotherapy or radiation therapy who experience intolerable side effects with other anti-emetics.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="218">For the treatment of emesis in patients receiving radiation therapy which consists of single fraction treatment to the abdominal cavity, hemi-body irradiation and total body irradiation.</lccNote><lccNote seq="008" type="N">The therapeutic value of Ondansetron Hydrochloride more than 24 hours after the last dose of chemotherapy is unproven.</lccNote><lccNote seq="009" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="010" reasonForUseId="454">For the treatment of emesis in cancer patients receiving moderately emetogenic chemotherapy (MEC) regimens.</lccNote><lccNote seq="011" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="012" reasonForUseId="696">For the treatment of emesis in patients receiving palliative care who are refractory to, intolerant to, or have a contraindication to at least two other anti-emetics.

Note: Pharmacists and prescribers should be informed of and stay current with a drug product&apos;s official indications in accordance with Health Canada&apos;s approved product monograph. Some aspects of the above criteria may differ from the official indications as described in the product monograph for the ondansetron product. The Executive Officer&apos;s funding of drug products is informed by advice from experts that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of drug products.</lccNote><lccNote seq="013" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="564000000"><name>MISCELLANEOUS G.I. DRUGS</name><genericName id="00821"><name>5-AMINOSALICYLIC ACID</name><pcgGroup><pcg9 id="564000137"><itemNumber>1663</itemNumber><strength>1g/Actuation</strength><dosageForm>14 Actuation-Foam Enema Canister Pk</dosageForm><drug id="02474026" sec3="Y"><name>Mezera</name><manufacturerId>AVP</manufacturerId><individualPrice>101.8220</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>101.8220</amountMOHLTCPays></drug></pcg9><pcg9 id="564000049"><itemNumber>1664</itemNumber><strength>500mg</strength><dosageForm>Del-Release Tab</dosageForm><drug id="02099683" sec3="Y"><name>Pentasa</name><manufacturerId>FEI</manufacturerId><individualPrice>.7544</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7544</amountMOHLTCPays></drug></pcg9><pcg9 id="564000107"><itemNumber>1665</itemNumber><strength>1.2g</strength><dosageForm>Delayed &amp; ER Tab</dosageForm><drug id="02297558" sec3="Y"><name>Mezavant</name><manufacturerId>TAK</manufacturerId><individualPrice>2.0020</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>2.0020</amountMOHLTCPays></drug></pcg9><pcg9 id="564000139"><itemNumber>1666</itemNumber><strength>500mg</strength><dosageForm>DR Tab</dosageForm><drug id="02524481" sec3="Y"><name>Mezera</name><manufacturerId>AVP</manufacturerId><individualPrice>.6627</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.6627</amountMOHLTCPays></drug></pcg9><pcg9 id="564000075"><itemNumber>1667</itemNumber><strength>1g/100mL</strength><dosageForm>Enema</dosageForm><drug id="02153521" sec3="Y"><name>Pentasa</name><manufacturerId>FEI</manufacturerId><individualPrice>6.6606</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>6.6606</amountMOHLTCPays></drug></pcg9><pcg9 id="564000077"><itemNumber>1668</itemNumber><strength>4g/100mL</strength><dosageForm>Enema</dosageForm><drug id="02153556" sec3="Y"><name>Pentasa</name><manufacturerId>FEI</manufacturerId><individualPrice>9.1942</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>9.1942</amountMOHLTCPays></drug></pcg9><pcg9 id="564000045"><itemNumber>1669</itemNumber><strength>500mg</strength><dosageForm>Ent Tab</dosageForm><drug id="02112787" sec3="Y"><name>Salofalk</name><manufacturerId>BFI</manufacturerId><individualPrice>.7050</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7050</amountMOHLTCPays></drug></pcg9><pcg9 id="564000127"><itemNumber>1670</itemNumber><strength>1g</strength><dosageForm>ER Tab</dosageForm><drug id="02399466" sec3="Y"><name>Pentasa</name><manufacturerId>FEI</manufacturerId><individualPrice>1.5086</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>1.5086</amountMOHLTCPays></drug></pcg9><pcg9 id="564000034"><itemNumber>1671</itemNumber><strength>4g</strength><dosageForm>Rect Susp-Pk</dosageForm><drug id="02112809" sec3="Y"><name>Salofalk</name><manufacturerId>BFI</manufacturerId><individualPrice>9.2100</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>9.2100</amountMOHLTCPays></drug></pcg9><pcg9 id="564000136"><itemNumber>1672</itemNumber><strength>1g</strength><dosageForm>Sup</dosageForm><drug id="02474018" sec3="Y"><name>Mezera</name><manufacturerId>AVP</manufacturerId><individualPrice>1.8702</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>1.8702</amountMOHLTCPays></drug></pcg9><pcg9 id="564000039"><itemNumber>1673</itemNumber><strength>500mg</strength><dosageForm>Sup</dosageForm><drug id="02112760" sec3="Y"><name>Salofalk</name><manufacturerId>BFI</manufacturerId><individualPrice>1.7337</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.7337</amountMOHLTCPays></drug></pcg9><pcg9 id="564000074"><itemNumber>1674</itemNumber><strength>1g</strength><dosageForm>Sup</dosageForm><drug id="02153564" sec3="Y"><name>Pentasa</name><manufacturerId>FEI</manufacturerId><individualPrice>2.6231</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>2.6231</amountMOHLTCPays></drug></pcg9><pcg9 id="564000100"><itemNumber>1675</itemNumber><strength>1000mg</strength><dosageForm>Sup</dosageForm><drug id="02242146" sec3="Y"><name>Salofalk</name><manufacturerId>BFI</manufacturerId><individualPrice>2.5463</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>2.5463</amountMOHLTCPays></drug></pcg9><pcg9 id="564000030"><itemNumber>1676</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="01997580" notABenefit="Y" sec3="Y"><name>Asacol</name><manufacturerId>WAR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02171929" sec3="Y"><name>Teva-5-ASA</name><manufacturerId>TEV</manufacturerId><individualPrice>.4758</individualPrice><listingDate>2008-12-23</listingDate><amountMOHLTCPays>.4758</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00696"><name>BUDESONIDE</name><pcgGroup><pcg9 id="564000142"><itemNumber>1677</itemNumber><strength>2mg/Act</strength><dosageForm>Rectal Foam-14 Act Canister</dosageForm><drug id="02498057" sec3="Y"><name>Uceris</name><manufacturerId>BHC</manufacturerId><individualPrice>99.9600</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>99.9600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00812"><name>CIMETIDINE</name><note>Cimetidine is less expensive than alternatives, and is effective and well tolerated in most patients. Adequate acid suppression can be achieved by giving cimetidine as opposed to using other longer acting H2-antagonists. Long-term use of these drugs for prevention of recurrent peptic ulcers should be reviewed; specific cure of Helicobacter pylori infection with antibiotics is a more effective and less costly approach.</note><pcgGroup><pcg9 id="564000008"><itemNumber>1678</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="00584215" chronicUseMed="Y" sec3="Y"><name>Cimetidine</name><manufacturerId>AAP</manufacturerId><individualPrice>.3557</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3557</amountMOHLTCPays></drug><drug id="01916793" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tagamet</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="564000003"><itemNumber>1679</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="00487872" chronicUseMed="Y" sec3="Y"><name>Cimetidine</name><manufacturerId>AAP</manufacturerId><individualPrice>.3423</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3423</amountMOHLTCPays></drug><drug id="01916815" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tagamet</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="564000011"><itemNumber>1680</itemNumber><strength>400mg</strength><dosageForm>Tab</dosageForm><drug id="00600059" chronicUseMed="Y" sec3="Y"><name>Cimetidine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2930</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2930</amountMOHLTCPays></drug><drug id="01916785" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tagamet</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="564000012"><itemNumber>1681</itemNumber><strength>600mg</strength><dosageForm>Tab</dosageForm><drug id="00600067" chronicUseMed="Y" sec3="Y"><name>Cimetidine</name><manufacturerId>AAP</manufacturerId><individualPrice>.3405</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3405</amountMOHLTCPays></drug><drug id="01916777" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tagamet</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="564000019"><itemNumber>1682</itemNumber><strength>800mg</strength><dosageForm>Tab</dosageForm><drug id="00749494" chronicUseMed="Y" sec3="Y"><name>Cimetidine</name><manufacturerId>AAP</manufacturerId><individualPrice>.2530</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2530</amountMOHLTCPays></drug><drug id="01916769" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Tagamet</name><manufacturerId>SMJ</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02387"><name>DEXLANSOPRAZOLE</name><pcgGroup><pcg9 id="564000140"><itemNumber>1683</itemNumber><strength>30mg</strength><dosageForm>DR Cap</dosageForm><drug id="02354950" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dexilant</name><manufacturerId>TAK</manufacturerId><listingDate>2024-01-31</listingDate></drug><drug id="02528991" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Dexlansoprazole</name><manufacturerId>APX</manufacturerId><individualPrice>2.2380</individualPrice><listingDate>2024-03-28</listingDate></drug><drug id="02536390" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dexlansoprazole</name><manufacturerId>ALH</manufacturerId><individualPrice>2.0526</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9><pcg9 id="564000141"><itemNumber>1684</itemNumber><strength>60mg</strength><dosageForm>DR Cap</dosageForm><drug id="02354969" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dexilant</name><manufacturerId>TAK</manufacturerId><listingDate>2024-01-31</listingDate></drug><drug id="02529025" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Dexlansoprazole</name><manufacturerId>APX</manufacturerId><individualPrice>2.2380</individualPrice><listingDate>2024-03-28</listingDate></drug><drug id="02536404" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dexlansoprazole</name><manufacturerId>ALH</manufacturerId><individualPrice>2.0526</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00824"><name>DOMPERIDONE MALEATE</name><pcgGroup><pcg9 id="564000043"><itemNumber>1685</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00855820" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Motilium</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01912070" chronicUseMed="Y" sec3="Y"><name>Teva-Domperidone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0428</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02103613" chronicUseMed="Y" sec3="Y"><name>Apo-Domperidone</name><manufacturerId>APX</manufacturerId><individualPrice>.0428</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02238341" chronicUseMed="Y" sec3="Y"><name>Domperidone</name><manufacturerId>SIV</manufacturerId><individualPrice>.0428</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02268078" chronicUseMed="Y" sec3="Y"><name>Ran-Domperidone</name><manufacturerId>RAN</manufacturerId><individualPrice>.0428</individualPrice><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02350440" chronicUseMed="Y" sec3="Y"><name>Domperidone</name><manufacturerId>SAI</manufacturerId><individualPrice>.0428</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02369206" chronicUseMed="Y" sec3="Y"><name>Jamp-Domperidone</name><manufacturerId>JPC</manufacturerId><individualPrice>.0428</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02403870" chronicUseMed="Y" sec3="Y"><name>Mar-Domperidone</name><manufacturerId>MAR</manufacturerId><individualPrice>.0428</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug><drug id="02462834" chronicUseMed="Y" sec3="Y"><name>PRZ-Domperidone</name><manufacturerId>PRZ</manufacturerId><individualPrice>.0428</individualPrice><listingDate>2019-05-31</listingDate><amountMOHLTCPays>.0428</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01650"><name>ESOMEPRAZOLE</name><pcgGroup><pcg9 id="564000102"><itemNumber>1686</itemNumber><strength>40mg</strength><drug id="02244522" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nexium DR Tab</name><manufacturerId>AZC</manufacturerId><listingDate>2011-03-15</listingDate></drug><drug id="02339102" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Esomeprazole DR Tab</name><manufacturerId>APX</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2011-03-15</listingDate></drug><drug id="02423863" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Esomeprazole DR Tab</name><manufacturerId>TEV</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2016-01-28</listingDate></drug><drug id="02423987" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Esomeprazole DR Tab</name><manufacturerId>RAN</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2015-04-30</listingDate></drug><drug id="02431173" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esomeprazole DR Tab</name><manufacturerId>SAI</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2021-04-30</listingDate></drug><drug id="02442507" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esomeprazole DR Tab</name><manufacturerId>SIV</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02460939" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Esomeprazole DR Tab</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2018-11-29</listingDate></drug><drug id="02479427" notABenefit="Y" sec3b="Y" sec3="Y"><name>Myl-Esomeprazole DR Tab</name><manufacturerId>MYL</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02520117" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Esomeprazole DR Tab</name><manufacturerId>MAT</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02520702" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esomeprazole DR Tab</name><manufacturerId>JPC</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2022-03-31</listingDate></drug><drug id="02528487" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMSC-Esomeprazole DR</name><manufacturerId>PMS</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2023-04-28</listingDate></drug></pcg9><pcg9 id="564000110"><itemNumber>1687</itemNumber><strength>20mg</strength><dosageForm>DR Tab</dosageForm><drug id="02244521" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nexium</name><manufacturerId>AZC</manufacturerId><listingDate>2011-03-15</listingDate></drug><drug id="02339099" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Esomeprazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2011-03-15</listingDate></drug><drug id="02423855" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Esomeprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2016-01-28</listingDate></drug><drug id="02423979" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Esomeprazole</name><manufacturerId>RAN</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2015-04-30</listingDate></drug><drug id="02442493" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esomeprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02460920" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Esomeprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2018-11-29</listingDate></drug><drug id="02479419" notABenefit="Y" sec3b="Y" sec3="Y"><name>Myl-Esomeprazole</name><manufacturerId>MYL</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02520109" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Esomeprazole</name><manufacturerId>MAT</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2022-05-31</listingDate></drug><drug id="02520699" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esomeprazole</name><manufacturerId>JPC</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2022-03-31</listingDate></drug><drug id="02528479" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMSC-Esomeprazole DR</name><manufacturerId>PMS</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2023-04-28</listingDate></drug><drug id="02535335" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esomeprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.8690</individualPrice><listingDate>2024-02-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00819"><name>FAMOTIDINE</name><note>Cimetidine is less expensive than alternatives, and is effective and well tolerated in most patients. Adequate acid suppression can be achieved by giving cimetidine as opposed to using other longer acting H2-antagonists. Long-term use of these drugs for prevention of recurrent peptic ulcers should be reviewed; specific cure of Helicobacter pylori infection with antibiotics is a more effective and less costly approach.</note><pcgGroup><pcg9 id="564000025"><itemNumber>1688</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00710121" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Pepcid</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01953842" chronicUseMed="Y" sec3="Y"><name>Apo-Famotidine</name><manufacturerId>APX</manufacturerId><individualPrice>.2658</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug><drug id="02022133" chronicUseMed="Y" sec3="Y"><name>Teva-Famotidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2658</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug><drug id="02351102" chronicUseMed="Y" sec3="Y"><name>Famotidine</name><manufacturerId>SAI</manufacturerId><individualPrice>.2658</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug><drug id="02507749" chronicUseMed="Y" sec3="Y"><name>Jamp Famotidine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2658</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug><drug id="02509970" chronicUseMed="Y" sec3="Y"><name>AG-Famotidine</name><manufacturerId>ANG</manufacturerId><individualPrice>.2658</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug><drug id="02538628" chronicUseMed="Y" sec3="Y"><name>Mint-Famotidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.2658</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug><drug id="02549107" chronicUseMed="Y" sec3="Y"><name>Famotidine</name><manufacturerId>SIV</manufacturerId><individualPrice>.2658</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.2658</amountMOHLTCPays></drug></pcg9><pcg9 id="564000024"><itemNumber>1689</itemNumber><strength>40mg</strength><dosageForm>Tab</dosageForm><drug id="00710113" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Pepcid</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01953834" chronicUseMed="Y" sec3="Y"><name>Apo-Famotidine</name><manufacturerId>APX</manufacturerId><individualPrice>.4834</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug><drug id="02022141" chronicUseMed="Y" sec3="Y"><name>Teva-Famotidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.4834</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug><drug id="02351110" chronicUseMed="Y" sec3="Y"><name>Famotidine</name><manufacturerId>SAI</manufacturerId><individualPrice>.4834</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug><drug id="02507757" chronicUseMed="Y" sec3="Y"><name>Jamp Famotidine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4834</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug><drug id="02509989" chronicUseMed="Y" sec3="Y"><name>AG-Famotidine</name><manufacturerId>ANG</manufacturerId><individualPrice>.4834</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug><drug id="02538636" chronicUseMed="Y" sec3="Y"><name>Mint-Famotidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.4834</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug><drug id="02549115" chronicUseMed="Y" sec3="Y"><name>Famotidine</name><manufacturerId>SIV</manufacturerId><individualPrice>.4834</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.4834</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00779"><name>LACTULOSE</name><pcgGroup><pcg9 id="564000004"><itemNumber>1690</itemNumber><strength>667mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00854409" sec3="Y"><name>Ratio-Lactulose</name><manufacturerId>RPH</manufacturerId><individualPrice>.0145</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0145</amountMOHLTCPays></drug><drug id="02091925" notABenefit="Y" sec3="Y"><name>Cephulac</name><manufacturerId>MRR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242814" sec3="Y"><name>Apo-Lactulose Solution</name><manufacturerId>APX</manufacturerId><individualPrice>.0145</individualPrice><listingDate>2005-03-31</listingDate><amountMOHLTCPays>.0145</amountMOHLTCPays></drug><drug id="02247383" sec3="Y"><name>Pharma-Lactulose</name><manufacturerId>PMS</manufacturerId><individualPrice>.0145</individualPrice><listingDate>2013-06-27</listingDate><amountMOHLTCPays>.0145</amountMOHLTCPays></drug><drug id="02295881" sec3="Y"><name>Jamp-Lactulose</name><manufacturerId>JPC</manufacturerId><individualPrice>.0145</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.0145</amountMOHLTCPays></drug><drug id="02412268" sec3="Y"><name>Lactulose</name><manufacturerId>SAI</manufacturerId><individualPrice>.0145</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.0145</amountMOHLTCPays></drug><drug id="02469391" sec3="Y"><name>PMS-Lactulose-Pharma</name><manufacturerId>PMS</manufacturerId><individualPrice>.0145</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.0145</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00835"><name>LANSOPRAZOLE</name><pcgGroup lccId="00103"><pcg9 id="564000072"><itemNumber>1691</itemNumber><strength>15mg</strength><dosageForm>DR Cap</dosageForm><drug id="02165503" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Prevacid</name><manufacturerId>TPA</manufacturerId><individualPrice>2.4338</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02280515" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Teva-Lansoprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02293811" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Lansoprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02353830" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mylan-Lansoprazole</name><manufacturerId>MYL</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2010-09-09</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02357682" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lansoprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02385643" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Lansoprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02385767" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lansoprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02402610" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Taro-Lansoprazole</name><manufacturerId>SPC</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="564000073"><itemNumber>1692</itemNumber><strength>30mg</strength><dosageForm>DR Cap</dosageForm><drug id="02165511" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Prevacid</name><manufacturerId>TPA</manufacturerId><individualPrice>2.4338</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02280523" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Teva-Lansoprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02293838" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Lansoprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02353849" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mylan-Lansoprazole</name><manufacturerId>MYL</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2010-09-09</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02357690" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lansoprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02385651" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Lansoprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02402629" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Taro-Lansoprazole</name><manufacturerId>SPC</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug><drug id="02410389" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Lansoprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="293">Gastroesophageal Reflux Disease (GERD)

For the treatment of erosive GERD or upper GI malignancy; OR

For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.

Patients with GERD should be reassessed within 6 months after initial treatment with a PPI.  The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.

Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="295">H. pylori-positive Peptic Ulcers

For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.

Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="297">Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:

For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR

For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.

Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="401">Other Gastrointestinal Disorders:

For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.

Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="402">Severe Conditions:

For the treatment  of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.

For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01411"><name>LANSOPRAZOLE &amp; CLARITHROMYCIN &amp; AMOXICILLIN</name><pcgGroup lccId="00104"><pcg9 id="564000091"><itemNumber>1693</itemNumber><strength>30mg &amp; 500mg &amp; 500mg</strength><dosageForm>Tab/Cap Pk</dosageForm><drug id="02238525" notABenefit="Y" sec3="Y"><name>Hp-PAC</name><manufacturerId>TPA</manufacturerId><listingDate>1999-04-15</listingDate></drug><drug id="02470780" sec3="Y" sec12="Y"><name>AA-LansoprazoleAmoxicillinClarithromycin</name><manufacturerId>AAP</manufacturerId><individualPrice>67.9100</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>67.9100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="306">For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, breath test or endoscopy, for a course of up to 14 days.

Maximum duration: 14 days.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="307">For the retreatment of H. pylori-positive peptic ulcers where H. pylori recurrence or persistence is documented, by breath test or endoscopy, for a course of up to 14 days.

Maximum duration: 14 days (after a four-week period has elapsed since the end of the previous treatment)</lccNote><lccNote seq="004" type="R">Retreatment decisions should be based upon positive symptoms and positive endoscopy or positive urea breath test. Retreatment should not be based on a positive serology test, as serology tests may remain positive indefinitely. An alternative antibiotic regimen is recommended when initial therapy fails due to concerns of antimicrobial resistance.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02098"><name>MESALAZINE</name><pcgGroup><pcg9 id="564000145"><itemNumber>1694</itemNumber><strength>1g</strength><dosageForm>DR Tab</dosageForm><drug id="02545012" sec3="Y"><name>Mezera</name><manufacturerId>AVP</manufacturerId><individualPrice>1.2756</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>1.2756</amountMOHLTCPays></drug></pcg9><pcg9 id="564000143"><itemNumber>1695</itemNumber><strength>800mg</strength><dosageForm>DR Tab</dosageForm><drug id="02465752" sec3="Y"><name>Octasa</name><manufacturerId>TIP</manufacturerId><individualPrice>1.1358</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>1.1358</amountMOHLTCPays></drug></pcg9><pcg9 id="564000144"><itemNumber>1696</itemNumber><strength>1600mg</strength><dosageForm>DR Tab</dosageForm><drug id="02529610" sec3="Y"><name>Octasa</name><manufacturerId>TIP</manufacturerId><individualPrice>2.3740</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2.3740</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00813"><name>METOCLOPRAMIDE HCL</name><pcgGroup lccId="00271"><pcg9 id="564000082"><itemNumber>1697</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol (Preservative Free)</dosageForm><drug id="02185431" sec3="Y" sec12="Y"><name>Metoclopramide HCL Injection</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.3748</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>2.3748</amountMOHLTCPays></drug><drug id="02537397" sec3="Y" sec12="Y"><name>Metoclopramide Hydrochloride Injection</name><manufacturerId>JPC</manufacturerId><individualPrice>2.3748</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2.3748</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="481">For the management of patients receiving palliative care*.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" type="N">*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.</lccNote><lccNote seq="004" reasonForUseId="657">For the treatment of patients receiving care at home* who have failed or are unable to tolerate oral alternatives, and who require an injectable option to manage their condition.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" type="N">*e.g., home care recipients, long-term care home residents.</lccNote></pcgGroup><pcgGroup><pcg9 id="564000015"><itemNumber>1698</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02099195" notABenefit="Y" sec3="Y"><name>Maxeran</name><manufacturerId>HMR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230431" sec3="Y"><name>PMS-Metoclopramide Tablets</name><manufacturerId>PMS</manufacturerId><individualPrice>.0257</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.0257</amountMOHLTCPays></drug><drug id="02517795" sec3="Y"><name>Mar-Metoclopramide</name><manufacturerId>MAR</manufacturerId><individualPrice>.0257</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>.0257</amountMOHLTCPays></drug><drug id="02548747" sec3="Y"><name>PRZ-Metoclopramide</name><manufacturerId>PRZ</manufacturerId><individualPrice>.0257</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.0257</amountMOHLTCPays></drug></pcg9><pcg9 id="564000005"><itemNumber>1699</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02099209" notABenefit="Y" sec3="Y"><name>Maxeran</name><manufacturerId>HMR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02548755" sec3="Y"><name>PRZ-Metoclopramide</name><manufacturerId>PRZ</manufacturerId><individualPrice>.1513</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.1513</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00817"><name>MISOPROSTOL</name><pcgGroup><pcg9 id="564000029"><itemNumber>1700</itemNumber><strength>100mcg</strength><dosageForm>Tab</dosageForm><drug id="00813966" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cytotec</name><manufacturerId>SEA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02244022" chronicUseMed="Y" sec3="Y"><name>Misoprostol</name><manufacturerId>AAP</manufacturerId><individualPrice>.2636</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.2636</amountMOHLTCPays></drug></pcg9><pcg9 id="564000022"><itemNumber>1701</itemNumber><strength>200mcg</strength><dosageForm>Tab</dosageForm><drug id="00632600" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Cytotec</name><manufacturerId>SEA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02244023" chronicUseMed="Y" sec3="Y"><name>Misoprostol</name><manufacturerId>AAP</manufacturerId><individualPrice>.4389</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.4389</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00820"><name>NIZATIDINE</name><note>Cimetidine is less expensive than alternatives, and is effective and well tolerated in most patients. Adequate acid suppression can be achieved by giving cimetidine as opposed to using other longer acting H2-antagonists. Long-term use of these drugs for prevention of recurrent peptic ulcers should be reviewed; specific cure of Helicobacter pylori infection with antibiotics is a more effective and less costly approach.</note><pcgGroup><pcg9 id="564000027"><itemNumber>1702</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="00778338" chronicUseMed="Y" sec3="Y"><name>Axid</name><manufacturerId>PEN</manufacturerId><individualPrice>.9047</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9047</amountMOHLTCPays></drug></pcg9><pcg9 id="564000028"><itemNumber>1703</itemNumber><strength>300mg</strength><dosageForm>Cap</dosageForm><drug id="00778346" chronicUseMed="Y" sec3="Y"><name>Axid</name><manufacturerId>PHE</manufacturerId><individualPrice>1.5206</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.5206</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00826"><name>OLSALAZINE SODIUM</name><pcgGroup><pcg9 id="564000047"><itemNumber>1704</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="02063808" sec3="Y"><name>Dipentum</name><manufacturerId>APU</manufacturerId><individualPrice>.5330</individualPrice><listingDate>2009-05-20</listingDate><amountMOHLTCPays>.5330</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00836"><name>OMEPRAZOLE</name><pcgGroup><pcg9 id="564000087"><itemNumber>1705</itemNumber><strength>10mg</strength><drug id="02230737" notABenefit="Y" sec3b="Y" sec3="Y"><name>Losec DR Tab</name><manufacturerId>AZC</manufacturerId><listingDate>2010-04-23</listingDate></drug><drug id="02295407" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Omeprazole DR Tab</name><manufacturerId>TEV</manufacturerId><individualPrice>.8167</individualPrice><listingDate>2014-04-30</listingDate></drug></pcg9></pcgGroup><pcgGroup lccId="00168"><pcg9 id="564000070"><itemNumber>1706</itemNumber><strength>20mg</strength><drug id="02190915" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Losec DR Tab</name><manufacturerId>CHE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02245058" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Omeprazole Cap</name><manufacturerId>APX</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02260867" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Omeprazole DR Tab</name><manufacturerId>RPH</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02295415" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Teva-Omeprazole DR Tab</name><manufacturerId>TEV</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02296446" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Omeprazole  DR Cap</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02411857" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole-20 DR Cap</name><manufacturerId>SIV</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02416549" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole Magnesium Delayed Release Tab</name><manufacturerId>ACH</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02420198" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Omeprazole DR Tab</name><manufacturerId>JPC</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02439549" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Nat-Omeprazole DR Tab</name><manufacturerId>NAT</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02504294" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole Magnesium Delayed Release Tab</name><manufacturerId>SAI</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857342" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Omeprazole DR Cap</name><manufacturerId>PMS</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug></pcg9><pcg9 id="564000105"><itemNumber>1707</itemNumber><strength>20mg</strength><drug id="00846503" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Losec DR Cap</name><manufacturerId>CHE</manufacturerId><listingDate>2004-07-20</listingDate></drug><drug id="02348691" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole DR Cap</name><manufacturerId>SAI</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="02403617" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Omeprazole DR Cap</name><manufacturerId>RAN</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857285" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Omeprazole Cap</name><manufacturerId>APX</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857314" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Omeprazole DR Cap</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="293">Gastroesophageal Reflux Disease (GERD)

For the treatment of erosive GERD or upper GI malignancy; OR

For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.

Patients with GERD should be reassessed within 6 months after initial treatment with a PPI.  The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.

Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="297">Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:

For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR

For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.

Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="401">Other Gastrointestinal Disorders:

For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.

Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="402">Severe Conditions:

For the treatment  of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.

For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="564000094"><itemNumber>1708</itemNumber><strength>10mg</strength><dosageForm>DR Cap</dosageForm><drug id="02119579" notABenefit="Y" sec3b="Y" sec3="Y"><name>Losec</name><manufacturerId>AZC</manufacturerId><listingDate>2009-05-20</listingDate></drug><drug id="02296438" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Omeprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9470</individualPrice><listingDate>2009-05-20</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01645"><name>OMEPRAZOLE MAGNESIUM</name><pcgGroup lccId="00167"><pcg9 id="564000079"><itemNumber>1709</itemNumber><strength>20mg</strength><drug id="09857195" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Losec DR Tab</name><manufacturerId>CHE</manufacturerId><listingDate>2006-10-23</listingDate></drug><drug id="09857267" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Omeprazole DR Tab</name><manufacturerId>RPH</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857464" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Omeprazole DR Tab</name><manufacturerId>JPC</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857500" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole Magnesium Delayed Release Tab</name><manufacturerId>ACH</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857536" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Nat-Omeprazole DR Tab</name><manufacturerId>NAT</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857640" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole-20 DR Cap</name><manufacturerId>SIV</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug><drug id="09857656" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Omeprazole Magnesium Delayed Release Tab</name><manufacturerId>SAI</manufacturerId><individualPrice>.2287</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2287</amountMOHLTCPays></drug></pcg9><lccNote seq="003" reasonForUseId="295">H. pylori-positive Peptic Ulcers

For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.

Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01776"><name>PANTOPRAZOLE MAGNESIUM</name><pcgGroup><pcg9 id="564000108"><itemNumber>1710</itemNumber><strength>40mg</strength><dosageForm>Ent Coated Tab</dosageForm><drug id="02267233" chronicUseMed="Y" sec3="Y"><name>Tecta</name><manufacturerId>NYC</manufacturerId><individualPrice>.8260</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1875</amountMOHLTCPays></drug><drug id="02408570" chronicUseMed="Y" sec3="Y"><name>Mylan-Pantoprazole T</name><manufacturerId>MYL</manufacturerId><individualPrice>.1875</individualPrice><listingDate>2015-10-29</listingDate><amountMOHLTCPays>.1875</amountMOHLTCPays></drug><drug id="02440628" chronicUseMed="Y" sec3="Y"><name>Teva-Pantoprazole Magnesium</name><manufacturerId>TEV</manufacturerId><individualPrice>.1875</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.1875</amountMOHLTCPays></drug><drug id="02441853" chronicUseMed="Y" sec3="Y"><name>Pantoprazole Magnesium</name><manufacturerId>ALH</manufacturerId><individualPrice>.1875</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>.1875</amountMOHLTCPays></drug><drug id="02466147" chronicUseMed="Y" sec3="Y"><name>Pantoprazole T</name><manufacturerId>SAI</manufacturerId><individualPrice>.1875</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1875</amountMOHLTCPays></drug><drug id="02519534" chronicUseMed="Y" sec3="Y"><name>Pantoprazole T</name><manufacturerId>SIV</manufacturerId><individualPrice>.1875</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.1875</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01320"><name>PANTOPRAZOLE SODIUM</name><pcgGroup><pcg9 id="564000106"><itemNumber>1711</itemNumber><strength>20mg</strength><dosageForm>Ent Tab</dosageForm><drug id="02241804" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pantoloc</name><manufacturerId>NYC</manufacturerId><listingDate>2008-06-27</listingDate></drug><drug id="02285479" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Pantoprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2008-08-28</listingDate></drug><drug id="02292912" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Pantoprazole</name><manufacturerId>APX</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2008-06-27</listingDate></drug><drug id="02301075" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Pantoprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02305038" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Pantoprazole</name><manufacturerId>RAN</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2008-11-04</listingDate></drug><drug id="02392615" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Pantoprazole Sodium</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2021-11-30</listingDate></drug><drug id="02408414" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Pantoprazole</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2014-04-30</listingDate></drug><drug id="02416557" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Pantoprazole</name><manufacturerId>MAR</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2014-03-27</listingDate></drug><drug id="02428172" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pantoprazole-20</name><manufacturerId>SIV</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02536137" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pantoprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2750</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9></pcgGroup><pcgGroup lccId="00106"><pcg9 id="564000080"><itemNumber>1712</itemNumber><strength>40mg</strength><dosageForm>Ent Tab</dosageForm><drug id="02229453" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Pantoloc</name><manufacturerId>NYC</manufacturerId><individualPrice>2.0803</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02285487" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Teva-Pantoprazole</name><manufacturerId>TEV</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02292920" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Pantoprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2008-05-16</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02300486" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Co Pantoprazole</name><manufacturerId>COB</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02301083" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Pantoprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02305046" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ran-Pantoprazole</name><manufacturerId>RAN</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02307871" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Pantoprazole</name><manufacturerId>PMS</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02357054" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Pantoprazole</name><manufacturerId>JPC</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02370808" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Pantoprazole</name><manufacturerId>SAI</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02392623" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Pantoprazole Sodium</name><manufacturerId>JPC</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02415208" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Pantoprazole</name><manufacturerId>AUR</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02416565" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mar-Pantoprazole</name><manufacturerId>MAR</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2014-04-01</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02417448" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mint-Pantoprazole</name><manufacturerId>MIN</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02428180" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Pantoprazole-40</name><manufacturerId>SIV</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02431327" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Pantoprazole</name><manufacturerId>RIA</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02467372" chronicUseMed="Y" sec3="Y" sec12="Y"><name>M-Pantoprazole</name><manufacturerId>MAT</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02471825" chronicUseMed="Y" sec3="Y" sec12="Y"><name>NRA-Pantoprazole</name><manufacturerId>NRA</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug><drug id="02481588" chronicUseMed="Y" sec3="Y" sec12="Y"><name>AG-Pantoprazole Sodium</name><manufacturerId>ANG</manufacturerId><individualPrice>.2016</individualPrice><listingDate>2021-01-29</listingDate><amountMOHLTCPays>.2016</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="293">Gastroesophageal Reflux Disease (GERD)

For the treatment of erosive GERD or upper GI malignancy; OR

For the treatment of non-erosive GERD after failure of H2-receptor antagonist therapy.

Patients with GERD should be reassessed within 6 months after initial treatment with a PPI.  The reassessment could include confirmation of need for PPI with endoscopy, a trial of PPI withdrawal, or step-down therapy to H2-receptor antagonist therapy.

Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="295">H. pylori-positive Peptic Ulcers

For the treatment of H. pylori-positive peptic ulcers where H. pylori is documented, by serology, urea breath test or endoscopy, for a course of up to 14 days in combination with antimicrobial therapy. Retreatment of H. pylori-positive peptic ulcers must be documented by persistent H. pylori infection on urea breath test or endoscopy.

Maximum duration: 14 days (for retreatment, a four-week period must elapse since the end of the previous treatment).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="297">Confirmed Peptic Ulcers or NSAID-induced Ulcer Prophylaxis:

For the treatment of confirmed peptic ulcers and NSAID-induced ulcers; OR

For the prophylaxis of NSAID-induced ulcers for patients at increased risk of GI bleeding.

Note: There is a lack of published evidence to support double-dose PPI therapy in this setting.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="401">Other Gastrointestinal Disorders:

For the treatment of gastroduodenal Crohns disease, short-gut syndrome, scleroderma, or pancreatitis.

Note: There is a lack of published evidence to support double-dose PPI therapy in these settings.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="402">Severe Conditions:

For the treatment  of severe esophagitis, Zollinger-Ellison syndrome, esophageal stricture, persistent symptoms of GERD or persistent erosive esophagitis, or upon hospital discharge following a gastrointestinal bleed.

For patients receiving double-dose therapy, the need to continue treatment at higher doses should be reassessed after eight weeks. For re-treatment at higher doses, a four-week period should have elapsed from the end of the previous treatment. Reassessment could include a procedural assessment of the condition or step-down therapy to lower-dose proton pump inhibitor (PPI) therapy.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01984"><name>PRUCALOPRIDE</name><pcgGroup><pcg9 id="564000130"><itemNumber>1713</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02377012" notABenefit="Y" sec3b="Y" sec3="Y"><name>Resotran</name><manufacturerId>AMD</manufacturerId><listingDate>2020-02-28</listingDate></drug><drug id="02491591" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Prucalopride</name><manufacturerId>APX</manufacturerId><individualPrice>2.0145</individualPrice><listingDate>2020-02-28</listingDate></drug><drug id="02493489" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Prucalopride</name><manufacturerId>JPC</manufacturerId><individualPrice>2.0145</individualPrice><listingDate>2021-04-30</listingDate></drug><drug id="02550377" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Prucalopride</name><manufacturerId>NRA</manufacturerId><individualPrice>2.0145</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9><pcg9 id="564000131"><itemNumber>1714</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02377020" notABenefit="Y" sec3b="Y" sec3="Y"><name>Resotran</name><manufacturerId>AMD</manufacturerId><listingDate>2020-02-28</listingDate></drug><drug id="02491605" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Prucalopride</name><manufacturerId>APX</manufacturerId><individualPrice>3.1025</individualPrice><listingDate>2020-02-28</listingDate></drug><drug id="02493497" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Prucalopride</name><manufacturerId>JPC</manufacturerId><individualPrice>3.1025</individualPrice><listingDate>2021-04-30</listingDate></drug><drug id="02550385" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Prucalopride</name><manufacturerId>NRA</manufacturerId><individualPrice>3.1025</individualPrice><listingDate>2024-12-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01560"><name>RABEPRAZOLE SODIUM</name><pcgGroup><pcg9 id="564000098"><itemNumber>1715</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02243796" chronicUseMed="Y" sec3="Y"><name>Pariet</name><manufacturerId>JAN</manufacturerId><individualPrice>1.6353</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02296632" chronicUseMed="Y" sec3="Y"><name>Teva-Rabeprazole EC</name><manufacturerId>TEV</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02298074" chronicUseMed="Y" sec3="Y"><name>Ran-Rabeprazole</name><manufacturerId>RAN</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02314177" chronicUseMed="Y" sec3="Y"><name>Sandoz Rabeprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02345579" chronicUseMed="Y" sec3="Y"><name>Apo-Rabeprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02356511" chronicUseMed="Y" sec3="Y"><name>Rabeprazole EC</name><manufacturerId>SAI</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02385449" chronicUseMed="Y" sec3="Y"><name>Rabeprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug><drug id="02415283" chronicUseMed="Y" sec3="Y"><name>Jamp Rabeprazole</name><manufacturerId>JPC</manufacturerId><individualPrice>.0669</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.0669</amountMOHLTCPays></drug></pcg9><pcg9 id="564000104"><itemNumber>1716</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02243797" chronicUseMed="Y" sec3="Y"><name>Pariet</name><manufacturerId>JAN</manufacturerId><individualPrice>3.2706</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02296640" chronicUseMed="Y" sec3="Y"><name>Teva-Rabeprazole EC</name><manufacturerId>TEV</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02298082" chronicUseMed="Y" sec3="Y"><name>Ran-Rabeprazole</name><manufacturerId>RAN</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02314185" chronicUseMed="Y" sec3="Y"><name>Sandoz Rabeprazole</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2008-10-01</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02345587" chronicUseMed="Y" sec3="Y"><name>Apo-Rabeprazole</name><manufacturerId>APX</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02356538" chronicUseMed="Y" sec3="Y"><name>Rabeprazole EC</name><manufacturerId>SAI</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02385457" chronicUseMed="Y" sec3="Y"><name>Rabeprazole</name><manufacturerId>SIV</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug><drug id="02415291" chronicUseMed="Y" sec3="Y"><name>Jamp Rabeprazole</name><manufacturerId>JPC</manufacturerId><individualPrice>.1338</individualPrice><listingDate>2023-02-28</listingDate><amountMOHLTCPays>.1338</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00815"><name>RANITIDINE HCL</name><pcgGroup><pcg9 id="564000038"><itemNumber>1717</itemNumber><strength>15mg/mL</strength><dosageForm>Oral Sol</dosageForm><drug id="02212374" notABenefit="Y" sec3="Y"><name>Zantac</name><manufacturerId>GSK</manufacturerId><listingDate>1997-01-20</listingDate></drug><drug id="02242940" sec3="Y"><name>Teva-Ranitidine Solution</name><manufacturerId>TEV</manufacturerId><individualPrice>.1480</individualPrice><listingDate>2004-12-21</listingDate><amountMOHLTCPays>.1480</amountMOHLTCPays></drug><drug id="02280833" sec3="Y"><name>Apo-Ranitidine</name><manufacturerId>APX</manufacturerId><individualPrice>.1480</individualPrice><listingDate>2007-09-04</listingDate><amountMOHLTCPays>.1480</amountMOHLTCPays></drug></pcg9><pcg9 id="564000010"><itemNumber>1718</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="00733059" chronicUseMed="Y" sec3="Y"><name>Apo-Ranitidine</name><manufacturerId>APX</manufacturerId><individualPrice>.1197</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="00828564" chronicUseMed="Y" sec3="Y"><name>Teva-Ranitidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.1197</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02212331" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Zantac</name><manufacturerId>GSK</manufacturerId><listingDate>1997-07-12</listingDate></drug><drug id="02242453" chronicUseMed="Y" sec3="Y"><name>PMS-Ranitidine</name><manufacturerId>PMS</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02243229" chronicUseMed="Y" sec3="Y"><name>Sandoz Ranitidine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02248570" chronicUseMed="Y" sec3="Y"><name>Co Ranitidine</name><manufacturerId>COB</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02336480" chronicUseMed="Y" sec3="Y"><name>Ran-Ranitidine</name><manufacturerId>RAN</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02443708" chronicUseMed="Y" sec3="Y"><name>Mar-Ranitidine</name><manufacturerId>MAR</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02463717" chronicUseMed="Y" sec3="Y"><name>Jamp-Ranitidine</name><manufacturerId>JPC</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug><drug id="02526379" chronicUseMed="Y" sec3="Y"><name>Mint-Ranitidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.1197</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.1197</amountMOHLTCPays></drug></pcg9><pcg9 id="564000020"><itemNumber>1719</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="00733067" chronicUseMed="Y" sec3="Y"><name>Apo-Ranitidine</name><manufacturerId>APX</manufacturerId><individualPrice>.2253</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="00828556" chronicUseMed="Y" sec3="Y"><name>Teva-Ranitidine</name><manufacturerId>TEV</manufacturerId><individualPrice>.2253</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02212358" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Zantac</name><manufacturerId>GSK</manufacturerId><listingDate>1998-03-17</listingDate></drug><drug id="02242454" chronicUseMed="Y" sec3="Y"><name>PMS-Ranitidine</name><manufacturerId>PMS</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02243230" chronicUseMed="Y" sec3="Y"><name>Sandoz Ranitidine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02248571" chronicUseMed="Y" sec3="Y"><name>Co Ranitidine</name><manufacturerId>COB</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02336502" chronicUseMed="Y" sec3="Y"><name>Ran-Ranitidine</name><manufacturerId>RAN</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02443716" chronicUseMed="Y" sec3="Y"><name>Mar-Ranitidine</name><manufacturerId>MAR</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02463725" chronicUseMed="Y" sec3="Y"><name>Jamp-Ranitidine</name><manufacturerId>JPC</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug><drug id="02526387" chronicUseMed="Y" sec3="Y"><name>Mint-Ranitidine</name><manufacturerId>MIN</manufacturerId><individualPrice>.2253</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2253</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00814"><name>SUCRALFATE</name><pcgGroup><pcg9 id="564000050"><itemNumber>1720</itemNumber><strength>1g/5mL</strength><dosageForm>Oral Susp</dosageForm><drug id="02103567" sec3="Y"><name>Sulcrate Suspension Plus</name><manufacturerId>BFI</manufacturerId><individualPrice>.1313</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1313</amountMOHLTCPays></drug></pcg9><pcg9 id="564000009"><itemNumber>1721</itemNumber><strength>1g</strength><dosageForm>Tab</dosageForm><drug id="02045702" chronicUseMed="Y" sec3="Y"><name>Teva-Sucralfate</name><manufacturerId>TEV</manufacturerId><individualPrice>.3089</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3089</amountMOHLTCPays></drug><drug id="02100622" chronicUseMed="Y" sec3="Y"><name>Sulcrate</name><manufacturerId>BFI</manufacturerId><individualPrice>.7408</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3089</amountMOHLTCPays></drug><drug id="02125250" chronicUseMed="Y" sec3="Y"><name>Apo-Sucralfate</name><manufacturerId>APX</manufacturerId><individualPrice>.3089</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3089</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="600000000"><name>GOLD COMPOUNDS</name><pcg6><genericName id="00838"><name>AURANOFIN</name><pcgGroup><pcg9 id="600000005"><itemNumber>1722</itemNumber><strength>3mg</strength><dosageForm>Cap</dosageForm><drug id="01916823" sec3="Y"><name>Ridaura</name><manufacturerId>XED</manufacturerId><individualPrice>6.9127</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.9127</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="640000000"><name>HEAVY METAL ANTAGONISTS</name><pcg6><genericName id="01713"><name>DEFERASIROX</name><pcgGroup><pcg9 id="640000021"><itemNumber>1723</itemNumber><strength>90mg</strength><dosageForm>Tab</dosageForm><drug id="02452219" sec3="Y"><name>Jadenu</name><manufacturerId>NOV</manufacturerId><individualPrice>10.8920</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>2.6303</amountMOHLTCPays></drug><drug id="02485265" sec3="Y"><name>Apo-Deferasirox (Type J)</name><manufacturerId>APX</manufacturerId><individualPrice>2.6303</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>2.6303</amountMOHLTCPays></drug><drug id="02489899" sec3="Y"><name>Sandoz Deferasirox (Type J)</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.6303</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>2.6303</amountMOHLTCPays></drug><drug id="02507315" sec3="Y"><name>Taro-Deferasirox (Type J)</name><manufacturerId>TAR</manufacturerId><individualPrice>2.6303</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>2.6303</amountMOHLTCPays></drug><drug id="02527774" sec3="Y"><name>Auro-Deferasirox (Type J)</name><manufacturerId>AUR</manufacturerId><individualPrice>2.6303</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>2.6303</amountMOHLTCPays></drug><drug id="02528290" sec3="Y"><name>PMS-Deferasirox (Type J)</name><manufacturerId>PMS</manufacturerId><individualPrice>2.6303</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>2.6303</amountMOHLTCPays></drug></pcg9><pcg9 id="640000022"><itemNumber>1724</itemNumber><strength>180mg</strength><dosageForm>Tab</dosageForm><drug id="02452227" sec3="Y"><name>Jadenu</name><manufacturerId>NOV</manufacturerId><individualPrice>21.7850</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>5.2610</amountMOHLTCPays></drug><drug id="02485273" sec3="Y"><name>Apo-Deferasirox (Type J)</name><manufacturerId>APX</manufacturerId><individualPrice>5.2610</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>5.2610</amountMOHLTCPays></drug><drug id="02489902" sec3="Y"><name>Sandoz Deferasirox (Type J)</name><manufacturerId>SDZ</manufacturerId><individualPrice>5.2610</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>5.2610</amountMOHLTCPays></drug><drug id="02507323" sec3="Y"><name>Taro-Deferasirox (Type J)</name><manufacturerId>TAR</manufacturerId><individualPrice>5.2610</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>5.2610</amountMOHLTCPays></drug><drug id="02527782" sec3="Y"><name>Auro-Deferasirox (Type J)</name><manufacturerId>AUR</manufacturerId><individualPrice>5.2610</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>5.2610</amountMOHLTCPays></drug><drug id="02528304" sec3="Y"><name>PMS-Deferasirox (Type J)</name><manufacturerId>PMS</manufacturerId><individualPrice>5.2610</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>5.2610</amountMOHLTCPays></drug></pcg9><pcg9 id="640000023"><itemNumber>1725</itemNumber><strength>360mg</strength><dosageForm>Tab</dosageForm><drug id="02452235" sec3="Y"><name>Jadenu</name><manufacturerId>NOV</manufacturerId><individualPrice>43.5730</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>10.5228</amountMOHLTCPays></drug><drug id="02485281" sec3="Y"><name>Apo-Deferasirox (Type J)</name><manufacturerId>APX</manufacturerId><individualPrice>10.5228</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>10.5228</amountMOHLTCPays></drug><drug id="02489910" sec3="Y"><name>Sandoz Deferasirox (Type J)</name><manufacturerId>SDZ</manufacturerId><individualPrice>10.5228</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>10.5228</amountMOHLTCPays></drug><drug id="02507331" sec3="Y"><name>Taro-Deferasirox (Type J)</name><manufacturerId>TAR</manufacturerId><individualPrice>10.5228</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>10.5228</amountMOHLTCPays></drug><drug id="02527790" sec3="Y"><name>Auro-Deferasirox (Type J)</name><manufacturerId>AUR</manufacturerId><individualPrice>10.5228</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>10.5228</amountMOHLTCPays></drug><drug id="02528312" sec3="Y"><name>PMS-Deferasirox (Type J)</name><manufacturerId>PMS</manufacturerId><individualPrice>10.5228</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>10.5228</amountMOHLTCPays></drug></pcg9><pcg9 id="640000013"><itemNumber>1726</itemNumber><strength>125mg</strength><dosageForm>Tab for Susp</dosageForm><drug id="02287420" sec3="Y"><name>Exjade</name><manufacturerId>NOV</manufacturerId><individualPrice>11.0375</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>5.2408</amountMOHLTCPays></drug><drug id="02461544" sec3="Y"><name>Apo-Deferasirox</name><manufacturerId>APX</manufacturerId><individualPrice>5.2408</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>5.2408</amountMOHLTCPays></drug><drug id="02464454" sec3="Y"><name>Sandoz Deferasirox</name><manufacturerId>SDZ</manufacturerId><individualPrice>5.2408</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>5.2408</amountMOHLTCPays></drug></pcg9><pcg9 id="640000014"><itemNumber>1727</itemNumber><strength>250mg</strength><dosageForm>Tab for Susp</dosageForm><drug id="02287439" sec3="Y"><name>Exjade</name><manufacturerId>NOV</manufacturerId><individualPrice>22.0757</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>10.4820</amountMOHLTCPays></drug><drug id="02461552" sec3="Y"><name>Apo-Deferasirox</name><manufacturerId>APX</manufacturerId><individualPrice>10.4820</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>10.4820</amountMOHLTCPays></drug><drug id="02464462" sec3="Y"><name>Sandoz Deferasirox</name><manufacturerId>SDZ</manufacturerId><individualPrice>10.4820</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>10.4820</amountMOHLTCPays></drug></pcg9><pcg9 id="640000015"><itemNumber>1728</itemNumber><strength>500mg</strength><dosageForm>Tab for Susp</dosageForm><drug id="02287447" sec3="Y"><name>Exjade</name><manufacturerId>NOV</manufacturerId><individualPrice>44.1507</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>20.9649</amountMOHLTCPays></drug><drug id="02461560" sec3="Y"><name>Apo-Deferasirox</name><manufacturerId>APX</manufacturerId><individualPrice>20.9649</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>20.9649</amountMOHLTCPays></drug><drug id="02464470" sec3="Y"><name>Sandoz Deferasirox</name><manufacturerId>SDZ</manufacturerId><individualPrice>20.9649</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>20.9649</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02017"><name>DEFERIPRONE</name><pcgGroup><pcg9 id="640000020"><itemNumber>1729</itemNumber><strength>1000mg</strength><dosageForm>Tab</dosageForm><drug id="02436558" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ferriprox</name><manufacturerId>APO</manufacturerId><individualPrice>33.4740</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>18.4107</amountMOHLTCPays></drug><drug id="02553112" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Deferiprone</name><manufacturerId>TAR</manufacturerId><individualPrice>18.4107</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>18.4107</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00840"><name>PENICILLAMINE</name><pcgGroup><pcg9 id="640000003"><itemNumber>1730</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="00016055" sec3="Y"><name>Cuprimine</name><manufacturerId>ATO</manufacturerId><individualPrice>4.7355</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>4.7355</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="680000000"><name>HORMONES AND SUBSTITUTES</name><pcg6 id="680400000"><name>CORTICOSTEROIDS</name><genericName id="00687"><name>BECLOMETHASONE DIPROPIONATE</name><pcgGroup><pcg9 id="680400082"><itemNumber>1731</itemNumber><strength>50mcg/Metered Dose</strength><dosageForm>Aero Inh-200 Dose Pk</dosageForm><drug id="02242029" sec3="Y"><name>QVAR</name><manufacturerId>GRA</manufacturerId><individualPrice>43.0469</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>43.0469</amountMOHLTCPays></drug></pcg9><pcg9 id="680400083"><itemNumber>1732</itemNumber><strength>100mcg/Metered Dose</strength><dosageForm>Aero Inh-200 Dose Pk</dosageForm><drug id="02242030" sec3="Y"><name>QVAR</name><manufacturerId>GRA</manufacturerId><individualPrice>85.8405</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>85.8405</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00696"><name>BUDESONIDE</name><pcgGroup lccId="00107"><pcg9 id="680400072"><itemNumber>1733</itemNumber><strength>0.125mg/mL</strength><dosageForm>Inh Susp</dosageForm><drug id="02229099" sec3="Y" sec12="Y"><name>Pulmicort Nebuamp</name><manufacturerId>AZC</manufacturerId><individualPrice>.2724</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1143</amountMOHLTCPays></drug><drug id="02465949" sec3="Y" sec12="Y"><name>Teva-Budesonide</name><manufacturerId>TEV</manufacturerId><individualPrice>.1143</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>.1143</amountMOHLTCPays></drug><drug id="02494264" sec3="Y" sec12="Y"><name>Taro-Budesonide</name><manufacturerId>TAR</manufacturerId><individualPrice>.1143</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.1143</amountMOHLTCPays></drug></pcg9><pcg9 id="680400077"><itemNumber>1734</itemNumber><strength>0.25mg/mL</strength><dosageForm>Inh Susp</dosageForm><drug id="01978918" sec3="Y" sec12="Y"><name>Pulmicort Nebuamp</name><manufacturerId>AZC</manufacturerId><individualPrice>.5458</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3593</amountMOHLTCPays></drug><drug id="02494272" sec3="Y" sec12="Y"><name>Taro-Budesonide</name><manufacturerId>TAR</manufacturerId><individualPrice>.3593</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.3593</amountMOHLTCPays></drug></pcg9><pcg9 id="680400078"><itemNumber>1735</itemNumber><strength>0.5mg/mL</strength><dosageForm>Inh Susp</dosageForm><drug id="01978926" sec3="Y" sec12="Y"><name>Pulmicort Nebuamp</name><manufacturerId>AZC</manufacturerId><individualPrice>1.0888</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4559</amountMOHLTCPays></drug><drug id="02465957" sec3="Y" sec12="Y"><name>Teva-Budesonide</name><manufacturerId>TEV</manufacturerId><individualPrice>.4559</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>.4559</amountMOHLTCPays></drug><drug id="02494280" sec3="Y" sec12="Y"><name>Taro-Budesonide</name><manufacturerId>TAR</manufacturerId><individualPrice>.4559</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.4559</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the vast majority of patients, a metered dose inhaler is the preferred therapy. Nebulizer therapy will be reimbursed for patients who are unable to use a metered dose inhaler, including an inhaler with a spacer attachment, or a turbuhaler.</lccNote><lccNote seq="002" reasonForUseId="260">Children aged 6 years or less;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="261">Patients who have a tracheostomy;</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="262">Patients with cystic fibrosis in whom nebulizer therapy is indicated;</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="008" reasonForUseId="263">Patients with severe mental or physical disabilities;</lccNote><lccNote seq="009" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="010" reasonForUseId="264">Patients who have previously used nebulizer therapy within the last 12 month period.</lccNote><lccNote seq="011" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="680400051"><itemNumber>1736</itemNumber><strength>100mcg/Metered Dose</strength><dosageForm>Pd Inh-200 Dose Pk</dosageForm><drug id="00852074" sec3="Y"><name>Pulmicort Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>38.2735</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>38.2735</amountMOHLTCPays></drug></pcg9><pcg9 id="680400052"><itemNumber>1737</itemNumber><strength>200mcg/Metered Dose</strength><dosageForm>Pd Inh-200 Dose Pk</dosageForm><drug id="00851752" sec3="Y"><name>Pulmicort Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>78.2690</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>78.2690</amountMOHLTCPays></drug></pcg9><pcg9 id="680400053"><itemNumber>1738</itemNumber><strength>400mcg/Metered Dose</strength><dosageForm>Pd Inh-200 Dose Pk</dosageForm><drug id="00851760" sec3="Y"><name>Pulmicort Turbuhaler</name><manufacturerId>AZC</manufacturerId><individualPrice>114.2465</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>114.2465</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01698"><name>CICLESONIDE</name><pcgGroup><pcg9 id="680400093"><itemNumber>1739</itemNumber><strength>100mcg/Actuation</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02285606" sec3="Y"><name>Alvesco</name><manufacturerId>COV</manufacturerId><individualPrice>55.2807</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>55.2807</amountMOHLTCPays></drug></pcg9><pcg9 id="680400094"><itemNumber>1740</itemNumber><strength>200mcg/Actuation</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02285614" sec3="Y"><name>Alvesco</name><manufacturerId>COV</manufacturerId><individualPrice>91.4739</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>91.4739</amountMOHLTCPays></drug></pcg9><pcg9 id="680400095"><itemNumber>1741</itemNumber><strength>50mcg/Actuation</strength><dosageForm>Metered Dose Nas Sp-120 Dose Pk</dosageForm><drug id="02303671" sec3="Y"><name>Omnaris</name><manufacturerId>COP</manufacturerId><individualPrice>31.2444</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>31.2444</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00685"><name>DEXAMETHASONE</name><pcgGroup><pcg9 id="680400022"><itemNumber>1742</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="00016462" notABenefit="Y" sec3="Y"><name>Decadron</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01964976" sec3="Y"><name>PMS-Dexamethasone</name><manufacturerId>PMS</manufacturerId><individualPrice>.1564</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.1564</amountMOHLTCPays></drug><drug id="02261081" sec3="Y"><name>Apo-Dexamethasone</name><manufacturerId>APX</manufacturerId><individualPrice>.1564</individualPrice><listingDate>2005-04-28</listingDate><amountMOHLTCPays>.1564</amountMOHLTCPays></drug></pcg9><pcg9 id="680400031"><itemNumber>1743</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="00354309" notABenefit="Y" sec3="Y"><name>Decadron</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01964070" sec3="Y"><name>PMS-Dexamethasone</name><manufacturerId>PMS</manufacturerId><individualPrice>.6112</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.6112</amountMOHLTCPays></drug><drug id="02250055" sec3="Y"><name>Apo-Dexamethasone</name><manufacturerId>APX</manufacturerId><individualPrice>.6112</individualPrice><listingDate>2004-10-14</listingDate><amountMOHLTCPays>.6112</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00843"><name>DEXAMETHASONE 21-PHOSPHATE</name><pcgGroup><pcg9 id="680400005"><itemNumber>1744</itemNumber><strength>4mg/mL</strength><dosageForm>Inj Sol</dosageForm><drug id="00213624" notABenefit="Y" sec3="Y"><name>Decadron</name><manufacturerId>MSD</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00664227" sec3="Y"><name>Dexamethasone Sodium</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6900</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>1.6900</amountMOHLTCPays></drug><drug id="01977547" sec3="Y"><name>Dexamethasone Sodium</name><manufacturerId>STE</manufacturerId><individualPrice>1.6900</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.6900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00844"><name>FLUDROCORTISONE ACETATE</name><pcgGroup><pcg9 id="680400006"><itemNumber>1745</itemNumber><strength>0.1mg</strength><dosageForm>Tab</dosageForm><drug id="02086026" sec3="Y"><name>Florinef</name><manufacturerId>PPI</manufacturerId><individualPrice>.5692</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3131</amountMOHLTCPays></drug><drug id="02552248" sec3="Y"><name>Jamp Fludrocortisone</name><manufacturerId>JPC</manufacturerId><individualPrice>.3131</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>.3131</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02015"><name>FLUTICASONE FUROATE</name><pcgGroup><pcg9 id="680400111"><itemNumber>1746</itemNumber><strength>100mcg</strength><dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm><drug id="02446561" sec3="Y"><name>Arnuity Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>50.8100</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>50.8100</amountMOHLTCPays></drug></pcg9><pcg9 id="680400112"><itemNumber>1747</itemNumber><strength>200mcg</strength><dosageForm>Blister Pd Inh-30 Dose Pk</dosageForm><drug id="02446588" sec3="Y"><name>Arnuity Ellipta</name><manufacturerId>GSK</manufacturerId><individualPrice>101.5900</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>101.5900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00255"><name>FLUTICASONE PROPIONATE</name><pcgGroup><pcg9 id="680400086"><itemNumber>1748</itemNumber><strength>50mcg/Metered Dose</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02244291" sec3="Y"><name>Flovent HFA</name><manufacturerId>GSK</manufacturerId><individualPrice>33.7500</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>14.2080</amountMOHLTCPays></drug><drug id="02503115" sec3="Y"><name>PMS-Fluticasone HFA</name><manufacturerId>PMS</manufacturerId><individualPrice>14.2080</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>14.2080</amountMOHLTCPays></drug><drug id="02528428" sec3="Y"><name>Apo-Fluticasone HFA</name><manufacturerId>APX</manufacturerId><individualPrice>14.2080</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>14.2080</amountMOHLTCPays></drug></pcg9><pcg9 id="680400087"><itemNumber>1749</itemNumber><strength>125mcg/Metered Dose</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02244292" sec3="Y"><name>Flovent HFA</name><manufacturerId>GSK</manufacturerId><individualPrice>58.2100</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>23.4100</amountMOHLTCPays></drug><drug id="02503123" sec3="Y"><name>PMS-Fluticasone HFA</name><manufacturerId>PMS</manufacturerId><individualPrice>23.4100</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>23.4100</amountMOHLTCPays></drug><drug id="02526557" sec3="Y"><name>Apo-Fluticasone HFA</name><manufacturerId>APX</manufacturerId><individualPrice>23.4100</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>23.4100</amountMOHLTCPays></drug></pcg9><pcg9 id="680400088"><itemNumber>1750</itemNumber><strength>250mcg/Metered Dose</strength><dosageForm>Inh-120 Dose Pk</dosageForm><drug id="02244293" sec3="Y"><name>Flovent HFA</name><manufacturerId>GSK</manufacturerId><individualPrice>116.4200</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>45.0200</amountMOHLTCPays></drug><drug id="02503131" sec3="Y"><name>PMS-Fluticasone</name><manufacturerId>PMS</manufacturerId><individualPrice>45.0200</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>45.0200</amountMOHLTCPays></drug><drug id="02510987" sec3="Y"><name>Apo-Fluticasone HFA</name><manufacturerId>APX</manufacturerId><individualPrice>45.0200</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>45.0200</amountMOHLTCPays></drug></pcg9><pcg9 id="680400116"><itemNumber>1751</itemNumber><strength>55mcg/Actuation</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02467895" sec3="Y"><name>Aermony Respiclick</name><manufacturerId>TEV</manufacturerId><individualPrice>16.9560</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>16.9560</amountMOHLTCPays></drug></pcg9><pcg9 id="680400117"><itemNumber>1752</itemNumber><strength>113mcg/Actuation</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02467909" sec3="Y"><name>Aermony Respiclick</name><manufacturerId>TEV</manufacturerId><individualPrice>30.9619</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>30.9619</amountMOHLTCPays></drug></pcg9><pcg9 id="680400118"><itemNumber>1753</itemNumber><strength>232mcg/Actuation</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02467917" sec3="Y"><name>Aermony Respiclick</name><manufacturerId>TEV</manufacturerId><individualPrice>48.1524</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>48.1524</amountMOHLTCPays></drug></pcg9><pcg9 id="680400079"><itemNumber>1754</itemNumber><strength>250mcg/Blister</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02237246" sec3="Y"><name>Flovent Diskus</name><manufacturerId>GSK</manufacturerId><individualPrice>58.2100</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>58.2100</amountMOHLTCPays></drug></pcg9><pcg9 id="680400080"><itemNumber>1755</itemNumber><strength>500mcg/Blister</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02237247" sec3="Y"><name>Flovent Diskus</name><manufacturerId>GSK</manufacturerId><individualPrice>90.5500</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>90.5500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00823"><name>HYDROCORTISONE</name><pcgGroup><pcg9 id="680400057"><itemNumber>1756</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00030910" sec3="Y"><name>Cortef</name><manufacturerId>PFI</manufacturerId><individualPrice>.2259</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.1639</amountMOHLTCPays></drug><drug id="02524465" sec3="Y"><name>Auro-Hydrocortisone</name><manufacturerId>AUR</manufacturerId><individualPrice>.1639</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.1639</amountMOHLTCPays></drug></pcg9><pcg9 id="680400123"><itemNumber>1757</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="09858155" sec3c="Y"><name>Cortef</name><manufacturerId>PFI</manufacturerId><individualPrice>.2185</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.2185</amountMOHLTCPays></drug></pcg9><pcg9 id="680400007"><itemNumber>1758</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="00030929" sec3="Y"><name>Cortef</name><manufacturerId>PFI</manufacturerId><individualPrice>.4078</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2958</amountMOHLTCPays></drug><drug id="02524473" sec3="Y"><name>Auro-Hydrocortisone</name><manufacturerId>AUR</manufacturerId><individualPrice>.2958</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.2958</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02187"><name>INDACATEROL ACETATE &amp; GLYCOPYRRONIUM BROMIDE &amp; MOMETASONE FUROATE</name><pcgGroup lccId="00355"><pcg9 id="680400122"><itemNumber>1759</itemNumber><strength>150mcg &amp; 50mcg &amp; 160mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02501244" sec3="Y" sec12="Y"><name>Enerzair Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>3.4277</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>3.4277</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="627">For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="02186"><name>INDACATEROL ACETATE &amp; MOMETASONE FUROATE</name><pcgGroup lccId="00354"><pcg9 id="680400120"><itemNumber>1760</itemNumber><strength>150mcg &amp; 160mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02498707" sec3="Y" sec12="Y"><name>Atectura Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>1.3419</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>1.3419</amountMOHLTCPays></drug></pcg9><pcg9 id="680400121"><itemNumber>1761</itemNumber><strength>150mcg &amp; 320mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02498693" sec3="Y" sec12="Y"><name>Atectura Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>1.8473</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>1.8473</amountMOHLTCPays></drug></pcg9><pcg9 id="680400119"><itemNumber>1762</itemNumber><strength>150mcg &amp; 80mcg</strength><dosageForm>Inh Pd-Cap</dosageForm><drug id="02498685" sec3="Y" sec12="Y"><name>Atectura Breezhaler</name><manufacturerId>NOV</manufacturerId><individualPrice>1.0731</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>1.0731</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="626">For once-daily maintenance treatment of asthma in patients aged 12 years and older with reversible obstructive airways disease.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="00845"><name>METHYLPREDNISOLONE</name><pcgGroup><pcg9 id="680400014"><itemNumber>1763</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="00030988" sec3="Y"><name>Medrol</name><manufacturerId>PFI</manufacturerId><individualPrice>.5364</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5364</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00848"><name>METHYLPREDNISOLONE ACETATE</name><pcgGroup><pcg9 id="680400025"><itemNumber>1764</itemNumber><strength>40mg/mL</strength><dosageForm>Inj Susp-1mL Pk</dosageForm><drug id="00030759" sec3="Y"><name>Depo-Medrol</name><manufacturerId>PFI</manufacturerId><individualPrice>6.7480</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.7480</amountMOHLTCPays></drug></pcg9><pcg9 id="680400024"><itemNumber>1765</itemNumber><strength>80mg/mL</strength><dosageForm>Inj Susp-1mL Pk</dosageForm><drug id="00030767" sec3="Y"><name>Depo-Medrol</name><manufacturerId>PFI</manufacturerId><individualPrice>12.9359</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>12.9359</amountMOHLTCPays></drug></pcg9><pcg9 id="680400026"><itemNumber>1766</itemNumber><strength>100mg/5mL</strength><dosageForm>Inj Susp-5mL Pk</dosageForm><drug id="01934325" sec3="Y"><name>Depo-Medrol</name><manufacturerId>PFI</manufacturerId><individualPrice>15.0900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>15.0900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01029"><name>MOMETASONE FUROATE</name><pcgGroup><pcg9 id="680400109"><itemNumber>1767</itemNumber><strength>400mcg/Metered Dose</strength><dosageForm>Pd Inh-30 Dose Pk</dosageForm><drug id="02243596" sec3="Y"><name>Asmanex Twisthaler</name><manufacturerId>OCI</manufacturerId><individualPrice>42.4320</individualPrice><note>NOTES:   The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids.  The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents.  Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.</note><listingDate>2012-12-21</listingDate><amountMOHLTCPays>42.4320</amountMOHLTCPays></drug></pcg9><pcg9 id="680400108"><itemNumber>1768</itemNumber><strength>200mcg/Metered Dose</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="02243595" sec3="Y"><name>Asmanex Twisthaler</name><manufacturerId>OCI</manufacturerId><individualPrice>42.4320</individualPrice><note>NOTES:   The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids.  The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents.  Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.</note><listingDate>2012-12-21</listingDate><amountMOHLTCPays>42.4320</amountMOHLTCPays></drug></pcg9><pcg9 id="680400110"><itemNumber>1769</itemNumber><strength>400mcg/Metered Dose</strength><dosageForm>Pd Inh-60 Dose Pk</dosageForm><drug id="09857431" sec3="Y"><name>Asmanex Twisthaler</name><manufacturerId>OCI</manufacturerId><individualPrice>84.8280</individualPrice><note>NOTES:   The general direction of the therapy of asthma has been toward the use of anti-inflammatory agents, especially inhaled steroids, which are not associated with systemic side effects to the same degree as oral steroids.  The proper technique of inhalation or use of a spacer is very important to the efficacy of these agents.  Physicians and pharmacists should ensure that patients are appropriately instructed in the use of these devices.</note><listingDate>2012-12-21</listingDate><amountMOHLTCPays>84.8280</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00691"><name>PREDNISOLONE SODIUM PHOSPHATE</name><pcgGroup><pcg9 id="680400071"><itemNumber>1770</itemNumber><strength>6.7mg/5mL</strength><dosageForm>O/L</dosageForm><drug id="02230619" notABenefit="Y" sec3="Y"><name>Pediapred Oral Liquid</name><manufacturerId>SAV</manufacturerId><listingDate>2003-01-30</listingDate></drug><drug id="02245532" sec3="Y"><name>PMS-Prednisolone</name><manufacturerId>PMS</manufacturerId><individualPrice>.0900</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.0900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00846"><name>PREDNISONE</name><pcgGroup><pcg9 id="680400037"><itemNumber>1771</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="00271373" sec3="Y"><name>Winpred</name><manufacturerId>AAP</manufacturerId><individualPrice>.1276</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1276</amountMOHLTCPays></drug></pcg9><pcg9 id="680400018"><itemNumber>1772</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00021695" sec3="Y"><name>Teva-Prednisone</name><manufacturerId>TEV</manufacturerId><individualPrice>.0220</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0220</amountMOHLTCPays></drug><drug id="00210188" notABenefit="Y" sec3="Y"><name>Deltasone</name><manufacturerId>UPJ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00312770" sec3="Y"><name>Apo-Prednisone</name><manufacturerId>APX</manufacturerId><individualPrice>.0220</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0220</amountMOHLTCPays></drug></pcg9><pcg9 id="680400029"><itemNumber>1773</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00232378" sec3="Y"><name>Teva-Prednisone</name><manufacturerId>TEV</manufacturerId><individualPrice>.1900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1735</amountMOHLTCPays></drug><drug id="00252417" notABenefit="Y" sec3="Y"><name>Deltasone</name><manufacturerId>UPJ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00550957" sec3="Y"><name>Apo-Prednisone</name><manufacturerId>APX</manufacturerId><individualPrice>.1735</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1735</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00695"><name>TRIAMCINOLONE ACETONIDE</name><pcgGroup><pcg9 id="680400036"><itemNumber>1774</itemNumber><strength>40mg/mL</strength><dosageForm>Inj Susp-1mL Pk</dosageForm><drug id="00990876" sec3="Y"><name>Kenalog-40</name><manufacturerId>BQU</manufacturerId><individualPrice>8.9610</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>8.9610</amountMOHLTCPays></drug></pcg9><pcg9 id="680400035"><itemNumber>1775</itemNumber><strength>50mg/5mL</strength><dosageForm>Inj Susp-5mL Pk</dosageForm><drug id="01999761" sec3="Y"><name>Kenalog-10</name><manufacturerId>BQU</manufacturerId><individualPrice>19.4500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>19.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="680400034"><itemNumber>1776</itemNumber><strength>200mg/5mL</strength><dosageForm>Inj Susp-5mL Pk</dosageForm><drug id="01999869" sec3="Y"><name>Kenalog-40</name><manufacturerId>BQU</manufacturerId><individualPrice>31.6500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>31.6500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01523"><name>TRIAMCINOLONE HEXACETONIDE</name><pcgGroup lccId="00335"><pcg9 id="680400114"><itemNumber>1777</itemNumber><strength>20mg/mL</strength><dosageForm>1mL-Amp Pk</dosageForm><drug id="02470632" sec3="Y" sec12="Y"><name>Trispan</name><manufacturerId>MDX</manufacturerId><individualPrice>18.0000</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>18.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="580">For intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including:

- Rheumatoid arthritis
- Juvenile Idiopathic Arthritis (JIA)*
- Osteoarthritis and post-traumatic arthritis
- Synovitis, tendinitis, bursitis and epicondylitis

*Note: triamcinolone hexacetonide injectable suspension may also be used as an intra-articular injection in children aged 3-12 years with Juvenile Idiopathic Arthritis.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="680800000"><name>ANDROGENS</name><genericName id="00860"><name>DANAZOL</name><pcgGroup><pcg9 id="680800017"><itemNumber>1778</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="02018144" dinStatus="E" sec3="Y"><name>Cyclomen</name><manufacturerId>SAV</manufacturerId><individualPrice>1.0720</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0720</amountMOHLTCPays></drug></pcg9><pcg9 id="680800018"><itemNumber>1779</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02018152" sec3="Y"><name>Cyclomen</name><manufacturerId>SAV</manufacturerId><individualPrice>1.5910</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.5910</amountMOHLTCPays></drug></pcg9><pcg9 id="680800015"><itemNumber>1780</itemNumber><strength>200mg</strength><dosageForm>Cap</dosageForm><drug id="02018160" sec3="Y"><name>Cyclomen</name><manufacturerId>SAV</manufacturerId><individualPrice>2.5425</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.5425</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01630"><name>TESTOSTERONE</name><pcgGroup lccId="00160"><pcg9 id="680800030"><itemNumber>1781</itemNumber><strength>1%</strength><dosageForm>2.5g Foil Packet</dosageForm><drug id="02245345" sec3="Y" sec12="Y"><name>Androgel</name><manufacturerId>SPH</manufacturerId><individualPrice>2.4965</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>1.6726</amountMOHLTCPays></drug><drug id="02463792" sec3="Y" sec12="Y"><name>Taro-Testosterone Gel</name><manufacturerId>TAR</manufacturerId><individualPrice>1.6726</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>1.6726</amountMOHLTCPays></drug></pcg9><pcg9 id="680800031"><itemNumber>1782</itemNumber><strength>1%</strength><dosageForm>5.0g Foil Packet</dosageForm><drug id="02245346" sec3="Y" sec12="Y"><name>Androgel</name><manufacturerId>SPH</manufacturerId><individualPrice>4.4145</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>2.9575</amountMOHLTCPays></drug><drug id="02463806" sec3="Y" sec12="Y"><name>Taro-Testosterone Gel</name><manufacturerId>TAR</manufacturerId><individualPrice>2.9575</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>2.9575</amountMOHLTCPays></drug></pcg9><pcg9 id="680800033"><itemNumber>1783</itemNumber><strength>1%</strength><dosageForm>Top Gel-5g Pk</dosageForm><drug id="02280248" sec3="Y" sec12="Y"><name>Testim</name><manufacturerId>PPI</manufacturerId><individualPrice>4.3180</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>4.3180</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="397">For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.

Note: Older males with nonspecific symptoms of fatigue, malaise, depression who have a low normal random testosterone level do not satisfy these criteria.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00858"><name>TESTOSTERONE CYPIONATE</name><pcgGroup lccId="00175"><pcg9 id="680800013"><itemNumber>1784</itemNumber><strength>100mg/mL Oily</strength><dosageForm>Inj Sol-10mL Pk</dosageForm><drug id="00030783" sec3="Y" sec12="Y"><name>Depo-Testosterone</name><manufacturerId>PFI</manufacturerId><individualPrice>48.1300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>34.8780</amountMOHLTCPays></drug><drug id="02496003" sec3="Y" sec12="Y"><name>Taro-Testosterone Cypionate Injection</name><manufacturerId>TAR</manufacturerId><individualPrice>34.8780</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>34.8780</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="397">For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.

Note: Older males with nonspecific symptoms of fatigue, malaise, depression who have a low normal random testosterone level do not satisfy these criteria.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00859"><name>TESTOSTERONE ENANTHATE</name><pcgGroup lccId="00176"><pcg9 id="680800014"><itemNumber>1785</itemNumber><strength>1000mg/5mL</strength><dosageForm>Oily Inj Sol-5mL Pk</dosageForm><drug id="00029246" notABenefit="Y" sec3="Y"><name>Delatestryl</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02536315" sec3="Y" sec12="Y"><name>Testosterone Enanthate Injection, USP</name><manufacturerId>HIK</manufacturerId><individualPrice>35.5943</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>35.5943</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="397">For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.

Note: Older males with nonspecific symptoms of fatigue, malaise, depression who have a low normal random testosterone level do not satisfy these criteria.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00866"><name>TESTOSTERONE UNDECANOATE</name><pcgGroup lccId="00177"><pcg9 id="680800025"><itemNumber>1786</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><drug id="00782327" notABenefit="Y" sec3="Y"><name>Andriol</name><manufacturerId>ORG</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02322498" sec3="Y" sec12="Y"><name>PMS-Testosterone</name><manufacturerId>PMS</manufacturerId><individualPrice>.4700</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.4700</amountMOHLTCPays></drug><drug id="02421186" sec3="Y" sec12="Y"><name>Taro-Testosterone</name><manufacturerId>TAR</manufacturerId><individualPrice>.4700</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>.4700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="397">For male patients with confirmed low morning serum testosterone levels associated with documented, symptomatic hypothalamic, pituitary or testicular disease, or in HIV-infected patients.

Note: Older males with nonspecific symptoms of fatigue, malaise, depression who have a low normal random testosterone level do not satisfy these criteria.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="681200000"><name>CONTRACEPTIVES</name><genericName id="02171"><name>ETHINYL ESTRADIOL &amp; ETONOGESTREL</name><pcgGroup><pcg9 id="681200004"><itemNumber>1787</itemNumber><strength>0.120mg &amp; 0.015mg/24 hr</strength><dosageForm>Slow Release Vag Ring</dosageForm><drug id="02253186" notABenefit="Y" sec3b="Y" sec3="Y"><name>Nuvaring</name><manufacturerId>OCI</manufacturerId><listingDate>2021-11-30</listingDate></drug><drug id="02520028" notABenefit="Y" sec3b="Y" sec3="Y"><name>Haloette</name><manufacturerId>SLP</manufacturerId><individualPrice>14.2120</individualPrice><listingDate>2021-11-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02176"><name>ETONOGESTREL</name><pcgGroup><pcg9 id="681200005"><itemNumber>1788</itemNumber><strength>68mg/Implant</strength><dosageForm>ER Subdermal Implant</dosageForm><drug id="02499509" sec3="Y"><name>Nexplanon</name><manufacturerId>OCI</manufacturerId><individualPrice>314.2100</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>314.2100</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00951"><name>LEVONORGESTREL</name><pcgGroup><pcg9 id="681200002"><itemNumber>1789</itemNumber><strength>19.5mg</strength><dosageForm>Insert</dosageForm><drug id="02459523" sec3="Y"><name>Kyleena</name><manufacturerId>BAY</manufacturerId><individualPrice>348.6100</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>348.6100</amountMOHLTCPays></drug></pcg9><pcg9 id="681200003"><itemNumber>1790</itemNumber><strength>52mg</strength><dosageForm>Insert</dosageForm><drug id="02243005" sec3="Y"><name>Mirena</name><manufacturerId>BAY</manufacturerId><individualPrice>372.5500</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>372.5500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="681600000"><name>ESTROGENS</name><genericName id="00869"><name>CONJUGATED ESTROGENS</name><pcgGroup lccId="00172"><pcg9 id="681600075"><itemNumber>1791</itemNumber><strength>0.625mg</strength><dosageForm>SR Tab</dosageForm><drug id="02414686" sec3="Y" sec12="Y"><name>Premarin</name><manufacturerId>PFI</manufacturerId><individualPrice>.4088</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.4088</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="398">For short-term use in women who are experiencing symptoms of menopause.

Note: Recent evidence has demonstrated that use of hormone replacement therapy (HRT) increases the rate of coronary events, breast cancer, dementia, stroke, venous thromboembolism and referrals for abnormal vaginal bleeding. These risks should be discussed with patients and reviewed periodically.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="681600007"><itemNumber>1792</itemNumber><strength>0.625mg/g</strength><dosageForm>Vag Cr</dosageForm><drug id="02043440" sec3="Y"><name>Premarin Vaginal Cream</name><manufacturerId>PFI</manufacturerId><individualPrice>.9110</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9110</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00875"><name>ESTRADIOL</name><pcgGroup><pcg9 id="681600051"><itemNumber>1793</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02225190" notABenefit="Y" sec3="Y"><name>Estrace</name><manufacturerId>APC</manufacturerId><listingDate>2016-04-29</listingDate></drug><drug id="02449048" sec3="Y"><name>Lupin-Estradiol</name><manufacturerId>LUP</manufacturerId><individualPrice>.1199</individualPrice><listingDate>2016-04-29</listingDate><amountMOHLTCPays>.1199</amountMOHLTCPays></drug></pcg9><pcg9 id="681600036"><itemNumber>1794</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02148587" notABenefit="Y" sec3="Y"><name>Estrace</name><manufacturerId>APC</manufacturerId><listingDate>2016-04-29</listingDate></drug><drug id="02449056" sec3="Y"><name>Lupin-Estradiol</name><manufacturerId>LUP</manufacturerId><individualPrice>.2313</individualPrice><listingDate>2016-04-29</listingDate><amountMOHLTCPays>.2313</amountMOHLTCPays></drug></pcg9><pcg9 id="681600037"><itemNumber>1795</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02148595" notABenefit="Y" sec3="Y"><name>Estrace</name><manufacturerId>APC</manufacturerId><listingDate>2016-04-29</listingDate></drug><drug id="02449064" sec3="Y"><name>Lupin-Estradiol</name><manufacturerId>LUP</manufacturerId><individualPrice>.4083</individualPrice><listingDate>2016-04-29</listingDate><amountMOHLTCPays>.4083</amountMOHLTCPays></drug></pcg9><pcg9 id="681600041"><itemNumber>1796</itemNumber><strength>2mg</strength><dosageForm>Vag Ring</dosageForm><drug id="02168898" sec3="Y"><name>Estring</name><manufacturerId>PFI</manufacturerId><individualPrice>104.4500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>104.4500</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00880"><name>ESTRADIOL 17-B</name><pcgGroup><pcg9 id="681600074"><itemNumber>1797</itemNumber><strength>10mcg</strength><dosageForm>Vag Tab with Applicator</dosageForm><drug id="02325462" sec3="Y"><name>Vagifem 10</name><manufacturerId>NOO</manufacturerId><individualPrice>4.8056</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>4.8056</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02375"><name>ESTRADIOL HEMIHYDRATE</name><pcgGroup><pcg9 id="681600079"><itemNumber>1798</itemNumber><strength>4mcg</strength><dosageForm>Vag Insert</dosageForm><drug id="02503689" sec3="Y"><name>Imvexxy</name><manufacturerId>KNT</manufacturerId><individualPrice>3.6288</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>3.6288</amountMOHLTCPays></drug></pcg9><pcg9 id="681600080"><itemNumber>1799</itemNumber><strength>10mcg</strength><dosageForm>Vag Insert</dosageForm><drug id="02503697" sec3="Y"><name>Imvexxy</name><manufacturerId>KNT</manufacturerId><individualPrice>3.6288</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>3.6288</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02389"><name>ESTRADIOL HEMIHYDRATE &amp; PROGESTERONE</name><pcgGroup><pcg9 id="681600082"><itemNumber>1800</itemNumber><strength>1mg &amp; 100mg</strength><dosageForm>Cap</dosageForm><drug id="02505223" sec3="Y"><name>Bijuva</name><manufacturerId>KNT</manufacturerId><individualPrice>.8962</individualPrice><listingDate>2024-02-29</listingDate><amountMOHLTCPays>.8962</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="681800000"><name>GONADOTROPINS AND ANTIGONADOTROPINS</name><genericName id="02417"><name>RELUGOLIX</name><pcgGroup><pcg9 id="681800020"><itemNumber>1801</itemNumber><strength>120mg</strength><dosageForm>Tab</dosageForm><drug id="02542137" sec3="Y"><name>Orgovyx</name><manufacturerId>SMT</manufacturerId><individualPrice>9.0000</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>9.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="682002000"><name>ANTI-DIABETIC AGENTS ORAL ANTI-DIABETIC AGENTS</name><genericName id="00892"><name>ACARBOSE</name><pcgGroup lccId="00113"><pcg9 id="682002011"><itemNumber>1802</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02190885" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Glucobay</name><manufacturerId>BAY</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02494078" insOH="Y" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mar-Acarbose</name><manufacturerId>MAR</manufacturerId><individualPrice>.1348</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>.1348</amountMOHLTCPays></drug></pcg9><pcg9 id="682002012"><itemNumber>1803</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02190893" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Glucobay</name><manufacturerId>BAY</manufacturerId><listingDate>1996-12-19</listingDate></drug><drug id="02494086" insOH="Y" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mar-Acarbose</name><manufacturerId>MAR</manufacturerId><individualPrice>.2053</individualPrice><listingDate>2020-03-31</listingDate><amountMOHLTCPays>.2053</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the treatment of non-insulin-dependent diabetes mellitus (NIDDM):</lccNote><lccNote seq="002" reasonForUseId="175">In patients who cannot tolerate or have failed treatment with other oral hypoglycemic agents or in whom other oral hypoglycemic agents are contraindicated;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="176">In patients who require combination therapy with more than one oral hypoglycemic agent to control their serum glucose concentrations.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01983"><name>CANAGLIFLOZIN</name><pcgGroup><pcg9 id="682002055"><itemNumber>1804</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.</note><drug id="02425483" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Invokana</name><manufacturerId>JAN</manufacturerId><individualPrice>2.8910</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>2.8910</amountMOHLTCPays></drug></pcg9><pcg9 id="682002056"><itemNumber>1805</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.</note><drug id="02425491" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Invokana</name><manufacturerId>JAN</manufacturerId><individualPrice>3.0060</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>3.0060</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02020"><name>DAPAGLIFLOZIN</name><pcgGroup><pcg9 id="682002059"><itemNumber>1806</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><note>Added on to metformin for patients:
- Who have inadequate glycemic control on metformin and
- Who have a contraindication or intolerance to a sulfonylurea or
- For whom insulin is not an option.

Added on to a sulfonylurea for patients:
- Who have inadequate glycemic control on a sulfonylurea and
- Who have a contraindication or intolerance to metformin or
- For whom insulin is not an option.

For the treatment of adult patients with New York Heart Association (NYHA) class II and III heart failure, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) [Left ventricular ejection fraction (LVEF less than or equal to 40%)]. Standard of care therapies include beta-blockers, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), plus a mineralocorticoid receptor antagonist.</note><drug id="02435462" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Forxiga</name><manufacturerId>AZC</manufacturerId><individualPrice>2.7300</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02518732" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Dapagliflozin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02519852" insOH="Y" chronicUseMed="Y" sec3="Y"><name>GLN-Dapagliflozin</name><manufacturerId>GLP</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02527189" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Dapagliflozin</name><manufacturerId>APX</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02531364" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Dapagliflozin</name><manufacturerId>JPC</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02531402" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Dapagliflozin</name><manufacturerId>AUR</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02531550" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMS-Dapagliflozin</name><manufacturerId>PMS</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02535297" insOH="Y" chronicUseMed="Y" sec3="Y"><name>M-Dapagliflozin</name><manufacturerId>MAT</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02538334" insOH="Y" chronicUseMed="Y" sec3="Y"><name>NRA-Dapagliflozin</name><manufacturerId>NRA</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug></pcg9><pcg9 id="682002060"><itemNumber>1807</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><note>Added on to metformin for patients:
- Who have inadequate glycemic control on metformin and
- Who have a contraindication or intolerance to a sulfonylurea or
- For whom insulin is not an option.

Added on to a sulfonylurea for patients:
- Who have inadequate glycemic control on a sulfonylurea and
- Who have a contraindication or intolerance to metformin or
- For whom insulin is not an option.

For the treatment of adult patients with New York Heart Association (NYHA) class II and III heart failure, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) [Left ventricular ejection fraction (LVEF less than or equal to 40%)]. Standard of care therapies include beta-blockers, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), plus a mineralocorticoid receptor antagonist.</note><drug id="02435470" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Forxiga</name><manufacturerId>AZC</manufacturerId><individualPrice>2.7300</individualPrice><listingDate>2016-11-30</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02518740" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Dapagliflozin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02519860" insOH="Y" chronicUseMed="Y" sec3="Y"><name>GLN-Dapagliflozin</name><manufacturerId>GLP</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02527197" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Dapagliflozin</name><manufacturerId>APX</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02531372" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Dapagliflozin</name><manufacturerId>JPC</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02531410" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Dapagliflozin</name><manufacturerId>AUR</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02531569" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMS-Dapagliflozin</name><manufacturerId>PMS</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02535300" insOH="Y" chronicUseMed="Y" sec3="Y"><name>M-Dapagliflozin</name><manufacturerId>MAT</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug><drug id="02538342" insOH="Y" chronicUseMed="Y" sec3="Y"><name>NRA-Dapagliflozin</name><manufacturerId>NRA</manufacturerId><individualPrice>.6825</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>.6825</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02039"><name>DAPAGLIFLOZIN &amp; METFORMIN</name><pcgGroup><pcg9 id="682002064"><itemNumber>1808</itemNumber><strength>5mg &amp; 1000mg</strength><dosageForm>Tab</dosageForm><note>For the treatment of patients with type 2 diabetes mellitus who are already stabilized on therapy with metformin and dapagliflozin, to replace the individual components of dapagliflozin and metformin for those patients who have inadequate glycemic control on metformin, a contraindication or intolerance to a sulfonylurea, and for whom insulin is not an option.</note><drug id="02449943" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Xigduo</name><manufacturerId>AZC</manufacturerId><individualPrice>1.2863</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.6432</amountMOHLTCPays></drug><drug id="02533081" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Dapagliflozin / Metformin</name><manufacturerId>AUR</manufacturerId><individualPrice>.6432</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>.6432</amountMOHLTCPays></drug><drug id="02536161" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Dapagliflozin-Metformin</name><manufacturerId>APX</manufacturerId><individualPrice>.6432</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.6432</amountMOHLTCPays></drug></pcg9><pcg9 id="682002063"><itemNumber>1809</itemNumber><strength>5mg &amp; 850mg</strength><dosageForm>Tab</dosageForm><note>For the treatment of patients with type 2 diabetes mellitus who are already stabilized on therapy with metformin and dapagliflozin, to replace the individual components of dapagliflozin and metformin for those patients who have inadequate glycemic control on metformin, a contraindication or intolerance to a sulfonylurea, and for whom insulin is not an option.</note><drug id="02449935" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Xigduo</name><manufacturerId>AZC</manufacturerId><individualPrice>1.2863</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.6432</amountMOHLTCPays></drug><drug id="02533073" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Dapagliflozin / Metformin</name><manufacturerId>AUR</manufacturerId><individualPrice>.6432</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>.6432</amountMOHLTCPays></drug><drug id="02536153" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Dapagliflozin-Metformin</name><manufacturerId>APX</manufacturerId><individualPrice>.6432</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>.6432</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01998"><name>EMPAGLIFLOZIN</name><pcgGroup><pcg9 id="682002057"><itemNumber>1810</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

-  Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

-  Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.  


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07)  despite an adequate trial of metformin. Established CV disease is defined as one of the following:

-  history of MI

-  multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

-  single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

-  last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

-  history of ischemic or hemorrhagic stroke

-  occlusive peripheral artery disease.</note><drug id="02443937" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jardiance</name><manufacturerId>BOE</manufacturerId><individualPrice>2.7671</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>2.7671</amountMOHLTCPays></drug></pcg9><pcg9 id="682002058"><itemNumber>1811</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

-  Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

-  Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.  


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07)  despite an adequate trial of metformin. Established CV disease is defined as one of the following:

-  history of MI

-  multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

-  single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

-  last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

-  history of ischemic or hemorrhagic stroke

-  occlusive peripheral artery disease.</note><drug id="02443945" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jardiance</name><manufacturerId>BOE</manufacturerId><individualPrice>2.7671</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>2.7671</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02065"><name>EMPAGLIFLOZIN &amp; METFORMIN</name><pcgGroup><pcg9 id="682002068"><itemNumber>1812</itemNumber><strength>5mg &amp; 1000mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. 


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:

- history of MI

- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

- history of ischemic or hemorrhagic stroke

- occlusive peripheral artery disease.</note><drug id="02456591" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Synjardy</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3932</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.3932</amountMOHLTCPays></drug></pcg9><pcg9 id="682002066"><itemNumber>1813</itemNumber><strength>5mg &amp; 500mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. 


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:

- history of MI

- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

- history of ischemic or hemorrhagic stroke

- occlusive peripheral artery disease.</note><drug id="02456575" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Synjardy</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3932</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.3932</amountMOHLTCPays></drug></pcg9><pcg9 id="682002067"><itemNumber>1814</itemNumber><strength>5mg &amp; 850mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. 


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:

- history of MI

- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

- history of ischemic or hemorrhagic stroke

- occlusive peripheral artery disease.</note><drug id="02456583" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Synjardy</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3932</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.3932</amountMOHLTCPays></drug></pcg9><pcg9 id="682002071"><itemNumber>1815</itemNumber><strength>12.5mg &amp; 1000mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. 


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:

- history of MI

- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

- history of ischemic or hemorrhagic stroke

- occlusive peripheral artery disease.</note><drug id="02456621" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Synjardy</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3932</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.3932</amountMOHLTCPays></drug></pcg9><pcg9 id="682002069"><itemNumber>1816</itemNumber><strength>12.5mg &amp; 500mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. 


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:

- history of MI

- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

- history of ischemic or hemorrhagic stroke

- occlusive peripheral artery disease.</note><drug id="02456605" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Synjardy</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3932</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.3932</amountMOHLTCPays></drug></pcg9><pcg9 id="682002070"><itemNumber>1817</itemNumber><strength>12.5mg &amp; 850mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

- Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR 

- Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option. 


Used as an adjunct to diet, exercise, and standard care therapy to reduce the incidence of cardiovascular (CV) death in patients with Type 2 diabetes and established cardiovascular disease who have inadequate glycemic control (HbA1c greater than 0.07) despite an adequate trial of metformin. Established CV disease is defined as one of the following:

- history of MI

- multi-vessel coronary artery disease in two or more major coronary arteries (irrespective of revascularization status)

- single-vessel coronary artery disease with significant stenosis and either a positive non-invasive stress test or discharged from hospital with a documented diagnosis of unstable angina within 12 months prior to selection 

- last episode of unstable angina greater than 2 months prior with confirmed evidence of coronary multi-vessel or single-vessel disease

- history of ischemic or hemorrhagic stroke

- occlusive peripheral artery disease.</note><drug id="02456613" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Synjardy</name><manufacturerId>BOE</manufacturerId><individualPrice>1.3932</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.3932</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00891"><name>GLICLAZIDE</name><pcgGroup><pcg9 id="682002036"><itemNumber>1818</itemNumber><strength>60mg</strength><dosageForm>ER Tab</dosageForm><drug id="02356422" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Diamicron MR</name><manufacturerId>SEV</manufacturerId><individualPrice>.2932</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug><drug id="02407124" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Gliclazide MR</name><manufacturerId>APX</manufacturerId><individualPrice>.0632</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug><drug id="02423294" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Mint-Gliclazide MR</name><manufacturerId>MIN</manufacturerId><individualPrice>.0632</individualPrice><listingDate>2017-04-27</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug><drug id="02429772" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Gliclazide-MR</name><manufacturerId>JPC</manufacturerId><individualPrice>.0632</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug><drug id="02439328" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Gliclazide MR</name><manufacturerId>SPC</manufacturerId><individualPrice>.0632</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug><drug id="02461331" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Gliclazide MR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0632</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug><drug id="02524864" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Gliclazide MR</name><manufacturerId>SAI</manufacturerId><individualPrice>.0632</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>.0632</amountMOHLTCPays></drug></pcg9><pcg9 id="682002025"><itemNumber>1819</itemNumber><strength>30mg</strength><dosageForm>SR Tab</dosageForm><drug id="02242987" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Diamicron MR</name><manufacturerId>SEV</manufacturerId><individualPrice>.1628</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02297795" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Gliclazide MR</name><manufacturerId>APX</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02423286" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Mint-Gliclazide MR</name><manufacturerId>MIN</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02429764" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Gliclazide MR</name><manufacturerId>JPC</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02438658" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Mylan-Gliclazide MR</name><manufacturerId>MYL</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02461323" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Gliclazide MR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02463571" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Gliclazide MR</name><manufacturerId>SPC</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02524856" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Gliclazide MR</name><manufacturerId>SAI</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug></pcg9><pcg9 id="682002010"><itemNumber>1820</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="00765996" insOH="Y" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Diamicron</name><manufacturerId>SEV</manufacturerId><listingDate>2007-04-02</listingDate></drug><drug id="02238103" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Gliclazide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02245247" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Gliclazide</name><manufacturerId>APX</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug><drug id="02287072" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Gliclazide</name><manufacturerId>SAI</manufacturerId><individualPrice>.0931</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.0931</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01695"><name>GLIMEPIRIDE</name><pcgGroup><pcg9 id="682002031"><itemNumber>1821</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02245272" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amaryl</name><manufacturerId>SAV</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02269589" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Glimepiride</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8187</individualPrice><listingDate>2007-06-06</listingDate></drug></pcg9><pcg9 id="682002032"><itemNumber>1822</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02245273" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amaryl</name><manufacturerId>SAV</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02269597" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Glimepiride</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9800</individualPrice><listingDate>2007-06-06</listingDate></drug></pcg9><pcg9 id="682002033"><itemNumber>1823</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02245274" notABenefit="Y" sec3b="Y" sec3="Y"><name>Amaryl</name><manufacturerId>SAV</manufacturerId><listingDate>2007-06-06</listingDate></drug><drug id="02269619" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Glimepiride</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0487</individualPrice><listingDate>2007-06-06</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00888"><name>GLYBURIDE</name><pcgGroup><pcg9 id="682002009"><itemNumber>1824</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="01913654" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Glyburide</name><manufacturerId>APX</manufacturerId><individualPrice>.0321</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0321</amountMOHLTCPays></drug><drug id="01913670" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Glyburide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0321</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0321</amountMOHLTCPays></drug><drug id="02224550" insOH="Y" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Diabeta</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-06</listingDate></drug><drug id="02248008" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Glyburide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0321</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.0321</amountMOHLTCPays></drug></pcg9><pcg9 id="682002004"><itemNumber>1825</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="01913662" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Glyburide</name><manufacturerId>APX</manufacturerId><individualPrice>.0574</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0573</amountMOHLTCPays></drug><drug id="01913689" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Glyburide</name><manufacturerId>TEV</manufacturerId><individualPrice>.0574</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0573</amountMOHLTCPays></drug><drug id="02224569" insOH="Y" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Diabeta</name><manufacturerId>SAV</manufacturerId><listingDate>1999-01-06</listingDate></drug><drug id="02350467" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Glyburide</name><manufacturerId>SAI</manufacturerId><individualPrice>.0573</individualPrice><listingDate>2011-10-25</listingDate><amountMOHLTCPays>.0573</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01894"><name>LINAGLIPTIN</name><pcgGroup><pcg9 id="682002041"><itemNumber>1826</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.


</note><drug id="02370921" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Trajenta</name><manufacturerId>BOE</manufacturerId><individualPrice>2.6954</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>2.6954</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01939"><name>LINAGLIPTIN &amp; METFORMIN</name><pcgGroup><pcg9 id="682002050"><itemNumber>1827</itemNumber><strength>2.5mg &amp; 1000mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.</note><drug id="02403277" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jentadueto</name><manufacturerId>BOE</manufacturerId><individualPrice>1.4132</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.4132</amountMOHLTCPays></drug></pcg9><pcg9 id="682002048"><itemNumber>1828</itemNumber><strength>2.5mg &amp; 500mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.</note><drug id="02403250" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jentadueto</name><manufacturerId>BOE</manufacturerId><individualPrice>1.4132</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.4132</amountMOHLTCPays></drug></pcg9><pcg9 id="682002049"><itemNumber>1829</itemNumber><strength>2.5mg &amp; 850mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.</note><drug id="02403269" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jentadueto</name><manufacturerId>BOE</manufacturerId><individualPrice>1.4132</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.4132</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00890"><name>METFORMIN HCL</name><pcgGroup><pcg9 id="682002035"><itemNumber>1830</itemNumber><strength>500mg</strength><dosageForm>ER Tab</dosageForm><drug id="02268493" notABenefit="Y" sec3b="Y" sec3="Y"><name>Glumetza</name><manufacturerId>BIO</manufacturerId><listingDate>2010-06-14</listingDate></drug><drug id="02305062" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Metformin ER</name><manufacturerId>APX</manufacturerId><individualPrice>.6584</individualPrice><listingDate>2010-06-14</listingDate></drug><drug id="02547309" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Metformin XR</name><manufacturerId>MIN</manufacturerId><individualPrice>.6584</individualPrice><listingDate>2024-09-27</listingDate></drug><drug id="02550504" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Metformin XR</name><manufacturerId>MAR</manufacturerId><individualPrice>.6584</individualPrice><listingDate>2024-11-29</listingDate></drug><drug id="02552027" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Metformin XR</name><manufacturerId>TAR</manufacturerId><individualPrice>.6584</individualPrice><listingDate>2025-07-31</listingDate></drug></pcg9><pcg9 id="682002065"><itemNumber>1831</itemNumber><strength>1000mg</strength><dosageForm>ER Tab</dosageForm><drug id="02300451" notABenefit="Y" sec3b="Y" sec3="Y"><name>Glumetza</name><manufacturerId>VAL</manufacturerId><listingDate>2017-08-30</listingDate></drug><drug id="02460653" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Metformin ER</name><manufacturerId>APX</manufacturerId><individualPrice>1.3233</individualPrice><listingDate>2017-08-30</listingDate></drug><drug id="02547317" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Metformin XR</name><manufacturerId>MIN</manufacturerId><individualPrice>1.3233</individualPrice><listingDate>2024-09-27</listingDate></drug><drug id="02550512" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Metformin XR</name><manufacturerId>MAR</manufacturerId><individualPrice>1.3233</individualPrice><listingDate>2024-11-29</listingDate></drug></pcg9><pcg9 id="682002008"><itemNumber>1832</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02045710" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Novo-Metformin</name><manufacturerId>NOP</manufacturerId><individualPrice>.0247</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02099233" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Glucophage</name><manufacturerId>SAV</manufacturerId><individualPrice>.2821</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02167786" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Metformin</name><manufacturerId>APX</manufacturerId><individualPrice>.0247</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02223562" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMS-Metformin</name><manufacturerId>PMS</manufacturerId><individualPrice>.0247</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02242974" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Ratio-Metformin</name><manufacturerId>RPH</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2001-06-07</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02246820" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Metformin FC</name><manufacturerId>SDZ</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02257726" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Metformin</name><manufacturerId>TEV</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2004-12-21</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02269031" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Ran-Metformin</name><manufacturerId>RAN</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2006-03-01</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02353377" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Metformin</name><manufacturerId>SAI</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02378620" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Mar-Metformin</name><manufacturerId>MAR</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02379767" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Septa-Metformin</name><manufacturerId>SET</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02380196" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp-Metformin</name><manufacturerId>JPC</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02385341" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Metformin FC</name><manufacturerId>SIV</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02388766" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Mint-Metformin</name><manufacturerId>MIN</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02438275" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Metformin</name><manufacturerId>AUR</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02520303" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMSC-Metformin</name><manufacturerId>PMS</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02531895" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PRZ-Metformin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02536439" insOH="Y" chronicUseMed="Y" sec3="Y"><name>NRA-Metformin</name><manufacturerId>NRA</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug><drug id="02547767" insOH="Y" chronicUseMed="Y" sec3="Y"><name>M-Metformin</name><manufacturerId>MAT</manufacturerId><individualPrice>.0247</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.0247</amountMOHLTCPays></drug></pcg9><pcg9 id="682002022"><itemNumber>1833</itemNumber><strength>850mg</strength><dosageForm>Tab</dosageForm><drug id="02162849" notABenefit="Y" sec3b="Y" sec3="Y"><name>Glucophage</name><manufacturerId>SAV</manufacturerId><listingDate>2007-12-19</listingDate></drug><drug id="02229785" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Metformin</name><manufacturerId>APX</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2017-08-30</listingDate></drug><drug id="02242589" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Metformin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2008-04-09</listingDate></drug><drug id="02242931" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ratio-Metformin</name><manufacturerId>RPH</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02246821" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Metformin FC</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02257734" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Metformin</name><manufacturerId>TEV</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02269058" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Metformin</name><manufacturerId>RAN</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2008-04-09</listingDate></drug><drug id="02353385" notABenefit="Y" sec3b="Y" sec3="Y"><name>Metformin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2011-08-04</listingDate></drug><drug id="02378639" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Metformin</name><manufacturerId>MAR</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2012-06-26</listingDate></drug><drug id="02380218" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Metformin</name><manufacturerId>JPC</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2012-08-27</listingDate></drug><drug id="02380730" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp-Metformin Blackberry</name><manufacturerId>JPC</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2012-08-27</listingDate></drug><drug id="02385368" notABenefit="Y" sec3b="Y" sec3="Y"><name>Metformin FC</name><manufacturerId>SIV</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2020-11-30</listingDate></drug><drug id="02388774" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Metformin</name><manufacturerId>MIN</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2012-09-28</listingDate></drug><drug id="02421836" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ecl-Metformin</name><manufacturerId>ECL</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2014-12-18</listingDate></drug><drug id="02438283" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Metformin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2015-08-26</listingDate></drug><drug id="02520311" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMSC-Metformin</name><manufacturerId>PMS</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2022-03-31</listingDate></drug><drug id="02531909" notABenefit="Y" sec3b="Y" sec3="Y"><name>PRZ-Metformin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2023-07-31</listingDate></drug><drug id="02536447" notABenefit="Y" sec3b="Y" sec3="Y"><name>NRA-Metformin</name><manufacturerId>NRA</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2023-10-31</listingDate></drug><drug id="02547775" notABenefit="Y" sec3b="Y" sec3="Y"><name>M-Metformin</name><manufacturerId>MAT</manufacturerId><individualPrice>.2090</individualPrice><listingDate>2025-01-31</listingDate></drug></pcg9><pcg9 id="682002072"><itemNumber>1834</itemNumber><strength>1000mg</strength><dosageForm>Tab</dosageForm><drug id="02446065" notABenefit="Y" sec3b="Y" sec3="Y"><name>Glucophage</name><manufacturerId>SAV</manufacturerId><listingDate>2025-08-29</listingDate></drug><drug id="02534673" notABenefit="Y" sec3b="Y" sec3="Y"><name>PRZ-Metformin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.0399</individualPrice><listingDate>2025-08-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01504"><name>PIOGLITAZONE HCL</name><pcgGroup><pcg9 id="682002019"><itemNumber>1835</itemNumber><strength>15mg</strength><dosageForm>Tab</dosageForm><drug id="02242572" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Actos</name><manufacturerId>TAK</manufacturerId><individualPrice>2.5070</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02274914" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Pioglitazone</name><manufacturerId>TEV</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02297906" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pioglitazone</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02302861" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Pioglitazone</name><manufacturerId>TEV</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02302942" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pioglitazone</name><manufacturerId>APX</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02303442" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel Pioglitazone</name><manufacturerId>ACC</manufacturerId><individualPrice>1.3800</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.3800</amountMOHLTCPays></drug><drug id="02326477" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Pioglitazone</name><manufacturerId>MIN</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02384906" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Pioglitazone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02391600" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pioglitazone Hydrochloride Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug><drug id="02397307" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Pioglitazone</name><manufacturerId>JPC</manufacturerId><individualPrice>1.5716</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.5716</amountMOHLTCPays></drug></pcg9><pcg9 id="682002020"><itemNumber>1836</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02242573" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Actos</name><manufacturerId>TAK</manufacturerId><individualPrice>3.5124</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02274922" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Pioglitazone</name><manufacturerId>TEV</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02297914" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pioglitazone</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02302888" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Pioglitazone</name><manufacturerId>TEV</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02302950" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pioglitazone</name><manufacturerId>APX</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02303450" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel Pioglitazone</name><manufacturerId>ACC</manufacturerId><individualPrice>1.9600</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.9600</amountMOHLTCPays></drug><drug id="02326485" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Pioglitazone</name><manufacturerId>MIN</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02339587" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pioglitazone Hydrochloride Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02365529" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Pioglitazone</name><manufacturerId>JPC</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug><drug id="02384914" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Pioglitazone</name><manufacturerId>AUR</manufacturerId><individualPrice>2.2017</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>2.2017</amountMOHLTCPays></drug></pcg9><pcg9 id="682002021"><itemNumber>1837</itemNumber><strength>45mg</strength><dosageForm>Tab</dosageForm><drug id="02242574" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Actos</name><manufacturerId>TAK</manufacturerId><individualPrice>5.2710</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>5.2710</amountMOHLTCPays></drug><drug id="02274930" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Pioglitazone</name><manufacturerId>TEV</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02297922" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pioglitazone</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02302896" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Act Pioglitazone</name><manufacturerId>TEV</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02302977" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Pioglitazone</name><manufacturerId>APX</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02303469" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel Pioglitazone</name><manufacturerId>ACC</manufacturerId><individualPrice>2.9500</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>2.9500</amountMOHLTCPays></drug><drug id="02326493" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Pioglitazone</name><manufacturerId>MIN</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02339595" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pioglitazone Hydrochloride Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02365537" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Pioglitazone</name><manufacturerId>JPC</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug><drug id="02384922" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Pioglitazone</name><manufacturerId>AUR</manufacturerId><individualPrice>3.3105</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>3.3105</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01438"><name>REPAGLINIDE</name><pcgGroup><pcg9 id="682002013"><itemNumber>1838</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02239924" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>GlucoNorm</name><manufacturerId>NOO</manufacturerId><listingDate>2011-03-15</listingDate></drug><drug id="02321475" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Repaglinide</name><manufacturerId>COB</manufacturerId><individualPrice>.2083</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2083</amountMOHLTCPays></drug><drug id="02354926" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Repaglinide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2083</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2083</amountMOHLTCPays></drug><drug id="02355663" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Repaglinide</name><manufacturerId>APX</manufacturerId><individualPrice>.2083</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2083</amountMOHLTCPays></drug><drug id="02357453" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Repaglinide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2083</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2083</amountMOHLTCPays></drug><drug id="02424258" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Repaglinide</name><manufacturerId>AUR</manufacturerId><individualPrice>.2083</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2083</amountMOHLTCPays></drug></pcg9><pcg9 id="682002014"><itemNumber>1839</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02239925" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>GlucoNorm</name><manufacturerId>NOO</manufacturerId><listingDate>2011-03-15</listingDate></drug><drug id="02321483" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Repaglinide</name><manufacturerId>COB</manufacturerId><individualPrice>.2165</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2165</amountMOHLTCPays></drug><drug id="02354934" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Repaglinide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2165</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2165</amountMOHLTCPays></drug><drug id="02355671" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Repaglinide</name><manufacturerId>APX</manufacturerId><individualPrice>.2165</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2165</amountMOHLTCPays></drug><drug id="02357461" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Repaglinide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2165</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2165</amountMOHLTCPays></drug><drug id="02424266" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Repaglinide</name><manufacturerId>AUR</manufacturerId><individualPrice>.2165</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2165</amountMOHLTCPays></drug></pcg9><pcg9 id="682002015"><itemNumber>1840</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02239926" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>GlucoNorm</name><manufacturerId>NOO</manufacturerId><listingDate>2011-03-15</listingDate></drug><drug id="02321491" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Repaglinide</name><manufacturerId>COB</manufacturerId><individualPrice>.2441</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2441</amountMOHLTCPays></drug><drug id="02354942" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Repaglinide</name><manufacturerId>JPC</manufacturerId><individualPrice>.2441</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.2441</amountMOHLTCPays></drug><drug id="02355698" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Repaglinide</name><manufacturerId>APX</manufacturerId><individualPrice>.2441</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2441</amountMOHLTCPays></drug><drug id="02357488" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Repaglinide</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2440</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>.2440</amountMOHLTCPays></drug><drug id="02424274" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Repaglinide</name><manufacturerId>AUR</manufacturerId><individualPrice>.2441</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>.2441</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01481"><name>ROSIGLITAZONE</name><pcgGroup><pcg9 id="682002016"><itemNumber>1841</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02241112" notABenefit="Y" sec3b="Y" sec3="Y"><name>Avandia</name><manufacturerId>GSK</manufacturerId><listingDate>2007-01-02</listingDate></drug><drug id="02403366" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rosiglitazone</name><manufacturerId>AAP</manufacturerId><individualPrice>1.2234</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>1.2234</amountMOHLTCPays></drug></pcg9><pcg9 id="682002017"><itemNumber>1842</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02241113" notABenefit="Y" sec3b="Y" sec3="Y"><name>Avandia</name><manufacturerId>GSK</manufacturerId><listingDate>2007-01-02</listingDate></drug><drug id="02403374" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rosiglitazone</name><manufacturerId>AAP</manufacturerId><individualPrice>1.9197</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>1.9197</amountMOHLTCPays></drug></pcg9><pcg9 id="682002018"><itemNumber>1843</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02241114" notABenefit="Y" sec3b="Y" sec3="Y"><name>Avandia</name><manufacturerId>GSK</manufacturerId><listingDate>2007-01-02</listingDate></drug><drug id="02403382" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rosiglitazone</name><manufacturerId>AAP</manufacturerId><individualPrice>2.7452</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>2.7452</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01873"><name>SAXAGLIPTIN</name><pcgGroup><pcg9 id="682002045"><itemNumber>1844</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea.

</note><drug id="02375842" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Onglyza</name><manufacturerId>AZC</manufacturerId><individualPrice>2.8823</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>1.2650</amountMOHLTCPays></drug><drug id="02468603" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Saxagliptin</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2650</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1.2650</amountMOHLTCPays></drug><drug id="02507471" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Saxagliptin</name><manufacturerId>APX</manufacturerId><individualPrice>1.2650</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1.2650</amountMOHLTCPays></drug></pcg9><pcg9 id="682002040"><itemNumber>1845</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea.

</note><drug id="02333554" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Onglyza</name><manufacturerId>AZC</manufacturerId><individualPrice>3.4621</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>1.5195</amountMOHLTCPays></drug><drug id="02468611" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Saxagliptin</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.5195</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1.5195</amountMOHLTCPays></drug><drug id="02507498" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Saxagliptin</name><manufacturerId>APX</manufacturerId><individualPrice>1.5195</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>1.5195</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01962"><name>SAXAGLIPTIN &amp; METFORMIN</name><pcgGroup><pcg9 id="682002054"><itemNumber>1846</itemNumber><strength>2.5mg &amp; 1000mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02389185" insOH="Y" sec3="Y"><name>Komboglyze</name><manufacturerId>AZC</manufacturerId><individualPrice>1.4468</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>1.4468</amountMOHLTCPays></drug></pcg9><pcg9 id="682002052"><itemNumber>1847</itemNumber><strength>2.5mg &amp; 500mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02389169" insOH="Y" sec3="Y"><name>Komboglyze</name><manufacturerId>AZC</manufacturerId><individualPrice>1.4468</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>1.4468</amountMOHLTCPays></drug></pcg9><pcg9 id="682002053"><itemNumber>1848</itemNumber><strength>2.5mg &amp; 850mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02389177" insOH="Y" sec3="Y"><name>Komboglyze</name><manufacturerId>AZC</manufacturerId><individualPrice>1.4468</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>1.4468</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02322"><name>SITAGLIPTIN</name><pcgGroup><pcg9 id="682002046"><itemNumber>1849</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02388839" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Januvia</name><manufacturerId>MFC</manufacturerId><individualPrice>3.2787</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02503840" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMS-Sitagliptin</name><manufacturerId>PMS</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02504049" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02508656" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin Malate</name><manufacturerId>APX</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02512475" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Ach-Sitagliptin</name><manufacturerId>ACH</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02522705" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Sitagliptin Malate</name><manufacturerId>TEV</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02529033" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin</name><manufacturerId>SIV</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02529866" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Sitagliptin</name><manufacturerId>AUR</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02531631" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Sitagliptin Fumarate</name><manufacturerId>TAR</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02534134" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Sitagliptin</name><manufacturerId>JPC</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02548550" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin</name><manufacturerId>SAI</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug></pcg9><pcg9 id="682002047"><itemNumber>1850</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02388847" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Januvia</name><manufacturerId>MFC</manufacturerId><individualPrice>3.2787</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02503859" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMS-Sitagliptin</name><manufacturerId>PMS</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02504057" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02508664" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin Malate</name><manufacturerId>APX</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02512483" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Ach-Sitagliptin</name><manufacturerId>ACH</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02522713" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Sitagliptin Malate</name><manufacturerId>TEV</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02529041" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin</name><manufacturerId>SIV</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02529874" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Sitagliptin</name><manufacturerId>AUR</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02531658" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Sitagliptin Fumarate</name><manufacturerId>TAR</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02534142" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Sitagliptin</name><manufacturerId>JPC</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02548569" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin</name><manufacturerId>SAI</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug></pcg9><pcg9 id="682002034"><itemNumber>1851</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximal doses of metformin (2000mg/day)who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; or

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of a sulfonylurea and for whom insulin is not an option.</note><drug id="02303922" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Januvia</name><manufacturerId>MFC</manufacturerId><individualPrice>3.2787</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02503867" insOH="Y" chronicUseMed="Y" sec3="Y"><name>PMS-Sitagliptin</name><manufacturerId>PMS</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02504065" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02508672" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin Malate</name><manufacturerId>APX</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02512491" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Ach-Sitagliptin</name><manufacturerId>ACH</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02522721" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Sitagliptin Malate</name><manufacturerId>TEV</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02529068" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin</name><manufacturerId>SIV</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02529882" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Sitagliptin</name><manufacturerId>AUR</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02531666" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Taro-Sitagliptin Fumarate</name><manufacturerId>TAR</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02534150" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Sitagliptin</name><manufacturerId>JPC</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug><drug id="02548577" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin</name><manufacturerId>SAI</manufacturerId><individualPrice>.8197</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>.8197</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02323"><name>SITAGLIPTIN &amp; METFORMIN</name><pcgGroup><pcg9 id="682002051"><itemNumber>1852</itemNumber><strength>50mg &amp; 1000mg</strength><dosageForm>ER Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02416794" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Janumet XR</name><manufacturerId>MEK</manufacturerId><individualPrice>1.7785</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>.8893</amountMOHLTCPays></drug><drug id="02506289" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin/Metformin XR</name><manufacturerId>APX</manufacturerId><individualPrice>.8893</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.8893</amountMOHLTCPays></drug><drug id="02529114" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin-Metformin XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8893</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.8893</amountMOHLTCPays></drug></pcg9><pcg9 id="682002061"><itemNumber>1853</itemNumber><strength>50mg &amp; 500mg</strength><dosageForm>ER Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.</note><drug id="02416786" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Janumet XR</name><manufacturerId>MEK</manufacturerId><individualPrice>1.7785</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>.8893</amountMOHLTCPays></drug><drug id="02506270" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin/Metformin XR</name><manufacturerId>APX</manufacturerId><individualPrice>.8893</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.8893</amountMOHLTCPays></drug><drug id="02529106" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin-Metformin XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8893</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.8893</amountMOHLTCPays></drug></pcg9><pcg9 id="682002062"><itemNumber>1854</itemNumber><strength>100mg &amp; 1000mg</strength><dosageForm>ER Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.</note><drug id="02416808" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Janumet XR</name><manufacturerId>MEK</manufacturerId><individualPrice>3.5568</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>1.7784</amountMOHLTCPays></drug><drug id="02506297" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin/Metformin XR</name><manufacturerId>APX</manufacturerId><individualPrice>1.7785</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>1.7784</amountMOHLTCPays></drug><drug id="02529122" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin-Metformin XR</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7784</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>1.7784</amountMOHLTCPays></drug></pcg9><pcg9 id="682002039"><itemNumber>1855</itemNumber><strength>50mg &amp; 1000mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin
who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02333872" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Janumet</name><manufacturerId>MEK</manufacturerId><individualPrice>1.7785</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02503972" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin-Metformin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02509431" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin Malate/Metformin HCl</name><manufacturerId>APX</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02520516" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Sitagliptin Malate / Metformin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02529173" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin-Metformin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02540134" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Reddy-Sitagliptin and Metformin HCl</name><manufacturerId>DRR</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02547821" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Sitagliptin HCl and Metformin HCl</name><manufacturerId>AUR</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02556200" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Sitagliptin HCl / Metformin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug></pcg9><pcg9 id="682002037"><itemNumber>1856</itemNumber><strength>50mg &amp; 500mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.</note><drug id="02333856" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Janumet</name><manufacturerId>MEK</manufacturerId><individualPrice>1.7785</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02503956" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin-Metformin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02509415" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin Malate/Metformin HCl</name><manufacturerId>APX</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02520494" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Sitagliptin Malate / Metformin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02529157" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin-Metformin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02540118" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Reddy-Sitagliptin and Metformin HCl</name><manufacturerId>DRR</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02547805" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Sitagliptin HCl and Metformin HCl</name><manufacturerId>AUR</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02556189" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Sitagliptin HCl / Metformin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug></pcg9><pcg9 id="682002038"><itemNumber>1857</itemNumber><strength>50mg &amp; 850mg</strength><dosageForm>Tab</dosageForm><note>Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: 

. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR

. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
</note><drug id="02333864" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Janumet</name><manufacturerId>MEK</manufacturerId><individualPrice>1.7785</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02503964" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sandoz Sitagliptin-Metformin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02509423" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Sitagliptin Malate/Metformin HCl</name><manufacturerId>APX</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02520508" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Teva-Sitagliptin Malate / Metformin</name><manufacturerId>TEV</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02529165" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Sitagliptin-Metformin</name><manufacturerId>SIV</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02540126" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Reddy-Sitagliptin and Metformin HCl</name><manufacturerId>DRR</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02547813" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Auro-Sitagliptin HCl and Metformin HCl</name><manufacturerId>AUR</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug><drug id="02556197" insOH="Y" chronicUseMed="Y" sec3="Y"><name>Jamp Sitagliptin HCl / Metformin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4446</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.4446</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="682006000"><name>ANTI-DIABETIC AGENTS INCRETIN MIMETICS</name><genericName id="02115"><name>INSULIN GLARGINE &amp; LIXISENATIDE</name><pcgGroup><pcg9 id="682006005"><itemNumber>1858</itemNumber><strength>100U/mL &amp; 33mcg/mL</strength><dosageForm>Inj Sol-Pref Pen 5x3mL Pk</dosageForm><note>As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled on basal insulin (less than 60 units daily) in combination with metformin.</note><drug id="02478293" insOH="Y" sec3="Y"><name>Soliqua</name><manufacturerId>SAC</manufacturerId><individualPrice>198.3700</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>198.3700</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02100"><name>SEMAGLUTIDE</name><pcgGroup lccId="00382"><pcg9 id="682006009"><itemNumber>1859</itemNumber><strength>0.68mg/mL</strength><dosageForm>Inj Sol - Pref Pen 3mL Pk</dosageForm><drug id="02540258" insOH="Y" sec3="Y" sec12="Y"><name>Ozempic</name><manufacturerId>NOO</manufacturerId><individualPrice>223.2600</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>223.2600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="667">For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.

Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.

Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.

Reimbursed dose: As per the product monograph</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00383"><pcg9 id="682006002"><itemNumber>1860</itemNumber><strength>1.34mg/mL</strength><dosageForm>Inj Sol-Pref Pen 1.5mL Pk</dosageForm><drug id="02471477" insOH="Y" sec3="Y" sec12="Y"><name>Ozempic</name><manufacturerId>NOO</manufacturerId><individualPrice>223.2600</individualPrice><listingDate>2019-09-30</listingDate><amountMOHLTCPays>223.2600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="666">For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.

Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.

Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.

Reimbursed dose: As per the product monograph</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00384"><pcg9 id="682006001"><itemNumber>1861</itemNumber><strength>1.34mg/mL</strength><dosageForm>Inj Sol-Pref Pen 3mL Pk</dosageForm><drug id="02471469" insOH="Y" sec3="Y" sec12="Y"><name>Ozempic</name><manufacturerId>NOO</manufacturerId><individualPrice>223.2600</individualPrice><listingDate>2019-09-30</listingDate><amountMOHLTCPays>223.2600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="665">For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.

Semaglutide is not funded in combination with another glucagon-like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.

Injectable semaglutide is not funded in combination with oral semaglutide. Coverage is only provided for one dosage format.

Reimbursed dose: As per the product monograph</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00379"><pcg9 id="682006006"><itemNumber>1862</itemNumber><strength>3mg</strength><dosageForm>Tab</dosageForm><drug id="02497581" insOH="Y" sec3="Y" sec12="Y"><name>Rybelsus</name><manufacturerId>NOO</manufacturerId><individualPrice>7.3757</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>7.3757</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="662">For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.

Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.

Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.

Maximum reimbursed dose: 3mg once daily.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00380"><pcg9 id="682006007"><itemNumber>1863</itemNumber><strength>7mg</strength><dosageForm>Tab</dosageForm><drug id="02497603" insOH="Y" sec3="Y" sec12="Y"><name>Rybelsus</name><manufacturerId>NOO</manufacturerId><individualPrice>7.3757</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>7.3757</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="663">For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.

Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.

Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.

Maximum reimbursed dose: 7mg once daily.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00381"><pcg9 id="682006008"><itemNumber>1864</itemNumber><strength>14mg</strength><dosageForm>Tab</dosageForm><drug id="02497611" insOH="Y" sec3="Y" sec12="Y"><name>Rybelsus</name><manufacturerId>NOO</manufacturerId><individualPrice>7.3757</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>7.3757</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="664">For the treatment of adult patients with type 2 diabetes when adequate glycemic control is not achieved on the maximum tolerated dose of metformin or where metformin is contraindicated or inappropriate.

Semaglutide is not funded in combination with another glucagon like peptide-1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase-4 (DPP-4) inhibitor.

Oral semaglutide is not funded in combination with injectable semaglutide. Coverage is only provided for one dosage format.

Maximum reimbursed dose: 14mg once daily.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="682010000"><name>ANTI-DIABETIC AGENTS INSULINS (RAPID ACTING)</name><genericName id="00899"><name>INSULIN (ZINC CRYSTALLINE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)</name><pcgGroup><pcg9 id="682010009"><itemNumber>1865</itemNumber><strength>1000U/10mL</strength><dosageForm>Inj Sol-10mL Pk</dosageForm><drug id="00586714" insOH="Y" sec3="Y"><name>Humulin Regular</name><manufacturerId>LIL</manufacturerId><individualPrice>29.9800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>29.9800</amountMOHLTCPays></drug></pcg9><pcg9 id="682010018"><itemNumber>1866</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL Pk</dosageForm><drug id="09853766" insOH="Y" sec3="Y"><name>Humulin R</name><manufacturerId>LIL</manufacturerId><individualPrice>56.0200</individualPrice><listingDate>1998-12-15</listingDate><amountMOHLTCPays>56.0200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01575"><name>INSULIN ASPART</name><pcgGroup lccId="00146"><pcg9 id="682010023"><itemNumber>1867</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-10mL Pk</dosageForm><drug id="02245397" insOH="Y" sec3="Y" sec12="Y"><name>NovoRapid</name><manufacturerId>NOO</manufacturerId><individualPrice>31.9500</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>31.9500</amountMOHLTCPays></drug></pcg9><lccNote seq="005" reasonForUseId="646">Patient uses an insulin pump that has not been declared compatible with a funded biosimilar version by the insulin pump manufacturer&apos;s product labeling.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="682010054"><itemNumber>1868</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-10mL Vial Pk</dosageForm><drug id="02529254" insOH="Y" sec3="Y"><name>Trurapi</name><manufacturerId>SAC</manufacturerId><individualPrice>22.6430</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>22.6430</amountMOHLTCPays></drug></pcg9><pcg9 id="682010046"><itemNumber>1869</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL Cart Pk</dosageForm><drug id="02506564" insOH="Y" sec3="Y"><name>Trurapi</name><manufacturerId>SAC</manufacturerId><individualPrice>45.0000</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>45.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="682010049"><itemNumber>1870</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5X3mL Pref Pen Pk</dosageForm><drug id="02520974" insOH="Y" sec3="Y"><name>Kirsty</name><manufacturerId>BGP</manufacturerId><individualPrice>42.7125</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>42.7125</amountMOHLTCPays></drug></pcg9><pcg9 id="682010047"><itemNumber>1871</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL SoloSTAR Pref Pen Pk</dosageForm><drug id="02506572" insOH="Y" sec3="Y"><name>Trurapi</name><manufacturerId>SAC</manufacturerId><individualPrice>45.0000</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>45.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01758"><name>INSULIN GLULISINE (DNA ORIGIN)</name><pcgGroup><pcg9 id="682010030"><itemNumber>1872</itemNumber><strength>100U/mL</strength><dosageForm>Inj 5x3mL Cart ClickStar Pen</dosageForm><note>For the treatment of patients with Type 1 diabetes mellitus.

For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump.

For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on less intensive regimen of regular insulin (1-2 injections per day).</note><drug id="02279479" insOH="Y" sec3="Y"><name>Apidra</name><manufacturerId>SAV</manufacturerId><individualPrice>55.9500</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>55.9500</amountMOHLTCPays></drug></pcg9><pcg9 id="682010029"><itemNumber>1873</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-10mL Vial</dosageForm><note>Note:  
For the treatment of patients with Type 1 diabetes mellitus.

For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump.

For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on less intensive regimen of regular insulin (1-2 injections per day).
</note><drug id="02279460" insOH="Y" sec3="Y"><name>Apidra</name><manufacturerId>SAV</manufacturerId><individualPrice>28.2400</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>28.2400</amountMOHLTCPays></drug></pcg9><pcg9 id="682010028"><itemNumber>1874</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL SoloSTAR Pref Pen</dosageForm><note>For the treatment of patients with Type 1 diabetes mellitus.

For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day or an insulin pump.

For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on less intensive regimen of regular insulin (1-2 injections per day).
</note><drug id="02294346" insOH="Y" sec3="Y"><name>Apidra</name><manufacturerId>SAV</manufacturerId><individualPrice>56.4900</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>56.4900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00900"><name>INSULIN HUMAN BIOSYNTHETIC</name><pcgGroup><pcg9 id="682010013"><itemNumber>1875</itemNumber><strength>1000U/10mL</strength><dosageForm>Inj Sol-10mL Pk</dosageForm><drug id="02024233" insOH="Y" sec3="Y"><name>Novolin ge Toronto</name><manufacturerId>NOO</manufacturerId><individualPrice>25.2100</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>25.2100</amountMOHLTCPays></drug></pcg9><pcg9 id="682010019"><itemNumber>1876</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL Pk</dosageForm><drug id="09853774" insOH="Y" sec3="Y"><name>Novolin ge Toronto Penfill</name><manufacturerId>NOO</manufacturerId><individualPrice>49.5200</individualPrice><listingDate>1998-12-15</listingDate><amountMOHLTCPays>49.5200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02200"><name>INSULIN INJECTION, HUMAN BIOSYNTHETIC</name><pcgGroup><pcg9 id="682010048"><itemNumber>1877</itemNumber><strength>500U/mL</strength><dosageForm>Inj Sol-Pref Pen 2x3mL Pk</dosageForm><drug id="02466864" insOH="Y" sec3="Y"><name>Entuzity KwikPen</name><manufacturerId>LIL</manufacturerId><individualPrice>114.2200</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>114.2200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01373"><name>INSULIN LISPRO</name><pcgGroup lccId="00368"><pcg9 id="682010015"><itemNumber>1878</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-10mL Pk</dosageForm><drug id="02229704" insOH="Y" sec3="Y" sec12="Y"><name>Humalog</name><manufacturerId>LIL</manufacturerId><individualPrice>36.4200</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>36.4200</amountMOHLTCPays></drug></pcg9><lccNote seq="005" reasonForUseId="646">Patient uses an insulin pump that has not been declared compatible with a funded biosimilar version by the insulin pump manufacturer&apos;s product labeling.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="682010043"><itemNumber>1879</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-10mL Vial Pk</dosageForm><drug id="02469901" insOH="Y" sec3="Y"><name>Admelog</name><manufacturerId>SAC</manufacturerId><individualPrice>22.7000</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>22.7000</amountMOHLTCPays></drug></pcg9><pcg9 id="682010044"><itemNumber>1880</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL Cart Pk</dosageForm><drug id="02469898" insOH="Y" sec3="Y"><name>Admelog</name><manufacturerId>SAC</manufacturerId><individualPrice>45.0000</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>45.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="682010045"><itemNumber>1881</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL SoloSTAR Pref Pen Pk</dosageForm><drug id="02469871" insOH="Y" sec3="Y"><name>Admelog</name><manufacturerId>SAC</manufacturerId><individualPrice>45.0000</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>45.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="682010041"><itemNumber>1882</itemNumber><strength>200U/mL</strength><dosageForm>Inj Sol-Pref Pen 5x3mL Pk</dosageForm><note>Note: For the treatment of patients with Type 1 diabetes mellitus.

For the treatment of patients with Type 2 diabetes mellitus using insulin in an intensive regimen with 3 or more injections per day.

For the treatment of patients with Type 2 diabetes mellitus who are either experiencing recurrent hypoglycemia OR are unable to achieve adequate post-prandial glucose control while on less intensive regimen of regular insulin (1-2 injections per day).</note><drug id="02439611" insOH="Y" sec3="Y"><name>Humalog 200 units/mL KwikPen</name><manufacturerId>LIL</manufacturerId><individualPrice>133.7600</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>133.7600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="682012000"><name>ANTI-DIABETIC AGENTS INSULINS (INTERMEDIATE ACTING)</name><genericName id="00910"><name>INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC</name><pcgGroup><pcg9 id="682012013"><itemNumber>1883</itemNumber><strength>1000U/10mL</strength><dosageForm>Inj Susp-10mL Pk</dosageForm><drug id="02024225" insOH="Y" sec3="Y"><name>Novolin ge NPH</name><manufacturerId>NOO</manufacturerId><individualPrice>25.7800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>25.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="682012017"><itemNumber>1884</itemNumber><strength>100U/mL</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="09853782" insOH="Y" sec3="Y"><name>Novolin ge NPH Penfill</name><manufacturerId>NOO</manufacturerId><individualPrice>50.6900</individualPrice><listingDate>1998-12-15</listingDate><amountMOHLTCPays>50.6900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00908"><name>INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC (RDNA ORIGIN)</name><pcgGroup><pcg9 id="682012007"><itemNumber>1885</itemNumber><strength>1000U/10mL</strength><dosageForm>Inj Susp-10mL Pk</dosageForm><drug id="00587737" insOH="Y" sec3="Y"><name>Humulin NPH</name><manufacturerId>LIL</manufacturerId><individualPrice>29.9800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>29.9800</amountMOHLTCPays></drug></pcg9><pcg9 id="682012018"><itemNumber>1886</itemNumber><strength>100U/mL</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="09853804" insOH="Y" sec3="Y"><name>Humulin N</name><manufacturerId>LIL</manufacturerId><individualPrice>56.0200</individualPrice><listingDate>1998-12-15</listingDate><amountMOHLTCPays>56.0200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="682014000"><name>ANTI-DIABETIC AGENTS INSULINS (LONG ACTING)</name><genericName id="02060"><name>INSULIN DEGLUDEC</name><pcgGroup><pcg9 id="682014020"><itemNumber>1887</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-3X5mL Cart Pk</dosageForm><drug id="02467860" insOH="Y" sec3="Y"><name>Tresiba</name><manufacturerId>NOO</manufacturerId><individualPrice>114.1700</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>114.1700</amountMOHLTCPays></drug></pcg9><pcg9 id="682014016"><itemNumber>1888</itemNumber><strength>200U/mL</strength><dosageForm>Inj Sol-Flextouch Pref Pen 3x3mL Pk</dosageForm><drug id="02467887" insOH="Y" sec3="Y"><name>Tresiba</name><manufacturerId>NOO</manufacturerId><individualPrice>137.0100</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>137.0100</amountMOHLTCPays></drug></pcg9><pcg9 id="682014015"><itemNumber>1889</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-Flextouch Pref Pen 5x3mL Pk</dosageForm><drug id="02467879" insOH="Y" sec3="Y"><name>Tresiba</name><manufacturerId>NOO</manufacturerId><individualPrice>114.1700</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>114.1700</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01755"><name>INSULIN DETEMIR</name><pcgGroup><pcg9 id="682014007"><itemNumber>1890</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-5x3mL Pk</dosageForm><drug id="02271842" insOH="Y" sec3="Y"><name>Levemir Penfill</name><manufacturerId>NOO</manufacturerId><individualPrice>114.3600</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>114.3600</amountMOHLTCPays></drug></pcg9><pcg9 id="682014011"><itemNumber>1891</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-Pref Disp Pen 5X3mL Pk</dosageForm><drug id="02412829" insOH="Y" sec3="Y"><name>Levemir Flextouch</name><manufacturerId>NOO</manufacturerId><individualPrice>115.2900</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>115.2900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01667"><name>INSULIN GLARGINE</name><pcgGroup><pcg9 id="682014014"><itemNumber>1892</itemNumber><strength>300U/mL</strength><dosageForm>Inj Sol-1.5mL Pref Pen</dosageForm><drug id="02441829" insOH="Y" sec3="Y"><name>TOUJEO SoloSTAR</name><manufacturerId>SAC</manufacturerId><individualPrice>26.4333</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>26.4333</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00367"><pcg9 id="682014009"><itemNumber>1893</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-10mL Vial Pk</dosageForm><drug id="02245689" insOH="Y" sec3="Y" sec12="Y"><name>Lantus-(Vial)</name><manufacturerId>SAV</manufacturerId><individualPrice>61.6900</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>61.6900</amountMOHLTCPays></drug></pcg9><lccNote seq="005" reasonForUseId="644">Patient requires insulin therapy and is unable to use the insulin pen.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="682014019"><itemNumber>1894</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-3mL Pref Pen</dosageForm><drug id="02526441" insOH="Y" sec3="Y"><name>Semglee</name><manufacturerId>BGP</manufacturerId><individualPrice>12.7668</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>12.7668</amountMOHLTCPays></drug></pcg9><pcg9 id="682014018"><itemNumber>1895</itemNumber><strength>300U/mL</strength><dosageForm>Inj Sol-3mL Pref Pen</dosageForm><drug id="02493373" insOH="Y" sec3="Y"><name>Toujeo DoubleSTAR</name><manufacturerId>SAC</manufacturerId><individualPrice>52.8666</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>52.8666</amountMOHLTCPays></drug></pcg9><pcg9 id="682014012"><itemNumber>1896</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-Cartridge 5x3mL Pk</dosageForm><drug id="02444844" insOH="Y" sec3="Y"><name>Basaglar</name><manufacturerId>LIL</manufacturerId><individualPrice>83.0400</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>83.0400</amountMOHLTCPays></drug></pcg9><pcg9 id="682014017"><itemNumber>1897</itemNumber><strength>100U/mL</strength><dosageForm>Inj Sol-KwikPen (80U) Pref Pen 5x3mL Pk</dosageForm><drug id="02461528" insOH="Y" sec3="Y"><name>Basaglar</name><manufacturerId>LIL</manufacturerId><individualPrice>83.0400</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>83.0400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="682016000"><name>ANTI-DIABETIC AGENTS INSULINS (PRE-MIXED)</name><genericName id="00927"><name>INSULIN (30% NEUTRAL &amp; 70% ISOPHANE) HUMAN BIOSYNTHETIC</name><pcgGroup><pcg9 id="682016016"><itemNumber>1898</itemNumber><strength>1000U/10mL</strength><dosageForm>Inj Susp-10mL Pk</dosageForm><drug id="02024217" insOH="Y" sec3="Y"><name>Novolin ge 30/70</name><manufacturerId>NOO</manufacturerId><individualPrice>25.9100</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>25.9100</amountMOHLTCPays></drug></pcg9><pcg9 id="682016027"><itemNumber>1899</itemNumber><strength>100U/mL</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="09853812" insOH="Y" sec3="Y"><name>Novolin ge 30/70 Penfill</name><manufacturerId>NOO</manufacturerId><individualPrice>48.9900</individualPrice><listingDate>1998-12-15</listingDate><amountMOHLTCPays>48.9900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01757"><name>INSULIN ASPART 30% &amp; INSULIN ASPART PROTAMINE 70%</name><pcgGroup><pcg9 id="682016034"><itemNumber>1900</itemNumber><strength>100U/mL</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="02265435" insOH="Y" sec3="Y"><name>NovoMix 30 Penfill</name><manufacturerId>NOO</manufacturerId><individualPrice>59.4300</individualPrice><listingDate>2007-11-10</listingDate><amountMOHLTCPays>59.4300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00922"><name>INSULIN HUMAN BIOSYNTHETIC 30% &amp; ISOPHANE 70%</name><pcgGroup><pcg9 id="682016009"><itemNumber>1901</itemNumber><strength>1000U/10mL</strength><dosageForm>Inj Susp-10mL Pk</dosageForm><drug id="00795879" insOH="Y" sec3="Y"><name>Humulin 30/70</name><manufacturerId>LIL</manufacturerId><individualPrice>29.9800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>29.9800</amountMOHLTCPays></drug></pcg9><pcg9 id="682016030"><itemNumber>1902</itemNumber><strength>100U/mL</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="09853855" insOH="Y" sec3="Y"><name>Humulin 30/70</name><manufacturerId>LIL</manufacturerId><individualPrice>56.0200</individualPrice><listingDate>1998-12-15</listingDate><amountMOHLTCPays>56.0200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01440"><name>INSULIN LISPRO &amp; INSULIN LISPRO PROTAMINE</name><pcgGroup><pcg9 id="682016033"><itemNumber>1903</itemNumber><strength>25% &amp; 75%</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="02240294" insOH="Y" sec3="Y"><name>Humalog Mix25</name><manufacturerId>LIL</manufacturerId><individualPrice>73.2300</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>73.2300</amountMOHLTCPays></drug></pcg9><pcg9 id="682016036"><itemNumber>1904</itemNumber><strength>25% &amp; 75%</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="02403420" insOH="Y" sec3="Y"><name>Humalog Mix25 Kwikpen</name><manufacturerId>LIL</manufacturerId><individualPrice>72.6900</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>72.6900</amountMOHLTCPays></drug></pcg9><pcg9 id="682016035"><itemNumber>1905</itemNumber><strength>50% &amp; 50%</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="02240297" insOH="Y" sec3="Y"><name>Humalog Mix50</name><manufacturerId>LIL</manufacturerId><individualPrice>72.1100</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>72.1100</amountMOHLTCPays></drug></pcg9><pcg9 id="682016037"><itemNumber>1906</itemNumber><strength>50% &amp; 50%</strength><dosageForm>Inj Susp-5x3mL Pk</dosageForm><drug id="02403439" insOH="Y" sec3="Y"><name>Humalog Mix50 Kwikpen</name><manufacturerId>LIL</manufacturerId><individualPrice>71.4700</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>71.4700</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="682400000"><name>PARATHYROID AGENTS</name><genericName id="00935"><name>CALCITONIN (SALMON SYNTHETIC)</name><pcgGroup><pcg9 id="682400011"><itemNumber>1907</itemNumber><strength>100IU/mL</strength><dosageForm>Inj Sol-1mL Pk</dosageForm><drug id="02007134" sec3="Y"><name>Caltine 100</name><manufacturerId>FEI</manufacturerId><individualPrice>7.8200</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>7.8200</amountMOHLTCPays></drug></pcg9><pcg9 id="682400009"><itemNumber>1908</itemNumber><strength>400IU/2mL</strength><dosageForm>Inj Sol-2mL Pk</dosageForm><drug id="01926691" sec3="Y"><name>Calcimar</name><manufacturerId>SAV</manufacturerId><individualPrice>65.4400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>65.4400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01671"><name>TERIPARATIDE</name><pcgGroup lccId="00392"><pcg9 id="682400014"><itemNumber>1909</itemNumber><strength>250mcg/mL</strength><dosageForm>Inj Sol-2.4mL Pref Pen</dosageForm><drug id="02486423" sec3="Y" sec12="Y"><name>Teva-Teriparatide Injection</name><manufacturerId>TEV</manufacturerId><individualPrice>535.4700</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>535.4700</amountMOHLTCPays></drug><drug id="02498804" sec3="Y" sec12="Y"><name>Apo-Teriparatide Injection</name><manufacturerId>APX</manufacturerId><individualPrice>535.4700</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>535.4700</amountMOHLTCPays></drug><drug id="09857535" sec3="Y" sec12="Y"><name>Forteo</name><manufacturerId>LIL</manufacturerId><individualPrice>1238.8400</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>535.4700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="676">For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:

- 65 years of age or older; AND

- Has a documented bone mineral density [BMD] T-score of less than or equal to 3; AND

- Has a history of prior fragility fracture(s); AND

- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.

Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months</lccNote><lccNote seq="002" type="R">LU Authorization Period: 2 years</lccNote></pcgGroup><pcgGroup lccId="00361"><pcg9 id="682400015"><itemNumber>1910</itemNumber><strength>250mcg/mL</strength><dosageForm>Inj Sol-3mL Cart Pk</dosageForm><drug id="02495589" sec3="Y" sec12="Y"><name>Osnuvo</name><manufacturerId>AVP</manufacturerId><individualPrice>565.2600</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>565.2600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="635">For the treatment of osteoporosis in patients at a high risk of fragility fractures who meet ALL the following criteria:

- 65 years of age or older; AND

- Has a documented bone mineral density [BMD] T-score of less than or equal to 3; AND

- Has a history of prior fragility fracture(s); AND

- Has used an anti-resorptive agent for osteoporosis which resulted in osteonecrosis of the jaw and/or an atypical femur fracture.

Note: The maximum lifetime exposure to teriparatide for an individual patient is 24 months</lccNote><lccNote seq="002" type="R">LU Authorization Period: 2 years</lccNote></pcgGroup></genericName></pcg6><pcg6 id="682800000"><name>PITUITARY AGENTS</name><genericName id="00936"><name>DESMOPRESSIN ACETATE</name><pcgGroup><pcg9 id="682800007"><itemNumber>1911</itemNumber><strength>4mcg/mL</strength><dosageForm>Inj Sol-1mL Amp Pk</dosageForm><drug id="00873993" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>DDAVP</name><manufacturerId>RIP</manufacturerId><listingDate>2021-12-17</listingDate></drug><drug id="02513579" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Bipazen</name><manufacturerId>KVR</manufacturerId><individualPrice>9.0000</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>9.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="682800005"><itemNumber>1912</itemNumber><strength>0.1mg/mL</strength><dosageForm>Nas Sol-2.5mL Pk</dosageForm><drug id="00402516" sec3="Y"><name>DDAVP</name><manufacturerId>FEI</manufacturerId><individualPrice>52.0375</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>52.0375</amountMOHLTCPays></drug></pcg9><pcg9 id="682800006"><itemNumber>1913</itemNumber><strength>10mcg/Metered Dose</strength><dosageForm>Nas Sp-2.5mL Pk</dosageForm><drug id="00836362" notABenefit="Y" sec3="Y"><name>DDAVP</name><manufacturerId>FEI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242465" sec3="Y"><name>Desmopressin Spray</name><manufacturerId>AAP</manufacturerId><individualPrice>42.1661</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>42.1661</amountMOHLTCPays></drug></pcg9><pcg9 id="682800028"><itemNumber>1914</itemNumber><strength>240mcg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02285010" sec3="Y"><name>DDAVP Melt</name><manufacturerId>FEI</manufacturerId><individualPrice>3.9382</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>3.9382</amountMOHLTCPays></drug></pcg9><pcg9 id="682800026"><itemNumber>1915</itemNumber><strength>60mcg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02284995" sec3="Y"><name>DDAVP Melt</name><manufacturerId>FEI</manufacturerId><individualPrice>1.4556</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>1.4556</amountMOHLTCPays></drug></pcg9><pcg9 id="682800027"><itemNumber>1916</itemNumber><strength>120mcg</strength><dosageForm>Orally Disintegrating Tab</dosageForm><drug id="02285002" sec3="Y"><name>DDAVP Melt</name><manufacturerId>FEI</manufacturerId><individualPrice>2.9121</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>2.9121</amountMOHLTCPays></drug></pcg9><pcg9 id="682800010"><itemNumber>1917</itemNumber><strength>0.1mg</strength><dosageForm>Tab</dosageForm><drug id="00824305" sec3="Y"><name>DDAVP</name><manufacturerId>FEI</manufacturerId><individualPrice>1.3217</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.6609</amountMOHLTCPays></drug><drug id="02284030" sec3="Y"><name>Apo-Desmopressin</name><manufacturerId>APX</manufacturerId><individualPrice>.6609</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.6609</amountMOHLTCPays></drug><drug id="02304368" sec3="Y"><name>PMS-Desmopressin</name><manufacturerId>PMS</manufacturerId><individualPrice>.6609</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.6609</amountMOHLTCPays></drug></pcg9><pcg9 id="682800011"><itemNumber>1918</itemNumber><strength>0.2mg</strength><dosageForm>Tab</dosageForm><drug id="00824143" sec3="Y"><name>DDAVP</name><manufacturerId>FEI</manufacturerId><individualPrice>2.6434</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>1.3217</amountMOHLTCPays></drug><drug id="02284049" sec3="Y"><name>Apo-Desmopressin</name><manufacturerId>APX</manufacturerId><individualPrice>1.3217</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>1.3217</amountMOHLTCPays></drug><drug id="02304376" sec3="Y"><name>PMS-Desmopressin</name><manufacturerId>PMS</manufacturerId><individualPrice>1.3217</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>1.3217</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01580"><name>THYROTROPIN ALFA</name><pcgGroup><pcg9 id="682800013"><itemNumber>1919</itemNumber><strength>0.9mg/mL</strength><dosageForm>Inj Pd-2x1.1mg Vial Pk</dosageForm><drug id="02246016" sec3="Y"><name>Thyrogen</name><manufacturerId>GZM</manufacturerId><individualPrice>1887.4200</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>1887.4200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="683200000"><name>PROGESTOGENS AND ORAL CONTRACEPTIVES</name><genericName id="01388"><name>CYPROTERONE ACETATE &amp; ETHINYL ESTRADIOL</name><pcgGroup><pcg9 id="683200100"><itemNumber>1920</itemNumber><strength>2mg &amp; 0.035mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02233542" notABenefit="Y" sec3b="Y" sec3="Y"><name>Diane-35</name><manufacturerId>BAY</manufacturerId><listingDate>2007-12-19</listingDate></drug><drug id="02290308" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cyestra-35</name><manufacturerId>PAL</manufacturerId><individualPrice>23.3394</individualPrice><listingDate>2007-12-19</listingDate></drug><drug id="02309556" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Cyproterone/Ethinyl Estradiol</name><manufacturerId>TEV</manufacturerId><individualPrice>23.3400</individualPrice><listingDate>2008-12-03</listingDate></drug><drug id="02425017" notABenefit="Y" sec3b="Y" sec3="Y"><name>Ran-Cyproterone/Ethinyl Estradiol</name><manufacturerId>RAN</manufacturerId><individualPrice>23.3394</individualPrice><listingDate>2015-05-28</listingDate></drug><drug id="02436736" notABenefit="Y" sec3b="Y" sec3="Y"><name>Cleo-35</name><manufacturerId>ALH</manufacturerId><individualPrice>23.3394</individualPrice><listingDate>2024-10-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00952"><name>DESOGESTREL &amp; ETHINYL ESTRADIOL</name><pcgGroup><pcg9 id="683200094"><itemNumber>1921</itemNumber><strength>0.15mg &amp; 0.03mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02042487" sec3="Y"><name>Marvelon 21</name><manufacturerId>ORG</manufacturerId><individualPrice>21.1050</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>5.2773</amountMOHLTCPays></drug><drug id="02317192" sec3="Y"><name>Apri 21</name><manufacturerId>BAR</manufacturerId><individualPrice>5.2773</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>5.2773</amountMOHLTCPays></drug><drug id="02396491" sec3="Y"><name>Freya 21</name><manufacturerId>FAM</manufacturerId><individualPrice>5.2773</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>5.2773</amountMOHLTCPays></drug><drug id="02410249" sec3="Y"><name>Mirvala 21</name><manufacturerId>APX</manufacturerId><individualPrice>5.2773</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>5.2773</amountMOHLTCPays></drug><drug id="02556553" sec3="Y"><name>Miley 21</name><manufacturerId>AMB</manufacturerId><individualPrice>5.2773</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>5.2773</amountMOHLTCPays></drug></pcg9><pcg9 id="683200093"><itemNumber>1922</itemNumber><strength>0.15mg &amp; 0.03mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02042479" sec3="Y"><name>Marvelon 28</name><manufacturerId>ORG</manufacturerId><individualPrice>21.1050</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>5.2780</amountMOHLTCPays></drug><drug id="02317206" sec3="Y"><name>Apri 28</name><manufacturerId>BAR</manufacturerId><individualPrice>5.2780</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>5.2780</amountMOHLTCPays></drug><drug id="02396610" sec3="Y"><name>Freya 28</name><manufacturerId>FAM</manufacturerId><individualPrice>5.2780</individualPrice><listingDate>2013-05-31</listingDate><amountMOHLTCPays>5.2780</amountMOHLTCPays></drug><drug id="02410257" sec3="Y"><name>Mirvala 28</name><manufacturerId>APX</manufacturerId><individualPrice>5.2780</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>5.2780</amountMOHLTCPays></drug><drug id="02556561" sec3="Y"><name>Miley 28</name><manufacturerId>AMB</manufacturerId><individualPrice>5.2780</individualPrice><listingDate>2025-10-31</listingDate><amountMOHLTCPays>5.2780</amountMOHLTCPays></drug></pcg9><pcg9 id="683200113"><itemNumber>1923</itemNumber><strength>3 Phase</strength><dosageForm>Tabs-21 Pk</dosageForm><drug id="02272903" sec3="Y"><name>Linessa 21</name><manufacturerId>ASN</manufacturerId><individualPrice>19.7888</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>19.7888</amountMOHLTCPays></drug></pcg9><pcg9 id="683200114"><itemNumber>1924</itemNumber><strength>3 Phase</strength><dosageForm>Tabs-28 Pk</dosageForm><drug id="02257238" sec3="Y"><name>Linessa 28</name><manufacturerId>ASN</manufacturerId><individualPrice>19.7941</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>19.7941</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01887"><name>DIENOGEST</name><pcgGroup lccId="00223"><pcg9 id="683200112"><itemNumber>1925</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02374900" sec3="Y" sec12="Y"><name>Visanne</name><manufacturerId>BAH</manufacturerId><individualPrice>2.1876</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.5115</amountMOHLTCPays></drug><drug id="02493055" sec3="Y" sec12="Y"><name>Aspen-Dienogest</name><manufacturerId>ASI</manufacturerId><individualPrice>.5115</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.5115</amountMOHLTCPays></drug><drug id="02498189" sec3="Y" sec12="Y"><name>Jamp Dienogest</name><manufacturerId>JPC</manufacturerId><individualPrice>.5115</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.5115</amountMOHLTCPays></drug><drug id="02543613" sec3="Y" sec12="Y"><name>M-Dienogest</name><manufacturerId>MAT</manufacturerId><individualPrice>.5115</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.5115</amountMOHLTCPays></drug><drug id="02551683" sec3="Y" sec12="Y"><name>Mar-Dienogest</name><manufacturerId>MAR</manufacturerId><individualPrice>.5115</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>.5115</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="432">For the management of pelvic pain associated with endometriosis in patients for whom one or more less costly options are either ineffective or cannot be used.

Note: For example for patients who are refractory to 6 months of continuous combined oral contraceptives and/or medroxyprogesterone therapy OR have contraindications to these therapies.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02410"><name>DROSPIRENONE</name><pcgGroup><pcg9 id="683200119"><itemNumber>1926</itemNumber><strength>4mg</strength><dosageForm>Tab-28 Tab Pk</dosageForm><drug id="02522802" sec3="Y"><name>Slynd</name><manufacturerId>DUI</manufacturerId><individualPrice>12.6600</individualPrice><listingDate>2024-11-29</listingDate><amountMOHLTCPays>12.6600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01706"><name>DROSPIRENONE &amp; ETHINYL ESTRADIOL</name><pcgGroup><pcg9 id="683200107"><itemNumber>1927</itemNumber><strength>3.0mg &amp; 0.03mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02261723" sec3="Y"><name>Yasmin 21</name><manufacturerId>BAH</manufacturerId><individualPrice>12.4400</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>6.2181</amountMOHLTCPays></drug><drug id="02410788" sec3="Y"><name>Zamine 21</name><manufacturerId>APX</manufacturerId><individualPrice>6.2181</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>6.2181</amountMOHLTCPays></drug><drug id="02421437" sec3="Y"><name>Drospirenone&amp;Ethinyl Estradiol USP 21</name><manufacturerId>GLP</manufacturerId><individualPrice>6.2181</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>6.2181</amountMOHLTCPays></drug></pcg9><pcg9 id="683200111"><itemNumber>1928</itemNumber><strength>3.0mg &amp; 0.02mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02321157" sec3="Y"><name>Yaz</name><manufacturerId>BAH</manufacturerId><individualPrice>16.5200</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>8.2600</amountMOHLTCPays></drug><drug id="02415380" sec3="Y"><name>MYA</name><manufacturerId>APX</manufacturerId><individualPrice>8.2600</individualPrice><listingDate>2014-08-28</listingDate><amountMOHLTCPays>8.2600</amountMOHLTCPays></drug><drug id="02462060" sec3="Y"><name>Drospirenone&amp;Ethinyl Estradiol USP</name><manufacturerId>GLP</manufacturerId><individualPrice>8.2600</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>8.2600</amountMOHLTCPays></drug></pcg9><pcg9 id="683200108"><itemNumber>1929</itemNumber><strength>3.0mg &amp; 0.03mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02261731" sec3="Y"><name>Yasmin 28</name><manufacturerId>BAH</manufacturerId><individualPrice>12.4400</individualPrice><listingDate>2007-06-06</listingDate><amountMOHLTCPays>6.2188</amountMOHLTCPays></drug><drug id="02410796" sec3="Y"><name>Zamine 28</name><manufacturerId>APX</manufacturerId><individualPrice>6.2188</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>6.2188</amountMOHLTCPays></drug><drug id="02421445" sec3="Y"><name>Drospirenone&amp;Ethinyl Estradiol USP 28</name><manufacturerId>GLP</manufacturerId><individualPrice>6.2188</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>6.2188</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00945"><name>ETHINYL ESTRADIOL &amp; LEVONORGESTREL</name><pcgGroup><pcg9 id="683200102"><itemNumber>1930</itemNumber><strength>20mcg &amp; 100mcg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02236974" sec3="Y"><name>Alesse 21</name><manufacturerId>PFI</manufacturerId><individualPrice>15.7700</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02298538" sec3="Y"><name>Aviane 21</name><manufacturerId>TEV</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02387875" sec3="Y"><name>Alysena 21</name><manufacturerId>APX</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02424282" sec3="Y"><name>Laylaa 21</name><manufacturerId>LUP</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02532174" sec3="Y"><name>Audrina 21</name><manufacturerId>JPC</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug></pcg9><pcg9 id="683200064"><itemNumber>1931</itemNumber><strength>0.03mg &amp; 0.15mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02042320" sec3="Y"><name>Min-Ovral 21</name><manufacturerId>PFI</manufacturerId><individualPrice>19.2900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>7.2800</amountMOHLTCPays></drug><drug id="02295946" sec3="Y"><name>Portia 21</name><manufacturerId>BAR</manufacturerId><individualPrice>10.6600</individualPrice><listingDate>2007-10-03</listingDate><amountMOHLTCPays>7.2800</amountMOHLTCPays></drug><drug id="02387085" sec3="Y"><name>Ovima 21</name><manufacturerId>APX</manufacturerId><individualPrice>7.2800</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>7.2800</amountMOHLTCPays></drug></pcg9><pcg9 id="683200066"><itemNumber>1932</itemNumber><strength>3 Phase</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="00707600" sec3="Y"><name>Triquilar 21</name><manufacturerId>BAY</manufacturerId><individualPrice>15.7500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>15.7500</amountMOHLTCPays></drug></pcg9><pcg9 id="683200103"><itemNumber>1933</itemNumber><strength>20mcg &amp; 100mcg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02236975" sec3="Y"><name>Alesse 28</name><manufacturerId>PFI</manufacturerId><individualPrice>15.7700</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02298546" sec3="Y"><name>Aviane 28</name><manufacturerId>TEV</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2008-01-15</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02387883" sec3="Y"><name>Alysena 28</name><manufacturerId>APX</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02424290" sec3="Y"><name>Laylaa 28</name><manufacturerId>LUP</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug><drug id="02532182" sec3="Y"><name>Audrina 28</name><manufacturerId>JPC</manufacturerId><individualPrice>3.9425</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>3.9425</amountMOHLTCPays></drug></pcg9><pcg9 id="683200065"><itemNumber>1934</itemNumber><strength>0.03mg &amp; 0.15mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02042339" sec3="Y"><name>Min-Ovral 28</name><manufacturerId>PFI</manufacturerId><individualPrice>19.2900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>7.2800</amountMOHLTCPays></drug><drug id="02295954" sec3="Y"><name>Portia 28</name><manufacturerId>BAR</manufacturerId><individualPrice>10.6600</individualPrice><listingDate>2007-10-03</listingDate><amountMOHLTCPays>7.2800</amountMOHLTCPays></drug><drug id="02387093" sec3="Y"><name>Ovima 28</name><manufacturerId>APX</manufacturerId><individualPrice>7.2800</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>7.2800</amountMOHLTCPays></drug></pcg9><pcg9 id="683200067"><itemNumber>1935</itemNumber><strength>3 Phase</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="00707503" sec3="Y"><name>Triquilar 28</name><manufacturerId>BAY</manufacturerId><individualPrice>15.7500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>15.7500</amountMOHLTCPays></drug></pcg9><pcg9 id="683200116"><itemNumber>1936</itemNumber><strength>0.03mg &amp; 0.15mg</strength><dosageForm>Tab-91 Pk</dosageForm><drug id="02296659" notABenefit="Y" sec3b="Y" sec3="Y"><name>Seasonale</name><manufacturerId>TEW</manufacturerId><listingDate>2016-11-30</listingDate></drug><drug id="02398869" notABenefit="Y" sec3b="Y" sec3="Y"><name>Indayo</name><manufacturerId>MYL</manufacturerId><individualPrice>45.9550</individualPrice><listingDate>2016-11-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00944"><name>ETHINYL ESTRADIOL &amp; NORETHINDRONE</name><pcgGroup><pcg9 id="683200049"><itemNumber>1937</itemNumber><strength>0.035mg &amp; 0.5mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02187086" sec3="Y"><name>Brevicon</name><manufacturerId>PFI</manufacturerId><individualPrice>16.4500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="683200053"><itemNumber>1938</itemNumber><strength>0.035mg &amp; 1mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02189054" sec3="Y"><name>Brevicon 1/35</name><manufacturerId>PFI</manufacturerId><individualPrice>16.4500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="683200059"><itemNumber>1939</itemNumber><strength>3 Phase</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02187108" sec3="Y"><name>Synphasic</name><manufacturerId>PFI</manufacturerId><individualPrice>13.6400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>13.6400</amountMOHLTCPays></drug></pcg9><pcg9 id="683200050"><itemNumber>1940</itemNumber><strength>0.035mg &amp; 0.5mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02187094" sec3="Y"><name>Brevicon</name><manufacturerId>PFI</manufacturerId><individualPrice>16.4500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="683200054"><itemNumber>1941</itemNumber><strength>0.035mg &amp; 1mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02189062" sec3="Y"><name>Brevicon 1/35</name><manufacturerId>PFI</manufacturerId><individualPrice>16.4500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="683200060"><itemNumber>1942</itemNumber><strength>3 Phase</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02187116" sec3="Y"><name>Synphasic</name><manufacturerId>PFI</manufacturerId><individualPrice>13.6400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>13.6400</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00940"><name>ETHINYL ESTRADIOL &amp; NORETHINDRONE ACETATE</name><pcgGroup><pcg9 id="683200045"><itemNumber>1943</itemNumber><strength>0.02mg &amp; 1mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="00315966" sec3="Y"><name>Minestrin 1/20</name><manufacturerId>WAR</manufacturerId><individualPrice>16.9915</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.9915</amountMOHLTCPays></drug></pcg9><pcg9 id="683200006"><itemNumber>1944</itemNumber><strength>0.03mg &amp; 1.5mg</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="00297143" sec3="Y"><name>Loestrin 1.5/30</name><manufacturerId>WAR</manufacturerId><individualPrice>16.9915</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.9915</amountMOHLTCPays></drug></pcg9><pcg9 id="683200046"><itemNumber>1945</itemNumber><strength>0.02mg &amp; 1mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="00343838" sec3="Y"><name>Minestrin 1/20</name><manufacturerId>WAR</manufacturerId><individualPrice>16.9915</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.9915</amountMOHLTCPays></drug></pcg9><pcg9 id="683200048"><itemNumber>1946</itemNumber><strength>0.03mg &amp; 1.5mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="00353027" sec3="Y"><name>Loestrin 1.5/30</name><manufacturerId>WAR</manufacturerId><individualPrice>16.9915</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>16.9915</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00951"><name>LEVONORGESTREL</name><pcgGroup><pcg9 id="683200115"><itemNumber>1947</itemNumber><strength>1.5mg</strength><dosageForm>Tab-1 Tab Pk</dosageForm><drug id="02293854" sec3="Y"><name>Plan B</name><manufacturerId>TBP</manufacturerId><individualPrice>17.2000</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>4.3000</amountMOHLTCPays></drug><drug id="02425009" sec3="Y"><name>Contingency One</name><manufacturerId>MYL</manufacturerId><individualPrice>4.3000</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>4.3000</amountMOHLTCPays></drug><drug id="02433532" sec3="Y"><name>Backup Plan Onestep</name><manufacturerId>APX</manufacturerId><individualPrice>4.3000</individualPrice><listingDate>2017-06-29</listingDate><amountMOHLTCPays>4.3000</amountMOHLTCPays></drug><drug id="02548461" sec3="Y"><name>MyStep</name><manufacturerId>JPC</manufacturerId><individualPrice>4.3000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>4.3000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00941"><name>MEDROXYPROGESTERONE ACETATE</name><pcgGroup><pcg9 id="683200117"><itemNumber>1948</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr</dosageForm><drug id="09858134" sec3c="Y"><name>Depo-Provera</name><manufacturerId>PFI</manufacturerId><individualPrice>31.6900</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>31.6900</amountMOHLTCPays></drug></pcg9><pcg9 id="683200118"><itemNumber>1949</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr</dosageForm><drug id="02523493" sec3c="Y"><name>Depo-Provera</name><manufacturerId>PFI</manufacturerId><individualPrice>34.1400</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>34.1400</amountMOHLTCPays></drug></pcg9><pcg9 id="683200069"><itemNumber>1950</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="00708917" sec3="Y"><name>Provera</name><manufacturerId>PFI</manufacturerId><individualPrice>.2567</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1301</amountMOHLTCPays></drug><drug id="02244726" sec3="Y"><name>AA-Medroxy</name><manufacturerId>AAP</manufacturerId><individualPrice>.1301</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.1301</amountMOHLTCPays></drug></pcg9><pcg9 id="683200011"><itemNumber>1951</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00030937" sec3="Y"><name>Provera</name><manufacturerId>PFI</manufacturerId><individualPrice>.5274</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2602</amountMOHLTCPays></drug><drug id="02244727" sec3="Y"><name>AA-Medroxy</name><manufacturerId>AAP</manufacturerId><individualPrice>.2602</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2602</amountMOHLTCPays></drug></pcg9><pcg9 id="683200061"><itemNumber>1952</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="00729973" sec3="Y"><name>Provera</name><manufacturerId>PFI</manufacturerId><individualPrice>1.0271</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5649</amountMOHLTCPays></drug><drug id="02277298" sec3="Y"><name>AA-Medroxy</name><manufacturerId>AAP</manufacturerId><individualPrice>.5649</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.5649</amountMOHLTCPays></drug></pcg9><pcg9 id="683200037"><itemNumber>1953</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00030945" notABenefit="Y" sec3="Y"><name>Provera</name><manufacturerId>PFI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02267640" sec3="Y"><name>AA-Medroxy</name><manufacturerId>AAP</manufacturerId><individualPrice>1.2057</individualPrice><listingDate>2005-10-06</listingDate><amountMOHLTCPays>1.2057</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00943"><name>NORETHINDRONE</name><pcgGroup><pcg9 id="683200031"><itemNumber>1954</itemNumber><strength>0.35mg</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="00037605" notABenefit="Y" sec3="Y"><name>Micronor</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02410303" sec3="Y"><name>Movisse</name><manufacturerId>MYL</manufacturerId><individualPrice>10.9900</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>10.9900</amountMOHLTCPays></drug><drug id="02441306" sec3="Y"><name>Jencycla</name><manufacturerId>LUP</manufacturerId><individualPrice>10.9900</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>10.9900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00949"><name>NORGESTIMATE &amp; ETHINYL ESTRADIOL</name><pcgGroup><pcg9 id="683200082"><itemNumber>1955</itemNumber><strength>3 Phase</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02028700" notABenefit="Y" sec3="Y"><name>Tri-Cyclen</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02486296" sec3="Y"><name>Tri-Jordyna 21</name><manufacturerId>GLP</manufacturerId><individualPrice>14.3900</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>14.3900</amountMOHLTCPays></drug><drug id="02508087" sec3="Y"><name>Tri-Cira 21</name><manufacturerId>APX</manufacturerId><individualPrice>14.3900</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>14.3900</amountMOHLTCPays></drug></pcg9><pcg9 id="683200109"><itemNumber>1956</itemNumber><strength>3 Phase</strength><dosageForm>Tab-21 Pk</dosageForm><drug id="02258560" notABenefit="Y" sec3="Y"><name>Tri-Cyclen Lo</name><manufacturerId>JAN</manufacturerId><listingDate>2008-02-12</listingDate></drug><drug id="02401967" sec3="Y"><name>Tricira Lo (21 Day)</name><manufacturerId>APX</manufacturerId><individualPrice>13.3900</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>13.3900</amountMOHLTCPays></drug></pcg9><pcg9 id="683200083"><itemNumber>1957</itemNumber><strength>3 Phase</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02029421" notABenefit="Y" sec3="Y"><name>Tri-Cyclen</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02486318" sec3="Y"><name>Tri-Jordyna 28</name><manufacturerId>GLP</manufacturerId><individualPrice>14.3900</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>14.3900</amountMOHLTCPays></drug><drug id="02508095" sec3="Y"><name>Tri-Cira 28</name><manufacturerId>APX</manufacturerId><individualPrice>14.3900</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>14.3900</amountMOHLTCPays></drug></pcg9><pcg9 id="683200110"><itemNumber>1958</itemNumber><strength>3 Phase</strength><dosageForm>Tab-28 Pk</dosageForm><drug id="02258587" notABenefit="Y" sec3="Y"><name>Tri-Cyclen Lo</name><manufacturerId>JAN</manufacturerId><listingDate>2008-02-12</listingDate></drug><drug id="02401975" sec3="Y"><name>Tricira Lo (28 Day)</name><manufacturerId>APX</manufacturerId><individualPrice>13.3900</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>13.3900</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00948"><name>PROGESTERONE</name><pcgGroup><pcg9 id="683200098"><itemNumber>1959</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02166704" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Prometrium</name><manufacturerId>OCI</manufacturerId><listingDate>2015-07-29</listingDate></drug><drug id="02439913" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Progesterone</name><manufacturerId>TEV</manufacturerId><individualPrice>1.4358</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>1.4358</amountMOHLTCPays></drug><drug id="02463113" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Reddy-Progesterone</name><manufacturerId>DRR</manufacturerId><individualPrice>1.4358</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>1.4358</amountMOHLTCPays></drug><drug id="02476576" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Progesterone</name><manufacturerId>PMS</manufacturerId><individualPrice>1.4358</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>1.4358</amountMOHLTCPays></drug><drug id="02493578" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Progesterone</name><manufacturerId>AUR</manufacturerId><individualPrice>1.4358</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>1.4358</amountMOHLTCPays></drug><drug id="02516187" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Progesterone</name><manufacturerId>SAI</manufacturerId><individualPrice>1.4358</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>1.4358</amountMOHLTCPays></drug><drug id="02551268" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Progesterone</name><manufacturerId>MAT</manufacturerId><individualPrice>1.4358</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>1.4358</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="683600000"><name>THYROIDS</name><genericName id="00953"><name>LEVOTHYROXINE (SODIUM)</name><pcgGroup><pcg9 id="683600031"><itemNumber>1960</itemNumber><strength>0.137mg</strength><dosageForm>Tab</dosageForm><drug id="02233852" notABenefit="Y" sec3b="Y" sec3="Y"><name>Synthroid</name><manufacturerId>BGP</manufacturerId><listingDate>2025-04-30</listingDate></drug><drug id="02550776" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.1906</individualPrice><listingDate>2025-04-30</listingDate></drug></pcg9><pcg9 id="683600016"><itemNumber>1961</itemNumber><strength>0.025mg</strength><dosageForm>Tab</dosageForm><drug id="02172062" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1129</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0597</amountMOHLTCPays></drug><drug id="02550709" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0597</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0597</amountMOHLTCPays></drug></pcg9><pcg9 id="683600004"><itemNumber>1962</itemNumber><strength>0.05mg</strength><dosageForm>Tab</dosageForm><drug id="02172070" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.0775</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0373</amountMOHLTCPays></drug><drug id="02213192" sec3="Y"><name>Eltroxin</name><manufacturerId>ASN</manufacturerId><individualPrice>.0373</individualPrice><listingDate>1997-07-12</listingDate><amountMOHLTCPays>.0373</amountMOHLTCPays></drug><drug id="02550717" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0373</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0373</amountMOHLTCPays></drug></pcg9><pcg9 id="683600017"><itemNumber>1963</itemNumber><strength>0.075mg</strength><dosageForm>Tab</dosageForm><drug id="02172089" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1220</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0646</amountMOHLTCPays></drug><drug id="02550725" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0646</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0646</amountMOHLTCPays></drug></pcg9><pcg9 id="683600024"><itemNumber>1964</itemNumber><strength>0.088mg</strength><dosageForm>Tab</dosageForm><drug id="02172097" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1220</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.0646</amountMOHLTCPays></drug><drug id="02550733" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0646</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0646</amountMOHLTCPays></drug></pcg9><pcg9 id="683600003"><itemNumber>1965</itemNumber><strength>0.1mg</strength><dosageForm>Tab</dosageForm><drug id="02172100" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.0956</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0460</amountMOHLTCPays></drug><drug id="02213206" sec3="Y"><name>Eltroxin</name><manufacturerId>ASN</manufacturerId><individualPrice>.0460</individualPrice><listingDate>1997-07-12</listingDate><amountMOHLTCPays>.0460</amountMOHLTCPays></drug><drug id="02534681" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0460</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0460</amountMOHLTCPays></drug></pcg9><pcg9 id="683600018"><itemNumber>1966</itemNumber><strength>0.112mg</strength><dosageForm>Tab</dosageForm><drug id="02171228" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1289</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0682</amountMOHLTCPays></drug><drug id="02550741" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0682</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0682</amountMOHLTCPays></drug></pcg9><pcg9 id="683600019"><itemNumber>1967</itemNumber><strength>0.125mg</strength><dosageForm>Tab</dosageForm><drug id="02172119" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1304</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0690</amountMOHLTCPays></drug><drug id="02550768" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0690</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0690</amountMOHLTCPays></drug></pcg9><pcg9 id="683600011"><itemNumber>1968</itemNumber><strength>0.15mg</strength><dosageForm>Tab</dosageForm><drug id="02172127" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1028</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0495</amountMOHLTCPays></drug><drug id="02213214" sec3="Y"><name>Eltroxin</name><manufacturerId>ASN</manufacturerId><individualPrice>.0495</individualPrice><listingDate>1997-01-20</listingDate><amountMOHLTCPays>.0495</amountMOHLTCPays></drug><drug id="02550784" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0495</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0495</amountMOHLTCPays></drug></pcg9><pcg9 id="683600020"><itemNumber>1969</itemNumber><strength>0.175mg</strength><dosageForm>Tab</dosageForm><drug id="02172135" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1398</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0740</amountMOHLTCPays></drug><drug id="02550792" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0740</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0740</amountMOHLTCPays></drug></pcg9><pcg9 id="683600002"><itemNumber>1970</itemNumber><strength>0.2mg</strength><dosageForm>Tab</dosageForm><drug id="02172143" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1092</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0526</amountMOHLTCPays></drug><drug id="02213222" sec3="Y"><name>Eltroxin</name><manufacturerId>ASN</manufacturerId><individualPrice>.0526</individualPrice><listingDate>1997-01-20</listingDate><amountMOHLTCPays>.0526</amountMOHLTCPays></drug><drug id="02550806" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0526</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0526</amountMOHLTCPays></drug></pcg9><pcg9 id="683600001"><itemNumber>1971</itemNumber><strength>0.3mg</strength><dosageForm>Tab</dosageForm><drug id="02172151" sec3="Y"><name>Synthroid</name><manufacturerId>ABB</manufacturerId><individualPrice>.1506</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0797</amountMOHLTCPays></drug><drug id="02534703" sec3="Y"><name>Apo-Levothyroxine</name><manufacturerId>APX</manufacturerId><individualPrice>.0797</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.0797</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00954"><name>LIOTHYRONINE (SODIUM)</name><pcgGroup><pcg9 id="683600007"><itemNumber>1972</itemNumber><strength>5mcg</strength><dosageForm>Tab</dosageForm><drug id="01919458" sec3b="Y" sec3="Y"><name>Cytomel</name><manufacturerId>SKB</manufacturerId><listingDate>2020-09-30</listingDate></drug><drug id="02494337" sec3b="Y" sec3="Y"><name>Teva-Liothyronine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.1587</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>1.1587</amountMOHLTCPays></drug><drug id="02549999" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Liothyronine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1587</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>1.1587</amountMOHLTCPays></drug></pcg9><pcg9 id="683600006"><itemNumber>1973</itemNumber><strength>25mcg</strength><dosageForm>Tab</dosageForm><drug id="01919466" sec3b="Y" sec3="Y"><name>Cytomel</name><manufacturerId>SKB</manufacturerId><listingDate>2020-09-30</listingDate></drug><drug id="02494345" sec3b="Y" sec3="Y"><name>Teva-Liothyronine</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2595</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>1.2595</amountMOHLTCPays></drug><drug id="02550008" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Liothyronine</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2595</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>1.2595</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00959"><name>PROPYLTHIOURACIL</name><pcgGroup><pcg9 id="683600027"><itemNumber>1974</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="09858122" sec3c="Y"><name>PTU</name><manufacturerId>PHB</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="683600028"><itemNumber>1975</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="09858135" sec3c="Y"><name>Propylthiouracil</name><manufacturerId>ACP</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="683600029"><itemNumber>1976</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02521059" sec3c="Y"><name>Halycil</name><manufacturerId>HAL</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="683600030"><itemNumber>1977</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02523019" sec3c="Y"><name>Propylthiouracil Tablets</name><manufacturerId>PHB</manufacturerId><individualPrice>.5000</individualPrice><listingDate>2022-12-21</listingDate><amountMOHLTCPays>.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="683800000"><name>ANTI-THYROIDS</name><genericName id="00958"><name>METHIMAZOLE</name><pcgGroup><pcg9 id="683800001"><itemNumber>1978</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00015741" sec3="Y"><name>Tapazole</name><manufacturerId>PAL</manufacturerId><individualPrice>.3696</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1531</amountMOHLTCPays></drug><drug id="02480107" sec3="Y"><name>Mar-Methimazole</name><manufacturerId>MAR</manufacturerId><individualPrice>.1531</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.1531</amountMOHLTCPays></drug><drug id="02490625" sec3="Y"><name>Jamp Methimazole</name><manufacturerId>JPC</manufacturerId><individualPrice>.1531</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.1531</amountMOHLTCPays></drug></pcg9><pcg9 id="683800004"><itemNumber>1979</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02296039" notABenefit="Y" sec3b="Y" sec3="Y"><name>Tapazole</name><manufacturerId>PAL</manufacturerId><listingDate>2018-12-21</listingDate></drug><drug id="02480115" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mar-Methimazole</name><manufacturerId>MAR</manufacturerId><individualPrice>.5181</individualPrice><listingDate>2018-12-21</listingDate></drug><drug id="02490633" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Methimazole</name><manufacturerId>JPC</manufacturerId><individualPrice>.5181</individualPrice><listingDate>2020-10-30</listingDate></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="840000000"><name>SKIN AND MUCOUS MEMBRANE PREPARATIONS</name><pcg6 id="840404000"><name>ANTI-INFECTIVES ANTIBIOTICS</name><genericName id="00979"><name>CLINDAMYCIN</name><pcgGroup><pcg9 id="840404017"><itemNumber>1980</itemNumber><strength>1%</strength><dosageForm>Top Sol</dosageForm><drug id="00582301" notABenefit="Y" sec3b="Y" sec3="Y"><name>Dalacin T 1%</name><manufacturerId>PFI</manufacturerId><listingDate>2017-03-28</listingDate></drug><drug id="02266938" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Clindamycin</name><manufacturerId>TAR</manufacturerId><individualPrice>.5072</individualPrice><listingDate>2017-03-28</listingDate></drug><drug id="02483769" dinStatus="E" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clindamycin Phosphate Topical Solution</name><manufacturerId>TEP</manufacturerId><individualPrice>.2613</individualPrice><listingDate>2020-02-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="02425"><name>CLINDAMYCIN PHOSPHATE &amp; ADAPALENE &amp; BENZOYL PEROXIDE</name><pcgGroup lccId="00411"><pcg9 id="840404031"><itemNumber>1981</itemNumber><strength>1.2% w/w &amp; 0.15% w/w &amp; 3.1% w/w</strength><dosageForm>Top Gel Pump</dosageForm><drug id="02550423" sec3="Y" sec12="Y"><name>Cabtreo</name><manufacturerId>BHC</manufacturerId><individualPrice>2.9483</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>2.9483</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="724">For the treatment of acne vulgaris in patients 12 years of age and older.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01584"><name>CLINDAMYCIN PHOSPHATE &amp; BENZOYL PEROXIDE</name><pcgGroup><pcg9 id="840404028"><itemNumber>1982</itemNumber><strength>1% &amp; 5%</strength><dosageForm>Gel</dosageForm><drug id="02243158" sec3="Y"><name>Clindoxyl</name><manufacturerId>STI</manufacturerId><individualPrice>.7500</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>.6857</amountMOHLTCPays></drug><drug id="02440180" sec3="Y"><name>Taro-Clindamycin/Benzoyl Peroxide Gel</name><manufacturerId>TAR</manufacturerId><individualPrice>.6857</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.6857</amountMOHLTCPays></drug></pcg9><pcg9 id="840404029"><itemNumber>1983</itemNumber><strength>1% &amp; 5%</strength><dosageForm>Top Gel</dosageForm><drug id="02248472" sec3="Y"><name>BenzaClin Topical Gel</name><manufacturerId>VAL</manufacturerId><individualPrice>1.3169</individualPrice><listingDate>2006-01-12</listingDate><amountMOHLTCPays>.7422</amountMOHLTCPays></drug><drug id="02464519" sec3="Y"><name>Taro-Benzoyl Peroxide / Clindamycin Kit</name><manufacturerId>TAR</manufacturerId><individualPrice>.7422</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>.7422</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00097"><name>FUSIDIC ACID</name><pcgGroup><pcg9 id="840404006"><itemNumber>1984</itemNumber><strength>2%</strength><dosageForm>Cr</dosageForm><drug id="00586668" sec3="Y"><name>Fucidin</name><manufacturerId>LEO</manufacturerId><individualPrice>1.0950</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5676</amountMOHLTCPays></drug><drug id="02528096" sec3="Y"><name>Taro-Fusidic Acid</name><manufacturerId>TAR</manufacturerId><individualPrice>.5676</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>.5676</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00972"><name>MUPIROCIN</name><pcgGroup><pcg9 id="840404008"><itemNumber>1985</itemNumber><strength>2%</strength><dosageForm>Oint</dosageForm><drug id="01916947" notABenefit="Y" sec3="Y"><name>Bactroban</name><manufacturerId>GCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02279983" sec3="Y"><name>Taro-Mupirocin</name><manufacturerId>TAR</manufacturerId><individualPrice>.5069</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>.5069</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02136"><name>MUPIROCIN CALCIUM</name><pcgGroup><pcg9 id="840404030"><itemNumber>1986</itemNumber><strength>2% w/w</strength><dosageForm>Cr</dosageForm><drug id="02483459" sec3="Y"><name>Stramucin</name><manufacturerId>GLP</manufacturerId><individualPrice>1.6000</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>1.6000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00098"><name>SODIUM FUSIDATE</name><pcgGroup><pcg9 id="840404007"><itemNumber>1987</itemNumber><strength>2%</strength><dosageForm>Oint</dosageForm><drug id="00586676" sec3="Y"><name>Fucidin</name><manufacturerId>LEO</manufacturerId><individualPrice>1.0950</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0950</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="840406000"><name>ANTI-INFECTIVES ANTIVIRALS</name><genericName id="00109"><name>ACYCLOVIR</name><pcgGroup><pcg9 id="840406002"><itemNumber>1988</itemNumber><strength>5%</strength><dosageForm>Top Oint</dosageForm><drug id="00569771" notABenefit="Y" sec3b="Y" sec3="Y"><name>Zovirax</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02477130" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Acyclovir Ointment</name><manufacturerId>APX</manufacturerId><individualPrice>12.3114</individualPrice><listingDate>2019-05-31</listingDate></drug><drug id="02522306" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Acyclovir</name><manufacturerId>TAR</manufacturerId><individualPrice>12.3114</individualPrice><listingDate>2022-04-29</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="840408000"><name>ANTI-INFECTIVES FUNGICIDES</name><note>Due to its efficacy and significantly lower cost, clotrimazole should be the first line of treatment for Tinea corporis and cruris. In Tinea pedis, topical terbinafine should be considered the first line of treatment due to its efficacy and lower rate of relapse.</note><genericName id="02024"><name>CICLOPIROX</name><pcgGroup><pcg9 id="840408055"><itemNumber>1989</itemNumber><strength>8% W/W</strength><dosageForm>Top Sol</dosageForm><drug id="02250535" notABenefit="Y" sec3b="Y" sec3="Y"><name>Penlac</name><manufacturerId>VAL</manufacturerId><listingDate>2017-01-31</listingDate></drug><drug id="02298953" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Ciclopirox</name><manufacturerId>APX</manufacturerId><individualPrice>7.7433</individualPrice><listingDate>2017-01-31</listingDate></drug><drug id="02353288" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Ciclopirox</name><manufacturerId>TAR</manufacturerId><individualPrice>7.7433</individualPrice><listingDate>2017-03-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00981"><name>CLOTRIMAZOLE</name><pcgGroup><pcg9 id="840408012"><itemNumber>1990</itemNumber><strength>10mg/g</strength><dosageForm>Cr</dosageForm><drug id="00812382" sec3="Y"><name>Clotrimaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.2233</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2233</amountMOHLTCPays></drug><drug id="02150867" notABenefit="Y" sec3="Y"><name>Canesten 1% Topical Cream</name><manufacturerId>BAY</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="840408035"><itemNumber>1991</itemNumber><strength>500mg &amp; 1%</strength><dosageForm>Tab &amp; Cr</dosageForm><drug id="02264102" sec3="Y"><name>Canesten 1 Comfortab Combi-Pak</name><manufacturerId>BAY</manufacturerId><individualPrice>12.0800</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>12.0800</amountMOHLTCPays></drug></pcg9><pcg9 id="840408017"><itemNumber>1992</itemNumber><strength>10mg/g</strength><dosageForm>Vag Cr-App</dosageForm><drug id="00812366" sec3="Y"><name>Clotrimaderm Vaginal Cream</name><manufacturerId>TAR</manufacturerId><individualPrice>.1812</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1812</amountMOHLTCPays></drug><drug id="02150891" sec3="Y"><name>Canesten 6 Cream</name><manufacturerId>BAY</manufacturerId><individualPrice>.2212</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1812</amountMOHLTCPays></drug></pcg9><pcg9 id="840408027"><itemNumber>1993</itemNumber><strength>20mg/g</strength><dosageForm>Vag Cr-App</dosageForm><drug id="00812374" sec3="Y"><name>Clotrimaderm Vaginal Cream</name><manufacturerId>TAR</manufacturerId><individualPrice>.3624</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3624</amountMOHLTCPays></drug><drug id="02150905" sec3="Y"><name>Canesten 3 Cream</name><manufacturerId>BAY</manufacturerId><individualPrice>.4424</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3624</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02129"><name>CLOTRIMAZOLE &amp; BETAMETHASONE DIPROPIONATE</name><pcgGroup><pcg9 id="840408056"><itemNumber>1994</itemNumber><strength>1% w/w &amp; 0.05% w/w</strength><dosageForm>Top Cr</dosageForm><drug id="00611174" notABenefit="Y" sec3b="Y" sec3="Y"><name>Lotriderm Cream</name><manufacturerId>MEK</manufacturerId><listingDate>2020-06-30</listingDate></drug><drug id="02496410" notABenefit="Y" sec3b="Y" sec3="Y"><name>TaroClotrimazole/BetamethasoneDipropiona</name><manufacturerId>TAR</manufacturerId><individualPrice>1.0832</individualPrice><listingDate>2020-06-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00032"><name>FLUCONAZOLE</name><pcgGroup lccId="00116"><pcg9 id="840408048"><itemNumber>1995</itemNumber><strength>150mg</strength><dosageForm>Cap</dosageForm><drug id="02141442" sec3="Y" sec12="Y"><name>Diflucan-150</name><manufacturerId>PFI</manufacturerId><individualPrice>15.7697</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02241895" sec3="Y" sec12="Y"><name>Apo-Fluconazole-150</name><manufacturerId>APX</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02255510" sec3="Y" sec12="Y"><name>Riva-Fluconazole</name><manufacturerId>RIA</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02428792" sec3="Y" sec12="Y"><name>Mar-Fluconazole-150</name><manufacturerId>MAR</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2017-01-31</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02432471" sec3="Y" sec12="Y"><name>Jamp-Fluconazole</name><manufacturerId>JPC</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2015-03-31</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02433702" sec3="Y" sec12="Y"><name>Priva-Fluconazole</name><manufacturerId>PHP</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02521229" sec3="Y" sec12="Y"><name>Fluconazole-150</name><manufacturerId>SAI</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug><drug id="02547864" sec3="Y" sec12="Y"><name>Jamp Fluconazole 150mg</name><manufacturerId>JPC</manufacturerId><individualPrice>3.9424</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>3.9424</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="235">For the treatment of vaginal candidiasis. Dose: 150mg orally once daily for 1 day.</lccNote><lccNote seq="002" type="N">Repeats within a 25 day period will not be reimbursed.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="00027"><name>KETOCONAZOLE</name><pcgGroup><pcg9 id="840408034"><itemNumber>1996</itemNumber><strength>2%</strength><dosageForm>Cr</dosageForm><drug id="00703974" notABenefit="Y" sec3="Y"><name>Nizoral</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02245662" sec3="Y"><name>Ketoderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.4043</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4043</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00982"><name>MICONAZOLE NITRATE</name><pcgGroup><pcg9 id="840408015"><itemNumber>1997</itemNumber><strength>2%</strength><dosageForm>Cr</dosageForm><drug id="02085852" sec3="Y"><name>Micatin</name><manufacturerId>WEL</manufacturerId><individualPrice>.2970</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2970</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00025"><name>NYSTATIN</name><pcgGroup><pcg9 id="840408004"><itemNumber>1998</itemNumber><strength>100000U/g</strength><dosageForm>Cr</dosageForm><drug id="00029092" notABenefit="Y" sec3="Y"><name>Mycostatin</name><manufacturerId>BQU</manufacturerId><note>Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.

</note><listingDate>1996-10-01</listingDate></drug><drug id="00716871" sec3="Y"><name>Nyaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.2037</individualPrice><note>Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.
</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2037</amountMOHLTCPays></drug></pcg9><pcg9 id="840408005"><itemNumber>1999</itemNumber><strength>100000U/g</strength><dosageForm>Oint</dosageForm><drug id="00029556" notABenefit="Y" sec3="Y"><name>Mycostatin</name><manufacturerId>BQU</manufacturerId><note>Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.</note><listingDate>1996-10-01</listingDate></drug><drug id="02194228" sec3="Y"><name>Ratio-Nystatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.1277</individualPrice><note>Nystatin is not effective in the treatment of Dermatophyte infections or Tinea versicolor.

</note><listingDate>1997-10-31</listingDate><amountMOHLTCPays>.1277</amountMOHLTCPays></drug></pcg9><pcg9 id="840408006"><itemNumber>2000</itemNumber><strength>25000U/g</strength><dosageForm>Vag Cr</dosageForm><drug id="00295973" notABenefit="Y" sec3="Y"><name>Mycostatin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716901" sec3="Y"><name>Nyaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0834</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0834</amountMOHLTCPays></drug></pcg9><pcg9 id="840408010"><itemNumber>2001</itemNumber><strength>100000U/g</strength><dosageForm>Vag Cr</dosageForm><drug id="02194163" sec3="Y"><name>Ratio-Nystatin</name><manufacturerId>RPH</manufacturerId><individualPrice>.3191</individualPrice><listingDate>1997-10-31</listingDate><amountMOHLTCPays>.3191</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00030"><name>TERBINAFINE HCL</name><pcgGroup><pcg9 id="840408047"><itemNumber>2002</itemNumber><strength>1%</strength><dosageForm>Cr</dosageForm><drug id="02031094" sec3="Y"><name>Lamisil</name><manufacturerId>NOV</manufacturerId><individualPrice>.6596</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6596</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00985"><name>TERCONAZOLE</name><pcgGroup><pcg9 id="840408042"><itemNumber>2003</itemNumber><strength>0.4%</strength><dosageForm>Vag Cr</dosageForm><drug id="00894729" notABenefit="Y" sec3="Y"><name>Terazol 7</name><manufacturerId>JAN</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02247651" sec3="Y"><name>Taro-Terconazole</name><manufacturerId>TAR</manufacturerId><individualPrice>.6354</individualPrice><listingDate>2005-06-13</listingDate><amountMOHLTCPays>.6354</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="840412000"><name>ANTI-INFECTIVES PARASITICIDES</name><genericName id="01932"><name>DIMETHICONE.</name><pcgGroup><pcg9 id="840412020"><itemNumber>2004</itemNumber><strength>50% w/w</strength><dosageForm>Top Sol-50mL Pk</dosageForm><drug id="02373785" sec3="Y"><name>NYDA</name><manufacturerId>GPB</manufacturerId><individualPrice>22.4200</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>22.4200</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01724"><name>ISOPROPYL MYRISTATE</name><pcgGroup><pcg9 id="840412018"><itemNumber>2005</itemNumber><strength>50%</strength><dosageForm>Top Sol-120mL Pk</dosageForm><drug id="09857292" sec3="Y"><name>Resultz</name><manufacturerId>MEF</manufacturerId><individualPrice>12.6500</individualPrice><listingDate>2008-02-12</listingDate><amountMOHLTCPays>12.6500</amountMOHLTCPays></drug></pcg9><pcg9 id="840412019"><itemNumber>2006</itemNumber><strength>50%</strength><dosageForm>Top Sol-240mL Pk</dosageForm><drug id="02279592" sec3="Y"><name>Resultz</name><manufacturerId>ARZ</manufacturerId><individualPrice>24.6600</individualPrice><listingDate>2008-02-12</listingDate><amountMOHLTCPays>24.6600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00993"><name>PERMETHRIN</name><pcgGroup><pcg9 id="840412013"><itemNumber>2007</itemNumber><strength>5%</strength><dosageForm>Cr</dosageForm><drug id="02219905" sec3="Y"><name>Nix Dermal Cream</name><manufacturerId>HLN</manufacturerId><individualPrice>.4977</individualPrice><listingDate>1998-10-21</listingDate><amountMOHLTCPays>.4977</amountMOHLTCPays></drug></pcg9><pcg9 id="840412010"><itemNumber>2008</itemNumber><strength>1%</strength><dosageForm>Cr Rinse</dosageForm><drug id="00771368" sec3="Y"><name>Nix Creme Rinse</name><manufacturerId>IPL</manufacturerId><individualPrice>.1701</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1701</amountMOHLTCPays></drug></pcg9><pcg9 id="840412015"><itemNumber>2009</itemNumber><strength>1%</strength><dosageForm>Cr Rinse</dosageForm><drug id="02231480" sec3="Y"><name>Kwellada-P Creme Rinse</name><manufacturerId>MEP</manufacturerId><individualPrice>.1749</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.1749</amountMOHLTCPays></drug></pcg9><pcg9 id="840412014"><itemNumber>2010</itemNumber><strength>5%</strength><dosageForm>Lot</dosageForm><drug id="02231348" sec3="Y"><name>Kwellada-P Lotion</name><manufacturerId>MEP</manufacturerId><individualPrice>.5053</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>.5053</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00992"><name>PYRETHRINS &amp; PIPERONYL BUTOXIDE</name><pcgGroup><pcg9 id="840412009"><itemNumber>2011</itemNumber><strength>0.33% &amp; 3%</strength><dosageForm>Topical Shampoo</dosageForm><drug id="02125447" sec3="Y"><name>R &amp; C Shampoo with Conditioner</name><manufacturerId>MEP</manufacturerId><individualPrice>.1110</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.1110</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="840416000"><name>ANTI-INFECTIVES OTHER ANTI-INFECTIVES</name><genericName id="00029"><name>METRONIDAZOLE</name><pcgGroup><pcg9 id="840416037"><itemNumber>2012</itemNumber><strength>1%</strength><dosageForm>Top Cr</dosageForm><drug id="02156091" sec3="Y"><name>Noritate</name><manufacturerId>VAL</manufacturerId><individualPrice>.7989</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.7989</amountMOHLTCPays></drug></pcg9><pcg9 id="840416043"><itemNumber>2013</itemNumber><strength>1%</strength><dosageForm>Top Gel</dosageForm><drug id="02297809" sec3="Y"><name>Metrogel</name><manufacturerId>GAC</manufacturerId><individualPrice>.7235</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>.7235</amountMOHLTCPays></drug></pcg9><pcg9 id="840416004"><itemNumber>2014</itemNumber><strength>10%</strength><dosageForm>Vag Cr-App</dosageForm><drug id="01926861" sec3="Y"><name>Flagyl</name><manufacturerId>SAV</manufacturerId><individualPrice>.2740</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2740</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00998"><name>METRONIDAZOLE &amp; NYSTATIN</name><pcgGroup><pcg9 id="840416018"><itemNumber>2015</itemNumber><strength>500mg &amp; 100000U/g</strength><dosageForm>Vag Cr-App</dosageForm><drug id="01926845" sec3="Y"><name>Flagystatin</name><manufacturerId>SAV</manufacturerId><individualPrice>.6076</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.6076</amountMOHLTCPays></drug></pcg9><pcg9 id="840416020"><itemNumber>2016</itemNumber><strength>500mg &amp; 100000U</strength><dosageForm>Vag Sup</dosageForm><drug id="01926829" sec3="Y"><name>Flagystatin</name><manufacturerId>SAV</manufacturerId><individualPrice>3.6980</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>3.6980</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00997"><name>POVIDONE - IODINE</name><pcgGroup><pcg9 id="840416007" suppliedBy="L"><itemNumber>2017</itemNumber><strength>10%</strength><dosageForm>Top Sol</dosageForm><drug id="00158348" notABenefit="Y" selfMed="Y" sec3="Y"><name>Betadine</name><manufacturerId>PFP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00172944" notABenefit="Y" selfMed="Y" sec3="Y"><name>Proviodine</name><manufacturerId>ROG</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="00999"><name>SILVER SULFADIAZINE</name><pcgGroup><pcg9 id="840416023"><itemNumber>2018</itemNumber><strength>1%</strength><dosageForm>Cr</dosageForm><drug id="00323098" sec3="Y"><name>Flamazine</name><manufacturerId>SNE</manufacturerId><individualPrice>.1320</individualPrice><note>The listing of Flamazine 1% Cr (DIN 00323098) is for the 500g jar package format.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1320</amountMOHLTCPays></drug></pcg9><pcg9 id="840416039"><itemNumber>2019</itemNumber><strength>1%</strength><dosageForm>Cr-50g Pk</dosageForm><drug id="09854037" sec3="Y"><name>Flamazine</name><manufacturerId>SNE</manufacturerId><individualPrice>10.9600</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>10.9600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="840600000"><name>ANTI-INFLAMMATORY</name><genericName id="01020"><name>AMCINONIDE</name><pcgGroup><pcg9 id="840600064"><itemNumber>2020</itemNumber><strength>0.1%</strength><dosageForm>Cr</dosageForm><drug id="02192284" notABenefit="Y" sec3="Y"><name>Cyclocort</name><manufacturerId>STI</manufacturerId><listingDate>1998-03-17</listingDate></drug><drug id="02246714" sec3="Y"><name>Taro-Amcinonide</name><manufacturerId>TAR</manufacturerId><individualPrice>.4522</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.4522</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00687"><name>BECLOMETHASONE DIPROPIONATE</name><pcgGroup><pcg9 id="840600001"><itemNumber>2021</itemNumber><strength>0.025%</strength><dosageForm>Cr</dosageForm><drug id="02089602" sec3="Y"><name>Propaderm</name><manufacturerId>VAL</manufacturerId><individualPrice>.5969</individualPrice><listingDate>1998-11-17</listingDate><amountMOHLTCPays>.5969</amountMOHLTCPays></drug></pcg9><pcg9 id="840600002"><itemNumber>2022</itemNumber><strength>0.025%</strength><dosageForm>Oint</dosageForm><drug id="01927957" sec3="Y"><name>Propaderm</name><manufacturerId>GLA</manufacturerId><individualPrice>.4038</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4038</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01015"><name>BETAMETHASONE DIPROPIONATE</name><pcgGroup><pcg9 id="840600042"><itemNumber>2023</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="00323071" sec3="Y"><name>Diprosone</name><manufacturerId>OCI</manufacturerId><individualPrice>.2174</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2048</amountMOHLTCPays></drug><drug id="01925350" sec3="Y"><name>Taro-Sone</name><manufacturerId>TAR</manufacturerId><individualPrice>.2048</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2048</amountMOHLTCPays></drug></pcg9><pcg9 id="840600048"><itemNumber>2024</itemNumber><strength>0.05%</strength><dosageForm>Lot</dosageForm><drug id="00417246" sec3="Y"><name>Diprosone</name><manufacturerId>OCI</manufacturerId><individualPrice>.2100</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1980</amountMOHLTCPays></drug><drug id="00809187" sec3="Y"><name>Ratio-Topisone</name><manufacturerId>RPH</manufacturerId><individualPrice>.1980</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1980</amountMOHLTCPays></drug></pcg9><pcg9 id="840600047"><itemNumber>2025</itemNumber><strength>0.05%</strength><dosageForm>Oint</dosageForm><drug id="00344923" sec3="Y"><name>Diprosone</name><manufacturerId>OCI</manufacturerId><individualPrice>.2284</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2152</amountMOHLTCPays></drug><drug id="00805009" sec3="Y"><name>Ratio-Topisone</name><manufacturerId>RPH</manufacturerId><individualPrice>.2152</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2152</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01026"><name>BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL</name><pcgGroup><pcg9 id="840600094"><itemNumber>2026</itemNumber><strength>0.05%</strength><dosageForm>Oint</dosageForm><drug id="00629367" sec3="Y"><name>Diprolene</name><manufacturerId>OCI</manufacturerId><individualPrice>.5186</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5186</amountMOHLTCPays></drug><drug id="00849669" sec3="Y"><name>Ratio-Topilene</name><manufacturerId>RPH</manufacturerId><individualPrice>.5186</individualPrice><note>No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5186</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01027"><name>BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE</name><pcgGroup><pcg9 id="840600105"><itemNumber>2027</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="00688622" sec3="Y"><name>Diprolene Glycol</name><manufacturerId>SCH</manufacturerId><individualPrice>.5186</individualPrice><note>No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5186</amountMOHLTCPays></drug><drug id="00849650" sec3="Y"><name>Ratio-Topilene</name><manufacturerId>RPH</manufacturerId><individualPrice>.5186</individualPrice><note>No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.


</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5186</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01007"><name>BETAMETHASONE VALERATE</name><pcgGroup><pcg9 id="840600007"><itemNumber>2028</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="00011916" notABenefit="Y" sec3="Y"><name>Betnovate-1/2</name><manufacturerId>GLA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00535427" sec3="Y"><name>Ratio-Ectosone Mild</name><manufacturerId>RPH</manufacturerId><individualPrice>.0611</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0596</amountMOHLTCPays></drug><drug id="00716618" sec3="Y"><name>Betaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0596</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0596</amountMOHLTCPays></drug></pcg9><pcg9 id="840600004"><itemNumber>2029</itemNumber><strength>0.1%</strength><dosageForm>Cr</dosageForm><drug id="00011924" notABenefit="Y" sec3="Y"><name>Betnovate</name><manufacturerId>GLA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00535435" sec3="Y"><name>Ratio-Ectosone Regular</name><manufacturerId>RPH</manufacturerId><individualPrice>.0911</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0889</amountMOHLTCPays></drug><drug id="00716626" sec3="Y"><name>Betaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0889</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0889</amountMOHLTCPays></drug><drug id="02357844" sec3="Y"><name>Celestoderm-V</name><manufacturerId>VAE</manufacturerId><individualPrice>.0889</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.0889</amountMOHLTCPays></drug></pcg9><pcg9 id="840600009"><itemNumber>2030</itemNumber><strength>0.05%</strength><dosageForm>Lot</dosageForm><drug id="00653209" sec3="Y"><name>Ratio-Ectosone Mild</name><manufacturerId>RPH</manufacturerId><individualPrice>.2847</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2847</amountMOHLTCPays></drug><drug id="02100185" notABenefit="Y" sec3="Y"><name>Betnovate-1/2</name><manufacturerId>RBT</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="840600006"><itemNumber>2031</itemNumber><strength>0.1%</strength><dosageForm>Lot</dosageForm><drug id="00750050" sec3="Y"><name>Ratio-Ectosone Regular</name><manufacturerId>RPH</manufacturerId><individualPrice>.3125</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3125</amountMOHLTCPays></drug><drug id="02100193" notABenefit="Y" sec3="Y"><name>Betnovate</name><manufacturerId>SHI</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="840600008"><itemNumber>2032</itemNumber><strength>0.05%</strength><dosageForm>Oint</dosageForm><drug id="00012378" notABenefit="Y" sec3="Y"><name>Betnovate-1/2</name><manufacturerId>GLA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716642" sec3="Y"><name>Betaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0596</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0596</amountMOHLTCPays></drug><drug id="02357879" sec3="Y"><name>Celestoderm-V/2</name><manufacturerId>VAE</manufacturerId><individualPrice>.0596</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.0596</amountMOHLTCPays></drug></pcg9><pcg9 id="840600005"><itemNumber>2033</itemNumber><strength>0.1%</strength><dosageForm>Oint</dosageForm><drug id="00012386" notABenefit="Y" sec3="Y"><name>Betnovate</name><manufacturerId>GLA</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716650" sec3="Y"><name>Betaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0889</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0889</amountMOHLTCPays></drug><drug id="02357852" sec3="Y"><name>Celestoderm-V</name><manufacturerId>VAE</manufacturerId><individualPrice>.0889</individualPrice><listingDate>2012-04-24</listingDate><amountMOHLTCPays>.0889</amountMOHLTCPays></drug></pcg9><pcg9 id="840600035"><itemNumber>2034</itemNumber><strength>0.1%</strength><dosageForm>Scalp Lot</dosageForm><drug id="00027944" notABenefit="Y" sec3="Y"><name>Valisone</name><manufacturerId>VAE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716634" sec3="Y"><name>Betaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.1271</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1271</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01729"><name>CALCIPOTRIOL &amp; BETAMETHASONE DIPROPIONATE</name><pcgGroup><pcg9 id="840600151"><itemNumber>2035</itemNumber><strength>50mcg/g &amp; 0.5mg/g</strength><dosageForm>Oint</dosageForm><note>Note: For use in patients with psoriasis who have failed 1st line topical steroids and Dovonex (calcipotriol) therapy.</note><drug id="02244126" sec3="Y"><name>Dovobet</name><manufacturerId>LEO</manufacturerId><individualPrice>2.1425</individualPrice><listingDate>2008-05-16</listingDate><amountMOHLTCPays>1.2545</amountMOHLTCPays></drug><drug id="02427419" sec3="Y"><name>Teva-Betamethasone/Calcipotriol</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2545</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>1.2545</amountMOHLTCPays></drug></pcg9><pcg9 id="840600154"><itemNumber>2036</itemNumber><strength>50mcg/g &amp; 0.5mg/g</strength><dosageForm>Top Aero Foam</dosageForm><note>For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. 

For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.</note><drug id="02457393" sec3="Y"><name>Enstilar</name><manufacturerId>LEO</manufacturerId><individualPrice>1.6412</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>1.6412</amountMOHLTCPays></drug></pcg9><pcg9 id="840600152"><itemNumber>2037</itemNumber><strength>50mcg/g &amp; 0.5mg/g</strength><dosageForm>Top Gel</dosageForm><note>Notes: 

For the treatment of moderate to severe scalp psoriasis in patients who have failed first-line topical corticosteroid therapy. 

For the treatment of mild to moderate body psoriasis in patients who have failed first-line topical corticosteroid therapy and Dovonex (calcipotriol) therapy.
</note><drug id="02319012" sec3="Y"><name>Dovobet Gel</name><manufacturerId>LEO</manufacturerId><individualPrice>2.1375</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>1.3142</amountMOHLTCPays></drug><drug id="02525178" sec3="Y"><name>Taro-Calcipotriol / Betamethasone Gel</name><manufacturerId>TAR</manufacturerId><individualPrice>1.3142</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.3142</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01019"><name>CLOBETASOL PROPIONATE</name><note>No more than 50 grams per week of ultrapotent steroids for a maximum of 2 weeks is recommended.</note><pcgGroup><pcg9 id="840600061"><itemNumber>2038</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="01910272" sec3="Y"><name>Teva-Clobetasol</name><manufacturerId>TEV</manufacturerId><individualPrice>.2279</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02024187" sec3="Y"><name>Mylan-Clobetasol</name><manufacturerId>MYL</manufacturerId><individualPrice>.2279</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02213265" sec3="Y"><name>Dermovate</name><manufacturerId>TPH</manufacturerId><individualPrice>.9964</individualPrice><listingDate>1998-05-21</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02245523" sec3="Y"><name>Taro-Clobetasol Cream USP</name><manufacturerId>TAR</manufacturerId><individualPrice>.2279</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug></pcg9><pcg9 id="840600062"><itemNumber>2039</itemNumber><strength>0.05%</strength><dosageForm>Oint</dosageForm><drug id="01910280" sec3="Y"><name>Teva-Clobetasol</name><manufacturerId>TEV</manufacturerId><individualPrice>.2279</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02026767" sec3="Y"><name>Mylan-Clobetasol</name><manufacturerId>MYL</manufacturerId><individualPrice>.2279</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02213273" sec3="Y"><name>Dermovate</name><manufacturerId>TPH</manufacturerId><individualPrice>.9964</individualPrice><listingDate>1998-05-02</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug><drug id="02245524" sec3="Y"><name>Taro-Clobetasol Ointment USP</name><manufacturerId>TAR</manufacturerId><individualPrice>.2279</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2279</amountMOHLTCPays></drug></pcg9><pcg9 id="840600070"><itemNumber>2040</itemNumber><strength>0.05%</strength><dosageForm>Scalp Lot</dosageForm><drug id="02213281" sec3="Y"><name>Dermovate</name><manufacturerId>TPH</manufacturerId><individualPrice>.7992</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.3996</amountMOHLTCPays></drug><drug id="02216213" sec3="Y"><name>Mylan-Clobetasol Scalp Application</name><manufacturerId>MYL</manufacturerId><individualPrice>.3996</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3996</amountMOHLTCPays></drug><drug id="02245522" sec3="Y"><name>Taro-Clobetasol Topical Solution USP</name><manufacturerId>TAR</manufacturerId><individualPrice>.3996</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.3996</amountMOHLTCPays></drug></pcg9><pcg9 id="840600155"><itemNumber>2041</itemNumber><strength>0.05% w/w</strength><dosageForm>Top Shampoo</dosageForm><drug id="02256371" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clobex Shampoo</name><manufacturerId>GAC</manufacturerId><listingDate>2020-12-18</listingDate></drug><drug id="02506203" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Clobetasol Shampoo</name><manufacturerId>TAR</manufacturerId><individualPrice>1.0838</individualPrice><listingDate>2020-12-18</listingDate></drug><drug id="02519437" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reddy-Clobetasol Shampoo</name><manufacturerId>DRR</manufacturerId><individualPrice>1.0838</individualPrice><listingDate>2021-11-30</listingDate></drug></pcg9><pcg9 id="840600153"><itemNumber>2042</itemNumber><strength>0.05% w/w</strength><dosageForm>Top Sol Sp</dosageForm><drug id="02299739" notABenefit="Y" sec3b="Y" sec3="Y"><name>Clobex Spray</name><manufacturerId>GAC</manufacturerId><listingDate>2018-09-27</listingDate></drug><drug id="02475162" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Clobetasol Spray</name><manufacturerId>APX</manufacturerId><individualPrice>1.9259</individualPrice><listingDate>2018-09-27</listingDate></drug><drug id="02489619" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Clobetasol Spray</name><manufacturerId>TAR</manufacturerId><individualPrice>1.9259</individualPrice><listingDate>2019-11-29</listingDate></drug><drug id="02490706" notABenefit="Y" sec3b="Y" sec3="Y"><name>Odan Clobetasol</name><manufacturerId>ODN</manufacturerId><individualPrice>1.9260</individualPrice><listingDate>2019-11-29</listingDate></drug><drug id="02495023" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Clobetasol</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.9259</individualPrice><listingDate>2020-07-31</listingDate></drug><drug id="02534665" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Clobetasol Spray</name><manufacturerId>JPC</manufacturerId><individualPrice>1.9259</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01016"><name>DESONIDE</name><pcgGroup><pcg9 id="840600043"><itemNumber>2043</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="02154862" notABenefit="Y" sec3="Y"><name>Tridesilon</name><manufacturerId>CPL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229315" sec3="Y"><name>PDP-Desonide</name><manufacturerId>PEN</manufacturerId><individualPrice>.2857</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.2857</amountMOHLTCPays></drug></pcg9><pcg9 id="840600045"><itemNumber>2044</itemNumber><strength>0.05%</strength><dosageForm>Oint</dosageForm><drug id="02154870" notABenefit="Y" sec3="Y"><name>Tridesilon</name><manufacturerId>CPL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02229323" sec3="Y"><name>PDP-Desonide</name><manufacturerId>PEN</manufacturerId><individualPrice>.2853</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.2853</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01010"><name>FLUOCINONIDE</name><pcgGroup><pcg9 id="840600017"><itemNumber>2045</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="00716863" sec3="Y"><name>Lyderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.2550</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2550</amountMOHLTCPays></drug><drug id="02161923" notABenefit="Y" sec3="Y"><name>Lidex</name><manufacturerId>VAE</manufacturerId><listingDate>1999-01-20</listingDate></drug></pcg9><pcg9 id="840600069"><itemNumber>2046</itemNumber><strength>0.05%</strength><dosageForm>Emol Cr</dosageForm><drug id="00598933" sec3="Y"><name>Tiamol</name><manufacturerId>TAR</manufacturerId><individualPrice>.1980</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1980</amountMOHLTCPays></drug><drug id="02163152" notABenefit="Y" sec3="Y"><name>Lidemol</name><manufacturerId>VAE</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="840600044"><itemNumber>2047</itemNumber><strength>0.05%</strength><dosageForm>Gel</dosageForm><drug id="02161974" notABenefit="Y" sec3="Y"><name>Lidex</name><manufacturerId>VAE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02236997" sec3="Y"><name>Lyderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.3517</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.3517</amountMOHLTCPays></drug></pcg9><pcg9 id="840600100"><itemNumber>2048</itemNumber><strength>0.05%</strength><dosageForm>Oint</dosageForm><drug id="02161966" notABenefit="Y" sec3="Y"><name>Lidex</name><manufacturerId>VAE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02236996" sec3="Y"><name>Lyderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.3370</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.3370</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01038"><name>HALOBETASOL PROPIONATE</name><pcgGroup><pcg9 id="840600156"><itemNumber>2049</itemNumber><strength>0.01% w/w</strength><dosageForm>Lot</dosageForm><note>No more than 50 grams per week is recommended.</note><drug id="02506262" sec3="Y"><name>Bryhali</name><manufacturerId>BHC</manufacturerId><individualPrice>.9816</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>.9816</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00823"><name>HYDROCORTISONE</name><pcgGroup><pcg9 id="840600027"><itemNumber>2050</itemNumber><strength>0.5%</strength><dosageForm>Oint</dosageForm><drug id="00513261" notABenefit="Y" sec3="Y"><name>Cortate</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716685" sec3="Y"><name>Cortoderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.1400</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1400</amountMOHLTCPays></drug></pcg9><pcg9 id="840600026"><itemNumber>2051</itemNumber><strength>1%</strength><dosageForm>Oint</dosageForm><drug id="00502197" notABenefit="Y" sec3="Y"><name>Cortate</name><manufacturerId>SCH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716693" sec3="Y"><name>Cortoderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0390</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0390</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01023"><name>HYDROCORTISONE ACETATE</name><pcgGroup><pcg9 id="840600077"><itemNumber>2052</itemNumber><strength>1%</strength><dosageForm>Cr</dosageForm><drug id="00477699" notABenefit="Y" sec3="Y"><name>Corticreme</name><manufacturerId>ROG</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716839" sec3="Y"><name>Hyderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.2056</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2056</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01018"><name>HYDROCORTISONE VALERATE</name><pcgGroup><pcg9 id="840600060"><itemNumber>2053</itemNumber><strength>0.2%</strength><dosageForm>Cr</dosageForm><drug id="01910124" notABenefit="Y" sec3="Y"><name>Westcort</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242984" sec3="Y"><name>Hydroval</name><manufacturerId>TPH</manufacturerId><individualPrice>.1667</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1667</amountMOHLTCPays></drug></pcg9><pcg9 id="840600084"><itemNumber>2054</itemNumber><strength>0.2%</strength><dosageForm>Oint</dosageForm><drug id="01910132" notABenefit="Y" sec3="Y"><name>Westcort</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02242985" sec3="Y"><name>Hydroval</name><manufacturerId>TPH</manufacturerId><individualPrice>.1667</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.1667</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01029"><name>MOMETASONE FUROATE</name><pcgGroup><pcg9 id="840600109"><itemNumber>2055</itemNumber><strength>0.1%</strength><dosageForm>Cr</dosageForm><drug id="00851744" sec3="Y"><name>Elocom</name><manufacturerId>OCI</manufacturerId><individualPrice>.7393</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5542</amountMOHLTCPays></drug><drug id="02367157" sec3="Y"><name>Taro-Mometasone</name><manufacturerId>TAR</manufacturerId><individualPrice>.5542</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.5542</amountMOHLTCPays></drug></pcg9><pcg9 id="840600111"><itemNumber>2056</itemNumber><strength>0.1%</strength><dosageForm>Lot</dosageForm><drug id="00871095" sec3="Y"><name>Elocom</name><manufacturerId>OCI</manufacturerId><individualPrice>.5255</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3627</amountMOHLTCPays></drug><drug id="02266385" sec3="Y"><name>Taro-Mometasone</name><manufacturerId>TAR</manufacturerId><individualPrice>.3627</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.3627</amountMOHLTCPays></drug></pcg9><pcg9 id="840600110"><itemNumber>2057</itemNumber><strength>0.1%</strength><dosageForm>Oint</dosageForm><drug id="00851736" sec3="Y"><name>Elocom</name><manufacturerId>OCI</manufacturerId><individualPrice>.7342</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2252</amountMOHLTCPays></drug><drug id="02248130" sec3="Y"><name>Ratio-Mometasone</name><manufacturerId>RPH</manufacturerId><individualPrice>.2252</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.2252</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00695"><name>TRIAMCINOLONE ACETONIDE</name><pcgGroup><pcg9 id="840600029"><itemNumber>2058</itemNumber><strength>0.1%</strength><dosageForm>Cr</dosageForm><drug id="00029114" notABenefit="Y" sec3="Y"><name>Kenalog</name><manufacturerId>WSQ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00716960" sec3="Y"><name>Triaderm</name><manufacturerId>TAR</manufacturerId><individualPrice>.0533</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0533</amountMOHLTCPays></drug><drug id="02194058" notABenefit="Y" sec3="Y"><name>Aristocort R</name><manufacturerId>VAL</manufacturerId><listingDate>1998-03-17</listingDate></drug></pcg9><pcg9 id="840600030"><itemNumber>2059</itemNumber><strength>0.1%</strength><dosageForm>Oint</dosageForm><drug id="01999796" notABenefit="Y" sec3="Y"><name>Kenalog</name><manufacturerId>WSQ</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02194031" sec3="Y"><name>Aristocort R</name><manufacturerId>VAE</manufacturerId><individualPrice>.1821</individualPrice><listingDate>1998-03-17</listingDate><amountMOHLTCPays>.1821</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01012"><name>TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE</name><pcgGroup><pcg9 id="840600034"><itemNumber>2060</itemNumber><dosageForm>Oral Top Oint</dosageForm><drug id="01964054" sec3="Y"><name>Oracort</name><manufacturerId>TAR</manufacturerId><individualPrice>1.5607</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.5607</amountMOHLTCPays></drug><drug id="01999788" notABenefit="Y" sec3="Y"><name>Kenalog-Orabase</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="842800000"><name>KERATOLYTIC AGENTS</name><genericName id="02111"><name>ADAPALENE &amp; BENZOYL PEROXIDE</name><pcgGroup><pcg9 id="842800058"><itemNumber>2061</itemNumber><strength>0.1%w/w &amp; 2.5%w/w</strength><dosageForm>Top Gel</dosageForm><drug id="02365871" notABenefit="Y" sec3b="Y" sec3="Y"><name>TactuPump</name><manufacturerId>GAC</manufacturerId><listingDate>2019-11-29</listingDate></drug><drug id="02456923" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Adapalene/Benzoyl Peroxide</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2719</individualPrice><listingDate>2019-11-29</listingDate></drug><drug id="02489007" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Adapalene/ Benzoyl Peroxide</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2718</individualPrice><listingDate>2019-11-29</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01058"><name>TRETINOIN</name><pcgGroup lccId="00118"><pcg9 id="842800045"><itemNumber>2062</itemNumber><strength>0.01%</strength><dosageForm>Cr</dosageForm><drug id="00657204" dinStatus="E" sec3="Y" sec12="Y"><name>Stieva-A</name><manufacturerId>STI</manufacturerId><individualPrice>.3212</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3212</amountMOHLTCPays></drug></pcg9><pcg9 id="842800038"><itemNumber>2063</itemNumber><strength>0.025%</strength><dosageForm>Cr</dosageForm><drug id="00578576" dinStatus="E" sec3="Y" sec12="Y"><name>Stieva-A</name><manufacturerId>STI</manufacturerId><individualPrice>.3212</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3212</amountMOHLTCPays></drug></pcg9><pcg9 id="842800013"><itemNumber>2064</itemNumber><strength>0.05%</strength><dosageForm>Cr</dosageForm><drug id="00518182" dinStatus="E" sec3="Y" sec12="Y"><name>Stieva-A</name><manufacturerId>STI</manufacturerId><individualPrice>.2144</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2144</amountMOHLTCPays></drug><drug id="01926519" notABenefit="Y" sec3="Y"><name>Vitamin A Acid</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9><pcg9 id="842800031"><itemNumber>2065</itemNumber><strength>0.01%</strength><dosageForm>Gel</dosageForm><drug id="01926462" sec3="Y" sec12="Y"><name>Vitamin A Acid</name><manufacturerId>VAL</manufacturerId><individualPrice>.4266</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4266</amountMOHLTCPays></drug></pcg9><pcg9 id="842800010"><itemNumber>2066</itemNumber><strength>0.05%</strength><dosageForm>Gel</dosageForm><drug id="01926489" sec3="Y" sec12="Y"><name>Vitamin A Acid</name><manufacturerId>VAL</manufacturerId><individualPrice>.4266</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4266</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="269">For the treatment of acne vulgaris.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="843600000"><name>MISCELLANEOUS SKIN AND MUCOUS MEMBRANE AGENTS</name><genericName id="01106"><name>ACITRETIN</name><note>This drug should be used with extreme caution in females of childbearing potential due to its teratogenicity. Effective contraception must be practised for at least 2 years following discontinuation.</note><pcgGroup><pcg9 id="843600067"><itemNumber>2067</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02070847" sec3="Y"><name>Soriatane</name><manufacturerId>ALL</manufacturerId><individualPrice>3.2773</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2965</amountMOHLTCPays></drug><drug id="02466074" sec3="Y"><name>Taro-Acitretin</name><manufacturerId>TAR</manufacturerId><individualPrice>1.2965</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1.2965</amountMOHLTCPays></drug><drug id="02468840" sec3="Y"><name>Mint-Acitretin</name><manufacturerId>MIN</manufacturerId><individualPrice>1.2965</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>1.2965</amountMOHLTCPays></drug></pcg9><pcg9 id="843600068"><itemNumber>2068</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02070863" sec3="Y"><name>Soriatane</name><manufacturerId>ALL</manufacturerId><individualPrice>5.7557</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.2770</amountMOHLTCPays></drug><drug id="02466082" sec3="Y"><name>Taro-Acitretin</name><manufacturerId>TAR</manufacturerId><individualPrice>2.2770</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>2.2770</amountMOHLTCPays></drug><drug id="02468859" sec3="Y"><name>Mint-Acitretin</name><manufacturerId>MIN</manufacturerId><individualPrice>2.2770</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>2.2770</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02111"><name>ADAPALENE &amp; BENZOYL PEROXIDE</name><pcgGroup><pcg9 id="843600106"><itemNumber>2069</itemNumber><strength>0.3% w/w &amp; 2.5% w/w</strength><dosageForm>Top Gel</dosageForm><drug id="02446235" notABenefit="Y" sec3b="Y" sec3="Y"><name>TactuPump Forte</name><manufacturerId>GAC</manufacturerId><listingDate>2022-01-31</listingDate></drug><drug id="02505053" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Adapalene/Benzoyl Peroxide Forte</name><manufacturerId>TAR</manufacturerId><individualPrice>2.1577</individualPrice><listingDate>2022-02-28</listingDate></drug><drug id="02517205" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Adapalene/Benzoyl Peroxide</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.1576</individualPrice><listingDate>2022-01-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01915"><name>ALITRETINOIN</name><note>Alitretinoin should only be prescribed by physicians knowledgeable in the use of retinoids systemically, who understand the risk of teratogenicity in females of child bearing potential. Alitretinoin is contraindicated in pregnancy and females must not become pregnant while taking alitretinoin and for at least one month after its discontinuation. Please refer to the Toctino product monograph for details on use in women of child bearing potential.</note><pcgGroup lccId="00234"><pcg9 id="843600092"><itemNumber>2070</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02337630" notABenefit="Y" sec3="Y"><name>Toctino</name><manufacturerId>GSK</manufacturerId><listingDate>2013-04-30</listingDate></drug><drug id="02477432" sec3="Y" sec12="Y"><name>Hanzema</name><manufacturerId>DRR</manufacturerId><individualPrice>16.9868</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>16.9868</amountMOHLTCPays></drug></pcg9><pcg9 id="843600093"><itemNumber>2071</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><drug id="02337649" notABenefit="Y" sec3="Y"><name>Toctino</name><manufacturerId>GSK</manufacturerId><listingDate>2013-04-30</listingDate></drug><drug id="02477440" sec3="Y" sec12="Y"><name>Hanzema</name><manufacturerId>DRR</manufacturerId><individualPrice>16.9868</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>16.9868</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="442">For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids.

1.  Severe defined based on the Physician Global Assessment (PGA), including:

-  At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and
    
-  one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and

-  with an area of greater than 30% of affected hand surface

2.  Chronic defined as:

-  persists for greater than 3 months; OR

-  reoccurs greater than or equal to 2 times within 12 months</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01854"><name>AZELAIC ACID</name><pcgGroup><pcg9 id="843600091"><itemNumber>2072</itemNumber><strength>15%</strength><dosageForm>Top Gel</dosageForm><drug id="02270811" sec3="Y"><name>Finacea</name><manufacturerId>LEO</manufacturerId><individualPrice>.8566</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.8566</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02080"><name>BRODALUMAB</name><pcgGroup lccId="00316"><pcg9 id="843600104"><itemNumber>2073</itemNumber><strength>210mg/1.5mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02473623" sec3="Y" sec12="Y"><name>Siliq</name><manufacturerId>VAL</manufacturerId><individualPrice>645.0000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>645.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="553">For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.

Approvals will only allow for standard dosing for Siliq 210mg subcutaneously at weeks 0, 1 and 2, and then every 2 weeks. If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent.

Note 1: Definition of severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.


Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine


Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least 50% reduction in PASI, AND
- at least 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score
 

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01089"><name>CALCIPOTRIOL</name><pcgGroup lccId="00119"><pcg9 id="843600044"><itemNumber>2074</itemNumber><strength>50mcg/g</strength><dosageForm>Oint</dosageForm><drug id="01976133" sec3="Y" sec12="Y"><name>Dovonex</name><manufacturerId>LEO</manufacturerId><individualPrice>1.2208</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>1.2208</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="191">For the treatment of psoriasis in patients who have failed topical corticosteroids alone, or are intolerant to topical corticosteroids.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01135"><name>CALCITRIOL</name><pcgGroup lccId="00212"><pcg9 id="843600090"><itemNumber>2075</itemNumber><strength>3mcg/g</strength><dosageForm>Oint</dosageForm><drug id="02338572" sec3="Y" sec12="Y"><name>Silkis</name><manufacturerId>GAC</manufacturerId><individualPrice>1.3625</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>1.3625</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="191">For the treatment of psoriasis in patients who have failed topical corticosteroids alone, or are intolerant to topical corticosteroids.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01107"><name>COLLAGENASE</name><pcgGroup><pcg9 id="843600070"><itemNumber>2076</itemNumber><strength>250Unit/g</strength><dosageForm>30g Pk</dosageForm><drug id="02063670" sec3="Y"><name>Santyl Ointment</name><manufacturerId>SNE</manufacturerId><individualPrice>87.5000</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>87.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="843600111"><itemNumber>2077</itemNumber><strength>250Unit/g</strength><dosageForm>Oint-30g Pk</dosageForm><drug id="09858336" sec3c="Y"><name>Santyl</name><manufacturerId>SNE</manufacturerId><individualPrice>87.5000</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>87.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00162"><name>FLUOROURACIL</name><pcgGroup><pcg9 id="843600014"><itemNumber>2078</itemNumber><strength>5%</strength><dosageForm>Cr</dosageForm><drug id="00330582" sec3="Y"><name>Efudex</name><manufacturerId>VAL</manufacturerId><individualPrice>1.1341</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.1341</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01452"><name>IMIQUIMOD</name><pcgGroup><pcg9 id="843600103"><itemNumber>2079</itemNumber><strength>5%</strength><dosageForm>Top Cr</dosageForm><drug id="02482983" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Imiquimod Pump</name><manufacturerId>TAR</manufacturerId><individualPrice>54.2147</individualPrice><listingDate>2019-03-28</listingDate></drug><drug id="09857622" notABenefit="Y" sec3b="Y" sec3="Y"><name>Aldara P</name><manufacturerId>VAL</manufacturerId><listingDate>2019-03-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01084"><name>ISOTRETINOIN</name><pcgGroup><pcg9 id="843600035"><itemNumber>2080</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><note>Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.</note><drug id="00582344" sec3="Y"><name>Accutane</name><manufacturerId>HLR</manufacturerId><individualPrice>.9547</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9313</amountMOHLTCPays></drug><drug id="02257955" sec3="Y"><name>Clarus</name><manufacturerId>MYL</manufacturerId><individualPrice>.9313</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>.9313</amountMOHLTCPays></drug></pcg9><pcg9 id="843600095"><itemNumber>2081</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><note>Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.</note><drug id="02396971" sec3="Y"><name>Epuris</name><manufacturerId>CIP</manufacturerId><individualPrice>1.5134</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>1.5134</amountMOHLTCPays></drug></pcg9><pcg9 id="843600096"><itemNumber>2082</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><note>Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.</note><drug id="02396998" sec3="Y"><name>Epuris</name><manufacturerId>CIP</manufacturerId><individualPrice>2.0941</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>2.0941</amountMOHLTCPays></drug></pcg9><pcg9 id="843600097"><itemNumber>2083</itemNumber><strength>30mg</strength><dosageForm>Cap</dosageForm><note>Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.</note><drug id="02397005" sec3="Y"><name>Epuris</name><manufacturerId>CIP</manufacturerId><individualPrice>2.6337</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>2.6337</amountMOHLTCPays></drug></pcg9><pcg9 id="843600034"><itemNumber>2084</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><note>Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.</note><drug id="00582352" sec3="Y"><name>Accutane</name><manufacturerId>HLR</manufacturerId><individualPrice>1.9480</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.9003</amountMOHLTCPays></drug><drug id="02257963" sec3="Y"><name>Clarus</name><manufacturerId>MYL</manufacturerId><individualPrice>1.9003</individualPrice><listingDate>2006-07-19</listingDate><amountMOHLTCPays>1.9003</amountMOHLTCPays></drug></pcg9><pcg9 id="843600098"><itemNumber>2085</itemNumber><strength>40mg</strength><dosageForm>Cap</dosageForm><note>Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.</note><drug id="02397013" sec3="Y"><name>Epuris</name><manufacturerId>CIP</manufacturerId><individualPrice>3.0877</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>3.0877</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02049"><name>IXEKIZUMAB</name><pcgGroup lccId="00300"><pcg9 id="843600101"><itemNumber>2086</itemNumber><strength>80mg/mL</strength><dosageForm>Inj Sol-Pref Autoinj</dosageForm><drug id="02455102" sec3="Y" sec12="Y"><name>Taltz</name><manufacturerId>LIL</manufacturerId><individualPrice>1937.8800</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1937.8800</amountMOHLTCPays></drug></pcg9><pcg9 id="843600102"><itemNumber>2087</itemNumber><strength>80mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02455110" sec3="Y" sec12="Y"><name>Taltz</name><manufacturerId>LIL</manufacturerId><individualPrice>1951.0900</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>1951.0900</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="526">For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.

Approvals will only allow for standard dosing for Taltz 160mg at week 0, followed by 80mg subcutaneously at weeks 2, 4, 6, 8, 10, and 12, and then 80mg every 4 weeks.  If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent.

Note 1: Definiton of severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.

Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

       - Methotrexate 15-30mg per week
       - Acitretin (could have been used with phototherapy)
       - Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least 50% reduction in PASI, AND
- at least 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01605"><name>PIMECROLIMUS</name><pcgGroup lccId="00149"><pcg9 id="843600084"><itemNumber>2088</itemNumber><strength>1%</strength><dosageForm>Cr</dosageForm><drug id="02247238" sec3="Y" sec12="Y"><name>Elidel</name><manufacturerId>VAL</manufacturerId><individualPrice>2.9720</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>2.9720</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="383">For use in combination with moisturizers or oral antihistamines in patients with atopic dermatitis who have failed or are intolerant to an 8 week trial of an intermediate potency topical steroid.</lccNote><lccNote seq="002" type="R">Therapy should be reassessed at 6 months.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02118"><name>RISANKIZUMAB</name><pcgGroup lccId="00325"><pcg9 id="843600105"><itemNumber>2089</itemNumber><strength>75mg/0.83mL</strength><dosageForm>Inj Sol-0.83mL Pref Syr (Preservative-Free)</dosageForm><drug id="02487454" sec3="Y" sec12="Y"><name>Skyrizi</name><manufacturerId>ABV</manufacturerId><individualPrice>2467.5000</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>2467.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="843600108"><itemNumber>2090</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-Pref Pen (Preservative-Free)</dosageForm><drug id="02519291" sec3="Y" sec12="Y"><name>Skyrizi</name><manufacturerId>ABV</manufacturerId><individualPrice>4935.0000</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>4935.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="843600107"><itemNumber>2091</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-Pref Syr (Preservative-Free)</dosageForm><drug id="02519283" sec3="Y" sec12="Y"><name>Skyrizi</name><manufacturerId>ABV</manufacturerId><individualPrice>4935.0000</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>4935.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="574">For the treatment of severe plaque psoriasis (see Note 1 below) in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.

Approvals will only allow for standard dosing for Skyrizi 150mg subcutaneously at weeks 0 and 4, and then every 12 weeks. If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.

Note 1: Definition of severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face,
hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.

Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination
- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:
- at least 50% reduction in PASI, AND
- at least 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score.


  
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02013"><name>SECUKINUMAB</name><pcgGroup lccId="00267"><pcg9 id="843600100"><itemNumber>2092</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-Pref Pen</dosageForm><drug id="09857548" sec3="Y" sec12="Y"><name>Cosentyx</name><manufacturerId>NOV</manufacturerId><individualPrice>952.7200</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>952.7200</amountMOHLTCPays></drug></pcg9><pcg9 id="843600099"><itemNumber>2093</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02438070" dinStatus="E" sec3="Y" sec12="Y"><name>Cosentyx</name><manufacturerId>NOV</manufacturerId><individualPrice>952.7200</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>952.7200</amountMOHLTCPays></drug></pcg9><pcg9 id="843600112"><itemNumber>2094</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02547724" sec3="Y" sec12="Y"><name>Cosentyx</name><manufacturerId>NOV</manufacturerId><individualPrice>952.7200</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>952.7200</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="476">For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.

The recommended dose for Cosentyx is 300mg subcutaneously at weeks 0, 1, 2 and 3, and then monthly starting at week 4. A maintenance dose of 300mg every 2 weeks may be considered for adult patients with a body weight of 90kg or higher. If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved doses, higher doses are not recommended and the physician should consider switching to an alternative biologic agent.

Note 1: Definition of severe plaque psoriasis:
- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.

Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:
- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:
- At least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01083"><name>ZINC SULFATE</name><pcgGroup><pcg9 id="843600033" suppliedBy="L"><itemNumber>2095</itemNumber><strength>0.5%</strength><dosageForm>Oint</dosageForm><drug id="01945939" selfMed="Y" sec3="Y"><name>Anusol Ointment</name><manufacturerId>CDC</manufacturerId><individualPrice>.2187</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2187</amountMOHLTCPays></drug></pcg9><pcg9 id="843600020" suppliedBy="L"><itemNumber>2096</itemNumber><strength>10mg</strength><dosageForm>Sup</dosageForm><drug id="00621439" selfMed="Y" sec3="Y"><name>Anuzinc</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3542</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3542</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="849200000"><name>MISCELLANEOUS SKIN AND MUCOUS MEMBRANE AGENTS</name><genericName id="02321"><name>BIMEKIZUMAB</name><pcgGroup lccId="00366"><pcg9 id="849200010"><itemNumber>2097</itemNumber><strength>160mg/mL</strength><dosageForm>Inj Sol-1mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02525275" sec3="Y" sec12="Y"><name>Bimzelx</name><manufacturerId>UCB</manufacturerId><individualPrice>1625.0000</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>1625.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="849200011"><itemNumber>2098</itemNumber><strength>160mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02525267" sec3="Y" sec12="Y"><name>Bimzelx</name><manufacturerId>UCB</manufacturerId><individualPrice>1625.0000</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>1625.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="849200015"><itemNumber>2099</itemNumber><strength>320mg/2mL</strength><dosageForm>Inj Sol-2mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02553627" sec3="Y" sec12="Y"><name>Bimzelx</name><manufacturerId>UCB</manufacturerId><individualPrice>3250.0000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>3250.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="849200014"><itemNumber>2100</itemNumber><strength>320mg/2mL</strength><dosageForm>Inj Sol-2mL Pref Syr (Preservative-Free)</dosageForm><drug id="02553619" sec3="Y" sec12="Y"><name>Bimzelx</name><manufacturerId>UCB</manufacturerId><individualPrice>3250.0000</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>3250.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="641">For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.

Note 1: Definition of severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face,
hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.


Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will allow for standard dosing for Bimzelx, which is 320mg subcutaneously every 4 weeks for the first 16 weeks, and every 8 weeks thereafter. A dose of 320mg every 4 weeks after the first 16 weeks may be considered in patients with a body weight of 120kg or more who did not achieve a complete skin response. For patients with no improvement after 16 weeks of treatment at the Health Canada approved dose, higher or more frequent doses are not recommended and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02376"><name>GUSELKUMAB</name><pcgGroup lccId="00374"><pcg9 id="849200013"><itemNumber>2101</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Autoinj (Preservative-Free)</dosageForm><drug id="02487314" sec3="Y" sec12="Y"><name>Tremfya One-Press</name><manufacturerId>JAN</manufacturerId><individualPrice>3059.7400</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>3059.7400</amountMOHLTCPays></drug></pcg9><pcg9 id="849200012"><itemNumber>2102</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02469758" sec3="Y" sec12="Y"><name>Tremfya</name><manufacturerId>JAN</manufacturerId><individualPrice>3059.7400</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>3059.7400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="658">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 16 weeks is appropriate. Patients not responding adequately at 16 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

12 week trial of phototherapy (unless not accessible), AND

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 16 weeks of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for guselkumab.

The recommended dosing regimen is 100mg administered subcutaneously at week 0 and week 4, followed by maintenance dosing every 8 weeks thereafter, as approved by Health Canada. 

If the patient has not responded adequately after 16 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02184"><name>HALOBETASOL PROPIONATE &amp; TAZAROTENE</name><pcgGroup><pcg9 id="849200006"><itemNumber>2103</itemNumber><strength>0.01% &amp; 0.045%</strength><dosageForm>Lot</dosageForm><drug id="02499967" sec3="Y"><name>Duobrii</name><manufacturerId>BHC</manufacturerId><individualPrice>1.9300</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>1.9300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01407"><name>TAZAROTENE</name><pcgGroup lccId="00362"><pcg9 id="849200008"><itemNumber>2104</itemNumber><strength>0.045% w/w</strength><dosageForm>Lot</dosageForm><drug id="02517868" sec3="Y" sec12="Y"><name>Arazlo</name><manufacturerId>BHC</manufacturerId><individualPrice>1.4051</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>1.4051</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="636">For the treatment of acne vulgaris.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02188"><name>TILDRAKIZUMAB</name><pcgGroup lccId="00356"><pcg9 id="849200007"><itemNumber>2105</itemNumber><strength>100mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr (Preservative-Free)</dosageForm><drug id="02516098" sec3="Y" sec12="Y"><name>Ilumya</name><manufacturerId>SPC</manufacturerId><individualPrice>4935.0000</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>4935.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="629">For the treatment of severe plaque psoriasis (see Note 1 below) in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist. Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required. Patients not responding adequately at 12 weeks should have treatment discontinued.

Approvals will only allow for standard dosing for Ilumya 100mg subcutaneously at weeks 0 and 4, and then every 12 weeks. Ilumya should not be used in combination with other systemic or biologic treatments for severe plaque psoriasis.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.

Note 1: Definition of severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10%, or involvement of the face,
hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.


Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

- 6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least 75% reduction in PASI, AND
- at least 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score.
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6></pcg2><pcg2 id="860000000"><name>SPASMOLYTICS</name><pcg6><genericName id="01916"><name>FESOTERODINE FUMARATE</name><pcgGroup lccId="00233"><pcg9 id="860000072"><itemNumber>2106</itemNumber><strength>4mg</strength><dosageForm>Tab</dosageForm><drug id="02380021" sec3="Y" sec12="Y"><name>Toviaz</name><manufacturerId>PFI</manufacturerId><individualPrice>1.5500</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.1250</amountMOHLTCPays></drug><drug id="02521768" sec3="Y" sec12="Y"><name>Sandoz Fesoterodine Fumarate</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.1250</amountMOHLTCPays></drug></pcg9><pcg9 id="860000073"><itemNumber>2107</itemNumber><strength>8mg</strength><dosageForm>Tab</dosageForm><drug id="02380048" sec3="Y" sec12="Y"><name>Toviaz</name><manufacturerId>PFI</manufacturerId><individualPrice>1.5500</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.1250</amountMOHLTCPays></drug><drug id="02521776" sec3="Y" sec12="Y"><name>Sandoz Fesoterodine Fumarate</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1250</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>1.1250</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="290">For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01976"><name>MIRABEGRON</name><pcgGroup lccId="00254"><pcg9 id="860000074"><itemNumber>2108</itemNumber><strength>25mg</strength><dosageForm>ER Tab</dosageForm><drug id="02402874" sec3="Y" sec12="Y"><name>Myrbetriq</name><manufacturerId>ASE</manufacturerId><individualPrice>1.4600</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>1.4600</amountMOHLTCPays></drug></pcg9><pcg9 id="860000075"><itemNumber>2109</itemNumber><strength>50mg</strength><dosageForm>ER Tab</dosageForm><drug id="02402882" sec3="Y" sec12="Y"><name>Myrbetriq</name><manufacturerId>ASE</manufacturerId><individualPrice>1.4600</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>1.4600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="290">For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01111"><name>OXTRIPHYLLINE</name><pcgGroup><pcg9 id="860000013"><itemNumber>2110</itemNumber><strength>20mg/mL</strength><dosageForm>O/L</dosageForm><drug id="00476366" sec3="Y"><name>Choledyl</name><manufacturerId>SLP</manufacturerId><individualPrice>.0398</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0398</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01112"><name>THEOPHYLLINE ANHYDROUS</name><pcgGroup><pcg9 id="860000046"><itemNumber>2111</itemNumber><strength>400mg</strength><dosageForm>SR Tab</dosageForm><drug id="02014165" notABenefit="Y" sec3="Y"><name>Uniphyl</name><manufacturerId>ELV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02360101" sec3="Y"><name>Theo ER</name><manufacturerId>AAP</manufacturerId><individualPrice>.3735</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.3734</amountMOHLTCPays></drug></pcg9><pcg9 id="860000047"><itemNumber>2112</itemNumber><strength>600mg</strength><dosageForm>SR Tab</dosageForm><drug id="02014181" notABenefit="Y" sec3="Y"><name>Uniphyl</name><manufacturerId>ELV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02360128" sec3="Y"><name>Theo ER</name><manufacturerId>AAP</manufacturerId><individualPrice>.4524</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.4524</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="861204000"><name>GENITOURINARY SMOOTH MUSCLE RELAXANTS ANTIMUSCARINICS</name><genericName id="02054"><name>PROPIVERINE HYDROCHLORIDE</name><pcgGroup lccId="00303"><pcg9 id="861204001"><itemNumber>2113</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02460289" sec3="Y" sec12="Y"><name>Mictoryl Pediatric</name><manufacturerId>DUI</manufacturerId><individualPrice>.3889</individualPrice><listingDate>2018-05-31</listingDate><amountMOHLTCPays>.3889</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="530">For the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients with overactive bladder.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6></pcg2><pcg2 id="880000000"><name>VITAMINS</name><pcg6 id="880800000"><name>VITAMIN B</name><genericName id="01116"><name>CYANOCOBALAMIN</name><pcgGroup><pcg9 id="880800001" suppliedBy="L"><itemNumber>2114</itemNumber><strength>1mg/mL</strength><dosageForm>Inj Sol-10mL Pk</dosageForm><drug id="00029165" notABenefit="Y" sec3="Y"><name>Rubramin</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00521515" selfMed="Y" sec3="Y"><name>Vitamin B12-1000mcg/mL</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.0600</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>3.0600</amountMOHLTCPays></drug><drug id="01987003" selfMed="Y" sec3="Y"><name>Cyanocobalamin</name><manufacturerId>STE</manufacturerId><individualPrice>3.0600</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>3.0600</amountMOHLTCPays></drug><drug id="02413795" selfMed="Y" sec3="Y"><name>Cyanocobalamin Injection USP</name><manufacturerId>MYL</manufacturerId><individualPrice>3.0600</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>3.0600</amountMOHLTCPays></drug><drug id="02420147" selfMed="Y" sec3="Y"><name>Jamp-Cyanocobalamin</name><manufacturerId>JPC</manufacturerId><individualPrice>3.0600</individualPrice><listingDate>2015-08-26</listingDate><amountMOHLTCPays>3.0600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01117"><name>FOLIC ACID</name><pcgGroup><pcg9 id="880800003"><itemNumber>2115</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="00014966" notABenefit="Y" sec3="Y"><name>Folvite</name><manufacturerId>LED</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00426849" sec3="Y"><name>Folic Acid</name><manufacturerId>AAP</manufacturerId><individualPrice>.0404</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0404</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01121"><name>LEUCOVORIN CALCIUM</name><pcgGroup><pcg9 id="880800015"><itemNumber>2116</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02170493" sec3="Y"><name>Leucovorin Calcium</name><manufacturerId>WAY</manufacturerId><individualPrice>7.3552</individualPrice><listingDate>1999-01-07</listingDate><amountMOHLTCPays>1.8388</amountMOHLTCPays></drug><drug id="02493357" sec3="Y"><name>Riva Leucovorin</name><manufacturerId>RIA</manufacturerId><individualPrice>1.8388</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>1.8388</amountMOHLTCPays></drug><drug id="02496828" sec3="Y"><name>Mint-Leucovorin</name><manufacturerId>MIN</manufacturerId><individualPrice>1.8388</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>1.8388</amountMOHLTCPays></drug><drug id="02548208" sec3="Y"><name>Jamp Leucovorin</name><manufacturerId>JPC</manufacturerId><individualPrice>1.8388</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>1.8388</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01118"><name>NICOTINIC ACID</name><note>Nicotinic acid is the most cost-effective therapy for hyperlipidemia and is tolerated in approximately 80% of patients with adequate warning about expected flushing which disappears after 5 days in most cases, and is significantly reduced with regular use of ASA.</note><pcgGroup><pcg9 id="880800007" dpp="Y"><itemNumber>2117</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00268593" notABenefit="Y" sec3="Y"><name>Niacin-ICN</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00274496" notABenefit="Y" sec3="Y"><name>Novo-Niacin</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01120"><name>THIAMINE HCL</name><pcgGroup><pcg9 id="880800012" dpp="Y"><itemNumber>2118</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00268631" notABenefit="Y" sec3="Y"><name>Vitamin B1-ICN</name><manufacturerId>VAL</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00610267" notABenefit="Y" sec3="Y"><name>Vitamin B1</name><manufacturerId>LEA</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="881200000"><name>VITAMIN C</name><genericName id="01131"><name>ASCORBIC ACID</name><pcgGroup><pcg9 id="881200001" suppliedBy="L"><itemNumber>2119</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="00021997" notABenefit="Y" sec3="Y"><name>Novo-C</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00036188" notABenefit="Y" sec3="Y"><name>Vitamin C</name><manufacturerId>RPR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00466611" notABenefit="Y" sec3="Y"><name>Apo-C</name><manufacturerId>APX</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="881600000"><name>VITAMIN D</name><genericName id="01136"><name>ALFACALCIDOL</name><pcgGroup><pcg9 id="881600007" dpp="Y"><itemNumber>2120</itemNumber><strength>0.25mcg</strength><dosageForm>Cap</dosageForm><drug id="00474517" sec3="Y"><name>One-Alpha</name><manufacturerId>LEO</manufacturerId><individualPrice>.6289</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.4313</amountMOHLTCPays></drug><drug id="02533316" sec3="Y"><name>Sandoz Alfacalcidol</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4313</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.4313</amountMOHLTCPays></drug></pcg9><pcg9 id="881600006" dpp="Y"><itemNumber>2121</itemNumber><strength>1mcg</strength><dosageForm>Cap</dosageForm><drug id="00474525" sec3="Y"><name>One-Alpha</name><manufacturerId>LEO</manufacturerId><individualPrice>1.8827</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2911</amountMOHLTCPays></drug><drug id="02533324" sec3="Y"><name>Sandoz Alfacalcidol</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2911</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>1.2911</amountMOHLTCPays></drug></pcg9><pcg9 id="881600017"><itemNumber>2122</itemNumber><strength>2mcg/mL</strength><dosageForm>Oral Drops</dosageForm><drug id="02240329" sec3="Y"><name>One-Alpha Drops</name><manufacturerId>LEO</manufacturerId><individualPrice>7.5526</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>7.5526</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01135"><name>CALCITRIOL</name><pcgGroup><pcg9 id="881600005" dpp="Y"><itemNumber>2123</itemNumber><strength>0.25mcg</strength><dosageForm>Cap</dosageForm><drug id="00481823" sec3="Y"><name>Rocaltrol</name><manufacturerId>HLR</manufacturerId><individualPrice>.7071</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2341</amountMOHLTCPays></drug><drug id="02431637" sec3="Y"><name>Calcitriol-Odan</name><manufacturerId>ODN</manufacturerId><individualPrice>.2341</individualPrice><listingDate>2016-03-30</listingDate><amountMOHLTCPays>.2341</amountMOHLTCPays></drug><drug id="02485710" sec3="Y"><name>Taro-Calcitriol</name><manufacturerId>TAR</manufacturerId><individualPrice>.2341</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.2341</amountMOHLTCPays></drug><drug id="02495899" sec3="Y"><name>PMS-Calcitriol</name><manufacturerId>PMS</manufacturerId><individualPrice>.2341</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.2341</amountMOHLTCPays></drug></pcg9><pcg9 id="881600004" dpp="Y"><itemNumber>2124</itemNumber><strength>0.5mcg</strength><dosageForm>Cap</dosageForm><drug id="00481815" sec3="Y"><name>Rocaltrol</name><manufacturerId>HLR</manufacturerId><individualPrice>1.1246</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3723</amountMOHLTCPays></drug><drug id="02431645" sec3="Y"><name>Calcitriol-Odan</name><manufacturerId>ODN</manufacturerId><individualPrice>.3723</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3723</amountMOHLTCPays></drug><drug id="02485729" sec3="Y"><name>Taro-Calcitriol</name><manufacturerId>TAR</manufacturerId><individualPrice>.3723</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>.3723</amountMOHLTCPays></drug><drug id="02495902" sec3="Y"><name>PMS-Calcitriol</name><manufacturerId>PMS</manufacturerId><individualPrice>.3723</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>.3723</amountMOHLTCPays></drug></pcg9><pcg9 id="881600016"><itemNumber>2125</itemNumber><strength>1mcg/mL</strength><dosageForm>Inj Sol Amp-1mL Pk</dosageForm><drug id="00891738" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Calcijex</name><manufacturerId>ABV</manufacturerId><listingDate>2016-06-29</listingDate></drug><drug id="02399334" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Calcitriol Injection USP</name><manufacturerId>STE</manufacturerId><individualPrice>9.5132</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>9.5132</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01133"><name>ERGOCALCIFEROL</name><pcgGroup><pcg9 id="881600002"><itemNumber>2126</itemNumber><strength>8288IU/mL</strength><dosageForm>O/L</dosageForm><drug id="02017598" notABenefit="Y" sec3="Y"><name>Drisdol</name><manufacturerId>SAV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="80003615" sec3="Y"><name>Erdol</name><manufacturerId>ODN</manufacturerId><individualPrice>.5767</individualPrice><listingDate>2012-03-26</listingDate><amountMOHLTCPays>.5767</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="882400000"><name>VITAMIN K</name><genericName id="01142"><name>PHYTONADIONE</name><pcgGroup><pcg9 id="882400006"><itemNumber>2127</itemNumber><strength>1mg/0.5mL</strength><dosageForm>Inj-0.5mL Amp Pk (Preservative Free)</dosageForm><drug id="00781878" sec3="Y"><name>Vitamin K1 Inj 1mg/0.5mL USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>5.2950</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>5.2950</amountMOHLTCPays></drug></pcg9><pcg9 id="882400005"><itemNumber>2128</itemNumber><strength>10mg/mL</strength><dosageForm>Inj-1mL Amp Pk (Preservative Free)</dosageForm><drug id="00804312" sec3="Y"><name>Vitamin K1 Inj 10mg/mL USP</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.0000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>6.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="882800000"><name>MULTIVITAMINS</name><genericName id="01143"><name>HEXAVITAMINS USP</name><pcgGroup><pcg9 id="882800001" suppliedBy="L"><itemNumber>2129</itemNumber><dosageForm>Tab</dosageForm><drug id="00269034" notABenefit="Y" sec3="Y"><name>Hexavitamins</name><manufacturerId>NOP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00701130" notABenefit="Y" sec3="Y"><name>Apo-Hexa</name><manufacturerId>APX</manufacturerId><listingDate>1996-10-01</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01150"><name>MULTIVITAMINS</name><pcgGroup><pcg9 id="882800066"><itemNumber>2130</itemNumber><dosageForm>Tab</dosageForm><drug id="02451573" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pregvit</name><manufacturerId>DUI</manufacturerId><listingDate>2025-02-28</listingDate></drug><drug id="02535718" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pregnancy Multivitamin</name><manufacturerId>JPC</manufacturerId><individualPrice>.3125</individualPrice><listingDate>2025-02-28</listingDate></drug></pcg9><pcg9 id="882800067"><itemNumber>2131</itemNumber><dosageForm>Tab</dosageForm><drug id="02451581" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pregvit Folic 5</name><manufacturerId>DUI</manufacturerId><listingDate>2025-02-28</listingDate></drug><drug id="02537478" notABenefit="Y" sec3b="Y" sec3="Y"><name>Pregnancy Multivitamin Folic 5</name><manufacturerId>JPC</manufacturerId><individualPrice>.5025</individualPrice><listingDate>2025-02-28</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01169"><name>MULTIVITAMINS FOR INFUSION</name><pcgGroup><pcg9 id="882800041"><itemNumber>2132</itemNumber><dosageForm>Inj-2x5mL Vial Pk</dosageForm><drug id="02100606" sec3="Y"><name>Multi-12</name><manufacturerId>SDZ</manufacturerId><individualPrice>23.0000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>23.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="882800056"><itemNumber>2133</itemNumber><dosageForm>Inj-4mL+1mL Vial Pk</dosageForm><drug id="02242529" sec3="Y"><name>Multi 12/K1 Pediatric</name><manufacturerId>SDZ</manufacturerId><individualPrice>41.8000</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>41.8000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="920000000"><name>UNCLASSIFIED THERAPEUTIC AGENTS</name><pcg6><genericName id="01283"><name>ALENDRONATE</name><pcgGroup><pcg9 id="920000294"><itemNumber>2134</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02233055" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fosamax</name><manufacturerId>MFC</manufacturerId><listingDate>2007-10-03</listingDate></drug><drug id="02248251" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Alendronate</name><manufacturerId>TEV</manufacturerId><individualPrice>1.0370</individualPrice><listingDate>2007-10-03</listingDate></drug><drug id="02248727" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Alendronate</name><manufacturerId>APX</manufacturerId><individualPrice>1.0370</individualPrice><listingDate>2007-10-03</listingDate></drug><drug id="02381478" notABenefit="Y" sec3b="Y" sec3="Y"><name>Alendronate Sodium Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>1.0370</individualPrice><listingDate>2012-08-27</listingDate></drug></pcg9><pcg9 id="920000232"><itemNumber>2135</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02201011" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Fosamax</name><manufacturerId>MFC</manufacturerId><listingDate>2000-11-30</listingDate></drug><drug id="02247373" chronicUseMed="Y" sec3="Y"><name>Teva-Alendronate</name><manufacturerId>TEV</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug><drug id="02248728" chronicUseMed="Y" sec3="Y"><name>Apo-Alendronate</name><manufacturerId>APX</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug><drug id="02288087" chronicUseMed="Y" sec3="Y"><name>Sandoz Alendronate</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug><drug id="02381486" chronicUseMed="Y" sec3="Y"><name>Alendronate Sodium Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug><drug id="02384701" chronicUseMed="Y" sec3="Y"><name>Ran-Alendronate</name><manufacturerId>RAN</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2012-07-27</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug><drug id="02388545" chronicUseMed="Y" sec3="Y"><name>Auro-Alendronate</name><manufacturerId>AUR</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug><drug id="02394863" chronicUseMed="Y" sec3="Y"><name>Mint-Alendronate</name><manufacturerId>MIN</manufacturerId><individualPrice>.4987</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>.4987</amountMOHLTCPays></drug></pcg9><pcg9 id="920000426"><itemNumber>2136</itemNumber><strength>70mg</strength><dosageForm>Tab</dosageForm><drug id="02245329" chronicUseMed="Y" sec3="Y"><name>Fosamax</name><manufacturerId>OCI</manufacturerId><individualPrice>12.6250</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02248730" chronicUseMed="Y" sec3="Y"><name>Apo-Alendronate</name><manufacturerId>APX</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2005-07-14</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02261715" chronicUseMed="Y" sec3="Y"><name>Teva-Alendronate</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2005-08-19</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02270889" chronicUseMed="Y" sec3="Y"><name>Riva-Alendronate</name><manufacturerId>RIA</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02284006" chronicUseMed="Y" sec3="Y"><name>PMS-Alendronate-FC</name><manufacturerId>PMS</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02288109" chronicUseMed="Y" sec3="Y"><name>Sandoz Alendronate</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2007-03-09</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02299712" chronicUseMed="Y" sec3="Y"><name>Alendronate</name><manufacturerId>SIV</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2009-11-19</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02352966" chronicUseMed="Y" sec3="Y"><name>Alendronate</name><manufacturerId>SAI</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02381494" chronicUseMed="Y" sec3="Y"><name>Alendronate Sodium Tablets</name><manufacturerId>ACH</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02385031" chronicUseMed="Y" sec3="Y"><name>Jamp-Alendronate</name><manufacturerId>JPC</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02388553" chronicUseMed="Y" sec3="Y"><name>Auro-Alendronate</name><manufacturerId>AUR</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02394871" chronicUseMed="Y" sec3="Y"><name>Mint-Alendronate</name><manufacturerId>MIN</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02485184" chronicUseMed="Y" sec3="Y"><name>AG-Alendronate</name><manufacturerId>ANG</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2020-11-30</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02500175" chronicUseMed="Y" sec3="Y"><name>Jamp Alendronate Sodium</name><manufacturerId>JPC</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02523116" chronicUseMed="Y" sec3="Y"><name>NRA-Alendronate</name><manufacturerId>NRA</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug><drug id="02529394" chronicUseMed="Y" sec3="Y"><name>M-Alendronate</name><manufacturerId>MAT</manufacturerId><individualPrice>1.7804</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>1.7804</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01689"><name>ALENDRONATE &amp; CHOLECALCIFEROL</name><pcgGroup><pcg9 id="920000544"><itemNumber>2137</itemNumber><strength>70mg &amp; 70mcg</strength><dosageForm>Tab</dosageForm><drug id="02276429" chronicUseMed="Y" sec3="Y"><name>Fosavance</name><manufacturerId>OCI</manufacturerId><individualPrice>5.5335</individualPrice><note>Note:  The recommended dose of Vitamin D for osteoporosis prevention and treatment in adults over 50 years old is at least 800 IU/day, in conjunction with calcium.  This product does not provide the total recommended daily intake of Vitamin D; supplemental Vitamin D may be required. The appropriate dosage of ALENDRONATE &amp; CHOLECALCIFEROL must be determined by the physician based on the patient&apos;s vitamin D requirement.</note><listingDate>2007-01-02</listingDate><amountMOHLTCPays>2.4348</amountMOHLTCPays></drug><drug id="02454467" chronicUseMed="Y" sec3="Y"><name>Apo-Alendronate/Vitamin D3</name><manufacturerId>APX</manufacturerId><individualPrice>2.4348</individualPrice><note>Note:  The recommended dose of Vitamin D for osteoporosis prevention and treatment in adults over 50 years old is at least 800 IU/day, in conjunction with calcium.  This product does not provide the total recommended daily intake of Vitamin D; supplemental Vitamin D may be required. The appropriate dosage of ALENDRONATE &amp; CHOLECALCIFEROL must be determined by the physician based on the patient&apos;s vitamin D requirement.</note><listingDate>2016-09-29</listingDate><amountMOHLTCPays>2.4348</amountMOHLTCPays></drug><drug id="02519828" chronicUseMed="Y" sec3="Y"><name>Jamp Alendronate/Vitamin D3</name><manufacturerId>JPC</manufacturerId><individualPrice>2.4348</individualPrice><listingDate>2023-07-31</listingDate><amountMOHLTCPays>2.4348</amountMOHLTCPays></drug></pcg9><pcg9 id="920000596"><itemNumber>2138</itemNumber><strength>70mg &amp; 140mcg</strength><dosageForm>Tab</dosageForm><drug id="02314940" chronicUseMed="Y" sec3="Y"><name>Fosavance</name><manufacturerId>OCI</manufacturerId><individualPrice>5.4250</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>2.4348</amountMOHLTCPays></drug><drug id="02454475" chronicUseMed="Y" sec3="Y"><name>Apo-Alendronate/Vitamin D3</name><manufacturerId>APX</manufacturerId><individualPrice>2.4348</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>2.4348</amountMOHLTCPays></drug><drug id="02519836" chronicUseMed="Y" sec3="Y"><name>Jamp Alendronate/Vitamin D3</name><manufacturerId>JPC</manufacturerId><individualPrice>2.4348</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>2.4348</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01564"><name>ALFUZOSIN HYDROCHLORIDE</name><pcgGroup lccId="00121"><pcg9 id="920000421"><itemNumber>2139</itemNumber><strength>10mg</strength><dosageForm>Prolong-Rel Tab</dosageForm><drug id="02245565" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Xatral</name><manufacturerId>SAV</manufacturerId><individualPrice>1.0900</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2601</amountMOHLTCPays></drug><drug id="02304678" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Alfuzosin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2601</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.2601</amountMOHLTCPays></drug><drug id="02315866" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Alfuzosin</name><manufacturerId>APX</manufacturerId><individualPrice>.2601</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>.2601</amountMOHLTCPays></drug><drug id="02443201" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Alfuzosin</name><manufacturerId>AUR</manufacturerId><individualPrice>.2601</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.2601</amountMOHLTCPays></drug><drug id="02447576" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Alfuzosin</name><manufacturerId>SIV</manufacturerId><individualPrice>.2601</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2601</amountMOHLTCPays></drug><drug id="02519844" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Alfuzosin</name><manufacturerId>SAI</manufacturerId><individualPrice>.2601</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.2601</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="351">For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="352">For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01170"><name>ALLOPURINOL</name><note>Reduce dose of mercaptopurine or azathioprine if used concomitantly. Adjust dose of allopurinol in patients with renal impairment. Allopurinol should not be used to treat patients with hyperuricemia when decreased uricosuria is the cause.</note><pcgGroup><pcg9 id="920000001"><itemNumber>2140</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="00402818" chronicUseMed="Y" sec3="Y"><name>Apo-Allopurinol Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.0780</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.0780</amountMOHLTCPays></drug><drug id="02396327" chronicUseMed="Y" sec3="Y"><name>Mar-Allopurinol</name><manufacturerId>MAR</manufacturerId><individualPrice>.0780</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.0780</amountMOHLTCPays></drug><drug id="02402769" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Allopurinol</name><manufacturerId>APX</manufacturerId><listingDate>2013-07-30</listingDate></drug></pcg9><pcg9 id="920000028"><itemNumber>2141</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="00479799" chronicUseMed="Y" sec3="Y"><name>Apo-Allopurinol Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.1300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.1300</amountMOHLTCPays></drug><drug id="02396335" chronicUseMed="Y" sec3="Y"><name>Mar-Allopurinol</name><manufacturerId>MAR</manufacturerId><individualPrice>.1300</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.1300</amountMOHLTCPays></drug><drug id="02402777" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Allopurinol</name><manufacturerId>APX</manufacturerId><listingDate>2013-07-30</listingDate></drug></pcg9><pcg9 id="920000013"><itemNumber>2142</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="00294322" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Zyloprim</name><manufacturerId>BWE</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="00402796" chronicUseMed="Y" sec3="Y"><name>Apo-Allopurinol Tablets</name><manufacturerId>APX</manufacturerId><individualPrice>.2125</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.2125</amountMOHLTCPays></drug><drug id="02396343" chronicUseMed="Y" sec3="Y"><name>Mar-Allopurinol</name><manufacturerId>MAR</manufacturerId><individualPrice>.2125</individualPrice><listingDate>2013-02-28</listingDate><amountMOHLTCPays>.2125</amountMOHLTCPays></drug><drug id="02402785" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Apo-Allopurinol</name><manufacturerId>APX</manufacturerId><listingDate>2013-07-30</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01176"><name>AMANTADINE HCL</name><note>Amantadine increases central and peripheral effects of anticholinergic drugs.</note><pcgGroup><pcg9 id="920000021"><itemNumber>2143</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="01914006" notABenefit="Y" sec3="Y"><name>Symmetrel</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="01990403" sec3="Y"><name>PDP-Amantadine Hydrochloride Capsules</name><manufacturerId>PEN</manufacturerId><individualPrice>.5662</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.5662</amountMOHLTCPays></drug></pcg9><pcg9 id="920000032"><itemNumber>2144</itemNumber><strength>10mg/mL</strength><dosageForm>O/L</dosageForm><drug id="01913999" notABenefit="Y" sec3="Y"><name>Symmetrel</name><manufacturerId>BQU</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02022826" sec3="Y"><name>PDP-Amantadine Hydrochloride Syrup</name><manufacturerId>PEN</manufacturerId><individualPrice>.0988</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>.0988</amountMOHLTCPays></drug><drug id="02538601" sec3="Y"><name>Odan-Amantadine Syrup</name><manufacturerId>ODN</manufacturerId><individualPrice>.0988</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.0988</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01358"><name>ANAGRELIDE HCL</name><pcgGroup lccId="00164"><pcg9 id="920000273"><itemNumber>2145</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02236859" notABenefit="Y" sec3="Y"><name>Agrylin</name><manufacturerId>TAK</manufacturerId><listingDate>2020-02-28</listingDate></drug><drug id="02274949" sec3="Y" sec12="Y"><name>PMS-Anagrelide</name><manufacturerId>PMS</manufacturerId><individualPrice>4.6997</individualPrice><listingDate>2020-02-28</listingDate><amountMOHLTCPays>4.6997</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="400">For the treatment of essential thrombocytosis in patients who are intolerant of or who have failed hydroxyurea therapy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 5 years.</lccNote></pcgGroup><pcgGroup><pcg9 id="920000793"><itemNumber>2146</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="09858363" sec3c="Y"><name>Anagride</name><manufacturerId>SET</manufacturerId><individualPrice>5.9696</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>5.9696</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00196"><name>AZATHIOPRINE</name><pcgGroup><pcg9 id="920000003"><itemNumber>2147</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="00004596" sec3="Y"><name>Imuran</name><manufacturerId>ASN</manufacturerId><individualPrice>1.3820</individualPrice><note>Decrease dose of azathioprine to 25 -33% of initial dose if allopurinol used concomitantly.</note><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5185</amountMOHLTCPays></drug><drug id="02236819" sec3="Y"><name>Teva-Azathioprine</name><manufacturerId>TEV</manufacturerId><individualPrice>.5185</individualPrice><note>Decrease dose of azathioprine to 25 -33% of initial dose if allopurinol used concomitantly.</note><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.5185</amountMOHLTCPays></drug><drug id="02242907" sec3="Y"><name>Apo-Azathioprine</name><manufacturerId>APX</manufacturerId><individualPrice>.5185</individualPrice><note>Decrease dose of azathioprine to 25 -33% of initial dose if allopurinol used concomitantly.</note><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.5185</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01269"><name>BOTULINUM TOXIN TYPE A</name><pcgGroup lccId="00122"><pcg9 id="920000207"><itemNumber>2148</itemNumber><strength>100U/Vial</strength><dosageForm>Pd Inj-100U Vial Pk</dosageForm><drug id="01981501" sec3="Y" sec12="Y"><name>Botox</name><manufacturerId>ABV</manufacturerId><individualPrice>374.8500</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>374.8500</amountMOHLTCPays></drug></pcg9><pcg9 id="920000629"><itemNumber>2149</itemNumber><strength>200U/Vial</strength><dosageForm>Pd Inj-200U Vial Pk</dosageForm><drug id="09857387" dinStatus="E" sec3="Y" sec12="Y"><name>Botox</name><manufacturerId>ABV</manufacturerId><individualPrice>749.7000</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>749.7000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000745"><itemNumber>2150</itemNumber><strength>200U/Vial</strength><dosageForm>Pd Inj-200U Vial Pk</dosageForm><drug id="02531585" sec3="Y" sec12="Y"><name>Botox</name><manufacturerId>ABV</manufacturerId><individualPrice>749.7000</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>749.7000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000628"><itemNumber>2151</itemNumber><strength>50U/Vial</strength><dosageForm>Pd Inj-50U Vial Pk</dosageForm><drug id="09857386" dinStatus="E" sec3="Y" sec12="Y"><name>Botox</name><manufacturerId>ABV</manufacturerId><individualPrice>187.4300</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>187.4300</amountMOHLTCPays></drug></pcg9><pcg9 id="920000742"><itemNumber>2152</itemNumber><strength>50U/Vial</strength><dosageForm>Pd Inj-50U Vial Pk</dosageForm><drug id="02531577" sec3="Y" sec12="Y"><name>Botox</name><manufacturerId>ABV</manufacturerId><individualPrice>187.4300</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>187.4300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="10">For the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="130">To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="412">For the management of focal spasticity, due to stroke or spinal cord injury in adults.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="413">For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="440">For adult patients with urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury who fail to respond to behavioural medication and anticholinergics and/or are intolerant to anticholinergics.
The recommended dose is 200U injected into the detrusor muscle.
Subsequent injections should be provided at intervals of no less than every 36 weeks and patients who fail to respond to initial treatment with Botulinum Toxin Type A should not be retreated.
</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="460">For adult patients with urinary frequency, urgency or urge incontinence due to overactive bladder who have:


Failed to respond to behavioral techniques AND had an inadequate response or intolerance to adequate trials (i.e., at least 2 weeks at the maximum tolerated dose) of at least two medications for overactive bladder (e.g. anticholinergics, mirabegron).


The recommended dose is 100U injected into the detrusor muscle.


NOTES:


-Patients who fail to achieve a reduction of greater than 50 percent in the frequency of urinary incontinence episodes with 1 dose should not be retreated.


-Maximum 3 doses per year in responders, at a frequency of no more than once every 12 weeks.


-Patients must have a post-void residual (PVR) urine volume of less than 150mL.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" type="C">Note: Botox should be administered personally by a urologist, pediatrician, neurologist, physical medicine specialist or a physician with equivalent post-graduate training and experience with neuromuscular or urological disorders as appropriate.</lccNote></pcgGroup></genericName><genericName id="01179"><name>BROMOCRIPTINE</name><pcgGroup><pcg9 id="920000044"><itemNumber>2153</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="00568643" notABenefit="Y" sec3="Y"><name>Parlodel</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230454" sec3="Y"><name>Bromocriptine</name><manufacturerId>AAP</manufacturerId><individualPrice>1.7097</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>1.7097</amountMOHLTCPays></drug></pcg9><pcg9 id="920000029"><itemNumber>2154</itemNumber><strength>2.5mg</strength><dosageForm>Tab</dosageForm><drug id="00371033" notABenefit="Y" sec3="Y"><name>Parlodel</name><manufacturerId>NOV</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02087324" sec3="Y"><name>Bromocriptine</name><manufacturerId>AAP</manufacturerId><individualPrice>1.0800</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.0800</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01383"><name>BUPROPION HCL</name><pcgGroup lccId="00210"><pcg9 id="920000632"><itemNumber>2155</itemNumber><strength>150mg</strength><dosageForm>SR Tab</dosageForm><drug id="02238441" sec3="Y" sec12="Y"><name>Zyban</name><manufacturerId>VAL</manufacturerId><individualPrice>1.3275</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>1.3275</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="423">For smoking-cessation treatment in adults, in conjunction with smoking-cessation
counseling.

Network Note: Limited to 12 weeks (168 tablets) of reimbursement per 365 days per patient.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote></pcgGroup></genericName><genericName id="01495"><name>CABERGOLINE</name><pcgGroup lccId="00373"><pcg9 id="920000380"><itemNumber>2156</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02242471" sec3="Y" sec12="Y"><name>Dostinex</name><manufacturerId>PMJ</manufacturerId><individualPrice>23.0588</individualPrice><listingDate>2008-06-27</listingDate><amountMOHLTCPays>7.2907</amountMOHLTCPays></drug><drug id="02455897" sec3="Y" sec12="Y"><name>Apo-Cabergoline</name><manufacturerId>APX</manufacturerId><individualPrice>7.2907</individualPrice><listingDate>2017-05-31</listingDate><amountMOHLTCPays>7.2907</amountMOHLTCPays></drug><drug id="02549611" sec3="Y" sec12="Y"><name>Jamp Cabergoline</name><manufacturerId>JPC</manufacturerId><individualPrice>7.2907</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>7.2907</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="656">For the treatment of hyperprolactinemia.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01649"><name>CASPOFUNGIN</name><pcgGroup><pcg9 id="920000530"><itemNumber>2157</itemNumber><strength>70mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02244266" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cancidas</name><manufacturerId>FRS</manufacturerId><listingDate>2017-08-30</listingDate></drug><drug id="02460955" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Caspofungin for Injection</name><manufacturerId>JUN</manufacturerId><individualPrice>222.0000</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>222.0000</amountMOHLTCPays></drug><drug id="02486997" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Caspofungin for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>222.5000</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>222.5000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01700"><name>CINACALCET</name><pcgGroup><pcg9 id="920000557"><itemNumber>2158</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02257130" notABenefit="Y" sec3="Y"><name>Sensipar</name><manufacturerId>AMG</manufacturerId><listingDate>2016-05-31</listingDate></drug><drug id="02434539" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Cinacalcet</name><manufacturerId>MYL</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02441624" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Cinacalcet</name><manufacturerId>TEV</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2017-01-31</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02452693" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Cinacalcet</name><manufacturerId>APX</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02478900" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Cinacalcet</name><manufacturerId>AUR</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02480298" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Cinacalcet</name><manufacturerId>MAR</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02481987" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Cinacalcet</name><manufacturerId>MAT</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02500094" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Cinacalcet Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02517604" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Cinacalcet</name><manufacturerId>PMS</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug><drug id="02524880" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Cinacalcet</name><manufacturerId>SAI</manufacturerId><individualPrice>10.1947</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>10.1947</amountMOHLTCPays></drug></pcg9><pcg9 id="920000558"><itemNumber>2159</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="02257149" notABenefit="Y" sec3="Y"><name>Sensipar</name><manufacturerId>AMG</manufacturerId><listingDate>2016-05-31</listingDate></drug><drug id="02434547" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Cinacalcet</name><manufacturerId>MYL</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02441632" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Cinacalcet</name><manufacturerId>TEV</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2017-01-31</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02452707" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Cinacalcet</name><manufacturerId>APX</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02478919" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Cinacalcet</name><manufacturerId>AUR</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02480301" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Cinacalcet</name><manufacturerId>MAR</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02481995" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Cinacalcet</name><manufacturerId>MAT</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02500108" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Cinacalcet Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug><drug id="02517612" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Cinacalcet</name><manufacturerId>PMS</manufacturerId><individualPrice>18.5900</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>18.5900</amountMOHLTCPays></drug></pcg9><pcg9 id="920000660"><itemNumber>2160</itemNumber><strength>90mg</strength><dosageForm>Tab</dosageForm><drug id="02257157" notABenefit="Y" sec3="Y"><name>Sensipar</name><manufacturerId>AMG</manufacturerId><listingDate>2016-05-31</listingDate></drug><drug id="02434555" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Cinacalcet</name><manufacturerId>MYL</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02441640" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Cinacalcet</name><manufacturerId>TEV</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2017-01-31</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02452715" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Cinacalcet</name><manufacturerId>APX</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2016-05-31</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02478943" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Cinacalcet</name><manufacturerId>AUR</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02480328" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Cinacalcet</name><manufacturerId>MAR</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02482002" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Cinacalcet</name><manufacturerId>MAT</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2021-09-30</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02500116" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Cinacalcet Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2021-04-30</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug><drug id="02517620" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Cinacalcet</name><manufacturerId>PMS</manufacturerId><individualPrice>27.0517</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>27.0517</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01239"><name>CLODRONATE DISODIUM</name><pcgGroup lccId="00124"><pcg9 id="920000212"><itemNumber>2161</itemNumber><strength>400mg</strength><dosageForm>Cap</dosageForm><drug id="01927078" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Ostac</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02245828" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Clasteon</name><manufacturerId>SUO</manufacturerId><individualPrice>1.2083</individualPrice><listingDate>2004-10-14</listingDate><amountMOHLTCPays>1.2083</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="280">For the control and prophylaxis of hypercalcemia of malignancy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="358">For the treatment of bony metastases in patients with breast cancer.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="359">For the prevention and treatment of osteolytic lesions in patients with multiple myeloma.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01403"><name>CLOPIDOGREL BISULFATE</name><pcgGroup><pcg9 id="920000303"><itemNumber>2162</itemNumber><strength>75mg</strength><dosageForm>Tab</dosageForm><drug id="02238682" sec3="Y"><name>Plavix</name><manufacturerId>SAV</manufacturerId><individualPrice>2.8180</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02252767" sec3="Y"><name>Apo-Clopidogrel</name><manufacturerId>APX</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02293161" sec3="Y"><name>Teva-Clopidogrel</name><manufacturerId>TEV</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02303027" sec3="Y"><name>Co Clopidogrel</name><manufacturerId>COB</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02348004" sec3="Y"><name>PMS-Clopidogrel</name><manufacturerId>PMS</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02359316" sec3="Y"><name>Sandoz Clopidogrel</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02379813" sec3="Y"><name>Ran-Clopidogrel</name><manufacturerId>RAN</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02385813" sec3="Y"><name>Clopidogrel</name><manufacturerId>SIV</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02400553" sec3="Y"><name>Clopidogrel</name><manufacturerId>SAI</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02408910" sec3="Y"><name>Mint-Clopidogrel</name><manufacturerId>MIN</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02415550" sec3="Y"><name>Jamp-Clopidogrel</name><manufacturerId>JPC</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02416387" sec3="Y"><name>Auro-Clopidogrel</name><manufacturerId>AUR</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02422255" sec3="Y"><name>Mar-Clopidogrel</name><manufacturerId>MAR</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2014-06-26</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02482037" sec3="Y"><name>NRA-Clopidogrel</name><manufacturerId>NRA</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug><drug id="02502283" sec3="Y"><name>M-Clopidogrel</name><manufacturerId>MAT</manufacturerId><individualPrice>.2631</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.2631</amountMOHLTCPays></drug></pcg9><pcg9 id="920000663"><itemNumber>2163</itemNumber><strength>300mg</strength><dosageForm>Tab</dosageForm><drug id="02330555" notABenefit="Y" sec3b="Y" sec3="Y"><name>Plavix</name><manufacturerId>SAV</manufacturerId><listingDate>2012-08-27</listingDate></drug><drug id="02388065" notABenefit="Y" sec3b="Y" sec3="Y"><name>Teva-Clopidogrel</name><manufacturerId>TEV</manufacturerId><individualPrice>9.5447</individualPrice><listingDate>2012-08-27</listingDate></drug><drug id="02398591" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Clopidogrel</name><manufacturerId>APX</manufacturerId><individualPrice>9.5447</individualPrice><listingDate>2013-06-27</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01837"><name>CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A</name><pcgGroup lccId="00208"><pcg9 id="920000684"><itemNumber>2164</itemNumber><strength>50 LD50 Units</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><drug id="02371081" sec3="Y" sec12="Y"><name>Xeomin</name><manufacturerId>MEZ</manufacturerId><individualPrice>169.4550</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>169.4550</amountMOHLTCPays></drug></pcg9><pcg9 id="920000624"><itemNumber>2165</itemNumber><strength>100 LD50 Units</strength><dosageForm>Pd for Inj-Vial Pk</dosageForm><drug id="02324032" sec3="Y" sec12="Y"><name>Xeomin</name><manufacturerId>MEZ</manufacturerId><individualPrice>338.9100</individualPrice><listingDate>2011-05-19</listingDate><amountMOHLTCPays>338.9100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="130">To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="412">For the management of focal spasticity, due to stroke or spinal cord injury in adults.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="421">For the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in adults.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" type="N">Xeomin should be administered personally by a neurologist or a physician with equivalent post-graduate training and experience with neuromuscular disorders.</lccNote></pcgGroup></genericName><genericName id="01189"><name>CYCLOSPORINE</name><pcgGroup><pcg9 id="920000324"><itemNumber>2166</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02237671" sec3="Y"><name>Neoral</name><manufacturerId>NOV</manufacturerId><individualPrice>.7676</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>.7676</amountMOHLTCPays></drug></pcg9><pcg9 id="920000166"><itemNumber>2167</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02150689" sec3="Y"><name>Neoral</name><manufacturerId>NOV</manufacturerId><individualPrice>1.7850</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.8657</amountMOHLTCPays></drug><drug id="02247073" sec3="Y"><name>Sandoz Cyclosporine</name><manufacturerId>SDZ</manufacturerId><individualPrice>.8657</individualPrice><listingDate>2006-01-24</listingDate><amountMOHLTCPays>.8657</amountMOHLTCPays></drug></pcg9><pcg9 id="920000167"><itemNumber>2168</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="02150662" sec3="Y"><name>Neoral</name><manufacturerId>NOV</manufacturerId><individualPrice>3.4816</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.6885</amountMOHLTCPays></drug><drug id="02247074" sec3="Y"><name>Sandoz Cyclosporine</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6885</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>1.6885</amountMOHLTCPays></drug></pcg9><pcg9 id="920000169"><itemNumber>2169</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02150670" sec3="Y"><name>Neoral</name><manufacturerId>NOV</manufacturerId><individualPrice>6.9680</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>3.3792</amountMOHLTCPays></drug><drug id="02242821" sec3="Y"><name>Sandoz Cyclosporine</name><manufacturerId>SDZ</manufacturerId><individualPrice>3.3792</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>3.3792</amountMOHLTCPays></drug></pcg9><pcg9 id="920000168"><itemNumber>2170</itemNumber><strength>100mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02150697" sec3="Y"><name>Neoral</name><manufacturerId>NOV</manufacturerId><individualPrice>6.1952</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>6.1952</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01864"><name>DARIFENACIN</name><pcgGroup lccId="00216"><pcg9 id="920000640"><itemNumber>2171</itemNumber><strength>7.5mg</strength><dosageForm>ER Tab</dosageForm><drug id="02273217" sec3="Y" sec12="Y"><name>Enablex</name><manufacturerId>SLP</manufacturerId><individualPrice>1.6116</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.8058</amountMOHLTCPays></drug><drug id="02452510" sec3="Y" sec12="Y"><name>Apo-Darifenacin</name><manufacturerId>APX</manufacturerId><individualPrice>.8058</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.8058</amountMOHLTCPays></drug><drug id="02491869" sec3="Y" sec12="Y"><name>Jamp Darifenacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.8058</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.8058</amountMOHLTCPays></drug></pcg9><pcg9 id="920000641"><itemNumber>2172</itemNumber><strength>15mg</strength><dosageForm>ER Tab</dosageForm><drug id="02273225" sec3="Y" sec12="Y"><name>Enablex</name><manufacturerId>SLP</manufacturerId><individualPrice>1.6116</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.8058</amountMOHLTCPays></drug><drug id="02452529" sec3="Y" sec12="Y"><name>Apo-Darifenacin</name><manufacturerId>APX</manufacturerId><individualPrice>.8058</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.8058</amountMOHLTCPays></drug><drug id="02491877" sec3="Y" sec12="Y"><name>Jamp Darifenacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.8058</individualPrice><listingDate>2022-02-28</listingDate><amountMOHLTCPays>.8058</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="290">For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01874"><name>DENOSUMAB</name><pcgGroup lccId="00397"><pcg9 id="920000804"><itemNumber>2173</itemNumber><strength>60mg/mL</strength><dosageForm>Inj Sol-1.0mL Pref Syr Pk (Preservative-Free)</dosageForm><drug id="02560917" sec3="Y" sec12="Y"><name>Stoboclo</name><manufacturerId>CEI</manufacturerId><individualPrice>194.7000</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>194.7000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="687">To increase the bone mass in postmenopausal females with osteoporosis who are at high risk* for fracture who have failed, had intolerance to, or are unable to take a bisphosphonate therapy.

*High risk of fracture based on a clinician&apos;s evaluation of the individual&apos;s risk of fractures that may include prior fragility fracture history and the Fracture Risk Assessment (FRAX) scores or another validated tool.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="688">To increase the bone mass in males with osteoporosis who are at high risk* of fractures who have failed, had intolerance to, or are unable to take a bisphosphonate therapy.

*High risk of fracture based on a clinician&apos;s evaluation of the individual&apos;s risk of fractures that may include prior fragility fracture history and the Fracture Risk Assessment (FRAX) scores or another validated tool.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00414"><pcg9 id="920000657"><itemNumber>2174</itemNumber><strength>60mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02343541" sec3="Y" sec12="Y"><name>Prolia (Preservative Free)</name><manufacturerId>AMG</manufacturerId><individualPrice>440.1000</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>440.1000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="690">Only for a patient who is established on Prolia (denosumab) therapy prior to November 29, 2024 and who is or becomes palliative requiring end-of-life care during the biosimilar transition period between November 29, 2024 to August 29, 2025.

Patient must also meet the following criteria:

- The patient is a postmenopausal female or male with osteoporosis and Prolia (denosumab) is being used to increase the bone mass in the patient;

- The patient is at high risk* for fracture; and

- One of the following applies to the patient:

- The patient has failed other available osteoporosis therapy (i.e., fragility fracture or evidence of a decline in bone mineral density below pre-treatment baseline levels) despite adherence to the therapy for one year;

or

- bisphosphonates are contraindicated for the patient due to hypersensitivity, abnormalities of the esophagus (e.g., esophageal stricture or achalasia), or inability to stand or sit upright for at least 30 minutes.

*High risk of fracture is defined as one of the following:

- a prior fragility fracture AND a moderate 10-year fracture risk (10% to 20%) based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool;

- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; or

- where a patient&apos;s 10-year fracture risk based on the CAROC or FRAX tool is less than the thresholds defined above, a high fracture risk based on evaluation of clinical risk factors for fracture.

Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors.

Funded duration: One period of up to 12 months beginning on the date of the first prescription with RFU code 690 is dispensed for the patient.

Note: In all cases, patients receiving Prolia must not be receiving concomitant bisphosphonate therapy. The recommended dose of PROLIA (denosumab) is a single SC injection of 60mg, once every 6 months.

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00397"><pcg9 id="920000786"><itemNumber>2175</itemNumber><strength>60mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02545411" sec3="Y" sec12="Y"><name>Jubbonti (Preservative Free)</name><manufacturerId>SDZ</manufacturerId><individualPrice>194.7000</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>194.7000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="687">To increase the bone mass in postmenopausal females with osteoporosis who are at high risk* for fracture who have failed, had intolerance to, or are unable to take a bisphosphonate therapy.

*High risk of fracture based on a clinician&apos;s evaluation of the individual&apos;s risk of fractures that may include prior fragility fracture history and the Fracture Risk Assessment (FRAX) scores or another validated tool.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="688">To increase the bone mass in males with osteoporosis who are at high risk* of fractures who have failed, had intolerance to, or are unable to take a bisphosphonate therapy.

*High risk of fracture based on a clinician&apos;s evaluation of the individual&apos;s risk of fractures that may include prior fragility fracture history and the Fracture Risk Assessment (FRAX) scores or another validated tool.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00398"><pcg9 id="920000787"><itemNumber>2176</itemNumber><strength>120mg/1.7mL</strength><dosageForm>Inj Sol-Vial Pk</dosageForm><drug id="02545764" sec3="Y" sec12="Y"><name>Wyost (Preservative Free)</name><manufacturerId>SDZ</manufacturerId><individualPrice>312.0000</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>312.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000800"><itemNumber>2177</itemNumber><strength>120mg/1.7mL</strength><dosageForm>Inj Sol-Vial Pk (Preservative-Free)</dosageForm><drug id="02560895" sec3="Y" sec12="Y"><name>Osenvelt</name><manufacturerId>CEI</manufacturerId><individualPrice>312.0000</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>312.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="686">For the treatment of bony metastases for patients with hormone refractory prostate cancer as determined by an elevated PSA level, or evidence of progressive bony disease, despite castrate serum testosterone levels (less than 1.7nmol/L or less than 50ng/dL) or having undergone orchidectomy.

Dose: 120mg SC every 4 weeks
</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01644"><name>DUTASTERIDE</name><pcgGroup lccId="00166"><pcg9 id="920000524"><itemNumber>2178</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02247813" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Avodart</name><manufacturerId>GSK</manufacturerId><individualPrice>2.2293</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02404206" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Dutasteride</name><manufacturerId>APX</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02408287" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Teva-Dutasteride</name><manufacturerId>TEV</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02416298" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Med-Dutasteride</name><manufacturerId>GMP</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2014-12-18</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02424444" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Dutasteride</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02428873" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mint-Dutasteride</name><manufacturerId>MIN</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2014-11-27</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02429012" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Dutasteride</name><manufacturerId>SIV</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02443058" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Dutasteride</name><manufacturerId>SAI</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02469308" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Dutasteride</name><manufacturerId>AUR</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2018-07-31</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02484870" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Dutasteride</name><manufacturerId>JPC</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02490587" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Priva-Dutasteride</name><manufacturerId>PHP</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug><drug id="02546167" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Dutasteride Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.2565</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>.2565</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="384">For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="385">For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.</lccNote><lccNote seq="004" type="R">* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01180"><name>ETIDRONATE DISODIUM</name><pcgGroup lccId="00126"><pcg9 id="920000045"><itemNumber>2179</itemNumber><strength>200mg</strength><dosageForm>Tab</dosageForm><drug id="01997629" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Didronel</name><manufacturerId>PGP</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02248686" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Co Etidronate</name><manufacturerId>COB</manufacturerId><individualPrice>.3569</individualPrice><listingDate>2005-01-25</listingDate><amountMOHLTCPays>.3569</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="236">For the treatment of Paget&apos;s disease;</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="237">For the management of hypercalcemia of malignancy.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01877"><name>FEBUXOSTAT</name><pcgGroup><pcg9 id="920000658"><itemNumber>2180</itemNumber><strength>80mg</strength><dosageForm>Tab</dosageForm><drug id="02357380" notABenefit="Y" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Uloric</name><manufacturerId>TAK</manufacturerId><listingDate>2019-07-31</listingDate></drug><drug id="02466198" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Febuxostat</name><manufacturerId>TEV</manufacturerId><individualPrice>1.3515</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>1.3515</amountMOHLTCPays></drug><drug id="02473607" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Febuxostat</name><manufacturerId>MAR</manufacturerId><individualPrice>1.3515</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>1.3515</amountMOHLTCPays></drug><drug id="02490870" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Febuxostat</name><manufacturerId>JPC</manufacturerId><individualPrice>1.3515</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>1.3515</amountMOHLTCPays></drug><drug id="02533243" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Febuxostat</name><manufacturerId>AUR</manufacturerId><individualPrice>1.3515</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>1.3515</amountMOHLTCPays></drug><drug id="02539837" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Febuxostat</name><manufacturerId>SAI</manufacturerId><individualPrice>1.3515</individualPrice><listingDate>2024-01-31</listingDate><amountMOHLTCPays>1.3515</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01192"><name>FINASTERIDE</name><pcgGroup><pcg9 id="920000612"><itemNumber>2181</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02238213" notABenefit="Y" sec3b="Y" sec3="Y"><name>Propecia</name><manufacturerId>OCI</manufacturerId><listingDate>2010-07-20</listingDate></drug><drug id="02320169" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Finasteride</name><manufacturerId>PMS</manufacturerId><individualPrice>1.1453</individualPrice><listingDate>2010-07-20</listingDate></drug><drug id="02339471" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Finasteride A</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.1453</individualPrice><listingDate>2010-07-20</listingDate></drug><drug id="02428148" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Finasteride 1mg</name><manufacturerId>AUR</manufacturerId><individualPrice>1.1455</individualPrice><listingDate>2015-02-26</listingDate></drug><drug id="02445085" notABenefit="Y" sec3b="Y" sec3="Y"><name>Finasteride</name><manufacturerId>SAI</manufacturerId><individualPrice>1.1453</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02447568" notABenefit="Y" sec3b="Y" sec3="Y"><name>Finasteride</name><manufacturerId>SIV</manufacturerId><individualPrice>1.1455</individualPrice><listingDate>2020-06-30</listingDate></drug><drug id="02537427" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Finasteride</name><manufacturerId>MIN</manufacturerId><individualPrice>1.1453</individualPrice><listingDate>2024-02-29</listingDate></drug><drug id="02554461" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Finasteride Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.1453</individualPrice><listingDate>2025-11-28</listingDate></drug></pcg9></pcgGroup><pcgGroup lccId="00155"><pcg9 id="920000067"><itemNumber>2182</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02010909" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Proscar</name><manufacturerId>OCI</manufacturerId><individualPrice>2.5610</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02306905" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Ratio-Finasteride</name><manufacturerId>RPH</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02310112" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Finasteride</name><manufacturerId>PMS</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02322579" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Finasteride</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02348500" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Novo-Finasteride</name><manufacturerId>TEV</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2010-06-14</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02355043" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Finasteride Tablets USP</name><manufacturerId>ACH</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2010-12-14</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02357224" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp-Finasteride</name><manufacturerId>JPC</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02365383" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Finasteride</name><manufacturerId>APX</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02389878" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Mint-Finasteride</name><manufacturerId>MIN</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2012-09-28</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02405814" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Finasteride</name><manufacturerId>AUR</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02445077" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Finasteride</name><manufacturerId>SAI</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02447541" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Finasteride</name><manufacturerId>SIV</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02455013" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Riva-Finasteride</name><manufacturerId>RIA</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug><drug id="02522489" chronicUseMed="Y" sec3="Y" sec12="Y"><name>M-Finasteride</name><manufacturerId>MAT</manufacturerId><individualPrice>.3506</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>.3506</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="384">For use in combination with an alpha blocker for the treatment of men with symptomatic* Benign Prostatic Hyperplasia.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="385">For monotherapy, as a second line agent in patients with symptomatic* Benign Prostatic Hyperplasia following treatment failure or intolerance to an alpha blocker.</lccNote><lccNote seq="004" type="R">* Symptomatic is defined as having moderate (about half the time) to severe (almost always) symptoms related to the prostate in at least 4 of the following domains:
1. feeling of incomplete emptying of the bladder after voiding
2. needing to urinate again less than 2 hours after previous void
3. stopping and starting urine several times while voiding
4. difficulty postponing urination
5. weak urinary stream
6. pushing or straining to begin voiding
7. the need to get up to void at least 3 times in the night.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01910"><name>FINGOLIMOD</name><pcgGroup><pcg9 id="920000681"><itemNumber>2183</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02365480" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Gilenya</name><manufacturerId>NOV</manufacturerId><individualPrice>86.9525</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>73.9100</amountMOHLTCPays></drug><drug id="02469561" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Fingolimod</name><manufacturerId>TEV</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02469618" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Fingolimod</name><manufacturerId>TAR</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02469715" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Fingolimod</name><manufacturerId>MYL</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02469782" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Fingolimod</name><manufacturerId>PMS</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02469936" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Fingolimod</name><manufacturerId>APX</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02474743" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Fingolimod</name><manufacturerId>MAR</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02475669" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Fingolimod</name><manufacturerId>ACH</manufacturerId><individualPrice>73.9100</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>73.9100</amountMOHLTCPays></drug><drug id="02482606" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Fingolimod</name><manufacturerId>SDZ</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug><drug id="02487772" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Fingolimod</name><manufacturerId>JPC</manufacturerId><individualPrice>73.9096</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>73.9096</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01273"><name>FLUNARIZINE HCL</name><pcgGroup lccId="00127"><pcg9 id="920000216"><itemNumber>2184</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="00846341" notABenefit="Y" sec3="Y"><name>Sibelium</name><manufacturerId>PMS</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02246082" sec3="Y" sec12="Y"><name>Flunarizine</name><manufacturerId>AAP</manufacturerId><individualPrice>.8320</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.8320</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="60">For patients with migraine headaches who have not responded to propranolol.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="61">For patients who have tried propranolol and experienced significant adverse effects.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="62">For patients in whom propranolol is contraindicated.</lccNote><lccNote seq="006" type="C">Contraindicated in patients with clinical depression and in patients with extrapyramidal disorders.</lccNote><lccNote seq="007" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01346"><name>GLATIRAMER ACETATE</name><pcgGroup lccId="00309"><pcg9 id="920000422"><itemNumber>2185</itemNumber><strength>20mg/mL</strength><dosageForm>Inj Sol Pref Syr-1mL Pk</dosageForm><drug id="02245619" sec3="Y" sec12="Y"><name>Copaxone</name><manufacturerId>TEI</manufacturerId><individualPrice>50.6522</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>27.8587</amountMOHLTCPays></drug><drug id="02541440" sec3="Y" sec12="Y"><name>Glatiramer Acetate Injection</name><manufacturerId>MYL</manufacturerId><individualPrice>27.8587</individualPrice><listingDate>2024-05-31</listingDate><amountMOHLTCPays>27.8587</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="535">As monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) meeting ALL the following criteria:

-Recent neurological examination consistent with the diagnosis of RRMS; AND

-Lesions typical of multiple sclerosis on brain magnetic resonance imaging (MRI); AND

-Experienced at least 2 clinical attacks in their lifetime with one attack occurring within the prior year; AND

-EDSS score less than or equal to 6.0 prior to start of treatment; AND

-Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis.

Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="536">As monotherapy for the treatment of patients who have experienced a single demyelinating event/ Clinically Isolated Syndrome (CIS) meeting ALL the following criteria:

- CIS occurred within the prior 12 months; AND

- Recent neurological examination; AND

- Lesions typical of CIS confirmed on brain magnetic resonance imaging (MRI); AND

- EDSS score less than or equal to 6.0 prior to start of treatment; AND

- Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis

Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="537">Renewal of therapy for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) or a single demyelinating event /Clinically Isolated Syndrome (CIS) who meet ALL the following criteria:

- Used as monotherapy for the treatment of RRMS or CIS; AND

- EDSS score less than or equal to 6.0; AND

- Disease activity is stabilized as determined by a neurological exam and the number of clinical relapses experienced while on treatment; AND

- Prescribed by a neurologist experienced in the treatment of Multiple Sclerosis (MS) OR a prescriber in consultation with a neurologist overseeing the patient&apos;s MS.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01173"><name>GLUCAGON</name><pcgGroup><pcg9 id="920000743"><itemNumber>2186</itemNumber><strength>1mg/Vial</strength><dosageForm>Inj Pd-1mL Vial Pk (Kit)</dosageForm><drug id="09858279" sec3c="Y"><name>Glucagon Injection Kit</name><manufacturerId>AMP</manufacturerId><individualPrice>280.0000</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>280.0000</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00351"><pcg9 id="920000739"><itemNumber>2187</itemNumber><strength>3mg</strength><dosageForm>Nas Pd Device</dosageForm><drug id="02492415" sec3="Y" sec12="Y"><name>Baqsimi</name><manufacturerId>AMP</manufacturerId><individualPrice>160.5200</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>160.5200</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="625">For the treatment of severe hypoglycemia (SH) reactions in patients with diabetes mellitus who are receiving insulin therapy and are at high risk for SH, when impaired consciousness precludes oral carbohydrate.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01577"><name>GLUCAGON RDNA ORIGIN</name><pcgGroup><pcg9 id="920000644"><itemNumber>2188</itemNumber><strength>1mg/Vial</strength><dosageForm>Inj Pd-Syr Pk</dosageForm><drug id="02333627" sec3="Y"><name>GlucaGen HypoKit</name><manufacturerId>NOO</manufacturerId><individualPrice>112.6700</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>112.6700</amountMOHLTCPays></drug></pcg9><pcg9 id="920000643"><itemNumber>2189</itemNumber><strength>1mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02333619" sec3="Y"><name>GlucaGen</name><manufacturerId>NOO</manufacturerId><individualPrice>108.3300</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>108.3300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01941"><name>GRASS POLLEN ALLERGEN EXTRACT</name><pcgGroup lccId="00241"><pcg9 id="920000690"><itemNumber>2190</itemNumber><strength>100IR</strength><dosageForm>SL Tab</dosageForm><drug id="02381885" sec3="Y" sec12="Y"><name>Oralair</name><manufacturerId>STL</manufacturerId><individualPrice>1.3892</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>1.3892</amountMOHLTCPays></drug></pcg9><pcg9 id="920000691"><itemNumber>2191</itemNumber><strength>300IR</strength><dosageForm>SL Tab</dosageForm><drug id="02381893" sec3="Y" sec12="Y"><name>Oralair</name><manufacturerId>STL</manufacturerId><individualPrice>4.1895</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>4.1895</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="451">For the seasonal treatment of grass pollen allergic rhinitis in patients that have not adequately responded to, or tolerated, conventional pharmacotherapy.

Notes:

-  Treatment with grass pollen allergen extract must be initiated by physicians with adequate training and experience in the treatment of respiratory allergic diseases.

-  Treatment should be initiated four (4) months before the onset of pollen season and should only be continued until the end of the season.

-  Treatment should not be taken for more than three (3) consecutive years.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01989"><name>ICATIBANT</name><pcgGroup><pcg9 id="920000709"><itemNumber>2192</itemNumber><strength>30mg/3mL</strength><dosageForm>Inj Sol-Pref Syr 3mL Pk</dosageForm><drug id="02425696" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Firazyr</name><manufacturerId>TAK</manufacturerId><individualPrice>2700.0000</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>1485.0000</amountMOHLTCPays></drug><drug id="02547562" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Icatibant Injection</name><manufacturerId>JPC</manufacturerId><individualPrice>1485.0000</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>1485.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01737"><name>LANREOTIDE ACETATE</name><pcgGroup><pcg9 id="920000582"><itemNumber>2193</itemNumber><strength>60mg/0.3mL</strength><dosageForm>ER Pref Syr-0.3mL Pk</dosageForm><drug id="02283395" sec3="Y"><name>Somatuline Autogel</name><manufacturerId>IPS</manufacturerId><individualPrice>1381.8284</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>1381.8284</amountMOHLTCPays></drug></pcg9><pcg9 id="920000583"><itemNumber>2194</itemNumber><strength>90mg/0.3mL</strength><dosageForm>ER Pref Syr-0.3mL Pk</dosageForm><drug id="02283409" sec3="Y"><name>Somatuline Autogel</name><manufacturerId>IPS</manufacturerId><individualPrice>1843.2658</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>1843.2658</amountMOHLTCPays></drug></pcg9><pcg9 id="920000584"><itemNumber>2195</itemNumber><strength>120mg/0.5mL</strength><dosageForm>ER Pref Syr-0.5mL Pk</dosageForm><drug id="02283417" sec3="Y"><name>Somatuline Autogel</name><manufacturerId>IPS</manufacturerId><individualPrice>2307.2221</individualPrice><listingDate>2008-11-04</listingDate><amountMOHLTCPays>2307.2221</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01483"><name>LEFLUNOMIDE</name><pcgGroup><pcg9 id="920000369"><itemNumber>2196</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02241888" sec3="Y"><name>Arava</name><manufacturerId>SAV</manufacturerId><individualPrice>11.4440</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02256495" sec3="Y"><name>Apo-Leflunomide</name><manufacturerId>APX</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2004-11-16</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02261251" sec3="Y"><name>Teva-Leflunomide</name><manufacturerId>TEV</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2005-01-25</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02283964" sec3="Y"><name>Sandoz Leflunomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02351668" sec3="Y"><name>Leflunomide</name><manufacturerId>SAI</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02478862" sec3="Y"><name>Accel-Leflunomide</name><manufacturerId>ACC</manufacturerId><individualPrice>2.0000</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02543575" sec3="Y"><name>Leflunomide</name><manufacturerId>SIV</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02551918" sec3="Y"><name>Mar-Leflunomide</name><manufacturerId>MAR</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000370"><itemNumber>2197</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02241889" sec3="Y"><name>Arava</name><manufacturerId>SAV</manufacturerId><individualPrice>11.4443</individualPrice><listingDate>2001-03-07</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02256509" sec3="Y"><name>Apo-Leflunomide</name><manufacturerId>APX</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2004-11-16</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02261278" sec3="Y"><name>Teva-Leflunomide</name><manufacturerId>TEV</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2005-01-25</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02283972" sec3="Y"><name>Sandoz Leflunomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02351676" sec3="Y"><name>Leflunomide</name><manufacturerId>SAI</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02478870" sec3="Y"><name>Accel-Leflunomide</name><manufacturerId>ACC</manufacturerId><individualPrice>2.0000</individualPrice><listingDate>2019-12-20</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02543583" sec3="Y"><name>Leflunomide</name><manufacturerId>SIV</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug><drug id="02551926" sec3="Y"><name>Mar-Leflunomide</name><manufacturerId>MAR</manufacturerId><individualPrice>2.6433</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>2.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01748"><name>LENALIDOMIDE</name><pcgGroup lccId="00358"><pcg9 id="920000720"><itemNumber>2198</itemNumber><strength>2.5mg</strength><dosageForm>Cap</dosageForm><drug id="02459418" sec3="Y" sec12="Y"><name>Revlimid</name><manufacturerId>BQU</manufacturerId><individualPrice>329.5000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug><drug id="02484714" sec3="Y" sec12="Y"><name>Reddy-Lenalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>82.3750</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug><drug id="02493837" sec3="Y" sec12="Y"><name>Nat-Lenalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>82.3750</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug><drug id="02506130" sec3="Y" sec12="Y"><name>Jamp Lenalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>82.3750</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug><drug id="02507862" sec3="Y" sec12="Y"><name>Taro-Lenalidomide</name><manufacturerId>TAR</manufacturerId><individualPrice>82.3750</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug><drug id="02507927" sec3="Y" sec12="Y"><name>Apo-Lenalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>82.3750</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug><drug id="02518562" sec3="Y" sec12="Y"><name>Sandoz Lenalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>82.3750</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>82.3750</amountMOHLTCPays></drug></pcg9><pcg9 id="920000601"><itemNumber>2199</itemNumber><strength>15mg</strength><dosageForm>Cap</dosageForm><drug id="02317699" sec3="Y" sec12="Y"><name>Revlimid</name><manufacturerId>BQU</manufacturerId><individualPrice>382.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug><drug id="02483033" sec3="Y" sec12="Y"><name>Reddy-Lenalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>95.5000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug><drug id="02493888" sec3="Y" sec12="Y"><name>Nat-Lenalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>95.5000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug><drug id="02506165" sec3="Y" sec12="Y"><name>Jamp Lenalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>95.5000</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug><drug id="02507897" sec3="Y" sec12="Y"><name>Taro-Lenalidomide</name><manufacturerId>TAR</manufacturerId><individualPrice>95.5000</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug><drug id="02507951" sec3="Y" sec12="Y"><name>Apo-Lenalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>95.5000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug><drug id="02518597" sec3="Y" sec12="Y"><name>Sandoz Lenalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>95.5000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>95.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000715"><itemNumber>2200</itemNumber><strength>20mg</strength><dosageForm>Cap</dosageForm><drug id="02440601" sec3="Y" sec12="Y"><name>Revlimid</name><manufacturerId>BQU</manufacturerId><individualPrice>403.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug><drug id="02483041" sec3="Y" sec12="Y"><name>Reddy-Lenalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>100.7500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug><drug id="02493896" sec3="Y" sec12="Y"><name>Nat-Lenalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>100.7500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug><drug id="02506173" sec3="Y" sec12="Y"><name>Jamp Lenalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>100.7500</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug><drug id="02507900" sec3="Y" sec12="Y"><name>Taro-Lenalidomide</name><manufacturerId>TAR</manufacturerId><individualPrice>100.7500</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug><drug id="02507978" sec3="Y" sec12="Y"><name>Apo-Lenalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>100.7500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug><drug id="02518600" sec3="Y" sec12="Y"><name>Sandoz Lenalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>100.7500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>100.7500</amountMOHLTCPays></drug></pcg9><pcg9 id="920000602"><itemNumber>2201</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02317710" sec3="Y" sec12="Y"><name>Revlimid</name><manufacturerId>BQU</manufacturerId><individualPrice>424.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug><drug id="02483068" sec3="Y" sec12="Y"><name>Reddy-Lenalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>106.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug><drug id="02493918" sec3="Y" sec12="Y"><name>Nat-Lenalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>106.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug><drug id="02506181" sec3="Y" sec12="Y"><name>Jamp Lenalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>106.0000</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug><drug id="02507919" sec3="Y" sec12="Y"><name>Taro-Lenalidomide</name><manufacturerId>TAR</manufacturerId><individualPrice>106.0000</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug><drug id="02507986" sec3="Y" sec12="Y"><name>Apo-Lenalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>106.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug><drug id="02518619" sec3="Y" sec12="Y"><name>Sandoz Lenalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>106.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>106.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000586"><itemNumber>2202</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="02304899" sec3="Y" sec12="Y"><name>Revlimid</name><manufacturerId>BQU</manufacturerId><individualPrice>340.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug><drug id="02483017" sec3="Y" sec12="Y"><name>Reddy-Lenalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>85.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug><drug id="02493845" sec3="Y" sec12="Y"><name>Nat-Lenalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>85.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug><drug id="02506149" sec3="Y" sec12="Y"><name>Jamp Lenalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>85.0000</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug><drug id="02507870" sec3="Y" sec12="Y"><name>Taro-Lenalidomide</name><manufacturerId>TAR</manufacturerId><individualPrice>85.0000</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug><drug id="02507935" sec3="Y" sec12="Y"><name>Apo-Lenalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>85.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug><drug id="02518570" sec3="Y" sec12="Y"><name>Sandoz Lenalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>85.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>85.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000587"><itemNumber>2203</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02304902" sec3="Y" sec12="Y"><name>Revlimid</name><manufacturerId>BQU</manufacturerId><individualPrice>361.0000</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug><drug id="02483025" sec3="Y" sec12="Y"><name>Reddy-Lenalidomide</name><manufacturerId>DRR</manufacturerId><individualPrice>90.2500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug><drug id="02493861" sec3="Y" sec12="Y"><name>Nat-Lenalidomide</name><manufacturerId>NAT</manufacturerId><individualPrice>90.2500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug><drug id="02506157" sec3="Y" sec12="Y"><name>Jamp Lenalidomide</name><manufacturerId>JPC</manufacturerId><individualPrice>90.2500</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug><drug id="02507889" sec3="Y" sec12="Y"><name>Taro-Lenalidomide</name><manufacturerId>TAR</manufacturerId><individualPrice>90.2500</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug><drug id="02507943" sec3="Y" sec12="Y"><name>Apo-Lenalidomide</name><manufacturerId>APX</manufacturerId><individualPrice>90.2500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug><drug id="02518589" sec3="Y" sec12="Y"><name>Sandoz Lenalidomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>90.2500</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>90.2500</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="630">Myelodysplastic Syndrome

Initial criteria:
For the treatment of patients with anemia due to myelodysplastic syndrome (MDS) who meet all of the following clinical criteria:

1. Demonstrated diagnosis of myelodysplastic syndrome (MDS) on bone marrow aspiration

2. Presence of deletion 5q cytogenetic abnormality documented by standard cytogenetic, fluorescence in situ hybridization, or genomic testing

3. International Prognostic Scoring System (IPSS) risk category low or intermediate-1

4. Symptomatic anemia (transfusion dependent or non-transfusion dependent)

LU Authorization Period: 6 months

Renewal criteria:
There is at least a fifty percent (50%) reduction in transfusion requirements and/or evidence of hematologic response.

Renewal Duration: 1 year 

Recommended dose: 10mg daily adjusted based on clinical and laboratory findings.</lccNote><lccNote seq="002" type="R">Note: Pharmacists and prescribers should be informed of a drug product&apos;s official indications and recommended dosage as set out in Health Canada&apos;s approved product monograph. Some aspects of this criteria may differ from the official indications and recommended dosage as described in the product monographs for lenalidomide or other products that may be used as part of combination therapy with lenalidomide. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of the drug products. Where there is a difference between a product monograph and the LU criteria described above, the LU criteria governs for the purpose of funding under the Ontario Drug Benefit Program.</lccNote><lccNote seq="003" reasonForUseId="631">Multiple Myeloma (maintenance treatment following stem cell transplant)

Initial criteria:
For the maintenance treatment of patients with newly diagnosed multiple myeloma, following autologous stem-cell transplantation (ASCT) who have stable disease or better, with no evidence of disease progression.

LU Authorization Period: 1 year

Renewal criteria:
Lenalidomide may be continued until evidence of disease progression or development of unacceptable toxicity requiring discontinuation of lenalidomide

Renewal Duration: 1 year

Recommended Dosage: Initial dose of 10mg daily

Dose adjustments (5-15mg) may be necessary based on individual patient characteristics/responses.
</lccNote><lccNote seq="004" type="R">Note: Pharmacists and prescribers should be informed of a drug product&apos;s official indications and recommended dosage as set out in Health Canada&apos;s approved product monograph. Some aspects of this criteria may differ from the official indications and recommended dosage as described in the product monographs for lenalidomide or other products that may be used as part of combination therapy with lenalidomide. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of the drug products. Where there is a difference between a product monograph and the LU criteria described above, the LU criteria governs for the purpose of funding under the Ontario Drug Benefit Program.</lccNote><lccNote seq="005" reasonForUseId="632">Multiple Myeloma

Initial criteria

For the treatment of patients with multiple myeloma who meet ALL the following criteria:

1. Patient is deemed to be lenalidomide sensitive, defined as disease that has not been refractory to a lenalidomide-based regimen, and/or has not experienced progression while on a lenalidomide-based regimen in a treatment or maintenance setting (Note 1); AND

2. Patient has good performance status; AND

3. Lenalidomide is being used in ONE of the following situations:

a) In a transplant ineligible patient with previously untreated multiple myeloma, as first line therapy within a dual regimen in combination with dexamethasone OR as part of a triplet regimen in combination with dexamethasone and bortezomib (Note 2); OR as part of a triplet regimen in combination with dexamethasone and daratumumab (Note 3) OR

b) In a transplant ineligible patient with relapsed or refractory multiple myeloma as second or third line treatment within a dual regimen in combination with dexamethasone; OR as part of a triplet regimen in combination with dexamethasone and carfilzomib; OR as part of a triplet regimen in combination with dexamethasone and daratumumab (Note 3); OR

c) In a patient with relapsed or refractory multiple myeloma who received a stem-cell transplant as first line treatment and is using a lenalidomide based regimen as second or third line treatment within a dual regimen in combination with dexamethasone; OR as part of a triplet regimen in combination with dexamethasone and carfilzomib; OR as part of a triplet regimen in combination with dexamethasone and daratumumab (Note 3).

LU Authorization Period: 1 year

Renewal criteria:
Lenalidomide may be continued for the treatment of multiple myeloma in those who continue to respond to therapy and have not experienced refractory disease or progressive disease while on the lenalidomide-based regimen.

Renewal Duration: 1 year

Exclusion Criteria:

Patients meeting the following are not eligible for funding:

1. Patients with multiple myeloma who have experienced disease that has been refractory to treatment with a lenalidomide-based treatment.

2. Patients with multiple myeloma who have experienced disease progression while on a lenalidomide-based treatment used for multiple myeloma in any setting including in maintenance treatment.

3. Patients requesting lenalidomide as fourth line treatment for multiple myeloma.

4. Patients with monoclonal gammopathy of uncertain significance (MGUS), smoldering myeloma, or primary amyloidosis.

Recommended Dose: 25mg daily as a single 25mg capsule

Patients should be dispensed the most appropriate strength of lenalidomide to achieve the dose recommendation and with the fewest number of tablets per day.</lccNote><lccNote seq="006" type="R">Notes (Multiple Myeloma):

1. Refractory disease is defined as disease progression within 60 days after stopping treatment or progression on any dose of lenalidomide or bortezomib including while on maintenance therapy or non-responsive disease during therapy (either failure to achieve minimal response or disease progression).

Relapsed/Progressive disease is defined as having one or more of the following:

i) An increase of 25% from lowest response value in serum M-component (absolute increase must be greater than or equal to 0.5g/dL), and/or urine M-component (absolute increase must be greater than or equal to 200mg/24 hours).

ii) An absolute increase of greater than 10mg/dL in the difference between involved and uninvolved FLC levels (if no measurable serum and urine M-protein levels).

iii) Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas.

iv) Development of hypercalcemia (corrected serum calcium greater than 11.5mg/dL or 2.5mmol/L) that can be attributed solely to the plasma cell proliferative disorder.

2. Patients with multiple myeloma who experience disease progression on a lenalidomide-bortezomib-dexamethasone triplet will not be eligible for further bortezomib-based regimens subsequent to disease progression, in any multiple myeloma settings. Patients with multiple myeloma who experience disease progression on a lenalidomide-daratumumab-dexamethasone triplet will not be eligible for further daratumumab-based regimens subsequent to disease progression, in any multiple myeloma setting.

3. Patients using combination regimens must meet the eligibility requirements for bortezomib, carfilzomib and daratumumab through the New Drug Funding Program (NDFP).

4. Patients using lenalidomide in regimens that are not specified in the LU criteria may apply for case-by-case consideration through the EAP.</lccNote><lccNote seq="007" type="R">Note: Pharmacists and prescribers should be informed of a drug product&apos;s official indications and recommended dosage as set out in Health Canada&apos;s approved product monograph. Some aspects of this criteria may differ from the official indications and recommended dosage as described in the product monographs for lenalidomide or other products that may be used as part of combination therapy with lenalidomide. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of the drug products. Where there is a difference between a product monograph and the LU criteria described above, the LU criteria governs for the purpose of funding under the Ontario Drug Benefit Program.</lccNote><lccNote seq="008" reasonForUseId="659">Multiple Myeloma - Induction Therapy for Transplant Eligible, Newly Diagnosed Multiple Myeloma

Lenalidomide in combination with bortezomib and dexamethasone (RVd) as induction therapy before an autologous stem cell transplantation in patients with previously untreated, transplant-eligible, newly diagnosed multiple myeloma. Funding is for a total of 4 cycles.

Recommended Dose: 15mg or 25mg daily depending on the treatment regimen as a single 15mg capsule or 25mg capsule

Patients should be dispensed the most appropriate strength of lenalidomide to achieve the dose recommendation and with the fewest number of capsules per day.</lccNote><lccNote seq="009" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="010" type="R">Note: Pharmacists and prescribers should be informed of a drug product&apos;s official indications and recommended dosage as set out in Health Canada&apos;s approved product monograph. Some aspects of this criteria may differ from the official indications and recommended dosage as described in the product monographs for lenalidomide or other products that may be used as part of combination therapy with lenalidomide. The Executive Officer&apos;s funding of drug products is informed by advice from expert committees that consider evidence regarding the safety, clinical efficacy, and cost-effectiveness of the drug products. Where there is a difference between a product monograph and the LU criteria described above, the LU criteria governs for the purpose of funding under the Ontario Drug Benefit Program.</lccNote></pcgGroup></genericName><genericName id="01284"><name>LEVOCARNITINE</name><pcgGroup><pcg9 id="920000234"><itemNumber>2204</itemNumber><strength>100mg/mL</strength><dosageForm>Oral Sol (with preservative)</dosageForm><drug id="02144336" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Carnitor</name><manufacturerId>LBI</manufacturerId><individualPrice>.3809</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.3809</amountMOHLTCPays></drug><drug id="02492105" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Odan Levocarnitine</name><manufacturerId>ODN</manufacturerId><individualPrice>.3809</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>.3809</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01178"><name>LEVODOPA &amp; BENSERAZIDE</name><pcgGroup><pcg9 id="920000037"><itemNumber>2205</itemNumber><strength>50mg &amp; 12.5mg</strength><dosageForm>Cap</dosageForm><drug id="00522597" sec3="Y"><name>Prolopa 50-12.5</name><manufacturerId>HLR</manufacturerId><individualPrice>.3437</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.3437</amountMOHLTCPays></drug></pcg9><pcg9 id="920000027"><itemNumber>2206</itemNumber><strength>100mg &amp; 25mg</strength><dosageForm>Cap</dosageForm><drug id="00386464" sec3="Y"><name>Prolopa 100-25</name><manufacturerId>HLR</manufacturerId><individualPrice>.5660</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.5660</amountMOHLTCPays></drug></pcg9><pcg9 id="920000026"><itemNumber>2207</itemNumber><strength>200mg &amp; 50mg</strength><dosageForm>Cap</dosageForm><drug id="00386472" sec3="Y"><name>Prolopa 200-50</name><manufacturerId>HLR</manufacturerId><individualPrice>.9503</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.9503</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01177"><name>LEVODOPA &amp; CARBIDOPA</name><pcgGroup lccId="00130"><pcg9 id="920000218"><itemNumber>2208</itemNumber><strength>100mg &amp; 25mg</strength><dosageForm>CR Tab</dosageForm><drug id="02028786" notABenefit="Y" sec3="Y"><name>Sinemet CR</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02272873" sec3="Y" sec12="Y"><name>AA-Levocarb CR</name><manufacturerId>AAP</manufacturerId><individualPrice>.7974</individualPrice><listingDate>2009-08-18</listingDate><amountMOHLTCPays>.7974</amountMOHLTCPays></drug></pcg9><pcg9 id="920000217"><itemNumber>2209</itemNumber><strength>200mg &amp; 50mg</strength><dosageForm>CR Tab</dosageForm><drug id="00870935" notABenefit="Y" sec3="Y"><name>Sinemet CR</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02245211" sec3="Y" sec12="Y"><name>AA-Levocarb CR</name><manufacturerId>AAP</manufacturerId><individualPrice>1.4282</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>1.4282</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="64">For patients with Parkinson&apos;s disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="65">For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="920000030"><itemNumber>2210</itemNumber><strength>100mg &amp; 10mg</strength><dosageForm>Tab</dosageForm><drug id="00355658" notABenefit="Y" sec3="Y"><name>Sinemet</name><manufacturerId>MFC</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02195933" sec3="Y"><name>Apo-Levocarb</name><manufacturerId>APX</manufacturerId><individualPrice>.1479</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.1479</amountMOHLTCPays></drug><drug id="02244494" sec3="Y"><name>Teva-Levocarbidopa</name><manufacturerId>TEV</manufacturerId><individualPrice>.1479</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.1479</amountMOHLTCPays></drug><drug id="02457954" sec3="Y"><name>Mint-Levocarb</name><manufacturerId>MIN</manufacturerId><individualPrice>.1479</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.1479</amountMOHLTCPays></drug><drug id="02531593" sec3="Y"><name>Auro-Levocarb</name><manufacturerId>AUR</manufacturerId><individualPrice>.1479</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.1479</amountMOHLTCPays></drug><drug id="02546396" sec3="Y"><name>Jamp Levocarb</name><manufacturerId>JPC</manufacturerId><individualPrice>.1479</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.1479</amountMOHLTCPays></drug><drug id="02549719" sec3="Y"><name>PMS-Levodopa-Carbidopa</name><manufacturerId>PMS</manufacturerId><individualPrice>.1479</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.1479</amountMOHLTCPays></drug></pcg9><pcg9 id="920000036"><itemNumber>2211</itemNumber><strength>100mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="00513997" notABenefit="Y" sec3="Y"><name>Sinemet</name><manufacturerId>OCI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02195941" sec3="Y"><name>Apo-Levocarb</name><manufacturerId>APX</manufacturerId><individualPrice>.2209</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.2209</amountMOHLTCPays></drug><drug id="02244495" sec3="Y"><name>Teva-Levocarbidopa</name><manufacturerId>TEV</manufacturerId><individualPrice>.2209</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>.2209</amountMOHLTCPays></drug><drug id="02457962" sec3="Y"><name>Mint-Levocarb</name><manufacturerId>MIN</manufacturerId><individualPrice>.2209</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.2209</amountMOHLTCPays></drug><drug id="02531607" sec3="Y"><name>Auro-Levocarb</name><manufacturerId>AUR</manufacturerId><individualPrice>.2209</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.2209</amountMOHLTCPays></drug><drug id="02546418" sec3="Y"><name>Jamp Levocarb</name><manufacturerId>JPC</manufacturerId><individualPrice>.2209</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.2209</amountMOHLTCPays></drug><drug id="02549727" sec3="Y"><name>PMS-Levodopa-Carbidopa</name><manufacturerId>PMS</manufacturerId><individualPrice>.2209</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.2209</amountMOHLTCPays></drug></pcg9><pcg9 id="920000022"><itemNumber>2212</itemNumber><strength>250mg &amp; 25mg</strength><dosageForm>Tab</dosageForm><drug id="00328219" notABenefit="Y" sec3="Y"><name>Sinemet</name><manufacturerId>OCI</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02195968" sec3="Y"><name>Apo-Levocarb</name><manufacturerId>APX</manufacturerId><individualPrice>.2466</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>.2466</amountMOHLTCPays></drug><drug id="02244496" sec3="Y"><name>Teva-Levocarbidopa</name><manufacturerId>TEV</manufacturerId><individualPrice>.2466</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>.2466</amountMOHLTCPays></drug><drug id="02457970" sec3="Y"><name>Mint-Levocarb</name><manufacturerId>MIN</manufacturerId><individualPrice>.2466</individualPrice><listingDate>2017-02-28</listingDate><amountMOHLTCPays>.2466</amountMOHLTCPays></drug><drug id="02531615" sec3="Y"><name>Auro-Levocarb</name><manufacturerId>AUR</manufacturerId><individualPrice>.2466</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>.2466</amountMOHLTCPays></drug><drug id="02546426" sec3="Y"><name>Jamp Levocarb</name><manufacturerId>JPC</manufacturerId><individualPrice>.2466</individualPrice><listingDate>2025-01-31</listingDate><amountMOHLTCPays>.2466</amountMOHLTCPays></drug><drug id="02549735" sec3="Y"><name>PMS-Levodopa-Carbidopa</name><manufacturerId>PMS</manufacturerId><individualPrice>.2466</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.2466</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01750"><name>LEVODOPA &amp; CARBIDOPA &amp; ENTACAPONE</name><pcgGroup lccId="00199"><pcg9 id="920000615"><itemNumber>2213</itemNumber><strength>75 &amp; 18.75 &amp; 200mg</strength><dosageForm>Tab</dosageForm><drug id="02337827" sec3="Y" sec12="Y"><name>Stalevo</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7471</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.7471</amountMOHLTCPays></drug></pcg9><pcg9 id="920000616"><itemNumber>2214</itemNumber><strength>125 &amp; 31.25 &amp; 200mg</strength><dosageForm>Tab</dosageForm><drug id="02337835" sec3="Y" sec12="Y"><name>Stalevo</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7471</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.7471</amountMOHLTCPays></drug></pcg9><pcg9 id="920000588"><itemNumber>2215</itemNumber><strength>50 &amp; 12.5 &amp; 200mg</strength><dosageForm>Tab</dosageForm><drug id="02305933" sec3="Y" sec12="Y"><name>Stalevo</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7471</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>1.7471</amountMOHLTCPays></drug></pcg9><pcg9 id="920000589"><itemNumber>2216</itemNumber><strength>100 &amp; 25 &amp; 200mg</strength><dosageForm>Tab</dosageForm><drug id="02305941" sec3="Y" sec12="Y"><name>Stalevo</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7471</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>1.7471</amountMOHLTCPays></drug></pcg9><pcg9 id="920000590"><itemNumber>2217</itemNumber><strength>150 &amp; 37.5 &amp; 200mg</strength><dosageForm>Tab</dosageForm><drug id="02305968" sec3="Y" sec12="Y"><name>Stalevo</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7471</individualPrice><listingDate>2009-03-02</listingDate><amountMOHLTCPays>1.7471</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="367">For the treatment of patients with Parkinson&apos;s disease with 25% of the waking day in the off state despite maximally tolerated doses of levodopa.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01703"><name>MIGLUSTAT</name><pcgGroup><pcg9 id="920000559"><itemNumber>2218</itemNumber><strength>100mg</strength><dosageForm>Cap</dosageForm><drug id="02250519" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zavesca</name><manufacturerId>ACT</manufacturerId><individualPrice>128.9600</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>81.4125</amountMOHLTCPays></drug><drug id="02456257" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Miglustat</name><manufacturerId>SDZ</manufacturerId><individualPrice>81.4125</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>81.4125</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01408"><name>MONTELUKAST SODIUM</name><pcgGroup lccId="00154"><pcg9 id="920000406"><itemNumber>2219</itemNumber><strength>4mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02243602" sec3="Y" sec12="Y"><name>Singulair</name><manufacturerId>OCI</manufacturerId><individualPrice>1.7622</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02330385" sec3="Y" sec12="Y"><name>Sandoz Montelukast</name><manufacturerId>SDZ</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02354977" sec3="Y" sec12="Y"><name>PMS-Montelukast</name><manufacturerId>PMS</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02355507" sec3="Y" sec12="Y"><name>Teva-Montelukast</name><manufacturerId>TEV</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02377608" sec3="Y" sec12="Y"><name>Apo-Montelukast</name><manufacturerId>APX</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02382458" sec3="Y" sec12="Y"><name>Montelukast</name><manufacturerId>SIV</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02399865" sec3="Y" sec12="Y"><name>Mar-Montelukast</name><manufacturerId>MAR</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02408627" sec3="Y" sec12="Y"><name>Mint-Montelukast</name><manufacturerId>MIN</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02422867" sec3="Y" sec12="Y"><name>Auro-Montelukast Chewable Tablet</name><manufacturerId>AUR</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02442353" sec3="Y" sec12="Y"><name>Jamp-Montelukast</name><manufacturerId>JPC</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02514877" sec3="Y" sec12="Y"><name>Jamp Montelukast Chewable Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug><drug id="02522101" sec3="Y" sec12="Y"><name>Nat-Montelukast</name><manufacturerId>NAT</manufacturerId><individualPrice>.2758</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>.2758</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="382">For the treatment of asthma in patients aged 2-5 years old.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup><pcg9 id="920000315"><itemNumber>2220</itemNumber><strength>5mg</strength><dosageForm>Chew Tab</dosageForm><drug id="02238216" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Singulair</name><manufacturerId>OCI</manufacturerId><listingDate>2012-01-19</listingDate></drug><drug id="02330393" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Montelukast</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02354985" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Montelukast</name><manufacturerId>PMS</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02355515" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Montelukast</name><manufacturerId>TEV</manufacturerId><individualPrice>1.2077</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.2077</amountMOHLTCPays></drug><drug id="02377616" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Montelukast</name><manufacturerId>APX</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02379325" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Montelukast</name><manufacturerId>SAI</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02382466" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Montelukast</name><manufacturerId>SIV</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02399873" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Montelukast</name><manufacturerId>MAR</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02402807" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Montelukast</name><manufacturerId>RAN</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02408635" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Montelukast</name><manufacturerId>MIN</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02422875" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Montelukast Chewable Tablet</name><manufacturerId>AUR</manufacturerId><individualPrice>1.2077</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>1.2077</amountMOHLTCPays></drug><drug id="02442361" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Montelukast</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02514885" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Montelukast Chewable Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>1.2075</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>1.2075</amountMOHLTCPays></drug><drug id="02522128" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Montelukast</name><manufacturerId>NAT</manufacturerId><individualPrice>1.2077</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>1.2077</amountMOHLTCPays></drug></pcg9><pcg9 id="920000645"><itemNumber>2221</itemNumber><strength>4mg</strength><dosageForm>Gran Pk</dosageForm><drug id="02247997" notABenefit="Y" sec3b="Y" sec3="Y"><name>Singulair</name><manufacturerId>OCI</manufacturerId><listingDate>2012-01-19</listingDate></drug><drug id="02358611" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Montelukast</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.3440</individualPrice><listingDate>2012-01-19</listingDate></drug></pcg9><pcg9 id="920000316"><itemNumber>2222</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02238217" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Singulair</name><manufacturerId>OCI</manufacturerId><listingDate>2012-01-19</listingDate></drug><drug id="02328593" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Montelukast</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02355523" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Montelukast</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7737</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.7737</amountMOHLTCPays></drug><drug id="02373947" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Montelukast FC</name><manufacturerId>PMS</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02374609" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Montelukast</name><manufacturerId>APX</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02379236" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ach-Montelukast</name><manufacturerId>ACH</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02379333" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Montelukast</name><manufacturerId>SAI</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02382474" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Montelukast</name><manufacturerId>SIV</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02389517" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Ran-Montelukast</name><manufacturerId>RAN</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02391422" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Montelukast</name><manufacturerId>JPC</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02399997" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Montelukast</name><manufacturerId>MAR</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2013-03-20</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02401274" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Montelukast</name><manufacturerId>AUR</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02408643" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Montelukast</name><manufacturerId>MIN</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02488183" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Montelukast</name><manufacturerId>MAT</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02489821" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Montelukast</name><manufacturerId>NRA</manufacturerId><individualPrice>1.7735</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.7735</amountMOHLTCPays></drug><drug id="02522136" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Montelukast</name><manufacturerId>NAT</manufacturerId><individualPrice>1.7737</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>1.7737</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01277"><name>MYCOPHENOLATE MOFETIL</name><pcgGroup><pcg9 id="920000223"><itemNumber>2223</itemNumber><strength>250mg</strength><dosageForm>Cap</dosageForm><drug id="02192748" sec3="Y"><name>CellCept</name><manufacturerId>HLR</manufacturerId><individualPrice>2.2370</individualPrice><listingDate>1997-04-10</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug><drug id="02320630" sec3="Y"><name>Sandoz Mycophenolate Mofetil</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3712</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug><drug id="02352559" sec3="Y"><name>Apo-Mycophenolate</name><manufacturerId>APX</manufacturerId><individualPrice>.3712</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug><drug id="02364883" sec3="Y"><name>Teva-Mycophenolate</name><manufacturerId>TEV</manufacturerId><individualPrice>.3712</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug><drug id="02383780" sec3="Y"><name>Mycophenolate Mofetil Capsules</name><manufacturerId>ACH</manufacturerId><individualPrice>.3712</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug><drug id="02386399" sec3="Y"><name>Jamp-Mycophenolate Capsules</name><manufacturerId>JPC</manufacturerId><individualPrice>.3712</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug><drug id="02457369" sec3="Y"><name>Mycophenolate Mofetil</name><manufacturerId>SAI</manufacturerId><individualPrice>.3712</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.3712</amountMOHLTCPays></drug></pcg9></pcgGroup><pcgGroup lccId="00131"><pcg9 id="920000510"><itemNumber>2224</itemNumber><strength>200mg/mL</strength><dosageForm>Pd for Oral Susp-175mL Pk</dosageForm><drug id="02242145" sec3="Y" sec12="Y"><name>CellCept</name><manufacturerId>HLR</manufacturerId><individualPrice>350.8000</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>244.7025</amountMOHLTCPays></drug><drug id="02522233" sec3="Y" sec12="Y"><name>Mar-Mycophenolate Mofetil</name><manufacturerId>MAR</manufacturerId><individualPrice>244.7025</individualPrice><listingDate>2022-03-31</listingDate><amountMOHLTCPays>244.7025</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="556">For patients who are unable to swallow or tolerate solid oral dosage forms.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup><pcg9 id="920000339"><itemNumber>2225</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02237484" sec3="Y"><name>CellCept</name><manufacturerId>HLR</manufacturerId><individualPrice>4.4740</individualPrice><listingDate>2000-04-17</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug><drug id="02313855" sec3="Y"><name>Sandoz Mycophenolate Mofetil</name><manufacturerId>SDZ</manufacturerId><individualPrice>.7423</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug><drug id="02348675" sec3="Y"><name>Teva-Mycophenolate</name><manufacturerId>TEV</manufacturerId><individualPrice>.7423</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug><drug id="02352567" sec3="Y"><name>Apo-Mycophenolate</name><manufacturerId>APX</manufacturerId><individualPrice>.7423</individualPrice><listingDate>2012-01-19</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug><drug id="02378574" sec3="Y"><name>Ach-Mycophenolate</name><manufacturerId>ACH</manufacturerId><individualPrice>.7423</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug><drug id="02380382" sec3="Y"><name>Jamp-Mycophenolate</name><manufacturerId>JPC</manufacturerId><individualPrice>.7423</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug><drug id="02457377" sec3="Y"><name>Mycophenolate Mofetil</name><manufacturerId>SAI</manufacturerId><individualPrice>.7423</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>.7423</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01665"><name>MYCOPHENOLATE SODIUM</name><pcgGroup><pcg9 id="920000528"><itemNumber>2226</itemNumber><strength>180mg</strength><dosageForm>Ent Tab</dosageForm><drug id="02264560" sec3="Y"><name>Myfortic</name><manufacturerId>NOV</manufacturerId><individualPrice>1.9977</individualPrice><listingDate>2006-01-12</listingDate><amountMOHLTCPays>.4994</amountMOHLTCPays></drug><drug id="02372738" sec3="Y"><name>Apo-Mycophenolic Acid</name><manufacturerId>APX</manufacturerId><individualPrice>.4994</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.4994</amountMOHLTCPays></drug><drug id="02511673" sec3="Y"><name>Mar-Mycophenolic Acid</name><manufacturerId>MAR</manufacturerId><individualPrice>.4994</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.4994</amountMOHLTCPays></drug><drug id="02518538" sec3="Y"><name>Jamp Mycophenolic Acid</name><manufacturerId>JPC</manufacturerId><individualPrice>.4994</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.4994</amountMOHLTCPays></drug></pcg9><pcg9 id="920000529"><itemNumber>2227</itemNumber><strength>360mg</strength><dosageForm>Ent Tab</dosageForm><drug id="02264579" sec3="Y"><name>Myfortic</name><manufacturerId>NOV</manufacturerId><individualPrice>3.9953</individualPrice><listingDate>2006-01-12</listingDate><amountMOHLTCPays>.9988</amountMOHLTCPays></drug><drug id="02372746" sec3="Y"><name>Apo-Mycophenolic Acid</name><manufacturerId>APX</manufacturerId><individualPrice>.9988</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>.9988</amountMOHLTCPays></drug><drug id="02511681" sec3="Y"><name>Mar-Mycophenolic Acid</name><manufacturerId>MAR</manufacturerId><individualPrice>.9988</individualPrice><listingDate>2021-05-31</listingDate><amountMOHLTCPays>.9988</amountMOHLTCPays></drug><drug id="02518511" sec3="Y"><name>Jamp Mycophenolic Acid</name><manufacturerId>JPC</manufacturerId><individualPrice>.9988</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>.9988</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01199"><name>OCTREOTIDE</name><pcgGroup><pcg9 id="920000332"><itemNumber>2228</itemNumber><strength>10mg</strength><dosageForm>Inj Kit Pk</dosageForm><drug id="02239323" sec3="Y"><name>Sandostatin LAR</name><manufacturerId>NOV</manufacturerId><individualPrice>1320.9300</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>990.6975</amountMOHLTCPays></drug><drug id="02503751" sec3="Y"><name>Octreotide for Injectable Suspension</name><manufacturerId>TEV</manufacturerId><individualPrice>990.6975</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>990.6975</amountMOHLTCPays></drug></pcg9><pcg9 id="920000333"><itemNumber>2229</itemNumber><strength>20mg</strength><dosageForm>Inj Kit Pk</dosageForm><drug id="02239324" sec3="Y"><name>Sandostatin LAR</name><manufacturerId>NOV</manufacturerId><individualPrice>1706.5800</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>1279.9350</amountMOHLTCPays></drug><drug id="02503778" sec3="Y"><name>Octreotide for Injectable Suspension</name><manufacturerId>TEV</manufacturerId><individualPrice>1279.9350</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>1279.9350</amountMOHLTCPays></drug></pcg9><pcg9 id="920000334"><itemNumber>2230</itemNumber><strength>30mg</strength><dosageForm>Inj Kit Pk</dosageForm><drug id="02239325" sec3="Y"><name>Sandostatin LAR</name><manufacturerId>NOV</manufacturerId><individualPrice>2189.5200</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>1642.1400</amountMOHLTCPays></drug><drug id="02503786" sec3="Y"><name>Octreotide for Injectable Suspension</name><manufacturerId>TEV</manufacturerId><individualPrice>1642.1400</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>1642.1400</amountMOHLTCPays></drug></pcg9><pcg9 id="920000083"><itemNumber>2231</itemNumber><strength>50mcg/mL</strength><dosageForm>Inj Sol - 1mL Amp Pk</dosageForm><drug id="00839191" sec3="Y"><name>Sandostatin</name><manufacturerId>NOV</manufacturerId><individualPrice>5.3440</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>4.0080</amountMOHLTCPays></drug><drug id="02248639" sec3="Y"><name>Octreotide Acetate Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>4.0080</individualPrice><listingDate>2008-03-25</listingDate><amountMOHLTCPays>4.0080</amountMOHLTCPays></drug></pcg9><pcg9 id="920000084"><itemNumber>2232</itemNumber><strength>100mcg/mL</strength><dosageForm>Inj Sol - 1mL Amp Pk</dosageForm><drug id="00839205" sec3="Y"><name>Sandostatin</name><manufacturerId>NOV</manufacturerId><individualPrice>10.0880</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>7.5660</amountMOHLTCPays></drug><drug id="02248640" sec3="Y"><name>Octreotide Acetate Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>7.5660</individualPrice><listingDate>2008-03-25</listingDate><amountMOHLTCPays>7.5660</amountMOHLTCPays></drug></pcg9><pcg9 id="920000085"><itemNumber>2233</itemNumber><strength>500mcg/mL</strength><dosageForm>Inj Sol - 1mL Amp Pk</dosageForm><drug id="00839213" notABenefit="Y" sec3="Y"><name>Sandostatin</name><manufacturerId>NOV</manufacturerId><listingDate>2007-01-02</listingDate></drug><drug id="02248641" sec3="Y"><name>Octreotide Acetate Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>40.3019</individualPrice><listingDate>2008-03-25</listingDate><amountMOHLTCPays>40.3019</amountMOHLTCPays></drug></pcg9><pcg9 id="920000225"><itemNumber>2234</itemNumber><strength>200mcg/mL</strength><dosageForm>Inj Sol - 5mL Vial Pk</dosageForm><drug id="02049392" sec3="Y"><name>Sandostatin</name><manufacturerId>NOV</manufacturerId><individualPrice>97.0300</individualPrice><listingDate>2007-01-02</listingDate><amountMOHLTCPays>72.7725</amountMOHLTCPays></drug><drug id="02248642" sec3="Y"><name>Octreotide Acetate Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>72.7725</individualPrice><listingDate>2008-03-25</listingDate><amountMOHLTCPays>72.7725</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01869"><name>OMALIZUMAB</name><pcgGroup lccId="00415"><pcg9 id="920000797"><itemNumber>2235</itemNumber><strength>75mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr Pk</dosageForm><drug id="02553805" sec3="Y" sec12="Y"><name>Omlyclo</name><manufacturerId>CEI</manufacturerId><individualPrice>168.7440</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>168.7440</amountMOHLTCPays></drug></pcg9><pcg9 id="920000798"><itemNumber>2236</itemNumber><strength>150mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr Pk</dosageForm><drug id="02553813" sec3="Y" sec12="Y"><name>Omlyclo</name><manufacturerId>CEI</manufacturerId><individualPrice>384.9600</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>384.9600</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="726">For the treatment of adults with severe uncontrolled asthma who meet the following criteria:

1. Patient is 12 years of age or older; AND

2. Diagnosed with severe asthma that is not controlled despite treatment with a high-dose inhaled corticosteroid, defined as greater than or equal to 500mcg of fluticasone propionate or equivalent daily*, in addition to a long-acting inhaled beta 2-agonist;

*Note: Check dose comparison tables for high-dose inhaled corticosteroid equivalency comparisons for various inhaled corticosteroids.

Omalizumab will not be funded as a first line treatment for uncontrolled asthma and patients must try other conventional therapies for asthma that include a corticosteroid inhaler before being prescribed a biologic treatment.

Proper inhaler technique (with a spacer if required/appropriate) and adherence to prescribed treatment should be confirmed. Patients may also be on other concomitant therapies.

AND

3. In the past 12 months, inadequately controlled asthma has resulted in at least one of the following:


- Hospitalization for asthma

- Two or more urgent care visits to a physician/nurse practitioner or emergency department for asthma exacerbations.

- Use of two or more courses of high-dose oral corticosteroids (e.g. prednisone) or increase in the dose of chronic prednisone treatment to manage asthma exacerbations; AND

4. Patient has demonstrated a positive skin test or in vitro reactivity to a perennial aeroallergen (e.g. positive allergy testing by skin prick test or IgE RAST);

Note: Removal or reduction of allergic and environmental triggers of asthma to the fullest extent possible should be attempted.

AND

5. Has a baseline Immunoglobulin E (IgE) level between 30IU/mL and 700IU/mL inclusive prior to start of omalizumab;

Note: Serum total IgE levels increase following administration of omalizumab due to formation of omalizumab:IgE complexes. Elevated serum total IgE levels may persist for up to 1 year following discontinuation of omalizumab. Serum total IgE levels obtained less than 1 year following discontinuation may not reflect steady state free IgE levels and should not be used to reassess the dosing regimen in asthma patients.

AND

6. Has an actual body weight between 20 to 150kg inclusive (Refer to Omlyclo product monograph for dosing in individuals 12 years of age and older by IgE level and weight); AND

7. Prescribed by or in consultation with a specialist in respirology or allergy/clinical immunology.

8. Omalizumab is not being used in combination with another biologic drug used for the treatment of asthma.

Renewal of omalizumab is provided for patients who have responded to treatment by improving asthma control compared to baseline before omalizumab was initiated. Depending on the baseline parameters, this may be evidenced by clinical improvements of one or more of the following;

- Decreased utilization of rescue medications [as determined by reduction in nighttime awakenings or reduction in average number of puffs/day of short-acting beta-agonists (SABA)]; OR

- Decreased frequency of asthma exacerbations (as determined by reduction in exacerbations that require hospitalization and/or urgent care visits to a hospital emergency department or physician/nurse practitioner clinic.); OR

- Reduction in asthma exacerbations that require adding or increasing doses of corticosteroids; OR

- Increase in percent predicted FEV-1 from pre-treatment baselines.


Recommended dose: Omalizumab 75 to 375mg administered SC every 2 to 4 weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="727">For the treatment of moderate to severe chronic idiopathic urticaria (CIU) in patients who meet all the following criteria:


1. Patient is 12 years of age or older; AND

2. Diagnosed with moderate to severe CIU [Weekly urticaria activity score (UAS7) of 16 or greater]; AND

3. Remains symptomatic despite management with optimal doses of standard oral therapies for CIU (e.g. histamine H1 receptor antagonists [e.g. cetirizine, desloratadine, loratadine, fexofenadine]); AND

4. Omalizumab is not being used in combination with another biologic drug used for the treatment of CIU; AND

5. Prescribed by a specialist (e.g. allergist, immunologist, dermatologist, etc.).

Recommended dose: 300mg SC every 4 weeks

Note the following guidance:

Severe urticaria - UAS7 of 28 to 42

Moderate urticaria - UAS7 of 16 to 27

Mild urticaria - UAS7 of 7 to 15

Well-controlled urticaria - UAS7 of 1 to 6

Urticaria-free - UAS7 of 0 (zero)


Patients who achieve symptom control for at least 12 weeks while on therapy should have a trial of stopping treatment.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 6 Months</lccNote><lccNote seq="005" reasonForUseId="728">All patients new to the Ontario Drug Benefit (ODB) Program should meet the RFU Code for initiation.


Renewal of funding of omalizumab will be provided for the treatment of chronic idiopathic urticaria (CIU) in patients who meet the following criteria:


1. Patient is 12 years of age or older; AND


2. Omalizumab is prescribed by a specialist (e.g. allergist, immunologist, dermatologist, etc.); AND

3. Omalizumab is not being used in combination with another biologic drug used for the treatment of CIU; AND


4. Patient&apos;s response to omalizumab previously funded under the ODB program meets at least ONE of the following criteria:


- Has achieved symptom control on omalizumab and tried stopping therapy but experienced symptom relapse of their urticaria while off treatment.

- Has experienced a partial improvement in response with omalizumab treatment by demonstrating a reduction of the weekly urticaria activity score (UAS7) by 9.5 points or more but patient has not been able to achieve complete symptom control for more than 12 consecutive weeks.

- Has responded to omalizumab in the past but has been rediagnosed with moderate to severe CIU with UAS7 of 16 or higher.


Notes:

1. Patients who achieve complete symptom control for at least 12 weeks while on therapy should have a trial of stopping treatment to establish whether the condition has gone into spontaneous remission.


2. Patients must demonstrate a minimum response to omalizumab for CIU by reducing the UAS7 score by at least 9.5 points from baseline before initiation of omalizumab for CIU.


Note the following guidance:


Urticaria-free - UAS7 of 0 (zero)

Well-controlled urticaria - UAS7 of 1 to 6

Mild urticaria - UAS7 of 7 to 15

Moderate urticaria - UAS7 of 16 to 27

Severe urticaria - UAS7 of 28 to 42


Recommended dose: 300mg every 4 weeks</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01200"><name>PAMIDRONATE DISODIUM</name><pcgGroup><pcg9 id="920000562"><itemNumber>2237</itemNumber><strength>3mg/mL</strength><dosageForm>Inj Sol-10mL Vial</dosageForm><drug id="02059762" sec3b="Y" sec3="Y"><name>Aredia</name><manufacturerId>NOV</manufacturerId><listingDate>2007-07-12</listingDate></drug><drug id="02246597" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pamidronate Disodium for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>86.7800</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>86.7800</amountMOHLTCPays></drug><drug id="02249669" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pamidronate Disodium Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>86.7800</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>86.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="920000563"><itemNumber>2238</itemNumber><strength>6mg/mL</strength><dosageForm>Inj Sol-10mL Vial</dosageForm><drug id="02059770" sec3b="Y" sec3="Y"><name>Aredia</name><manufacturerId>NOV</manufacturerId><listingDate>2007-07-12</listingDate></drug><drug id="02246598" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pamidronate Disodium for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>176.7000</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>176.7000</amountMOHLTCPays></drug><drug id="02249677" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pamidronate Disodium Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>176.7000</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>176.7000</amountMOHLTCPays></drug></pcg9><pcg9 id="920000564"><itemNumber>2239</itemNumber><strength>9mg/mL</strength><dosageForm>Inj Sol-10mL Vial</dosageForm><drug id="02059789" sec3b="Y" sec3="Y"><name>Aredia</name><manufacturerId>NOV</manufacturerId><listingDate>2007-07-12</listingDate></drug><drug id="02246599" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pamidronate Disodium for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>260.3300</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>260.3300</amountMOHLTCPays></drug><drug id="02249685" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pamidronate Disodium Omega</name><manufacturerId>OMG</manufacturerId><individualPrice>260.3300</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>260.3300</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01231"><name>PINAVERIUM BROMIDE</name><pcgGroup><pcg9 id="920000124"><itemNumber>2240</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="01950592" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Dicetel</name><manufacturerId>BGP</manufacturerId><listingDate>2018-10-31</listingDate></drug><drug id="02469677" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pinaverium</name><manufacturerId>AAP</manufacturerId><individualPrice>.3100</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.3100</amountMOHLTCPays></drug></pcg9><pcg9 id="920000349"><itemNumber>2241</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02230684" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Dicetel</name><manufacturerId>BGP</manufacturerId><listingDate>2018-10-31</listingDate></drug><drug id="02469685" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Pinaverium</name><manufacturerId>AAP</manufacturerId><individualPrice>.5405</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.5405</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01953"><name>PIRFENIDONE</name><pcgGroup><pcg9 id="920000699"><itemNumber>2242</itemNumber><strength>267mg</strength><dosageForm>Cap</dosageForm><drug id="02393751" notABenefit="Y" sec3b="Y" sec3="Y"><name>Esbriet</name><manufacturerId>INT</manufacturerId><listingDate>2021-07-30</listingDate></drug><drug id="02488833" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Pirfenidone Capsules</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.7120</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug><drug id="02509938" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Pirfenidone</name><manufacturerId>JPC</manufacturerId><individualPrice>6.7120</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>6.7120</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01682"><name>QUINAGOLIDE HCL</name><pcgGroup lccId="00197"><pcg9 id="920000542"><itemNumber>2243</itemNumber><strength>0.15mg</strength><dosageForm>Tab</dosageForm><drug id="02223775" sec3="Y" sec12="Y"><name>Norprolac</name><manufacturerId>FEI</manufacturerId><individualPrice>1.7294</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>1.7294</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="405">For the treatment of hyperprolactinemia in patients who have:

* Failed to respond to a greater than or equal to 3 month trial of bromocriptine; or
* Failed to tolerate bromocriptine; or
* Failed to shrink a prolactinoma by greater than 1 cm after 12 months of bromocriptine therapy</lccNote><lccNote seq="002" type="R">LU Authorization Period: 5 years.</lccNote></pcgGroup></genericName><genericName id="01420"><name>RALOXIFENE HCL</name><pcgGroup lccId="00133"><pcg9 id="920000323"><itemNumber>2244</itemNumber><strength>60mg</strength><dosageForm>Tab</dosageForm><drug id="02239028" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Evista</name><manufacturerId>LIL</manufacturerId><individualPrice>2.3757</individualPrice><listingDate>2000-11-30</listingDate><amountMOHLTCPays>.5134</amountMOHLTCPays></drug><drug id="02279215" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Apo-Raloxifene</name><manufacturerId>APX</manufacturerId><individualPrice>.5134</individualPrice><listingDate>2009-05-20</listingDate><amountMOHLTCPays>.5134</amountMOHLTCPays></drug><drug id="02358840" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Co Raloxifene</name><manufacturerId>COB</manufacturerId><individualPrice>.5134</individualPrice><listingDate>2012-10-30</listingDate><amountMOHLTCPays>.5134</amountMOHLTCPays></drug><drug id="02540681" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Raloxifene</name><manufacturerId>JPC</manufacturerId><individualPrice>.5134</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.5134</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">For the treatment of osteoporosis in postmenopausal women who have:</lccNote><lccNote seq="002" reasonForUseId="373">Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate.</lccNote><lccNote seq="003" type="R">Failure is defined as: continued loss of bone mineral density (loss of more than 3%) after two years of therapy; or a new osteoporosis related fracture after one year of therapy.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01548"><name>RILUZOLE</name><pcgGroup><pcg9 id="920000417"><itemNumber>2245</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02242763" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Rilutek</name><manufacturerId>SAC</manufacturerId><individualPrice>10.5500</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>7.3630</amountMOHLTCPays></drug><drug id="02352583" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Riluzole</name><manufacturerId>APX</manufacturerId><individualPrice>7.3630</individualPrice><listingDate>2012-11-27</listingDate><amountMOHLTCPays>7.3630</amountMOHLTCPays></drug><drug id="02390299" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mylan-Riluzole</name><manufacturerId>MYL</manufacturerId><individualPrice>7.3630</individualPrice><listingDate>2012-12-21</listingDate><amountMOHLTCPays>7.3630</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01441"><name>RISEDRONATE SODIUM</name><pcgGroup><pcg9 id="920000656"><itemNumber>2246</itemNumber><strength>35mg</strength><dosageForm>DR Tab</dosageForm><drug id="02370417" chronicUseMed="Y" sec3="Y"><name>Actonel DR</name><manufacturerId>WAR</manufacturerId><individualPrice>11.8653</individualPrice><listingDate>2012-02-29</listingDate><amountMOHLTCPays>2.9663</amountMOHLTCPays></drug><drug id="02493268" chronicUseMed="Y" sec3="Y"><name>AA-Risedronate DR</name><manufacturerId>AAP</manufacturerId><individualPrice>2.9663</individualPrice><listingDate>2021-07-30</listingDate><amountMOHLTCPays>2.9663</amountMOHLTCPays></drug></pcg9><pcg9 id="920000372"><itemNumber>2247</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02242518" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Actonel</name><manufacturerId>WAR</manufacturerId><listingDate>2001-03-07</listingDate></drug><drug id="02298376" chronicUseMed="Y" sec3="Y"><name>Teva-Risedronate</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7567</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>1.7567</amountMOHLTCPays></drug></pcg9><pcg9 id="920000340"><itemNumber>2248</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02239146" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Actonel</name><manufacturerId>WAR</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02298384" chronicUseMed="Y" sec3="Y"><name>Teva-Risedronate</name><manufacturerId>TEV</manufacturerId><individualPrice>11.3807</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>11.3807</amountMOHLTCPays></drug></pcg9><pcg9 id="920000430"><itemNumber>2249</itemNumber><strength>35mg</strength><dosageForm>Tab</dosageForm><drug id="02246896" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Actonel</name><manufacturerId>WAR</manufacturerId><listingDate>2003-04-16</listingDate></drug><drug id="02298392" chronicUseMed="Y" sec3="Y"><name>Teva-Risedronate</name><manufacturerId>TEV</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02302209" chronicUseMed="Y" sec3="Y"><name>PMS-Risedronate</name><manufacturerId>PMS</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02319861" chronicUseMed="Y" sec3="Y"><name>Ratio-Risedronate</name><manufacturerId>RPH</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02327295" chronicUseMed="Y" sec3="Y"><name>Sandoz Risedronate</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02341077" chronicUseMed="Y" sec3="Y"><name>Riva-Risedronate</name><manufacturerId>RIA</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02353687" chronicUseMed="Y" sec3="Y"><name>Apo-Risedronate</name><manufacturerId>APX</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02368552" chronicUseMed="Y" sec3="Y"><name>Jamp-Risedronate</name><manufacturerId>JPC</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2012-08-27</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02370255" chronicUseMed="Y" sec3="Y"><name>Risedronate</name><manufacturerId>SAI</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02406306" chronicUseMed="Y" sec3="Y"><name>Auro-Risedronate</name><manufacturerId>AUR</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug><drug id="02411407" chronicUseMed="Y" sec3="Y"><name>Risedronate</name><manufacturerId>SIV</manufacturerId><individualPrice>1.6764</individualPrice><listingDate>2020-05-29</listingDate><amountMOHLTCPays>1.6764</amountMOHLTCPays></drug></pcg9><pcg9 id="920000595"><itemNumber>2250</itemNumber><strength>150mg</strength><dosageForm>Tab</dosageForm><drug id="02316838" chronicUseMed="Y" sec3="Y"><name>Actonel</name><manufacturerId>WAR</manufacturerId><individualPrice>47.3370</individualPrice><listingDate>2009-06-23</listingDate><amountMOHLTCPays>11.1875</amountMOHLTCPays></drug><drug id="02377721" chronicUseMed="Y" sec3="Y"><name>Apo-Risedronate</name><manufacturerId>APX</manufacturerId><individualPrice>11.1875</individualPrice><listingDate>2012-06-26</listingDate><amountMOHLTCPays>11.1875</amountMOHLTCPays></drug><drug id="02413809" chronicUseMed="Y" sec3="Y"><name>Teva-Risedronate</name><manufacturerId>TEV</manufacturerId><individualPrice>11.1875</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>11.1875</amountMOHLTCPays></drug><drug id="02424177" chronicUseMed="Y" sec3="Y"><name>PMS-Risedronate</name><manufacturerId>PMS</manufacturerId><individualPrice>11.1875</individualPrice><listingDate>2014-07-30</listingDate><amountMOHLTCPays>11.1875</amountMOHLTCPays></drug><drug id="02442760" chronicUseMed="Y" sec3="Y"><name>Auro-Risedronate</name><manufacturerId>AUR</manufacturerId><individualPrice>11.1875</individualPrice><listingDate>2018-04-30</listingDate><amountMOHLTCPays>11.1875</amountMOHLTCPays></drug><drug id="02528460" chronicUseMed="Y" sec3="Y"><name>Risedronate</name><manufacturerId>SAI</manufacturerId><individualPrice>11.1875</individualPrice><listingDate>2022-11-30</listingDate><amountMOHLTCPays>11.1875</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01354"><name>ROPINIROLE</name><pcgGroup><pcg9 id="920000289"><itemNumber>2251</itemNumber><strength>0.25mg</strength><dosageForm>Tab</dosageForm><drug id="02232565" notABenefit="Y" sec3="Y"><name>ReQuip</name><manufacturerId>GSK</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02314037" sec3="Y"><name>Ran-Ropinirole</name><manufacturerId>RAN</manufacturerId><individualPrice>.1441</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1441</amountMOHLTCPays></drug><drug id="02316846" sec3="Y"><name>Teva-Ropinirole</name><manufacturerId>TEV</manufacturerId><individualPrice>.1441</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.1441</amountMOHLTCPays></drug></pcg9><pcg9 id="920000290"><itemNumber>2252</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02232567" notABenefit="Y" sec3="Y"><name>ReQuip</name><manufacturerId>GSK</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02314053" sec3="Y"><name>Ran-Ropinirole</name><manufacturerId>RAN</manufacturerId><individualPrice>.5762</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.5762</amountMOHLTCPays></drug><drug id="02316854" sec3="Y"><name>Teva-Ropinirole</name><manufacturerId>TEV</manufacturerId><individualPrice>.5762</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.5762</amountMOHLTCPays></drug></pcg9><pcg9 id="920000291"><itemNumber>2253</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02232568" notABenefit="Y" sec3="Y"><name>ReQuip</name><manufacturerId>GSK</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02314061" sec3="Y"><name>Ran-Ropinirole</name><manufacturerId>RAN</manufacturerId><individualPrice>.6338</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.6338</amountMOHLTCPays></drug><drug id="02316862" sec3="Y"><name>Teva-Ropinirole</name><manufacturerId>TEV</manufacturerId><individualPrice>.6338</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>.6338</amountMOHLTCPays></drug></pcg9><pcg9 id="920000292"><itemNumber>2254</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02232569" notABenefit="Y" sec3="Y"><name>ReQuip</name><manufacturerId>GSK</manufacturerId><listingDate>2000-04-17</listingDate></drug><drug id="02314088" sec3="Y"><name>Ran-Ropinirole</name><manufacturerId>RAN</manufacturerId><individualPrice>1.7450</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.7450</amountMOHLTCPays></drug><drug id="02316870" sec3="Y"><name>Teva-Ropinirole</name><manufacturerId>TEV</manufacturerId><individualPrice>1.7450</individualPrice><listingDate>2009-09-30</listingDate><amountMOHLTCPays>1.7450</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01908"><name>SAPROPTERIN DIHYDROCHLORIDE</name><pcgGroup><pcg9 id="920000778"><itemNumber>2255</itemNumber><strength>100mg</strength><dosageForm>Pd for Sol (Sachet Pk)</dosageForm><drug id="02482207" notABenefit="Y" sec3b="Y" sec3="Y"><name>Kuvan</name><manufacturerId>BIM</manufacturerId><listingDate>2024-01-31</listingDate></drug><drug id="02534533" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reddy-Sapropterin</name><manufacturerId>DRR</manufacturerId><individualPrice>24.7500</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9><pcg9 id="920000779"><itemNumber>2256</itemNumber><strength>500mg</strength><dosageForm>Pd for Sol (Sachet Pk)</dosageForm><drug id="02482215" notABenefit="Y" sec3b="Y" sec3="Y"><name>Kuvan</name><manufacturerId>BIM</manufacturerId><listingDate>2024-01-31</listingDate></drug><drug id="02535610" notABenefit="Y" sec3b="Y" sec3="Y"><name>Reddy-Sapropterin</name><manufacturerId>DRR</manufacturerId><individualPrice>123.7500</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01184"><name>SELEGILINE HCL</name><pcgGroup><pcg9 id="920000056"><itemNumber>2257</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02123312" notABenefit="Y" sec3="Y"><name>Eldepryl</name><manufacturerId>BJH</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02230641" sec3="Y"><name>Selegiline</name><manufacturerId>AAP</manufacturerId><individualPrice>1.7072</individualPrice><listingDate>1997-08-28</listingDate><amountMOHLTCPays>1.7072</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01610"><name>SILDENAFIL</name><pcgGroup><pcg9 id="920000565"><itemNumber>2258</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02279401" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Revatio</name><manufacturerId>UJC</manufacturerId><individualPrice>13.2401</individualPrice><listingDate>2010-09-09</listingDate><amountMOHLTCPays>7.2940</amountMOHLTCPays></drug><drug id="02319500" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sildenafil R</name><manufacturerId>TEV</manufacturerId><individualPrice>7.2940</individualPrice><listingDate>2010-09-09</listingDate><amountMOHLTCPays>7.2940</amountMOHLTCPays></drug><drug id="02412179" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Sildenafil R</name><manufacturerId>PMS</manufacturerId><individualPrice>7.2940</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>7.2940</amountMOHLTCPays></drug><drug id="02418118" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Sildenafil R</name><manufacturerId>APX</manufacturerId><individualPrice>7.2940</individualPrice><listingDate>2014-02-27</listingDate><amountMOHLTCPays>7.2940</amountMOHLTCPays></drug><drug id="02469669" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Sildenafil R</name><manufacturerId>JPC</manufacturerId><individualPrice>7.2940</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>7.2940</amountMOHLTCPays></drug></pcg9><pcg9 id="920000550"><itemNumber>2259</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02239766" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Viagra</name><manufacturerId>UJC</manufacturerId><listingDate>2013-01-29</listingDate></drug><drug id="02248201" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Sildenafil</name><manufacturerId>APX</manufacturerId><individualPrice>8.2894</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02308738" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sildenafil</name><manufacturerId>TEV</manufacturerId><individualPrice>8.2900</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02317559" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>PMS</manufacturerId><individualPrice>8.2894</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02372053" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Sildenafil</name><manufacturerId>COB</manufacturerId><individualPrice>8.2894</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02393069" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Sildenafil</name><manufacturerId>MIN</manufacturerId><individualPrice>8.2900</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02400693" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>SIV</manufacturerId><individualPrice>8.2900</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02405660" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Sildenafil</name><manufacturerId>JPC</manufacturerId><individualPrice>8.2900</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02414368" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Sildenafil</name><manufacturerId>AUR</manufacturerId><individualPrice>8.2894</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02479796" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel-Sildenafil</name><manufacturerId>ACC</manufacturerId><individualPrice>3.1850</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>3.1850</amountMOHLTCPays></drug><drug id="02505150" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Sildenafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>8.2894</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug><drug id="02540770" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>SAI</manufacturerId><individualPrice>8.2894</individualPrice><listingDate>2024-07-31</listingDate><amountMOHLTCPays>8.2894</amountMOHLTCPays></drug></pcg9><pcg9 id="920000497"><itemNumber>2260</itemNumber><strength>50mg</strength><dosageForm>Tab</dosageForm><drug id="02239767" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Viagra</name><manufacturerId>UJC</manufacturerId><listingDate>2013-01-29</listingDate></drug><drug id="02248202" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Sildenafil</name><manufacturerId>APX</manufacturerId><individualPrice>8.8481</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>8.8481</amountMOHLTCPays></drug><drug id="02308746" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sildenafil</name><manufacturerId>TEV</manufacturerId><individualPrice>8.8481</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>8.8481</amountMOHLTCPays></drug><drug id="02317575" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>PMS</manufacturerId><individualPrice>8.8481</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>8.8481</amountMOHLTCPays></drug><drug id="02372061" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Sildenafil</name><manufacturerId>COB</manufacturerId><individualPrice>8.8481</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>8.8481</amountMOHLTCPays></drug><drug id="02393077" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Sildenafil</name><manufacturerId>MIN</manufacturerId><individualPrice>8.8475</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>8.8475</amountMOHLTCPays></drug><drug id="02400707" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>SIV</manufacturerId><individualPrice>8.8481</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>8.8481</amountMOHLTCPays></drug><drug id="02405679" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Sildenafil</name><manufacturerId>JPC</manufacturerId><individualPrice>8.8475</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>8.8475</amountMOHLTCPays></drug><drug id="02406152" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>SAI</manufacturerId><individualPrice>8.8475</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>8.8475</amountMOHLTCPays></drug><drug id="02414376" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Sildenafil</name><manufacturerId>AUR</manufacturerId><individualPrice>8.8475</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>8.8475</amountMOHLTCPays></drug><drug id="02479818" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel-Sildenafil</name><manufacturerId>ACC</manufacturerId><individualPrice>3.4000</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>3.4000</amountMOHLTCPays></drug><drug id="02505169" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Sildenafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>8.8475</individualPrice><listingDate>2022-01-31</listingDate><amountMOHLTCPays>8.8475</amountMOHLTCPays></drug></pcg9><pcg9 id="920000504"><itemNumber>2261</itemNumber><strength>100mg</strength><dosageForm>Tab</dosageForm><drug id="02239768" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Viagra</name><manufacturerId>UJC</manufacturerId><listingDate>2013-01-29</listingDate></drug><drug id="02248203" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Sildenafil</name><manufacturerId>APX</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02308754" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sildenafil</name><manufacturerId>TEV</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02317583" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>PMS</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02372088" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Co Sildenafil</name><manufacturerId>COB</manufacturerId><individualPrice>9.2016</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>9.2016</amountMOHLTCPays></drug><drug id="02393085" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mint-Sildenafil</name><manufacturerId>MIN</manufacturerId><individualPrice>9.2000</individualPrice><listingDate>2013-08-29</listingDate><amountMOHLTCPays>9.2000</amountMOHLTCPays></drug><drug id="02400715" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>SIV</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02402548" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Mar-Sildenafil</name><manufacturerId>MAR</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2017-03-28</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02405687" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Sildenafil</name><manufacturerId>JPC</manufacturerId><individualPrice>9.2000</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>9.2000</amountMOHLTCPays></drug><drug id="02406160" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sildenafil</name><manufacturerId>SAI</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02414384" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Sildenafil</name><manufacturerId>AUR</manufacturerId><individualPrice>9.2000</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>9.2000</amountMOHLTCPays></drug><drug id="02430037" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>M-Sildenafil</name><manufacturerId>MAT</manufacturerId><individualPrice>9.2000</individualPrice><listingDate>2016-10-27</listingDate><amountMOHLTCPays>9.2000</amountMOHLTCPays></drug><drug id="02452413" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Riva-Sildenafil</name><manufacturerId>RIA</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02468557" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PRZ-Sildenafil</name><manufacturerId>PRZ</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2019-03-28</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02476819" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>NRA-Sildenafil</name><manufacturerId>NRA</manufacturerId><individualPrice>9.2006</individualPrice><listingDate>2020-07-31</listingDate><amountMOHLTCPays>9.2006</amountMOHLTCPays></drug><drug id="02479826" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Accel-Sildenafil</name><manufacturerId>ACC</manufacturerId><individualPrice>3.5350</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>3.5350</amountMOHLTCPays></drug><drug id="02503506" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Sildenafil Tablets</name><manufacturerId>JPC</manufacturerId><individualPrice>9.2000</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>9.2000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01909"><name>SILODOSIN</name><pcgGroup lccId="00229"><pcg9 id="920000678"><itemNumber>2262</itemNumber><strength>4mg</strength><dosageForm>Cap</dosageForm><drug id="02361663" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Rapaflo</name><manufacturerId>WAT</manufacturerId><listingDate>2013-02-28</listingDate></drug><drug id="02475421" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Silodosin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug><drug id="02478501" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Silodosin</name><manufacturerId>AUR</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug><drug id="02517779" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Silodosin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug><drug id="02539519" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Silodosin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug></pcg9><pcg9 id="920000679"><itemNumber>2263</itemNumber><strength>8mg</strength><dosageForm>Cap</dosageForm><drug id="02361671" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Rapaflo</name><manufacturerId>WAT</manufacturerId><listingDate>2013-02-28</listingDate></drug><drug id="02475448" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Sandoz Silodosin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug><drug id="02478528" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Auro-Silodosin</name><manufacturerId>AUR</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2022-04-29</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug><drug id="02517787" chronicUseMed="Y" sec3="Y" sec12="Y"><name>PMS-Silodosin</name><manufacturerId>PMS</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug><drug id="02539527" chronicUseMed="Y" sec3="Y" sec12="Y"><name>Jamp Silodosin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4742</individualPrice><listingDate>2024-06-28</listingDate><amountMOHLTCPays>.4742</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="351">For the management of benign prostatic hyperplasia where six weeks of treatment with other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have been ineffective.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="352">For the management of benign prostatic hyperplasia where other formulary alpha blockers (e.g. doxazosin, terazosin, tamsulosin) have produced intolerable side effects.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01525"><name>SIROLIMUS</name><pcgGroup lccId="00163"><pcg9 id="920000403"><itemNumber>2264</itemNumber><strength>1mg/mL</strength><dosageForm>O/L</dosageForm><drug id="02243237" sec3="Y" sec12="Y"><name>Rapamune</name><manufacturerId>WAY</manufacturerId><individualPrice>9.6855</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>9.6855</amountMOHLTCPays></drug></pcg9><pcg9 id="920000450"><itemNumber>2265</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02247111" sec3="Y" sec12="Y"><name>Rapamune</name><manufacturerId>WAY</manufacturerId><individualPrice>9.6855</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>9.6855</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="392">For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01866"><name>SOLIFENACIN SUCCINATE</name><pcgGroup lccId="00218"><pcg9 id="920000638"><itemNumber>2266</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02277263" sec3="Y" sec12="Y"><name>Vesicare</name><manufacturerId>ASE</manufacturerId><individualPrice>1.6892</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02397900" sec3="Y" sec12="Y"><name>Teva-Solifenacin</name><manufacturerId>TEV</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02399032" sec3="Y" sec12="Y"><name>Sandoz Solifenacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02417723" sec3="Y" sec12="Y"><name>PMS-Solifenacin</name><manufacturerId>PMS</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02422239" sec3="Y" sec12="Y"><name>Act Solifenacin</name><manufacturerId>ACV</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02423375" sec3="Y" sec12="Y"><name>Apo-Solifenacin</name><manufacturerId>APX</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02424339" sec3="Y" sec12="Y"><name>Jamp-Solifenacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02428911" sec3="Y" sec12="Y"><name>Jamp Solifenacin Succinate</name><manufacturerId>JPC</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02437988" sec3="Y" sec12="Y"><name>Ran-Solifenacin</name><manufacturerId>RAN</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02439344" sec3="Y" sec12="Y"><name>Ach-Solifenacin Succinate</name><manufacturerId>ACH</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02446375" sec3="Y" sec12="Y"><name>Auro-Solifenacin</name><manufacturerId>AUR</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02448335" sec3="Y" sec12="Y"><name>Solifenacin Succinate Tablets</name><manufacturerId>MDI</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02458241" sec3="Y" sec12="Y"><name>Solifenacin</name><manufacturerId>SAI</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02493039" sec3="Y" sec12="Y"><name>PRZ-Solifenacin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02529696" sec3="Y" sec12="Y"><name>M-Solifenacin Succinate</name><manufacturerId>MAT</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug></pcg9><pcg9 id="920000639"><itemNumber>2267</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02277271" sec3="Y" sec12="Y"><name>Vesicare</name><manufacturerId>ASE</manufacturerId><individualPrice>1.6892</individualPrice><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02397919" sec3="Y" sec12="Y"><name>Teva-Solifenacin</name><manufacturerId>TEV</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2015-09-30</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02399040" sec3="Y" sec12="Y"><name>Sandoz Solifenacin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02417731" sec3="Y" sec12="Y"><name>PMS-Solifenacin</name><manufacturerId>PMS</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-01-28</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02422247" sec3="Y" sec12="Y"><name>Act Solifenacin</name><manufacturerId>ACV</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2015-11-26</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02423383" sec3="Y" sec12="Y"><name>Apo-Solifenacin</name><manufacturerId>APX</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02424347" sec3="Y" sec12="Y"><name>Jamp-Solifenacin</name><manufacturerId>JPC</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02428938" sec3="Y" sec12="Y"><name>Jamp Solifenacin Succinate</name><manufacturerId>JPC</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-07-28</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02437996" sec3="Y" sec12="Y"><name>Ran-Solifenacin</name><manufacturerId>RAN</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02439352" sec3="Y" sec12="Y"><name>Ach-Solifenacin Succinate</name><manufacturerId>ACH</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2023-05-31</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02446383" sec3="Y" sec12="Y"><name>Auro-Solifenacin</name><manufacturerId>AUR</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02448343" sec3="Y" sec12="Y"><name>Solifenacin Succinate Tablets</name><manufacturerId>MDI</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2017-11-30</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02458268" sec3="Y" sec12="Y"><name>Solifenacin</name><manufacturerId>SAI</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2020-10-30</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02493047" sec3="Y" sec12="Y"><name>PRZ-Solifenacin</name><manufacturerId>PRZ</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2021-02-26</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug><drug id="02529718" sec3="Y" sec12="Y"><name>M-Solifenacin Succinate</name><manufacturerId>MAT</manufacturerId><individualPrice>.3041</individualPrice><listingDate>2023-10-31</listingDate><amountMOHLTCPays>.3041</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="290">For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01971"><name>STANDARDIZED SHORT RAGWEED POLLEN ALLERGENIC EXTRACT</name><pcgGroup lccId="00250"><pcg9 id="920000704"><itemNumber>2268</itemNumber><strength>12U</strength><dosageForm>SL Tab</dosageForm><drug id="02423723" sec3="Y" sec12="Y"><name>Ragwitek</name><manufacturerId>ALK</manufacturerId><individualPrice>4.6533</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>4.6533</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="457">For the seasonal treatment of short ragweed pollen induced allergic rhinitis in patients that have not adequately responded to, or tolerated, conventional pharmacotherapy.

Notes:

Treatment with short ragweed pollen allergen extract must be initiated by physicians with adequate training and experience in the treatment of respiratory allergic diseases.

Treatment should be initiated at least twelve (12) weeks before the onset of ragweed pollen season and should only be continued until the end of the season.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01693"><name>SUNITINIB MALATE</name><pcgGroup><pcg9 id="920000554"><itemNumber>2269</itemNumber><strength>12.5mg</strength><dosageForm>Cap</dosageForm><drug id="02280795" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sutent</name><manufacturerId>PFI</manufacturerId><individualPrice>65.1240</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>55.3553</amountMOHLTCPays></drug><drug id="02524058" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Sunitinib</name><manufacturerId>TAR</manufacturerId><individualPrice>55.3553</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>55.3553</amountMOHLTCPays></drug><drug id="02526204" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sunitinib</name><manufacturerId>TEV</manufacturerId><individualPrice>55.3553</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>55.3553</amountMOHLTCPays></drug><drug id="02532190" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Sunitinib</name><manufacturerId>AUR</manufacturerId><individualPrice>55.3553</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>55.3553</amountMOHLTCPays></drug><drug id="02532840" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Sunitinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>55.3553</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>55.3553</amountMOHLTCPays></drug><drug id="02552892" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Sunitinib</name><manufacturerId>NAT</manufacturerId><individualPrice>55.3553</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>55.3553</amountMOHLTCPays></drug></pcg9><pcg9 id="920000555"><itemNumber>2270</itemNumber><strength>25mg</strength><dosageForm>Cap</dosageForm><drug id="02280809" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sutent</name><manufacturerId>PFI</manufacturerId><individualPrice>130.2470</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>110.7100</amountMOHLTCPays></drug><drug id="02524066" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Sunitinib</name><manufacturerId>TAR</manufacturerId><individualPrice>110.7100</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>110.7100</amountMOHLTCPays></drug><drug id="02526212" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sunitinib</name><manufacturerId>TEV</manufacturerId><individualPrice>110.7100</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>110.7100</amountMOHLTCPays></drug><drug id="02532204" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Sunitinib</name><manufacturerId>AUR</manufacturerId><individualPrice>110.7100</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>110.7100</amountMOHLTCPays></drug><drug id="02532867" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Sunitinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>110.7100</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>110.7100</amountMOHLTCPays></drug><drug id="02552906" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Sunitinib</name><manufacturerId>NAT</manufacturerId><individualPrice>110.7100</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>110.7100</amountMOHLTCPays></drug></pcg9><pcg9 id="920000556"><itemNumber>2271</itemNumber><strength>50mg</strength><dosageForm>Cap</dosageForm><drug id="02280817" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sutent</name><manufacturerId>PFI</manufacturerId><individualPrice>260.4950</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>221.4208</amountMOHLTCPays></drug><drug id="02524082" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Sunitinib</name><manufacturerId>TAR</manufacturerId><individualPrice>221.4208</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>221.4208</amountMOHLTCPays></drug><drug id="02526220" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Teva-Sunitinib</name><manufacturerId>TEV</manufacturerId><individualPrice>221.4208</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>221.4208</amountMOHLTCPays></drug><drug id="02532220" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Auro-Sunitinib</name><manufacturerId>AUR</manufacturerId><individualPrice>221.4208</individualPrice><listingDate>2023-08-31</listingDate><amountMOHLTCPays>221.4208</amountMOHLTCPays></drug><drug id="02532883" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Sandoz Sunitinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>221.4208</individualPrice><listingDate>2023-03-31</listingDate><amountMOHLTCPays>221.4208</amountMOHLTCPays></drug><drug id="02539284" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nat-Sunitinib</name><manufacturerId>NAT</manufacturerId><individualPrice>221.4208</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>221.4208</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01276"><name>TACROLIMUS</name><pcgGroup lccId="00137"><pcg9 id="920000224"><itemNumber>2272</itemNumber><strength>5mg/mL</strength><dosageForm>Amp</dosageForm><drug id="02176009" sec3="Y" sec12="Y"><name>Prograf</name><manufacturerId>ASE</manufacturerId><individualPrice>128.2350</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>128.2350</amountMOHLTCPays></drug></pcg9><pcg9 id="920000391"><itemNumber>2273</itemNumber><strength>0.5mg</strength><dosageForm>Cap</dosageForm><drug id="02243144" sec3="Y" sec12="Y"><name>Prograf</name><manufacturerId>ASE</manufacturerId><individualPrice>2.0291</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>1.0146</amountMOHLTCPays></drug><drug id="02416816" sec3="Y" sec12="Y"><name>Sandoz Tacrolimus</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.0146</individualPrice><listingDate>2015-01-28</listingDate><amountMOHLTCPays>1.0146</amountMOHLTCPays></drug><drug id="02454068" sec3="Y" sec12="Y"><name>Ach-Tacrolimus</name><manufacturerId>ACH</manufacturerId><individualPrice>1.0146</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>1.0146</amountMOHLTCPays></drug></pcg9><pcg9 id="920000221"><itemNumber>2274</itemNumber><strength>1mg</strength><dosageForm>Cap</dosageForm><drug id="02175991" sec3="Y" sec12="Y"><name>Prograf</name><manufacturerId>ASE</manufacturerId><individualPrice>2.5956</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>1.2978</amountMOHLTCPays></drug><drug id="02416824" sec3="Y" sec12="Y"><name>Sandoz Tacrolimus</name><manufacturerId>SDZ</manufacturerId><individualPrice>1.2978</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>1.2978</amountMOHLTCPays></drug><drug id="02456095" sec3="Y" sec12="Y"><name>Ach-Tacrolimus</name><manufacturerId>ACH</manufacturerId><individualPrice>1.2978</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>1.2978</amountMOHLTCPays></drug></pcg9><pcg9 id="920000222"><itemNumber>2275</itemNumber><strength>5mg</strength><dosageForm>Cap</dosageForm><drug id="02175983" sec3="Y" sec12="Y"><name>Prograf</name><manufacturerId>ASE</manufacturerId><individualPrice>12.9986</individualPrice><listingDate>1996-12-19</listingDate><amountMOHLTCPays>6.4993</amountMOHLTCPays></drug><drug id="02416832" sec3="Y" sec12="Y"><name>Sandoz Tacrolimus</name><manufacturerId>SDZ</manufacturerId><individualPrice>6.4993</individualPrice><listingDate>2014-01-30</listingDate><amountMOHLTCPays>6.4993</amountMOHLTCPays></drug><drug id="02456109" sec3="Y" sec12="Y"><name>Ach-Tacrolimus</name><manufacturerId>ACH</manufacturerId><individualPrice>6.4993</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>6.4993</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="173">For solid organ transplant and bone marrow transplant.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00200"><pcg9 id="920000591"><itemNumber>2276</itemNumber><strength>0.5mg</strength><dosageForm>ER Cap</dosageForm><drug id="02296462" sec3="Y" sec12="Y"><name>Advagraf</name><manufacturerId>ASE</manufacturerId><individualPrice>2.2199</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>2.2199</amountMOHLTCPays></drug></pcg9><pcg9 id="920000592"><itemNumber>2277</itemNumber><strength>1mg</strength><dosageForm>ER Cap</dosageForm><drug id="02296470" sec3="Y" sec12="Y"><name>Advagraf</name><manufacturerId>ASE</manufacturerId><individualPrice>2.8396</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>2.8396</amountMOHLTCPays></drug></pcg9><pcg9 id="920000621"><itemNumber>2278</itemNumber><strength>3mg</strength><dosageForm>ER Cap</dosageForm><drug id="02331667" sec3="Y" sec12="Y"><name>Advagraf</name><manufacturerId>ASE</manufacturerId><individualPrice>8.5188</individualPrice><listingDate>2011-03-15</listingDate><amountMOHLTCPays>8.5188</amountMOHLTCPays></drug></pcg9><pcg9 id="920000593"><itemNumber>2279</itemNumber><strength>5mg</strength><dosageForm>ER Cap</dosageForm><drug id="02296489" sec3="Y" sec12="Y"><name>Advagraf</name><manufacturerId>ASE</manufacturerId><individualPrice>14.2205</individualPrice><listingDate>2009-04-01</listingDate><amountMOHLTCPays>14.2205</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="410">For prophylaxis of organ rejection in adult patients receiving allogeneic kidney transplants

</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00153"><pcg9 id="920000411"><itemNumber>2280</itemNumber><strength>0.03%</strength><dosageForm>Oint</dosageForm><drug id="02244149" sec3="Y" sec12="Y"><name>Protopic</name><manufacturerId>LEO</manufacturerId><individualPrice>3.3530</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>3.3530</amountMOHLTCPays></drug></pcg9><pcg9 id="920000402"><itemNumber>2281</itemNumber><strength>0.1%</strength><dosageForm>Oint</dosageForm><drug id="02244148" sec3="Y" sec12="Y"><name>Protopic</name><manufacturerId>LEO</manufacturerId><individualPrice>3.5866</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>3.5866</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="383">For use in combination with moisturizers or oral antihistamines in patients with atopic dermatitis who have failed or are intolerant to an 8 week trial of an intermediate potency topical steroid.</lccNote><lccNote seq="002" type="R">Therapy should be reassessed at 6 months.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01392"><name>TAMSULOSIN HCL</name><pcgGroup><pcg9 id="920000534"><itemNumber>2282</itemNumber><strength>0.4mg</strength><drug id="02270102" chronicUseMed="Y" sec3="Y"><name>Flomax CR Tab</name><manufacturerId>BOE</manufacturerId><individualPrice>.6700</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2006-06-15</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug><drug id="02340208" chronicUseMed="Y" sec3="Y"><name>Sandoz Tamsulosin CR Tab</name><manufacturerId>SDZ</manufacturerId><individualPrice>.1500</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2011-05-19</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug><drug id="02362406" chronicUseMed="Y" sec3="Y"><name>Apo-Tamsulosin CR Tab</name><manufacturerId>APX</manufacturerId><individualPrice>.1500</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2011-12-15</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug><drug id="02368242" chronicUseMed="Y" sec3="Y"><name>Teva-Tamsulosin CR Tab</name><manufacturerId>TEV</manufacturerId><individualPrice>.1500</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug><drug id="02427117" chronicUseMed="Y" sec3="Y"><name>Tamsulosin CR Tab</name><manufacturerId>SAI</manufacturerId><individualPrice>.1500</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2020-06-30</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug><drug id="02429667" chronicUseMed="Y" sec3="Y"><name>Tamsulosin CR Tab</name><manufacturerId>SIV</manufacturerId><individualPrice>.1500</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2020-04-30</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug><drug id="02545179" chronicUseMed="Y" sec3="Y"><name>Auro-Tamsulosin CR Tab</name><manufacturerId>AUR</manufacturerId><individualPrice>.1500</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.1500</amountMOHLTCPays></drug></pcg9><pcg9 id="920000298"><itemNumber>2283</itemNumber><strength>0.4mg</strength><dosageForm>ER Cap</dosageForm><drug id="02238123" notABenefit="Y" chronicUseMed="Y" sec3="Y"><name>Flomax</name><manufacturerId>BOE</manufacturerId><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2002-04-04</listingDate></drug><drug id="02319217" chronicUseMed="Y" sec3="Y"><name>Sandoz Tamsulosin</name><manufacturerId>SDZ</manufacturerId><individualPrice>.4750</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2014-05-29</listingDate><amountMOHLTCPays>.4750</amountMOHLTCPays></drug><drug id="02352419" chronicUseMed="Y" sec3="Y"><name>Jamp Tamsulosin</name><manufacturerId>JPC</manufacturerId><individualPrice>.4750</individualPrice><note>Note: Randomized controlled trials have shown no significant differences in efficacy between daily doses of 0.4mg and 0.8mg of tamsulosin. Therefore, the daily tamsulosin dose should not exceed 0.4mg.</note><listingDate>2010-10-28</listingDate><amountMOHLTCPays>.4750</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01960"><name>TERIFLUNOMIDE</name><pcgGroup lccId="00370"><pcg9 id="920000701"><itemNumber>2284</itemNumber><strength>14mg</strength><dosageForm>Tab</dosageForm><drug id="02416328" notABenefit="Y" sec3="Y"><name>Aubagio</name><manufacturerId>SAG</manufacturerId><listingDate>2022-07-29</listingDate></drug><drug id="02500310" sec3="Y" sec12="Y"><name>Nat-Teriflunomide</name><manufacturerId>NAT</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02500434" sec3="Y" sec12="Y"><name>PMS-Teriflunomide</name><manufacturerId>PMS</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02500469" sec3="Y" sec12="Y"><name>Mar-Teriflunomide</name><manufacturerId>MAR</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02500639" sec3="Y" sec12="Y"><name>Apo-Teriflunomide</name><manufacturerId>APX</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02501090" sec3="Y" sec12="Y"><name>Teva-Teriflunomide</name><manufacturerId>TEV</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02502933" sec3="Y" sec12="Y"><name>Ach-Teriflunomide</name><manufacturerId>ACH</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02504170" sec3="Y" sec12="Y"><name>Jamp Teriflunomide</name><manufacturerId>JPC</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02505843" sec3="Y" sec12="Y"><name>Sandoz Teriflunomide</name><manufacturerId>SDZ</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug><drug id="02523833" sec3="Y" sec12="Y"><name>M-Teriflunomide</name><manufacturerId>MAT</manufacturerId><individualPrice>14.9300</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>14.9300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="647">For the treatment of Relapsing Remitting Multiple Sclerosis (RRMS) in adult patients with active disease meeting ALL the following criteria:

1. 18 years of age or older; AND

2. Diagnosis of RRMS is in accordance with the McDonald 2017 criteria demonstrating dissemination of lesions in the central nervous system in space and time meeting the following:

- 2 or more attacks (Note 1) and clinical evidence of 2 or more lesions (Note 2); OR

- 2 or more attacks and clinical evidence of 1 lesion with clear historical evidence of a prior attack involving a lesion in a different location;

Note 1: If the patient has experienced only one attack, the patient must meet ONE of the additional criteria of dissemination in time in the list below:

- Additional clinical attack
- Simultaneous presence of both enhancing and non-enhancing, symptomatic or asymptomatic MS-typical MRI lesions; OR a new T2 or enhancing MRI lesion compared to a baseline scan (without regard to timing of baseline scan)
- Presence of cerebrospinal fluid (CSF)-specific oligoclonal bands

Note 2: If the patient has evidence of only one lesion the patient must meet ONE of the additional criteria of dissemination in space in the list below:

- additional clinical attack implicating different CNS site
- 1 or more MS-typical T2 lesions in 2 or more areas of the Central Nervous System (CNS): periventricular, cortical, juxtacortical, infratentorial or spinal cord

AND

3. Patient has experienced a clinical relapse and/or new MS lesions in the last 2 years; AND

4. Patient has an Expanded Disability Status Scale (EDSS) score less than 6.0 before start of therapy; AND

5. Teriflunomide is used as monotherapy; AND

6. The drug request is from a neurologist experienced in the management of RRMS.

Exclusion Criteria:

1. Combination therapy with another disease modifying therapy for RRMS will not be reimbursed.
2. Patients with an EDSS score equal to or greater than 7.0. 

LU Authorization Period: 1 year


Renewal Criteria:

Teriflunomide may be continued for the treatment of RRMS for patients who have not experienced a suboptimal response with teriflunomide monotherapy and who have an EDSS score less than 7.0.

Patients who continue to experience clinical attacks or increased lesions or worsening EDSS should be evaluated for appropriateness of therapy and consideration of other treatment options available on the ODB formulary or through the Exceptional Access Program.

Renewal duration: 1 year

Recommended Dose: 14mg once daily

Refer to the product monograph for prescribing information.</lccNote></pcgGroup></genericName><genericName id="00388"><name>TETRABENAZINE</name><pcgGroup><pcg9 id="920000447"><itemNumber>2285</itemNumber><strength>25mg</strength><dosageForm>Tab</dosageForm><drug id="02199270" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Nitoman</name><manufacturerId>VAL</manufacturerId><listingDate>2013-04-30</listingDate></drug><drug id="02402424" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>PMS-Tetrabenazine</name><manufacturerId>PMS</manufacturerId><individualPrice>4.8551</individualPrice><listingDate>2013-04-30</listingDate><amountMOHLTCPays>4.8551</amountMOHLTCPays></drug><drug id="02407590" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Apo-Tetrabenazine</name><manufacturerId>APX</manufacturerId><individualPrice>4.8551</individualPrice><listingDate>2013-11-28</listingDate><amountMOHLTCPays>4.8551</amountMOHLTCPays></drug><drug id="02410338" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Tetrabenazine Tablets</name><manufacturerId>STE</manufacturerId><individualPrice>4.8551</individualPrice><listingDate>2014-01-03</listingDate><amountMOHLTCPays>4.8551</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01275"><name>TICLOPIDINE HCL</name><pcgGroup lccId="00139"><pcg9 id="920000219"><itemNumber>2286</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02162776" notABenefit="Y" sec3="Y"><name>Ticlid</name><manufacturerId>HLR</manufacturerId><listingDate>1996-10-01</listingDate></drug><drug id="02237701" sec3="Y" sec12="Y"><name>Ticlopidine</name><manufacturerId>AAP</manufacturerId><individualPrice>1.0679</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>1.0679</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="R">Ticlopidine is restricted to patients with transient cerebral ischemia. Ticlopidine may be somewhat more effective than ASA in preventing fatal and non-fatal strokes. However, it is associated with neutropenia in 0.8-2.4% of patients, a serious side-effect which may be fatal. Patients on ticlopidine require blood tests every two weeks for the first three months of therapy. There have been more than 60 cases of ticlopidine associated thrombotic thrombocytopenic purpura (TTP) with 33% mortality rate. As well, there are other side-effects such as diarrhea that occurs in 12.5% of patients. Ticlopidine should be used only after careful consideration. The appropriate use of ticlopidine in the management of patients with cerebral ischemic events (TIA or stroke) is based on the following:
(a) Determining that the symptoms are due to focal cerebral ischemia, and differentiating the symptoms of dizziness due to vestibular dysfunction, lightheadedness, or syncope from antihypertensive drugs or cardiac dysfunction, and from symptoms due to migraine, epilepsy, hypoglycemia, or other causes, such as tumor.
(b) If investigation demonstrates that the events are caused by emboli from the heart, the patient should be treated with anticoagulants, such as warfarin.
(c) If the events are due to artery-to-artery emboli from the carotid bifurcation with a severe stenosis, the patient should probably be treated with ASA and offered carotid endarterectomy if medically suitable (70% to 99% stenosis).
(d) ASA should be the first line of defense for patients with TIA and threatened stroke, and after an initial stroke of any severity.
(e) The only drugs other than ASA that are available as platelet inhibitors and which have been shown to be of value for such patients are ticlopidine and clopidogrel.
(f) Before abandoning ASA in favour of ticlopidine, efforts should be made to improve the tolerability of ASA by reducing the dose, taking it with food, and using enteric coated ASA.

Ticlopidine will be reimbursed for patients:</lccNote><lccNote seq="002" reasonForUseId="219">Who are known to be, or become, intolerant of ASA;</lccNote><lccNote seq="003" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="004" reasonForUseId="220">Where ASA is contraindicated;</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="006" reasonForUseId="221">Who continue to have TIA or stroke symptoms while being treated with ASA.</lccNote><lccNote seq="007" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01419"><name>TOLTERODINE L-TARTRATE</name><pcgGroup lccId="00140"><pcg9 id="920000451"><itemNumber>2287</itemNumber><strength>2mg</strength><dosageForm>SR Cap</dosageForm><drug id="02244612" sec3="Y" sec12="Y"><name>Detrol LA</name><manufacturerId>UJC</manufacturerId><individualPrice>2.3187</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.9822</amountMOHLTCPays></drug><drug id="02412195" sec3="Y" sec12="Y"><name>Teva-Tolterodine LA</name><manufacturerId>TEV</manufacturerId><individualPrice>.9822</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.9822</amountMOHLTCPays></drug><drug id="02413140" sec3="Y" sec12="Y"><name>Sandoz Tolterodine LA</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9822</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.9822</amountMOHLTCPays></drug></pcg9><pcg9 id="920000452"><itemNumber>2288</itemNumber><strength>4mg</strength><dosageForm>SR Cap</dosageForm><drug id="02244613" sec3="Y" sec12="Y"><name>Detrol LA</name><manufacturerId>UJC</manufacturerId><individualPrice>2.3187</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.9822</amountMOHLTCPays></drug><drug id="02412209" sec3="Y" sec12="Y"><name>Teva-Tolterodine LA</name><manufacturerId>TEV</manufacturerId><individualPrice>.9822</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.9822</amountMOHLTCPays></drug><drug id="02413159" sec3="Y" sec12="Y"><name>Sandoz Tolterodine LA</name><manufacturerId>SDZ</manufacturerId><individualPrice>.9822</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.9822</amountMOHLTCPays></drug></pcg9><pcg9 id="920000318"><itemNumber>2289</itemNumber><strength>1mg</strength><dosageForm>Tab</dosageForm><drug id="02239064" sec3="Y" sec12="Y"><name>Detrol</name><manufacturerId>UJC</manufacturerId><individualPrice>1.1592</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.4910</amountMOHLTCPays></drug><drug id="02423308" sec3="Y" sec12="Y"><name>Mint-Tolterodine</name><manufacturerId>MIN</manufacturerId><individualPrice>.4910</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.4910</amountMOHLTCPays></drug><drug id="02496836" sec3="Y" sec12="Y"><name>Jamp Tolterodine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4910</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>.4910</amountMOHLTCPays></drug></pcg9><pcg9 id="920000319"><itemNumber>2290</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02239065" sec3="Y" sec12="Y"><name>Detrol</name><manufacturerId>UJC</manufacturerId><individualPrice>1.1592</individualPrice><listingDate>1999-09-15</listingDate><amountMOHLTCPays>.4910</amountMOHLTCPays></drug><drug id="02423316" sec3="Y" sec12="Y"><name>Mint-Tolterodine</name><manufacturerId>MIN</manufacturerId><individualPrice>.4910</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.4910</amountMOHLTCPays></drug><drug id="02496844" sec3="Y" sec12="Y"><name>Jamp Tolterodine</name><manufacturerId>JPC</manufacturerId><individualPrice>.4910</individualPrice><listingDate>2022-09-29</listingDate><amountMOHLTCPays>.4910</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="290">For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.</lccNote><lccNote seq="005" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01058"><name>TRETINOIN</name><pcgGroup><pcg9 id="920000164"><itemNumber>2291</itemNumber><strength>10mg</strength><dosageForm>Cap</dosageForm><drug id="02145839" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Vesanoid</name><manufacturerId>HLR</manufacturerId><listingDate>2023-11-30</listingDate></drug><drug id="02520036" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp Tretinoin</name><manufacturerId>JPC</manufacturerId><individualPrice>13.9284</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>13.9284</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01865"><name>TROSPIUM CHLORIDE</name><pcgGroup lccId="00217"><pcg9 id="920000642"><itemNumber>2292</itemNumber><strength>20mg</strength><dosageForm>Tab</dosageForm><drug id="02275066" notABenefit="Y" sec3="Y"><name>Trosec</name><manufacturerId>SUO</manufacturerId><listingDate>2011-12-15</listingDate></drug><drug id="02488353" sec3="Y" sec12="Y"><name>Mar-Trospium</name><manufacturerId>MAR</manufacturerId><individualPrice>.4072</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>.4072</amountMOHLTCPays></drug><drug id="02506661" sec3="Y" sec12="Y"><name>Jamp Trospium</name><manufacturerId>JPC</manufacturerId><individualPrice>.4072</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>.4072</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="290">For patients with urinary frequency, urgency or urge incontinence who have:

Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.

NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.

Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01203"><name>URSODIOL</name><pcgGroup lccId="00141"><pcg9 id="920000308"><itemNumber>2293</itemNumber><strength>250mg</strength><dosageForm>Tab</dosageForm><drug id="02238984" notABenefit="Y" sec3="Y"><name>Urso</name><manufacturerId>BFI</manufacturerId><listingDate>2000-01-17</listingDate></drug><drug id="02273497" sec3="Y" sec12="Y"><name>PMS-Ursodiol C</name><manufacturerId>PMS</manufacturerId><individualPrice>.3818</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.3818</amountMOHLTCPays></drug><drug id="02426900" sec3="Y" sec12="Y"><name>GLN-Ursodiol</name><manufacturerId>GLP</manufacturerId><individualPrice>.3818</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.3818</amountMOHLTCPays></drug><drug id="02472392" sec3="Y" sec12="Y"><name>Jamp-Ursodiol</name><manufacturerId>JPC</manufacturerId><individualPrice>.3818</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.3818</amountMOHLTCPays></drug><drug id="02505363" sec3="Y" sec12="Y"><name>AG-Ursodiol</name><manufacturerId>ANG</manufacturerId><individualPrice>.3818</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>.3818</amountMOHLTCPays></drug><drug id="02515520" sec3="Y" sec12="Y"><name>Ursodiol C</name><manufacturerId>SAI</manufacturerId><individualPrice>.3818</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.3818</amountMOHLTCPays></drug><drug id="02544032" sec3="Y" sec12="Y"><name>NRA-Ursodiol</name><manufacturerId>NRA</manufacturerId><individualPrice>.3818</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.3818</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="273">For the treatment of primary biliary cirrhosis.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="534">For the treatment of primary sclerosing cholangitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup><pcgGroup lccId="00158"><pcg9 id="920000494"><itemNumber>2294</itemNumber><strength>500mg</strength><dosageForm>Tab</dosageForm><drug id="02245894" sec3="Y" sec12="Y"><name>Urso DS</name><manufacturerId>BFI</manufacturerId><individualPrice>3.1751</individualPrice><listingDate>2004-04-06</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug><drug id="02273500" sec3="Y" sec12="Y"><name>PMS-Ursodiol C</name><manufacturerId>PMS</manufacturerId><individualPrice>.7242</individualPrice><listingDate>2007-04-02</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug><drug id="02426919" sec3="Y" sec12="Y"><name>GLN-Ursodiol</name><manufacturerId>GLP</manufacturerId><individualPrice>.7242</individualPrice><listingDate>2016-06-29</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug><drug id="02472406" sec3="Y" sec12="Y"><name>Jamp-Ursodiol</name><manufacturerId>JPC</manufacturerId><individualPrice>.7242</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug><drug id="02505371" sec3="Y" sec12="Y"><name>AG-Ursodiol</name><manufacturerId>ANG</manufacturerId><individualPrice>.7242</individualPrice><listingDate>2021-06-30</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug><drug id="02515539" sec3="Y" sec12="Y"><name>Ursodiol C</name><manufacturerId>SAI</manufacturerId><individualPrice>.7242</individualPrice><listingDate>2021-12-17</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug><drug id="02544024" sec3="Y" sec12="Y"><name>NRA-Ursodiol</name><manufacturerId>NRA</manufacturerId><individualPrice>.7242</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>.7242</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="273">For the treatment of primary biliary cirrhosis.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="386">For the treatment of primary sclerosing cholangitis.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName><genericName id="01787"><name>USTEKINUMAB</name><pcgGroup lccId="00388"><pcg9 id="920000794"><itemNumber>2295</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02553317" sec3="Y" sec12="Y"><name>Wezlana</name><manufacturerId>AMG</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="670">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab for adult patients is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00387"><pcg9 id="920000780"><itemNumber>2296</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr Pk</dosageForm><drug id="02543036" sec3="Y" sec12="Y"><name>Jamteki</name><manufacturerId>JPC</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="668">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00388"><pcg9 id="920000782"><itemNumber>2297</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr Pk</dosageForm><drug id="02544180" sec3="Y" sec12="Y"><name>Wezlana</name><manufacturerId>AMG</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="670">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab for adult patients is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00420"><pcg9 id="920000802"><itemNumber>2298</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr Pk (Preservative-Free)</dosageForm><drug id="02554283" sec3="Y" sec12="Y"><name>Otulfi</name><manufacturerId>FKC</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="733">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00388"><pcg9 id="920000784"><itemNumber>2299</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Vial Pk</dosageForm><drug id="02544202" sec3="Y" sec12="Y"><name>Wezlana</name><manufacturerId>AMG</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="670">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab for adult patients is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00420"><pcg9 id="920000803"><itemNumber>2300</itemNumber><strength>90mg/mL</strength><dosageForm>Inj Sol-1.0mL Pref Syr Pk (Preservative-Free)</dosageForm><drug id="02554291" sec3="Y" sec12="Y"><name>Otulfi</name><manufacturerId>FKC</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="733">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00388"><pcg9 id="920000795"><itemNumber>2301</itemNumber><strength>90mg/mL</strength><dosageForm>Inj Sol-1mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02553309" sec3="Y" sec12="Y"><name>Wezlana</name><manufacturerId>AMG</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="670">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab for adult patients is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00387"><pcg9 id="920000781"><itemNumber>2302</itemNumber><strength>90mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr Pk</dosageForm><drug id="02543044" sec3="Y" sec12="Y"><name>Jamteki</name><manufacturerId>JPC</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="668">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00388"><pcg9 id="920000783"><itemNumber>2303</itemNumber><strength>90mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr Pk</dosageForm><drug id="02544199" sec3="Y" sec12="Y"><name>Wezlana</name><manufacturerId>AMG</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="670">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab for adult patients is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00389"><pcg9 id="920000785"><itemNumber>2304</itemNumber><strength>130mg/26mL</strength><dosageForm>Inj Sol-26mL Vial Pk</dosageForm><drug id="02544210" sec3="Y" sec12="Y"><name>Wezlana I.V.</name><manufacturerId>AMG</manufacturerId><individualPrice>1248.0000</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>1248.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00207"><pcg9 id="920000614"><itemNumber>2305</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-Pref Syr Pk</dosageForm><drug id="02320673" sec3="Y" sec12="Y"><name>Stelara</name><manufacturerId>JAN</manufacturerId><individualPrice>4593.1400</individualPrice><listingDate>2010-09-09</listingDate><amountMOHLTCPays>4593.1400</amountMOHLTCPays></drug></pcg9><pcg9 id="920000683"><itemNumber>2306</itemNumber><strength>90mg/mL</strength><dosageForm>Inj Sol-Pref Syr Pk</dosageForm><drug id="02320681" sec3="Y" sec12="Y"><name>Stelara</name><manufacturerId>JAN</manufacturerId><individualPrice>4593.1400</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>4593.1400</amountMOHLTCPays></drug></pcg9><lccNote seq="003" reasonForUseId="680">For the treatment of severe plaque psoriasis in patients who meet the following criteria:

- Patients who become pregnant during the transition period of July 31, 2024, to January 31, 2025.

</lccNote><lccNote seq="004" type="R">LU Authorization Period: 12 months from date of authorization.</lccNote><lccNote seq="005" reasonForUseId="681">For the treatment of severe plaque psoriasis in patients who meet the following criteria:

- Patients who require palliative care during the transition period of July 31, 2024, to January 31, 2025.

</lccNote><lccNote seq="006" type="R">LU Authorization Period: 12 months from date of authorization.</lccNote></pcgGroup><pcgGroup lccId="00420"><pcg9 id="920000801"><itemNumber>2307</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol-Vial Pk (Preservative-Free)</dosageForm><drug id="02554305" sec3="Y" sec12="Y"><name>Otulfi</name><manufacturerId>FKC</manufacturerId><individualPrice>1248.0000</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>1248.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="733">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01844"><name>VARENICLINE TARTRATE</name><pcgGroup lccId="00211"><pcg9 id="920000630"><itemNumber>2308</itemNumber><strength>0.5mg</strength><dosageForm>Tab</dosageForm><drug id="02291177" notABenefit="Y" sec3="Y"><name>Champix</name><manufacturerId>PFI</manufacturerId><listingDate>2011-08-04</listingDate></drug><drug id="02419882" sec3="Y" sec12="Y"><name>Apo-Varenicline</name><manufacturerId>APX</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug><drug id="02426226" sec3="Y" sec12="Y"><name>Teva-Varenicline</name><manufacturerId>TEV</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2019-07-31</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug><drug id="02542951" sec3="Y" sec12="Y"><name>NRA-Varenicline</name><manufacturerId>NRA</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug><drug id="02546949" sec3="Y" sec12="Y"><name>Mint-Varenicline</name><manufacturerId>MIN</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug></pcg9><pcg9 id="920000631"><itemNumber>2309</itemNumber><strength>1.0mg</strength><dosageForm>Tab</dosageForm><drug id="02291185" notABenefit="Y" sec3="Y"><name>Champix</name><manufacturerId>PFI</manufacturerId><listingDate>2011-08-04</listingDate></drug><drug id="02419890" sec3="Y" sec12="Y"><name>Apo-Varenicline</name><manufacturerId>APX</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug><drug id="02426234" sec3="Y" sec12="Y"><name>Teva-Varenicline</name><manufacturerId>TEV</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2019-06-28</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug><drug id="02542978" sec3="Y" sec12="Y"><name>NRA-Varenicline</name><manufacturerId>NRA</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug><drug id="02546957" sec3="Y" sec12="Y"><name>Mint-Varenicline</name><manufacturerId>MIN</manufacturerId><individualPrice>.4618</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>.4618</amountMOHLTCPays></drug></pcg9><pcg9 id="920000702"><itemNumber>2310</itemNumber><strength>0.5mg &amp; 1.0mg</strength><dosageForm>Tab (Starter Pack-53 Tabs)</dosageForm><drug id="02435675" sec3="Y" sec12="Y"><name>Apo-Varenicline</name><manufacturerId>APX</manufacturerId><individualPrice>24.3853</individualPrice><listingDate>2018-10-31</listingDate><amountMOHLTCPays>24.3853</amountMOHLTCPays></drug><drug id="02542986" sec3="Y" sec12="Y"><name>NRA-Varenicline</name><manufacturerId>NRA</manufacturerId><individualPrice>24.3853</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>24.3853</amountMOHLTCPays></drug><drug id="02546965" sec3="Y" sec12="Y"><name>Mint-Varenicline</name><manufacturerId>MIN</manufacturerId><individualPrice>24.3853</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>24.3853</amountMOHLTCPays></drug><drug id="09857519" notABenefit="Y" sec3="Y"><name>Champix</name><manufacturerId>PFI</manufacturerId><listingDate>2015-01-28</listingDate></drug><drug id="09857631" sec3="Y" sec12="Y"><name>Teva-Varenicline</name><manufacturerId>TEV</manufacturerId><individualPrice>24.3853</individualPrice><note>PIN 09857631 includes 25 tablets (0.5mg &amp; 1.0mg) from the Teva-Varenicline Starter Pack (DIN 02426781) and 28 tablets of Teva-Varenicline 1.0mg tablets (DIN 02426234). Dispensers need to ensure that only 1 claim is submitted by using the assigned PIN 09857631 when dispensing a total of 53 tablets from the combination of 28 tablets of Teva-Varenicline 1.0mg (DIN 02426234) with 25 tablets of the Teva-Varenicline Starter Pack (DIN 02426781).</note><listingDate>2019-08-30</listingDate><amountMOHLTCPays>24.3853</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="423">For smoking-cessation treatment in adults, in conjunction with smoking-cessation
counseling.

Network Note: Limited to 12 weeks (168 tablets) of reimbursement per 365 days per patient.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 12 Weeks.</lccNote></pcgGroup></genericName><genericName id="01599"><name>ZOLEDRONIC ACID</name><pcgGroup lccId="00195"><pcg9 id="920000536"><itemNumber>2311</itemNumber><strength>5mg/100mL</strength><dosageForm>Inj Sol-100mL Pk (Preservative-Free)</dosageForm><drug id="02269198" sec3="Y" sec12="Y"><name>Aclasta</name><manufacturerId>SDZ</manufacturerId><individualPrice>882.0900</individualPrice><listingDate>2006-10-23</listingDate><amountMOHLTCPays>356.0100</amountMOHLTCPays></drug><drug id="02415100" sec3="Y" sec12="Y"><name>Taro-Zoledronic Acid</name><manufacturerId>TAR</manufacturerId><individualPrice>356.0100</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>356.0100</amountMOHLTCPays></drug><drug id="02422433" sec3="Y" sec12="Y"><name>Zoledronic Acid Injection</name><manufacturerId>DRR</manufacturerId><individualPrice>356.0100</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>356.0100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="319">For the treatment of Paget&apos;s disease.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="003" reasonForUseId="436">For the treatment of osteoporosis in postmenopausal females who meet the following criteria:

- High risk* for fracture; and

- For whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) OR inability to stand or sit upright for at least 30 minutes.

*High fracture risk is defined as either:

- a prior fragility fracture AND a moderate 10-year fracture risk (10% to 20%) based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool; OR

- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; OR

- where a patient&apos;s 10-year fracture risk based on the CAROC or FRAX tool, is less than the thresholds defined above, a high fracture risk based on evaluation of clinical risk factors for fracture

Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors.</lccNote><lccNote seq="004" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="005" reasonForUseId="523">For the treatment of osteoporosis in males who meet the following criteria:

- High risk* for fracture; and

- For whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) OR inability to stand or sit upright for at least 30 minutes.

*High fracture risk is defined as either:

- a moderate 10-year fracture risk (10% to 20%) with a prior fragility fracture  based on the Canadian Association of Radiologists and Osteoporosis Canada (CAROC) tool or the Fracture Risk Assessment (FRAX) tool; OR

- a high 10-year fracture risk (greater than or equal to 20%) based on the CAROC or FRAX tool; OR

- where the patient&apos;s 10-year fracture risk is below 10% based on the CAROC or FRAX tool, a high fracture risk based on evaluation of clinical risk factors for fracture

Note: Use of the CAROC or FRAX tool may underestimate fracture risk in certain circumstances and may not include all risk factors.</lccNote><lccNote seq="006" type="R">LU Authorization Period: Indefinite</lccNote><lccNote seq="007" type="N">In all cases, patients receiving Aclasta should not be receiving concomitant bisphosphonate therapy. The recommended dose of Aclasta (zoledronic acid) is a single IV injection of 5mg, once yearly.</lccNote></pcgGroup><pcgGroup><pcg9 id="920000575"><itemNumber>2312</itemNumber><strength>4mg/5mL</strength><dosageForm>Inj Sol-5mL Pk (Preservative-Free)</dosageForm><drug id="02248296" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zometa Concentrate</name><manufacturerId>NOV</manufacturerId><listingDate>2014-04-30</listingDate></drug><drug id="02401606" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid-Z</name><manufacturerId>SDZ</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2014-04-30</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02407639" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid for Injection</name><manufacturerId>TEV</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02413701" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid for Inj. Concentrate</name><manufacturerId>OMG</manufacturerId><individualPrice>415.0000</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>415.0000</amountMOHLTCPays></drug><drug id="02415186" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Taro-Zoledronic Acid Concentrate</name><manufacturerId>TAR</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2014-05-29</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02422425" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid for Inj. Concentrate</name><manufacturerId>DRR</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02434458" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid for Injection</name><manufacturerId>FKC</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2018-12-21</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02444739" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid for Injection</name><manufacturerId>MDI</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02472805" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Zoledronic Acid for Injection</name><manufacturerId>MAR</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2019-04-30</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug><drug id="02482525" sec3b="Y" sec3bEAP="Y" sec3="Y"><name>Jamp-Zoledronic Acid</name><manufacturerId>JPC</manufacturerId><individualPrice>415.5600</individualPrice><listingDate>2019-10-31</listingDate><amountMOHLTCPays>415.5600</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="922000000"><name>BIOLOGIC RESPONSE MODIFIERS</name><genericName id="01346"><name>GLATIRAMER ACETATE</name><pcgGroup lccId="00309"><pcg9 id="922000001"><itemNumber>2313</itemNumber><strength>20mg/mL</strength><dosageForm>Inj Sol-Pref Syr 1mL Pk</dosageForm><drug id="02460661" sec3="Y" sec12="Y"><name>Glatect</name><manufacturerId>PMS</manufacturerId><individualPrice>35.0000</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>35.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="535">As monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) meeting ALL the following criteria:

-Recent neurological examination consistent with the diagnosis of RRMS; AND

-Lesions typical of multiple sclerosis on brain magnetic resonance imaging (MRI); AND

-Experienced at least 2 clinical attacks in their lifetime with one attack occurring within the prior year; AND

-EDSS score less than or equal to 6.0 prior to start of treatment; AND

-Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis.

Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="536">As monotherapy for the treatment of patients who have experienced a single demyelinating event/ Clinically Isolated Syndrome (CIS) meeting ALL the following criteria:

- CIS occurred within the prior 12 months; AND

- Recent neurological examination; AND

- Lesions typical of CIS confirmed on brain magnetic resonance imaging (MRI); AND

- EDSS score less than or equal to 6.0 prior to start of treatment; AND

- Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis

Note: Transition from another Disease Modifying therapy (DMT) is permitted in those who are deemed to have met the above criteria prior to initiation of the other DMT and if glatiramer acetate is used as monotherapy.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="537">Renewal of therapy for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) or a single demyelinating event /Clinically Isolated Syndrome (CIS) who meet ALL the following criteria:

- Used as monotherapy for the treatment of RRMS or CIS; AND

- EDSS score less than or equal to 6.0; AND

- Disease activity is stabilized as determined by a neurological exam and the number of clinical relapses experienced while on treatment; AND

- Prescribed by a neurologist experienced in the treatment of Multiple Sclerosis (MS) OR a prescriber in consultation with a neurologist overseeing the patient&apos;s MS.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01787"><name>USTEKINUMAB</name><pcgGroup lccId="00399"><pcg9 id="922000009"><itemNumber>2314</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr Pk  (Preservative-Free)</dosageForm><drug id="02550245" sec3="Y" sec12="Y"><name>Steqeyma</name><manufacturerId>CEH</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="668">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00387"><pcg9 id="922000013"><itemNumber>2315</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Vial Pk (Preservative-Free)</dosageForm><drug id="09858364" sec3="Y" sec12="Y"><name>Jamteki</name><manufacturerId>JPC</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="668">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00399"><pcg9 id="922000014"><itemNumber>2316</itemNumber><strength>45mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Vial Pk (Preservative-Free)</dosageForm><drug id="02558270" sec3="Y" sec12="Y"><name>Steqeyma</name><manufacturerId>CEH</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2025-08-29</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><pcg9 id="922000010"><itemNumber>2317</itemNumber><strength>90mg/1.0mL</strength><dosageForm>Inj Sol-1.0mL Pref Syr Pk  (Preservative-Free)</dosageForm><drug id="02550253" sec3="Y" sec12="Y"><name>Steqeyma</name><manufacturerId>CEH</manufacturerId><individualPrice>2755.8840</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>2755.8840</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="668">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids; AND

12 week trial of phototherapy (unless not accessible); AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

Recommended dose:

The recommended dose of ustekinumab is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. 

Alternatively, 90mg may be used in patients with a body weight of over 100kg. In patients weighing over 100kg, both the 45mg and 90mg doses were shown to be efficacious. However, 90mg was efficacious in a higher percentage of these patients.

Refer to the appropriate product monograph for dosing in pediatric patients weighing less than 60kg.

For patients who inadequately respond to dosing every 12 weeks, consideration may be given to treating as often as every 8 weeks.

If the patient has not responded after 12 weeks of treatment, the prescriber should consider switching to an alternative biologic agent.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="669">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 45mg administered subcutaneously at weeks 0 and 4, then every 12 weeks thereafter. Alternatively, 90mg may be used in patients with a body weight greater than 100kg.

Ustekinumab may be used alone or in combination with methotrexate (MTX).</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00401"><pcg9 id="922000011"><itemNumber>2318</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol-26mL Vial Pk (Preservative-Free)</dosageForm><drug id="02550261" sec3="Y" sec12="Y"><name>Steqeyma I.V.</name><manufacturerId>CEH</manufacturerId><individualPrice>1248.0000</individualPrice><listingDate>2024-09-27</listingDate><amountMOHLTCPays>1248.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00412"><pcg9 id="922000012"><itemNumber>2319</itemNumber><strength>5mg/mL</strength><dosageForm>Inj Sol-26mL Vial Pk (Preservative-Free)</dosageForm><drug id="02553120" sec3="Y" sec12="Y"><name>Jamteki I.V.</name><manufacturerId>JPC</manufacturerId><individualPrice>1248.0000</individualPrice><listingDate>2025-07-31</listingDate><amountMOHLTCPays>1248.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="671">For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter.

Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="672">For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe luminal Crohn&apos;s disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Ustekinumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing is a single intravenous (IV) dose based on body weight (for patients less than or equal to 55kg a dose of ustekinumab IV 260mg, for patients greater than 55kg to less than or equal to 85kg a dose of ustekinumab IV 390mg, and for patients greater than 85kg a dose of ustekinumab IV 520mg).

The recommended maintenance dosing regimen is 90mg administered subcutaneously at week 8 following the IV induction dose, followed by subsequent doses every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who show no evidence of therapeutic benefit 16 weeks after the IV induction dose.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.

Patients with fistulising Crohn&apos;s disease may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="923600000"><name>DISEASE-MODIFYING ANTIRHEUMATIC AGENTS</name><genericName id="01633"><name>ADALIMUMAB</name><pcgGroup lccId="00390"><pcg9 id="923600052"><itemNumber>2320</itemNumber><strength>20mg/0.2mL</strength><dosageForm>Inj Sol-0.2mL Pref Syr (Preservative-Free)</dosageForm><drug id="02542315" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>235.6350</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>235.6350</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600047"><itemNumber>2321</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Autoinj (Preservative-Free)</dosageForm><drug id="02533480" sec3="Y" sec12="Y"><name>Hadlima PushTouch</name><manufacturerId>SAM</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00359"><pcg9 id="923600031"><itemNumber>2322</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Autoinj Pen (Preservative-Free)</dosageForm><drug id="02523779" sec3="Y" sec12="Y"><name>Yuflyma</name><manufacturerId>CEH</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="923600034"><itemNumber>2323</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Autoinj Syr (Preservative-Free)</dosageForm><drug id="02523957" sec3="Y" sec12="Y"><name>Simlandi</name><manufacturerId>JPC</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="633">Polyarticular Juvenile Idiopathic Arthritis

For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 30kg and greater: 40mg every other week

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats. 

</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="634">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an ophthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years or older) with anterior uveitis is:

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600054"><itemNumber>2324</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Pen (Preservative-Free)</dosageForm><drug id="02542331" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600019"><itemNumber>2325</itemNumber><strength>20mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02459310" sec3="Y" sec12="Y"><name>Amgevita</name><manufacturerId>AMG</manufacturerId><individualPrice>235.6400</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>235.6400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600027"><itemNumber>2326</itemNumber><strength>20mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02505258" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>235.6350</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>235.6350</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00360"><pcg9 id="923600038"><itemNumber>2327</itemNumber><strength>20mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02502380" sec3="Y" sec12="Y"><name>Hulio</name><manufacturerId>BGP</manufacturerId><individualPrice>235.6350</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>235.6350</amountMOHLTCPays></drug></pcg9><pcg9 id="923600067"><itemNumber>2328</itemNumber><strength>20mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02511061" sec3="Y" sec12="Y"><name>Abrilada</name><manufacturerId>PFI</manufacturerId><individualPrice>235.6300</individualPrice><listingDate>2025-06-30</listingDate><amountMOHLTCPays>235.6300</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00359"><pcg9 id="923600032"><itemNumber>2329</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02523760" sec3="Y" sec12="Y"><name>Yuflyma</name><manufacturerId>CEH</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="923600033"><itemNumber>2330</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02523949" sec3="Y" sec12="Y"><name>Simlandi</name><manufacturerId>JPC</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="633">Polyarticular Juvenile Idiopathic Arthritis

For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 30kg and greater: 40mg every other week

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats. 

</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="634">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an ophthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years or older) with anterior uveitis is:

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600046"><itemNumber>2331</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02533472" sec3="Y" sec12="Y"><name>Hadlima</name><manufacturerId>SAM</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600053"><itemNumber>2332</itemNumber><strength>40mg/0.4mL</strength><dosageForm>Inj Sol-0.4mL Pref Syr (Preservative-Free)</dosageForm><drug id="02542323" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600020"><itemNumber>2333</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02459302" sec3="Y" sec12="Y"><name>Amgevita</name><manufacturerId>AMG</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="923600026"><itemNumber>2334</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02473100" sec3="Y" sec12="Y"><name>Hadlima PushTouch</name><manufacturerId>SAM</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600028"><itemNumber>2335</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Autoinj (Preservative-Free)</dosageForm><drug id="02492156" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600022"><itemNumber>2336</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Pen (Preservative-Free)</dosageForm><drug id="02502402" sec3="Y" sec12="Y"><name>Hulio</name><manufacturerId>BGP</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="923600024"><itemNumber>2337</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Pen (Preservative-Free)</dosageForm><drug id="02502674" sec3="Y" sec12="Y"><name>Idacio</name><manufacturerId>FKC</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00360"><pcg9 id="923600036"><itemNumber>2338</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Pen (Preservative-Free)</dosageForm><drug id="02511045" sec3="Y" sec12="Y"><name>Abrilada</name><manufacturerId>PFI</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00359"><pcg9 id="923600048"><itemNumber>2339</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Pen (Preservative-Free)</dosageForm><drug id="02535084" sec3="Y" sec12="Y"><name>Yuflyma</name><manufacturerId>CEH</manufacturerId><individualPrice>942.5400</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>942.5400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="633">Polyarticular Juvenile Idiopathic Arthritis

For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 30kg and greater: 40mg every other week

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats. 

</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="634">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an ophthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years or older) with anterior uveitis is:

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600056"><itemNumber>2340</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Pen (Preservative-Free)</dosageForm><drug id="02542366" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>942.5400</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>942.5400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600021"><itemNumber>2341</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02459299" sec3="Y" sec12="Y"><name>Amgevita</name><manufacturerId>AMG</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="923600023"><itemNumber>2342</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02502399" sec3="Y" sec12="Y"><name>Hulio</name><manufacturerId>BGP</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="923600025"><itemNumber>2343</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02473097" sec3="Y" sec12="Y"><name>Hadlima</name><manufacturerId>SAM</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600029"><itemNumber>2344</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02492164" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-03-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00345"><pcg9 id="923600030"><itemNumber>2345</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02502682" sec3="Y" sec12="Y"><name>Idacio</name><manufacturerId>FKC</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2021-10-29</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00360"><pcg9 id="923600037"><itemNumber>2346</itemNumber><strength>40mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02511053" sec3="Y" sec12="Y"><name>Abrilada</name><manufacturerId>PFI</manufacturerId><individualPrice>471.2700</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>471.2700</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00359"><pcg9 id="923600035"><itemNumber>2347</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02523965" sec3="Y" sec12="Y"><name>Simlandi</name><manufacturerId>JPC</manufacturerId><individualPrice>942.5400</individualPrice><listingDate>2022-05-31</listingDate><amountMOHLTCPays>942.5400</amountMOHLTCPays></drug></pcg9><pcg9 id="923600049"><itemNumber>2348</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02535076" sec3="Y" sec12="Y"><name>Yuflyma</name><manufacturerId>CEH</manufacturerId><individualPrice>942.5400</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>942.5400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="633">Polyarticular Juvenile Idiopathic Arthritis

For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 30kg and greater: 40mg every other week

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats. 

</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="634">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an ophthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years or older) with anterior uveitis is:

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00346"><pcg9 id="923600055"><itemNumber>2349</itemNumber><strength>80mg/0.8mL</strength><dosageForm>Inj Sol-0.8mL Pref Syr (Preservative-Free)</dosageForm><drug id="02542358" sec3="Y" sec12="Y"><name>Hyrimoz</name><manufacturerId>SDZ</manufacturerId><individualPrice>942.5400</individualPrice><listingDate>2024-04-30</listingDate><amountMOHLTCPays>942.5400</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="600">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Approvals will only allow for standard dosing for adalimumab.

The recommended dosing regimen is 40mg every two weeks.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="601">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen is for pediatric patients 2 years of age and older:

- 10kg to less than 30kg: 20mg every other week*

- 30kg and greater: 40mg every other week

*a dose of 10mg every other week can be considered for patients weighing 10kg to less than 15kg

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="602">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite:

i) treatment with methotrexate (20mg/week) for at least 3 months; AND

ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="603">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 40mg every 2 weeks.

Higher doses may be considered case-by-case through the Exceptional Access Program.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="604">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate); 

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="605">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease with concomitant luminal disease in patients who meet the following criteria:

A. Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole);

AND

B. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease)

The recommended induction dosing regimen is 160mg at week 0, followed by 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="606">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Adalimumab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is up to 160mg at week 0, followed by up to 80mg at week 2.

The recommended maintenance dosing regimen is up to 40mg every 2 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission.

Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="015" reasonForUseId="607">For the treatment of patients with active moderate to severe hidradenitis suppurativa (HS) who have not responded to conventional therapy (including systemic antibiotics) and who meet all of the following:

A. A total abscess and nodule count of 3 or greater; AND

B. Lesions in at least two distinct anatomic areas, one of which must be Hurley Stage II or III; AND

C. Experienced an inadequate response to a 90-day trial of oral antibiotics.

Therapy must be prescribed by a practitioner with expertise in the management of patients with HS.

The recommended adult dosing regimen is 160mg at week 0, followed by 80mg at week 2, then 40mg at week 4, and 40mg weekly thereafter.

The recommended adolescent dosing regimen is 80mg at week 0, followed by 40mg every other week starting at week 1 up to 40mg weekly in those with inadequate response.

If there is no improvement after 12 weeks of treatment with adalimumab at the Health Canada approved dose, higher doses are not recommended and the prescriber should discontinue treatment.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewal:

Maintenance therapy is funded for patients beyond the first 12 weeks in those who meet the Ministry initiation criteria and who have responded to treatment defined as at least a 50% reduction in abscesses and inflammatory nodule count with no increase in abscess count or draining fistula count relative to baseline.

Maintenance therapy beyond the second year is funded for patients using adalimumab for HS, where there is objective evidence of the preservation of treatment effect (i.e. the current abscess and inflammatory nodule count should be compared to the count prior to initiating treatment with adalimumab).

The recommended maintenance dose is 40mg weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="016" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="017" reasonForUseId="609">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

**Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids

12 week trial of phototherapy (unless not accessible)

6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15-30mg per week
- Acitretin (could have been used with phototherapy)
- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

- at least a 50% reduction in PASI, AND
- at least a 50% reduction in BSA involvement, AND
- at least a 5 point reduction in DLQI score

Approvals will only allow for standard dosing for adalimumab.

The recommended dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subcutaneously given every other week starting at week 1, as approved by Health Canada.

If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended, and the physician should consider switching to an alternative biologic agent.</lccNote><lccNote seq="018" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="019" reasonForUseId="611">For the treatment of severe uveitis in patients meeting the following criteria:

A. Has experienced failure or intolerance to an oral corticosteroid (or topical corticosteroid for anterior uveitis) or where the use of corticosteroids is contraindicated, and has experienced failure or intolerance to at least one immunosuppressive therapy; AND

B. Treatment must be prescribed by an opthalmologist specialized in uveitis or retinal disease, a uveitis specialist, or a retina specialist familiar with ocular inflammatory diseases.

Requests not meeting the above criteria may be considered on a case-by-case basis through the Exceptional Access Program.

The recommended adult dose is an initial 80mg administered subcutaneously at week 0, followed by 40mg subsubcutaneously given every other week starting at week 1, as approved by Health Canada. Note: Higher doses up to 40mg weekly may be considered in patients who have failed to respond to lower doses.

The recommended dose for pediatric patients (2 years of age and older) with anterior uveitis is:

Less than 30kg: 20mg every other week in combination with methotrexate

30kg or greater: 40mg every other week in combination with methotrexate

For patients 6 years of age or older and less than 30kg, an optional loading dose of 40mg at week 0 may be administered before starting maintenance therapy.

For patients 6 years of age or older and weighing 30kg or greater, an optional loading dose of 80mg at week 0 may be administered before starting maintenance therapy.

It should be noted that some adalimumab products may not be available as 20mg injectables.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.

Maintenance/Renewals:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and who have experienced improvement and/or stability of vision and other treatment goals (e.g. reduction or control of ocular inflammation).</lccNote><lccNote seq="020" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02314"><name>APREMILAST</name><pcgGroup><pcg9 id="923600040"><itemNumber>2350</itemNumber><strength>30mg</strength><dosageForm>Tab</dosageForm><drug id="02434334" notABenefit="Y" sec3b="Y" sec3="Y"><name>Otezla</name><manufacturerId>AMG</manufacturerId><listingDate>2023-01-31</listingDate></drug><drug id="02518910" notABenefit="Y" sec3b="Y" sec3="Y"><name>GLN-Apremilast</name><manufacturerId>GLP</manufacturerId><individualPrice>18.7238</individualPrice><listingDate>2023-01-31</listingDate></drug><drug id="02521733" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Apremilast</name><manufacturerId>PMS</manufacturerId><individualPrice>18.7238</individualPrice><listingDate>2023-01-31</listingDate></drug><drug id="02524104" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Apremilast</name><manufacturerId>AUR</manufacturerId><individualPrice>18.7237</individualPrice><listingDate>2023-03-31</listingDate></drug><drug id="02525747" notABenefit="Y" sec3b="Y" sec3="Y"><name>Mint-Apremilast</name><manufacturerId>MIN</manufacturerId><individualPrice>18.7238</individualPrice><listingDate>2023-04-28</listingDate></drug><drug id="02528959" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Apremilast</name><manufacturerId>JPC</manufacturerId><individualPrice>18.7238</individualPrice><listingDate>2023-03-31</listingDate></drug><drug id="02529084" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Apremilast</name><manufacturerId>SDZ</manufacturerId><individualPrice>18.7238</individualPrice><listingDate>2023-01-31</listingDate></drug><drug id="02538180" notABenefit="Y" sec3b="Y" sec3="Y"><name>Apo-Apremilast</name><manufacturerId>APX</manufacturerId><individualPrice>18.7238</individualPrice><listingDate>2023-09-28</listingDate></drug></pcg9><pcg9 id="923600041"><itemNumber>2351</itemNumber><strength>10mg &amp; 20mg &amp; 30mg</strength><dosageForm>Tab-27 Blister Starter Pk</dosageForm><drug id="02434318" notABenefit="Y" sec3b="Y" sec3="Y"><name>Otezla</name><manufacturerId>AMG</manufacturerId><listingDate>2023-03-31</listingDate></drug><drug id="02524120" notABenefit="Y" sec3b="Y" sec3="Y"><name>Auro-Apremilast</name><manufacturerId>AUR</manufacturerId><individualPrice>505.5426</individualPrice><listingDate>2023-05-31</listingDate></drug><drug id="02528967" notABenefit="Y" sec3b="Y" sec3="Y"><name>Jamp Apremilast</name><manufacturerId>JPC</manufacturerId><individualPrice>505.5426</individualPrice><listingDate>2023-03-31</listingDate></drug><drug id="02529092" notABenefit="Y" sec3b="Y" sec3="Y"><name>Sandoz Apremilast</name><manufacturerId>SDZ</manufacturerId><individualPrice>505.5426</individualPrice><listingDate>2024-01-31</listingDate></drug></pcg9></pcgGroup></genericName><genericName id="01513"><name>ETANERCEPT</name><pcgGroup lccId="00291"><pcg9 id="923600008"><itemNumber>2352</itemNumber><strength>25mg/0.5mL</strength><dosageForm>Inj Sol-0.5mL Pref Syr Pk</dosageForm><drug id="02462877" sec3="Y" sec12="Y"><name>Erelzi</name><manufacturerId>SDZ</manufacturerId><individualPrice>120.5000</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>120.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="923600007"><itemNumber>2353</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr Pk</dosageForm><drug id="02462869" sec3="Y" sec12="Y"><name>Erelzi</name><manufacturerId>SDZ</manufacturerId><individualPrice>241.0000</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>241.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="923600006"><itemNumber>2354</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol-1mL Prefilled SensoReady Pen Pk</dosageForm><drug id="02462850" sec3="Y" sec12="Y"><name>Erelzi</name><manufacturerId>SDZ</manufacturerId><individualPrice>241.0000</individualPrice><listingDate>2017-12-21</listingDate><amountMOHLTCPays>241.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="512">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i)  Methotrexate (20mg/week) for at least 3 months, AND
     ii) leflunomide (20mg/day) for at least 3 months, in addition to
    iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
     ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine(400mg/day) for at least 3 months. 
       (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 50mg per week or 25mg twice weekly.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="513">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset equal to or younger than 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

NOTE: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 50mg per week or 25mg twice weekly.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="514">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen for pediatric patients ages 4 to 17 years with active pJIA is 0.8mg/kg per week (up to a maximum of 50mg per week).

Prescribers should be informed and stay current with a drug&apos;s official Health Canada product monograph including available dosage formats.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="563">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite treatment with methotrexate (20mg/week) for at least 3 months and one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20% reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 50mg per week or 25mg twice weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="591">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

12 week trial of phototherapy (unless not accessible), AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score


Approvals will only allow for standard dosing for etanercept: 

The recommended dose is 50mg subcutaneous twice weekly for 12 weeks followed by maintenance therapy at 25-50mg subcutaneous once weekly as approved by Health Canada.  If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00289"><pcg9 id="923600051"><itemNumber>2355</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol-Pref Autoinj Pen</dosageForm><drug id="02530309" sec3="Y" sec12="Y"><name>Rymti</name><manufacturerId>LUP</manufacturerId><individualPrice>236.1800</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>236.1800</amountMOHLTCPays></drug></pcg9><pcg9 id="923600004"><itemNumber>2356</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02455323" sec3="Y" sec12="Y"><name>Brenzys</name><manufacturerId>SAM</manufacturerId><individualPrice>236.1800</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>236.1800</amountMOHLTCPays></drug></pcg9><pcg9 id="923600050"><itemNumber>2357</itemNumber><strength>50mg/mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02530295" sec3="Y" sec12="Y"><name>Rymti</name><manufacturerId>LUP</manufacturerId><individualPrice>236.1800</individualPrice><listingDate>2024-03-28</listingDate><amountMOHLTCPays>236.1800</amountMOHLTCPays></drug></pcg9><pcg9 id="923600005"><itemNumber>2358</itemNumber><strength>50mg/mL</strength><dosageForm>Sol- Pref AutoInj</dosageForm><drug id="02455331" sec3="Y" sec12="Y"><name>Brenzys</name><manufacturerId>SAM</manufacturerId><individualPrice>236.1800</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>236.1800</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="498">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see note below) with:

- Age of disease onset less than or equal to 50; AND

- Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

- Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

- Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

NOTE: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 50mg per week.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="499">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i)  Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
    iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine(400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 50mg per week.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="514">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication should be documented.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

The recommended dosing regimen for pediatric patients ages 4 to 17 years with active pJIA is 0.8mg/kg per week (up to a maximum of 50mg per week).

Prescribers should be informed and stay current with a drug&apos;s official Health Canada product monograph including available dosage formats.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="563">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite treatment with methotrexate (20mg/week) for at least 3 months and one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20% reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 50mg per week or 25mg twice weekly.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="591">For the treatment of severe* plaque psoriasis in patients who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.
  
Patients not responding adequately at 12 weeks should have treatment discontinued.

* Definition of severe plaque psoriasis:

Body Surface Area (BSA) involvement of at least 10%, or involvement of the face, hands, feet or genital regions, AND

Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

Dermatology Life Quality Index (DLQI) score of at least 10.

** Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

12 week trial of phototherapy (unless not accessible), AND

6 month trial of at least 2 systemic, oral agents used alone or in combination
  
-Methotrexate 15-30mg per week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50% reduction in PASI, AND
-at least a 50% reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score


Approvals will only allow for standard dosing for etanercept: 

The recommended dose is 50mg subcutaneous twice weekly for 12 weeks followed by maintenance therapy at 25-50mg subcutaneous once weekly as approved by Health Canada.  If the patient has not responded adequately after 12 weeks of treatment at the Health Canada approved dose, higher doses are not recommended and the physician should consider switching to an alternative biologic agent.

Prescribers should be informed and stay current with a drug&apos;s official Health Canada approved product monograph including available dosage formats.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01538"><name>INFLIXIMAB</name><pcgGroup lccId="00417"><pcg9 id="923600001"><itemNumber>2359</itemNumber><strength>100mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02419475" sec3="Y" sec12="Y"><name>Remdantry</name><manufacturerId>CEI</manufacturerId><individualPrice>493.0000</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>493.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="468">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide (20mg/day) for at least 3 months, in addition to 
 iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 3mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 3mg/kg/dose every 8 weeks up to a maximum of six maintenance doses per year.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="469">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease (confirmed by radiographic evidence (see notes below) with:

-Age of disease onset less than or equal to 50; AND
-Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND
-Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND
-Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 3 to 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of up to 5mg/kg/dose every 6 to 8 weeks.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="470">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite: i) treatment with methotrexate (20mg/week) for at least 3 months; AND  ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.
If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation
of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.

</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="471">For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

Note 1: Definition of severe plaque psoriasis:

-Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND
-Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND
-Dermatology Life Quality Index (DLQI) score of at least 10.

Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

-6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND
-12 week trial of phototherapy (unless not accessible), AND
-6 month trial of at least 2 systemic, oral agents used alone or in combination
-Methotrexate 15 to 30mg/week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50 percent reduction in PASI, AND
-at least a 50 percent reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="477">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);
 
AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="478">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="479">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease in patients who meet the following criteria:

- Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole)

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00310"><pcg9 id="923600009"><itemNumber>2360</itemNumber><strength>100mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02470373" sec3="Y" sec12="Y"><name>Renflexis</name><manufacturerId>SAM</manufacturerId><individualPrice>493.0000</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>493.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="541">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 3mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 3mg/kg/dose every 8 weeks up to a maximum of six maintenance doses per year.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="542">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see notes below) with:

I.    Age of disease onset less than or equal to 50; AND

II.   Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

III.  Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

IV.   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 3 to 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of up to 5mg/kg/dose every 6 to 8 weeks.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="543">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite: i) treatment with methotrexate (20mg/week) for at least 3 months; AND ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="544">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.

**Failure, intolerance or contraindication to adequate trials of standard therapies:

-6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15 to 30mg/week

- Acitretin (could have been used with phototherapy)

- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:
- At least a 50% reduction in PASI, AND

- at least a 50% reduction in BSA involvement, AND

- at least a 5 point reduction in DLQI score

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="545">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease); 

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is 5mg/kg/dose at 0,2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

-Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="546">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="547">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease in patients who meet the following criteria:

- Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole)

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00417"><pcg9 id="923600061"><itemNumber>2361</itemNumber><strength>100mg/Vial</strength><dosageForm>Inj Pd-Vial Pk</dosageForm><drug id="02523191" sec3="Y" sec12="Y"><name>Ixifi</name><manufacturerId>PFI</manufacturerId><individualPrice>493.0000</individualPrice><listingDate>2025-04-30</listingDate><amountMOHLTCPays>493.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="468">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide (20mg/day) for at least 3 months, in addition to 
 iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 3mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 3mg/kg/dose every 8 weeks up to a maximum of six maintenance doses per year.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="469">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease (confirmed by radiographic evidence (see notes below) with:

-Age of disease onset less than or equal to 50; AND
-Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND
-Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND
-Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 3 to 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of up to 5mg/kg/dose every 6 to 8 weeks.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="470">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite: i) treatment with methotrexate (20mg/week) for at least 3 months; AND  ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.
If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation
of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.

</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="471">For the treatment of severe (see Note 1 below) plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies (see Note 2 below).

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

Note 1: Definition of severe plaque psoriasis:

-Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND
-Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND
-Dermatology Life Quality Index (DLQI) score of at least 10.

Note 2: Definition of failure, intolerance or contraindication to adequate trials of standard therapies:

-6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND
-12 week trial of phototherapy (unless not accessible), AND
-6 month trial of at least 2 systemic, oral agents used alone or in combination
-Methotrexate 15 to 30mg/week
-Acitretin (could have been used with phototherapy)
-Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:

-At least a 50 percent reduction in PASI, AND
-at least a 50 percent reduction in BSA involvement, AND
-at least a 5 point reduction in DLQI score

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="477">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);
 
AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="478">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="479">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease in patients who meet the following criteria:

- Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole)

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00406"><pcg9 id="923600059"><itemNumber>2362</itemNumber><strength>120mg/mL</strength><dosageForm>Inj Sol-1mL Pref Pen Pk (Preservative-Free)</dosageForm><drug id="02511584" sec3="Y" sec12="Y"><name>Remsima SC</name><manufacturerId>CEH</manufacturerId><individualPrice>474.5100</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>474.5100</amountMOHLTCPays></drug></pcg9><pcg9 id="923600058"><itemNumber>2363</itemNumber><strength>120mg/mL</strength><dosageForm>Inj Sol-1mL Pref Syr Pk (Preservative-Free)</dosageForm><drug id="02511576" sec3="Y" sec12="Y"><name>Remsima SC</name><manufacturerId>CEH</manufacturerId><individualPrice>474.5100</individualPrice><listingDate>2025-02-28</listingDate><amountMOHLTCPays>474.5100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="715">For the treatment of rheumatoid arthritis (RA) in adult patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

Recommended dose: Refer to the product monograph for full instructions.

Loading dose of 120mg subcutaneous (SC) at week 0, 1, 2, 3, and 4, followed by maintenance with 120mg SC infliximab every 2 weeks thereafter.

OR

If intravenous loading doses of infliximab are given to initiate treatment, 2 intravenous infusions of infliximab 3mg/kg should be given 2 weeks apart, and the first dose of 120mg infliximab SC should be initiated 4 weeks after the second IV infliximab dose.

Maintenance dose: 120mg SC once every 2 weeks.

Infliximab SC should be given in combination with methotrexate.

Note: There is insufficient information available to inform the use of appropriate SC dosing in patients who are using infliximab intravenously at doses greater than 3mg/kg for rheumatoid arthritis.   

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="716">I. For the treatment of moderate to severe ulcerative colitis in adult patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine) and subcutaneous (SC) infliximab is used as a steroid-sparing option in the maintenance setting;

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. SC infliximab is being used in the maintenance setting after completing an induction regimen with intravenously administered infliximab;

OR

II. SC infliximab is being used in the maintenance setting in a patient stabilized on intravenous infliximab** in the maintenance setting.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

**Note that there is insufficient information to inform the use and appropriate dosing of infliximab SC in patients who are using infliximab intravenously at doses greater than 5mg/kg for ulcerative colitis.

Approved doses:

120mg SC every 2 weeks as maintenance dosing.

The recommended maintenance dosing regimen is 120mg (given as one subcutaneous injection) once every 2 weeks, starting 4 weeks following completion of an induction regimen. For patients who have been on maintenance therapy with intravenous infliximab and who are switching to subcutaneous infliximab maintenance therapy, the first dose of subcutaneous infliximab may be administered 8 weeks after the last infliximab intravenous infusion.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (Applies to both initial and renewal coverage):

- Combination therapy with other advanced treatment options such as, biological treatments, sphingosine-1-phosphate receptor modulators, or JAK inhibitors used to treat inflammatory bowel disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="718">I. For the treatment of moderate to severe (luminal) Crohn&apos;s disease in adult patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate) and infliximab subcutaneous (SC) is used as a steroid-sparing option in the maintenance setting;

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. SC infliximab is being used in the maintenance setting after completing an induction regimen with intravenously administered infliximab

OR

II. SC infliximab is being used in the maintenance setting in a patient stabilized on intravenous infliximab** in the maintenance setting.

Approved doses:

120mg SC every 2 weeks as maintenance dosing.

The recommended maintenance dosing regimen is 120mg (given as one subcutaneous injection) once every 2 weeks, starting 4 weeks following completion of an induction regimen. For patients who have been on maintenance therapy with intravenous infliximab and who are switching to subcutaneous infliximab maintenance therapy, the first dose of subcutaneous infliximab may be administered 8 weeks after the last infliximab intravenous infusion.

**Note that there is insufficient information to inform the use and appropriate dosing of infliximab SC in patients who are using infliximab intravenously at doses greater than 5mg/kg for Crohn&apos;s disease.

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (Applies to both initial and renewal coverage):

- Combination therapy with other advanced treatment options such as, biological treatments, or JAK inhibitors used to treat Crohn&apos;s disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00342"><pcg9 id="923600017"><itemNumber>2364</itemNumber><strength>100mg/Vial</strength><dosageForm>Pd for Sol-Vial Pk</dosageForm><drug id="02496933" sec3="Y" sec12="Y"><name>Avsola</name><manufacturerId>AMG</manufacturerId><individualPrice>493.0000</individualPrice><listingDate>2020-12-18</listingDate><amountMOHLTCPays>493.0000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="592">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide (20mg/day) for at least 3 months, in addition to
   iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B.  i) Methotrexate (20mg/week) for at least 3 months, AND
    ii) leflunomide in combination with methotrexate for at least 3 months; OR

C.  i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 3mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 3mg/kg/dose every 8 weeks up to a maximum of six maintenance doses per year.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="593">For the treatment of ankylosing spondylitis (AS) in patients who have severe active disease confirmed by radiographic evidence (see notes below) with:

I.    Age of disease onset less than or equal to 50; AND

II.   Low back pain and stiffness for greater than 3 months that improves with exercise and not relieved by rest; AND

III.  Failure to respond to or documented intolerance to adequate trials of 2 non-steroidal anti-inflammatory drugs (NSAIDs) for at least 4 weeks each; AND

IV.   Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of greater than or equal to 4 for at least 4 weeks while on standard therapy.

Note: Radiographic evidence demonstrating the presence of &quot;SI joint fusion&quot; or &quot;SI joint erosion&quot; on x-ray or CT scan, or MRI demonstrating the presence of &quot;inflammation&quot; or &quot;edema&quot; of the SI joint.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 50 percent reduction in BASDAI score or greater than or equal to 2 absolute point reduction in BASDAI score. For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology. 

The recommended dosing regimen is 3 to 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of up to 5mg/kg/dose every 6 to 8 weeks.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="594">For the treatment of psoriatic arthritis in patients who have severe active disease (greater than or equal to 5 swollen joints and radiographic evidence of psoriatic arthritis) despite: i) treatment with methotrexate (20mg/week) for at least 3 months; AND ii) one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months.

If the patient has documented contraindications or intolerances to methotrexate, then only one of leflunomide (20mg/day) or sulfasalazine (1g twice daily) for at least 3 months is required.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year. For funding beyond the second year, the patient must have objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="595">For the treatment of severe* plaque psoriasis in patients 18 years of age or older who have experienced failure, intolerance, or have a contraindication to adequate trials of several standard therapies**.

Claims for the first 6 months must be written by a dermatologist.

Monitoring of patients is required to determine if continuation of therapy beyond 12 weeks is required.

Patients not responding adequately at 12 weeks should have treatment discontinued.

*Severe plaque psoriasis:

- Body Surface Area (BSA) involvement of at least 10 percent, or involvement of the face, hands, feet or genital regions, AND

- Psoriasis Area and Severity Index (PASI) score of at least 10 (not required if there is involvement of the face, hands, feet or genital regions), AND

- Dermatology Life Quality Index (DLQI) score of at least 10.

**Failure, intolerance or contraindication to adequate trials of standard therapies:

-6 month trial of at least 3 topical agents including vitamin D analogues and steroids, AND

- 12 week trial of phototherapy (unless not accessible), AND

- 6 month trial of at least 2 systemic, oral agents used alone or in combination

- Methotrexate 15 to 30mg/week

- Acitretin (could have been used with phototherapy)

- Cyclosporine

Maintenance/Renewal:

After 3 months of therapy, patients who respond to therapy should have:
- At least a 50% reduction in PASI, AND

- at least a 50% reduction in BSA involvement, AND

- at least a 5 point reduction in DLQI score

The recommended dosing regimen is 5mg/kg/dose at 0, 2 and 6 weeks followed by maintenance therapy of 5mg/kg/dose every 8 weeks.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="009" reasonForUseId="596">Ulcerative Colitis

For the treatment of moderate to severe ulcerative colitis in patients who meet the following criteria:

A. Mayo score greater than or equal to 6 with an endoscopic subscore* of at least 2 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., Mayo score less than 6), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild ulcerative colitis (e.g., Mayo score less than 6) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="010" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="011" reasonForUseId="597">Luminal Crohn&apos;s disease

For the treatment of moderate to severe (luminal) Crohn&apos;s disease in patients who meet the following criteria:

A. Harvey Bradshaw Index (HBI) score greater than or equal to 7 (or other validated disease activity score confirming moderate to severe disease);

AND

B. Failed conventional treatment with a corticosteroid (prednisone 40-60mg/day [or equivalent]) for a minimum of 14 days (or intravenous corticosteroid for 1 week);

OR

Responded to/stabilized on conventional treatment with a corticosteroid, with or without an immunosuppressant (e.g., azathioprine, 6-mercaptopurine, methotrexate);

OR

Conventional treatment with a corticosteroid is contraindicated;

AND

C. Infliximab is being used to induce remission or as a steroid-sparing maintenance therapy.

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and have demonstrated a treatment response or are in remission. Examples of treatment response include clinically meaningful reductions in disease activity scores (e.g., HBI score decrease greater than or equal to 50% from pre-treatment measurement), along with improvements in endoscopic findings and reduction or discontinuation of corticosteroids.

Prescribers may wish to consider other funded alternatives for patients unable to discontinue corticosteroid therapy.

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.

Patients with mild Crohn&apos;s disease (e.g., HBI less than 7) may be considered on a case-by-case basis through the Exceptional Access Program.</lccNote><lccNote seq="012" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="013" reasonForUseId="598">Fistulising Crohn&apos;s disease

For the treatment of fistulising Crohn&apos;s disease in patients who meet the following criteria:

- Patient has actively draining perianal or enterocutaneous fistula(e) that have recurred OR persist despite a course of appropriate antibiotic therapy (e.g., ciprofloxacin and/or metronidazole)

The recommended induction dosing regimen is 5mg/kg/dose at 0, 2, and 6 weeks.

The recommended maintenance dosing regimen is 5mg/kg/dose every 8 weeks. (Note: higher doses up to 10mg/kg/dose may be considered in patients who have failed to respond to lower doses.)

Maintenance/Renewal:

Maintenance therapy is funded for patients who met the initiation criteria and achieve and maintain response to therapy (e.g., partial or complete resolution of fistulae and symptom improvement).

Exclusion criteria (initial and renewal coverage):

- Combination therapy with another biologic used to treat inflammatory bowel disease will not be funded.</lccNote><lccNote seq="014" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01841"><name>TOCILIZUMAB</name><pcgGroup lccId="00408"><pcg9 id="923600065"><itemNumber>2365</itemNumber><strength>200mg/10mL</strength><dosageForm>Inj Sol-10mL Vial Pk</dosageForm><drug id="02552469" sec3="Y" sec12="Y"><name>Tyenne</name><manufacturerId>FKC</manufacturerId><individualPrice>311.9025</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>311.9025</amountMOHLTCPays></drug></pcg9><pcg9 id="923600066"><itemNumber>2366</itemNumber><strength>400mg/20mL</strength><dosageForm>Inj Sol-20mL Vial Pk</dosageForm><drug id="02552477" sec3="Y" sec12="Y"><name>Tyenne</name><manufacturerId>FKC</manufacturerId><individualPrice>623.8050</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>623.8050</amountMOHLTCPays></drug></pcg9><pcg9 id="923600064"><itemNumber>2367</itemNumber><strength>80mg/4mL</strength><dosageForm>Inj Sol-4mL Vial Pk</dosageForm><drug id="02552450" sec3="Y" sec12="Y"><name>Tyenne</name><manufacturerId>FKC</manufacturerId><individualPrice>124.7610</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>124.7610</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="697">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide (20mg/day) for at least 3 months, in addition to
 iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.); AND

Tocilizumab is not being used in combination with another biologic drug used for the treatment of RA; AND

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Maintenance/Renewal:

After 12 months of treatment, ongoing maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints compared to baseline prior to the use of tocilizumab.

For second and subsequent renewals (i.e., beyond 2 years of ongoing use of tocilizumab) the patient must demonstrate objective evidence of preservation of treatment effect.

For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of RA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Recommended Dose:

The recommended intravenous dose of tocilizumab for adult patients is 4mg/kg followed by an increase to 8mg/kg (up to 800mg per dose as per product monograph) based on clinical response, given once every 4 weeks.

The recommended subcutaneous dose of tocilizumab for adult patients weighing less than 100kg is a starting dose of 162mg sc every other week, followed by an increase to every week based on clinical response; AND

For patients weighing 100 kg or more, a dosage of 162mg sc every week is recommended.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="698">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication must be documented.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Tocilizumab is not being used in combination with another biologic drug used for the treatment of pJIA.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints compared to baseline prior to the start of tocilizumab therapy.

For second and subsequent renewals (i.e., beyond 2 years of ongoing use of tocilizumab) the patient must demonstrate objective evidence of preservation of treatment effect.

For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of pJIA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Recommended Dose:

The recommended intravenous (IV) dose of tocilizumab for patients 2 years of age and older:
- 10mg/kg IV every 4 weeks for patients weighing less than 30kg
- 8mg/kg IV every 4 weeks for patients weighing 30kg or greater (up to 800mg per dose as per product monograph)

The recommended subcutaneous (sc) dose of tocilizumab for patients 2 years of age and older:
- 162mg sc once every 3 weeks for patients weighing less than 30kg.
- 162mg sc once every 2 weeks for patients weighing 30kg or greater.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="720">For the treatment of systemic juvenile idiopathic arthritis (sJIA) in patients who meet all the following:

1. Patient is at least 2 years of age; AND

2. Diagnosed with sJIA with fever (temperature greater than 38 degrees Celsius) for at least two weeks; AND

3. Patient has at least one of the following:
- rash of systemic JIA; OR
- serositis (e.g. pericarditis, pleuritis, or peritonitis); OR
- lymphadenopathy (e.g. cervical, axillary, inguinal); OR
- hepatomegaly; OR
- splenomegaly

4. Other potential etiologies such as malignancies, serious clinical infections, other inflammatory or connective tissue diseases, have been ruled out by the prescriber; AND

5. Patient was less than 16 years of age at the onset of sJIA; AND

6. Systemic glucocorticoids cannot be used for one or more of the following reasons:
- The patient is unresponsive and/or refractory to systemic glucocorticoids; OR
- The patient is glucocorticoid dependent (i.e., the patient has experienced a systemic reaction such as fever, rash of sJIA, serositis, lymphadenopathy, hepatomegaly or splenomegaly while on tapering doses of systemic glucocorticoids); OR
- The patient has experienced an adverse drug reaction to a systemic glucocorticoid; OR
- The use of systemic glucocorticoids is contraindicated; AND

7. Tocilizumab is not being used in combination with another biologic drug used for the treatment of sJIA; AND

8. Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Maintenance/Renewals:

Renewal will be considered for patients who have at least a 50% reduction in glucocorticoid dose (unless contraindicated, not tolerated, unresponsive or refractory at the time of initial request) and no evidence of active systemic disease (e.g., fever, rash of sJIA, serositis, lymphadenopathy, hepatomegaly or splenomegaly).

For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of sJIA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Recommended Dose:

The recommended intravenous (IV) dose of tocilizumab for patients 2 years of age and older:

- 12mg/kg IV every 2 weeks for patients less than 30kg
- 8mg/kg IV every 2 weeks for patients weighing 30kg or more (up to 800mg per dose as per product monograph).

The recommended subcutaneous (sc) dose of tocilizumab for patients 2 years of age and older:
- 162mg sc once every 2 weeks for patients less than 30kg.
- 162mg sc once every week for patients weighing 30kg or more</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00410"><pcg9 id="923600062"><itemNumber>2368</itemNumber><strength>162mg/0.9mL</strength><dosageForm>Inj Sol-Pref Autoinj</dosageForm><drug id="02552485" sec3="Y" sec12="Y"><name>Tyenne</name><manufacturerId>FKC</manufacturerId><individualPrice>242.2875</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>242.2875</amountMOHLTCPays></drug></pcg9><pcg9 id="923600063"><itemNumber>2369</itemNumber><strength>162mg/0.9mL</strength><dosageForm>Inj Sol-Pref Syr</dosageForm><drug id="02552493" sec3="Y" sec12="Y"><name>Tyenne</name><manufacturerId>FKC</manufacturerId><individualPrice>244.9525</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>244.9525</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="697">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide (20mg/day) for at least 3 months, in addition to
 iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.); AND

Tocilizumab is not being used in combination with another biologic drug used for the treatment of RA; AND

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Maintenance/Renewal:

After 12 months of treatment, ongoing maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints compared to baseline prior to the use of tocilizumab.

For second and subsequent renewals (i.e., beyond 2 years of ongoing use of tocilizumab) the patient must demonstrate objective evidence of preservation of treatment effect.

For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of RA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Recommended Dose:

The recommended intravenous dose of tocilizumab for adult patients is 4mg/kg followed by an increase to 8mg/kg (up to 800mg per dose as per product monograph) based on clinical response, given once every 4 weeks.

The recommended subcutaneous dose of tocilizumab for adult patients weighing less than 100kg is a starting dose of 162mg sc every other week, followed by an increase to every week based on clinical response; AND

For patients weighing 100 kg or more, a dosage of 162mg sc every week is recommended.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="698">For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15mg/m2 per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication must be documented.

Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Tocilizumab is not being used in combination with another biologic drug used for the treatment of pJIA.

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints compared to baseline prior to the start of tocilizumab therapy.

For second and subsequent renewals (i.e., beyond 2 years of ongoing use of tocilizumab) the patient must demonstrate objective evidence of preservation of treatment effect.

For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of pJIA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Recommended Dose:

The recommended intravenous (IV) dose of tocilizumab for patients 2 years of age and older:
- 10mg/kg IV every 4 weeks for patients weighing less than 30kg
- 8mg/kg IV every 4 weeks for patients weighing 30kg or greater (up to 800mg per dose as per product monograph)

The recommended subcutaneous (sc) dose of tocilizumab for patients 2 years of age and older:
- 162mg sc once every 3 weeks for patients weighing less than 30kg.
- 162mg sc once every 2 weeks for patients weighing 30kg or greater.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="005" reasonForUseId="720">For the treatment of systemic juvenile idiopathic arthritis (sJIA) in patients who meet all the following:

1. Patient is at least 2 years of age; AND

2. Diagnosed with sJIA with fever (temperature greater than 38 degrees Celsius) for at least two weeks; AND

3. Patient has at least one of the following:
- rash of systemic JIA; OR
- serositis (e.g. pericarditis, pleuritis, or peritonitis); OR
- lymphadenopathy (e.g. cervical, axillary, inguinal); OR
- hepatomegaly; OR
- splenomegaly

4. Other potential etiologies such as malignancies, serious clinical infections, other inflammatory or connective tissue diseases, have been ruled out by the prescriber; AND

5. Patient was less than 16 years of age at the onset of sJIA; AND

6. Systemic glucocorticoids cannot be used for one or more of the following reasons:
- The patient is unresponsive and/or refractory to systemic glucocorticoids; OR
- The patient is glucocorticoid dependent (i.e., the patient has experienced a systemic reaction such as fever, rash of sJIA, serositis, lymphadenopathy, hepatomegaly or splenomegaly while on tapering doses of systemic glucocorticoids); OR
- The patient has experienced an adverse drug reaction to a systemic glucocorticoid; OR
- The use of systemic glucocorticoids is contraindicated; AND

7. Tocilizumab is not being used in combination with another biologic drug used for the treatment of sJIA; AND

8. Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Maintenance/Renewals:

Renewal will be considered for patients who have at least a 50% reduction in glucocorticoid dose (unless contraindicated, not tolerated, unresponsive or refractory at the time of initial request) and no evidence of active systemic disease (e.g., fever, rash of sJIA, serositis, lymphadenopathy, hepatomegaly or splenomegaly).

For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of sJIA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology.

Recommended Dose:

The recommended intravenous (IV) dose of tocilizumab for patients 2 years of age and older:

- 12mg/kg IV every 2 weeks for patients less than 30kg
- 8mg/kg IV every 2 weeks for patients weighing 30kg or more (up to 800mg per dose as per product monograph).

The recommended subcutaneous (sc) dose of tocilizumab for patients 2 years of age and older:
- 162mg sc once every 2 weeks for patients less than 30kg.
- 162mg sc once every week for patients weighing 30kg or more</lccNote><lccNote seq="006" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="007" reasonForUseId="721">For the treatment of giant cell arteritis (GCA) in symptomatic adult patients who meet the following:

1. A confirmed diagnosis of GCA by temporal artery biopsy and/or imaging tests (i.e., ultrasonography, magnetic resonance angiography, computed tomography angiography or positron emission scanning); AND

2. Tocilizumab is initiated as combination therapy with 20mg to 60mg of prednisone (or an equivalent glucocorticoid) with subsequent glucocorticoid tapering as symptoms stabilize; AND

3. Therapy must be prescribed by a rheumatologist or a prescriber with expertise in the diagnosis and management of GCA; AND

4. The patient is using tocilizumab for up to 52 weeks.

Note: Patients with other sight-threatening ocular diseases must have their prescribers apply for case-by-case funding consideration through the ministry&apos;s Compassionate Review Policy.

Limited Renewal:

Renewal after an initial treatment period of 52 weeks can occur in limited circumstances when directed by a prescriber based on the patient&apos;s clinical remission status, disease activity and relevant bloodwork, imaging results, severity of disease manifestations, and risk of relapse.

Recommended Dose:

The recommended dose of tocilizumab for adult patients is 162mg subcutaneously once every week in combination with a tapering dose of glucocorticoids.

A dose of 162mg subcutaneously once every other week, in combination with a tapering dose of glucocorticoids, may be considered based on clinical considerations.</lccNote><lccNote seq="008" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02009"><name>TOFACITINIB</name><pcgGroup lccId="00269"><pcg9 id="923600003"><itemNumber>2370</itemNumber><strength>5mg</strength><dosageForm>Tab</dosageForm><drug id="02423898" sec3="Y" sec12="Y"><name>Xeljanz</name><manufacturerId>PFI</manufacturerId><individualPrice>24.7733</individualPrice><listingDate>2016-12-22</listingDate><amountMOHLTCPays>5.9897</amountMOHLTCPays></drug><drug id="02511304" sec3="Y" sec12="Y"><name>Taro-Tofacitinib</name><manufacturerId>TAR</manufacturerId><individualPrice>5.9897</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>5.9897</amountMOHLTCPays></drug><drug id="02522799" sec3="Y" sec12="Y"><name>PMS-Tofacitinib</name><manufacturerId>PMS</manufacturerId><individualPrice>5.9897</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>5.9897</amountMOHLTCPays></drug><drug id="02522896" sec3="Y" sec12="Y"><name>Jamp Tofacitinib</name><manufacturerId>JPC</manufacturerId><individualPrice>5.9897</individualPrice><listingDate>2023-11-30</listingDate><amountMOHLTCPays>5.9897</amountMOHLTCPays></drug><drug id="02530007" sec3="Y" sec12="Y"><name>Auro-Tofacitinib</name><manufacturerId>AUR</manufacturerId><individualPrice>5.9897</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>5.9897</amountMOHLTCPays></drug><drug id="02551691" sec3="Y" sec12="Y"><name>Sandoz Tofacitinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>5.9897</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>5.9897</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="480">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide (20mg/day) for at least 3 months, in addition to 
 iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 5mg administered twice daily</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="589">For the treatment of ulcerative colitis disease in patients who meet the following criteria:

1. Moderate disease

a. Mayo score between 6 and 10 (inclusive) AND
b. Endoscopic* subscore of 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or a 1 week course of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

2. Severe disease

a. Mayo score greater than 10 AND
b. Endoscopy* subscore of greater than or equal to 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended dosing regimen for induction is 10mg twice daily for at least 8 weeks.

Maintenance/Renewal:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and whose disease is maintained at Mayo score less than 6 AND who demonstrate at least 50% reduction in the dose of prednisone compared with the starting dose following the first 6 months of treatment with tofacitinib or be off corticosteroids after the first year of treatment.

The recommended dosing regimen is 5mg twice daily.

Depending on therapeutic response; 10mg twice daily may also be used for maintenance in some patients. However, the lowest effective dose possible should be used for maintenance therapy to minimize adverse effects.  
 
</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00341"><pcg9 id="923600016"><itemNumber>2371</itemNumber><strength>10mg</strength><dosageForm>Tab</dosageForm><drug id="02480786" sec3="Y" sec12="Y"><name>Xeljanz</name><manufacturerId>PFI</manufacturerId><individualPrice>43.7833</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>10.5859</amountMOHLTCPays></drug><drug id="02511312" sec3="Y" sec12="Y"><name>Taro-Tofacitinib</name><manufacturerId>TAR</manufacturerId><individualPrice>10.5859</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>10.5859</amountMOHLTCPays></drug><drug id="02530015" sec3="Y" sec12="Y"><name>Auro-Tofacitinib</name><manufacturerId>AUR</manufacturerId><individualPrice>10.5859</individualPrice><listingDate>2023-01-31</listingDate><amountMOHLTCPays>10.5859</amountMOHLTCPays></drug><drug id="02551705" sec3="Y" sec12="Y"><name>Sandoz Tofacitinib</name><manufacturerId>SDZ</manufacturerId><individualPrice>10.5859</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>10.5859</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="589">For the treatment of ulcerative colitis disease in patients who meet the following criteria:

1. Moderate disease

a. Mayo score between 6 and 10 (inclusive) AND
b. Endoscopic* subscore of 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or a 1 week course of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

2. Severe disease

a. Mayo score greater than 10 AND
b. Endoscopy* subscore of greater than or equal to 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

The recommended dosing regimen for induction is 10mg twice daily for at least 8 weeks.

Maintenance/Renewal:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and whose disease is maintained at Mayo score less than 6 AND who demonstrate at least 50% reduction in the dose of prednisone compared with the starting dose following the first 6 months of treatment with tofacitinib or be off corticosteroids after the first year of treatment.

The recommended dosing regimen is 5mg twice daily.

Depending on therapeutic response; 10mg twice daily may also be used for maintenance in some patients. However, the lowest effective dose possible should be used for maintenance therapy to minimize adverse effects.  
 
</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02099"><name>TOFACITINIB CITRATE</name><pcgGroup lccId="00320"><pcg9 id="923600015"><itemNumber>2372</itemNumber><strength>11mg</strength><dosageForm>ER Tab</dosageForm><drug id="02470608" sec3="Y" sec12="Y"><name>Xeljanz XR</name><manufacturerId>PFI</manufacturerId><individualPrice>49.5467</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>27.2507</amountMOHLTCPays></drug><drug id="02553988" sec3="Y" sec12="Y"><name>Taro-Tofacitinib XR</name><manufacturerId>TAR</manufacturerId><individualPrice>27.2507</individualPrice><listingDate>2025-03-31</listingDate><amountMOHLTCPays>27.2507</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="565">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide (20mg/day) for at least 3 months, in addition to 
 iii) an adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

Maintenance/Renewal:

After 12 months of treatment, maintenance therapy is funded for patients with objective evidence of at least a 20 percent reduction in swollen joint count and a minimum of improvement in 2 swollen joints over the previous year.

For renewals beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 11mg once daily.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02251"><name>UPADACITINIB</name><pcgGroup lccId="00364"><pcg9 id="923600039"><itemNumber>2373</itemNumber><strength>15mg</strength><dosageForm>ER Tab</dosageForm><drug id="02495155" sec3="Y" sec12="Y"><name>Rinvoq</name><manufacturerId>ABV</manufacturerId><individualPrice>51.6810</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>51.6810</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="637">For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of treatment with other disease modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

i) Methotrexate (i.e. 20mg/week for at least 3 months)

ii) Methotrexate (20mg/week) for at least 3 months AND leflunomide (20mg/day) for at least 3 months

iii) Methotrexate 20mg/week, sulfasalazine (2g/day) AND hydroxychloroquine (dose based on weight up to 400mg per day) for at least 3 months.

In patients who demonstrated initial response to treatment (defined as an achievement of an American College of Rheumatology [ACR] improvement criteria of at least 20% [ACR20] at week 12), ongoing maintenance therapy is funded.

Maintenance/Renewal:

After 12 weeks of treatment, maintenance therapy is funded for patients who achieved an American College of Rheumatology (ACR) improvement criteria of at least 20% (ACR20) and a minimum of improvement in 2 swollen joints by week 12.

For renewals beyond 12 months, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 15mg administered once daily.

Upadacitinib shoud not be used in combination with other Janus kinase (JAK) inhibitors or other biologic DMARDs to treat the patient&apos;s RA. 

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="003" reasonForUseId="684">For the treatment of ulcerative colitis disease in patients who meet the following criteria:

1. Moderate disease

a. Mayo score between 6 and 10 (inclusive) AND
b. Endoscopic* subscore of 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or a 1 week course of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

2. Severe disease

a. Mayo score greater than 10 AND
b. Endoscopy* subscore of greater than or equal to 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

Maintenance/Renewal:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and whose disease is maintained at Mayo score less than 6 AND who demonstrate at least 50% reduction in the dose of prednisone compared with the starting dose following the first 6 months of treatment with upadacitinib or be off corticosteroids after the first year of treatment.

Approved Dose:

Induction: Up to 45mg once daily for 8 weeks

Maintenance: 15mg or 30mg once daily.

For patients greater or equal to 65 years of age, the maintenance dose is 15mg once daily.

Depending on therapeutic response, 30mg once daily may also be used for maintenance in some patients younger than 65 years of age. However, the lowest effective dose possible should be used for maintenance therapy to minimize adverse effects.</lccNote><lccNote seq="004" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup><pcgGroup lccId="00396"><pcg9 id="923600045"><itemNumber>2374</itemNumber><strength>30mg</strength><dosageForm>ER Tab</dosageForm><drug id="02520893" sec3="Y" sec12="Y"><name>Rinvoq</name><manufacturerId>ABV</manufacturerId><individualPrice>76.9600</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>76.9600</amountMOHLTCPays></drug></pcg9><pcg9 id="923600057"><itemNumber>2375</itemNumber><strength>45mg</strength><dosageForm>ER Tab</dosageForm><drug id="02539721" sec3="Y" sec12="Y"><name>Rinvoq</name><manufacturerId>ABV</manufacturerId><individualPrice>101.8100</individualPrice><listingDate>2024-08-30</listingDate><amountMOHLTCPays>101.8100</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="684">For the treatment of ulcerative colitis disease in patients who meet the following criteria:

1. Moderate disease

a. Mayo score between 6 and 10 (inclusive) AND
b. Endoscopic* subscore of 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or a 1 week course of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

2. Severe disease

a. Mayo score greater than 10 AND
b. Endoscopy* subscore of greater than or equal to 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).

*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.

Maintenance/Renewal:

Maintenance therapy is funded for patients who meet the Ministry initiation criteria and whose disease is maintained at Mayo score less than 6 AND who demonstrate at least 50% reduction in the dose of prednisone compared with the starting dose following the first 6 months of treatment with upadacitinib or be off corticosteroids after the first year of treatment.

Approved Dose:

Induction: Up to 45mg once daily for 8 weeks

Maintenance: 15mg or 30mg once daily.

For patients greater or equal to 65 years of age, the maintenance dose is 15mg once daily.

Depending on therapeutic response, 30mg once daily may also be used for maintenance in some patients younger than 65 years of age. However, the lowest effective dose possible should be used for maintenance therapy to minimize adverse effects.</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName></pcg6><pcg6 id="924400000"><name>IMMUNOSUPPRESSIVE AGENTS</name><genericName id="02158"><name>BARICITINIB</name><pcgGroup lccId="00347"><pcg9 id="924400011"><itemNumber>2376</itemNumber><strength>2mg</strength><dosageForm>Tab</dosageForm><drug id="02480018" sec3="Y" sec12="Y"><name>Olumiant</name><manufacturerId>LIL</manufacturerId><individualPrice>59.4367</individualPrice><listingDate>2021-08-31</listingDate><amountMOHLTCPays>59.4367</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="615">For the treatment of rheumatoid arthritis (RA) in combination with methotrexate in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments:

A. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) Leflunomide (20mg/day) for at least 3 months, in addition to
 iii) An adequate trial of at least one combination of DMARDs for 3 months; OR

B. i) Methotrexate (20mg/week) for at least 3 months, AND
  ii) Leflunomide in combination with methotrexate for at least 3 months; OR

C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.)

In patients who demonstrated initial response to treatment (defined as an achievement of an American College of Rheumatology [ACR] improvement criteria of at least 20% [ACR20] at week 12), ongoing maintenance therapy is funded.

Maintenance/Renewal:

After 12 weeks of treatment, maintenance therapy is funded for patients who achieved an American College of Rheumatology (ACR) improvement criteria of at least 20% (ACR20) and a minimum of improvement in 2 swollen joints by week 12.

For renewals beyond 12 months, the patient must demonstrate objective evidence of preservation of treatment effect.

Therapy must be prescribed by a rheumatologist or a physician with expertise in rheumatology.

The recommended dosing regimen is 2mg administered once daily.

Baricitinib should not be used in combination with other Janus kinase (JAK) inhibitors or other biologic DMARDs to treat the patient&apos;s RA.

</lccNote><lccNote seq="002" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="01276"><name>TACROLIMUS</name><pcgGroup lccId="00340"><pcg9 id="924400008"><itemNumber>2377</itemNumber><strength>0.75mg</strength><dosageForm>ER Tab</dosageForm><drug id="02485877" sec3="Y" sec12="Y"><name>Envarsus PA</name><manufacturerId>EVL</manufacturerId><individualPrice>2.0999</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>2.0999</amountMOHLTCPays></drug></pcg9><pcg9 id="924400009"><itemNumber>2378</itemNumber><strength>1mg</strength><dosageForm>ER Tab</dosageForm><drug id="02485885" sec3="Y" sec12="Y"><name>Envarsus PA</name><manufacturerId>EVL</manufacturerId><individualPrice>2.7430</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>2.7430</amountMOHLTCPays></drug></pcg9><pcg9 id="924400010"><itemNumber>2379</itemNumber><strength>4mg</strength><dosageForm>ER Tab</dosageForm><drug id="02485893" sec3="Y" sec12="Y"><name>Envarsus PA</name><manufacturerId>EVL</manufacturerId><individualPrice>10.9719</individualPrice><listingDate>2020-09-30</listingDate><amountMOHLTCPays>10.9719</amountMOHLTCPays></drug></pcg9><lccNote seq="001" reasonForUseId="590">For the prophylaxis of organ rejection in allogenic kidney or liver transplant adult patients in combination with other immunosuppressants.</lccNote><lccNote seq="002" type="R">LU Authorization Period: Indefinite</lccNote></pcgGroup></genericName></pcg6><pcg6 id="929200000"><name>OTHER MISCELLANEOUS THERAPEUTIC AGENTS</name><genericName id="02059"><name>ABOBOTULINUM TOXIN A</name><pcgGroup lccId="00308"><pcg9 id="929200001"><itemNumber>2380</itemNumber><strength>300U/Vial</strength><dosageForm>Pd Inj-Vial Pk</dosageForm><drug id="02460203" sec3="Y" sec12="Y"><name>Dysport Therapeutic</name><manufacturerId>IPS</manufacturerId><individualPrice>385.5600</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>385.5600</amountMOHLTCPays></drug></pcg9><pcg9 id="929200002"><itemNumber>2381</itemNumber><strength>500U/Vial</strength><dosageForm>Pd Inj-Vial Pk</dosageForm><drug id="02456117" sec3="Y" sec12="Y"><name>Dysport Therapeutic</name><manufacturerId>IPS</manufacturerId><individualPrice>642.6000</individualPrice><listingDate>2018-09-27</listingDate><amountMOHLTCPays>642.6000</amountMOHLTCPays></drug></pcg9><lccNote seq="001" type="N">Dysport Therapeutic should be administered personally by a neurologist, pediatrician, or a physician with equivalent post-graduate training and experience with neuromuscular disorders.</lccNote><lccNote seq="002" reasonForUseId="130">To reduce the subjective symptoms and objective signs of cervical dystonia (spasmodic torticollis) in adults.</lccNote><lccNote seq="003" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="004" reasonForUseId="412">For the management of focal spasticity, due to stroke or spinal cord injury in adults.</lccNote><lccNote seq="005" type="R">LU Authorization Period: 1 year</lccNote><lccNote seq="006" reasonForUseId="413">For the treatment of focal spasticity secondary to cerebral palsy in patients two years of age or older.</lccNote><lccNote seq="007" type="R">LU Authorization Period: 1 year</lccNote></pcgGroup></genericName><genericName id="02139"><name>FAMPRIDINE</name><pcgGroup><pcg9 id="929200006"><itemNumber>2382</itemNumber><strength>10mg</strength><dosageForm>ER Tab</dosageForm><drug id="02379910" notABenefit="Y" sec3b="Y" sec3="Y"><name>Fampyra</name><manufacturerId>BIG</manufacturerId><listingDate>2020-12-18</listingDate></drug><drug id="02482398" notABenefit="Y" sec3b="Y" sec3="Y"><name>Taro-Fampridine</name><manufacturerId>TAR</manufacturerId><individualPrice>8.4730</individualPrice><listingDate>2020-12-18</listingDate></drug><drug id="02496216" notABenefit="Y" sec3b="Y" sec3="Y"><name>PMS-Fampridine</name><manufacturerId>PMS</manufacturerId><individualPrice>8.4730</individualPrice><listingDate>2021-04-30</listingDate></drug></pcg9></pcgGroup></genericName></pcg6></pcg2><pcg2 id="960000000"><name>MISCELLANEOUS</name><pcg6 id="960100000"><name>NUTRITION PRODUCTS</name><genericName id="01352"><name>NUTRITIONAL PRODUCT</name><pcgGroup><pcg9 id="960100211"><strength>1.2kcal/mL</strength><dosageForm>1500mL Ready-to-hang</dosageForm><drug id="09857559" additionalBenefitType="N" sec9="Y"><name>Isosource Fibre 1.2</name><manufacturerId>NES</manufacturerId><individualPrice>13.8244</individualPrice><listingDate>2017-05-31</listingDate><amountMOHLTCPays>13.8244</amountMOHLTCPays></drug></pcg9><pcg9 id="960100213"><strength>1.5kcal/mL</strength><dosageForm>1500mL Ready-to-hang</dosageForm><drug id="09857561" additionalBenefitType="N" sec9="Y"><name>Isosource Fibre 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>17.2564</individualPrice><listingDate>2017-05-31</listingDate><amountMOHLTCPays>17.2564</amountMOHLTCPays></drug></pcg9><pcg9 id="960100219"><strength>1.5kcal/mL</strength><dosageForm>1500mL Ready-to-Hang</dosageForm><drug id="09857569" additionalBenefitType="N" sec9="Y"><name>Isosource 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>11.4975</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>11.4975</amountMOHLTCPays></drug></pcg9><pcg9 id="960100254"><strength>2kcal/mL</strength><dosageForm>200mL Pk bottle</dosageForm><drug id="09858353" additionalBenefitType="N" sec9="Y"><name>Renastep</name><manufacturerId>VIT</manufacturerId><individualPrice>9.2300</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>9.2300</amountMOHLTCPays></drug></pcg9><pcg9 id="960100210"><strength>1.2kcal/mL</strength><dosageForm>250mL Tetra Pk</dosageForm><drug id="09857558" additionalBenefitType="N" sec9="Y"><name>Isosource Fibre 1.2</name><manufacturerId>NES</manufacturerId><individualPrice>2.3040</individualPrice><listingDate>2017-05-31</listingDate><amountMOHLTCPays>2.3040</amountMOHLTCPays></drug></pcg9><pcg9 id="960100216"><strength>1.2Kcal/mL</strength><dosageForm>250mL Tetra Pk</dosageForm><drug id="09857566" additionalBenefitType="N" sec9="Y"><name>Isosource 1.2</name><manufacturerId>NES</manufacturerId><individualPrice>1.5330</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>1.5330</amountMOHLTCPays></drug></pcg9><pcg9 id="960100212"><strength>1.5kcal/mL</strength><dosageForm>250mL Tetra Pk</dosageForm><drug id="09857560" additionalBenefitType="N" sec9="Y"><name>Isosource Fibre 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>2.8760</individualPrice><listingDate>2017-05-31</listingDate><amountMOHLTCPays>2.8760</amountMOHLTCPays></drug></pcg9><pcg9 id="960100218"><strength>1.5kcal/mL</strength><dosageForm>250mL Tetra Pk</dosageForm><drug id="09857568" additionalBenefitType="N" sec9="Y"><name>Isosource 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>1.9163</individualPrice><listingDate>2017-09-28</listingDate><amountMOHLTCPays>1.9163</amountMOHLTCPays></drug></pcg9><pcg9 id="960100214"><strength>1.5Kcal/mL</strength><dosageForm>Liq - 250mL Tetra Pk</dosageForm><drug id="09857562" additionalBenefitType="N" sec9="Y"><name>Peptamen Junior 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>13.2224</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>13.2224</amountMOHLTCPays></drug></pcg9><pcg9 id="960100264"><strength>1.5kcal/mL</strength><dosageForm>Liq - 250mL Tetra Pk</dosageForm><drug id="09858355" additionalBenefitType="N" sec9="Y"><name>Peptamen 1.5 with Prebio</name><manufacturerId>NES</manufacturerId><individualPrice>13.2225</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>13.2225</amountMOHLTCPays></drug></pcg9><pcg9 id="960100131"><dosageForm>Liq-1000mL Pk</dosageForm><drug id="09854391" additionalBenefitType="N" sec9="Y"><name>Perative</name><manufacturerId>ROS</manufacturerId><individualPrice>11.4800</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>11.4800</amountMOHLTCPays></drug></pcg9><pcg9 id="960100145"><strength>1.2kcal/mL</strength><dosageForm>Liq-1000mL Pk</dosageForm><drug id="09857109" additionalBenefitType="N" sec9="Y"><name>Jevity 1.2 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>9.1300</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>9.1300</amountMOHLTCPays></drug></pcg9><pcg9 id="960100159"><strength>1.5kcal/mL</strength><dosageForm>Liq-1000mL Pk</dosageForm><drug id="09857126" additionalBenefitType="N" sec9="Y"><name>Peptamen 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>52.8900</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>52.8900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100163"><strength>1.5kcal/mL</strength><dosageForm>Liq-1000mL Pk</dosageForm><drug id="09857310" additionalBenefitType="N" sec9="Y"><name>Jevity 1.5 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>11.5200</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>11.5200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100125"><dosageForm>Liq-1000mL Ready-To-Hang</dosageForm><drug id="09854231" additionalBenefitType="N" sec9="Y"><name>Compleat 1.06</name><manufacturerId>NES</manufacturerId><individualPrice>7.9700</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>7.9700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100140"><strength>1.06kcal/mL</strength><dosageForm>Liq-1500mL Pk</dosageForm><drug id="09854452" additionalBenefitType="N" sec9="Y"><name>Osmolite 1 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>8.0100</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>8.0100</amountMOHLTCPays></drug></pcg9><pcg9 id="960100142"><strength>1.06kcal/mL</strength><dosageForm>Liq-1500mL Pk</dosageForm><drug id="09854479" additionalBenefitType="N" sec9="Y"><name>Jevity 1 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>12.2200</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>12.2200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100144"><strength>1.2kcal/mL</strength><dosageForm>Liq-1500mL Pk</dosageForm><drug id="09857095" additionalBenefitType="N" sec9="Y"><name>Osmolite 1.2 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>9.0700</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>9.0700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100146"><strength>1.2kcal/mL</strength><dosageForm>Liq-1500mL Pk</dosageForm><drug id="09857117" additionalBenefitType="N" sec9="Y"><name>Jevity 1.2 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>13.7000</individualPrice><listingDate>2003-04-16</listingDate><amountMOHLTCPays>13.7000</amountMOHLTCPays></drug></pcg9><pcg9 id="960100164"><strength>1.5kcal/mL</strength><dosageForm>Liq-1500mL Pk</dosageForm><drug id="09857312" additionalBenefitType="N" sec9="Y"><name>Jevity 1.5 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>17.2800</individualPrice><listingDate>2008-12-03</listingDate><amountMOHLTCPays>17.2800</amountMOHLTCPays></drug></pcg9><pcg9 id="960100157"><strength>1kcal/mL</strength><dosageForm>Liq-1500mL Pk</dosageForm><drug id="09857102" additionalBenefitType="N" sec9="Y"><name>Peptamen with Prebio</name><manufacturerId>NES</manufacturerId><individualPrice>52.8900</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>52.8900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100265"><strength>1.5kcal/mL</strength><dosageForm>Liq-1500mL Ready-to-Hang</dosageForm><drug id="09858356" additionalBenefitType="N" sec9="Y"><name>Peptamen 1.5 with Prebio</name><manufacturerId>NES</manufacturerId><individualPrice>79.3351</individualPrice><listingDate>2025-05-30</listingDate><amountMOHLTCPays>79.3351</amountMOHLTCPays></drug></pcg9><pcg9 id="960100037"><dosageForm>Liq-235mL Pk</dosageForm><drug id="97973165" additionalBenefitType="N" sec9="Y"><name>Osmolite 1 CAL</name><manufacturerId>ABB</manufacturerId><individualPrice>1.2600</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.2600</amountMOHLTCPays></drug></pcg9><pcg9 id="960100058"><dosageForm>Liq-235mL Pk</dosageForm><drug id="97984370" additionalBenefitType="N" sec9="Y"><name>PediaSure</name><manufacturerId>ABB</manufacturerId><individualPrice>2.4700</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.4700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100107"><dosageForm>Liq-235mL Pk</dosageForm><drug id="09853731" additionalBenefitType="N" sec9="Y"><name>Suplena</name><manufacturerId>ABB</manufacturerId><individualPrice>2.0900</individualPrice><listingDate>1998-12-31</listingDate><amountMOHLTCPays>2.0900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100118"><dosageForm>Liq-235mL Pk</dosageForm><drug id="09854169" additionalBenefitType="N" sec9="Y"><name>Osmolite 1.2 CAL</name><manufacturerId>ABB</manufacturerId><individualPrice>1.4400</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>1.4400</amountMOHLTCPays></drug></pcg9><pcg9 id="960100059"><strength>1.06kcal/mL</strength><dosageForm>Liq-235mL Pk</dosageForm><drug id="97984060" additionalBenefitType="N" sec9="Y"><name>Jevity 1 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>1.9200</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.9200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100108"><strength>1.2kcal/mL</strength><dosageForm>Liq-235mL Pk</dosageForm><drug id="09854096" additionalBenefitType="N" sec9="Y"><name>Jevity 1.2 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>2.1700</individualPrice><listingDate>2000-01-17</listingDate><amountMOHLTCPays>2.1700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100149"><strength>1.5kcal/mL</strength><dosageForm>Liq-235mL Pk</dosageForm><drug id="09857419" additionalBenefitType="N" sec9="Y"><name>Pediasure Plus with Fibre</name><manufacturerId>ROS</manufacturerId><individualPrice>2.7400</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>2.7400</amountMOHLTCPays></drug></pcg9><pcg9 id="960100169"><strength>1.5kcal/mL</strength><dosageForm>Liq-235mL Pk</dosageForm><drug id="09857344" additionalBenefitType="N" sec9="Y"><name>Jevity 1.5 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>2.7025</individualPrice><listingDate>2010-04-23</listingDate><amountMOHLTCPays>2.7025</amountMOHLTCPays></drug></pcg9><pcg9 id="960100135"><strength>1kcal/mL</strength><dosageForm>Liq-235mL Pk</dosageForm><drug id="09854371" additionalBenefitType="N" sec9="Y"><name>Pediasure with Fibre</name><manufacturerId>ROS</manufacturerId><individualPrice>2.4700</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>2.4700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100136"><strength>2kcal/mL</strength><dosageForm>Liq-235mL Pk</dosageForm><drug id="09854380" additionalBenefitType="N" sec9="Y"><name>TwoCal HN</name><manufacturerId>ABB</manufacturerId><individualPrice>2.3688</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>2.3688</amountMOHLTCPays></drug></pcg9><pcg9 id="960100009"><dosageForm>Liq-235mL Pk Cans</dosageForm><drug id="97904333" additionalBenefitType="N" sec9="Y"><name>Ensure Plus</name><manufacturerId>ABB</manufacturerId><individualPrice>1.7900</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.7900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100088"><dosageForm>Liq-237mL Pk</dosageForm><drug id="09853154" additionalBenefitType="N" sec9="Y"><name>Boost Fruit Flavoured Beverage</name><manufacturerId>NES</manufacturerId><individualPrice>1.5300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.5300</amountMOHLTCPays></drug></pcg9><pcg9 id="960100111"><dosageForm>Liq-237mL Pk</dosageForm><drug id="09853170" additionalBenefitType="N" sec9="Y"><name>Resource 2.0</name><manufacturerId>NES</manufacturerId><individualPrice>2.4041</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>2.4041</amountMOHLTCPays></drug></pcg9><pcg9 id="960100127"><dosageForm>Liq-237mL Pk</dosageForm><drug id="09854258" additionalBenefitType="N" sec9="Y"><name>NovaSource Renal</name><manufacturerId>NES</manufacturerId><individualPrice>2.3940</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>2.3940</amountMOHLTCPays></drug></pcg9><pcg9 id="960100130"><dosageForm>Liq-237mL Pk</dosageForm><drug id="09854390" additionalBenefitType="N" sec9="Y"><name>Perative</name><manufacturerId>ROS</manufacturerId><individualPrice>2.7200</individualPrice><listingDate>2002-07-29</listingDate><amountMOHLTCPays>2.7200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100047"><strength>1.5kcal/mL</strength><dosageForm>Liq-237mL Pk</dosageForm><drug id="97982610" additionalBenefitType="N" sec9="Y"><name>Boost 1.5 Plus Calories</name><manufacturerId>NES</manufacturerId><individualPrice>1.7392</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>1.7392</amountMOHLTCPays></drug></pcg9><pcg9 id="960100160"><strength>1.5kcal/mL</strength><dosageForm>Liq-237mL Pk</dosageForm><drug id="09857142" additionalBenefitType="N" sec9="Y"><name>Resource Kid Essentials 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>3.2978</individualPrice><listingDate>2005-09-27</listingDate><amountMOHLTCPays>3.2978</amountMOHLTCPays></drug></pcg9><pcg9 id="960100226"><strength>1kcal/mL</strength><dosageForm>Liq-237mL Pk</dosageForm><drug id="09857615" additionalBenefitType="N" sec9="Y"><name>Neocate Splash (Grape Flavour)</name><manufacturerId>NUT</manufacturerId><individualPrice>7.0561</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>7.0561</amountMOHLTCPays></drug></pcg9><pcg9 id="960100227"><strength>1kcal/mL</strength><dosageForm>Liq-237mL Pk</dosageForm><drug id="09857616" additionalBenefitType="N" sec9="Y"><name>Neocate Splash(Orange-Pineapple Flavour)</name><manufacturerId>NUT</manufacturerId><individualPrice>7.0561</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>7.0561</amountMOHLTCPays></drug></pcg9><pcg9 id="960100228"><strength>1kcal/mL</strength><dosageForm>Liq-237mL Pk</dosageForm><drug id="09857603" additionalBenefitType="N" sec9="Y"><name>Neocate Splash (Unflavoured)</name><manufacturerId>NUT</manufacturerId><individualPrice>7.0561</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>7.0561</amountMOHLTCPays></drug></pcg9><pcg9 id="960100229"><strength>1kcal/mL</strength><dosageForm>Liq-237mL Pk</dosageForm><drug id="09857604" additionalBenefitType="N" sec9="Y"><name>Neocate Splash (Tropical Fruit Flavour)</name><manufacturerId>NUT</manufacturerId><individualPrice>7.0561</individualPrice><listingDate>2019-01-31</listingDate><amountMOHLTCPays>7.0561</amountMOHLTCPays></drug></pcg9><pcg9 id="960100209"><strength>1.0kcal/mL</strength><dosageForm>Liq-237mL Pk Reclosable Plastic Bottle</dosageForm><drug id="09857523" additionalBenefitType="N" sec9="Y"><name>PediaSure Peptide 1 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>2.6892</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>2.6892</amountMOHLTCPays></drug></pcg9><pcg9 id="960100268"><strength>1.2kcal/mL</strength><dosageForm>Liq-237mL Reclosable Carton Pk</dosageForm><drug id="09858384" additionalBenefitType="N" sec9="Y"><name>Osmolite 1.2 CAL</name><manufacturerId>ABB</manufacturerId><individualPrice>1.4533</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>1.4533</amountMOHLTCPays></drug></pcg9><pcg9 id="960100269"><strength>1.2kcal/mL</strength><dosageForm>Liq-237mL Reclosable Carton Pk</dosageForm><drug id="09858383" additionalBenefitType="N" sec9="Y"><name>Jevity 1.2 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>2.1842</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>2.1842</amountMOHLTCPays></drug></pcg9><pcg9 id="960100266"><strength>1.5kcal/mL</strength><dosageForm>Liq-237mL Reclosable Carton Pk</dosageForm><drug id="09858367" additionalBenefitType="N" sec9="Y"><name>Jevity 1.5 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>2.7302</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>2.7302</amountMOHLTCPays></drug></pcg9><pcg9 id="960100267"><strength>2kcal/mL</strength><dosageForm>Liq-237mL Reclosable Carton Pk</dosageForm><drug id="09858368" additionalBenefitType="N" sec9="Y"><name>TwoCal HN</name><manufacturerId>ABB</manufacturerId><individualPrice>2.3890</individualPrice><listingDate>2025-09-29</listingDate><amountMOHLTCPays>2.3890</amountMOHLTCPays></drug></pcg9><pcg9 id="960100171"><strength>1.5kcal/mL</strength><dosageForm>Liq-237mL Tetra Pk</dosageForm><drug id="09857388" additionalBenefitType="N" sec9="Y"><name>KetoCal 4:1 (Vanilla Flavoured)</name><manufacturerId>NUT</manufacturerId><individualPrice>5.7463</individualPrice><listingDate>2011-08-04</listingDate><amountMOHLTCPays>5.7463</amountMOHLTCPays></drug></pcg9><pcg9 id="960100208"><strength>1.5kcal/mL</strength><dosageForm>Liq-237mL Tetra Pk</dosageForm><drug id="09857497" additionalBenefitType="N" sec9="Y"><name>KetoCal 4:1 (Unflavoured)</name><manufacturerId>NUT</manufacturerId><individualPrice>5.7463</individualPrice><listingDate>2014-09-25</listingDate><amountMOHLTCPays>5.7463</amountMOHLTCPays></drug></pcg9><pcg9 id="960100248"><strength>1.50kcal/mL</strength><dosageForm>Liq-250mL Carton</dosageForm><drug id="09858245" additionalBenefitType="N" sec9="Y"><name>KetoVie 4:1 Plant Based Protein(Vanilla)</name><manufacturerId>CAM</manufacturerId><individualPrice>9.2448</individualPrice><listingDate>2023-06-30</listingDate><amountMOHLTCPays>9.2448</amountMOHLTCPays></drug></pcg9><pcg9 id="960100246"><strength>1.50kcal/mL</strength><dosageForm>Liq-250mL Carton Box</dosageForm><drug id="09858161" additionalBenefitType="N" sec9="Y"><name>KetoVie 4:1 Unflavoured</name><manufacturerId>CAM</manufacturerId><individualPrice>6.5451</individualPrice><listingDate>2022-08-31</listingDate><amountMOHLTCPays>6.5451</amountMOHLTCPays></drug></pcg9><pcg9 id="960100247"><strength>1.04kcal/mL</strength><dosageForm>Liq-250mL Carton Box (Unflavoured)</dosageForm><drug id="09858166" additionalBenefitType="N" sec9="Y"><name>KetoVie 3:1</name><manufacturerId>CAM</manufacturerId><individualPrice>6.5451</individualPrice><listingDate>2022-10-31</listingDate><amountMOHLTCPays>6.5451</amountMOHLTCPays></drug></pcg9><pcg9 id="960100082"><dosageForm>Liq-250mL Pk</dosageForm><drug id="97984779" additionalBenefitType="N" sec9="Y"><name>Peptamen</name><manufacturerId>NES</manufacturerId><individualPrice>8.8150</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>8.8150</amountMOHLTCPays></drug></pcg9><pcg9 id="960100098"><dosageForm>Liq-250mL Pk</dosageForm><drug id="09853588" additionalBenefitType="N" sec9="Y"><name>Peptamen Junior</name><manufacturerId>NES</manufacturerId><individualPrice>8.8150</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>8.8150</amountMOHLTCPays></drug></pcg9><pcg9 id="960100150"><strength>1.06kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09857427" additionalBenefitType="N" sec9="Y"><name>Resource Diabetic 1.05</name><manufacturerId>NES</manufacturerId><individualPrice>2.0352</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>2.0352</amountMOHLTCPays></drug></pcg9><pcg9 id="960100239"><strength>1.49kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09858139" additionalBenefitType="N" sec9="Y"><name>KetoVie Peptide 4:1</name><manufacturerId>CAM</manufacturerId><individualPrice>9.2448</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>9.2448</amountMOHLTCPays></drug></pcg9><pcg9 id="960100109"><strength>1.5kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09853090" additionalBenefitType="N" sec9="Y"><name>Peptamen 1.5</name><manufacturerId>NES</manufacturerId><individualPrice>13.2225</individualPrice><listingDate>2000-07-17</listingDate><amountMOHLTCPays>13.2225</amountMOHLTCPays></drug></pcg9><pcg9 id="960100123"><strength>1kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09854215" additionalBenefitType="N" sec9="Y"><name>Nutren Junior 1.0</name><manufacturerId>NES</manufacturerId><individualPrice>2.6275</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>2.6275</amountMOHLTCPays></drug></pcg9><pcg9 id="960100124"><strength>1kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09854223" additionalBenefitType="N" sec9="Y"><name>Nutren Junior Fibre 1.0</name><manufacturerId>NES</manufacturerId><individualPrice>2.6275</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>2.6275</amountMOHLTCPays></drug></pcg9><pcg9 id="960100156"><strength>1kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09857101" additionalBenefitType="N" sec9="Y"><name>Peptamen with Prebio</name><manufacturerId>NES</manufacturerId><individualPrice>8.8150</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>8.8150</amountMOHLTCPays></drug></pcg9><pcg9 id="960100162"><strength>1kcal/mL</strength><dosageForm>Liq-250mL Pk</dosageForm><drug id="09857173" additionalBenefitType="N" sec9="Y"><name>Compleat Junior 1.0</name><manufacturerId>NES</manufacturerId><individualPrice>2.5920</individualPrice><listingDate>2006-01-12</listingDate><amountMOHLTCPays>2.5920</amountMOHLTCPays></drug></pcg9><pcg9 id="960100006"><dosageForm>Liq-250mL Tetra Pk</dosageForm><drug id="97983330" additionalBenefitType="N" sec9="Y"><name>Compleat 1.06</name><manufacturerId>NES</manufacturerId><individualPrice>2.0300</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>2.0300</amountMOHLTCPays></drug></pcg9><pcg9 id="960100242"><itemNumber>2383</itemNumber><strength>68kcal/100mL</strength><dosageForm>Liq-384mL Can</dosageForm><drug id="09858157" sec3c="Y"><name>Nutramigen Liquid Concentrate</name><manufacturerId>MJC</manufacturerId><individualPrice>8.3200</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>8.3200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100045"><dosageForm>Liq-384mL Pk</dosageForm><drug id="97973084" additionalBenefitType="N" sec9="Y"><name>RCF</name><manufacturerId>ABB</manufacturerId><individualPrice>6.2700</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.2700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100066"><dosageForm>Liq-4x237mL Pk</dosageForm><drug id="97984558" additionalBenefitType="N" sec9="Y"><name>Alimentum</name><manufacturerId>ABB</manufacturerId><individualPrice>6.7152</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>6.7152</amountMOHLTCPays></drug></pcg9><pcg9 id="960100025"><strength>7.7kcal/mL</strength><dosageForm>Liq-946mL Pk</dosageForm><drug id="97904473" additionalBenefitType="N" sec9="Y"><name>MCT Oil</name><manufacturerId>NES</manufacturerId><individualPrice>39.2833</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>39.2833</amountMOHLTCPays></drug></pcg9><pcg9 id="960100236"><strength>1.56kcal/mL</strength><dosageForm>Liq-Chocolate Flavour, 250mL Pk</dosageForm><drug id="09858117" additionalBenefitType="N" sec9="Y"><name>KetoVie 4:1</name><manufacturerId>CAM</manufacturerId><individualPrice>6.5451</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>6.5451</amountMOHLTCPays></drug></pcg9><pcg9 id="960100234"><strength>1.5Kcal/mL</strength><dosageForm>Liq-Vanilla Flavour, 220mL Pk bottle</dosageForm><drug id="09858102" additionalBenefitType="N" sec9="Y"><name>Vital Peptide 1.5 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>7.7472</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>7.7472</amountMOHLTCPays></drug></pcg9><pcg9 id="960100233"><strength>1Kcal/mL</strength><dosageForm>Liq-Vanilla Flavour, 220mL Pk bottle</dosageForm><drug id="09858101" additionalBenefitType="N" sec9="Y"><name>Vital Peptide 1 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>5.3721</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>5.3721</amountMOHLTCPays></drug></pcg9><pcg9 id="960100237"><strength>1.44kcal/mL</strength><dosageForm>Liq-Vanilla Flavour, 250mL Pk</dosageForm><drug id="09858118" additionalBenefitType="N" sec9="Y"><name>KetoVie 4:1</name><manufacturerId>CAM</manufacturerId><individualPrice>6.5451</individualPrice><listingDate>2020-06-30</listingDate><amountMOHLTCPays>6.5451</amountMOHLTCPays></drug></pcg9><pcg9 id="960100235"><strength>1.5Kcal/mL</strength><dosageForm>Liq-Vanilla Flavour,1000mL Ready to Hang container</dosageForm><drug id="09858103" additionalBenefitType="N" sec9="Y"><name>Vital Peptide 1.5 Cal</name><manufacturerId>ABB</manufacturerId><individualPrice>35.2145</individualPrice><listingDate>2020-01-31</listingDate><amountMOHLTCPays>35.2145</amountMOHLTCPays></drug></pcg9><pcg9 id="960100161"><strength>22kcal/30mL</strength><dosageForm>Pd for Liq-363g Pk</dosageForm><drug id="09857172" additionalBenefitType="N" sec9="Y"><name>Enfamil EnfaCare A+</name><manufacturerId>MJS</manufacturerId><individualPrice>17.3700</individualPrice><listingDate>2006-01-12</listingDate><amountMOHLTCPays>17.3700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100232"><strength>810.7143Kcal/227g</strength><dosageForm>Pd-227g Pk Canister (Unflavoured)</dosageForm><drug id="09857635" additionalBenefitType="N" sec9="Y"><name>Beneprotein</name><manufacturerId>NES</manufacturerId><individualPrice>12.8904</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>12.8904</amountMOHLTCPays></drug></pcg9><pcg9 id="960100225"><strength>7.05kcal/g</strength><dosageForm>Pd-300g Pk</dosageForm><drug id="09857599" additionalBenefitType="N" sec9="Y"><name>KetoCal 4:1 (Vanilla Flavour)</name><manufacturerId>NUT</manufacturerId><individualPrice>31.8000</individualPrice><listingDate>2018-11-29</listingDate><amountMOHLTCPays>31.8000</amountMOHLTCPays></drug></pcg9><pcg9 id="960100158"><strength>5.15kcal/g</strength><dosageForm>Pd-363g Pk</dosageForm><drug id="09857124" additionalBenefitType="N" sec9="Y"><name>Similac Advance NeoSure</name><manufacturerId>ABB</manufacturerId><individualPrice>14.9900</individualPrice><listingDate>2004-07-20</listingDate><amountMOHLTCPays>14.9900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100243"><itemNumber>2384</itemNumber><strength>4.9301kcal/g</strength><dosageForm>Pd-400g Bottle</dosageForm><drug id="09858156" sec3c="Y"><name>Gerber Good Start Extensive HA</name><manufacturerId>NEC</manufacturerId><individualPrice>17.6200</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>17.6200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100240"><strength>1976kcal/400g</strength><dosageForm>Pd-400g Can</dosageForm><drug id="09858140" additionalBenefitType="N" sec9="Y"><name>Renastart</name><manufacturerId>VIT</manufacturerId><individualPrice>42.2750</individualPrice><listingDate>2021-11-30</listingDate><amountMOHLTCPays>42.2750</amountMOHLTCPays></drug></pcg9><pcg9 id="960100244"><itemNumber>2385</itemNumber><strength>1976Kcal/400g</strength><dosageForm>Pd-400g Can</dosageForm><drug id="09858159" sec3c="Y"><name>Alfamino</name><manufacturerId>NES</manufacturerId><individualPrice>64.0200</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>64.0200</amountMOHLTCPays></drug></pcg9><pcg9 id="960100245"><itemNumber>2386</itemNumber><strength>2024Kcal/400g</strength><dosageForm>Pd-400g Can</dosageForm><drug id="09858160" sec3c="Y"><name>Althera</name><manufacturerId>NES</manufacturerId><individualPrice>18.0700</individualPrice><listingDate>2022-07-29</listingDate><amountMOHLTCPays>18.0700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100230"><strength>0.2071g/kcal</strength><dosageForm>Pd-400g Can Pk</dosageForm><drug id="09857627" additionalBenefitType="N" sec9="Y"><name>Neocate DHA &amp; ARA</name><manufacturerId>NUT</manufacturerId><individualPrice>62.5600</individualPrice><listingDate>2019-08-30</listingDate><amountMOHLTCPays>62.5600</amountMOHLTCPays></drug></pcg9><pcg9 id="960100220"><strength>5.17Kcal/g</strength><dosageForm>Pd-400g Can Pk</dosageForm><drug id="09857564" additionalBenefitType="N" sec9="Y"><name>Similac Alimentum</name><manufacturerId>ABB</manufacturerId><individualPrice>16.4700</individualPrice><listingDate>2017-10-30</listingDate><amountMOHLTCPays>16.4700</amountMOHLTCPays></drug></pcg9><pcg9 id="960100249"><itemNumber>2387</itemNumber><strength>4.41cal/g</strength><dosageForm>Pd-400g Can with DHA &amp; ARA (Unflavoured)</dosageForm><drug id="09858280" sec3c="Y"><name>Monogen</name><manufacturerId>NUT</manufacturerId><individualPrice>38.3333</individualPrice><listingDate>2023-09-28</listingDate><amountMOHLTCPays>38.3333</amountMOHLTCPays></drug></pcg9><pcg9 id="960100250"><strength>1.0kcal/mL</strength><dosageForm>Pd-400g Canister</dosageForm><drug id="09858320" additionalBenefitType="N" sec9="Y"><name>Alfamino Junior</name><manufacturerId>NES</manufacturerId><individualPrice>64.6759</individualPrice><listingDate>2023-12-29</listingDate><amountMOHLTCPays>64.6759</amountMOHLTCPays></drug></pcg9><pcg9 id="960100122"><strength>1kcal/mL</strength><dosageForm>Pd-400g Pk</dosageForm><drug id="09854207" additionalBenefitType="N" sec9="Y"><name>Neocate Junior (Unflavoured)</name><manufacturerId>NUT</manufacturerId><individualPrice>54.2699</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>54.2699</amountMOHLTCPays></drug></pcg9><pcg9 id="960100172"><strength>1kcal/mL</strength><dosageForm>Pd-400g Pk</dosageForm><drug id="09857393" additionalBenefitType="N" sec9="Y"><name>Modulen</name><manufacturerId>NES</manufacturerId><individualPrice>34.7964</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>34.7964</amountMOHLTCPays></drug></pcg9><pcg9 id="960100224"><strength>1kcal/mL</strength><dosageForm>Pd-400g Pk</dosageForm><drug id="09857594" additionalBenefitType="N" dinStatus="E" sec9="Y"><name>Neocate Junior (Tropical Flavour)</name><manufacturerId>NUT</manufacturerId><individualPrice>54.2699</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>54.2699</amountMOHLTCPays></drug></pcg9><pcg9 id="960100170"><strength>5kcal/g</strength><dosageForm>Pd-400g Pk</dosageForm><drug id="09857369" additionalBenefitType="N" sec9="Y"><name>PurAmino A+</name><manufacturerId>MJN</manufacturerId><individualPrice>55.7900</individualPrice><listingDate>2010-10-28</listingDate><amountMOHLTCPays>55.7900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100263"><strength>1.0kcal/mL</strength><dosageForm>Pd-400g Pouch Pk</dosageForm><drug id="09858354" additionalBenefitType="N" sec9="Y"><name>Essential Care Junior (Unflavored)</name><manufacturerId>CAM</manufacturerId><individualPrice>57.7800</individualPrice><listingDate>2024-12-30</listingDate><amountMOHLTCPays>57.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="960100138"><strength>1.02kcal/mL</strength><dosageForm>Pd-454g Pk</dosageForm><drug id="09854401" additionalBenefitType="N" sec9="Y"><name>Portagen</name><manufacturerId>MJN</manufacturerId><individualPrice>55.7800</individualPrice><listingDate>2003-01-30</listingDate><amountMOHLTCPays>55.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="960100167"><strength>5kcal/g</strength><dosageForm>Pd-454g Pk</dosageForm><drug id="09857345" additionalBenefitType="N" sec9="Y"><name>Nutramigen A+</name><manufacturerId>MJN</manufacturerId><individualPrice>29.1300</individualPrice><listingDate>2010-03-02</listingDate><amountMOHLTCPays>29.1300</amountMOHLTCPays></drug></pcg9><pcg9 id="960100215"><strength>5Kcal/g</strength><dosageForm>Pd-561g Can Pk</dosageForm><drug id="09857565" additionalBenefitType="N" sec9="Y"><name>Nutramigen A+ with LGG</name><manufacturerId>MJN</manufacturerId><individualPrice>35.9900</individualPrice><listingDate>2017-08-30</listingDate><amountMOHLTCPays>35.9900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100270"><strength>5kcal/g</strength><dosageForm>Pd-561g Pk</dosageForm><drug id="09858387" additionalBenefitType="N" sec9="Y"><name>Nutramigen A+</name><manufacturerId>MJN</manufacturerId><individualPrice>35.9900</individualPrice><listingDate>2025-11-28</listingDate><amountMOHLTCPays>35.9900</amountMOHLTCPays></drug></pcg9><pcg9 id="960100054"><dosageForm>Pd-79.5g Pk</dosageForm><drug id="97982830" additionalBenefitType="N" sec9="Y"><name>Vivonex Plus</name><manufacturerId>NES</manufacturerId><individualPrice>9.8345</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>9.8345</amountMOHLTCPays></drug></pcg9><pcg9 id="960100231"><strength>25Kcal/7g</strength><dosageForm>Pd-7g Pk Sachet (Unflavoured)</dosageForm><drug id="09857634" additionalBenefitType="N" sec9="Y"><name>Beneprotein</name><manufacturerId>NES</manufacturerId><individualPrice>.3975</individualPrice><listingDate>2019-11-29</listingDate><amountMOHLTCPays>.3975</amountMOHLTCPays></drug></pcg9><pcg9 id="960100097"><dosageForm>Pd-80.4g Pk</dosageForm><drug id="09853618" additionalBenefitType="N" sec9="Y"><name>Vivonex T.E.N.</name><manufacturerId>NES</manufacturerId><individualPrice>9.7843</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>9.7843</amountMOHLTCPays></drug></pcg9><pcg9 id="960100052"><dosageForm>Pd-80g Pk</dosageForm><drug id="97982750" additionalBenefitType="N" sec9="Y"><name>Tolerex</name><manufacturerId>NES</manufacturerId><individualPrice>7.0643</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>7.0643</amountMOHLTCPays></drug></pcg9><pcg9 id="960100241"><itemNumber>2388</itemNumber><strength>0.677kcal/mL</strength><dosageForm>Pd-946mL Bottle</dosageForm><drug id="09858158" sec3c="Y"><name>Similac Alimentum</name><manufacturerId>ABB</manufacturerId><individualPrice>5.6278</individualPrice><listingDate>2022-06-30</listingDate><amountMOHLTCPays>5.6278</amountMOHLTCPays></drug></pcg9><pcg9 id="960100252"><strength>1.5Kcal/mL</strength><dosageForm>Ready-to-Hang - 1L Pk</dosageForm><drug id="09858352" additionalBenefitType="N" sec9="Y"><name>Pivot 1.5 CAL</name><manufacturerId>ABB</manufacturerId><individualPrice>52.7999</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>52.7999</amountMOHLTCPays></drug></pcg9><pcg9 id="960100238"><strength>2.0kcal/mL</strength><dosageForm>Ready-To-Hang 1000mL Pk</dosageForm><drug id="09858121" additionalBenefitType="N" sec9="Y"><name>Isosource 2.0</name><manufacturerId>NES</manufacturerId><individualPrice>10.0800</individualPrice><listingDate>2020-08-28</listingDate><amountMOHLTCPays>10.0800</amountMOHLTCPays></drug></pcg9><pcg9 id="960100251"><strength>1.5Kcal/mL</strength><dosageForm>Tetrapack-237mL Pk</dosageForm><drug id="09858351" additionalBenefitType="N" sec9="Y"><name>Pivot 1.5 CAL</name><manufacturerId>ABB</manufacturerId><individualPrice>12.5135</individualPrice><listingDate>2024-10-31</listingDate><amountMOHLTCPays>12.5135</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="960500000"><name>DIABETIC TESTING AGENTS</name><genericName id="01928"><name>FAD GLUCOSE DEHYDROGENASE (ASPERGILLUS SP.)</name><pcgGroup><pcg9 id="960500046"><dosageForm>Strip</dosageForm><drug id="09857453" additionalBenefitType="D" sec9="Y"><name>Contour Next Blood Glucose Test Strips</name><manufacturerId>ADC</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2013-09-27</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01977"><name>FAD-GLUCOSE DEHYDROGENASE (FAD-GDH)</name><pcgGroup><pcg9 id="960500051"><dosageForm>Strip</dosageForm><drug id="09857525" additionalBenefitType="D" sec9="Y"><name>GE200 Blood Glucose Test Strips</name><manufacturerId>BIN</manufacturerId><individualPrice>.5508</individualPrice><listingDate>2015-05-28</listingDate><amountMOHLTCPays>.5508</amountMOHLTCPays></drug></pcg9><pcg9 id="960500056"><dosageForm>Strip</dosageForm><drug id="09857563" additionalBenefitType="D" sec9="Y"><name>Accu-Chek Guide Test Strips</name><manufacturerId>RCH</manufacturerId><individualPrice>.7154</individualPrice><listingDate>2017-07-31</listingDate><amountMOHLTCPays>.7154</amountMOHLTCPays></drug></pcg9><pcg9 id="960500057"><dosageForm>Strip</dosageForm><drug id="09857593" additionalBenefitType="D" sec9="Y"><name>GlucoDr. Auto Test Strip</name><manufacturerId>AMC</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2018-03-29</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500055"><dosageForm>Test Strip</dosageForm><drug id="09857549" additionalBenefitType="D" sec9="Y"><name>Fora Test N&apos; Go Test Strip</name><manufacturerId>TAI</manufacturerId><individualPrice>.7244</individualPrice><listingDate>2016-09-29</listingDate><amountMOHLTCPays>.7244</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01926"><name>GDH-FAD ENZYME</name><pcgGroup><pcg9 id="960500037"><dosageForm>Strip</dosageForm><drug id="09857297" additionalBenefitType="D" sec9="Y"><name>Freestyle Lite</name><manufacturerId>ABB</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2008-08-28</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01852"><name>GDH-FAD GLUCOSE DEHYDROGENASE</name><pcgGroup><pcg9 id="960500042"><dosageForm>Strip</dosageForm><drug id="09857392" additionalBenefitType="D" sec9="Y"><name>One Touch Verio</name><manufacturerId>LIF</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2011-09-15</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01770"><name>GLUCOSE DEHYDROGENASE</name><pcgGroup><pcg9 id="960500032"><dosageForm>Strip</dosageForm><drug id="09857127" additionalBenefitType="D" sec9="Y"><name>Contour Blood Glucose Test Strips</name><manufacturerId>ADC</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2004-11-04</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500049"><dosageForm>Strip</dosageForm><drug id="09857502" additionalBenefitType="D" sec9="Y"><name>FreeStyle Precision Test Strips</name><manufacturerId>ABD</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2014-10-29</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01919"><name>GLUCOSE OXI-REDUCTASE</name><pcgGroup><pcg9 id="960500045"><dosageForm>Strip</dosageForm><drug id="09857452" additionalBenefitType="D" sec9="Y"><name>Accu-Chek Mobile</name><manufacturerId>RCH</manufacturerId><individualPrice>.7481</individualPrice><listingDate>2013-07-30</listingDate><amountMOHLTCPays>.7481</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01972"><name>GLUCOSE OXIDASE</name><pcgGroup><pcg9 id="960500054"><strength>Strip</strength><drug id="09857547" additionalBenefitType="D" sec9="Y"><name>Spirit Blood Glucose Test Strip</name><manufacturerId>ARA</manufacturerId><individualPrice>.6912</individualPrice><listingDate>2016-08-30</listingDate><amountMOHLTCPays>.6912</amountMOHLTCPays></drug></pcg9><pcg9 id="960500050"><dosageForm>Strip</dosageForm><drug id="09857522" additionalBenefitType="D" sec9="Y"><name>Suretest Blood Glucose Test Strips</name><manufacturerId>SKY</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2015-04-30</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500052"><dosageForm>Strip</dosageForm><drug id="09857526" additionalBenefitType="D" sec9="Y"><name>CareSens N Blood Glucose Test Strip</name><manufacturerId>ISE</manufacturerId><individualPrice>.6912</individualPrice><listingDate>2015-07-29</listingDate><amountMOHLTCPays>.6912</amountMOHLTCPays></drug></pcg9><pcg9 id="960500053"><dosageForm>Strip</dosageForm><drug id="09857538" additionalBenefitType="D" sec9="Y"><name>Ideal Life Glucose Test Strip</name><manufacturerId>IDL</manufacturerId><individualPrice>.6800</individualPrice><listingDate>2016-02-25</listingDate><amountMOHLTCPays>.6800</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02325"><name>GLUCOSE OXIDASE A. NIGER</name><pcgGroup><pcg9 id="960500058"><dosageForm>Strip</dosageForm><drug id="09858179" additionalBenefitType="D" sec9="Y"><name>Tykess Blood Glucose Test Strips</name><manufacturerId>TAI</manufacturerId><individualPrice>1.0798</individualPrice><listingDate>2023-04-28</listingDate><amountMOHLTCPays>1.0798</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="00590"><name>GLUCOSE OXIDASE REAGENT</name><pcgGroup><pcg9 id="960500002"><dosageForm>Strip</dosageForm><drug id="09853162" additionalBenefitType="D" sec9="Y"><name>Accutrend</name><manufacturerId>ROD</manufacturerId><individualPrice>.7679</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7679</amountMOHLTCPays></drug></pcg9><pcg9 id="960500017"><dosageForm>Strip</dosageForm><drug id="09853626" additionalBenefitType="D" sec9="Y"><name>Accu-Chek Advantage</name><manufacturerId>ROD</manufacturerId><individualPrice>.7481</individualPrice><listingDate>1996-10-01</listingDate><amountMOHLTCPays>.7481</amountMOHLTCPays></drug></pcg9><pcg9 id="960500022"><dosageForm>Strip</dosageForm><drug id="09854002" additionalBenefitType="D" sec9="Y"><name>Advantage Comfort</name><manufacturerId>ROD</manufacturerId><individualPrice>.7481</individualPrice><listingDate>1999-04-15</listingDate><amountMOHLTCPays>.7481</amountMOHLTCPays></drug></pcg9><pcg9 id="960500026"><dosageForm>Strip</dosageForm><drug id="09854070" additionalBenefitType="D" sec9="Y"><name>Precision Xtra</name><manufacturerId>ABB</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2001-10-11</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500027"><dosageForm>Strip</dosageForm><drug id="09854282" additionalBenefitType="D" sec9="Y"><name>Accu-Chek Compact</name><manufacturerId>RCH</manufacturerId><individualPrice>.7481</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.7481</amountMOHLTCPays></drug></pcg9><pcg9 id="960500028"><dosageForm>Strip</dosageForm><drug id="09854290" additionalBenefitType="D" sec9="Y"><name>One Touch Ultra</name><manufacturerId>LIF</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2002-04-04</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500030"><dosageForm>Strip</dosageForm><drug id="09857141" additionalBenefitType="D" sec9="Y"><name>Freestyle</name><manufacturerId>TER</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2003-09-04</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500033"><dosageForm>Strip</dosageForm><drug id="09857132" additionalBenefitType="D" sec9="Y"><name>BD</name><manufacturerId>BED</manufacturerId><individualPrice>.7655</individualPrice><listingDate>2005-02-22</listingDate><amountMOHLTCPays>.7655</amountMOHLTCPays></drug></pcg9><pcg9 id="960500034"><dosageForm>Strip</dosageForm><drug id="09857178" additionalBenefitType="D" sec9="Y"><name>Accu-Chek Aviva</name><manufacturerId>RCH</manufacturerId><individualPrice>.7481</individualPrice><listingDate>2006-04-19</listingDate><amountMOHLTCPays>.7481</amountMOHLTCPays></drug></pcg9><pcg9 id="960500035"><dosageForm>Strip</dosageForm><drug id="09857283" additionalBenefitType="D" sec9="Y"><name>TrueTrack Smart System</name><manufacturerId>HOM</manufacturerId><individualPrice>.4000</individualPrice><listingDate>2007-12-19</listingDate><amountMOHLTCPays>.4000</amountMOHLTCPays></drug></pcg9><pcg9 id="960500036"><dosageForm>Strip</dosageForm><drug id="09857293" additionalBenefitType="D" sec9="Y"><name>Breeze 2 Blood Glucose Test Strip</name><manufacturerId>ADC</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2008-04-09</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500038"><dosageForm>Strip</dosageForm><drug id="09857313" additionalBenefitType="D" sec9="Y"><name>Nova Max</name><manufacturerId>NOB</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2008-12-23</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500039"><dosageForm>Strip</dosageForm><drug id="09857340" additionalBenefitType="D" sec9="Y"><name>On Call Plus</name><manufacturerId>ACO</manufacturerId><individualPrice>.4500</individualPrice><listingDate>2010-01-05</listingDate><amountMOHLTCPays>.4500</amountMOHLTCPays></drug></pcg9><pcg9 id="960500041"><dosageForm>Strip</dosageForm><drug id="09857357" additionalBenefitType="D" sec9="Y"><name>EZ Health Oracle</name><manufacturerId>TRE</manufacturerId><individualPrice>.7290</individualPrice><listingDate>2010-07-20</listingDate><amountMOHLTCPays>.7290</amountMOHLTCPays></drug></pcg9><pcg9 id="960500044"><dosageForm>Strip</dosageForm><drug id="09857432" additionalBenefitType="D" sec9="Y"><name>MediSure Blood Glucose Strip</name><manufacturerId>MEH</manufacturerId><individualPrice>.6900</individualPrice><listingDate>2013-01-29</listingDate><amountMOHLTCPays>.6900</amountMOHLTCPays></drug></pcg9><pcg9 id="960500047"><dosageForm>Strip</dosageForm><drug id="09857454" additionalBenefitType="D" sec9="Y"><name>MyGlucoHealth</name><manufacturerId>EHS</manufacturerId><individualPrice>.6851</individualPrice><listingDate>2013-10-31</listingDate><amountMOHLTCPays>.6851</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="01940"><name>QUINOPROTEIN GLUCOSE DEHYDROGENASE</name><pcgGroup><pcg9 id="960500048"><dosageForm>Strip</dosageForm><drug id="09857456" additionalBenefitType="D" sec9="Y"><name>Accu-Chek Inform II Test Strips</name><manufacturerId>ROD</manufacturerId><individualPrice>.6595</individualPrice><listingDate>2014-03-27</listingDate><amountMOHLTCPays>.6595</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="960800000"><name>VALVED HOLDING CHAMBERS</name><genericName id="02044"><name>VALVED HOLDING CHAMBER</name><pcgGroup><pcg9 id="960800006"><drug id="09858006" additionalBenefitType="C" sec9="Y"><name>A2A Spacer with Small Mask</name><manufacturerId>CCI</manufacturerId><individualPrice>12.0000</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>12.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="960800007"><drug id="09858007" additionalBenefitType="C" sec9="Y"><name>A2A Spacer with Medium Mask</name><manufacturerId>CCI</manufacturerId><individualPrice>12.0000</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>12.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="960800008"><drug id="09858008" additionalBenefitType="C" sec9="Y"><name>Optichamber Diamond Chamber</name><manufacturerId>RRD</manufacturerId><individualPrice>16.3400</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>16.3400</amountMOHLTCPays></drug></pcg9><pcg9 id="960800009"><drug id="09858009" additionalBenefitType="C" sec9="Y"><name>Optichamber Diamond Chamber + Small Mask</name><manufacturerId>RRD</manufacturerId><individualPrice>27.9300</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>27.9300</amountMOHLTCPays></drug></pcg9><pcg9 id="960800010"><drug id="09858010" additionalBenefitType="C" sec9="Y"><name>Optichamber Diamond Chamber+Medium Mask</name><manufacturerId>RRD</manufacturerId><individualPrice>27.9300</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>27.9300</amountMOHLTCPays></drug></pcg9><pcg9 id="960800011"><drug id="09858011" additionalBenefitType="C" sec9="Y"><name>Optichamber Diamond Chamber + Large Mask</name><manufacturerId>RRD</manufacturerId><individualPrice>30.7800</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>30.7800</amountMOHLTCPays></drug></pcg9><pcg9 id="960800012"><drug id="09858012" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Infant Sm. Mask</name><manufacturerId>TMI</manufacturerId><individualPrice>40.5000</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>40.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="960800013"><drug id="09858013" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Child Med. Mask</name><manufacturerId>TMI</manufacturerId><individualPrice>40.5000</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>40.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="960800014"><drug id="09858014" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Youth Mouthpiece</name><manufacturerId>TMI</manufacturerId><individualPrice>25.3200</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>25.3200</amountMOHLTCPays></drug></pcg9><pcg9 id="960800015"><drug id="09858015" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Girls Mouthpiece</name><manufacturerId>TMI</manufacturerId><individualPrice>25.3200</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>25.3200</amountMOHLTCPays></drug></pcg9><pcg9 id="960800016"><drug id="09858016" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Adult Mouthpiece</name><manufacturerId>TMI</manufacturerId><individualPrice>25.3200</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>25.3200</amountMOHLTCPays></drug></pcg9><pcg9 id="960800017"><drug id="09858017" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Adult Sm. Mask</name><manufacturerId>TMI</manufacturerId><individualPrice>42.8500</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>42.8500</amountMOHLTCPays></drug></pcg9><pcg9 id="960800018"><drug id="09858018" additionalBenefitType="C" sec9="Y"><name>AeroChamber Plus FlowVu Adult Large Mask</name><manufacturerId>TMI</manufacturerId><individualPrice>42.8500</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>42.8500</amountMOHLTCPays></drug></pcg9><pcg9 id="960800005"><dosageForm>Chamber</dosageForm><drug id="09858005" additionalBenefitType="C" sec9="Y"><name>A2A Aerosol to Airways Spacer</name><manufacturerId>CCI</manufacturerId><individualPrice>9.0000</individualPrice><listingDate>2018-01-01</listingDate><amountMOHLTCPays>9.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6><pcg6 id="960900000"><name>CONTINUOUS GLUCOSE MONITORING SYSTEMS</name><genericName id="02430"><name>GLUCOSE MONITORING SYSTEM</name><pcgGroup><pcg9 id="960900007"><itemNumber>2389</itemNumber><dosageForm>Continuous Glucose Monitoring System - Reader</dosageForm><drug id="09858386" additionalBenefitType="F" sec3="Y" sec9="Y"><name>FreeStyle Libre 3 Reader</name><manufacturerId>ABD</manufacturerId><individualPrice>60.0000</individualPrice><note>Reimbursement Criteria and Maximum Reimbursed Quantity:

All ODB eligible recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or a CGM reader/receiver designated on the Formulary are eligible to receive the prescribed ODB-funded CGM sensors and/or reader/receiver.

Patients who meet the reimbursement criteria are eligible for a maximum reimbursed quantity of 31 sensors over the course of a 365-day period.

Please refer to the Ontario Drug Programs Reference Manual for more information related to CGM systems (e.g., pharmacy billing procedure, HNS response codes and messages).</note><listingDate>2025-11-28</listingDate><amountMOHLTCPays>60.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="960900008"><itemNumber>2390</itemNumber><dosageForm>Continuous Glucose Monitoring System - Sensor</dosageForm><drug id="09858385" additionalBenefitType="F" sec3="Y" sec9="Y"><name>FreeStyle Libre 3 Plus Sensor</name><manufacturerId>ABD</manufacturerId><individualPrice>97.5000</individualPrice><note>Reimbursement Criteria and Maximum Reimbursed Quantity:

All ODB eligible recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or a CGM reader/receiver designated on the Formulary are eligible to receive the prescribed ODB-funded CGM sensors and/or reader/receiver.

Patients who meet the reimbursement criteria are eligible for a maximum reimbursed quantity of 31 sensors over the course of a 365-day period.

Please refer to the Ontario Drug Programs Reference Manual for more information related to CGM systems (e.g., pharmacy billing procedure, HNS response codes and messages).</note><listingDate>2025-11-28</listingDate><amountMOHLTCPays>97.5000</amountMOHLTCPays></drug></pcg9><pcg9 id="960900005"><itemNumber>2391</itemNumber><dosageForm>Continuous Glucose Monitoring System-Receiver Kit</dosageForm><drug id="09858361" additionalBenefitType="F" sec3="Y" sec9="Y"><name>Dexcom G7 Receiver</name><manufacturerId>DEX</manufacturerId><individualPrice>60.0000</individualPrice><note>Reimbursement Criteria and Maximum Reimbursed Quantity:

All ODB eligible recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or a CGM reader/receiver designated on the Formulary are eligible to receive the prescribed ODB-funded CGM sensors and/or reader/receiver.

Patients who meet the reimbursement criteria are eligible for a maximum reimbursed quantity of 45 sensors over the course of a 365-day period.

Please refer to the Ontario Drug Programs Reference Manual for more information related to CGM systems (e.g., pharmacy billing procedure, HNS response codes and messages).</note><listingDate>2025-07-31</listingDate><amountMOHLTCPays>60.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="960900006"><itemNumber>2392</itemNumber><dosageForm>Continuous Glucose Monitoring System-Sensor Kit</dosageForm><drug id="09858362" additionalBenefitType="F" sec3="Y" sec9="Y"><name>Dexcom G7 Sensor</name><manufacturerId>DEX</manufacturerId><individualPrice>75.0000</individualPrice><note>Reimbursement Criteria and Maximum Reimbursed Quantity:

All ODB eligible recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or a CGM reader/receiver designated on the Formulary are eligible to receive the prescribed ODB-funded CGM sensors and/or reader/receiver.

Patients who meet the reimbursement criteria are eligible for a maximum reimbursed quantity of 45 sensors over the course of a 365-day period.

Please refer to the Ontario Drug Programs Reference Manual for more information related to CGM systems (e.g., pharmacy billing procedure, HNS response codes and messages).</note><listingDate>2025-07-31</listingDate><amountMOHLTCPays>75.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName><genericName id="02106"><name>READER KIT AND SENSOR KIT</name><pcgGroup><pcg9 id="960900004"><itemNumber>2393</itemNumber><dosageForm>Flash Glucose Monitoring System - Reader</dosageForm><drug id="09858148" additionalBenefitType="F" sec3="Y" sec9="Y"><name>FreeStyle Libre 2 Reader</name><manufacturerId>ABD</manufacturerId><individualPrice>49.0000</individualPrice><note>Reimbursement Criteria and Maximum Reimbursed Quantity:

All ODB eligible recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or a CGM reader/receiver designated on the Formulary are eligible to receive the prescribed ODB-funded CGM sensors and/or reader/receiver.

Patients who meet the reimbursement criteria are eligible for a maximum reimbursed quantity of 33 sensors over the course of a 365-day period.

Please refer to the Ontario Drug Programs Reference Manual for more information related to CGM systems (e.g., pharmacy billing procedure, HNS response codes and messages).</note><listingDate>2021-11-30</listingDate><amountMOHLTCPays>49.0000</amountMOHLTCPays></drug></pcg9><pcg9 id="960900003"><itemNumber>2394</itemNumber><dosageForm>Flash Glucose Monitoring System - Sensor</dosageForm><drug id="09858147" additionalBenefitType="F" sec3="Y" sec9="Y"><name>FreeStyle Libre 2 Sensor</name><manufacturerId>ABD</manufacturerId><individualPrice>91.0000</individualPrice><note>Reimbursement Criteria and Maximum Reimbursed Quantity:

All ODB eligible recipients on insulin therapy for diabetes who have a valid prescription from a physician or nurse practitioner for CGM sensors and/or a CGM reader/receiver designated on the Formulary are eligible to receive the prescribed ODB-funded CGM sensors and/or reader/receiver.

Patients who meet the reimbursement criteria are eligible for a maximum reimbursed quantity of 33 sensors over the course of a 365-day period.

Please refer to the Ontario Drug Programs Reference Manual for more information related to CGM systems (e.g., pharmacy billing procedure, HNS response codes and messages).</note><listingDate>2021-11-30</listingDate><amountMOHLTCPays>91.0000</amountMOHLTCPays></drug></pcg9></pcgGroup></genericName></pcg6></pcg2></formulary></extract>